Physical	O
mapping	O
220	O
kb	O
centromeric	O
of	O
the	O
human	B-GENE
MHC	I-GENE
and	O
DNA	O
sequence	O
analysis	O
of	O
the	O
43	O
-	O
kb	O
segment	O
including	O
the	O
RING1	B-GENE
,	O
HKE6	B-GENE
,	O
and	O
HKE4	B-GENE
genes	I-GENE
.	O

The	O
synthesis	O
of	O
endo	O
-	O
adduct	O
[	O
4aS	O
,	O
5S	O
,	O
8R	O
,	O
8aR	O
,	O
SS	O
]	O
-	O
9d	O
resulting	O
from	O
cycloaddition	O
on	O
the	O
substituted	O
C	O
(	O
2	O
)	O
-	O
C	O
(	O
3	O
)	O
double	O
bond	O
was	O
achieved	O
in	O
a	O
chemo	O
-	O
and	O
diastereoselective	O
way	O
from	O
quinone	O
1d	O
in	O
the	O
presence	O
of	O
ZnBr	O
(	O
2	O
)	O
.	O

DNA	O
elements	O
recognizing	O
NF	B-GENE
-	I-GENE
Y	I-GENE
and	O
Sp1	B-GENE
regulate	O
the	O
human	B-GENE
multidrug	I-GENE
-	I-GENE
resistance	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

Radioimmunoassay	O
of	O
plasma	B-GENE
gonadotropins	I-GENE
;	O
problems	O
of	O
specificity	O

Patients	O
randomized	O
into	O
the	O
active	O
treatment	O
groups	O
A30	O
(	O
n	O
=	O
49	O
)	O
and	O
A60	O
(	O
n	O
=	O
48	O
)	O
received	O
topical	O
treatment	O
with	O
3	O
.	O
0	O
%	O
diclofenac	O
in	O
2	O
.	O
5	O
%	O
hyaluronan	O
gel	O
0	O
.	O
5	O
g	O
twice	O
daily	O
for	O
30	O
or	O
60	O
days	O
,	O
respectively	O
.	O

As	O
tat	B-GENE
itself	O
dramatically	O
increases	O
HIV	O
-	O
1	O
gene	O
expression	O
,	O
it	O
too	O
is	O
presumably	O
regulated	O
in	O
the	O
latent	O
state	O
,	O
and	O
may	O
also	O
be	O
activated	O
by	O
mitogenic	O
stimulation	O
.	O

To	O
clarify	O
the	O
difference	O
,	O
both	O
the	O
Crk	B-GENE
II	I-GENE
and	O
Crk	B-GENE
II	I-GENE
-	I-GENE
23	I-GENE
,	O
proteins	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
examined	O
their	O
binding	O
capacity	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
Systemic	O
factors	O
that	O
increase	O
bone	O
mineral	O
density	O
appear	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
,	O
and	O
these	O
factors	O
may	O
be	O
activated	O
after	O
middle	O
age	O
.	O

Thus	O
,	O
in	O
V	O
.	O
furnissii	O
,	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
manX	I-GENE
equivalent	I-GENE
comprises	O
two	O
genes	O
,	O
which	O
are	O
separated	O
in	O
the	O
genome	O
by	O
two	O
other	O
genes	O
of	O
the	O
ptsM	B-GENE
complex	I-GENE
.	O

Id	B-GENE
-	I-GENE
1H	I-GENE
and	O
Id	B-GENE
-	I-GENE
2H	I-GENE
seem	O
to	O
be	O
human	O
homologues	O
of	O
mouse	B-GENE
Id	I-GENE
-	I-GENE
1	I-GENE
and	O
Id	B-GENE
-	I-GENE
2	I-GENE
,	O
respectively	O
,	O
and	O
have	O
potential	O
to	O
encode	O
154	O
and	O
135	O
amino	O
acid	O
proteins	O
.	O

Characterization	O
of	O
insertion	O
mutations	O
in	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
MSH1	I-GENE
and	O
MSH2	B-GENE
genes	I-GENE
:	O
evidence	O
for	O
separate	O
mitochondrial	O
and	O
nuclear	O
functions	O
.	O

Transcription	O
of	O
FN	B-GENE
promoter	I-GENE
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
fusion	O
genes	O
carrying	O
the	O
base	O
substitution	O
in	O
one	O
or	O
more	O
of	O
these	O
G	O
-	O
rich	O
sequences	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
revealed	O
that	O
the	O
base	O
substitution	O
in	O
any	O
G	O
-	O
rich	O
sequence	O
results	O
in	O
reduction	O
of	O
promoter	O
activity	O
,	O
although	O
the	O
downstream	O
GC	O
box	O
(	O
GCd	O
)	O
plays	O
a	O
primary	O
role	O
.	O

Morphologically	O
,	O
corrugation	O
of	O
the	O
internal	O
elastic	O
lamina	O
of	O
vessels	O
was	O
often	O
observed	O
in	O
the	O
vehicle	O
-	O
treated	O
group	O
,	O
but	O
was	O
not	O
prominent	O
in	O
the	O
GLNVA	O
-	O
treated	O
groups	O
or	O
healthy	O
controls	O
.	O

A	O
GT	O
-	O
rich	O
sequence	O
binding	O
the	O
transcription	B-GENE
factor	I-GENE
Sp1	I-GENE
is	O
crucial	O
for	O
high	O
expression	O
of	O
the	O
human	B-GENE
type	I-GENE
VII	I-GENE
collagen	I-GENE
gene	I-GENE
(	O
COL7A1	B-GENE
)	O
in	O
fibroblasts	O
and	O
keratinocytes	O
.	O

Each	O
received	O
20	O
mL	O
of	O
one	O
of	O
three	O
test	O
solutions	O
:	O
levobupivacaine	O
control	O
,	O
levobupivacaine	O
and	O
fentanyl	O
2	O
microg	O
/	O
mL	O
,	O
or	O
levobupivacaine	O
and	O
fentanyl	O
3	O
microg	O
/	O
mL	O
.	O

The	O
XPR2	B-GENE
gene	I-GENE
from	O
Yarrowia	O
lipolytica	O
encodes	O
an	O
inducible	O
alkaline	B-GENE
extracellular	I-GENE
protease	I-GENE
.	O

CONCLUSIONS	O
:	O
This	O
study	O
shows	O
that	O
the	O
annual	O
rate	O
of	O
de	O
novo	O
aneurysm	O
formation	O
is	O
relatively	O
high	O
(	O
0	O
.	O
89	O
%	O
)	O
and	O
that	O
the	O
cumulative	O
risk	O
becomes	O
significant	O
after	O
9	O
years	O
.	O

It	O
was	O
found	O
that	O
Nopp140	B-GENE
binds	O
primarily	O
to	O
the	O
CK2	B-GENE
regulatory	I-GENE
subunit	I-GENE
,	I-GENE
beta	I-GENE
.	O

Juvenile	O
idiopathic	O
inflammatory	O
myopathies	O
:	O
the	O
value	O
of	O
magnetic	O
resonance	O
imaging	O
in	O
the	O
detection	O
of	O
muscle	O
involvement	O
.	O

Previous	O
analysis	O
of	O
this	O
motif	O
in	O
the	O
lactose	B-GENE
permease	I-GENE
(	O
A	O
.	O

Combined	O
chemotherapy	O
with	O
VM	O
26	O
and	O
BCNU	O
for	O
recurrent	O
malignant	O
gliomas	O
after	O
operation	O
and	O
irradiation	O
.	O

Like	O
other	O
IAPs	B-GENE
,	O
ch	B-GENE
-	I-GENE
IAP1	I-GENE
contains	O
the	O
N	B-GENE
-	I-GENE
terminal	I-GENE
baculovirus	I-GENE
IAP	I-GENE
repeats	I-GENE
and	O
C	O
-	O
terminal	O
RING	O
finger	O
motifs	O
.	O

Effects	O
of	O
long	O
-	O
term	O
use	O
of	O
raloxifene	O
,	O
a	O
selective	O
estrogen	B-GENE
receptor	I-GENE
modulator	O
,	O
on	O
thyroid	O
function	O
test	O
profiles	O
.	O

The	O
donors	O
of	O
10	O
patients	O
were	O
ABO	O
-	O
incompatible	O
,	O
and	O
for	O
five	O
pairs	O
the	O
ABO	O
incompatibility	O
was	O
major	O
.	O

Alternative	O
splicing	O
of	O
the	O
human	B-GENE
serotonin	I-GENE
transporter	I-GENE
gene	I-GENE
.	O

Interestingly	O
,	O
basal	O
MAPK	B-GENE
,	O
but	O
not	O
Raf	B-GENE
-	I-GENE
1	I-GENE
,	O
activity	O
was	O
constitutively	O
enhanced	O
in	O
Jak1	B-GENE
-	O
deficient	O
HeLa	O
cells	O
.	O

This	O
case	O
report	O
describes	O
the	O
treatment	O
of	O
a	O
patient	O
with	O
periodontosis	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
organize	O
chemical	O
data	O
in	O
a	O
client	O
-	O
server	O
environment	O
using	O
Database	O
Management	O
System	O
and	O
Web	O
fashion	O
for	O
the	O
client	O
interface	O
.	O

Cerumen	O
management	O
in	O
hearing	O
conservation	O
:	O
the	O
Dallas	O
(	O
Texas	O
)	O
Independent	O
School	O
District	O
program	O
.	O

Lactate	O
,	O
pyruvate	O
and	O
actual	O
pH	O
values	O
in	O
the	O
venous	O
blood	O
of	O
newborn	O
calves	O

This	O
article	O
focuses	O
on	O
a	O
general	O
approach	O
to	O
the	O
use	O
of	O
ARV	O
agents	O
.	O

Platelets	O
and	O
RBCs	O
from	O
each	O
animal	O
were	O
labeled	O
with	O
51Cr	O
and	O
99mTc	O
,	O
respectively	O
,	O
and	O
were	O
rapidly	O
injected	O
into	O
the	O
right	O
atrium	O
while	O
blood	O
was	O
sampled	O
from	O
the	O
ascending	O
aorta	O
.	O

The	O
comparisons	O
of	O
swimming	O
performance	O
before	O
and	O
after	O
treatments	O
with	O
deltamethrin	O
have	O
shown	O
a	O
significant	O
effect	O
on	O
locomotory	O
ability	O
of	O
rainbow	O
trout	O
which	O
at	O
the	O
end	O
of	O
strong	O
exposure	O
(	O
e	O
.	O
g	O
.	O

Protection	O
levels	O
of	O
33	O
.	O
3	O
%	O
,	O
36	O
.	O
6	O
%	O
and	O
37	O
.	O
0	O
%	O
were	O
achieved	O
in	O
groups	O
which	O
had	O
received	O
,	O
respectively	O
,	O
1000	O
20	O
-	O
krad	O
cercariae	O
,	O
1000	O
10	O
-	O
krad	O
cercariae	O
,	O
2000	O
40	O
-	O
krad	O
cercariae	O
and	O
2000	O
60	O
-	O
krad	O
cercariae	O
.	O

In	O
Types	O
I	O
and	O
II	O
,	O
capillary	O
walls	O
became	O
thinner	O
and	O
more	O
capillary	O
lumens	O
were	O
visiable	O
.	O

Thus	O
,	O
primate	O
vs	O
.	O
rodent	O
promoter	O
selectivity	O
mediated	O
by	O
the	O
TBP	B-GENE
-	O
TAFI	B-GENE
complex	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
cumulative	O
subtle	O
differences	O
between	O
individual	O
subunits	O
that	O
lead	O
to	O
species	O
-	O
specific	O
properties	O
of	O
RNA	B-GENE
polymerase	I-GENE
I	I-GENE
transcription	O
.	O

The	O
effects	O
of	O
pretreatment	O
with	O
the	O
non	O
-	O
competitive	O
NMDA	O
antagonist	O
(	O
+	O
)	O
MK	O
-	O
801	O
on	O
the	O
behavioral	O
alterations	O
induced	O
by	O
repeated	O
restraint	O
stress	O
were	O
investigated	O
.	O

When	O
gene	O
conversion	O
is	O
initiated	O
by	O
a	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
,	O
any	O
nonhomologous	O
DNA	O
that	O
may	O
be	O
present	O
at	O
the	O
ends	O
must	O
be	O
removed	O
before	O
new	O
DNA	O
synthesis	O
can	O
be	O
initiated	O
.	O

In	O
this	O
reconstituted	O
system	O
,	O
RNAP	B-GENE
IIA	I-GENE
,	O
but	O
not	O
RNAP	B-GENE
IIB	I-GENE
,	O
can	O
transcribe	O
from	O
the	O
DHFR	B-GENE
promoter	I-GENE
.	O

The	O
cDNA	O
clones	O
encode	O
a	O
polypeptide	O
of	O
657	O
amino	O
acids	O
with	O
a	O
bHLH	O
(	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
)	O
domain	O
,	O
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	O
factors	O
,	O
and	O
a	O
PAS	B-GENE
(	O
Per	B-GENE
-	O
Arnt	B-GENE
-	O
Sim	B-GENE
)	O
domain	O
in	O
the	O
amino	O
-	O
terminal	O
half	O
region	O
.	O

FTF	O
(	O
Joint	O
Council	O
of	O
Civil	O
Servants	O
and	O
Functionaries	O
)	O
:	O
clarification	O
about	O
membership	O
in	O
the	O
main	O
organizations	O

Lumbar	O
spine	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
by	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DXA	O
)	O
increased	O
by	O
0	O
.	O
6	O
%	O
,	O
3	O
.	O
6	O
%	O
and	O
8	O
.	O
1	O
%	O
after	O
48	O
weeks	O
in	O
groups	O
L	O
,	O
M	O
and	O
H	O
respectively	O
,	O
responses	O
in	O
groups	O
M	O
and	O
H	O
being	O
significantly	O
higher	O
than	O
in	O
L	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O

Synergy	O
between	O
interferon	B-GENE
-	I-GENE
gamma	I-GENE
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
in	O
transcriptional	O
activation	O
is	O
mediated	O
by	O
cooperation	O
between	O
signal	B-GENE
transducer	I-GENE
and	I-GENE
activator	I-GENE
of	I-GENE
transcription	I-GENE
1	I-GENE
and	O
nuclear	B-GENE
factor	I-GENE
kappaB	I-GENE
.	O

1H	O
and	O
15N	O
magnetic	O
resonance	O
assignments	O
,	O
secondary	O
structure	O
,	O
and	O
tertiary	O
fold	O
of	O
Escherichia	B-GENE
coli	I-GENE
DnaJ	I-GENE
(	I-GENE
1	I-GENE
-	I-GENE
78	I-GENE
)	I-GENE
.	O

A	O
cDNA	O
for	O
human	B-GENE
microfibril	I-GENE
-	I-GENE
associated	I-GENE
glycoprotein	I-GENE
-	I-GENE
2	I-GENE
(	O
MAGP	B-GENE
-	I-GENE
2	I-GENE
)	O
was	O
used	O
to	O
screen	O
a	O
human	O
leukocyte	O
genomic	O
DNA	O
library	O
in	O
EMBL	O
-	O
3	O
vector	O
.	O

Furthermore	O
,	O
ERK	B-GENE
phosphorylation	O
was	O
substantially	O
prolonged	O
in	O
LC	O
/	O
BRY	O
-	O
treated	O
cells	O
compared	O
to	O
those	O
exposed	O
to	O
BRY	O
alone	O
,	O
and	O
pretreatment	O
with	O
the	O
highly	O
specific	O
MEK	B-GENE
inhibitors	O
,	O
PD98059	O
,	O
U0126	O
,	O
and	O
SL327	O
,	O
opposed	O
ERK	B-GENE
activation	O
while	O
protecting	O
cells	O
from	O
LC	O
/	O
BRY	O
-	O
induced	O
lethality	O
.	O

The	O
cholesterol	B-GENE
7alpha	I-GENE
-	I-GENE
hydroxylase	I-GENE
gene	I-GENE
(	O
CYP7A	B-GENE
)	O
is	O
transcriptionally	O
regulated	O
by	O
a	O
number	O
of	O
factors	O
,	O
including	O
hormones	O
,	O
bile	O
acids	O
,	O
and	O
diurnal	O
rhythm	O
.	O

CNS	O
preventive	O
treatment	O
without	O
cranial	O
irradiation	O
was	O
effective	O
in	O
all	O
the	O
groups	O
of	O
ALL	O
patients	O
.	O

Additionally	O
,	O
the	O
members	O
of	O
this	O
family	O
display	O
strong	O
sequence	O
homologies	O
between	O
their	O
larger	O
C	O
-	O
terminal	O
effector	O
binding	O
/	O
oligomerization	O
domains	O
.	O

Aspartame	O
is	O
a	O
synthetic	O
sweetener	O
commonly	O
used	O
in	O
soft	O
drinks	O
and	O
many	O
foods	O
.	O

The	O
rat	O
anococcygeus	O
muscle	O
was	O
used	O
in	O
postsynaptic	O
studies	O
.	O

The	O
purpose	O
of	O
this	O
presentation	O
is	O
to	O
review	O
the	O
current	O
state	O
of	O
knowledge	O
regarding	O
5	O
,	O
8	O
,	O
11	O
,	O
14	O
-	O
eicosatetraynoic	O
acid	O
(	O
ETYA	O
,	O
Ro	O
3	O
-	O
1428	O
)	O
and	O
its	O
effects	O
on	O
lipid	O
metabolism	O
.	O

A	O
Meis1	B-GENE
cDNA	I-GENE
clone	O
that	O
encoded	O
a	O
novel	O
member	O
of	O
the	O
homeobox	B-GENE
gene	I-GENE
family	I-GENE
was	O
identified	O
.	O

The	O
S	B-GENE
.	I-GENE
typhimurium	I-GENE
aspartyl	I-GENE
/	I-GENE
asparaginyl	I-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
homologue	I-GENE
(	O
designated	O
lpxO	B-GENE
)	O
was	O
cloned	O
into	O
pBluescriptSK	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
K	O
-	O
12	O
,	O
which	O
does	O
not	O
contain	O
lpxO	B-GENE
.	O

The	O
levels	O
of	O
soluble	O
L	B-GENE
-	I-GENE
selectin	I-GENE
and	O
ICAM	B-GENE
-	I-GENE
1	I-GENE
in	O
the	O
serum	O
were	O
determined	O
by	O
the	O
ELISA	O
method	O
.	O

The	O
highest	O
TTX	B-GENE
content	O
is	O
10	O
.	O
0	O
microg	O
/	O
g	O
in	O
N	O
.	O
livescens	O
.	O

On	O
the	O
other	O
hand	O
hypokalemia	O
,	O
induced	O
by	O
diuretics	O
,	O
may	O
also	O
be	O
accompanied	O
by	O
a	O
significant	O
depletion	O
of	O
total	O
body	O
K	O
,	O
bringing	O
about	O
more	O
general	O
consequences	O
.	O

Glutathione	B-GENE
reductase	I-GENE
activities	O
in	O
liver	O
,	O
kidney	O
,	O
lung	O
,	O
and	O
brain	O
were	O
not	O
affected	O
by	O
diet	O
.	O

Here	O
,	O
we	O
describe	O
the	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
and	O
genomic	O
organization	O
of	O
ipiB	B-GENE
and	O
ipiO	B-GENE
.	O

Vancomycin	O
and	O
tetracycline	O
eliminated	O
toxin	O
in	O
stools	O
and	O
delayed	O
death	O
.	O

Soluble	O
fibrin	B-GENE
monomer	O
complexes	O
in	O
thromboembolism	O

Comparison	O
to	O
the	O
murine	O
homologues	O
of	O
these	O
molecules	O
reveals	O
a	O
high	O
degree	O
of	O
conservation	O
between	O
the	O
products	O
of	O
one	O
of	O
these	O
genes	O
,	O
Fc	B-GENE
gamma	I-GENE
RIIb	I-GENE
,	O
and	O
the	O
murine	B-GENE
beta	I-GENE
gene	I-GENE
in	O
primary	O
sequence	O
,	O
splicing	O
pattern	O
,	O
and	O
tissue	O
distribution	O
.	O

Acidosis	O
provoked	O
by	O
30	O
%	O
CO2	O
irreversibly	O
increased	O
the	O
BDRT	O
,	O
however	O
the	O
TRT	O
were	O
not	O
changed	O
.	O

Others	O
as	O
for	O
example	O
C	O
-	O
11	O
labeled	O
short	O
chain	O
fatty	O
acids	O
are	O
on	O
the	O
horizon	O
.	O

The	O
average	O
progression	O
was	O
11	O
.	O
6	O
(	O
SD	O
9	O
.	O
0	O
)	O
.	O

80	O
bp	O
)	O
surrounding	O
the	O
site	O
of	O
transcription	O
initiation	O
.	O

Ultrastructure	O
and	O
toxin	O
formation	O
of	O
Cor	O
.	O
diphtheriae	O
PW	O
-	O
8	O
cultured	O
in	O
the	O
presence	O
of	O
penicillin	O

EMT	B-GENE
was	O
localized	O
to	O
chromosome	O
5q31	O
-	O
32	O
,	O
a	O
region	O
that	O
contains	O
the	O
genes	O
for	O
several	O
growth	O
factors	O
and	O
receptors	O
as	O
well	O
as	O
early	O
activation	O
genes	O
,	O
particularly	O
those	O
involved	O
in	O
the	O
hematopoietic	O
system	O
.	O

Tbx6	B-GENE
maps	O
to	O
chromosome	O
7	O
and	O
does	O
not	O
appear	O
to	O
be	O
linked	O
to	O
any	O
known	O
mutation	O
.	O

Kaposi	O
'	O
s	O
eruptive	O
disease	O
.	O

It	O
is	O
not	O
tested	O
yet	O
,	O
whether	O
the	O
extent	O
of	O
glaucoma	O
damage	O
should	O
be	O
better	O
quantified	O
using	O
reference	O
plane	O
1	O
or	O
2	O
.	O

Importin	B-GENE
beta	I-GENE
mediates	O
nuclear	O
translocation	O
of	O
Smad	B-GENE
3	I-GENE
.	O

The	O
encoded	O
protein	O
contains	O
an	O
amino	O
terminal	O
PDZ	B-GENE
domain	O
,	O
followed	O
by	O
a	O
predicted	O
coiled	O
-	O
coil	O
region	O
,	O
a	O
PEST	O
domain	O
,	O
and	O
a	O
carboxy	O
-	O
terminal	O
SAM	O
domain	O
.	O

Using	O
lasers	O
,	O
PRK	O
involves	O
reshaping	O
the	O
cornea	O
so	O
that	O
its	O
refractive	O
power	O
is	O
increased	O
.	O

However	O
,	O
sphincter	O
length	O
decreased	O
with	O
age	O
from	O
24	O
.	O
3	O
to	O
14	O
.	O
8	O
mm	O
.	O
,	O
maximal	O
urethral	O
pressure	O
from	O
88	O
.	O
7	O
to	O
55	O
cm	O
.	O
water	O
and	O
maximal	O
urethral	O
pressure	O
during	O
voluntary	O
contraction	O
from	O
221	O
.	O
4	O
to	O
166	O
.	O
3	O
cm	O
.	O
water	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
the	O
corticotropin	B-GENE
-	I-GENE
releasing	I-GENE
factor	I-GENE
test	O
(	O
CRF	B-GENE
)	O
is	O
useful	O
for	O
the	O
aetiological	O
diagnosis	O
of	O
Cushing	O
'	O
s	O
syndrome	O
:	O
in	O
Cushing	O
'	O
s	O
disease	O
,	O
as	O
opposed	O
to	O
ectopic	O
ACTH	B-GENE
secretion	O
syndrome	O
,	O
the	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
can	O
still	O
be	O
stimulated	O
by	O
CRF	B-GENE
.	O

Transcription	O
initiation	O
from	O
this	O
region	O
was	O
also	O
detected	O
in	O
vivo	O
,	O
when	O
the	O
cloned	O
rRNA	O
gene	O
cluster	O
was	O
present	O
on	O
a	O
multi	O
-	O
copy	O
plasmid	O
.	O

The	O
results	O
of	O
the	O
transient	O
-	O
transfection	O
assay	O
showed	O
that	O
the	O
Sp1	B-GENE
binding	I-GENE
element	I-GENE
located	O
in	O
the	O
core	O
region	O
(	O
positions	O
-	O
-	O
64	O
to	O
+	O
1	O
)	O
of	O
the	O
alpha2	B-GENE
-	I-GENE
integrin	I-GENE
promoter	I-GENE
plays	O
an	O
essential	O
role	O
in	O
the	O
alpha2	B-GENE
-	I-GENE
integrin	I-GENE
promoter	I-GENE
activity	O
and	O
its	O
downregulation	O
by	O
Erb	B-GENE
-	O
B2	B-GENE
.	O

Principal	O
component	O
analysis	O
using	O
psychosocial	O
factors	O
in	O
women	O
showed	O
two	O
psychosocial	O
structures	O
,	O
i	O
.	O
e	O
.	O
the	O
second	O
principal	O
(	O
high	O
SOC	O
,	O
high	O
lifestyle	O
,	O
and	O
low	O
stress	O
)	O
and	O
the	O
4th	O
principal	O
components	O
(	O
high	O
supernatural	O
HLC	O
,	O
and	O
high	O
PHLC	O
)	O
.	O

Expression	O
of	O
FNCAT	B-GENE
increased	O
on	O
serum	O
treatment	O
indicating	O
that	O
the	O
region	O
of	O
the	O
FN	B-GENE
gene	I-GENE
between	O
positions	O
+	O
69	O
and	O
-	O
510	O
bp	O
mediated	O
serum	O
responsiveness	O
.	O

Interaction	O
of	O
the	O
v	B-GENE
-	I-GENE
rel	I-GENE
protein	I-GENE
with	O
an	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
DNA	I-GENE
binding	I-GENE
site	I-GENE
.	O

This	O
increase	O
is	O
not	O
the	O
result	O
of	O
alterations	O
in	O
the	O
deposition	O
of	O
inhaled	O
particles	O
of	O
capsaicin	O
brought	O
about	O
by	O
volume	O
restriction	O
.	O

Providing	O
appropriate	O
care	O
to	O
both	O
sexes	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
developed	O
a	O
system	O
of	O
transient	O
transfection	O
of	O
rat	O
adipocytes	O
with	O
constructs	O
containing	O
glyceraldehyde	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
GAPDH	B-GENE
)	O
and	O
fatty	B-GENE
acid	I-GENE
synthetase	I-GENE
(	O
FAS	B-GENE
)	O
promoters	O
fused	O
to	O
gene	B-GENE
reporter	I-GENE
CAT	I-GENE
.	O

In	O
the	O
green	O
unicellular	O
alga	O
Chlamydomonas	O
eugametos	O
,	O
cellular	O
division	O
is	O
readily	O
synchronized	O
by	O
light	O
/	O
dark	O
cycles	O
.	O

SHBG	B-GENE
concentrations	O
in	O
women	O
were	O
also	O
significantly	O
higher	O
at	O
T	O
-	O
2	O
and	O
T	O
-	O
3	O
when	O
compared	O
to	O
T	O
-	O
1	O
values	O
.	O

Simvastatin	O
decreased	O
levels	O
of	O
total	O
cholesterol	O
by	O
20	O
.	O
8	O
%	O
,	O
LDL	B-GENE
cholesterol	I-GENE
by	O
29	O
.	O
7	O
%	O
,	O
triglycerides	O
by	O
13	O
.	O
6	O
%	O
,	O
apolipoprotein	B-GENE
B	I-GENE
by	O
22	O
.	O
4	O
%	O
,	O
alpha	O
-	O
tocopherol	O
by	O
16	O
.	O
2	O
%	O
,	O
beta	O
-	O
carotene	O
by	O
19	O
.	O
5	O
%	O
,	O
and	O
ubiquinol	O
-	O
10	O
by	O
22	O
.	O
0	O
%	O
(	O
P	O
<	O
.	O
001	O
for	O
all	O
)	O
and	O
increased	O
levels	O
of	O
HDL	B-GENE
cholesterol	I-GENE
by	O
7	O
.	O
0	O
%	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
serum	B-GENE
insulin	I-GENE
by	O
13	O
.	O
2	O
%	O
(	O
P	O
=	O
.	O
005	O
)	O
.	O

The	O
more	O
severe	O
the	O
CRF	O
,	O
the	O
more	O
likely	O
that	O
total	O
HDL	B-GENE
and	O
HDL2	B-GENE
cholesterol	I-GENE
will	O
be	O
low	O
.	O

They	O
are	O
growth	O
-	O
inhibited	O
by	O
TGF	B-GENE
-	I-GENE
beta1	I-GENE
.	O

To	O
investigate	O
the	O
in	O
vivo	O
role	O
of	O
this	O
chimeric	B-GENE
bZIP	I-GENE
protein	I-GENE
in	O
oncogenic	O
transformation	O
,	O
its	O
expression	O
was	O
directed	O
to	O
the	O
lymphoid	O
compartments	O
of	O
transgenic	O
mice	O
.	O

This	O
is	O
consistent	O
with	O
the	O
need	O
for	O
a	O
nuclear	O
retinoid	B-GENE
receptor	I-GENE
function	O
in	O
RA	O
-	O
induced	O
ERK2	B-GENE
activation	O
.	O

In	O
the	O
virus	O
-	O
infected	O
cells	O
,	O
translation	O
of	O
the	O
M1	B-GENE
protein	I-GENE
was	O
reduced	O
to	O
10	O
to	O
20	O
%	O
of	O
that	O
of	O
the	O
wild	O
-	O
type	O
virus	O
;	O
however	O
,	O
the	O
translation	O
of	O
neither	O
the	O
nucleoprotein	O
nor	O
NS1	B-GENE
was	O
significantly	O
interfered	O
with	O
,	O
indicating	O
the	O
important	O
role	O
of	O
NS1	B-GENE
in	O
translational	O
stimulation	O
of	O
the	O
M1	B-GENE
protein	I-GENE
.	O

Some	O
cells	O
were	O
excited	O
,	O
others	O
inhibited	O
by	O
,	O
and	O
only	O
some	O
were	O
directionally	O
sensitive	O
to	O
the	O
optomotor	O
stimulus	O
.	O

LT	B-GENE
-	I-GENE
beta	I-GENE
transcription	O
is	O
maximal	O
in	O
the	O
thymic	O
medulla	O
and	O
in	O
splenic	O
white	O
pulp	O
.	O

A	O
novel	O
Cdc42Hs	B-GENE
mutant	I-GENE
induces	O
cellular	O
transformation	O
.	O

Interactions	O
were	O
also	O
detected	O
between	O
full	O
-	O
length	O
HSF1	B-GENE
and	O
the	O
small	O
subunit	O
(	O
gamma	O
)	O
of	O
TFIIA	B-GENE
.	O

We	O
report	O
that	O
Nim1	B-GENE
possesses	O
intrinsic	O
serine	B-GENE
-	I-GENE
kinase	I-GENE
,	O
threonine	B-GENE
-	I-GENE
kinase	I-GENE
and	O
tyrosine	B-GENE
-	I-GENE
kinase	I-GENE
activities	O
.	O

A	O
short	O
conserved	O
motif	O
is	O
required	O
for	O
repressor	O
domain	O
function	O
in	O
the	O
myeloid	O
-	O
specific	O
transcription	O
factor	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
epsilon	I-GENE
.	O

Androgen	O
ablation	O
-	O
-	O
50	O
years	O
later	O
.	O

In	O
conclusion	O
,	O
ORCA3	B-GENE
regulates	O
jasmonate	O
-	O
responsive	O
expression	O
of	O
the	O
Str	B-GENE
gene	I-GENE
via	O
direct	O
interaction	O
with	O
the	O
JERE	O
.	O

Also	O
,	O
the	O
absence	O
of	O
PdNi	O
between	O
the	O
segments	O
reduces	O
the	O
heat	O
production	O
of	O
the	O
seed	O
.	O

Theoretical	O
mechanisms	O
of	O
hyperuricemia	O
.	O

ORF3	O
encodes	O
a	O
putative	O
periplasmic	B-GENE
c	I-GENE
-	I-GENE
type	I-GENE
cytochrome	I-GENE
with	O
a	O
molecular	O
mass	O
of	O
94	O
,	O
000	O
Da	O
and	O
contains	O
seven	O
c	O
-	O
heme	O
-	O
binding	O
motifs	O
but	O
shows	O
no	O
sequence	O
homology	O
to	O
occ	B-GENE
or	O
ORF1	O
.	O

Doxazosin	O
produced	O
increases	O
in	O
both	O
mean	O
and	O
maximum	O
urinary	O
flow	O
rates	O
of	O
1	O
.	O
01	O
ml	O
/	O
s	O
and	O
3	O
.	O
2	O
ml	O
/	O
s	O
respectively	O
,	O
compared	O
with	O
0	O
.	O
21	O
ml	O
/	O
s	O
and	O
2	O
.	O
2	O
ml	O
/	O
s	O
on	O
placebo	O
.	O

Hypoxia	O
decreased	O
the	O
rate	O
of	O
spontaneous	O
impulse	O
initiation	O
in	O
SA	O
nodal	O
fibers	O
by	O
decreasing	O
the	O
slope	O
of	O
diastolic	O
depolarization	O
.	O

BACKGROUND	O
-	O
-	O
Platelet	B-GENE
activating	I-GENE
factor	I-GENE
(	O
PAF	B-GENE
)	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
airway	O
hyperresponsiveness	O
in	O
asthma	O
.	O

TFEC	B-GENE
RNA	I-GENE
is	O
found	O
in	O
many	O
tissues	O
of	O
adult	O
rats	O
,	O
but	O
the	O
relative	O
concentrations	O
of	O
TFEC	B-GENE
and	O
TFE3	B-GENE
RNAs	I-GENE
vary	O
considerably	O
in	O
these	O
different	O
tissues	O
.	O

Our	O
results	O
show	O
that	O
unlike	O
the	O
case	O
for	O
sos1	B-GENE
,	O
sos2	B-GENE
gene	I-GENE
function	O
is	O
dispensable	O
for	O
normal	O
mouse	O
development	O
,	O
growth	O
,	O
and	O
fertility	O
.	O

Studies	O
of	O
HS2	B-GENE
-	I-GENE
gamma	I-GENE
gene	I-GENE
reporter	I-GENE
constructs	I-GENE
carrying	O
CACCC	O
box	O
deletions	O
revealed	O
that	O
the	O
CACCC	O
box	O
sequence	O
of	O
the	O
gamma	O
gene	O
promoter	O
mediates	O
the	O
activation	O
of	O
the	O
gamma	O
gene	O
by	O
FKLF	B-GENE
.	O

Advisory	O
Committee	O
report	O
recommends	O
that	O
US	O
make	O
amends	O
for	O
human	O
radiation	O
experiments	O
.	O

Animals	O
were	O
divided	O
into	O
six	O
equal	O
groups	O
as	O
follows	O
:	O
(	O
1	O
)	O
no	O
oral	O
drug	O
(	O
water	O
)	O
,	O
no	O
hemodilution	O
,	O
no	O
IV	O
drug	O
(	O
saline	O
)	O
;	O
(	O
2	O
)	O
oral	O
water	O
,	O
hemodilution	O
,	O
IV	O
saline	O
;	O
(	O
3	O
)	O
oral	O
water	O
,	O
no	O
hemodilution	O
,	O
IV	O
propranolol	O
;	O
(	O
4	O
)	O
oral	O
water	O
,	O
hemodilution	O
,	O
IV	O
propranolol	O
;	O
(	O
5	O
)	O
oral	O
propranolol	O
,	O
no	O
hemodilution	O
,	O
IV	O
saline	O
;	O
and	O
(	O
6	O
)	O
oral	O
propranolol	O
,	O
hemodilution	O
,	O
IV	O
saline	O
.	O

First	O
,	O
a	O
GATA	B-GENE
-	I-GENE
1	I-GENE
motif	I-GENE
was	O
found	O
to	O
bind	O
nuclear	O
factor	O
(	O
s	O
)	O
,	O
presumably	O
the	O
GATA	B-GENE
-	I-GENE
1	I-GENE
factor	I-GENE
,	O
present	O
in	O
K	O
-	O
562	O
cell	O
extracts	O
and	O
in	O
living	O
K	O
-	O
562	O
cells	O
.	O

BPN	O
can	O
be	O
experimentally	O
produced	O
by	O
intratracheal	O
inoculation	O
of	O
microorganisms	O
in	O
high	O
concentrations	O
and	O
ventilator	O
-	O
associated	O
BPN	O
by	O
ventilating	O
baboons	O
with	O
oleic	O
-	O
acid	O
lung	O
injury	O
.	O

A	O
mouth	O
asymmetry	O
study	O
.	O

Additionally	O
,	O
these	O
findings	O
have	O
important	O
implications	O
for	O
the	O
understanding	O
of	O
the	O
mechanisms	O
of	O
HIV	O
-	O
1	O
latency	O
and	O
reactivation	O
.	O

This	O
inhibition	O
was	O
due	O
to	O
competition	O
from	O
the	O
EMC	O
virus	O
IRES	O
present	O
in	O
pEP	B-GENE
-	I-GENE
2A	I-GENE
transcripts	I-GENE
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
proteolytically	O
active	O
2Apro	B-GENE
.	O

Some	O
may	O
affect	O
the	O
folding	O
pathway	O
or	O
the	O
affinity	O
for	O
chaperonins	B-GENE
.	O

Diet	O
imbalances	O
and	O
aflatoxicosis	O

48	O
.	O
35	O
+	O
/	O
-	O
5	O
.	O
07	O
mg	O
/	O
l	O
in	O
R3	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
in	O
the	O
AUC	O
(	O
0	O
.	O
50	O
h	O
)	O
(	O
1429	O
.	O
92	O
+	O
/	O
-	O
284	O
.	O
23	O
in	O
PR	O
vs	O
.	O

The	O
effect	O
on	O
FIV	B-GENE
LTR	I-GENE
promoter	I-GENE
activity	O
of	O
progressively	O
deleting	O
these	O
nuclear	O
factor	O
binding	O
sites	O
was	O
examined	O
by	O
linking	O
LTR	O
deletion	O
mutants	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
.	O

A	O
series	O
of	O
sequence	O
fragments	O
were	O
placed	O
5	O
'	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
gene	O
and	O
ability	O
to	O
mediate	O
transcription	O
of	O
CAT	B-GENE
in	O
response	O
to	O
IFN	B-GENE
gamma	I-GENE
or	O
LPS	O
treatment	O
was	O
studied	O
following	O
transient	O
transfection	O
in	O
the	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
.	O

As	O
part	O
of	O
a	O
large	O
Dutch	O
prospective	O
multicenter	O
study	O
(	O
Netherlands	O
Cooperative	O
Study	O
on	O
the	O
Adequacy	O
of	O
Dialysis	O
-	O
2	O
)	O
,	O
we	O
consecutively	O
included	O
all	O
new	O
patients	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
for	O
whom	O
residual	O
renal	O
function	O
could	O
be	O
obtained	O
0	O
to	O
4	O
weeks	O
before	O
the	O
start	O
of	O
dialysis	O
therapy	O
.	O

Module	O
2	O
of	O
RifA	B-GENE
lacks	O
a	O
beta	B-GENE
-	I-GENE
ketoacyl	I-GENE
:	I-GENE
acyl	I-GENE
carrier	I-GENE
protein	I-GENE
reductase	I-GENE
(	O
KR	B-GENE
)	O
domain	O
and	O
the	O
one	O
in	O
module	O
3	O
has	O
an	O
apparently	O
inactive	O
NADPH	B-GENE
binding	I-GENE
motif	I-GENE
,	O
similar	O
to	O
one	O
found	O
in	O
the	O
Er	B-GENE
PKS	I-GENE
,	O
while	O
the	O
other	O
eight	O
KR	B-GENE
domains	I-GENE
of	O
the	O
Rf	B-GENE
PKS	I-GENE
should	O
be	O
functional	O
.	O

In	O
murine	O
cells	O
,	O
FPGS	B-GENE
expression	O
is	O
controlled	O
by	O
two	O
promoters	O
that	O
,	O
as	O
we	O
show	O
here	O
,	O
vary	O
substantially	O
in	O
their	O
efficiency	O
,	O
at	O
least	O
in	O
the	O
context	O
of	O
a	O
reporter	O
gene	O
assay	O
.	O

Should	O
we	O
use	O
thiazide	O
diuretics	O
in	O
hypertensive	O
patients	O
with	O
non	O
-	O
insulin	B-GENE
-	O
dependent	O
diabetes	O
mellitus	O
?	O

Reduced	O
glutathione	O
in	O
whole	O
blood	O
decreases	O
within	O
a	O
blood	O
Se	O
range	O
of	O
1	O
.	O
01	O
to	O
2	O
.	O
28	O
micrograms	O
in	O
the	O
high	O
Se	O
area	O
.	O

Sucrose	O
produced	O
in	O
source	O
leaves	O
is	O
the	O
predominant	O
carbon	O
source	O
for	O
developing	O
sink	O
tissues	O
in	O
most	O
higher	O
plants	O
.	O

A	O
personal	O
view	O
of	O
future	O
trends	O
in	O
the	O
field	O
of	O
immunoassay	O
concludes	O
this	O
review	O
.	O

In	O
accordance	O
with	O
Ann	O
Arbor	O
classification	O
,	O
we	O
observed	O
12	O
CS	O
IA	O
(	O
21	O
.	O
3	O
%	O
)	O
,	O
2	O
CS	O
IB	O
(	O
3	O
.	O
5	O
%	O
)	O
,	O
14	O
CS	O
IIA	O
(	O
25	O
.	O
4	O
%	O
)	O
and	O
27	O
CS	O
IIB	O
(	O
49	O
.	O
7	O
%	O
)	O
.	O

Numerous	O
genes	O
of	O
this	O
family	O
have	O
been	O
identified	O
in	O
animals	O
,	O
with	O
the	O
largest	O
number	O
found	O
in	O
vertebrates	O
.	O

The	O
GST	B-GENE
-	O
CBL	B-GENE
-	O
LZIP	B-GENE
fusion	O
protein	O
contains	O
a	O
binding	O
site	O
for	O
the	O
SH2	B-GENE
domain	I-GENE
of	O
the	O
p85	B-GENE
subunit	I-GENE
of	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
,	O
which	O
mapped	O
to	O
Tyr731	O
,	O
which	O
is	O
present	O
in	O
the	O
sequence	O
YEAM	O
.	O

We	O
have	O
previously	O
shown	O
that	O
UNC	B-GENE
-	I-GENE
4	I-GENE
expression	O
in	O
the	O
VA	O
motor	O
neurons	O
specifies	O
the	O
wild	O
-	O
type	O
pattern	O
of	O
presynaptic	O
input	O
.	O

Significant	O
differences	O
were	O
observed	O
in	O
the	O
composition	O
of	O
nuclear	O
transcription	O
factors	O
bound	O
to	O
cis	O
-	O
elements	O
within	O
the	O
LDH	B-GENE
/	I-GENE
C	I-GENE
proximal	I-GENE
promoter	I-GENE
region	I-GENE
in	O
somatic	O
versus	O
germ	O
cells	O
.	O

Above	O
this	O
transition	O
temperature	O
the	O
calcium	O
antagonist	O
lowers	O
fm	O
more	O
pronouncedly	O
than	O
below	O
.	O

(	O
1986	O
)	O
described	O
optic	O
nerve	O
degenerations	O
in	O
patients	O
with	O
Alzheimer	O
'	O
s	O
disease	O
and	O
Sadun	O
published	O
a	O
dropout	O
of	O
retinal	O
ganglion	O
cells	O
that	O
range	O
from	O
30	O
%	O
to	O
60	O
%	O
.	O

It	O
has	O
become	O
clear	O
that	O
there	O
is	O
not	O
one	O
mediator	O
responsible	O
for	O
ALI	O
,	O
but	O
rather	O
a	O
complex	O
interplay	O
exists	O
between	O
diverse	O
proinflammatory	O
(	O
e	O
.	O
g	O
.	O
,	O
lipopolysaccharide	O
,	O
complement	O
products	O
,	O
cytocains	O
,	O
chemocains	O
,	O
reactive	O
oxygen	O
species	O
and	O
arachidonic	O
acid	O
products	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
IL	B-GENE
-	I-GENE
10	I-GENE
,	O
IL	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
RA	I-GENE
,	O
PGI2	O
)	O
mediators	O
.	O

We	O
then	O
supplemented	O
these	O
spliceosomes	O
with	O
purified	O
proteins	O
or	O
yeast	O
extract	O
fractions	O
as	O
a	O
functional	O
assay	O
for	O
second	O
-	O
step	O
splicing	O
factors	O
.	O

Contrast	O
radiography	O
appears	O
to	O
be	O
an	O
especially	O
inaccurate	O
method	O
to	O
document	O
PUD	O
in	O
CF	O
because	O
the	O
duodenal	O
mucosa	O
typically	O
appears	O
nodular	O
and	O
distorted	O
with	O
poor	O
definition	O
of	O
the	O
mucosal	O
folds	O
.	O

We	O
now	O
show	O
that	O
the	O
FRAP	B-GENE
Ser2035	O
-	O
-	O
>	O
Ala	O
mutant	O
displays	O
similar	O
binding	O
affinity	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
protein	O
,	O
whereas	O
all	O
other	O
mutations	O
at	O
this	O
site	O
,	O
including	O
mimics	O
of	O
phosphoserine	O
,	O
abolish	O
binding	O
,	O
presumably	O
due	O
to	O
either	O
unfavorable	O
steric	O
interactions	O
or	O
induced	O
conformational	O
changes	O
.	O

A	O
Brassica	O
cDNA	O
clone	O
encoding	O
a	O
bifunctional	O
hydroxymethylpyrimidine	B-GENE
kinase	I-GENE
/	O
thiamin	B-GENE
-	I-GENE
phosphate	I-GENE
pyrophosphorylase	I-GENE
involved	O
in	O
thiamin	O
biosynthesis	O
.	O

Titres	O
of	O
antistreptolysin	B-GENE
O	I-GENE
in	O
mothers	O
of	O
children	O
affected	O
with	O
Down	O
'	O
s	O
syndrome	O
.	O

Differential	O
decay	O
of	O
a	O
polycistronic	O
Escherichia	O
coli	O
transcript	O
is	O
initiated	O
by	O
RNaseE	B-GENE
-	O
dependent	O
endonucleolytic	O
processing	O
.	O

Defects	O
in	O
RT6	B-GENE
expression	O
coincide	O
with	O
increased	O
susceptibility	O
in	O
animal	O
models	O
for	O
insulin	B-GENE
-	O
dependent	O
diabetes	O
mellitus	O
and	O
other	O
autoimmune	O
diseases	O
.	O

By	O
means	O
of	O
early	O
detection	O
and	O
correction	O
of	O
the	O
possible	O
causes	O
,	O
the	O
goal	O
of	O
increasing	O
therapeutic	O
efficacy	O
can	O
be	O
achieved	O
.	O

We	O
have	O
previously	O
described	O
the	O
partial	O
purification	O
of	O
Ap4A	B-GENE
hydrolase	I-GENE
from	O
S	O
.	O
pombe	O
[	O
Robinson	O
,	O
de	O
la	O
Pena	O
and	O
Barnes	O
(	O
1993	O
)	O
Biochim	O
.	O

Effect	O
of	O
a	O
new	O
positive	O
inotropic	O
agent	O
(	O
OPC	O
-	O
8212	O
)	O
on	O
intracellular	O
potential	O
of	O
isolated	O
canine	O
ventricular	O
papillary	O
muscle	O

The	O
unc	B-GENE
-	I-GENE
101	I-GENE
,	O
sli	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
rok	B-GENE
-	I-GENE
1	I-GENE
genes	I-GENE
encode	O
a	O
distinct	O
set	O
of	O
negative	O
regulators	O
of	O
vulval	O
differentiation	O
.	O

Thirty	O
-	O
seven	O
patients	O
with	O
severe	O
temporal	O
lobe	O
epilepsy	O
were	O
studied	O
interictally	O
with	O
[	O
18F	O
]	O
fluorodeoxyglucose	O
-	O
PET	O
in	O
each	O
of	O
three	O
conditions	O
:	O
resting	O
,	O
during	O
emotional	O
speech	O
,	O
and	O
while	O
performing	O
a	O
visual	O
recognition	O
task	O
.	O

SYC1	B-GENE
(	O
suppressor	B-GENE
of	I-GENE
yeast	I-GENE
cbf5	I-GENE
-	I-GENE
1	I-GENE
)	O
was	O
identified	O
as	O
a	O
multicopy	O
suppressor	O
of	O
cbf5	B-GENE
-	I-GENE
1	I-GENE
and	O
subsequently	O
was	O
found	O
to	O
be	O
identical	O
to	O
RRN3	B-GENE
,	O
an	O
RNA	B-GENE
polymerase	I-GENE
I	I-GENE
transcription	I-GENE
factor	I-GENE
.	O

Newly	O
hatched	O
F1	O
nymphs	O
of	O
Aiolopus	O
thalassinus	O
(	O
Fabr	O
.	O
)	O
were	O
fed	O
on	O
food	O
treated	O
with	O
various	O
concentrations	O
of	O
HgCl2	O
,	O
CdCl2	O
,	O
and	O
PbCl2	O
until	O
the	O
end	O
of	O
adult	O
life	O
.	O

Neuronal	O
activity	O
of	O
58	O
dopaminergic	O
(	O
DA	O
)	O
and	O
200	O
non	O
-	O
dopaminergic	O
(	O
non	O
-	O
DA	O
)	O
neurons	O
in	O
the	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
of	O
female	O
monkeys	O
was	O
recorded	O
,	O
and	O
correlation	O
to	O
bar	O
press	O
feeding	O
,	O
sensory	O
stimulation	O
and	O
change	O
in	O
motivation	O
was	O
investigated	O
.	O

Both	O
sequence	O
analysis	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
revealed	O
a	O
high	O
degree	O
of	O
sequence	O
(	O
97	O
%	O
homology	O
)	O
and	O
structural	O
similarity	O
among	O
members	O
of	O
the	O
ART	B-GENE
-	O
CH	B-GENE
family	O
,	O
indicating	O
their	O
common	O
origin	O
and	O
recent	O
penetration	O
into	O
chicken	O
DNA	O
.	O

Three	O
of	O
these	O
positions	O
are	O
novel	O
in	O
that	O
they	O
had	O
not	O
been	O
identified	O
to	O
be	O
important	O
for	O
binding	O
PC	O
by	O
previous	O
crystallographic	O
analysis	O
.	O

We	O
demonstrate	O
inhibition	O
of	O
2	O
-	O
deoxyglucose	O
uptake	O
in	O
isolated	O
primary	O
rat	O
adipocytes	O
and	O
3T3	O
-	O
L1	O
adipocytes	O
pretreated	O
with	O
U73122	O
.	O

The	O
elevated	O
levels	O
of	O
inositol	O
phosphates	O
resulting	O
from	O
N	B-GENE
(	I-GENE
epi	I-GENE
)	I-GENE
alpha	I-GENE
qQ209L	I-GENE
expression	O
were	O
similar	O
to	O
those	O
obtained	O
with	O
carbachol	O
activation	O
of	O
the	O
M1	B-GENE
muscarinic	I-GENE
acetylcholine	I-GENE
receptor	I-GENE
.	O

In	O
addition	O
,	O
wild	O
-	O
type	O
and	O
mutated	O
DNA	O
templates	O
were	O
used	O
as	O
probes	O
in	O
DNase	B-GENE
I	I-GENE
protection	O
experiments	O
to	O
determine	O
sites	O
of	O
protein	O
-	O
DNA	O
interaction	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
PEH	O
is	O
associated	O
with	O
reductions	O
in	O
TPR	O
and	O
sympathetic	O
nerve	O
activity	O
(	O
SNA	O
)	O
.	O

Salt	O
wars	O
.	O

RESULTS	O
:	O
BMK	B-GENE
-	I-GENE
1	I-GENE
and	O
other	O
19	O
contents	O
significantly	O
decreased	O
depolarization	O
parameters	O
Vmax	O
,	O
APA	O
,	O
OS	O
,	O
and	O
MDP	O
,	O
which	O
was	O
similar	O
to	O
that	O
of	O
TTX	B-GENE
and	O
different	O
from	O
that	O
of	O
Nim	O
and	O
BaCl2	O
.	O

In	O
the	O
latter	O
,	O
the	O
cells	O
and	O
adjacent	O
matrix	O
had	O
several	O
characteristics	O
of	O
fibrocartilage	O
,	O
including	O
chondrocytes	O
.	O

Mannich	O
bases	O
of	O
vanillin	O
oxime	O
.	O

All	O
exon	O
/	O
intron	O
splice	O
junctions	O
follow	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
glucose	O
repression	O
of	O
PRB1	B-GENE
transcription	O
is	O
not	O
mediated	O
by	O
HXK2	B-GENE
or	O
by	O
the	O
SNF1	B-GENE
,	O
SNF4	B-GENE
,	O
and	O
SNF6	B-GENE
genes	I-GENE
(	O
C	O
.	O

Comparison	O
of	O
the	O
encoded	O
ERCC3Dm	B-GENE
protein	I-GENE
with	O
the	O
homologous	O
proteins	O
of	O
mouse	O
and	O
man	O
shows	O
a	O
strong	O
amino	O
acid	O
conservation	O
(	O
71	O
%	O
identity	O
)	O
,	O
especially	O
in	O
the	O
postulated	O
DNA	O
binding	O
region	O
and	O
seven	O
'	B-GENE
helicase	I-GENE
'	I-GENE
domains	I-GENE
.	O

The	O
pyridostigmine	O
inhibited	O
AChE	B-GENE
recovered	O
only	O
in	O
the	O
100	O
mumol	O
kg	O
-	O
1	O
kg	O
oxime	O
groups	O
at	O
the	O
end	O
of	O
the	O
experiment	O
.	O

In	O
the	O
case	O
of	O
a	O
moderate	O
buccal	O
Class	O
II	O
tendency	O
,	O
55	O
%	O
of	O
the	O
molars	O
were	O
in	O
a	O
Class	O
I	O
relationship	O
when	O
evaluated	O
from	O
the	O
lingual	O
side	O
,	O
whereas	O
45	O
%	O
belonged	O
to	O
mild	O
(	O
1st	O
degrees	O
)	O
Class	O
II	O
with	O
molar	O
rotations	O
present	O
in	O
81	O
%	O
of	O
the	O
cases	O
.	O

Mutation	O
of	O
this	O
threonine	O
to	O
isoleucine	O
had	O
no	O
observable	O
effect	O
on	O
either	O
nuclear	O
localization	O
of	O
E1	B-GENE
or	O
DNA	O
replication	O
of	O
the	O
intact	O
viral	O
genome	O
.	O

Serum	B-GENE
prolactin	I-GENE
and	O
oestradiol	O
levels	O
at	O
different	O
stages	O
of	O
puberty	O
.	O

This	O
suggests	O
that	O
the	O
duration	O
of	O
varicocele	O
per	O
se	O
could	O
affect	O
DHT	O
seminal	O
plasma	O
levels	O
.	O

Left	O
ventricular	O
responses	O
to	O
dopamine	O
in	O
dilated	O
cardiomyopathy	O
as	O
assessed	O
by	O
two	O
-	O
dimensional	O
echocardiography	O
and	O
compared	O
with	O
findings	O
of	O
thallium	O
-	O
201	O
scintigraphy	O
.	O

Detailed	O
comparison	O
of	O
the	O
urinary	O
excretion	O
of	O
purines	O
in	O
a	O
patient	O
with	O
the	O
Lesch	O
-	O
Nyhan	O
syndrome	O
and	O
a	O
control	O
subject	O
.	O

This	O
enzyme	O
is	O
distinct	O
from	O
other	O
known	O
E3s	B-GENE
,	O
including	O
E3	B-GENE
alpha	I-GENE
/	O
UBR1	B-GENE
,	O
E3	B-GENE
beta	I-GENE
,	O
and	O
E6	B-GENE
-	I-GENE
AP	I-GENE
.	O

This	O
evidence	O
,	O
together	O
with	O
the	O
ability	O
of	O
a	O
carboxyl	O
-	O
terminal	O
coding	O
sequence	O
starting	O
from	O
the	O
BamHI	B-GENE
site	I-GENE
to	O
complement	O
a	O
shy1	B-GENE
mutant	I-GENE
,	O
suggests	O
that	O
the	O
Shy1p	B-GENE
contains	O
two	O
domains	O
that	O
can	O
be	O
separately	O
expressed	O
to	O
form	O
a	O
functional	O
protein	O
.	O

The	O
zinc	B-GENE
finger	I-GENE
protein	I-GENE
A20	I-GENE
is	O
a	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	B-GENE
)	O
-	O
and	O
interleukin	B-GENE
1	I-GENE
(	O
IL	B-GENE
-	I-GENE
1	I-GENE
)	O
-	O
inducible	O
protein	O
that	O
negatively	O
regulates	O
nuclear	B-GENE
factor	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
(	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
)	O
-	O
dependent	O
gene	O
expression	O
.	O

A	O
visibly	O
distinct	O
muscular	O
hypertrophy	O
(	O
mh	O
)	O
,	O
commonly	O
known	O
as	O
double	O
muscling	O
,	O
occurs	O
with	O
high	O
frequency	O
in	O
the	O
Belgian	O
Blue	O
and	O
Piedmontese	O
cattle	O
breeds	O
.	O

For	O
the	O
population	O
of	O
patients	O
with	O
melanoma	O
levels	O
III	O
and	O
IV	O
significant	O
differences	O
in	O
survival	O
rate	O
were	O
associated	O
with	O
thickness	O
(	O
less	O
than	O
2	O
mm	O
or	O
greater	O
than	O
or	O
equal	O
to	O
2	O
mm	O
;	O
p	O
less	O
than	O
0	O
,	O
001	O
)	O
,	O
though	O
not	O
with	O
level	O
.	O

At	O
least	O
one	O
such	O
complex	O
is	O
eliminated	O
by	O
preincubating	O
the	O
nuclear	O
extract	O
with	O
an	O
antibody	O
with	O
broad	O
cross	O
-	O
reactivity	O
with	O
Ets	B-GENE
-	I-GENE
1	I-GENE
and	O
Ets	B-GENE
-	I-GENE
2	I-GENE
proteins	I-GENE
,	O
thus	O
confirming	O
that	O
an	O
ETS	B-GENE
transcription	I-GENE
factor	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
recognizes	O
the	O
-	O
12	O
motif	O
.	O

Mutant	O
beta2	B-GENE
-	I-GENE
adrenergic	I-GENE
receptors	I-GENE
with	O
a	O
Tyr	O
-	O
to	O
-	O
Phe	O
substitution	O
at	O
Tyr	O
-	O
350	O
do	O
not	O
display	O
agonist	O
-	O
induced	O
desensitization	O
,	O
Src	B-GENE
recruitment	O
,	O
or	O
Src	B-GENE
activation	O
.	O

Role	O
of	O
distinct	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
pathways	O
and	O
cooperation	O
between	O
Ets	B-GENE
-	I-GENE
2	I-GENE
,	O
ATF	B-GENE
-	I-GENE
2	I-GENE
,	O
and	O
Jun	B-GENE
family	I-GENE
members	I-GENE
in	O
human	B-GENE
urokinase	I-GENE
-	I-GENE
type	I-GENE
plasminogen	I-GENE
activator	I-GENE
gene	I-GENE
induction	O
by	O
interleukin	B-GENE
-	I-GENE
1	I-GENE
and	O
tetradecanoyl	O
phorbol	O
acetate	O
.	O

Immunoblot	O
analysis	O
of	O
purified	O
and	O
protease	O
-	O
digested	O
intracellular	O
mature	O
virus	O
(	O
IMV	O
)	O
and	O
extracellular	O
enveloped	O
virus	O
(	O
EEV	O
)	O
showed	O
that	O
the	O
A36R	B-GENE
proteins	I-GENE
were	O
present	O
on	O
the	O
surface	O
of	O
EEV	O
with	O
type	O
II	O
membrane	O
topology	O
,	O
but	O
were	O
absent	O
from	O
IMV	O
.	O

Here	O
we	O
demonstrate	O
that	O
several	O
genes	O
associated	O
with	O
NHEJ	O
perform	O
essential	O
functions	O
in	O
the	O
repair	O
of	O
endonuclease	O
-	O
induced	O
DSBs	O
in	O
vivo	O
.	O

The	O
failure	O
suggests	O
that	O
these	O
assembly	O
competent	O
but	O
complementation	O
-	O
negative	O
alpha	O
mutants	O
lack	O
an	O
as	O
yet	O
unidentified	O
function	O
(	O
s	O
)	O
.	O

Psychopathological	O
,	O
vegetative	O
,	O
and	O
vital	O
parameters	O
were	O
assessed	O
every	O
hour	O
.	O

RESULTS	O
:	O
Considering	O
an	O
inulin	O
clearance	O
of	O
less	O
than	O
80	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
,	O
the	O
cut	O
-	O
off	O
value	O
for	O
serum	O
creatinine	O
was	O
11	O
.	O
5	O
mumol	O
/	O
liter	O
for	O
men	O
and	O
90	O
mumol	O
/	O
liter	O
for	O
women	O
.	O

These	O
data	O
may	O
indicate	O
redundancy	O
between	O
members	O
of	O
the	O
NGFI	B-GENE
-	I-GENE
B	I-GENE
/	O
Nurr1	B-GENE
/	O
Nor1	B-GENE
subfamily	O
and	O
could	O
explain	O
why	O
no	O
phenotypic	O
disturbances	O
have	O
yet	O
been	O
found	O
in	O
mice	O
in	O
which	O
the	O
NGFI	B-GENE
-	I-GENE
B	I-GENE
gene	I-GENE
has	O
been	O
inactivated	O
.	O

Manual	O
sample	O
clean	O
-	O
up	O
procedures	O
as	O
well	O
as	O
the	O
addition	O
of	O
an	O
internal	O
standard	O
are	O
not	O
needed	O
.	O

To	O
directly	O
address	O
this	O
issue	O
,	O
we	O
used	O
a	O
tetracycline	O
-	O
regulated	O
system	O
in	O
human	O
U2OS	O
osteosarcoma	O
cells	O
and	O
thus	O
found	O
that	O
BCL6	B-GENE
mediates	O
growth	O
suppression	O
associated	O
with	O
impaired	O
S	O
phase	O
progression	O
and	O
apoptosis	O
.	O

TAAG	O
sites	O
that	O
serve	O
as	O
functional	O
late	O
promoters	O
in	O
OpMNPV	O
were	O
found	O
to	O
mediate	O
transcription	O
initiation	O
at	O
only	O
basal	O
levels	O
in	O
the	O
context	O
of	O
the	O
AcMNPV	O
genome	O
,	O
suggesting	O
that	O
late	O
promoter	O
activation	O
may	O
be	O
virus	O
specific	O
within	O
the	O
family	O
Baculoviridae	O
.	O

Stability	O
of	O
125	O
I	O
-	O
labeled	O
insulin	B-GENE
used	O
in	O
radioimmunoassay	O
of	O
insulin	B-GENE
.	O

In	O
absence	O
of	O
i	O
.	O
m	O
.	O
medication	O
,	O
levels	O
over	O
1	O
,	O
000	O
U	O
must	O
be	O
carefully	O
screened	O
in	O
order	O
to	O
rule	O
out	O
SNM	O
or	O
organic	O
pathology	O
associated	O
.	O

Paclitaxel	O
caused	O
a	O
rapid	O
and	O
transient	O
increase	O
in	O
c	B-GENE
-	I-GENE
Jun	I-GENE
NH2	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
activity	O
,	O
a	O
proposed	O
mediator	O
of	O
stress	O
activation	O
pathways	O
.	O

These	O
results	O
indicate	O
that	O
H	B-GENE
-	I-GENE
2RIIBP	I-GENE
(	O
i	O
)	O
is	O
a	O
member	O
of	O
the	O
superfamily	O
of	O
nuclear	B-GENE
hormone	I-GENE
receptors	I-GENE
and	O
(	O
ii	O
)	O
may	O
regulate	O
not	O
only	O
MHC	B-GENE
class	I-GENE
I	I-GENE
genes	I-GENE
but	O
also	O
genes	O
containing	O
the	O
ERE	O
and	O
related	O
sequences	O
.	O

Two	O
courses	O
of	O
chemotherapy	O
(	O
CBCDA	O
+	O
VDS	O
)	O
failed	O
to	O
gain	O
any	O
improvement	O
,	O
and	O
the	O
pain	O
resulting	O
from	O
recurrent	O
bone	O
metastases	O
was	O
managed	O
mainly	O
by	O
the	O
administration	O
of	O
the	O
best	O
supportive	O
care	O
.	O

We	O
show	O
here	O
that	O
Spb1p	B-GENE
is	O
able	O
to	O
bind	O
[	O
(	O
3	O
)	O
H	O
]	O
AdoMet	O
in	O
vitro	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
novel	O
methylase	O
,	O
whose	O
possible	O
substrates	O
will	O
be	O
discussed	O
.	O

RESULTS	O
:	O
Lateral	O
PF	O
OA	O
was	O
more	O
common	O
than	O
medial	O
PF	O
OA	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSION	O
:	O
Urbanisation	O
is	O
associated	O
with	O
an	O
increase	O
in	O
the	O
prevalence	O
rates	O
of	O
some	O
risk	O
behaviours	O
.	O

However	O
,	O
additional	O
studies	O
on	O
cell	O
lines	O
and	O
whole	O
animals	O
are	O
required	O
to	O
understand	O
GnRH	B-GENE
signaling	O
in	O
the	O
context	O
of	O
other	O
hormones	O
during	O
the	O
reproductive	O
cycle	O
of	O
mouse	O
and	O
human	O
.	O

Serum	B-GENE
angiogenin	I-GENE
concentrations	O
in	O
young	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

This	O
duplicated	O
genomic	O
region	O
is	O
also	O
linked	O
tightly	O
to	O
D1Z2	B-GENE
,	O
a	O
genetic	O
marker	O
containing	O
a	O
highly	O
polymorphic	O
VNTR	O
(	O
variable	O
number	O
tandem	O
repeat	O
)	O
consisting	O
of	O
an	O
unusual	O
40	O
-	O
bp	O
reiterated	O
sequence	O
.	O

ATF6	B-GENE
,	O
a	O
basic	B-GENE
-	I-GENE
leucine	I-GENE
zipper	I-GENE
protein	I-GENE
,	O
was	O
isolated	O
by	O
binding	O
to	O
SRF	B-GENE
and	O
in	O
particular	O
to	O
its	O
transcriptional	O
activation	O
domain	O
.	O

Cetn1	B-GENE
possesses	O
the	O
sequence	O
features	O
of	O
an	O
expressed	O
retroposon	O
:	O
the	O
gene	O
lacks	O
introns	O
,	O
the	O
open	O
reading	O
frame	O
is	O
not	O
interrupted	O
by	O
stop	O
codons	O
,	O
and	O
the	O
coding	O
region	O
is	O
flanked	O
by	O
a	O
pair	O
of	O
direct	O
repeats	O
.	O

The	O
largest	O
one	O
probably	O
corresponds	O
to	O
the	O
precursor	O
form	O
of	O
PS2	B-GENE
in	O
E	O
.	O
coli	O
.	O

The	O
Aspergillus	B-GENE
uvsH	I-GENE
gene	I-GENE
encodes	O
a	O
product	O
homologous	O
to	O
yeast	B-GENE
RAD18	I-GENE
and	O
Neurospora	B-GENE
UVS	I-GENE
-	I-GENE
2	I-GENE
.	O

On	O
average	O
these	O
maximum	O
potency	O
estimates	O
were	O
within	O
one	O
order	O
of	O
magnitude	O
of	O
the	O
inverse	O
maximum	O
dose	O
tested	O
.	O

VAV	B-GENE
and	O
SOCS1	B-GENE
form	O
a	O
protein	O
complex	O
through	O
interactions	O
between	O
the	O
VAV	B-GENE
NH	I-GENE
(	I-GENE
2	I-GENE
)	I-GENE
-	I-GENE
terminal	I-GENE
regulatory	I-GENE
region	I-GENE
and	O
the	O
SH2	B-GENE
domain	I-GENE
of	O
SOCS1	B-GENE
in	O
a	O
phosphotyrosine	O
-	O
independent	O
manner	O
.	O

The	O
originally	O
embryonic	B-GENE
gamma	I-GENE
-	I-GENE
globin	I-GENE
locus	I-GENE
duplicated	O
and	O
acquired	O
a	O
novel	O
(	O
fetal	O
)	O
pattern	O
of	O
expression	O
in	O
a	O
defined	O
time	O
period	O
(	O
55	O
-	O
40	O
million	O
years	O
ago	O
)	O
during	O
primate	O
phylogeny	O
.	O

Clostridium	O
botulinum	O
in	O
marine	O
sediment	O

Northern	O
blot	O
analysis	O
with	O
GPR37	B-GENE
probes	O
revealed	O
a	O
main	O
3	O
.	O
8	O
-	O
kb	O
mRNA	O
and	O
a	O
less	O
abundant	O
8	O
-	O
kb	O
mRNA	O
,	O
both	O
expressed	O
in	O
human	O
brain	O
tissues	O
,	O
particularly	O
in	O
corpus	O
callosum	O
,	O
medulla	O
,	O
putamen	O
,	O
and	O
caudate	O
nucleus	O
.	O

Our	O
studies	O
indicate	O
no	O
single	O
trans	O
-	O
acting	O
factor	O
is	O
absolutely	O
essential	O
for	O
enhancer	O
activity	O
,	O
and	O
that	O
the	O
enhancer	O
activity	O
of	O
MerI	B-GENE
is	O
mediated	O
via	O
a	O
combinatorial	O
and	O
additive	O
mechanism	O
.	O

In	O
human	O
WI38	O
cells	O
,	O
the	O
E1B	B-GENE
19K	I-GENE
gene	I-GENE
mutant	I-GENE
viruses	O
had	O
a	O
substantial	O
growth	O
advantage	O
over	O
the	O
wild	O
-	O
type	O
virus	O
,	O
yielding	O
500	O
-	O
fold	O
-	O
higher	O
titers	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
these	O
hormonal	O
effects	O
,	O
we	O
have	O
studied	O
the	O
regulatory	O
regions	O
of	O
the	O
PFK	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
in	O
transfection	O
experiments	O
.	O

Consequently	O
,	O
during	O
the	O
evolution	O
of	O
mammals	O
,	O
it	O
is	O
the	O
CKbeta4GT	B-GENE
-	I-GENE
I	I-GENE
gene	I-GENE
lineage	O
that	O
has	O
been	O
recruited	O
for	O
the	O
biosynthesis	O
of	O
lactose	O
.	O

Furthermore	O
,	O
disruption	O
of	O
pcr1	B-GENE
reduced	O
expression	O
of	O
fbp1	B-GENE
,	O
a	O
glucose	O
-	O
repressible	O
gene	O
negatively	O
regulated	O
by	O
PKA	B-GENE
.	O

In	O
solution	O
,	O
[	O
(	O
125	O
)	O
I	O
]	O
-	O
labeled	O
ankyrin	B-GENE
was	O
found	O
by	O
ND	O
-	O
PAGE3	O
to	O
enhance	O
the	O
affinity	O
of	O
spectrin	B-GENE
self	O
-	O
association	O
by	O
10	O
-	O
fold	O
.	O

Transcription	O
analysis	O
of	O
the	O
EcoRI	B-GENE
D	I-GENE
region	I-GENE
of	O
the	O
baculovirus	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
identifies	O
an	O
early	O
4	O
-	O
kilobase	O
RNA	O
encoding	O
the	O
essential	O
p143	B-GENE
gene	I-GENE
.	O

Anesthesia	O
in	O
the	O
radical	O
surgery	O
of	O
arteriosclerotic	O
coronary	O
disease	O

5	O
Intravenous	O
prizidilol	O
hydrochloride	O
decreases	O
resting	O
blood	O
pressure	O
and	O
left	O
ventricular	O
area	O
,	O
increases	O
pulse	O
rate	O
and	O
has	O
virtually	O
no	O
effect	O
on	O
left	O
ventricular	O
ejection	O
fraction	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
location	O
,	O
domain	O
structure	O
,	O
and	O
biochemical	O
function	O
of	O
metaxin	B-GENE
were	O
investigated	O
.	O

The	O
human	O
cDNA	O
was	O
cloned	O
and	O
sequenced	O
;	O
it	O
was	O
shown	O
to	O
have	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
296	O
-	O
amino	O
-	O
acid	O
protein	O
in	O
which	O
could	O
be	O
identified	O
four	O
peptides	O
previously	O
identified	O
by	O
micro	O
-	O
sequencing	O
purified	O
protein	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
this	O
technique	O
by	O
cross	O
-	O
calibrating	O
the	O
DXA	O
method	O
with	O
the	O
carcass	O
chemical	O
analysis	O
in	O
a	O
heterogeneous	O
population	O
of	O
nondiabetic	O
Wistar	O
and	O
diabetic	O
GK	O
rats	O
(	O
21	O
animals	O
were	O
used	O
for	O
precision	O
error	O
and	O
reproducibility	O
determinations	O
and	O
26	O
were	O
used	O
for	O
accuracy	O
studies	O
)	O
.	O

Flux	O
of	O
the	O
paramyxovirus	O
hemagglutinin	B-GENE
-	O
neuraminidase	B-GENE
glycoprotein	O
through	O
the	O
endoplasmic	O
reticulum	O
activates	O
transcription	O
of	O
the	O
GRP78	B-GENE
-	O
BiP	B-GENE
gene	O
.	O

The	O
preference	O
for	O
third	O
base	O
codon	O
in	O
Y	O
position	O
prolines	O
is	O
U	O
for	O
the	O
alpha	B-GENE
2	I-GENE
(	I-GENE
VI	I-GENE
)	I-GENE
collagen	I-GENE
as	O
it	O
is	O
for	O
the	O
human	B-GENE
fibrillar	I-GENE
collagen	I-GENE
genes	I-GENE
.	O

Small	O
cell	O
tumors	O
in	O
children	O
:	O
contribution	O
to	O
the	O
solution	O
of	O
the	O
problem	O
of	O
differential	O
diagnosis	O
with	O
immunohistochemistry	O
and	O
electron	O
microscopy	O

Detonation	O
-	O
traumatic	O
load	O
during	O
military	O
service	O

In	O
static	O
conditions	O
,	O
body	O
sway	O
was	O
assessed	O
using	O
a	O
conventional	O
force	O
platform	O
with	O
eyes	O
open	O
and	O
with	O
eyes	O
closed	O
.	O

Soggy	B-GENE
,	O
a	O
spermatocyte	O
-	O
specific	O
gene	O
,	O
lies	O
3	O
.	O
8	O
kb	O
upstream	O
of	O
and	O
antipodal	O
to	O
TEAD	B-GENE
-	I-GENE
2	I-GENE
,	O
a	O
transcription	O
factor	O
expressed	O
at	O
the	O
beginning	O
of	O
mouse	O
development	O
.	O

Teratospermia	O
is	O
therefore	O
an	O
important	O
factor	O
in	O
evaluating	O
fertilization	O
capacity	O
.	O

Results	O
of	O
the	O
study	O
suggest	O
that	O
Chinese	O
medicine	O
use	O
among	O
this	O
population	O
depends	O
on	O
health	O
conditions	O
,	O
and	O
that	O
having	O
a	O
regular	O
source	O
of	O
care	O
for	O
Chinese	O
medicine	O
as	O
well	O
as	O
a	O
preference	O
for	O
Chinese	O
medicine	O
are	O
two	O
predictors	O
for	O
its	O
use	O
.	O

The	O
greatest	O
risk	O
of	O
preterm	O
prelabour	O
rupture	O
of	O
membranes	O
(	O
PPROM	O
)	O
is	O
preterm	O
delivery	O
.	O

DISCUSSION	O
:	O
The	O
higher	O
absolute	O
knee	O
extension	O
strength	O
measures	O
of	O
leg	O
and	O
the	O
similar	O
extension	O
strength	O
of	O
the	O
trunk	O
in	O
the	O
obese	O
sample	O
compared	O
to	O
the	O
lean	O
might	O
be	O
explained	O
by	O
the	O
training	O
effect	O
of	O
weight	O
bearing	O
and	O
support	O
of	O
a	O
larger	O
body	O
mass	O
.	O

Residues	O
of	O
Stauffer	O
R	O
-	O
3828	O
and	O
its	O
oxygen	O
analogue	O
in	O
the	O
body	O
tissues	O
of	O
cattle	O
fed	O
R	O
-	O
3828	O
in	O
the	O
diet	O
.	O

The	O
goals	O
of	O
these	O
experiments	O
were	O
to	O
determine	O
whether	O
lactational	O
anestrus	O
would	O
be	O
prolonged	O
by	O
a	O
48	O
-	O
h	O
fast	O
at	O
days	O
13	O
and	O
14	O
postpartum	O
(	O
pp	O
)	O
and	O
,	O
if	O
so	O
,	O
to	O
determine	O
whether	O
this	O
effect	O
could	O
be	O
reversed	O
by	O
treatment	O
with	O
the	O
Ob	B-GENE
protein	I-GENE
leptin	B-GENE
.	O

In	O
pituitary	O
GH3	O
cells	O
,	O
vitamin	O
D	O
increases	O
the	O
levels	O
of	O
PRL	B-GENE
transcripts	I-GENE
and	O
stimulates	O
the	O
PRL	B-GENE
promoter	I-GENE
.	O

However	O
,	O
electron	O
microscopy	O
revealed	O
that	O
while	O
sec4	B-GENE
mutant	I-GENE
cells	O
accumulate	O
secretory	O
vesicles	O
,	O
ypt31	B-GENE
/	I-GENE
32	I-GENE
mutant	I-GENE
cells	O
accumulate	O
aberrant	O
Golgi	O
structures	O
.	O

METHODS	O
:	O
We	O
retrospectively	O
analyzed	O
the	O
data	O
of	O
20	O
patients	O
who	O
underwent	O
both	O
gated	O
fluorine	O
18	O
deoxyglucose	O
(	O
FDG	O
)	O
-	O
PET	O
and	O
equilibrium	O
radionuclide	O
angiography	O
(	O
ERNA	O
)	O
.	O

However	O
,	O
it	O
is	O
now	O
suggested	O
that	O
the	O
use	O
of	O
more	O
slowly	O
digested	O
starchy	O
foods	O
may	O
have	O
positive	O
health	O
benefits	O
.	O

Northern	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
genes	O
are	O
transcribed	O
separately	O
.	O

Complete	O
activation	O
of	O
signal	B-GENE
transducer	I-GENE
and	I-GENE
activator	I-GENE
of	I-GENE
transcription	I-GENE
1	I-GENE
(	O
STAT1	B-GENE
)	O
requires	O
phosphorylation	O
at	O
both	O
Y701	O
and	O
a	O
conserved	O
PMS	O
(	O
727	O
)	O
P	O
sequence	O
.	O

Over	O
half	O
of	O
the	O
children	O
initially	O
unresponsive	O
to	O
H	O
.	O
influenzae	O
type	O
b	O
meningitis	O
subsequently	O
developed	O
specific	O
antibodies	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
etiology	O
of	O
HITT	O
because	O
of	O
its	O
devastating	O
clinical	O
consequences	O
.	O

Five	O
sequence	O
variants	O
were	O
identified	O
.	O

The	O
Ras	B-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
-	I-GENE
protein	I-GENE
-	I-GENE
related	I-GENE
human	I-GENE
protein	I-GENE
IQGAP2	B-GENE
harbors	O
a	O
potential	O
actin	B-GENE
binding	I-GENE
domain	I-GENE
and	O
interacts	O
with	O
calmodulin	B-GENE
and	O
Rho	B-GENE
family	I-GENE
GTPases	I-GENE
.	O

We	O
anticipated	O
SNS	O
function	O
after	O
CVA	O
to	O
be	O
asymmetric	O
and	O
selected	O
null	O
hypotheses	O
of	O
bilaterally	O
symmetric	O
SSR	O
latencies	O
and	O
amplitudes	O
irrespective	O
of	O
side	O
of	O
stimulation	O
and	O
/	O
or	O
recording	O
.	O

Partial	O
hepatectomy	O
in	O
metastatic	O
Wilms	O
'	O
tumor	O
.	O

The	O
adoption	O
of	O
a	O
twisted	O
structure	O
of	O
importin	B-GENE
-	I-GENE
beta	I-GENE
is	O
essential	O
for	O
the	O
protein	O
-	O
protein	O
interaction	O
required	O
for	O
nuclear	O
transport	O
.	O

The	O
presence	O
of	O
a	O
short	O
(	O
70	O
bp	O
)	O
intron	O
near	O
the	O
N	O
-	O
terminus	O
of	O
the	O
atX	B-GENE
gene	I-GENE
was	O
predicted	O
that	O
contains	O
the	O
canonical	O
GT	O
and	O
AG	O
dinucleotides	O
at	O
its	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
splicing	O
junctions	O
.	O

Moreover	O
,	O
a	O
hybrid	O
protein	O
composed	O
of	O
a	O
PvALF	B-GENE
activation	I-GENE
domain	I-GENE
and	O
the	O
DNA	O
binding	O
and	O
dimerization	O
domain	O
of	O
ROM2	B-GENE
activated	O
gene	O
expression	O
,	O
indicating	O
that	O
ROM2	B-GENE
recognizes	O
the	O
DLEC2	B-GENE
enhancer	I-GENE
in	O
vivo	O
;	O
consequently	O
,	O
ROM2	B-GENE
functions	O
as	O
a	O
DNA	O
binding	O
site	O
-	O
dependent	O
repressor	O
.	O

Tc	O
-	O
99m	O
HMPAO	O
brain	O
SPECT	O
compared	O
to	O
CT	O
and	O
EEG	O
after	O
seizures	O
in	O
childhood	O
.	O

We	O
found	O
that	O
the	O
central	O
nonconserved	O
region	O
of	O
the	O
large	O
subunit	O
is	O
not	O
essential	O
for	O
function	O
and	O
likely	O
acts	O
as	O
a	O
spacer	O
between	O
the	O
conserved	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
.	O

On	O
the	O
other	O
hand	O
,	O
NE	O
transport	O
and	O
antagonist	O
(	O
[	O
125I	O
]	O
RTI	O
-	O
55	O
)	O
binding	O
assays	O
on	O
whole	O
LLC	O
-	O
NET	O
cells	O
treated	O
with	O
tunicamycin	O
reveal	O
a	O
pronounced	O
reduction	O
in	O
NE	O
transport	O
activity	O
and	O
hNET	B-GENE
membrane	O
density	O
paralleled	O
by	O
an	O
inability	O
of	O
NET	B-GENE
proteins	I-GENE
to	O
replenish	O
the	O
higher	O
M	O
(	O
r	O
)	O
hNET	B-GENE
pool	O
.	O

We	O
show	O
that	O
the	O
upstream	O
region	O
of	O
the	O
beta	B-GENE
-	I-GENE
MyHC	I-GENE
gene	I-GENE
(	O
-	O
5518	O
to	O
-	O
2490	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
)	O
directed	O
high	O
levels	O
of	O
transcriptional	O
activity	O
only	O
when	O
stably	O
integrated	O
,	O
but	O
not	O
when	O
expressed	O
extrachromosomally	O
in	O
transient	O
assays	O
.	O

DNase	B-GENE
I	I-GENE
protection	O
analysis	O
as	O
well	O
as	O
oligonucleotide	O
competition	O
experiments	O
indicate	O
that	O
this	O
binding	O
is	O
sequence	O
specific	O
.	O

Plasmid	O
pSP64E6E7	O
which	O
contains	O
the	O
reading	O
frames	O
of	O
both	O
E6	B-GENE
and	O
E7	B-GENE
was	O
constructed	O
in	O
order	O
to	O
study	O
the	O
expression	O
of	O
both	O
proteins	O
in	O
a	O
coupled	O
transcription	O
/	O
rabbit	O
reticulocyte	O
translation	O
system	O
.	O

In	O
transient	O
transfections	O
using	O
luciferase	B-GENE
reporter	I-GENE
genes	I-GENE
driven	O
by	O
1	O
kb	O
of	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
three	O
CALM	B-GENE
genes	I-GENE
,	O
the	O
promoter	O
activity	O
correlated	O
with	O
the	O
endogenous	B-GENE
CALM	I-GENE
transcriptional	O
activity	O
,	O
but	O
only	O
when	O
the	O
5	O
'	O
untranslated	O
regions	O
were	O
included	O
in	O
the	O
constructs	O
.	O

These	O
findings	O
suggest	O
that	O
PGE1	O
is	O
effective	O
in	O
increasing	O
PVF	O
in	O
the	O
liver	O
transplanted	O
condition	O
;	O
however	O
,	O
the	O
hepatic	O
circulatory	O
improvement	O
attributed	O
to	O
this	O
agent	O
would	O
be	O
limited	O
to	O
the	O
first	O
few	O
days	O
following	O
transplantation	O
.	O

The	O
derepressed	O
expression	O
of	O
fixN	B-GENE
was	O
not	O
observed	O
in	O
a	O
purH	B-GENE
mutant	I-GENE
.	O

Nearly	O
1	O
.	O
5	O
million	O
American	O
men	O
age	O
65	O
and	O
older	O
have	O
osteoporosis	O
,	O
and	O
another	O
3	O
.	O
5	O
million	O
are	O
at	O
risk	O
.	O

Both	O
viruses	O
express	O
the	O
mil	B-GENE
/	O
raf	B-GENE
oncogene	O
product	O
as	O
a	O
gag	B-GENE
-	I-GENE
fusion	I-GENE
polyprotein	O
,	O
while	O
the	O
myc	B-GENE
oncogene	O
of	O
MH2	O
is	O
expressed	O
via	O
a	O
subgenomic	O
mRNA	O
.	O

CONCLUSION	O
:	O
DaunoXome	O
has	O
an	O
improved	O
pharmacokinetic	O
profile	O
compared	O
with	O
free	O
daunorubicin	O
,	O
and	O
is	O
well	O
tolerated	O
.	O

This	O
regimen	O
may	O
be	O
considered	O
front	O
-	O
line	O
therapy	O
when	O
autologous	O
stem	O
cell	O
transplantation	O
is	O
not	O
feasible	O
and	O
when	O
a	O
rapid	O
response	O
is	O
particularly	O
important	O
.	O

Recombinant	O
protein	O
encoded	O
by	O
ESX	B-GENE
(	O
for	O
epithelial	B-GENE
-	I-GENE
restricted	I-GENE
with	I-GENE
serine	I-GENE
box	I-GENE
)	O
exhibits	O
Ets	B-GENE
-	I-GENE
like	I-GENE
DNA	O
binding	O
specificity	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
transactivates	O
Ets	B-GENE
-	I-GENE
responsive	I-GENE
promoter	I-GENE
elements	I-GENE
including	O
that	O
found	O
in	O
the	O
HER2	B-GENE
/	O
neu	B-GENE
oncogene	O
.	O

In	O
area	O
CA1	O
of	O
the	O
hippocampus	O
,	O
numbers	O
of	O
normal	O
neurons	O
were	O
increased	O
11	O
-	O
to	O
14	O
-	O
fold	O
by	O
MK	O
-	O
801	O
treatment	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
temporal	O
changes	O
in	O
the	O
plasma	O
concentration	O
of	O
immunoreactive	B-GENE
atrial	I-GENE
natriuretic	I-GENE
factor	I-GENE
(	O
iANF	B-GENE
)	O
were	O
studied	O
in	O
six	O
conscious	O
dogs	O
with	O
an	O
arteriovenous	O
(	O
AV	O
)	O
fistula	O
,	O
a	O
model	O
of	O
chronic	O
high	O
-	O
output	O
heart	O
failure	O
.	O

The	O
revaluation	O
at	O
the	O
end	O
of	O
the	O
study	O
showed	O
a	O
good	O
compliance	O
for	O
the	O
proposed	O
diet	O
scheme	O
by	O
children	O
,	O
but	O
a	O
poor	O
compliance	O
by	O
their	O
families	O
.	O

The	O
delta	O
G	O
values	O
of	O
these	O
regions	O
were	O
higher	O
,	O
i	O
.	O
e	O
.	O
potential	O
secondary	O
structural	O
elements	O
were	O
fewer	O
,	O
than	O
in	O
TIR	O
of	O
genes	O
from	O
E	O
.	O
coli	O
.	O

Two	O
closely	O
related	O
groups	O
of	O
transcripts	O
,	O
Sagrp1	B-GENE
and	O
Sagrp2	B-GENE
,	O
controlled	O
by	O
a	O
circadian	O
rhythm	O
have	O
been	O
isolated	O
.	O

Of	O
921	O
specimens	O
,	O
95	O
yielded	O
non	O
-	O
albicans	O
species	O
,	O
mainly	O
from	O
patients	O
with	O
low	O
CD4	B-GENE
lymphocyte	O
counts	O
and	O
extensive	O
previous	O
azole	O
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
eIF5	B-GENE
-	O
eIF2beta	B-GENE
interaction	O
plays	O
an	O
essential	O
role	O
in	O
eIF5	B-GENE
function	O
in	O
eukaryotic	O
cells	O
.	O

Three	O
simple	O
methods	O
of	O
detecting	O
malnutrition	O
on	O
medical	O
wards	O
.	O

Compared	O
with	O
controls	O
,	O
patients	O
in	O
the	O
unmedicated	O
state	O
had	O
low	O
smooth	O
pursuit	O
gain	O
,	O
had	O
a	O
higher	O
rate	O
of	O
corrective	O
catch	O
-	O
up	O
saccades	O
,	O
and	O
tended	O
to	O
spend	O
less	O
time	O
engaged	O
in	O
the	O
tracking	O
task	O
.	O

Cytokine	O
-	O
mediated	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
reappearance	O
was	O
completely	O
blocked	O
by	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

Development	O
of	O
P	O
carinii	O
pneumonia	O
was	O
associated	O
with	O
the	O
stage	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
,	O
B	O
subtype	O
disease	O
,	O
and	O
the	O
presence	O
of	O
0	O
.	O
20	O
X	O
10	O
(	O
9	O
)	O
/	O
L	O
(	O
200	O
/	O
mm3	O
)	O
or	O
fewer	O
CD4	B-GENE
cells	O
at	O
study	O
entry	O
.	O

The	O
effects	O
of	O
tilmicosin	O
administration	O
in	O
the	O
feed	O
at	O
400	O
mg	O
/	O
kg	O
and	O
an	O
injection	O
therapy	O
of	O
clinically	O
diseased	O
pigs	O
with	O
long	O
-	O
acting	O
oxytetracycline	O
(	O
Terramycine	O
LA	O
)	O
at	O
20	O
mg	O
/	O
kg	O
bodyweight	O
were	O
compared	O
.	O

Those	O
participating	O
in	O
this	O
investigation	O
(	O
65	O
centers	O
=	O
79	O
%	O
)	O
received	O
a	O
series	O
of	O
computer	O
disks	O
containing	O
50	O
99mTc	O
-	O
DMSA	O
studies	O
.	O

Pathogenesis	O
of	O
fever	O
.	O

Two	O
full	O
-	O
length	O
clones	O
(	O
pBCH1	O
and	O
pBCH2	O
)	O
were	O
isolated	O
.	O

Childbirth	O
and	O
authoritative	O
knowledge	O
.	O

The	O
ends	O
of	O
the	O
barrel	O
are	O
capped	O
by	O
short	O
helices	O
.	O

Non	O
-	O
finger	O
-	O
coding	O
modules	O
conserved	O
among	O
members	O
of	O
subfamilies	O
of	O
zinc	B-GENE
finger	I-GENE
genes	I-GENE
have	O
been	O
described	O
in	O
the	O
murine	O
genome	O
(	O
finger	O
-	O
associated	O
boxes	O
,	O
or	O
FAX	O
domain	O
)	O
and	O
the	O
human	O
genome	O
(	O
Kruppel	B-GENE
-	I-GENE
associated	I-GENE
boxes	I-GENE
,	O
or	O
KRAB	B-GENE
domain	I-GENE
)	O
.	O

This	O
combination	O
is	O
considered	O
pathognomonic	O
for	O
factitious	O
hyperinsulinism	O
.	O

Comparison	O
of	O
the	O
5	O
'	O
flanking	O
regions	O
of	O
the	O
mouse	B-GENE
J	I-GENE
kappa	I-GENE
elements	I-GENE
,	O
including	O
the	O
conserved	O
putative	O
recombination	O
target	O
sequences	O
,	O
shows	O
no	O
obvious	O
differences	O
consistent	O
with	O
the	O
variation	O
in	O
recombinational	O
efficiency	O
,	O
so	O
we	O
conclude	O
that	O
,	O
although	O
the	O
consensus	O
heptamer	O
and	O
nonamer	O
signals	O
may	O
be	O
sufficient	O
to	O
identify	O
a	O
recombination	O
site	O
,	O
the	O
probability	O
that	O
that	O
site	O
will	O
be	O
used	O
depends	O
also	O
on	O
other	O
determinants	O
.	O

The	O
melanoma	B-GENE
growth	I-GENE
stimulatory	I-GENE
activity	I-GENE
/	I-GENE
growth	I-GENE
-	I-GENE
regulated	I-GENE
protein	I-GENE
,	O
CXCL1	B-GENE
,	O
is	O
constitutively	O
expressed	O
at	O
high	O
levels	O
during	O
inflammation	O
and	O
progression	O
of	O
melanocytes	O
into	O
malignant	O
melanoma	O
.	O

Genetic	O
analysis	O
places	O
CWH43	B-GENE
upstream	O
of	O
the	O
BCK2	B-GENE
branch	O
of	O
the	O
PKC1	B-GENE
signalling	O
pathway	O
,	O
since	O
cwh43	B-GENE
mutations	O
were	O
synthetic	O
lethal	O
with	O
pkc1	B-GENE
deletion	O
,	O
whereas	O
the	O
cwh43	B-GENE
defects	O
could	O
be	O
rescued	O
by	O
overexpression	O
of	O
BCK2	B-GENE
and	O
not	O
by	O
high	O
-	O
copy	O
-	O
number	O
expression	O
of	O
genes	O
encoding	O
downstream	O
proteins	O
of	O
the	O
PKC1	B-GENE
pathway	O
However	O
,	O
unlike	O
BCK2	B-GENE
,	O
whose	O
disruption	O
in	O
a	O
cln3	B-GENE
mutant	I-GENE
resulted	O
in	O
growth	O
arrest	O
in	O
G	O
(	O
1	O
)	O
,	O
no	O
growth	O
defect	O
was	O
observed	O
in	O
a	O
double	O
cwh43	B-GENE
cln3	B-GENE
mutants	I-GENE
.	O

Twelve	O
(	O
92	O
%	O
)	O
showed	O
cognitive	O
dysfunction	O
including	O
impairments	O
in	O
memory	O
,	O
attention	O
,	O
and	O
affective	O
disturbances	O
(	O
anxiety	O
,	O
depression	O
,	O
irritability	O
,	O
and	O
poor	O
frustration	O
tolerance	O
)	O
.	O

To	O
clarify	O
the	O
mechanisms	O
that	O
regulate	O
transcription	O
of	O
the	O
GTP	B-GENE
cyclohydrolase	I-GENE
I	I-GENE
gene	I-GENE
and	O
to	O
generate	O
multiple	O
species	O
of	O
mRNA	O
,	O
we	O
isolated	O
genomic	O
DNA	O
clones	O
for	O
the	O
human	O
and	O
mouse	O
GTP	B-GENE
cyclohydrolase	I-GENE
I	I-GENE
genes	I-GENE
.	O

Therefore	O
,	O
a	O
structural	O
interaction	O
between	O
PsaL	B-GENE
and	O
PsaI	B-GENE
may	O
stabilize	O
the	O
association	O
of	O
PsaL	B-GENE
with	O
the	O
photosystem	B-GENE
I	I-GENE
core	I-GENE
.	O

Reversal	O
of	O
'	O
refractory	O
septic	O
shock	O
'	O
by	O
infusion	O
of	O
amrinone	O
and	O
angiotensin	B-GENE
II	I-GENE
in	O
an	O
anthracycline	O
-	O
treated	O
patient	O
.	O

The	O
present	O
study	O
deals	O
with	O
the	O
screening	O
of	O
11	O
of	O
these	O
plants	O
against	O
the	O
opportunistic	O
pathogen	O
fungus	O
Candida	O
albicans	O
.	O

Negative	O
modulation	O
of	O
alpha1	B-GENE
(	I-GENE
I	I-GENE
)	I-GENE
procollagen	I-GENE
gene	I-GENE
expression	O
in	O
human	O
skin	O
fibroblasts	O
:	O
transcriptional	O
inhibition	O
by	O
interferon	B-GENE
-	I-GENE
gamma	I-GENE
.	O

On	O
the	O
basis	O
of	O
this	O
homology	O
,	O
we	O
examined	O
the	O
potential	O
role	O
of	O
c	B-GENE
-	I-GENE
Rel	I-GENE
in	O
controlling	O
IL	B-GENE
-	I-GENE
2R	I-GENE
alpha	I-GENE
transcription	O
.	O

Expression	O
of	O
CBP	B-GENE
/	O
p300	B-GENE
potentiated	O
HS2	O
-	O
mediated	O
transactivation	O
.	O

We	O
next	O
developed	O
a	O
rapid	O
purification	O
method	O
for	O
bacterial	B-GENE
recombinant	I-GENE
MyoD	I-GENE
-	I-GENE
bHLH	I-GENE
domain	I-GENE
by	O
affinity	O
chromatography	O
using	O
a	O
calmodulin	B-GENE
-	O
Sepharose	O
column	O
and	O
investigated	O
the	O
phosphorylation	O
of	O
that	O
peptide	O
by	O
PKC	B-GENE
and	O
its	O
interactions	O
with	O
calmodulin	B-GENE
and	O
S100a	B-GENE
.	O

According	O
to	O
the	O
penetration	O
of	O
Ca	O
-	O
45	O
,	O
the	O
microleakage	O
level	O
was	O
scored	O
for	O
each	O
section	O
.	O

HL	B-GENE
is	O
hypothesized	O
to	O
directly	O
couple	O
HDL	B-GENE
lipid	O
metabolism	O
to	O
tissue	O
/	O
cellular	O
lipid	O
metabolism	O
.	O

Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
nuclear	I-GENE
antigen	I-GENE
2	I-GENE
exerts	O
its	O
transactivating	O
function	O
through	O
interaction	O
with	O
recombination	B-GENE
signal	I-GENE
binding	I-GENE
protein	I-GENE
RBP	I-GENE
-	I-GENE
J	I-GENE
kappa	I-GENE
,	O
the	O
homologue	O
of	O
Drosophila	B-GENE
Suppressor	I-GENE
of	I-GENE
Hairless	I-GENE
.	O

Maduromycosis	O
in	O
Italy	O

Two	O
patient	O
groups	O
were	O
studied	O
:	O
Type	O
I	O
-	O
-	O
with	O
a	O
new	O
ePTFE	O
graft	O
;	O
and	O
Type	O
II	O
-	O
-	O
with	O
thrombectomy	O
and	O
/	O
or	O
revision	O
of	O
a	O
previously	O
placed	O
ePTFE	O
graft	O
.	O

The	O
author	O
describes	O
the	O
technique	O
in	O
detail	O
and	O
presents	O
the	O
findings	O
for	O
25	O
patients	O
(	O
10	O
men	O
and	O
15	O
women	O
)	O
examined	O
for	O
suspected	O
ileostomy	O
dysfunction	O
,	O
recurrent	O
Crohn	O
'	O
s	O
disease	O
or	O
ileal	O
obstruction	O
remote	O
from	O
the	O
stoma	O
.	O

Increased	O
susceptibility	O
of	O
aphasics	O
to	O
a	O
distractor	O
task	O
in	O
the	O
recall	O
of	O
verbal	O
commands	O
.	O

Lasting	O
paraplegia	O
caused	O
by	O
loss	O
of	O
lumbar	O
spinal	O
cord	O
interneurons	O
in	O
rats	O
:	O
no	O
direct	O
correlation	O
with	O
motor	O
neuron	O
loss	O
.	O

The	O
existence	O
of	O
universal	O
non	O
-	O
specific	O
mechanism	O
of	O
action	O
of	O
external	O
factors	O
upon	O
the	O
living	O
tissue	O
based	O
on	O
the	O
DEL	O
-	O
reaction	O
is	O
suggested	O
.	O

Rv	O
was	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
4	O
mmHg	O
.	O
ml	O
-	O
1	O
.	O
min	O
.	O
100	O
g	O
-	O
1	O
and	O
Cv	O
was	O
0	O
.	O
59	O
+	O
/	O
-	O
0	O
.	O
25	O
ml	O
/	O
mmHg	O
,	O
tau	O
v	O
calculated	O
from	O
the	O
product	O
of	O
Rv	O
and	O
Cv	O
was	O
4	O
.	O
20	O
+	O
/	O
-	O
1	O
.	O
58	O
s	O
and	O
from	O
the	O
ratio	O
of	O
delta	O
V	O
to	O
delta	O
Q	O
was	O
4	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
53	O
s	O
(	O
P	O
=	O
NS	O
)	O
at	O
a	O
mean	O
Pel	O
of	O
17	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
7	O
mmHg	O
.	O
delta	O
V	O
was	O
also	O
produced	O
by	O
changing	O
Pv	O
;	O
the	O
average	O
tau	O
v	O
(	O
1	O
.	O
95	O
+	O
/	O
-	O
0	O
.	O
37	O
s	O
)	O
,	O
was	O
shorter	O
than	O
that	O
with	O
changes	O
in	O
flow	O
.	O

We	O
constructed	O
a	O
stable	O
,	O
doubly	O
transfected	O
cell	O
line	O
(	O
TIS	O
-	O
10	O
)	O
carrying	O
a	O
chromosomally	O
integrated	O
ptetO7	B-GENE
-	I-GENE
CMV	I-GENE
-	I-GENE
L	I-GENE
reporter	O
construct	O
and	O
expressing	O
the	O
TetR	B-GENE
-	O
KRAB	B-GENE
protein	O
.	O

We	O
suggest	O
that	O
electrical	O
stimulation	O
of	O
the	O
NTS	O
in	O
rats	O
undergoing	O
such	O
surgical	O
preparation	O
to	O
observe	O
the	O
pressor	O
response	O
and	O
/	O
or	O
increase	O
in	O
pVP	O
,	O
represents	O
a	O
rapid	O
approach	O
for	O
screening	O
the	O
neurosecretory	O
function	O
of	O
the	O
central	O
neural	O
integration	O
to	O
release	O
vasopressin	B-GENE
.	O

To	O
study	O
adaptive	O
processes	O
following	O
spinal	O
cord	O
injury	O
,	O
unstructured	O
audiotaped	O
interviews	O
were	O
conducted	O
on	O
an	O
almost	O
daily	O
basis	O
with	O
a	O
30	O
-	O
year	O
-	O
old	O
divorced	O
male	O
during	O
the	O
first	O
3	O
months	O
of	O
his	O
initial	O
comprehensive	O
inpatient	O
rehabilitation	O
.	O

Melioidosis	O
in	O
Sika	O
deer	O
(	O
Cervus	O
nippon	O
nippon	O
)	O
.	O

Enterobius	O
vermicularis	O
eggs	O
were	O
demonstrated	O
during	O
microscopic	O
examination	O
of	O
a	O
smear	O
taken	O
from	O
the	O
posterior	O
fornix	O
of	O
the	O
vagina	O
.	O

Together	O
with	O
previous	O
work	O
our	O
results	O
suggest	O
that	O
C	B-GENE
/	I-GENE
EBP	I-GENE
may	O
be	O
a	O
general	O
cooperation	O
partner	O
for	O
v	B-GENE
-	I-GENE
Myb	I-GENE
in	O
myelomonocytic	O
cells	O
.	O

When	O
medical	O
aid	O
was	O
sought	O
a	O
false	O
history	O
was	O
given	O
and	O
the	O
true	O
nature	O
of	O
the	O
child	O
'	O
s	O
illness	O
,	O
heat	O
stroke	O
,	O
was	O
not	O
determined	O
until	O
after	O
death	O
.	O

Both	O
DMP2	B-GENE
and	O
DMP3	B-GENE
are	O
closely	O
localized	O
on	O
mouse	O
chromosome	O
5q21	O
,	O
corresponding	O
to	O
human	O
chromosome	O
4q21	O
.	O

This	O
article	O
expands	O
the	O
analysis	O
of	O
a	O
numeric	O
example	O
included	O
in	O
the	O
SAS	O
GLM	O
procedure	O
to	O
cover	O
several	O
crucial	O
statistical	O
aspects	O
relevant	O
to	O
ANCOVA	O
,	O
and	O
to	O
highlight	O
the	O
meaning	O
of	O
the	O
statistical	O
results	O
obtained	O
.	O

A	O
novel	O
alternative	O
spliced	O
variant	O
of	O
the	O
transcription	O
factor	O
AP2alpha	B-GENE
is	O
expressed	O
in	O
the	O
murine	O
ocular	O
lens	O
.	O

Fig1p	B-GENE
and	O
Fig2p	B-GENE
are	O
likely	O
to	O
act	O
at	O
the	O
cell	O
surface	O
as	O
Fig1	B-GENE
:	O
:	O
beta	B-GENE
-	I-GENE
gal	I-GENE
and	O
Fig2	B-GENE
:	O
:	O
beta	B-GENE
-	I-GENE
gal	I-GENE
fusion	I-GENE
proteins	I-GENE
localize	O
to	O
the	O
periphery	O
of	O
mating	O
cells	O
.	O

Crystals	O
of	O
the	O
triple	O
mutant	O
A42D	B-GENE
/	O
D47P	B-GENE
/	O
A63L	B-GENE
,	O
which	O
are	O
stable	O
for	O
days	O
in	O
its	O
oxidized	O
form	O
,	O
were	O
grown	O
from	O
ammonium	O
sulfate	O
,	O
with	O
the	O
cell	O
constants	O
a	O
=	O
b	O
=	O
34	O
.	O
3	O
A	O
and	O
c	O
=	O
111	O
.	O
8	O
A	O
belonging	O
to	O
space	O
group	O
P3	O
(	O
2	O
)	O
21	O
.	O

Nevertheless	O
,	O
PEG	O
influenced	O
in	O
vitro	O
drug	O
availability	O
considerably	O
,	O
by	O
increasing	O
both	O
drug	O
solubility	O
and	O
dissolution	O
rate	O
.	O

Normal	O
replication	O
of	O
DNA	B-GENE
A	I-GENE
still	O
carrying	O
the	O
AC3	B-GENE
ORF	I-GENE
mutation	O
was	O
found	O
in	O
extracts	O
from	O
these	O
plants	O
.	O

Such	O
saturation	O
often	O
occurs	O
for	O
several	O
recording	O
sweeps	O
after	O
large	O
amplitude	O
signals	O
such	O
as	O
eye	O
blinks	O
are	O
rejected	O
.	O

Muscle	O
and	O
liver	O
biopsies	O
demonstrated	O
the	O
same	O
anomalies	O
,	O
again	O
without	O
branching	B-GENE
enzyme	I-GENE
deficiency	O
in	O
the	O
liver	O
.	O

Possibility	O
of	O
using	O
gynecologic	O
nurses	O
in	O
the	O
independently	O
administered	O
health	O
centers	O

Airborne	O
rabies	O
encephalitis	O
:	O
demonstration	O
of	O
rabies	O
virus	O
in	O
the	O
human	O
central	O
nervous	O
system	O
.	O

T1	O
and	O
T2	O
values	O
were	O
calculated	O
from	O
guinea	O
pig	O
brain	O
in	O
vivo	O
at	O
0	O
.	O
5	O
T	O
.	O

Autophosphorylation	O
on	O
the	O
major	O
phosphorylation	O
site	O
Y1235	O
upregulates	O
the	O
kinase	O
activity	O
of	O
the	O
receptor	O
,	O
increasing	O
the	O
Vmax	O
of	O
the	O
phosphotransfer	O
reaction	O
.	O

Clinical	O
development	O
of	O
interleukin	B-GENE
-	I-GENE
10	I-GENE
.	O

By	O
cloning	O
genes	O
encoding	O
benzene	O
-	O
degradative	O
enzymes	O
,	O
we	O
found	O
that	O
strain	O
JS150	O
also	O
carries	O
genes	O
for	O
a	O
toluene	B-GENE
/	I-GENE
benzene	I-GENE
-	I-GENE
2	I-GENE
-	I-GENE
monooxygenase	I-GENE
.	O

Our	O
data	O
suggest	O
that	O
association	O
of	O
TBP	B-GENE
with	O
the	O
TATA	O
box	O
may	O
be	O
regulated	O
,	O
directly	O
or	O
indirectly	O
,	O
by	O
a	O
substrate	O
of	O
Snf1	B-GENE
.	O

Fusion	O
proteins	O
were	O
isolated	O
by	O
affinity	O
chromatography	O
on	O
APTG	O
-	O
Sepharose	O
.	O

It	O
differed	O
from	O
cued	O
recall	O
only	O
in	O
the	O
instructions	O
,	O
which	O
directed	O
subjects	O
away	O
from	O
the	O
memory	O
aspects	O
of	O
the	O
test	O
and	O
asked	O
them	O
to	O
complete	O
each	O
three	O
-	O
letter	O
cue	O
with	O
the	O
first	O
word	O
that	O
came	O
to	O
mind	O
.	O

Real	O
-	O
time	O
two	O
-	O
dimensional	O
echocardiographic	O
studies	O
of	O
the	O
mitral	O
valve	O
in	O
short	O
-	O
axis	O
view	O
were	O
obtained	O
from	O
10	O
normal	O
subjects	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
one	O
percent	O
of	O
the	O
patients	O
had	O
damage	O
within	O
7	O
years	O
of	O
onset	O
(	O
mean	O
3	O
.	O
8	O
yrs	O
)	O
.	O

It	O
was	O
previously	O
shown	O
that	O
Vi	B-GENE
antigen	I-GENE
expression	O
was	O
regulated	O
by	O
a	O
system	O
similar	O
to	O
the	O
rcs	B-GENE
regulatory	O
system	O
involved	O
in	O
colanic	O
acid	O
synthesis	O
in	O
Escherichia	O
coli	O
.	O

The	O
map	O
is	O
based	O
on	O
the	O
CEPH	O
reference	O
pedigrees	O
and	O
includes	O
over	O
4000	O
new	O
genotypes	O
,	O
our	O
previously	O
reported	O
data	O
plus	O
29	O
allele	O
systems	O
from	O
the	O
published	O
CEPH	O
version	O
5	O
database	O
,	O
and	O
was	O
constructed	O
using	O
the	O
program	O
package	O
CRI	O
-	O
MAP	O
.	O

To	O
identify	O
the	O
GRK6	B-GENE
homologue	I-GENE
on	O
chromsome	O
13	O
,	O
several	O
sets	O
of	O
closely	O
-	O
spaced	O
primers	O
were	O
designed	O
based	O
on	O
the	O
GRK6	B-GENE
cDNA	I-GENE
sequence	I-GENE
and	O
then	O
used	O
to	O
amplify	O
human	O
genomic	O
DNA	O
by	O
PCR	O
.	O

In	O
the	O
absence	O
of	O
Mg2	O
+	O
,	O
the	O
extent	O
of	O
destabilization	O
of	O
tRNAPhe	B-GENE
is	O
greater	O
but	O
appears	O
to	O
be	O
confined	O
to	O
internal	O
regions	O
of	O
the	O
acceptor	O
and	O
T	O
psi	O
C	O
helices	O
,	O
as	O
evidenced	O
by	O
the	O
selectively	O
enhanced	O
exchange	O
rates	O
for	O
imino	O
protons	O
associated	O
with	O
these	O
base	O
pairs	O
.	O

Studies	O
in	O
26	O
patients	O
.	O

Serum	B-GENE
alpha	I-GENE
-	I-GENE
amylase	I-GENE
,	O
trypsin	B-GENE
,	O
trypsin	B-GENE
inhibitor	I-GENE
,	O
lipase	B-GENE
and	O
total	O
protease	O
activity	O
in	O
the	O
pancreatic	O
tissue	O
was	O
studied	O
as	O
indicator	O
of	O
the	O
treatment	O
efficacy	O
with	O
5	O
-	O
fluorouracil	O
electro	O
-	O
cumulation	O
.	O

1	O
The	O
effects	O
of	O
high	O
doses	O
of	O
piretanide	O
,	O
a	O
new	O
diuretic	O
agent	O
chemically	O
related	O
to	O
frusemide	O
and	O
bumetanide	O
were	O
evaluated	O
in	O
twelve	O
patients	O
with	O
severe	O
chronic	O
renal	O
insufficiency	O
(	O
creatinine	O
clearance	O
below	O
25	O
ml	O
/	O
min	O
)	O
.	O

Synthesis	O
of	O
22	O
-	O
oxavitamin	O
D3	O
analogues	O
.	O

This	O
effect	O
is	O
independent	O
of	O
the	O
Gal4	B-GENE
protein	I-GENE
,	O
as	O
it	O
operates	O
in	O
a	O
gal4	B-GENE
mutant	I-GENE
background	O
as	O
well	O
.	O

Consistent	O
with	O
the	O
large	O
pocket	O
of	O
Rb	B-GENE
binding	O
to	O
TAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
250	I-GENE
,	O
the	O
large	O
pocket	O
domains	O
of	O
both	O
p107	B-GENE
and	O
p130	B-GENE
are	O
able	O
to	O
bind	O
to	O
TAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
250	I-GENE
in	O
vivo	O
.	O

50	O
-	O
nucleotide	O
)	O
intron	O
to	O
AA	O
.	O

The	O
educational	O
program	O
was	O
the	O
significant	O
factor	O
that	O
influenced	O
the	O
change	O
of	O
concern	O
trajectories	O
,	O
and	O
the	O
recurrent	O
/	O
non	O
-	O
recurrent	O
factor	O
influenced	O
the	O
change	O
of	O
concern	O
only	O
in	O
pamphlet	O
group	O
.	O

Amplification	O
of	O
4q21	O
-	O
q22	O
and	O
the	O
MXR	B-GENE
gene	I-GENE
in	O
independently	O
derived	O
mitoxantrone	O
-	O
resistant	O
cell	O
lines	O
.	O

Activation	O
of	O
the	O
receptor	O
induces	O
Ret	B-GENE
phosphorylation	O
that	O
leads	O
the	O
survival	O
-	O
promoting	O
effects	O
.	O

In	O
patients	O
in	O
which	O
these	O
criteria	O
were	O
not	O
met	O
only	O
the	O
reproducibility	O
of	O
the	O
VO2	O
obtained	O
in	O
both	O
the	O
P	O
-	O
MET	O
and	O
the	O
C	O
-	O
MET	O
indicated	O
that	O
the	O
maximal	O
VO2	O
for	O
these	O
4	O
patients	O
had	O
been	O
reached	O
.	O

This	O
paper	O
describes	O
a	O
course	O
of	O
therapy	O
with	O
an	O
agoraphobic	O
female	O
patient	O
.	O

A	O
previously	O
developed	O
kinetic	O
model	O
was	O
used	O
to	O
identify	O
major	O
chemical	O
reaction	O
pathways	O
involving	O
PAH	O
in	O
the	O
afterburner	O
.	O

Henry	O
Quastler	O
brought	O
experience	O
from	O
an	O
actual	O
x	O
-	O
ray	O
treatment	O
,	O
and	O
Dr	O
.	O

Critical	O
review	O
of	O
tests	O
for	O
the	O
HBs	B-GENE
antigen	I-GENE
in	O
the	O
detection	O
of	O
infectious	O
blood	O

A	O
direct	O
statistically	O
reliable	O
correction	O
of	O
decrease	O
of	O
the	O
enzymes	O
with	O
the	O
initial	O
state	O
of	O
the	O
patients	O
has	O
been	O
established	O
in	O
an	O
analysis	O
of	O
25	O
patients	O
aged	O
from	O
18	O
to	O
60	O
years	O
in	O
prosthesis	O
of	O
+	O
the	O
mitral	O
valve	O
(	O
n	O
-	O
9	O
)	O
and	O
closed	O
mitral	O
commissurotomy	O
(	O
n	O
-	O
16	O
)	O
.	O

DSS4	B-GENE
-	I-GENE
1	I-GENE
is	O
a	O
dominant	O
suppressor	O
of	O
sec4	B-GENE
-	I-GENE
8	I-GENE
that	O
encodes	O
a	O
nucleotide	O
exchange	O
protein	O
that	O
aids	O
Sec4p	B-GENE
function	O
.	O

These	O
findings	O
indicate	O
that	O
KCTG	O
can	O
contribute	O
to	O
improved	O
monitoring	O
in	O
high	O
-	O
risk	O
pregnancies	O
.	O

The	O
MI	O
site	O
is	O
predictive	O
of	O
hemodynamic	O
left	O
ventricular	O
dysfunction	O
both	O
at	O
rest	O
and	O
during	O
exercise	O
:	O
anterior	O
MIs	O
are	O
more	O
impaired	O
than	O
inferior	O
MIs	O
.	O

The	O
vaccine	O
was	O
highly	O
immunogenic	O
,	O
since	O
111	O
of	O
113	O
patients	O
(	O
98	O
%	O
)	O
produced	O
anti	B-GENE
-	I-GENE
HBs	I-GENE
(	O
10	O
mIU	O
/	O
ml	O
or	O
more	O
)	O
.	O

The	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
receptor	I-GENE
alpha	I-GENE
(	O
IL	B-GENE
-	I-GENE
2R	I-GENE
alpha	I-GENE
)	O
chain	O
gene	O
contains	O
a	O
sequence	O
similar	O
to	O
the	O
immunoglobulin	B-GENE
(	I-GENE
Ig	I-GENE
)	I-GENE
kappa	I-GENE
(	O
kappa	O
)	O
enhancer	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
binding	I-GENE
site	I-GENE
.	O

Comparison	O
of	O
the	O
derived	O
amino	O
acid	O
sequence	O
with	O
that	O
of	O
the	O
HCMV	B-GENE
UL99	I-GENE
gene	I-GENE
product	I-GENE
reveals	O
34	O
.	O
8	O
%	O
identity	O
in	O
an	O
overlap	O
of	O
66	O
amino	O
acids	O
.	O

Although	O
mutant	B-GENE
pex5delta	I-GENE
cells	O
expressing	O
a	O
yeast	B-GENE
/	I-GENE
tobacco	I-GENE
Pex5p	I-GENE
chimaera	I-GENE
failed	O
to	O
import	O
a	O
GFP	B-GENE
-	O
Eci1p	B-GENE
reporter	O
protein	O
,	O
they	O
were	O
able	O
to	O
grow	O
on	O
oleic	O
acid	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
introduction	O
of	O
Smad	B-GENE
sites	I-GENE
into	O
a	O
TGFbeta	B-GENE
-	O
insensitive	O
LEF1	B-GENE
/	O
TCF	B-GENE
target	O
gene	O
confers	O
cooperative	O
TGFbeta	B-GENE
and	O
Wnt	B-GENE
responsiveness	O
to	O
the	O
promoter	O
.	O

In	O
analogy	O
to	O
human	B-GENE
CD70	I-GENE
,	O
mCD70	B-GENE
transcript	I-GENE
levels	O
are	O
strongly	O
but	O
transiently	O
up	O
-	O
regulated	O
during	O
lymphocyte	O
activation	O
,	O
which	O
is	O
in	O
line	O
with	O
a	O
role	O
for	O
the	O
CD27	B-GENE
-	I-GENE
CD70	I-GENE
receptor	I-GENE
pair	O
early	O
in	O
the	O
immune	O
response	O
.	O

Serum	B-GENE
IgM	I-GENE
levels	O
showed	O
a	O
highly	O
significant	O
increase	O
in	O
all	O
types	O
of	O
brain	O
tumour	O
when	O
compared	O
to	O
controls	O
.	O

Beyond	O
the	O
first	O
year	O
post	O
-	O
renal	O
transplantation	O
there	O
was	O
no	O
difference	O
in	O
C	O
(	O
IO	O
)	O
between	O
LRD	O
and	O
CAD	O
allografts	O
.	O

Vk8	B-GENE
/	O
Jk2	B-GENE
and	O
Vk1	B-GENE
/	O
Jk5	B-GENE
rearrangements	O
encoded	O
the	O
respective	O
L	B-GENE
chain	I-GENE
V	I-GENE
-	I-GENE
regions	I-GENE
.	O

The	O
phenomena	O
of	O
nursing	O
are	O
deeply	O
rooted	O
in	O
the	O
human	O
condition	O
.	O

Clinical	O
findings	O
plaque	O
index	O
,	O
PI	O
;	O
gingival	O
index	O
,	O
GI	O
;	O
bleeding	O
on	O
probing	O
,	O
BOP	O
;	O
pus	O
discharge	O
,	O
pus	O
;	O
and	O
probing	O
depth	O
,	O
PD	O
at	O
both	O
PT	O
-	O
01	O
and	O
control	O
sites	O
were	O
measured	O
at	O
every	O
visit	O
for	O
4	O
weeks	O
.	O

One	O
of	O
these	O
elements	O
resembles	O
the	O
binding	O
site	O
of	O
a	O
previously	O
identified	O
cellular	O
"	O
transcription	O
"	O
factor	O
.	O

NER	O
was	O
also	O
measured	O
by	O
a	O
plasmid	O
host	O
cell	O
re	O
-	O
activation	O
assay	O
using	O
a	O
vector	O
containing	O
a	O
luciferase	B-GENE
reporter	I-GENE
gene	I-GENE
.	O

Plasma	O
Pi	O
,	O
tibia	O
breaking	O
strength	O
,	O
and	O
percentage	O
of	O
tibia	O
ash	O
were	O
increased	O
by	O
raising	O
dietary	O
Pav	O
in	O
the	O
presence	O
of	O
.	O
392	O
%	O
A1	O
with	O
either	O
level	O
of	O
Ca	O
.	O

A	O
total	O
of	O
114	O
animals	O
were	O
infected	O
by	O
E	O
.	O
coli	O
O2	O
:	O
K1	O
:	O
H4	O
by	O
the	O
hematogenic	O
route	O
.	O

In	O
the	O
fungus	O
Neurospora	O
crassa	O
,	O
nit	B-GENE
-	I-GENE
2	I-GENE
,	O
the	O
major	O
nitrogen	O
regulatory	O
gene	O
,	O
activates	O
the	O
expression	O
of	O
unlinked	O
structural	O
genes	O
that	O
specify	O
nitrogen	O
-	O
catabolic	O
enzymes	O
during	O
conditions	O
of	O
nitrogen	O
limitation	O
.	O

The	O
matrix	O
of	O
the	O
CBs	O
contains	O
the	O
diagnostic	O
protein	O
p80	B-GENE
-	O
coilin	B-GENE
,	O
which	O
is	O
colocalized	O
with	O
the	O
U7	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
(	O
snRNP	O
)	O
,	O
whereas	O
the	O
attached	O
and	O
embedded	O
B	O
-	O
snurposomes	O
contain	O
splicing	O
snRNPs	O
.	O

During	O
an	O
observation	O
period	O
of	O
12	O
weeks	O
after	O
halving	O
atenolol	O
from	O
a	O
mean	O
dose	O
of	O
82	O
mg	O
to	O
41	O
mg	O
,	O
no	O
significant	O
changes	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
or	O
in	O
response	O
rate	O
(	O
defined	O
as	O
a	O
diastolic	O
blood	O
pressure	O
of	O
95	O
mm	O
Hg	O
or	O
less	O
)	O
were	O
observed	O
.	O

Comparative	O
volumetric	O
analysis	O
is	O
defined	O
as	O
the	O
difference	O
between	O
mean	O
corpuscular	O
erythrocyte	O
volume	O
in	O
peripheral	O
blood	O
(	O
MCVB	O
)	O
diluted	O
in	O
urine	O
supernatant	O
after	O
centrifugation	O
and	O
mean	O
corpuscular	O
volume	O
of	O
urinary	O
erythrocytes	O
(	O
MCVU	O
)	O
.	O

PATIENTS	O
:	O
33	O
HIV	O
-	O
infected	O
,	O
zidovudine	O
-	O
experienced	O
patients	O
with	O
serum	O
HIV	O
RNA	O
levels	O
of	O
at	O
least	O
20	O
,	O
000	O
copies	O
/	O
mL	O
and	O
CD4	B-GENE
counts	O
ranging	O
from	O
50	O
to	O
400	O
cells	O
/	O
mm3	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
the	O
WWW	O
has	O
grown	O
enormously	O
.	O

These	O
data	O
,	O
taken	O
together	O
,	O
suggest	O
that	O
CRF	B-GENE
produces	O
its	O
behavioral	O
activating	O
and	O
anxiogenic	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
increasing	O
the	O
activity	O
of	O
LC	O
noradrenergic	O
neurons	O
.	O

On	O
the	O
basis	O
of	O
8	O
cases	O
,	O
the	O
authors	O
report	O
different	O
clinical	O
pictures	O
all	O
caused	O
by	O
cardiac	O
toxicity	O
of	O
5FU	O
.	O

The	O
sequence	O
of	O
Vac1p	B-GENE
contains	O
two	O
putative	O
zinc	O
-	O
binding	O
RING	O
motifs	O
,	O
a	O
zinc	O
finger	O
motif	O
,	O
and	O
a	O
coiled	O
-	O
coil	O
motif	O
.	O

Although	O
cardiac	O
output	O
decreased	O
slightly	O
with	O
PCF	O
,	O
hemodynamic	O
changes	O
due	O
to	O
PCF	O
were	O
unlikely	O
to	O
account	O
for	O
the	O
observed	O
fall	O
in	O
PaO2	O
.	O

Anti	B-GENE
-	I-GENE
Jo	I-GENE
-	I-GENE
1	I-GENE
antibody	I-GENE
was	O
not	O
present	O
.	O

The	O
first	O
operon	O
,	O
orf1	O
-	O
tolQRA	B-GENE
,	O
is	O
iron	O
regulated	O
throughout	O
growth	O
,	O
but	O
iron	O
-	O
regulated	O
expression	O
of	O
tolB	B-GENE
and	O
oprL	B-GENE
fusions	I-GENE
occurs	O
only	O
in	O
late	O
log	O
phase	O
.	O

S	O
.	O
aureus	O
leakage	O
into	O
the	O
totally	O
submerged	O
test	O
specimens	O
was	O
detected	O
in	O
1	O
of	O
5	O
samples	O
incubated	O
for	O
4	O
weeks	O
,	O
while	O
no	O
leakage	O
was	O
detected	O
in	O
specimens	O
incubated	O
for	O
3	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
and	O
8	O
weeks	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
a	O
cryptic	O
plasmid	O
,	O
pRmeGR4b	O
,	O
to	O
the	O
nodulation	O
of	O
Medicago	O
sativa	O
by	O
strain	O
GR4	O
of	O
Rhizobium	O
meliloti	O
.	O

It	O
also	O
appears	O
that	O
in	O
patients	O
with	O
laboratory	O
diagnosis	O
of	O
prerenal	O
acute	O
renal	O
failure	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
RFT	O
less	O
than	O
1	O
.	O
0	O
)	O
,	O
the	O
response	O
to	O
treatment	O
is	O
unpredictable	O
and	O
in	O
fact	O
may	O
have	O
a	O
worse	O
prognosis	O
than	O
in	O
those	O
with	O
a	O
RFI	O
greater	O
than	O
1	O
.	O
0	O
(	O
5	O
/	O
7	O
deaths	O
vs	O
10	O
/	O
48	O
deaths	O
)	O
.	O

Paraplegia	O
associated	O
with	O
intraaortic	O
balloon	O
pump	O
counterpulsation	O
.	O

CTP	O
,	O
GDP	O
,	O
GTP	O
,	O
ITP	O
)	O
did	O
not	O
affect	O
the	O
response	O
.	O

Using	O
green	B-GENE
fluorescent	I-GENE
protein	I-GENE
fusions	O
we	O
demonstrate	O
that	O
the	O
SYT	B-GENE
,	O
SSX	B-GENE
and	O
the	O
SYT	B-GENE
-	O
SSX	B-GENE
proteins	O
are	O
nuclear	O
proteins	O
.	O

The	O
anaesthetic	O
management	O
of	O
41	O
patients	O
who	O
underwent	O
cardiac	O
transplantation	O
during	O
a	O
40	O
month	O
period	O
at	O
Clinica	O
Puerta	O
de	O
Hierro	O
is	O
reviewed	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
data	O
suggested	O
that	O
mutant	B-GENE
PS1	I-GENE
may	O
cause	O
disease	O
as	O
a	O
result	O
of	O
reduction	O
in	O
PS1	B-GENE
function	O
.	O

The	O
analysis	O
of	O
the	O
organization	O
of	O
the	O
sequence	O
of	O
the	O
human	O
ABP	B-GENE
/	O
DAO	B-GENE
gene	O
reveals	O
that	O
the	O
2	O
.	O
4	O
-	O
kilobase	O
messenger	O
RNA	O
is	O
transcribed	O
from	O
two	O
close	O
origins	O
identifying	O
the	O
proximal	O
promoter	O
.	O

Most	O
important	O
,	O
after	O
all	O
,	O
is	O
not	O
the	O
ionization	O
technique	O
but	O
the	O
stage	O
with	O
a	O
47	O
.	O
1	O
%	O
five	O
-	O
year	O
survival	O
rate	O
in	O
T1N0	O
as	O
compared	O
to	O
T2N0	O
with	O
28	O
.	O
6	O
%	O
and	O
T1N1	O
with	O
19	O
.	O
4	O
%	O
.	O

To	O
investigate	O
the	O
step	O
of	O
spliceosome	O
assembly	O
at	O
which	O
Snu17p	B-GENE
acts	O
,	O
we	O
have	O
used	O
nondenaturing	O
gel	O
electrophoresis	O
.	O

We	O
also	O
show	O
that	O
an	O
internal	O
fragment	O
of	O
U24	B-GENE
methylation	I-GENE
guide	I-GENE
snoRNA	I-GENE
,	O
encompassing	O
the	O
upstream	O
antisense	O
element	O
and	O
the	O
D	O
'	O
and	O
C	O
'	O
box	O
motifs	O
,	O
can	O
support	O
the	O
site	O
-	O
specific	O
methylation	O
of	O
rRNA	O
.	O

Mammalian	O
ribonucleotide	B-GENE
reductase	I-GENE
shows	O
S	O
-	O
phase	O
specific	O
expression	O
and	O
consists	O
of	O
two	O
non	O
-	O
identical	O
subunits	O
,	O
proteins	B-GENE
R1	I-GENE
(	O
large	O
subunit	O
)	O
and	O
R2	B-GENE
(	O
small	O
subunit	O
)	O
.	O

Effects	O
of	O
dexamethasone	O
on	O
the	O
development	O
of	O
radiation	O
nephropathy	O
in	O
the	O
rat	O
.	O

Recombinant	B-GENE
MsERK1	I-GENE
(	O
rMsERK1	B-GENE
)	O
,	O
when	O
overexpressed	O
in	O
Escherichia	O
coli	O
,	O
is	O
recognized	O
by	O
antibodies	O
raised	O
against	O
MAP	B-GENE
kinases	I-GENE
from	I-GENE
rat	I-GENE
,	I-GENE
Xenopus	I-GENE
,	I-GENE
and	I-GENE
sea	I-GENE
star	I-GENE
and	O
by	O
anti	B-GENE
-	I-GENE
phosphotyrosine	I-GENE
antibodies	I-GENE
.	O

The	O
identification	O
of	O
SRP54sc	B-GENE
and	O
SRP54sp	B-GENE
provides	O
the	O
first	O
evidence	O
for	O
SRP	B-GENE
related	O
proteins	O
in	O
yeast	O
.	O

We	O
previously	O
demonstrated	O
that	O
AKT2	B-GENE
,	O
a	O
member	O
of	O
protein	B-GENE
kinase	I-GENE
B	I-GENE
family	I-GENE
,	O
is	O
activated	O
by	O
a	O
number	O
of	O
growth	O
factors	O
via	O
Ras	B-GENE
and	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
signaling	O
pathways	O
.	O

So	O
it	O
is	O
sometimes	O
more	O
convenient	O
to	O
use	O
the	O
back	O
Radon	O
transform	O
R	O
-	O
1	O
and	O
then	O
to	O
correct	O
the	O
result	O
,	O
taking	O
into	O
account	O
attenuation	O
.	O

Before	O
flecainide	O
,	O
all	O
patients	O
had	O
easily	O
inducible	O
VT	O
that	O
was	O
morphologically	O
identical	O
to	O
their	O
spontaneously	O
occurring	O
arrhythmia	O
.	O

An	O
additional	O
dose	O
of	O
20	O
-	O
25	O
Gy	O
was	O
delivered	O
to	O
the	O
site	O
of	O
original	O
involvement	O
using	O
an	O
implant	O
when	O
feasible	O
.	O

The	O
prominent	O
fracture	O
of	O
women	O
older	O
than	O
75	O
years	O
is	O
the	O
hip	O
fracture	O
(	O
type	O
II	O
osteoporosis	O
)	O
.	O

The	O
expected	O
products	O
of	O
the	O
cloned	O
bph	B-GENE
genes	I-GENE
,	O
except	O
bphA3	B-GENE
,	O
were	O
observed	O
in	O
E	O
.	O
coli	O
in	O
an	O
in	O
vitro	O
transcription	O
-	O
translation	O
system	O
.	O

It	O
is	O
our	O
conclusion	O
that	O
Sonoclot	O
coagulation	O
analysis	O
is	O
unlikely	O
to	O
identify	O
patients	O
with	O
prolonged	O
bleeding	O
time	O
in	O
whom	O
platelet	O
count	O
and	O
other	O
coagulation	O
factors	O
are	O
normal	O
.	O

RESULTS	O
:	O
Analysis	O
by	O
Pearson	O
'	O
s	O
correlation	O
showed	O
that	O
the	O
subjects	O
who	O
had	O
higher	O
scores	O
of	O
SSMS	O
during	O
the	O
drum	O
rotation	O
generated	O
the	O
following	O
:	O
a	O
)	O
a	O
higher	O
rating	O
of	O
over	O
-	O
all	O
sickness	O
(	O
r	O
=	O
0	O
.	O
76	O
)	O
;	O
b	O
)	O
a	O
higher	O
ratio	O
of	O
spectral	O
power	O
of	O
EGG	O
at	O
4	O
-	O
9	O
cycles	O
per	O
minute	O
(	O
cpm	O
)	O
between	O
drum	O
rotation	O
and	O
baseline	O
periods	O
(	O
r	O
=	O
0	O
.	O
63	O
)	O
;	O
c	O
)	O
a	O
higher	O
net	O
percent	O
increase	O
of	O
spectral	O
power	O
in	O
the	O
EEG	O
frequency	O
band	O
0	O
.	O
5	O
-	O
4	O
Hz	O
between	O
drum	O
rotation	O
and	O
baseline	O
periods	O
on	O
C3	O
(	O
r	O
=	O
0	O
.	O
29	O
)	O
and	O
C4	O
(	O
r	O
=	O
0	O
.	O
31	O
)	O
;	O
d	O
)	O
a	O
higher	O
ratio	O
of	O
spectral	O
power	O
of	O
EEG	O
frequency	O
band	O
0	O
.	O
5	O
-	O
4	O
Hz	O
between	O
drum	O
rotation	O
and	O
baseline	O
periods	O
on	O
C3	O
(	O
r	O
=	O
0	O
.	O
31	O
)	O
;	O
and	O
e	O
)	O
a	O
higher	O
level	O
of	O
net	O
increase	O
in	O
skin	O
conductance	O
from	O
baseline	O
to	O
drum	O
rotation	O
(	O
r	O
=	O
0	O
.	O
30	O
)	O
.	O

Salts	O
of	O
these	O
four	O
metal	O
ions	O
may	O
be	O
added	O
to	O
the	O
growth	O
medium	O
to	O
facilitate	O
selective	O
isolation	O
of	O
Acinetobacter	O
.	O

The	O
consensus	O
mammalian	O
ER	O
stress	O
response	O
element	O
(	O
ERSE	O
)	O
conserved	O
among	O
grp	B-GENE
promoters	I-GENE
consists	O
of	O
a	O
tripartite	O
structure	O
CCAAT	O
(	O
N9	O
)	O
CCACG	O
,	O
with	O
N	O
being	O
a	O
strikingly	O
GC	O
-	O
rich	O
region	O
of	O
9	O
bp	O
.	O

Acute	O
toxicity	O
tests	O
were	O
conducted	O
to	O
measure	O
the	O
response	O
of	O
first	O
instar	O
Toxorhynchites	O
splendens	O
to	O
commonly	O
used	O
mosquito	O
adulticides	O
:	O
malathion	O
,	O
naled	O
and	O
resmethrin	O
.	O

A	O
positive	O
correlation	O
was	O
also	O
established	O
between	O
the	O
level	O
of	O
FP9C	B-GENE
binding	O
and	O
the	O
degree	O
of	O
cell	O
differentiation	O
in	O
vitro	O
.	O

Effects	O
of	O
acute	O
exposure	O
to	O
cold	O
on	O
pulmonary	O
arterial	O
blood	O
pressure	O
in	O
awake	O
rats	O
.	O

When	O
labeled	O
by	O
the	O
described	O
method	O
,	O
99mTc	O
on	O
DTPA	O
coupled	O
antibodies	O
shows	O
instability	O
in	O
serum	O
but	O
superior	O
stability	O
than	O
99mTc	O
on	O
antibodies	O
without	O
the	O
attached	O
DTPA	O
.	O

Unlike	O
CSK	B-GENE
,	O
the	O
SH3	B-GENE
domain	I-GENE
of	O
HYL	B-GENE
was	O
unique	O
since	O
the	O
ALYDY	O
motif	O
was	O
absent	O
.	O

As	O
the	O
mechanism	O
of	O
the	O
intractability	O
,	O
cell	O
function	O
involved	O
in	O
the	O
defense	O
against	O
infection	O
was	O
evaluated	O
.	O

88	O
,	O
3739	O
-	O
3743	O
)	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fulminant	O
neuropathy	O
with	O
severe	O
quadriparesis	O
associated	O
with	O
vincristine	O
chemotherapy	O
.	O

The	O
median	O
survival	O
time	O
was	O
18	O
months	O
.	O

Hemorrheological	O
evaluation	O
and	O
proposed	O
pharmacological	O
uses	O
.	O

Its	O
phosphorylation	O
strongly	O
potentiates	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
promoter	I-GENE
through	O
a	O
ternary	O
complex	O
assembled	O
on	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
serum	I-GENE
response	I-GENE
element	I-GENE
.	O

Fus3p	B-GENE
and	O
Kss1p	B-GENE
together	O
increase	O
the	O
expression	O
of	O
CLN3	B-GENE
and	O
PCL2	B-GENE
genes	I-GENE
that	O
promote	O
budding	O
,	O
and	O
Kss1p	B-GENE
inhibits	O
the	O
MAP	B-GENE
kinase	I-GENE
cascade	O
.	O

Consistent	O
with	O
our	O
observation	O
that	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	O
does	O
not	O
contribute	O
to	O
c	B-GENE
-	I-GENE
Jun	I-GENE
coactivation	O
is	O
the	O
observation	O
that	O
the	O
activation	O
of	O
PU	B-GENE
.	I-GENE
1	I-GENE
by	O
c	B-GENE
-	I-GENE
Jun	I-GENE
is	O
blocked	O
by	O
overexpression	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
.	O

A	O
possible	O
correlation	O
between	O
mandibular	O
growth	O
retardation	O
and	O
palatal	O
clefting	O
is	O
discussed	O
.	O

Time	O
dependence	O
of	O
frequency	O
potentiation	O
in	O
the	O
isolated	O
guinea	O
-	O
pig	O
'	O
s	O
atrium	O
.	O

We	O
found	O
4	O
highly	O
conserved	O
regions	O
to	O
vertebrate	B-GENE
Hsp90	I-GENE
exclusively	O
and	O
27	O
amino	O
acids	O
conserved	O
among	O
but	O
differing	O
between	O
Hsp90	B-GENE
alpha	I-GENE
and	O
Hsp90	B-GENE
beta	I-GENE
sequences	I-GENE
.	O

Characterization	O
of	O
trinucleotide	O
-	O
and	O
tandem	O
repeat	O
-	O
containing	O
transcripts	O
obtained	O
from	O
human	O
spinal	O
cord	O
cDNA	O
library	O
by	O
high	O
-	O
density	O
filter	O
hybridization	O
.	O

We	O
present	O
here	O
the	O
complete	O
primary	O
structure	O
of	O
human	B-GENE
gp330	I-GENE
,	O
the	O
human	O
variant	O
of	O
the	O
principal	O
kidney	O
autoantigen	O
causing	O
Heymann	O
membranous	O
glomerulonephritis	O
in	O
rats	O
.	O

The	O
platelet	B-GENE
membrane	I-GENE
glycoprotein	I-GENE
IIb	I-GENE
/	I-GENE
IIIa	I-GENE
receptor	I-GENE
inhibitor	O
abciximab	O
is	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
undergoing	O
high	O
-	O
risk	O
percutaneous	O
coronary	O
interventions	O
and	O
is	O
used	O
in	O
approximately	O
one	O
third	O
of	O
coronary	O
interventions	O
in	O
the	O
United	O
States	O
and	O
a	O
growing	O
number	O
of	O
procedures	O
in	O
Europe	O
.	O

In	O
the	O
conscious	O
animals	O
the	O
increase	O
reached	O
statistical	O
significance	O
when	O
the	O
animals	O
were	O
exposed	O
to	O
12	O
%	O
oxygen	O
in	O
nitrogen	O
,	O
which	O
produced	O
a	O
fall	O
in	O
arterial	O
PaO2	O
of	O
44	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
0	O
%	O
.	O

Prenatal	O
diagnosis	O
of	O
genetic	O
diseases	O
.	O

Human	B-GENE
epidermal	I-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
,	O
a	O
naturally	O
occurring	O
protein	O
,	O
has	O
been	O
implicated	O
in	O
the	O
protection	O
of	O
gastrointestinal	O
mucosal	O
integrity	O
.	O

A	O
ready	O
-	O
made	O
prosthesis	O
is	O
placed	O
on	O
the	O
external	O
side	O
of	O
the	O
ribs	O
vertically	O
bridging	O
the	O
flailed	O
chest	O
segment	O
,	O
and	O
fixed	O
to	O
the	O
first	O
upper	O
and	O
first	O
lower	O
intact	O
rib	O
as	O
well	O
as	O
to	O
the	O
mobile	O
segments	O
of	O
the	O
affected	O
ribs	O
.	O

DESIGN	O
:	O
Prospective	O
case	O
study	O
(	O
Canadian	O
Task	O
Force	O
classification	O
II	O
-	O
2	O
)	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
T4	B-GENE
endonuclease	I-GENE
V	I-GENE
gene	I-GENE
:	O
role	O
of	O
lysine	O
-	O
130	O
.	O

A	O
minimal	O
pheromone	O
induction	O
domain	O
,	O
delineated	O
as	O
residues	O
301	O
to	O
335	O
of	O
Ste12p	B-GENE
,	O
is	O
dependent	O
on	O
the	O
pheromone	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
pathway	O
for	O
induction	O
activity	O
.	O

The	O
library	O
will	O
thus	O
be	O
useful	O
for	O
the	O
selection	O
of	O
cosmid	O
clones	O
which	O
carry	O
CDC	B-GENE
genes	I-GENE
from	I-GENE
yeast	I-GENE
by	O
complementing	O
first	O
,	O
with	O
the	O
vectorial	O
yeast	B-GENE
gene	I-GENE
URA1	I-GENE
,	O
the	O
pyrimidine	O
auxotrophy	O
of	O
most	O
cdc	B-GENE
-	O
strains	O
and	O
then	O
,	O
with	O
the	O
respective	O
CDC	B-GENE
wild	I-GENE
-	I-GENE
type	I-GENE
genes	I-GENE
,	O
of	O
the	O
temperature	O
-	O
sensitive	O
mutant	O
alleles	O
.	O

These	O
mutant	B-GENE
rps7	I-GENE
leaders	O
were	O
ligated	O
into	O
an	O
aadA	O
expression	O
cassette	O
and	O
transformed	O
into	O
the	O
chloroplast	O
of	O
C	O
.	O
reinhardtii	O
and	O
into	O
E	O
.	O
coli	O
.	O

In	O
addition	O
,	O
both	O
activated	O
Ral	B-GENE
-	I-GENE
GDS	I-GENE
-	I-GENE
like	I-GENE
factor	O
and	O
Raf	B-GENE
stimulate	O
cyclin	B-GENE
D	I-GENE
(	I-GENE
1	I-GENE
)	I-GENE
transcription	O
and	O
E2F	B-GENE
activity	O
and	O
act	O
in	O
synergy	O
with	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
.	O

From	O
the	O
present	O
results	O
a	O
concept	O
of	O
hormone	O
-	O
dependent	O
AR	B-GENE
activation	O
is	O
proposed	O
,	O
which	O
requires	O
a	O
functional	O
,	O
direct	O
or	O
indirect	O
intramolecular	O
interaction	O
between	O
the	O
TAD	O
and	O
the	O
LBD	O
.	O

Like	O
the	O
DMA	B-GENE
,	O
but	O
unlike	O
all	O
other	O
mammalian	B-GENE
class	I-GENE
II	I-GENE
A	I-GENE
genes	I-GENE
,	O
the	O
zebrafish	O
gene	O
codes	O
for	O
two	O
cysteine	O
residues	O
which	O
might	O
potentially	O
be	O
involved	O
in	O
the	O
formation	O
of	O
a	O
disulfide	O
bond	O
in	O
the	O
alpha	O
1	O
domain	O
.	O

Down	O
-	O
regulation	O
of	O
Id1	B-GENE
mRNA	I-GENE
correlated	O
with	O
mitogenesis	O
and	O
occurred	O
when	O
quiescent	O
cells	O
were	O
treated	O
with	O
growth	O
factors	O
that	O
activate	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptors	I-GENE
and	O
receptor	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinases	I-GENE
but	O
not	O
with	O
a	O
non	O
-	O
mitogenic	O
cAMP	O
analog	O
.	O

Secretogranin	B-GENE
II	I-GENE
(	O
SgII	B-GENE
)	O
is	O
a	O
secretory	O
polypeptide	O
stored	O
in	O
large	O
dense	O
core	O
vesicles	O
of	O
neuroendocrine	O
and	O
neuronal	O
cells	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
results	O
of	O
this	O
study	O
,	O
SDB	O
,	O
even	O
snoring	O
,	O
was	O
independently	O
associated	O
with	O
hypertension	O
in	O
both	O
men	O
and	O
women	O
.	O

The	O
electron	O
spin	O
resonance	O
study	O
also	O
demonstrated	O
that	O
the	O
formation	O
of	O
superoxide	O
-	O
DMPO	O
spin	O
adduct	O
was	O
strongly	O
inhibited	O
by	O
a	O
selective	O
cyclooxygenase	B-GENE
-	I-GENE
2	I-GENE
inhibitor	O
,	O
etodolac	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

BK	B-GENE
-	O
induced	O
translocation	O
and	O
overexpression	O
of	O
PKC	B-GENE
isoforms	I-GENE
as	O
well	O
as	O
coexpression	O
of	O
inactive	O
or	O
constitutively	O
active	O
mutants	O
of	O
different	O
PKC	B-GENE
isozymes	I-GENE
provided	O
evidence	O
for	O
a	O
role	O
of	O
the	O
diacylglycerol	O
-	O
sensitive	O
PKCs	B-GENE
alpha	I-GENE
and	I-GENE
epsilon	I-GENE
in	O
BK	B-GENE
signaling	O
toward	O
MAPK	B-GENE
.	O

Embryonal	O
mortality	O

A	O
lead	O
phthalocyanin	O
method	O
for	O
the	O
demonstration	O
of	O
acid	B-GENE
hydrolases	I-GENE
in	O
plant	O
and	O
animal	O
tissues	O
.	O

Here	O
we	O
describe	O
the	O
characterization	O
of	O
cDNAs	O
encoding	O
two	O
unusual	O
E2Fs	B-GENE
,	O
E2F	B-GENE
-	I-GENE
4	I-GENE
and	O
E2F	B-GENE
-	I-GENE
5	I-GENE
,	O
each	O
identified	O
by	O
the	O
ability	O
of	O
their	O
gene	O
product	O
to	O
interact	O
with	O
p130	B-GENE
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

Interestingly	O
,	O
unlike	O
PAK65	B-GENE
,	O
HPK1	B-GENE
does	O
not	O
contain	O
the	O
small	B-GENE
GTPase	I-GENE
Rac1	B-GENE
/	O
Cdc42	B-GENE
-	O
binding	O
domain	O
and	O
does	O
not	O
bind	O
to	O
either	O
Rac1	B-GENE
or	O
Cdc42	B-GENE
,	O
suggesting	O
that	O
HPK1	B-GENE
.	O
activation	O
is	O
Rac1	B-GENE
/	O
Cdc42	B-GENE
-	O
independent	O
.	O

The	O
results	O
were	O
compared	O
with	O
the	O
findings	O
in	O
pair	O
-	O
fed	O
non	O
-	O
treated	O
animals	O
(	O
Control	O
Group	O
)	O
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
levels	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunoabsorbent	O
assay	O
in	O
plasma	O
samples	O
obtained	O
from	O
the	O
hyperthermic	O
isolated	O
limb	O
perfusion	O
circuit	O
and	O
systemic	O
circulation	O
.	O

However	O
,	O
only	O
plasma	B-GENE
fibrinogen	I-GENE
concentrations	O
showed	O
statistically	O
significant	O
positive	O
associations	O
with	O
IMT	O
in	O
both	O
groups	O
.	O

Without	O
a	O
team	O
,	O
there	O
is	O
little	O
hope	O
for	O
fetal	O
survival	O
;	O
mortality	O
will	O
be	O
80	O
-	O
100	O
%	O
.	O

Analysis	O
of	O
deletion	O
and	O
substitution	O
mutations	O
in	O
the	O
MER2	B-GENE
5	I-GENE
'	I-GENE
exon	I-GENE
demonstrates	O
that	O
the	O
unusually	O
large	O
size	O
of	O
this	O
exon	O
plays	O
an	O
important	O
role	O
in	O
splicing	O
regulation	O
.	O

To	O
study	O
the	O
signaling	O
pathways	O
that	O
regulate	O
cytoskeletal	O
rearrangements	O
in	O
T	O
lymphocytes	O
,	O
we	O
set	O
up	O
a	O
conjugate	O
formation	O
assay	O
using	O
Jurkat	O
T	O
cells	O
as	O
effectors	O
and	O
cell	O
-	O
sized	O
latex	O
beads	O
coated	O
with	O
various	O
antibodies	O
as	O
artificial	O
APCs	O
.	O

Reexamination	O
of	O
the	O
cdc4	B-GENE
-	I-GENE
1	I-GENE
mutant	I-GENE
revealed	O
that	O
,	O
in	O
addition	O
to	O
being	O
defective	O
in	O
the	O
onset	O
of	O
S	O
phase	O
,	O
it	O
is	O
also	O
defective	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
transition	O
when	O
released	O
from	O
hydroxyurea	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
.	O

All	O
such	O
polypeptides	O
containing	O
263	O
or	O
more	O
residues	O
derived	O
from	O
the	O
C	O
-	O
terminus	O
of	O
P130gag	B-GENE
-	O
fps	B-GENE
(	O
i	O
.	O
e	O
.	O
residues	O
920	O
-	O
1182	O
)	O
were	O
enzymatically	O
active	O
as	O
tyrosine	B-GENE
kinases	I-GENE
.	O

A	O
structural	O
model	O
for	O
Vpu	B-GENE
is	O
proposed	O
in	O
which	O
the	O
membrane	O
anchor	O
precedes	O
a	O
region	O
comprising	O
two	O
amphipathic	O
alpha	O
-	O
helices	O
of	O
opposed	O
polarity	O
,	O
joined	O
by	O
a	O
strongly	O
acidic	O
turn	O
that	O
protrudes	O
into	O
the	O
cytoplasm	O
and	O
contains	O
the	O
CK	B-GENE
-	I-GENE
2	I-GENE
phosphorylation	I-GENE
sites	I-GENE
.	O

The	O
recombinant	O
containing	O
the	O
full	O
-	O
length	O
polyhedrin	B-GENE
leader	O
sequence	O
gave	O
levels	O
of	O
N	B-GENE
mRNA	I-GENE
comparable	O
to	O
those	O
of	O
AcNPV	B-GENE
polyhedrin	I-GENE
mRNA	I-GENE
.	O

Immune	O
and	O
clinical	O
impact	O
of	O
Lactobacillus	O
acidophilus	O
on	O
asthma	O
.	O

Thus	O
,	O
CARP	B-GENE
is	O
a	O
YB	B-GENE
-	I-GENE
1	I-GENE
associated	I-GENE
factor	I-GENE
and	O
represents	O
the	O
first	O
identified	O
cardiac	O
-	O
restricted	O
downstream	O
regulatory	O
gene	O
in	O
the	O
homeobox	O
gene	O
Nkx2	B-GENE
-	I-GENE
5	I-GENE
pathway	O
and	O
may	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
HF	B-GENE
-	I-GENE
1	I-GENE
-	O
dependent	O
pathways	O
for	O
ventricular	O
muscle	O
gene	O
expression	O
.	O

Each	O
receptor	O
must	O
therefore	O
engage	O
a	O
unique	O
subset	O
of	O
the	O
available	O
signaling	O
elements	O
-	O
-	O
at	O
least	O
partly	O
through	O
the	O
selection	O
of	O
proteins	O
with	O
src	B-GENE
-	I-GENE
homology	I-GENE
2	I-GENE
domains	I-GENE
(	O
SH2	B-GENE
proteins	I-GENE
)	O
.	O

A	O
proposed	O
method	O
.	O

A	O
model	O
for	O
the	O
SMase	B-GENE
-	O
sphingomyelin	O
complex	O
structure	O
was	O
built	O
to	O
investigate	O
how	O
the	O
SMase	B-GENE
specifically	O
recognizes	O
its	O
substrate	O
.	O

Two	O
estimates	O
of	O
the	O
fractal	O
exponent	O
are	O
considered	O
which	O
do	O
not	O
suffer	O
from	O
this	O
limit	O
:	O
one	O
derived	O
from	O
the	O
Allan	O
variance	O
,	O
which	O
was	O
developed	O
by	O
the	O
authors	O
,	O
and	O
one	O
based	O
on	O
the	O
periodogram	O
.	O

Births	O
,	O
marriages	O
,	O
divorces	O
,	O
and	O
deaths	O
for	O
July	O
1997	O
.	O

In	O
conclusion	O
,	O
in	O
coronary	O
artery	O
disease	O
patients	O
,	O
exercise	O
-	O
redistribution	O
201Thallium	O
cardiac	O
imaging	O
with	O
reinjection	O
at	O
rest	O
can	O
identify	O
severely	O
ischemic	O
but	O
still	O
viable	O
myocardium	O
and	O
may	O
be	O
particularly	O
useful	O
in	O
the	O
prognosis	O
of	O
such	O
patients	O
.	O

However	O
,	O
the	O
recovery	O
curve	O
of	O
the	O
R2	O
component	O
of	O
the	O
blink	O
reflex	O
diminished	O
in	O
patients	O
with	O
tension	O
-	O
type	O
headache	O
compared	O
with	O
the	O
other	O
groups	O
.	O

When	O
recombinant	B-GENE
gE	I-GENE
produced	O
in	O
HeLa	O
cells	O
was	O
probed	O
with	O
the	O
same	O
antiphosphotyrosine	O
antibody	O
,	O
a	O
dimeric	B-GENE
gE	I-GENE
form	O
at	O
130	O
kDa	O
was	O
detected	O
on	O
the	O
cell	O
surface	O
.	O

Transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
(	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
)	O
inhibits	O
cell	O
cycle	O
progression	O
,	O
in	O
part	O
through	O
up	O
-	O
regulation	O
of	O
gene	O
expression	O
of	O
the	O
p21	B-GENE
(	O
WAF1	B-GENE
/	O
Cip1	B-GENE
)	O
(	O
p21	B-GENE
)	O
cell	O
cycle	O
inhibitor	O
.	O

The	O
results	O
suggest	O
that	O
both	O
superficial	O
and	O
deep	O
cortical	O
venous	O
drainage	O
of	O
the	O
cat	O
kidney	O
should	O
be	O
considered	O
when	O
measuring	O
renal	B-GENE
renin	I-GENE
release	O
.	O

CONCLUSION	O
:	O
Detection	O
of	O
recurrent	O
head	O
and	O
neck	O
cancer	O
is	O
feasible	O
with	O
FDG	O
PET	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
incidence	O
of	O
fractured	O
zonas	O
.	O

DSIP	O
was	O
found	O
to	O
significantly	O
increase	O
slow	O
-	O
waves	O
(	O
delta	O
sleep	O
)	O
in	O
the	O
sleep	O
EEG	O
.	O

Accuracy	O
and	O
predictive	O
value	O
of	O
ultrasound	O
in	O
acute	O
rejection	O
.	O

7	O
-	O
Nitroindazole	O
(	O
7NI	O
)	O
,	O
a	O
relatively	O
selective	O
neuronal	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
nNOS	B-GENE
)	O
inhibitor	O
.	O
was	O
intraperitoneally	O
administered	O
to	O
the	O
guinea	O
pigs	O
30	O
minutes	O
before	O
the	O
onset	O
of	O
local	O
anoxia	O
.	O

Mutations	O
that	O
extend	O
the	O
specificity	O
of	O
the	O
endonuclease	O
activity	O
of	O
lambda	B-GENE
terminase	I-GENE
.	O

The	O
gene	O
set	O
in	O
this	O
mitochondrial	O
genome	O
is	O
a	O
subset	O
of	O
that	O
of	O
Reclinomonas	O
americana	O
,	O
an	O
amoeboid	O
protozoan	O
.	O

An	O
evaluation	O
of	O
a	O
positive	O
control	O
for	O
platelet	O
neutralization	O
procedure	O
testing	O
with	O
seven	O
commercial	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
reagents	O
.	O

The	O
prosomal	B-GENE
RNA	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
p27K	I-GENE
is	O
a	O
member	O
of	O
the	O
alpha	B-GENE
-	I-GENE
type	I-GENE
human	I-GENE
prosomal	I-GENE
gene	I-GENE
family	I-GENE
.	O

A	O
single	O
clone	O
,	O
which	O
was	O
conserved	O
and	O
had	O
near	O
-	O
perfect	O
homology	O
to	O
eight	O
human	O
/	O
rodent	O
expressed	O
sequence	O
tags	O
,	O
was	O
used	O
as	O
template	O
for	O
5	O
'	O
and	O
3	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
and	O
SPICE	O
(	O
system	O
for	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
cDNA	O
ends	O
)	O
reactions	O
to	O
obtain	O
the	O
3	O
.	O
6	O
-	O
kb	O
cDNA	O
,	O
LGL2	B-GENE
(	O
Genbank	B-GENE
,	I-GENE
AF	I-GENE
110195	I-GENE
)	O
encoding	O
a	O
deduced	O
polypeptide	O
(	O
lgl2	B-GENE
)	O
of	O
963	O
amino	O
acids	O
.	O

These	O
tiny	O
premature	O
infants	O
also	O
received	O
PN	O
for	O
significantly	O
longer	O
periods	O
of	O
time	O
,	O
and	O
the	O
longer	O
the	O
infusions	O
were	O
administered	O
the	O
greater	O
was	O
the	O
risk	O
of	O
cholestasis	O
developing	O
.	O

The	O
SM	O
-	O
specific	O
selection	O
of	O
exon	O
2	O
results	O
from	O
the	O
inhibition	O
of	O
exon	O
3	O
.	O

It	O
is	O
always	O
present	O
and	O
has	O
a	O
discrete	O
origin	O
and	O
insertion	O
.	O

Medical	O
management	O
of	O
early	O
-	O
stage	O
breast	O
cancer	O
.	O

Five	O
girls	O
with	O
Turner	O
'	O
s	O
syndrome	O
aged	O
12	O
to	O
17	O
years	O
showed	O
LH	B-GENE
values	O
(	O
5	O
.	O
0	O
-	O
14	O
.	O
5	O
IU	O
/	O
12	O
h	O
)	O
at	O
the	O
upper	O
end	O
of	O
or	O
slightly	O
above	O
the	O
normal	O
range	O
and	O
pathologically	O
high	O
values	O
(	O
22	O
.	O
2	O
-	O
43	O
.	O
5	O
IU	O
/	O
12	O
h	O
)	O
for	O
FSH	B-GENE
.	O

In	O
vitro	O
death	O
assays	O
with	O
transient	O
overexpression	O
of	O
deletion	O
constructs	O
of	O
both	O
isoforms	O
using	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
as	O
a	O
reporter	O
gene	O
in	O
MCF7	O
cells	O
suggest	O
the	O
following	O
:	O
1	O
)	O
the	O
nucleotide	O
binding	O
domain	O
may	O
act	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
killing	O
activity	O
of	O
DEFCAP	B-GENE
;	O
2	O
)	O
the	O
LRR	B-GENE
/	O
CARD	B-GENE
represents	O
a	O
putative	O
constitutively	O
active	O
inducer	O
of	O
apoptosis	O
;	O
3	O
)	O
the	O
killing	O
activity	O
of	O
LRR	B-GENE
/	O
CARD	B-GENE
is	O
inhibitable	O
by	O
benzyloxycarbonyl	O
-	O
Val	O
-	O
Ala	O
-	O
Asp	O
(	O
OMe	O
)	O
-	O
fluoromethyl	O
ketone	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
Asp	O
-	O
Glu	O
-	O
Val	O
-	O
Asp	O
(	O
OMe	O
)	O
-	O
fluoromethyl	O
ketone	O
;	O
and	O
4	O
)	O
the	O
CARD	B-GENE
is	O
critical	O
for	O
killing	O
activity	O
of	O
DEFCAP	B-GENE
.	O

In	O
6	O
patients	O
(	O
9	O
kidneys	O
)	O
irrigation	O
with	O
Solution	O
G	O
in	O
the	O
renal	O
pelvis	O
was	O
performed	O
for	O
the	O
dissolution	O
of	O
their	O
infectious	O
stones	O
.	O

The	O
use	O
of	O
sigma	B-GENE
54	I-GENE
promoters	I-GENE
,	O
known	O
to	O
require	O
cognate	O
binding	O
proteins	O
,	O
could	O
allow	O
the	O
fine	O
-	O
tuning	O
that	O
provides	O
the	O
temporal	O
ordering	O
of	O
flagellar	O
gene	O
transcription	O
.	O

The	O
association	O
of	O
I	B-GENE
-	I-GENE
92	I-GENE
with	O
p92	B-GENE
,	O
p84	B-GENE
,	O
p75	B-GENE
,	O
p73	B-GENE
,	O
p69	B-GENE
,	O
and	O
p57	B-GENE
was	O
completely	O
reversible	O
after	O
treatment	O
with	O
the	O
detergent	O
deoxycholate	O
(	O
DOC	O
)	O
.	O

To	O
our	O
knowledge	O
no	O
transcription	O
factors	O
have	O
previously	O
been	O
identified	O
that	O
exhibit	O
androgen	O
-	O
dependent	O
expression	O
in	O
the	O
epididymis	O
.	O

Focal	O
or	O
regional	O
8	O
-	O
to	O
20	O
-	O
Hz	O
low	O
-	O
voltage	O
epileptiform	O
paroxysms	O
in	O
either	O
hippocampus	O
(	O
10	O
patients	O
)	O
,	O
amygdala	O
(	O
1	O
patient	O
)	O
,	O
or	O
both	O
(	O
1	O
patient	O
)	O
preceded	O
initial	O
motionless	O
staring	O
.	O

The	O
lack	O
of	O
heterozygous	O
positions	O
essentially	O
facilitates	O
on	O
the	O
one	O
hand	O
the	O
data	O
analysis	O
and	O
on	O
the	O
other	O
hand	O
the	O
detection	O
of	O
new	O
alleles	O
.	O

Epithelial	O
cell	O
-	O
specific	O
activation	O
is	O
achieved	O
by	O
the	O
cooperative	O
interaction	O
of	O
apparently	O
ubiquitous	O
transcriptional	O
factors	O
.	O

Human	B-GENE
parvovirus	I-GENE
B19	I-GENE
gene	I-GENE
expression	O
from	O
the	O
viral	B-GENE
p6	I-GENE
promoter	I-GENE
(	O
B19p6	B-GENE
)	O
is	O
restricted	O
to	O
primary	O
human	O
hematopoietic	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O

The	O
effectiveness	O
and	O
pathogenetic	O
expediency	O
of	O
correcting	O
disorders	O
of	O
lipid	O
metabolism	O
in	O
atherosclerosis	O
with	O
enterosorbents	O
is	O
substantiated	O
.	O

To	O
prevent	O
section	O
wrinkles	O
usually	O
encountered	O
with	O
the	O
use	O
of	O
coated	O
single	O
-	O
hole	O
grids	O
,	O
a	O
simple	O
method	O
was	O
developed	O
.	O

The	O
Cryotherapy	O
for	O
Retinopathy	O
of	O
Prematurity	O
Study	O
has	O
shown	O
that	O
this	O
number	O
can	O
be	O
halved	O
with	O
treatment	O
.	O

Ultrasound	O
-	O
guided	O
fine	O
-	O
needle	O
aspiration	O
biopsy	O
(	O
US	O
-	O
FNAB	O
)	O
revealed	O
normal	O
-	O
looking	O
squamous	O
cells	O
.	O

Bleeding	O
was	O
successfully	O
prevented	O
in	O
28	O
patients	O
with	O
the	O
use	O
of	O
a	O
combined	O
treatment	O
incorporating	O
IV	O
desmopressin	O
,	O
an	O
antifibrinolytic	O
agent	O
(	O
tranexamic	O
acid	O
)	O
,	O
and	O
local	O
methods	O
(	O
surgical	O
glue	O
and	O
compression	O
techniques	O
)	O
.	O

Hetero	O
-	O
oligomerization	O
of	O
Smad4	B-GENE
with	O
the	O
pathway	O
-	O
restricted	O
SMAD	B-GENE
proteins	I-GENE
is	O
essential	O
for	O
Smad4	B-GENE
-	O
mediated	O
transcription	O
.	O

This	O
fragment	O
contains	O
two	O
complete	O
endo	B-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
1	I-GENE
,	I-GENE
4	I-GENE
-	I-GENE
glucanase	I-GENE
-	I-GENE
encoding	I-GENE
genes	I-GENE
,	O
designated	O
celCCC	B-GENE
and	O
celCCG	B-GENE
.	O

One	O
of	O
them	O
is	O
its	O
limited	O
sensitivity	O
to	O
weak	O
interactions	O
,	O
which	O
are	O
common	O
in	O
the	O
mammalian	O
cerebral	O
cortex	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
termini	O
of	O
the	O
transcripts	O
produced	O
in	O
vivo	O
from	O
the	O
puf	B-GENE
operon	I-GENE
of	I-GENE
R	I-GENE
.	I-GENE
sphaeroides	I-GENE
PUF	B-GENE
delta	I-GENE
348	I-GENE
-	I-GENE
420	I-GENE
(	O
three	O
transcripts	O
;	O
0	O
.	O
59	O
,	O
0	O
.	O
64	O
,	O
and	O
2	O
.	O
63	O
kilobases	O
)	O
lacking	O
the	O
puf	O
-	O
intercistronic	O
terminator	O
structure	O
were	O
identical	O
to	O
those	O
of	O
the	O
corresponding	O
puf	B-GENE
transcripts	I-GENE
derived	O
from	O
wild	O
-	O
type	O
R	O
.	O
sphaeroides	O
2	O
.	O
4	O
.	O
1	O
(	O
four	O
transcripts	O
;	O
0	O
.	O
50	O
,	O
0	O
.	O
66	O
,	O
0	O
.	O
71	O
,	O
and	O
2	O
.	O
7	O
kilobases	O
)	O
showing	O
that	O
the	O
transcripts	O
begin	O
and	O
end	O
at	O
the	O
same	O
sites	O
.	O

The	O
optimum	O
cooling	O
rate	O
from	O
RT	O
to	O
5	O
degrees	O
C	O
resulting	O
in	O
maximum	O
survival	O
of	O
human	O
spermatozoa	O
was	O
found	O
to	O
be	O
0	O
.	O
5	O
to	O
1	O
degree	O
per	O
minute	O
when	O
cooled	O
from	O
RT	O
to	O
5	O
degrees	O
C	O
and	O
subsequently	O
frozen	O
-	O
thawed	O
in	O
liquid	O
nitrogen	O
(	O
LN2	O
)	O
.	O

The	O
cerebellar	O
cortical	O
vessels	O
:	O
they	O
are	O
compared	O
to	O
the	O
cerebral	O
vessels	O
.	O

Transesophageal	O
echocardiography	O
risk	O
factors	O
for	O
stroke	O
in	O
nonvalvular	O
atrial	O
fibrillation	O
.	O

22	O
-	O
Veneto	O
Region	O
)	O

Preventive	O
health	O
counseling	O
tailored	O
to	O
the	O
needs	O
of	O
this	O
group	O
may	O
be	O
most	O
beneficial	O
.	O

Strains	O
lacking	O
a	O
functional	B-GENE
RPL16A	I-GENE
gene	I-GENE
grow	O
as	O
rapidly	O
as	O
wild	O
type	O
,	O
whereas	O
those	O
containing	O
a	O
null	O
allele	O
of	O
RPL16B	B-GENE
grow	O
more	O
slowly	O
than	O
wild	O
type	O
.	O

Neonatal	O
hyperthyroidism	O

After	O
Northern	O
blot	O
hybridization	O
,	O
two	O
Cx31	B-GENE
transcripts	I-GENE
of	I-GENE
2	I-GENE
.	I-GENE
2	I-GENE
and	I-GENE
1	I-GENE
.	I-GENE
8	I-GENE
kb	I-GENE
were	O
detected	O
in	O
total	O
RNA	O
of	O
the	O
human	O
keratinocyte	O
cell	O
line	O
HaCaT	O
and	O
two	O
transcripts	O
of	O
2	O
.	O
2	O
and	O
1	O
.	O
9	O
kb	O
in	O
total	O
RNA	O
of	O
E6	B-GENE
/	O
E7	B-GENE
transfected	O
human	O
keratinocytes	O
(	O
HEK	O
cells	O
)	O
.	O

In	O
summary	O
,	O
FGFR3	B-GENE
signaling	O
pathway	O
utilizes	O
two	O
GRB2	B-GENE
-	I-GENE
containing	I-GENE
complexes	I-GENE
;	O
Shc	B-GENE
.	O
GRB2	B-GENE
.	O
Sos	B-GENE
and	O
80K	B-GENE
-	I-GENE
H	I-GENE
.	O
pp66	B-GENE
.	O
GRB2	B-GENE
.	O
Sos	B-GENE
;	O
these	O
two	O
complexes	O
may	O
alternatively	O
link	O
FGFG3	B-GENE
to	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
.	O

In	O
an	O
effort	O
to	O
identify	O
factors	O
involved	O
in	O
the	O
expression	O
of	O
this	O
important	O
erythroid	O
-	O
specific	O
regulatory	O
protein	O
,	O
we	O
have	O
isolated	O
the	O
mouse	B-GENE
EKLF	I-GENE
gene	I-GENE
and	O
systematically	O
analyzed	O
the	O
promoter	O
region	O
.	O

Their	O
main	O
representatives	O
are	O
the	O
American	O
diagnostic	O
and	O
statistical	O
manual	O
of	O
mental	O
disorders	O
,	O
DSM	O
-	O
III	O
,	O
its	O
revised	O
version	O
DSM	O
-	O
III	O
-	O
R	O
and	O
the	O
new	O
international	O
classification	O
of	O
mental	O
disorders	O
iCD	O
-	O
10	O
.	O

Any	O
opacity	O
on	O
a	O
chest	O
radiograph	O
has	O
a	O
wide	O
differential	O
diagnosis	O
.	O

At	O
the	O
same	O
acoustic	O
power	O
,	O
the	O
rate	O
of	O
chloride	O
formation	O
with	O
20	O
kHz	O
ultrasound	O
was	O
greater	O
when	O
a	O
probe	O
with	O
a	O
larger	O
tip	O
area	O
was	O
used	O
,	O
but	O
significantly	O
less	O
than	O
the	O
rate	O
with	O
900	O
kHz	O
.	O

In	O
contrast	O
to	O
Torpedo	O
,	O
where	O
only	O
a	O
single	O
transcript	O
is	O
seen	O
,	O
the	O
mouse	O
expresses	O
several	O
mRNAs	O
encoding	O
different	O
isoforms	O
.	O

Four	O
families	O
of	O
homing	B-GENE
endonucleases	I-GENE
have	O
been	O
identified	O
,	O
including	O
the	O
LAGLIDADG	B-GENE
,	O
the	O
His	B-GENE
-	I-GENE
Cys	I-GENE
box	I-GENE
,	O
the	O
GIY	B-GENE
-	I-GENE
YIG	I-GENE
and	O
the	O
H	B-GENE
-	I-GENE
N	I-GENE
-	I-GENE
H	I-GENE
endonucleases	I-GENE
.	O

Convergence	O
of	O
trigeminal	O
input	O
with	O
visceral	O
and	O
phrenic	O
inputs	O
on	O
primate	O
C1	O
-	O
C2	O
spinothalamic	O
tract	O
neurons	O
.	O

The	O
GvpE	B-GENE
protein	I-GENE
involved	O
in	O
the	O
regulation	O
of	O
gas	O
vesicles	O
synthesis	O
in	O
halophilic	O
archaea	O
has	O
been	O
identified	O
as	O
the	O
transcriptional	O
activator	O
for	O
the	O
promoter	O
located	O
upstream	O
of	O
the	O
gvpA	B-GENE
gene	I-GENE
encoding	O
the	O
major	O
gas	O
vesicle	O
structural	O
protein	O
GvpA	B-GENE
.	O

Nosographic	O
problems	O

In	O
early	O
midgestation	O
embryos	O
it	O
is	O
expressed	O
in	O
telencephalic	O
,	O
diencephalic	O
and	O
mesencephalic	O
regions	O
but	O
from	O
day	O
11	O
.	O
75	O
of	O
gestation	O
its	O
expression	O
disappears	O
from	O
dorsal	O
telencephalon	O
and	O
is	O
confined	O
to	O
diencephalic	O
and	O
mesencephalic	O
regions	O
.	O

The	O
training	O
programs	O
had	O
a	O
duration	O
of	O
30	O
days	O
,	O
5	O
days	O
/	O
week	O
,	O
and	O
was	O
performed	O
on	O
a	O
motor	O
-	O
driven	O
treadmill	O
.	O

Phylogenetic	O
analysis	O
using	O
a	O
neighbor	O
-	O
joining	O
algorithm	O
showed	O
closest	O
similarity	O
of	O
the	O
horse	B-GENE
mu	I-GENE
chain	I-GENE
-	I-GENE
encoding	I-GENE
constant	I-GENE
region	I-GENE
gene	I-GENE
to	O
human	O
and	O
dog	O
sequences	O
.	O

Using	O
probes	O
from	O
these	O
regions	O
,	O
rearrangements	O
have	O
been	O
identified	O
in	O
each	O
of	O
nine	O
cases	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
examined	O
.	O

Cloning	O
and	O
nucleotide	O
sequence	O
analysis	O
reveals	O
that	O
BUR6	B-GENE
encodes	O
a	O
homolog	O
of	O
DRAP1	B-GENE
(	O
also	O
called	O
NC2alpha	B-GENE
)	O
,	O
a	O
mammalian	O
repressor	O
of	O
basal	O
transcription	O
.	O

BRAP2	B-GENE
also	O
shares	O
significant	O
homology	O
with	O
a	O
hypothetical	O
protein	O
from	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
especially	O
in	O
the	O
zinc	O
finger	O
region	O
.	O

Earlier	O
published	O
data	O
,	O
indicating	O
Sp1	B-GENE
binding	O
to	O
the	O
R1	B-GENE
alpha	I-GENE
/	I-GENE
beta	I-GENE
regions	I-GENE
,	O
could	O
not	O
be	O
confirmed	O
,	O
suggesting	O
that	O
the	O
R1	O
initiator	O
element	O
may	O
function	O
independent	O
of	O
Sp1	B-GENE
.	O

In	O
addition	O
,	O
reduced	O
metabolism	O
to	O
cotinine	O
from	O
the	O
proliposomes	O
and	O
MP	O
was	O
apparently	O
responsible	O
for	O
the	O
sustained	O
plasma	O
nicotine	O
levels	O
.	O

Activation	O
of	O
HIV	O
-	O
1	O
requires	O
the	O
binding	O
of	O
host	O
cell	O
transcription	O
factors	O
to	O
cis	O
elements	O
in	O
the	O
proviral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

The	O
yeast	B-GENE
mitochondrial	I-GENE
Hsp70	I-GENE
,	O
Ssc1p	B-GENE
,	O
functions	O
as	O
a	O
molecular	O
chaperone	O
with	O
its	O
partner	O
proteins	O
,	O
Mdj1p	B-GENE
(	O
DnaJ	B-GENE
homologue	I-GENE
)	O
and	O
Yge1p	B-GENE
(	O
GrpE	B-GENE
homologue	I-GENE
)	O
.	O

Increased	O
TRE	O
DNA	O
binding	O
failed	O
to	O
lead	O
to	O
increased	O
transactivation	O
correlating	O
with	O
the	O
inability	O
of	O
SB	O
203580	O
to	O
increase	O
phosphorylation	O
of	O
these	O
AP	B-GENE
-	I-GENE
1	I-GENE
proteins	I-GENE
.	O

The	O
rice	O
gene	O
consists	O
of	O
four	O
exons	O
.	O

However	O
,	O
and	O
in	O
contrast	O
to	O
other	O
MMP	B-GENE
genes	I-GENE
,	O
no	O
significative	O
synergistic	O
effect	O
on	O
CAT	B-GENE
activity	O
between	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
and	O
PEA	B-GENE
-	I-GENE
3	I-GENE
elements	I-GENE
found	O
in	O
the	O
collagenase	B-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
promoter	I-GENE
was	O
found	O
.	O

The	O
equation	O
for	O
mean	O
trabecular	O
number	O
passed	O
the	O
test	O
,	O
whereas	O
the	O
validity	O
of	O
the	O
equations	O
for	O
mean	O
trabecular	O
separation	O
and	O
Tb	O
.	O
Wi	O
appeared	O
limited	O
.	O

Methodological	O
considerations	O
limiting	O
causal	O
assertions	O
permissible	O
with	O
nonexperimental	O
data	O
are	O
discussed	O
.	O

In	O
contrast	O
,	O
postmitotic	O
neurons	O
possessed	O
extremely	O
low	O
levels	O
of	O
E2F1	B-GENE
protein	I-GENE
as	O
assessed	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
Western	O
blotting	O
.	O

Recurrence	O
of	O
the	O
hepatic	O
cyst	O
after	O
partial	O
excision	O
and	O
drainage	O
was	O
complicated	O
by	O
fistula	O
formation	O
between	O
the	O
cyst	O
and	O
the	O
duodenum	O
.	O

Reversal	O
of	O
mefloquine	O
resistance	O
in	O
rodent	O
Plasmodium	O
.	O

Possible	O
consequences	O
of	O
such	O
binder	O
distribution	O
through	O
powder	O
aggregates	O
are	O
discussed	O
.	O

The	O
human	B-GENE
parvalbumin	I-GENE
mRNA	I-GENE
contains	O
the	O
putative	O
polyadenylation	O
signal	O
AATAAA	O
13	O
nucleotides	O
upstream	O
from	O
the	O
polyadenylation	O
site	O
.	O

The	O
delta	O
Mo	O
+	O
SV	O
tumor	O
DNAs	O
from	O
B	O
-	O
lineage	O
tumors	O
were	O
typically	O
rearranged	O
at	O
the	O
immunoglobulin	B-GENE
gene	I-GENE
loci	I-GENE
and	O
contained	O
germ	O
line	O
configurations	O
of	O
the	O
T	B-GENE
-	I-GENE
cell	I-GENE
receptor	I-GENE
beta	I-GENE
gene	I-GENE
.	O

The	O
experimental	O
results	O
suggest	O
equilibrium	O
complex	O
formation	O
between	O
OTC	O
and	O
PVP	O
,	O
it	O
being	O
mainly	O
the	O
complex	O
which	O
is	O
i	O
.	O
v	O
.	O
injected	O
when	O
both	O
products	O
are	O
combined	O
in	O
an	O
injection	O
formulation	O
.	O

We	O
conclude	O
that	O
the	O
MMF	O
lesion	O
is	O
secondary	O
to	O
intramuscular	O
injection	O
of	O
aluminium	O
hydroxide	O
-	O
containing	O
vaccines	O
,	O
shows	O
both	O
long	O
-	O
term	O
persistence	O
of	O
aluminium	O
hydroxide	O
and	O
an	O
ongoing	O
local	O
immune	O
reaction	O
,	O
and	O
is	O
detected	O
in	O
patients	O
with	O
systemic	O
symptoms	O
which	O
appeared	O
subsequently	O
to	O
vaccination	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
on	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
catalytic	O
subunit	O
of	O
glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphatase	I-GENE
(	O
G6Pase	B-GENE
)	O
,	O
G6Pase	B-GENE
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
fusion	O
genes	O
were	O
transiently	O
transfected	O
into	O
either	O
the	O
liver	O
-	O
derived	O
HepG2	O
or	O
kidney	O
-	O
derived	O
LLC	O
-	O
PK	O
cell	O
line	O
.	O

Whereas	O
the	O
sequence	O
of	O
alpha	B-GENE
-	I-GENE
actinin	I-GENE
(	O
Noegel	O
,	O
A	O
.	O
,	O
W	O
.	O

By	O
contrast	O
,	O
clonidine	O
(	O
1	O
micrograms	O
/	O
kg	O
)	O
elicited	O
an	O
immediate	O
and	O
prolonged	O
fall	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
when	O
given	O
into	O
the	O
vertebral	O
artery	O
,	O
but	O
not	O
intravenously	O
.	O

The	O
shift	O
from	O
complex	O
I	O
to	O
complex	O
II	O
seen	O
only	O
in	O
SCM	B-GENE
-	I-GENE
1	I-GENE
-	O
producer	O
T	O
cell	O
lines	O
upon	O
activation	O
was	O
completely	O
suppressed	O
by	O
cyclosporin	O
A	O
.	O

(	O
We	O
observed	O
a	O
ferritin	B-GENE
value	O
as	O
high	O
as	O
47	O
mg	O
/	O
L	O
in	O
one	O
patient	O
.	O
)	O
Results	O
with	O
all	O
these	O
kits	O
did	O
not	O
inter	O
-	O
compare	O
well	O
for	O
ferritin	B-GENE
concentrations	O
greater	O
than	O
300	O
micrograms	O
/	O
L	O
,	O
a	O
finding	O
that	O
casts	O
further	O
doubt	O
on	O
the	O
controversial	O
use	O
of	O
serum	B-GENE
ferritin	I-GENE
measurement	O
in	O
cases	O
of	O
iron	O
overload	O
.	O

Post	O
-	O
CPB	O
cardiac	O
index	O
was	O
superior	O
in	O
group	O
B	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
3	O
vs	O
.	O

ER	B-GENE
beta	I-GENE
was	O
less	O
potent	O
than	O
ER	B-GENE
alpha	I-GENE
in	O
activating	O
E2	O
-	O
stimulated	O
ERELuc	B-GENE
activity	O
(	O
4	O
-	O
vs	O
.	O

The	O
expression	O
pattern	O
of	O
LjEmx	B-GENE
changed	O
dramatically	O
during	O
embryogenesis	O
;	O
expression	O
was	O
seen	O
initially	O
in	O
the	O
entire	O
neural	O
tube	O
and	O
mesoderm	O
,	O
which	O
were	O
secondarily	O
downregulated	O
,	O
and	O
secondarily	O
in	O
cranial	O
nerve	O
ganglia	O
and	O
in	O
the	O
craniofacial	O
mesenchyme	O
.	O

Disruption	O
of	O
PML	B-GENE
subnuclear	I-GENE
domains	I-GENE
by	O
the	O
acidic	B-GENE
IE1	I-GENE
protein	I-GENE
of	O
human	O
cytomegalovirus	O
is	O
mediated	O
through	O
interaction	O
with	O
PML	B-GENE
and	O
may	O
modulate	O
a	O
RING	O
finger	O
-	O
dependent	O
cryptic	O
transactivator	O
function	O
of	O
PML	B-GENE
.	O

Furthermore	O
,	O
the	O
GC	O
-	O
rich	O
sequences	O
could	O
confer	O
Sp1	B-GENE
-	O
dependent	O
transactivation	O
to	O
a	O
heterologous	O
prolactin	B-GENE
minimal	I-GENE
promoter	I-GENE
.	O

Twelve	O
patients	O
of	O
leprosy	O
with	O
arthritis	O
and	O
161	O
patients	O
without	O
arthritis	O
were	O
studied	O
for	O
immunological	O
parameters	O
like	O
immunoglobulins	B-GENE
(	O
IgG	B-GENE
,	O
IgM	B-GENE
,	O
IgA	B-GENE
)	O
,	O
C	B-GENE
-	I-GENE
reactive	I-GENE
proteins	I-GENE
and	O
rheumatoid	B-GENE
factor	I-GENE
.	O

Several	O
reports	O
assert	O
that	O
prolactin	B-GENE
affects	O
the	O
delta	O
5	O
and	O
delta	O
4	O
pathways	O
through	O
its	O
effect	O
on	O
the	O
activity	O
of	O
3beta	B-GENE
-	I-GENE
hydroxysteroid	I-GENE
dehydrogenase	I-GENE
(	O
3beta	B-GENE
-	I-GENE
OHSD	I-GENE
)	O
.	O

The	O
NrfC	B-GENE
polypeptide	I-GENE
,	O
M	B-GENE
(	I-GENE
r	I-GENE
)	I-GENE
24	I-GENE
,	I-GENE
567	I-GENE
,	O
contains	O
16	O
cysteine	O
residues	O
arranged	O
in	O
four	O
clusters	O
typical	O
of	O
the	O
CooF	B-GENE
super	I-GENE
-	I-GENE
family	I-GENE
of	O
non	O
-	O
haem	O
iron	O
-	O
sulphur	O
proteins	O
.	O

Zonography	O
in	O
urology	O
(	O
author	O
'	O
s	O
transl	O
)	O

(	O
i	O
)	O
p60	B-GENE
bound	O
fast	O
-	O
migrating	O
,	O
underprocessed	O
wild	B-GENE
-	I-GENE
type	I-GENE
ICP22	I-GENE
and	O
ICP22	B-GENE
lacking	O
the	O
carboxyl	O
-	O
terminal	O
24	O
amino	O
acids	O
but	O
not	O
ICP22	B-GENE
lacking	O
the	O
carboxyl	O
-	O
terminal	O
40	O
amino	O
acids	O
,	O
whereas	O
the	O
previously	O
identified	O
cellular	B-GENE
protein	I-GENE
p78	I-GENE
(	O
R	O
.	O

Stress	O
thallium	O
-	O
201	O
myocardial	O
imaging	O
was	O
used	O
in	O
two	O
angina	O
-	O
free	O
patients	O
with	O
severe	O
congestive	O
heart	O
failure	O
to	O
identify	O
clinically	O
silent	O
areas	O
of	O
ischemic	O
myocardium	O
and	O
to	O
distinguish	O
between	O
scar	O
and	O
reversibly	O
ischemic	O
myocardium	O
as	O
a	O
cause	O
for	O
akinesia	O
of	O
left	O
ventricular	O
wall	O
segments	O
.	O

The	O
community	O
-	O
acquired	O
bacteremia	O
was	O
mainly	O
due	O
to	O
E	O
.	O
coli	O
.	O

Y1	B-GENE
,	O
Y2	B-GENE
,	O
and	O
Y4	B-GENE
/	O
PP1	B-GENE
.	O

Low	O
plasma	O
glucose	O
concentrations	O
that	O
may	O
or	O
may	O
not	O
be	O
sufficiently	O
low	O
to	O
result	O
in	O
symptoms	O
can	O
be	O
observed	O
as	O
a	O
concomitant	O
of	O
several	O
diverse	O
diseases	O
.	O

Developmentally	O
-	O
regulated	O
interaction	O
of	O
a	O
transcription	O
factor	O
complex	O
containing	O
CDP	B-GENE
/	O
cut	B-GENE
with	O
the	O
early	B-GENE
histone	I-GENE
H3	I-GENE
gene	I-GENE
promoter	I-GENE
of	I-GENE
the	I-GENE
sea	I-GENE
urchin	I-GENE
Tetrapygus	I-GENE
niger	I-GENE
is	O
associated	O
with	O
changes	O
in	O
chromatin	O
structure	O
and	O
gene	O
expression	O
.	O

Procedures	O
with	O
perfected	O
method	O

After	O
a	O
shift	O
to	O
37	O
degrees	O
C	O
,	O
the	O
mutant	O
Rat7	B-GENE
-	I-GENE
1p	I-GENE
/	O
Nup159	B-GENE
-	I-GENE
1p	I-GENE
is	O
lost	O
from	O
the	O
nuclear	O
rim	O
of	O
rat7	O
-	O
1	O
cells	O
and	O
NPCs	O
,	O
which	O
are	O
clustered	O
together	O
in	O
these	O
cells	O
grown	O
under	O
permissive	O
conditions	O
become	O
substantially	O
less	O
clustered	O
.	O

The	O
mRNA	O
for	O
this	O
protein	O
is	O
expressed	O
in	O
the	O
T	O
-	O
ALL	O
cell	O
line	O
Jurkat	O
and	O
has	O
been	O
designated	O
HUG1	B-GENE
,	O
for	O
HOX11	B-GENE
Upstream	I-GENE
Gene	I-GENE
.	O

The	O
STS	B-GENE
sequence	I-GENE
WI	I-GENE
-	I-GENE
14920	I-GENE
is	O
in	O
fact	O
derived	O
from	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
human	B-GENE
PUNC	I-GENE
gene	I-GENE
.	O

Its	O
activity	O
was	O
twice	O
that	O
of	O
a	O
construct	O
where	O
the	O
CAT	B-GENE
gene	I-GENE
was	O
driven	O
by	O
the	O
H	B-GENE
-	I-GENE
2Kb	I-GENE
5	I-GENE
'	I-GENE
enhancer	I-GENE
region	I-GENE
(	O
H2TF1	B-GENE
/	O
KBF1	B-GENE
site	O
)	O
and	O
comparable	O
to	O
that	O
of	O
pRSVCAT	O
construct	B-GENE
carrying	I-GENE
the	I-GENE
strong	I-GENE
Rous	I-GENE
sarcoma	I-GENE
virus	I-GENE
LTR	I-GENE
enhancer	I-GENE
.	O

ORF3	O
appears	O
to	O
encode	O
the	O
homologue	O
of	O
the	O
well	O
-	O
conserved	O
proteasomal	B-GENE
26S	I-GENE
regulatory	I-GENE
subunit	I-GENE
.	O

The	O
tam	B-GENE
A	I-GENE
gene	I-GENE
of	I-GENE
Aspergillus	I-GENE
nidulans	I-GENE
encodes	O
a	O
739	O
-	O
amino	O
acid	O
protein	O
with	O
similarity	O
to	O
Uga35p	B-GENE
/	O
Dal81p	B-GENE
/	O
DurLp	B-GENE
of	O
Saccharomyces	O
cerevisiae	O
.	O

Little	O
honoured	O
in	O
his	O
own	O
country	O
:	O
statues	O
in	O
recognition	O
of	O
Edward	O
Jenner	O
MD	O
FRS	O
.	O

A	O
pharmacokinetic	O
interaction	O
between	O
LY354740	O
and	O
diazepam	O
,	O
leading	O
to	O
the	O
lowering	O
of	O
the	O
plasma	O
level	O
of	O
free	O
diazepam	O
,	O
was	O
also	O
demonstrated	O
.	O

The	O
promoter	O
of	O
this	O
methyltransferase	O
gene	O
lacks	O
an	O
identifiable	O
TATA	O
box	O
but	O
is	O
characterized	O
by	O
a	O
CpG	O
island	O
which	O
begins	O
approximately	O
723	O
nucleotides	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
and	O
extends	O
through	O
exon	O
1	O
and	O
into	O
the	O
first	O
intron	O
.	O

No	O
promoter	O
activity	O
could	O
be	O
detected	O
with	O
various	O
mouse	B-GENE
Fli	I-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
-	O
CAT	B-GENE
constructs	O
containing	O
600	O
bp	O
of	O
the	O
5	O
'	O
flanking	O
region	O
,	O
the	O
complete	O
exon	O
1	O
,	O
the	O
5	O
'	O
end	O
of	O
intron	O
1	O
and	O
/	O
or	O
retroviral	O
LTR	O
sequence	O
.	O

The	O
D	O
.	O
discoideum	O
proteins	O
were	O
entirely	O
conserved	O
over	O
the	O
four	O
regions	O
known	O
to	O
be	O
important	O
for	O
GTP	O
binding	O
and	O
all	O
contained	O
the	O
C	O
-	O
terminal	O
CAAX	O
aa	O
motifs	O
shared	O
by	O
other	O
Rho	B-GENE
proteins	I-GENE
.	O

An	O
81	O
-	O
nt	O
tandem	O
duplication	O
of	O
the	O
C	O
-	O
terminal	O
coding	O
region	O
is	O
located	O
adjacent	O
to	O
the	O
termination	O
codon	O
of	O
the	O
CyIIIb	B-GENE
gene	I-GENE
,	O
a	O
potential	O
relic	O
of	O
a	O
slipped	O
mispairing	O
and	O
replication	O
event	O
.	O

Only	O
53	O
%	O
of	O
all	O
injuries	O
and	O
12	O
.	O
5	O
%	O
of	O
serious	O
injuries	O
involved	O
children	O
,	O
and	O
in	O
contrast	O
to	O
the	O
1950s	O
and	O
early	O
1960s	O
,	O
young	O
adults	O
appear	O
at	O
greatest	O
risk	O
in	O
the	O
1980s	O
.	O

The	O
method	O
was	O
tested	O
on	O
7	O
rats	O
with	O
48	O
-	O
hr	O
-	O
old	O
myocardial	O
infarction	O
and	O
4	O
sham	O
-	O
operated	O
controls	O
.	O

Here	O
we	O
examine	O
the	O
population	O
of	O
gammaS	B-GENE
transcripts	I-GENE
in	O
adult	O
human	O
lens	O
and	O
the	O
structure	O
of	O
the	O
human	B-GENE
CRYGS	I-GENE
genes	I-GENE
.	O

The	O
slope	O
of	O
QD	O
versus	O
QEMF	O
for	O
the	O
four	O
tubes	O
was	O
near	O
unity	O
.	O

The	O
extent	O
of	O
the	O
odontoblast	O
process	O
in	O
human	O
dentin	O
.	O

Mouse	B-GENE
macrophage	I-GENE
beta	I-GENE
subunit	I-GENE
(	I-GENE
CD11b	I-GENE
)	I-GENE
cDNA	I-GENE
for	O
the	O
CR3	B-GENE
complement	I-GENE
receptor	I-GENE
/	O
Mac	B-GENE
-	I-GENE
1	I-GENE
antigen	I-GENE
.	O

Enoxacin	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
well	O
tolerated	O
and	O
convenient	O
treatment	O
for	O
gonorrhoea	O
.	O

We	O
assessed	O
cardiovascular	O
variables	O
and	O
blood	O
O2	O
contents	O
in	O
order	O
to	O
characterize	O
O2	O
transport	O
in	O
ponies	O
during	O
treadmill	O
exercise	O
.	O

The	O
findings	O
are	O
discussed	O
with	O
reference	O
to	O
possible	O
mechanisms	O
by	O
which	O
parasite	O
development	O
might	O
be	O
controlled	O
.	O

The	O
80	O
kb	O
preceding	O
the	O
expression	O
site	O
has	O
few	O
,	O
if	O
any	O
,	O
functional	O
ORFs	O
,	O
but	O
contains	O
50	O
bp	O
repeats	O
,	O
INGI	B-GENE
retrotransposon	I-GENE
-	I-GENE
like	I-GENE
elements	I-GENE
,	O
and	O
novel	O
4	O
-	O
12	O
kb	O
repeats	O
found	O
near	O
other	O
telomeres	O
.	O

The	O
predicted	O
proteins	O
show	O
strong	O
homology	O
to	O
an	O
ABA	B-GENE
-	I-GENE
inducible	I-GENE
glycine	I-GENE
-	I-GENE
rich	I-GENE
protein	I-GENE
from	O
maize	O
embryos	O
and	O
to	O
the	O
mammalian	B-GENE
RNA	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
A1	I-GENE
of	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
complex	O
involved	O
in	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Increase	O
in	O
[	O
Ca	O
+	O
+	O
]	O
counteracted	O
the	O
effects	O
of	O
verapamil	O
on	O
RAD	O
.	O

We	O
compared	O
the	O
quantities	O
collected	O
with	O
both	O
pollen	O
traps	O
during	O
February	O
,	O
March	O
and	O
April	O
1988	O
and	O
1989	O
.	O

Cbl	B-GENE
is	O
a	O
signaling	O
molecule	O
with	O
multiple	O
functional	O
domains	O
:	O
an	O
SH2	B-GENE
domain	I-GENE
which	O
binds	O
phosphotyrosine	O
residues	O
,	O
a	O
RING	O
finger	O
domain	O
which	O
acts	O
as	O
a	O
ubiquitin	B-GENE
ligase	I-GENE
,	O
a	O
proline	O
-	O
rich	O
region	O
which	O
serves	O
as	O
a	O
docking	O
site	O
for	O
SH3	B-GENE
-	I-GENE
containing	I-GENE
proteins	I-GENE
,	O
phosphotyrosine	O
residues	O
which	O
serve	O
as	O
docking	O
sites	O
for	O
SH2	B-GENE
-	I-GENE
containing	I-GENE
proteins	I-GENE
such	O
a	O
CrkL	B-GENE
and	O
the	O
p85	B-GENE
subunit	I-GENE
of	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
,	O
and	O
a	O
nuclear	O
localization	O
signal	O
.	O

Surprisingly	O
,	O
apo	B-GENE
-	I-GENE
iso	I-GENE
-	I-GENE
1	I-GENE
-	I-GENE
cytochrome	I-GENE
c	I-GENE
is	O
absent	O
in	O
cyc3	B-GENE
-	I-GENE
strains	O
,	O
although	O
apo	B-GENE
-	I-GENE
iso	I-GENE
-	I-GENE
2	I-GENE
-	I-GENE
cytochrome	I-GENE
c	I-GENE
is	O
present	O
at	O
approximately	O
the	O
same	O
level	O
at	O
which	O
holo	B-GENE
-	I-GENE
iso	I-GENE
-	I-GENE
2	I-GENE
-	I-GENE
cytochrome	I-GENE
c	I-GENE
is	O
found	O
in	O
CYC3	B-GENE
+	I-GENE
strains	O
.	O

Here	O
,	O
we	O
identify	O
the	O
analytical	O
form	O
of	O
the	O
PDF	O
of	O
one	O
such	O
measure	O
,	O
the	O
order	O
parameter	O
in	O
the	O
low	O
temperature	O
phase	O
of	O
the	O
2D	O
XY	O
model	O
.	O

The	O
ventricular	O
demand	O
pacemaker	O
(	O
VVI	O
)	O
was	O
implanted	O
three	O
years	O
ago	O
and	O
because	O
of	O
further	O
impairment	O
of	O
cardiac	O
performance	O
an	O
av	O
-	O
sequential	O
pacemaker	O
(	O
DDD	O
)	O
was	O
used	O
to	O
restore	O
atrio	O
-	O
ventricular	O
synchronisation	O
.	O

It	O
was	O
predicted	O
that	O
the	O
Stroop	O
task	O
would	O
trigger	O
greater	O
consumption	O
of	O
ice	O
cream	O
than	O
a	O
fearful	O
film	O
,	O
and	O
that	O
this	O
effect	O
would	O
be	O
more	O
pronounced	O
for	O
binge	O
-	O
eaters	O
than	O
non	O
-	O
binge	O
-	O
eaters	O
.	O

Our	O
data	O
are	O
in	O
line	O
with	O
the	O
hypothesis	O
that	O
E2F	B-GENE
functions	O
as	O
a	O
growth	O
-	O
and	O
cell	O
cycle	O
regulated	O
tethering	O
factor	O
between	O
Sp1	B-GENE
and	O
the	O
basic	O
transcription	O
machinery	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
change	O
from	O
baseline	O
in	O
parietal	O
lobe	O
gray	O
-	O
matter	O
cytosolic	O
choline	O
,	O
expressed	O
in	O
terms	O
of	O
choline	O
/	O
creatine	O
resonance	O
ratios	O
,	O
and	O
cognitive	O
performance	O
as	O
measured	O
with	O
the	O
Alzheimer	O
'	O
s	O
Disease	O
Assessment	O
Scale	O
Cognitive	O
Subscale	O
.	O

Colonization	O
increased	O
with	O
level	O
of	O
care	O
:	O
from	O
9	O
per	O
cent	O
in	O
independent	O
residents	O
of	O
apartments	O
to	O
60	O
per	O
cent	O
in	O
patients	O
on	O
an	O
acute	O
hospital	O
ward	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

IRA2	B-GENE
,	O
a	O
second	O
gene	O
of	O
Saccharomyces	O
cerevisiae	O
that	O
encodes	O
a	O
protein	O
with	O
a	O
domain	O
homologous	O
to	O
mammalian	O
ras	B-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
.	O

Exon	O
A1a	O
encodes	O
most	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
.	O

Co	O
-	O
operativity	O
of	O
functional	O
domains	O
in	O
the	O
muscle	B-GENE
-	I-GENE
specific	I-GENE
transcription	I-GENE
factor	I-GENE
Myf	I-GENE
-	I-GENE
5	I-GENE
.	O

Creatinine	O
and	O
creatine	B-GENE
phosphokinase	I-GENE
(	O
CPK	B-GENE
)	O
.	O

In	O
our	O
initial	O
studies	O
,	O
we	O
treated	O
MCF	O
-	O
7	O
cells	O
with	O
paclitaxel	O
,	O
which	O
results	O
in	O
the	O
arrest	O
of	O
cells	O
in	O
G1	O
with	O
4n	O
DNA	O
content	O
(	O
pseudo	O
G1	O
)	O
.	O

These	O
alterations	O
occurred	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
but	O
did	O
not	O
significantly	O
affect	O
the	O
subcellular	O
distribution	O
of	O
any	O
of	O
the	O
four	O
isoforms	O
.	O

The	O
glyoxysomal	O
and	O
plastid	O
molecular	O
chaperones	O
(	O
70	B-GENE
-	I-GENE
kDa	I-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
)	O
of	O
watermelon	O
cotyledons	O
are	O
encoded	O
by	O
a	O
single	O
gene	O
.	O

Suspected	O
pelvic	O
endometriosis	O
was	O
prospectively	O
evaluated	O
in	O
31	O
women	O
with	O
T1	O
-	O
and	O
T2	O
-	O
weighted	O
conventional	O
spin	O
-	O
echo	O
(	O
CSE	O
)	O
magnetic	O
resonance	O
imaging	O
alone	O
and	O
in	O
combination	O
with	O
T1	O
-	O
weighted	O
fat	O
-	O
suppressed	O
(	O
T1FS	O
)	O
and	O
gadolinium	O
-	O
enhanced	O
T1FS	O
(	O
Gd	O
-	O
T1FS	O
)	O
spin	O
-	O
echo	O
techniques	O
.	O

Seroconversion	O
after	O
hepatitis	O
B	O
vaccination	O
.	O

A	O
case	O
of	O
bilateral	O
testicular	O
germ	O
cell	O
tumors	O
in	O
a	O
23	O
-	O
year	O
-	O
old	O
male	O
is	O
reported	O
.	O

Total	O
body	O
BMD	O
(	O
r	O
=	O
0	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
femoral	O
neck	O
BMD	O
(	O
r	O
=	O
0	O
.	O
39	O
;	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
positively	O
correlated	O
with	O
weight	O
-	O
bearing	O
activity	O
but	O
not	O
with	O
non	O
-	O
weight	O
-	O
bearing	O
activity	O
.	O

The	O
effects	O
of	O
castor	O
oil	O
,	O
alone	O
,	O
as	O
well	O
as	O
in	O
combination	O
with	O
PGI2	O
and	O
indomethacin	O
on	O
gastrointestinal	O
functions	O
have	O
been	O
examined	O
in	O
rats	O
.	O

Checking	O
for	O
patient	O
compliance	O
,	O
samples	O
(	O
n	O
=	O
10	O
)	O
with	O
a	O
FK	O
I	O
concentration	O
of	O
0	O
ng	O
/	O
mL	O
were	O
re	O
-	O
analyzed	O
.	O

K	O
.	O

The	O
hematopoietic	O
form	O
of	O
PTPN6	B-GENE
transcript	I-GENE
is	O
initiated	O
at	O
a	O
downstream	O
promoter	O
separated	O
by	O
7	O
kb	O
from	O
the	O
first	O
.	O

The	O
residual	O
small	O
rRNAs	O
in	O
[	O
poky	O
]	O
appear	O
to	O
be	O
synthesized	O
via	O
the	O
upstream	O
promoter	O
(	O
s	O
)	O
,	O
but	O
are	O
missing	O
37	O
-	O
44	O
nucleotides	O
from	O
their	O
5	O
'	O
ends	O
,	O
indicating	O
either	O
that	O
pre	O
-	O
rRNAs	O
are	O
processed	O
abnormally	O
or	O
that	O
abnormal	O
5	O
'	O
RNA	O
ends	O
are	O
unstable	O
.	O

Extra	O
dose	O
due	O
to	O
extravehicular	O
activity	O
during	O
the	O
NASA4	O
mission	O
measured	O
by	O
an	O
on	O
-	O
board	O
TLD	O
system	O
.	O

Unconventional	O
mRNA	O
processing	O
in	O
the	O
expression	O
of	O
two	O
calcineurin	B-GENE
B	I-GENE
isoforms	I-GENE
in	O
Dictyostelium	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
this	O
open	O
reading	O
frame	O
is	O
significantly	O
homologous	O
to	O
the	O
HSV	B-GENE
1	I-GENE
UL49	I-GENE
.	I-GENE
5	I-GENE
gene	I-GENE
product	I-GENE
,	O
and	O
as	O
with	O
UL49	B-GENE
.	I-GENE
5	I-GENE
,	O
it	O
contains	O
a	O
potential	O
signal	O
sequence	O
and	O
transmembrane	O
domain	O
characteristic	O
of	O
membrane	O
-	O
associated	O
proteins	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
stimulation	O
of	O
the	O
pontomesencephalic	O
parabrachial	O
region	O
(	O
PBR	O
)	O
by	O
microinjection	O
of	O
cholinergic	O
drugs	O
or	O
electricity	O
in	O
the	O
cat	O
produces	O
potent	O
pain	O
suppression	O
which	O
is	O
not	O
antagonized	O
by	O
the	O
opiate	O
antagonist	O
,	O
naloxone	O
.	O

GAGA	B-GENE
factor	I-GENE
is	O
known	O
to	O
remodel	O
the	O
chromatin	O
structure	O
in	O
concert	O
with	O
nucleosome	B-GENE
-	I-GENE
remodeling	I-GENE
factor	I-GENE
NURF	B-GENE
in	O
a	O
Drosophila	O
embryonic	O
S150	O
extract	O
.	O

Also	O
,	O
like	O
TUB	B-GENE
,	O
it	O
has	O
a	O
wider	O
pattern	O
of	O
tissue	O
expression	O
than	O
either	O
TULP1	B-GENE
or	O
TULP2	B-GENE
.	O

After	O
nine	O
months	O
GFR	O
improved	O
spontaneously	O
to	O
32	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
despite	O
no	O
improvement	O
in	O
his	O
hypertension	O
.	O

First	O
,	O
ste12Delta	B-GENE
cells	O
differ	O
from	O
cells	O
with	O
disruptions	O
of	O
the	O
upstream	O
signaling	O
elements	O
(	O
e	O
.	O
g	O
.	O
,	O
ste4Delta	B-GENE
,	O
ste20Delta	B-GENE
,	O
ste5Delta	B-GENE
,	O
ste11Delta	B-GENE
,	O
ste7Delta	B-GENE
,	O
or	O
fus3Delta	B-GENE
kss1Delta	B-GENE
cells	O
)	O
in	O
that	O
they	O
clearly	O
retain	O
some	O
capacity	O
for	O
inducing	O
Ste3p	B-GENE
phosphorylation	O
.	O

Herein	O
,	O
we	O
report	O
that	O
CRE	O
-	O
decoy	O
oligonucleotide	O
treatment	O
results	O
in	O
an	O
increase	O
in	O
the	O
p53	B-GENE
protein	I-GENE
level	O
in	O
MCF	O
-	O
7	O
human	O
breast	O
cancer	O
cells	O
that	O
express	O
wild	O
-	O
type	O
p53	B-GENE
.	O

The	O
selective	O
5	B-GENE
-	I-GENE
HT2	I-GENE
receptor	I-GENE
blocker	O
ketanserin	O
was	O
found	O
to	O
reduce	O
maximal	O
urethral	O
pressures	O
in	O
healthy	O
females	O
by	O
about	O
40	O
%	O
without	O
reducing	O
blood	O
pressure	O
.	O

It	O
thus	O
seems	O
likely	O
that	O
genistein	O
affects	O
a	O
common	O
pathway	O
downstream	O
of	O
these	O
signals	O
.	O

Studies	O
in	O
B	O
.	O
glabrata	O
,	O
B	O
.	O
straminea	O
and	O
B	O
.	O
tenagophila	O
under	O
outdoor	O
conditions	O
.	O

The	O
electrocardiogram	O
in	O
tachycardia	O
.	O

Identification	O
of	O
a	O
putative	O
chromosomal	O
replication	O
origin	O
from	O
Helicobacter	O
pylori	O
and	O
its	O
interaction	O
with	O
the	O
initiator	B-GENE
protein	I-GENE
DnaA	I-GENE
.	O

The	O
primary	O
structure	O
of	O
cholesterol	B-GENE
esterase	I-GENE
displayed	O
no	O
significant	O
homology	O
with	O
other	O
lipases	B-GENE
,	O
although	O
the	O
putative	O
lipid	O
interfacial	O
recognition	O
site	O
of	O
G	O
-	O
X	O
-	O
S	O
-	O
X	O
-	O
G	O
is	O
present	O
in	O
the	O
cholesterol	B-GENE
esterase	I-GENE
sequence	I-GENE
.	O

The	O
essential	O
questions	O
about	O
hepatitis	O
C	O

The	O
transcriptional	O
initiation	O
site	O
of	O
RAG1	B-GENE
was	O
localized	O
at	O
A	O
,	O
26	O
bp	O
upstream	O
of	O
the	O
putative	O
translational	O
initiation	O
codon	O
,	O
ATG	O
,	O
by	O
the	O
primer	O
extension	O
assay	O
.	O

Coronary	O
arteriographies	O
and	O
ventriculographies	O
corresponding	O
to	O
274	O
consecutive	O
patients	O
(	O
January	O
,	O
1975	O
-	O
October	O
,	O
1978	O
)	O
with	O
significant	O
coronary	O
lesions	O
are	O
reviewed	O
.	O

Visualization	O
of	O
the	O
cells	O
by	O
phase	O
contrast	O
microscopy	O
indicated	O
that	O
murine	B-GENE
PKCepsilon	I-GENE
expression	O
in	O
the	O
presence	O
of	O
glycerol	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
yeast	O
cells	O
exhibiting	O
very	O
small	O
buds	O
.	O

Sonography	O
depicted	O
the	O
true	O
morphology	O
of	O
these	O
cystic	O
lesions	O
more	O
clearly	O
than	O
CT	O
,	O
and	O
the	O
sonographic	O
findings	O
virtually	O
excluded	O
uncomplicated	O
hepatic	O
cyst	O
as	O
a	O
diagnosis	O
.	O

Protein	B-GENE
kinase	I-GENE
C	I-GENE
transiently	O
activated	O
heteromeric	B-GENE
N	I-GENE
-	I-GENE
methyl	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
aspartate	I-GENE
receptor	I-GENE
channels	I-GENE
independent	O
of	O
the	O
phosphorylatable	O
C	O
-	O
terminal	O
splice	O
domain	O
and	O
of	O
consensus	O
phosphorylation	O
sites	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
started	O
to	O
have	O
hyperemesis	O
gravidarum	O
6	O
weeks	O
before	O
admission	O
.	O

Highly	O
significant	O
similarities	O
were	O
detected	O
between	O
the	O
N	O
-	O
terminal	O
region	O
of	O
P30	B-GENE
and	O
those	O
of	O
GENA	B-GENE
[	O
the	O
product	O
of	O
another	O
unidentified	O
gene	O
(	O
geneA	B-GENE
)	O
located	O
upstream	O
of	O
the	O
aceEF	B-GENE
-	O
lpd	B-GENE
operon	O
]	O
,	O
and	O
GNTR	B-GENE
(	O
a	O
putative	O
transcriptional	O
repressor	O
of	O
the	O
gluconate	B-GENE
operon	I-GENE
of	O
Bacillus	O
subtilis	O
)	O
.	O

In	O
vitro	O
DNA	O
binding	O
assays	O
indicate	O
that	O
the	O
elements	O
identified	O
can	O
specifically	O
interact	O
with	O
c	B-GENE
-	I-GENE
Ets	I-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
.	O

They	O
are	O
found	O
to	O
have	O
several	O
advantages	O
over	O
the	O
conventional	O
indices	O
of	O
skewness	O
and	O
kurtosis	O
(	O
square	O
root	O
of	O
b1	O
and	O
b2	O
)	O
and	O
no	O
serious	O
drawbacks	O
.	O

They	O
elicit	O
similar	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
patterns	O
,	O
even	O
though	O
sign	O
language	O
is	O
dependent	O
on	O
spatial	O
information	O
.	O

Siglec	B-GENE
-	I-GENE
9	I-GENE
is	O
predicted	O
to	O
contain	O
three	O
extracellular	O
immunoglobulin	B-GENE
-	I-GENE
like	I-GENE
domains	I-GENE
that	O
comprise	O
an	O
N	B-GENE
-	I-GENE
terminal	I-GENE
V	I-GENE
-	I-GENE
set	I-GENE
domain	I-GENE
and	O
two	O
C2	B-GENE
-	I-GENE
set	I-GENE
domains	I-GENE
,	O
a	O
transmembrane	O
region	O
and	O
a	O
cytoplasmic	O
tail	O
containing	O
two	O
putative	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

Determination	O
of	O
the	O
LD	O
50	O
(	O
30	O
)	O
during	O
infant	O
period	O
and	O
growth	O
period	O

The	O
availability	O
of	O
a	O
commercial	O
program	O
(	O
PCNONLIN	O
)	O
is	O
needed	O
to	O
carry	O
out	O
matrix	O
handling	O
calculations	O
.	O

The	O
introduction	O
gives	O
also	O
the	O
history	O
of	O
Research	O
Programme	O
MZ	O
-	O
XVII	O
and	O
its	O
implementation	O
in	O
several	O
regions	O
of	O
Poland	O
.	O

The	O
fecal	O
excretion	O
is	O
found	O
to	O
be	O
only	O
one	O
third	O
of	O
that	O
measured	O
in	O
urine	O
.	O

The	O
COR	B-GENE
biosynthetic	O
gene	O
cluster	O
in	O
P	O
.	O
syringae	O
pv	O
.	O
glycinea	O
PG4180	O
is	O
encoded	O
by	O
a	O
32	O
-	O
kb	O
region	O
which	O
contains	O
both	O
the	O
structural	O
and	O
regulatory	O
genes	O
needed	O
for	O
COR	B-GENE
synthesis	O
.	O

Model	O
experiments	O
on	O
pheasants	O
using	O
single	O
doses	O
of	O
the	O
insecticide	O
(	O
Lindane	O
)	O
the	O
herbicide	O
(	O
Terbutryn	O
)	O
a	O
mineral	O
fertilizer	O
(	O
calcium	O
ammonium	O
nitrate	O
)	O
and	O
the	O
fungicide	O
(	O
HCB	O
)	O
.	O

In	O
this	O
technique	O
,	O
the	O
posterior	O
wall	O
of	O
the	O
neopharynx	O
consists	O
only	O
of	O
the	O
prevertebral	O
tissue	O
,	O
while	O
the	O
flap	O
forms	O
the	O
anterior	O
and	O
lateral	O
walls	O
.	O

The	O
most	O
common	O
hosts	O
were	O
equines	O
(	O
31	O
%	O
)	O
,	O
bovines	O
(	O
25	O
%	O
)	O
and	O
raccoons	O
(	O
19	O
%	O
)	O
.	O

A	O
single	O
HD	O
session	O
using	O
cellulose	O
triacetate	O
or	O
polysulfone	O
membrane	O
significantly	O
increased	O
water	O
content	O
both	O
at	O
forearm	O
and	O
lower	O
leg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Both	O
claR	B-GENE
and	O
car	B-GENE
are	O
expressed	O
as	O
monocistronic	O
transcripts	O
;	O
the	O
level	O
of	O
transcript	O
declined	O
rapidly	O
after	O
48h	O
in	O
complex	O
media	O
,	O
but	O
low	O
sustained	O
levels	O
of	O
both	O
transcripts	O
were	O
observed	O
in	O
defined	O
GSPG	O
medium	O
until	O
96h	O
.	O

claR	B-GENE
and	O
car	B-GENE
were	O
not	O
significantly	O
expressed	O
in	O
mutants	O
disrupted	O
in	O
the	O
ccaR	B-GENE
gene	I-GENE
,	O
a	O
regulatory	O
gene	O
that	O
controls	O
positively	O
clavulanic	O
acid	O
and	O
cephamycin	O
biosynthesis	O
.	O

Whereas	O
mutant	B-GENE
6C4	I-GENE
specified	O
a	O
wild	B-GENE
-	I-GENE
type	I-GENE
-	I-GENE
size	I-GENE
Pol	I-GENE
protein	I-GENE
,	O
we	O
detected	O
no	O
full	B-GENE
-	I-GENE
length	I-GENE
Pol	I-GENE
protein	I-GENE
in	O
7E4	O
-	O
infected	O
cell	O
extracts	O
.	O

The	O
hepatic	O
isoform	O
of	O
6	B-GENE
-	I-GENE
phosphofructo	I-GENE
-	I-GENE
2	I-GENE
-	I-GENE
kinase	I-GENE
/	O
fructose	B-GENE
-	I-GENE
2	I-GENE
,	I-GENE
6	I-GENE
-	I-GENE
bisphosphatase	I-GENE
(	O
PF2K	B-GENE
/	O
Fru	B-GENE
-	I-GENE
2	I-GENE
,	I-GENE
6	I-GENE
-	I-GENE
BPase	I-GENE
)	O
is	O
transcriptionally	O
stimulated	O
by	O
glucocorticoids	O
,	O
whereas	O
insulin	B-GENE
blocks	O
this	O
stimulatory	O
effect	O
.	O

Being	O
implicated	O
in	O
insulin	B-GENE
and	O
GK	B-GENE
gene	I-GENE
regulations	O
as	O
a	O
common	O
transcription	O
factor	O
,	O
IPF1	B-GENE
/	O
STF	B-GENE
-	I-GENE
1	I-GENE
/	O
PDX	B-GENE
-	I-GENE
1	I-GENE
is	O
likely	O
to	O
play	O
an	O
essential	O
role	O
in	O
maintaining	O
normal	O
beta	O
-	O
cell	O
functions	O
.	O

The	O
Caenorhabditis	B-GENE
elegans	I-GENE
NK	I-GENE
-	I-GENE
2	I-GENE
class	I-GENE
homeoprotein	I-GENE
CEH	I-GENE
-	I-GENE
22	I-GENE
is	O
involved	O
in	O
combinatorial	O
activation	O
of	O
gene	O
expression	O
in	O
pharyngeal	O
muscle	O
.	O

Mouse	O
embryo	O
cells	O
(	O
C57BL	O
/	O
6	O
,	O
H	O
-	O
2b	O
)	O
transformed	O
by	O
the	O
E1A	B-GENE
and	O
E1B	B-GENE
genes	O
of	O
adenovirus	O
type	O
5	O
(	O
Ad5E1	O
MEC	O
)	O
are	O
highly	O
immunogenic	O
.	O

The	O
largest	O
age	O
adjusted	O
differences	O
between	O
men	O
with	O
low	O
and	O
normal	O
mood	O
were	O
for	O
the	O
AH4	O
(	O
3	O
points	O
,	O
t	O
=	O
5	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
the	O
CAMCOG	O
(	O
2	O
points	O
,	O
t	O
=	O
5	O
.	O
8	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
resting	O
Tl	O
-	O
201	O
scintigraphy	O
has	O
limited	O
value	O
in	O
the	O
detection	O
of	O
coronary	O
artery	O
disease	O
in	O
patients	O
with	O
Hurler	O
syndrome	O
.	O

We	O
demonstrate	O
that	O
the	O
WRM	B-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
binds	O
to	O
LIT	B-GENE
-	I-GENE
1	I-GENE
in	O
vivo	O
and	O
that	O
WRM	B-GENE
-	I-GENE
1	I-GENE
can	O
activate	O
the	O
LIT	B-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
kinase	I-GENE
when	O
coexpressed	O
in	O
vertebrate	O
tissue	O
culture	O
cells	O
.	O

RESULTS	O
:	O
All	O
primary	O
tumors	O
were	O
positive	O
for	O
CAM5	B-GENE
.	I-GENE
2	I-GENE
.	O

Nuclear	O
extracts	O
from	O
Sertoli	O
cells	O
were	O
found	O
to	O
cause	O
an	O
E	O
-	O
box	O
gel	O
shift	O
when	O
the	O
cells	O
were	O
stimulated	O
to	O
differentiate	O
in	O
culture	O
,	O
but	O
not	O
under	O
basal	O
conditions	O
.	O

On	O
the	O
sixth	O
postirradiation	O
day	O
the	O
absorption	O
of	O
phenobarbitone	O
,	O
sulphafurazole	O
and	O
mecamylamine	O
had	O
returned	O
to	O
the	O
control	O
level	O
,	O
but	O
the	O
absorption	O
of	O
quinidine	O
and	O
isoniazid	O
was	O
still	O
retarded	O
.	O

To	O
determine	O
the	O
transactivation	O
potential	O
of	O
each	O
of	O
the	O
four	O
Ahr	B-GENE
Sp1	B-GENE
sites	I-GENE
,	O
we	O
fused	O
the	O
Ahr	B-GENE
promoter	I-GENE
to	O
a	O
luciferase	B-GENE
(	O
LUC	B-GENE
)	O
reporter	O
gene	O
and	O
transfected	O
the	O
construct	O
into	O
the	O
Drosophila	O
cell	O
line	O
Schneider	O
-	O
2	O
,	O
which	O
contains	O
no	O
Sp1	B-GENE
or	O
Sp1	B-GENE
-	I-GENE
like	I-GENE
factors	I-GENE
.	O

We	O
determined	O
that	O
Hop	B-GENE
(	I-GENE
T42	I-GENE
)	I-GENE
contains	O
a	O
glutamic	O
acid	O
-	O
to	O
-	O
lysine	O
substitution	O
at	O
amino	O
acid	O
residue	O
695	O
(	O
E695K	O
)	O
.	O

The	O
organotins	O
.	O

Results	O
of	O
these	O
studies	O
indicate	O
that	O
binding	O
of	O
biotin	O
to	O
the	O
protein	O
results	O
in	O
protection	O
of	O
regions	O
of	O
the	O
central	O
domain	O
in	O
the	O
vicinity	O
of	O
the	O
active	O
site	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
from	O
chemical	O
cleavage	O
.	O

The	O
psh3	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
gene	I-GENE
encodes	O
a	O
protein	O
of	O
215	O
amino	O
acids	O
,	O
which	O
shares	O
a	O
high	O
degree	O
of	O
structural	O
and	O
functional	O
similarity	O
with	O
Shr3p	B-GENE
.	O

The	O
impairment	O
of	O
the	O
nocturnal	O
secretion	O
was	O
related	O
to	O
the	O
subjects	O
'	O
age	O
and	O
,	O
for	O
the	O
GH	B-GENE
secretory	O
pattern	O
only	O
,	O
also	O
to	O
the	O
MMSE	O
score	O
.	O

Thus	O
,	O
the	O
antibody	O
class	O
switch	O
appears	O
to	O
be	O
directed	O
by	O
induction	O
of	O
accessibility	O
,	O
as	O
assayed	O
by	O
transcription	O
of	O
germ	O
line	O
CH	B-GENE
genes	O
.	O

This	O
growth	O
-	O
inhibitory	O
effect	O
was	O
suppressed	O
by	O
the	O
mpk1	B-GENE
delta	I-GENE
mutation	O
,	O
suggesting	O
that	O
hyperactivation	O
of	O
the	O
Mpk1	B-GENE
pathway	O
is	O
toxic	O
to	O
cells	O
.	O

The	O
chicken	O
genome	O
contains	O
two	O
functional	O
nonallelic	O
beta1	B-GENE
,	I-GENE
4	I-GENE
-	I-GENE
galactosyltransferase	I-GENE
genes	I-GENE
.	O

Recombinant	B-GENE
Human	I-GENE
Erythropoietin	I-GENE
and	O
Platinum	O
-	O
Based	O
Chemotherapy	O
In	O
Advanced	O
Ovarian	O
Cancer	O

Homodimers	O
of	O
RIP60	B-GENE
(	O
replication	B-GENE
initiation	I-GENE
-	I-GENE
region	I-GENE
protein	I-GENE
60	I-GENE
kDA	I-GENE
)	O
purified	O
from	O
nuclear	O
extract	O
bind	O
two	O
ATT	O
-	O
rich	O
sites	O
in	O
oribeta	O
and	O
foster	O
the	O
formation	O
of	O
a	O
twisted	O
720	O
bp	O
DNA	O
loop	O
in	O
vitro	O
.	O

Endodontic	O
treatment	O
of	O
deciduous	O
teeth	O
using	O
the	O
formocresol	O
amputation	O
method	O

Some	O
of	O
these	O
physiological	O
responses	O
are	O
regulated	O
via	O
activation	O
of	O
transcription	O
factors	O
such	O
as	O
activator	B-GENE
protein	I-GENE
1	I-GENE
(	O
AP	B-GENE
-	I-GENE
1	I-GENE
)	O
.	O

To	O
test	O
the	O
role	O
of	O
myb	B-GENE
family	I-GENE
members	I-GENE
in	O
progression	O
through	O
the	O
cell	O
cycle	O
,	O
we	O
comicroinjected	O
c	B-GENE
-	I-GENE
myc	I-GENE
and	O
myb	B-GENE
expression	O
vectors	O
into	O
serum	O
-	O
deprived	O
quiescent	O
SMCs	O
.	O

Overall	O
graft	O
and	O
patient	O
survival	O
after	O
HAT	O
were	O
33	O
.	O
3	O
%	O
and	O
75	O
%	O
,	O
respectively	O
.	O

LAC9	B-GENE
is	O
a	O
DNA	O
-	O
binding	O
protein	O
that	O
regulates	O
transcription	O
of	O
the	O
lactose	B-GENE
-	I-GENE
galactose	I-GENE
regulon	I-GENE
in	O
Kluyveromyces	O
lactis	O
.	O

We	O
determined	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
the	O
gypsy	B-GENE
element	I-GENE
present	O
at	O
the	O
forked	B-GENE
locus	I-GENE
of	O
Drosophila	O
melanogaster	O
in	O
the	O
f1	O
allele	O
.	O

The	O
same	O
high	O
degree	O
of	O
sequence	O
homology	O
between	O
the	O
two	O
F	O
.	O
diplosiphon	O
PC	B-GENE
alpha	I-GENE
and	O
PC	B-GENE
beta	I-GENE
sequences	I-GENE
(	O
85	O
and	O
77	O
%	O
,	O
respectively	O
)	O
was	O
found	O
at	O
both	O
the	O
nucleotide	O
and	O
amino	O
acid	O
levels	O
,	O
and	O
similar	O
results	O
were	O
obtained	O
for	O
interspecies	O
comparisons	O
.	O

A	O
wound	O
model	O
for	O
decubitus	O
and	O
leg	O
ulcers	O
consisting	O
of	O
human	O
dermal	O
fibroblasts	O
in	O
type	B-GENE
I	I-GENE
collagen	I-GENE
dermal	O
"	O
equivalent	O
"	O
matrix	O
(	O
DEM	O
)	O
was	O
exposed	O
in	O
vitro	O
to	O
electric	O
fields	O
similar	O
to	O
postulated	O
endogenous	O
fields	O
in	O
wounds	O
.	O

A	O
group	O
of	O
factors	O
known	O
as	O
activating	B-GENE
transcription	I-GENE
factors	I-GENE
(	O
ATF	B-GENE
)	O
have	O
been	O
found	O
to	O
bind	O
to	O
the	O
latter	O
and	O
related	O
sequences	O
found	O
upstream	O
of	O
early	O
adenovirus	O
promoters	O
induced	O
by	O
E1A	B-GENE
,	O
and	O
these	O
factors	O
are	O
highly	O
homologous	O
to	O
the	O
CREB	B-GENE
protein	I-GENE
.	O

In	O
addition	O
to	O
these	O
cases	O
,	O
patients	O
w	O
with	O
high	O
Loa	O
microfilaremia	O
also	O
developed	O
milder	O
neurologic	O
manifestations	O
causing	O
functional	O
impairment	O
lasting	O
for	O
at	O
least	O
one	O
week	O
after	O
treatment	O
.	O

The	O
vertebrate	B-GENE
transcription	I-GENE
factors	I-GENE
TCF	I-GENE
(	O
T	B-GENE
cell	I-GENE
factor	I-GENE
)	O
and	O
LEF	B-GENE
(	O
lymphocyte	B-GENE
enhancer	I-GENE
binding	I-GENE
factor	I-GENE
)	O
interact	O
with	O
beta	B-GENE
-	I-GENE
catenin	I-GENE
and	O
are	O
hypothesized	O
to	O
mediate	O
Wingless	B-GENE
/	O
Wnt	B-GENE
signaling	O
.	O

Some	O
of	O
these	O
DNA	O
:	O
protein	O
complexes	O
were	O
also	O
present	O
,	O
but	O
at	O
lower	O
levels	O
,	O
in	O
nuclear	O
extracts	O
from	O
untransformed	O
rat	O
cells	O
suggesting	O
the	O
possible	O
involvement	O
of	O
cellular	O
factors	O
in	O
the	O
mechanism	O
of	O
down	O
-	O
regulation	O
mediated	O
by	O
Ad12	B-GENE
E1A	I-GENE
.	O

Hypocalcemia	O
is	O
usually	O
due	O
to	O
either	O
a	O
disturbance	O
in	O
the	O
parathyroid	B-GENE
hormone	I-GENE
-	O
adenylate	B-GENE
cyclase	I-GENE
system	O
or	O
a	O
disturbance	O
in	O
vitamin	O
D	O
metabolism	O
.	O

Activity	O
was	O
reconstituted	O
,	O
however	O
,	O
by	O
combining	O
fractions	O
that	O
were	O
enriched	O
in	O
the	O
two	O
components	O
.	O

If	O
failure	O
to	O
solve	O
invisible	O
displacements	O
was	O
due	O
to	O
increased	O
memory	O
requirements	O
,	O
then	O
the	O
primates	O
should	O
perform	O
at	O
chance	O
level	O
on	O
all	O
3	O
problems	O
.	O

In	O
seven	O
patients	O
(	O
7	O
.	O
8	O
%	O
)	O
with	O
new	O
Q	O
-	O
waves	O
and	O
a	O
pathologic	O
CK	B-GENE
-	I-GENE
MB	I-GENE
profile	O
(	O
group	O
II	O
)	O
troponin	B-GENE
T	I-GENE
reached	O
median	O
levels	O
of	O
10	O
.	O
47	O
micrograms	O
/	O
l	O
(	O
quartile	O
6	O
.	O
34	O
-	O
12	O
.	O
50	O
micrograms	O
/	O
l	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
I	O
vs	O
II	O
)	O
.	O

Mineralized	O
bone	O
nodule	O
formation	O
in	O
vitro	O
by	O
cell	O
populations	O
from	O
young	O
adult	O
rabbit	O
alveolar	O
bone	O
.	O

Mouse	B-GENE
GRK6	I-GENE
-	I-GENE
C	I-GENE
displays	O
none	O
of	O
these	O
motifs	O
.	O

Comparisons	O
of	O
the	O
efficacy	O
of	O
benazepril	O
and	O
hydrochlorothiazide	O
alone	O
and	O
in	O
combination	O
have	O
shown	O
that	O
benazepril	O
20	O
mg	O
once	O
daily	O
is	O
as	O
effective	O
as	O
or	O
more	O
effective	O
in	O
lowering	O
diastolic	O
blood	O
pressure	O
than	O
hydrochlorothiazide	O
25	O
mg	O
once	O
daily	O
and	O
that	O
the	O
combination	O
of	O
benazepril	O
20	O
mg	O
and	O
hydrochlorothiazide	O
25	O
mg	O
has	O
a	O
possibly	O
synergistic	O
effect	O
on	O
diastolic	O
blood	O
pressure	O
.	O

The	O
132	B-GENE
-	I-GENE
bp	I-GENE
PHO8p	I-GENE
fragment	I-GENE
,	O
connected	O
at	O
position	O
-	O
281	O
of	O
the	O
5	O
'	O
upstream	O
region	O
of	O
a	O
HIS5	B-GENE
'	I-GENE
-	O
'	B-GENE
lacZ	I-GENE
fused	O
gene	O
,	O
could	O
sense	O
Pi	O
signals	O
in	O
vivo	O
,	O
but	O
a	O
20	O
-	O
bp	O
synthetic	O
oligonucleotide	O
having	O
the	O
same	O
sequence	O
from	O
-	O
544	O
to	O
-	O
525	O
of	O
the	O
PHO8p	B-GENE
DNA	I-GENE
could	O
not	O
.	O

1988	O
)	O
.	O

Sequences	O
within	O
the	O
UAS2	O
element	O
of	O
the	O
ENO2	B-GENE
gene	I-GENE
bound	O
a	O
second	O
protein	O
which	O
corresponded	O
to	O
the	O
ABFI	B-GENE
(	O
autonomously	B-GENE
replicating	I-GENE
sequence	I-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
)	O
protein	O
.	O

Plasmid	O
subclones	O
of	O
recombinant	O
phage	O
lambda	O
Asm152	O
were	O
able	O
to	O
complement	O
both	O
Escherichia	B-GENE
coli	I-GENE
gltB	I-GENE
and	O
A	O
.	O
sesbaniae	O
Asm	O
-	O
Vi	O
mutants	O
;	O
NADPH	B-GENE
-	I-GENE
glutamate	I-GENE
synthase	I-GENE
activity	O
was	O
detected	O
in	O
all	O
such	O
strains	O
complemented	O
to	O
Asm	O
+	O
.	O

The	O
sequence	O
of	O
LZ321	B-GENE
matched	O
that	O
of	O
RREB1	B-GENE
,	O
a	O
transcription	O
factor	O
that	O
bound	O
to	O
a	O
Ras	B-GENE
responsive	I-GENE
element	I-GENE
(	O
RRE	B-GENE
)	O
very	O
different	O
from	O
the	O
sequence	O
with	O
which	O
we	O
isolated	O
LZ321	B-GENE
.	O

Steady	O
-	O
state	O
levels	O
of	O
murine	B-GENE
MMR	I-GENE
mRNA	I-GENE
were	O
measured	O
in	O
the	O
macrophage	O
cell	O
line	O
J774E	O
,	O
which	O
is	O
known	O
to	O
express	O
the	O
protein	O
at	O
the	O
cell	O
surface	O
.	O

Basal	O
level	O
expression	O
was	O
reduced	O
to	O
20	O
and	O
50	O
%	O
when	O
the	O
UGA	O
stop	O
codon	O
was	O
replaced	O
by	O
UAG	O
or	O
UAA	O
,	O
respectively	O
,	O
consistent	O
with	O
the	O
finding	O
that	O
in	O
E	O
.	O
coli	O
translation	O
terminates	O
more	O
efficiently	O
at	O
UAG	O
and	O
UAA	O
than	O
at	O
UGA	O
.	O

Discriminant	O
function	O
analysis	O
suggests	O
that	O
AUDIT	O
scores	O
can	O
successfully	O
identify	O
SAT	O
-	O
positive	O
and	O
SAT	O
-	O
negative	O
patients	O
;	O
the	O
analysis	O
accounted	O
for	O
42	O
.	O
5	O
%	O
of	O
the	O
variance	O
and	O
correctly	O
classified	O
84	O
.	O
6	O
%	O
of	O
the	O
sample	O
.	O

Coronatine	B-GENE
(	O
COR	B-GENE
)	O
is	O
a	O
plasmid	O
-	O
encoded	O
phytotoxin	O
synthesized	O
by	O
several	O
pathovars	O
of	O
phytopathogenic	O
Pseudomonas	O
syringae	O
.	O

Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
also	O
show	O
significant	O
similarity	O
to	O
the	O
murine	O
gene	O
,	O
with	O
79	O
and	O
70	O
%	O
sequence	O
identity	O
,	O
respectively	O
.	O

One	O
patient	O
exhibited	O
a	O
non	O
-	O
sense	O
mutation	O
(	O
codon	O
388	O
)	O
,	O
which	O
changed	O
a	O
glutamine	O
codon	O
(	O
CAG	O
)	O
to	O
a	O
stop	O
codon	O
(	O
TAG	O
)	O
.	O

The	O
transcriptional	O
activity	O
of	O
P	B-GENE
-	I-GENE
450	I-GENE
(	I-GENE
11	I-GENE
beta	I-GENE
)	I-GENE
gene	I-GENE
was	O
studied	O
with	O
an	O
in	O
vitro	O
transcription	O
system	O
using	O
nuclear	O
extracts	O
prepared	O
from	O
bovine	O
adrenal	O
cortex	O
.	O

Renal	O
dysplasia	O
with	O
multisystem	O
malformation	O
-	O
-	O
a	O
study	O
of	O
9	O
cases	O
.	O

This	O
bud	O
morphology	O
results	O
at	O
least	O
in	O
part	O
from	O
a	O
cell	O
cycle	O
delay	O
imposed	O
by	O
the	O
Cdc28p	B-GENE
-	O
inhibitory	O
kinase	O
Swe1p	B-GENE
.	O

Eleven	O
of	O
the	O
12	O
exons	O
have	O
complete	O
sequence	O
homology	O
with	O
the	O
RBM	B-GENE
-	I-GENE
1	I-GENE
sequence	I-GENE
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Laparoscopic	O
examination	O
1	O
year	O
after	O
surgery	O
revealed	O
an	O
enlarged	O
,	O
thin	O
-	O
walled	O
,	O
and	O
fluid	O
-	O
filled	O
uterine	O
segment	O
cranial	O
to	O
the	O
midcornus	O
occlusion	O
sites	O
in	O
all	O
animals	O
.	O

The	O
three	O
proteins	O
copurified	O
through	O
several	O
biochemical	O
fractionation	O
steps	O
and	O
could	O
be	O
coimmunoprecipitated	O
by	O
using	O
antibodies	O
against	O
GCD1	B-GENE
or	O
GCD2	B-GENE
.	O

Cellular	O
fractionation	O
and	O
Percoll	O
gradient	O
centrifugation	O
combined	O
with	O
immunoblotting	O
show	O
that	O
p67	B-GENE
cofractionates	O
with	O
nuclei	O
and	O
is	O
enriched	O
in	O
resistant	O
structure	O
that	O
is	O
insoluble	O
in	O
2	O
M	O
NaCl	O
,	O
25	O
mM	O
lithium	O
3	O
,	O
5	O
'	O
-	O
diiodosalicylate	O
,	O
and	O
1	O
%	O
Triton	O
but	O
is	O
soluble	O
in	O
8	O
M	O
urea	O
.	O

For	O
the	O
first	O
time	O
also	O
a	O
genomic	O
sequence	O
for	O
a	O
red	B-GENE
algal	I-GENE
lhc	I-GENE
gene	I-GENE
is	O
presented	O
.	O

Elimination	O
of	O
brush	O
border	O
as	O
well	O
as	O
of	O
glomerular	O
marker	O
proteins	O
was	O
significantly	O
lower	O
after	O
intravenous	O
injection	O
of	O
low	O
-	O
osmolar	O
CM	O
iopamidol	O
370	O
(	O
832	O
mOsm	O
/	O
kg	O
)	O
than	O
after	O
meglumine	O
diatrizoate	O
76	O
(	O
2100	O
mOsm	O
/	O
kg	O
)	O
.	O

Raman	O
scattering	O
from	O
VO2	O
single	O
crystals	O
:	O
A	O
study	O
of	O
the	O
effects	O
of	O
surface	O
oxidation	O
.	O

Combination	O
chemotherapy	O
in	O
advanced	O
ovarian	O
cancer	O
.	O

Making	O
sense	O
out	O
of	O
oxygen	O
sensor	O
.	O

In	O
comparison	O
to	O
a	O
silent	O
baseline	O
,	O
CBF	O
increases	O
were	O
observed	O
in	O
auditory	O
cortex	O
bilaterally	O
and	O
in	O
the	O
right	O
superior	O
parietal	O
,	O
right	O
dorsolateral	O
frontal	O
,	O
and	O
right	O
premotor	O
regions	O
,	O
with	O
no	O
modulation	O
as	O
a	O
function	O
of	O
attentional	O
condition	O
.	O

In	O
vitro	O
,	O
c	B-GENE
-	I-GENE
Src	I-GENE
phosphorylated	O
FAK	B-GENE
Tyr	I-GENE
-	I-GENE
925	I-GENE
in	O
a	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
-	O
FAK	B-GENE
C	O
-	O
terminal	O
domain	O
fusion	O
protein	O
,	O
whereas	O
FAK	O
did	O
not	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
effect	O
of	O
prolonged	O
nitrate	O
therapy	O
between	O
2	O
days	O
and	O
6	O
weeks	O
during	O
healing	O
after	O
infarction	O
on	O
serial	O
parameters	O
of	O
ventricular	O
remodeling	O
(	O
scar	O
expansion	O
,	O
scar	O
thinning	O
,	O
ventricular	O
dilation	O
,	O
and	O
hypertrophy	O
)	O
and	O
function	O
(	O
asynergy	O
or	O
akinesis	O
plus	O
dyskinesis	O
and	O
ejection	O
fraction	O
)	O
by	O
serial	O
two	O
-	O
dimensional	O
echocardiography	O
,	O
hemodynamics	O
,	O
postmortem	O
topography	O
(	O
computerized	O
planimetry	O
,	O
geometric	O
maps	O
,	O
and	O
radiographs	O
)	O
,	O
and	O
collagen	B-GENE
content	O
(	O
hydroxyproline	O
)	O
was	O
studied	O
in	O
64	O
instrumented	O
dogs	O
randomized	O
2	O
days	O
after	O
left	O
anterior	O
descending	O
coronary	O
artery	O
ligation	O
to	O
various	O
nitrate	O
regimens	O
(	O
n	O
=	O
32	O
)	O
over	O
the	O
first	O
2	O
weeks	O
(	O
subgroup	O
1	O
:	O
2	O
%	O
transdermal	O
nitroglycerin	O
at	O
8	O
AM	O
and	O
4	O
PM	O
,	O
n	O
=	O
6	O
;	O
subgroup	O
2	O
:	O
2	O
%	O
transdermal	O
nitroglycerin	O
plus	O
2	O
.	O
6	O
mg	O
of	O
sustained	O
-	O
release	O
oral	O
nitroglycerin	O
at	O
8	O
AM	O
,	O
3	O
PM	O
,	O
and	O
10	O
PM	O
,	O
n	O
=	O
5	O
;	O
subgroup	O
3	O
:	O
oral	O
isosorbide	O
dinitrate	O
,	O
30	O
mg	O
at	O
8	O
AM	O
and	O
4	O
PM	O
,	O
n	O
=	O
11	O
)	O
or	O
6	O
weeks	O
(	O
subgroup	O
4	O
:	O
isosorbide	O
dinitrate	O
,	O
n	O
=	O
10	O
)	O
and	O
in	O
matching	O
controls	O
(	O
n	O
=	O
32	O
)	O
.	O

The	O
essential	O
oil	O
composition	O
of	O
three	O
Zingiberaceae	O
widely	O
used	O
as	O
medicinal	O
aromatic	O
plants	O
from	O
S	O
.	O

Gel	O
shift	O
analysis	O
of	O
protein	O
binding	O
from	O
nuclear	O
extracts	O
to	O
these	O
caveolin	B-GENE
promoter	I-GENE
DNA	I-GENE
sequences	I-GENE
,	O
together	O
with	O
DNase	B-GENE
I	I-GENE
footprinting	O
,	O
confirmed	O
nucleoprotein	O
binding	O
to	O
the	O
SRE	O
-	O
like	O
elements	O
as	O
part	O
of	O
the	O
transcriptional	O
response	O
to	O
LDL	B-GENE
-	I-GENE
FC	I-GENE
.	O

A	O
new	O
model	O
for	O
objective	O
assessment	O
of	O
cervical	O
ripening	O
:	O
the	O
effect	O
of	O
prostaglandin	O
E2	O
and	O
prelabor	O
contractility	O
.	O

CONCLUSIONS	O
:	O
The	O
MC	O
/	O
UA	O
ratio	O
improves	O
the	O
sensitivity	O
for	O
the	O
prediction	O
of	O
poor	O
perinatal	O
outcome	O
when	O
it	O
is	O
combined	O
with	O
the	O
NST	O
.	O

Evaluation	O
of	O
materials	O
and	O
technics	O
in	O
vascular	O
surgery	O
using	O
111	O
-	O
Indium	O

The	O
claustrocortical	O
connection	O
was	O
investigated	O
in	O
13	O
cats	O
with	O
selective	O
injections	O
of	O
30	O
%	O
HRP	O
in	O
the	O
three	O
subdivisions	O
of	O
the	O
auditory	O
cortex	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Applying	O
the	O
experience	O
mentioned	O
above	O
,	O
4	O
-	O
META	O
was	O
used	O
to	O
bond	O
a	O
proprietary	O
photocuring	O
microfilled	O
composite	O
material	O
to	O
Class	O
V	O
cavities	O
in	O
freshly	O
extracted	O
human	O
teeth	O
.	O

The	O
phP1	B-GENE
mutation	O
was	O
induced	O
by	O
insertion	O
of	O
a	O
1	O
.	O
2	O
-	O
kb	O
P	B-GENE
element	I-GENE
into	O
the	O
5	O
'	O
transcribed	O
nontranslated	O
region	O
of	O
the	O
proximal	O
polyhomeotic	B-GENE
gene	I-GENE
.	O

METHOD	O
:	O
Six	O
instruments	O
were	O
reviewed	O
:	O
the	O
Berg	O
Balance	O
Scale	O
(	O
Berg	O
)	O
,	O
the	O
Clinical	O
Test	O
of	O
Sensory	O
Interaction	O
and	O
Balance	O
(	O
CTSIB	O
)	O
,	O
the	O
Functional	O
Reach	O
Test	O
,	O
the	O
Tinetti	O
Balance	O
Test	O
of	O
the	O
Performance	O
-	O
Oriented	O
Assessment	O
of	O
Mobility	O
Problems	O
(	O
Tinetti	O
)	O
,	O
the	O
Timed	O
"	O
Up	O
and	O
Go	O
"	O
Test	O
(	O
TU	O
&	O
GT	O
)	O
,	O
and	O
the	O
Physical	O
Performance	O
Test	O
(	O
PPT	O
)	O
.	O

Genome	O
timeline	O
.	O

Initial	O
computer	O
based	O
similarity	O
searches	O
identified	O
human	B-GENE
retinoblastoma	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
(	O
RBP	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
Drosophila	B-GENE
melanogaster	I-GENE
male	I-GENE
specific	I-GENE
lethal	I-GENE
-	I-GENE
3	I-GENE
(	O
Msl	B-GENE
-	I-GENE
3	I-GENE
)	O
,	O
S	B-GENE
.	I-GENE
pombe	I-GENE
altered	I-GENE
polarity	I-GENE
-	I-GENE
13	I-GENE
(	O
Alp13	B-GENE
)	O
and	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
Eaf3p	I-GENE
,	O
a	O
component	O
of	O
the	O
yeast	B-GENE
NuA4	I-GENE
HAT	B-GENE
complex	O
(	O
Galarneau	O
et	O
al	O
.	O
,	O
2000	O
.	O

The	O
pressure	O
measurements	O
under	O
steady	O
flow	O
conditions	O
showed	O
that	O
the	O
hemodynamic	O
performance	O
(	O
including	O
pressure	O
gradient	O
and	O
effective	O
orifice	O
area	O
)	O
of	O
SPAB	O
is	O
superior	O
to	O
that	O
of	O
its	O
stented	O
counterpart	O
,	O
especially	O
in	O
the	O
smaller	O
sizes	O
.	O

Serum	O
prolactin	B-GENE
rapidly	O
decreased	O
after	O
institution	O
of	O
treatment	O
,	O
with	O
actual	O
normalization	O
(	O
less	O
than	O
20	O
ng	O
/	O
ml	O
)	O
by	O
the	O
3rd	O
month	O
.	O

We	O
report	O
five	O
of	O
13	O
evaluable	O
patients	O
undergoing	O
allogeneic	O
sibling	O
BM	O
or	O
PBSC	O
transplantation	O
for	O
MM	O
between	O
1990	O
and	O
1997	O
who	O
met	O
the	O
criteria	O
for	O
adjuvant	O
alpha	B-GENE
-	I-GENE
IFN	I-GENE
therapy	O
.	O

Moist	O
healing	O
versus	O
wet	O
-	O
to	O
-	O
dry	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
Tyr319	O
as	O
a	O
functionally	O
important	O
phosphorylation	O
site	O
in	O
the	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
interdomain	I-GENE
B	I-GENE
region	I-GENE
.	O

These	O
findings	O
suggest	O
that	O
low	O
-	O
power	O
laser	O
irradiation	O
can	O
be	O
used	O
for	O
promotion	O
of	O
vascularization	O
and	O
take	O
of	O
tissue	O
transplants	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
26	O
IDDM	O
patients	O
with	O
normoalbuminuria	O
were	O
randomized	O
into	O
two	O
groups	O
,	O
with	O
one	O
group	O
receiving	O
placebo	O
(	O
n	O
=	O
13	O
,	O
age	O
36	O
+	O
/	O
-	O
3	O
years	O
,	O
BMI	O
24	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
1	O
kg	O
/	O
m2	O
)	O
and	O
the	O
other	O
group	O
receiving	O
an	O
average	O
of	O
15	O
mg	O
lisinopril	O
daily	O
(	O
n	O
=	O
13	O
,	O
age	O
34	O
+	O
/	O
-	O
2	O
years	O
,	O
BMI	O
24	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
kg	O
/	O
m2	O
)	O
.	O

Previously	O
,	O
a	O
cDNA	O
(	O
GT2	B-GENE
)	O
encoding	O
this	O
protein	O
was	O
isolated	O
from	O
a	O
mouse	O
3T3	O
-	O
L1	O
adipocyte	O
library	O
and	O
was	O
sequenced	O
.	O

Expression	O
of	O
human	B-GENE
complement	I-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
(	O
CR2	B-GENE
/	O
CD21	B-GENE
)	O
is	O
primarily	O
restricted	O
to	O
mature	O
B	O
cells	O
and	O
follicular	O
dendritic	O
cells	O
.	O

The	O
6	O
.	O
5	O
-	O
kb	O
genomic	O
fragment	O
contains	O
the	O
complete	O
coding	O
region	O
of	O
MyoD	B-GENE
,	O
distributed	O
over	O
three	O
exons	O
,	O
plus	O
2	O
.	O
3	O
kb	O
of	O
5	O
'	O
-	O
noncoding	O
sequence	O
and	O
1	O
.	O
4	O
kb	O
of	O
3	O
'	O
-	O
noncoding	O
sequence	O
.	O

Synthetic	O
studies	O
on	O
furan	O
derivatives	O
by	O
the	O
wittig	O
reaction	O

The	O
apparent	O
binding	O
constant	O
of	O
6	O
to	O
calf	O
thymus	O
DNA	O
is	O
1	O
.	O
68	O
X	O
10	O
(	O
5	O
)	O
M	O
-	O
1	O
whereas	O
netropsin	B-GENE
under	O
similar	O
conditions	O
gives	O
a	O
value	O
of	O
1	O
.	O
85	O
X	O
10	O
(	O
7	O
)	O
M	O
-	O
1	O
.	O

Phenotypic	O
screening	O
of	O
mutations	O
in	O
Pmr1	B-GENE
,	O
the	O
yeast	B-GENE
secretory	I-GENE
pathway	I-GENE
Ca2	I-GENE
+	I-GENE
/	I-GENE
Mn2	I-GENE
+	I-GENE
-	I-GENE
ATPase	I-GENE
,	O
reveals	O
residues	O
critical	O
for	O
ion	O
selectivity	O
and	O
transport	O
.	O

Molecular	O
cloning	O
of	O
cDNAs	O
encoding	O
alpha	O
-	O
subunits	O
of	O
guanine	B-GENE
nucleotide	I-GENE
-	I-GENE
binding	I-GENE
regulatory	I-GENE
proteins	I-GENE
(	O
G	B-GENE
-	I-GENE
proteins	I-GENE
)	O
has	O
revealed	O
the	O
existence	O
of	O
nine	O
species	O
of	O
alpha	O
-	O
subunits	O
.	O

No	O
transactivation	O
of	O
the	O
ovalbumin	B-GENE
promoter	I-GENE
(	O
pLovTATA	B-GENE
)	O
template	O
control	O
was	O
observed	O
.	O

Pros	O
and	O
cons	O
of	O
selective	O
inhibition	O
of	O
cyclooxygenase	B-GENE
-	I-GENE
2	I-GENE
versus	O
dual	O
lipoxygenase	B-GENE
/	O
cyclooxygenase	B-GENE
inhibition	O
:	O
is	O
two	O
better	O
than	O
one	O
?	O

At	O
11	O
.	O
5	O
years	O
of	O
follow	O
-	O
up	O
,	O
521	O
major	O
coronary	O
disease	O
events	O
had	O
occurred	O
,	O
261	O
fatal	O
and	O
260	O
non	O
-	O
fatal	O
.	O

The	O
etiology	O
was	O
established	O
in	O
73	O
(	O
76	O
.	O
8	O
%	O
)	O
out	O
of	O
95	O
cases	O
.	O

Morphometry	O
of	O
the	O
intestine	O
of	O
the	O
pig	O
.	O

Serum	O
zinc	O
and	O
copper	O
levels	O
and	O
urine	O
copper	O
concentrations	O
in	O
men	O
were	O
significantly	O
lower	O
than	O
in	O
women	O
,	O
while	O
there	O
were	O
no	O
differences	O
in	O
serum	O
or	O
urinary	O
zinc	O
and	O
copper	O
levels	O
with	O
age	O
.	O

HDE	B-GENE
was	O
found	O
to	O
be	O
exclusively	O
targeted	O
to	O
and	O
imported	O
into	O
peroxisomes	O
in	O
both	O
heterologous	O
expression	O
systems	O
.	O

GeneCalling	O
analysis	O
was	O
successful	O
in	O
detecting	O
members	O
of	O
complex	O
metabolic	O
pathways	O
and	O
uncovering	O
novel	O
genes	O
that	O
were	O
either	O
coincidentally	O
regulated	O
or	O
directly	O
involved	O
in	O
such	O
pathways	O
.	O

Transformations	O
with	O
circular	O
plasmids	O
yielded	O
slowly	O
and	O
irregularly	O
growing	O
geneticin	O
-	O
resistant	O
mycelia	O
in	O
which	O
1	O
%	O
of	O
nuclei	O
contained	O
plasmid	O
sequences	O
.	O

CONCLUSION	O
:	O
In	O
these	O
patients	O
control	O
of	O
ventricular	O
response	O
rate	O
with	O
either	O
HBA	O
+	O
VVIR	O
pacemaker	O
or	O
atrioventricular	O
modifying	O
drugs	O
+	O
VVI	O
pacemaker	O
will	O
lead	O
to	O
a	O
significant	O
improvement	O
in	O
exercise	O
duration	O
and	O
quality	O
of	O
life	O
.	O

The	O
other	O
regions	O
include	O
potential	O
binding	O
sites	O
for	O
transcription	O
factors	O
ATF	B-GENE
,	O
NF1	B-GENE
,	O
and	O
a	O
CCAAT	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
.	O

Both	O
purH	B-GENE
and	O
purD	B-GENE
genes	I-GENE
constitute	O
a	O
single	O
operon	O
and	O
are	O
coregulated	O
in	O
expression	O
by	O
purines	O
as	O
other	O
purine	B-GENE
genes	I-GENE
are	O
.	O

The	O
patient	O
demographics	O
(	O
means	O
+	O
/	O
-	O
standard	O
deviations	O
)	O
were	O
as	O
follows	O
:	O
age	O
,	O
57	O
+	O
/	O
-	O
12	O
years	O
;	O
sex	O
,	O
nine	O
males	O
and	O
three	O
females	O
;	O
APACHE	O
II	O
score	O
,	O
15	O
+	O
/	O
-	O
3	O
;	O
diagnosis	O
,	O
9	O
of	O
12	O
patients	O
with	O
pneumonia	O
.	O

In	O
situ	O
hybridization	O
reveals	O
strong	O
signals	O
for	O
Zep	B-GENE
mRNA	I-GENE
in	O
the	O
cerebellum	O
and	O
olfactory	O
bulb	O
with	O
moderate	O
signals	O
detected	O
in	O
the	O
hippocampus	O
and	O
cortex	O
.	O

TNF	B-GENE
-	I-GENE
alpha	I-GENE
effect	O
was	O
eliminated	O
by	O
a	O
2	O
-	O
bp	O
substitution	O
mutation	O
in	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B1	I-GENE
binding	I-GENE
half	I-GENE
site	I-GENE
of	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
cis	I-GENE
element	I-GENE
.	O

UV	O
-	O
cross	O
-	O
linking	O
studies	O
suggested	O
that	O
these	O
two	O
complexes	O
represent	O
one	O
and	O
two	O
molecules	O
of	O
ADR1	B-GENE
bound	O
to	O
DNA	O
.	O

As	O
already	O
available	O
for	O
the	O
other	O
known	O
mammalian	O
members	O
of	O
this	O
enzyme	O
family	O
,	O
we	O
here	O
define	O
structural	O
and	O
functional	O
features	O
of	O
human	B-GENE
lymphoma	I-GENE
proprotein	I-GENE
convertase	I-GENE
(	O
LPC	B-GENE
)	O
.	O

The	O
M	O
-	O
phase	O
induction	O
activity	O
of	O
Cdc2	B-GENE
-	O
Cdc13	B-GENE
is	O
inhibited	O
by	O
Wee1	B-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
which	O
phosphorylates	O
Cdc2	B-GENE
on	O
tyrosine	O
-	O
15	O
.	O

Nucleotide	O
sequencing	O
revealed	O
a	O
2076	O
-	O
base	O
pair	O
open	O
reading	O
frame	O
encoding	O
a	O
692	O
-	O
amino	O
acid	O
protein	O
.	O

But	O
it	O
is	O
possible	O
that	O
the	O
two	O
hemispheres	O
differ	O
in	O
the	O
manner	O
in	O
which	O
they	O
make	O
use	O
of	O
semantic	O
structures	O
:	O
the	O
left	O
hemisphere	O
in	O
a	O
selective	O
manner	O
,	O
appropriate	O
for	O
the	O
solution	O
of	O
a	O
specific	O
task	O
,	O
and	O
the	O
right	O
hemisphere	O
in	O
a	O
more	O
diffuse	O
and	O
global	O
manner	O
.	O

Supportive	O
therapy	O
with	O
xenogenous	O
peptides	O
in	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
undergoing	O
aggressive	O
chemotherapy	O
(	O
modified	O
AC	O
-	O
protocol	O
)	O
:	O
a	O
prospective	O
,	O
randomized	O
double	O
-	O
blind	O
study	O

The	O
pregnancies	O
were	O
terminated	O
at	O
19	O
and	O
12	O
weeks	O
of	O
gestation	O
,	O
respectively	O
.	O

Single	O
substitutions	O
of	O
three	O
highly	O
conserved	O
phenylalanine	O
residues	O
(	O
Phe	O
-	O
15	O
,	O
Phe	O
-	O
17	O
,	O
Phe	O
-	O
27	O
)	O
by	O
alanine	O
and	O
substitution	O
of	O
one	O
histidine	O
(	O
His	O
-	O
29	O
)	O
by	O
glutamine	O
,	O
all	O
located	O
within	O
the	O
putative	O
RNA	O
-	O
binding	O
sites	O
RNP	B-GENE
-	I-GENE
1	I-GENE
and	O
RNP	B-GENE
-	I-GENE
2	I-GENE
,	O
abolished	O
the	O
nucleic	O
acid	O
-	O
binding	O
activity	O
of	O
CspB	B-GENE
.	O

The	O
cases	O
with	O
terminal	O
forces	O
of	O
left	O
ventricular	O
activation	O
in	O
the	O
same	O
direction	O
as	O
the	O
delta	O
wave	O
,	O
superiorly	O
and	O
to	O
the	O
left	O
at	O
-	O
60	O
degrees	O
or	O
inferiorly	O
and	O
to	O
the	O
right	O
at	O
+	O
120	O
degrees	O
,	O
forming	O
a	O
single	O
deflection	O
of	O
over	O
0	O
,	O
12	O
seconds	O
'	O
duration	O
,	O
are	O
the	O
result	O
of	O
delayed	O
activation	O
of	O
the	O
anterior	O
or	O
posterior	O
fascicle	O
of	O
the	O
left	O
bundle	O
after	O
a	O
long	O
delay	O
.	O

The	O
genes	O
encoding	O
these	O
carotenoids	O
in	O
E	O
.	O
herbicola	O
Eho13	O
are	O
clustered	O
in	O
a	O
7	O
kb	O
DNA	O
fragment	O
.	O

The	O
results	O
show	O
that	O
while	O
a	O
larger	O
polypeptide	O
substrate	O
carrying	O
the	O
HD1	B-GENE
/	I-GENE
3C	I-GENE
site	I-GENE
was	O
processed	O
more	O
efficiently	O
than	O
a	O
polypeptide	O
substrate	O
carrying	O
the	O
POL	B-GENE
/	I-GENE
Zn	I-GENE
site	I-GENE
,	O
cleavage	O
of	O
the	O
synthetic	O
peptide	O
substrates	O
containing	O
these	O
two	O
cleavage	O
sites	O
occurred	O
at	O
similar	O
efficiencies	O
.	O

Using	O
transgenic	O
lines	O
a	O
detailed	O
analysis	O
of	O
the	O
Hoxa	B-GENE
-	I-GENE
7	I-GENE
enhancer	O
-	O
directed	O
expression	O
during	O
embryogenesis	O
was	O
performed	O
.	O

lacZ	B-GENE
expression	O
was	O
first	O
detected	O
in	O
the	O
allantois	O
at	O
day	O
7	O
.	O
5	O
p	O
.	O
c	O
.	O
and	O
in	O
mesoderm	O
and	O
ectoderm	O
at	O
day	O
8	O
.	O
5	O
of	O
gestation	O
.	O

An	O
ERp60	B-GENE
-	I-GENE
like	I-GENE
protein	I-GENE
from	O
the	O
filarial	O
parasite	O
Dirofilaria	O
immitis	O
has	O
both	O
transglutaminase	O
and	O
protein	O
disulfide	O
isomerase	O
activity	O
.	O

At	O
promoters	O
that	O
initiate	O
with	O
+	O
1	O
GGG	O
,	O
T7	B-GENE
RNAP	I-GENE
synthesizes	O
a	O
ladder	O
of	O
poly	O
(	O
G	O
)	O
products	O
as	O
a	O
result	O
of	O
slippage	O
of	O
the	O
transcript	O
on	O
the	O
three	O
C	O
residues	O
in	O
the	O
template	O
strand	O
from	O
+	O
1	O
to	O
+	O
3	O
.	O

Serum	O
levels	O
of	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
were	O
well	O
maintained	O
.	O

The	O
UL3	B-GENE
ORF	I-GENE
of	O
204	O
amino	O
acids	O
shows	O
significant	O
homology	O
to	O
UL3	B-GENE
(	O
nuclear	O
phosphoprotein	O
)	O
of	O
HSV	O
-	O
1	O
(	O
62	O
%	O
)	O
and	O
PRV	O
(	O
53	O
%	O
)	O
.	O

On	O
Western	O
blots	O
,	O
the	O
same	O
antibodies	O
recognized	O
the	O
recombinant	O
protein	O
migrating	O
slightly	O
slower	O
on	O
SDS	O
/	O
PAGE	O
than	O
chicken	B-GENE
axonin	I-GENE
-	I-GENE
1	I-GENE
.	O

For	O
routine	O
medical	O
applications	O
,	O
no	O
sophisticated	O
adjustment	O
of	O
the	O
CHESS	O
pulse	O
is	O
needed	O
,	O
as	O
reported	O
in	O
previous	O
methods	O
.	O

The	O
10	O
eyes	O
injected	O
with	O
human	O
RPE	O
cells	O
showed	O
STAGE	O
2	O
or	O
less	O
in	O
4	O
weeks	O
.	O

This	O
report	O
establishes	O
that	O
the	O
effect	O
of	O
homozygous	O
sickle	O
cell	O
disease	O
on	O
growth	O
patterns	O
in	O
childhood	O
is	O
apparent	O
before	O
the	O
age	O
of	O
6	O
years	O
.	O

The	O
remaining	O
77	O
nucleotides	O
at	O
the	O
3	O
'	O
end	O
of	O
domain	O
II	O
and	O
all	O
of	O
domains	O
III	O
(	O
655	O
nucleotides	O
)	O
and	O
IV	O
(	O
770	O
nucleotides	O
)	O
are	O
not	O
present	O
in	O
DIssE	B-GENE
RNA	I-GENE
.	O

The	O
biological	O
actions	O
of	O
VHR	B-GENE
in	O
oocytes	O
clearly	O
distinguish	O
it	O
from	O
other	O
dual	O
specificity	O
phosphatases	O
,	O
which	O
have	O
shown	O
inhibitory	O
effects	O
when	O
tested	O
in	O
oocytes	O
.	O

The	O
presence	O
of	O
chloroquine	O
in	O
saliva	O
from	O
seven	O
healthy	O
volunteers	O
for	O
21	O
days	O
after	O
a	O
single	O
600	O
mg	O
oral	O
dose	O
of	O
the	O
drug	O
was	O
established	O
by	O
chromatographic	O
and	O
spectroscopic	O
methods	O
.	O

The	O
gp41	B-GENE
peptide	I-GENE
(	I-GENE
Glu	I-GENE
-	I-GENE
Leu	I-GENE
-	I-GENE
Asp	I-GENE
-	I-GENE
Lys	I-GENE
-	I-GENE
Trp	I-GENE
-	I-GENE
Ala	I-GENE
)	I-GENE
fused	O
to	O
the	O
C	O
-	O
terminus	O
of	O
Sj	B-GENE
GST	I-GENE
forms	O
a	O
loop	O
stabilized	O
by	O
symmetry	O
-	O
related	O
GSTs	B-GENE
.	O

Comparison	O
of	O
bioreactive	O
and	O
immunoreactive	O
gastrin	B-GENE
.	O

Also	O
,	O
PTx	B-GENE
had	O
no	O
effect	O
on	O
shear	O
-	O
dependent	O
activation	O
of	O
JNK	B-GENE
.	O

A	O
score	O
(	O
APACHE	O
II	O
)	O
was	O
calculated	O
to	O
assess	O
the	O
severity	O
of	O
disease	O
.	O

We	O
tested	O
several	O
growth	O
regulatory	O
genes	O
that	O
are	O
repressed	O
in	O
senescent	O
cells	O
for	O
ability	O
to	O
restore	O
activity	O
to	O
T	B-GENE
[	I-GENE
K1	I-GENE
]	I-GENE
.	O

We	O
analyzed	O
the	O
contribution	O
of	O
the	O
three	O
different	O
types	O
of	O
UV	O
-	O
inducible	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinases	I-GENE
(	O
ERK	B-GENE
,	O
JNK	B-GENE
/	O
SAPK	B-GENE
,	O
and	O
p38	B-GENE
)	O
to	O
the	O
activation	O
of	O
the	O
murine	O
uPA	B-GENE
promoter	O
by	O
UV	O
.	O

The	O
high	O
degree	O
of	O
sequence	O
conservation	O
together	O
with	O
the	O
ability	O
to	O
direct	O
nucleolar	O
protein	O
transport	O
supports	O
the	O
hypothesis	O
that	O
MAK16	B-GENE
proteins	I-GENE
play	O
a	O
key	O
role	O
in	O
the	O
biogenesis	O
of	O
60S	B-GENE
subunits	I-GENE
.	O

Characterization	O
of	O
a	O
nuclear	B-GENE
deformed	I-GENE
epidermal	I-GENE
autoregulatory	I-GENE
factor	I-GENE
-	I-GENE
1	I-GENE
(	O
DEAF	B-GENE
-	I-GENE
1	I-GENE
)	O
-	O
related	O
(	O
NUDR	B-GENE
)	O
transcriptional	O
regulator	O
protein	O
.	O

Here	O
we	O
show	O
that	O
the	O
sck1	B-GENE
gene	I-GENE
,	O
cloned	O
as	O
a	O
high	O
copy	O
number	O
suppressor	O
of	O
a	O
mutation	O
in	O
git3	B-GENE
,	O
is	O
able	O
to	O
suppress	O
the	O
defects	O
conferred	O
by	O
a	O
mutation	O
in	O
any	O
of	O
these	O
git	B-GENE
genes	I-GENE
.	O

Hamdija	O
Karamehmedovic	O
;	O
Ibn	O
al	O
-	O
Nefis	O
,	O
"	O
Mudzez	O
al	O
-	O
Kanum	O
"	O
,	O
Republicki	O
zavod	O
za	O
zdravstvenu	O
zastitu	O
Sarajevo	O
,	O
1961	O
,	O
1	O
-	O
219	O
;	O
Mr	O
ph	O
Samuel	O
Elazar	O
,	O
Ajnija	O
Omanic	O
:	O
"	O
Bibliografija	O
medicinskih	O
djela	O
u	O
SR	O
BiH	O
do	O
1895	O
.	O
"	O
Medicinska	O
knjiga	O
Beograd	O
-	O
Zagreb	O
1984	O
;	O
Besides	O
,	O
the	O
great	O
contribution	O
in	O
bibliography	O
was	O
given	O
by	O
dr	O
Lujo	O
Taler	O
,	O
prof	O
.	O

dr	O
.	O

The	O
longest	O
cDNA	O
insert	O
identified	O
was	O
2	O
.	O
2	O
kb	O
and	O
encoded	O
the	O
entire	O
462	O
-	O
amino	O
acid	O
open	O
reading	O
frame	O
of	O
rat	B-GENE
CgA	I-GENE
including	O
an	O
18	O
-	O
amino	O
acid	O
hydrophobic	O
signal	O
peptide	O
.	O

We	O
have	O
used	O
systemic	O
application	O
of	O
the	O
ototoxic	O
drug	O
amikacin	O
,	O
to	O
induce	O
total	O
cochlear	O
haircell	O
loss	O
in	O
the	O
chinchilla	O
,	O
in	O
order	O
to	O
create	O
an	O
animal	O
model	O
of	O
profound	O
deafness	O
.	O

Cotransfection	O
with	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
and	O
GATA	B-GENE
-	I-GENE
1	I-GENE
expression	O
vectors	O
produced	O
a	O
5	O
-	O
fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
or	O
GATA	B-GENE
-	I-GENE
1	I-GENE
expression	O
vectors	O
individually	O
.	O

Among	O
the	O
different	O
epithelial	O
cell	O
lines	O
tested	O
,	O
only	O
RTS3b	O
cells	O
allowed	O
an	O
expression	O
pattern	O
similar	O
to	O
that	O
observed	O
in	O
naturally	O
infected	O
benign	O
condylomas	O
.	O

In	O
contrast	O
to	O
the	O
p16	B-GENE
-	O
mediated	O
G1	O
block	O
,	O
G1	O
arrest	O
mediated	O
by	O
the	O
cdk	B-GENE
inhibitors	O
p21Cip1	B-GENE
or	O
p27Kip1	B-GENE
cannot	O
be	O
bypassed	O
either	O
by	O
inactivation	O
of	O
pRb	B-GENE
or	O
overexpression	O
of	O
E2F	B-GENE
family	I-GENE
members	I-GENE
.	O

In	O
addition	O
,	O
the	O
authors	O
found	O
one	O
an3	B-GENE
allele	I-GENE
(	O
an3	B-GENE
-	I-GENE
W138A	I-GENE
)	O
in	O
which	O
a	O
dTph1	B-GENE
element	I-GENE
had	O
inserted	O
30	O
bp	O
upstream	O
the	O
translation	O
start	O
,	O
without	O
inactivating	O
the	O
gene	O
.	O

Case	O
of	O
nephrotic	O
syndrome	O
caused	O
by	O
gold	O
preparations	O

To	O
investigate	O
the	O
role	O
of	O
bHLH	B-GENE
proteins	I-GENE
in	O
MC3T3	O
-	O
E1	O
osteoblasts	O
,	O
which	O
undergo	O
a	O
developmental	O
sequence	O
in	O
vitro	O
,	O
we	O
analyzed	O
the	O
transcriptional	O
control	O
of	O
osteocalcin	B-GENE
gene	I-GENE
expression	O
by	O
stable	O
transfection	O
of	O
an	O
osteocalcin	B-GENE
promoter	I-GENE
-	O
luciferase	B-GENE
chimeric	O
gene	O
(	O
p637OC	B-GENE
-	I-GENE
luc	I-GENE
)	O
and	O
assessed	O
the	O
role	O
of	O
E	O
-	O
box	O
cis	O
-	O
acting	O
elements	O
in	O
osteocalcin	B-GENE
promoter	I-GENE
by	O
DNA	O
binding	O
assays	O
.	O

In	O
summary	O
,	O
the	O
only	O
treatment	O
-	O
related	O
effect	O
noted	O
in	O
this	O
study	O
was	O
hydrocarbon	O
nephropathy	O
in	O
male	O
rats	O
,	O
which	O
is	O
not	O
considered	O
relevant	O
for	O
human	O
health	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF	B-GENE
-	I-GENE
4	I-GENE
,	O
a	O
member	O
of	O
the	O
steroid	B-GENE
hormone	I-GENE
receptor	I-GENE
superfamily	I-GENE
,	O
binds	O
the	O
AF	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
on	O
the	O
apoB	B-GENE
promoter	I-GENE
and	O
through	O
it	O
activates	O
transcription	O
in	O
transient	O
transfection	O
assays	O
in	O
both	O
liver	O
and	O
non	O
-	O
liver	O
cell	O
lines	O
,	O
HepG2	O
and	O
HeLa	O
,	O
respectively	O
.	O

Gastrointestinal	O
accumulation	O
of	O
indium	O
-	O
111	O
labelled	O
granulocytes	O
in	O
reactive	O
arthritis	O
.	O

Acute	O
intoxication	O
with	O
cypermethrin	O
(	O
NRDC	O
149	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
transcriptional	O
activator	O
CREM	B-GENE
is	O
highly	O
expressed	O
in	O
postmeiotic	O
cells	O
.	O

No	O
interaction	O
with	O
epidural	O
anesthesia	O
was	O
observed	O
.	O

In	O
late	O
October	O
,	O
1974	O
,	O
Staphylococcus	O
aureus	O
postoperative	O
wound	O
infection	O
was	O
recorded	O
in	O
a	O
nonhuman	O
primate	O
(	O
Macaca	O
mulatta	O
)	O
which	O
had	O
recently	O
undergone	O
surgical	O
operation	O
.	O

Twenty	O
-	O
six	O
calves	O
were	O
subjected	O
to	O
a	O
technique	O
of	O
cryoablation	O
in	O
order	O
to	O
establish	O
an	O
animal	O
model	O
of	O
complete	O
cardiac	O
denervation	O
.	O

Our	O
current	O
study	O
aims	O
at	O
clarifying	O
the	O
role	O
of	O
myristoylation	O
in	O
caveolar	O
targeting	O
using	O
well	O
-	O
characterized	O
acylation	O
mutants	O
of	O
two	O
model	O
proteins	O
,	O
namely	O
Gi1	B-GENE
alpha	I-GENE
and	O
c	B-GENE
-	I-GENE
Src	I-GENE
.	O

The	O
effect	O
of	O
deferoxamine	O
B	O
on	O
the	O
blood	O
sugar	O
behavior	O
in	O
intravenous	O
glucose	O
loading	O
in	O
healthy	O
persons	O

We	O
infer	O
that	O
RecA	B-GENE
-	O
mediated	O
cleavage	O
of	O
UmuD	B-GENE
is	O
another	O
role	O
for	O
RecA	B-GENE
in	O
SOS	O
mutagenesis	O
,	O
probably	O
activating	O
UmuD	B-GENE
for	O
its	O
mutagenic	O
function	O
.	O

SETTING	O
:	O
Participants	O
in	O
the	O
Physicians	O
'	O
Health	O
Study	O
,	O
a	O
randomized	O
trial	O
of	O
aspirin	O
and	O
beta	O
-	O
carotene	O
among	O
U	O
.	O
S	O
.	O
male	O
physicians	O
.	O

The	O
prevalence	O
of	O
microalbuminuria	O
,	O
defined	O
as	O
an	O
UAER	O
in	O
the	O
range	O
of	O
15	O
-	O
150	O
micrograms	O
min	O
-	O
1	O
in	O
an	O
overnight	O
urine	O
sample	O
,	O
was	O
3	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O
interval	O
:	O
1	O
.	O
9	O
-	O
4	O
.	O
0	O
)	O
.	O

The	O
Rep	B-GENE
proteins	I-GENE
of	O
adeno	O
-	O
associated	O
virus	O
type	O
2	O
(	O
AAV	O
)	O
are	O
known	O
to	O
bind	O
to	O
Rep	B-GENE
recognition	I-GENE
sequences	I-GENE
(	O
RRSs	B-GENE
)	O
in	O
the	O
AAV	O
inverted	O
terminal	O
repeats	O
(	O
ITRs	O
)	O
,	O
the	O
AAV	B-GENE
p5	I-GENE
promoter	I-GENE
,	O
and	O
the	O
preferred	O
AAV	O
integration	O
site	O
in	O
human	O
chromosome	O
19	O
,	O
called	O
AAVS1	O
.	O

LIP	O
and	O
DIP	O
are	O
less	O
common	O
IIPs	O
,	O
both	O
characterized	O
by	O
ground	O
-	O
glass	O
attenuation	O
.	O

The	O
levels	O
of	O
TPAR1	B-GENE
mRNAs	I-GENE
were	O
dramatically	O
down	O
-	O
regulated	O
in	O
regenerating	O
rat	O
liver	O
when	O
compared	O
to	O
normal	O
adult	O
liver	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

The	O
authors	O
suggest	O
that	O
alprazolam	O
may	O
have	O
enhanced	O
specificity	O
for	O
a	O
subpopulation	O
of	O
benzodiazepine	B-GENE
receptors	I-GENE
.	O

Southern	O
hybridization	O
analysis	O
of	O
BenR	B-GENE
and	O
BenS	B-GENE
transformants	I-GENE
suggested	O
that	O
plasmid	O
integration	O
occurred	O
most	O
frequently	O
at	O
the	O
chromosomal	O
bens	B-GENE
locus	I-GENE
,	O
however	O
evidence	O
for	O
gene	O
conversion	O
and	O
heterologous	O
recombination	O
was	O
also	O
observed	O
.	O

The	O
analysis	O
of	O
the	O
effects	O
of	O
eight	O
signaling	O
molecules	O
in	O
the	O
TGFbeta	B-GENE
,	O
FGF	B-GENE
,	O
Hh	B-GENE
,	O
Wnt	B-GENE
,	O
and	O
EGF	B-GENE
families	I-GENE
in	O
tooth	O
explant	O
cultures	O
revealed	O
that	O
the	O
expression	O
of	O
edar	B-GENE
was	O
induced	O
by	O
activinbetaA	B-GENE
,	O
whereas	O
Wnt6	B-GENE
induced	O
ectodysplasin	B-GENE
expression	O
.	O

In	O
mouse	O
,	O
two	O
high	O
-	O
affinity	O
binding	O
sites	O
with	O
an	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
50	O
to	O
100	O
nM	O
have	O
been	O
mapped	O
in	O
the	O
5	O
'	O
ETS	B-GENE
upstream	O
from	O
the	O
early	O
pre	O
-	O
rRNA	O
processing	O
site	O
.	O

Single	O
oblique	O
-	O
view	O
mammography	O
for	O
periodic	O
screening	O
for	O
breast	O
cancer	O
in	O
women	O
.	O

Radiative	O
corrections	O
to	O
pi	O
l2	O
decays	O
.	O

This	O
deletion	O
disrupts	O
the	O
PU	B-GENE
.	I-GENE
1	I-GENE
Ets	B-GENE
domain	I-GENE
.	O

In	O
turn	O
,	O
production	O
of	O
sufficient	O
amounts	O
of	O
TraR	B-GENE
apparently	O
is	O
sensitive	O
to	O
a	O
cellular	O
function	O
requiring	O
RNase	B-GENE
D	I-GENE
.	O

The	O
predicted	O
product	O
exhibits	O
91	O
%	O
amino	O
acid	O
identity	O
to	O
the	O
murine	B-GENE
voltage	I-GENE
-	I-GENE
gated	I-GENE
potassium	I-GENE
channel	I-GENE
protein	I-GENE
Kv1	I-GENE
.	I-GENE
7	I-GENE
(	O
Kcna7	B-GENE
)	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
repolarization	O
of	O
cell	O
membranes	O
.	O

Phytohemagglutinin	B-GENE
(	O
PHA	B-GENE
)	O
,	O
the	O
seed	B-GENE
lectin	I-GENE
of	O
the	O
common	O
bean	O
,	O
accumulates	O
in	O
protein	O
storage	O
vacuoles	O
of	O
storage	O
parenchyma	O
cells	O
in	O
cotyledons	O
.	O

This	O
dynamic	O
nature	O
may	O
be	O
relevant	O
to	O
the	O
ability	O
of	O
E47	B-GENE
both	O
to	O
homodimerize	O
and	O
to	O
heterodimerize	O
with	O
MyoD	B-GENE
,	O
Id	B-GENE
,	O
and	O
Tal1	B-GENE
.	O

Blood	O
samples	O
(	O
30	O
ml	O
)	O
were	O
collected	O
via	O
an	O
indwelling	O
arm	O
catheter	O
at	O
rest	O
,	O
and	O
at	O
minutes	O
13	O
and	O
28	O
of	O
exercise	O
for	O
determinations	O
of	O
plasma	O
EPI	O
,	O
serum	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
,	O
serum	O
glycerol	O
(	O
GLY	O
)	O
,	O
blood	O
glucose	O
(	O
GLU	O
)	O
,	O
and	O
blood	O
lactate	O
(	O
LA	O
)	O
concentrations	O
.	O

Among	O
these	O
,	O
four	O
patients	O
had	O
the	O
AIDS	O
syndrome	O
,	O
while	O
42	O
individuals	O
were	O
HIV	O
carriers	O
.	O

Subjects	O
were	O
73	O
male	O
and	O
female	O
employees	O
of	O
the	O
Xerox	O
Corporation	O
joining	O
a	O
newly	O
developed	O
health	O
fitness	O
program	O
.	O

Overexpression	O
of	O
p50	B-GENE
in	O
transient	O
cotransfection	O
studies	O
using	O
the	O
proximal	O
CRP	B-GENE
promoter	I-GENE
(	O
-	O
125	O
/	O
+	O
9	O
)	O
linked	O
to	O
a	O
luciferase	B-GENE
reporter	I-GENE
caused	O
a	O
3	O
-	O
fold	O
increase	O
of	O
luciferase	B-GENE
activity	O
,	O
while	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
overexpression	O
caused	O
an	O
18	O
-	O
fold	O
increase	O
;	O
simultaneous	O
overexpression	O
of	O
both	O
transcription	O
factors	O
increased	O
luciferase	B-GENE
activity	O
approximately	O
600	O
-	O
fold	O
.	O

Our	O
results	O
suggest	O
that	O
it	O
might	O
be	O
possible	O
to	O
augment	O
IN	B-GENE
function	O
in	O
vivo	O
through	O
a	O
heterologous	O
domain	O
.	O

While	O
differential	O
expression	O
of	O
the	O
two	O
transcripts	O
was	O
not	O
found	O
,	O
the	O
promoter	O
controlling	O
LT1	B-GENE
/	O
LT2	B-GENE
transcription	O
is	O
regulated	O
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
.	O

Schottky	O
-	O
barrier	O
heights	O
of	O
Ti	O
and	O
TiSi2	O
on	O
n	O
-	O
type	O
and	O
p	O
-	O
type	O
Si	O
(	O
100	O
)	O
.	O

A	O
survey	O
of	O
children	O
with	O
HBsAg	B-GENE
markers	I-GENE
related	O
to	O
their	O
parents	O
HBV	O
markers	O
.	O

Immunological	O
studies	O
also	O
failed	O
to	O
demonstrate	O
any	O
significant	O
change	O
except	O
for	O
a	O
significant	O
increase	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
after	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
infusion	O
.	O

Fetal	O
PaO2	O
fell	O
somewhat	O
during	O
the	O
recovery	O
stages	O
in	O
both	O
NIT	O
and	O
control	O
groups	O
.	O

Genetic	O
analyses	O
indicate	O
that	O
most	O
of	O
the	O
dominant	O
mutants	O
are	O
cis	O
-	O
acting	O
and	O
that	O
the	O
recessive	O
mutants	O
define	O
a	O
minimum	O
of	O
three	O
complementation	O
groups	O
,	O
indicating	O
that	O
defects	O
in	O
several	O
different	O
genes	O
can	O
restore	O
higher	O
levels	O
of	O
HIS4C	B-GENE
expression	O
.	O

Rat	B-GENE
cholesterol	I-GENE
side	I-GENE
-	I-GENE
chain	I-GENE
cleavage	I-GENE
cytochrome	I-GENE
P	I-GENE
-	I-GENE
450	I-GENE
(	O
P	B-GENE
-	I-GENE
450scc	I-GENE
)	O
gene	O
.	O

Histopathologic	O
studies	O
displaying	O
spongiform	O
changes	O
in	O
the	O
gray	O
matter	O
,	O
neuronal	O
loss	O
,	O
and	O
atrogliosis	O
confirmed	O
the	O
clinical	O
diagnosis	O
of	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
.	O

Pig	O
uPA	B-GENE
promoter	O
-	O
CAT	B-GENE
constructs	O
were	O
more	O
active	O
than	O
mouse	O
constructs	O
in	O
this	O
assay	O
.	O

Cloning	O
the	O
cDNA	O
for	O
a	O
new	O
human	B-GENE
zinc	I-GENE
finger	I-GENE
protein	I-GENE
defines	O
a	O
group	O
of	O
closely	O
related	O
Kruppel	B-GENE
-	I-GENE
like	I-GENE
transcription	I-GENE
factors	I-GENE
.	O

By	O
computed	O
homology	O
search	O
,	O
we	O
noticed	O
significant	O
similarities	O
between	O
US3	B-GENE
PK	I-GENE
and	O
p21	B-GENE
-	I-GENE
activated	I-GENE
kinase	I-GENE
(	O
PAK	B-GENE
)	O
,	O
which	O
is	O
activated	O
by	O
the	O
Cdc42	B-GENE
or	O
Rac	B-GENE
.	O

The	O
mean	O
amount	O
of	O
blood	O
loss	O
prior	O
to	O
time	O
of	O
injection	O
was	O
4	O
.	O
5	O
units	O
(	O
a	O
range	O
of	O
3	O
to	O
10	O
units	O
)	O
.	O

In	O
response	O
to	O
acoustical	O
stimulation	O
the	O
properties	O
of	O
response	O
latency	O
,	O
discharge	O
pattern	O
,	O
frequency	O
tuning	O
,	O
binaural	O
interaction	O
,	O
and	O
habituation	O
were	O
examined	O
to	O
allow	O
an	O
appraisal	O
of	O
the	O
differentiation	O
of	O
the	O
MGB	O
by	O
electrophysiological	O
means	O
.	O

These	O
8	B-GENE
-	I-GENE
oxoguanine	I-GENE
DNA	I-GENE
glycosylases	I-GENE
,	O
hOgg1	B-GENE
(	O
human	O
)	O
and	O
mOgg1	B-GENE
(	O
murine	O
)	O
,	O
are	O
homologous	O
to	O
each	O
other	O
and	O
to	O
yeast	B-GENE
Ogg1	I-GENE
.	O

The	O
CHED	B-GENE
protein	I-GENE
includes	O
the	O
consensus	O
ATP	O
binding	O
and	O
phosphorylation	O
domains	O
characteristic	O
of	O
kinases	O
,	O
displays	O
34	O
-	O
42	O
%	O
identically	O
aligned	O
amino	O
acid	O
residues	O
with	O
other	O
cdc2	B-GENE
-	I-GENE
related	I-GENE
kinases	I-GENE
,	O
and	O
is	O
considerably	O
longer	O
at	O
its	O
amino	O
and	O
carboxyl	O
termini	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
,	O
by	O
interacting	O
with	O
cellular	O
transcription	O
factors	O
and	O
cofactors	O
,	O
vIRF	B-GENE
-	I-GENE
2	I-GENE
may	O
modulate	O
the	O
expression	O
of	O
the	O
early	O
inflammatory	O
genes	O
and	O
potentially	O
deregulate	O
the	O
immune	O
system	O
.	O

However	O
,	O
in	O
7	O
patients	O
with	O
normal	O
CT	O
results	O
the	O
latter	O
method	O
showed	O
areas	O
of	O
cerebral	O
activity	O
anatomically	O
correlated	O
with	O
neurological	O
signs	O
or	O
vascular	O
lesions	O
.	O

We	O
report	O
that	O
Gcn5	B-GENE
,	O
a	O
histone	B-GENE
H3	I-GENE
acetylase	I-GENE
,	O
plays	O
a	O
central	O
role	O
in	O
initiation	O
of	O
meiosis	O
via	O
effects	O
on	O
IME2	B-GENE
expression	O
.	O

The	O
carboxy	O
-	O
proximal	O
regions	O
of	O
the	O
VP1	B-GENE
,	O
which	O
contain	O
very	O
low	O
amino	O
acid	O
homology	O
,	O
displayed	O
evidence	O
of	O
conservation	O
in	O
structural	O
features	O
such	O
as	O
a	O
hydrophilic	O
,	O
highly	O
basic	O
domain	O
.	O

Interferon	B-GENE
-	I-GENE
alpha	I-GENE
inducibility	O
of	O
IFI16	B-GENE
may	O
be	O
regulated	O
by	O
an	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
/	I-GENE
beta	I-GENE
-	O
stimulated	O
response	O
consensus	O
element	O
in	O
the	O
5	O
'	O
UT	O
exon	O
,	O
as	O
a	O
similar	O
motif	O
is	O
conserved	O
in	O
the	O
corresponding	O
position	O
in	O
the	O
related	O
myeloid	B-GENE
cell	I-GENE
nuclear	I-GENE
differentiation	I-GENE
antigen	I-GENE
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

DESIGN	O
-	O
-	O
A	O
randomised	O
double	O
blind	O
placebo	O
controlled	O
parallel	O
arm	O
trial	O
.	O

Genealogical	O
analysis	O
suggested	O
mainly	O
a	O
mother	O
-	O
to	O
-	O
offspring	O
transmission	O
of	O
this	O
STLV	O
-	O
1	O
.	O

These	O
back	O
mutations	O
led	O
to	O
a	O
modest	O
decrease	O
in	O
kinase	O
activity	O
,	O
decreased	O
tumorigenic	O
potential	O
in	O
chickens	O
,	O
and	O
an	O
unexpected	O
increase	O
in	O
transforming	O
activity	O
in	O
rat	O
cells	O
.	O

The	O
quantification	O
limit	O
was	O
50	O
ng	O
/	O
ml	O
for	O
each	O
of	O
PHT	O
,	O
m	O
-	O
HPPH	O
and	O
p	O
-	O
HPPH	O
.	O

Individual	O
intolerance	O
to	O
betaxolol	O
will	O
continue	O
to	O
occur	O
and	O
care	O
is	O
always	O
required	O
when	O
patients	O
with	O
cardiac	O
or	O
respiratory	O
dysfunction	O
are	O
exposed	O
to	O
any	O
beta	O
-	O
antagonist	O
.	O

Pretoria	O
Pasteurisation	O
is	O
feasible	O
and	O
reliable	O
under	O
a	O
range	O
of	O
conditions	O
.	O

In	O
the	O
present	O
study	O
we	O
use	O
a	O
tnaC	B-GENE
-	O
UGA	O
-	O
'	B-GENE
lacZ	I-GENE
construct	O
lacking	O
the	O
tnaC	B-GENE
-	O
tnaA	B-GENE
spacer	O
region	O
to	O
analyze	O
the	O
effect	O
of	O
TnaC	B-GENE
synthesis	O
on	O
the	O
behavior	O
of	O
the	O
ribosome	O
that	O
translates	O
tnaC	B-GENE
.	O

The	O
in	O
vitro	O
activity	O
of	O
KP	O
-	O
103	O
,	O
a	O
novel	O
triazole	O
derivative	O
,	O
against	O
pathogenic	O
fungi	O
that	O
cause	O
dermatomycoses	O
and	O
its	O
therapeutic	O
efficacy	O
against	O
plantar	O
tinea	O
pedis	O
and	O
cutaneous	O
candidiasis	O
in	O
guinea	O
pigs	O
were	O
investigated	O
.	O

Restriction	O
analysis	O
of	O
the	O
isolated	O
genomic	O
clones	O
indicated	O
that	O
the	O
endogenous	O
sequences	O
abutting	O
the	O
3	O
'	O
ends	O
of	O
the	O
94	O
-	O
A	O
and	O
94	O
-	O
K	O
transgenes	O
are	O
separated	O
by	O
less	O
than	O
20	O
kb	O
,	O
providing	O
strong	O
support	O
for	O
the	O
single	O
integration	O
model	O
.	O

Serum	O
triglycerides	O
also	O
showed	O
an	O
increase	O
from	O
birth	O
to	O
6	O
months	O
of	O
age	O
,	O
but	O
a	O
decrease	O
from	O
6	O
months	O
to	O
1	O
years	O
of	O
age	O
.	O

Female	O
Wistar	O
rats	O
receiving	O
alcohol	O
(	O
5	O
%	O
)	O
in	O
drinking	O
water	O
during	O
lactation	O
(	O
N	O
=	O
7	O
)	O
were	O
compared	O
to	O
normal	O
controls	O
fed	O
ad	O
libitum	O
(	O
N	O
=	O
6	O
)	O
.	O

Antisense	O
oligonucleotides	O
complementary	O
to	O
the	O
5	O
'	O
end	O
of	O
PKC	B-GENE
-	I-GENE
zeta	I-GENE
mRNA	I-GENE
sequences	I-GENE
significantly	O
reduced	O
the	O
collagen	B-GENE
lattice	O
-	O
stimulated	O
alpha2	O
and	O
MMP	B-GENE
-	I-GENE
1	I-GENE
mRNA	I-GENE
levels	O
.	O

Overexpression	O
of	O
a	O
HIF	B-GENE
-	I-GENE
1alpha	I-GENE
construct	O
with	O
deletions	O
of	O
the	O
basic	O
domain	O
and	O
carboxy	O
terminus	O
blocked	O
reporter	O
gene	O
activation	O
by	O
endogenous	O
HIF	B-GENE
-	I-GENE
1	I-GENE
in	O
hypoxic	O
cells	O
.	O

We	O
hypothesized	O
that	O
conjugated	O
estrogens	O
,	O
which	O
contain	O
several	O
vasoactive	O
estrogenic	O
compounds	O
,	O
may	O
favorably	O
influence	O
the	O
vasomotor	O
response	O
to	O
acetylcholine	O
in	O
men	O
.	O

In	O
Experiment	O
2	O
,	O
levels	O
were	O
:	O
amprolium	O
and	O
ethopabate	O
,	O
.	O
02	O
%	O
;	O
salinomycin	O
,	O
55	O
mg	O
/	O
kg	O
;	O
monensin	O
,	O
99	O
mg	O
/	O
kg	O
;	O
and	O
lasalocid	O
,	O
110	O
mg	O
/	O
kg	O
.	O

Residues	O
crucial	O
for	O
Ras	B-GENE
interaction	O
with	O
GDP	B-GENE
-	I-GENE
GTP	I-GENE
exchangers	I-GENE
.	O

4	O
.	O

In	O
serum	O
-	O
starved	O
NIH	O
3T3	O
cells	O
,	O
v	B-GENE
-	I-GENE
raf	I-GENE
increased	O
mdr1	B-GENE
promoter	I-GENE
activity	O
approximately	O
10	O
-	O
fold	O
compared	O
to	O
a	O
v	B-GENE
-	I-GENE
raf	I-GENE
frame	O
-	O
shift	O
control	O
.	O

Searching	O
the	O
human	O
DNA	O
data	O
base	O
of	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
revealed	O
novel	O
partial	O
sequences	O
similar	O
to	O
,	O
but	O
distinct	O
from	O
,	O
the	O
sequences	O
of	O
the	O
previously	O
known	O
PEF	B-GENE
proteins	I-GENE
.	O

Under	O
control	O
conditions	O
and	O
in	O
the	O
presence	O
of	O
3	O
micromol	O
/	O
kg	O
MIB	O
and	O
VER	O
the	O
maximal	O
effect	O
of	O
noradrenaline	O
was	O
reached	O
at	O
0	O
.	O
1	O
micromol	O
/	O
kg	O
whereas	O
in	O
the	O
presence	O
of	O
10	O
micromol	O
/	O
kg	O
MIB	O
and	O
VER	O
it	O
was	O
reached	O
at	O
a	O
dose	O
of	O
1	O
micromol	O
/	O
kg	O
.	O

It	O
is	O
also	O
affected	O
by	O
the	O
HAP2	B-GENE
/	I-GENE
3	I-GENE
/	I-GENE
4	I-GENE
transcription	I-GENE
factor	I-GENE
complex	I-GENE
and	O
by	O
SNF1	B-GENE
and	O
SSN6	B-GENE
.	O

The	O
effective	O
use	O
of	O
superoxide	B-GENE
dismutase	I-GENE
from	O
human	O
erythrocytes	O
in	O
the	O
late	O
stages	O
of	O
experimental	O
influenza	O
infection	O

Two	O
different	O
genes	O
(	O
polA	B-GENE
and	O
polB	B-GENE
)	O
encoding	O
family	B-GENE
B	I-GENE
DNA	I-GENE
polymerases	I-GENE
were	O
cloned	O
from	O
the	O
organism	O
by	O
PCR	O
using	O
degenerated	O
primers	O
based	O
on	O
the	O
two	O
conserved	O
motifs	O
(	O
motif	O
A	O
and	O
B	O
)	O
.	O

The	O
effects	O
on	O
survival	O
of	O
adjuvant	O
treatments	O
,	O
including	O
pre	O
-	O
or	O
postoperative	O
systemic	O
or	O
postoperative	O
intra	O
-	O
arterial	O
chemotherapy	O
,	O
are	O
currently	O
under	O
evaluation	O
.	O

Structure	O
and	O
regulation	O
of	O
the	O
luteinizing	B-GENE
hormone	I-GENE
receptor	I-GENE
gene	I-GENE
.	O

The	O
disease	O
processes	O
that	O
affect	O
transplant	O
patients	O
both	O
before	O
and	O
after	O
transplantation	O
are	O
not	O
seen	O
frequently	O
in	O
the	O
general	O
practice	O
of	O
gastroenterology	O
.	O

METHODS	O
:	O
Single	O
white	O
flash	O
ERG	O
,	O
photopic	O
ERG	O
,	O
scotopic	O
ERG	O
and	O
flicker	O
ERG	O
were	O
recorded	O
in	O
30	O
cases	O
of	O
unilateral	O
CRVO	O
.	O

However	O
,	O
to	O
encourage	O
good	O
contact	O
between	O
the	O
farmers	O
and	O
the	O
inseminating	O
personnel	O
,	O
it	O
is	O
beneficial	O
that	O
herdsmen	O
are	O
present	O
when	O
cows	O
are	O
inseminated	O
.	O

Soft	O
independent	O
modelling	O
of	O
class	O
analogy	O
(	O
SIMCA	O
)	O
is	O
applied	O
to	O
identify	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
spectra	O
of	O
ten	O
excipients	O
used	O
in	O
the	O
pharmaceutical	O
industry	O
.	O

Multiple	O
organ	O
failure	O
(	O
MOF	O
)	O
following	O
major	O
trauma	O
occurs	O
in	O
response	O
to	O
perfusion	O
deficits	O
,	O
a	O
persistent	O
inflammatory	O
focus	O
,	O
or	O
a	O
persistent	O
focus	O
of	O
dead	O
and	O
/	O
or	O
injured	O
tissue	O
.	O

Western	O
immunoblot	O
analysis	O
detected	O
p55gag	B-GENE
and	O
its	O
cleavage	O
products	O
p39	B-GENE
and	O
p27	B-GENE
in	O
purified	O
particles	O
derived	O
by	O
expression	O
of	O
gag	B-GENE
and	O
gag	B-GENE
-	O
pol	B-GENE
,	O
respectively	O
.	O

Cefminox	O
shows	O
greater	O
in	O
vivo	O
activity	O
than	O
that	O
expected	O
for	O
the	O
MICs	O
,	O
excellent	O
efficacy	O
and	O
safety	O
.	O

CONCLUSION	O
:	O
high	O
resolution	O
MF	O
-	O
ERG	O
seems	O
more	O
sensitive	O
than	O
low	O
resolution	O
MF	O
-	O
ERG	O
.	O

3	O
-	O
5	O
-	O
fold	O
increases	O
in	O
EGF	B-GENE
receptor	I-GENE
but	O
not	O
p185	B-GENE
(	O
neu	B-GENE
)	O
tyrosine	O
phosphorylation	O
occur	O
following	O
Gi	B-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
stimulation	O
.	O

Next	O
,	O
to	O
examine	O
the	O
regulation	O
mechanism	O
of	O
CD44	B-GENE
/	O
ERM	B-GENE
interaction	O
in	O
vivo	O
,	O
we	O
reexamined	O
the	O
immunoprecipitated	O
CD44	B-GENE
/	O
ERM	B-GENE
complex	O
from	O
BHK	O
cells	O
and	O
found	O
that	O
it	O
contains	O
Rho	B-GENE
-	I-GENE
GDP	I-GENE
dissociation	I-GENE
inhibitor	I-GENE
(	O
GDI	B-GENE
)	O
,	O
a	O
regulator	O
of	O
Rho	B-GENE
GTPase	I-GENE
.	O

The	O
results	O
showed	O
a	O
significant	O
group	O
effect	O
only	O
on	O
the	O
active	O
task	O
.	O

On	O
days	O
7	O
,	O
21	O
,	O
and	O
35	O
postinoculation	O
(	O
PI	O
)	O
,	O
all	O
birds	O
received	O
sheep	O
erythrocytes	O
intravenously	O
.	O

To	O
determine	O
cis	O
-	O
acting	O
elements	O
controlling	O
the	O
rat	O
B	B-GENE
-	I-GENE
50	I-GENE
/	O
GAP	B-GENE
-	I-GENE
43	I-GENE
gene	O
expression	O
,	O
the	O
genomic	O
DNA	O
encoding	O
exon	O
1	O
and	O
the	O
5	O
'	O
flanking	O
sequence	O
was	O
isolated	O
.	O

In	O
this	O
paper	O
,	O
the	O
authors	O
used	O
measured	O
weight	O
for	O
1	O
,	O
259	O
white	O
women	O
aged	O
65	O
-	O
74	O
years	O
from	O
the	O
Epidemiologic	O
Follow	O
-	O
up	O
Study	O
of	O
the	O
First	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
to	O
examine	O
the	O
effect	O
of	O
overweight	O
on	O
coronary	O
heart	O
disease	O
incidence	O
(	O
mean	O
length	O
of	O
follow	O
-	O
up	O
,	O
14	O
years	O
)	O
.	O

Through	O
genomic	O
library	O
screening	O
and	O
PCR	O
-	O
based	O
genomic	O
walking	O
we	O
have	O
now	O
cloned	O
the	O
mouse	B-GENE
E	I-GENE
-	I-GENE
Tmod	I-GENE
gene	I-GENE
,	O
whose	O
coding	O
region	O
spans	O
approximately	O
60kb	O
containing	O
nine	O
exons	O
and	O
eight	O
introns	O
.	O

TNF	B-GENE
-	I-GENE
alpha	I-GENE
stimulated	O
these	O
changes	O
in	O
part	O
by	O
increasing	O
transcription	O
and	O
stabilization	O
of	O
RNA	O
for	O
amphiregulin	B-GENE
,	O
an	O
EGF	B-GENE
receptor	I-GENE
ligand	O
,	O
and	O
amphiregulin	B-GENE
directly	O
increased	O
HPV	O
-	O
16	O
E6	B-GENE
/	O
E7	B-GENE
and	O
cyclin	B-GENE
A	I-GENE
RNAs	I-GENE
.	O

The	O
data	O
obtained	O
included	O
1	O
)	O
the	O
mean	O
frequency	O
of	O
abnormal	O
teased	O
myelinated	O
fibers	O
and	O
its	O
upper	O
limit	O
value	O
of	O
95	O
%	O
confidence	O
interval	O
,	O
and	O
2	O
)	O
the	O
mean	O
densities	O
of	O
total	O
,	O
large	O
and	O
small	O
myelinated	O
fibers	O
and	O
of	O
unmyelinated	O
fibers	O
and	O
their	O
lower	O
limit	O
value	O
of	O
95	O
%	O
confidence	O
interval	O
for	O
each	O
decade	O
.	O

Fusions	O
between	O
the	O
GAL	B-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
and	O
full	B-GENE
-	I-GENE
length	I-GENE
mSin3	I-GENE
were	O
also	O
capable	O
of	O
repression	O
.	O

None	O
of	O
the	O
19	O
women	O
with	O
probable	O
RA	O
and	O
100	O
of	O
the	O
116	O
women	O
with	O
definite	O
RA	O
met	O
the	O
1987	O
criteria	O
.	O

The	O
initial	O
oral	O
administration	O
of	O
the	O
1	O
and	O
2	O
mg	O
/	O
kg	O
doses	O
of	O
enoximone	O
improved	O
central	O
hemodynamic	O
parameters	O
with	O
apparent	O
preferential	O
reduction	O
of	O
limb	O
vascular	O
resistance	O
and	O
augmentation	O
of	O
blood	O
flow	O
to	O
the	O
limb	O
region	O
(	O
peripheral	O
musculoskeletal	O
system	O
)	O
.	O

Antibodies	O
against	O
REAP	B-GENE
-	I-GENE
1	I-GENE
inhibit	O
in	O
vitro	O
RNA	O
editing	O
reactions	O
confirming	O
its	O
role	O
in	O
RNA	O
editing	O
.	O

The	O
full	O
-	O
length	O
cDNA	O
was	O
cloned	O
and	O
sequenced	O
,	O
and	O
the	O
inferred	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
encode	O
a	O
novel	O
protein	O
,	O
which	O
we	O
named	O
cystatin	B-GENE
M	I-GENE
,	O
with	O
40	O
%	O
homology	O
to	O
human	B-GENE
family	I-GENE
2	I-GENE
cystatins	I-GENE
and	O
similar	O
overall	O
structure	O
.	O

42nd	O
annual	O
meeting	O
of	O
the	O
American	O
Academy	O
of	O
Oral	O
Pathology	O
.	O

BAG	B-GENE
-	I-GENE
1	I-GENE
also	O
prevented	O
growth	O
arrest	O
following	O
UV	O
-	O
irradiation	O
-	O
induced	O
genotoxic	O
injury	O
without	O
interfering	O
with	O
accumulation	O
of	O
p53	B-GENE
protein	I-GENE
or	O
p21	B-GENE
(	O
waf	B-GENE
-	I-GENE
1	I-GENE
)	O
expression	O
.	O

The	O
side	O
effect	O
of	O
pulmonary	O
fibrosis	O
occurs	O
in	O
20	O
to	O
30	O
percent	O
of	O
patients	O
receiving	O
this	O
drug	O
.	O

These	O
larger	O
sizes	O
,	O
however	O
,	O
are	O
consistent	O
with	O
predictions	O
from	O
the	O
DNA	O
sequence	O
of	O
the	O
pol	B-GENE
gene	I-GENE
.	O

Primary	O
care	O
programs	O
for	O
the	O
indigent	O
.	O

N0	O
disease	O
is	O
more	O
favorable	O
than	O
N1	O
or	O
N2	O
disease	O
.	O

In	O
serial	O
recall	O
from	O
short	O
-	O
term	O
memory	O
,	O
repeated	O
items	O
are	O
recalled	O
well	O
when	O
close	O
together	O
(	O
repetition	O
facilitation	O
)	O
,	O
but	O
not	O
when	O
far	O
apart	O
(	O
repetition	O
inhibition	O
;	O
the	O
Ranschburg	O
effect	O
)	O
.	O

In	O
addition	O
,	O
two	O
cis	O
-	O
acting	O
elements	O
direct	O
the	O
first	O
zygotic	O
expression	O
of	O
Kr	B-GENE
in	O
a	O
striped	O
subpattern	O
within	O
the	O
central	O
region	O
of	O
the	O
blastoderm	O
embryo	O
.	O

Two	O
hundred	O
and	O
eighty	O
-	O
three	O
patients	O
,	O
217	O
females	O
(	O
median	O
age	O
24	O
years	O
,	O
range	O
0	O
.	O
5	O
-	O
73	O
)	O
and	O
66	O
males	O
(	O
median	O
age	O
20	O
years	O
,	O
range	O
0	O
.	O
75	O
-	O
72	O
)	O
,	O
were	O
examined	O
.	O

The	O
Robert	O
Wood	O
Johnson	O
Foundation	O
:	O
billion	O
dollar	O
force	O
for	O
health	O
-	O
care	O
change	O
.	O

We	O
have	O
isolated	O
a	O
unique	O
murine	B-GENE
FLT3	I-GENE
cDNA	I-GENE
that	O
codes	O
for	O
a	O
variant	O
isoform	O
of	O
FLT3	B-GENE
,	O
devoid	O
of	O
the	O
fifth	O
Ig	B-GENE
-	I-GENE
like	I-GENE
domain	I-GENE
,	O
by	O
comparison	O
with	O
the	O
prototypic	O
form	O
.	O

P53	B-GENE
mutations	I-GENE
also	O
offer	O
new	O
approaches	O
to	O
the	O
study	O
of	O
the	O
origins	O
of	O
mutations	O
in	O
human	O
cancer	O
.	O

(	O
1993	O
)	O
8	O
,	O
94	O
-	O
99	O
)	O
.	O

Desarrollo	O
de	O
un	O
modelo	O
matematico	O
general	O
para	O
los	O
procesos	O
fermentativos	O
,	O
Cinetica	O
de	O
la	O
degradacion	O
anaerobia	O
,	O
Ph	O
.	O
D	O
.	O

Particle	O
bombardment	O
of	O
barley	O
aleurone	O
with	O
a	O
B22EL8	B-GENE
promoter	I-GENE
-	O
GUS	B-GENE
(	O
beta	B-GENE
-	I-GENE
glucuronidase	I-GENE
)	O
construct	O
demonstrates	O
that	O
the	O
promoter	O
(	O
3	O
kb	O
)	O
is	O
active	O
in	O
developing	O
barley	O
grains	O
.	O

Changes	O
in	O
BHR	O
were	O
found	O
to	O
correlate	O
significantly	O
with	O
changes	O
in	O
the	O
levels	O
of	O
24	O
h	O
mean	O
SO2	O
,	O
NO2	O
and	O
smoke	O
;	O
48	O
h	O
mean	O
NO2	O
and	O
smoke	O
;	O
24	O
h	O
lag	O
NO2	O
;	O
although	O
the	O
effect	O
was	O
only	O
small	O
,	O
accounting	O
for	O
approximately	O
10	O
%	O
of	O
the	O
variability	O
in	O
within	O
-	O
subject	O
BHR	O
between	O
visits	O
.	O

The	O
N	O
-	O
terminal	O
sequences	O
of	O
isoforms	O
beta	O
to	O
epsilon	O
contain	O
a	O
PEST	O
region	O
which	O
could	O
induce	O
rapid	O
intracellular	O
degradation	O
of	O
isoforms	O
beta	O
and	O
delta	O
.	O

Characterization	O
of	O
regions	O
of	O
fibronectin	B-GENE
besides	O
the	O
arginine	O
-	O
glycine	O
-	O
aspartic	O
acid	O
sequence	O
required	O
for	O
adhesive	O
function	O
of	O
the	O
cell	O
-	O
binding	O
domain	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
clinical	O
effects	O
of	O
valproate	O
and	O
ethosuximide	O
can	O
be	O
related	O
to	O
this	O
differential	O
modulation	O
of	O
thalamocortical	O
excitability	O
.	O

Elements	O
regulating	O
cell	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
C	O
.	O
elegans	O
MyoD	B-GENE
family	O
homolog	O
hlh	B-GENE
-	I-GENE
1	I-GENE
.	O

An	O
analysis	O
of	O
the	O
c	B-GENE
-	I-GENE
kit	I-GENE
5	I-GENE
'	I-GENE
flanking	I-GENE
region	I-GENE
using	O
the	O
bacterial	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
gene	I-GENE
(	O
CAT	B-GENE
assay	O
)	O
in	O
human	O
erythroleukemia	O
HEL	O
cells	O
,	O
which	O
express	O
the	O
endogenous	O
c	B-GENE
-	I-GENE
kit	I-GENE
mRNA	I-GENE
at	O
high	O
levels	O
,	O
showed	O
that	O
a	O
region	O
from	O
-	O
180	O
to	O
-	O
22	O
is	O
important	O
for	O
the	O
expression	O
of	O
the	O
c	B-GENE
-	I-GENE
kit	I-GENE
gene	I-GENE
.	O

After	O
5	O
days	O
stimulation	O
with	O
G	B-GENE
-	I-GENE
CSF	I-GENE
(	O
10	O
micrograms	O
/	O
kg	O
)	O
1l	O
of	O
blood	O
was	O
drawn	O
,	O
kept	O
unprocessed	O
for	O
3	O
days	O
and	O
reinfused	O
24	O
h	O
after	O
completion	O
of	O
chemotherapy	O
.	O

OAT	O
has	O
become	O
safer	O
in	O
recent	O
years	O
,	O
particularly	O
if	O
monitored	O
in	O
special	O
anticoagulation	O
clinics	O
.	O

However	O
,	O
the	O
relative	O
substrate	O
specificity	O
of	O
RSK3	B-GENE
differed	O
from	O
that	O
reported	O
for	O
other	O
isoforms	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
various	O
subunits	O
of	O
the	O
human	O
P	B-GENE
-	I-GENE
TEFb	I-GENE
complex	O
may	O
play	O
distinct	O
roles	O
at	O
multiple	O
stages	O
to	O
mediate	O
Tat	B-GENE
activation	O
of	O
HIV	O
-	O
1	O
transcription	O
elongation	O
.	O

Corresponding	O
oligonucleotides	O
were	O
used	O
to	O
screen	O
a	O
rat	O
liver	O
cDNA	O
library	O
constructed	O
in	O
the	O
plasmid	O
cloning	O
vector	O
,	O
pcDV	O
.	O

In	O
fifty	O
non	O
selected	O
ductal	O
carcinomas	O
of	O
the	O
breast	O
we	O
found	O
that	O
a	O
marked	O
tumoral	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
,	O
perinodal	O
tumoral	O
infiltrate	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
sinus	O
catarrh	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
follicular	O
hyperplasia	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
,	O
mixed	O
pattern	O
in	O
lymph	O
nodes	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
with	O
54	O
years	O
of	O
age	O
or	O
younger	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
correlated	O
significantly	O
with	O
lymph	O
node	O
metastases	O
and	O
/	O
or	O
high	O
histologic	O
grade	O
.	O

Capillary	O
tortuosity	O
was	O
a	O
function	O
of	O
sarcomere	O
length	O
in	O
all	O
animals	O
and	O
this	O
relationship	O
was	O
not	O
changed	O
by	O
hypoxia	O
.	O

Sox8	B-GENE
maps	O
to	O
the	O
t	B-GENE
complex	I-GENE
on	O
mouse	O
chromosome	O
17	O
and	O
to	O
human	O
chromosome	O
16p13	O
.	O
3	O
,	O
a	O
region	O
associated	O
with	O
the	O
microphthalmia	O
-	O
cataract	O
syndrome	O
CATM	O
and	O
the	O
alpha	O
-	O
thalassemia	O
/	O
mental	O
retardation	O
syndrome	O
ATR	O
-	O
16	O
.	O

Directional	O
growth	O
of	O
a	O
smectic	O
-	O
A	O
-	O
smectic	O
-	O
B	O
interface	O
lying	O
along	O
a	O
forbidden	O
orientation	O
.	O

The	O
TCR	B-GENE
beta	I-GENE
enhancer	I-GENE
was	O
active	O
on	O
both	O
the	O
minimal	B-GENE
simian	I-GENE
virus	I-GENE
40	I-GENE
promoter	I-GENE
and	O
a	O
TCR	B-GENE
beta	I-GENE
variable	I-GENE
gene	I-GENE
promoter	I-GENE
in	O
both	O
TCR	B-GENE
alpha	I-GENE
/	I-GENE
beta	I-GENE
+	O
and	O
TCR	B-GENE
gamma	I-GENE
/	I-GENE
delta	I-GENE
+	O
T	O
cells	O
.	O

U	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
PDGF	I-GENE
)	I-GENE
-	I-GENE
beta	I-GENE
receptor	I-GENE
stimulation	O
,	O
but	O
not	O
various	O
other	O
growth	O
factors	O
,	O
inhibits	O
transcription	O
of	O
alpha1D	B-GENE
-	O
,	O
but	O
not	O
alpha1A	B-GENE
-	O
or	O
alpha1B	B-GENE
-	I-GENE
ARs	I-GENE
,	O
resulting	O
in	O
reduced	O
norepinephrine	O
-	O
mediated	O
SMC	O
growth	O
.	O

Southern	O
blot	O
analysis	O
following	O
reverse	O
transcription	O
and	O
PCR	O
showed	O
that	O
B2R	B-GENE
is	O
expressed	O
in	O
most	O
mouse	O
tissues	O
,	O
except	O
the	O
liver	O
and	O
spleen	O
,	O
which	O
is	O
consistent	O
with	O
the	O
wide	O
distribution	O
of	O
B2R	B-GENE
activity	O
as	O
deduced	O
from	O
pharmacological	O
studies	O
.	O

Long	O
-	O
term	O
renal	O
function	O
in	O
on	O
-	O
heart	O
-	O
beating	O
donor	O
kidney	O
transplantation	O
:	O
a	O
single	O
-	O
center	O
experience	O
.	O

The	O
study	O
of	O
the	O
intensity	O
of	O
pain	O
evoked	O
by	O
heat	O
is	O
relatively	O
exhaustive	O
:	O
the	O
influence	O
of	O
various	O
local	O
,	O
stimulus	O
-	O
dependent	O
or	O
general	O
factors	O
upon	O
threshold	O
values	O
has	O
been	O
well	O
studied	O
,	O
as	O
has	O
the	O
relation	O
between	O
pain	O
and	O
stimulus	O
intensities	O
.	O

The	O
vaccine	O
was	O
at	O
least	O
80	O
%	O
efficacious	O
against	O
Chlamydia	O
and	O
Campylobacter	O
spp	O
and	O
appeared	O
to	O
be	O
protective	O
.	O

The	O
centromeric	O
dodeca	O
-	O
satellite	O
of	O
Drosophila	O
forms	O
altered	O
DNA	O
structures	O
in	O
vitro	O
in	O
which	O
its	O
purine	O
-	O
rich	O
strand	O
(	O
G	O
-	O
strand	O
)	O
forms	O
stable	O
fold	O
-	O
back	O
structures	O
,	O
while	O
the	O
complementary	O
C	O
-	O
strand	O
remains	O
unstructured	O
.	O

Pneumatic	O
dilation	O
of	O
the	O
lower	O
esophageal	O
sphincter	O
was	O
accomplished	O
by	O
endoscopic	O
visualization	O
and	O
positioning	O
of	O
a	O
modified	O
polyurethane	O
dilator	O
(	O
90	O
F	O
diameter	O
)	O
without	O
fluoroscopy	O
in	O
17	O
consecutive	O
patients	O
with	O
advanced	O
symptomatic	O
achalasia	O
.	O

Mean	O
CD4	B-GENE
percentages	O
were	O
lower	O
postpartum	O
(	O
21	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
4	O
)	O
than	O
prepartum	O
(	O
45	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
7	O
)	O
in	O
all	O
five	O
patients	O
studied	O
,	O
although	O
proliferative	O
responses	O
to	O
the	O
mitogens	B-GENE
phytohemagglutinin	I-GENE
and	I-GENE
pokeweed	I-GENE
were	O
unchanged	O
during	O
the	O
study	O
period	O
.	O

The	O
second	O
system	O
(	O
VacFix	O
)	O
uses	O
a	O
0	O
.	O
15	O
mm	O
thick	O
plastic	O
bag	O
loosely	O
filled	O
with	O
1	O
mm	O
polysterol	O
spheres	O
.	O

Mean	O
24	O
h	O
urinary	O
excretion	O
values	O
confirmed	O
this	O
observation	O
.	O

However	O
,	O
the	O
safety	O
of	O
design	O
4	O
was	O
assured	O
as	O
long	O
as	O
all	O
patients	O
received	O
three	O
courses	O
of	O
chemotherapy	O
,	O
which	O
is	O
unusual	O
in	O
phase	O
I	O
studies	O
in	O
Japan	O
.	O

The	O
results	O
indicate	O
that	O
the	O
RNA	O
in	O
T7	B-GENE
RNA	I-GENE
polymerase	I-GENE
is	O
not	O
free	O
of	O
steric	O
interactions	O
in	O
the	O
ternary	O
complex	O
and	O
not	O
available	O
for	O
structure	O
formation	O
until	O
it	O
is	O
at	O
least	O
10	O
bases	O
away	O
from	O
the	O
site	O
of	O
polymerization	O
.	O

The	O
STP1	B-GENE
locus	I-GENE
is	O
located	O
on	O
chromosome	O
IV	O
close	O
to	O
at	O
least	O
two	O
other	O
genes	O
involved	O
in	O
RNA	O
splicing	O
:	O
PRP3	B-GENE
and	O
SPP41	B-GENE
.	O

An	O
ICU	O
length	O
of	O
stay	O
shorter	O
than	O
24	O
h	O
was	O
not	O
related	O
to	O
the	O
frequency	O
of	O
group	O
C	O
errors	O
.	O

In	O
vitro	O
,	O
SHIP	B-GENE
catalyzes	O
the	O
conversion	O
of	O
the	O
phosphoinositide	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
(	O
PI3K	B-GENE
)	O
product	O
phosphatidylinositol	O
3	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
(	O
PIP3	O
)	O
into	O
phosphatidylinositol	O
3	O
,	O
4	O
-	O
bisphosphate	O
.	O

Like	O
pimethixene	O
and	O
cyproheptadine	O
,	O
WA	O
335	O
has	O
no	O
distinct	O
antagonistic	O
qualities	O
against	O
bradykinin	B-GENE
.	O

To	O
confirm	O
the	O
data	O
obtained	O
using	O
the	O
HPLC	O
-	O
ESI	O
-	O
MS	O
procedure	O
,	O
fractions	O
of	O
the	O
glycosides	O
from	O
four	O
berries	O
were	O
separated	O
,	O
hydrolyzed	O
,	O
silylated	O
and	O
the	O
sugars	O
were	O
analyzed	O
using	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

This	O
clone	O
will	O
be	O
useful	O
for	O
identifying	O
the	O
genetic	O
determinants	O
of	O
FIV	O
-	O
Oma	O
'	O
s	O
biological	O
activities	O
.	O

The	O
WEB2	B-GENE
gene	I-GENE
encodes	O
a	O
1	O
,	O
522	O
-	O
amino	O
-	O
acid	O
protein	O
with	O
homology	O
to	O
nucleic	B-GENE
acid	I-GENE
-	I-GENE
dependent	I-GENE
ATPases	I-GENE
.	O

Evidence	O
that	O
the	O
AT1A	B-GENE
receptor	I-GENE
activates	O
transcription	B-GENE
factor	I-GENE
-	I-GENE
Stat91	I-GENE
and	O
/	O
or	O
a	O
related	O
protein	O
.	O

There	O
was	O
91	O
%	O
concordance	O
between	O
ST	O
-	O
RD	O
/	O
RI	O
/	O
LRD	O
201Tl	O
and	O
R	O
-	O
ST	O
/	O
N	O
+	O
Inf	O
99Tcm	O
-	O
tetrofosmin	O
imaging	O
regarding	O
reversibility	O
.	O

The	O
two	O
complexes	O
were	O
detected	O
with	O
a	O
similar	O
activation	O
kinetics	O
upon	O
IL	B-GENE
-	I-GENE
4	I-GENE
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
dauricine	O
and	O
verapamil	O
have	O
a	O
salutary	O
effect	O
in	O
extracorporeal	O
circulation	O
.	O

These	O
results	O
demonstrate	O
the	O
preferential	O
endometrial	O
cell	O
-	O
type	O
expression	O
of	O
BTEB	B-GENE
and	O
suggest	O
its	O
regulatory	O
role	O
in	O
pregnancy	O
-	O
associated	O
endometrial	O
epithelial	O
gene	O
expression	O
.	O

Spen	B-GENE
is	O
the	O
only	O
known	O
homeotic	B-GENE
protein	I-GENE
with	O
RNP	O
binding	O
motifs	O
,	O
which	O
indicates	O
that	O
splicing	O
,	O
transport	O
,	O
or	O
other	O
RNA	O
regulatory	O
steps	O
are	O
involved	O
in	O
the	O
diversification	O
of	O
segmental	O
morphology	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
kidney	O
donors	O
:	O
a	O
longitudinal	O
study	O
.	O

Recent	O
research	O
on	O
lipolysis	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
showed	O
it	O
is	O
possible	O
to	O
use	O
a	O
modified	O
Stroop	O
task	O
as	O
a	O
measure	O
of	O
implicit	O
processing	O
of	O
alcohol	O
stimuli	O
.	O

Six	O
patients	O
(	O
24	O
%	O
)	O
developed	O
sepsis	O
and	O
only	O
one	O
survived	O
.	O

None	O
of	O
the	O
10	O
sequences	O
has	O
hitherto	O
been	O
recognized	O
as	O
part	O
of	O
the	O
p53	B-GENE
signaling	O
pathway	O
.	O

The	O
Prompt	O
and	O
Praise	O
condition	O
was	O
superior	O
to	O
the	O
other	O
two	O
conditions	O
in	O
encouraging	O
participation	O
in	O
low	O
-	O
interest	O
recreational	O
activities	O
.	O

The	O
majority	O
of	O
the	O
human	B-GENE
Ig	I-GENE
heavy	I-GENE
chain	I-GENE
(	I-GENE
IgH	I-GENE
)	I-GENE
constant	I-GENE
(	I-GENE
C	I-GENE
)	I-GENE
region	I-GENE
locus	I-GENE
has	O
been	O
cloned	O
and	O
mapped	O
.	O

A	O
.	O

We	O
analyzed	O
right	O
ventricular	O
size	O
and	O
function	O
and	O
201Tl	O
uptake	O
to	O
determine	O
if	O
there	O
was	O
a	O
relationship	O
between	O
201Tl	O
uptake	O
and	O
systolic	O
function	O
in	O
19	O
patients	O
with	O
pulmonary	O
artery	O
hypertension	O
who	O
were	O
being	O
evaluated	O
for	O
heart	O
-	O
lung	O
transplantation	O
.	O

The	O
transcriptional	O
start	O
site	O
(	O
s	O
)	O
of	O
the	O
IA	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
was	O
mapped	O
by	O
5	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
to	O
97	O
bp	O
upstream	O
of	O
the	O
translational	O
start	O
site	O
.	O

The	O
RAG	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
encodes	O
a	O
component	O
of	O
the	O
V	B-GENE
(	I-GENE
D	I-GENE
)	I-GENE
J	I-GENE
recombinase	I-GENE
which	O
is	O
essential	O
for	O
the	O
assembly	O
of	O
antigen	O
receptor	O
genes	O
in	O
B	O
and	O
T	O
lymphocytes	O
.	O

The	O
lamina	O
densa	O
was	O
always	O
interrupted	O
by	O
numerous	O
small	O
gaps	O
and	O
in	O
some	O
areas	O
the	O
basement	O
membrane	O
could	O
not	O
be	O
identified	O
over	O
a	O
long	O
distance	O
.	O

We	O
have	O
characterized	O
21	O
mutations	O
in	O
the	O
type	B-GENE
VII	I-GENE
collagen	I-GENE
gene	I-GENE
(	O
COL7A1	B-GENE
)	O
encoding	O
the	O
anchoring	O
fibrils	O
,	O
18	O
of	O
which	O
were	O
not	O
previously	O
reported	O
,	O
in	O
patients	O
from	O
15	O
unrelated	O
families	O
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
.	O

The	O
data	O
when	O
used	O
to	O
stimulate	O
the	O
collection	O
of	O
the	O
information	O
at	O
antenatal	O
or	O
postnatal	O
visits	O
,	O
nonetheless	O
provide	O
an	O
accurate	O
description	O
of	O
under	O
-	O
3	O
mortality	O
trends	O
and	O
differences	O
for	O
the	O
two	O
periods	O
examined	O
-	O
-	O
before	O
1984	O
and	O
before	O
1989	O
.	O

Both	O
residues	O
are	O
conserved	O
in	O
the	O
three	O
phosphorylated	O
paralogs	O
but	O
are	O
absent	O
in	O
the	O
ones	O
that	O
were	O
not	O
substrates	O
of	O
RsbT	B-GENE
:	O
YetI	B-GENE
and	O
YezB	B-GENE
,	O
each	O
of	O
which	O
bears	O
only	O
one	O
of	O
the	O
conserved	O
residues	O
;	O
and	O
YtvA	B-GENE
,	O
which	O
lacks	O
both	O
residues	O
and	O
instead	O
possesses	O
an	O
N	O
-	O
terminal	O
PAS	B-GENE
domain	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
the	O
occurrence	O
in	O
any	O
particular	O
vascular	O
segment	O
of	O
the	O
transient	O
contractile	O
response	O
and	O
intrinsic	O
tone	O
as	O
assessed	O
by	O
relaxation	O
to	O
papaverine	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

Both	O
atracurium	O
1	O
-	O
100	O
mumol	O
litre	O
-	O
1	O
and	O
laudanosine	O
1	O
-	O
50	O
mumol	O
litre	O
-	O
1	O
enhanced	O
the	O
release	O
of	O
3H	O
-	O
NA	O
evoked	O
by	O
field	O
stimulation	O
(	O
2	O
Hz	O
,	O
24	O
stimuli	O
)	O
,	O
but	O
did	O
not	O
affect	O
resting	O
release	O
.	O

S16	O
,	O
16	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
Zn	B-GENE
-	I-GENE
15	I-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
domain	I-GENE
comprises	O
three	O
zinc	O
fingers	O
separated	O
by	O
unusually	O
long	O
linker	O
sequences	O
that	O
would	O
be	O
expected	O
to	O
interrupt	O
specific	O
DNA	O
site	O
recognition	O
.	O

Replication	O
regions	O
from	O
plant	O
-	O
pathogenic	O
Pseudomonas	O
syringae	O
plasmids	O
are	O
similar	O
to	O
ColE2	O
-	O
related	O
replicons	O
.	O

There	O
has	O
been	O
no	O
significant	O
toxicity	O
associated	O
with	O
repeated	O
5	O
-	O
FU	O
instillation	O
into	O
the	O
airway	O
.	O

Twenty	O
male	O
volunteers	O
were	O
studied	O
during	O
almokalant	O
infusion	O
aiming	O
at	O
plasma	O
concentrations	O
(	O
Cpl	O
)	O
of	O
20	O
,	O
50	O
,	O
100	O
,	O
and	O
150	O
nmol	O
/	O
l	O
.	O

Consistently	O
,	O
we	O
show	O
that	O
phosphorylation	O
by	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
inhibits	O
Sfl1	B-GENE
DNA	O
binding	O
in	O
vitro	O
,	O
and	O
that	O
a	O
tpk2Delta	B-GENE
mutation	O
increases	O
the	O
levels	O
of	O
Sfl1	B-GENE
protein	I-GENE
associated	O
with	O
specific	O
promoter	O
elements	O
in	O
vivo	O
.	O

The	O
response	O
sequences	O
were	O
localized	O
between	O
-	O
67	O
and	O
+	O
30	O
in	O
the	O
simian	O
cytomegalovirus	O
IE94	B-GENE
promoter	I-GENE
and	O
upstream	O
of	O
position	O
+	O
9	O
in	O
the	O
HCMV	B-GENE
IE68	I-GENE
promoter	I-GENE
.	O

Some	O
CHOP	B-GENE
-	O
C	B-GENE
/	I-GENE
EBP	I-GENE
heterodimers	O
apparently	O
bind	O
to	O
alternative	O
DNA	O
sequence	O
and	O
thereby	O
regulate	O
the	O
transcription	O
of	O
other	O
genes	O
.	O

To	O
identify	O
and	O
determine	O
the	O
function	O
of	O
Ino2p	B-GENE
in	O
yeast	O
cells	O
,	O
we	O
raised	O
antibodies	O
to	O
a	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
/	O
Ino2	B-GENE
fusion	O
protein	O
.	O

Northern	O
blot	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
regulated	O
expression	O
of	O
the	O
cys	B-GENE
-	I-GENE
14	I-GENE
+	I-GENE
gene	I-GENE
.	O

Typicality	O
is	O
probably	O
a	O
better	O
representation	O
of	O
Alexander	O
,	O
Dunbar	O
and	O
others	O
'	O
conclusions	O
than	O
specificity	O
,	O
which	O
was	O
always	O
too	O
absolute	O
a	O
term	O
.	O

Additions	O
of	O
NH4	O
+	O
up	O
to	O
200	O
micrograms	O
1	O
(	O
-	O
1	O
)	O
were	O
not	O
stimulatory	O
,	O
whereas	O
at	O
1	O
.	O
0	O
mg	O
1	O
(	O
-	O
1	O
)	O
levels	O
,	O
Ke	O
was	O
50	O
%	O
greater	O
than	O
for	O
NO3	O
-	O
enriched	O
medium	O
.	O

Cardiovascular	O
drug	O
use	O
and	O
hospitalizations	O
attributable	O
to	O
type	O
2	O
diabetes	O
.	O

The	O
arrangement	O
of	O
amino	O
acids	O
in	O
the	O
helix	O
1	O
and	O
helix	O
2	O
regions	O
is	O
quite	O
similar	O
to	O
those	O
of	O
Mxi	B-GENE
and	O
Mad	B-GENE
,	O
but	O
different	O
from	O
those	O
of	O
E2F	B-GENE
-	I-GENE
1	I-GENE
and	O
DP	B-GENE
-	I-GENE
1	I-GENE
.	O

They	O
contain	O
a	O
large	O
(	O
0	O
.	O
9	O
X	O
10	O
(	O
3	O
)	O
to	O
1	O
.	O
88	O
X	O
10	O
(	O
3	O
)	O
base	O
-	O
pairs	O
)	O
intron	O
in	O
the	O
middle	O
of	O
the	O
gene	O
and	O
are	O
further	O
interrupted	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

The	O
present	O
study	O
also	O
emphasizes	O
the	O
need	O
of	O
establishing	O
dose	O
-	O
response	O
curves	O
to	O
correctly	O
assess	O
the	O
relative	O
contribution	O
of	O
the	O
different	O
regions	O
of	O
steroid	B-GENE
hormone	I-GENE
receptors	I-GENE
in	O
activation	O
of	O
transcription	O
.	O

Routine	O
and	O
default	O
retrieval	O
home	O
visits	O
were	O
given	O
to	O
ensure	O
maximal	O
drug	O
compliance	O
.	O

D	O
.	O
,	O
and	O
Long	O
,	O
C	O
.	O

By	O
contrast	O
with	O
ama	B-GENE
-	I-GENE
1	I-GENE
,	O
rpc	B-GENE
-	I-GENE
1	I-GENE
was	O
not	O
deleted	O
by	O
mDf4	O
or	O
larger	O
deficiencies	O
examined	O
,	O
indicating	O
that	O
these	O
genes	O
are	O
no	O
closer	O
than	O
150	O
kb	O
.	O

Accordingly	O
,	O
constitutive	O
downregulation	O
of	O
expression	O
of	O
accessory	O
molecules	O
of	O
the	O
MHC	B-GENE
class	I-GENE
I	I-GENE
pathway	I-GENE
can	O
reveal	O
differences	O
between	O
H2	B-GENE
class	I-GENE
I	I-GENE
alleles	I-GENE
in	O
antigen	O
presentation	O
not	O
encountered	O
when	O
the	O
expression	O
levels	O
are	O
augmented	O
.	O

Anovulatory	O
cycles	O
with	O
an	O
apparently	O
normal	O
level	O
of	O
blood	O
prolactin	B-GENE
.	O

Legionella	B-GENE
antibodies	I-GENE
in	O
domestic	O
animals	O

By	O
differential	O
screening	O
of	O
a	O
Xenopus	O
laevis	O
egg	O
cDNA	O
library	O
,	O
we	O
have	O
isolated	O
a	O
2	O
,	O
111	O
bp	O
cDNA	O
which	O
corresponds	O
to	O
a	O
maternal	O
mRNA	O
specifically	O
deadenylated	O
after	O
fertilisation	O
.	O

Similar	O
immunological	O
disturbances	O
were	O
observed	O
in	O
SCI	O
but	O
not	O
in	O
the	O
PC2	O
subgroup	O
,	O
i	O
.	O
e	O
.	O
patients	O
examined	O
later	O
than	O
6	O
months	O
after	O
injury	O
.	O

This	O
study	O
demonstrates	O
that	O
Fluosol	O
significantly	O
attenuates	O
neutrophil	O
adherence	O
,	O
cytotoxicity	O
,	O
and	O
enzyme	O
release	O
in	O
an	O
in	O
vitro	O
model	O
of	O
microvascular	O
injury	O
.	O

Using	O
the	O
same	O
electrical	O
analog	O
,	O
we	O
present	O
an	O
analysis	O
that	O
allows	O
calculation	O
of	O
these	O
parameters	O
,	O
as	O
well	O
as	O
the	O
corner	O
frequency	O
of	O
the	O
network	O
(	O
f1	O
)	O
,	O
without	O
need	O
for	O
similar	O
assumptions	O
.	O

We	O
further	O
examined	O
the	O
interaction	O
of	O
JAK2	B-GENE
with	O
the	O
GHR	B-GENE
cytoplasmic	O
domain	O
by	O
two	O
lines	O
of	O
investigation	O
.	O

These	O
p21	B-GENE
-	O
E2F	B-GENE
complexes	O
,	O
while	O
present	O
in	O
young	O
G1	O
cells	O
at	O
very	O
low	O
levels	O
,	O
were	O
elevated	O
in	O
senescent	O
cells	O
.	O

There	O
is	O
little	O
similarity	O
among	O
the	O
sequences	O
upstream	O
from	O
the	O
CAP	O
site	O
of	O
the	O
Spec2	B-GENE
genes	I-GENE
except	O
the	O
TATA	O
consensus	O
sequence	O
and	O
a	O
repeating	O
trinucleotide	O
,	O
AAC	O
.	O

Thus	O
,	O
d	O
-	O
delta3	O
-	O
carene	O
was	O
about	O
four	O
times	O
more	O
potent	O
as	O
a	O
sensory	O
irritant	O
than	O
I	O
-	O
beta	O
-	O
pinene	O
,	O
whereas	O
the	O
difference	O
with	O
I	O
-	O
alpha	O
-	O
pinene	O
was	O
more	O
marked	O
;	O
as	O
a	O
sensory	O
irritant	O
,	O
I	O
-	O
alpha	O
-	O
pinene	O
is	O
almost	O
inactive	O
.	O

The	O
reconstituted	O
RNA	B-GENE
polymerases	I-GENE
containing	O
the	O
mutant	O
alpha	O
subunits	O
were	O
examined	O
for	O
their	O
response	O
to	O
transcription	O
activation	O
by	O
cAMP	B-GENE
-	I-GENE
CRP	I-GENE
and	O
the	O
rrnBP1	B-GENE
UP	I-GENE
element	I-GENE
.	O

The	O
study	O
drugs	O
(	O
combination	O
vinblastine	O
-	O
CCNU	O
and	O
single	O
-	O
agent	O
triazinate	O
or	O
dactinomycin	O
)	O
failed	O
to	O
provide	O
any	O
meaningful	O
antitumor	O
activity	O
for	O
these	O
patients	O
with	O
advanced	O
renal	O
cell	O
cancer	O
.	O

Our	O
results	O
indicate	O
that	O
GCN4	B-GENE
contains	O
two	O
activation	O
domains	O
of	O
similar	O
potency	O
that	O
can	O
function	O
independently	O
to	O
promote	O
high	O
-	O
level	O
transcription	O
of	O
the	O
target	O
genes	O
HIS3	B-GENE
and	O
HIS4	B-GENE
.	O

Those	O
diagnosed	O
as	O
having	O
affective	O
disorder	O
(	O
n	O
=	O
96	O
)	O
,	O
according	O
to	O
DSM	O
-	O
IIIR	O
criteria	O
,	O
were	O
compared	O
with	O
the	O
other	O
non	O
-	O
affective	O
suicide	O
attempters	O
(	O
n	O
=	O
161	O
)	O
.	O

Tax	B-GENE
was	O
demonstrated	O
to	O
interact	O
directly	O
with	O
CREB1	B-GENE
but	O
not	O
with	O
other	O
bZIP	B-GENE
proteins	I-GENE
,	O
including	O
CREB2	B-GENE
and	O
Jun	B-GENE
.	O

Anxiogenic	O
effects	O
of	O
pentagastrin	O
in	O
patients	O
with	O
social	O
phobia	O
and	O
healthy	O
controls	O
.	O

Ischaemia	O
and	O
reperfusion	O
injury	O
in	O
the	O
kidney	O
:	O
current	O
status	O
and	O
future	O
direction	O
.	O

Non	O
-	O
dialyzable	O
transfer	B-GENE
factor	I-GENE

We	O
also	O
demonstrate	O
that	O
a	O
p110RB1	B-GENE
mutant	I-GENE
,	O
which	O
is	O
refractory	O
to	O
cell	O
cycle	O
phosphorylation	O
but	O
intact	O
in	O
E1a	B-GENE
/	O
large	B-GENE
T	I-GENE
antigen	I-GENE
-	O
binding	O
properties	O
,	O
represses	O
EIIaE	B-GENE
with	O
50	O
-	O
to	O
80	O
-	O
fold	O
greater	O
efficiency	O
than	O
wild	B-GENE
-	I-GENE
type	I-GENE
p110RB1	I-GENE
.	O

Subgroup	O
analysis	O
failed	O
to	O
show	O
any	O
benefit	O
for	O
etoposide	O
in	O
patients	O
with	O
monocytic	O
or	O
myelomonocytic	O
disease	O
,	O
or	O
in	O
any	O
other	O
diagnostic	O
subgroup	O
.	O

The	O
IGFBP	B-GENE
-	I-GENE
1	I-GENE
IRS	B-GENE
and	O
PEPCK	B-GENE
IRS	B-GENE
both	O
bind	O
the	O
alpha	O
and	O
beta	O
forms	O
of	O
hepatic	B-GENE
nuclear	I-GENE
factor	I-GENE
3	I-GENE
(	O
HNF	B-GENE
-	I-GENE
3	I-GENE
)	O
,	O
although	O
the	O
latter	O
does	O
so	O
with	O
a	O
sixfold	O
-	O
lower	O
relative	O
affinity	O
.	O

Polyglutamine	O
-	O
containing	O
protein	O
fragments	O
have	O
been	O
shown	O
to	O
accumulate	O
as	O
aggregates	O
in	O
the	O
nucleus	O
and	O
in	O
the	O
cytoplasm	O
,	O
and	O
to	O
induce	O
cell	O
death	O
when	O
expressed	O
in	O
cultured	O
cells	O
,	O
leading	O
to	O
the	O
proposal	O
that	O
polyglutamine	O
aggregation	O
is	O
an	O
important	O
step	O
in	O
the	O
pathogenesis	O
.	O

It	O
is	O
suggested	O
that	O
on	O
presentation	O
of	O
tail	O
tip	O
necrosis	O
in	O
kittens	O
a	O
diagnosis	O
of	O
neonatal	O
isoerythrolysis	O
or	O
isoagglutination	O
should	O
be	O
considered	O
.	O

Microscopically	O
,	O
cartilage	O
showed	O
markedly	O
stunted	O
and	O
disorganized	O
endochondral	O
ossification	O
.	O

Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
differential	O
splicing	O
in	O
the	O
extracellular	O
region	O
of	O
a	O
receptor	O
gene	O
generates	O
receptor	O
variants	O
with	O
different	O
ligand	O
-	O
binding	O
specificities	O
.	O

Sucrose	O
-	O
specific	O
signalling	O
represses	O
translation	O
of	O
the	O
Arabidopsis	B-GENE
ATB2	I-GENE
bZIP	I-GENE
transcription	I-GENE
factor	I-GENE
gene	I-GENE
.	O

Wolf	O
-	O
Hirschhorn	O
syndrome	O
(	O
WHS	O
)	O
is	O
a	O
malformation	O
syndrome	O
associated	O
with	O
a	O
hemizygous	O
deletion	O
of	O
the	O
distal	O
short	O
arm	O
of	O
chromosome	O
4	O
(	O
4p16	O
.	O
3	O
)	O
.	O

Our	O
aim	O
was	O
to	O
check	O
whether	O
,	O
during	O
PG	O
-	O
DS	O
administration	O
,	O
serum	O
lipase	B-GENE
activity	O
changes	O
simultaneously	O
with	O
serum	O
amylase	B-GENE
activity	O
,	O
and	O
,	O
if	O
so	O
,	O
what	O
the	O
reason	O
is	O
for	O
the	O
detected	O
change	O
.	O

A	O
long	O
-	O
term	O
follow	O
-	O
up	O
study	O
of	O
a	O
children	O
'	O
s	O
psychiatric	O
day	O
treatment	O
center	O
.	O

Sequencing	O
and	O
restriction	O
enzyme	O
analysis	O
demonstrated	O
that	O
this	O
single	O
-	O
copy	O
gene	O
contains	O
11	O
exons	O
and	O
spans	O
9596	O
base	O
pairs	O
.	O

In	O
phase	O
II	O
studies	O
,	O
MDL	O
72	O
,	O
974A	O
is	O
proving	O
to	O
be	O
a	O
useful	O
adjunct	O
to	O
conventional	O
therapy	O
.	O

However	O
,	O
no	O
consensus	O
on	O
indications	O
exists	O
and	O
,	O
according	O
to	O
the	O
literature	O
,	O
results	O
are	O
contradictory	O
.	O

The	O
effect	O
of	O
the	O
NMDA	B-GENE
-	I-GENE
receptor	I-GENE
antagonist	O
(	O
+	O
/	O
-	O
)	O
-	O
CPP	O
on	O
the	O
conditioned	O
-	O
reflex	O
activation	O
of	O
an	O
operant	O
reaction	O
in	O
the	O
brain	O
electrical	O
self	O
-	O
stimulation	O
test	O
in	O
rats	O

Within	O
any	O
cell	O
line	O
,	O
several	O
Tcfs	B-GENE
and	O
TLEs	B-GENE
are	O
co	O
-	O
expressed	O
.	O

Constructs	O
containing	O
fragments	O
of	O
the	O
upstream	O
region	O
of	O
the	O
cytotactin	B-GENE
gene	I-GENE
fused	O
to	O
a	O
promoterless	O
gene	O
for	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
were	O
transiently	O
transfected	O
into	O
chicken	O
embryo	O
fibroblasts	O
to	O
define	O
functional	O
promoter	O
sequences	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
evolution	O
of	O
bronchial	O
albumin	B-GENE
,	O
IgA	B-GENE
,	O
and	O
IgG	B-GENE
levels	O
in	O
ventilated	O
ICU	O
patients	O
in	O
relation	O
to	O
nosocomial	O
pneumonia	O
.	O

Mortality	O
among	O
patients	O
with	O
CAVB	O
is	O
still	O
high	O
and	O
has	O
not	O
declined	O
within	O
the	O
last	O
decade	O
.	O

Mutations	O
away	O
from	O
splice	O
site	O
recognition	O
sequences	O
might	O
cis	O
-	O
modulate	O
alternative	O
splicing	O
of	O
goat	O
alpha	B-GENE
s1	I-GENE
-	I-GENE
casein	I-GENE
transcripts	I-GENE
.	O

SETTING	O
:	O
A	O
private	O
office	O
-	O
based	O
fertility	O
program	O
.	O

Promoter	O
,	O
spliced	O
leader	O
,	O
and	O
coding	O
sequence	O
for	O
BICP4	B-GENE
,	O
the	O
largest	O
of	O
the	O
immediate	B-GENE
-	I-GENE
early	I-GENE
proteins	I-GENE
of	I-GENE
bovine	I-GENE
herpesvirus	I-GENE
1	I-GENE
.	O

The	O
limb	O
defects	O
,	O
oligodactyly	O
and	O
syndactyly	O
,	O
have	O
been	O
traced	O
to	O
improper	O
differentiation	O
of	O
the	O
apical	O
ectodermal	O
ridge	O
(	O
AER	O
)	O
and	O
shortening	O
of	O
the	O
anteroposterior	O
limb	O
axis	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
ZF	B-GENE
-	I-GENE
HD	I-GENE
class	O
of	O
homeodomain	B-GENE
proteins	I-GENE
may	O
be	O
involved	O
in	O
the	O
establishment	O
of	O
the	O
characteristic	O
expression	O
pattern	O
of	O
the	O
C4	B-GENE
PEPCase	I-GENE
gene	I-GENE
.	O

There	O
was	O
no	O
correlation	O
between	O
starting	O
platelet	O
-	O
associated	O
IgG	B-GENE
levels	O
or	O
changes	O
in	O
platelet	O
-	O
associated	O
IgG	B-GENE
levels	O
with	O
therapy	O
and	O
the	O
increment	O
in	O
the	O
patient	O
'	O
s	O
platelet	O
count	O
.	O

We	O
investigated	O
whether	O
two	O
WT1	B-GENE
splice	I-GENE
variants	I-GENE
lacking	O
or	O
including	O
a	O
three	O
-	O
amino	O
-	O
acid	O
(	O
KTS	O
)	O
insertion	O
between	O
the	O
third	O
and	O
fourth	O
zinc	O
finger	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
could	O
repress	O
the	O
IR	B-GENE
promoter	I-GENE
in	O
vitro	O
.	O

An	O
oligomer	O
synthesized	O
to	O
this	O
region	O
of	O
homology	O
produced	O
two	O
DNA	O
-	O
protein	O
complexes	O
with	O
oviduct	O
nuclear	O
proteins	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
exhibits	O
95	O
.	O
3	O
and	O
76	O
.	O
1	O
%	O
identity	O
with	O
the	O
CAD	B-GENE
sequences	I-GENE
of	I-GENE
hamster	I-GENE
and	I-GENE
Squalus	I-GENE
acanthias	I-GENE
.	O

In	O
contrast	O
translocation	O
of	O
G1	B-GENE
to	O
the	O
Golgi	O
was	O
not	O
observed	O
when	O
G1	B-GENE
was	O
coexpressed	O
with	O
NSm	B-GENE
,	O
although	O
NSm	B-GENE
itself	O
was	O
still	O
detected	O
in	O
the	O
Golgi	O
.	O

Since	O
simian	B-GENE
virus	I-GENE
40	I-GENE
(	I-GENE
SV40	I-GENE
)	I-GENE
large	I-GENE
T	I-GENE
antigen	I-GENE
and	O
human	B-GENE
papillomavirus	I-GENE
type	I-GENE
16	I-GENE
(	I-GENE
HPV16	I-GENE
)	I-GENE
E7	I-GENE
protein	I-GENE
also	O
bind	O
host	O
regulatory	O
factors	O
,	O
we	O
investigated	O
whether	O
these	O
viral	O
proteins	O
can	O
complement	O
E1A	B-GENE
mutants	I-GENE
which	O
are	O
defective	O
in	O
early	O
gene	O
activation	O
.	O

We	O
further	O
showed	O
a	O
significant	O
repression	O
of	O
promoter	O
activity	O
(	O
>	O
40	O
fold	O
)	O
by	O
E2	B-GENE
-	I-GENE
2	I-GENE
(	O
lacking	O
the	O
amino	O
acid	O
sequence	O
RSRS	O
)	O
when	O
the	O
E47	B-GENE
reporter	I-GENE
construct	I-GENE
,	O
containing	O
a	O
hexameric	O
E	O
-	O
box	O
site	O
,	O
was	O
used	O
.	O

Similar	O
observations	O
were	O
obtained	O
when	O
these	O
mutated	O
versions	O
of	O
site	O
A	O
were	O
evaluated	O
by	O
transient	O
cotransfection	O
assays	O
in	O
CV1	O
cells	O
.	O

The	O
shear	O
bond	O
strength	O
recorded	O
for	O
the	O
Novabond	O
system	O
was	O
significantly	O
lower	O
(	O
17	O
MPa	O
)	O
.	O

A	O
400	O
-	O
bp	O
fragment	O
(	O
bp	O
-	O
339	O
through	O
+	O
71	O
)	O
of	O
the	O
CD22	B-GENE
promoter	I-GENE
region	I-GENE
was	O
subcloned	O
into	O
a	O
pGEM	O
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
vector	O
and	O
after	O
transfection	O
into	O
B	O
and	O
T	O
cells	O
was	O
found	O
to	O
be	O
active	O
in	O
both	O
B	O
and	O
T	O
cells	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
mean	O
serum	O
vitamin	O
A	O
,	O
E	O
concentrations	O
and	O
vitamin	O
E	O
/	O
cholesterol	O
ratio	O
between	O
pregnant	O
women	O
with	O
normal	O
hemoglobin	B-GENE
and	O
hemoglobinopathies	O
,	O
while	O
confounding	O
variables	O
that	O
might	O
affect	O
serum	O
vitamin	O
levels	O
i	O
.	O
e	O
.	O
maternal	O
age	O
,	O
gravida	O
,	O
BMI	O
,	O
gestational	O
age	O
,	O
hematocrit	O
,	O
hemoglobin	B-GENE
,	O
mean	O
corpuscular	O
hemoglobin	B-GENE
concentration	O
and	O
blood	O
group	O
were	O
not	O
different	O
.	O

Fourteen	O
samples	O
,	O
seven	O
each	O
of	O
IR64	O
and	O
IR66	O
were	O
studied	O
with	O
regard	O
to	O
moisture	O
content	O
,	O
germination	O
test	O
,	O
abnormal	O
seedlings	O
,	O
speed	O
of	O
germination	O
,	O
conductance	O
of	O
leachates	O
,	O
total	O
dehydrogenase	O
activity	O
,	O
total	O
free	O
amino	O
acids	O
,	O
total	O
soluble	O
sugar	O
,	O
fat	O
acidity	O
,	O
gelatinization	O
temperature	O
,	O
gel	O
consistency	O
,	O
amylose	O
content	O
,	O
translucency	O
,	O
and	O
per	O
cent	O
whiteness	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
between	O
viral	O
RNA	O
and	O
BMV	B-GENE
CP	I-GENE
peptides	I-GENE
with	O
either	O
proline	O
or	O
alanine	O
substitutions	O
revealed	O
that	O
the	O
interaction	O
is	O
nonspecific	O
.	O

Thus	O
,	O
over	O
a	O
wide	O
range	O
of	O
arterial	O
dimensions	O
,	O
results	O
obtained	O
with	O
caliper	O
estimates	O
of	O
luminal	O
area	O
and	O
diameter	O
are	O
comparable	O
to	O
those	O
obtained	O
with	O
videodensitometry	O
using	O
the	O
XR	O
-	O
70	O
system	O
.	O

CONCLUSIONS	O
:	O
Neurodevelopmental	O
assessment	O
at	O
1	O
year	O
is	O
predictive	O
of	O
school	O
performance	O
and	O
outcome	O
in	O
the	O
adolescent	O
period	O
.	O

We	O
reviewed	O
the	O
different	O
published	O
cases	O
of	O
acute	O
high	O
dose	O
methotrexate	O
neurotoxicity	O
and	O
the	O
different	O
underlying	O
mechanisms	O
.	O

Drug	O
therapy	O
of	O
AAPMC	O
is	O
directed	O
at	O
reducing	O
the	O
amount	O
of	O
Cl	O
.	O
difficile	O
in	O
the	O
colon	O
and	O
promoting	O
normalization	O
of	O
intestinal	O
flora	O
.	O

The	O
yield	O
of	O
endocervical	O
cells	O
and	O
the	O
incidence	O
of	O
dysplasia	O
was	O
determined	O
for	O
both	O
the	O
prenatal	O
and	O
the	O
postpartum	O
Pap	O
smears	O
performed	O
for	O
this	O
group	O
of	O
patients	O
.	O

No	O
significant	O
difference	O
in	O
plasma	O
ET	B-GENE
levels	O
was	O
found	O
between	O
cardiac	O
and	O
peripheral	O
sampling	O
sites	O
(	O
pulmonary	O
artery	O
;	O
1	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
28	O
,	O
right	O
atrium	O
;	O
1	O
.	O
02	O
+	O
/	O
-	O
0	O
.	O
28	O
,	O
peripheral	O
artery	O
;	O
1	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
23	O
,	O
peripheral	O
vein	O
;	O
1	O
.	O
14	O
+	O
/	O
-	O
0	O
.	O
38	O
fmol	O
/	O
ml	O
:	O
N	O
.	O
S	O
.	O
)	O
,	O
or	O
among	O
patients	O
with	O
uncomplicated	O
MI	O
,	O
unstable	O
angina	O
(	O
1	O
.	O
00	O
+	O
/	O
-	O
0	O
.	O
32	O
fmol	O
/	O
ml	O
)	O
,	O
and	O
healthy	O
subjects	O
(	O
1	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
29	O
fmol	O
/	O
ml	O
)	O
.	O

Dose	O
-	O
dependent	O
pharmacokinetics	O
:	O
emphasis	O
on	O
phase	O
I	O
metabolism	O
.	O

Inhibition	O
of	O
DNA	B-GENE
topoisomerase	I-GENE
II	I-GENE
alpha	I-GENE
gene	I-GENE
expression	O
by	O
the	O
p53	B-GENE
tumor	I-GENE
suppressor	I-GENE
.	O

Activation	O
of	O
HIV	O
gene	O
expression	O
by	O
UV	O
must	O
therefore	O
involve	O
additional	O
cellular	O
processes	O
,	O
such	O
as	O
those	O
triggered	O
by	O
DNA	O
damage	O
,	O
for	O
generation	O
of	O
a	O
full	O
gene	O
expression	O
response	O
.	O

4	O
.	O

Microsporum	O
persicolor	O
,	O
an	O
easily	O
misinterpreted	O
dermatophyt	O

We	O
propose	O
that	O
,	O
while	O
Y	O
.	O
lipolytica	O
CEN	O
DNA	O
is	O
essential	O
for	O
plasmid	O
maintenance	O
,	O
this	O
function	O
can	O
be	O
supplied	O
by	O
several	O
sub	O
-	O
fragments	O
which	O
,	O
together	O
,	O
form	O
the	O
active	O
chromosomal	O
centromere	O
.	O

In	O
this	O
second	O
clinical	O
paper	O
,	O
the	O
genetic	O
features	O
of	O
the	O
case	O
of	O
microphthalmia	O
in	O
sheep	O
reported	O
by	O
Wagenaar	O
is	O
discussed	O
in	O
greater	O
detail	O
.	O

Our	O
study	O
reveals	O
a	O
consequence	O
of	O
adhesion	O
receptor	O
-	O
mediated	O
signaling	O
in	O
T	O
cells	O
,	O
which	O
is	O
potentially	O
important	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
activation	O
,	O
including	O
production	O
of	O
cytokines	O
and	O
expression	O
of	O
proto	O
-	O
oncogenes	O
,	O
many	O
of	O
which	O
are	O
controlled	O
through	O
3	O
'	O
AU	O
-	O
rich	O
elements	O
.	O

The	O
gap	B-GENE
protein	O
knirps	B-GENE
mediates	O
both	O
quenching	O
and	O
direct	O
repression	O
in	O
the	O
Drosophila	O
embryo	O
.	O

The	O
family	O
histories	O
were	O
obtained	O
from	O
the	O
parents	O
.	O

The	O
DW	O
directions	O
uniformly	O
sampled	O
the	O
diffusion	O
ellipsoid	O
surface	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD40	B-GENE
or	O
IgM	B-GENE
receptor	I-GENE
stimulation	O
of	O
primary	O
B	O
cells	O
results	O
in	O
transactivation	O
of	O
this	O
enhancer	O
.	O

This	O
cell	O
line	O
expresses	O
productively	O
rearranged	O
immunoglobulin	B-GENE
genes	I-GENE
as	O
well	O
as	O
the	O
Oct	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
at	O
high	O
levels	O
which	O
are	O
comparable	O
to	O
those	O
observed	O
in	O
activated	O
murine	O
splenic	O
B	O
cells	O
.	O

The	O
relationship	O
between	O
CSF	B-GENE
somatostatin	I-GENE
and	O
peripheral	O
thyroid	O
hormones	O
was	O
assessed	O
in	O
11	O
affectively	O
ill	O
patients	O
before	O
and	O
during	O
carbamazepine	O
treatment	O
.	O

Both	O
RNA14	B-GENE
and	O
RNA15	B-GENE
wild	I-GENE
-	I-GENE
type	I-GENE
genes	I-GENE
,	O
when	O
cloned	O
on	O
a	O
multicopy	O
plasmid	O
,	O
are	O
able	O
to	O
suppress	O
the	O
temperature	O
-	O
sensitive	O
phenotype	O
of	O
strains	O
bearing	O
either	O
the	O
rna14	B-GENE
or	O
the	O
rna15	B-GENE
mutation	I-GENE
,	O
suggesting	O
that	O
the	O
encoded	O
proteins	O
could	O
interact	O
with	O
each	O
other	O
.	O

Treatments	O
were	O
two	O
adrenocorticotrophin	B-GENE
(	O
ACTH	B-GENE
)	O
preparations	O
given	O
intramuscularly	O
at	O
2	O
.	O
2	O
U	O
/	O
kg	O
,	O
one	O
of	O
the	O
ACTH	B-GENE
preparations	O
given	O
intramuscularly	O
at	O
1	O
U	O
/	O
kg	O
and	O
a	O
synthetic	O
polypeptide	O
with	O
ACTH	B-GENE
-	I-GENE
like	I-GENE
activity	O
(	O
tetracosactrin	O
,	O
cosyntropin	O
)	O
given	O
intravenously	O
at	O
5	O
micrograms	O
/	O
kg	O
.	O

It	O
is	O
very	O
probable	O
that	O
this	O
change	O
was	O
due	O
to	O
mechanical	O
effects	O
induced	O
by	O
injecting	O
a	O
hypertonic	O
solution	O
of	O
MT	O
-	O
141	O
at	O
a	O
rate	O
of	O
70	O
-	O
-	O
130	O
ml	O
/	O
dog	O
.	O

It	O
is	O
not	O
well	O
known	O
that	O
giant	O
cell	O
arteritis	O
can	O
cause	O
fatal	O
complications	O
due	O
to	O
rupture	O
of	O
aortic	O
aneurysms	O
or	O
cerebral	O
and	O
myocardial	O
infarctions	O
.	O

PRIP	B-GENE
contains	O
two	O
LXXLL	O
signature	O
motifs	O
.	O

Basal	O
urinary	O
17	O
-	O
hydroxycorticoid	O
(	O
17	O
-	O
OHCS	O
)	O
values	O
were	O
elevated	O
in	O
9	O
/	O
12	O
patients	O
and	O
low	O
dose	O
dexamethasone	O
suppression	O
test	O
favoured	O
Cushing	O
'	O
s	O
syndrome	O
in	O
8	O
/	O
9	O
patients	O
.	O

Like	O
the	O
human	O
gene	O
,	O
the	O
Drosophila	O
gene	O
encodes	O
at	O
least	O
three	O
isoforms	O
of	O
full	B-GENE
length	I-GENE
dystrophin	I-GENE
-	I-GENE
like	I-GENE
proteins	I-GENE
(	O
dmDLP1	B-GENE
,	O
dmDLP2	B-GENE
and	O
dmDLP3	B-GENE
,	O
)	O
,	O
regulated	O
by	O
different	O
promoters	O
located	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
,	O
and	O
a	O
smaller	O
product	O
regulated	O
by	O
an	O
internal	O
promoter	O
(	O
dmDp186	B-GENE
)	O
.	O

Accordingly	O
,	O
infection	O
of	O
IFN	B-GENE
-	O
pretreated	O
HeLa	O
S3	O
cells	O
with	O
an	O
E3L	O
-	O
deficient	O
VV	O
(	O
VVDeltaE3L	O
)	O
resulted	O
in	O
increased	O
phosphorylation	O
levels	O
of	O
both	O
PKR	B-GENE
and	O
eIF2alpha	B-GENE
.	O

The	O
goal	O
of	O
our	O
work	O
was	O
to	O
determine	O
hearing	O
thresholds	O
in	O
patients	O
with	O
hearing	O
impairment	O
due	O
to	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
(	O
HMSN	O
I	O
)	O
.	O

Influence	O
of	O
dietary	O
supplementation	O
with	O
Streptococcus	O
faecium	O
M	O
-	O
74	O
on	O
broiler	O
body	O
weight	O
,	O
feed	O
conversion	O
,	O
carcass	O
characteristics	O
,	O
and	O
intestinal	O
microbial	O
colonization	O
.	O

The	O
results	O
reveal	O
preferences	O
for	O
particular	O
initiating	O
nucleotides	O
(	O
ATP	O
>	O
or	O
=	O
GTP	O
>	O
UTP	O
>	O
>	O
CTP	O
)	O
and	O
for	O
starting	O
positions	O
downstream	O
of	O
the	O
Pribnow	O
box	O
(	O
7	O
>	O
>	O
6	O
and	O
8	O
>	O
9	O
>	O
10	O
)	O
.	O

Trimethylcolchicinic	O
acid	O
methyl	O
ether	O
d	O
-	O
tartrate	O
(	O
TMCA	O
;	O
NSC	O
-	O
36351	O
)	O
was	O
administered	O
daily	O
by	O
mouth	O
to	O
71	O
patients	O
with	O
malignant	O
lymphomas	O
.	O

Gene	O
transcripts	O
are	O
detected	O
on	O
tissues	O
such	O
as	O
bovine	O
liver	O
,	O
kidney	O
,	O
lung	O
,	O
and	O
brain	O
.	O

Assessment	O
of	O
ammonia	O
and	O
urea	O
blood	O
content	O
in	O
metabolic	O
acid	O
-	O
base	O
disorders	O
in	O
white	O
rats	O
.	O

The	O
immediate	O
and	O
remote	O
results	O
of	O
surgical	O
treatment	O
of	O
renal	O
adenocarcinomas	O
.	O

Vibrio	O
cholerae	O
iron	O
transport	O
:	O
haem	O
transport	O
genes	O
are	O
linked	O
to	O
one	O
of	O
two	O
sets	O
of	O
tonB	B-GENE
,	O
exbB	B-GENE
,	O
exbD	B-GENE
genes	I-GENE
.	O

The	O
predicted	O
amino	O
-	O
acid	O
sequence	O
includes	O
an	O
N	O
-	O
terminal	O
signal	O
sequence	O
of	O
27	O
amino	O
acids	O
,	O
a	O
27	O
amino	O
-	O
acid	O
pro	O
-	O
region	O
,	O
a	O
251	O
amino	O
-	O
acid	O
catalytic	O
domain	O
typical	O
of	O
a	O
serine	B-GENE
protease	I-GENE
with	O
trypsin	B-GENE
-	O
like	O
specificity	O
,	O
and	O
a	O
C	O
-	O
terminal	O
hydrophobic	O
extension	O
which	O
is	O
predicted	O
to	O
function	O
as	O
a	O
membrane	O
anchor	O
.	O

To	O
examine	O
the	O
biochemical	O
mechanism	O
of	O
Tax1	B-GENE
transactivation	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
transactivation	O
assay	O
in	O
which	O
wild	O
-	O
type	O
Tax1	B-GENE
is	O
able	O
to	O
specifically	O
transactivate	O
a	O
polymerase	B-GENE
II	I-GENE
promoter	O
through	O
upstream	O
Tax1	B-GENE
-	I-GENE
responsive	I-GENE
elements	I-GENE
.	O

Interestingly	O
,	O
PMA	O
-	O
,	O
PDGF	B-GENE
-	O
,	O
and	O
serum	O
-	O
induced	O
GHR	B-GENE
proteolysis	O
was	O
associated	O
with	O
substantial	O
decreases	O
in	O
GH	B-GENE
-	O
induced	O
activation	O
of	O
Janus	B-GENE
kinase	I-GENE
-	I-GENE
2	I-GENE
,	O
which	O
were	O
also	O
prevented	O
by	O
IC3	O
.	O

Thus	O
,	O
IF	O
-	O
laser	O
therapy	O
has	O
a	O
certain	O
antioxidative	O
effect	O
by	O
increasing	O
SOD	B-GENE
activity	O
in	O
RA	O
patients	O
'	O
blood	O
cells	O
and	O
reducing	O
the	O
production	O
of	O
highly	O
reactive	O
oxygen	O
and	O
nitrogen	O
forms	O
.	O

Reactive	O
mesothelial	O
cells	O
,	O
usually	O
seen	O
as	O
exfoliated	O
cells	O
,	O
were	O
consistently	O
strongly	O
positive	O
for	O
alpha	B-GENE
1	I-GENE
-	I-GENE
antichymotrypsin	I-GENE
and	O
more	O
variably	O
for	O
alpha	B-GENE
1	I-GENE
-	I-GENE
antitrypsin	I-GENE
and	O
lysozyme	B-GENE
.	O

Recombinant	O
propeptides	O
containing	O
mutations	O
of	O
one	O
of	O
the	O
three	O
tryptophan	O
residues	O
were	O
three	O
orders	O
of	O
magnitude	O
less	O
effective	O
as	O
inhibitors	O
of	O
mature	B-GENE
cathepsin	I-GENE
S	I-GENE
than	O
the	O
wild	O
-	O
type	O
propeptide	O
.	O

The	O
highest	O
incidence	O
was	O
observed	O
for	O
V	O
.	O
alginolyticus	O
(	O
92	O
-	O
100	O
%	O
)	O
,	O
followed	O
by	O
V	O
.	O
parahaemolyticus	O
(	O
67	O
-	O
92	O
%	O
)	O
,	O
V	O
.	O
fluvialis	O
(	O
34	O
-	O
67	O
%	O
)	O
,	O
V	O
.	O
vulnificus	O
(	O
8	O
-	O
17	O
%	O
)	O
,	O
V	O
.	O
furnissii	O
(	O
0	O
-	O
17	O
%	O
)	O
,	O
V	O
.	O
mimicus	O
(	O
0	O
-	O
17	O
%	O
)	O
and	O
V	O
.	O
cholerae	O
non	O
-	O
O1	O
(	O
0	O
-	O
8	O
%	O
)	O
.	O

Acute	O
morphine	O
treatment	O
did	O
not	O
increase	O
the	O
locomotor	O
activity	O
of	O
mice	O
withdrawn	O
for	O
1	O
day	O
,	O
after	O
withdrawal	O
for	O
3	O
days	O
the	O
increase	O
was	O
similar	O
to	O
that	O
in	O
controls	O
,	O
and	O
after	O
5	O
days	O
the	O
increase	O
was	O
clearly	O
larger	O
than	O
in	O
controls	O
.	O

In	O
patients	O
with	O
active	O
TB	O
,	O
cytokines	O
that	O
were	O
elevated	O
in	O
serum	O
were	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
,	O
IL	B-GENE
-	I-GENE
6	I-GENE
and	O
IL	B-GENE
-	I-GENE
10	I-GENE
.	O

Isolation	O
and	O
properties	O
of	O
Drosophila	B-GENE
melanogaster	I-GENE
ferritin	I-GENE
-	O
-	O
molecular	O
cloning	O
of	O
a	O
cDNA	O
that	O
encodes	O
one	O
subunit	O
,	O
and	O
localization	O
of	O
the	O
gene	O
on	O
the	O
third	O
chromosome	O
.	O

We	O
show	O
that	O
Fos	B-GENE
down	O
regulates	O
several	O
immediate	B-GENE
-	I-GENE
early	I-GENE
genes	I-GENE
(	O
c	B-GENE
-	I-GENE
fos	I-GENE
,	O
Egr	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
Egr	B-GENE
-	I-GENE
2	I-GENE
)	O
after	O
mitogenic	O
stimulation	O
.	O

This	O
study	O
demonstrates	O
a	O
novel	O
link	O
between	O
alterations	O
in	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
regulation	O
of	O
ornithine	B-GENE
decarboxylase	I-GENE
(	O
ODC	B-GENE
)	O
expression	O
during	O
malignant	O
conversion	O
.	O

Circulating	O
immune	O
complexes	O
were	O
determined	O
by	O
the	O
method	O
of	O
phagocytosis	O
and	O
immunofluorescence	O
.	O

The	O
human	B-GENE
IFI16	I-GENE
gene	I-GENE
is	O
a	O
member	O
of	O
an	O
interferon	B-GENE
-	O
inducible	O
family	O
of	O
mouse	O
and	O
human	O
genes	O
closely	O
linked	O
on	O
syntenic	O
regions	O
of	O
chromosome	O
1	O
.	O

In	O
agreement	O
with	O
this	O
model	O
,	O
elimination	O
of	O
the	O
ADAM13	B-GENE
cytoplasmic	I-GENE
domain	I-GENE
increased	O
developmental	O
alterations	O
attributable	O
to	O
ADAM13	B-GENE
proteolytic	O
activity	O
.	O

Diabetic	O
osteopathy	O
.	O

A	O
third	O
GEF	B-GENE
,	O
GRP3	B-GENE
(	O
KIAA0846	B-GENE
)	O
,	O
activated	O
both	O
Ras	B-GENE
and	O
Rap1	B-GENE
and	O
shared	O
significant	O
sequence	O
homology	O
with	O
the	O
calcium	O
-	O
and	O
diacylglycerol	O
-	O
activated	O
GEFs	B-GENE
,	O
GRP1	B-GENE
and	O
GRP2	B-GENE
.	O

A	O
new	O
simple	O
identification	O
of	O
rheumatoid	B-GENE
factor	I-GENE
on	O
nitrocellulose	O
was	O
developed	O
that	O
allows	O
quantitative	O
detection	O
.	O

Comparisons	O
of	O
defective	O
HTLV	O
-	O
I	O
proviruses	O
predict	O
the	O
mode	O
of	O
origin	O
and	O
coding	O
potential	O
of	O
internally	O
deleted	O
genomes	O
.	O

Reversal	O
of	O
biliary	O
sphincter	O
spasm	O
with	O
low	O
dose	O
glucagon	B-GENE
during	O
operative	O
cholangiography	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
IME1	B-GENE
gene	I-GENE
is	O
required	O
for	O
sporulation	O
and	O
the	O
expression	O
of	O
meiosis	O
specific	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
case	O
comparison	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
in	O
homosexual	O
males	O
with	O
spindle	O
-	O
endothelial	O
cell	O
abnormalities	O
and	O
with	O
recrudescent	O
melioidosis	O
.	O

Intrathecal	O
injections	O
of	O
small	O
volumes	O
of	O
the	O
alpha	B-GENE
2	I-GENE
-	I-GENE
adrenoceptor	I-GENE
agonists	O
,	O
xylazine	O
and	O
clonidine	O
,	O
into	O
the	O
cervical	O
region	O
of	O
the	O
spinal	O
cord	O
of	O
conscious	O
unrestrained	O
sheep	O
produced	O
a	O
dose	O
-	O
dependent	O
analgesia	O
of	O
the	O
forelimbs	O
as	O
measured	O
using	O
a	O
mechanical	O
pressure	O
device	O
.	O

Second	O
,	O
CGGA	O
-	O
containing	O
sequences	O
placed	O
at	O
-	O
88	O
in	O
the	O
delta	B-GENE
MTV	I-GENE
-	I-GENE
CAT	I-GENE
reporter	I-GENE
plasmid	O
conferred	O
insulin	B-GENE
responsiveness	O
to	O
the	O
mammary	B-GENE
tumor	I-GENE
virus	I-GENE
promoter	I-GENE
.	O

In	O
the	O
absence	O
of	O
c	B-GENE
-	I-GENE
fos	I-GENE
gene	I-GENE
expression	O
,	O
c	B-GENE
-	I-GENE
Fos	I-GENE
protein	I-GENE
appears	O
to	O
be	O
replaced	O
by	O
proteins	O
of	O
Fos	B-GENE
family	I-GENE
(	O
Fra	B-GENE
-	I-GENE
1	I-GENE
)	O
and	O
ATF	B-GENE
family	I-GENE
(	O
ATF	B-GENE
-	I-GENE
2	I-GENE
and	O
ATFa	B-GENE
)	O
.	O

The	O
dopamine	B-GENE
D1	I-GENE
dopamine	I-GENE
receptor	I-GENE
antagonist	O
SCH	O
23390	O
dose	O
dependently	O
(	O
7	O
.	O
5	O
-	O
30	O
micrograms	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
antagonized	O
the	O
stimulant	O
locomotor	O
effect	O
on	O
both	O
drugs	O
but	O
did	O
not	O
prevent	O
their	O
antiimmobility	O
effect	O
on	O
the	O
behavioral	O
despair	O
test	O
.	O

The	O
results	O
obtained	O
show	O
that	O
expression	O
of	O
the	O
gene	O
is	O
low	O
at	O
23	O
degrees	O
C	O
and	O
is	O
induced	O
rapidly	O
at	O
37	O
degrees	O
C	O
.	O

Characterization	O
of	O
Chlamydomonas	O
reinhardtii	O
zygote	O
-	O
specific	O
cDNAs	O
that	O
encode	O
novel	O
proteins	O
containing	O
ankyrin	B-GENE
repeats	O
and	O
WW	O
domains	O
.	O

Adenomas	O
in	O
the	O
upper	O
gastrointestinal	O
tract	O
were	O
found	O
in	O
all	O
of	O
the	O
patients	O
:	O
Vater	O
'	O
s	O
papilla	O
-	O
-	O
12	O
,	O
duodenum	O
-	O
-	O
nine	O
,	O
and	O
gastric	O
antrum	O
-	O
-	O
seven	O
.	O

Microenvironments	O
dominated	O
by	O
cyanobacteria	O
(	O
BPC	O
)	O
had	O
a	O
higher	O
pH	O
(	O
pH	O
7	O
-	O
8	O
)	O
than	O
those	O
dominated	O
by	O
lichen	O
(	O
LTL	O
)	O
(	O
pH	O
4	O
.	O
5	O
-	O
5	O
.	O
5	O
)	O
.	O

A	O
total	O
of	O
64	O
uncomplicated	O
Type	O
-	O
2	O
diabetic	O
individuals	O
of	O
higher	O
middle	O
class	O
to	O
rich	O
socio	O
-	O
economic	O
status	O
were	O
studied	O
.	O

A	O
drop	O
of	O
methylprednisolone	O
acetate	O
or	O
vehicle	O
constituent	O
was	O
placed	O
on	O
the	O
dissected	O
plantar	O
nerve	O
proximal	O
to	O
the	O
stimulating	O
electrodes	O
after	O
recording	O
control	O
responses	O
(	O
A	O
-	O
fibre	O
volley	O
in	O
the	O
sciatic	O
nerve	O
and	O
C	O
-	O
fibre	O
evoked	O
reflex	O
discharge	O
in	O
flexor	O
motoneurons	O
)	O
.	O

Basic	B-GENE
helix	I-GENE
-	I-GENE
loop	I-GENE
-	I-GENE
helix	I-GENE
proteins	I-GENE
can	O
act	O
at	O
the	O
E	O
-	O
box	O
within	O
the	O
serum	O
response	O
element	O
of	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
promoter	I-GENE
to	O
influence	O
hormone	O
-	O
induced	O
promoter	O
activation	O
in	O
Sertoli	O
cells	O
.	O

Using	O
yeast	O
two	O
-	O
hybrid	O
screening	O
,	O
we	O
isolated	O
histone	B-GENE
H3	I-GENE
as	O
an	O
interacting	O
factor	O
of	O
CIA	B-GENE
.	O

Concentrations	O
of	O
Co	O
,	O
Cu	O
,	O
Fe	O
,	O
Hg	O
,	O
Mn	O
,	O
Sb	O
,	O
Se	O
and	O
Zn	O
in	O
IAEA	O
milk	O
(	O
dry	O
)	O
standard	O
A	O
-	O
11	O
were	O
re	O
-	O
evaluated	O
with	O
the	O
help	O
of	O
instrumental	O
and	O
radiochemical	O
neutron	O
activation	O
analysis	O
(	O
NAA	O
)	O
.	O

Gallstone	O
-	O
formation	O
has	O
traditionally	O
been	O
attributed	O
to	O
supersaturation	O
of	O
bile	O
with	O
cholesterol	O
.	O

Sixteen	O
patients	O
on	O
maintenance	O
hemodialysis	O
underwent	O
dialysis	O
with	O
either	O
cuprophane	O
(	O
n	O
=	O
8	O
)	O
or	O
polymethylmethacrylate	O
(	O
PMMA	O
;	O
n	O
=	O
8	O
)	O
membranes	O
for	O
1	O
week	O
and	O
then	O
switched	O
to	O
the	O
opposite	O
membrane	O
during	O
the	O
second	O
week	O
.	O

Gene	O
expression	O
is	O
in	O
part	O
controlled	O
by	O
chromatin	O
remodeling	O
factors	O
and	O
the	O
acetylation	O
state	O
of	O
nucleosomal	B-GENE
histones	I-GENE
.	O

Each	O
patient	O
was	O
seen	O
for	O
5	O
to	O
13	O
postsurgical	O
maintenance	O
visits	O
.	O

Furthermore	O
,	O
Grap	B-GENE
is	O
associated	O
with	O
a	O
Ras	B-GENE
guanine	I-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
mSos1	B-GENE
,	O
primarily	O
through	O
its	O
N	B-GENE
-	I-GENE
terminal	I-GENE
SH3	I-GENE
domain	I-GENE
.	O

Recurrent	O
infections	O
,	O
episodic	O
lymphopenia	O
and	O
impaired	O
cellular	O
immunity	O
.	O

After	O
3	O
months	O
of	O
intervention	O
,	O
sustained	O
physical	O
training	O
was	O
associated	O
with	O
the	O
decrease	O
of	O
FVII	B-GENE
and	O
PAI	B-GENE
-	I-GENE
1	I-GENE
levels	O
.	O

Thirty	O
-	O
three	O
percent	O
had	O
elevated	O
titers	O
(	O
above	O
1	O
:	O
20	O
dilution	O
)	O
.	O

Xa4	B-GENE
is	O
a	O
dominantly	O
inherited	O
rice	O
gene	O
that	O
confers	O
resistance	O
to	O
Philippine	O
race	O
1	O
of	O
the	O
bacterial	O
blight	O
pathogen	O
Xanthomonas	O
oryzae	O
pv	O
.	O
oryzae	O
in	O
rice	O
.	O

In	O
uraemic	O
patients	O
,	O
similar	O
maximum	O
serum	O
concentrations	O
were	O
found	O
after	O
a	O
single	O
7	O
.	O
5	O
mg	O
/	O
kg	O
iv	O
dose	O
.	O

The	O
effect	O
of	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
and	O
disulfiram	O
(	O
DSF	O
)	O
on	O
the	O
urotoxicity	O
induced	O
by	O
cyclophosphamide	O
(	O
CPA	O
)	O
was	O
examined	O
in	O
mice	O
.	O

All	O
the	O
previously	O
mapped	O
structural	O
protein	O
-	O
encoding	O
genes	O
of	O
phage	O
LL	O
-	O
H	O
were	O
included	O
in	O
the	O
sequence	O
.	O

When	O
a	O
longer	O
-	O
714	O
to	O
+	O
78	O
fragment	O
of	O
the	O
PBGD	B-GENE
promoter	I-GENE
is	O
used	O
,	O
the	O
-	O
70	O
GATA	O
mutant	O
still	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
is	O
cis	O
-	O
activated	O
by	O
the	O
5	B-GENE
'	I-GENE
HS	I-GENE
-	I-GENE
2	I-GENE
enhancer	I-GENE
,	O
while	O
the	O
-	O
100	O
CCACC	O
mutant	O
is	O
completely	O
inactive	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
the	O
5	B-GENE
'	I-GENE
HS	I-GENE
-	I-GENE
2	I-GENE
enhancer	I-GENE
.	O

Surprisingly	O
,	O
in	O
adult	O
animals	O
,	O
the	O
suprabasal	O
expression	O
of	O
dnRXR	B-GENE
alpha	I-GENE
significantly	O
reduced	O
the	O
ability	O
of	O
topically	O
applied	O
tRA	O
to	O
stimulate	O
proliferation	O
of	O
undifferentiated	O
keratinocytes	O
in	O
the	O
basal	O
layer	O
of	O
epidermis	O
.	O

In	O
many	O
other	O
contractile	O
protein	O
gene	O
families	O
,	O
genes	O
encoding	O
cardiac	O
isoforms	O
are	O
expressed	O
early	O
in	O
skeletal	O
muscle	O
development	O
and	O
are	O
later	O
repressed	O
.	O

1995	O
.	O

For	O
il8ra	B-GENE
,	O
it	O
is	O
formed	O
from	O
two	O
exons	O
,	O
whereas	O
for	O
il8rb	B-GENE
,	O
seven	O
distinct	O
neutrophil	O
mRNAs	O
are	O
formed	O
by	O
alternative	O
splicing	O
of	O
11	O
exons	O
.	O

Endocarditis	O
remains	O
a	O
life	O
-	O
threatening	O
disease	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

The	O
gene	O
encoding	O
the	O
cellulase	B-GENE
(	O
Avicelase	B-GENE
)	O
Cel1	B-GENE
from	O
Streptomyces	O
reticuli	O
and	O
analysis	O
of	O
protein	O
domains	O
.	O

From	O
this	O
comparison	O
of	O
aa	O
sequences	O
,	O
the	O
ATPK7	B-GENE
protein	I-GENE
is	O
considered	O
to	O
be	O
a	O
member	O
of	O
a	O
novel	O
subfamily	O
of	O
Ser	B-GENE
/	I-GENE
Thr	I-GENE
PKs	I-GENE
in	O
plants	O
.	O

Of	O
these	O
,	O
23	O
(	O
13	O
.	O
6	O
%	O
)	O
were	O
due	O
to	O
GIB	O
(	O
Upper	O
GIB	O
=	O
19	O
,	O
Lower	O
GIB	O
=	O
4	O
)	O
.	O

The	O
E	O
.	O
multilocularis	O
/	O
Mongolian	O
gerbil	O
system	O
can	O
replace	O
the	O
natural	O
canid	O
hosts	O
as	O
a	O
new	O
way	O
to	O
obtain	O
infective	O
eggs	O
and	O
to	O
analyze	O
host	O
-	O
parasite	O
interactions	O
.	O

E1	B-GENE
recognition	O
sequences	O
in	O
the	O
bovine	O
papillomavirus	O
type	O
1	O
origin	O
of	O
DNA	O
replication	O
:	O
interaction	O
between	O
half	O
sites	O
of	O
the	O
inverted	O
repeats	O
.	O

We	O
found	O
that	O
secretion	O
of	O
chitinolytic	O
enzymes	O
by	O
cultured	O
L	O
.	O
major	O
parasites	O
is	O
inhibited	O
by	O
blood	O
or	O
hemoglobin	B-GENE
,	O
and	O
hence	O
these	O
enzymes	O
are	O
apparently	O
absent	O
from	O
the	O
blood	O
-	O
fed	O
infected	O
flies	O
,	O
where	O
the	O
cardiac	O
valve	O
appears	O
undamaged	O
.	O

Patients	O
in	O
the	O
mucinous	O
cyst	O
group	O
had	O
significantly	O
lower	O
CA	B-GENE
125	I-GENE
cystic	O
fluid	O
levels	O
compared	O
with	O
women	O
with	O
endometriomas	O
and	O
dermoids	O
(	O
P	O
&	O
lt	O
;	O
0	O
.	O
05	O
)	O
.	O

SATB1	B-GENE
interacted	O
with	O
CDP	B-GENE
through	O
its	O
DNA	O
-	O
binding	O
domain	O
,	O
as	O
demonstrated	O
by	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
(	O
GST	B-GENE
)	O
pull	O
-	O
down	O
assays	O
.	O

Plasma	B-GENE
prolactin	I-GENE
concentrations	O
in	O
pinealectomized	O
ewes	O
receiving	O
melatonin	O
treatment	O
and	O
in	O
pineal	O
intact	O
ewes	O
maintained	O
under	O
a	O
non	O
-	O
24	O
-	O
hour	O
photoperiod	O
.	O

It	O
is	O
targeted	O
to	O
peroxisomes	O
when	O
expressed	O
in	O
mammalian	O
cells	O
and	O
yeast	O
.	O

The	O
transcriptional	O
start	O
site	O
,	O
identified	O
by	O
primer	O
extension	O
and	O
S1	B-GENE
nuclease	I-GENE
assay	O
,	O
is	O
34	O
nt	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
.	O

Nonlinearities	O
in	O
cochlear	O
hydrodynamics	O
.	O

Electronic	O
structure	O
and	O
optical	O
properties	O
of	O
the	O
B12O2	O
crystal	O
.	O

Spongiosa	O
regeneration	O
in	O
the	O
millipore	O
chamber	O

The	O
predicted	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
the	O
transcript	O
are	O
in	O
very	O
good	O
agreement	O
with	O
the	O
previously	O
determined	O
size	O
of	O
the	O
LEU3	B-GENE
message	O
.	O

This	O
cDNA	O
corresponded	O
to	O
FGF	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
FGF	B-GENE
-	I-GENE
BP	I-GENE
)	O
,	O
a	O
secreted	O
protein	O
previously	O
shown	O
to	O
bind	O
acidic	O
and	O
basic	B-GENE
FGF	I-GENE
and	O
to	O
modulate	O
their	O
activities	O
.	O

Analysis	O
of	O
replicative	O
intermediates	O
shows	O
that	O
plasmid	O
YRp7	O
,	O
which	O
contains	O
the	O
chromosomal	O
replicator	O
ARS1	O
,	O
initiates	O
bidirectional	O
replication	O
in	O
a	O
100	O
bp	O
region	O
within	O
the	O
sequence	O
required	O
for	O
autonomous	O
replication	O
in	O
vivo	O
.	O

Such	O
results	O
suggest	O
that	O
there	O
are	O
no	O
differences	O
in	O
the	O
BMR	O
of	O
age	O
-	O
and	O
weight	O
-	O
matched	O
Asian	O
Indian	O
males	O
,	O
other	O
tropical	O
populations	O
and	O
Americans	O
.	O

Rewarding	O
properties	O
of	O
methylphenidate	O
:	O
sensitization	O
by	O
prior	O
exposure	O
to	O
the	O
drug	O
and	O
effects	O
of	O
dopamine	B-GENE
D1	I-GENE
-	I-GENE
and	I-GENE
D2	I-GENE
-	I-GENE
receptor	I-GENE
antagonists	O
.	O

Similar	O
to	O
what	O
was	O
observed	O
for	O
P	O
.	O
putida	O
,	O
a	O
psrA	B-GENE
null	O
mutant	O
of	O
P	O
.	O
aeruginosa	O
also	O
showed	O
a	O
90	O
%	O
reduction	O
in	O
rpoS	B-GENE
promoter	I-GENE
activity	O
;	O
both	O
mutants	O
could	O
be	O
complemented	O
for	O
rpoS	B-GENE
promoter	I-GENE
activity	O
when	O
the	O
psrA	B-GENE
gene	I-GENE
was	O
provided	O
in	O
trans	O
.	O

psrA	B-GENE
mutants	I-GENE
of	O
both	O
Pseudomonas	O
species	O
lost	O
the	O
ability	O
to	O
induce	O
rpoS	B-GENE
expression	O
at	O
stationary	O
phase	O
,	O
but	O
they	O
retained	O
the	O
ability	O
to	O
produce	O
quorum	O
-	O
sensing	O
autoinducer	O
molecules	O
.	O

The	O
role	O
of	O
the	O
putative	O
C2	B-GENE
domain	O
of	O
Nedd4	B-GENE
has	O
not	O
been	O
elucidated	O
.	O

ZF87	B-GENE
specifically	O
binds	O
the	O
ME1a1	O
element	O
with	O
higher	O
affinity	O
than	O
the	O
ME1a2	O
element	O
.	O

We	O
found	O
a	O
significant	O
increase	O
of	O
thromboxane	O
as	O
evidenced	O
by	O
the	O
major	O
urinary	O
metabolite	O
2	O
,	O
3	O
-	O
dinorthromboxane	O
B2	O
in	O
the	O
oestrogen	O
group	O
as	O
compared	O
to	O
the	O
orchidectomy	O
group	O
.	O

Multivariable	O
logistic	O
regression	O
showed	O
that	O
mean	O
blood	O
glucose	O
level	O
for	O
the	O
first	O
2	O
days	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
obesity	O
(	O
p	O
<	O
0	O
.	O
002	O
)	O
,	O
and	O
use	O
of	O
the	O
internal	O
mammary	O
artery	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
were	O
all	O
independent	O
predictors	O
of	O
deep	O
wound	O
infection	O
.	O

However	O
the	O
precise	O
function	O
of	O
DNA	B-GENE
-	I-GENE
PK	I-GENE
in	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
is	O
not	O
known	O
.	O

This	O
new	O
receptor	O
,	O
TOR	B-GENE
(	O
thymus	B-GENE
orphan	I-GENE
receptor	I-GENE
)	O
,	O
is	O
most	O
closely	O
related	O
in	O
both	O
its	O
DNA	O
-	O
binding	O
domain	O
and	O
ligand	O
-	O
binding	O
domain	O
,	O
90	O
%	O
and	O
53	O
%	O
,	O
respectively	O
,	O
to	O
ROR	B-GENE
alpha	I-GENE
/	O
RZR	B-GENE
alpha	I-GENE
and	O
clusters	O
with	O
these	O
two	O
receptors	O
and	O
RZR	B-GENE
beta	I-GENE
in	O
a	O
phylogenetic	O
tree	O
,	O
when	O
both	O
the	O
DNA	O
-	O
binding	O
domain	O
and	O
the	O
ligand	O
-	O
binding	O
domain	O
sequences	O
of	O
nuclear	O
receptors	O
are	O
compared	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
examined	O
whether	O
PTP1B	B-GENE
effects	O
transformation	O
induced	O
by	O
p210	B-GENE
bcr	B-GENE
-	O
abl	B-GENE
.	O

S1	B-GENE
nuclease	I-GENE
analysis	O
of	O
the	O
RNA	O
from	O
a	O
number	O
of	O
QT6	O
-	O
LD	O
clones	O
gave	O
similar	O
results	O
,	O
indicating	O
that	O
the	O
LD	O
population	O
was	O
composed	O
of	O
viruses	O
with	O
similar	O
but	O
not	O
identical	O
deletion	O
endpoints	O
.	O

Association	O
of	O
Smads	B-GENE
with	O
lymphoid	B-GENE
enhancer	I-GENE
binding	I-GENE
factor	I-GENE
1	I-GENE
/	O
T	B-GENE
cell	I-GENE
-	I-GENE
specific	I-GENE
factor	I-GENE
mediates	O
cooperative	O
signaling	O
by	O
the	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
and	O
wnt	B-GENE
pathways	O
.	O

The	O
three	O
OAS	B-GENE
genes	I-GENE
are	O
flanked	O
by	O
markers	B-GENE
WI	I-GENE
-	I-GENE
10614	I-GENE
(	O
cen	B-GENE
)	O
and	O
D12S2293	B-GENE
(	O
tel	B-GENE
)	O
and	O
are	O
contained	O
within	O
three	O
sets	O
of	O
overlapping	O
cosmid	O
clones	O
.	O

22	O
.	O
6	O
%	O
of	O
patients	O
were	O
found	O
to	O
be	O
positive	O
at	O
histology	O
in	O
the	O
corpus	O
mucosa	O
;	O
all	O
but	O
one	O
of	O
these	O
patients	O
had	O
elevated	O
circulating	O
IgG	B-GENE
to	O
H	O
.	O
pylori	O
(	O
Group	O
C	O
)	O
.	O

Rottlerin	O
also	O
inhibited	O
the	O
activation	O
of	O
MAP	B-GENE
kinase	I-GENE
kinase	I-GENE
(	O
MEK	B-GENE
)	O
in	O
response	O
to	O
activated	O
Raf	B-GENE
,	O
but	O
had	O
no	O
effect	O
upon	O
c	B-GENE
-	I-GENE
Raf	I-GENE
activity	O
or	O
ERK	B-GENE
activation	O
by	O
activated	O
MEK	B-GENE
.	O

Quasidiatomic	O
study	O
of	O
Ly	O
-	O
alpha	O
-	O
producing	O
H2	O
+	O
-	O
Ne	O
collisions	O
at	O
keV	O
energies	O
.	O

The	O
NH	O
(	O
2	O
)	O
-	O
terminus	O
of	O
all	O
three	O
proteins	O
contains	O
a	O
POZ	O
domain	O
,	O
a	O
conserved	O
120	O
amino	O
acid	O
motif	O
involved	O
in	O
transcriptional	O
repression	O
and	O
protein	O
dimerization	O
.	O

The	O
isolation	O
of	O
crt5	B-GENE
-	I-GENE
262	I-GENE
,	O
an	O
additional	O
cdc	B-GENE
allele	I-GENE
of	O
POL1	B-GENE
/	O
CDC17	B-GENE
,	O
suggests	O
for	O
the	O
first	O
time	O
that	O
directly	O
blocking	O
DNA	O
replication	O
can	O
provide	O
a	O
signal	O
to	O
induce	O
the	O
DNA	O
damage	O
response	O
.	O

crt2	B-GENE
mutants	I-GENE
show	O
a	O
defect	O
in	O
basal	O
level	O
expression	O
of	O
RNR1	B-GENE
-	O
lacZ	B-GENE
reporter	O
constructs	O
.	O

Greer	O
,	O
and	O
L	O
.	O
A	O
.	O

We	O
prospectively	O
studied	O
serum	B-GENE
prolactin	I-GENE
(	O
PRL	B-GENE
)	O
elevation	O
after	O
different	O
types	O
of	O
documented	O
seizures	O
in	O
17	O
patients	O
.	O

However	O
,	O
both	O
peptides	O
1	O
-	O
49	O
and	O
63	O
-	O
87	O
bound	O
to	O
PDE	B-GENE
alpha	I-GENE
/	I-GENE
beta	I-GENE
in	O
a	O
solid	O
-	O
phase	O
binding	O
assay	O
.	O

Values	O
of	O
K1	O
and	O
Vd	O
were	O
significantly	O
increased	O
in	O
the	O
tumour	O
tissue	O
.	O

The	O
mutation	O
also	O
preferentially	O
limits	O
(	O
compared	O
with	O
total	O
protein	O
synthesis	O
)	O
translation	O
of	O
an	O
induced	O
gene	O
that	O
depends	O
on	O
five	O
AGA	O
codons	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
lambda	B-GENE
cI	I-GENE
repressor	I-GENE
gene	I-GENE
.	O

Five	O
RNA	O
transcripts	O
of	O
about	O
1	O
.	O
2	O
to	O
1	O
.	O
7	O
kilobases	O
were	O
mapped	O
to	O
a	O
part	O
of	O
the	O
genome	O
of	O
insect	O
iridescent	O
virus	O
type	O
6	O
(	O
Chilo	O
iridescent	O
virus	O
;	O
CIV	O
)	O
between	O
genome	O
coordinates	O
0	O
.	O
832	O
and	O
0	O
.	O
856	O
within	O
the	O
EcoRI	B-GENE
DNA	I-GENE
fragment	I-GENE
F	I-GENE
.	O

Other	O
similar	O
patients	O
must	O
be	O
found	O
before	O
it	O
is	O
established	O
that	O
the	O
colloid	O
cyst	O
is	O
part	O
of	O
the	O
nevoid	O
basal	O
cell	O
carcinoma	O
syndrome	O
.	O

Portions	O
of	O
the	O
3	O
'	O
-	O
coding	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
were	O
found	O
to	O
be	O
missing	O
from	O
the	O
7	B-GENE
.	I-GENE
2	I-GENE
-	I-GENE
and	I-GENE
4	I-GENE
.	I-GENE
8	I-GENE
-	I-GENE
kb	I-GENE
topo	I-GENE
II	I-GENE
alpha	I-GENE
mRNAs	I-GENE
by	O
Northern	O
blot	O
analysis	O
.	O

In	O
addition	O
,	O
a	O
double	O
mutant	O
(	O
E482A	O
,	O
D489A	O
)	O
which	O
removed	O
negative	O
charges	O
along	O
one	O
side	O
of	O
the	O
helix	O
had	O
negligible	O
effects	O
on	O
fusion	O
activity	O
.	O

A	O
GTP	O
/	O
GDP	O
exchange	O
assay	O
was	O
used	O
to	O
assess	O
the	O
potential	O
role	O
of	O
Ras	B-GENE
in	O
the	O
pathway	O
leading	O
to	O
ERK	B-GENE
phosphorylation	O
;	O
DADLE	O
failed	O
to	O
stimulate	O
GTP	O
/	O
GDP	O
exchange	O
in	O
comparison	O
to	O
PMA	O
.	O

Phenotypic	O
analysis	O
demonstrates	O
that	O
trio	B-GENE
and	O
Abl	B-GENE
cooperate	O
in	O
regulating	O
axon	O
outgrowth	O
in	O
the	O
embryonic	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Recombinant	B-GENE
caspases	I-GENE
are	O
typically	O
produced	O
in	O
Escherichia	O
coli	O
expression	O
systems	O
with	O
the	O
attendant	O
problems	O
of	O
solubilization	O
,	O
re	O
-	O
folding	O
and	O
activation	O
of	O
the	O
protease	O
.	O

The	O
gene	O
encoding	O
rat	O
peptidylglycine	B-GENE
alpha	I-GENE
-	I-GENE
amidating	I-GENE
monooxygenase	I-GENE
(	O
PAM	B-GENE
)	O
contains	O
26	O
protein	O
-	O
coding	O
exons	O
.	O

This	O
bound	O
[	O
3H	O
]	O
iloprost	O
with	O
high	O
affinity	O
and	O
stimulated	O
cAMP	O
production	O
when	O
exposed	O
to	O
agonist	O
.	O

Structure	O
of	O
the	O
connective	O
stroma	O
of	O
the	O
epididymis	O
in	O
the	O
zebu	O

Free	O
protein	B-GENE
S	I-GENE
deficiency	O
in	O
acute	O
ischemic	O
stroke	O
.	O

In	O
a	O
series	O
of	O
papers	O
,	O
the	O
staging	O
system	O
for	O
melanoma	O
was	O
critically	O
analyzed	O
,	O
and	O
many	O
shortcomings	O
were	O
identified	O
.	O

Reproduction	O
and	O
maternal	O
response	O
of	O
the	O
rat	O
when	O
thiamine	O
intake	O
is	O
limited	O
.	O

Total	O
meso	O
-	O
pore	O
volume	O
and	O
surface	O
area	O
ranged	O
from	O
0	O
.	O
004	O
-	O
0	O
.	O
08	O
cm3	O
g	O
(	O
-	O
1	O
)	O
and	O
from	O
0	O
.	O
33	O
-	O
6	O
.	O
9	O
m2	O
g	O
(	O
-	O
1	O
)	O
respectively	O
,	O
accounting	O
for	O
up	O
33	O
%	O
of	O
the	O
BET	O
surface	O
area	O
.	O

The	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
precursor	O
p100	B-GENE
(	O
lyt	B-GENE
-	I-GENE
10	I-GENE
,	O
p97	B-GENE
,	O
p98	B-GENE
)	O
generates	O
after	O
proteolytic	O
processing	O
a	O
52	O
kDa	O
subunit	O
,	O
which	O
can	O
bind	O
to	O
kappa	B-GENE
B	I-GENE
-	I-GENE
motifs	I-GENE
.	O

CONCLUSION	O
:	O
The	O
biodistribution	O
of	O
111In	O
IgG	B-GENE
is	O
similar	O
to	O
that	O
of	O
99mTc	O
-	O
HMPAO	O
-	O
labeled	O
leukocytes	O
.	O

Based	O
on	O
29	O
determinations	O
of	O
the	O
glucose	O
from	O
sinigrin	O
,	O
analyzed	O
under	O
different	O
conditions	O
,	O
accuracy	O
of	O
the	O
total	O
glucosinolate	O
determination	O
was	O
94	O
.	O
8	O
+	O
/	O
-	O
7	O
.	O
3	O
%	O
.	O

Receptor	B-GENE
-	I-GENE
type	I-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinases	I-GENE
(	O
RSKs	B-GENE
)	O
have	O
been	O
organized	O
into	O
two	O
distinct	O
classes	O
known	O
as	O
types	O
I	O
and	O
II	O
on	O
the	O
basis	O
of	O
sequence	O
similarity	O
.	O

In	O
a	O
previous	O
study	O
of	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta1	I-GENE
-	O
mediated	O
inhibition	O
of	O
the	O
cyclin	B-GENE
A	I-GENE
promoter	I-GENE
,	O
we	O
mapped	O
the	O
inhibitory	O
effect	O
to	O
the	O
ATF	B-GENE
site	I-GENE
;	O
in	O
the	O
present	O
study	O
of	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
treatment	O
,	O
functional	O
analysis	O
by	O
transient	O
transfection	O
showed	O
that	O
inhibition	O
of	O
the	O
cyclin	B-GENE
A	I-GENE
promoter	I-GENE
persisted	O
despite	O
mutation	O
of	O
the	O
ATF	B-GENE
,	O
NF	B-GENE
-	I-GENE
Y	I-GENE
,	O
or	O
CDE	O
elements	O
.	O

The	O
RsmA	B-GENE
-	I-GENE
mutant	I-GENE
,	O
like	O
its	O
parent	O
,	O
produces	O
N	O
-	O
(	O
3	O
-	O
oxohexanoyl	O
)	O
-	O
L	O
-	O
homoserine	O
lactone	O
(	O
HSL	O
)	O
,	O
a	O
starvation	O
/	O
cell	O
density	O
-	O
sensing	O
signal	O
required	O
for	O
extracellular	O
enzyme	O
production	O
.	O

The	O
inactive	O
X	O
allele	O
,	O
however	O
,	O
is	O
hypermethylated	O
in	O
leukocytes	O
,	O
presumably	O
reflecting	O
early	O
X	O
inactivation	O
events	O
that	O
become	O
important	O
for	O
gene	O
dosage	O
in	O
expressing	O
lineages	O
.	O

Intensive	O
therapy	O
of	O
viral	O
hepatitis	O

Also	O
,	O
the	O
RVW	O
hypertrophy	O
,	O
the	O
IVS	O
hypertrophy	O
,	O
and	O
the	O
RV	O
high	O
pressure	O
load	O
to	O
the	O
LV	O
through	O
the	O
IVS	O
may	O
be	O
related	O
to	O
the	O
small	O
LV	O
,	O
high	O
EF	O
,	O
and	O
abnormal	O
two	O
chamber	O
inflow	O
in	O
the	O
PS	O
group	O
before	O
BV	O
.	O

Analysis	O
of	O
the	O
DNA	O
-	O
binding	O
and	O
transcriptional	O
activation	O
functions	O
of	O
human	B-GENE
Fli	I-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
.	O

This	O
pattern	O
of	O
expression	O
and	O
differential	O
processing	O
suggests	O
a	O
role	O
for	O
inrpk1	B-GENE
in	O
some	O
aspect	O
of	O
SD	O
photoperiodic	O
-	O
induced	O
flowering	O
in	O
morning	O
glory	O
.	O

Progressive	O
immunodeficiency	O
in	O
a	O
patient	O
with	O
IgA	B-GENE
deficiency	O

RMR	O
was	O
positively	O
correlated	O
with	O
TEF	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
net	O
TEF	O
(	O
r	O
=	O
0	O
.	O
648	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
in	O
the	O
luteal	O
but	O
not	O
the	O
follicular	O
phase	O
.	O

ESR	O
spectra	O
of	O
Er3	O
+	O
in	O
SmB6	O
single	O
crystals	O
:	O
Dynamic	O
Jahn	O
-	O
Teller	O
effect	O
in	O
a	O
mixed	O
-	O
valence	O
compound	O
.	O

The	O
N	O
-	O
terminal	O
exon1	O
had	O
no	O
homology	O
at	O
the	O
amino	O
acid	O
level	O
with	O
NGFI	B-GENE
-	I-GENE
B	I-GENE
,	O
the	O
mammalian	O
homologue	O
.	O

This	O
paper	O
describes	O
a	O
longitudinal	O
study	O
in	O
which	O
clinical	O
parameters	O
and	O
aspartate	B-GENE
aminotransferase	I-GENE
(	O
AST	B-GENE
)	O
in	O
gingival	O
crevicular	O
fluid	O
(	O
GCF	O
)	O
were	O
monitored	O
bimonthly	O
over	O
a	O
6	O
-	O
12	O
months	O
period	O
in	O
970	O
sites	O
from	O
7	O
treated	O
periodontitis	O
patients	O
.	O

We	O
conclude	O
from	O
these	O
observations	O
that	O
the	O
cTnC	B-GENE
3	I-GENE
'	I-GENE
Ile	I-GENE
element	I-GENE
is	O
a	O
composite	O
enhancer	O
that	O
functions	O
through	O
the	O
combined	O
interactions	O
of	O
at	O
least	O
five	O
regulatory	O
elements	O
and	O
their	O
cognate	O
binding	O
factors	O
:	O
three	O
or	O
four	O
E	O
-	O
boxes	O
,	O
a	O
MEF	B-GENE
-	I-GENE
2	I-GENE
site	I-GENE
,	O
and	O
a	O
MEF	B-GENE
-	I-GENE
3	I-GENE
site	I-GENE
.	O

The	O
analysis	O
consisted	O
of	O
1	O
)	O
fitting	O
first	O
-	O
and	O
second	O
-	O
order	O
autoregressive	O
models	O
(	O
AR1	O
and	O
AR2	O
)	O
and	O
2	O
)	O
obtaining	O
the	O
power	O
spectra	O
of	O
the	O
data	O
by	O
fast	O
-	O
Fourier	O
transform	O
.	O

We	O
identified	O
Tyr	O
(	O
112	O
)	O
and	O
Leu	O
(	O
175	O
)	O
within	O
the	O
RNA	O
-	O
binding	O
domain	O
of	O
the	O
U1	B-GENE
70K	I-GENE
protein	I-GENE
to	O
be	O
cross	O
-	O
linked	O
to	O
G	O
(	O
28	O
)	O
and	O
U	O
(	O
30	O
)	O
in	O
stem	O
-	O
loop	O
I	O
,	O
respectively	O
.	O

Kudzu	O
extract	O
shows	O
potential	O
for	O
moderating	O
alcohol	O
abuse	O
.	O

Furthermore	O
,	O
the	O
data	O
suggest	O
an	O
immunological	O
non	O
-	O
responsiveness	O
to	O
enterotoxin	B-GENE
A	I-GENE
in	O
a	O
considerable	O
portion	O
of	O
the	O
patients	O
.	O

BCV	B-GENE
mRNAs	I-GENE
5	I-GENE
and	I-GENE
5	I-GENE
-	I-GENE
1	I-GENE
appear	O
to	O
be	O
used	O
for	O
the	O
synthesis	O
of	O
the	O
12	O
.	O
7	O
-	O
and	O
9	O
.	O
5	O
-	O
kDa	O
proteins	O
,	O
respectively	O
,	O
which	O
demonstrates	O
a	O
pattern	O
of	O
expression	O
strikingly	O
different	O
from	O
that	O
utilized	O
by	O
MHV	O
.	O

Disaster	O
medicine	O

The	O
longest	O
S1	O
-	O
S2	O
interval	O
at	O
which	O
S2	O
failed	O
to	O
capture	O
(	O
effective	O
refractory	O
period	O
)	O
was	O
longer	O
by	O
5	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
2	O
msec	O
at	O
twice	O
threshold	O
(	O
0	O
.	O
05	O
less	O
than	O
p	O
less	O
than	O
0	O
.	O
10	O
)	O
and	O
5	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
5	O
msec	O
at	O
5	O
times	O
threshold	O
stimulation	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
when	O
the	O
basic	O
drive	O
and	O
extrastimuli	O
were	O
delivered	O
to	O
separate	O
sites	O
.	O

The	O
use	O
of	O
specific	O
somatic	O
cell	O
hybrids	O
have	O
allowed	O
us	O
to	O
locate	O
the	O
YAC	O
contig	O
telomeric	O
to	O
the	O
D3F15S2	B-GENE
locus	I-GENE
,	O
in	O
a	O
region	O
which	O
is	O
frequently	O
deleted	O
in	O
lung	O
carcinomas	O
.	O

Experiments	O
were	O
performed	O
without	O
polarization	O
or	O
with	O
cathodic	O
and	O
anodic	O
polarization	O
of	O
the	O
adsorbent	O
.	O

Chronic	O
active	O
hepatitis	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O

This	O
regulation	O
is	O
mediated	O
by	O
several	O
kinases	O
that	O
phosphorylate	O
specific	O
residues	O
in	O
the	O
different	O
functional	O
domains	O
of	O
the	O
p53	B-GENE
molecule	I-GENE
.	O

These	O
data	O
show	O
that	O
the	O
processing	O
of	O
specific	O
target	O
transcripts	O
,	O
such	O
as	O
the	O
P	B-GENE
-	I-GENE
element	I-GENE
mRNA	I-GENE
,	O
is	O
regulated	O
by	O
a	O
functional	O
PSI	B-GENE
-	O
U1	B-GENE
snRNP	O
interaction	O
in	O
Drosophila	O
.	O

Effect	O
of	O
dimethyl	O
sulfoxide	O
on	O
cooling	O
rates	O
of	O
unrestrained	O
rats	O
.	O

In	O
four	O
calves	O
given	O
Haemonchus	O
contortus	O
larvae	O
,	O
the	O
serum	B-GENE
pepsinogen	I-GENE
concentration	O
rose	O
quickly	O
to	O
reach	O
a	O
mean	O
of	O
3	O
.	O
5	O
iu	O
tyrosine	O
on	O
day	O
14	O
after	O
infection	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HSV	O
-	O
1	O
infection	O
inhibits	O
host	O
cell	O
splicing	O
through	O
the	O
action	O
of	O
ICP27	B-GENE
.	O

The	O
T	O
(	O
CCO2	O
)	O
was	O
related	O
to	O
the	O
PCO2	O
by	O
a	O
Pearson	O
product	O
coefficient	O
of	O
0	O
.	O
79	O
(	O
p	O
<	O
.	O
0005	O
)	O
,	O
with	O
a	O
mean	O
difference	O
of	O
1	O
.	O
94	O
(	O
T	O
(	O
CCO2	O
)	O
>	O
P	O
(	O
CO2	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
of	O
-	O
0	O
.	O
12	O
to	O
4	O
.	O
07	O
.	O

Transformation	O
of	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
with	O
the	O
Gag	B-GENE
-	O
Crk	B-GENE
fusion	O
protein	O
results	O
in	O
the	O
elevation	O
of	O
tyrosine	O
phosphorylation	O
on	O
specific	O
cellular	O
proteins	O
with	O
molecular	O
weights	O
of	O
130	O
,	O
000	O
,	O
110	O
,	O
000	O
,	O
and	O
70	O
,	O
000	O
(	O
p130	B-GENE
,	O
p110	B-GENE
,	O
and	O
p70	B-GENE
,	O
respectively	O
)	O
,	O
an	O
event	O
which	O
has	O
been	O
correlated	O
with	O
cell	O
transformation	O
.	O

Urease	B-GENE
activity	O
,	O
judged	O
as	O
the	O
amount	O
of	O
ammonia	O
production	O
from	O
urea	O
,	O
could	O
be	O
measured	O
at	O
25	O
ng	O
per	O
tube	O
(	O
S	O
/	O
N	O
=	O
1	O
.	O
5	O
)	O
with	O
Jack	B-GENE
bean	I-GENE
meal	I-GENE
urease	I-GENE
.	O

Here	O
,	O
we	O
provide	O
direct	O
evidence	O
that	O
the	O
meiotic	O
defect	O
caused	O
by	O
either	O
unregulated	O
cAPK	B-GENE
activity	O
or	O
unregulated	O
ran1	B-GENE
+	I-GENE
kinase	I-GENE
activity	O
is	O
due	O
to	O
inability	O
to	O
induce	O
transcription	O
of	O
the	O
mei2	B-GENE
+	I-GENE
gene	I-GENE
,	O
which	O
is	O
required	O
for	O
meiotic	O
initiation	O
.	O

Optical	O
rotation	O
of	O
the	O
second	O
harmonic	O
radiation	O
from	O
retinal	O
in	O
bacteriorhodopsin	B-GENE
monomers	I-GENE
in	O
Langmuir	O
-	O
Blodgett	O
film	O
:	O
evidence	O
for	O
nonplanar	O
retinal	O
structure	O
.	O

Ultrasonography	O
is	O
a	O
diagnostic	O
alternative	O
which	O
may	O
replace	O
arthrography	O
.	O

In	O
K562	O
cells	O
,	O
using	O
the	O
bicistronic	O
vector	O
,	O
selection	O
with	O
colchicine	O
led	O
to	O
at	O
least	O
20	O
-	O
fold	O
higher	O
expression	O
of	O
the	O
MDR1	B-GENE
gene	I-GENE
product	I-GENE
than	O
did	O
selection	O
with	O
G418	O
,	O
suggesting	O
that	O
the	O
stringent	O
MDR1	B-GENE
selection	O
system	O
is	O
very	O
efficient	O
for	O
obtaining	O
overexpression	O
of	O
foreign	O
genes	O
.	O

In	O
this	O
report	O
,	O
several	O
health	O
behaviors	O
were	O
investigated	O
in	O
relation	O
to	O
maintaining	O
mobility	O
during	O
4	O
years	O
of	O
follow	O
-	O
up	O
among	O
6	O
,	O
981	O
men	O
and	O
women	O
aged	O
65	O
years	O
and	O
older	O
with	O
intact	O
mobility	O
at	O
baseline	O
between	O
1981	O
and	O
1983	O
who	O
lived	O
in	O
one	O
of	O
three	O
communities	O
:	O
East	O
Boston	O
,	O
Massachusetts	O
;	O
Iowa	O
and	O
Washington	O
counties	O
,	O
Iowa	O
;	O
and	O
New	O
Haven	O
,	O
Connecticut	O
.	O

Our	O
analysis	O
indicates	O
that	O
a	O
gene	O
correction	O
mechanism	O
has	O
been	O
operating	O
on	O
the	O
Hbbs	B-GENE
chromosome	O
to	O
keep	O
beta	B-GENE
s	I-GENE
and	O
beta	B-GENE
t	I-GENE
evolving	O
in	O
concert	O
,	O
whereas	O
on	O
the	O
Hbbd	B-GENE
chromosome	O
,	O
beta	B-GENE
dmin	I-GENE
has	O
diverged	O
considerably	O
from	O
beta	B-GENE
dmaj	I-GENE
.	O

Structure	O
and	O
regulation	O
of	O
KGD2	B-GENE
,	O
the	O
structural	O
gene	O
for	O
yeast	B-GENE
dihydrolipoyl	I-GENE
transsuccinylase	I-GENE
.	O

In	O
dehydrated	O
animals	O
at	O
Ta	O
38	O
degrees	O
C	O
,	O
Tb	O
and	O
EWL	O
were	O
both	O
significantly	O
altered	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
from	O
the	O
normally	O
hydrated	O
state	O
and	O
were	O
measured	O
at	O
39	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
2	O
degree	O
C	O
and	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
09	O
W	O
.	O

kg	O
-	O
1	O
respectively	O
.	O

We	O
identify	O
YY1	B-GENE
recognition	O
sequences	O
within	O
the	O
vitamin	O
D	O
response	O
element	O
(	O
VDRE	O
)	O
of	O
the	O
osteocalcin	B-GENE
gene	I-GENE
that	O
are	O
critical	O
for	O
YY1	B-GENE
-	O
dependent	O
repression	O
of	O
vitamin	O
D	O
-	O
enhanced	O
promoter	O
activity	O
.	O

Back	O
-	O
ground	O
factors	O
which	O
affect	O
the	O
outcome	O
of	O
steroid	O
withdrawal	O
therapy	O
in	O
patients	O
with	O
chronic	O
type	O
B	O
hepatitis	O
-	O
-	O
statistical	O
evaluation	O
of	O
the	O
importance	O
of	O
the	O
mode	O
of	O
HBV	O
transmission	O

Point	O
mutations	O
of	O
Stat3	B-GENE
within	O
the	O
interacting	O
domains	O
blocked	O
both	O
physical	O
interaction	O
of	O
Stat3	B-GENE
with	O
c	B-GENE
-	I-GENE
Jun	I-GENE
and	O
their	O
cooperation	O
in	O
IL	B-GENE
-	I-GENE
6	I-GENE
-	O
induced	O
transcription	O
directed	O
by	O
the	O
alpha	B-GENE
(	I-GENE
2	I-GENE
)	I-GENE
-	I-GENE
macroglobulin	I-GENE
enhancer	I-GENE
.	O

Three	O
patients	O
with	O
Mirizzi	O
type	O
II	O
syndrome	O
and	O
two	O
patients	O
with	O
Mirizzi	O
type	O
I	O
syndrome	O
were	O
treated	O
laparoscopically	O
.	O

Synchronous	O
multicentric	O
giant	O
cell	O
tumour	O
:	O
a	O
case	O
report	O
with	O
review	O
of	O
literature	O
.	O

From	O
the	O
comparison	O
of	O
the	O
nod	B-GENE
box	I-GENE
sequences	I-GENE
of	O
(	O
brady	O
)	O
rhizobia	O
with	O
a	O
more	O
divergent	O
nod	B-GENE
box	I-GENE
from	O
Azorhizobium	O
caulinodans	O
,	O
we	O
now	O
propose	O
a	O
modular	O
build	O
-	O
up	O
of	O
the	O
nod	B-GENE
box	I-GENE
with	O
the	O
sequence	O
A	O
-	O
T	O
-	O
C	O
-	O
N9	O
-	O
G	O
-	O
A	O
-	O
T	O
as	O
the	O
binding	O
target	O
of	O
the	O
NodD	B-GENE
protein	I-GENE
(	O
the	O
NodD	B-GENE
box	I-GENE
)	O
.	O

The	O
prgX	B-GENE
gene	I-GENE
is	O
adjacent	O
to	O
prgQ	B-GENE
which	O
provides	O
the	O
promoter	O
for	O
prgB	B-GENE
expression	O
.	O

METHODS	O
:	O
A	O
discriminant	O
function	O
predicting	O
surgery	O
outcome	O
(	O
seizure	O
-	O
free	O
vs	O
.	O
non	O
-	O
seizure	O
-	O
free	O
)	O
was	O
computed	O
separately	O
for	O
samples	O
of	O
patients	O
with	O
left	O
(	O
n	O
=	O
79	O
)	O
and	O
right	O
(	O
n	O
=	O
62	O
)	O
temporal	O
lobectomy	O
(	O
LATL	O
,	O
RATL	O
)	O
.	O

It	O
is	O
likely	O
that	O
these	O
recordings	O
are	O
incomplete	O
;	O
the	O
actual	O
number	O
of	O
activated	O
neurons	O
is	O
estimated	O
to	O
be	O
about	O
300	O
in	O
the	O
acutely	O
sensitized	O
preparation	O
.	O

The	O
possibility	O
to	O
use	O
this	O
method	O
for	O
common	O
diagnostic	O
problems	O
is	O
indicated	O
.	O

Genetic	O
analysis	O
of	O
the	O
role	O
of	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
glycoprotein	I-GENE
K	I-GENE
in	O
infectious	O
virus	O
production	O
and	O
egress	O
.	O

A	O
conventional	O
N	O
-	O
terminal	O
signal	O
sequence	O
was	O
not	O
detected	O
in	O
the	O
NodO	B-GENE
protein	I-GENE
.	O

Dynamic	O
expression	O
of	O
broad	B-GENE
-	I-GENE
complex	I-GENE
isoforms	I-GENE
mediates	O
temporal	O
control	O
of	O
an	O
ecdysteroid	O
target	O
gene	O
at	O
the	O
onset	O
of	O
Drosophila	O
metamorphosis	O
.	O

The	O
study	O
was	O
carried	O
out	O
according	O
to	O
the	O
BSI	O
(	O
1980	O
)	O
recommendations	O
for	O
testing	O
restorative	O
materials	O
in	O
vivo	O
.	O

Cellular	O
lysates	O
were	O
analyzed	O
for	O
luciferase	B-GENE
and	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
activities	O
.	O

Cytokines	O
and	O
steroid	O
hormones	O
use	O
different	O
sets	O
of	O
signal	O
transduction	O
pathways	O
,	O
which	O
seem	O
to	O
be	O
unrelated	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
proteolipids	O
of	O
the	O
vacuolar	B-GENE
H	I-GENE
+	I-GENE
-	I-GENE
ATPases	I-GENE
were	O
evolved	O
in	O
parallel	O
with	O
the	O
eubacterial	O
proteolipid	O
,	O
from	O
a	O
common	O
ancestral	O
gene	O
that	O
underwent	O
gene	O
duplication	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	B-GENE
long	I-GENE
terminal	I-GENE
repeat	I-GENE
(	O
which	O
contains	O
two	O
potential	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
binding	I-GENE
sites	I-GENE
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	B-GENE
+	I-GENE
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

In	O
addition	O
,	O
measurements	O
of	O
shielded	O
and	O
unshielded	O
syringes	O
containing	O
99mTc	O
-	O
labelled	O
radiopharmaceuticals	O
were	O
carried	O
out	O
.	O

This	O
study	O
tests	O
the	O
hypothesis	O
that	O
O2	O
is	O
a	O
critical	O
component	O
in	O
myocardial	O
protection	O
afforded	O
by	O
BCP	O
.	O

Biomass	O
growth	O
monitoring	O
using	O
pressure	O
drop	O
in	O
a	O
cocurrent	O
biofilter	O

This	O
alternative	O
splice	O
acceptor	O
site	O
is	O
also	O
used	O
by	O
a	O
biologically	O
active	O
provirus	O
with	O
an	O
efficiency	O
of	O
approximately	O
5	O
%	O
compared	O
with	O
the	O
upstream	O
site	O
.	O

Homology	O
is	O
much	O
higher	O
(	O
64	O
%	O
)	O
between	O
the	O
28	O
-	O
kDa	O
protein	O
and	O
regions	O
that	O
are	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
serine	B-GENE
protease	I-GENE
family	I-GENE
.	O

We	O
have	O
isolated	O
and	O
structurally	O
characterized	O
genomic	O
DNA	O
and	O
cDNA	O
sequences	O
encoding	O
ribulose	B-GENE
-	I-GENE
1	I-GENE
,	I-GENE
5	I-GENE
-	I-GENE
bisphosphate	I-GENE
carboxylase	I-GENE
/	I-GENE
oxygenase	I-GENE
(	I-GENE
Rbu	I-GENE
-	I-GENE
P2	I-GENE
carboxylase	I-GENE
)	I-GENE
activase	I-GENE
from	O
barley	O
(	O
Hordeum	O
vulgare	O
L	O
.	O
)	O
.	O

Expression	O
of	O
putative	O
constitutively	O
active	O
forms	O
of	O
DdMEK1	B-GENE
in	O
a	O
ddmek1	B-GENE
null	O
background	O
is	O
capable	O
,	O
at	O
least	O
partially	O
,	O
of	O
complementing	O
the	O
small	O
aggregate	O
size	O
defect	O
and	O
the	O
ability	O
to	O
activate	O
guanylyl	B-GENE
cyclase	I-GENE
.	O

Constant	O
slowing	O
of	O
median	O
MNCV	O
and	O
SNCV	O
and	O
ulnar	O
SNCV	O
without	O
changes	O
in	O
morphology	O
,	O
amplitude	O
and	O
duration	O
of	O
MAP	O
and	O
SAP	O
have	O
been	O
observed	O
in	O
92	O
patients	O
,	O
with	O
persistent	O
abnormalities	O
in	O
64	O
cases	O
after	O
six	O
months	O
.	O

Moreover	O
,	O
such	O
mutations	O
lead	O
to	O
a	O
dramatic	O
transition	O
in	O
chromatin	O
structure	O
:	O
the	O
DNase	B-GENE
I	I-GENE
hypersensitive	I-GENE
region	I-GENE
is	O
replaced	O
by	O
two	O
stable	O
,	O
sequence	O
-	O
positioned	O
nucleosomes	O
.	O

During	O
chronic	O
treatment	O
with	O
salmon	B-GENE
calcitonin	I-GENE
,	O
alkaline	B-GENE
phosphatase	I-GENE
activity	O
and	O
urinary	O
hydroxyproline	O
excretion	O
decrease	O
on	O
an	O
average	O
of	O
50	O
%	O
in	O
patients	O
with	O
Paget	O
'	O
s	O
disease	O
.	O

187	O
-	O
200	O
.	O

Because	O
of	O
the	O
structural	O
similarities	O
the	O
new	O
gene	O
will	O
be	O
termed	O
scERV2	B-GENE
from	O
now	O
on	O
.	O

Experience	O
in	O
a	O
Kenya	O
district	O
hospital	O

The	O
2	B-GENE
.	I-GENE
3	I-GENE
x	I-GENE
10	I-GENE
(	I-GENE
3	I-GENE
)	I-GENE
base	I-GENE
SUF12	I-GENE
+	I-GENE
transcript	I-GENE
contains	O
an	O
open	O
reading	O
frame	O
sufficient	O
to	O
encode	O
a	O
88	O
x	O
10	O
(	O
3	O
)	O
Mr	O
protein	O
.	O

Cortical	O
somatosensory	O
evoked	O
potentials	O
to	O
median	O
nerve	O
stimulation	O
revealed	O
significantly	O
delayed	O
peak	O
latencies	O
of	O
N20	O
,	O
P20	O
,	O
P25	O
,	O
and	O
N26	O
,	O
although	O
N16	O
latency	O
was	O
normal	O
.	O

A	O
new	O
family	O
of	O
rate	O
-	O
adaptive	O
pacemakers	O
accomplishes	O
this	O
circadian	O
rate	O
variation	O
by	O
modeling	O
the	O
patient	O
'	O
s	O
sleep	O
-	O
wake	O
cycle	O
using	O
a	O
time	O
-	O
of	O
-	O
day	O
clock	O
inside	O
the	O
device	O
.	O

Progestins	O
:	O
present	O
and	O
future	O
.	O

Bilirubin	O
and	O
red	O
cell	O
metabolism	O
in	O
relation	O
to	O
neonatal	O
jaundice	O
.	O

Each	O
of	O
these	O
materials	O
were	O
placed	O
by	O
means	O
of	O
three	O
different	O
placement	O
techniques	O
(	O
Bulk	O
pack	O
,	O
Horizontal	O
layering	O
and	O
Vertical	O
layering	O
)	O
into	O
class	O
II	O
cavities	O
in	O
extracted	O
human	O
molars	O
.	O

This	O
ligand	O
-	O
independent	O
pathway	O
can	O
function	O
through	O
another	O
androgen	O
-	O
regulated	O
promoter	O
as	O
shown	O
by	O
the	O
use	O
of	O
the	O
mouse	B-GENE
mammary	I-GENE
tumor	I-GENE
virus	I-GENE
MMTV	I-GENE
-	I-GENE
CAT	I-GENE
reporter	I-GENE
.	O

Stress	O
-	O
induced	O
suppression	O
of	O
the	O
prolactin	B-GENE
afternoon	O
surge	O
in	O
ovariectomized	O
,	O
estrogen	O
-	O
treated	O
rats	O
and	O
the	O
nocturnal	O
surge	O
in	O
pseudopregnant	O
rats	O
are	O
accompanied	O
by	O
an	O
increase	O
in	O
median	O
eminence	O
dihydroxyphenylacetic	O
acid	O
concentrations	O
.	O

The	O
sensitivity	O
for	O
ergometry	O
and	O
treadmill	O
testing	O
was	O
75	O
and	O
62	O
%	O
respectively	O
.	O

Morphologic	O
evidence	O
that	O
rhe	O
renal	O
calyx	O
and	O
pelvis	O
control	O
ureteric	O
activity	O
in	O
the	O
rabbit	O
.	O

Children	O
with	O
repeated	O
proteinuria	O
during	O
follow	O
-	O
up	O
tend	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
pathologic	O
findings	O
on	O
the	O
i	O
.	O
v	O
.	O
-	O
pyelogram	O
.	O

Parelaphostrongylus	O
odocoilei	O
is	O
redescribed	O
from	O
worms	O
collected	O
from	O
the	O
type	O
host	O
(	O
Odocoileus	O
hemionus	O
columbianus	O
)	O
in	O
California	O
,	O
as	O
well	O
as	O
material	O
from	O
experimentally	O
infected	O
mule	O
deer	O
(	O
O	O
.	O
h	O
.	O
heminus	O
)	O
in	O
Alberta	O
.	O

The	O
carboxyl	O
globular	O
domain	O
was	O
found	O
to	O
be	O
encoded	O
by	O
six	O
exons	O
which	O
appear	O
to	O
delineate	O
its	O
structural	O
subdomains	O
.	O

Expression	O
of	O
the	O
Asp	O
but	O
not	O
the	O
Ala	O
gB	B-GENE
mutation	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
expression	O
of	O
gB	B-GENE
at	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
in	O
U373	O
cells	O
.	O

Thus	O
integration	B-GENE
host	I-GENE
factor	I-GENE
is	O
required	O
for	O
normal	O
type	B-GENE
1	I-GENE
fimbriae	I-GENE
phase	O
variation	O
in	O
E	O
.	O
coli	O
.	O

Insulin	B-GENE
therapy	O
has	O
been	O
expanded	O
by	O
development	O
of	O
human	B-GENE
insulin	I-GENE
and	O
new	O
modes	O
of	O
injection	O
,	O
including	O
insulin	B-GENE
pumps	O
.	O

Because	O
levels	O
of	O
Vo2DIR	O
and	O
Vo2INDIR	O
were	O
similar	O
in	O
both	O
groups	O
,	O
we	O
pooled	O
data	O
from	O
septic	O
and	O
control	O
animals	O
.	O

Further	O
interventions	O
were	O
:	O
nephrectomy	O
(	O
2x	O
)	O
,	O
resection	O
and	O
ligation	O
of	O
the	O
inferior	O
vena	O
cava	O
(	O
1x	O
)	O
,	O
resection	O
and	O
replacement	O
of	O
the	O
left	O
renal	O
vein	O
(	O
1x	O
)	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
stimulating	O
the	O
central	O
noradrenergic	O
system	O
using	O
the	O
new	O
noradrenaline	O
re	O
-	O
uptake	O
inhibitor	O
reboxetine	O
would	O
result	O
in	O
a	O
dose	O
-	O
dependent	O
enhancement	O
of	O
memory	O
for	O
emotional	O
material	O
in	O
man	O
.	O

We	O
examined	O
the	O
mechanisms	O
by	O
which	O
two	O
different	O
types	O
of	O
photonic	O
radiation	O
,	O
short	O
wavelength	O
UV	O
(	O
UV	O
-	O
C	O
)	O
and	O
gamma	O
radiation	O
,	O
activate	O
transcription	O
factor	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
.	O

However	O
,	O
coligation	O
of	O
Fc	B-GENE
gamma	I-GENE
RIIB1	I-GENE
with	O
B	B-GENE
cell	I-GENE
Ag	I-GENE
receptors	I-GENE
(	O
BCR	B-GENE
)	O
inhibits	O
BCR	B-GENE
-	O
mediated	O
signaling	O
by	O
a	O
mechanism	O
that	O
may	O
involve	O
recruitment	O
of	O
phosphatases	B-GENE
SHP	I-GENE
-	I-GENE
1	I-GENE
,	O
SHP	B-GENE
-	I-GENE
2	I-GENE
,	O
and	O
the	O
SH2	B-GENE
containing	I-GENE
inositol	I-GENE
5	I-GENE
'	I-GENE
phosphatase	I-GENE
(	O
SHIP	B-GENE
)	O
to	O
the	O
phosphorylated	O
Fc	B-GENE
gamma	I-GENE
RIIB1	I-GENE
immunoreceptor	I-GENE
tyrosine	I-GENE
-	I-GENE
based	I-GENE
inhibitory	I-GENE
motif	I-GENE
.	O

Using	O
the	O
standard	O
scoring	O
,	O
children	O
with	O
full	O
scale	O
IQ	O
<	O
or	O
=	O
84	O
on	O
the	O
Wechsler	O
Preschool	O
and	O
Primary	O
Scale	O
of	O
Intelligence	O
at	O
age	O
4	O
-	O
5	O
years	O
were	O
poorly	O
identified	O
(	O
sensitivity	O
54	O
%	O
)	O
from	O
the	O
composite	O
S	O
-	O
B	O
IV	O
score	O
at	O
age	O
3	O
.	O

11	O
:	O
5801	O
-	O
5812	O
,	O
1991	O
)	O
present	O
evidence	O
that	O
the	O
Vps18	B-GENE
/	O
Pep3	B-GENE
protein	O
colocalizes	O
with	O
the	O
Vps11	B-GENE
/	O
Pep5	B-GENE
protein	O
to	O
the	O
cytosolic	O
face	O
of	O
the	O
vacuolar	O
membrane	O
.	O

This	O
study	O
includes	O
200	O
patients	O
treated	O
from	O
1964	O
to	O
1978	O
,	O
with	O
an	O
age	O
range	O
from	O
15	O
to	O
102	O
years	O
,	O
who	O
required	O
329	O
generators	O
.	O

We	O
conclude	O
that	O
the	O
BR	B-GENE
-	I-GENE
C	I-GENE
early	I-GENE
gene	I-GENE
directly	O
activates	O
late	B-GENE
gene	I-GENE
transcription	O
by	O
interacting	O
with	O
late	B-GENE
gene	I-GENE
cis	O
-	O
acting	O
regulatory	O
elements	O
and	O
that	O
this	O
interaction	O
is	O
responsible	O
for	O
the	O
temporal	O
linkage	O
of	O
early	O
and	O
late	O
ecdysone	O
-	O
induced	O
gene	O
expression	O
.	O

The	O
specificity	O
and	O
sensitivity	O
of	O
this	O
method	O
(	O
limit	O
of	O
detection	O
in	O
plasma	O
0	O
.	O
025	O
micrograms	O
/	O
mL	O
and	O
<	O
or	O
=	O
0	O
.	O
0125	O
micrograms	O
/	O
mL	O
for	O
febantel	O
and	O
its	O
metabolites	O
,	O
respectively	O
)	O
were	O
sufficiently	O
high	O
to	O
enable	O
us	O
to	O
characterize	O
the	O
time	O
course	O
of	O
the	O
drug	O
in	O
the	O
plasma	O
after	O
oral	O
administration	O
of	O
therapeutic	O
doses	O
to	O
sheep	O
.	O

We	O
have	O
identified	O
the	O
gene	O
encoding	O
sigma	B-GENE
E	I-GENE
using	O
a	O
genetic	O
screen	O
designed	O
to	O
isolate	O
trans	O
-	O
acting	O
mutations	O
that	O
abolish	O
expression	O
from	O
either	O
htrA	B-GENE
or	O
rpoHP3	B-GENE
,	O
two	O
promoters	O
recognized	O
uniquely	O
by	O
sigma	B-GENE
E	I-GENE
-	O
containing	O
RNA	B-GENE
polymerase	I-GENE
.	O

Cytokinetics	O
of	O
the	O
Krebs	O
2	O
carcinoma	O
.	O

Through	O
effective	O
use	O
of	O
laboratory	O
testing	O
database	O
,	O
it	O
will	O
be	O
possible	O
to	O
shift	O
away	O
our	O
vague	O
management	O
of	O
pre	O
-	O
analytic	O
phase	O
of	O
quality	O
control	O
so	O
far	O
to	O
its	O
established	O
system	O
based	O
on	O
objective	O
evaluation	O
.	O

These	O
patients	O
developed	O
severe	O
diabetic	O
symptoms	O
including	O
glucose	O
intolerance	O
,	O
weight	O
loss	O
,	O
impaired	O
energy	O
utilization	O
,	O
and	O
nerve	O
and	O
brain	O
disorders	O
that	O
were	O
refractory	O
to	O
insulin	B-GENE
.	O

One	O
promoter	O
,	O
p53P1	B-GENE
,	O
is	O
located	O
100	O
-	O
250	O
bp	O
upstream	O
of	O
the	O
218	O
-	O
bp	O
noncoding	O
first	O
exon	O
;	O
a	O
second	O
,	O
stronger	O
promoter	O
,	O
p53P2	B-GENE
,	O
maps	O
within	O
the	O
first	O
intron	O
.	O

Both	O
PMP20	B-GENE
gene	I-GENE
products	I-GENE
contain	O
the	O
carboxyl	O
-	O
terminal	O
sequence	O
AKL	O
,	O
similar	O
to	O
the	O
putative	O
SKL	O
peroxisomal	O
sorting	O
sequence	O
(	O
Gould	O
,	O
S	O
.	O

The	O
likelihood	O
of	O
death	O
was	O
more	O
than	O
3	O
times	O
higher	O
among	O
patients	O
in	O
the	O
ERA	O
-	O
II	O
group	O
(	O
mortality	O
risk	O
ratio	O
3	O
.	O
82	O
[	O
95	O
%	O
CI	O
1	O
.	O
48	O
%	O
to	O
9	O
.	O
84	O
]	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

Barium	O
mucosal	O
coating	O
was	O
judged	O
to	O
be	O
better	O
in	O
the	O
members	O
to	O
whom	O
magnesium	O
sulphate	O
was	O
administered	O
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
.	O

In	O
both	O
immortalized	O
and	O
normal	O
diploid	O
human	O
cells	O
,	O
wt	O
AAV	O
targeted	O
integration	O
to	O
ch	O
-	O
19	O
.	O

The	O
corresponding	O
tetrapeptide	O
sequences	O
SSPD	O
and	O
SATD	O
for	O
human	B-GENE
and	I-GENE
mouse	I-GENE
PKC	I-GENE
-	I-GENE
epsilon	I-GENE
,	O
respectively	O
,	O
are	O
unusual	O
for	O
caspase	B-GENE
-	I-GENE
3	I-GENE
.	O

The	O
lipopolysaccharide	O
-	O
binding	O
protein	O
is	O
a	O
secretory	B-GENE
class	I-GENE
1	I-GENE
acute	I-GENE
-	I-GENE
phase	I-GENE
protein	I-GENE
whose	O
gene	O
is	O
transcriptionally	O
activated	O
by	O
APRF	B-GENE
/	O
STAT	B-GENE
/	I-GENE
3	I-GENE
and	O
other	O
cytokine	O
-	O
inducible	O
nuclear	O
proteins	O
.	O

Tritium	O
concentrations	O
in	O
environmental	O
water	O
samples	O
were	O
found	O
to	O
be	O
determined	O
within	O
an	O
accuracy	O
of	O
10	O
%	O
by	O
this	O
method	O
when	O
Vi	O
/	O
Vf	O
was	O
14	O
-	O
25	O
.	O

This	O
region	O
does	O
not	O
contain	O
a	O
consensus	O
estrogen	O
response	O
element	O
,	O
and	O
ER	B-GENE
binding	O
to	O
this	O
DNA	O
sequence	O
was	O
not	O
observed	O
.	O

These	O
proteins	O
,	O
called	O
variant	B-GENE
surface	I-GENE
glycoproteins	I-GENE
(	O
VSGs	B-GENE
)	O
,	O
are	O
expressed	O
from	O
a	O
specific	O
locus	O
,	O
the	O
VSG	B-GENE
gene	I-GENE
expression	I-GENE
site	I-GENE
(	I-GENE
ES	I-GENE
)	I-GENE
.	O

The	O
strangulated	O
intestinal	O
pathologies	O
of	O
horses	O
are	O
accompanied	O
by	O
a	O
local	O
activation	O
of	O
the	O
neutrophils	O
,	O
that	O
can	O
be	O
revealed	O
by	O
measuring	O
the	O
tissular	O
enzymatic	O
activity	O
of	O
the	O
granulocytic	O
enzyme	O
myeloperoxidase	B-GENE
(	O
MPO	B-GENE
)	O
.	O

A	O
deletion	O
analysis	O
of	O
the	O
FAS1	B-GENE
promoter	I-GENE
lacking	O
the	O
previously	O
characterized	O
inositol	O
/	O
choline	O
-	O
responsive	O
-	O
element	O
motif	O
defined	O
a	O
region	O
(	O
nucleotides	O
-	O
760	O
to	O
-	O
850	O
)	O
responsible	O
for	O
most	O
of	O
the	O
remaining	O
activation	O
potency	O
.	O

Here	O
we	O
report	O
the	O
fabrication	O
of	O
single	O
-	O
molecule	O
transistors	O
based	O
on	O
individual	O
C60	O
molecules	O
connected	O
to	O
gold	O
electrodes	O
.	O

The	O
homeodomain	B-GENE
transcription	I-GENE
factor	I-GENE
CDP	B-GENE
/	O
cut	B-GENE
interacts	O
with	O
the	O
cell	O
cycle	O
regulatory	O
element	O
of	O
histone	B-GENE
H4	I-GENE
genes	I-GENE
packaged	O
into	O
nucleosomes	O
.	O

They	O
encode	O
proteins	O
whose	O
core	O
regions	O
display	O
great	O
similarity	O
to	O
Aspergillus	B-GENE
HAPB	I-GENE
,	O
HAPC	B-GENE
and	O
HAPE	B-GENE
and	O
to	O
known	O
HAP	B-GENE
homologs	I-GENE
from	O
other	O
organisms	O
.	O

Furthermore	O
,	O
the	O
cognate	O
binding	O
protein	O
is	O
present	O
in	O
both	O
rat	O
and	O
human	O
(	O
HeLa	O
)	O
cell	O
nuclear	O
extracts	O
.	O

Transient	O
cotransfection	O
analyses	O
indicate	O
that	O
the	O
cooperative	O
association	O
of	O
NF	B-GENE
-	I-GENE
IL	I-GENE
-	I-GENE
6	I-GENE
and	O
RelA	B-GENE
with	O
the	O
IL	B-GENE
-	I-GENE
8	I-GENE
promoter	I-GENE
results	O
in	O
synergistic	O
transcriptional	O
activation	O
.	O

Heart	O
rate	O
during	O
the	O
behavioral	O
avoidance	O
test	O
was	O
shown	O
to	O
be	O
as	O
susceptible	O
to	O
experimental	O
demand	O
as	O
other	O
studies	O
have	O
shown	O
approach	O
behaviors	O
to	O
be	O
influenced	O
.	O

Function	O
was	O
retained	O
when	O
one	O
copy	O
of	O
the	O
sequence	O
was	O
present	O
,	O
suggesting	O
that	O
this	O
sequence	O
represents	O
an	O
essential	O
element	O
.	O

Decreased	O
plasma	O
level	O
of	O
antithrombin	B-GENE
III	I-GENE
was	O
assumed	O
to	O
be	O
one	O
of	O
the	O
major	O
factors	O
underlying	O
hypercoagulable	O
state	O
in	O
nephrotic	O
syndrome	O
.	O

NO2	O
pollution	O
on	O
major	O
trunk	O
roads	O
frequently	O
exceeded	O
British	O
and	O
European	O
Union	O
air	O
quality	O
standards	O
,	O
while	O
particle	O
pollution	O
was	O
lower	O
.	O

Cotransfection	O
of	O
pINV	O
-	O
2473	O
,	O
a	O
construct	O
containing	O
2473	O
base	O
pairs	O
of	O
hINV	B-GENE
upstream	I-GENE
sequence	I-GENE
linked	O
to	O
luciferase	B-GENE
,	O
with	O
POU	B-GENE
homeodomain	I-GENE
transcription	I-GENE
factors	I-GENE
Oct1	B-GENE
,	O
Oct2	B-GENE
,	O
Brn4	B-GENE
,	O
SCIP	B-GENE
,	O
Skn1a	B-GENE
or	O
Skn1i	B-GENE
,	O
results	O
in	O
a	O
strong	O
suppression	O
of	O
basal	O
promoter	O
activity	O
.	O

87	O
,	O
7270	O
-	O
7274	O
)	O
.	O

I	O
.	O

Transcripts	O
initiating	O
at	O
the	O
CAGT	O
motif	O
(	O
proximal	O
transcripts	O
)	O
were	O
abolished	O
by	O
deletion	O
of	O
the	O
proximal	O
TATA	O
box	O
located	O
at	O
-	O
29	O
relative	O
to	O
CAGT	O
.	O

Genomic	O
DNA	O
blot	O
analysis	O
indicates	O
that	O
the	O
trout	B-GENE
L2	I-GENE
locus	I-GENE
has	O
a	O
cluster	O
-	O
like	O
organization	O
similar	O
to	O
the	O
trout	B-GENE
L1	I-GENE
locus	I-GENE
and	O
the	O
IgL	B-GENE
locus	I-GENE
of	O
several	O
teleost	O
fish	O
.	O

Although	O
the	O
energy	O
-	O
based	O
DFT	O
was	O
not	O
affected	O
by	O
isoproterenol	O
(	O
from	O
6	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
6	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
7	O
J	O
)	O
,	O
it	O
was	O
decreased	O
to	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
6	O
J	O
in	O
the	O
third	O
stage	O
by	O
infusion	O
of	O
E4031	O
and	O
isoproterenol	O
(	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
baseline	O
and	O
vs	O
.	O
isoproterenol	O
)	O
.	O

Gore	O
&	O
Associates	O
,	O
Inc	O
.	O
)	O
standard	O
wall	O
graft	O
segments	O
varying	O
in	O
length	O
from	O
4	O
to	O
12	O
cm	O
.	O

The	O
dynamics	O
of	O
N	O
-	O
interaction	O
and	O
N	O
-	O
retention	O
during	O
3	O
hr	O
CPB	O
was	O
quantified	O
with	O
autologous	O
In	O
-	O
111	O
labeled	O
neutrophils	O
(	O
INN	O
)	O
in	O
4	O
groups	O
of	O
20	O
Yorkshire	O
pigs	O
(	O
28	O
-	O
35	O
kg	O
,	O
5	O
sham	O
;	O
5	O
CPB	O
,	O
1	O
hr	O
;	O
5	O
CPB	O
,	O
3	O
hr	O
and	O
5	O
CPB	O
with	O
heparinized	O
circuit	O
,	O
3	O
hr	O
)	O
;	O
anesthetized	O
pigs	O
were	O
injected	O
with	O
INN	O
(	O
500	O
-	O
650	O
microCi	O
)	O
,	O
30	O
min	O
before	O
CPB	O
and	O
heparinized	O
,	O
and	O
underwent	O
CPB	O
with	O
a	O
roller	O
pump	O
,	O
a	O
hollow	O
fiber	O
OX	O
(	O
Bentley	O
CM	O
50	O
,	O
5	O
.	O
0	O
m2	O
)	O
and	O
AF	O
(	O
Bentley	O
AF	O
025	O
,	O
0	O
.	O
25	O
m2	O
)	O
at	O
2	O
.	O
5	O
-	O
3	O
.	O
6	O
l	O
/	O
min	O
for	O
3	O
hr	O
.	O

The	O
region	O
immediately	O
following	O
the	O
promoter	O
and	O
5	O
'	O
to	O
ORF1	O
has	O
a	O
potential	O
transcription	O
terminator	O
sequence	O
.	O

Studies	O
on	O
recurrences	O
in	O
gingival	O
hyperplasia	O

Preface	O
and	O
acknowledgements	O
.	O

We	O
conclude	O
that	O
clonidine	O
3	O
micrograms	O
/	O
kg	O
produces	O
sedation	O
comparable	O
to	O
diazepam	O
0	O
.	O
2	O
mg	O
/	O
kg	O
and	O
also	O
attenuates	O
the	O
intubation	O
response	O
without	O
increasing	O
the	O
incidence	O
of	O
complications	O
.	O

Pancreatic	O
expression	O
of	O
the	O
glucagon	B-GENE
gene	I-GENE
depends	O
on	O
multiple	O
transcription	O
factors	O
interacting	O
with	O
at	O
least	O
three	O
DNA	O
control	O
elements	O
:	O
G1	O
,	O
the	O
upstream	O
promoter	O
element	O
,	O
and	O
G2	O
and	O
G3	O
,	O
two	O
enhancer	O
-	O
like	O
sequences	O
.	O

We	O
have	O
compared	O
the	O
ability	O
of	O
GST	B-GENE
-	O
Bem3	B-GENE
to	O
serve	O
as	O
a	O
GAP	B-GENE
for	O
Cdc42Hs	B-GENE
relative	O
to	O
other	O
members	O
of	O
the	O
rho	B-GENE
-	O
GAP	B-GENE
subfamily	O
and	O
found	O
the	O
following	O
order	O
of	O
potency	O
:	O
human	B-GENE
platelet	I-GENE
Cdc42Hs	I-GENE
GAP	I-GENE
>	O
p190	B-GENE
>	O
Bem3	B-GENE
>	O
break	B-GENE
point	I-GENE
cluster	I-GENE
region	I-GENE
protein	I-GENE
,	O
whereas	O
p85	B-GENE
,	O
like	O
Bem2	B-GENE
,	O
shows	O
no	O
GAP	B-GENE
activity	O
or	O
any	O
ability	O
to	O
bind	O
to	O
the	O
GTP	O
-	O
bound	O
form	O
of	O
Cdc42Hs	B-GENE
.	O

CONCLUSION	O
:	O
Men	O
presenting	O
with	O
urethritis	O
and	O
women	O
presenting	O
with	O
PID	O
both	O
have	O
significantly	O
greater	O
peripheral	O
blood	O
mononuclear	O
cell	O
proliferative	O
responses	O
to	O
the	O
DK20	O
strain	O
of	O
C	O
trachomatis	O
than	O
controls	O
.	O

The	O
PDSS	O
identified	O
17	O
(	O
94	O
%	O
)	O
of	O
the	O
women	O
diagnosed	O
with	O
major	O
postpartum	O
depression	O
,	O
the	O
EPDS	O
identified	O
14	O
of	O
these	O
women	O
(	O
78	O
%	O
)	O
,	O
and	O
the	O
BDI	O
-	O
II	O
identified	O
10	O
of	O
the	O
18	O
women	O
(	O
56	O
%	O
)	O
.	O

Men	O
and	O
women	O
entering	O
psychotherapy	O
more	O
often	O
had	O
negative	O
Wish	O
elements	O
than	O
others	O
.	O

Single	O
amino	O
acid	O
substitutions	O
were	O
shown	O
to	O
result	O
from	O
the	O
mutations	O
pdr1	B-GENE
-	I-GENE
2	I-GENE
(	O
M308I	O
)	O
,	O
pdr1	B-GENE
-	I-GENE
3	I-GENE
(	O
F815S	O
)	O
,	O
pdr1	B-GENE
-	I-GENE
6	I-GENE
(	O
K302Q	O
)	O
,	O
pdr1	B-GENE
-	I-GENE
7	I-GENE
(	O
P298A	O
)	O
and	O
pdr1	B-GENE
-	I-GENE
8	I-GENE
(	O
L1036	O
W	O
)	O
,	O
whereas	O
the	O
intragenic	O
suppressor	O
mutant	O
pdr1	B-GENE
-	I-GENE
100	I-GENE
is	O
deleted	O
for	O
the	O
two	O
amino	O
acids	O
L537	O
and	O
A538	O
.	O

Both	O
merR	B-GENE
genes	I-GENE
consist	O
of	O
a	O
408	O
bp	O
ORF	O
coding	O
for	O
135	O
amino	O
acids	O
.	O

Amniotic	O
fluid	O
ionic	O
concentration	O
in	O
response	O
to	O
chronic	O
fetal	B-GENE
vasopressin	I-GENE
infusion	O
.	O

The	O
same	O
slice	O
was	O
imaged	O
three	O
times	O
each	O
with	O
sequences	O
using	O
spatial	O
presaturation	O
or	O
not	O
.	O

Molecular	O
cloning	O
of	O
the	O
alpha	B-GENE
-	I-GENE
globin	I-GENE
transcription	I-GENE
factor	I-GENE
CP2	B-GENE
.	O

The	O
most	O
distal	O
active	O
site	O
in	O
TIGA	B-GENE
is	O
created	O
by	O
excision	O
of	O
a	O
66	O
-	O
bp	O
intron	O
.	O

Denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
with	O
sequence	O
analysis	O
showed	O
that	O
PGCL4	B-GENE
is	O
a	O
major	O
member	O
in	O
the	O
female	O
mammary	O
gland	O
,	O
and	O
in	O
the	O
submaxillary	O
and	O
lachrymal	O
glands	O
of	O
both	O
sexes	O
,	O
while	O
the	O
counterpart	O
in	O
male	O
liver	O
and	O
the	O
coagulate	O
glands	O
was	O
found	O
to	O
be	O
PGCL1	B-GENE
.	O

All	O
possessed	O
cutaneous	O
receptive	O
fields	O
on	O
the	O
distal	O
segments	O
of	O
digits	O
2	O
,	O
3	O
,	O
or	O
4	O
.	O

Sesame	O
seed	O
should	O
also	O
be	O
considered	O
a	O
cause	O
of	O
allergic	O
reactions	O
to	O
drug	O
products	O
and	O
cosmetics	O
.	O

Ligand	O
binding	O
of	O
multi	O
-	O
chain	O
antigen	O
receptors	O
and	O
hematopoietin	B-GENE
/	O
cytokine	O
receptors	O
results	O
in	O
rapid	O
activation	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
PTK	B-GENE
)	O
-	O
dependent	O
signalling	O
molecules	O
such	O
as	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
(	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
)	O
.	O

The	O
UASB	O
reactors	O
treated	O
a	O
VFA	O
mixture	O
(	O
with	O
an	O
acetate	O
:	O
propionate	O
:	O
butyrate	O
ratio	O
of	O
5	O
:	O
3	O
:	O
2	O
on	O
COD	O
basis	O
)	O
or	O
acetate	O
as	O
the	O
sole	O
substrate	O
at	O
different	O
COD	O
:	O
sulfate	O
ratios	O
.	O

The	O
authors	O
emphasize	O
absence	O
of	O
specific	O
signs	O
of	O
vagal	O
involvement	O
,	O
importance	O
for	O
diagnosis	O
of	O
surgical	O
extirpation	O
,	O
and	O
mildness	O
of	O
post	O
operative	O
course	O
.	O

Now	O
:	O
pleasure	O
in	O
work	O

This	O
article	O
reviews	O
current	O
concepts	O
of	O
pathophysiology	O
and	O
summarises	O
clinical	O
features	O
,	O
natural	O
history	O
and	O
available	O
treatments	O
.	O

Previous	O
data	O
suggested	O
a	O
subtle	O
increase	O
in	O
serum	O
P	O
at	O
the	O
time	O
of	O
hCG	B-GENE
injection	O
without	O
LH	B-GENE
surge	O
reduces	O
the	O
PR	O
of	O
women	O
having	O
oocyte	O
retrievals	O
for	O
IVF	O
;	O
this	O
study	O
compared	O
PRs	O
of	O
recipients	O
in	O
a	O
shared	O
oocyte	O
program	O
according	O
to	O
the	O
donors	O
'	O
pre	B-GENE
-	I-GENE
hCG	I-GENE
P	O
level	O
.	O

Adequacy	O
of	O
the	O
Haldane	O
transformation	O
in	O
the	O
computation	O
of	O
exercise	O
V	O
O2	O
in	O
man	O
.	O

M	O
.	O
,	O
Adrich	O
,	O
Z	O
.	O
,	O
Fournet	O
,	O
B	O
.	O
,	O
Capon	O
,	O
C	O
.	O
,	O
Bonicel	O
,	O
J	O
.	O

Association	O
between	O
hyperhomocysteinemia	O
and	O
ischemic	O
heart	O
disease	O
in	O
Sri	O
Lankans	O
.	O

Radiological	O
imaging	O
such	O
as	O
UGI	O
series	O
and	O
CT	O
scan	O
was	O
useful	O
to	O
arrive	O
at	O
an	O
accurate	O
diagnosis	O
.	O

The	O
architecture	O
of	O
the	O
hRap1	B-GENE
Myb	B-GENE
domain	I-GENE
is	O
very	O
close	O
to	O
that	O
of	O
each	O
of	O
the	O
Myb	B-GENE
domains	I-GENE
from	O
TRF1	B-GENE
,	O
scRap1p	B-GENE
and	O
c	B-GENE
-	I-GENE
Myb	I-GENE
.	O

80	O
v	B-GENE
-	I-GENE
ets	I-GENE
-	O
encoded	O
amino	O
-	O
acids	O
located	O
immediately	O
after	O
the	O
v	B-GENE
-	I-GENE
myb	I-GENE
/	O
v	B-GENE
-	I-GENE
ets	I-GENE
junction	O
are	O
not	O
found	O
in	O
P54	B-GENE
/	O
56c	B-GENE
-	I-GENE
ets	I-GENE
,	O
the	O
translation	O
product	O
of	O
the	O
c	B-GENE
-	I-GENE
ets	I-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
,	O
nor	O
in	O
a	O
set	O
of	O
cellular	O
proteins	O
of	O
64	O
,	O
62	O
,	O
and	O
60	O
kDa	O
related	O
to	O
but	O
distinct	O
from	O
P54	B-GENE
/	O
56c	B-GENE
-	I-GENE
ets	I-GENE
.	O

We	O
have	O
raised	O
antibodies	O
against	O
a	O
peptide	O
specific	O
to	O
the	O
predicted	O
protein	O
product	O
of	O
this	O
second	O
mRNA	O
.	O

Because	O
controlled	O
-	O
release	O
niacin	O
seems	O
to	O
be	O
more	O
potent	O
than	O
crystalline	O
niacin	O
,	O
product	O
substitution	O
without	O
dose	O
adjustment	O
should	O
be	O
avoided	O
.	O

Interobserver	O
agreement	O
of	O
the	O
Nottingham	O
histologic	O
grading	O
scheme	O
for	O
infiltrating	O
duct	O
carcinoma	O
breast	O
.	O

This	O
dose	O
of	O
Na3	O
citrate	O
produced	O
no	O
clinical	O
symptoms	O
suggestive	O
of	O
hypocalcaemia	O
in	O
these	O
subjects	O
,	O
even	O
though	O
the	O
use	O
of	O
acid	O
-	O
citrate	O
-	O
dextrose	O
,	O
NIH	O
formula	O
A	O
(	O
ACD	O
-	O
A	O
)	O
under	O
identical	O
conditions	O
has	O
been	O
reported	O
to	O
reduce	O
significantly	O
the	O
level	O
of	O
total	O
calcium	O
in	O
serum	O
,	O
and	O
concomitantly	O
increase	O
the	O
number	O
or	O
reactions	O
occurring	O
in	O
donors	O
.	O

Latex	O
products	O
(	O
gloves	O
,	O
balloons	O
,	O
and	O
condoms	O
)	O
directly	O
bound	O
IgE	B-GENE
from	O
all	O
four	O
patients	O
.	O

The	O
phosphoprotein	B-GENE
pUL69	I-GENE
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
which	O
is	O
a	O
herpesvirus	O
of	O
considerable	O
medical	O
importance	O
in	O
immunosuppressed	O
patients	O
and	O
newborns	O
,	O
has	O
previously	O
been	O
identified	O
as	O
an	O
early	B-GENE
-	I-GENE
late	I-GENE
viral	I-GENE
protein	I-GENE
that	O
can	O
stimulate	O
several	O
viral	O
and	O
cellular	O
promoters	O
and	O
thus	O
exerts	O
a	O
rather	O
broad	O
activation	O
pattern	O
.	O

Southern	O
blot	O
analysis	O
performed	O
on	O
genomic	O
DNA	O
demonstrated	O
altered	O
CpG	O
methylation	O
within	O
intron	O
1	O
in	O
DNA	O
from	O
all	O
BCC	O
compared	O
to	O
normal	O
,	O
mortal	O
human	O
mammary	O
epithelial	O
cells	O
(	O
HMEC	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
TGFbeta1	B-GENE
expression	O
is	O
upregulated	O
in	O
mouse	O
keratinocytes	O
infected	O
with	O
a	O
v	B-GENE
-	I-GENE
rasHa	I-GENE
retrovirus	O
,	O
although	O
the	O
functional	O
significance	O
of	O
this	O
has	O
not	O
been	O
clear	O
.	O

An	O
increased	O
incidence	O
of	O
ATN	O
has	O
been	O
reported	O
since	O
the	O
introduction	O
of	O
cyclosporin	O
A	O
.	O

Using	O
a	O
GTP	O
-	O
dependent	O
,	O
brefeldin	O
A	O
-	O
sensitive	O
in	O
vitro	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	O
assay	O
,	O
we	O
have	O
determined	O
here	O
the	O
parameters	O
of	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	O
reaction	O
.	O

The	O
overall	O
rate	O
of	O
biohydrogenation	O
of	O
C18	O
:	O
2	O
was	O
14	O
.	O
3	O
%	O
/	O
h	O
,	O
but	O
declined	O
1	O
.	O
2	O
%	O
/	O
h	O
for	O
each	O
percentage	O
unit	O
increase	O
in	O
C18	O
:	O
2	O
added	O
to	O
the	O
substrate	O
.	O

Plasma	B-GENE
enteroglucagon	I-GENE
was	O
measured	O
before	O
and	O
during	O
three	O
hours	O
after	O
a	O
standard	O
meal	O
in	O
21	O
untreated	O
adult	O
patients	O
with	O
suspected	O
coeliac	O
disease	O
who	O
all	O
had	O
villous	O
atrophy	O
of	O
the	O
small	O
intestinal	O
mucosa	O
and	O
malabsorption	O
,	O
and	O
in	O
nine	O
control	O
subjects	O
.	O

After	O
control	O
for	O
body	O
mass	O
index	O
,	O
trait	O
anxiety	O
and	O
anger	O
-	O
in	O
remained	O
independent	O
predictors	O
of	O
diastolic	O
blood	O
pressure	O
among	O
the	O
women	O
.	O

Regulation	O
of	O
the	O
human	B-GENE
stress	I-GENE
response	I-GENE
gene	I-GENE
GADD153	I-GENE
expression	O
:	O
role	O
of	O
ETS1	B-GENE
and	O
FLI	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
products	I-GENE
.	O

The	O
PRP4	B-GENE
protein	I-GENE
of	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
is	O
an	O
essential	O
part	O
of	O
the	O
U4	B-GENE
/	O
U6	B-GENE
snRNP	O
,	O
a	O
component	O
of	O
the	O
mRNA	O
splicing	O
apparatus	O
.	O

132	O
varix	O
ligations	O
were	O
performed	O
during	O
44	O
separate	O
EVL	O
sessions	O
.	O

Here	O
RFX	B-GENE
/	O
X2BP	B-GENE
/	O
DNA	O
complexes	O
were	O
formed	O
on	O
all	O
class	O
II	O
isotypes	O
regardless	O
of	O
the	O
ability	O
of	O
the	O
X	O
box	O
region	O
to	O
bind	O
either	O
factor	O
individually	O
.	O

The	O
psi	B-GENE
zeta	I-GENE
gene	I-GENE
has	O
a	O
nonsense	O
mutation	O
in	O
exon	O
1	O
but	O
has	O
identical	O
promoter	O
sequence	O
and	O
RNA	O
processing	O
sites	O
to	O
the	O
zeta	B-GENE
gene	I-GENE
,	O
raising	O
the	O
possibility	O
that	O
both	O
psi	B-GENE
zeta	I-GENE
and	O
zeta	B-GENE
are	O
transcriptionally	O
active	O
.	O

Prospects	O
of	O
chemosterilant	O
and	O
genetic	O
control	O
of	O
rodents	O
.	O

Serum	O
PRL	B-GENE
concentrations	O
significantly	O
increased	O
after	O
MCP	O
administration	O
in	O
normal	O
women	O
,	O
hyperprolactinemic	O
patients	O
with	O
normal	O
sella	O
and	O
patients	O
with	O
microadenoma	O
,	O
but	O
not	O
in	O
macroadenoma	O
patients	O
with	O
and	O
without	O
suprasellar	O
expansion	O
(	O
SSE	O
)	O
.	O

The	O
Id4	B-GENE
protein	I-GENE
contains	O
a	O
HLH	O
domain	O
highly	O
conserved	O
among	O
the	O
dnHLH	B-GENE
proteins	I-GENE
from	O
mouse	O
and	O
drosophila	O
.	O

The	O
coding	O
region	O
of	O
nifA	B-GENE
was	O
determined	O
using	O
a	O
translational	O
lacZ	B-GENE
fusion	I-GENE
and	O
by	O
site	O
-	O
directed	O
mutagenesis	O
to	O
identify	O
which	O
of	O
four	O
in	O
frame	O
AUG	O
codons	O
was	O
used	O
.	O

Peptide	O
competition	O
studies	O
have	O
localized	O
a	O
cyclin	B-GENE
A	I-GENE
interaction	I-GENE
site	I-GENE
to	O
a	O
Lys381Lys382Leu383Met384Phe385	O
sequence	O
within	O
C	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
of	O
human	B-GENE
p53	I-GENE
.	O

Heterodimerization	B-GENE
mutant	I-GENE
RXR	I-GENE
failed	O
to	O
alter	O
GFP	B-GENE
-	O
VDR	B-GENE
and	O
nlsGFP	B-GENE
-	O
VDR	B-GENE
distribution	O
or	O
activity	O
.	O

Like	O
troponin	B-GENE
Cs	I-GENE
and	O
calmodulins	B-GENE
,	O
PfCPK	B-GENE
also	O
contains	O
four	O
EF	O
hand	O
calcium	O
-	O
binding	O
motifs	O
.	O

A	O
third	O
group	O
(	O
n	O
=	O
10	O
)	O
was	O
assigned	O
to	O
receive	O
the	O
canalith	O
repositioning	O
maneuver	O
without	O
mastoid	O
vibration	O
.	O

Upstream	O
of	O
the	O
afa	B-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
cluster	I-GENE
,	O
a	O
1	O
.	O
2	O
-	O
kb	O
region	O
was	O
found	O
to	O
be	O
96	O
%	O
identical	O
to	O
the	O
RepFIB	B-GENE
sequence	I-GENE
of	O
one	O
of	O
the	O
enterotoxigenic	O
E	O
.	O
coli	O
plasmids	O
(	O
P307	O
)	O
,	O
suggesting	O
a	O
common	O
ancestor	O
plasmid	O
.	O

The	O
cats	O
with	O
stage	O
-	O
2	O
lymphomas	O
that	O
were	O
FeLV	O
-	O
test	O
negative	O
had	O
the	O
best	O
response	O
to	O
treatment	O
.	O

We	O
hypothesize	O
that	O
the	O
ability	O
of	O
these	O
acidic	O
activators	O
to	O
specifically	O
interact	O
with	O
multiple	O
components	O
of	O
the	O
transcription	O
initiation	O
complex	O
likely	O
underlies	O
the	O
dramatic	O
functional	O
synergy	O
exhibited	O
by	O
this	O
class	O
of	O
activation	O
domains	O
in	O
vivo	O
.	O

Where	O
the	O
resonator	O
has	O
two	O
holes	O
,	O
these	O
terms	O
should	O
be	O
somewhat	O
modified	O
:	O
A	O
is	O
the	O
combined	O
area	O
of	O
the	O
two	O
holes	O
,	O
L	O
is	O
16	O
/	O
3pi	O
r	O
(	O
~	O
1	O
.	O
7r	O
)	O
for	O
a	O
simple	O
hole	O
in	O
a	O
thin	O
-	O
walled	O
vessel	O
and	O
r	O
is	O
the	O
radius	O
of	O
one	O
hole	O
(	O
Seto	O
,	O
1971	O
)	O
.	O

Histological	O
and	O
immunophenotypic	O
studies	O
revealed	O
12	O
large	O
cell	O
lymphomas	O
(	O
11	O
B	O
cell	O
and	O
one	O
T	O
cell	O
)	O
,	O
two	O
small	O
noncleaved	O
cell	O
lymphomas	O
(	O
B	O
-	O
cell	O
phenotype	O
)	O
,	O
and	O
five	O
low	O
grade	O
B	O
-	O
cell	O
lymphomas	O
(	O
two	O
small	O
lymphocytic	O
and	O
three	O
follicular	O
mixed	O
lymphomas	O
)	O
.	O

The	O
deviation	O
site	O
is	O
equivalent	O
to	O
the	O
exon	O
1	O
/	O
exon	O
2	O
splice	O
site	O
of	O
the	O
mouse	O
C	O
-	O
subunit	O
.	O

The	O
determination	O
of	O
diacetyl	O
,	O
2	O
,	O
3	O
-	O
pentanedione	O
and	O
acetoin	O
was	O
performed	O
in	O
two	O
steps	O
.	O

There	O
also	O
may	O
be	O
osmotic	O
challenges	O
to	O
mucosal	O
cell	O
function	O
as	O
evidenced	O
by	O
the	O
different	O
reaction	O
rates	O
with	O
hyper	O
-	O
and	O
hypotonic	O
saline	O
.	O

In	O
F9	O
,	O
which	O
is	O
a	O
prototype	O
of	O
embryonal	O
carcinoma	O
cells	O
expressing	O
hst	B-GENE
,	O
the	O
expression	O
of	O
hst	B-GENE
gene	I-GENE
is	O
positively	O
regulated	O
by	O
a	O
downstream	O
octamer	O
motif	O
that	O
functions	O
as	O
an	O
enhancer	O
.	O

The	O
reading	O
achievement	O
of	O
students	O
with	O
learning	O
disabilities	O
who	O
received	O
reading	O
instruction	O
through	O
the	O
DISTAR	O
program	O
was	O
compared	O
to	O
that	O
of	O
similar	O
students	O
using	O
basal	O
reader	O
materials	O
.	O

Two	O
putative	O
ATP	O
-	O
binding	O
domains	O
were	O
identified	O
,	O
one	O
in	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
argA	B-GENE
-	I-GENE
encoded	I-GENE
protein	I-GENE
and	O
the	O
other	O
in	O
the	O
carboxy	O
-	O
terminal	O
half	O
.	O

Chronic	O
granulocytic	O
leukemia	O
in	O
children	O
.	O

Purified	O
phosphorylated	O
PhoP	B-GENE
(	O
PhoPP	B-GENE
)	O
had	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2	O
.	O
5	O
h	O
,	O
which	O
was	O
reduced	O
to	O
about	O
15	O
min	O
by	O
addition	O
of	O
the	O
same	O
molar	O
amount	O
of	O
*	B-GENE
PhoR	I-GENE
(	O
the	O
cytoplasmic	O
region	O
of	O
PhoR	B-GENE
)	O
.	O

This	O
transformation	O
suppression	O
by	O
Rb	B-GENE
was	O
further	O
shown	O
to	O
be	O
due	O
to	O
transcriptional	O
repression	O
of	O
neu	B-GENE
using	O
Rb	B-GENE
expressing	O
effector	O
plasmid	O
and	O
neu	B-GENE
promoter	O
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	O
gene	O
.	O

Before	O
therapy	O
was	O
started	O
,	O
trabecular	O
bone	O
alterations	O
could	O
be	O
observed	O
which	O
were	O
typical	O
for	O
Paget	O
'	O
s	O
disease	O
of	O
bone	O
as	O
there	O
were	O
bulky	O
trabeculare	O
,	O
increased	O
remodelling	O
surfaces	O
and	O
giant	O
osteoclasts	O
.	O

T	O
.	O
infestans	O
,	O
T	O
.	O
delpontei	O
,	O
T	O
.	O
rubrovaria	O
,	O
T	O
.	O
sordida	O
,	O
T	O
.	O
guasayana	O
and	O
T	O
.	O
vitticeps	O
from	O
infestans	O
subgroup	O
and	O
T	O
.	O
pallidipennis	O
from	O
rubrofasciata	O
,	O
were	O
studied	O
.	O

Overexpression	O
of	O
N	O
-	O
terminal	O
mutations	O
disturbs	O
mitosis	O
and	O
produces	O
elongated	O
cells	O
,	O
Using	O
a	O
PCR	O
approach	O
,	O
we	O
isolated	O
a	O
putative	O
homologue	O
of	O
Prp4	B-GENE
from	O
human	O
and	O
mouse	O
cells	O
.	O

1	O
.	O

Biochemical	O
studies	O
and	O
studies	O
of	O
cells	O
expressing	O
mutant	O
IL	B-GENE
-	I-GENE
2	I-GENE
receptors	I-GENE
indicate	O
that	O
IL	B-GENE
-	I-GENE
2	I-GENE
-	O
induced	O
tyrosine	B-GENE
kinase	I-GENE
activation	O
initiates	O
a	O
complex	O
signaling	O
cascade	O
.	O

BACKGROUND	O
:	O
Peripheral	O
kappa	B-GENE
receptor	I-GENE
agonists	O
may	O
provide	O
a	O
new	O
therapeutic	O
approach	O
for	O
the	O
treatment	O
of	O
functional	O
dyspepsia	O
.	O

Fourteen	O
eyes	O
(	O
38	O
.	O
9	O
%	O
)	O
developed	O
DLK	O
after	O
an	O
epithelial	O
defect	O
,	O
representing	O
an	O
odds	O
ratio	O
of	O
13	O
times	O
.	O

The	O
yeast	O
genome	O
contains	O
a	O
single	O
ORD1	B-GENE
gene	I-GENE
that	O
resides	O
on	O
chromosome	O
XI	O
.	O

The	O
system	O
consists	O
of	O
a	O
TV	O
unit	O
compatible	O
to	O
IBM	O
PC	O
/	O
AT	O
and	O
software	O
.	O

The	O
N	O
-	O
terminal	O
sequence	O
of	O
the	O
extracellular	B-GENE
MEP20	I-GENE
,	O
TKVAS	B-GENE
,	O
was	O
found	O
at	O
aa	O
194	O
-	O
198	O
within	O
the	O
ORF	O
.	O

Isolates	O
of	O
B	O
.	O
burgdorferi	O
from	O
humans	O
,	O
rodents	O
,	O
and	O
I	O
.	O
dammini	O
are	O
usually	O
indistinguishable	O
,	O
but	O
strains	O
of	O
B	O
.	O
burgdorferi	O
with	O
different	O
major	O
proteins	O
have	O
been	O
identified	O
.	O

Cloning	O
of	O
the	O
GATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
that	O
regulates	O
endothelin	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
expression	O
in	O
endothelial	O
cells	O
.	O

The	O
Synechococcus	B-GENE
gene	I-GENE
rps1	I-GENE
encoding	O
S1	B-GENE
is	O
located	O
1	O
.	O
1	O
kb	O
downstream	O
from	O
psbB	B-GENE
,	O
which	O
encodes	O
the	O
photosystem	B-GENE
II	I-GENE
P680	I-GENE
chlorophyll	I-GENE
a	I-GENE
apoprotein	I-GENE
.	O

Two	O
-	O
dimensional	O
echocardiographic	O
parasternal	O
long	O
-	O
and	O
short	O
-	O
axis	O
views	O
were	O
obtained	O
during	O
graded	O
bleeding	O
by	O
rapid	O
withdrawal	O
of	O
blood	O
from	O
an	O
arterial	O
cannula	O
,	O
with	O
increments	O
of	O
5	O
%	O
each	O
up	O
to	O
30	O
%	O
of	O
calculated	O
blood	O
volume	O
.	O

A	O
comparison	O
of	O
the	O
rate	O
of	O
recovery	O
and	O
time	O
for	O
detection	O
of	O
mycobacteria	O
from	O
clinical	O
specimens	O
of	O
the	O
newly	O
developed	O
Mycobacteria	O
Growth	O
Indicator	O
Tube	O
(	O
MGIT	O
)	O
,	O
the	O
biphasic	O
Septi	O
-	O
Chek	O
,	O
and	O
the	O
egg	O
-	O
based	O
Ogawa	O
medium	O
was	O
made	O
.	O

As	O
in	O
IncP	O
alpha	O
plasmids	O
,	O
these	O
operons	O
are	O
transcribed	O
from	O
a	O
bidirectional	O
promoter	O
region	O
consisting	O
of	O
trfAp	B-GENE
for	O
the	O
trfA	B-GENE
operon	I-GENE
and	O
trbAp	B-GENE
and	O
trbBp	B-GENE
for	O
the	O
trb	B-GENE
operon	I-GENE
.	O

CONCLUSIONS	O
:	O
These	O
principally	O
structural	O
studies	O
support	O
the	O
hypothesis	O
that	O
the	O
thrombus	O
is	O
a	O
self	O
-	O
sustaining	O
entity	O
that	O
may	O
have	O
significance	O
in	O
the	O
pathophysiologic	O
mechanism	O
of	O
abdominal	O
aortic	O
aneurysms	O
.	O

The	O
BHV	B-GENE
-	I-GENE
1	I-GENE
UL24	I-GENE
,	O
UL25	B-GENE
,	O
UL26	B-GENE
and	O
UL26	B-GENE
.	I-GENE
5	I-GENE
transcripts	I-GENE
all	O
terminated	O
at	O
a	O
common	O
3	O
'	O
-	O
polyadenylation	O
site	O
and	O
varied	O
significantly	O
in	O
their	O
relative	O
abundance	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
of	O
protein	O
-	O
DNA	O
complexes	O
formed	O
with	O
nuclear	O
proteins	O
isolated	O
from	O
I3C	O
-	O
treated	O
and	O
-	O
untreated	O
cells	O
,	O
in	O
combination	O
with	O
supershift	O
assays	O
using	O
Sp1	B-GENE
antibodies	I-GENE
,	O
demonstrated	O
that	O
the	O
Sp1	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
CDK6	B-GENE
promoter	I-GENE
forms	O
a	O
specific	O
I3C	O
-	O
responsive	O
DNA	O
-	O
protein	O
complex	O
that	O
contains	O
the	O
Sp1	B-GENE
transcription	I-GENE
factor	I-GENE
.	O

These	O
results	O
suggest	O
that	O
both	O
the	O
distinct	O
DNA	O
binding	O
properties	O
of	O
PMLRAR	B-GENE
homodimers	I-GENE
and	O
the	O
sequestration	O
of	O
RXR	B-GENE
by	O
PMLRARs	B-GENE
may	O
contribute	O
to	O
the	O
molecular	O
mechanisms	O
which	O
underlie	O
the	O
pathogenesis	O
of	O
APL	O
.	O

The	O
analysis	O
showed	O
that	O
the	O
morning	O
active	O
(	O
MA	O
)	O
individuals	O
rose	O
earlier	O
and	O
went	O
to	O
bed	O
earlier	O
than	O
the	O
evening	O
active	O
(	O
EA	O
)	O
individuals	O
,	O
and	O
the	O
former	O
had	O
a	O
longer	O
sleep	O
length	O
than	O
the	O
latter	O
during	O
days	O
with	O
a	O
morning	O
shift	O
,	O
while	O
the	O
opposite	O
was	O
true	O
for	O
afternoon	O
and	O
night	O
shifts	O
.	O

This	O
ERD	O
is	O
recorded	O
over	O
the	O
contralateral	O
central	O
region	O
.	O

Deletion	O
mutations	O
were	O
constructed	O
,	O
removing	O
residues	O
2	O
-	O
30	O
,	O
31	O
-	O
60	O
,	O
61	O
-	O
90	O
,	O
and	O
49	O
-	O
78	O
of	O
the	O
N	O
-	O
terminal	O
cytoplasmic	O
domain	O
,	O
as	O
well	O
as	O
a	O
missense	O
mutation	O
of	O
a	O
dileucine	O
motif	O
.	O

Kluyveromyces	O
lactis	O
,	O
a	O
budding	O
yeast	O
related	O
to	O
Saccharomyces	O
cerevisiae	O
,	O
can	O
grow	O
on	O
a	O
wider	O
variety	O
of	O
substrates	O
and	O
shows	O
less	O
sensitivity	O
to	O
glucose	O
repression	O
than	O
does	O
Saccharomyces	O
cerevisiae	O
.	O

Low	O
-	O
affinity	O
E2	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
mediates	O
downmodulation	O
of	O
E2	B-GENE
transactivation	O
of	O
the	O
human	B-GENE
papillomavirus	I-GENE
type	I-GENE
8	I-GENE
late	I-GENE
promoter	I-GENE
.	O

Untransformed	O
3T3	O
cells	O
carry	O
abundant	O
1	O
.	O
9	O
kb	O
Hox	B-GENE
1	I-GENE
.	I-GENE
3	I-GENE
RNA	O
,	O
whereas	O
the	O
methylcholanthrene	O
-	O
transformed	O
MB66	O
and	O
LTK	O
-	O
cells	O
or	O
3T3	O
cells	O
transformed	O
by	O
the	O
oncogenes	O
src	B-GENE
,	O
fos	B-GENE
or	O
SV40	B-GENE
T	I-GENE
antigen	I-GENE
express	O
only	O
low	O
levels	O
.	O

Although	O
analysis	O
of	O
the	O
similarity	O
between	O
the	O
44	O
-	O
kDa	O
protein	O
and	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
RecA	I-GENE
protein	I-GENE
did	O
not	O
show	O
any	O
significant	O
homology	O
between	O
them	O
,	O
it	O
revealed	O
their	O
identity	O
by	O
five	O
amino	O
-	O
acid	O
residues	O
involved	O
in	O
the	O
formation	O
of	O
the	O
epitope	O
that	O
recognized	O
the	O
paratope	O
of	O
the	O
RecA	B-GENE
protein	I-GENE
antibody	I-GENE
for	O
subsequent	O
epitope	O
-	O
paratope	O
binding	O
of	O
these	O
proteins	O
.	O

Ureases	B-GENE
were	O
purified	O
from	O
the	O
recombinant	O
cells	O
and	O
shown	O
to	O
be	O
identical	O
to	O
control	O
enzyme	O
when	O
analyzed	O
by	O
gel	O
filtration	O
chromatography	O
and	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
;	O
however	O
,	O
in	O
every	O
case	O
the	O
activity	O
levels	O
correlated	O
to	O
nickel	O
contents	O
as	O
analyzed	O
by	O
atomic	O
absorption	O
analysis	O
.	O

Deoxyuridine	O
-	O
suppression	O
test	O
and	O
bone	O
marrow	O
culture	O
for	O
the	O
diagnosis	O
of	O
macrocytic	O
refractory	O
anaemias	O
.	O

Finally	O
,	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
mutant	O
proteins	O
were	O
assessed	O
for	O
the	O
ability	O
to	O
act	O
as	O
substrates	O
for	O
PR	B-GENE
.	O

These	O
psoralens	O
are	O
being	O
used	O
in	O
research	O
projects	O
sponsored	O
by	O
the	O
National	O
Toxicology	O
Program	O
.	O

Root	O
surface	O
caries	O
incidence	O
in	O
the	O
groups	O
inoculated	O
with	O
A	O
.	O
viscosus	O
and	O
A	O
.	O
viscosus	O
plus	O
S	O
.	O
sobrinus	O
did	O
not	O
differ	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
entire	O
E3L	B-GENE
gene	I-GENE
is	O
required	O
for	O
pathogenesis	O
in	O
the	O
mouse	O
model	O
.	O

The	O
development	O
of	O
various	O
pathological	O
lesions	O
in	O
thymus	O
,	O
spleen	O
,	O
lymph	O
nodes	O
and	O
bone	O
-	O
marrow	O
is	O
frequently	O
observed	O
.	O

Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
mouse	O
microglial	O
cells	O
,	O
the	O
brain	O
macrophages	O
,	O
express	O
both	O
IL	B-GENE
-	I-GENE
15	I-GENE
and	O
IL	B-GENE
-	I-GENE
15	I-GENE
/	I-GENE
IL	I-GENE
-	I-GENE
2	I-GENE
receptors	I-GENE
.	O

We	O
have	O
analyzed	O
the	O
role	O
of	O
the	O
HU	B-GENE
protein	I-GENE
in	O
invertasome	O
assembly	O
when	O
the	O
enhancer	O
is	O
located	O
at	O
variable	O
positions	O
close	O
to	O
one	O
of	O
the	O
recombination	O
sites	O
.	O

The	O
mode	O
of	O
action	O
is	O
often	O
suggested	O
as	O
an	O
explanation	O
for	O
the	O
different	O
slopes	O
of	O
concentration	O
-	O
effect	O
curves	O
.	O

This	O
may	O
be	O
another	O
example	O
of	O
the	O
principle	O
-	O
-	O
less	O
is	O
more	O
.	O

A	O
wide	O
conservation	O
of	O
iscSUA	B-GENE
genes	I-GENE
in	O
nature	O
and	O
evidence	O
that	O
NifU	B-GENE
and	O
NifS	B-GENE
participate	O
in	O
the	O
mobilization	O
of	O
iron	O
and	O
sulfur	O
for	O
nitrogenase	B-GENE
-	O
specific	O
iron	O
-	O
sulfur	O
cluster	O
formation	O
suggest	O
that	O
the	O
products	O
of	O
the	O
iscSUA	B-GENE
genes	I-GENE
could	O
play	O
a	O
general	O
role	O
in	O
the	O
formation	O
or	O
repair	O
of	O
iron	O
-	O
sulfur	O
clusters	O
.	O

On	O
transfer	O
from	O
glucose	O
,	O
succinate	O
,	O
malate	O
,	O
or	O
glycerol	O
medium	O
to	O
citrate	O
medium	O
,	O
the	O
Cit	O
+	O
Escherichia	O
coli	O
strains	O
showed	O
a	O
delay	O
of	O
36	O
to	O
48	O
h	O
before	O
growth	O
.	O

These	O
results	O
suggest	O
that	O
camptothecin	O
resistance	O
in	O
CEM	O
/	O
DOX	O
cells	O
is	O
due	O
to	O
different	O
mechanism	O
(	O
s	O
)	O
than	O
topoisomerase	B-GENE
-	O
or	O
P	B-GENE
-	I-GENE
glycoprotein	I-GENE
-	O
associated	O
multidrug	O
resistance	O
.	O

Jornvall	O
,	O
B	O
.	O

The	O
pattern	O
of	O
expression	O
of	O
this	O
and	O
other	O
Chi26	B-GENE
/	O
Chi33	B-GENE
chimeric	O
promoters	O
suggest	O
that	O
the	O
E	B-GENE
-	I-GENE
region	I-GENE
contains	O
cis	O
-	O
acting	O
sequences	O
which	O
activate	O
transcription	O
in	O
aleurone	O
and	O
silence	O
transcription	O
in	O
leaves	O
.	O

Spontaneous	O
coronary	O
artery	O
spasm	O
during	O
coronary	O
angiography	O
in	O
a	O
patient	O
with	O
exercise	O
-	O
induced	O
ST	O
segment	O
elevation	O
.	O

Four	O
newborns	O
in	O
this	O
group	O
became	O
HBsAg	B-GENE
carriers	O
.	O

Effectively	O
,	O
the	O
upstream	O
,	O
housekeeping	O
-	O
type	O
promoter	O
responds	O
to	O
FIXK	B-GENE
and	O
positively	O
regulates	O
the	O
downstream	O
,	O
sigma	B-GENE
54	I-GENE
-	I-GENE
type	I-GENE
promoter	I-GENE
.	O

K	O
.	O
,	O
Weiss	O
,	O
M	O
.	O

New	O
TB	O
respirator	O
standards	O
mean	O
more	O
choices	O
at	O
less	O
cost	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
using	O
oligonucleotides	O
derived	O
from	O
these	O
sites	O
demonstrated	O
formation	O
of	O
specific	O
DNA	O
-	O
protein	O
complexes	O
.	O

A	O
5789	B-GENE
-	I-GENE
nucleotide	I-GENE
-	I-GENE
long	I-GENE
EcoRI	I-GENE
fragment	I-GENE
from	O
the	O
genome	O
of	O
Thermotoga	O
maritima	O
,	O
identified	O
by	O
cross	O
-	O
hybridization	O
to	O
L11	B-GENE
,	O
L1	B-GENE
,	O
L10	B-GENE
,	O
and	O
L12	B-GENE
ribosomal	I-GENE
protein	I-GENE
gene	I-GENE
sequences	I-GENE
from	I-GENE
Escherichia	I-GENE
coli	I-GENE
,	O
was	O
cloned	O
and	O
sequenced	O
.	O

Background	O
reduction	O
with	O
various	O
agents	O
had	O
a	O
prominent	O
effect	O
on	O
DTIn1	O
as	O
well	O
as	O
99mTc	O
-	O
DTPA	O
biodistribution	O
.	O

These	O
data	O
suggest	O
that	O
reduction	O
in	O
PRA	O
may	O
have	O
contributed	O
to	O
the	O
hemodynamic	O
effects	O
of	O
this	O
peak	B-GENE
III	I-GENE
PDE	I-GENE
inhibitor	O
.	O

The	O
following	O
parameters	O
were	O
measured	O
:	O
onset	O
time	O
(	O
time	O
interval	O
from	O
injection	O
to	O
maximal	O
or	O
total	O
block	O
)	O
,	O
T125	O
/	O
75	O
(	O
time	O
for	O
T1	O
to	O
reach	O
25	O
%	O
or	O
75	O
%	O
of	O
control	O
)	O
,	O
TOF70	O
(	O
time	O
for	O
TOF	O
ratio	O
to	O
reach	O
70	O
%	O
of	O
control	O
)	O
,	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

A	O
.	O

Prematurely	O
inactivating	O
p42	B-GENE
MAPK	I-GENE
in	O
egg	O
extracts	O
resulted	O
in	O
a	O
corresponding	O
hastening	O
of	O
the	O
first	O
mitosis	O
.	O

The	O
use	O
of	O
ALAD	B-GENE
activity	O
and	O
EP	O
as	O
cumulative	O
lead	O
exposure	O
indicators	O
is	O
suggested	O
.	O

Binding	O
of	O
C	B-GENE
/	I-GENE
EBPs	I-GENE
to	O
all	O
three	O
spi	B-GENE
2	I-GENE
.	I-GENE
3	I-GENE
3	I-GENE
'	I-GENE
UTR	I-GENE
repressor	I-GENE
sites	I-GENE
,	O
although	O
rather	O
weak	O
,	O
was	O
confirmed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
that	O
otherwise	O
failed	O
to	O
reveal	O
specific	O
interactions	O
with	O
other	O
liver	O
nuclear	O
proteins	O
in	O
vitro	O
.	O

Cell	O
cycle	O
regulatory	O
components	O
have	O
been	O
largely	O
conserved	O
in	O
eukaryotes	O
;	O
however	O
,	O
orthologs	O
of	O
neither	O
CAK1	B-GENE
nor	O
csk1	B-GENE
have	O
been	O
identified	O
in	O
other	O
species	O
to	O
date	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
the	O
full	O
-	O
length	O
cDNA	O
of	O
mouse	O
PAX4	B-GENE
by	O
RACE	O
(	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
)	O
using	O
RNA	O
from	O
MIN6	O
cells	O
,	O
a	O
mouse	O
insulinoma	O
cell	O
line	O
.	O

Kohtz	O
,	O
J	O
.	O

Hence	O
the	O
GAP1	B-GENE
gene	I-GENE
encodes	O
a	O
protein	O
with	O
characteristics	O
typical	O
of	O
integral	O
membrane	O
proteins	O
translocating	O
ligants	O
across	O
cellular	O
membranes	O
.	O

The	O
results	O
suggest	O
that	O
proenzyme	O
processing	O
is	O
not	O
essential	O
for	O
secretion	O
of	O
PC2	B-GENE
,	O
but	O
peptides	O
containing	O
mutations	O
that	O
affect	O
the	O
ability	O
of	O
the	O
propeptide	O
(	O
and	O
cleavage	O
sites	O
)	O
to	O
fold	O
within	O
the	O
catalytic	O
pocket	O
are	O
not	O
transferred	O
beyond	O
the	O
early	O
stages	O
of	O
the	O
secretory	O
pathway	O
.	O

These	O
results	O
suggest	O
that	O
transcription	O
influences	O
aspects	O
of	O
gene	O
conversion	O
after	O
initiation	O
,	O
such	O
as	O
strand	O
invasion	O
and	O
/	O
or	O
mismatch	O
repair	O
(	O
MMR	O
)	O
.	O

Important	O
prognostic	O
factors	O
for	O
the	O
results	O
of	O
physiotherapeutic	O
exercises	O
in	O
intermittent	O
claudication	O

Finally	O
,	O
in	O
samples	O
obtained	O
from	O
two	O
patients	O
with	O
drug	O
refractory	O
ALL	O
,	O
BAC	O
-	O
derived	O
probes	O
applied	O
to	O
archived	O
marrow	O
cells	O
demonstrated	O
that	O
a	O
breakpoint	O
occurred	O
between	O
MDR1	B-GENE
and	O
sequences	O
500	O
-	O
1000	O
KB	O
telomeric	O
to	O
MDR1	B-GENE
,	O
consistent	O
with	O
a	O
random	O
chromosomal	O
rearrangement	O
.	O

Application	O
of	O
the	O
method	O
using	O
an	O
11	O
-	O
year	O
microseismicity	O
record	O
revealed	O
systematic	O
spatial	O
and	O
temporal	O
changes	O
in	O
the	O
slip	O
rate	O
that	O
were	O
synchronous	O
with	O
earthquake	O
activity	O
and	O
other	O
independent	O
measures	O
of	O
fault	O
-	O
zone	O
slip	O
.	O

PC12	O
cultures	O
that	O
had	O
been	O
"	O
primed	O
"	O
in	O
this	O
way	O
showed	O
an	O
accelerated	O
and	O
augmented	O
differentiation	O
response	O
to	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
.	O

One	O
of	O
these	O
clones	O
encodes	O
Xenopus	B-GENE
N	I-GENE
-	I-GENE
ras	I-GENE
.	O

The	O
Molteno	O
implant	O
is	O
an	O
effective	O
procedure	O
in	O
the	O
treatment	O
of	O
complicated	O
and	O
refractory	O
cases	O
of	O
glaucoma	O
in	O
high	O
-	O
risk	O
eyes	O
.	O

The	O
median	O
levels	O
of	O
t	B-GENE
-	I-GENE
PA	I-GENE
Ag	I-GENE
and	O
PAI	B-GENE
in	O
plasma	O
were	O
respectively	O
10	O
.	O
7	O
ng	O
/	O
ml	O
(	O
interquartile	O
range	O
8	O
.	O
6	O
ng	O
/	O
ml	O
)	O
and	O
15	O
.	O
7	O
IU	O
/	O
ml	O
(	O
interquartile	O
range	O
12	O
.	O
2	O
IU	O
/	O
ml	O
)	O
.	O

In	O
the	O
remaining	O
91	O
patients	O
(	O
group	O
2	O
)	O
,	O
Pseudomonas	O
(	O
18	O
)	O
,	O
coagulase	B-GENE
-	O
negative	O
Staphylococci	O
(	O
15	O
)	O
,	O
Staphylococcus	O
epidermidis	O
(	O
23	O
)	O
,	O
Staphylococcus	O
aureus	O
(	O
16	O
)	O
,	O
Corynebacterium	O
species	O
(	O
12	O
)	O
,	O
and	O
others	O
(	O
seven	O
)	O
were	O
isolated	O
.	O

Stamps	O
in	O
cardiology	O
:	O
de	O
Musset	O
sign	O
.	O

A	O
factor	O
present	O
in	O
nuclear	O
extracts	O
of	O
wounded	O
potato	O
tubers	O
was	O
found	O
to	O
bind	O
specifically	O
to	O
nucleotides	O
located	O
between	O
-	O
135	O
to	O
-	O
105	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
important	O
cis	O
-	O
regulatory	O
elements	O
.	O

The	O
leucine	O
zipper	O
region	O
of	O
ATF	B-GENE
proteins	I-GENE
is	O
also	O
similar	O
to	O
that	O
of	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
/	O
c	B-GENE
-	I-GENE
jun	I-GENE
family	O
of	O
transcription	O
factors	O
,	O
whose	O
DNA	O
-	O
binding	O
site	O
differs	O
from	O
the	O
ATF	B-GENE
-	O
binding	O
site	O
at	O
a	O
single	O
position	O
.	O

The	O
R260A	O
mutant	O
,	O
as	O
expected	O
,	O
was	O
unable	O
to	O
support	O
mRNA	O
synthesis	O
in	O
vitro	O
in	O
a	O
transcription	O
reconstitution	O
reaction	O
as	O
well	O
as	O
transcription	O
in	O
vivo	O
of	O
a	O
minigenome	O
using	O
a	O
reverse	O
genetic	O
approach	O
.	O

PEAP	O
was	O
significantly	O
higher	O
in	O
IDC	O
patients	O
compared	O
to	O
controls	O
(	O
48	O
.	O
7	O
+	O
/	O
-	O
32	O
.	O
6	O
vs	O
.	O

Uterine	O
contractions	O
began	O
with	O
a	O
mean	O
latency	O
of	O
62	O
min	O
in	O
the	O
PGF2	O
alpha	O
infused	O
women	O
,	O
in	O
controls	O
uterine	O
activity	O
remained	O
unchanged	O
.	O

Were	O
this	O
hypothesis	O
correct	O
,	O
the	O
requirement	O
for	O
elF4A	B-GENE
should	O
correlate	O
with	O
the	O
degree	O
of	O
mRNA	O
secondary	O
structure	O
.	O

In	O
spite	O
of	O
the	O
presence	O
of	O
a	O
physician	O
,	O
the	O
real	O
pathology	O
of	O
an	O
indian	O
population	O
of	O
Colombie	O
is	O
not	O
very	O
well	O
known	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
BSMV	B-GENE
coat	I-GENE
protein	I-GENE
is	O
the	O
sole	O
translation	O
product	O
of	O
the	O
genomic	B-GENE
RNA	I-GENE
beta	I-GENE
,	O
whereas	O
sgRNA	B-GENE
beta	I-GENE
1	I-GENE
serves	O
as	O
a	O
messenger	O
for	O
translation	O
of	O
the	O
beta	B-GENE
b	I-GENE
protein	I-GENE
,	O
and	O
sgRNA	B-GENE
beta	I-GENE
2	I-GENE
functions	O
as	O
a	O
messenger	O
for	O
translation	O
of	O
beta	B-GENE
c	I-GENE
and	O
beta	B-GENE
d	I-GENE
and	O
the	O
newly	O
discovered	O
beta	B-GENE
d	I-GENE
'	I-GENE
protein	I-GENE
.	O

A	O
retrospective	O
study	O
of	O
clozapine	O
and	O
electroencephalographic	O
abnormalities	O
in	O
schizophrenic	O
patients	O
.	O

The	O
concepts	O
were	O
developed	O
by	O
Mines	O
and	O
Garrey	O
during	O
the	O
next	O
10	O
years	O
.	O

When	O
the	O
measured	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
activity	O
in	O
the	O
pWP	O
-	O
transfected	O
cells	O
was	O
normalized	O
to	O
the	O
pCH110	O
-	O
transfected	O
cells	O
(	O
an	O
appropriate	O
control	O
if	O
the	O
SV40	B-GENE
early	I-GENE
region	I-GENE
promoter	I-GENE
functions	O
constitutively	O
in	O
various	O
cell	O
lines	O
)	O
,	O
the	O
results	O
suggested	O
that	O
the	O
promoter	O
region	O
of	O
the	O
PLP	B-GENE
gene	I-GENE
contains	O
the	O
information	O
necessary	O
for	O
initiation	O
of	O
transcription	O
in	O
a	O
C6	O
cell	O
-	O
specific	O
manner	O
.	O

PKK	B-GENE
exists	O
in	O
three	O
discernible	O
forms	O
at	O
steady	O
state	O
:	O
an	O
underphosphorylated	O
form	O
of	O
100	O
kDa	O
;	O
a	O
soluble	O
,	O
cytosolic	O
,	O
phosphorylated	O
form	O
of	O
110	O
kDa	O
;	O
and	O
a	O
phosphorylated	O
,	O
detergent	O
-	O
insoluble	O
form	O
of	O
112	O
kDa	O
.	O

The	O
P	B-GENE
-	I-GENE
ITIM	I-GENE
-	I-GENE
compelled	I-GENE
multi	I-GENE
-	I-GENE
phosphoprotein	I-GENE
complex	I-GENE
binds	O
to	O
and	O
activates	O
SHP	B-GENE
-	I-GENE
2	I-GENE
,	O
which	O
in	O
turn	O
dephosphorylates	O
SHIP	B-GENE
and	O
Shc	B-GENE
and	O
probably	O
other	O
substrates	O
.	O

When	O
PCR	O
was	O
used	O
to	O
amplify	O
agar	O
cultures	O
which	O
do	O
not	O
express	O
the	O
fimbriae	O
,	O
the	O
switch	O
region	O
was	O
OFF	O
only	O
.	O

Mechanisms	O
of	O
action	O
of	O
local	O
anaesthetics	O
.	O

Student	O
health	O

We	O
now	O
report	O
that	O
both	O
HSCR	B-GENE
mutations	O
impair	O
the	O
fixation	O
of	O
Shc	B-GENE
to	O
RET	B-GENE
and	O
consequently	O
prevent	O
its	O
phosphorylation	O
.	O

The	O
only	O
quantities	O
which	O
were	O
significantly	O
different	O
between	O
appendicitis	O
and	O
a	O
normal	O
appendix	O
were	O
sex	O
,	O
duration	O
of	O
symptoms	O
,	O
anorexia	O
and	O
vomiting	O
.	O

We	O
propose	O
that	O
U73	B-GENE
is	O
involved	O
in	O
methylation	O
of	O
the	O
G1739	O
residue	O
of	O
the	O
human	B-GENE
28S	I-GENE
rRNA	I-GENE
.	O

At	O
the	O
start	O
of	O
the	O
performance	O
ride	O
,	O
plasma	O
glucose	O
averaged	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
,	O
5	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
,	O
and	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
mmol	O
.	O
l	O
-	O
1	O
in	O
CON	O
,	O
CHO	O
-	O
7	O
,	O
and	O
CHO	O
-	O
0	O
/	O
21	O
,	O
respectively	O
(	O
all	O
different	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Therefore	O
prostaglandin	O
E2	O
is	O
characterized	O
in	O
relation	O
to	O
prostaglandin	O
F2	O
-	O
alpha	O
not	O
only	O
by	O
a	O
stronger	O
uterine	O
effectiveness	O
,	O
but	O
also	O
at	O
the	O
same	O
time	O
a	O
pronounced	O
influence	O
on	O
the	O
cardiovascular	O
system	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Ganglia	O
are	O
cysts	O
which	O
frequently	O
occur	O
in	O
the	O
proximity	O
of	O
joints	O
.	O

Lysates	O
of	O
COS	O
cells	O
transfected	O
with	O
modified	B-GENE
hGrzB	I-GENE
cDNA	I-GENE
were	O
able	O
to	O
hydrolyze	O
tert	O
-	O
butyloxycarbonyl	O
-	O
Ala	O
-	O
Ala	O
-	O
Asp	O
-	O
thiobenzyl	O
ester	O
(	O
Boc	O
-	O
Ala	O
-	O
Ala	O
-	O
Asp	O
-	O
SBzl	O
)	O
,	O
whereas	O
lysates	O
transfected	O
with	O
unmodified	B-GENE
hGrzB	I-GENE
cDNA	I-GENE
were	O
inactive	O
.	O

Proteins	O
PBP	B-GENE
-	I-GENE
1	I-GENE
and	O
PBP	B-GENE
-	I-GENE
2	I-GENE
bind	O
to	O
two	O
of	O
the	O
three	O
promoter	O
elements	O
in	O
the	O
trypanosomatid	O
Leptomonas	O
seymouri	O
.	O

Expression	O
of	O
medical	O
efficiency	O
by	O
integration	O
indicators	O
with	O
the	O
rational	O
utilization	O
of	O
budgeted	O
funds	O

The	O
present	O
study	O
tries	O
to	O
associate	O
some	O
of	O
the	O
causes	O
of	O
hot	O
ischaemia	O
during	O
the	O
agony	O
of	O
the	O
corpse	O
donor	O
and	O
to	O
evaluate	O
those	O
that	O
may	O
be	O
caused	O
by	O
sympathetic	O
efference	O
during	O
removal	O
.	O

The	O
enzyme	O
encoded	O
by	O
the	O
cloned	O
fragment	O
is	O
equally	O
active	O
on	O
pyruvate	O
and	O
hydroxypyruvate	O
,	O
indicating	O
that	O
the	O
enzyme	O
has	O
both	O
D	B-GENE
-	I-GENE
lactate	I-GENE
and	I-GENE
D	I-GENE
-	I-GENE
glycerate	I-GENE
dehydrogenase	I-GENE
activities	O
.	O

Noise	O
in	O
STM	O
due	O
to	O
atoms	O
moving	O
in	O
the	O
tunneling	O
space	O
.	O

The	O
human	O
sequence	O
contains	O
the	O
element	O
TGACTCT	O
that	O
also	O
is	O
found	O
in	O
a	O
murine	B-GENE
ras	I-GENE
-	I-GENE
responsive	I-GENE
enhancer	I-GENE
.	O

There	O
is	O
an	O
overall	O
functional	O
similarity	O
between	O
IL	B-GENE
-	I-GENE
6	I-GENE
and	O
c	B-GENE
-	I-GENE
fos	I-GENE
promoters	I-GENE
,	O
since	O
transfection	O
of	O
excess	O
amounts	O
of	O
either	O
promoter	O
DNA	O
into	O
intact	O
HeLa	O
cells	O
modulates	O
the	O
function	O
of	O
the	O
heterologous	O
promoter	O
construct	O
.	O

Enhanced	O
phospholipid	O
hydrolysis	O
with	O
free	O
fatty	O
acid	O
and	O
thromboxane	O
accumulation	O
,	O
increased	O
release	O
of	O
excitatory	O
amino	O
acids	O
,	O
and	O
decreased	O
tissue	O
magnesium	O
levels	O
may	O
each	O
serve	O
to	O
worsen	O
secondary	O
tissue	O
damage	O
and	O
diminish	O
neurologic	O
recovery	O
after	O
spinal	O
cord	O
injury	O
associated	O
with	O
acute	O
alcohol	O
intoxication	O
.	O

To	O
determine	O
whether	O
the	O
transcript	O
encodes	O
an	O
active	O
enzyme	O
,	O
we	O
developed	O
a	O
novel	O
transient	O
embryonic	O
excision	O
assay	O
in	O
which	O
zebrafish	O
fertilized	O
eggs	O
were	O
co	O
-	O
injected	O
with	O
RNA	O
transcribed	O
in	O
vitro	O
using	O
the	O
Tol2	B-GENE
cDNA	I-GENE
as	O
a	O
template	O
and	O
a	O
plasmid	O
DNA	O
harboring	O
a	O
nonautonomous	O
Tol2	B-GENE
element	I-GENE
,	O
which	O
has	O
a	O
deletion	O
in	O
the	O
transposase	B-GENE
coding	I-GENE
region	I-GENE
.	O

The	O
overall	O
objective	O
response	O
rate	O
(	O
RR	O
)	O
was	O
50	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
29	O
-	O
71	O
%	O
]	O
including	O
four	O
complete	O
responses	O
and	O
eight	O
partial	O
responses	O
.	O

We	O
suggest	O
that	O
this	O
relatively	O
small	O
deletion	O
affects	O
a	O
segment	O
containing	O
3	B-GENE
'	I-GENE
VH	I-GENE
genes	I-GENE
with	O
important	O
regulatory	O
functions	O
,	O
the	O
loss	O
of	O
which	O
leads	O
to	O
the	O
ali	O
phenotype	O
.	O

Two	O
SH2	B-GENE
domains	I-GENE
of	O
p120	B-GENE
Ras	B-GENE
GTPase	B-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
bind	O
synergistically	O
to	O
tyrosine	O
phosphorylated	O
p190	B-GENE
Rho	O
GTPase	B-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
.	O

p120	B-GENE
GTPase	B-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
(	O
GAP	B-GENE
)	O
is	O
a	O
negative	O
regulator	O
of	O
Ras	B-GENE
that	O
functions	O
at	O
a	O
key	O
relay	O
point	O
in	O
signal	O
transduction	O
pathways	O
that	O
control	O
cell	O
proliferation	O
.	O

A	O
homologue	O
of	O
the	O
MAP	B-GENE
/	O
ERK	B-GENE
family	O
of	O
protein	O
kinase	O
genes	O
is	O
expressed	O
in	O
vegetative	O
and	O
in	O
female	O
reproductive	O
organs	O
of	O
Petunia	O
hybrida	O
.	O

Its	O
prognostic	O
impact	O
is	O
superior	O
to	O
the	O
T1	O
/	O
2	O
one	O
(	O
RR	O
=	O
2	O
.	O
9	O
;	O
p	O
=	O
0	O
.	O
0010	O
)	O
.	O

It	O
encodes	O
a	O
sequence	O
-	O
specific	O
transcription	O
factor	O
that	O
controls	O
,	O
in	O
concert	O
with	O
other	O
gene	O
products	O
,	O
differentiative	O
pathways	O
of	O
tissues	O
in	O
which	O
Scr	B-GENE
is	O
expressed	O
.	O

CONCLUSION	O
:	O
DMIPP	O
detects	O
regionally	O
hypoperfused	O
myocardium	O
,	O
in	O
which	O
agreement	O
between	O
MBF	O
and	O
fatty	O
acid	O
uptake	O
deteriorates	O
.	O

The	O
effect	O
of	O
guaiphenesin	O
on	O
absorption	O
and	O
bioavailability	O
of	O
paracetamol	O
from	O
composite	O
analgesic	O
preparations	O
.	O

Transcription	O
of	O
the	O
inserted	O
gene	O
into	O
the	O
predicted	O
subgenomic	O
polyadenylated	O
mRNA	O
was	O
demonstrated	O
by	O
Northern	O
(	O
RNA	O
)	O
blot	O
hybridization	O
analysis	O
,	O
and	O
the	O
encoded	O
protein	O
was	O
detected	O
by	O
enzyme	O
assay	O
and	O
by	O
radioimmunoprecipitation	O
.	O

These	O
results	O
suggest	O
that	O
panretinal	O
photocoagulation	O
offers	O
a	O
highly	O
effective	O
means	O
of	O
dealing	O
with	O
early	O
and	O
moderately	O
advanced	O
cases	O
of	O
angle	O
neovascularization	O
.	O

NBSII	O
is	O
essential	O
for	O
ribosome	O
-	O
stimulated	O
activity	O
.	O

Sixteen	O
patients	O
(	O
25	O
.	O
4	O
%	O
)	O
encountered	O
rejection	O
while	O
weaning	O
at	O
median	O
period	O
of	O
9	O
.	O
5	O
months	O
(	O
range	O
,	O
1	O
-	O
63	O
months	O
)	O
from	O
the	O
start	O
of	O
weaning	O
.	O

ALT	B-GENE
(	O
alanine	B-GENE
aminotransferase	I-GENE
)	O
and	O
Hb	B-GENE
(	O
hemoglobin	B-GENE
)	O
appeared	O
to	O
be	O
predictive	O
for	O
efficacy	O
.	O

Theophylline	O
QID	O
,	O
TID	O
,	O
BID	O
and	O
now	O
QD	O
?	O

A	O
report	O
on	O
24	O
-	O
hour	O
dosing	O
with	O
slow	O
-	O
release	O
theophylline	O
formulations	O
with	O
emphasis	O
on	O
analyses	O
of	O
data	O
used	O
to	O
obtain	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
Theo	O
-	O
24	O
.	O

Signal	O
transduction	O
in	O
fibroblasts	O
stably	O
transformed	O
by	O
[	O
Val12	O
]	O
Ras	O
-	O
-	O
the	O
activities	O
of	O
extracellular	B-GENE
-	I-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
and	O
Jun	B-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
are	O
only	O
moderately	O
increased	O
,	O
and	O
the	O
activity	O
of	O
the	O
delta	O
-	O
inhibitor	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
is	O
not	O
alleviated	O
.	O

Time	O
for	O
action	O
on	O
hepatitis	O
B	O
immunisation	O
.	O

Escherichia	O
coli	O
cells	O
expressing	O
a	O
mutant	B-GENE
glyV	I-GENE
(	O
glycine	B-GENE
tRNA	I-GENE
)	O
gene	O
have	O
a	O
UVM	O
-	O
constitutive	O
phenotype	O
:	O
implications	O
for	O
mechanisms	O
underlying	O
the	O
mutA	B-GENE
or	O
mutC	B-GENE
mutator	I-GENE
effect	O
.	O

By	O
24	O
h	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
FFA	O
levels	O
from	O
shams	O
.	O

This	O
result	O
suggests	O
that	O
the	O
target	O
protein	O
specificity	O
of	O
E2s	B-GENE
can	O
be	O
altered	O
by	O
the	O
addition	O
of	O
appropriate	O
C	O
-	O
terminal	O
extensions	O
,	O
thus	O
providing	O
a	O
way	O
to	O
modify	O
the	O
selectivity	O
of	O
the	O
ubiquitin	B-GENE
system	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
the	O
hemF	B-GENE
gene	I-GENE
,	O
encoding	O
the	O
aerobic	O
coproporphyrinogen	B-GENE
III	I-GENE
oxidase	I-GENE
from	I-GENE
Escherichia	I-GENE
coli	I-GENE
,	O
by	O
functional	O
complementation	O
of	O
a	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
HEM13	I-GENE
mutant	I-GENE
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
physical	O
and	O
biological	O
characteristics	O
of	O
nebulized	O
interleukin	B-GENE
2	I-GENE
liposomes	O
.	O

The	O
atopic	O
disposition	O
,	O
indicated	O
by	O
positive	O
skin	O
reactions	O
and	O
IgE	B-GENE
antibody	O
titers	O
etc	O
.	O
,	O
and	O
the	O
bronchial	O
reactivity	O
to	O
inhaled	O
acetylcholine	O
were	O
examined	O
on	O
the	O
following	O
three	O
groups	O
:	O
(	O
1	O
)	O
20	O
young	O
adults	O
with	O
a	O
history	O
of	O
childhood	O
asthma	O
who	O
have	O
been	O
symptom	O
-	O
free	O
for	O
more	O
than	O
4	O
yr	O
;	O
(	O
2	O
)	O
20	O
current	O
asthmatics	O
,	O
and	O
(	O
3	O
)	O
20	O
healthy	O
young	O
adults	O
.	O

Previous	O
studies	O
showed	O
that	O
a	O
palindromic	O
sequence	O
located	O
at	O
-	O
159	O
base	O
pairs	O
is	O
essential	O
for	O
induction	O
of	O
cutinase	B-GENE
gene	I-GENE
in	O
Fusarium	O
solani	O
f	O
.	O

sp	O
.	O
pisi	O
(	O
Nectria	O
haematococca	O
mating	O
type	O
VI	O
)	O
by	O
the	O
hydroxy	O
fatty	O
acids	O
from	O
plant	O
cutin	O
and	O
that	O
a	O
50	O
-	O
kDa	O
nuclear	O
protein	O
binds	O
to	O
a	O
promoter	O
that	O
contains	O
this	O
element	O
.	O

This	O
preliminary	O
study	O
reports	O
an	O
initial	O
evaluation	O
of	O
HMPAO	O
-	O
SPECT	O
imaging	O
for	O
assessing	O
regional	O
alterations	O
in	O
brain	O
function	O
during	O
opiate	O
dependence	O
and	O
withdrawal	O
.	O

We	O
conclude	O
that	O
these	O
cDNAs	O
belong	O
to	O
a	O
novel	O
GST	B-GENE
class	O
hereby	O
designated	O
Kappa	O
,	O
with	O
the	O
rat	B-GENE
GST	I-GENE
subunit	I-GENE
13	I-GENE
gene	I-GENE
designated	O
rGSTK1	B-GENE
and	O
the	O
human	O
gene	O
being	O
called	O
hGSTK1	B-GENE
.	O

Based	O
on	O
PCR	O
strategies	O
and	O
expression	O
studies	O
,	O
we	O
define	O
the	O
genomic	O
organization	O
of	O
the	O
FUT8b	B-GENE
gene	I-GENE
.	O

The	O
present	O
study	O
demonstrates	O
that	O
the	O
proto	B-GENE
-	I-GENE
oncogene	I-GENE
c	I-GENE
-	I-GENE
jun	I-GENE
represses	O
transcription	O
of	O
the	O
human	B-GENE
CG	I-GENE
alpha	I-GENE
and	O
CG	B-GENE
beta	I-GENE
promoters	I-GENE
.	O

c	B-GENE
-	I-GENE
Jun	I-GENE
repressed	O
the	O
CG	B-GENE
alpha	I-GENE
promoter	I-GENE
through	O
a	O
canonical	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
that	O
is	O
known	O
to	O
bind	O
c	B-GENE
-	I-GENE
Jun	I-GENE
and	O
other	O
members	O
of	O
the	O
B	B-GENE
-	I-GENE
Zip	I-GENE
transcription	I-GENE
factor	I-GENE
family	I-GENE
.	O

Pulse	O
monitors	O
in	O
outpatient	O
dental	O
anaesthesia	O
.	O

Previous	O
studies	O
using	O
partial	O
sequences	O
have	O
suggested	O
the	O
potential	O
of	O
26S	B-GENE
or	O
large	B-GENE
-	I-GENE
subunit	I-GENE
(	O
LSU	B-GENE
)	O
rDNA	O
for	O
phylogeny	O
retrieval	O
at	O
taxonomic	O
levels	O
comparable	O
to	O
those	O
investigated	O
with	O
18S	B-GENE
rDNA	I-GENE
.	O

The	O
sensitivity	O
of	O
99mTc	O
-	O
IgG	B-GENE
scintigraphy	O
ranged	O
between	O
71	O
%	O
and	O
100	O
%	O
.	O

The	O
index	O
patient	O
,	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
,	O
presents	O
typical	O
symptoms	O
of	O
OPD	O
type	O
I	O
together	O
with	O
bowing	O
of	O
the	O
long	O
bones	O
and	O
abnormalities	O
of	O
the	O
thorax	O
and	O
spinal	O
column	O
.	O

The	O
cause	O
for	O
the	O
increase	O
in	O
plasma	B-GENE
ANP	I-GENE
levels	O
in	O
the	O
active	O
phase	O
remains	O
to	O
be	O
determined	O
.	O

A	O
genomic	O
clone	O
representing	O
the	O
5	O
'	O
part	O
of	O
the	O
message	O
was	O
also	O
isolated	O
.	O

Antibiotics	O
and	O
CDCA	O
-	O
mediation	O
are	O
essential	O
for	O
symptomatic	O
therapy	O
.	O

The	O
main	O
side	O
-	O
effects	O
were	O
myelosuppression	O
,	O
mucositis	O
and	O
peripheral	O
neuropathy	O
,	O
which	O
were	O
all	O
common	O
and	O
often	O
severe	O
.	O

The	O
column	O
densities	O
of	O
frozen	O
molecular	O
hydrogen	O
and	O
methanol	O
are	O
inferred	O
to	O
be	O
about	O
2	O
.	O
5	O
x	O
10	O
(	O
18	O
)	O
and	O
3	O
.	O
0	O
x	O
10	O
(	O
19	O
)	O
,	O
respectively	O
.	O

Similarly	O
,	O
an	O
increase	O
in	O
CAT	B-GENE
expression	O
from	O
the	O
same	O
construct	O
(	O
pBLCAT	O
-	O
ENDOA	B-GENE
)	O
was	O
also	O
observed	O
in	O
7AQS2	O
.	O
1	O
cells	O
.	O

The	O
prevalence	O
of	O
antibodies	O
to	O
HRES	B-GENE
-	I-GENE
1	I-GENE
peptides	I-GENE
pep14	I-GENE
-	I-GENE
24	I-GENE
and	I-GENE
pep117	I-GENE
-	I-GENE
127	I-GENE
was	O
determined	O
in	O
65	O
normal	O
blood	O
donors	O
and	O
146	O
patients	O
with	O
immunological	O
disorders	O
.	O

We	O
recently	O
reported	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
alpha	B-GENE
7	I-GENE
integrin	I-GENE
chain	I-GENE
and	O
its	O
regulated	O
expression	O
during	O
the	O
development	O
of	O
skeletal	O
muscle	O
(	O
Song	O
et	O
al	O
.	O

The	O
contractile	O
effects	O
of	O
oxytocin	B-GENE
,	O
prostaglandin	O
F2	O
alpha	O
and	O
their	O
combined	O
use	O
on	O
human	O
pregnant	O
myometrium	O
were	O
studied	O
in	O
vitro	O
.	O

These	O
involve	O
(	O
1	O
)	O
subcloning	O
a	O
promoterless	O
sucCD	B-GENE
fragment	I-GENE
downstream	O
of	O
the	O
lac	B-GENE
promoter	I-GENE
in	O
M13mp10	O
,	O
and	O
(	O
2	O
)	O
precise	O
splicing	O
of	O
the	O
suc	B-GENE
coding	I-GENE
regions	I-GENE
with	O
the	O
efficient	O
atpE	B-GENE
ribosome	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
and	O
expression	O
from	O
the	O
thermoinducible	O
lambda	O
promoters	O
in	O
the	O
pJLA503	O
vector	O
.	O

These	O
mutations	O
prevent	O
FKBP12	B-GENE
-	O
rapamycin	O
binding	O
to	O
TOR2	B-GENE
,	O
as	O
assayed	O
with	O
the	O
two	O
-	O
hybrid	O
system	O
.	O

Transcription	O
of	O
eukaryotic	O
tRNA	O
genes	O
is	O
dependent	O
on	O
the	O
A	O
-	O
and	O
B	O
-	O
Box	O
internal	O
control	O
regions	O
(	O
ICRs	O
)	O
and	O
the	O
upstream	O
transcription	O
modulatory	O
region	O
.	O

Failure	O
to	O
demonstrate	O
a	O
major	O
anti	O
-	O
inflammatory	O
effect	O
with	O
alpha	O
tocopherol	O
supplementation	O
(	O
400	O
IU	O
/	O
day	O
)	O
in	O
normal	O
subjects	O
.	O

Results	O
on	O
the	O
use	O
of	O
amiodarone	O
in	O
the	O
prevention	O
of	O
paroxysmal	O
AF	O
have	O
been	O
equivocal	O
;	O
this	O
may	O
be	O
attributed	O
to	O
differences	O
in	O
defining	O
paroxysmal	O
AF	O
.	O

High	O
-	O
level	O
expression	O
of	O
sccypB	B-GENE
as	O
well	O
as	O
of	O
sccypA	B-GENE
cloned	O
into	O
the	O
expression	O
vector	O
pIJ702	O
did	O
not	O
produce	O
detectable	O
changes	O
in	O
growth	O
and	O
morphology	O
of	O
S	O
.	O
chrysomallus	O
and	O
S	O
.	O
lividans	O
.	O

Fas	B-GENE
(	O
APO	B-GENE
-	I-GENE
1	I-GENE
/	O
CD95	B-GENE
)	O
,	O
which	O
is	O
a	O
member	O
of	O
the	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
receptor	I-GENE
superfamily	I-GENE
,	O
is	O
a	O
cell	O
surface	O
receptor	O
that	O
induces	O
apoptosis	O
.	O

In	O
the	O
future	O
,	O
transoesophageal	O
echocardiography	O
may	O
be	O
used	O
to	O
measure	O
variations	O
in	O
wall	O
thickness	O
which	O
change	O
the	O
global	O
loading	O
conditions	O
in	O
the	O
basal	O
midwall	O
compartments	O
of	O
the	O
left	O
ventricle	O
.	O

We	O
studied	O
18	O
dogs	O
,	O
anaesthetised	O
and	O
spontaneously	O
breathing	O
both	O
room	O
air	O
and	O
after	O
the	O
inhalation	O
of	O
a	O
gas	O
mixture	O
containing	O
10	O
%	O
CO2	O
,	O
20	O
.	O
9	O
%	O
O2	O
,	O
and	O
69	O
.	O
1	O
%	O
N2	O
,	O
to	O
determine	O
the	O
role	O
of	O
histamine	O
,	O
serotonin	O
,	O
and	O
acidaemia	O
in	O
pulmonary	O
hypertension	O
produced	O
by	O
hypercapnia	O
.	O

Sequencing	O
of	O
this	O
fragment	O
showed	O
that	O
the	O
MRP13	B-GENE
coding	O
region	O
specifies	O
a	O
324	O
-	O
amino	O
-	O
acid	O
basic	O
protein	O
with	O
a	O
calculated	O
Mr	O
of	O
37	O
,	O
366	O
.	O

Viral	O
complementary	O
15	B-GENE
S	I-GENE
mRNA	I-GENE
that	O
directs	O
the	O
synthesis	O
of	O
N	B-GENE
protein	I-GENE
and	O
hybridizes	O
to	O
the	O
predicted	O
N	B-GENE
gene	I-GENE
DNA	O
has	O
been	O
identified	O
in	O
infected	O
cell	O
extracts	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B-GENE
I	I-GENE
protection	O
analyses	O
revealed	O
that	O
FP	B-GENE
I	I-GENE
was	O
bound	O
by	O
the	O
transcription	O
factor	O
PU	B-GENE
.	I-GENE
1	I-GENE
/	O
Spi	B-GENE
-	I-GENE
1	I-GENE
.	O

Retroviral	O
vector	O
producer	O
cell	O
populations	O
and	O
cell	O
clones	O
were	O
established	O
for	O
each	O
chLTR	B-GENE
vector	O
,	O
and	O
all	O
were	O
capable	O
of	O
yielding	O
high	O
vector	O
titers	O
(	O
>	O
10	O
(	O
5	O
)	O
G418R	B-GENE
cfu	O
/	O
ml	O
on	O
NIH	O
-	O
3T3	O
)	O
.	O

However	O
,	O
a	O
few	O
sites	O
in	O
the	O
genomes	O
of	O
EC	O
cells	O
permit	O
M	B-GENE
-	I-GENE
MuLVneo	I-GENE
delta	I-GENE
Enh	I-GENE
proviral	O
expression	O
.	O

Increasing	O
insulin	B-GENE
sensitivity	O
in	O
type	O
I	O
diabetic	O
patients	O
should	O
alert	O
clinicians	O
to	O
the	O
possibility	O
of	O
glucocorticoid	O
deficiency	O
.	O

However	O
,	O
differential	O
utilization	O
of	O
these	O
determinants	O
mediate	O
RAR	B-GENE
-	O
RXR	B-GENE
heterodimer	O
binding	O
to	O
DR	O
-	O
2	O
and	O
DR	O
-	O
5	O
RAREs	O
.	O

Galactorrhoea	O
is	O
a	O
rare	O
presentation	O
of	O
an	O
empty	O
sella	O
syndrome	O
.	O

The	O
addition	O
of	O
novel	O
techniques	O
,	O
such	O
as	O
histopathologic	O
ultrastaging	O
,	O
immunohistochemistry	O
staining	O
,	O
and	O
reverse	B-GENE
transcriptase	I-GENE
polymerase	O
chain	O
reaction	O
assays	O
,	O
will	O
help	O
increase	O
the	O
accuracy	O
and	O
rate	O
of	O
detection	O
of	O
disease	O
.	O

Several	O
of	O
the	O
drugs	O
used	O
in	O
the	O
management	O
of	O
MAC	O
have	O
been	O
associated	O
with	O
significant	O
drug	O
interactions	O
involving	O
the	O
cytochrome	B-GENE
P450	I-GENE
(	O
CYP	B-GENE
)	O
enzyme	O
system	O
.	O

Arterial	O
compliance	O
measurements	O
using	O
intraarterial	O
pulse	O
contour	O
analysis	O
and	O
a	O
modified	O
Windkessel	O
model	O
were	O
carried	O
out	O
in	O
19	O
patients	O
with	O
isolated	O
systolic	O
hypertension	O
(	O
>	O
or	O
=	O
160	O
/	O
<	O
or	O
=	O
90	O
mm	O
Hg	O
)	O
and	O
compared	O
to	O
measurements	O
in	O
29	O
patients	O
with	O
essential	O
hypertension	O
(	O
diastolic	O
blood	O
pressure	O
[	O
BP	O
]	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
)	O
and	O
47	O
normotensive	O
control	O
subjects	O
.	O

Rather	O
than	O
seeking	O
a	O
blanket	O
characterization	O
of	O
an	O
essentially	O
heterogeneous	O
group	O
,	O
it	O
may	O
be	O
more	O
useful	O
to	O
consider	O
idiom	O
comprehension	O
a	O
secondary	O
manifestation	O
of	O
semantic	O
and	O
/	O
or	O
pragmatic	O
difficulties	O
.	O

Methylprednisolone	O
and	O
U	O
-	O
74006F	O
were	O
equally	O
effective	O
at	O
preventing	O
neurological	O
dysfunction	O
compared	O
to	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
U	O
-	O
78517F	O
was	O
slightly	O
less	O
effective	O
than	O
U	O
-	O
74006F	O
and	O
methylprednisolone	O
but	O
was	O
significantly	O
better	O
than	O
vehicle	O
in	O
preventing	O
neurological	O
dysfunction	O
.	O

The	O
women	O
in	O
the	O
intermediate	O
calcium	O
group	O
had	O
approximately	O
the	O
same	O
mean	O
BMD	O
values	O
as	O
those	O
in	O
the	O
low	O
calcium	O
group	O
.	O

International	O
efforts	O
are	O
now	O
being	O
made	O
to	O
standardize	O
haemolytic	O
test	O
conditions	O
and	O
the	O
present	O
study	O
is	O
meant	O
as	O
a	O
contribution	O
to	O
this	O
.	O

The	O
transition	O
from	O
expression	O
of	O
early	O
meiotic	O
genes	O
to	O
expression	O
of	O
middle	O
sporulation	O
-	O
specific	O
genes	O
occurs	O
at	O
about	O
the	O
time	O
that	O
cells	O
exit	O
from	O
pachytene	O
and	O
form	O
the	O
meiosis	O
I	O
spindle	O
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
DNA	O
-	O
protein	O
binding	O
and	O
ICAM	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
activity	O
were	O
enhanced	O
by	O
IL	B-GENE
-	I-GENE
1beta	I-GENE
and	O
these	O
effects	O
were	O
inhibited	O
by	O
tyrphostin	O
23	O
,	O
but	O
not	O
by	O
PD	O
98059	O
or	O
SB	O
203580	O
.	O

Peripheral	O
neuropathy	O
in	O
the	O
cherry	O
-	O
red	O
spot	O
-	O
myoclonus	O
syndrome	O
(	O
sialidosis	O
type	O
I	O
)	O
.	O

Using	O
the	O
two	O
-	O
hybrid	O
screening	O
method	O
,	O
we	O
have	O
identified	O
an	O
additional	O
component	O
of	O
the	O
CCAAT	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
.	O

The	O
myb	B-GENE
proto	I-GENE
oncogene	I-GENE
product	I-GENE
(	O
c	B-GENE
-	I-GENE
Myb	I-GENE
)	O
is	O
a	O
transcriptional	O
regulator	O
and	O
its	O
expression	O
and	O
function	O
are	O
tightly	O
linked	O
to	O
the	O
cellular	O
entry	O
into	O
S	O
phase	O
and	O
DNA	O
synthesis	O
.	O

Both	O
the	O
p38	B-GENE
kinase	I-GENE
inhibitor	O
SB205380	O
(	O
SB	O
)	O
and	O
cotransfection	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
p38	B-GENE
kinase	I-GENE
reduced	O
IL	B-GENE
-	I-GENE
1beta	I-GENE
stimulation	O
of	O
the	O
hBNP	B-GENE
promoter	I-GENE
.	O

CLINICAL	O
FEATURES	O
:	O
This	O
30	O
-	O
yr	O
-	O
old	O
gravida	O
V	O
para	O
0	O
woman	O
presented	O
to	O
the	O
anaesthesia	O
consultation	O
clinic	O
at	O
37	O
-	O
wk	O
gestation	O
to	O
discuss	O
pain	O
relief	O
options	O
for	O
labour	O
and	O
delivery	O
.	O

The	O
TaqI	B-GENE
and	O
HaeIII	B-GENE
RFLPs	O
will	O
provide	O
tools	O
for	O
the	O
genetic	O
analysis	O
of	O
CR2	B-GENE
.	O

In	O
addition	O
,	O
because	O
SB203580	O
had	O
no	O
effect	O
of	O
TNF	B-GENE
-	O
or	O
ceramide	O
-	O
induced	O
apoptosis	O
,	O
our	O
results	O
strongly	O
argue	O
against	O
a	O
role	O
for	O
p38	B-GENE
MAPK	I-GENE
in	O
the	O
induction	O
of	O
TNF	B-GENE
-	O
-	O
or	O
ceramide	O
-	O
induced	O
apoptosis	O
.	O

Cognitive	O
measures	O
of	O
attention	O
included	O
the	O
Stroop	O
and	O
Controlled	O
Oral	O
Word	O
Association	O
Test	O
using	O
the	O
letters	O
"	O
C	O
,	O
"	O
"	O
F	O
,	O
"	O
and	O
"	O
L	O
"	O
(	O
COWAT	O
,	O
CFL	O
version	O
)	O
.	O

Ptx1	B-GENE
belongs	O
to	O
an	O
expanding	O
family	O
of	O
bicoid	B-GENE
-	I-GENE
related	I-GENE
vertebrate	O
homeobox	O
genes	O
.	O

Effects	O
of	O
dietary	O
lipids	O
on	O
whole	O
-	O
body	O
retention	O
and	O
organ	O
distribution	O
of	O
organic	O
and	O
inorganic	O
mercury	O
in	O
mice	O
.	O

Differential	O
transcription	O
of	O
plastome	O
-	O
encoded	O
genes	O
in	O
the	O
mesophyll	O
and	O
bundle	O
-	O
sheath	O
chloroplasts	O
of	O
the	O
monocotyledonous	O
NADP	O
-	O
malic	B-GENE
enzyme	I-GENE
-	O
type	O
C4	O
plants	O
maize	O
and	O
Sorghum	O
.	O

Sequential	O
immunoprecipitation	O
showed	O
all	O
detectable	O
p53	B-GENE
to	O
be	O
of	O
the	O
PAb246	B-GENE
+	I-GENE
class	O
in	O
each	O
LPV	O
-	O
transformed	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
stable	O
p53	B-GENE
was	O
indeed	O
wild	O
type	O
.	O

Tissue	O
-	O
specific	O
gene	O
regulation	O
of	O
eukaryotic	O
organisms	O
is	O
to	O
a	O
large	O
extent	O
mediated	O
by	O
transcription	O
factors	O
that	O
interact	O
with	O
genomic	O
DNA	O
sequences	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

Enhanced	O
quantum	O
correlations	O
in	O
bound	O
higher	O
-	O
order	O
solitons	O
Quantum	O
effects	O
in	O
N	O
-	O
bound	O
solitons	O
can	O
be	O
drastically	O
enhanced	O
compared	O
to	O
the	O
fundamental	O
soliton	O
.	O

The	O
data	O
suggest	O
that	O
compromised	O
fibrinolytic	O
capacity	O
may	O
be	O
a	O
contributing	O
factor	O
in	O
the	O
development	O
of	O
thrombosis	O
in	O
patients	O
with	O
the	O
lupus	O
anticoagulant	O
.	O

The	O
MEE	O
was	O
significantly	O
greater	O
than	O
the	O
BEE	O
and	O
significantly	O
less	O
than	O
the	O
calculated	O
energy	O
expenditure	O
.	O

These	O
results	O
suggest	O
that	O
E6010	B-GENE
may	O
be	O
of	O
clinical	O
value	O
in	O
the	O
treatment	O
of	O
coronary	O
occlusion	O
.	O

To	O
better	O
understand	O
the	O
relationship	O
between	O
expression	O
of	O
an	O
oncogene	O
and	O
genetic	O
instability	O
,	O
we	O
have	O
studied	O
a	O
cell	O
line	O
expressing	O
an	O
activated	B-GENE
human	I-GENE
Ha	I-GENE
-	I-GENE
ras	I-GENE
under	O
the	O
control	O
of	O
bacterial	B-GENE
lactose	I-GENE
operon	I-GENE
regulatory	I-GENE
elements	I-GENE
for	O
changes	O
in	O
methotrexate	O
resistance	O
and	O
dihydrofolate	B-GENE
reductase	I-GENE
(	O
dhfr	B-GENE
)	O
gene	O
amplification	O
following	O
mutant	B-GENE
Ha	I-GENE
-	I-GENE
ras	I-GENE
induction	O
.	O

On	O
a	O
variety	O
of	O
fronts	O
,	O
chronic	O
bacterial	O
infection	O
is	O
being	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
atherosclerosis	O
and	O
the	O
clinical	O
complications	O
of	O
unstable	O
angina	O
,	O
myocardial	O
infarction	O
,	O
and	O
stroke	O
.	O

Long	O
-	O
term	O
results	O
and	O
curative	O
mechanisms	O
of	O
vesicoureteral	O
reflux	O
by	O
endoscopic	O
injection	O
of	O
blood	O
.	O

Inspection	O
of	O
X	B-GENE
.	I-GENE
tropicalis	I-GENE
,	I-GENE
mouse	I-GENE
and	I-GENE
human	I-GENE
U6	I-GENE
DNA	I-GENE
upstream	I-GENE
sequences	I-GENE
revealed	O
the	O
presence	O
of	O
a	O
TATA	O
box	O
as	O
well	O
as	O
of	O
the	O
proximal	O
and	O
enhancer	O
(	O
octamer	O
motif	O
)	O
elements	O
contained	O
in	O
snRNA	O
genes	O
transcribed	O
by	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
.	O

Characterization	O
of	O
an	O
unusual	O
tRNA	O
-	O
like	O
sequence	O
found	O
inserted	O
in	O
a	O
Neurospora	O
retroplasmid	O
.	O

Repeated	O
time	O
course	O
studies	O
in	O
the	O
same	O
patient	O
were	O
reproducible	O
although	O
the	O
absolute	O
concentrations	O
showed	O
some	O
variation	O
.	O

The	O
present	O
work	O
represents	O
an	O
attempt	O
to	O
develop	O
a	O
method	O
for	O
measuring	O
relative	O
blood	O
flow	O
in	O
intestinal	O
capillaries	O
,	O
by	O
the	O
use	O
of	O
sodium	O
fluorescein	O
(	O
Na	O
-	O
F	O
)	O
as	O
an	O
indicator	O
substance	O
.	O

The	O
human	B-GENE
PAX8	I-GENE
gene	I-GENE
generates	O
at	O
least	O
five	O
different	O
alternatively	O
spliced	O
transcripts	O
encoding	O
different	O
PAX8	B-GENE
isoforms	I-GENE
.	O

These	O
data	O
show	O
that	O
both	O
Sp1	B-GENE
and	O
Sp3	B-GENE
transcription	I-GENE
factors	I-GENE
upregulate	O
HGF	B-GENE
promoter	I-GENE
activity	O
by	O
binding	O
to	O
the	O
Sp1	B-GENE
binding	I-GENE
site	I-GENE
at	O
position	O
-	O
318	O
to	O
-	O
303	O
bp	O
in	O
the	O
HGF	B-GENE
gene	I-GENE
promoter	I-GENE
.	O

After	O
a	O
1	O
-	O
h	O
rest	O
(	O
for	O
T2	O
return	O
to	O
baseline	O
)	O
,	O
subjects	O
repeated	O
the	O
5	O
-	O
min	O
protocol	O
,	O
followed	O
by	O
a	O
final	O
MRI	O
/	O
MRS	O
.	O

The	O
cells	O
arrest	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
grow	O
a	O
projection	O
towards	O
one	O
another	O
forming	O
a	O
shmoo	O
projection	O
.	O

Mammalian	O
homologues	O
of	O
the	O
Polycomb	B-GENE
-	I-GENE
group	I-GENE
gene	I-GENE
Enhancer	B-GENE
of	I-GENE
zeste	I-GENE
mediate	O
gene	O
silencing	O
in	O
Drosophila	O
heterochromatin	O
and	O
at	O
S	O
.	O
cerevisiae	O
telomeres	O
.	O

With	O
six	O
reports	O
in	O
the	O
literature	O
that	O
show	O
there	O
is	O
an	O
order	O
to	O
melanoma	O
nodal	O
metastases	O
and	O
that	O
the	O
SLN	O
histology	O
is	O
reflective	O
of	O
the	O
histology	O
of	O
the	O
remainder	O
of	O
the	O
nodal	O
basin	O
,	O
the	O
more	O
conservative	O
SLN	O
biopsy	O
can	O
be	O
performed	O
to	O
adequately	O
stage	O
nodally	O
the	O
patient	O
with	O
melanoma	O
.	O

The	O
results	O
obtained	O
with	O
[	B-GENE
F304	I-GENE
]	I-GENE
R2	I-GENE
indicate	O
that	O
structural	O
changes	O
in	O
E	B-GENE
.	I-GENE
coli	I-GENE
R2	I-GENE
in	O
the	O
vicinity	O
of	O
this	O
helix	O
distortion	O
can	O
influence	O
the	O
catalytic	O
activity	O
of	O
the	O
holoenzyme	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
human	B-GENE
ATP	I-GENE
-	I-GENE
citrate	I-GENE
lyase	I-GENE
gene	I-GENE
.	O

Cryoglobulinaemia	O
among	O
maintenance	O
haemodialysis	O
patients	O
and	O
its	O
relation	O
to	O
hepatitis	O
C	O
infection	O
.	O

The	O
S3	B-GENE
protein	I-GENE
also	O
contains	O
a	O
DNA	O
repair	O
activity	O
,	O
efficiently	O
processing	O
8	O
-	O
oxoguanine	O
residues	O
in	O
DNA	O
via	O
an	O
N	B-GENE
-	I-GENE
glycosylase	I-GENE
/	O
apurinic	B-GENE
-	I-GENE
apyrimidinic	I-GENE
(	I-GENE
AP	I-GENE
)	I-GENE
lyase	I-GENE
activity	O
.	O

25	O
patients	O
received	O
20	O
mgs	O
of	O
hyoscine	O
N	O
-	O
butyl	O
bromide	O
and	O
the	O
rest	O
5	O
mgs	O
propinoxate	O
,	O
i	O
.	O
v	O
.	O
plus	O
diazepam	O
.	O

We	O
present	O
here	O
a	O
statistical	O
technique	O
we	O
developed	O
to	O
identify	O
the	O
sequence	O
elements	O
that	O
may	O
be	O
responsible	O
for	O
this	O
cell	O
cycle	O
regulation	O
.	O

Computed	O
tomographic	O
(	O
CT	O
)	O
findings	O
of	O
pancreatic	O
ductal	O
adenocarcinoma	O
were	O
studied	O
with	O
the	O
combined	O
method	O
of	O
early	O
enhancement	O
CT	O
and	O
high	O
dose	O
enhancement	O
CT	O
in	O
72	O
carcinomas	O
.	O

No	O
other	O
transcripts	O
of	O
different	O
length	O
could	O
be	O
detected	O
after	O
prolonged	O
exposure	O
.	O

We	O
conclude	O
,	O
therefore	O
,	O
that	O
in	O
the	O
absence	O
of	O
E1A	B-GENE
,	O
E4orf4	B-GENE
is	O
sufficient	O
by	O
itself	O
to	O
trigger	O
a	O
p53	B-GENE
-	O
independent	O
apoptosis	O
pathway	O
that	O
may	O
operate	O
independently	O
of	O
the	O
known	O
zVAD	O
-	O
inhibitable	O
caspases	B-GENE
,	O
and	O
that	O
may	O
involve	O
an	O
as	O
yet	O
uncharacterized	O
mechanism	O
.	O

The	O
antiserum	O
used	O
for	O
immunoblotting	O
specifically	O
supershifts	O
uteroglobin	B-GENE
promoter	I-GENE
-	I-GENE
protein	I-GENE
complexes	I-GENE
in	O
gel	O
shift	O
experiments	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
estrogen	B-GENE
receptor	I-GENE
gene	I-GENE
of	I-GENE
Oreochromis	I-GENE
aureus	I-GENE
(	O
OaER	B-GENE
)	O
indicates	O
that	O
the	O
hormone	O
-	O
binding	O
E	O
domain	O
is	O
composed	O
of	O
4	O
exons	O
interspersed	O
by	O
short	O
introns	O
of	O
only	O
0	O
.	O
18	O
-	O
1	O
.	O
3	O
kb	O
each	O
.	O

The	O
expression	O
of	O
Scmh1	B-GENE
and	O
rae28	B-GENE
/	O
mph1	B-GENE
is	O
well	O
correlated	O
in	O
most	O
tissues	O
of	O
embryos	O
.	O

The	O
nucleoporin	B-GENE
98	I-GENE
gene	I-GENE
(	O
NUP98	B-GENE
)	O
,	O
which	O
is	O
rearranged	O
in	O
several	O
acute	O
myeloid	O
leukemia	O
translocations	O
,	O
is	O
located	O
within	O
this	O
region	O
.	O

We	O
have	O
isolated	O
and	O
sequenced	O
cDNA	O
sequences	O
corresponding	O
to	O
two	O
novel	O
genes	O
that	O
map	O
to	O
Xq28	O
.	O

A	O
new	O
direct	O
hemagglutination	O
test	O
(	O
HI	O
-	O
GONAVIS	O
)	O
for	O
urinary	O
LH	B-GENE
was	O
compared	O
with	O
the	O
serum	O
radioimmuno	O
-	O
assay	O
of	O
LH	B-GENE
.	O

Diffusion	O
epidemic	O
models	O
with	O
incubation	O
and	O
crisscross	O
dynamics	O
.	O

CERIP	B-GENE
interaction	O
.	O

The	O
encoded	O
Arabidopsis	B-GENE
U3	I-GENE
snRNAs	I-GENE
can	O
be	O
folded	O
into	O
a	O
secondary	O
structure	O
which	O
is	O
more	O
similar	O
to	O
that	O
of	O
U3	B-GENE
RNAs	I-GENE
from	O
lower	O
eukaryotes	O
rather	O
than	O
from	O
metazoa	O
.	O

Therapy	O
and	O
prevention	O
of	O
irreversible	O
shock	O
with	O
pharmacological	O
doses	O
of	O
some	O
corticosteroids	O

Fentanyl	O
citrate	O
(	O
0	O
.	O
1	O
mL	O
)	O
and	O
2H5	O
-	O
fentanyl	O
(	O
internal	O
standard	O
,	O
0	O
.	O
05	O
mL	O
,	O
100	O
mg	O
/	O
L	O
)	O
were	O
extracted	O
with	O
Toxi	O
-	O
A	O
tubes	O
(	O
Toxi	O
-	O
Lab	O
,	O
Irvine	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Positive	O
effects	O
of	O
radioactive	O
therapy	O
in	O
Guarapari	O

The	O
LT	B-GENE
-	I-GENE
beta	I-GENE
gene	I-GENE
is	O
expressed	O
in	O
lymphoid	O
cells	O
and	O
organs	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
inducible	O
regulation	O
.	O

Ciprofloxacin	O
attained	O
a	O
peak	O
serum	O
concentration	O
of	O
1	O
.	O
2	O
mg	O
/	O
l	O
and	O
a	O
serum	O
half	O
-	O
life	O
of	O
34	O
min	O
.	O

Dmyd	B-GENE
clone	O
encodes	O
a	O
polypeptide	O
of	O
332	O
amino	O
acids	O
with	O
82	O
%	O
identity	O
to	O
MyoD	B-GENE
in	O
the	O
41	O
amino	O
acids	O
of	O
the	O
putative	O
helix	O
-	O
loop	O
-	O
helix	O
region	O
and	O
100	O
%	O
identity	O
in	O
the	O
13	O
amino	O
acids	O
of	O
the	O
basic	O
domain	O
proposed	O
to	O
contain	O
the	O
essential	O
recognition	O
code	O
for	O
muscle	O
-	O
specific	O
gene	O
activation	O
.	O

Identification	O
of	O
an	O
osteocalcin	B-GENE
gene	I-GENE
promoter	I-GENE
sequence	I-GENE
that	O
binds	O
AP1	B-GENE
.	O

Treatment	O
is	O
based	O
on	O
antifungal	O
drugs	O
,	O
most	O
frequently	O
nystatin	O
,	O
amphotericin	O
B	O
and	O
ketoconazole	O
.	O

Mutations	O
abolishing	O
MalK	B-GENE
function	O
not	O
only	O
result	O
in	O
inability	O
to	O
transport	O
maltose	O
but	O
also	O
cause	O
constitutive	O
expression	O
of	O
the	O
maltose	B-GENE
regulon	I-GENE
.	O

Drosophila	B-GENE
melanogaster	I-GENE
casein	I-GENE
kinase	I-GENE
II	I-GENE
(	O
DmCKII	B-GENE
)	O
is	O
composed	O
of	O
catalytic	O
(	O
alpha	O
)	O
and	O
regulatory	O
(	O
beta	O
)	O
subunits	O
associated	O
as	O
an	O
alpha2beta2	O
heterotetramer	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
whether	O
the	O
EORTC	O
(	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
)	O
QLQ	O
-	O
C30	O
core	O
questionnaire	O
alone	O
could	O
distinguish	O
between	O
two	O
clinically	O
different	O
groups	O
of	O
patients	O
and	O
to	O
design	O
a	O
module	O
,	O
which	O
included	O
relevant	O
patient	O
-	O
defined	O
gastric	O
cancer	O
-	O
specific	O
variables	O
.	O

On	O
both	O
indocyanine	O
green	O
video	O
and	O
fluorescein	O
angiography	O
,	O
hypofluorescent	O
lesions	O
were	O
almost	O
the	O
same	O
size	O
as	O
the	O
light	O
yellow	O
area	O
and	O
the	O
dark	O
yellow	O
center	O
of	O
a	O
placoid	O
lesion	O
.	O

We	O
have	O
measured	O
percentage	O
O3	O
uptake	O
in	O
30	O
adult	O
Sprague	O
-	O
Dawley	O
rats	O
exposed	O
,	O
nose	O
only	O
,	O
for	O
1	O
hr	O
to	O
0	O
.	O
3	O
,	O
0	O
.	O
6	O
,	O
or	O
1	O
.	O
0	O
ppm	O
O3	O
.	O

The	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
was	O
calculated	O
in	O
the	O
T2	O
-	O
weighted	O
sequence	O
.	O

Cell	O
rounding	O
was	O
abrogated	O
by	O
expression	O
of	O
either	O
kinase	O
-	O
dead	O
forms	O
of	O
US3	B-GENE
PK	I-GENE
or	O
a	O
mutant	O
protein	O
lacking	O
the	O
acidic	O
cluster	O
in	O
the	O
kinase	O
regulatory	O
domain	O
.	O

Three	O
distinct	O
human	B-GENE
HDACs	I-GENE
are	O
homologous	O
to	O
RPD3	B-GENE
,	O
a	O
yeast	O
transcriptional	O
regulator	O
.	O

The	O
4	O
-	O
nt	O
sequence	O
of	O
the	O
rotavirus	O
3	O
'	O
TE	O
represents	O
by	O
far	O
the	O
shortest	O
of	O
any	O
of	O
the	O
sequence	O
enhancers	O
known	O
to	O
stimulate	O
translation	O
.	O

OBJECTIVE	O
:	O
The	O
audiologic	O
presentation	O
of	O
vestibular	O
schwannoma	O
(	O
VS	O
)	O
associated	O
with	O
neurofibromatosis	O
type	O
2	O
(	O
NF2	O
)	O
has	O
not	O
been	O
well	O
characterized	O
.	O

Expression	O
of	O
these	O
chemokines	O
is	O
similar	O
in	O
that	O
both	O
require	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
element	I-GENE
and	O
additional	O
regions	O
such	O
as	O
the	O
CAAT	B-GENE
/	I-GENE
enhancer	I-GENE
binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
element	O
of	O
the	O
IL	B-GENE
-	I-GENE
8	I-GENE
promoter	I-GENE
.	O

The	O
meaning	O
of	O
hope	O
in	O
health	O
and	O
illness	O
.	O

Assessment	O
of	O
two	O
anion	O
-	O
exchange	O
resins	O
for	O
direct	O
use	O
in	O
the	O
screening	O
method	O
for	O
urinary	O
porphobilinogen	O
.	O

Aggravation	O
of	O
peripheral	O
-	O
blood	O
cytopenia	O
during	O
the	O
first	O
weeks	O
and	O
hypocellularity	O
of	O
bone	O
-	O
marrow	O
aspirates	O
at	O
the	O
end	O
of	O
therapy	O
suggest	O
that	O
low	O
-	O
dose	O
Ara	O
C	O
exerts	O
its	O
main	O
activity	O
by	O
suppression	O
of	O
leukaemic	O
growth	O
,	O
rather	O
than	O
by	O
induction	O
of	O
differentiation	O
in	O
malignant	O
cells	O
.	O

All	O
depressive	O
groups	O
showed	O
improved	O
error	O
measures	O
post	O
-	O
treatment	O
.	O

Triaxiality	O
in	O
the	O
proton	O
-	O
neutron	O
interacting	O
boson	O
model	O
:	O
Perturbed	O
O	O
(	O
6	O
)	O
symmetry	O
with	O
application	O
to	O
the	O
mass	O
A	O

The	O
best	O
sequences	O
for	O
pelvic	O
study	O
are	O
,	O
in	O
our	O
experience	O
,	O
IR	O
or	O
short	O
TR	O
spin	O
-	O
echo	O
for	O
T1	O
-	O
weighted	O
images	O
,	O
and	O
spin	O
-	O
echo	O
with	O
1200	O
TR	O
for	O
T2	O
images	O
.	O

Cells	O
were	O
co	O
-	O
infected	O
simultaneously	O
with	O
IBV	O
,	O
the	O
recombinant	O
FPV	O
(	O
rFPV	O
)	O
containing	O
the	O
D	O
-	O
RNA	O
sequence	O
and	O
a	O
second	O
rFPV	O
expressing	O
T7	B-GENE
RNA	I-GENE
polymerase	I-GENE
for	O
the	O
initial	O
expression	O
of	O
the	O
D	O
-	O
RNA	O
transcript	O
,	O
subsequently	O
rescued	O
by	O
helper	O
IBV	O
.	O

Seasonal	O
variation	O
of	O
the	O
cadmium	O
content	O
of	O
Murex	O
trunculus	O
in	O
a	O
non	O
-	O
cadmium	O
polluted	O
environment	O
.	O

These	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
predicted	O
isoform	O
L	O
diversity	O
across	O
human	O
tissues	O
and	O
cells	O
.	O

Doctors	O
given	O
intrathecal	O
methotrexate	O
had	O
headache	O
when	O
20	O
gauge	O
standard	O
needle	O
was	O
used	O
.	O

The	O
AP	B-GENE
-	I-GENE
1	I-GENE
recruited	O
by	O
ARF1	B-GENE
.	I-GENE
GTP	I-GENE
is	O
released	O
from	O
the	O
Golgi	O
membrane	O
by	O
treatment	O
with	O
1	O
M	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
)	O
or	O
upon	O
reincubation	O
at	O
37	O
degreesC	O
,	O
whereas	O
AP	B-GENE
-	I-GENE
1	I-GENE
recruited	O
with	O
GTPgammaS	O
or	O
by	O
a	O
constitutively	O
active	O
point	O
mutant	O
,	O
ARF1	B-GENE
(	I-GENE
Q71L	I-GENE
)	I-GENE
,	O
remains	O
membrane	O
bound	O
after	O
either	O
treatment	O
.	O

The	O
formation	O
of	O
tumorlike	O
lesions	O
in	O
the	O
cockroach	O
leucophaea	O
maderae	O
after	O
anal	O
blockage	O
.	O

Fine	O
tangled	O
pili	O
expressed	O
by	O
Haemophilus	O
ducreyi	O
are	O
a	O
novel	O
class	O
of	O
pili	O
.	O

We	O
found	O
remarkable	O
differences	O
in	O
the	O
expression	O
patterns	O
of	O
MTB	B-GENE
-	I-GENE
Zf	I-GENE
mRNA	I-GENE
and	O
two	O
other	O
hybridizable	O
mRNAs	O
of	O
5kb	O
and	O
8	O
.	O
5	O
kb	O
when	O
human	O
brain	O
and	O
primary	O
brain	O
tumors	O
were	O
compared	O
.	O

The	O
two	O
redox	O
centers	O
in	O
the	O
protein	O
,	O
FAD	O
and	O
a	O
[	O
4Fe4S	O
]	O
+	O
2	O
,	O
+	O
1	O
cluster	O
,	O
are	O
present	O
in	O
a	O
64	O
-	O
kDa	O
monomer	O
.	O

The	O
pra2	B-GENE
gene	I-GENE
encodes	O
a	O
pea	B-GENE
(	I-GENE
Pisum	I-GENE
sativum	I-GENE
)	I-GENE
small	I-GENE
GTPase	I-GENE
belonging	O
to	O
the	O
YPT	B-GENE
/	O
rab	B-GENE
family	O
,	O
and	O
its	O
expression	O
is	O
down	O
-	O
regulated	O
by	O
light	O
,	O
mediated	O
by	O
phytochrome	B-GENE
.	O

Carotid	O
body	O
chemoreceptor	O
activity	O
as	O
recorded	O
from	O
the	O
petrosal	O
ganglion	O
in	O
cats	O
.	O

Human	B-GENE
and	I-GENE
murine	I-GENE
cytotoxic	I-GENE
T	I-GENE
lymphocyte	I-GENE
serine	I-GENE
proteases	I-GENE
:	O
subsite	O
mapping	O
with	O
peptide	O
thioester	O
substrates	O
and	O
inhibition	O
of	O
enzyme	O
activity	O
and	O
cytolysis	O
by	O
isocoumarins	O
.	O

To	O
explore	O
further	O
the	O
role	O
of	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
in	O
determining	O
the	O
cell	O
cycle	O
function	O
of	O
CDC34	B-GENE
,	O
we	O
constructed	O
and	O
characterized	O
genes	O
encoding	O
chimeric	B-GENE
E2s	I-GENE
incorporating	O
sequences	O
from	O
CDC34	B-GENE
and	O
the	O
related	O
but	O
functionally	O
distinct	O
E2	B-GENE
RAD6	B-GENE
(	O
UBC2	B-GENE
)	O
.	O

MAPKK	B-GENE
kinase	I-GENE
/	O
MEKK	B-GENE
phosphorylates	O
and	O
activates	O
its	O
downstream	O
protein	O
kinase	O
,	O
MAPK	B-GENE
kinase	I-GENE
/	O
MEK	B-GENE
,	O
which	O
in	O
turn	O
activates	O
MAPK	B-GENE
.	O

Kondo	O
effect	O
in	O
Cu	O
(	O
Fe	O
)	O
films	O
.	O

However	O
,	O
ADAR1	B-GENE
and	O
the	O
related	O
deaminase	B-GENE
ADAR2	I-GENE
showed	O
significant	O
expression	O
in	O
all	O
regions	O
of	O
the	O
brain	O
examined	O
,	O
including	O
cortex	O
,	O
hippocampus	O
,	O
olfactory	O
bulb	O
,	O
and	O
striatum	O
,	O
where	O
the	O
5	B-GENE
-	I-GENE
HT2CR	I-GENE
pre	I-GENE
-	I-GENE
mRNA	I-GENE
was	O
extensively	O
edited	O
.	O

To	O
investigate	O
its	O
transcription	O
,	O
1	O
.	O
1	O
kilobases	O
of	O
the	O
5	O
'	O
-	O
flanking	O
sequence	O
were	O
fused	O
to	O
a	O
luciferase	B-GENE
reporter	I-GENE
gene	I-GENE
.	O

Influence	O
of	O
copper	O
addition	O
.	O

The	O
0	O
.	O
018	O
-	O
inch	O
FloWire	O
provides	O
a	O
high	O
-	O
fidelity	O
continuous	O
Doppler	O
signal	O
.	O

Monosulfates	O
of	O
16	O
-	O
oxygenated	O
ketonic	O
C19	O
steroids	O
in	O
adult	O
human	O
urine	O
.	O

Under	O
anaerobic	O
conditions	O
(	O
a	O
50	O
-	O
day	O
experiment	O
)	O
these	O
organisms	O
degraded	O
15	O
-	O
18	O
%	O
of	O
the	O
TEM	O
,	O
20	O
-	O
25	O
%	O
of	O
some	O
alkanes	O
,	O
and	O
15	O
-	O
18	O
%	O
of	O
selected	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

In	O
addition	O
,	O
WR	O
-	O
3689	O
,	O
WR	O
-	O
109342	O
,	O
and	O
WR	O
-	O
168643	O
were	O
used	O
with	O
per	O
os	O
administration	O
to	O
determine	O
hematopoietic	O
lethality	O
.	O

Further	O
,	O
we	O
will	O
review	O
our	O
evaluation	O
of	O
the	O
survival	O
rate	O
and	O
prognostic	O
factors	O
for	O
9	O
,	O
262	O
patients	O
from	O
1981	O
to	O
1996	O
.	O

MEASURES	O
:	O
SF	O
-	O
36	O
questionnaires	O
were	O
completed	O
by	O
patients	O
at	O
both	O
initial	O
and	O
discharge	O
examinations	O
.	O

In	O
contrast	O
,	O
corticotropin	B-GENE
releasing	I-GENE
factor	I-GENE
(	O
CRF	B-GENE
)	O
,	O
injected	O
centrally	O
produces	O
a	O
suppression	O
of	O
punished	O
and	O
non	O
-	O
punished	O
responding	O
in	O
the	O
conflict	O
test	O
consistent	O
with	O
its	O
hypothesized	O
role	O
in	O
mediating	O
behavioral	O
responses	O
to	O
stress	O
.	O

Temporal	O
recruitment	O
of	O
the	O
mSin3A	B-GENE
-	O
histone	B-GENE
deacetylase	I-GENE
corepressor	O
complex	O
to	O
the	O
ETS	B-GENE
domain	I-GENE
transcription	I-GENE
factor	I-GENE
Elk	B-GENE
-	I-GENE
1	I-GENE
.	O

The	O
cluster	O
was	O
mapped	O
to	O
nucleotides	O
-	O
464	O
to	O
-	O
434	O
(	O
relative	O
to	O
nucleotide	O
A	O
in	O
the	O
initiation	O
codon	O
)	O
in	O
genomic	O
DNA	O
.	O

In	O
addition	O
,	O
FOP	B-GENE
-	O
FGFR1	B-GENE
-	O
expressing	O
cells	O
show	O
constitutive	O
phosphorylation	O
of	O
the	O
positive	O
regulator	O
of	O
translation	O
p70S6	B-GENE
kinase	I-GENE
;	O
this	O
phosphorylation	O
is	O
inhibited	O
by	O
PI3	B-GENE
-	I-GENE
kinase	I-GENE
and	O
mTOR	B-GENE
(	O
mammalian	B-GENE
target	I-GENE
of	I-GENE
rapamycin	I-GENE
)	O
inhibitors	O
.	O

The	O
authors	O
report	O
two	O
cases	O
of	O
orbital	O
cavernous	O
hemangioma	O
diagnosed	O
by	O
Tc	O
-	O
99m	O
RBC	O
SPECT	O
.	O

Ciprofloxacin	O
levels	O
in	O
serum	O
and	O
blister	O
fluid	O
at	O
the	O
end	O
of	O
the	O
dosing	O
interval	O
(	O
8	O
h	O
)	O
were	O
superior	O
or	O
almost	O
superior	O
to	O
MICs	O
for	O
sensitive	O
organisms	O
including	O
Pseudomonas	O
aeruginosa	O
.	O

Antibiotic	O
prophylaxis	O
in	O
a	O
surgical	O
setting	O

We	O
identified	O
clones	O
of	O
Chlamydomonas	O
genomic	O
DNA	O
that	O
rescued	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
axonemal	O
microtubule	O
severing	O
defect	O
of	O
fa1	B-GENE
mutants	I-GENE
.	O

These	O
changes	O
persisted	O
during	O
the	O
first	O
week	O
.	O

Hyperlipemia	O
has	O
been	O
recently	O
described	O
in	O
children	O
with	O
migraine	O
,	O
being	O
suggested	O
that	O
this	O
alteration	O
is	O
in	O
the	O
base	O
of	O
the	O
disease	O
.	O

Plasma	B-GENE
hemopexin	I-GENE
homeostasis	O
during	O
the	O
acute	O
phase	O
response	O
.	O

The	O
newly	O
identified	O
repressor	O
element	O
is	O
a	O
rare	O
example	O
of	O
a	O
naturally	O
occurring	O
perfect	O
palindromic	O
binding	O
motif	O
for	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
/	O
Rel	B-GENE
family	O
of	O
transcription	O
factors	O
.	O

Tryptophan	O
induction	O
prevents	O
Rho	B-GENE
-	O
dependent	O
transcription	O
termination	O
in	O
the	O
leader	O
region	O
of	O
the	O
operon	O
.	O

There	O
remains	O
the	O
physiological	O
problem	O
-	O
-	O
one	O
which	O
has	O
always	O
been	O
foremost	O
in	O
Moruzzi	O
'	O
s	O
thinking	O
about	O
the	O
intrinsic	O
regulation	O
of	O
brain	O
activity	O
-	O
-	O
of	O
how	O
the	O
separate	O
actions	O
of	O
the	O
different	O
arousal	O
systems	O
are	O
brought	O
together	O
into	O
a	O
functional	O
whole	O
.	O

The	O
nramp2	B-GENE
gene	I-GENE
is	O
comprised	O
of	O
17	O
exons	O
and	O
spans	O
more	O
than	O
36	O
kb	O
.	O

The	O
immune	O
response	O
seems	O
to	O
be	O
partially	O
responsible	O
for	O
both	O
protection	O
and	O
the	O
destructive	O
consequences	O
of	O
chlamydial	O
infection	O
.	O

Results	O
:	O
hepatic	O
hydatidosis	O
:	O
177	O
patients	O
.	O

This	O
is	O
similar	O
to	O
previous	O
reports	O
of	O
muscle	B-GENE
creatine	I-GENE
phosphokinase	I-GENE
release	O
in	O
psychiatric	O
patients	O
.	O

The	O
majority	O
of	O
putative	O
TSC2	B-GENE
mutations	I-GENE
were	O
found	O
in	O
sporadic	O
rather	O
than	O
TSC2	B-GENE
-	O
linked	O
families	O
.	O

Murine	B-GENE
ELAM	I-GENE
-	I-GENE
1	I-GENE
is	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
gene	O
,	O
spanning	O
about	O
13	O
kb	O
,	O
which	O
is	O
structurally	O
organized	O
into	O
14	O
exons	O
and	O
13	O
introns	O
;	O
very	O
similar	O
to	O
that	O
of	O
its	O
human	O
counterpart	O
.	O

A	O
biopsy	O
specimen	O
taken	O
from	O
the	O
frontal	O
branch	O
of	O
the	O
right	O
superficial	O
artery	O
revealed	O
segmental	O
intimal	O
thickening	O
consistent	O
with	O
intimal	O
fibroplasia	O
type	O
FMD	O
upon	O
histological	O
examination	O
.	O

Thus	O
in	O
this	O
study	O
we	O
used	O
in	O
vitro	O
methods	O
to	O
directly	O
evaluate	O
whether	O
isolated	O
human	O
saphenous	O
vein	O
segments	O
respond	O
to	O
vasoconstrictor	O
agents	O
at	O
arterial	O
pressure	O
levels	O
.	O

We	O
found	O
that	O
the	O
PRP20	B-GENE
gene	I-GENE
is	O
identical	O
to	O
the	O
yeast	B-GENE
SRM1	I-GENE
gene	I-GENE
(	O
Clark	O
and	O
Sprague	O
1989	O
)	O
.	O

Basal	O
JNK	B-GENE
MAPK	I-GENE
kinase	I-GENE
activity	O
was	O
also	O
specifically	O
induced	O
by	O
deltaEGFR	B-GENE
,	O
which	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
a	O
54	B-GENE
-	I-GENE
kDa	I-GENE
JNK2	I-GENE
protein	I-GENE
observed	O
in	O
deltaEGFR	B-GENE
-	O
containing	O
cells	O
.	O

Deletion	O
analysis	O
defines	O
distinct	O
functional	O
domains	O
for	O
protein	O
-	O
protein	O
and	O
nucleic	O
acid	O
interactions	O
in	O
the	O
ORF1	B-GENE
protein	I-GENE
of	O
mouse	O
LINE	B-GENE
-	I-GENE
1	I-GENE
.	O

PMA	O
produced	O
similar	O
results	O
,	O
but	O
the	O
induction	O
of	O
the	O
WT	B-GENE
AP1	I-GENE
c	B-GENE
-	I-GENE
jun	I-GENE
promoter	O
-	O
CAT	O
plasmid	O
was	O
smaller	O
.	O

The	O
determination	O
of	O
antithrombin	B-GENE
III	I-GENE
(	O
AT	B-GENE
III	I-GENE
)	O
and	O
its	O
clinical	O
significance	O

One	O
ORF	O
extends	O
from	O
nucleotides	O
415	O
to	O
1620	O
,	O
encodes	O
402	O
amino	O
acids	O
,	O
and	O
is	O
preceded	O
by	O
a	O
ribosome	O
-	O
binding	O
site	O
.	O

Glucose	O
consumption	O
of	O
the	O
human	O
brain	O
under	O
the	O
influence	O
of	O
intravenous	O
infusions	O
of	O
glucose	O
,	O
glucagon	B-GENE
and	O
glucose	O
-	O
insulin	B-GENE

D	O
.	O
,	O
Hughes	O
,	O
F	O
.	O

Deletion	O
of	O
CDC5	B-GENE
was	O
lethal	O
and	O
resulted	O
in	O
a	O
dumbbell	O
-	O
shaped	O
terminal	O
morphology	O
,	O
with	O
the	O
nuclei	O
almost	O
divided	O
but	O
still	O
connected	O
.	O

These	O
cDNAs	O
were	O
found	O
to	O
be	O
derived	O
from	O
the	O
3	O
"	O
-	O
untranslated	O
region	O
(	O
3	O
"	O
-	O
UTR	O
)	O
of	O
the	O
methyl	B-GENE
-	I-GENE
CpG	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
2	I-GENE
gene	I-GENE
(	O
MeCP2	B-GENE
)	O
.	O

A	O
)	O
During	O
O2	O
-	O
ischemia	O
both	O
extracellular	O
[	O
K	O
+	O
]	O
and	O
change	O
of	O
pH	O
in	O
the	O
subepicardium	O
are	O
significantly	O
less	O
than	O
in	O
the	O
midmyocardium	O
.	O

The	O
generation	O
of	O
dorso	O
-	O
ventral	O
polarity	O
during	O
Drosophila	O
embryogenesis	O
is	O
regulated	O
by	O
the	O
action	O
of	O
12	O
maternally	O
expressed	O
gene	O
products	O
,	O
the	O
dorsal	B-GENE
group	I-GENE
.	O

Ultimobranchial	O
body	O
and	O
parathyroid	O
glands	O
of	O
the	O
freshwater	O
snake	O
Natrix	O
piscator	O
in	O
response	O
to	O
vitamin	O
D3	O
administration	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
AF	O
-	O
1	O
region	O
of	O
PPARalpha	B-GENE
is	O
partially	O
silenced	O
by	O
corepressor	O
proteins	O
,	O
which	O
might	O
interact	O
in	O
a	O
phosphorylation	O
-	O
dependent	O
manner	O
.	O

Two	O
authors	O
,	O
two	O
journal	O
titles	O
,	O
two	O
drug	O
names	O
,	O
and	O
two	O
topics	O
of	O
a	O
general	O
medical	O
nature	O
were	O
retrieved	O
under	O
identical	O
circumstances	O
and	O
conditions	O
on	O
the	O
hosts	O
DATA	O
-	O
STAR	O
,	O
DIALOG	O
,	O
DIMDI	O
,	O
and	O
STN	O
.	O

However	O
,	O
in	O
a	O
variation	O
of	O
this	O
assay	O
in	O
which	O
the	O
protease	O
is	O
omitted	O
,	O
the	O
mutant	O
enzymes	O
exhibited	O
substantial	O
levels	O
of	O
prolyl	B-GENE
isomerase	I-GENE
activity	O
(	O
5	O
-	O
20	O
%	O
of	O
wild	O
-	O
type	O
)	O
,	O
revealing	O
that	O
these	O
mutations	O
confer	O
sensitivity	O
to	O
protease	O
digestion	O
and	O
that	O
the	O
classic	O
in	O
vitro	O
assay	O
for	O
prolyl	B-GENE
isomerase	I-GENE
activity	O
may	O
be	O
misleading	O
.	O

As	O
a	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
predicted	O
that	O
mice	O
which	O
have	O
altered	O
expression	O
of	O
class	O
I	O
gene	O
products	O
,	O
the	O
beta2	B-GENE
-	I-GENE
microglobulin	I-GENE
knockout	O
mice	O
,	O
[	B-GENE
beta2m	I-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
]	I-GENE
,	O
would	O
develop	O
Fe	O
overload	O
.	O

Nucleotide	O
sequence	O
of	O
the	O
gag	B-GENE
gene	I-GENE
and	O
gag	B-GENE
-	O
pol	B-GENE
junction	O
of	O
feline	O
leukemia	O
virus	O
.	O

Clinical	O
trial	O
endpoints	O
based	O
on	O
magnitude	O
of	O
reduction	O
in	O
HIV	O
-	O
1	O
RNA	O
levels	O
provide	O
an	O
important	O
complement	O
to	O
endpoints	O
based	O
on	O
percentage	O
of	O
patients	O
achieving	O
complete	O
virologic	O
suppression	O
.	O

It	O
also	O
describes	O
the	O
preliminary	O
results	O
of	O
a	O
Phase	O
II	O
trial	O
going	O
on	O
at	O
the	O
Central	O
Institute	O
for	O
Tumors	O
in	O
Zagreb	O
,	O
using	O
a	O
combination	O
of	O
cis	O
-	O
DDP	O
,	O
5	O
-	O
fluorouracil	O
and	O
vincristine	O
.	O

On	O
the	O
basis	O
of	O
the	O
physical	O
interactions	O
between	O
Sxl	B-GENE
and	O
Snf	B-GENE
,	O
we	O
present	O
a	O
model	O
for	O
Sxl	B-GENE
splicing	O
regulation	O
.	O

Though	O
it	O
has	O
been	O
established	O
that	O
skinfold	O
anthropometry	O
has	O
severe	O
limitations	O
as	O
a	O
method	O
of	O
deriving	O
total	O
body	O
fat	O
(	O
TBF	O
)	O
,	O
the	O
possibility	O
that	O
the	O
problem	O
might	O
be	O
related	O
more	O
to	O
the	O
assumptions	O
implicit	O
in	O
densitometry	O
has	O
to	O
be	O
addressed	O
.	O

The	O
average	O
mean	O
difference	O
compared	O
with	O
the	O
low	O
and	O
the	O
intermediate	O
calcium	O
group	O
was	O
11	O
%	O
for	O
the	O
femoral	O
neck	O
,	O
8	O
-	O
11	O
%	O
for	O
the	O
lumbar	O
spine	O
and	O
5	O
-	O
6	O
%	O
for	O
total	O
body	O
BMDs	O
.	O

We	O
cloned	O
the	O
BamHI	B-GENE
-	I-GENE
F	I-GENE
fragment	I-GENE
from	O
the	O
left	O
end	O
of	O
Ad4	O
in	O
pUC13	O
-	O
1	O
between	O
the	O
SalI	B-GENE
and	O
BamHI	B-GENE
sites	I-GENE
in	O
order	O
to	O
carry	O
out	O
the	O
structural	O
analysis	O
of	O
the	O
E1A	B-GENE
region	I-GENE
of	I-GENE
Ad4	I-GENE
.	O

We	O
reviewed	O
81	O
patients	O
with	O
dementia	O
and	O
autopsy	O
findings	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
to	O
identify	O
patients	O
with	O
seizures	O
or	O
myoclonus	O
after	O
onset	O
of	O
dementia	O
.	O

BACKGROUND	O
:	O
In	O
lung	O
protective	O
strategy	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
slightly	O
higher	O
than	O
the	O
Pflex	O
(	O
the	O
airway	O
pressure	O
corresponding	O
to	O
the	O
lower	O
inflection	O
point	O
(	O
LIP	O
)	O
on	O
the	O
inspiratory	O
pressure	O
-	O
volume	O
(	O
P	O
-	O
V	O
)	O
curve	O
measured	O
with	O
ZEEP	O
)	O
is	O
generally	O
recommended	O
.	O

3	O
.	O

In	O
both	O
RAW	O
cells	O
and	O
the	O
microglia	O
cell	O
line	O
EOC20	O
,	O
two	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
-	O
activated	O
transcription	O
factors	O
,	O
STAT	B-GENE
-	I-GENE
1alpha	I-GENE
and	O
IRF	B-GENE
-	I-GENE
1	I-GENE
,	O
bind	O
the	O
GAS	B-GENE
and	O
IRF	B-GENE
elements	I-GENE
,	O
respectively	O
.	O

Thermal	O
changes	O
of	O
the	O
bovine	O
uterus	O
following	O
administration	O
of	O
estradiol	O
-	O
17beta	O
.	O

The	O
starting	O
dose	O
was	O
8	O
mg	O
/	O
m2	O
administered	O
intravenously	O
(	O
IV	O
)	O
as	O
a	O
short	O
infusion	O
daily	O
for	O
5	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
with	O
dose	O
adjustments	O
depending	O
on	O
patient	O
tolerance	O
.	O

In	O
agreement	O
with	O
other	O
authors	O
,	O
we	O
recommend	O
the	O
procedure	O
as	O
a	O
safe	O
one	O
,	O
providing	O
satisfactory	O
results	O
.	O

After	O
inhibition	O
of	O
monoamine	B-GENE
oxidase	I-GENE
with	O
pargyline	O
(	O
10	O
mg	O
/	O
kg	O
.	O
i	O
.	O
v	O
.	O
)	O
,	O
the	O
effects	O
of	O
tyramine	O
(	O
1000	O
micrograms	O
)	O
injected	O
into	O
the	O
hepatic	O
artery	O
were	O
potentiated	O
.	O

Helenalin	O
triggers	O
a	O
CD95	B-GENE
death	I-GENE
receptor	I-GENE
-	O
independent	O
apoptosis	O
that	O
is	O
not	O
affected	O
by	O
overexpression	O
of	O
Bcl	B-GENE
-	I-GENE
x	I-GENE
(	I-GENE
L	I-GENE
)	I-GENE
or	O
Bcl	B-GENE
-	I-GENE
2	I-GENE
.	O

Of	O
the	O
47	O
women	O
with	O
AGCUS	O
,	O
16	O
had	O
intraepithelial	O
or	O
invasive	O
neoplasms	O
(	O
34	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
21	O
-	O
49	O
%	O
)	O
,	O
including	O
9	O
low	O
or	O
high	O
grade	O
squamous	O
intraepithelial	O
lesions	O
,	O
1	O
adenocarcinoma	O
in	O
situ	O
of	O
the	O
cervix	O
,	O
3	O
adenocarcinomas	O
of	O
the	O
cervix	O
,	O
2	O
adenocarcinomas	O
of	O
the	O
endometrium	O
and	O
1	O
adenoid	O
basal	O
cell	O
carcinoma	O
of	O
the	O
cervix	O
.	O

The	O
DF3	B-GENE
/	O
MUC1	B-GENE
gene	O
encodes	O
a	O
high	B-GENE
molecular	I-GENE
weight	I-GENE
mucin	I-GENE
-	I-GENE
like	I-GENE
glycoprotein	I-GENE
which	O
is	O
overexpressed	O
at	O
the	O
transcriptional	O
level	O
in	O
the	O
majority	O
of	O
human	O
breast	O
cancers	O
.	O

The	O
organization	O
of	O
the	O
MBP	B-GENE
-	I-GENE
A	I-GENE
gene	I-GENE
is	O
very	O
similar	O
to	O
the	O
arrangement	O
of	O
the	O
gene	O
encoding	O
the	O
highly	O
homologous	B-GENE
pulmonary	I-GENE
surfactant	I-GENE
apoprotein	I-GENE
,	O
although	O
one	O
of	O
the	O
intron	O
positions	O
is	O
shifted	O
by	O
a	O
single	O
amino	O
acid	O
.	O

Hip	O
fracture	O
mortality	O
and	O
prospective	O
payment	O
system	O
.	O

These	O
results	O
indicate	O
that	O
patients	O
with	O
SS	O
and	O
evidence	O
of	O
exercise	O
-	O
induced	O
ST	O
-	O
segment	O
depression	O
may	O
have	O
decreased	O
myocardial	O
oxygen	O
supply	O
due	O
to	O
low	O
hemoglobin	B-GENE
levels	O
and	O
increased	O
myocardial	O
oxygen	O
demand	O
(	O
elevated	O
double	O
products	O
)	O
when	O
compared	O
to	O
subjects	O
with	O
SS	O
who	O
do	O
not	O
have	O
exercise	O
-	O
induced	O
ST	O
-	O
segment	O
depression	O
.	O

Although	O
hSSTR5	B-GENE
displays	O
approximately	O
75	O
%	O
sequence	O
identity	O
with	O
rat	B-GENE
SSTR5	I-GENE
,	O
the	O
two	O
receptors	O
display	O
significantly	O
different	O
pharmacological	O
profiles	O
,	O
especially	O
with	O
respect	O
to	O
their	O
binding	O
affinities	O
for	O
the	O
SST	B-GENE
analogue	O
SMS	O
201	O
-	O
995	O
.	O

A	O
significant	O
and	O
specific	O
reduction	O
in	O
binaural	O
peak	O
amplitude	O
and	O
area	O
of	O
the	O
echo	O
-	O
evoked	O
middle	O
-	O
latency	O
component	O
Pa	O
was	O
observed	O
.	O

EMBO	O
(	O
Eur	O
.	O

Using	O
this	O
oligonucleotide	O
as	O
a	O
probe	O
,	O
an	O
8	O
-	O
kilobase	O
HindIII	B-GENE
fragment	O
of	O
genomic	O
DNA	O
was	O
isolated	O
and	O
subjected	O
to	O
Sanger	O
dideoxy	O
DNA	O
sequencing	O
.	O

Arg	O
-	O
130	O
,	O
Gly	O
-	O
132	O
and	O
Lys	O
-	O
167	O
are	O
conserved	O
in	O
all	O
members	O
of	O
the	O
type	B-GENE
IB	I-GENE
topoisomerase	I-GENE
family	I-GENE
.	O

Four	O
cDNAs	O
(	O
Kox4	B-GENE
,	O
Kox7	B-GENE
,	O
Kox12	B-GENE
,	O
and	O
Kox15	B-GENE
)	O
were	O
identified	O
that	O
match	O
one	O
or	O
more	O
genomic	O
clones	O
;	O
these	O
matches	O
were	O
confirmed	O
by	O
nucleotide	O
sequence	O
analysis	O
.	O

2	O
.	O

Prevalence	O
of	O
use	O
,	O
claims	O
volume	O
,	O
and	O
expenditures	O
were	O
compared	O
for	O
cisapride	O
,	O
proton	O
pump	O
inhibitors	O
,	O
histamine	B-GENE
-	I-GENE
2	I-GENE
receptor	I-GENE
antagonists	O
,	O
and	O
the	O
prokinetic	O
agent	O
metoclopramide	O
during	O
these	O
periods	O
.	O

Relaxant	O
effect	O
of	O
prostaglandin	O
E1	O
(	O
PGE1	O
)	O
and	O
papaverine	O
(	O
PAP	O
)	O
were	O
measured	O
in	O
strips	O
of	O
corpus	O
cavernosum	O
smooth	O
muscle	O
taken	O
from	O
a	O
healthy	O
control	O
group	O
of	O
men	O
(	O
A	O
;	O
n	O
=	O
5	O
)	O
,	O
from	O
arteriogenically	O
impotent	O
men	O
(	O
B	O
;	O
n	O
=	O
6	O
)	O
and	O
from	O
additionally	O
diabetic	O
impotent	O
men	O
(	O
C	O
;	O
n	O
=	O
5	O
)	O
with	O
venous	O
leakage	O
.	O

Primer	O
extension	O
experiments	O
using	O
dbcAMP	O
-	O
differentiated	O
U937	O
RNA	O
indicated	O
a	O
single	O
transcriptional	O
initiation	O
site	O
.	O

In	O
contrast	O
,	O
group	O
II	O
showed	O
a	O
significant	O
improvement	O
in	O
peak	O
VO2	O
with	O
rate	O
adaptive	O
AV	O
delay	O
compared	O
to	O
fixed	O
AV	O
delay	O
programming	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Effect	O
of	O
family	O
visits	O
on	O
the	O
blood	O
pressure	O
and	O
heart	O
rate	O
of	O
patients	O
in	O
the	O
coronary	O
-	O
care	O
unit	O
.	O

Sequence	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
experiments	O
suggest	O
that	O
GnSE	B-GENE
response	I-GENE
elements	I-GENE
interact	O
,	O
in	O
these	O
two	O
regions	O
,	O
with	O
GATA	B-GENE
-	I-GENE
and	I-GENE
LIM	I-GENE
-	I-GENE
related	I-GENE
factors	I-GENE
,	O
respectively	O
.	O

The	O
transfer	O
by	O
conjugation	O
to	O
E	O
.	O
coli	O
K12	O
of	O
ampicillin	O
and	O
carbenicillin	O
resistance	O
was	O
obtained	O
with	O
14	O
strains	O
:	O
(	O
E	O
.	O
coli	O
:	O
9	O
,	O
C	O
.	O
freundii	O
:	O
1	O
,	O
K	O
.	O
pneumoniae	O
:	O
1	O
,	O
E	O
.	O
cloacae	O
:	O
2	O
,	O
P	O
.	O
stuartii	O
:	O
1	O
)	O
.	O

Wild	O
type	O
MEKK1	B-GENE
enhances	O
promoter	O
activity	O
and	O
the	O
activity	O
can	O
be	O
inhibited	O
by	O
dominant	O
negative	O
MEKK1	B-GENE
,	O
MEK1	B-GENE
,	O
MEK7	B-GENE
,	O
MEK3	B-GENE
,	O
p38	B-GENE
/	O
RK	B-GENE
,	O
and	O
c	B-GENE
-	I-GENE
Jun	I-GENE
.	O

250	O
,	O
302	O
-	O
311	O
]	O
.	O

The	O
studies	O
permit	O
considering	O
the	O
detected	O
shifts	O
in	O
the	O
immunity	O
system	O
an	O
important	O
component	O
of	O
the	O
pathogenesis	O
of	O
chronic	O
nontumorous	O
diseases	O
of	O
the	O
parotid	O
glands	O
.	O

Coexistence	O
of	O
Turner	O
'	O
s	O
syndrome	O
and	O
schizophrenia	O

An	O
scrR	B-GENE
promoter	I-GENE
fragment	I-GENE
,	O
which	O
dose	O
not	O
contain	O
a	O
sequence	O
resembling	O
OB	B-GENE
,	O
was	O
not	O
shifted	O
by	O
the	O
fusion	O
protein	O
.	O

Using	O
the	O
conflict	O
drinking	O
test	O
as	O
a	O
model	O
,	O
we	O
studied	O
in	O
rats	O
the	O
effect	O
of	O
the	O
nonselective	O
beta	B-GENE
-	I-GENE
adrenoceptor	I-GENE
blockers	O
pindolol	O
and	O
cyanopindolol	O
which	O
bind	O
to	O
5	B-GENE
-	I-GENE
HT1A	I-GENE
and	I-GENE
5	I-GENE
-	I-GENE
HT1B	I-GENE
receptors	I-GENE
,	O
and	O
of	O
the	O
selective	O
beta	B-GENE
1	I-GENE
-	I-GENE
and	I-GENE
beta	I-GENE
2	I-GENE
-	I-GENE
adrenoceptor	I-GENE
antagonists	O
betaxolol	O
and	O
ICI	O
118	O
,	O
551	O
,	O
respectively	O
,	O
which	O
have	O
a	O
negligible	O
affinity	O
for	O
5	B-GENE
-	I-GENE
HT	I-GENE
receptors	I-GENE
.	O

Although	O
several	O
other	O
signal	O
transduction	O
molecules	O
also	O
contain	O
tandemly	O
occurring	O
SH3	B-GENE
and	O
SH2	B-GENE
domains	I-GENE
,	O
the	O
function	O
of	O
these	O
closely	O
spaced	O
domains	O
is	O
not	O
well	O
understood	O
.	O

Glycoprotein	O
biosynthesis	O
in	O
Saccharomyces	O
cerevisiae	O
:	O
ngd29	B-GENE
,	O
an	O
N	O
-	O
glycosylation	O
mutant	O
allelic	O
to	O
och1	B-GENE
having	O
a	O
defect	O
in	O
the	O
initiation	O
of	O
outer	O
chain	O
formation	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
majority	O
of	O
patients	O
with	O
severe	O
ulcerative	O
colitis	O
,	O
circulating	O
concentrations	O
of	O
NOX	O
are	O
increased	O
at	O
presentation	O
and	O
fall	O
promptly	O
during	O
parenteral	O
steroid	O
therapy	O
,	O
irrespective	O
of	O
clinical	O
outcome	O
.	O

The	O
duration	O
of	O
naloxone	O
appears	O
to	O
be	O
dose	O
-	O
related	O
,	O
statistically	O
significant	O
up	O
to	O
approximately	O
1	O
.	O
5	O
hr	O
.	O

But	O
if	O
one	O
equalizes	O
the	O
upper	O
limits	O
of	O
normal	O
for	O
both	O
markers	O
to	O
a	O
common	O
95	O
%	O
specificity	O
,	O
the	O
tumour	O
-	O
indicating	O
sensitivity	O
of	O
CA	B-GENE
19	I-GENE
-	I-GENE
9	I-GENE
clearly	O
surpasses	O
that	O
of	O
CA	B-GENE
50	I-GENE
.	O

These	O
motions	O
were	O
found	O
in	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
tails	O
,	O
in	O
segment	O
33	O
-	O
35	O
which	O
forms	O
the	O
turn	O
between	O
beta	O
-	O
strands	O
S1	O
and	O
S2	O
,	O
and	O
residues	O
47	O
-	O
52	O
located	O
in	O
a	O
long	O
loop	O
preceding	O
strand	O
S3	O
.	O

Genomic	O
Southern	O
analysis	O
reveals	O
10	O
to	O
15	O
hybridising	O
fragments	O
,	O
suggesting	O
that	O
maize	O
contains	O
a	O
small	O
gene	O
family	O
.	O

Custom	O
-	O
made	O
orthoses	O
play	O
an	O
invaluable	O
role	O
in	O
achieving	O
a	O
wide	O
range	O
of	O
therapeutic	O
goals	O
:	O
improving	O
function	O
and	O
pinch	O
,	O
stabilizing	O
individual	O
joints	O
,	O
preventing	O
positional	O
contractures	O
,	O
protecting	O
joints	O
from	O
trauma	O
,	O
stretching	O
the	O
intrinsic	O
muscles	O
,	O
correcting	O
joint	O
-	O
and	O
soft	O
-	O
tissue	O
contractures	O
,	O
and	O
controlling	O
inflammation	O
.	O

Is	O
exposure	O
to	O
a	O
patient	O
with	O
Crohn	O
'	O
s	O
disease	O
an	O
environmental	O
factor	O
for	O
developing	O
the	O
disease	O
.	O

The	O
ZAG1	B-GENE
protein	I-GENE
from	O
in	O
vitro	O
translations	O
binds	O
to	O
a	O
consensus	O
target	O
site	O
that	O
is	O
recognized	O
by	O
the	O
AG	B-GENE
protein	I-GENE
.	O

The	O
uap100	B-GENE
cis	O
-	O
acting	O
,	O
up	O
-	O
promoter	O
,	O
constitutive	O
mutation	O
is	O
a	O
duplication	O
that	O
comprises	O
two	O
GATA	O
sites	O
and	O
suppresses	O
weakly	O
the	O
AREA	B-GENE
zinc	I-GENE
finger	I-GENE
mutation	I-GENE
but	O
does	O
not	O
alleviate	O
the	O
need	O
for	O
functional	O
UAY	B-GENE
and	O
AREA	B-GENE
proteins	I-GENE
.	O

Pituitary	O
thyrotropic	O
adenoma	O
associated	O
with	O
congenital	O
hypothyroidism	O
.	O

This	O
region	O
was	O
unfavourable	O
,	O
due	O
to	O
malaria	O
in	O
the	O
past	O
.	O

Indeed	O
,	O
after	O
a	O
single	O
oral	O
dose	O
,	O
the	O
role	O
of	O
the	O
mu	B-GENE
-	I-GENE
receptor	I-GENE
agonist	O
component	O
of	O
the	O
antinociceptive	O
effect	O
of	O
tramadol	O
appears	O
to	O
be	O
minor	O
,	O
with	O
most	O
of	O
the	O
analgesic	O
effect	O
being	O
attributable	O
to	O
nonopioid	O
properties	O
of	O
the	O
parent	O
compound	O
.	O

CHIEF	O
OUTCOME	O
MEASURES	O
:	O
Endoluminal	O
release	O
of	O
prostacyclin	O
(	O
6	O
-	O
Keto	O
-	O
PGF1	O
alpha	O
)	O
and	O
thromboxane	O
B2	O
(	O
TxB2	O
)	O
,	O
patency	O
,	O
EC	O
coverage	O
and	O
cell	O
identity	O
.	O

Somatic	O
and	O
visceral	O
inputs	O
to	O
the	O
thoracic	O
spinal	O
cord	O
of	O
the	O
cat	O
:	O
effects	O
of	O
noxious	O
stimulation	O
of	O
the	O
biliary	O
system	O
.	O

We	O
have	O
produced	O
the	O
Ure2	B-GENE
protein	I-GENE
to	O
high	O
yield	O
in	O
Escherichia	O
coli	O
from	O
a	O
synthetic	O
gene	O
.	O

Transfection	O
of	O
both	O
Calu	O
-	O
6	O
and	O
JEG	O
-	O
3	O
cells	O
with	O
a	O
PKA	B-GENE
expression	O
vector	O
resulted	O
in	O
a	O
10	O
-	O
fold	O
induction	O
of	O
human	B-GENE
renin	I-GENE
transcriptional	O
activity	O
in	O
constructs	O
containing	O
the	O
native	O
or	O
consensus	O
CRE	O
and	O
5	O
-	O
fold	O
activation	O
in	O
a	O
construct	O
containing	O
a	O
nonfunctional	O
CRE	O
.	O

We	O
undertook	O
this	O
study	O
to	O
examine	O
the	O
relationship	O
between	O
systemic	O
oxygen	O
delivery	O
(	O
DO2	O
)	O
and	O
tissue	O
oxygen	O
tension	O
(	O
TPO2	O
)	O
in	O
hypovolemic	O
shock	O
.	O

White	O
female	O
cases	O
were	O
more	O
likely	O
to	O
have	O
worked	O
as	O
registered	O
nurses	O
than	O
were	O
the	O
controls	O
(	O
OR	O
=	O
1	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
3	O
.	O
5	O
)	O
.	O

METHODS	O
:	O
Children	O
with	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
;	O
n	O
=	O
282	O
)	O
,	O
all	O
subtypes	O
,	O
ages	O
6	O
to	O
12	O
years	O
,	O
were	O
randomized	O
to	O
placebo	O
(	O
n	O
=	O
90	O
)	O
,	O
immediate	O
-	O
release	O
methylphenidate	O
(	O
IR	O
MPH	O
)	O
3	O
times	O
a	O
day	O
(	O
tid	O
;	O
dosed	O
every	O
4	O
hours	O
;	O
n	O
=	O
97	O
)	O
,	O
or	O
OROS	O
MPH	O
once	O
a	O
day	O
(	O
qd	O
;	O
n	O
=	O
95	O
)	O
in	O
a	O
double	O
-	O
blind	O
,	O
28	O
-	O
day	O
trial	O
.	O

Immunologic	O
tolerance	O
in	O
rats	O
during	O
13	O
weeks	O
of	O
inhalation	O
exposure	O
to	O
trimellitic	O
anhydride	O
.	O

They	O
cause	O
temporary	O
disability	O
,	O
invalidity	O
and	O
mortality	O
of	O
a	O
great	O
part	O
of	O
the	O
productive	O
population	O
,	O
significantly	O
damaging	O
the	O
economic	O
status	O
of	O
the	O
country	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
a	O
chymotrypsinlike	B-GENE
protease	I-GENE
from	I-GENE
Treponema	I-GENE
denticola	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
QTd	O
and	O
JTd	O
intervals	O
in	O
39	O
children	O
with	O
long	O
QT	O
syndrome	O
were	O
compared	O
to	O
those	O
of	O
50	O
normal	O
age	O
-	O
matched	O
children	O
.	O

V	B-GENE
-	I-GENE
ErbB	I-GENE
-	I-GENE
mediated	I-GENE
complex	I-GENE
formation	O
and	O
transformation	O
have	O
been	O
shown	O
to	O
occur	O
independently	O
of	O
Ras	B-GENE
activation	O
.	O

Both	O
parameters	O
were	O
determined	O
in	O
an	O
individual	O
eye	O
by	O
applying	O
the	O
dye	O
first	O
by	O
iontophoresis	O
and	O
then	O
by	O
intravitreal	O
injection	O
,	O
which	O
allows	O
the	O
influence	O
of	O
fluorescein	O
glucuronide	O
on	O
the	O
fluorophotometric	O
measurements	O
to	O
be	O
excluded	O
.	O

Organization	O
of	O
exons	O
suggests	O
that	O
,	O
similar	O
to	O
the	O
human	B-GENE
VEGF	I-GENE
gene	I-GENE
,	O
alternative	O
splicing	O
generates	O
the	O
120	O
-	O
,	O
164	O
-	O
,	O
and	O
188	O
-	O
amino	O
acid	O
isoforms	O
,	O
but	O
does	O
not	O
predict	O
a	O
fourth	O
VEGF	B-GENE
isoform	I-GENE
corresponding	O
to	O
human	B-GENE
VEGF206	I-GENE
.	O

Electron	O
microscopy	O
of	O
pH	O
7	O
.	O
5	O
-	O
treated	O
TMV	O
particles	O
incubated	O
in	O
SPN	B-GENE
-	O
treated	O
wheatgerm	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
,	O
showed	O
that	O
approximately	O
10	O
%	O
of	O
virions	O
complexed	O
with	O
one	O
ribosome	O
and	O
approximately	O
10	O
%	O
with	O
two	O
bound	O
ribosomes	O
,	O
confirming	O
that	O
omega	O
at	O
least	O
had	O
been	O
uncoated	O
.	O

The	O
sequence	O
contained	O
five	O
repeats	O
of	O
the	O
hypothetical	O
leucine	O
zipper	O
motif	O
:	O
one	O
is	O
in	O
the	O
N	O
-	O
terminal	O
globular	O
domain	O
,	O
and	O
four	O
are	O
in	O
the	O
central	O
alpha	O
-	O
helical	O
stalk	O
.	O

Postheparin	O
lipoprotein	B-GENE
lipase	I-GENE
,	O
measured	O
using	O
fat	O
emulsion	O
as	O
substrate	O
,	O
also	O
was	O
significantly	O
greater	O
in	O
female	O
rats	O
compared	O
with	O
males	O
.	O

The	O
authors	O
report	O
a	O
case	O
of	O
a	O
painful	O
wrist	O
related	O
to	O
a	O
"	O
Manieux	O
muscle	O
"	O
of	O
the	O
dorsal	O
aspect	O
of	O
the	O
hand	O
.	O

Genomic	O
organization	O
of	O
the	O
human	B-GENE
multidrug	I-GENE
resistance	I-GENE
(	I-GENE
MDR1	I-GENE
)	I-GENE
gene	I-GENE
and	O
origin	O
of	O
P	B-GENE
-	I-GENE
glycoproteins	I-GENE
.	O

The	O
response	O
to	O
nitroglycerin	O
,	O
however	O
,	O
remained	O
intact	O
regardless	O
of	O
initial	O
reperfusion	O
pressure	O
.	O

Deletion	O
analysis	O
revealed	O
that	O
only	O
the	O
TM	O
domain	O
of	O
E2	B-GENE
was	O
required	O
for	O
Golgi	O
targeting	O
.	O

In	O
addition	O
,	O
putative	O
binding	O
sites	O
for	O
SH3	B-GENE
and	O
SH2	B-GENE
domains	I-GENE
are	O
present	O
in	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
molecule	O
.	O

Since	O
nearly	O
all	O
transformants	O
involving	O
homeologous	O
DNAs	O
carried	O
a	O
single	O
recombinant	O
plasmid	O
in	O
both	O
Pms	B-GENE
+	I-GENE
and	O
Pms	B-GENE
-	I-GENE
strains	O
,	O
stable	O
heteroduplex	O
DNA	O
appears	O
less	O
likely	O
than	O
for	O
homologous	O
DNAs	O
.	O

All	O
rights	O
reserved	O
.	O

One	O
new	O
ORF	O
,	O
YBR0224	B-GENE
,	O
was	O
detected	O
,	O
coding	O
for	O
a	O
protein	O
with	O
918	O
amino	O
acids	O
.	O

A	O
sequence	O
-	O
ready	O
3	O
-	O
Mb	O
PAC	O
contig	O
covering	O
16	O
breakpoints	O
of	O
the	O
Wilms	B-GENE
tumor	I-GENE
/	I-GENE
anirida	I-GENE
region	I-GENE
of	O
human	O
chromosome	O
11p13	O
.	O

The	O
MAP	B-GENE
kinase	I-GENE
kinase	I-GENE
kinase	I-GENE
MLK2	B-GENE
co	O
-	O
localizes	O
with	O
activated	O
JNK	B-GENE
along	O
microtubules	O
and	O
associates	O
with	O
kinesin	B-GENE
superfamily	I-GENE
motor	O
KIF3	B-GENE
.	O

Bone	O
scintigraphy	O
is	O
an	O
excellent	O
screening	O
test	O
for	O
bone	O
lesions	O
and	O
Ga	O
-	O
67	O
scintigraphy	O
is	O
a	O
useful	O
tool	O
for	O
detecting	O
inflammatory	O
lesions	O
.	O

Spontaneous	O
fracture	O
of	O
the	O
tarsal	O
bone	O
in	O
2	O
cases	O
of	O
leprosy	O

They	O
are	O
transduced	O
through	O
TM	O
to	O
the	O
cytoplasmic	O
portion	O
(	O
cytoloops	O
and	O
the	O
C	O
-	O
terminal	O
tail	O
)	O
of	O
the	O
receptor	O
and	O
then	O
,	O
transferred	O
to	O
cytoplasmic	O
signaling	O
molecules	O
,	O
such	O
as	O
G	B-GENE
protein	I-GENE
.	O

Serum	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
and	O
creatine	B-GENE
kinase	I-GENE
activities	O
were	O
significantly	O
increased	O
in	O
the	O
A	O
praelongus	O
-	O
fed	O
pigs	O
and	O
significantly	O
decreased	O
in	O
Na2SeO4	O
-	O
fed	O
pigs	O
.	O

This	O
group	O
showed	O
the	O
presence	O
of	O
bacteria	O
infiltrated	O
at	O
the	O
dentinal	O
tubules	O
coronally	O
and	O
into	O
the	O
root	O
canals	O
.	O

Seven	O
Zebu	O
cattle	O
were	O
also	O
exposed	O
to	O
challenge	O
at	O
the	O
same	O
time	O
.	O

However	O
,	O
the	O
quasiparticle	O
scattering	O
rate	O
tau	O
(	O
-	O
1	O
)	O
is	O
such	O
that	O
Planck	O
'	O
s	O
over	O
2pi	O
/	O
tau	O
approximately	O
6t	O
(	O
perpendicular	O
)	O
,	O
implying	O
that	O
kappa	O
-	O
(	O
BEDT	O
-	O
TTF	O
)	O
2Cu	O
(	O
NCS	O
)	O
(	O
2	O
)	O
meets	O
the	O
criterion	O
used	O
to	O
identify	O
interlayer	O
incoherence	O
.	O

The	O
effect	O
on	O
kidney	O
length	O
was	O
considerably	O
prolonged	O
compared	O
with	O
the	O
vascular	O
effect	O
.	O

Although	O
polyubiquitin	B-GENE
chains	I-GENE
linked	O
through	O
Lys	O
(	O
29	O
)	O
of	O
ubiquitin	B-GENE
have	O
been	O
implicated	O
in	O
the	O
targeting	O
of	O
certain	O
substrates	O
to	O
proteasomes	O
,	O
the	O
signaling	O
properties	O
of	O
these	O
chains	O
are	O
poorly	O
understood	O
.	O

Diabetic	O
osteopenia	O
,	O
a	O
known	O
chronic	O
complication	O
of	O
diabetes	O
,	O
has	O
been	O
demonstrated	O
with	O
alterations	O
in	O
the	O
calcium	O
-	O
vitamin	O
D	O
endocrine	O
system	O
.	O

An	O
in	O
vitro	O
Raf	B-GENE
-	I-GENE
1	I-GENE
kinase	I-GENE
assay	O
,	O
however	O
,	O
failed	O
to	O
detect	O
LPS	O
-	O
induced	O
Raf	B-GENE
-	I-GENE
1	I-GENE
kinase	I-GENE
activity	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
suggesting	O
that	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
Raf	B-GENE
-	I-GENE
1	I-GENE
kinase	I-GENE
is	O
not	O
an	O
activating	O
component	O
of	O
the	O
LPS	O
signaling	O
pathway	O
regulating	O
MAPK	B-GENE
activity	O
or	O
sIL	B-GENE
-	I-GENE
1Ra	I-GENE
promoter	I-GENE
activity	O
.	O

Phosphorylation	O
of	O
the	O
ras	B-GENE
GTPase	B-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
(	O
GAP	B-GENE
)	O
by	O
the	O
p93c	B-GENE
-	I-GENE
fes	I-GENE
protein	B-GENE
-	I-GENE
tyrosine	I-GENE
kinase	I-GENE
in	O
vitro	O
and	O
formation	O
of	O
GAP	B-GENE
-	O
fes	B-GENE
complexes	O
via	O
an	O
SH2	B-GENE
domain	O
-	O
dependent	O
mechanism	O
.	O

Gingival	O
retraction	O
for	O
class	O
V	O
restorations	O
.	O

Two	O
methods	O
for	O
the	O
routine	O
determination	O
of	O
blood	O
hemoglobin	B-GENE
oxygen	O
affinity	O
are	O
described	O
.	O

Thirty	O
minutes	O
after	O
reperfusion	O
,	O
lung	O
lymph	O
flow	O
(	O
QL	O
)	O
increased	O
from	O
4	O
.	O
3	O
to	O
8	O
.	O
3	O
ml	O
/	O
30	O
minutes	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
lymph	O
/	O
plasma	O
protein	O
ratio	O
was	O
unchanged	O
from	O
0	O
.	O
6	O
,	O
and	O
the	O
lymph	O
protein	O
clearance	O
increased	O
from	O
2	O
.	O
6	O
to	O
4	O
.	O
6	O
ml	O
/	O
30	O
minutes	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
data	O
consistent	O
with	O
increased	O
microvascular	O
permeability	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

RET	B-GENE
/	O
PTC	B-GENE
oncogenes	O
,	O
generated	O
by	O
chromosomal	O
rearrangements	O
in	O
papillary	O
thyroid	O
carcinomas	O
,	O
are	O
constitutively	O
activated	O
versions	O
of	O
proto	B-GENE
-	I-GENE
RET	I-GENE
,	O
a	O
gene	O
coding	O
for	O
a	O
receptor	B-GENE
-	I-GENE
type	I-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
TK	B-GENE
)	O
whose	O
ligand	O
is	O
still	O
unknown	O
.	O

PCC	O
6803	O
mutant	O
impaired	O
in	O
cytochrome	B-GENE
c	I-GENE
maturation	O
.	O

STUDY	O
OBJECTIVE	O
:	O
to	O
characterize	O
gas	O
exchange	O
and	O
cardiopulmonary	O
performance	O
during	O
maximal	O
progressive	O
arm	O
crank	O
exercise	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
activating	O
effect	O
of	O
this	O
mutation	O
is	O
not	O
the	O
result	O
of	O
creating	O
an	O
exonic	O
splicing	O
enhancer	O
(	O
ESE	O
)	O
or	O
disrupting	O
a	O
putative	O
secondary	O
structure	O
.	O

The	O
kinase	O
domains	O
encoded	O
in	O
the	O
COOH	O
-	O
terminal	O
moiety	O
are	O
94	O
%	O
conserved	O
;	O
the	O
NH2	O
-	O
terminal	O
moieties	O
are	O
approximately	O
65	O
%	O
homologous	O
,	O
suggesting	O
this	O
region	O
may	O
encode	O
sequences	O
conferring	O
differential	O
regulation	O
of	O
the	O
two	O
kinases	O
.	O

In	O
rats	O
exposed	O
to	O
Cd	O
for	O
30	O
d	O
,	O
the	O
levels	O
of	O
urinary	O
excretion	O
of	O
cAMP	O
after	O
treatment	O
with	O
parathyroid	B-GENE
hormone	I-GENE
(	O
PTH	B-GENE
)	O
,	O
parathyroidectomy	O
(	O
PTX	O
)	O
,	O
or	O
1	O
alpha	O
-	O
hydroxycholecalciferol	O
(	O
1	O
alpha	O
-	O
OH	O
-	O
D3	O
)	O
showed	O
almost	O
the	O
same	O
patterns	O
as	O
those	O
of	O
control	O
rats	O
:	O
the	O
response	O
of	O
urinary	O
cAMP	O
to	O
treatment	O
with	O
PTH	B-GENE
was	O
not	O
influenced	O
by	O
continuous	O
oral	O
administration	O
of	O
Cd	O
.	O

The	O
goal	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
BMIPP	O
uptake	O
can	O
be	O
used	O
to	O
differentiate	O
viable	O
myocardium	O
from	O
scar	O
tissue	O
soon	O
after	O
coronary	O
thrombolysis	O
for	O
acute	O
myocardial	O
infarction	O
.	O

There	O
are	O
three	O
types	O
of	O
problems	O
:	O
problems	O
arising	O
before	O
the	O
drug	O
enters	O
the	O
body	O
(	O
solubilization	O
,	O
stabilization	O
and	O
improved	O
acceptability	O
)	O
;	O
problems	O
associated	O
with	O
the	O
penetration	O
and	O
fate	O
of	O
the	O
drug	O
in	O
the	O
body	O
(	O
absorption	O
,	O
barrier	O
crossing	O
,	O
duration	O
of	O
action	O
)	O
;	O
problems	O
relating	O
to	O
the	O
therapeutic	O
target	O
(	O
selective	O
local	O
delivery	O
)	O
.	O

In	O
the	O
absence	O
of	O
shock	O
,	O
sepsis	O
,	O
or	O
other	O
identifiable	O
causes	O
of	O
lactic	O
acidosis	O
,	O
the	O
severe	O
anemia	O
(	O
hemoglobin	B-GENE
1	O
.	O
2	O
g	O
/	O
dl	O
)	O
appeared	O
to	O
be	O
the	O
primary	O
etiologic	O
factor	O
.	O

The	O
cumulative	O
experience	O
in	O
liver	O
transplantation	O
since	O
the	O
introduction	O
of	O
cyclosporine	O
A	O
has	O
confirmed	O
its	O
efficacy	O
in	O
the	O
treatment	O
of	O
diverse	O
liver	O
diseases	O
in	O
children	O
and	O
adults	O
.	O

Northern	O
blot	O
analysis	O
of	O
liver	O
,	O
muscle	O
,	O
fat	O
,	O
and	O
pituitary	O
RNA	O
from	O
normal	O
(	O
DwDw	O
)	O
chickens	O
shows	O
a	O
major	O
transcript	O
of	O
4	O
.	O
3	O
kilobases	O
(	O
kb	O
)	O
and	O
three	O
minor	O
transcripts	O
(	O
0	O
.	O
8	O
,	O
1	O
.	O
7	O
,	O
and	O
3	O
.	O
2	O
kb	O
)	O
,	O
which	O
correspond	O
to	O
the	O
cGHR	B-GENE
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Despite	O
a	O
lowering	O
of	O
her	O
plasma	O
ACTH	B-GENE
concentration	O
during	O
therapy	O
with	O
valproic	O
acid	O
,	O
the	O
patient	O
'	O
s	O
tumour	O
showed	O
no	O
evidence	O
of	O
regression	O
while	O
she	O
was	O
taking	O
the	O
drug	O
.	O

The	O
Htf9	B-GENE
-	I-GENE
a	I-GENE
gene	I-GENE
encodes	O
the	O
RanBP1	B-GENE
protein	I-GENE
,	O
a	O
major	O
partner	O
of	O
the	O
Ran	B-GENE
GTPase	I-GENE
.	O

STUDY	O
DESIGN	O
:	O
Retrospective	O
review	O
.	O

Sequence	O
divergence	O
of	O
approximately	O
16	O
%	O
reduced	O
transformation	O
frequencies	O
by	O
at	O
least	O
10	O
-	O
fold	O
.	O

Our	O
studies	O
suggest	O
that	O
the	O
helicase	B-GENE
assembly	O
protein	O
is	O
responsible	O
for	O
loading	O
T4	B-GENE
gene	I-GENE
41	I-GENE
helicase	I-GENE
specifically	O
at	O
replication	O
forks	O
,	O
and	O
that	O
its	O
binding	O
sites	O
for	O
each	O
arm	O
must	O
hold	O
more	O
than	O
six	O
,	O
but	O
not	O
more	O
than	O
12	O
nucleotides	O
.	O

During	O
the	O
1st	O
week	O
of	O
treatment	O
all	O
subjects	O
received	O
either	O
mianserin	O
30	O
mg	O
or	O
clomipramine	O
75	O
mg	O
once	O
daily	O
.	O

CBD	O
exploration	O
was	O
avoided	O
in	O
7	O
patients	O
with	O
normal	O
POC	O
.	O

The	O
human	B-GENE
SHBG	I-GENE
proximal	I-GENE
promoter	I-GENE
was	O
analyzed	O
by	O
DNase	B-GENE
I	I-GENE
footprinting	O
,	O
and	O
the	O
functional	O
significance	O
of	O
6	O
footprinted	O
regions	O
(	O
FP1	O
-	O
FP6	O
)	O
within	O
the	O
proximal	O
promoter	O
was	O
studied	O
in	O
human	O
HepG2	O
hepatoblastoma	O
cells	O
.	O

We	O
exposed	O
Dorper	O
-	O
cross	O
ewes	O
at	O
approximately	O
120	O
-	O
135	O
days	O
of	O
gestation	O
to	O
a	O
hot	O
(	O
40	O
degrees	O
C	O
,	O
60	O
%	O
relative	O
humidity	O
)	O
and	O
a	O
cold	O
(	O
4	O
degrees	O
C	O
,	O
90	O
%	O
relative	O
humidity	O
)	O
environment	O
and	O
to	O
treadmill	O
exercise	O
(	O
2	O
.	O
1	O
km	O
/	O
h	O
,	O
5	O
degrees	O
gradient	O
)	O
and	O
measured	O
fetal	O
lamb	O
and	O
ewe	O
body	O
temperatures	O
using	O
previously	O
implanted	O
abdominal	O
radiotelemeters	O
.	O

Previously	O
identified	O
mutations	O
in	O
this	O
variant	O
have	O
been	O
within	O
or	O
close	O
to	O
the	O
coding	O
region	O
of	O
exon	O
1	O
of	O
the	O
HMBS	B-GENE
gene	I-GENE
,	O
the	O
only	O
exon	O
that	O
is	O
expressed	O
solely	O
in	O
the	O
ubiquitous	O
isoform	O
.	O

As	O
an	O
approach	O
to	O
the	O
determination	O
of	O
structure	O
-	O
function	O
relationships	O
in	O
the	O
PRP4	B-GENE
protein	I-GENE
,	O
we	O
have	O
isolated	O
more	O
than	O
fifty	O
new	O
alleles	O
of	O
the	O
PRP4	B-GENE
gene	I-GENE
through	O
random	O
and	O
site	O
-	O
directed	O
mutagenesis	O
,	O
and	O
have	O
analyzed	O
the	O
phenotypes	O
of	O
many	O
of	O
them	O
.	O

Over	O
a	O
period	O
of	O
five	O
training	O
sessions	O
(	O
2	O
.	O
5	O
days	O
)	O
,	O
the	O
animals	O
learned	O
not	O
to	O
breathe	O
,	O
and	O
the	O
number	O
of	O
stimuli	O
received	O
in	O
the	O
fifth	O
session	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
first	O
session	O
.	O

The	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
,	O
approximately	O
1	O
.	O
1	O
kbp	O
long	O
,	O
had	O
no	O
known	O
regulatory	O
elements	O
for	O
transcription	O
such	O
as	O
TATA	O
,	O
GC	O
,	O
and	O
CCAAT	O
boxes	O
.	O

We	O
find	O
that	O
Fus3p	B-GENE
and	O
Kss1p	B-GENE
both	O
control	O
G1	O
arrest	O
through	O
multiple	O
functions	O
that	O
operate	O
in	O
parallel	O
with	O
Far1p	B-GENE
.	O

Tag	B-GENE
expression	O
induced	O
apoptosis	O
in	O
mammary	O
epithelial	O
cells	O
during	O
late	O
pregnancy	O
.	O

The	O
composition	O
of	O
renal	O
stones	O
analysed	O
by	O
infrared	O
spectroscopy	O
.	O

14	O
.	O
9	O
x	O
109	O
L	O
-	O
1	O
)	O
was	O
equal	O
for	O
both	O
groups	O
,	O
but	O
CCI	O
values	O
were	O
significantly	O
higher	O
for	O
the	O
bedside	O
filtered	O
PC	O
(	O
14	O
.	O
1	O
+	O
/	O
-	O
9	O
.	O
5	O
vs	O
.	O

In	O
this	O
study	O
,	O
the	O
case	O
of	O
a	O
patient	O
presenting	O
a	O
second	O
hepatocellular	O
carcinoma	O
13	O
years	O
after	O
resection	O
of	O
a	O
first	O
tumor	O
of	O
the	O
same	O
type	O
is	O
reported	O
.	O

The	O
time	O
-	O
dependent	O
changes	O
in	O
measured	O
facility	O
of	O
outflow	O
or	O
"	O
washout	O
phenomenon	O
"	O
appeared	O
to	O
result	O
from	O
the	O
gradual	O
dissolution	O
of	O
the	O
hyaluronidase	B-GENE
-	O
sensitive	O
component	O
of	O
the	O
barriers	O
to	O
aqueous	O
outflow	O
in	O
the	O
canine	O
eye	O
.	O

The	O
factors	O
defective	O
in	O
groups	O
A	O
(	O
CIITA	B-GENE
)	O
,	O
C	O
(	O
RFX5	B-GENE
)	O
and	O
D	O
(	O
RFXAP	B-GENE
)	O
have	O
been	O
identified	O
.	O

It	O
differed	O
significantly	O
by	O
country	O
(	O
from	O
2	O
.	O
4	O
%	O
in	O
the	O
United	O
Kingdom	O
to	O
24	O
.	O
7	O
%	O
in	O
Portugal	O
)	O
and	O
by	O
transmission	O
category	O
(	O
2	O
.	O
7	O
%	O
among	O
homo	O
/	O
bisexuals	O
,	O
5	O
.	O
8	O
%	O
among	O
injecting	O
drug	O
users	O
,	O
13	O
.	O
6	O
%	O
among	O
heterosexual	O
subgroup	O
1	O
)	O
.	O

On	O
a	O
national	O
level	O
,	O
undiscounted	O
costs	O
are	O
expected	O
to	O
increase	O
up	O
to	O
approximately	O
DF1	O
42	O
million	O
annually	O
during	O
the	O
first	O
40	O
years	O
after	O
introduction	O
of	O
the	O
preventative	O
strategy	O
.	O

By	O
deletion	O
analysis	O
,	O
we	O
identified	O
the	O
regions	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
encoding	O
transformation	O
and	O
transactivation	O
functions	O
.	O

A	O
survey	O
of	O
274	O
late	O
detected	O
cases	O
of	O
CDH	O
born	O
in	O
the	O
years	O
1970	O
-	O
-	O
74	O
is	O
presented	O
.	O

To	O
test	O
for	O
progesterone	B-GENE
receptor	I-GENE
-	O
mediated	O
activation	O
of	O
transcription	O
in	O
yeast	O
,	O
reporter	O
plasmids	O
were	O
constructed	O
to	O
transform	O
yeast	O
cells	O
expressing	O
PRB	B-GENE
or	O
C1C2	B-GENE
receptors	I-GENE
.	O

Fli	B-GENE
-	I-GENE
1	I-GENE
is	O
a	O
proto	O
-	O
oncogene	O
which	O
is	O
rearranged	O
in	O
tumors	O
induced	O
by	O
three	O
different	O
retroviruses	O
,	O
Cas	O
-	O
Br	O
-	O
E	O
,	O
F	O
-	O
MuLV	O
,	O
and	O
10A1	O
.	O

Ionic	O
composition	O
(	O
Na	O
+	O
,	O
K	O
+	O
,	O
Ca	O
+	O
2	O
,	O
and	O
Mg2	O
+	O
)	O
of	O
cerebrospinal	O
fluid	O
and	O
feeding	O
behavior	O
in	O
sheep	O
.	O

Materials	O
are	O
presented	O
of	O
a	O
comparative	O
study	O
of	O
morphological	O
and	O
cultural	O
properties	O
and	O
virulence	O
of	O
liophylized	O
cultures	O
of	O
Leishmania	O
tropica	O
major	O
after	O
their	O
rehydration	O
or	O
after	O
a	O
long	O
passage	O
on	O
the	O
NNN	O
medium	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
imply	O
that	O
the	O
spinal	O
cord	O
is	O
not	O
a	O
simple	O
command	O
-	O
carrying	O
medium	O
from	O
the	O
brain	O
to	O
the	O
limbs	O
,	O
and	O
implies	O
that	O
some	O
computational	O
activities	O
take	O
place	O
at	O
the	O
spinal	O
cord	O
level	O
.	O

The	O
101st	O
annual	O
meeting	O
of	O
the	O
Japanese	O
Ophthalmological	O
Society	O
.	O

The	O
results	O
corroborate	O
the	O
proposed	O
physiological	O
function	O
of	O
CCoAOMT	B-GENE
in	O
elicited	O
plant	O
cells	O
and	O
may	O
shed	O
new	O
light	O
on	O
the	O
sequential	O
action	O
of	O
trans	O
-	O
active	O
factors	O
in	O
the	O
regulation	O
of	O
phenylpropanoid	O
genes	O
.	O

In	O
src	B-GENE
-	O
transformed	O
cells	O
GAP	B-GENE
forms	O
heteromeric	O
complexes	O
,	O
notably	O
with	O
a	O
highly	O
tyrosine	O
phosphorylated	O
62	B-GENE
-	I-GENE
kDa	I-GENE
protein	I-GENE
(	I-GENE
p62	I-GENE
)	I-GENE
.	O

A	O
study	O
of	O
characteristics	O
in	O
adult	O
asthmatics	O
who	O
are	O
sensitized	O
by	O
cats	O
and	O
dogs	O
allergens	O

PrRP	B-GENE
rapidly	O
and	O
transiently	O
activated	O
extracellular	B-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
ERK	B-GENE
)	O
in	O
both	O
types	O
of	O
cells	O
.	O

Cell	O
-	O
free	O
extracts	O
of	O
E	O
.	O
coli	O
(	O
fpg	B-GENE
mutY	B-GENE
)	O
harboring	O
pYSB10	O
possess	O
an	O
enzymatic	O
activity	O
that	O
cleaves	O
a	O
34	O
-	O
mer	O
oligonucleotide	O
containing	O
a	O
single	O
8	O
-	O
oxoG	O
opposite	O
a	O
cytosine	O
(	O
8	O
-	O
OxoG	O
/	O
C	O
)	O
.	O

Estrogen	O
pretreated	O
castrated	O
males	O
also	O
showed	O
no	O
change	O
in	O
myocardial	O
blood	O
flow	O
after	O
17	O
beta	O
-	O
estradiol	O
,	O
but	O
coronary	O
flow	O
velocity	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
baseline	O
1	O
h	O
after	O
the	O
200	O
ng	O
/	O
kg	O
dose	O
(	O
from	O
1	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
61	O
to	O
1	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
42	O
kHz	O
)	O
and	O
diastolic	O
coronary	O
resistance	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
with	O
control	O
at	O
this	O
time	O
(	O
51	O
+	O
/	O
-	O
15	O
compared	O
with	O
39	O
+	O
/	O
-	O
14	O
mmHg	O
/	O
mkHz	O
)	O
.	O

Acute	O
renal	O
vein	O
thrombosis	O
in	O
renal	O
allografts	O
:	O
detection	O
with	O
duplex	O
Doppler	O
US	O
.	O

Several	O
DNA	O
clones	O
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	O
18	O
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

Long	O
-	O
range	O
mapping	O
by	O
pulse	O
-	O
field	O
gel	O
electrophoresis	O
indicated	O
that	O
the	O
three	O
mdr	B-GENE
genes	I-GENE
are	O
closely	O
linked	O
on	O
a	O
genomic	O
DNA	O
segment	O
of	O
approximately	O
625	O
kilobases	O
.	O

These	O
sequences	O
were	O
further	O
tested	O
for	O
the	O
presence	O
of	O
an	O
enhancer	O
element	O
,	O
by	O
their	O
ability	O
to	O
activate	O
a	O
fusion	O
reporter	O
gene	O
consisting	O
of	O
the	O
CAT	B-GENE
gene	I-GENE
linked	O
to	O
the	O
gamma	B-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
promoter	I-GENE
,	O
in	O
erythroid	O
(	O
K562	O
)	O
and	O
non	O
-	O
erythroid	O
(	O
HeLa	O
)	O
cells	O
.	O

Two	O
sibs	O
with	O
identical	O
features	O
of	O
short	O
-	O
limbed	O
dwarfism	O
,	O
a	O
normal	O
skull	O
and	O
face	O
and	O
normal	O
intelligence	O
are	O
described	O
.	O

This	O
article	O
describes	O
a	O
program	O
that	O
resulted	O
in	O
a	O
75	O
-	O
percent	O
reduction	O
of	O
inventory	O
over	O
a	O
five	O
-	O
year	O
interval	O
.	O

Further	O
comparative	O
analysis	O
identified	O
an	O
ADNP	B-GENE
paralog	O
(	O
33	O
%	O
identity	O
and	O
46	O
%	O
similarity	O
)	O
,	O
indicating	O
that	O
these	O
genes	O
belong	O
to	O
a	O
novel	O
protein	O
family	O
with	O
a	O
nine	O
-	O
zinc	O
finger	O
motif	O
followed	O
by	O
a	O
homeobox	O
domain	O
.	O

All	O
patients	O
received	O
marrow	O
from	O
HLA	B-GENE
-	O
identical	O
sibling	O
donors	O
,	O
underwent	O
similar	O
myeloablative	O
regimens	O
,	O
and	O
had	O
similar	O
pretreatment	O
characteristics	O
.	O

In	O
female	O
toads	O
,	O
Bufo	O
bufo	O
,	O
feeding	O
at	O
different	O
rates	O
,	O
the	O
uncorrected	O
value	O
of	O
n	O
was	O
0	O
.	O
44	O
,	O
when	O
metabolism	O
and	O
growth	O
were	O
expressed	O
as	O
kJ	O
kJ	O
-	O
1	O
.	O

METHODS	O
:	O
Two	O
patients	O
developed	O
cervical	O
myelopathy	O
or	O
radiculopathy	O
after	O
spinal	O
manipulation	O
therapy	O
,	O
and	O
magnetic	O
resonance	O
imaging	O
showed	O
herniated	O
cervical	O
discs	O
at	O
C4	O
-	O
C5	O
and	O
C6	O
-	O
C7	O
,	O
respectively	O
.	O

Subclones	O
stably	O
expressing	O
alpha1A	B-GENE
-	O
,	O
alpha1B	B-GENE
-	O
,	O
and	O
alpha1D	B-GENE
-	O
ARs	O
under	O
control	O
of	O
an	O
inducible	O
promoter	O
,	O
or	O
at	O
high	O
and	O
low	O
receptor	O
density	O
,	O
were	O
isolated	O
and	O
characterized	O
.	O

Analysis	O
of	O
WT1	B-GENE
target	I-GENE
gene	I-GENE
expression	O
in	O
stably	O
transfected	O
cell	O
lines	O
.	O

Soluble	O
recombinant	O
RI	B-GENE
and	O
soluble	O
recombinant	O
C	B-GENE
alpha	I-GENE
can	O
associate	O
in	O
vitro	O
and	O
be	O
activated	O
by	O
cyclic	O
AMP	O
.	O

IRIS	B-GENE
/	O
GAS	B-GENE
DNA	O
also	O
formed	O
a	O
number	O
of	O
specific	O
complexes	O
with	O
constitutively	O
expressed	O
factors	O
,	O
none	O
of	O
which	O
were	O
affected	O
by	O
the	O
above	O
Abs	O
.	O

Simulation	O
results	O
based	O
on	O
the	O
presented	O
model	O
are	O
compared	O
with	O
the	O
experimental	O
data	O
for	O
two	O
types	O
of	O
cMUTs	O
reported	O
in	O
the	O
recent	O
literature	O
.	O

Tre	O
during	O
exercise	O
at	O
35	O
W	O
at	O
23	O
degrees	O
C	O
correlated	O
r	O
=	O
-	O
70	O
with	O
Vo2max	O
and	O
r	O
=	O
0	O
.	O
80	O
with	O
Tre	O
during	O
exercise	O
in	O
heat	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
with	O
nuclear	O
extracts	O
from	O
COS	O
-	O
1	O
cells	O
transfected	O
with	O
expression	O
vectors	O
for	O
SMADs	B-GENE
1	I-GENE
-	I-GENE
5	I-GENE
indicate	O
that	O
SMAD3	B-GENE
forms	O
a	O
complex	O
with	O
a	O
migration	O
similar	O
to	O
that	O
of	O
the	O
endogenous	B-GENE
TGF	I-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
specific	I-GENE
complex	I-GENE
observed	O
in	O
fibroblast	O
extracts	O
.	O

The	O
newly	O
identified	O
NF	B-GENE
kappa	I-GENE
B	I-GENE
enhancer	I-GENE
(	O
TGGAAATTCC	O
)	O
is	O
bound	O
by	O
a	O
TNF	B-GENE
alpha	I-GENE
-	O
induced	O
nuclear	O
protein	O
and	O
appears	O
to	O
be	O
the	O
key	O
element	O
in	O
rapid	O
transcription	O
induction	O
by	O
TNF	B-GENE
alpha	I-GENE
(	O
and	O
TPA	O
)	O
,	O
while	O
transactivation	O
of	O
this	O
element	O
is	O
repressed	O
by	O
the	O
ligand	O
-	O
bound	O
glucocorticoid	B-GENE
receptor	I-GENE
.	O

Our	O
results	O
showed	O
that	O
the	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
)	O
content	O
in	O
platelets	O
was	O
:	O
(	O
1	O
)	O
increased	O
in	O
the	O
subgroup	O
of	O
anti	O
-	O
social	O
alcoholics	O
;	O
(	O
2	O
)	O
transiently	O
and	O
differently	O
altered	O
in	O
alcoholics	O
compared	O
to	O
opiate	O
addicts	O
;	O
and	O
(	O
3	O
)	O
lowered	O
in	O
drinking	O
alcoholics	O
and	O
normal	O
in	O
alcoholics	O
who	O
were	O
drinking	O
as	O
well	O
as	O
smoking	O
(	O
that	O
may	O
occur	O
via	O
MAO	B-GENE
-	I-GENE
B	I-GENE
inhibition	O
by	O
smoke	O
)	O
.	O

In	O
the	O
second	O
group	O
,	O
which	O
consisted	O
of	O
babies	O
of	O
33	O
to	O
36	O
weeks	O
of	O
gestational	O
age	O
,	O
haptoglobin	B-GENE
was	O
detected	O
in	O
6	O
infants	O
,	O
with	O
levels	O
less	O
than	O
25	O
mg	O
/	O
dl	O
in	O
3	O
.	O

The	O
polypeptide	O
encoded	O
by	O
the	O
cDNA	O
contained	O
450	O
amino	O
acids	O
with	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
52	O
,	O
057	O
,	O
and	O
showed	O
significant	O
homology	O
with	O
human	O
and	O
mouse	B-GENE
CAD	I-GENE
(	O
22	O
%	O
identity	O
)	O
.	O

Correlation	O
of	O
alpha	O
activity	O
between	O
the	O
frontal	O
and	O
occipital	O
cortex	O
.	O

In	O
situ	O
localization	O
of	O
PCP	B-GENE
-	I-GENE
A1	I-GENE
transcripts	I-GENE
revealed	O
that	O
they	O
accumulate	O
specifically	O
in	O
pollen	O
at	O
the	O
late	O
binucleate	O
/	O
trinucleate	O
stage	O
of	O
development	O
rather	O
than	O
in	O
the	O
tapetum	O
,	O
which	O
previously	O
was	O
taken	O
to	O
be	O
the	O
principal	O
source	O
of	O
the	O
pollen	O
coat	O
.	O

Successful	O
resolution	O
of	O
progressive	O
multifocal	O
leukoencephalopathy	O
after	O
combination	O
therapy	O
with	O
cidofovir	O
and	O
cytosine	O
arabinoside	O
.	O

The	O
species	O
composition	O
and	O
abundance	O
upon	O
treatment	O
of	O
manure	O
with	O
polyethylene	O
,	O
polystyrene	O
and	O
glass	O
particles	O
was	O
similar	O
to	O
that	O
of	O
the	O
treatment	O
control	O
,	O
i	O
.	O
e	O
.	O
natural	O
and	O
inert	O
sand	O
.	O

However	O
,	O
H19	B-GENE
and	O
IGF2	B-GENE
lie	O
within	O
a	O
larger	O
imprinted	O
domain	O
,	O
and	O
the	O
gene	O
specificity	O
of	O
H19	B-GENE
epimutation	O
has	O
been	O
a	O
persistent	O
question	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
,	O
by	O
either	O
peptide	O
sequencing	O
or	O
by	O
sequence	O
similarity	O
to	O
the	O
human	O
cDNAs	O
,	O
of	O
the	O
S	O
.	O
cerevisiae	O
genes	O
RFC1	B-GENE
,	O
RFC2	B-GENE
,	O
RFC3	B-GENE
,	O
RFC4	B-GENE
,	O
and	O
RFC5	B-GENE
.	O

It	O
is	O
of	O
interest	O
that	O
,	O
aside	O
from	O
starvation	O
,	O
the	O
nutrition	O
catastrophes	O
of	O
the	O
past	O
,	O
including	O
scurvy	O
(	O
vitamin	O
C	O
deficiency	O
)	O
resulting	O
from	O
lack	O
of	O
fresh	O
vegetables	O
and	O
fruit	O
and	O
beriberi	O
(	O
vitamin	O
B1	O
deficiency	O
)	O
from	O
consumption	O
of	O
polished	O
rice	O
,	O
are	O
forgotten	O
and	O
only	O
of	O
interest	O
as	O
history	O
.	O

This	O
sequence	O
can	O
interact	O
with	O
at	O
least	O
two	O
proteins	O
in	O
a	O
fibroblast	O
nuclear	O
extract	O
that	O
have	O
binding	O
characteristics	O
of	O
an	O
Ets	B-GENE
family	I-GENE
protein	I-GENE
and	O
a	O
serum	B-GENE
response	I-GENE
factor	I-GENE
-	I-GENE
like	I-GENE
protein	I-GENE
.	O

As	O
much	O
thrombin	B-GENE
was	O
formed	O
during	O
cardiopulmonary	O
bypass	O
(	O
measured	O
by	O
the	O
prothrombin	B-GENE
activation	I-GENE
fragment	I-GENE
F1	I-GENE
+	I-GENE
2	I-GENE
and	O
thrombin	B-GENE
-	O
antithrombin	B-GENE
complexes	O
)	O
as	O
in	O
normal	O
patients	O
,	O
showing	O
that	O
factor	B-GENE
XII	I-GENE
was	O
not	O
necessary	O
for	O
thrombin	B-GENE
generation	O
.	O

The	O
molecular	O
event	O
(	O
s	O
)	O
underlying	O
the	O
functional	O
specificities	O
of	O
these	O
receptors	O
(	O
in	O
regulating	O
the	O
expression	O
of	O
their	O
native	O
target	O
genes	O
)	O
is	O
a	O
very	O
important	O
issue	O
that	O
remains	O
poorly	O
understood	O
.	O

MUS81	B-GENE
encodes	O
a	O
novel	O
helix	B-GENE
-	I-GENE
hairpin	I-GENE
-	I-GENE
helix	I-GENE
protein	I-GENE
involved	O
in	O
the	O
response	O
to	O
UV	O
-	O
and	O
methylation	O
-	O
induced	O
DNA	O
damage	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Treatment	O
of	O
chronic	O
hepatitis	O
B	O
with	O
interferon	B-GENE
:	O
experience	O
in	O
western	O
countries	O
.	O

Several	O
positive	O
clones	O
were	O
isolated	O
,	O
one	O
of	O
which	O
encoded	O
the	O
C	O
-	O
terminal	O
253	O
amino	O
acids	O
of	O
a	O
putative	O
RNA	B-GENE
helicase	I-GENE
,	O
a	O
DEAD	B-GENE
box	I-GENE
protein	I-GENE
designated	O
DDX3	B-GENE
.	O

Kerstin	O
takes	O
the	O
abbreviated	O
medical	O
education	O
.	O

In	O
vitro	O
binding	O
studies	O
previously	O
showed	O
that	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
p50	B-GENE
homodimer	O
binds	O
the	O
switch	B-GENE
nuclear	I-GENE
B	I-GENE
-	I-GENE
site	I-GENE
protein	I-GENE
(	O
SNIP	B-GENE
)	O
of	O
the	O
S	B-GENE
gamma	I-GENE
3	I-GENE
tandem	I-GENE
repeat	I-GENE
.	O

In	O
this	O
case	O
myogenic	O
factors	O
are	O
not	O
initially	O
expressed	O
and	O
these	O
migratory	O
cells	O
are	O
characterized	O
by	O
the	O
expression	O
of	O
the	O
paired	B-GENE
-	O
box	O
gene	O
Pax3	B-GENE
.	O

It	O
is	O
concluded	O
that	O
the	O
atherogenic	O
process	O
includes	O
stimulation	O
of	O
collagen	B-GENE
and	O
elastin	B-GENE
synthesis	O
.	O

These	O
results	O
indicate	O
that	O
(	O
1	O
)	O
RXR	B-GENE
-	O
TR	B-GENE
heterodimers	O
play	O
a	O
role	O
in	O
basal	O
transactivation	O
and	O
T3	O
suppression	O
of	O
negatively	O
regulated	O
genes	O
,	O
and	O
(	O
2	O
)	O
RXRs	B-GENE
increase	O
the	O
dominant	O
negative	O
effect	O
of	O
some	O
mutant	O
TRs	B-GENE
on	O
specific	O
negative	O
TREs	O
.	O

Phenotypic	O
responses	O
of	O
additional	O
mutants	O
,	O
including	O
exo1	B-GENE
,	O
srs2	B-GENE
,	O
rad5	B-GENE
,	O
and	O
rdh54	B-GENE
strains	O
,	O
suggest	O
roles	O
in	O
recombinational	O
repair	O
,	O
but	O
not	O
in	O
NHEJ	O
.	O

Furthermore	O
,	O
the	O
induction	O
of	O
cytochrome	B-GENE
P	I-GENE
-	I-GENE
450	I-GENE
1A1	I-GENE
observed	O
in	O
the	O
cormorant	O
indicates	O
that	O
the	O
Ah	B-GENE
receptor	I-GENE
-	O
mediated	O
process	O
,	O
by	O
which	O
TCDD	O
and	O
related	O
chemicals	O
exert	O
many	O
of	O
their	O
toxicities	O
,	O
has	O
been	O
activated	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
prospective	O
study	O
was	O
conducted	O
with	O
44	O
cycles	O
for	O
34	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
1	O
)	O
and	O
47	O
cycles	O
for	O
40	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
2	O
)	O
with	O
a	O
long	O
IVF	O
protocol	O
;	O
68	O
cycles	O
for	O
46	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
3	O
)	O
and	O
56	O
cycles	O
for	O
39	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
4	O
)	O
with	O
a	O
short	O
IVF	O
protocol	O
;	O
39	O
cycles	O
for	O
32	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
5	O
)	O
and	O
50	O
cycles	O
for	O
30	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
6	O
)	O
with	O
a	O
long	O
ICSI	O
protocol	O
;	O
and	O
87	O
cycles	O
for	O
60	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
7	O
)	O
and	O
81	O
cycles	O
for	O
61	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
8	O
)	O
with	O
a	O
short	O
ICSI	O
protocol	O
.	O

This	O
study	O
demonstrates	O
the	O
feasibility	O
and	O
potential	O
usefulness	O
of	O
syngeneic	O
BM	O
Txp	O
in	O
myeloma	O
.	O

5	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
6	O
for	O
risperidone	O
(	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
determined	O
the	O
sequences	O
of	O
eight	O
VirF	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
from	O
four	O
different	O
genes	O
,	O
by	O
DNase	B-GENE
I	I-GENE
or	O
hydroxyl	O
radical	O
footprinting	O
.	O

Although	O
they	O
are	O
similar	O
to	O
the	O
IL9R	B-GENE
gene	I-GENE
(	O
approximately	O
90	O
%	O
identity	O
)	O
,	O
none	O
of	O
these	O
copies	O
encodes	O
a	O
functional	O
receptor	O
:	O
none	O
of	O
them	O
contains	O
sequences	O
homologous	O
to	O
the	O
5	O
'	O
flanking	O
region	O
or	O
exon	O
1	O
of	O
the	O
IL9R	B-GENE
gene	I-GENE
,	O
and	O
the	O
remaining	O
ORFs	O
have	O
been	O
inactivated	O
by	O
various	O
point	O
mutations	O
and	O
deletions	O
.	O

Type	O
II	O
neuroleptanalgesia	O
in	O
odonto	O
-	O
stomatology	O

273	O
,	O
27420	O
-	O
27429	O
)	O
a	O
putative	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
response	O
element	O
(	O
PPRE	O
)	O
is	O
present	O
from	O
-	O
458	O
to	O
-	O
474	O
.	O

While	O
reviewing	O
gastric	O
specimens	O
from	O
215	O
baboons	O
,	O
we	O
found	O
diffuse	O
giant	O
mucosal	O
folds	O
in	O
2	O
specimens	O
and	O
multiple	O
giant	O
mucosal	O
nodules	O
in	O
another	O
3	O
.	O

To	O
investigate	O
whether	O
the	O
two	O
RPG	B-GENE
-	I-GENE
boxes	I-GENE
mediate	O
transcription	O
activation	O
of	O
both	O
the	O
L46	B-GENE
and	O
S24	B-GENE
gene	I-GENE
,	O
two	O
experimental	O
strategies	O
were	O
followed	O
:	O
cloning	O
of	O
the	O
respective	O
genes	O
on	O
multicopy	O
vectors	O
and	O
construction	O
of	O
fusion	O
genes	O
.	O

When	O
the	O
opioid	O
antagonist	O
was	O
administered	O
to	O
animals	O
24	O
hr	O
after	O
termination	O
of	O
single	O
or	O
multiple	O
exposures	O
to	O
restraint	O
,	O
NALT	O
-	O
induced	O
increases	O
in	O
basal	O
plasma	B-GENE
LH	I-GENE
were	O
significantly	O
attenuated	O
in	O
the	O
chronically	O
stressed	O
rats	O
compared	O
to	O
animals	O
subjected	O
to	O
stress	O
only	O
once	O
or	O
not	O
at	O
all	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
psychosocial	O
features	O
of	O
people	O
using	O
self	O
-	O
ignition	O
as	O
a	O
method	O
of	O
suicide	O
are	O
consistent	O
with	O
those	O
of	O
suicide	O
in	O
general	O
.	O

This	O
was	O
further	O
suggested	O
by	O
transactivation	O
assays	O
in	O
which	O
mouse	O
fibroblasts	O
were	O
transiently	O
transfected	O
with	O
a	O
human	B-GENE
beta	I-GENE
-	I-GENE
globin	I-GENE
reporter	I-GENE
gene	I-GENE
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
LKLF	B-GENE
cDNA	I-GENE
construct	I-GENE
.	O

Plasma	B-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
analysis	O
and	O
the	O
clinical	O
significance	O

Thus	O
,	O
in	O
addition	O
to	O
the	O
previously	O
characterized	O
FAS	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
1	I-GENE
interacting	O
with	O
the	O
inositol	O
/	O
choline	O
-	O
responsive	O
-	O
element	O
motif	O
,	O
a	O
second	O
motif	O
common	O
to	O
the	O
promoter	O
regions	O
of	O
both	O
FAS	B-GENE
genes	I-GENE
could	O
be	O
identified	O
.	O

Reconstruction	O
time	O
for	O
a	O
64	O
x	O
64	O
matrix	O
is	O
approximately	O
45	O
s	O
/	O
transaxial	O
slice	O
.	O

Sequence	O
analysis	O
identifies	O
a	O
ras	B-GENE
-	I-GENE
associating	I-GENE
(	O
RA	B-GENE
)	O
-	O
like	O
domain	O
in	O
the	O
N	O
-	O
termini	O
of	O
band	B-GENE
4	I-GENE
.	I-GENE
1	I-GENE
/	I-GENE
JEF	I-GENE
domains	I-GENE
and	O
in	O
the	O
Grb7	B-GENE
/	I-GENE
10	I-GENE
/	I-GENE
14	I-GENE
adapter	I-GENE
family	I-GENE
.	O

Patients	O
received	O
BPB	O
using	O
bupivacaine	O
2	O
mg	O
kg	O
-	O
1	O
with	O
adrenaline	O
1	O
in	O
200	O
,	O
000	O
,	O
either	O
with	O
or	O
without	O
hyaluronidase	B-GENE
3000	O
iu	O
,	O
in	O
a	O
volume	O
of	O
0	O
.	O
5	O
ml	O
per	O
2	O
.	O
54	O
cm	O
of	O
the	O
patient	O
'	O
s	O
height	O
.	O

Rhinovirus	B-GENE
2A	I-GENE
protease	I-GENE
and	O
foot	B-GENE
-	I-GENE
and	I-GENE
-	I-GENE
mouth	I-GENE
-	I-GENE
disease	I-GENE
virus	I-GENE
L	I-GENE
protease	I-GENE
were	O
used	O
to	O
analyze	O
the	O
association	O
of	O
eIF4G	B-GENE
with	O
eIF4A	B-GENE
,	O
eIF4E	B-GENE
,	O
and	O
eIF3	B-GENE
.	O

One	O
hundred	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
8	O
RTKs	B-GENE
were	O
identified	O
,	O
as	O
well	O
as	O
12	O
non	O
-	O
RTKs	B-GENE
and	O
2	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
kinases	I-GENE
.	O

Roller	O
pumps	O
,	O
coronary	O
suction	O
and	O
an	O
open	O
cardiotomy	O
reservoir	O
were	O
used	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
Shb	B-GENE
-	O
overexpressing	O
cells	O
extended	O
neurites	O
in	O
response	O
to	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
.	O

Levels	O
of	O
p53	B-GENE
were	O
substantially	O
increased	O
by	O
E1A	B-GENE
expression	O
during	O
adenovirus	O
infection	O
.	O

In	O
cases	O
of	O
intracapsular	O
prostatic	O
cancer	O
the	O
level	O
of	O
prostatic	B-GENE
acid	I-GENE
phosphatase	I-GENE
(	O
PAP	B-GENE
)	O
measured	O
by	O
radioimmunoassay	O
was	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
8	O
micrograms	O
/	O
l	O
.	O

Healthy	O
subjects	O
received	O
the	O
following	O
regimens	O
,	O
dosed	O
to	O
steady	O
state	O
:	O
trovafloxacin	O
300	O
mg	O
/	O
24	O
h	O
;	O
ciprofloxacin	O
400	O
mg	O
/	O
12	O
h	O
;	O
trovafloxacin	O
300	O
mg	O
/	O
24	O
h	O
plus	O
cefepime	O
2	O
g	O
/	O
12	O
h	O
,	O
and	O
ciprofloxacin	O
400	O
mg	O
/	O
12	O
h	O
plus	O
cefepime	O
2	O
g	O
/	O
12	O
h	O
.	O

In	O
EGF	B-GENE
receptor	I-GENE
-	O
mediated	O
signaling	O
,	O
the	O
protein	B-GENE
kinase	I-GENE
PKB	I-GENE
/	O
Akt	B-GENE
and	O
the	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
c	I-GENE
-	I-GENE
Jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
,	O
but	O
not	O
extracellular	B-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
2	I-GENE
,	O
function	O
downstream	O
of	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
(	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
)	O
.	O

Immunoprecipitation	O
of	O
cell	O
lysates	O
with	O
anti	B-GENE
-	I-GENE
phosphotyrosine	I-GENE
and	O
immunoblotting	O
showed	O
phosphorylated	O
forms	O
of	O
the	O
mitogenic	O
pathway	O
proteins	O
Shc	B-GENE
and	O
MAPK	B-GENE
in	O
addition	O
to	O
p185	B-GENE
(	O
neu	B-GENE
)	O
,	O
suggesting	O
that	O
the	O
Ras	B-GENE
to	O
MAPK	B-GENE
mitogenic	O
pathway	O
is	O
activated	O
.	O

Acad	O
.	O

We	O
suggest	O
that	O
this	O
effect	O
of	O
Myc	B-GENE
is	O
mediated	O
by	O
its	O
action	O
upstream	O
of	O
cyclin	B-GENE
E	I-GENE
-	O
CDK2	B-GENE
,	O
and	O
occurs	O
via	O
the	O
neutralization	O
of	O
p27	B-GENE
(	O
Kip1	B-GENE
)	O
family	O
proteins	O
,	O
rather	O
than	O
induction	O
of	O
Cdc25A	B-GENE
.	O

Bile	O
reflux	O
demonstrated	O
by	O
99m	O
Tc	O
disofenin	O
.	O

These	O
data	O
suggest	O
that	O
certain	O
of	O
the	O
nuclear	O
protein	O
import	O
functions	O
of	O
NTF2	B-GENE
and	O
Ran	B-GENE
/	O
TC4	B-GENE
are	O
closely	O
linked	O
and	O
that	O
NTF2	B-GENE
may	O
serve	O
to	O
modulate	O
a	O
transport	O
step	O
involving	O
Ran	B-GENE
/	O
TC4	B-GENE
.	O

Almost	O
every	O
image	O
that	O
appears	O
during	O
a	O
therapy	O
session	O
reveals	O
a	O
symbolic	O
nature	O
,	O
but	O
the	O
very	O
concept	O
of	O
symbol	O
is	O
not	O
free	O
from	O
ambiguity	O
some	O
positions	O
originated	O
in	O
different	O
areas	O
of	O
investigation	O
are	O
mentioned	O
,	O
ending	O
with	O
a	O
description	O
of	O
the	O
traits	O
that	O
,	O
according	O
to	O
the	O
writer	O
,	O
bestow	O
a	O
symbolic	O
character	O
to	O
images	O
.	O

The	O
severity	O
of	O
the	O
psychomotor	O
retardation	O
varied	O
from	O
mild	O
to	O
severe	O
.	O

Both	O
oligonucleotide	O
cross	O
-	O
competition	O
and	O
antibody	O
supershift	O
experiments	O
established	O
that	O
the	O
double	O
-	O
strand	O
binding	O
protein	O
is	O
equivalent	O
to	O
Sp1	B-GENE
.	O

The	O
wet	O
and	O
dry	O
methods	O
of	O
the	O
HA	O
synthesis	O
are	O
considered	O
.	O

All	O
these	O
abnormalities	O
returned	O
to	O
normal	O
after	O
removal	O
of	O
the	O
tumor	O
.	O

Although	O
FKH2	B-GENE
is	O
redundant	O
with	O
FKH1	B-GENE
in	O
controlling	O
pseudohyphal	O
growth	O
,	O
the	O
two	O
genes	O
have	O
different	O
functions	O
in	O
silencing	O
HMRa	B-GENE
.	O

Molecular	O
analysis	O
indicated	O
that	O
inactivation	O
of	O
H	B-GENE
-	I-GENE
2L	I-GENE
expression	O
in	O
nearly	O
every	O
null	O
clone	O
resulted	O
from	O
an	O
apparent	O
deletion	O
or	O
rearrangement	O
of	O
5	B-GENE
'	I-GENE
-	I-GENE
flanking	I-GENE
and	I-GENE
5	I-GENE
'	I-GENE
-	I-GENE
coding	I-GENE
H	I-GENE
-	I-GENE
2L	I-GENE
sequences	I-GENE
,	O
with	O
breakpoints	O
consistently	O
mapping	O
to	O
within	O
a	O
550	O
bp	O
GC	O
-	O
rich	O
region	O
between	O
exon	O
1	O
and	O
the	O
middle	O
of	O
intron	O
2	O
.	O

However	O
,	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
stimulated	O
transcription	O
primarily	O
through	O
the	O
cAMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
,	O
which	O
maps	O
between	O
positions	O
-	O
77	O
to	O
-	O
94	O
,	O
but	O
not	O
at	O
the	O
more	O
5	O
'	O
-	O
binding	O
sites	O
.	O

Heliox	O
improves	O
pulsus	O
paradoxus	O
and	O
peak	O
expiratory	O
flow	O
in	O
nonintubated	O
patients	O
with	O
severe	O
asthma	O
.	O

50	O
-	O
fold	O
increase	O
in	O
foreign	O
protein	O
production	O
.	O

Ion	O
-	O
Bernstein	O
-	O
wave	O
heating	O
and	O
improved	O
confinement	O
in	O
the	O
Alcator	O
C	O
tokamak	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
specific	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
factors	O
control	O
activity	O
of	O
the	O
prodynorphin	B-GENE
promoter	I-GENE
are	O
not	O
as	O
clearly	O
defined	O
.	O

Finally	O
,	O
antisense	O
mediated	O
reduction	O
of	O
Elk	B-GENE
-	I-GENE
1	I-GENE
in	O
GH4	O
cells	O
decreased	O
insulin	B-GENE
-	O
increased	O
prolactin	B-GENE
gene	I-GENE
expression	O
and	O
confirmed	O
the	O
requirement	O
for	O
Elk	B-GENE
-	I-GENE
1	I-GENE
for	O
insulin	B-GENE
-	O
increased	O
prolactin	B-GENE
gene	I-GENE
expression	O
.	O

Substitutions	O
of	O
Asp11	O
led	O
to	O
dominant	O
lethality	O
.	O

Three	O
modern	O
hematology	O
analyzers	O
(	O
Abbott	O
Cell	O
-	O
Dyn	O
3000	O
,	O
Coulter	O
STKS	O
,	O
and	O
Sysmex	O
NE	O
-	O
8000	O
)	O
with	O
high	O
throughput	O
and	O
5	O
-	O
part	O
differential	O
capability	O
were	O
evaluated	O
using	O
a	O
protocol	O
designed	O
by	O
a	O
quality	O
team	O
.	O

Each	O
subject	O
was	O
injected	O
in	O
the	O
antecubital	O
vein	O
with	O
7	O
mg	O
/	O
kg	O
of	O
sodium	O
fluorescein	O
(	O
25	O
%	O
solution	O
)	O
and	O
measurements	O
were	O
taken	O
1	O
hr	O
postinjection	O
at	O
4	O
.	O
5	O
mm	O
and	O
7	O
.	O
5	O
mm	O
from	O
the	O
retina	O
.	O

The	O
cleft	O
walls	O
are	O
lined	O
with	O
highly	O
conserved	O
residues	O
and	O
NADP	O
is	O
bound	O
along	O
one	O
wall	O
.	O

cDNA	O
cloning	O
,	O
sequencing	O
and	O
chromosome	O
mapping	O
of	O
a	O
non	B-GENE
-	I-GENE
erythroid	I-GENE
spectrin	I-GENE
,	O
human	B-GENE
alpha	I-GENE
-	I-GENE
fodrin	I-GENE
.	O

The	O
aromatic	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
(	O
AHR	B-GENE
)	O
is	O
a	O
ligand	O
-	O
activated	O
transcription	O
factor	O
that	O
regulates	O
the	O
expression	O
of	O
several	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
has	O
been	O
implicated	O
in	O
immunosuppression	O
,	O
teratogenesis	O
,	O
cell	O
-	O
specific	O
hyperplasia	O
,	O
and	O
certain	O
types	O
of	O
malignancies	O
and	O
toxicities	O
.	O

(	O
1996	O
)	O
J	O
.	O

To	O
define	O
the	O
molecular	O
mechanism	O
regulating	O
FGFR	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
expression	O
in	O
proliferating	O
myoblasts	O
and	O
post	O
-	O
mitotic	O
muscle	O
fibers	O
,	O
we	O
have	O
isolated	O
and	O
partially	O
characterized	O
the	O
avian	O
FGFR	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
promoter	O
.	O

Moreover	O
,	O
FACT	B-GENE
specifically	O
interacts	O
with	O
nucleosomes	O
and	O
histone	O
H2A	B-GENE
/	O
H2B	B-GENE
dimers	O
,	O
indicating	O
that	O
it	O
may	O
work	O
by	O
promoting	O
nucleosome	O
disassembly	O
upon	O
transcription	O
.	O

Measures	O
of	O
sedation	O
,	O
BIS	O
,	O
deltaBIS	O
(	O
absolute	O
change	O
of	O
BIS	O
after	O
a	O
painful	O
stimulus	O
)	O
,	O
memory	O
,	O
and	O
drug	O
concentration	O
were	O
obtained	O
at	O
each	O
target	O
drug	O
concentration	O
.	O

ER	O
and	O
DR	O
were	O
significantly	O
correlated	O
with	O
MIB	B-GENE
-	I-GENE
1	I-GENE
LI	O
(	O
P	O
<	O
0	O
.	O
01	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
,	O
but	O
RI	O
and	O
Td	O
/	O
Te	O
were	O
not	O
.	O

Positive	O
linear	O
correlations	O
were	O
found	O
when	O
the	O
AUC	O
(	O
0	O
-	O
12	O
)	O
(	O
r	O
=	O
0	O
.	O
68	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
r	O
=	O
0	O
.	O
34	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
the	O
minimum	O
plasma	O
concentration	O
(	O
r	O
=	O
0	O
.	O
55	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
elimination	O
t1	O
/	O
2	O
(	O
r	O
=	O
0	O
.	O
46	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
were	O
regressed	O
with	O
age	O
.	O

Psychophysical	O
evidence	O
is	O
given	O
for	O
the	O
existence	O
of	O
two	O
distinct	O
systems	O
in	O
human	O
vision	O
:	O
a	O
fast	O
,	O
sign	O
-	O
invariant	O
system	O
concerned	O
with	O
extracting	O
contours	O
and	O
a	O
slower	O
,	O
sign	O
-	O
sensitive	O
system	O
concerned	O
with	O
assigning	O
surface	O
color	O
.	O

Peripheral	O
visual	O
acuity	O
with	O
monovision	O
and	O
other	O
contact	O
lens	O
corrections	O
for	O
presbyopia	O
.	O

Fourteen	O
Centers	O
participated	O
in	O
this	O
trial	O
.	O

The	O
program	O
for	O
myogenic	O
differentiation	O
is	O
subject	O
to	O
negative	O
control	O
by	O
several	O
peptide	O
growth	O
factors	O
and	O
by	O
the	O
products	O
of	O
mutationally	O
activated	O
ras	B-GENE
oncogenes	I-GENE
,	O
which	O
persistently	O
activate	O
intracellular	O
cascades	O
normally	O
triggered	O
by	O
specific	O
growth	O
factors	O
.	O

Tetrazepam	O
:	O
a	O
benzodiazepine	O
which	O
dissociates	O
sedation	O
from	O
other	O
benzodiazepine	O
activities	O
.	O

The	O
difference	O
between	O
the	O
effects	O
of	O
the	O
two	O
dose	O
levels	O
of	O
Z	O
.	O

Mutation	O
of	O
the	O
distal	O
E2F	B-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
cdc25A	B-GENE
promoter	I-GENE
abolished	O
E2	B-GENE
-	O
induced	O
repression	O
,	O
whereas	O
mutation	O
of	O
the	O
proximal	O
E2F	B-GENE
site	I-GENE
or	O
the	O
E2	B-GENE
site	I-GENE
had	O
no	O
effect	O
.	O

Plasmid	O
pNK21	O
,	O
in	O
which	O
2	O
.	O
05	O
-	O
kb	O
sequence	O
covering	O
the	O
region	O
encoding	O
the	O
nitrilase	B-GENE
was	O
was	O
placed	O
under	O
the	O
control	O
of	O
the	O
lac	B-GENE
promoter	I-GENE
,	O
directed	O
overproduction	O
of	O
enzymatically	B-GENE
active	I-GENE
nitrilase	I-GENE
in	O
response	O
to	O
addition	O
of	O
isopropyl	O
beta	O
-	O
D	O
-	O
thiogalactopyranoside	O
in	O
Escherichia	O
coli	O
.	O

A	O
method	O
for	O
determining	O
the	O
toxicity	O
of	O
neutralizers	O
for	O
antimicrobial	O
agents	O
to	O
A	O
.	O
castellanii	O
was	O
also	O
evaluated	O
.	O

Expression	O
in	O
all	O
lines	O
was	O
decreased	O
by	O
the	O
inclusion	O
of	O
regions	O
further	O
upstream	O
,	O
and	O
extinguished	O
by	O
the	O
inclusion	O
of	O
the	O
first	O
intron	O
.	O

Static	O
and	O
dynamic	O
MRI	O
of	O
the	O
normal	O
and	O
pathological	O
female	O
pelvic	O
floor	O

IENF	O
density	O
at	O
the	O
calf	O
was	O
lower	O
than	O
that	O
obtained	O
from	O
skin	O
at	O
more	O
proximal	O
sites	O
,	O
indicating	O
the	O
length	O
dependency	O
of	O
small	O
-	O
fiber	O
loss	O
in	O
these	O
neuropathies	O
.	O

These	O
results	O
demonstrate	O
a	O
specific	O
association	O
of	O
SIV	O
and	O
HIV	B-GENE
-	I-GENE
2	I-GENE
nef	I-GENE
,	O
but	O
not	O
HIV	B-GENE
-	I-GENE
1	I-GENE
nef	I-GENE
,	O
with	O
TCRzeta	B-GENE
.	O

Insertion	O
of	O
alternatively	O
spliced	O
exon	O
W	O
into	O
CREB	B-GENE
mRNA	I-GENE
during	O
spermatogenesis	O
results	O
in	O
a	O
polycistronic	O
RNA	O
that	O
encodes	O
two	O
novel	O
internally	O
translated	O
CREB	B-GENE
repressor	I-GENE
isoforms	I-GENE
called	O
I	B-GENE
-	I-GENE
CREBs	I-GENE
,	O
consisting	O
of	O
the	O
carboxy	O
-	O
terminal	O
DNA	O
-	O
binding	O
domain	O
devoid	O
of	O
the	O
transactivation	O
domains	O
.	O

A	O
continuous	O
-	O
flow	O
BIPAP	O
system	O
consists	O
of	O
a	O
high	O
-	O
flow	O
CPAP	O
system	O
,	O
a	O
reservoir	O
bag	O
,	O
and	O
a	O
pneumatically	O
controlled	O
membrane	O
valve	O
in	O
the	O
expiratory	O
limb	O
.	O

Older	O
females	O
had	O
lumbar	O
(	O
0	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
)	O
and	O
TB	O
(	O
1	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
1	O
)	O
BMD	O
Z	O
scores	O
greater	O
than	O
0	O
(	O
both	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Smooth	O
pursuit	O
gain	O
and	O
the	O
percentage	O
of	O
total	O
eye	O
movement	O
due	O
to	O
various	O
saccadic	O
subtypes	O
were	O
computed	O
using	O
infrared	O
oculography	O
and	O
computerized	O
pattern	O
recognition	O
software	O
.	O

Upon	O
incubation	O
of	O
the	O
most	O
highly	O
purified	O
fractions	O
with	O
Mn	O
-	O
ATP	O
or	O
Mg	O
-	O
ATP	O
,	O
p40	B-GENE
was	O
the	O
only	O
protein	O
phosphorylated	O
on	O
tyrosine	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
alpha1	B-GENE
-	I-GENE
PDX	I-GENE
prevents	O
cleavage	O
of	O
BMP	B-GENE
-	I-GENE
4	I-GENE
in	O
an	O
oocyte	O
translation	O
assay	O
.	O

A	O
p53	B-GENE
cDNA	I-GENE
deletion	O
mutant	O
(	O
delta	O
pro	O
AE	O
)	O
,	O
which	O
lacks	O
this	O
entire	O
proline	O
-	O
rich	O
domain	O
(	O
deleted	O
for	O
amino	O
acids	O
62	O
-	O
91	O
)	O
,	O
was	O
created	O
and	O
characterized	O
for	O
a	O
variety	O
of	O
p53	B-GENE
functions	O
.	O

Multiple	O
aortic	O
thrombi	O
associated	O
with	O
protein	B-GENE
C	I-GENE
and	O
S	B-GENE
deficiency	O
.	O

Our	O
results	O
suggest	O
that	O
Bry1	B-GENE
/	O
Skn7	B-GENE
can	O
influence	O
the	O
expression	O
of	O
MCB	O
-	O
and	O
SCB	O
-	O
driven	O
gene	O
expression	O
in	O
budding	O
yeast	O
,	O
perhaps	O
including	O
genes	O
involved	O
in	O
cell	O
wall	O
metabolism	O
,	O
via	O
a	O
two	O
-	O
component	O
signal	O
transduction	O
pathway	O
which	O
activates	O
Bry1	B-GENE
/	O
Skn7	B-GENE
in	O
response	O
to	O
an	O
unidentified	O
signal	O
.	O

(	O
1992	O
)	O
J	O
.	O

A	O
constructed	O
phylogenetic	O
tree	O
suggests	O
that	O
the	O
UbcP1	B-GENE
protein	I-GENE
may	O
represent	O
a	O
member	O
of	O
a	O
distinct	O
subfamily	O
of	O
E2s	B-GENE
.	O

Platelet	B-GENE
factor	I-GENE
4	I-GENE
levels	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

We	O
functionally	O
characterised	O
AtXPO1	B-GENE
by	O
its	O
interaction	O
with	O
NESs	O
of	O
animal	O
and	O
plant	O
proteins	O
,	O
which	O
is	O
inhibited	O
by	O
the	O
cytotoxin	O
leptomycin	O
B	O
(	O
LMB	O
)	O
,	O
and	O
also	O
by	O
its	O
interaction	O
with	O
the	O
small	B-GENE
GTPase	I-GENE
Ran1	B-GENE
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

A	O
backward	O
look	O
at	O
urinary	O
tract	O
infections	O
.	O

The	O
expression	O
of	O
cor14b	B-GENE
was	O
strongly	O
impaired	O
in	O
the	O
barley	O
albino	O
mutant	O
an	O
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
plastidial	O
factor	O
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

MRS	O
allowed	O
the	O
differentiation	O
of	O
the	O
following	O
metabolites	O
in	O
5	O
patients	O
:	O
N	O
-	O
acetyl	O
-	O
aspartate	O
(	O
NAA	O
)	O
,	O
creatine	O
and	O
phosphocreatine	O
,	O
phosphorylcholine	O
and	O
glycerophosphorylcholine	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
glutamate	O
(	O
GLU	O
)	O
.	O

Overall	O
,	O
free	O
-	O
chlorine	O
treatments	O
(	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
mg	O
/	O
L	O
)	O
showed	O
significantly	O
lower	O
heterotrophic	O
plate	O
numbers	O
than	O
those	O
without	O
free	O
chlorine	O
.	O

S1	B-GENE
nuclease	I-GENE
protection	O
mapping	O
and	O
primer	O
extension	O
analysis	O
allowed	O
us	O
to	O
propose	O
that	O
the	O
A	O
residue	O
located	O
19	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
is	O
the	O
site	O
of	O
transcription	O
initiation	O
.	O

Various	O
stimuli	O
inactivate	O
IkappaB	B-GENE
alpha	I-GENE
by	O
triggering	O
phosphorylation	O
of	O
the	O
N	O
-	O
terminal	O
residues	O
Ser32	O
and	O
Ser36	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
day	O
-	O
42	O
cure	O
rates	O
between	O
the	O
QC7	O
(	O
n	O
=	O
65	O
)	O
and	O
A7	O
(	O
n	O
=	O
64	O
)	O
regimens	O
with	O
an	O
efficacy	O
of	O
100	O
%	O
in	O
both	O
,	O
confirmed	O
by	O
parasite	O
genotyping	O
.	O

In	O
addition	O
,	O
the	O
results	O
suggest	O
that	O
N	O
region	O
diversity	O
at	O
V	B-GENE
(	O
D	B-GENE
)	O
J	B-GENE
junctions	O
within	O
rearranged	O
immunoglobulin	B-GENE
and	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
gene	I-GENE
loci	I-GENE
can	O
only	O
be	O
introduced	O
after	O
the	O
generation	O
of	O
RAG	B-GENE
-	O
catalyzed	O
DNA	O
double	O
-	O
strand	O
breaks	O
,	O
i	O
.	O
e	O
.	O
during	O
the	O
DNA	O
end	O
joining	O
phase	O
of	O
the	O
V	B-GENE
(	O
D	B-GENE
)	O
J	B-GENE
recombination	O
reaction	O
.	O

We	O
conclude	O
that	O
99mTc	O
-	O
HL91	O
is	O
a	O
potent	O
marker	O
of	O
myocardial	O
viability	O
when	O
used	O
during	O
the	O
early	O
acute	O
phase	O
after	O
reperfusion	O
.	O

Three	O
patients	O
treated	O
with	O
amphotericin	O
B	O
,	O
single	O
course	O
as	O
well	O
as	O
multiple	O
courses	O
,	O
and	O
other	O
antifungal	O
agents	O
(	O
hydroxystilbamidine	O
and	O
miconazole	O
)	O
have	O
all	O
relapsed	O
.	O

An	O
infant	O
of	O
8	O
months	O
with	O
congenital	O
glaucoma	O
and	O
hemophilia	O
A	O
lost	O
one	O
eye	O
due	O
to	O
haemorrhages	O
after	O
trabeculotomy	O
in	O
an	O
eye	O
hospital	O
.	O

Anderson	O
Hospital	O
and	O
Tumor	O
Institute	O
at	O
Houston	O
during	O
a	O
30	O
-	O
year	O
interval	O
(	O
1944	O
to	O
1974	O
)	O
,	O
with	O
a	O
minimum	O
of	O
ten	O
years	O
of	O
follow	O
-	O
up	O
,	O
we	O
determined	O
that	O
the	O
major	O
prognostic	O
factor	O
of	O
survival	O
was	O
the	O
number	O
of	O
positive	O
nodes	O
.	O

We	O
have	O
now	O
isolated	O
cDNA	O
for	O
an	O
invertebrate	B-GENE
Pax	I-GENE
-	I-GENE
6	I-GENE
protein	I-GENE
from	I-GENE
sea	I-GENE
urchin	I-GENE
embryos	I-GENE
.	O

To	O
study	O
structural	O
diversity	O
of	O
the	O
three	O
homologous	O
loci	O
encoding	O
a	O
KN1	B-GENE
-	I-GENE
like	I-GENE
homeobox	I-GENE
protein	I-GENE
in	O
the	O
hexaploid	O
wheat	O
genome	O
,	O
we	O
isolated	O
clones	O
from	O
a	O
cDNA	O
library	O
of	O
young	O
spikes	O
of	O
Japanese	O
common	O
wheat	O
cultivar	O
'	O
Norin	O
26	O
'	O
.	O

Whether	O
or	O
not	O
these	O
novel	O
repeated	O
sequences	O
throughout	O
the	O
SMA	B-GENE
region	I-GENE
are	O
involved	O
in	O
the	O
disease	O
remains	O
to	O
be	O
determined	O
.	O

Thus	O
,	O
Shp2	B-GENE
regulates	O
phosphotyrosine	O
-	O
signalling	O
events	O
during	O
the	O
complex	O
ectodermal	O
-	O
mesenchymal	O
interactions	O
that	O
regulate	O
mammalian	O
budding	O
morphogenesis	O
.	O

Moyamoya	O
is	O
an	O
intriguing	O
and	O
controversial	O
syndrome	O
.	O

However	O
,	O
elimination	O
of	O
the	O
kinase	O
activity	O
of	O
DCAMKL1	B-GENE
has	O
no	O
detectable	O
effect	O
on	O
its	O
microtubule	O
polymerization	O
activity	O
.	O

We	O
have	O
thus	O
cloned	O
two	O
yeast	O
homologs	O
of	O
mammalian	B-GENE
p220	I-GENE
.	O

The	O
glucose	O
effect	O
on	O
the	O
pyruvate	B-GENE
kinase	I-GENE
gene	I-GENE
is	O
reversibly	O
antagonized	O
by	O
agents	O
increasing	O
intracellular	O
cAMP	O
.	O

An	O
identical	O
polypeptide	O
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
of	O
K1F	O
virions	O
.	O

Patients	O
with	O
PLM	O
show	O
excessive	O
daytime	O
sleepiness	O
or	O
insomnia	O
.	O

Coexpression	O
of	O
CREB	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CBP	B-GENE
)	O
/	O
p300	B-GENE
with	O
TReP	B-GENE
-	I-GENE
132	I-GENE
has	O
an	O
additive	O
effect	O
on	O
promoter	O
activity	O
,	O
and	O
the	O
proteins	O
were	O
demonstrated	O
to	O
interact	O
physically	O
.	O

It	O
is	O
believed	O
that	O
the	O
operation	O
is	O
effective	O
because	O
it	O
cuts	O
the	O
spinothalamic	O
tract	O
(	O
STT	O
)	O
,	O
a	O
primary	O
pathway	O
carrying	O
nociceptive	O
information	O
from	O
the	O
spinal	O
cord	O
to	O
the	O
brain	O
in	O
humans	O
.	O

Catalase	B-GENE
plays	O
a	O
key	O
role	O
as	O
an	O
antioxidant	O
,	O
protecting	O
aerobic	O
organisms	O
from	O
the	O
toxic	O
effects	O
of	O
hydrogen	O
peroxide	O
,	O
and	O
in	O
some	O
cases	O
has	O
been	O
postulated	O
to	O
be	O
a	O
virulence	O
factor	O
.	O

Recovery	O
rates	O
of	O
energy	O
level	O
and	O
intracellular	O
pH	O
during	O
stimulation	O
at	O
100Hz	O
were	O
greater	O
than	O
those	O
observed	O
during	O
stimulation	O
at	O
30Hz	O
.	O

Exhaled	O
NO	O
was	O
assessed	O
by	O
controlled	O
-	O
flow	O
chemoluminescence	O
after	O
adjusting	O
for	O
trapped	O
air	O
and	O
after	O
generating	O
pressure	O
in	O
the	O
oral	O
cavity	O
that	O
was	O
sufficient	O
to	O
close	O
the	O
soft	O
palate	O
(	O
Eco	O
Physics	O
CLD	O
77	O
AM	O
analyzer	O
)	O
.	O

Recent	O
developments	O
in	O
the	O
study	O
of	O
growth	O
factors	O
:	O
GRF	B-GENE
and	O
somatomedins	B-GENE
.	O

New	O
concepts	O
of	O
condyloma	O
acuminata	O
in	O
children	O
.	O

This	O
is	O
the	O
first	O
clinical	O
case	O
report	O
of	O
NIHF	O
due	O
to	O
fetal	O
Kasabach	O
-	O
Merritt	O
syndrome	O
that	O
was	O
prenatally	O
diagnosed	O
by	O
sonography	O
,	O
computerized	O
tomography	O
,	O
and	O
percutaneous	O
umbilical	O
blood	O
sampling	O
.	O

Acetoacetate	B-GENE
decarboxylase	I-GENE
(	O
ADC	B-GENE
)	O
(	O
EC4	B-GENE
.	I-GENE
1	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
4	I-GENE
)	O
of	O
Clostridium	O
acetobutylicum	O
DSM	O
792	O
was	O
purified	O
to	O
homogeneity	O
,	O
and	O
its	O
first	O
25	O
N	O
-	O
terminal	O
amino	O
acids	O
were	O
determined	O
.	O

Transfer	O
of	O
health	O
care	O
to	O
natives	O
holds	O
much	O
promise	O
,	O
lecturers	O
say	O
.	O

The	O
sequence	O
of	O
the	O
127	B-GENE
residue	I-GENE
NrfF	I-GENE
polypeptide	I-GENE
,	I-GENE
M	I-GENE
(	I-GENE
r	I-GENE
)	I-GENE
14	I-GENE
,	I-GENE
522	I-GENE
,	O
is	O
strikingly	O
similar	O
to	O
the	O
CcI2	B-GENE
protein	I-GENE
of	O
R	O
.	O
capsulatus	O
,	O
especially	O
in	O
the	O
putative	O
haem	O
-	O
binding	O
motif	O
,	O
RCPQCQNQN	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

CAT	B-GENE
assays	O
demonstrated	O
that	O
overexpression	O
of	O
RXRalpha	B-GENE
conferred	O
the	O
best	O
RA	O
response	O
,	O
consistent	O
with	O
our	O
previous	O
observation	O
that	O
9	O
-	O
cis	O
-	O
RA	O
is	O
more	O
potent	O
than	O
all	O
-	O
trans	O
-	O
RA	O
for	O
inducing	O
the	O
expression	O
of	O
the	O
AFP	B-GENE
gene	I-GENE
.	O

For	O
rotating	O
stimuli	O
presented	O
to	O
the	O
dominant	O
eye	O
,	O
this	O
class	O
of	O
neurons	O
responded	O
best	O
to	O
rotation	O
of	O
the	O
visual	O
world	O
about	O
an	O
axis	O
oriented	O
near	O
the	O
horizontal	O
plane	O
and	O
approximately	O
45	O
degrees	O
azimuth	O
.	O

None	O
of	O
these	O
patients	O
developed	O
clinical	O
events	O
before	O
disappearance	O
of	O
the	O
phospholipid	O
-	O
dependent	O
inhibitors	O
of	O
coagulation	O
.	O

In	O
spite	O
of	O
the	O
variability	O
of	O
DD95	O
with	O
regard	O
to	O
body	O
weight	O
,	O
the	O
recovery	O
of	O
neuromuscular	O
transmission	O
in	O
the	O
patients	O
of	O
the	O
three	O
groups	O
is	O
comparable	O
.	O

We	O
have	O
studied	O
some	O
of	O
the	O
parameters	O
governing	O
the	O
expression	O
of	O
a	O
foreign	O
promoter	O
-	O
reporter	O
gene	O
construct	O
incorporated	O
into	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
type	O
1	O
.	O

Relation	O
between	O
clinical	O
and	O
roentgenological	O
scores	O
and	O
measures	O
of	O
lung	O
function	O
in	O
cystic	O
fibrosis	O
,	O
with	O
special	O
reference	O
to	O
pulmonary	O
Xenon133	O
elimination	O
.	O

Each	O
fusion	O
leads	O
,	O
in	O
principle	O
,	O
to	O
the	O
same	O
effect	O
:	O
The	O
ret	B-GENE
tyrosine	I-GENE
kinase	I-GENE
is	O
uncoupled	O
from	O
its	O
stringent	O
physiological	O
regulation	O
by	O
replacement	O
of	O
its	O
5	O
'	O
end	O
and	O
is	O
aberrantly	O
activated	O
by	O
the	O
5	O
'	O
parts	O
of	O
fused	O
genes	O
in	O
thyrocytes	O
that	O
do	O
not	O
normally	O
express	O
ret	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

He	O
had	O
complained	O
of	O
fever	O
and	O
right	O
hypochondralgia	O
2	O
months	O
after	O
being	O
operated	O
for	O
appendicitis	O
.	O

In	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
NPS1	B-GENE
,	O
sequences	O
homologous	O
to	O
the	O
catalytic	O
domain	O
of	O
protein	O
kinases	O
were	O
found	O
.	O

Carcinoma	B-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
production	O
may	O
have	O
played	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
observed	O
renal	O
lesions	O
.	O

These	O
results	O
provide	O
strong	O
evidence	O
that	O
conserved	O
interhelical	O
packing	O
interactions	O
in	O
the	O
gp41	B-GENE
core	I-GENE
are	O
important	O
determinants	O
of	O
HIV	O
-	O
1	O
entry	O
and	O
its	O
inhibition	O
.	O

Lag	O
phases	O
were	O
14	O
.	O
89	O
hours	O
+	O
/	O
-	O
0	O
.	O
77	O
,	O
13	O
.	O
33	O
hours	O
+	O
/	O
-	O
0	O
.	O
50	O
,	O
20	O
.	O
22	O
hours	O
+	O
/	O
-	O
0	O
.	O
76	O
,	O
and	O
20	O
.	O
00	O
hours	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
respectively	O
,	O
for	O
endothelial	O
cell	O
-	O
induced	O
LDL	B-GENE
oxidation	O
.	O

Forty	O
-	O
eight	O
pregnant	O
adult	O
and	O
122	O
fetal	O
guinea	O
pigs	O
were	O
sacrificed	O
at	O
intervals	O
throughout	O
gestation	O
and	O
the	O
carcasses	O
analyzed	O
for	O
a	O
variety	O
of	O
growth	O
parameters	O
.	O

Here	O
we	O
demonstrate	O
the	O
ability	O
of	O
oligonucleotides	O
containing	O
the	O
C4T	O
sequence	O
to	O
confer	O
heat	O
shock	O
inducibility	O
on	O
the	O
reporter	O
gene	O
and	O
show	O
that	O
the	O
presence	O
of	O
two	O
such	O
elements	O
produces	O
more	O
than	O
additive	O
effects	O
on	O
induction	O
.	O

The	O
HPV	O
E1	B-GENE
and	O
E2	B-GENE
proteins	O
along	O
with	O
cellular	O
factors	O
,	O
are	O
required	O
for	O
replication	O
of	O
the	O
viral	O
genome	O
.	O

The	O
observed	O
alterations	O
in	O
lung	O
functions	O
in	O
these	O
subjects	O
indicate	O
that	O
individuals	O
performing	O
heavy	O
continuous	O
exercise	O
are	O
more	O
likely	O
to	O
be	O
affected	O
by	O
lower	O
O3	O
levels	O
.	O

In	O
ten	O
other	O
endotoxin	O
-	O
albumin	B-GENE
-	O
treated	O
pigs	O
PGE1	O
infusion	O
(	O
0	O
.	O
25	O
micrograms	O
X	O
kg	O
-	O
1	O
X	O
min	O
-	O
1	O
)	O
was	O
begun	O
after	O
established	O
pulmonary	O
and	O
cardiovascular	O
dysfunction	O
,	O
for	O
closer	O
mimicking	O
of	O
clinical	O
use	O
.	O

The	O
main	O
new	O
features	O
of	O
this	O
version	O
are	O
that	O
end	O
-	O
tidal	O
PO2	O
instead	O
of	O
inspiratory	O
PO2	O
can	O
be	O
kept	O
constant	O
,	O
and	O
that	O
the	O
correcting	O
activity	O
of	O
both	O
controllers	O
(	O
capnostat	O
and	O
oxystat	O
)	O
is	O
proportional	O
to	O
the	O
magnitude	O
of	O
the	O
difference	O
between	O
the	O
actual	O
and	O
the	O
adjusted	O
end	O
-	O
tidal	O
PCO2	O
or	O
PO2	O
.	O

Like	O
the	O
human	B-GENE
erythrocyte	I-GENE
P4	I-GENE
.	I-GENE
2	I-GENE
,	O
mouse	B-GENE
erythrocyte	I-GENE
P4	I-GENE
.	I-GENE
2	I-GENE
contains	O
regions	O
strikingly	O
homologous	O
with	O
the	O
transglutaminase	O
(	O
TGase	O
)	O
proteins	O
although	O
it	O
too	O
most	O
likely	O
lacks	O
TGase	O
crosslinking	O
activity	O
.	O

It	O
spans	O
20	O
kilobases	O
,	O
consists	O
of	O
7	O
exons	O
and	O
6	O
introns	O
,	O
and	O
contains	O
a	O
TATA	O
motif	O
24	O
nucleotides	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Nine	O
months	O
after	O
the	O
end	O
of	O
the	O
vaccination	O
anti	B-GENE
-	I-GENE
HBsAg	I-GENE
levels	O
had	O
dropped	O
to	O
9	O
+	O
/	O
-	O
4	O
IU	O
/	O
1	O
(	O
M	O
+	O
/	O
-	O
SE	O
)	O
,	O
with	O
a	O
geometric	O
mean	O
of	O
5	O
IU	O
/	O
1	O
,	O
in	O
the	O
nine	O
remaining	O
evaluable	O
patients	O
.	O

CONCLUSION	O
:	O
Ultrasound	O
biomicroscopy	O
is	O
a	O
useful	O
tool	O
for	O
the	O
evaluation	O
of	O
APVR	O
,	O
which	O
is	O
difficult	O
by	O
ordinary	O
methods	O
.	O

It	O
is	O
postulated	O
that	O
the	O
synthesis	O
of	O
the	O
peptidoglycan	O
layer	O
was	O
affected	O
by	O
the	O
antimetabolites	O
since	O
the	O
morphological	O
effects	O
were	O
strikingly	O
similar	O
to	O
those	O
caused	O
by	O
treatment	O
of	O
E	O
.	O
cloacae	O
with	O
disodium	O
edetate	O
plus	O
lysozyme	B-GENE
.	O

DRAP27	B-GENE
is	O
recognized	O
by	O
CD9	B-GENE
antibodies	I-GENE
.	O

Furthermore	O
we	O
elucidate	O
the	O
subtle	O
highly	O
anisotropic	O
interchain	O
correlations	O
and	O
reveal	O
the	O
detailed	O
atomic	O
structure	O
of	O
the	O
low	O
-	O
temperature	O
(	O
8x2	O
)	O
phase	O
.	O

Control	O
oligomers	O
of	O
scrambled	O
sequence	O
but	O
identical	O
base	O
composition	O
were	O
ineffective	O
,	O
and	O
no	O
TFO	O
-	O
induced	O
recombination	O
was	O
seen	O
in	O
a	O
control	O
LTK	O
(	O
-	O
)	O
cell	O
line	O
carrying	O
an	O
otherwise	O
identical	O
dual	O
TK	B-GENE
gene	I-GENE
construct	I-GENE
lacking	O
the	O
30	O
-	O
bp	O
polypurine	O
target	O
site	O
.	O

To	O
quantify	O
the	O
normal	O
coupling	O
patterns	O
,	O
fresh	O
cadaveric	O
human	O
lumbar	O
spine	O
specimens	O
(	O
L1	O
-	O
S1	O
)	O
were	O
used	O
.	O

One	O
cytoplasmic	O
target	O
which	O
reflects	O
the	O
functional	O
state	O
of	O
the	O
plastids	O
is	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
.	O

These	O
three	O
chromosomes	O
share	O
the	O
transferrin	B-GENE
gene	I-GENE
(	O
TF	B-GENE
)	O
,	O
the	O
myosin	B-GENE
light	I-GENE
polypeptide	I-GENE
3	I-GENE
gene	I-GENE
(	O
MYL3	B-GENE
)	O
,	O
and	O
the	O
acylpeptide	B-GENE
hydrolase	I-GENE
gene	I-GENE
(	O
APEH	B-GENE
)	O
.	O

(	O
i	O
)	O
Several	O
ribosomal	O
proteins	O
were	O
synthesized	O
in	O
substantial	O
excess	O
.	O

This	O
experience	O
would	O
recommend	O
consideration	O
of	O
home	O
nutritional	O
support	O
in	O
patients	O
with	O
systemic	O
scleroderma	O
when	O
the	O
disease	O
is	O
relatively	O
stable	O
and	O
no	O
major	O
organ	O
failure	O
is	O
present	O
.	O

Based	O
on	O
our	O
sequence	O
data	O
,	O
ORF2	O
from	O
most	O
isolates	O
excluding	O
G1	O
encode	O
truncated	O
49	O
aa	O
(	O
pORF2a	O
)	O
because	O
of	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
,	O
although	O
ORF2s	O
from	O
most	O
G1	O
isolates	O
encode	O
202	O
aa	O
(	O
pORF2ab	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
prospectively	O
compared	O
side	O
effects	O
occurring	O
in	O
12	O
patients	O
after	O
the	O
first	O
administration	O
of	O
low	O
-	O
dose	O
OKT3	O
(	O
0	O
.	O
5	O
mg	O
twice	O
daily	O
)	O
induction	O
therapy	O
with	O
those	O
in	O
10	O
patients	O
who	O
were	O
treated	O
with	O
a	O
conventional	O
dose	O
of	O
OKT3	O
(	O
5	O
mg	O
daily	O
)	O
for	O
acute	O
rejection	O
.	O

These	O
data	O
indicate	O
that	O
SB	O
203580	O
sensitive	O
p38	B-GENE
MAP	I-GENE
kinases	I-GENE
are	O
not	O
involved	O
in	O
okadaic	O
acid	O
mediated	O
increases	O
in	O
TRE	O
DNA	O
binding	O
and	O
transactivation	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
YTS1	B-GENE
is	O
a	O
bifunctional	O
protein	O
active	O
in	O
both	O
splicing	O
and	O
protein	O
synthesis	O
.	O

Oscillatory	O
flow	O
is	O
reestablished	O
in	O
the	O
model	O
at	O
the	O
capillary	O
-	O
cerebrospinal	O
fluid	O
and	O
capillary	O
-	O
venous	O
interfaces	O
.	O

Sgs	B-GENE
-	I-GENE
4	I-GENE
is	O
one	O
of	O
the	O
eight	O
known	O
genes	O
coding	O
for	O
larval	O
secretion	O
proteins	O
in	O
Drosophila	O
melanogaster	O
.	O

We	O
conclude	O
that	O
although	O
the	O
G3	O
sequence	O
contains	O
two	O
protein	O
-	O
binding	O
motifs	O
,	O
the	O
organization	O
of	O
the	O
G3	O
enhancer	O
-	O
like	O
element	O
is	O
not	O
bipartite	O
.	O

Human	B-GENE
myotonic	I-GENE
dystrophy	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
DMPK	B-GENE
)	O
is	O
a	O
member	O
of	O
a	O
novel	O
class	O
of	O
multidomain	O
protein	O
kinases	O
that	O
regulate	O
cell	O
size	O
and	O
shape	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

The	O
human	B-GENE
BRCA1	I-GENE
promoter	I-GENE
also	O
contains	O
a	O
conserved	O
E2F	B-GENE
site	I-GENE
and	O
is	O
similarly	O
regulated	O
by	O
E2F1	B-GENE
and	O
Rb	B-GENE
.	O

The	O
translated	O
sequence	O
of	O
the	O
FLI	B-GENE
LRR	I-GENE
associated	I-GENE
protein	I-GENE
(	O
FLAP	B-GENE
)	O
encodes	O
a	O
novel	O
protein	O
not	O
represented	O
in	O
the	O
data	O
base	O
.	O

Corticosteroid	O
treatment	O
before	O
,	O
during	O
,	O
or	O
after	O
fludarabine	O
treatment	O
in	O
patients	O
with	O
alkylator	O
-	O
resistant	O
,	O
low	O
-	O
grade	O
lymphoid	O
malignancies	O
who	O
have	O
not	O
received	O
PCP	O
prophylaxis	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
opportunistic	O
pulmonary	O
infections	O
.	O

In	O
this	O
respect	O
,	O
the	O
promoter	O
structure	O
of	O
COX	B-GENE
genes	I-GENE
resemble	O
those	O
of	O
many	O
house	O
-	O
keeping	O
genes	O
.	O

In	O
vitro	O
,	O
cytokine	O
-	O
or	O
hypoxia	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
Fas	B-GENE
expression	O
is	O
associated	O
with	O
RTC	O
apoptosis	O
.	O

The	O
site	O
of	O
acetylation	O
of	O
Tat	B-GENE
was	O
mapped	O
to	O
the	O
double	O
-	O
lysine	O
motif	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
(	O
49	O
)	O
RKKRRQ	O
(	O
54	O
)	O
,	O
of	O
the	O
basic	O
RNA	O
-	O
binding	O
motif	O
of	O
Tat	B-GENE
.	O

These	O
results	O
suggest	O
that	O
the	O
PVB	O
therapy	O
is	O
not	O
sufficient	O
to	O
cure	O
the	O
cases	O
with	O
choriocarcinoma	O
element	O
or	O
bulky	O
metastasis	O
.	O

The	O
KEMAR	O
measurements	O
show	O
that	O
the	O
two	O
models	O
give	O
an	O
improvement	O
of	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
approximately	O
7	O
.	O
5	O
dB	O
in	O
a	O
diffuse	O
sound	O
field	O
.	O

Indirect	O
determination	O
of	O
maximal	O
O2	O
consumption	O
in	O
man	O
.	O

Using	O
unidirectional	O
PCR	O
we	O
isolated	O
a	O
361	O
-	O
bp	O
5	O
'	O
promoter	O
region	O
and	O
delineated	O
the	O
intronic	O
/	O
exonic	O
boundaries	O
which	O
include	O
a	O
non	O
-	O
coding	O
exon	O
1	O
,	O
a	O
single	O
intron	O
,	O
and	O
a	O
coding	O
exon	O
2	O
,	O
a	O
structure	O
that	O
is	O
typical	O
of	O
genes	O
of	O
the	O
RNase	B-GENE
A	I-GENE
superfamily	I-GENE
.	O

When	O
severe	O
hypoxia	O
was	O
acutely	O
produced	O
by	O
ventilation	O
with	O
low	O
-	O
oxygen	O
mixtures	O
in	O
experimental	O
(	O
PaO2	O
,	O
23	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
7	O
torr	O
)	O
and	O
control	O
animals	O
(	O
PaO2	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
torr	O
)	O
,	O
plasma	B-GENE
insulin	I-GENE
responses	O
were	O
markedly	O
inhibited	O
in	O
both	O
.	O

Uptake	O
of	O
colicins	B-GENE
required	O
different	O
domains	O
in	O
TonB	B-GENE
,	O
for	O
colicin	B-GENE
B	I-GENE
and	I-GENE
M	I-GENE
around	O
residue	O
160	O
and	O
for	O
colicin	B-GENE
Ia	I-GENE
,	O
a	O
domain	O
closer	O
to	O
the	O
C	O
-	O
terminal	O
end	O
.	O

D	O
.	O

When	O
lipid	O
X	O
was	O
combined	O
with	O
ticarcillin	O
,	O
survival	O
differences	O
were	O
both	O
significant	O
and	O
prolonged	O
.	O

Central	O
treatment	O
unit	O
saves	O
nurses	O
,	O
adds	O
income	O
,	O
improves	O
care	O
.	O

Gold	O
flaxseed	O
(	O
whole	O
or	O
ground	O
)	O
fed	O
at	O
levels	O
of	O
5	O
or	O
15	O
%	O
were	O
compared	O
to	O
a	O
1	O
.	O
5	O
%	O
menhaden	O
oil	O
or	O
a	O
typical	O
control	O
layer	O
ration	O
.	O

It	O
is	O
dangerous	O
to	O
label	O
such	O
conditions	O
as	O
'	O
inappropriate	O
'	O
secretion	O
of	O
ADH	B-GENE
since	O
the	O
maintenance	O
of	O
circulating	O
volume	O
is	O
at	O
least	O
as	O
important	O
a	O
physiological	O
requirement	O
as	O
the	O
defence	O
of	O
tonicity	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
of	O
odontoglossum	O
ringspot	O
virus	O
(	O
Cy	O
-	O
1	O
strain	O
)	O
genomic	O
RNA	O
.	O

An	O
enhancement	O
of	O
benign	O
liver	O
tumors	O
(	O
tumorigenic	O
effect	O
)	O
was	O
observed	O
only	O
in	O
CF1	O
male	O
mice	O
(	O
17	O
/	O
56	O
at	O
the	O
only	O
tested	O
dose	O
:	O
400	O
ppm	O
vs	O
.	O

Cells	O
were	O
cotransfected	O
with	O
this	O
plasmid	O
,	O
and	O
the	O
appropriate	O
responder	O
plasmids	O
and	O
clonies	O
were	O
selected	O
on	O
the	O
basis	O
of	O
their	O
resistance	O
to	O
Geneticin	O
(	O
via	O
the	O
neomycin	B-GENE
aminoglycoside	I-GENE
phosphotransferase	I-GENE
gene	I-GENE
)	O
.	O

This	O
C	O
-	O
terminal	O
domain	O
contains	O
several	O
YxxI	O
/	O
L	O
motifs	O
reminiscent	O
of	O
LMP2A	B-GENE
and	O
a	O
putative	O
TRAF	B-GENE
binding	I-GENE
site	I-GENE
as	O
in	O
LMP1	B-GENE
.	O

Omitting	O
part	O
of	O
the	O
experimental	O
NOE	O
-	O
derived	O
distances	O
results	O
in	O
reduced	O
restraint	O
violations	O
and	O
lower	O
R	O
factors	O
but	O
impairs	O
structural	O
convergence	O
in	O
the	O
rMD	O
refinement	O
.	O

Cardiac	O
lesion	O
in	O
exotoxic	O
shock	O

Risk	O
factors	O
for	O
atherosclerosis	O
related	O
to	O
nutrition	O
are	O
hypercholesterolemia	O
,	O
hyperglycemia	O
-	O
diabetes	O
,	O
and	O
for	O
hypertension	O
,	O
obesity	O
,	O
high	O
salt	O
intake	O
,	O
and	O
excessive	O
use	O
of	O
alcohol	O
.	O

This	O
mutation	O
was	O
associated	O
with	O
reduced	O
or	O
absent	O
expression	O
of	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
RI	I-GENE
protein	I-GENE
and	O
p53	B-GENE
protein	I-GENE
in	O
tumor	O
tissues	O
.	O

SCAN	B-GENE
boxes	O
are	O
found	O
in	O
eight	O
other	O
genes	O
in	O
the	O
GenBank	O
database	O
,	O
five	O
of	O
which	O
are	O
also	O
in	O
the	O
Kruppel	B-GENE
family	I-GENE
of	O
zinc	B-GENE
finger	I-GENE
proteins	I-GENE
lacking	O
KRAB	B-GENE
A	I-GENE
and	I-GENE
B	I-GENE
domains	O
and	O
thereby	O
define	O
a	O
new	O
subclass	O
of	O
zinc	B-GENE
finger	I-GENE
proteins	I-GENE
.	O

However	O
,	O
they	O
had	O
no	O
cross	O
-	O
resistance	O
to	O
quinolone	O
,	O
josamycin	O
and	O
tylosin	O
.	O

Seventy	O
-	O
nine	O
percent	O
of	O
the	O
children	O
screened	O
and	O
91	O
.	O
0	O
%	O
of	O
the	O
children	O
with	O
PbB	O
at	O
least	O
10	O
micrograms	O
/	O
dL	O
were	O
Hispanic	O
.	O

Normal	O
dogs	O
were	O
exposed	O
to	O
either	O
10	O
,	O
15	O
,	O
or	O
30	O
Gy	O
of	O
X	O
rays	O
to	O
a	O
single	O
hemisphere	O
and	O
the	O
gross	O
and	O
histopathologic	O
changes	O
were	O
evaluated	O
qualitatively	O
.	O

YACs	O
selected	O
from	O
our	O
contig	O
will	O
be	O
the	O
starting	O
point	O
for	O
the	O
cloning	O
of	O
the	O
LGMD2B	B-GENE
gene	I-GENE
and	O
thereby	O
establish	O
the	O
biological	O
basis	O
for	O
this	O
form	O
of	O
muscular	O
dystrophy	O
and	O
its	O
relationship	O
with	O
the	O
other	O
limb	O
-	O
girdle	O
muscular	O
dystrophies	O
.	O

The	O
amount	O
of	O
ERCC1	B-GENE
detectable	O
by	O
immunoblotting	O
is	O
reduced	O
in	O
group	O
1	O
,	O
group	O
4	O
and	O
XP	O
-	O
F	O
extracts	O
.	O

In	O
the	O
plant	B-GENE
malate	I-GENE
synthases	I-GENE
,	O
the	O
extension	O
is	O
probably	O
involved	O
in	O
routing	O
to	O
the	O
microbodies	O
,	O
since	O
it	O
contains	O
the	O
potential	O
peroxisomal	O
targeting	O
signal	O
,	O
Ser	O
-	O
Arg	O
/	O
Lys	O
-	O
Leu	O
,	O
at	O
the	O
carboxy	O
terminus	O
.	O

Optimized	O
USF	B-GENE
and	O
MYC	B-GENE
DNA	O
-	O
binding	O
sites	O
,	O
which	O
differ	O
in	O
the	O
nucleotides	O
bordering	O
the	O
hexanucleotide	O
box	O
displace	O
the	O
E	B-GENE
-	I-GENE
C4	I-GENE
factor	I-GENE
in	O
competition	O
assays	O
but	O
with	O
lesser	O
efficiency	O
than	O
the	O
E	B-GENE
-	I-GENE
C4	I-GENE
site	I-GENE
itself	O
.	O

Screening	O
of	O
human	O
cDNA	O
libraries	O
has	O
identified	O
two	O
different	O
5	O
'	O
-	O
termini	O
and	O
alternatively	O
spliced	O
forms	O
of	O
the	O
human	B-GENE
Fli	I-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
(	O
Fli	B-GENE
-	I-GENE
1b	I-GENE
)	O
,	O
suggesting	O
the	O
possible	O
existence	O
of	O
two	O
independent	O
promoters	O
.	O

A	O
surge	O
in	O
the	O
rate	O
of	O
ascorbyl	O
radical	O
production	O
,	O
directly	O
correlated	O
with	O
oxyradical	O
stress	O
and	O
an	O
abrupt	O
fall	O
in	O
superoxide	B-GENE
dismutase	I-GENE
activity	O
in	O
the	O
granuloma	O
,	O
indicates	O
'	O
switching	O
on	O
'	O
of	O
a	O
free	O
radical	O
-	O
dependent	O
machinery	O
for	O
the	O
formation	O
of	O
granuloma	O
after	O
vasectomy	O
.	O

After	O
5	O
-	O
h	O
thermal	O
induction	O
of	O
cells	O
carrying	O
the	O
runaway	O
recombinant	O
pBS1	O
,	O
protein	B-GENE
B2	I-GENE
constituted	O
40	O
%	O
of	O
the	O
soluble	O
protein	O
fraction	O
of	O
the	O
cells	O
.	O

A	O
regulatory	O
element	O
of	O
the	O
empty	B-GENE
spiracles	I-GENE
homeobox	O
gene	O
is	O
composed	O
of	O
three	O
distinct	O
conserved	O
regions	O
that	O
bind	O
regulatory	O
proteins	O
.	O

Peak	O
reactive	O
hyperemia	O
(	O
mL	O
.	O
min	O
-	O
1	O
.	O
100	O
mL	O
-	O
1	O
)	O
was	O
determined	O
in	O
the	O
calf	O
and	O
forearm	O
immediately	O
before	O
and	O
after	O
12	O
weeks	O
of	O
training	O
.	O

These	O
characteristics	O
add	O
to	O
the	O
suitability	O
of	O
NM441	O
as	O
an	O
effective	O
prodrug	O
of	O
NM394	O
.	O

Vorozole	O
(	O
Rivizor	O
)	O
is	O
a	O
potent	O
and	O
stereospecific	O
inhibitor	O
of	O
aromatase	B-GENE
having	O
shown	O
promising	O
endocrine	O
effects	O
in	O
phase	O
I	O
studies	O
.	O

In	O
5	O
cases	O
,	O
combined	O
sensitization	O
to	O
mercury	O
and	O
other	O
metal	O
salts	O
,	O
particularly	O
gold	O
sodium	O
thiosulfate	O
(	O
GST	O
)	O
and	O
palladium	O
chloride	O
(	O
PDC	O
)	O
,	O
was	O
observed	O
.	O

Gene	O
structure	O
and	O
precursor	O
processing	O
.	O

The	O
content	O
of	O
monoamine	O
metabolites	O
,	O
5	O
-	O
hydroxyindoleacetic	O
acid	O
,	O
5	O
-	O
HIAA	O
,	O
and	O
homovanillic	O
acid	O
(	O
HVA	O
)	O
,	O
and	O
-	O
-	O
for	O
17	O
patients	O
-	O
-	O
tryptophan	O
,	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
determined	O
.	O

One	O
month	O
after	O
administration	O
of	O
131I	O
,	O
the	O
29	O
cats	O
evaluated	O
were	O
clinically	O
improved	O
,	O
and	O
24	O
(	O
83	O
%	O
)	O
of	O
the	O
29	O
cats	O
evaluated	O
had	O
normal	O
serum	O
T4	O
concentrations	O
,	O
3	O
cats	O
(	O
10	O
%	O
)	O
remained	O
hyperthyroxinemic	O
,	O
and	O
2	O
cats	O
(	O
7	O
%	O
)	O
were	O
hypothyroxinemic	O
.	O

These	O
findings	O
suggest	O
that	O
T3R	B-GENE
can	O
repress	O
or	O
activate	O
transcription	O
while	O
tethered	O
to	O
the	O
LBD	O
of	O
GAL4	B-GENE
-	O
RXR	B-GENE
and	O
that	O
heterodimerization	O
can	O
occur	O
in	O
vivo	O
without	O
stabilization	O
by	O
hormone	O
response	O
elements	O
.	O

Most	O
interestingly	O
,	O
although	O
the	O
effector	O
plasmid	O
containing	O
the	O
ICP27	B-GENE
gene	I-GENE
had	O
little	O
effect	O
on	O
its	O
own	O
,	O
two	O
different	O
and	O
marked	O
effects	O
depending	O
on	O
the	O
target	O
were	O
observed	O
when	O
ICP27	B-GENE
was	O
combined	O
with	O
ICP4	B-GENE
or	O
ICP0	B-GENE
or	O
both	O
.	O

In	O
renal	O
vein	O
thrombosis	O
,	O
similar	O
pattern	O
to	O
acute	O
tubular	O
necrosis	O
was	O
found	O
but	O
RI	O
venography	O
was	O
helpful	O
.	O

TOM1	B-GENE
encodes	O
a	O
member	O
of	O
the	O
hect	B-GENE
-	O
domain	O
-	O
containing	O
E3	B-GENE
ubiquitin	B-GENE
-	I-GENE
protein	I-GENE
ligase	I-GENE
family	O
that	O
is	O
required	O
for	O
growth	O
at	O
elevated	O
temperatures	O
.	O

Genomic	O
clones	O
containing	O
the	O
C	O
.	O
briggsae	O
gene	O
are	O
able	O
to	O
completely	O
rescue	O
the	O
unc	B-GENE
-	I-GENE
119	I-GENE
phenotype	I-GENE
in	O
transgenic	O
C	O
.	O
elegans	O
mutants	O
.	O

The	O
rapid	O
decrease	O
of	O
plasma	O
potassium	O
during	O
the	O
first	O
two	O
hours	O
of	O
standard	O
HD	O
causes	O
a	O
membrane	O
hyperpolarization	O
.	O

Region	O
-	O
specific	O
enhancers	O
near	O
two	O
mammalian	B-GENE
homeo	I-GENE
box	I-GENE
genes	I-GENE
define	O
adjacent	O
rostrocaudal	O
domains	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
several	O
overlapping	O
cDNAs	O
encoding	O
approximately	O
4	O
.	O
1	O
kb	O
of	O
the	O
human	B-GENE
homologue	I-GENE
of	I-GENE
Wnt	I-GENE
-	I-GENE
5A	I-GENE
.	O

Subtype	O
-	O
and	O
response	O
element	O
-	O
dependent	O
differences	O
in	O
transactivation	O
by	O
peroxisome	B-GENE
proliferator	I-GENE
-	I-GENE
activated	I-GENE
receptors	I-GENE
alpha	I-GENE
and	I-GENE
gamma	I-GENE
.	O

MRI	O
visualization	O
of	O
proteoglycan	O
depletion	O
in	O
articular	O
cartilage	O
via	O
intravenous	O
administration	O
of	O
Gd	O
-	O
DTPA	O
.	O

We	O
then	O
developed	O
a	O
yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
contig	O
for	O
this	O
region	O
.	O

We	O
suggest	O
that	O
the	O
induction	O
of	O
IFNA	B-GENE
promoter	I-GENE
region	I-GENE
requires	O
cooperation	O
between	O
alpha	B-GENE
F1	I-GENE
binding	I-GENE
proteins	I-GENE
and	O
IRF	B-GENE
-	I-GENE
1	I-GENE
.	O

Heterologous	O
hybridization	O
with	O
a	O
rps12	B-GENE
gene	I-GENE
specific	O
probe	O
from	O
Euglena	O
has	O
revealed	O
the	O
presence	O
of	O
rps12	B-GENE
homologous	I-GENE
sequences	I-GENE
within	O
the	O
inverted	O
repeat	O
of	O
Spirodela	O
chloroplast	O
DNA	O
on	O
the	O
fragment	B-GENE
BamHI	I-GENE
-	I-GENE
V	I-GENE
.	O

To	O
investigate	O
the	O
effect	O
of	O
hyperthyroidism	O
on	O
the	O
pattern	O
and	O
time	O
course	O
of	O
O2	O
uptake	O
(	O
VO2	O
)	O
following	O
the	O
transition	O
from	O
rest	O
to	O
exercise	O
,	O
six	O
patients	O
and	O
six	O
healthy	O
subjects	O
performed	O
cycle	O
exercise	O
at	O
an	O
average	O
work	O
rate	O
(	O
WR	O
)	O
of	O
18	O
and	O
20	O
W	O
respectively	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
viable	O
in	O
vitro	O
-	O
generated	O
deletion	O
mutant	O
of	O
PSTVd	O
has	O
been	O
reported	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
recombination	O
occurred	O
between	O
corresponding	O
LTR	O
and	O
vif	B-GENE
loci	I-GENE
of	O
the	O
quasi	O
-	O
species	O
present	O
in	O
the	O
isolates	O
described	O
here	O
.	O

In	O
HMEC	O
stably	O
transfected	O
with	O
an	O
ER	B-GENE
mutant	I-GENE
containing	O
a	O
deletion	O
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
,	O
E	O
and	O
HT	O
had	O
different	O
effects	O
on	O
EBBP	B-GENE
gene	I-GENE
expression	O
;	O
EBBP	B-GENE
regulation	O
by	O
E	O
was	O
dramatically	O
reduced	O
while	O
the	O
effects	O
of	O
HT	O
were	O
augmented	O
.	O

The	O
gene	B-GENE
atp6	I-GENE
,	O
encoding	O
subunit	O
6	O
of	O
the	O
mitochondrial	O
F0	B-GENE
-	O
ATPase	B-GENE
complex	O
,	O
has	O
been	O
characterized	O
from	O
both	O
the	O
normal	O
(	O
fertile	O
)	O
and	O
Ogura	O
(	O
male	O
-	O
sterile	O
)	O
radish	O
cytoplasms	O
in	O
order	O
to	O
determine	O
if	O
previously	O
identified	O
atp6	B-GENE
transcriptional	O
differences	O
could	O
play	O
a	O
role	O
in	O
cytoplasmic	O
male	O
sterility	O
.	O

When	O
the	O
same	O
single	O
-	O
amino	O
-	O
acid	O
mutations	O
were	O
directly	O
introduced	O
into	O
the	O
parental	O
PV	O
/	O
CBV4	O
-	O
2A	O
genome	O
,	O
chimeric	O
viruses	O
with	O
a	O
large	O
-	O
plaque	O
phenotype	O
and	O
a	O
wild	O
-	O
type	O
PV	O
-	O
like	O
growth	O
pattern	O
were	O
obtained	O
upon	O
transfection	O
,	O
an	O
observation	O
demonstrating	O
that	O
these	O
point	O
mutations	O
alone	O
had	O
a	O
drastic	O
effect	O
on	O
the	O
growth	O
of	O
the	O
PV	O
/	O
CBV4	O
chimeric	O
virus	O
.	O

The	O
gag	B-GENE
-	O
myc	B-GENE
proteins	O
encoded	O
by	O
these	O
variants	O
efficiently	O
localized	O
to	O
the	O
cell	O
nucleus	O
.	O

Hpr1	B-GENE
forms	O
,	O
together	O
with	O
Tho2	B-GENE
,	O
Mft1	B-GENE
,	O
and	O
Thp2	B-GENE
,	O
the	O
THO	B-GENE
complex	I-GENE
,	O
which	O
controls	O
transcription	O
elongation	O
and	O
genome	O
stability	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

UPR	O
elements	O
present	O
in	O
other	O
ER	O
chaperone	O
genes	O
,	O
such	O
as	O
yeast	B-GENE
KAR2	I-GENE
(	O
BiP	B-GENE
)	O
,	O
mammalian	B-GENE
GRP78	I-GENE
(	O
BiP	B-GENE
)	O
,	O
and	O
GRP94	B-GENE
,	O
function	O
in	O
an	O
analogous	O
manner	O
to	O
that	O
in	O
FKB2	B-GENE
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
determine	O
if	O
ergotamine	O
,	O
an	O
ergopeptine	O
alkaloid	O
isolated	O
from	O
Neotyphodium	O
-	O
infected	O
grasses	O
and	O
associated	O
with	O
toxicoses	O
in	O
livestock	O
,	O
altered	O
plasma	O
concentrations	O
of	O
reproductive	O
hormones	O
in	O
follicular	O
phase	O
heifers	O
and	O
in	O
cows	O
given	O
a	O
progestin	O
implant	O
.	O

Acute	O
spontaneous	O
subdural	O
haematoma	O
.	O

Strains	O
carrying	O
a	O
snf1	B-GENE
mutation	I-GENE
are	O
unable	O
to	O
grow	O
on	O
sucrose	O
,	O
galactose	O
,	O
maltose	O
,	O
melibiose	O
,	O
or	O
nonfermentable	O
carbon	O
sources	O
;	O
utilization	O
of	O
these	O
carbon	O
sources	O
is	O
regulated	O
by	O
glucose	O
repression	O
.	O

2	O
)	O
Depending	O
on	O
the	O
structure	O
,	O
certain	O
compounds	O
are	O
sequestered	O
in	O
the	O
cornea	O
(	O
presumably	O
the	O
stroma	O
)	O
and	O
form	O
a	O
release	O
system	O
into	O
the	O
anterior	O
aqueous	O
.	O

The	O
results	O
of	O
the	O
neural	O
network	O
were	O
compared	O
with	O
those	O
of	O
a	O
density	O
mask	O
(	O
thresholds	O
,	O
-	O
750	O
/	O
-	O
300	O
H	O
)	O
,	O
with	O
a	O
radiologist	O
serving	O
as	O
the	O
gold	O
standard	O
.	O

These	O
data	O
also	O
suggest	O
the	O
existence	O
of	O
a	O
mechanism	O
by	O
which	O
regulatory	O
subunits	O
modulate	O
the	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
-	O
mediated	O
signals	O
,	O
independent	O
of	O
the	O
kinase	O
activity	O
,	O
possibly	O
through	O
subcellular	O
localization	O
of	O
the	O
catalytic	O
subunit	O
or	O
interaction	O
with	O
additional	O
signaling	O
molecules	O
.	O

These	O
results	O
suggest	O
that	O
the	O
PVB	O
therapy	O
is	O
not	O
sufficient	O
to	O
cure	O
the	O
cases	O
with	O
choriocarcinoma	O
element	O
or	O
bulky	O
metastasis	O
.	O

Right	O
-	O
sided	O
hemiplegia	O
of	O
5	O
years	O
duration	O
occurred	O
in	O
the	O
remaining	O
case	O
.	O

Plasmid	O
subclones	O
of	O
the	O
hr1a	B-GENE
-	O
containing	O
AcMNPV	O
HindIII	B-GENE
-	O
N	O
fragment	O
were	O
examined	O
for	O
their	O
ability	O
to	O
replicate	O
in	O
virus	O
-	O
infected	O
(	O
Spodoptera	O
frugiperda	O
)	O
Sf9	O
cells	O
,	O
and	O
to	O
stimulate	O
transcription	O
when	O
linked	O
in	O
cis	O
with	O
a	O
39K	B-GENE
gene	I-GENE
promoter	I-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
glucuronidase	I-GENE
fusion	I-GENE
and	O
cotransfected	O
into	O
cells	O
along	O
with	O
a	O
plasmid	O
(	O
ple	O
-	O
1	O
)	O
containing	O
the	O
gene	O
encoding	O
the	O
trans	O
-	O
acting	O
factor	O
IE	B-GENE
-	I-GENE
1	I-GENE
.	O

Transfection	O
of	O
H	B-GENE
chain	I-GENE
loss	I-GENE
variant	I-GENE
myeloma	O
with	O
the	O
complete	O
12	O
kb	O
construct	O
,	O
termed	O
238H	B-GENE
-	I-GENE
Cmicro	I-GENE
,	O
resulted	O
in	O
secretion	O
of	O
intact	O
Ig	O
pairing	O
238H	B-GENE
-	I-GENE
Cmicro	I-GENE
,	O
with	O
a	O
lambda	B-GENE
L	I-GENE
chain	I-GENE
;	O
however	O
,	O
transfectant	B-GENE
Ig	I-GENE
lacked	O
autoreactivity	O
and	O
pathogenicity	O
.	O

Divergent	O
regions	O
of	O
the	O
posterior	O
left	O
hemisphere	O
used	O
for	O
decoding	O
and	O
storage	O
of	O
information	O
emerged	O
in	O
each	O
working	O
memory	O
versus	O
control	O
task	O
comparison	O
.	O

In	O
normal	O
B	O
cells	O
stimulated	O
by	O
LPS	O
or	O
IL	B-GENE
-	I-GENE
4	I-GENE
,	O
new	O
complexes	O
appear	O
that	O
bind	O
to	O
C	B-GENE
/	I-GENE
EBP	I-GENE
and	O
NF	B-GENE
-	I-GENE
IL	I-GENE
-	I-GENE
4	I-GENE
elements	I-GENE
,	O
respectively	O
,	O
located	O
within	O
the	O
-	O
125	O
/	O
-	O
101	O
region	O
.	O

Here	O
,	O
we	O
describe	O
the	O
crystal	O
structure	O
at	O
2	O
.	O
5	O
A	O
resolution	O
of	O
a	O
fragment	O
of	O
the	O
integrase	B-GENE
of	I-GENE
Rous	I-GENE
sarcoma	I-GENE
virus	I-GENE
(	I-GENE
residues	I-GENE
49	I-GENE
-	I-GENE
286	I-GENE
)	I-GENE
containing	O
both	O
the	O
conserved	O
catalytic	O
domain	O
and	O
a	O
modulatory	O
DNA	O
-	O
binding	O
domain	O
(	O
C	O
domain	O
)	O
.	O

Vectorcardiography	O
in	O
coronary	O
patients	O
with	O
the	O
electrocardiographic	O
RS	O
segment	O
in	O
the	O
V1	O
lead	O

The	O
B	B-GENE
.	I-GENE
aphidicola	I-GENE
argS	I-GENE
-	I-GENE
rrn	I-GENE
DNA	I-GENE
fragments	I-GENE
from	O
endosymbionts	O
from	O
seven	O
species	O
of	O
aphids	O
had	O
promoter	O
activities	O
in	O
E	O
.	O
coli	O
which	O
ranged	O
from	O
6	O
to	O
135	O
%	O
of	O
that	O
observed	O
with	O
a	O
comparable	O
DNA	O
fragment	O
of	O
E	B-GENE
.	I-GENE
coli	I-GENE
rrnB	I-GENE
.	O

The	O
adeno	O
-	O
associated	O
virus	O
type	O
2	O
(	O
AAV	O
-	O
2	O
)	O
Rep78	B-GENE
/	O
Rep68	B-GENE
regulatory	O
proteins	O
are	O
pleiotropic	O
effectors	O
of	O
viral	O
and	O
cellular	O
DNA	O
replication	O
,	O
of	O
cellular	O
transformation	O
by	O
viral	O
and	O
cellular	O
oncogenes	O
,	O
and	O
of	O
homologous	O
and	O
heterologous	O
gene	O
expression	O
.	O

Role	O
of	O
the	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
alpha	I-GENE
transcription	I-GENE
factor	I-GENE
in	O
the	O
glucocorticoid	O
stimulation	O
of	O
p21waf1	B-GENE
/	O
cip1	B-GENE
gene	O
promoter	O
activity	O
in	O
growth	O
-	O
arrested	O
rat	O
hepatoma	O
cells	O
.	O

Long	O
-	O
term	O
ambulatory	O
measurement	O
of	O
transcutaneous	O
arterial	O
CO2	O
pressure	O
(	O
PCO2	O
)	O
offers	O
an	O
opportunity	O
to	O
test	O
directly	O
the	O
co	O
-	O
occurrence	O
of	O
panic	O
and	O
hyperventilation	O
under	O
natural	O
conditions	O
.	O

The	O
highly	O
conserved	O
region	O
of	O
U6	B-GENE
snRNA	I-GENE
has	O
a	O
structural	O
similarity	O
with	O
the	O
catalytic	O
domain	O
of	O
the	O
negative	O
strand	O
of	O
the	O
satellite	O
RNA	O
of	O
tobacco	O
ring	O
spot	O
virus	O
[	O
(	O
-	O
)	O
sTRSV	O
]	O
,	O
suggesting	O
that	O
the	O
highly	O
conserved	O
region	O
of	O
U6	B-GENE
snRNA	I-GENE
forms	O
the	O
catalytic	O
center	O
.	O

Here	O
we	O
show	O
that	O
one	O
nudF	B-GENE
suppressor	I-GENE
also	O
suppresses	O
hs	O
-	O
mutations	O
in	O
nudA	B-GENE
,	O
nudC	B-GENE
,	O
and	O
nudG	B-GENE
and	O
deletions	O
in	O
nudA	B-GENE
and	O
nudF	B-GENE
.	O

Treatment	O
of	O
cells	O
for	O
10	O
min	O
with	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
resulted	O
in	O
activation	O
of	O
p44	B-GENE
/	I-GENE
42	I-GENE
MAPK	O
,	O
p38	B-GENE
,	O
and	O
JNK	B-GENE
.	O

This	O
report	O
describes	O
the	O
isolation	O
and	O
recombinant	O
expression	O
of	O
a	O
cDNA	O
clone	O
encoding	O
HER4	B-GENE
,	O
the	O
fourth	O
member	O
of	O
the	O
human	B-GENE
epidermal	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
family	O
.	O

In	O
conclusion	O
,	O
when	O
pulmonary	O
abnormalities	O
are	O
found	O
in	O
HTLV	O
-	O
1	O
carriers	O
,	O
we	O
should	O
be	O
careful	O
in	O
determining	O
whether	O
such	O
pulmonary	O
involvements	O
are	O
etiologically	O
related	O
to	O
HTLV	O
-	O
1	O
infection	O
.	O

A	O
clinical	O
trial	O
of	O
a	O
new	O
mitomycin	O
C	O
derivative	O
,	O
KW	O
-	O
2083	O
(	O
7	O
-	O
N	O
-	O
(	O
p	O
-	O
hydroxyphenyl	O
)	O
-	O
mitomycin	O
C	O
)	O

Excess	O
recombinant	B-GENE
PTB	I-GENE
squelches	O
the	O
splicing	O
switch	O
and	O
reestablishes	O
exon	O
skipping	O
as	O
the	O
predominant	O
splicing	O
pathway	O
.	O

A	O
child	O
presumed	O
to	O
have	O
the	O
21	B-GENE
-	I-GENE
hydroxylase	I-GENE
deficiency	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
was	O
studied	O
extensively	O
as	O
an	O
infant	O
.	O

Sixtieth	O
anniversary	O
of	O
Angiotensin	B-GENE
.	O

Inability	O
of	O
niacin	O
to	O
protect	O
from	O
in	O
vivo	O
hyperoxia	O
or	O
in	O
vitro	O
microsomal	O
lipid	O
peroxidation	O
.	O

MDA	O
-	O
MB	O
-	O
468	O
cells	O
were	O
stably	O
transfected	O
with	O
either	O
a	O
plasmid	O
having	O
a	O
CMV	B-GENE
promoter	I-GENE
-	O
driven	O
rabbit	B-GENE
beta	I-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
or	O
plasmids	O
having	O
a	O
CMV	B-GENE
promoter	I-GENE
-	O
driven	O
chimeric	O
gadd45	B-GENE
5	O
"	O
-	O
UTR	O
-	O
rabbit	B-GENE
beta	I-GENE
-	I-GENE
globin	I-GENE
gene	O
,	O
where	O
the	O
entire	B-GENE
gadd45	I-GENE
5	I-GENE
"	I-GENE
-	I-GENE
UTR	I-GENE
(	I-GENE
from	I-GENE
+	I-GENE
1	I-GENE
to	I-GENE
+	I-GENE
298	I-GENE
)	I-GENE
or	O
a	O
45	O
bp	O
subfragment	O
of	O
the	O
gadd45	B-GENE
5	I-GENE
"	I-GENE
-	I-GENE
UTR	I-GENE
(	I-GENE
from	I-GENE
+	I-GENE
10	I-GENE
to	I-GENE
+	I-GENE
55	I-GENE
)	I-GENE
was	O
positioned	O
at	O
the	O
5	O
"	O
-	O
end	O
of	O
the	O
rabbit	B-GENE
beta	I-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
.	O

The	O
University	O
of	O
North	O
Carolina	O
caries	O
risk	O
assessment	O
was	O
conducted	O
between	O
1986	O
and	O
1989	O
with	O
5000	O
children	O
initially	O
in	O
grades	O
1	O
and	O
5	O
from	O
low	O
fluoride	O
sites	O
in	O
South	O
Carolina	O
and	O
Maine	O
.	O

Following	O
EGF	B-GENE
or	O
NGF	B-GENE
stimulation	O
of	O
the	O
v	O
-	O
CrkPC12	O
cells	O
,	O
the	O
v	B-GENE
-	I-GENE
Crk	I-GENE
protein	O
itself	O
became	O
tyrosine	O
phosphorylated	O
within	O
1	O
min	O
.	O

BCR	B-GENE
-	O
ABL	B-GENE
expression	O
confers	O
cross	O
-	O
resistance	O
to	O
multiple	O
genotoxic	O
anticancer	O
drugs	O
by	O
inhibition	O
of	O
the	O
apoptotic	O
response	O
to	O
DNA	O
damage	O
in	O
association	O
with	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2	O
-	O
M	O
restriction	O
point	O
.	O

RESULTS	O
:	O
After	O
lavage	O
,	O
a	O
rapid	O
decrease	O
in	O
arterial	O
pH	O
and	O
PaO2	O
,	O
and	O
an	O
increase	O
in	O
PaCO2	O
and	O
PIP	O
were	O
observed	O
in	O
all	O
animals	O
.	O

CONCLUSIONS	O
:	O
Elevation	O
of	O
TBARS	O
and	O
decrease	O
of	O
GSH	O
show	O
the	O
presence	O
of	O
oxidative	O
stress	O
during	O
the	O
PFD	O
treatment	O
with	O
hemodiafilter	O
SG3	O
.	O

Ozone	O
uptake	O
was	O
assessed	O
in	O
awake	O
,	O
spontaneously	O
breathing	O
Fischer	O
-	O
344	O
Sprague	O
-	O
Dawley	O
,	O
and	O
Long	O
-	O
Evans	O
rats	O
and	O
Hartley	O
guinea	O
pigs	O
to	O
provide	O
data	O
on	O
the	O
dosimetry	O
of	O
O3	O
in	O
small	O
laboratory	O
animals	O
.	O

E	O
.	O
R	O
.	O
C	O
.	O
P	O
.	O

is	O
an	O
important	O
advance	O
in	O
diagnosis	O
.	O

Deletion	O
analysis	O
of	O
the	O
3	O
.	O
5kb	O
DNA	O
fragment	O
revealed	O
that	O
the	O
region	O
between	O
-	O
125	O
to	O
+	O
1	O
,	O
containing	O
a	O
single	O
Sp1	B-GENE
binding	I-GENE
site	I-GENE
,	O
is	O
essential	O
for	O
transcription	O
of	O
the	O
embigin	B-GENE
gene	I-GENE
.	O

Resistance	O
to	O
Mup	O
was	O
classified	O
as	O
low	O
(	O
minimal	O
inhibitory	O
concentration	O
[	O
MIC	O
]	O
>	O
or	O
=	O
8	O
microg	O
/	O
mL	O
)	O
or	O
high	O
(	O
MIC	O
>	O
or	O
=	O
512	O
microg	O
/	O
mL	O
)	O
degree	O
.	O

Extragonadal	O
endodermal	O
sinus	O
tumors	O
in	O
the	O
head	O
and	O
neck	O
are	O
very	O
rare	O
.	O

Lesions	O
of	O
this	O
kind	O
resemble	O
those	O
in	O
vitamin	O
A	O
-	O
deficient	O
chickens	O
and	O
are	O
the	O
first	O
to	O
be	O
induced	O
by	O
excess	O
vitamin	O
E	O
.	O

Essential	O
fatty	O
acid	O
deficiency	O
in	O
childhood	O

The	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitor	O
GF	O
-	O
109203X	O
abolished	O
the	O
activation	O
by	O
phorbol	O
ester	O
and	O
inhibited	O
the	O
effect	O
of	O
CCK	B-GENE
by	O
78	O
%	O
but	O
had	O
no	O
effect	O
on	O
EGF	B-GENE
-	O
activated	O
MAPK	B-GENE
activity	O
.	O

Activated	O
FGFR3	B-GENE
predominantly	O
interacts	O
with	O
GRB2	B-GENE
.	I-GENE
Sos	I-GENE
in	O
complex	O
with	O
a	O
previously	O
identified	O
90	O
-	O
kDa	O
protein	O
and	O
designated	O
protein	B-GENE
80K	I-GENE
-	I-GENE
H	I-GENE
.	O

The	O
rate	O
of	O
collagen	B-GENE
synthesis	O
in	O
normal	O
scar	O
was	O
approximately	O
constant	O
between	O
6	O
months	O
and	O
20	O
years	O
after	O
the	O
initial	O
wounding	O
,	O
but	O
in	O
both	O
hypertrophic	O
scar	O
and	O
keloid	O
the	O
rate	O
was	O
initially	O
approximately	O
twice	O
that	O
in	O
normal	O
scar	O
,	O
and	O
2	O
-	O
3	O
years	O
after	O
wounding	O
it	O
fell	O
to	O
approximately	O
the	O
same	O
level	O
as	O
in	O
normal	O
scar	O
.	O

Evidence	O
for	O
a	O
role	O
of	O
Smad6	B-GENE
in	O
chick	O
cardiac	O
development	O
.	O

Excellent	O
results	O
were	O
recorded	O
in	O
390	O
(	O
83	O
.	O
69	O
%	O
)	O
of	O
the	O
patients	O
,	O
improvement	O
in	O
46	O
(	O
9	O
.	O
87	O
%	O
)	O
where	O
in	O
the	O
majority	O
a	O
varicose	O
complex	O
was	O
involved	O
.	O

Mutational	O
analysis	O
of	O
yeast	B-GENE
CEG1	I-GENE
demonstrated	O
that	O
four	O
of	O
the	O
five	O
conserved	O
motifs	O
are	O
essential	O
for	O
capping	B-GENE
enzyme	I-GENE
function	O
in	O
vivo	O
.	O

We	O
report	O
on	O
a	O
case	O
discovered	O
in	O
a	O
13	O
year	O
-	O
old	O
girl	O
presenting	O
with	O
anaemia	O
.	O

The	O
LIF	B-GENE
appeared	O
to	O
be	O
released	O
by	O
the	O
patient	O
'	O
s	O
peripheral	O
blood	O
lymphocytes	O
when	O
cultured	O
with	O
optimal	O
doses	O
of	O
propranolol	O
.	O

STUDY	O
SELECTION	O
:	O
Not	O
applicable	O
.	O

Co	O
-	O
expression	O
of	O
PLD1	B-GENE
in	O
COS	O
-	O
7	O
cells	O
with	O
the	O
two	O
recombinant	B-GENE
CK2	I-GENE
subunits	I-GENE
,	O
alpha	O
or	O
beta	O
,	O
suggests	O
that	O
the	O
association	O
of	O
PLD1	B-GENE
with	O
the	O
kinase	O
is	O
through	O
the	O
beta	O
subunit	O
.	O

For	O
capsules	O
containing	O
only	O
the	O
drug	O
,	O
the	O
value	O
of	O
T50	O
increased	O
as	O
the	O
particle	O
size	O
of	O
the	O
drug	O
decreased	O
.	O

The	O
LAB	O
in	O
the	O
cecum	O
(	O
mean	O
9	O
.	O
4	O
log	O
CFU	O
/	O
g	O
)	O
increased	O
slightly	O
with	O
increasing	O
abattoir	O
holding	O
time	O
.	O

Our	O
objective	O
was	O
to	O
find	O
possible	O
predictors	O
for	O
the	O
expression	O
and	O
progression	O
of	O
LJM	O
and	O
to	O
evaluate	O
the	O
relationship	O
between	O
LJM	O
and	O
other	O
long	O
-	O
term	O
complications	O
of	O
insulin	B-GENE
-	O
dependent	O
diabetes	O
mellitus	O
.	O

Human	B-GENE
recombinant	I-GENE
erythropoietin	I-GENE
(	O
r	B-GENE
-	I-GENE
HuEPO	I-GENE
,	O
EprexR	B-GENE
)	O
was	O
administered	O
to	O
8	O
children	O
with	O
chronic	O
renal	O
failure	O
and	O
high	O
transfusion	O
requirement	O
.	O

CONCLUSIONS	O
:	O
LHB	O
is	O
simple	O
,	O
easy	O
and	O
safe	O
to	O
implement	O
,	O
and	O
is	O
the	O
only	O
technique	O
capable	O
of	O
maintaining	O
independent	O
upper	O
and	O
lower	O
body	O
perfusion	O
pressure	O
.	O

Northern	O
analyses	O
further	O
confirm	O
that	O
the	O
expression	O
of	O
endogenous	O
alpha	B-GENE
-	I-GENE
ENaC	I-GENE
gene	I-GENE
in	O
salivary	O
Pa	O
-	O
4	O
cells	O
is	O
suppressed	O
by	O
an	O
ectopic	O
HMGI	B-GENE
-	I-GENE
C	I-GENE
overexpression	O
.	O

Removal	O
of	O
cyclin	B-GENE
-	I-GENE
dependant	I-GENE
kinases	I-GENE
(	O
cdks	B-GENE
)	O
or	O
cdk2	B-GENE
from	O
these	O
extracts	O
using	O
affinity	O
matrices	O
severely	O
inhibits	O
initiation	O
of	O
S	O
phase	O
.	O

Gel	O
mobility	O
shift	O
analyses	O
reveal	O
that	O
FRTL	O
-	O
5	O
thyroid	O
cell	O
nuclear	O
extracts	O
form	O
a	O
specific	O
protein	O
/	O
DNA	O
complex	O
with	O
this	O
region	O
,	O
which	O
is	O
prevented	O
by	O
the	O
TTF	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
element	I-GENE
from	O
the	O
TG	B-GENE
promoter	I-GENE
;	O
FRT	O
and	O
BRL	O
cell	O
nuclear	O
extracts	O
do	O
not	O
have	O
TTF	B-GENE
-	I-GENE
1	I-GENE
and	O
do	O
not	O
form	O
this	O
complex	O
.	O

The	O
Sty1	B-GENE
kinase	I-GENE
is	O
stimulated	O
by	O
a	O
variety	O
of	O
different	O
stress	O
conditions	O
including	O
osmotic	O
and	O
oxidative	O
stress	O
and	O
heat	O
shock	O
.	O

No	O
viral	O
RNA	O
replication	O
could	O
be	O
detected	O
in	O
cells	O
transfected	O
with	O
mutant	O
RNAs	O
.	O

Acad	O
.	O

Comparison	O
of	O
the	O
genes	O
coding	O
for	O
mouse	O
and	O
human	O
p36	B-GENE
(	O
annexin	B-GENE
II	I-GENE
)	O
and	O
mouse	O
,	O
rat	O
and	O
human	O
p35	B-GENE
(	O
annexin	B-GENE
I	I-GENE
)	O
and	O
pigeon	O
cp35	B-GENE
(	O
an	O
annexin	B-GENE
I	I-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
)	O
shows	O
strong	O
genomic	O
structural	O
conservation	O
supporting	O
the	O
hypothesis	O
that	O
these	O
genes	O
had	O
a	O
common	O
ancestor	O
.	O

When	O
incubated	O
with	O
infective	O
larvae	O
which	O
had	O
penetrated	O
mouse	O
skin	O
,	O
both	O
normal	O
and	O
immune	O
cells	O
attached	O
to	O
larvae	O
in	O
the	O
absence	O
of	O
serum	O
.	O

A	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
primary	O
myelofibrosis	O
initially	O
received	O
low	O
dose	O
Ara	O
C	O
.	O

Collectively	O
,	O
these	O
studies	O
suggest	O
that	O
the	O
major	O
EGF	B-GENE
-	O
stimulated	O
mitotic	O
growth	O
pathways	O
may	O
not	O
be	O
absolutely	O
linked	O
to	O
the	O
stat91	B-GENE
signaling	O
pathways	O
and	O
that	O
such	O
transcription	O
complexes	O
are	O
more	O
complex	O
than	O
previously	O
reported	O
.	O

FEurea	O
was	O
also	O
measured	O
during	O
stable	O
graft	O
function	O
,	O
7	O
-	O
14	O
days	O
prior	O
to	O
allograft	O
dysfunction	O
.	O

Nonsuicidal	O
mortality	O
in	O
late	O
-	O
life	O
depression	O
.	O

Few	O
triers	O
or	O
users	O
had	O
received	O
SLT	O
counseling	O
from	O
their	O
dentist	O
despite	O
high	O
dental	O
utilization	O
rates	O
.	O

However	O
,	O
UV	O
resistance	O
is	O
only	O
minimally	O
restored	O
,	O
and	O
mutant	O
cells	O
remain	O
sensitive	O
to	O
gamma	O
radiation	O
.	O

The	O
oxalate	B-GENE
oxidase	I-GENE
method	O
results	O
in	O
a	O
mean	O
and	O
reference	O
interval	O
for	O
oxalate	O
excretion	O
that	O
are	O
comparable	O
with	O
those	O
by	O
isotope	O
dilution	O
,	O
gas	O
-	O
chromatographic	O
,	O
colorimetric	O
,	O
and	O
other	O
enzymic	O
procedures	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
expression	O
of	O
antisense	O
mRNA	O
for	O
p130CAS	B-GENE
resulted	O
in	O
reversion	O
of	O
the	O
transformed	O
phenotype	O
of	O
all	O
these	O
cell	O
lines	O
.	O

Starches	O
had	O
no	O
effect	O
.	O

Maximal	O
Expiratory	O
Flow	O
Rates	O
such	O
as	O
Peak	O
Expiratory	O
Flow	O
Rate	O
(	O
PEFR	O
)	O
,	O
rates	O
at	O
25	O
%	O
,	O
50	O
%	O
and	O
75	O
%	O
of	O
forced	O
vital	O
capacity	O
(	O
V	O
max	O
25	O
%	O
,	O
V	O
max	O
50	O
%	O
and	O
V	O
max	O
75	O
%	O
)	O
and	O
forced	O
expiratory	O
flow	O
during	O
the	O
middle	O
half	O
of	O
forced	O
vital	O
capacity	O
(	O
FEF	O
25	O
-	O
75	O
%	O
)	O
were	O
measured	O
in	O
273	O
healthy	O
non	O
-	O
smoking	O
adults	O
(	O
144	O
males	O
,	O
129	O
females	O
)	O
aged	O
15	O
-	O
63	O
years	O
living	O
in	O
Madras	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
encoded	O
by	O
MSK1	B-GENE
is	O
homologous	O
to	O
yeast	B-GENE
cytoplasmic	I-GENE
lysyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
and	O
to	O
the	O
product	O
of	O
the	O
herC	B-GENE
gene	I-GENE
,	O
which	O
has	O
recently	O
been	O
suggested	O
to	O
code	O
for	O
the	O
Escherichia	O
coli	O
enzyme	O
.	O

Similar	O
to	O
the	O
D	B-GENE
,	O
B	B-GENE
/	O
B	B-GENE
'	I-GENE
and	O
E	B-GENE
proteins	I-GENE
,	O
the	O
F	B-GENE
and	O
G	B-GENE
proteins	I-GENE
do	O
not	O
possess	O
any	O
of	O
the	O
known	O
RNA	O
binding	O
motifs	O
,	O
suggesting	O
that	O
other	O
types	O
of	O
RNA	O
-	O
protein	O
interactions	O
occur	O
in	O
the	O
snRNP	O
core	O
.	O

These	O
observations	O
suggest	O
that	O
clr4	B-GENE
+	I-GENE
and	O
rik1	B-GENE
+	I-GENE
must	O
play	O
a	O
role	O
in	O
the	O
assembly	O
of	O
Swi6p	B-GENE
into	O
a	O
transcriptionally	O
silent	O
,	O
inaccessible	O
chromatin	O
structure	O
at	O
fission	O
yeast	O
centromeres	O
which	O
is	O
required	O
to	O
facilitate	O
interactions	O
with	O
spindle	O
microtubules	O
and	O
to	O
ensure	O
normal	O
chromosome	O
segregation	O
.	O

Characterization	O
of	O
a	O
DEAD	B-GENE
box	I-GENE
ATPase	I-GENE
/	O
RNA	B-GENE
helicase	I-GENE
protein	O
of	O
Arabidopsis	O
thaliana	O
.	O

Amplitude	O
of	O
late	O
surface	O
(	O
P2	O
and	O
N2	O
)	O
and	O
depth	O
(	O
B	O
and	O
C	O
)	O
components	O
significantly	O
decreased	O
when	O
patients	O
shifted	O
from	O
SWS	O
IV	O
to	O
PS	O
and	O
increased	O
from	O
PS	O
to	O
W2	O
.	O

Oligo	O
-	O
[	O
alpha	O
]	O
-	O
deoxynucleotides	O
can	O
be	O
derived	O
by	O
stabilizing	O
(	O
intercalating	O
)	O
agents	O
or	O
reactive	O
groups	O
(	O
cleaving	O
reagents	O
,	O
cross	O
-	O
linkers	O
.	O
.	O
.	O
)	O
.	O

This	O
vector	O
should	O
be	O
applicable	O
for	O
high	O
-	O
throughput	O
characterization	O
of	O
new	O
open	O
reading	O
frames	O
found	O
in	O
genome	O
sequencing	O
.	O

The	O
subjects	O
were	O
17	O
patients	O
with	O
android	O
obesity	O
(	O
four	O
men	O
and	O
13	O
women	O
)	O
aged	O
21	O
to	O
58	O
years	O
with	O
a	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
ranging	O
from	O
32	O
.	O
0	O
to	O
52	O
.	O
2	O
kg	O
/	O
m2	O
and	O
an	O
abdominal	O
-	O
gluteal	O
ratio	O
greater	O
than	O
1	O
.	O
0	O
.	O

No	O
universally	O
accepted	O
standardized	O
classification	O
system	O
for	O
acne	O
vulgaris	O
exists	O
,	O
although	O
there	O
is	O
a	O
strong	O
need	O
for	O
it	O
.	O

Blood	O
samples	O
for	O
determination	O
of	O
fibrinolytic	O
activity	O
and	O
factor	B-GENE
VIII	I-GENE
in	O
plasma	O
were	O
obtained	O
before	O
and	O
immediately	O
after	O
the	O
end	O
of	O
compression	O
and	O
application	O
of	O
a	O
stocking	O
,	O
respectively	O
.	O

Neither	O
symptoms	O
,	O
virions	O
,	O
nor	O
viral	O
RNA	O
was	O
detectable	O
in	O
plants	O
inoculated	O
with	O
this	O
mutant	O
or	O
a	O
mutant	O
with	O
a	O
frameshift	O
mutation	O
in	O
the	O
coat	B-GENE
gene	I-GENE
.	O

The	O
cumulative	O
length	O
of	O
the	O
RGSV	O
genome	O
,	O
including	O
RNAs	O
5	O
and	O
6	O
,	O
was	O
25142	O
nt	O
.	O

Risk	O
ratios	O
decreased	O
with	O
increasing	O
age	O
and	O
increased	O
with	O
number	O
of	O
breast	O
biopsies	O
,	O
family	O
history	O
of	O
breast	O
cancer	O
,	O
estrogen	O
use	O
,	O
time	O
between	O
screenings	O
,	O
no	O
comparison	O
with	O
previous	O
mammograms	O
,	O
and	O
the	O
radiologist	O
'	O
s	O
tendency	O
to	O
call	O
mammograms	O
abnormal	O
.	O

The	O
AtNMT1	B-GENE
expression	O
profile	O
indicated	O
ubiquity	O
in	O
roots	O
,	O
stem	O
,	O
leaves	O
,	O
flowers	O
,	O
and	O
siliques	O
(	O
approximately	O
1	O
.	O
7	O
kb	O
transcript	O
and	O
approximately	O
50	O
kDa	O
immunoreactive	O
polypeptide	O
)	O
but	O
a	O
greater	O
level	O
in	O
the	O
younger	O
tissue	O
,	O
which	O
are	O
developmentally	O
very	O
active	O
.	O

The	O
ossification	O
was	O
located	O
on	O
the	O
left	O
side	O
of	O
C3	O
-	O
4	O
.	O

At	O
a	O
cutoff	O
point	O
for	O
KISA	O
%	O
of	O
100	O
,	O
280	O
of	O
281	O
participants	O
(	O
99	O
.	O
6	O
%	O
)	O
were	O
correctly	O
classified	O
.	O

Following	O
replicate	O
control	O
measurements	O
,	O
test	O
ramps	O
were	O
repeated	O
in	O
the	O
presence	O
of	O
sodium	O
nitroprusside	O
(	O
1	O
microM	O
)	O
and	O
phentolamine	O
(	O
1	O
microM	O
)	O
to	O
eliminate	O
potential	O
smooth	O
muscle	O
and	O
alpha	B-GENE
1	I-GENE
-	I-GENE
adrenoceptor	I-GENE
effects	O
,	O
respectively	O
.	O

Behavioral	O
effects	O
of	O
benzodiazepine	O
ligands	O
in	O
non	O
-	O
dependent	O
,	O
diazepam	O
-	O
dependent	O
and	O
diazepam	O
-	O
withdrawn	O
baboons	O
.	O

This	O
paper	O
reports	O
estimates	O
of	O
the	O
prevalence	O
of	O
mental	O
retardation	O
and	O
associated	O
factors	O
based	O
on	O
a	O
population	O
survey	O
of	O
2	O
-	O
to	O
9	O
-	O
year	O
-	O
old	O
children	O
in	O
Greater	O
Karachi	O
,	O
Pakistan	O
.	O

Thus	O
,	O
an	O
increase	O
in	O
lactate	O
concentration	O
of	O
the	O
magnitude	O
observed	O
during	O
alkali	O
therapy	O
need	O
not	O
indicate	O
a	O
worsening	O
of	O
the	O
metabolic	O
picture	O
in	O
lactic	O
acidosis	O
.	O

Adjusting	O
a	O
steady	O
-	O
state	O
warfarin	O
dose	O
depends	O
on	O
the	O
measured	O
INR	O
values	O
and	O
clinical	O
factors	O
:	O
the	O
dose	O
does	O
not	O
need	O
to	O
be	O
adjusted	O
for	O
a	O
single	O
INR	O
that	O
is	O
slightly	O
out	O
of	O
range	O
,	O
and	O
most	O
changes	O
should	O
alter	O
the	O
total	O
weekly	O
dose	O
by	O
5	O
%	O
to	O
20	O
%	O
.	O

All	O
of	O
this	O
region	O
is	O
part	O
of	O
a	O
prominent	O
CpG	O
island	O
that	O
may	O
be	O
acting	O
as	O
an	O
extended	O
,	O
enhancer	O
-	O
independent	O
promoter	O
.	O

Comparison	O
of	O
Healon	O
and	O
Amvisc	O
.	O

Large	O
volumes	O
of	O
bone	O
marrow	O
may	O
be	O
required	O
for	O
certain	O
types	O
of	O
autologous	O
bone	O
marrow	O
transplants	O
.	O

Further	O
analysis	O
of	O
the	O
CAP59	B-GENE
locus	I-GENE
of	I-GENE
Cryptococcus	I-GENE
neoformans	I-GENE
:	O
structure	O
defined	O
by	O
forced	O
expression	O
and	O
description	O
of	O
a	O
new	O
ribosomal	B-GENE
protein	I-GENE
-	I-GENE
encoding	I-GENE
gene	I-GENE
.	O

We	O
speculate	O
that	O
the	O
enhancing	O
effect	O
of	O
glucose	O
and	O
galactose	O
on	O
fructose	O
absorption	O
may	O
be	O
due	O
to	O
activation	O
of	O
the	O
fructose	B-GENE
carrier	I-GENE
.	O

Virol	O
.	O

The	O
DFGF	B-GENE
-	I-GENE
R	I-GENE
protein	I-GENE
may	O
thus	O
participate	O
in	O
receiving	O
spatial	O
cues	O
that	O
guide	O
tracheal	O
cell	O
outgrowth	O
.	O

The	O
data	O
from	O
animal	O
experiments	O
indicate	O
that	O
the	O
incidence	O
of	O
solid	O
tumors	O
in	O
marrow	O
transplant	O
patients	O
may	O
still	O
rise	O
in	O
the	O
coming	O
decades	O
.	O

Patients	O
adopt	O
new	O
sets	O
based	O
partly	O
on	O
the	O
original	O
topic	O
and	O
partly	O
on	O
their	O
own	O
personal	O
idiosyncratic	O
concerns	O
.	O

The	O
NS	B-GENE
-	I-GENE
2	I-GENE
isoforms	I-GENE
were	O
resolved	O
at	O
a	O
pI	O
value	O
close	O
to	O
5	O
.	O
5	O
as	O
three	O
groups	O
of	O
unevenly	O
phosphorylated	O
polypeptides	O
,	O
each	O
composed	O
of	O
at	O
least	O
two	O
protein	O
species	O
.	O

Prevalence	O
of	O
rheumatic	O
diseases	O
in	O
a	O
rural	O
population	O
in	O
western	O
India	O
:	O
a	O
WHO	O
-	O
ILAR	O
COPCORD	O
Study	O
.	O

A	O
.	O
nidulans	O
transformants	O
secreted	O
high	O
amounts	O
of	O
PGI	B-GENE
and	O
PGII	B-GENE
in	O
comparison	O
to	O
the	O
previously	O
characterized	O
A	O
.	O
niger	O
transformants	O
and	O
a	O
novel	O
polygalacturonase	B-GENE
(	O
PGC	B-GENE
)	O
was	O
produced	O
at	O
high	O
levels	O
by	O
A	O
.	O
nidulans	O
transformed	O
with	O
the	O
subcloned	O
pgaC	B-GENE
gene	I-GENE
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
p50	B-GENE
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

The	O
orf2	O
gene	O
product	O
is	O
a	O
protein	O
of	O
79	O
amino	O
acids	O
with	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
Tat	B-GENE
(	O
transactivator	B-GENE
)	O
proteins	O
of	O
the	O
ungulate	O
lentiviruses	O
.	O

The	O
use	O
of	O
medication	O
is	O
of	O
minor	O
importance	O
in	O
the	O
treatment	O
of	O
flight	O
phobia	O
.	O

Elevated	O
total	O
serum	O
calcium	O
to	O
a	O
level	O
of	O
11	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dl	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
compared	O
to	O
control	O
group	O
)	O
developed	O
in	O
the	O
gentamicin	O
/	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
vitamin	O
D3	O
group	O
on	O
day	O
4	O
,	O
2	O
days	O
prior	O
to	O
pronounced	O
structural	O
damage	O
,	O
and	O
continued	O
to	O
be	O
elevated	O
through	O
day	O
7	O
.	O

Rac2	B-GENE
,	O
a	O
member	O
of	O
the	O
Rho	B-GENE
family	I-GENE
of	O
GTPases	B-GENE
,	O
is	O
highly	O
expressed	O
in	O
myeloid	O
cells	O
and	O
is	O
a	O
regulator	O
of	O
the	O
NADPH	B-GENE
-	I-GENE
oxidase	I-GENE
complex	I-GENE
.	O

In	O
vitro	O
kinase	O
assays	O
on	O
isolated	O
microvilli	O
and	O
microvillar	O
fractions	O
enriched	O
in	O
the	O
putative	O
signal	O
transduction	O
particle	O
showed	O
a	O
high	O
specific	O
activity	O
of	O
tyrosine	B-GENE
kinase	I-GENE
activity	O
compared	O
to	O
that	O
of	O
membranes	O
from	O
EGF	B-GENE
receptor	I-GENE
-	O
overexpressing	O
A431	O
cells	O
maximally	O
activated	O
by	O
EGF	B-GENE
.	O

Effect	O
of	O
infantile	O
undernutrition	O
on	O
adult	O
sucrose	O
solution	O
consumption	O
in	O
the	O
rat	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B-GENE
binding	O
sites	O
,	O
EBS1	B-GENE
and	O
EBS2	B-GENE
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	O
and	O
murine	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
enhancers	O
.	O

KatA	B-GENE
,	O
AhpCF	B-GENE
,	O
heme	O
biosynthesis	O
enzymes	O
,	O
and	O
MrgA	B-GENE
are	O
also	O
induced	O
upon	O
entry	O
into	O
stationary	O
phase	O
under	O
conditions	O
of	O
iron	O
and	O
manganese	O
limitation	O
.	O

Although	O
the	O
Gly252Arg	O
substitution	O
observed	O
in	O
UM	O
:	O
JG5	O
is	O
non	O
-	O
conservative	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
whether	O
it	O
is	O
a	O
mutation	O
or	O
a	O
polymorphism	O
.	O

This	O
region	O
shows	O
46	O
%	O
identity	O
with	O
the	O
calmodulin	B-GENE
-	I-GENE
binding	I-GENE
region	I-GENE
of	O
rat	B-GENE
brain	I-GENE
Ca2	I-GENE
+	I-GENE
/	I-GENE
calmodulin	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
II	I-GENE
and	O
32	O
%	O
identity	O
with	O
the	O
equivalent	O
region	O
of	O
chicken	B-GENE
smooth	I-GENE
muscle	I-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
kinase	I-GENE
.	O

The	O
perforated	O
splint	O
gives	O
superior	O
results	O
by	O
virtue	O
of	O
the	O
fact	O
that	O
it	O
does	O
not	O
require	O
to	O
be	O
removed	O
for	O
purposes	O
of	O
hygiene	O
and	O
can	O
thus	O
produce	O
a	O
satisfactory	O
result	O
even	O
in	O
those	O
patients	O
who	O
fail	O
to	O
grasp	O
the	O
technique	O
of	O
removal	O
and	O
replacement	O
of	O
the	O
splint	O
.	O

It	O
contains	O
31	O
exons	O
and	O
a	O
high	O
proportion	O
of	O
class	O
0	O
introns	O
,	O
alternative	O
splicing	O
of	O
which	O
results	O
in	O
significant	O
levels	O
of	O
variant	O
transcripts	O
that	O
maintain	O
the	O
original	O
open	O
reading	O
frame	O
of	O
MRP	B-GENE
mRNA	I-GENE
.	O

Issues	O
discussed	O
include	O
the	O
validity	O
of	O
the	O
MMPI	O
Mf	O
scale	O
,	O
questions	O
of	O
sample	O
representativeness	O
,	O
whether	O
"	O
straights	O
"	O
can	O
do	O
adequate	O
research	O
on	O
homosexuality	O
,	O
differences	O
in	O
heterosexual	O
and	O
homosexual	O
sexuality	O
,	O
the	O
role	O
of	O
subculture	O
acculturation	O
in	O
homosexual	O
psychological	O
adjustment	O
,	O
and	O
the	O
use	O
of	O
cluster	O
-	O
analysis	O
to	O
generate	O
typologies	O
of	O
homosexualities	O
.	O

A	O
brief	O
discussion	O
for	O
the	O
relationship	O
among	O
these	O
formulas	O
is	O
given	O
.	O

Lamivudine	O
therapy	O
for	O
acute	O
hepatitis	O
B	O
infection	O
following	O
peripheral	O
blood	O
stem	O
cell	O
transplantation	O
.	O

These	O
findings	O
suggest	O
that	O
NMDA	B-GENE
receptor	I-GENE
blockade	O
may	O
ameliorate	O
the	O
dyskinetic	O
complications	O
of	O
long	O
-	O
term	O
levodopa	O
therapy	O
,	O
without	O
diminishing	O
the	O
beneficial	O
effects	O
on	O
parkinsonian	O
signs	O
.	O

Furthermore	O
,	O
the	O
secondary	O
stress	O
responses	O
were	O
more	O
pronounced	O
and	O
the	O
ability	O
to	O
recover	O
from	O
them	O
seemed	O
to	O
be	O
impaired	O
in	O
exposed	O
fish	O
as	O
compared	O
to	O
unexposed	O
fish	O
.	O

The	O
distinct	O
spatial	O
pattern	O
of	O
expression	O
,	O
and	O
unusual	O
amino	O
acid	O
sequence	O
in	O
its	O
DNA	O
binding	O
domain	O
,	O
may	O
indicate	O
a	O
particular	O
role	O
for	O
DTEF	B-GENE
-	I-GENE
1	I-GENE
in	O
cell	O
-	O
specific	O
gene	O
regulation	O
.	O

As	O
usual	O
tests	O
,	O
such	O
as	O
"	O
time	O
"	O
of	O
cephalin	O
are	O
slightly	O
sensible	O
to	O
LMW	O
-	O
Hep	O
,	O
only	O
anti	O
-	O
Xa	O
activity	O
can	O
be	O
used	O
.	O

Usher	O
syndrome	O
1C	O
(	O
USH1C	O
)	O
is	O
a	O
congenital	O
condition	O
manifesting	O
profound	O
hearing	O
loss	O
,	O
the	O
absence	O
of	O
vestibular	O
function	O
,	O
and	O
eventual	O
retinal	O
degeneration	O
.	O

Implantation	O
is	O
contraindicated	O
for	O
severe	O
dysplasia	O
of	O
the	O
cochlea	O
and	O
for	O
the	O
recently	O
described	O
variety	O
of	O
x	O
-	O
linked	O
deafness	O
with	O
deficient	O
bone	O
at	O
the	O
fundus	O
of	O
the	O
internal	O
auditory	O
meatus	O
.	O

Over	O
9	O
kb	O
of	O
DNA	O
sequence	O
was	O
obtained	O
for	O
one	O
clone	O
(	O
A1	O
)	O
with	O
a	O
total	O
IGS	O
length	O
of	O
approximately	O
12	O
.	O
4	O
kb	O
.	O

Scleraxis	B-GENE
overexpression	O
enhanced	O
expression	O
of	O
the	O
aggrecan	B-GENE
gene	I-GENE
,	O
which	O
is	O
not	O
normally	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
osteoblastic	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
exposure	O
to	O
sulphur	O
mustard	O
results	O
in	O
very	O
low	O
androgen	O
levels	O
and	O
hypo	O
-	O
responsiveness	O
to	O
GnRH	B-GENE
in	O
the	O
first	O
five	O
weeks	O
and	O
normalization	O
by	O
the	O
twelfth	O
week	O
after	O
injury	O
.	O

New	O
results	O
of	O
importance	O
for	O
optimization	O
of	O
the	O
postoperative	O
course	O
]	O
Complications	O
after	O
major	O
surgery	O
may	O
be	O
related	O
to	O
factors	O
in	O
the	O
surgical	O
stress	O
response	O
with	O
endocrine	O
-	O
metabolic	O
and	O
inflammatory	O
changes	O
.	O

Four	O
multicannulated	O
Holstein	O
steers	O
(	O
initial	O
BW	O
424	O
+	O
/	O
-	O
16	O
kg	O
)	O
were	O
used	O
in	O
a	O
4	O
x	O
4	O
Latin	O
square	O
to	O
determine	O
the	O
influence	O
of	O
protein	O
supplementation	O
on	O
forage	O
intake	O
,	O
site	O
and	O
extent	O
of	O
digestion	O
,	O
and	O
nutrient	O
flow	O
in	O
steers	O
consuming	O
dormant	O
bluestem	O
-	O
range	O
forage	O
(	O
2	O
.	O
3	O
%	O
CP	O
)	O
.	O

Patients	O
with	O
risk	O
factors	O
were	O
compared	O
with	O
those	O
without	O
risk	O
factors	O
.	O

The	O
dermatoglyphic	O
pattern	O
demostrates	O
a	O
distal	O
triradius	O
and	O
small	O
whorl	O
abnormalities	O
.	O

The	O
term	O
Kartagener	O
syndrome	O
applies	O
to	O
this	O
syndrome	O
when	O
accompanied	O
by	O
infertility	O
and	O
dextrocardia	O
or	O
situs	O
inversus	O
.	O

Finally	O
,	O
we	O
tested	O
whether	O
activation	O
by	O
either	O
of	O
these	O
factors	O
is	O
dependent	O
on	O
components	O
of	O
the	O
SAGA	B-GENE
complex	I-GENE
.	O

Eight	O
of	O
the	O
17	O
seropositive	O
patients	O
failed	O
to	O
develop	O
detectable	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antibody	I-GENE
within	O
three	O
months	O
of	O
the	O
third	O
injection	O
compared	O
with	O
only	O
one	O
of	O
the	O
18	O
seronegative	O
patients	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
antimicrobial	O
of	O
choice	O
for	O
initial	O
prophylactic	O
therapy	O
among	O
asymptomatic	O
pregnant	O
women	O
exposed	O
to	O
Bacillus	O
anthracis	O
is	O
ciprofloxacin	O
,	O
500	O
mg	O
twice	O
a	O
day	O
for	O
60	O
days	O
.	O

Overexpression	O
of	O
eIF4E	B-GENE
transforms	O
cells	O
,	O
and	O
mutations	O
in	O
eIF4E	B-GENE
arrest	O
cells	O
in	O
G	O
,	O
in	O
cdc33	B-GENE
mutants	I-GENE
.	O

Benzyl	O
alcohol	O
administration	O
in	O
neonates	O
.	O

Repression	O
of	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
1	I-GENE
alpha	I-GENE
4	I-GENE
gene	I-GENE
by	O
its	O
gene	O
product	O
(	O
ICP4	B-GENE
)	O
within	O
the	O
context	O
of	O
the	O
viral	O
genome	O
is	O
conditioned	O
by	O
the	O
distance	O
and	O
stereoaxial	O
alignment	O
of	O
the	O
ICP4	B-GENE
DNA	I-GENE
binding	I-GENE
site	I-GENE
relative	O
to	O
the	O
TATA	O
box	O
.	O

As	O
anticipated	O
,	O
both	O
intracellular	O
p54	B-GENE
-	O
SAPKbeta	B-GENE
activation	O
and	O
Bcl	B-GENE
-	I-GENE
2	I-GENE
phosphorylation	O
are	O
blocked	O
by	O
co	O
-	O
transfection	O
with	O
the	O
MAP	B-GENE
kinase	I-GENE
specific	O
phosphatase	O
MKP3	B-GENE
/	O
PYST1	B-GENE
.	O

Relation	O
between	O
circulating	O
immune	O
complexes	O
and	O
serum	B-GENE
ferritin	I-GENE
in	O
hemosiderosis	O
of	O
different	O
etiologies	O

PATIENT	O
(	O
S	O
)	O
:	O
Two	O
hundred	O
thirty	O
-	O
eight	O
patients	O
with	O
RPLs	O
,	O
48	O
patients	O
with	O
recurrent	O
IVF	O
-	O
ET	O
failure	O
and	O
179	O
nonpregnant	O
and	O
120	O
pregnant	O
control	O
group	O
women	O
.	O

Many	O
of	O
the	O
metabolic	O
effects	O
induced	O
by	O
thiazide	O
diuretics	O
,	O
however	O
,	O
can	O
be	O
limited	O
by	O
the	O
use	O
of	O
low	O
doses	O
.	O

Teboroxime	O
is	O
a	O
new	O
boronic	O
acid	O
adduct	O
of	O
technetium	O
dioxime	O
(	O
BATO	O
)	O
compound	O
that	O
demonstrates	O
favorable	O
characteristics	O
in	O
preliminary	O
studies	O
.	O

The	O
total	O
area	O
under	O
the	O
blood	O
glucose	O
curve	O
over	O
the	O
initial	O
value	O
was	O
not	O
altered	O
2	O
h	O
after	O
treatment	O
with	O
SH	O
B	O
209	O
AB	O
or	O
Neogynon	O
.	O

Treatment	O
of	O
excessive	O
bleeding	O
after	O
cardiopulmonary	O
bypass	O
was	O
based	O
on	O
an	O
algorithm	O
using	O
point	O
-	O
of	O
-	O
care	O
testing	O
with	O
whole	O
blood	B-GENE
prothrombin	I-GENE
time	O
,	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
,	O
heparinase	B-GENE
activated	O
clotting	O
time	O
,	O
and	O
platelet	O
count	O
.	O

In	O
all	O
cases	O
,	O
a	O
large	O
fraction	O
of	O
soluble	O
Al	O
became	O
insoluble	O
in	O
the	O
stomach	O
after	O
ingestion	O
.	O

To	O
assess	O
the	O
safety	O
of	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitor	O
enalapril	O
a	O
multicenter	O
,	O
open	O
,	O
randomized	O
,	O
prazosin	O
-	O
controlled	O
trial	O
was	O
designed	O
comparing	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	O
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O

Glucose	O
may	O
reduce	O
slightly	O
the	O
pool	O
of	O
amino	O
nitrogen	O
available	O
for	O
albumin	B-GENE
and	O
urea	O
synthesis	O
by	O
diverting	O
some	O
of	O
the	O
infused	O
amino	O
acids	O
from	O
protein	O
synthesis	O
by	O
the	O
liver	O
to	O
muscle	O
.	O

BACKGROUND	O
.	O

We	O
have	O
previously	O
reported	O
the	O
first	O
isolation	O
of	O
a	O
c	B-GENE
-	I-GENE
myc	I-GENE
-	I-GENE
null	I-GENE
cell	O
line	O
.	O

Results	O
demonstrated	O
that	O
for	O
both	O
S	O
.	O
europaea	O
and	O
A	O
.	O
prostrata	O
,	O
the	O
total	O
number	O
of	O
seeds	O
that	O
germinated	O
decreased	O
throughout	O
the	O
growing	O
season	O
.	O

A	O
nationwide	O
record	O
linkage	O
of	O
the	O
Finnish	O
Twin	O
Cohort	O
Study	O
(	O
FTCS	O
)	O
with	O
the	O
Hospital	O
Discharge	O
Registry	O
and	O
the	O
Registry	O
of	O
Rights	O
for	O
Free	O
medication	O
is	O
presented	O
.	O

Considering	O
these	O
two	O
facts	O
together	O
,	O
we	O
propose	O
that	O
vasectomy	O
may	O
lead	O
to	O
decrease	O
in	O
the	O
incidence	O
of	O
prostatic	O
tumors	O
-	O
a	O
disease	O
that	O
claims	O
nearly	O
22	O
,	O
000	O
lives	O
each	O
year	O
in	O
the	O
United	O
States	O
alone	O
.	O

Antibodies	O
specific	O
to	O
the	O
different	O
members	O
of	O
the	O
Jun	B-GENE
and	O
Fos	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
show	O
that	O
,	O
in	O
gel	O
retardation	O
assays	O
,	O
a	O
Jun	B-GENE
-	I-GENE
like	I-GENE
factor	I-GENE
is	O
a	O
component	O
of	O
the	O
H3	B-GENE
.	I-GENE
2	I-GENE
specific	I-GENE
complex	I-GENE
.	O

She	O
had	O
been	O
diagnosed	O
with	O
severe	O
aplastic	O
anemia	O
1	O
year	O
previously	O
and	O
,	O
while	O
hospitalized	O
,	O
had	O
received	O
methyl	O
prednisolone	O
pulse	O
therapy	O
,	O
which	O
was	O
not	O
successful	O
.	O

The	O
recombinant	B-GENE
L	I-GENE
/	I-GENE
F	I-GENE
-	I-GENE
transferase	I-GENE
is	O
as	O
active	O
as	O
the	O
previously	O
purified	O
wild	O
type	O
enzyme	O
and	O
contains	O
no	O
detectable	O
RNA	O
component	O
.	O

Cord	O
formation	O
in	O
BACTEC	O
7H12	O
medium	O
for	O
rapid	O
,	O
presumptive	O
identification	O
of	O
Mycobacterium	O
tuberculosis	O
complex	O
.	O

Moreover	O
,	O
site	O
-	O
specific	O
integration	O
of	O
the	O
ITR	O
-	O
flanked	O
DNA	O
was	O
also	O
detected	O
by	O
PCR	O
amplification	O
of	O
the	O
ITR	B-GENE
-	I-GENE
aavs1	I-GENE
junction	I-GENE
in	O
transduced	O
human	O
fibroblasts	O
.	O

Oct	B-GENE
-	I-GENE
1	I-GENE
is	O
a	O
ubiquitously	O
expressed	O
regulatory	O
gene	O
of	O
the	O
POU	B-GENE
domain	I-GENE
family	I-GENE
.	O

In	O
both	O
study	O
stages	O
.	O
post	O
-	O
exposure	O
treatment	O
consisted	O
of	O
five	O
injections	O
of	O
vaccine	O
[	O
(	O
D	O
)	O
ays	O
0	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
28	O
]	O
,	O
together	O
with	O
a	O
dose	O
of	O
rabies	B-GENE
immunoglobulin	I-GENE
(	O
RIG	B-GENE
)	O
of	O
equine	O
or	O
human	O
origin	O
on	O
D0	O
.	O

(	O
3	O
)	O
With	O
the	O
exception	O
of	O
the	O
anteroposterior	O
direction	O
of	O
layers	O
II	O
-	O
-	O
III	O
and	O
the	O
mediolateral	O
direction	O
of	O
layer	O
IV	O
,	O
the	O
vertical	O
conductivity	O
of	O
the	O
cortex	O
was	O
always	O
greater	O
than	O
either	O
of	O
the	O
horizontal	O
conductivities	O
.	O

Our	O
study	O
investigated	O
the	O
hypothesis	O
that	O
the	O
combination	O
of	O
a	O
high	O
NaCl	O
diet	O
and	O
social	O
isolation	O
stress	O
would	O
increase	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
endogenous	O
sodium	O
pump	O
ligands	O
(	O
SPL	O
)	O
,	O
ouabainlike	O
compound	O
(	O
OLC	O
)	O
,	O
and	O
marinobufagenin	O
(	O
MBG	O
)	O
.	O

The	O
relationship	O
between	O
polymorphonuclear	O
granulocytes	O
and	O
cartilage	O
destruction	O
in	O
rheumatoid	O
arthritis	O
.	O

It	O
is	O
suggested	O
that	O
the	O
loss	O
of	O
weight	O
,	O
the	O
decrease	O
in	O
food	O
intake	O
and	O
the	O
increase	O
in	O
brain	O
MOPEG	O
-	O
SO4	O
induced	O
by	O
cyanamide	O
reflect	O
possible	O
anorectic	O
properties	O
of	O
the	O
drug	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
two	O
patients	O
(	O
30	O
%	O
)	O
showed	O
ST	O
-	O
segment	O
depression	O
during	O
AEM	O
and	O
34	O
(	O
49	O
%	O
)	O
on	O
ExT	O
.	O

The	O
virus	O
must	O
progress	O
past	O
the	O
immediate	O
-	O
early	O
phase	O
and	O
express	O
an	O
early	B-GENE
gene	I-GENE
product	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
for	O
activation	O
of	O
cyclin	B-GENE
E	I-GENE
expression	O
.	O

In	O
CYP7A1	B-GENE
transgenic	O
mice	O
,	O
livers	O
contained	O
approximately	O
3	O
-	O
fold	O
more	O
sterol	B-GENE
response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
2	I-GENE
mRNA	I-GENE
.	O

Adenocarcinoma	O
and	O
large	O
cell	O
carcinoma	O
have	O
a	O
worse	O
prognosis	O
than	O
squamous	O
cell	O
carcinoma	O
in	O
the	O
T1N1	O
and	O
T2N1	O
subsets	O
.	O

In	O
group	O
I	O
during	O
the	O
pain	O
free	O
period	O
26	O
of	O
81	O
patients	O
had	O
positive	O
thallium	O
-	O
201	O
scans	O
,	O
whereas	O
20	O
patients	O
had	O
an	O
abnormal	O
ECG	O
at	O
that	O
time	O
;	O
during	O
angina	O
18	O
patients	O
had	O
transient	O
ECG	O
changes	O
.	O

The	O
prototype	O
now	O
structures	O
oncology	O
-	O
related	O
information	O
available	O
on	O
the	O
Internet	O
and	O
also	O
places	O
resources	O
maintained	O
locally	O
at	O
users	O
'	O
disposal	O
.	O

Binding	O
of	O
the	O
TorR	B-GENE
regulator	I-GENE
to	O
cis	O
-	O
acting	O
direct	O
repeats	O
activates	O
tor	B-GENE
operon	I-GENE
expression	O
.	O

For	O
the	O
most	O
part	O
,	O
only	O
aerobic	O
microbial	O
degradation	O
systems	O
have	O
been	O
reported	O
so	O
far	O
.	O

Asymptomatic	O
ischaemia	O
during	O
daily	O
life	O
in	O
stable	O
coronary	O
artery	O
disease	O
:	O
relevant	O
or	O
redundant	O
?	O

This	O
is	O
a	O
consensus	O
casein	B-GENE
kinase	I-GENE
II	I-GENE
(	O
CKII	B-GENE
)	O
site	O
and	O
,	O
using	O
purified	O
wild	O
-	O
type	O
and	O
mutant	O
proteins	O
,	O
we	O
show	O
that	O
it	O
is	O
the	O
main	O
CKII	B-GENE
site	I-GENE
in	O
the	O
body	O
of	O
the	O
N	O
-	O
terminal	O
complex	O
-	O
forming	O
region	O
.	O

In	O
contrast	O
to	O
Phase	O
III	O
,	O
which	O
has	O
a	O
single	O
study	O
design	O
-	O
-	O
the	O
controlled	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
-	O
-	O
Phase	O
IV	O
requires	O
different	O
designs	O
for	O
each	O
of	O
the	O
many	O
different	O
questions	O
.	O

Treatment	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
to	O
induce	O
expression	O
of	O
Cre	B-GENE
resulted	O
in	O
complete	O
disruption	O
of	O
the	O
Arnt	B-GENE
gene	I-GENE
and	O
loss	O
of	O
ARNT	B-GENE
messenger	I-GENE
RNA	I-GENE
(	O
mRNA	O
)	O
expression	O
in	O
liver	O
.	O

Physical	O
map	O
of	O
the	O
genome	O
of	O
sonchus	O
yellow	O
net	O
virus	O
,	O
a	O
plant	O
rhabdovirus	O
with	O
six	O
genes	O
and	O
conserved	O
gene	O
junction	O
sequences	O
.	O

Tubular	O
dysfunction	O
in	O
renal	O
lithiasis	O
:	O
cause	O
or	O
consequence	O
?	O
]	O
To	O
investigate	O
whether	O
overall	O
tubular	O
dysfunction	O
is	O
encountered	O
in	O
a	O
particular	O
subgroup	O
of	O
patients	O
with	O
urolithiasis	O
,	O
the	O
following	O
parameters	O
of	O
renal	O
tubular	O
function	O
have	O
been	O
measured	O
in	O
fasting	O
morning	O
urine	O
in	O
124	O
male	O
stone	O
formers	O
:	O
excretion	O
of	O
lysozyme	B-GENE
and	O
gamma	B-GENE
-	I-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
(	O
gamma	B-GENE
-	I-GENE
GT	I-GENE
)	O
,	O
fractional	O
excretion	O
(	O
FE	O
)	O
or	O
glucose	O
,	O
insulin	B-GENE
,	O
bicarbonate	O
after	O
an	O
alkali	O
load	O
,	O
and	O
theoretical	O
phosphate	O
threshold	O
(	O
TmP	O
/	O
GFR	O
)	O
.	O

Interaction	O
between	O
the	O
tobacco	O
DNA	O
-	O
binding	O
activity	O
CBF	B-GENE
and	O
the	O
cyt	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
element	I-GENE
of	O
the	O
Agrobacterium	O
tumefaciens	O
T	O
-	O
DNA	O
gene	O
T	B-GENE
-	I-GENE
CYT	I-GENE
correlates	O
with	O
cyt	B-GENE
-	I-GENE
1	I-GENE
directed	O
gene	O
expression	O
in	O
multiple	O
tobacco	O
tissue	O
types	O
.	O

As	O
expected	O
,	O
the	O
QOLS	O
-	O
N	O
had	O
a	O
lower	O
correlation	O
with	O
physical	O
health	O
(	O
r	O
=	O
0	O
.	O
24	O
,	O
p	O
<	O
0	O
.	O
000	O
)	O
and	O
self	O
-	O
reported	O
symptoms	O
(	O
r	O
=	O
-	O
0	O
.	O
20	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
a	O
higher	O
correlation	O
with	O
mental	O
health	O
(	O
r	O
=	O
0	O
.	O
52	O
,	O
p	O
<	O
0	O
.	O
000	O
)	O
.	O

The	O
N1	O
-	O
P2	O
amplitudes	O
of	O
the	O
AEP	O
decreased	O
with	O
increasing	O
strength	O
of	O
muscular	O
innervation	O
.	O

SN	O
-	O
38	O
rebound	O
concentrations	O
were	O
observed	O
in	O
many	O
courses	O
at	O
about	O
0	O
.	O
5	O
to	O
1	O
hour	O
following	O
the	O
end	O
of	O
the	O
i	O
.	O
v	O
.	O
infusion	O
,	O
which	O
is	O
suggestive	O
of	O
enterohepatic	O
recycling	O
.	O

Sequence	O
analysis	O
of	O
AEBP2	B-GENE
cDNA	I-GENE
revealed	O
that	O
it	O
encodes	O
a	O
protein	O
containing	O
three	O
Gli	B-GENE
-	O
Kruppel	B-GENE
(	O
Cys2	O
-	O
His2	O
)	O
-	O
type	O
zinc	O
fingers	O
.	O

In	O
the	O
case	O
of	O
the	O
pT181	O
plasmid	O
,	O
inactivation	O
of	O
the	O
initiator	B-GENE
RepC	I-GENE
protein	I-GENE
occurs	O
by	O
the	O
attachment	O
of	O
an	O
oligonucleotide	O
to	O
its	O
active	O
tyrosine	O
residue	O
.	O

Xanthoepocin	O
,	O
a	O
new	O
antibiotic	O
from	O
Penicillium	O
simplicissimum	O
IFO5762	O
.	O

Extracellular	B-GENE
regulated	I-GENE
kinases	I-GENE
(	I-GENE
ERK	I-GENE
)	I-GENE
1	I-GENE
and	O
ERK2	B-GENE
are	O
authentic	O
substrates	O
for	O
the	O
dual	B-GENE
-	I-GENE
specificity	I-GENE
protein	I-GENE
-	I-GENE
tyrosine	I-GENE
phosphatase	I-GENE
VHR	I-GENE
.	O

Leukocytoclasic	O
vasculitis	O
during	O
treatment	O
with	O
low	O
-	O
dose	O
captopril	O

H	O
.	O

Truncations	O
from	O
Hip	B-GENE
'	O
s	O
N	O
terminus	O
resulted	O
in	O
an	O
apparent	O
loss	O
of	O
Hip	B-GENE
homo	O
-	O
oligomerization	O
,	O
but	O
these	O
mutants	O
retained	O
association	O
with	O
hsp70	B-GENE
and	O
were	O
recovered	O
in	O
receptor	O
complexes	O
.	O

The	O
biological	O
basis	O
for	O
the	O
changes	O
in	O
CNAPs	O
produced	O
by	O
CS2	O
is	O
under	O
investigation	O
.	O

A	O
very	O
large	O
PC	O
LAN	O
as	O
the	O
basis	O
for	O
a	O
hospital	O
information	O
system	O
.	O

This	O
was	O
tragically	O
highlighted	O
by	O
the	O
death	O
of	O
a	O
17	O
year	O
old	O
dental	O
nurse	O
after	O
taking	O
a	O
single	O
1	O
g	O
tablet	O
of	O
sodium	O
nitrite	O
.	O

The	O
human	O
protein	O
is	O
encoded	O
by	O
a	O
900	O
-	O
base	O
pair	O
-	O
long	O
mRNA	O
that	O
is	O
expressed	O
in	O
the	O
glandular	O
epithelial	O
cells	O
of	O
the	O
endometrium	O
in	O
a	O
cyclic	O
manner	O
;	O
in	O
addition	O
,	O
it	O
is	O
found	O
in	O
the	O
mucosal	O
epithelial	O
cells	O
of	O
the	O
fallopian	O
tubes	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
renal	O
cell	O
carcinoma	O
who	O
experienced	O
ventricular	O
tachycardia	O
while	O
undergoing	O
treatment	O
with	O
high	O
-	O
dose	O
bolus	O
IL	B-GENE
-	I-GENE
2	I-GENE
.	O

Four	O
antifungal	O
agents	O
were	O
compared	O
:	O
amphotericin	O
B	O
,	O
flucytosine	O
,	O
miconazole	O
,	O
and	O
ketoconazole	O
.	O

The	O
regulatory	O
genes	O
cnrYXH	B-GENE
have	O
been	O
cloned	O
,	O
overexpressed	O
,	O
and	O
purified	O
in	O
Escherichia	O
coli	O
.	O

Examination	O
of	O
the	O
Coomassie	O
-	O
stained	O
gels	O
revealed	O
that	O
the	O
capsid	O
-	O
like	O
particles	O
composed	O
of	O
the	O
N11	B-GENE
-	I-GENE
VP1	I-GENE
protein	O
did	O
not	O
contain	O
any	O
host	O
-	O
derived	O
histones	B-GENE
.	O

Conversion	O
of	O
an	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
into	O
a	O
GABP	B-GENE
binding	O
site	O
is	O
likely	O
to	O
have	O
occurred	O
also	O
during	O
the	O
worldwide	O
spread	O
of	O
HIV	O
-	O
1	O
,	O
as	O
we	O
noticed	O
the	O
same	O
LTR	O
modification	O
in	O
subtype	O
E	O
isolates	O
from	O
Thailand	O
.	O

Protein	O
binding	O
to	O
UAS1MLS1	B-GENE
was	O
observed	O
with	O
extracts	O
from	O
derepressed	O
but	O
not	O
from	O
repressed	O
cells	O
,	O
and	O
could	O
be	O
competed	O
for	O
by	O
an	O
excess	O
of	O
the	O
unlabelled	O
CSRE	O
(	O
ICL1	B-GENE
)	O
sequence	O
.	O

We	O
then	O
isolated	O
the	O
full	O
-	O
length	O
coding	O
region	O
of	O
the	O
human	B-GENE
BACH1	I-GENE
gene	I-GENE
using	O
expressed	O
sequence	O
tags	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

Authors	O
present	O
the	O
anatomical	O
variations	O
of	O
the	O
course	O
of	O
the	O
inferior	O
mesenteric	O
artery	O
and	O
its	O
branches	O
in	O
62	O
human	O
fetus	O
.	O

The	O
7	B-GENE
.	I-GENE
2	I-GENE
kb	I-GENE
EcoRI	I-GENE
fragment	I-GENE
of	I-GENE
AfMNPV	I-GENE
was	O
cloned	O
and	O
the	O
nucleotide	O
sequences	O
of	O
the	O
polyhedrin	B-GENE
coding	O
region	O
and	O
its	O
flanking	O
regions	O
were	O
determined	O
.	O

1	O
.	O

The	O
increments	O
in	O
median	O
plasma	B-GENE
secretin	I-GENE
concentration	O
were	O
1	O
.	O
6	O
,	O
3	O
.	O
0	O
,	O
and	O
6	O
.	O
4	O
pmol	O
x	O
1	O
(	O
-	O
1	O
)	O
after	O
secretin	B-GENE
,	O
125	O
,	O
250	O
and	O
500	O
fmol	O
x	O
kg	O
-	O
1	O
,	O
and	O
the	O
corresponding	O
15	O
-	O
min	O
bicarbonate	O
output	O
283	O
,	O
442	O
,	O
and	O
1435	O
micromol	O
,	O
respectively	O
.	O

The	O
resulting	O
threshold	O
elevation	O
curves	O
fell	O
into	O
a	O
small	O
number	O
of	O
distinct	O
groups	O
,	O
suggesting	O
the	O
existence	O
of	O
discrete	O
spatial	O
frequency	O
mechanisms	O
in	O
human	O
central	O
vision	O
.	O

Because	O
c	B-GENE
-	I-GENE
myb	I-GENE
encodes	O
a	O
transcriptional	O
activator	O
that	O
functions	O
via	O
DNA	O
binding	O
,	O
it	O
is	O
likely	O
that	O
c	B-GENE
-	I-GENE
myb	I-GENE
exerts	O
its	O
biological	O
activity	O
by	O
regulating	O
the	O
transcription	O
of	O
genes	O
required	O
for	O
DNA	O
synthesis	O
and	O
cell	O
cycle	O
progression	O
.	O

The	O
rest	O
of	O
the	O
3	O
'	O
untranslated	O
sequences	O
were	O
common	O
to	O
both	O
cDNA	O
clones	O
.	O

Coexpression	O
of	O
c	B-GENE
-	I-GENE
Rel	I-GENE
in	O
combination	O
with	O
ATF	B-GENE
-	I-GENE
1	I-GENE
,	O
CREB2	B-GENE
,	O
or	O
ATF	B-GENE
-	I-GENE
1	I-GENE
/	O
CREB2	B-GENE
leads	O
to	O
synergistic	O
transactivation	O
of	O
a	O
CD28RE	B-GENE
-	I-GENE
TRE	I-GENE
reporter	I-GENE
plasmid	O
in	O
quiescent	O
Jurkat	O
T	O
-	O
cells	O
.	O

Conventional	O
toxicological	O
considerations	O
suggest	O
that	O
the	O
adverse	O
health	O
effects	O
of	O
any	O
necessary	O
increase	O
in	O
coal	O
combustion	O
effluents	O
would	O
be	O
greatest	O
per	O
unit	O
of	O
coal	O
in	O
those	O
areas	O
which	O
are	O
most	O
heavily	O
populated	O
and	O
have	O
the	O
highest	O
preexisting	O
levels	O
of	O
the	O
gas	O
-	O
aerosol	O
complex	O
.	O

The	O
genes	O
on	O
each	O
chromosome	O
involved	O
in	O
this	O
translocation	O
have	O
been	O
identified	O
as	O
the	O
transcription	O
factor	O
-	O
encoding	O
genes	O
PAX3	B-GENE
and	O
FKHR	B-GENE
.	O

A	O
search	O
was	O
conducted	O
for	O
suppressors	O
of	O
the	O
inositol	O
auxotrophic	O
phenotype	O
of	O
the	O
ino4	B-GENE
-	I-GENE
8	I-GENE
mutant	I-GENE
of	O
yeast	O
.	O

Anesthesia	O
was	O
induced	O
by	O
droperidol	O
0	O
.	O
2	O
mg	O
.	O
kg	O
-	O
1	O
,	O
fentanyl	O
50	O
micrograms	O
,	O
thiamylal	O
150	O
-	O
250	O
mg	O
,	O
and	O
succinylcholine	O
1	O
mg	O
.	O
kg	O
-	O
1	O
,	O
and	O
maintained	O
with	O
nitrous	O
oxide	O
and	O
O2	O
(	O
67	O
:	O
33	O
)	O
supplemented	O
with	O
repeated	O
i	O
.	O
v	O
.	O
doses	O
of	O
fentanyl	O
(	O
within	O
15	O
micrograms	O
.	O
kg	O
-	O
1	O
)	O
.	O

Complexities	O
in	O
the	O
host	O
-	O
pathogen	O
interactions	O
during	O
actual	O
infection	O
with	O
Gram	O
-	O
negative	O
bacteria	O
may	O
account	O
for	O
the	O
difficulties	O
in	O
demonstrating	O
this	O
phenomena	O
in	O
vivo	O
.	O

This	O
novel	O
TRPC7	B-GENE
gene	I-GENE
could	O
be	O
a	O
candidate	O
gene	O
for	O
genetic	O
disorders	O
such	O
as	O
bipolar	O
affective	O
disorder	O
,	O
nonsyndromic	O
hereditary	O
deafness	O
,	O
Knobloch	O
syndrome	O
,	O
and	O
holoprosencephaly	O
,	O
which	O
were	O
mapped	O
to	O
this	O
region	O
.	O

Paradoxically	O
,	O
loop	O
3i	O
from	O
the	O
M1Ach	B-GENE
-	I-GENE
muscarinic	I-GENE
receptor	I-GENE
also	O
maximally	O
inhibited	O
GnRH	B-GENE
agonist	O
-	O
stimulated	O
cAMP	O
accumulation	O
and	O
PRL	B-GENE
release	O
by	O
40	O
%	O
(	O
both	O
effects	O
mediated	O
through	O
activation	O
of	O
the	O
Gs	B-GENE
protein	I-GENE
)	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
presented	O
an	O
unusually	O
large	O
mucoid	O
cyst	O
measuring	O
38	O
x	O
25	O
mm	O
in	O
an	O
uncommon	O
localization	O
,	O
the	O
right	O
maxillary	O
.	O

Acoustic	O
-	O
property	O
measurements	O
of	O
the	O
oxide	O
superconductor	O
BaPb1	O
-	O
xBixO3	O
by	O
the	O
sphere	O
-	O
resonance	O
method	O
.	O

In	O
7	O
men	O
and	O
1	O
woman	O
who	O
died	O
suddenly	O
the	O
functionally	O
important	O
areas	O
of	O
myocardium	O
in	O
the	O
sino	O
-	O
auricular	O
area	O
and	O
the	O
subendocardial	O
layers	O
of	O
left	O
ventricle	O
were	O
obtained	O
by	O
necropsy	O
no	O
more	O
than	O
3	O
h	O
after	O
death	O
,	O
and	O
then	O
prepared	O
for	O
study	O
by	O
electron	O
microscopy	O
.	O

IGF	B-GENE
-	I-GENE
I	I-GENE
levels	O
were	O
measured	O
in	O
the	O
CSF	O
of	O
11	O
children	O
with	O
autism	O
(	O
4	O
females	O
,	O
7	O
males	O
;	O
mean	O
age	O
3	O
.	O
8	O
years	O
,	O
SD	O
1	O
.	O
1	O
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
method	O
and	O
compared	O
with	O
levels	O
in	O
11	O
control	O
participants	O
(	O
6	O
females	O
,	O
5	O
males	O
;	O
mean	O
age	O
3	O
.	O
8	O
years	O
)	O
.	O

In	O
a	O
subsequent	O
phase	O
-	O
II	O
clinical	O
trial	O
safety	O
and	O
efficacy	O
of	O
transrectal	O
HIFU	O
as	O
a	O
novel	O
minimally	O
invasive	O
treatment	O
modality	O
for	O
patients	O
with	O
symptomatic	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
;	O
n	O
=	O
102	O
)	O
was	O
determined	O
.	O

Three	O
high	O
-	O
amylose	O
rice	O
varieties	O
,	O
IR42	O
,	O
IR36	O
,	O
and	O
IR62	O
,	O
with	O
similar	O
chemical	O
composition	O
including	O
amylose	O
content	O
(	O
26	O
.	O
7	O
-	O
27	O
.	O
0	O
%	O
)	O
,	O
were	O
cooked	O
under	O
the	O
same	O
conditions	O
and	O
tested	O
for	O
in	O
vitro	O
digestibility	O
as	O
well	O
as	O
blood	O
glucose	O
and	O
insulin	B-GENE
responses	O
in	O
healthy	O
human	O
volunteers	O
.	O

Slowly	O
adapting	O
type	O
I	O
mechanoreceptor	O
discharge	O
as	O
a	O
function	O
of	O
dynamic	O
force	O
versus	O
dynamic	O
displacement	O
of	O
glabrous	O
skin	O
of	O
raccoon	O
and	O
squirrel	O
monkey	O
hand	O
.	O

Using	O
beta	B-GENE
1	I-GENE
-	I-GENE
AR	I-GENE
-	O
luciferase	B-GENE
reporter	O
recombinants	O
,	O
we	O
have	O
previously	O
determined	O
that	O
important	O
beta	B-GENE
1	I-GENE
-	I-GENE
AR	I-GENE
genetic	O
elements	O
controlling	O
expression	O
within	O
the	O
C6	O
glioma	O
cell	O
line	O
are	O
contained	O
within	O
the	O
region	O
-	O
396	O
to	O
-	O
299	O
,	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O

FACS	O
analysis	O
demonstrated	O
that	O
MCs	O
had	O
reached	O
middle	O
to	O
late	O
G1	O
phase	O
of	O
cell	O
cycle	O
progression	O
at	O
this	O
timepoint	O
.	O

Our	O
case	O
,	O
however	O
,	O
had	O
no	O
histologic	O
evidence	O
of	O
malignancy	O
,	O
no	O
serum	B-GENE
alpha	I-GENE
fetoprotein	I-GENE
at	O
7	O
months	O
of	O
age	O
,	O
and	O
no	O
recurrence	O
at	O
1	O
years	O
.	O

Analysis	O
of	O
tobacco	O
mRNA	O
using	O
the	O
ACBF	B-GENE
cDNA	I-GENE
as	O
probe	O
showed	O
that	O
while	O
ACBF	B-GENE
mRNA	I-GENE
was	O
present	O
in	O
all	O
tissues	O
examined	O
,	O
the	O
highest	O
transcript	O
accumulation	O
occurred	O
in	O
stem	O
tissues	O
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA	B-GENE
-	I-GENE
4	I-GENE
and	O
PMA	O
/	O
A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL	B-GENE
-	I-GENE
5	I-GENE
promoter	I-GENE
activation	O
.	O

Here	O
we	O
show	O
that	O
expression	O
of	O
KRAB	B-GENE
domain	I-GENE
suppresses	O
in	O
vivo	O
the	O
activating	O
function	O
of	O
various	O
defined	O
activating	B-GENE
transcription	I-GENE
factors	I-GENE
,	O
and	O
we	O
demonstrate	O
that	O
the	O
KRAB	B-GENE
domain	I-GENE
specifically	O
silences	O
the	O
activity	O
of	O
promoters	O
whose	O
initiation	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
TATA	O
box	O
.	O

Adult	O
-	O
onset	O
parkinsonism	O
has	O
appeared	O
in	O
several	O
previously	O
unaffected	O
members	O
in	O
families	O
with	O
DRD	O
suggesting	O
that	O
this	O
may	O
be	O
an	O
additional	O
phenotypical	O
expression	O
of	O
the	O
disease	O
.	O

We	O
tested	O
the	O
effects	O
of	O
antifungal	O
drugs	O
on	O
adherence	O
of	O
Candida	O
albicans	O
in	O
vitro	O
.	O

The	O
signs	O
of	O
enterocolitis	O
,	O
pathological	O
microbial	O
flora	O
in	O
the	O
stool	O
and	O
changes	O
in	O
the	O
colon	O
mucosa	O
were	O
absent	O
.	O

These	O
results	O
support	O
an	O
in	O
vivo	O
interaction	O
between	O
Nck	B-GENE
and	O
CKI	B-GENE
-	I-GENE
gamma2	I-GENE
and	O
suggest	O
that	O
CKI	B-GENE
-	I-GENE
gamma2	I-GENE
could	O
be	O
involved	O
in	O
signaling	O
pathways	O
downstream	O
of	O
RTKs	B-GENE
.	O

Correlation	O
of	O
nitrogen	O
,	O
carbohydrate	O
and	O
lipid	O
metabolic	O
indices	O
in	O
rats	O
cooled	O
under	O
conditions	O
of	O
an	O
altered	O
gaseous	O
environment	O

Reactivation	O
of	O
hepatitis	O
B	O
virus	O
replication	O
is	O
a	O
rare	O
event	O
during	O
the	O
natural	O
history	O
of	O
chronic	O
hepatitis	O
B	O
.	O

A	O
minimal	O
region	O
which	O
stimulates	O
origin	O
function	O
mapped	O
to	O
50	O
amino	O
acids	O
within	O
the	O
C	O
-	O
terminus	O
of	O
Abf1p	B-GENE
.	O

Cutaneous	O
melanoma	O
and	O
bilateral	O
retinoblastoma	O
.	O

Treatment	O
of	O
JEA2	O
cells	O
with	O
interleukin	B-GENE
(	I-GENE
IL	I-GENE
)	I-GENE
-	I-GENE
7	I-GENE
induces	O
CBLB	B-GENE
phosphorylation	O
as	O
well	O
.	O

Phosphorylation	O
by	O
Cdc28	B-GENE
activates	O
the	O
Cdc20	B-GENE
-	O
dependent	O
activity	O
of	O
the	O
anaphase	O
-	O
promoting	O
complex	O
.	O

METHOD	O
:	O
After	O
eligibility	O
,	O
patients	O
were	O
randomly	O
allocated	O
in	O
one	O
of	O
the	O
following	O
groups	O
:	O
M	O
=	O
methylprednisolone	O
30	O
mg	O
.	O
kg	O
-	O
1	O
over	O
1	O
hour	O
,	O
followed	O
by	O
5	O
.	O
4	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
for	O
23	O
hours	O
,	O
N	O
=	O
nimodipine	O
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
over	O
2	O
hours	O
followed	O
by	O
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
for	O
7	O
days	O
,	O
MN	O
or	O
P	O
.	O

The	O
amount	O
of	O
overlap	O
in	O
VFI	O
,	O
EF	O
,	O
and	O
RVF	O
values	O
among	O
the	O
clinical	O
groups	O
was	O
considerable	O
.	O

After	O
5	O
,	O
850	O
C14	O
BP	O
,	O
the	O
decrease	O
in	O
Acer	O
stands	O
could	O
be	O
attributed	O
to	O
fire	O
as	O
suggested	O
by	O
the	O
strong	O
increase	O
in	O
Betula	O
and	O
by	O
the	O
delayed	O
expansion	O
of	O
Pinus	O
cembra	O
.	O

Assays	O
of	O
APRE	O
-	O
luciferase	B-GENE
reporter	O
plasmids	O
transfected	O
into	O
HepG2	O
cells	O
show	O
that	O
a	O
mutated	O
APRE	O
that	O
binds	O
only	O
BPi	B-GENE
functions	O
as	O
an	O
IL	B-GENE
-	I-GENE
1	I-GENE
alpha	I-GENE
inducible	O
enhancer	O
,	O
whereas	O
a	O
mutated	O
APRE	O
that	O
binds	O
only	O
BPc	B-GENE
does	O
not	O
.	O

RNA	O
unwinding	O
in	O
U4	B-GENE
/	O
U6	B-GENE
snRNPs	O
requires	O
ATP	O
hydrolysis	O
and	O
the	O
DEIH	O
-	O
box	O
splicing	O
factor	O
Brr2	B-GENE
.	O

Several	O
sequences	O
resembling	O
binding	O
sites	O
for	O
liver	O
-	O
and	O
fat	O
body	O
-	O
specific	O
transcription	O
factors	O
were	O
identified	O
within	O
1	O
kb	O
upstream	O
and	O
downstream	O
of	O
the	O
gene	O
.	O

Northern	O
blot	O
analysis	O
linked	O
Plk	B-GENE
expression	O
to	O
the	O
proliferative	O
activity	O
of	O
cells	O
and	O
tissues	O
.	O

It	O
also	O
showed	O
which	O
amino	O
acid	O
residues	O
would	O
contact	O
an	O
extended	O
TATA	O
box	O
with	O
a	O
B	B-GENE
recognition	I-GENE
element	I-GENE
,	O
and	O
evolutionary	O
conservation	O
of	O
the	O
TBP	B-GENE
-	O
TFB	B-GENE
-	O
DNA	O
complex	O
orientation	O
between	O
two	O
archaeal	O
organisms	O
with	O
widely	O
different	O
optimal	O
temperature	O
for	O
growth	O
(	O
37	O
and	O
100	O
degrees	O
C	O
)	O
.	O

Studies	O
with	O
and	O
without	O
attenuating	O
media	O
were	O
performed	O
,	O
and	O
myocardium	O
-	O
to	O
-	O
defect	O
count	O
ratios	O
and	O
defect	O
sizes	O
from	O
dual	O
-	O
isotope	O
SPECT	O
images	O
were	O
compared	O
to	O
myocardium	O
-	O
to	O
-	O
defect	O
count	O
ratios	O
and	O
defect	O
sizes	O
from	O
single	O
-	O
isotope	O
(	O
201Tl	O
and	O
99mTc	O
)	O
SPECT	O
images	O
.	O

Comparison	O
of	O
this	O
gene	O
with	O
the	O
available	O
databases	O
reveals	O
very	O
significant	O
homology	O
to	O
the	O
ETS	B-GENE
factor	I-GENE
PE	B-GENE
-	I-GENE
1	I-GENE
and	O
probable	O
near	O
-	O
identity	O
with	O
the	O
recently	O
cloned	O
factor	O
ERF	B-GENE
.	O

Patients	O
with	O
Eales	O
'	O
disease	O
,	O
chorioretinitis	O
,	O
central	O
serous	O
retinopathy	O
,	O
or	O
malignant	O
choroidal	O
melanoma	O
were	O
tested	O
for	O
HLA	B-GENE
antigen	O
deviation	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

The	O
1	O
.	O
5	O
-	O
Mb	O
region	O
was	O
covered	O
by	O
137	O
cosmids	O
with	O
a	O
minimum	O
overlap	O
set	O
of	O
52	O
cosmids	O
assigned	O
to	O
17	O
bins	O
and	O
9	O
contigs	O
.	O

Similarly	O
,	O
beta	B-GENE
adrenoceptors	I-GENE
blockade	O
has	O
been	O
shown	O
to	O
be	O
of	O
value	O
in	O
achieving	O
continence	O
in	O
a	O
small	O
group	O
of	O
patients	O
.	O

Estrogen	O
has	O
positive	O
effects	O
on	O
mood	O
,	O
sexual	O
function	O
,	O
target	O
end	O
organs	O
and	O
cognitive	O
function	O
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
by	O
acting	O
to	O
prevent	O
amyloid	O
plaque	O
formation	O
,	O
oxidative	O
stress	O
,	O
or	O
deterioration	O
of	O
the	O
cholinergic	O
neurotransmitter	O
system	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
insulin	B-GENE
and	O
TPA	O
activate	O
MBP	B-GENE
/	O
MAP2	B-GENE
kinase	O
activity	O
by	O
de	O
novo	O
phosphorylation	O
of	O
threonine	O
and	O
tyrosine	O
residues	O
via	O
a	O
very	O
similar	O
pathway	O
.	O

Effect	O
of	O
capsaicin	O
on	O
hexobarbital	O
-	O
anesthetized	O
rats	O

Triethylene	O
glycol	O
.	O

Such	O
tetranucleotides	O
are	O
common	O
in	O
promoter	O
regions	O
,	O
particularly	O
in	O
activating	B-GENE
transcription	I-GENE
factor	I-GENE
/	O
cyclic	B-GENE
AMP	I-GENE
response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
ATF	B-GENE
/	O
CREB	B-GENE
)	O
and	O
E	O
-	O
box	O
motifs	O
,	O
suggesting	O
that	O
PIF	B-GENE
may	O
modulate	O
the	O
transcription	O
of	O
many	O
genes	O
.	O

Red	O
blood	O
cell	O
binding	O
of	O
99mTc	O
-	O
EC	O
and	O
131I	O
-	O
OIH	O
was	O
6	O
.	O
1	O
%	O
and	O
20	O
%	O
,	O
respectively	O
.	O

The	O
dominant	O
inhibitory	O
biological	O
activity	O
of	O
the	O
N	O
terminus	O
correlated	O
with	O
its	O
ability	O
to	O
impair	O
EGF	B-GENE
-	O
dependent	O
activation	O
of	O
GTP	B-GENE
-	I-GENE
Ras	I-GENE
and	O
of	O
MAP	B-GENE
kinase	I-GENE
,	O
as	O
well	O
with	O
the	O
ability	O
of	O
endogenous	O
Sos	B-GENE
to	O
form	O
a	O
stable	O
complex	O
with	O
activated	O
EGF	B-GENE
receptors	I-GENE
.	O

Brainstem	O
auditory	O
evoked	O
potential	O
responses	O
(	O
BAEPs	O
)	O
were	O
recorded	O
from	O
CZ	O
-	O
A1	O
and	O
CZ	O
-	O
A2	O
scalp	O
regions	O
in	O
23	O
hypertensive	O
and	O
14	O
normotensive	O
subjects	O
.	O

SM	B-GENE
binds	O
RNA	O
in	O
vitro	O
,	O
suggesting	O
that	O
sequence	O
-	O
or	O
structure	O
-	O
specific	O
mRNA	O
interactions	O
might	O
mediate	O
SM	B-GENE
specificity	O
.	O

The	O
characterization	O
of	O
fly	O
receptors	O
with	O
features	O
similar	O
to	O
mammalian	B-GENE
glycoprotein	I-GENE
hormone	I-GENE
receptors	I-GENE
allows	O
a	O
better	O
understanding	O
of	O
the	O
evolution	O
of	O
this	O
unique	O
group	O
of	O
GPCRs	B-GENE
and	O
future	O
elucidation	O
of	O
their	O
ligand	O
signaling	O
mechanisms	O
.	O

Here	O
we	O
show	O
that	O
these	O
sequences	O
are	O
essential	O
for	O
processing	O
of	O
U18	B-GENE
and	O
snR38	B-GENE
snoRNAs	I-GENE
and	O
that	O
they	O
compensate	O
for	O
the	O
lack	O
of	O
a	O
canonical	O
terminal	O
stem	O
.	O

The	O
use	O
of	O
aluminum	O
hydroxide	O
was	O
associated	O
with	O
an	O
increase	O
in	O
fecal	O
fluoride	O
excretion	O
and	O
a	O
decrease	O
in	O
net	O
absorption	O
of	O
fluoride	O
regardless	O
of	O
the	O
intake	O
fluoride	O
,	O
calcium	O
,	O
phosphorus	O
,	O
or	O
magnesium	O
.	O

In	O
humans	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
of	O
TEWL	O
on	O
both	O
forearm	O
and	O
thigh	O
in	O
CS	O
-	O
treated	O
patients	O
compared	O
to	O
non	O
-	O
CS	O
-	O
treated	O
patients	O
and	O
controls	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Kramer	O
Hamburg	O
1988	O
,	O
ISBN	O
:	O
3	O
926952	O
07	O
5	O
)	O
,	O
the	O
syndromatic	O
day	O
-	O
to	O
-	O
day	O
shifting	O
of	O
the	O
psychopathological	O
features	O
with	O
manic	O
,	O
depressive	O
and	O
several	O
mixed	O
states	O
has	O
a	O
well	O
-	O
defined	O
time	O
structure	O
,	O
as	O
in	O
25	O
patients	O
studied	O
and	O
reported	O
on	O
in	O
this	O
paper	O
.	O

Ras	B-GENE
involvement	O
in	O
signal	O
transduction	O
by	O
the	O
serotonin	B-GENE
5	I-GENE
-	I-GENE
HT2B	I-GENE
receptor	I-GENE
.	O

Analysis	O
of	O
exon	O
2	O
of	O
the	O
factor	B-GENE
IX	I-GENE
gene	I-GENE
revealed	O
a	O
C	O
-	O
-	O
>	O
T	O
mutation	O
in	O
codon	O
10	O
of	O
the	O
propeptide	O
region	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
alanine	O
by	O
valine	O
.	O

There	O
was	O
a	O
direct	O
proportional	O
relationship	O
between	O
the	O
spiral	O
artery	O
flow	O
and	O
the	O
pressure	O
difference	O
between	O
the	O
spiral	O
artery	O
and	O
the	O
amniotic	O
fluid	O
;	O
the	O
pressure	O
difference	O
per	O
flow	O
(	O
the	O
resistance	O
of	O
the	O
cotyledonary	O
unit	O
)	O
was	O
found	O
to	O
be	O
1	O
-	O
-	O
3	O
mm	O
Hg	O
.	O

ml	O
-	O
1	O
.	O
min	O
(	O
8	O
-	O
-	O
24kPa	O
.	O
ml	O
-	O
1	O
.	O
s	O
)	O
.	O

Three	O
putative	O
ORFs	O
have	O
significant	O
homology	O
with	O
known	O
proteins	O
:	O
L0968	B-GENE
is	O
a	O
new	O
member	O
of	O
the	O
very	O
large	O
'	B-GENE
seripauperins	I-GENE
'	I-GENE
family	O
,	O
comprising	O
at	O
least	O
20	O
yeast	O
members	O
;	O
L1313	B-GENE
is	O
a	O
new	O
ABC	B-GENE
transporter	I-GENE
highly	O
homologous	O
to	O
the	O
yeast	O
cadmium	O
resistance	O
protein	O
Ycf1p	B-GENE
and	O
to	O
the	O
human	B-GENE
multidrug	I-GENE
resistance	I-GENE
protein	I-GENE
hMRP1	B-GENE
;	O
the	O
C	O
-	O
terminal	O
part	O
of	O
L1325	B-GENE
present	O
in	O
our	O
sequence	O
is	O
very	O
homologous	O
to	O
the	O
fruit	O
fly	O
abdominal	O
segment	O
formation	O
protein	O
Pumilio	B-GENE
.	O

The	O
cells	O
were	O
densely	O
ciliated	O
,	O
each	O
cilium	O
showing	O
a	O
typical	O
9	O
+	O
2	O
fibrilar	O
pattern	O
.	O

Immunofluorescence	O
obtained	O
using	O
antibodies	O
against	O
alphaI	B-GENE
SigmaI	I-GENE
/	I-GENE
+	I-GENE
+	I-GENE
betaI	I-GENE
SigmaI	I-GENE
spectrin	I-GENE
and	O
Abl	B-GENE
tyrosine	I-GENE
kinase	I-GENE
but	O
not	O
against	O
alphaII	B-GENE
/	I-GENE
betaII	I-GENE
spectrin	I-GENE
colocalized	O
with	O
the	O
overexpressed	O
green	B-GENE
fluorescent	I-GENE
protein	I-GENE
-	O
SH3	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
.	O

Extracellular	B-GENE
protein	I-GENE
kinase	I-GENE
A	I-GENE
as	O
a	O
cancer	O
biomarker	O
:	O
its	O
expression	O
by	O
tumor	O
cells	O
and	O
reversal	O
by	O
a	O
myristate	O
-	O
lacking	O
Calpha	O
and	O
RIIbeta	O
subunit	O
overexpression	O
.	O

Detection	O
of	O
sinusoidal	O
gratings	O
by	O
pattern	O
-	O
specific	O
detectors	O
:	O
further	O
evidence	O
for	O
the	O
correlation	O
principle	O
in	O
human	O
vision	O
.	O

This	O
B	O
-	O
box	O
is	O
not	O
present	O
in	O
ETS1	B-GENE
,	O
ETS2	B-GENE
,	O
PEA3	B-GENE
or	O
PU	B-GENE
.	I-GENE
1	I-GENE
and	O
these	O
proteins	O
were	O
unable	O
to	O
form	O
ternary	O
complexes	O
with	O
SRF	B-GENE
and	O
Egrl	B-GENE
-	O
SREs	O
or	O
c	B-GENE
-	I-GENE
fos	I-GENE
SRE	O
.	O

MADS	B-GENE
-	I-GENE
box	I-GENE
genes	I-GENE
in	O
plants	O
are	O
a	O
diverse	O
class	O
of	O
transcription	O
factors	O
that	O
are	O
involved	O
in	O
regulating	O
developmental	O
processes	O
,	O
particularly	O
meristem	O
and	O
organ	O
identity	O
during	O
floral	O
development	O
.	O

Elevated	O
systolic	O
blood	O
pressure	O
and	O
high	O
postglucose	O
serum	B-GENE
insulin	I-GENE
levels	O
showed	O
an	O
independent	O
,	O
significant	O
association	O
with	O
left	O
ventricular	O
mass	O
in	O
female	O
diabetic	O
subjects	O
.	O

This	O
study	O
investigated	O
if	O
signal	O
-	O
averaged	O
low	O
amplitude	O
atrial	O
potentials	O
predict	O
atrial	O
fibrillation	O
or	O
flutter	O
(	O
AFF	O
)	O
.	O

Thirty	O
-	O
five	O
pts	O
were	O
transplanted	O
for	O
constitutional	O
disease	O
:	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
(	O
26	O
pts	O
)	O
,	O
Dyskeratosis	O
congenita	O
(	O
2	O
pts	O
)	O
,	O
Blackfan	O
-	O
Diamond	O
erythroblastopenia	O
(	O
2	O
pts	O
)	O
,	O
Glanzmann	O
thrombasthenia	O
(	O
1	O
pt	O
)	O
,	O
osteopetrosis	O
(	O
1	O
pt	O
)	O
and	O
Gaucher	O
'	O
s	O
disease	O
(	O
1	O
pt	O
)	O
.	O

Viral	B-GENE
protein	I-GENE
U	I-GENE
(	O
Vpu	B-GENE
)	O
is	O
a	O
protein	O
encoded	O
by	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
that	O
promotes	O
the	O
degradation	O
of	O
the	O
virus	O
receptor	O
,	O
CD4	B-GENE
,	O
and	O
enhances	O
the	O
release	O
of	O
virus	O
particles	O
from	O
cells	O
.	O

Because	O
the	O
variation	O
in	O
the	O
carbohydrate	O
content	O
of	O
human	O
milk	O
is	O
very	O
small	O
,	O
a	O
more	O
simple	O
alternative	O
approach	O
would	O
be	O
to	O
include	O
only	O
an	O
average	O
carbohydrate	O
value	O
for	O
an	O
estimate	O
of	O
energy	O
content	O
.	O

Level	O
II	O
mosaicism	O
occurred	O
in	O
0	O
.	O
9	O
per	O
cent	O
of	O
CVS	O
mesenchyme	O
and	O
1	O
.	O
5	O
per	O
cent	O
of	O
amniotic	O
fluid	O
cultures	O
and	O
in	O
general	O
was	O
not	O
perceived	O
to	O
be	O
of	O
sufficient	O
concern	O
to	O
warrant	O
cytogenetic	O
follow	O
-	O
up	O
studies	O
.	O

Biol	O
.	O

IV	O
.	O

Sleeping	O
position	O
and	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
:	O
effect	O
of	O
an	O
intervention	O
programme	O
to	O
avoid	O
prone	O
sleeping	O
.	O

CSEn	B-GENE
stimulated	O
transcription	O
of	O
a	O
variety	O
of	O
promoters	O
,	O
including	O
the	O
hCS	B-GENE
,	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
,	O
thymidine	B-GENE
kinase	I-GENE
,	O
and	O
Rous	B-GENE
sarcoma	I-GENE
virus	I-GENE
promoters	I-GENE
,	O
in	O
human	O
choriocarcinoma	O
cell	O
lines	O
(	O
BeWo	O
and	O
JEG	O
-	O
3	O
)	O
but	O
not	O
HeLa	O
cells	O
or	O
rat	O
somatolactotrophes	O
(	O
GC	O
)	O
.	O

Pretreatment	O
of	O
human	O
skin	O
with	O
tRA	O
inhibited	O
UV	O
induction	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
protein	I-GENE
and	O
,	O
consequently	O
,	O
AP	B-GENE
-	I-GENE
1	I-GENE
.	O

c	B-GENE
-	I-GENE
Jun	I-GENE
protein	I-GENE
inhibition	O
occurred	O
via	O
a	O
posttranscriptional	O
mechanism	O
,	O
since	O
tRA	O
did	O
not	O
inhibit	O
UV	O
induction	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
mRNA	I-GENE
.	O

Thus	O
,	O
apoptosis	O
in	O
hematopoietic	O
cells	O
is	O
the	O
end	O
result	O
of	O
a	O
conflict	O
between	O
death	O
and	O
survival	O
signals	O
,	O
rather	O
than	O
a	O
simple	O
death	O
by	O
default	O
.	O

Effect	O
of	O
age	O
on	O
glucose	O
,	O
reducing	O
sugars	O
and	O
plasma	B-GENE
insulin	I-GENE
in	O
blood	O
of	O
milk	O
-	O
fed	O
calves	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
this	O
study	O
suggest	O
that	O
both	O
male	O
and	O
female	O
soldiers	O
who	O
are	O
diagnosed	O
with	O
chlamydia	O
infections	O
have	O
relatively	O
high	O
risks	O
of	O
reinfection	O
through	O
their	O
20s	O
.	O

During	O
seed	O
maturation	O
,	O
the	O
transcriptional	O
activity	O
of	O
napin	B-GENE
genes	I-GENE
is	O
regulated	O
by	O
developmental	O
signals	O
involving	O
the	O
transcriptional	B-GENE
activator	I-GENE
ABI3	I-GENE
and	O
abscisic	O
acid	O
(	O
ABA	O
)	O
.	O

DESIGN	O
:	O
Intradermally	O
injected	O
human	O
squamous	O
cell	O
carcinoma	O
cells	O
were	O
grown	O
to	O
40	O
to	O
80	O
mm3	O
in	O
athymic	O
nude	O
mice	O
and	O
irradiated	O
with	O
675	O
-	O
nm	O
light	O
(	O
75	O
J	O
/	O
cm2	O
,	O
75	O
mW	O
/	O
cm2	O
)	O
24	O
hours	O
after	O
the	O
intraperitoneal	O
injection	O
of	O
SiPc	O
IV	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

This	O
results	O
in	O
a	O
decreased	O
secretion	O
of	O
immunoglobulin	B-GENE
A	I-GENE
,	O
and	O
,	O
consequently	O
,	O
a	O
decreased	O
resistance	O
against	O
infections	O
.	O

The	O
absolute	O
CD4	B-GENE
count	O
of	O
patients	O
with	O
de	O
novo	O
IBD	O
was	O
210	O
-	O
700	O
cells	O
/	O
ml	O
at	O
the	O
time	O
of	O
IBD	O
.	O

Categorisation	O
of	O
the	O
different	O
substructures	O
within	O
the	O
sections	O
allows	O
them	O
to	O
be	O
analysed	O
and	O
displayed	O
separately	O
.	O

To	O
study	O
the	O
mechanisms	O
and	O
the	O
signaling	O
pathways	O
involved	O
,	O
IGF	B-GENE
-	I-GENE
1R	I-GENE
promoter	I-GENE
reporter	I-GENE
constructs	I-GENE
were	O
transiently	O
transfected	O
in	O
CHO	O
-	O
AT1	O
cells	O
that	O
overexpress	O
angiotensin	B-GENE
AT1	I-GENE
receptors	I-GENE
.	O

With	O
this	O
study	O
,	O
a	O
total	O
of	O
13	O
operators	O
for	O
the	O
glp	B-GENE
regulon	I-GENE
have	O
been	O
characterized	O
.	O

Natl	O
.	O

Coexpression	O
of	O
a	O
dominant	B-GENE
negative	I-GENE
c	I-GENE
-	I-GENE
jun	I-GENE
antagonized	O
the	O
ras	B-GENE
-	O
dependent	O
stimulation	O
of	O
the	O
92	B-GENE
-	I-GENE
kDa	I-GENE
gelatinase	I-GENE
B	I-GENE
promoter	O
-	O
driven	O
CAT	B-GENE
reporter	I-GENE
.	O

In	O
two	O
patients	O
,	O
a	O
male	O
homosexual	O
and	O
an	O
hemophiliac	O
,	O
thrombocytopenia	O
was	O
associated	O
with	O
AIDS	O
-	O
related	O
complex	O
.	O

However	O
,	O
LXRalpha	B-GENE
inhibited	O
binding	O
of	O
PPARalpha	B-GENE
/	O
RXRalpha	B-GENE
heterodimers	O
to	O
PPREs	O
,	O
and	O
coexpression	O
of	O
LXRalpha	B-GENE
in	O
mammalian	O
cells	O
antagonized	O
peroxisome	O
proliferator	O
signaling	O
mediated	O
by	O
PPARalpha	B-GENE
/	O
RXRalpha	B-GENE
in	O
vivo	O
.	O

The	O
results	O
can	O
be	O
summarized	O
as	O
follows	O
.	O

A	O
case	O
of	O
heterotopic	O
gastric	O
mucosa	O
(	O
pyloric	O
gland	O
)	O
in	O
the	O
wall	O
of	O
the	O
gallbladder	O
was	O
reported	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
mechanism	O
of	O
ribosomal	O
frameshifting	O
at	O
the	O
PVM	O
signal	O
is	O
different	O
from	O
the	O
one	O
described	O
by	O
the	O
'	O
simultaneous	O
slippage	O
'	O
model	O
in	O
that	O
only	O
the	O
string	O
of	O
four	O
adenosine	O
nucleotides	O
represents	O
the	O
slippery	O
sequence	O
involved	O
in	O
a	O
-	O
1	O
P	O
-	O
site	O
slippage	O
.	O

CTDK1	B-GENE
and	O
CTDK2	B-GENE
also	O
differ	O
in	O
their	O
protein	O
substrate	O
specificity	O
.	O

This	O
communication	O
presents	O
two	O
patients	O
with	O
clinically	O
massive	O
PE	O
of	O
recent	O
onset	O
(	O
confirmed	O
by	O
lung	O
perfusion	O
scans	O
)	O
who	O
were	O
successfully	O
treated	O
with	O
a	O
single	O
i	O
.	O
v	O
.	O
dose	O
of	O
30	O
mg	O
of	O
anisoylated	B-GENE
lys	I-GENE
-	I-GENE
plasminogen	I-GENE
streptokinase	I-GENE
activator	I-GENE
complex	I-GENE
(	O
APSAC	B-GENE
,	O
comparable	O
to	O
1	O
,	O
500	O
,	O
000	O
U	O
of	O
streptokinase	B-GENE
)	O
followed	O
by	O
systemic	O
heparinization	O
for	O
7	O
days	O
.	O

A	O
Laboratory	O
Manual	O
,	O
2nd	O
ed	O
.	O

Engineering	O
temperature	O
-	O
sensitive	O
SH3	B-GENE
domains	I-GENE
.	O

A	O
mean	O
value	O
for	O
HbA1	B-GENE
greater	O
than	O
10	O
%	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
progression	O
of	O
retinopathy	O
and	O
a	O
mean	O
value	O
less	O
than	O
8	O
.	O
7	O
%	O
was	O
associated	O
with	O
a	O
diminished	O
risk	O
.	O

Allergic	O
field	O
:	O
how	O
to	O
detect	O
it	O
?	O

At	O
1	O
min	O
postalfentanil	O
,	O
N2O	O
caused	O
significantly	O
more	O
rigidity	O
than	O
100	O
%	O
O2	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
preparative	O
regimen	O
consisted	O
of	O
fractionated	O
total	O
body	O
irradiation	O
(	O
TBI	O
)	O
and	O
cyclophosphamide	O
(	O
CY	O
)	O
.	O

NGF	B-GENE
also	O
induced	O
a	O
synthetic	O
promoter	O
with	O
repeated	O
Sp1	B-GENE
sites	I-GENE
linked	O
to	O
a	O
core	O
promoter	O
,	O
and	O
a	O
plasmid	O
regulated	O
by	O
a	O
chimeric	O
transactivator	O
in	O
which	O
the	O
Gal4	B-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
is	O
fused	O
to	O
the	O
Sp1	B-GENE
transactivation	I-GENE
domain	I-GENE
,	O
indicating	O
that	O
this	O
transactivation	O
domain	O
is	O
regulated	O
by	O
NGF	B-GENE
.	O

The	O
toxicity	O
of	O
copper	O
to	O
the	O
collembolan	O
Folsomia	O
fimetaria	O
L	O
.	O
was	O
studied	O
in	O
soil	O
incubated	O
with	O
copper	O
sulfate	O
for	O
different	O
periods	O
before	O
the	O
introduction	O
of	O
collembolans	O
,	O
to	O
assess	O
the	O
effect	O
of	O
aging	O
of	O
contamination	O
on	O
the	O
toxicity	O
of	O
copper	O
.	O

The	O
frequency	O
of	O
severe	O
congestive	O
heart	O
failure	O
(	O
Killip	O
class	O
III	O
or	O
IV	O
)	O
at	O
admission	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
early	O
presentation	O
,	O
than	O
with	O
late	O
presentation	O
(	O
30	O
.	O
7	O
%	O
vs	O
7	O
.	O
6	O
%	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Comparative	O
ultrafiltration	O
(	O
UF	O
)	O
studies	O
with	O
BiGG	O
and	O
standard	O
lactate	O
(	O
La	O
)	O
solutions	O
in	O
rabbits	O
showed	O
that	O
net	O
UF	O
with	O
La	O
solution	O
peaked	O
at	O
2	O
h	O
and	O
decreased	O
significantly	O
at	O
4	O
h	O
and	O
6	O
h	O
.	O

The	O
Giessener	O
Tumordokumentationssystem	O
(	O
GTDS	O
)	O
is	O
such	O
a	O
disease	O
specific	O
system	O
.	O

Measurement	O
of	O
protein	O
in	O
natural	O
rubber	O
latex	O
.	O

In	O
cotransfection	O
assays	O
,	O
a	O
small	O
fragment	O
of	O
Sin	B-GENE
retaining	O
the	O
Src	B-GENE
-	O
SH3	B-GENE
-	O
binding	O
site	O
and	O
one	O
tyrosine	O
-	O
containing	O
motif	O
induced	O
c	B-GENE
-	I-GENE
Src	I-GENE
activation	O
as	O
measured	O
by	O
a	O
transcriptional	O
reporter	O
.	O

The	O
related	O
tumor	O
suppressor	O
,	O
p130	B-GENE
,	O
also	O
effects	O
this	O
function	O
.	O

p107	B-GENE
levels	O
increase	O
substantially	O
as	O
cells	O
progress	O
through	O
S	O
phase	O
.	O

p107	B-GENE
induction	O
of	O
E2F	B-GENE
DNA	O
binding	O
was	O
observed	O
primarily	O
in	O
S	O
phase	O
cells	O
coincident	O
with	O
the	O
increase	O
in	O
p107	B-GENE
protein	I-GENE
levels	O
.	O

Both	O
flavoproteins	O
are	O
active	O
as	O
AhpC	B-GENE
reductases	I-GENE
and	O
mediate	O
electron	O
transfer	O
,	O
resulting	O
in	O
the	O
NADH	O
-	O
dependent	O
reduction	O
of	O
hydrogen	O
peroxide	O
and	O
cumene	O
hydroperoxide	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
murine	B-GENE
k	I-GENE
-	I-GENE
fgf	I-GENE
gene	I-GENE
.	O

Further	O
,	O
cells	O
cotransfected	O
with	O
a	O
UF	B-GENE
promoter	I-GENE
-	O
luciferase	B-GENE
(	O
-	O
1935UF	B-GENE
-	O
Luc	B-GENE
)	O
reporter	O
gene	O
and	O
the	O
BTEB	B-GENE
expression	O
vector	O
had	O
2	O
-	O
fold	O
higher	O
Luc	B-GENE
activity	O
than	O
those	O
cotransfected	O
with	O
reporter	O
gene	O
and	O
pcDNA	O
-	O
3	O
.	O

Evasion	O
of	O
host	O
immunity	O
by	O
Toxocara	O
canis	O
infective	O
larvae	O
is	O
mediated	O
by	O
the	O
nematode	O
surface	O
coat	O
,	O
which	O
is	O
shed	O
in	O
response	O
to	O
binding	O
by	O
host	O
antibody	O
molecules	O
or	O
effector	O
cells	O
.	O

A	O
Frank	O
vectorcardiogram	O
was	O
recorded	O
before	O
and	O
every	O
15	O
-	O
30	O
minutes	O
for	O
10	O
hours	O
after	O
the	O
occlusion	O
.	O

In	O
agreement	O
with	O
this	O
,	O
archaea	O
appear	O
to	O
lack	O
eIF5	B-GENE
,	O
eIF2B	B-GENE
and	O
the	O
lysine	O
-	O
rich	O
binding	O
domain	O
for	O
these	O
factors	O
in	O
their	O
eIF2beta	B-GENE
homolog	I-GENE
.	O

Derepression	O
of	O
RAR	B-GENE
signaling	O
by	O
expressing	O
a	O
dominant	O
-	O
negative	O
corepressor	O
resulted	O
in	O
embryos	O
that	O
exhibited	O
phenotypes	O
similar	O
to	O
those	O
treated	O
by	O
RA	O
.	O

Chemiluminescence	O
induced	O
by	O
opsonized	O
zymosan	O
increased	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
after	O
treatment	O
with	O
bacterial	O
extracts	O
,	O
whereas	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
fMLP	O
-	O
stimulated	O
PMNs	O
.	O

Lastly	O
,	O
several	O
restriction	O
length	O
polymorphisms	O
were	O
identified	O
and	O
mapped	O
within	O
a	O
1	O
kb	O
region	O
located	O
immediately	O
upstream	O
from	O
the	O
JH	B-GENE
cluster	I-GENE
.	O

Radiographic	O
spatial	O
frequencies	O
essential	O
to	O
the	O
diagnosis	O
of	O
incipient	O
interproximal	O
lesions	O
.	O

Promoter	O
region	O
of	O
the	O
human	B-GENE
alpha	I-GENE
2A	I-GENE
adrenergic	I-GENE
receptor	I-GENE
gene	I-GENE
.	O

(	O
1982	O
)	O
.	O

(	O
99m	O
)	O
Tc	O
Ethyl	O
Cysteinate	O
Dimer	O
stable	O
during	O
6h	O
has	O
contributed	O
to	O
develop	O
ictal	O
studies	O
to	O
evaluate	O
the	O
location	O
of	O
partial	O
seizure	O
.	O

LiF	O
thermoluminescence	O
dosimeters	O
(	O
TLD	O
)	O
in	O
chip	O
form	O
were	O
placed	O
onto	O
1	O
eyelid	O
,	O
the	O
skin	O
over	O
the	O
thyroid	O
,	O
and	O
the	O
patient	O
'	O
s	O
clothes	O
covering	O
the	O
region	O
of	O
breasts	O
and	O
ovaries	O
of	O
female	O
patients	O
and	O
the	O
testicles	O
of	O
male	O
patients	O
.	O

Thus	O
,	O
the	O
in	O
vivo	O
function	O
of	O
Gle2p	B-GENE
is	O
strictly	O
coupled	O
to	O
the	O
short	O
GLEBS	B-GENE
within	O
Nup116p	B-GENE
which	O
links	O
this	O
putative	O
mRNA	O
transport	O
factor	O
to	O
the	O
nuclear	O
pores	O
.	O

DNMT2	B-GENE
binds	O
AdoHcy	O
in	O
the	O
same	O
conformation	O
as	O
confirmed	O
m	B-GENE
(	I-GENE
5	I-GENE
)	I-GENE
C	I-GENE
MTases	I-GENE
and	O
,	O
while	O
DNMT2	B-GENE
shares	O
all	O
sequence	O
and	O
structural	O
features	O
with	O
m	B-GENE
(	I-GENE
5	I-GENE
)	I-GENE
C	I-GENE
MTases	I-GENE
,	O
it	O
has	O
failed	O
to	O
demonstrate	O
detectable	O
transmethylase	O
activity	O
.	O

The	O
structure	O
of	O
the	O
murine	B-GENE
Dtk	I-GENE
gene	I-GENE
has	O
been	O
determined	O
.	O

In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
the	O
nuclear	O
import	O
of	O
SREBP	B-GENE
-	I-GENE
2	I-GENE
occurs	O
via	O
the	O
direct	O
interaction	O
of	O
importin	B-GENE
beta	I-GENE
with	O
the	O
HLH	O
-	O
Zip	O
domain	O
.	O

In	O
the	O
normal	O
controls	O
the	O
plasma	B-GENE
FPA	I-GENE
level	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
1	O
.	O
43	O
+	O
/	O
-	O
0	O
.	O
46	O
ng	O
/	O
ml	O
.	O

In	O
this	O
study	O
we	O
cloned	O
the	O
cDNA	O
of	O
AD1	B-GENE
Ag	I-GENE
from	O
a	O
rat	O
basophilic	O
leukemia	O
2H3	O
cDNA	O
library	O
.	O

Ten	O
patients	O
(	O
aged	O
28	O
-	O
76	O
years	O
)	O
with	O
a	O
terminal	O
jejunostomy	O
located	O
within	O
the	O
first	O
meter	O
of	O
jejunum	O
were	O
treated	O
by	O
infusion	O
of	O
an	O
elemental	O
diet	O
into	O
the	O
distal	O
small	O
bowel	O
(	O
IEDDSB	O
)	O
.	O

The	O
procedure	O
was	O
technically	O
successful	O
in	O
12	O
of	O
14	O
(	O
86	O
%	O
)	O
stenoses	O
in	O
the	O
fibromuscular	O
dysplasia	O
subgroup	O
but	O
in	O
only	O
one	O
of	O
five	O
(	O
20	O
%	O
)	O
lesions	O
in	O
the	O
neurofibromatosis	O
subgroup	O
.	O

Conventional	O
and	O
digital	O
radiography	O
of	O
the	O
heart	O
,	O
aorta	O
,	O
and	O
pulmonary	O
vascularity	O
.	O

Regulation	O
of	O
the	O
p21	B-GENE
-	I-GENE
activated	I-GENE
kinase	I-GENE
(	O
PAK	B-GENE
)	O
by	O
a	O
human	B-GENE
Gbeta	I-GENE
-	I-GENE
like	I-GENE
WD	O
-	O
repeat	O
protein	O
,	O
hPIP1	B-GENE
.	O

Other	O
clinicopathological	O
features	O
have	O
no	O
definite	O
influence	O
in	O
survival	O
expectancy	O
.	O

These	O
studies	O
suggest	O
that	O
tandem	O
alpha	O
-	O
helices	O
located	O
near	O
the	O
C	O
-	O
terminus	O
of	O
PC	B-GENE
-	I-GENE
TP	I-GENE
facilitate	O
membrane	O
binding	O
and	O
extraction	O
of	O
phosphatidylcholines	O
.	O

The	O
striking	O
similarity	O
in	O
preference	O
for	O
mismatched	O
and	O
weakly	O
paired	O
nucleotides	O
for	O
binding	O
and	O
for	O
excision	O
suggests	O
a	O
functional	O
relationship	O
between	O
binding	O
and	O
cleavage	O
reactions	O
.	O

Interestingly	O
,	O
these	O
"	O
activation	O
-	O
defective	O
"	O
mutants	O
segregated	O
into	O
two	O
classes	O
:	O
1	O
)	O
those	O
that	O
were	O
unable	O
to	O
form	O
dimers	O
but	O
that	O
could	O
still	O
form	O
higher	O
order	O
oligomers	O
and	O
transform	O
cells	O
,	O
and	O
2	O
)	O
those	O
that	O
were	O
defective	O
for	O
PDGF	B-GENE
-	I-GENE
R	I-GENE
binding	O
and	O
were	O
transformation	O
-	O
incompetent	O
.	O

APL	O
patients	O
showed	O
a	O
low	O
,	O
yet	O
variable	O
,	O
level	O
of	O
JEM	B-GENE
-	I-GENE
1	I-GENE
mRNA	I-GENE
in	O
bone	O
marrow	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
show	O
that	O
intranasal	O
challenge	O
with	O
FLU	O
induces	O
changes	O
in	O
leukocyte	O
histamine	O
release	O
,	O
but	O
not	O
other	O
systemic	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
shown	O
previously	O
that	O
EGF	B-GENE
receptor	I-GENE
activation	O
stimulates	O
gastrin	B-GENE
gene	O
expression	O
through	O
a	O
GC	O
-	O
rich	O
element	O
called	O
gERE	O
.	O

We	O
have	O
earlier	O
proposed	O
that	O
CG	O
rich	O
sequences	O
resembling	O
CpG	O
islands	O
,	O
which	O
are	O
associated	O
with	O
many	O
imprinted	O
genes	O
and	O
often	O
subject	O
to	O
parental	O
-	O
specific	O
methylation	O
,	O
could	O
act	O
as	O
a	O
common	O
imprinting	O
element	O
.	O

The	O
secondary	O
end	O
points	O
included	O
creatine	B-GENE
kinase	I-GENE
peak	O
,	O
ventricular	O
fibrillation	O
/	O
tachycardia	O
within	O
the	O
first	O
24	O
hours	O
,	O
death	O
and	O
congestive	O
heart	O
failure	O
within	O
the	O
30	O
-	O
day	O
follow	O
-	O
up	O
,	O
and	O
30	O
-	O
day	O
left	O
ventricular	O
ejection	O
fraction	O
.	O

Prevention	O
of	O
gravid	O
Rhesus	O
isoimmunization	O

All	O
relapses	O
occurred	O
within	O
the	O
first	O
year	O
and	O
were	O
confined	O
to	O
patients	O
with	O
PS	O
II	O
disease	O
and	O
four	O
or	O
more	O
sites	O
of	O
involvement	O
.	O

This	O
demonstrates	O
the	O
presence	O
of	O
a	O
PKC	B-GENE
-	O
dependent	O
pathway	O
which	O
functions	O
independently	O
from	O
Lck	B-GENE
in	O
MAP	B-GENE
kinase	I-GENE
activation	O
.	O

This	O
interesting	O
exon	O
junction	O
resulted	O
in	O
novel	O
deduced	O
amino	O
terminal	O
open	O
reading	O
frames	O
,	O
which	O
are	O
completely	O
in	O
-	O
frame	O
with	O
sequences	O
located	O
further	O
downstream	O
.	O

Cell	O
lines	O
expressing	O
single	O
amino	O
acid	O
substitutions	O
of	O
the	O
carboxyl	O
-	O
terminal	O
asparagine	O
of	O
CD2	B-GENE
are	O
incapable	O
of	O
avidity	O
regulation	O
by	O
TCR	B-GENE
signaling	O
,	O
PMA	O
treatment	O
,	O
or	O
elevation	O
of	O
intracellular	O
cAMP	O
levels	O
,	O
demonstrating	O
that	O
each	O
of	O
these	O
stimuli	O
utilizes	O
a	O
common	O
structural	O
element	O
for	O
regulating	O
CD2	B-GENE
avidity	O
.	O

12	O
per	O
cent	O
was	O
observed	O
with	O
the	O
use	O
of	O
tetracycline	O
and	O
4	O
-	O
epianhydrotetracycline	O
in	O
doses	O
of	O
1000	O
and	O
100gamma	O
per	O
embryo	O
respectively	O
.	O

Present	O
investigation	O
was	O
undertaken	O
to	O
elucidate	O
what	O
pharmacokinetic	O
parameters	O
in	O
animal	O
experiment	O
could	O
be	O
of	O
more	O
predictable	O
for	O
human	O
clinical	O
trial	O
of	O
beta	O
-	O
blocking	O
agents	O
.	O

The	O
atpA	B-GENE
reading	O
frame	O
ends	O
with	O
four	O
tandem	O
UGA	O
codons	O
which	O
overlap	O
four	O
tandem	O
AUG	O
codons	O
initiating	O
an	O
unidentified	O
reading	O
frame	O
,	O
orf214	O
.	O

When	O
transfected	O
into	O
HepG2	O
cells	O
,	O
which	O
lack	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
,	O
the	O
mouse	B-GENE
ob	I-GENE
promoter	I-GENE
was	O
only	O
weakly	O
active	O
.	O

Vasodilator	O
and	O
hypotensive	O
effects	O
of	O
the	O
optical	O
isomers	O
of	O
nicardipine	O
(	O
YC	O
-	O
93	O
)	O
,	O
a	O
new	O
Ca2	O
+	O
-	O
antagonist	O
.	O

Between	O
1988	O
and	O
1995	O
,	O
341	O
children	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
were	O
treated	O
on	O
the	O
Medical	O
Research	O
Council	O
Acute	O
Myeloid	O
Leukaemia	O
Trial	O
(	O
MRC	O
AML10	O
)	O
.	O

A	O
heterologous	O
promoter	O
construct	O
containing	O
three	O
repeats	O
of	O
a	O
consensus	O
Sp1	B-GENE
site	I-GENE
,	O
cloned	O
upstream	O
of	O
a	O
single	O
copy	O
of	O
the	O
ZII	B-GENE
(	O
CREB	B-GENE
/	O
AP1	B-GENE
)	O
element	O
from	O
the	O
BZLF1	B-GENE
promoter	I-GENE
linked	O
to	O
the	O
beta	B-GENE
-	I-GENE
globin	I-GENE
TATA	O
box	O
,	O
exhibited	O
phorbol	O
ester	O
inducibility	O
.	O

Nicotinic	B-GENE
receptor	I-GENE
antagonists	O
mecamylamine	O
(	O
0	O
.	O
5	O
and	O
1	O
mg	O
/	O
kg	O
)	O
and	O
hexamethonium	O
(	O
5	O
and	O
10	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
response	O
induced	O
by	O
nicotine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
.	O

Appl	O
.	O

Thus	O
,	O
the	O
predicted	O
M3	O
ORF	O
is	O
a	O
functional	O
gene	O
that	O
encodes	O
an	O
abundant	O
secreted	O
protein	O
which	O
is	O
a	O
candidate	O
for	O
interacting	O
with	O
host	O
cellular	O
receptors	O
or	O
cytokines	O
.	O

Protein	O
metabolism	O
disorders	O
in	O
burns	O

The	O
cumulative	O
dose	O
to	O
nursing	O
staff	O
for	O
the	O
week	O
after	O
treatment	O
was	O
dependent	O
on	O
patient	O
mobility	O
and	O
was	O
estimated	O
at	O
0	O
.	O
08	O
mSv	O
for	O
a	O
self	O
-	O
caring	O
patient	O
to	O
6	O
.	O
3	O
mSv	O
for	O
a	O
totally	O
helpless	O
patient	O
(	O
1840	O
MBq	O
/	O
group	O
A	O
)	O
.	O

JCAHO	O
to	O
use	O
ORYX	O
data	O
to	O
detect	O
sentinel	O
events	O
.	O

We	O
also	O
show	O
that	O
psbH	B-GENE
and	O
psbT	B-GENE
are	O
transcribed	O
from	O
the	O
upstream	O
psbB	B-GENE
gene	I-GENE
promoter	I-GENE
,	O
and	O
that	O
the	O
psbH	B-GENE
mRNA	I-GENE
has	O
its	O
own	O
target	O
sequence	O
for	O
Mbb1	B-GENE
function	O
.	O

To	O
test	O
whether	O
Cd	O
exposure	O
would	O
increase	O
Ca	O
release	O
from	O
bone	O
during	O
pregnancy	O
and	O
lactation	O
in	O
relation	O
to	O
the	O
etiological	O
mechanism	O
of	O
Itai	O
-	O
Itai	O
disease	O
,	O
virgin	O
female	O
mice	O
with	O
45Ca	O
prelabeled	O
skeletons	O
(	O
15	O
microCi	O
/	O
mouse	O
)	O
were	O
subjected	O
to	O
one	O
round	O
of	O
pregnancy	O
/	O
lactation	O
and	O
were	O
exposed	O
to	O
a	O
Ca	O
-	O
deficient	O
diet	O
containing	O
0	O
,	O
5	O
,	O
or	O
25	O
ppm	O
Cd	O
or	O
25	O
ppm	O
Pb	O
for	O
32	O
days	O
,	O
from	O
conception	O
until	O
Lactation	O
Day	O
14	O
.	O

O5257	B-GENE
shows	O
homology	O
with	O
the	O
SAS2	B-GENE
protein	I-GENE
and	O
another	O
hypothetical	O
protein	O
from	O
yeast	O
.	O

Principles	O
of	O
thyroid	O
hormone	O
treatment	O

Significance	O
of	O
esophagocardiac	O
reflexes	O
for	O
inducing	O
thoracic	O
pain	O

The	O
fate	O
of	O
ochratoxin	O
A	O
during	O
malting	O
and	O
brewing	O
.	O

METHODS	O
:	O
Precision	O
and	O
accuracy	O
were	O
measured	O
using	O
controls	O
and	O
method	O
comparison	O
studies	O
.	O

Messenger	O
RNA	O
for	O
the	O
Ad2	B-GENE
DNA	I-GENE
binding	I-GENE
protein	I-GENE
:	O
DNA	O
sequences	O
encoding	O
the	O
first	O
leader	O
and	O
heterogenity	O
at	O
the	O
mRNA	O
5	O
'	O
end	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
stimulation	O
of	O
A	B-GENE
(	I-GENE
2A	I-GENE
)	I-GENE
-	I-GENE
R	I-GENE
or	O
PKA	B-GENE
enhanced	O
nuclear	B-GENE
aPKC	I-GENE
activity	O
.	O

Atrial	O
dissociation	O
.	O

The	O
gene	O
sequence	O
predicts	O
a	O
150	O
,	O
825	O
mol	O
wt	O
apoprotein	O
of	O
1363	O
amino	O
acids	O
having	O
an	O
N	O
-	O
terminal	O
hydrophobic	O
signal	O
sequence	O
of	O
17	O
amino	O
acids	O
,	O
19	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
a	O
hydrophobic	O
anchor	O
sequence	O
of	O
approximately	O
17	O
amino	O
acids	O
near	O
the	O
C	O
terminus	O
,	O
and	O
a	O
hydrophilic	O
cysteine	O
-	O
rich	O
C	O
terminus	O
of	O
35	O
amino	O
acids	O
.	O

However	O
,	O
depending	O
upon	O
the	O
promoter	O
context	O
,	O
we	O
observed	O
cooperative	O
interactions	O
between	O
the	O
two	O
domains	O
to	O
confer	O
high	O
DNA	O
-	O
binding	O
affinity	O
and	O
specificity	O
.	O

As	O
a	O
result	O
,	O
relative	O
biological	O
effects	O
(	O
RBE	O
)	O
of	O
2	O
.	O
3	O
-	O
2	O
.	O
7	O
was	O
obtained	O
from	O
the	O
straight	O
line	O
that	O
was	O
given	O
by	O
modifying	O
by	O
the	O
method	O
of	O
least	O
squares	O
the	O
curves	O
of	O
the	O
frequency	O
of	O
anomalous	O
fetuses	O
in	O
total	O
implants	O
and	O
survived	O
embryos	O
irradiated	O
from	O
20	O
to	O
120	O
rad	O
by	O
Cf	O
-	O
252	O
and	O
from	O
80	O
to	O
220	O
rad	O
by	O
Co	O
-	O
60	O
on	O
day	O
8	O
of	O
pregnancy	O
.	O

Samples	O
(	O
1	O
g	O
)	O
were	O
extracted	O
with	O
0	O
.	O
5	O
%	O
potassium	O
chloride	O
(	O
KCl	O
)	O
in	O
70	O
%	O
methanol	O
(	O
5	O
ml	O
)	O
and	O
diluted	O
subsequently	O
to	O
give	O
two	O
-	O
fold	O
to	O
ten	O
-	O
fold	O
step	O
-	O
wise	O
dilutions	O
in	O
phosphate	O
-	O
buffered	O
saline	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
20	O
and	O
0	O
.	O
2	O
%	O
bovine	B-GENE
serum	I-GENE
albumin	I-GENE
(	O
PBS	O
-	O
T	O
BSA	B-GENE
)	O
.	O

To	O
our	O
knowledge	O
108	O
cases	O
of	O
EAT	O
treated	O
by	O
catheter	O
ablation	O
of	O
the	O
ectopic	O
focus	O
are	O
reported	O
in	O
the	O
literature	O
with	O
a	O
success	O
rate	O
superior	O
to	O
90	O
%	O
.	O

Following	O
immunization	O
of	O
transgenic	O
mice	O
,	O
hybrid	O
molecules	O
were	O
isolated	O
from	O
B	O
cell	O
DNA	O
which	O
contained	O
the	O
transgene	O
recombined	O
with	O
the	O
endogenous	B-GENE
IgH	I-GENE
locus	I-GENE
.	O

It	O
produced	O
extrapyramidal	O
disturbances	O
in	O
nearly	O
every	O
subject	O
,	O
the	O
most	O
common	O
being	O
akathisia	O
and	O
the	O
most	O
severe	O
,	O
in	O
the	O
case	O
of	O
one	O
individual	O
,	O
being	O
acute	O
dystonia	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
that	O
both	O
human	O
and	O
murine	O
genes	O
encode	O
approximately	O
6	O
-	O
kb	O
transcripts	O
.	O

Transforming	B-GENE
growth	I-GENE
factor	I-GENE
beta	I-GENE
activates	O
the	O
promoter	O
of	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
inhibitor	O
p15INK4B	B-GENE
through	O
an	O
Sp1	B-GENE
consensus	I-GENE
site	I-GENE
.	O

Cox	O
proportional	O
hazard	O
analysis	O
identified	O
dialysis	O
modality	O
and	O
pre	O
-	O
dialysis	O
UV	O
of	O
less	O
than	O
1	O
,	O
000	O
ml	O
/	O
m2	O
per	O
24	O
h	O
as	O
the	O
only	O
significant	O
risk	O
factors	O
for	O
UV	O
survival	O
.	O

The	O
hyperpigmentation	O
is	O
linked	O
to	O
the	O
presence	O
of	O
numerous	O
single	O
melanosomes	O
and	O
polymelanosomes	O
in	O
keratinocytes	O
at	O
all	O
levels	O
of	O
the	O
epidermis	O
,	O
and	O
in	O
dermal	O
Factor	B-GENE
XIIIa	I-GENE
-	O
positive	O
dendrocytes	O
.	O

Possible	O
or	O
definite	O
neglect	O
or	O
abuse	O
before	O
36	O
months	O
of	O
age	O
was	O
correlated	O
with	O
low	O
DBH	B-GENE
activity	O
.	O

Previously	O
,	O
we	O
identified	O
two	O
human	B-GENE
SMC	I-GENE
family	I-GENE
proteins	I-GENE
,	O
hCAP	B-GENE
-	I-GENE
C	I-GENE
and	O
hCAP	B-GENE
-	I-GENE
E	I-GENE
,	O
which	O
form	O
a	O
heterodimeric	O
complex	O
(	O
hCAP	B-GENE
-	I-GENE
C	I-GENE
-	O
hCAP	B-GENE
-	I-GENE
E	I-GENE
)	O
in	O
the	O
cell	O
.	O

The	O
mouse	B-GENE
alpha	I-GENE
A	I-GENE
-	I-GENE
CRYBP1	I-GENE
gene	I-GENE
specifies	O
a	O
2	O
,	O
688	O
-	O
amino	O
acid	O
protein	O
with	O
72	O
%	O
amino	O
acid	O
identity	O
to	O
its	O
human	O
homologue	O
,	O
PRDII	B-GENE
-	I-GENE
BF1	I-GENE
.	O

Methylation	O
interference	O
analysis	O
established	O
at	O
single	O
nucleotide	O
resolution	O
that	O
purified	O
recombinant	O
Fos	B-GENE
and	O
Jun	B-GENE
proteins	I-GENE
bind	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
sites	I-GENE
within	O
the	O
VDRE	O
and	O
OC	B-GENE
box	I-GENE
.	O

These	O
include	O
urinalysis	O
,	O
chest	O
X	O
-	O
P	O
,	O
ECG	O
,	O
hematological	O
examinations	O
(	O
RBC	O
,	O
WBC	O
,	O
Ht	O
,	O
Hb	B-GENE
,	O
PLT	O
and	O
ESR	O
)	O
and	O
biochemical	O
tests	O
(	O
AST	B-GENE
,	O
ALT	B-GENE
,	O
ALP	B-GENE
,	O
gamma	B-GENE
GTP	I-GENE
,	O
LDH	B-GENE
,	O
CPK	B-GENE
,	O
Chol	O
,	O
T	O
-	O
Bil	O
,	O
TP	O
,	O
Alb	B-GENE
,	O
TG	O
,	O
BUN	O
,	O
Cr	O
,	O
Glu	O
,	O
Na	O
,	O
K	O
,	O
Ca	O
,	O
P	O
and	O
CRP	B-GENE
)	O
.	O

Both	O
the	O
inactive	O
domain	B-GENE
II	I-GENE
P68	I-GENE
mutant	I-GENE
and	O
the	O
deletion	O
mutant	O
lacking	O
aa	O
91	O
-	O
243	O
were	O
less	O
inhibitory	O
to	O
growth	O
in	O
yeast	O
due	O
to	O
the	O
reduced	O
ability	O
to	O
phosphorylate	O
initiation	B-GENE
factor	I-GENE
2	I-GENE
alpha	I-GENE
in	O
vivo	O
.	O

All	O
patients	O
studied	O
were	O
pregnant	O
women	O
and	O
their	O
delivered	O
children	O
.	O

Current	O
body	O
size	O
(	O
wt	O
/	O
ht2	O
)	O
was	O
significantly	O
associated	O
with	O
life	O
-	O
time	O
weight	O
dissatisfaction	O
in	O
both	O
sexes	O
(	O
P	O
less	O
than	O
0	O
.	O
0005	O
)	O
.	O

Mad3	B-GENE
and	O
Mad4	B-GENE
:	O
novel	O
Max	B-GENE
-	O
interacting	O
transcriptional	O
repressors	O
that	O
suppress	O
c	B-GENE
-	I-GENE
myc	I-GENE
dependent	O
transformation	O
and	O
are	O
expressed	O
during	O
neural	O
and	O
epidermal	O
differentiation	O
.	O

CONCLUSIONS	O
:	O
Patients	O
'	O
attainment	O
of	O
TGB	O
monotherapy	O
was	O
associated	O
with	O
their	O
achievement	O
of	O
positive	O
changes	O
of	O
varying	O
degree	O
on	O
psychological	O
tests	O
.	O

The	O
pcaR	B-GENE
regulatory	I-GENE
locus	I-GENE
has	O
been	O
found	O
to	O
be	O
required	O
for	O
both	O
induction	O
of	O
all	O
of	O
the	O
genes	O
within	O
the	O
pca	B-GENE
regulon	I-GENE
(	O
pcaBDC	B-GENE
,	O
pcaIJ	B-GENE
,	O
and	O
pcaF	B-GENE
)	O
and	O
the	O
chemotactic	O
response	O
of	O
the	O
bacteria	O
to	O
aromatic	O
compounds	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
the	O
major	O
open	O
reading	O
frame	O
(	O
RF4	O
;	O
2	O
.	O
3	O
kb	O
)	O
as	O
being	O
essential	O
for	O
activation	O
,	O
and	O
we	O
have	O
shown	O
that	O
the	O
NF	B-GENE
kappa	I-GENE
B	I-GENE
,	O
SP1	B-GENE
,	O
and	O
TATA	O
box	O
motifs	O
in	O
the	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
LTR	I-GENE
are	O
all	O
required	O
for	O
full	O
induction	O
of	O
the	O
promoter	O
by	O
the	O
HHV	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
encoded	I-GENE
transactivator	I-GENE
.	O

However	O
,	O
mutations	O
of	O
the	O
C	O
-	O
rich	O
element	O
that	O
disrupted	O
a	O
GC	O
box	O
located	O
on	O
the	O
inverse	O
strand	O
eliminated	O
PMA	O
responsiveness	O
and	O
,	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
eliminated	O
binding	O
of	O
Sp1	B-GENE
.	O

TFIIB	B-GENE
and	O
VDR	B-GENE
can	O
also	O
interact	O
directly	O
,	O
and	O
these	O
factors	O
synergize	O
to	O
mediate	O
transactivation	O
.	O

Both	O
algorithms	O
have	O
been	O
implemented	O
and	O
applied	O
to	O
data	O
simulated	O
for	O
a	O
scanner	O
with	O
a	O
large	O
axial	O
aperture	O
(	O
30	O
degrees	O
)	O
,	O
and	O
also	O
to	O
data	O
acquired	O
with	O
the	O
ECAT	O
HR	O
and	O
the	O
ECAT	O
HR	O
+	O
scanners	O
.	O

The	O
well	O
-	O
trained	O
group	O
was	O
measured	O
once	O
in	O
the	O
respiration	O
chamber	O
for	O
36	O
h	O
according	O
to	O
the	O
same	O
protocol	O
.	O

Samarium	O
-	O
153	O
for	O
intravascular	O
irradiation	O
therapy	O
with	O
liquid	O
-	O
filled	O
balloons	O
to	O
prevent	O
restenosis	O
:	O
acute	O
and	O
long	O
-	O
term	O
results	O
in	O
a	O
hypercholesterolemic	O
rabbit	O
restenosis	O
model	O
.	O

Only	O
viable	O
bacteria	O
at	O
a	O
high	O
concentration	O
induced	O
purulent	O
otitis	O
media	O
,	O
which	O
was	O
culture	O
positive	O
in	O
58	O
%	O
of	O
the	O
cases	O
on	O
day	O
4	O
.	O

Polyoma	O
virus	O
in	O
urine	O
during	O
pregnancy	O
.	O

Transfer	O
of	O
F	O
-	O
like	O
plasmids	O
is	O
regulated	O
by	O
the	O
FinOP	B-GENE
system	O
,	O
which	O
controls	O
the	O
expression	O
of	O
traJ	B-GENE
,	O
a	O
positive	O
regulator	O
of	O
the	O
transfer	O
operon	O
.	O

PKCI	B-GENE
-	I-GENE
1	I-GENE
is	O
a	O
member	O
of	O
the	O
HIT	B-GENE
family	I-GENE
of	O
proteins	O
,	O
shown	O
by	O
sequence	O
identity	O
to	O
be	O
conserved	O
in	O
a	O
broad	O
range	O
of	O
organisms	O
including	O
mycoplasma	O
,	O
plants	O
,	O
and	O
humans	O
.	O

Conversion	O
of	O
glucose	O
phosphate	O
-	O
14C	O
to	O
glucose	O
-	O
14C	O
in	O
passage	O
through	O
human	O
brain	O
in	O
vivo	O
.	O

A	O
simple	O
technique	O
for	O
obtaining	O
ultra	O
-	O
thin	O
sections	O
of	O
coccidian	O
oocysts	O
is	O
reported	O
.	O

It	O
was	O
found	O
that	O
on	O
the	O
14th	O
and	O
21st	O
day	O
after	O
cimetidine	O
administration	O
serum	B-GENE
gastrin	I-GENE
levels	O
were	O
significantly	O
elevated	O
.	O

Dual	O
signal	O
peptides	O
mediate	O
the	O
signal	B-GENE
recognition	I-GENE
particle	I-GENE
/	O
Sec	B-GENE
-	O
independent	O
insertion	O
of	O
a	O
thylakoid	O
membrane	O
polyprotein	O
,	O
PsbY	B-GENE
.	O

The	O
resulting	O
score	O
,	O
which	O
allowed	O
the	O
disease	O
to	O
be	O
expressed	O
as	O
a	O
continuous	O
variable	O
,	O
was	O
effectively	O
utilized	O
to	O
see	O
the	O
correlations	O
between	O
the	O
severity	O
of	O
coronary	O
arterial	O
disease	O
(	O
CAD	O
)	O
and	O
individual	O
risk	O
factors	O
/	O
risk	O
markers	O
.	O

On	O
guanidine	O
and	O
the	O
treatment	O
of	O
botulism	O
.	O

Electronic	O
structure	O
of	O
Si	O
(	O
111	O
)	O
-	O
NiSi2	O
(	O
111	O
)	O
A	O
-	O
type	O
and	O
B	O
-	O
type	O
interfaces	O
.	O

In	O
our	O
case	O
the	O
development	O
of	O
the	O
tumor	O
at	O
the	O
posterior	O
side	O
of	O
the	O
prostate	O
,	O
the	O
lack	O
of	O
PSA	B-GENE
immunoreactivity	O
and	O
the	O
presence	O
of	O
mucinous	O
glands	O
,	O
sometimes	O
"	O
endocervical	O
-	O
like	O
"	O
,	O
could	O
suggest	O
an	O
origin	O
from	O
embryonic	O
mullerian	O
remnants	O
in	O
the	O
prostatic	O
utricle	O
rather	O
than	O
urogenital	O
sinus	O
.	O

Upon	O
increasing	O
the	O
Marangoni	O
number	O
beyond	O
this	O
threshold	O
,	O
the	O
initially	O
stationary	O
flow	O
becomes	O
quickly	O
time	O
dependent	O
.	O

The	O
results	O
showed	O
differential	O
activation	O
of	O
each	O
parahippocampal	O
region	O
during	O
verbal	O
memory	O
tasks	O
in	O
which	O
the	O
side	O
activated	O
shifted	O
depending	O
on	O
the	O
nature	O
of	O
the	O
task	O
employed	O
;	O
an	O
increase	O
in	O
rCBF	O
in	O
the	O
left	O
parahippocampal	O
gyrus	O
was	O
associated	O
with	O
retrieval	O
strategy	O
of	O
non	O
-	O
matching	O
,	O
and	O
an	O
increase	O
in	O
rCBF	O
in	O
the	O
right	O
parahippocampal	O
gyrus	O
was	O
associated	O
with	O
retrieval	O
strategy	O
of	O
matching	O
.	O

Evolution	O
of	O
cytomegalovirus	O
antibodies	O
of	O
maternal	O
origin	O
and	O
acquired	O
,	O
throughout	O
the	O
first	O
year	O
of	O
life	O

Demonstration	O
of	O
changes	O
in	O
fetal	O
liver	O
erythropoiesis	O
using	O
echo	O
-	O
planar	O
magnetic	O
resonance	O
imaging	O
.	O

The	O
actual	O
placement	O
of	O
the	O
lesions	O
was	O
determined	O
after	O
mapping	O
of	O
the	O
GPi	O
by	O
microrecording	O
,	O
using	O
stimulation	O
to	O
identify	O
the	O
sensorimotor	O
region	O
and	O
its	O
somatotopic	O
organization	O
.	O

Effect	O
of	O
prostaglandin	O
E2	O
on	O
experimental	O
atherosclerosis	O
.	O

Both	O
the	O
arterial	O
and	O
venous	O
thrombi	O
were	O
clearly	O
discernible	O
at	O
2	O
to	O
8	O
h	O
after	O
injection	O
of	O
99Tcm	O
-	O
SZ	O
-	O
51	O
.	O

The	O
effect	O
of	O
lung	O
edema	O
on	O
pulmonary	O
vasoactivity	O
of	O
furosemide	O
.	O

However	O
,	O
the	O
malaria	O
vectors	O
Anopheles	O
funestus	O
and	O
An	O
.	O
gambiae	O
have	O
both	O
become	O
more	O
abundant	O
during	O
the	O
1970s	O
and	O
1980s	O
and	O
sporozoite	O
-	O
positive	O
specimens	O
of	O
both	O
have	O
been	O
found	O
.	O

Soluble	O
extracts	O
from	O
FGF	B-GENE
-	O
treated	O
as	O
compared	O
with	O
quiescent	O
fibroblasts	O
exhibited	O
up	O
to	O
3	O
-	O
fold	O
higher	O
kinase	O
activity	O
towards	O
S6	B-GENE
in	O
exogenously	O
added	O
rat	B-GENE
liver	I-GENE
40S	I-GENE
ribosomes	I-GENE
and	O
a	O
synthetic	O
peptide	O
,	O
RRLSSLRA	O
.	O

In	O
bell	O
pepper	O
,	O
a	O
gene	O
encoding	O
a	O
major	O
plastid	O
-	O
lipid	O
associated	O
protein	O
is	O
expressed	O
as	O
both	O
partially	O
and	O
totally	O
spliced	O
transcripts	O
(	O
respectively	O
PAP2	B-GENE
and	O
PAP1	B-GENE
)	O
.	O

Inhibitory	O
receptors	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
characteristic	O
sequence	O
known	O
as	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
(	O
ITIM	O
)	O
in	O
their	O
cytoplasmic	O
tail	O
.	O

We	O
conclude	O
that	O
LGCS	O
is	O
successful	O
in	O
treating	O
esophageal	O
varices	O
in	O
the	O
setting	O
of	O
hyperdynamic	O
portal	O
circulation	O
with	O
acceptable	O
liver	O
function	O
.	O

Candidate	O
factors	O
have	O
been	O
identified	O
by	O
the	O
observation	O
that	O
changes	O
in	O
glucocorticoid	O
induction	O
parameters	O
in	O
CV	O
-	O
1	O
cells	O
could	O
be	O
reproduced	O
by	O
varying	O
the	O
cellular	O
levels	O
of	O
coactivators	O
[	O
transcriptional	B-GENE
intermediary	I-GENE
factor	I-GENE
2	I-GENE
(	O
TIF2	B-GENE
)	O
,	O
steroid	B-GENE
receptor	I-GENE
coactivator	I-GENE
1	I-GENE
(	O
SRC	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
and	O
amplified	B-GENE
in	I-GENE
breast	I-GENE
cancer	I-GENE
1	I-GENE
(	O
AIB1	B-GENE
)	O
]	O
,	O
comodulator	O
[	O
CREB	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CBP	B-GENE
)	O
]	O
,	O
or	O
corepressor	O
[	O
silencing	B-GENE
mediator	I-GENE
for	I-GENE
retinoid	I-GENE
and	I-GENE
thyroid	I-GENE
-	I-GENE
hormone	I-GENE
receptors	I-GENE
(	O
SMRT	B-GENE
)	O
]	O
without	O
concomitant	O
increases	O
in	O
GR	B-GENE
.	O

Immunoblot	O
analyses	O
revealed	O
that	O
the	O
loss	O
of	O
activator	O
function	O
coincides	O
with	O
selective	O
removal	O
of	O
the	O
C	B-GENE
-	I-GENE
terminal	I-GENE
domain	I-GENE
(	I-GENE
CTD	I-GENE
)	I-GENE
-	I-GENE
hyperphosphorylated	I-GENE
RNAP	I-GENE
IIO	I-GENE
along	O
with	O
NC2	B-GENE
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
gene	O
encoding	O
this	O
product	O
was	O
determined	O
and	O
the	O
amino	O
acid	O
sequence	O
deduced	O
.	O

At	O
9	O
months	O
postpartum	O
,	O
serum	O
fT4	O
and	O
fT3	O
levels	O
were	O
low	O
normal	O
(	O
8	O
.	O
0	O
and	O
1	O
.	O
7	O
pmol	O
/	O
L	O
,	O
respectively	O
)	O
,	O
but	O
TSH	B-GENE
was	O
not	O
raised	O
(	O
0	O
.	O
4	O
mU	O
/	O
L	O
)	O
.	O

RESULTS	O
:	O
Three	O
patients	O
did	O
not	O
tolerate	O
PPI	O
medication	O
and	O
were	O
managed	O
by	O
treatment	O
with	O
type	O
2	O
histamine	O
(	O
H2	O
)	O
blockers	O
.	O

It	O
is	O
considered	O
important	O
,	O
therefore	O
,	O
when	O
treating	O
diabetic	O
patients	O
with	O
peripheral	O
neuropathy	O
not	O
to	O
assume	O
that	O
the	O
diabetes	O
itself	O
is	O
the	O
cause	O
in	O
all	O
cases	O
.	O

TFIIIB	B-GENE
assembles	O
autonomously	O
on	O
the	O
upstream	O
promoter	O
of	O
the	O
yeast	B-GENE
U6	I-GENE
snRNA	I-GENE
(	O
SNR6	B-GENE
)	O
gene	O
in	O
vitro	O
,	O
through	O
the	O
interaction	O
of	O
its	O
TBP	B-GENE
subunit	I-GENE
with	O
a	O
consensus	O
TATA	O
box	O
located	O
at	O
base	O
pair	O
-	O
30	O
.	O

Mutational	O
analysis	O
of	O
the	O
IME2	B-GENE
UAS	I-GENE
reveals	O
two	O
critical	O
sequence	O
elements	O
:	O
a	O
G	O
+	O
C	O
-	O
rich	O
sequence	O
(	O
called	O
URS1	O
)	O
,	O
previously	O
identified	O
at	O
many	O
meiotic	O
genes	O
,	O
and	O
a	O
newly	O
described	O
element	O
,	O
the	O
T4C	O
site	O
,	O
that	O
we	O
found	O
at	O
a	O
subset	O
of	O
meiotic	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
mannitol	O
operon	O
of	O
Clostridium	O
acetobutylicum	O
encoding	O
a	O
phosphotransferase	O
system	O
and	O
a	O
putative	O
PTS	O
-	O
modulated	O
regulator	O
.	O

Our	O
results	O
show	O
that	O
a	O
combination	O
of	O
Pfu	B-GENE
exo	I-GENE
(	I-GENE
-	I-GENE
)	I-GENE
at	O
the	O
primer	O
extension	O
step	O
and	O
Taq	B-GENE
at	O
the	O
PCR	O
amplification	O
step	O
is	O
ideal	O
for	O
in	O
vivo	O
DNA	O
analysis	O
and	O
DNA	O
damage	O
mapping	O
using	O
LMPCR	O
.	O

Effect	O
of	O
TNF	B-GENE
,	O
IL	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
IL	B-GENE
-	I-GENE
6	I-GENE
on	O
the	O
proliferation	O
of	O
human	O
Tenon	O
'	O
s	O
capsule	O
fibroblasts	O
in	O
tissue	O
culture	O
.	O

Estimating	O
the	O
health	O
care	O
costs	O
of	O
smokers	O
.	O

Using	O
lacZ	B-GENE
-	O
inducible	O
T	O
cells	O
as	O
a	O
probe	O
,	O
we	O
screened	O
a	O
splenic	O
cDNA	O
library	O
in	O
transiently	O
transfected	O
antigen	O
-	O
presenting	O
cells	O
(	O
APCs	O
)	O
and	O
isolated	O
a	O
cDNA	O
clone	O
that	O
allowed	O
expression	O
of	O
the	O
appropriate	O
peptide	B-GENE
/	I-GENE
Kb	I-GENE
MHC	I-GENE
complex	I-GENE
in	O
APC	O
.	O

Endotoxemia	O
and	O
bacteremia	O
in	O
patients	O
with	O
sepsis	O
syndrome	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

Early	O
attempts	O
for	O
modifying	O
growth	O
functions	O
to	O
annual	O
variations	O
dating	O
back	O
up	O
to	O
2	O
decades	O
are	O
recalled	O
together	O
with	O
examples	O
for	O
their	O
application	O
showing	O
rather	O
different	O
degrees	O
of	O
approximation	O
.	O

A	O
significant	O
reduction	O
in	O
total	O
cellular	O
p27	B-GENE
protein	I-GENE
levels	O
and	O
a	O
moderate	O
reduction	O
in	O
p27	B-GENE
mRNA	I-GENE
are	O
observed	O
,	O
but	O
no	O
changes	O
in	O
Cdk	B-GENE
regulatory	O
kinases	O
and	O
phosphatases	O
occur	O
.	O

Genetic	O
linkage	O
mapping	O
of	O
the	O
CYP11A1	B-GENE
gene	I-GENE
encoding	O
the	O
cholesterol	O
side	O
-	O
chain	O
cleavage	O
P450scc	B-GENE
close	O
to	O
the	O
CYP1A1	B-GENE
gene	I-GENE
and	O
D15S204	B-GENE
in	O
the	O
chromosome	O
15q22	O
.	O
33	O
-	O
q23	O
region	O
.	O

Genetic	O
and	O
physiological	O
experiments	O
suggest	O
a	O
close	O
relationship	O
between	O
cdc27	B-GENE
+	I-GENE
and	O
the	O
cdc2	B-GENE
+	I-GENE
gene	I-GENE
,	O
a	O
key	O
regulator	O
of	O
mitosis	O
in	O
yeast	O
and	O
also	O
in	O
higher	O
eukaryotic	O
cells	O
.	O

The	O
study	O
was	O
performed	O
in	O
a	O
class	O
100	O
laminar	O
flow	O
clean	O
bench	O
in	O
order	O
to	O
minimize	O
particulate	O
contamination	O
from	O
extraneous	O
sources	O
.	O

The	O
cloned	O
rRNA	O
operon	O
was	O
transcribed	O
in	O
vitro	O
by	O
using	O
purified	B-GENE
RNA	I-GENE
polymerase	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

Of	O
the	O
CSF	O
tested	O
,	O
24	O
stimulated	O
oxygen	O
consumption	O
above	O
our	O
cut	O
off	O
,	O
and	O
8	O
did	O
not	O
(	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
34	O
,	O
n	O
=	O
24	O
compared	O
with	O
the	O
rate	O
of	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
1	O
mumol	O
/	O
min	O
/	O
g	O
dry	O
wt	O
,	O
respectively	O
;	O
SD	O
n	O
=	O
8	O
)	O
at	O
180	O
minutes	O
.	O

The	O
sequence	O
of	O
the	O
gene	O
upstream	O
to	O
the	O
cap	O
site	O
contains	O
characteristic	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
promoter	I-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
:	O
a	O
putative	O
TATA	O
box	O
at	O
position	O
-	O
29	O
and	O
a	O
Sp	B-GENE
1	I-GENE
binding	I-GENE
site	I-GENE
(	O
GGGGCGGAGA	O
)	O
at	O
position	O
-	O
48	O
.	O

The	O
kinetics	O
of	O
[	O
14C	O
]	O
NG	O
in	O
the	O
blood	O
of	O
the	O
dosed	O
animals	O
was	O
followed	O
.	O

These	O
clones	O
contain	O
most	O
of	O
the	O
exon	O
of	O
cyclin	B-GENE
D2	I-GENE
except	O
exon	O
5	O
.	O

One	O
had	O
a	O
48	O
-	O
hour	O
cycle	O
and	O
the	O
other	O
a	O
24	O
-	O
hour	O
cycle	O
.	O

This	O
action	O
could	O
be	O
antagonized	O
by	O
aminophylline	O
,	O
a	O
competitive	O
antagonist	O
on	O
P1	B-GENE
purinoceptors	I-GENE
.	O

Evidence	O
for	O
Gcr1p	B-GENE
/	O
Gcr2p	B-GENE
interaction	O
has	O
been	O
presented	O
earlier	O
and	O
is	O
now	O
supported	O
by	O
the	O
isolation	O
of	O
mutations	O
in	O
Gcr1p	B-GENE
suppressing	O
gcr2	B-GENE
,	O
as	O
assessed	O
by	O
growth	O
and	O
enzyme	O
assay	O
.	O

Keys	O
can	O
be	O
used	O
for	O
identifying	O
species	O
from	O
the	O
European	O
part	O
of	O
the	O
USSR	O
and	O
north	O
-	O
eastern	O
Kazakhstan	O
.	O

Promoter	O
constructs	O
containing	O
mutations	O
in	O
the	O
PTRE	B-GENE
sequence	I-GENE
that	O
selectively	O
abolished	O
the	O
binding	O
of	O
either	O
one	O
or	O
both	O
complexes	O
exerted	O
opposite	O
effects	O
on	O
the	O
transcriptional	O
activity	O
of	O
trypsin	B-GENE
promoters	I-GENE
in	O
A	O
.	O
gambiae	O
and	O
Aedes	O
aegypti	O
cell	O
lines	O
.	O

The	O
Rep78	B-GENE
protein	I-GENE
of	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
contains	O
amino	O
acid	O
sequence	O
motifs	O
common	O
to	O
rolling	B-GENE
-	I-GENE
circle	I-GENE
replication	I-GENE
(	I-GENE
RCR	I-GENE
)	I-GENE
initiator	I-GENE
proteins	I-GENE
.	O

Plasma	O
prolactin	B-GENE
in	O
patients	O
with	O
colorectal	O
cancer	O
.	O

Reality	O
and	O
clinical	O
application	O
of	O
immunoglobulin	B-GENE
preparations	O

The	O
extent	O
of	O
myocardial	O
ischemia	O
in	O
the	O
coronary	O
sinus	O
study	O
was	O
significantly	O
correlated	O
to	O
the	O
coronary	O
diameters	O
of	O
the	O
proximal	O
and	O
middle	O
segments	O
of	O
the	O
Ramus	O
interventricularis	O
anterior	O
and	O
the	O
middle	O
segment	O
of	O
the	O
Ramus	O
circumflexus	O
(	O
r	O
=	O
0	O
.	O
87	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
in	O
-	O
plane	O
orientational	O
anisotropy	O
of	O
the	O
8CB	O
films	O
grown	O
on	O
unidirectionally	O
photopolymerized	O
PVCN	O
substrates	O
is	O
considerably	O
lower	O
than	O
the	O
intrinsic	O
surface	O
orientational	O
anisotropy	O
of	O
these	O
substrates	O
,	O
which	O
can	O
explain	O
the	O
generally	O
found	O
weak	O
surface	O
anchoring	O
of	O
liquid	O
crystals	O
on	O
PVCN	O
alignment	O
layers	O
.	O

Nuclear	O
transcription	O
assays	O
confirmed	O
that	O
cys	B-GENE
-	I-GENE
3	I-GENE
+	I-GENE
was	O
under	O
sulfur	O
-	O
regulated	O
transcriptional	O
control	O
and	O
that	O
cys	B-GENE
-	I-GENE
3	I-GENE
+	I-GENE
transcription	O
was	O
constitutive	O
in	O
sulfur	B-GENE
controller	I-GENE
(	O
scon	B-GENE
)	O
-	O
negative	O
regulator	O
mutants	O
.	O

The	O
rifampicin	O
resistance	O
of	O
uvsW	B-GENE
-	O
repressed	O
replication	O
suggests	O
that	O
it	O
involves	O
either	O
tertiary	O
initiation	O
or	O
some	O
novel	O
mode	O
of	O
initiation	O
.	O

Pharmacokinetics	O
of	O
skin	O
penetration	O
.	O

Furthermore	O
,	O
the	O
regulation	O
conferred	O
on	O
a	O
reporter	O
gene	O
in	O
Drosophila	O
by	O
three	O
closely	O
related	O
sequences	O
demonstrates	O
that	O
even	O
subtle	O
sequence	O
changes	O
within	O
an	O
E	O
box	O
or	O
flanking	O
bases	O
have	O
dramatic	O
consequences	O
on	O
the	O
overall	O
repertoire	O
of	O
proteins	O
that	O
can	O
bind	O
in	O
vivo	O
.	O

Buspirone	O
therapy	O
for	O
Type	O
A	O
behavior	O
,	O
hostility	O
,	O
and	O
perceived	O
stress	O
in	O
cardiac	O
patients	O
.	O

Recently	O
we	O
have	O
performed	O
a	O
detailed	O
analysis	O
of	O
specific	O
neuronal	O
populations	O
affected	O
by	O
the	O
mutation	O
which	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
Krox	B-GENE
-	I-GENE
20	I-GENE
in	O
the	O
segmentation	O
and	O
on	O
the	O
physiological	O
consequences	O
of	O
its	O
inactivation	O
.	O

A	O
species	O
comparison	O
of	O
cDNA	O
sequences	O
and	O
isolation	O
of	O
a	O
genomic	O
clone	O
.	O

The	O
inhibition	O
of	O
monoamine	B-GENE
oxidase	I-GENE
(	O
MAO	B-GENE
)	O
by	O
tranylcypromine	O
was	O
studied	O
in	O
6	O
healthy	O
volunteers	O
given	O
increasing	O
doses	O
of	O
10	O
,	O
15	O
,	O
20	O
and	O
25	O
mg	O
/	O
day	O
over	O
a	O
4	O
-	O
week	O
period	O
.	O

Deletion	O
mutagenesis	O
of	O
the	O
promoter	O
indicated	O
that	O
a	O
positive	O
regulatory	O
element	O
(	O
PRE	O
)	O
was	O
likely	O
to	O
exist	O
downstream	O
of	O
the	O
UL94	B-GENE
mRNA	I-GENE
start	I-GENE
site	I-GENE
,	O
while	O
a	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
was	O
present	O
upstream	O
of	O
the	O
TATA	O
box	O
.	O

Expression	O
of	O
Helios	B-GENE
was	O
detected	O
in	O
the	O
earliest	O
hematopoietic	O
sites	O
of	O
the	O
embryo	O
,	O
in	O
hematopoietic	O
stem	O
cells	O
in	O
the	O
adult	O
and	O
was	O
subsequently	O
restricted	O
to	O
a	O
subset	O
of	O
cells	O
in	O
the	O
T	O
cell	O
lineage	O
.	O

Metapsychiatry	O
is	O
a	O
term	O
born	O
of	O
necessity	O
to	O
designate	O
the	O
important	O
but	O
hitherto	O
unclassified	O
interface	O
between	O
psychiatry	O
and	O
mysticism	O
.	O

Effects	O
of	O
negative	O
pi	O
mesons	O
on	O
mouse	O
bone	O
marrow	O
cells	O
.	O

Using	O
probes	O
containing	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
from	O
the	O
iNOS	B-GENE
gene	I-GENE
revealed	O
further	O
binding	O
of	O
different	O
complexes	O
,	O
all	O
of	O
which	O
were	O
strongly	O
inducible	O
by	O
cAMP	O
and	O
to	O
a	O
lower	O
extent	O
also	O
by	O
IL	B-GENE
-	I-GENE
1beta	I-GENE
.	O

The	O
Pi	O
signals	O
are	O
conveyed	O
to	O
PHO8	B-GENE
by	O
binding	O
of	O
PHO4	B-GENE
protein	I-GENE
,	O
a	O
positive	O
regulatory	O
factor	O
,	O
to	O
a	O
promoter	O
region	O
of	O
PHO8	B-GENE
(	O
PHO8p	B-GENE
)	O
under	O
the	O
influence	O
of	O
the	O
PHO	B-GENE
regulatory	O
circuit	O
.	O

Thus	O
,	O
the	O
end	O
of	O
a	O
linearized	O
DNA	O
fragment	O
can	O
initiate	O
new	O
DNA	O
synthesis	O
by	O
BIR	O
in	O
which	O
the	O
newly	O
synthesized	O
DNA	O
is	O
displaced	O
and	O
subsequently	O
forms	O
circles	O
by	O
NHEJ	O
.	O

It	O
would	O
seem	O
that	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
HPL	B-GENE
values	O
as	O
an	O
index	O
of	O
placental	O
function	O
in	O
anaemic	O
women	O
.	O

A	O
case	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
before	O
1980	O
.	O

These	O
data	O
suggest	O
that	O
multiple	O
genetic	O
recombination	O
among	O
bacteriophages	O
with	O
different	O
immunities	O
took	O
place	O
to	O
generate	O
the	O
prophage	O
VT1	O
-	O
Sakai	O
.	O

The	O
adenovirus	B-GENE
E1B	I-GENE
19	I-GENE
,	I-GENE
000	I-GENE
-	I-GENE
molecular	I-GENE
-	I-GENE
weight	I-GENE
(	I-GENE
19K	I-GENE
)	I-GENE
protein	I-GENE
is	O
a	O
potent	O
inhibitor	O
of	O
apoptosis	O
and	O
cooperates	O
with	O
E1A	B-GENE
to	O
transform	O
primary	O
rodent	O
cells	O
.	O

Desensitization	O
of	O
the	O
growth	B-GENE
hormone	I-GENE
-	O
induced	O
Janus	B-GENE
kinase	I-GENE
2	I-GENE
(	O
Jak	B-GENE
2	I-GENE
)	O
/	O
signal	B-GENE
transducer	I-GENE
and	I-GENE
activator	I-GENE
of	I-GENE
transcription	I-GENE
5	I-GENE
(	O
Stat5	B-GENE
)	O
-	O
signaling	O
pathway	O
requires	O
protein	O
synthesis	O
and	O
phospholipase	B-GENE
C	I-GENE
.	O

In	O
two	O
separate	O
studies	O
,	O
specimens	O
of	O
saliva	O
from	O
57	O
individuals	O
over	O
the	O
age	O
of	O
65	O
years	O
(	O
mean	O
age	O
,	O
76	O
.	O
7	O
years	O
)	O
and	O
37	O
persons	O
under	O
the	O
age	O
of	O
40	O
years	O
(	O
mean	O
age	O
,	O
28	O
.	O
8	O
years	O
)	O
were	O
examined	O
for	O
concentrations	O
of	O
IgA	B-GENE
as	O
functions	O
of	O
volume	O
,	O
total	O
protein	O
,	O
and	O
electrolyte	O
conductivity	O
;	O
some	O
were	O
also	O
tested	O
for	O
IgG	B-GENE
and	O
IgM	B-GENE
content	O
.	O

E2A	B-GENE
-	O
HLF	B-GENE
-	O
mediated	O
cell	O
transformation	O
requires	O
both	O
the	O
trans	O
-	O
activation	O
domains	O
of	O
E2A	B-GENE
and	O
the	O
leucine	O
zipper	O
dimerization	O
domain	O
of	O
HLF	B-GENE
.	O

Two	O
adjacent	O
,	O
highly	O
homologous	B-GENE
endoglucanase	I-GENE
genes	I-GENE
,	O
celD	B-GENE
and	O
celE	B-GENE
from	O
Fibrobacter	O
succinogenes	O
S85	O
,	O
which	O
were	O
separated	O
by	O
an	O
AT	O
-	O
rich	O
223	O
-	O
nucleotide	O
intergenic	O
region	O
were	O
characterized	O
.	O

The	O
Seldinger	O
technique	O
for	O
difficult	O
transurethral	O
catheterization	O
:	O
a	O
gentle	O
alternative	O
to	O
suprapubic	O
puncture	O
(	O
Br	O
J	O
Surg	O
2000	O
;	O
87	O
:	O
1729	O
-	O
30	O
)	O
.	O

We	O
screened	O
an	O
A	O
.	O
thaliana	O
cDNA	O
library	O
,	O
whose	O
inserts	O
are	O
under	O
the	O
control	O
of	O
the	O
galactose	O
-	O
inducible	O
GAL10	B-GENE
promoter	I-GENE
,	O
for	O
cDNAs	O
which	O
enabled	O
YDH8	O
cells	O
to	O
grow	O
at	O
the	O
restrictive	O
temperature	O
.	O

We	O
generated	O
"	O
signature	O
"	O
oligonucleotides	O
from	O
these	O
CDR3s	B-GENE
and	O
probed	O
PCR	O
amplified	O
V	B-GENE
kappa	I-GENE
products	I-GENE
from	O
the	O
synovium	O
and	O
PBLs	O
of	O
the	O
same	O
patient	O
,	O
and	O
from	O
PBLs	O
and	O
spleen	O
of	O
individuals	O
without	O
rheumatic	O
disease	O
.	O

One	O
of	O
the	O
major	O
transcripts	O
encodes	O
MEQ	B-GENE
,	O
a	O
339	O
-	O
amino	O
-	O
acid	O
bZIP	B-GENE
protein	I-GENE
which	O
is	O
homologous	O
to	O
the	O
Jun	B-GENE
/	O
Fos	B-GENE
family	O
of	O
transcription	O
factors	O
.	O

It	O
is	O
concluded	O
that	O
the	O
new	O
class	O
of	O
competitive	O
NMDA	B-GENE
receptor	I-GENE
antagonists	O
,	O
exemplified	O
by	O
CGP	O
37849	O
,	O
is	O
the	O
most	O
promising	O
candidate	O
for	O
clinical	O
trials	O
in	O
anxiety	O
disorders	O
.	O

An	O
emended	O
diagnosis	O
of	O
Tylocephalum	O
is	O
proposed	O
excluding	O
this	O
feature	O
,	O
along	O
with	O
distribution	O
of	O
the	O
testes	O
in	O
the	O
preovarian	O
field	O
and	O
circummedullary	O
distribution	O
of	O
vitelline	O
follicles	O
.	O

Induction	O
of	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
(	O
IFNalpha	B-GENE
)	O
gene	O
expression	O
in	O
virus	O
-	O
infected	O
cells	O
requires	O
phosphorylation	O
-	O
induced	O
activation	O
of	O
the	O
transcription	O
factors	O
IRF3	B-GENE
and	O
IRF7	B-GENE
.	O

METHODS	O
:	O
The	O
prevalence	O
of	O
haemagglutination	B-GENE
inhibiting	I-GENE
(	I-GENE
HI	I-GENE
)	I-GENE
antibodies	I-GENE
to	O
JE	O
virus	O
(	O
JEV	O
)	O
,	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
and	O
dengue	O
-	O
2	O
virus	O
(	O
DEN	O
-	O
2	O
)	O
was	O
detected	O
by	O
HI	O
test	O
and	O
IgM	B-GENE
antibody	I-GENE
capture	O
ELISA	O
(	O
MAC	O
ELISA	O
)	O
was	O
performed	O
to	O
determine	O
recent	O
infections	O
with	O
JE	O
virus	O
.	O

Moreover	O
,	O
since	O
the	O
integrated	O
transforming	O
DNA	O
was	O
not	O
altered	O
or	O
lost	O
expression	O
of	O
the	O
RbcS2	B-GENE
:	O
:	O
aadA	B-GENE
:	O
:	O
RbcS2	B-GENE
gene	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
appears	O
to	O
be	O
repressed	O
.	O

Donehower	O
and	O
H	O
.	O

A	O
characteristic	O
feature	O
is	O
their	O
tendency	O
to	O
form	O
homo	O
-	O
and	O
/	O
or	O
heterodimeric	O
complexes	O
.	O

Further	O
,	O
more	O
recent	O
communications	O
suggest	O
that	O
liver	O
disease	O
led	O
to	O
a	O
differential	O
alteration	O
of	O
the	O
cytochrome	B-GENE
P	I-GENE
-	I-GENE
450s	I-GENE
with	O
regard	O
to	O
protein	O
content	O
and	O
activity	O
.	O

Apparent	O
Buschke	O
-	O
Loewenstein	O
tumour	O
of	O
the	O
penis	O
.	O

This	O
effect	O
was	O
stronger	O
after	O
multiple	O
predoses	O
of	O
sertraline	O
,	O
when	O
imipramine	O
Cmax	O
and	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
were	O
increased	O
by	O
39	O
%	O
and	O
68	O
%	O
,	O
respectively	O
.	O

Mutations	O
in	O
nifR1	B-GENE
(	O
ntrC	B-GENE
)	O
and	O
nifR4	B-GENE
(	O
rpoN	B-GENE
,	O
encoding	O
sigma54	B-GENE
)	O
had	O
no	O
influence	O
on	O
xdh	B-GENE
gene	I-GENE
expression	O
.	O

We	O
therefore	O
propose	O
that	O
PRR2	B-GENE
,	O
and	O
not	O
PVR	B-GENE
,	O
is	O
the	O
true	O
human	O
homolog	O
of	O
MPH	B-GENE
.	O

Swarming	O
of	O
Moraxella	O

Biochem	O
.	O

In	O
contrast	O
,	O
vRel	B-GENE
lacks	O
a	O
strong	O
C	O
-	O
terminal	O
gene	O
activation	O
function	O
,	O
since	O
a	O
LexA	B-GENE
fusion	I-GENE
protein	I-GENE
containing	O
C	B-GENE
-	I-GENE
terminal	I-GENE
vRel	I-GENE
sequences	I-GENE
alone	O
only	O
weakly	O
activated	O
transcription	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
yeast	O
Phe	B-GENE
-	I-GENE
tRNAPhe	I-GENE
ternary	I-GENE
complex	I-GENE
with	O
Thermus	O
aquaticus	O
EF	B-GENE
-	I-GENE
Tu	I-GENE
-	O
GDPNP	O
(	O
Phe	B-GENE
-	I-GENE
TC	I-GENE
)	O
has	O
previously	O
been	O
determined	O
as	O
one	O
representative	O
of	O
this	O
general	O
yet	O
highly	O
discriminating	O
complex	O
formation	O
.	O

Bovine	O
anaplasmosis	O
:	O
susceptibility	O
of	O
seronegative	O
cows	O
from	O
an	O
infected	O
herd	O
to	O
experimental	O
infection	O
with	O
Anaplasma	O
marginale	O
.	O

Because	O
of	O
gut	O
fermentation	O
,	O
a	O
substantial	O
portion	O
(	O
16	O
-	O
80	O
%	O
)	O
of	O
N	O
is	O
absorbed	O
as	O
ammonia	O
N	O
(	O
NH3N	O
)	O
.	O

Quantitative	O
measurement	O
of	O
antigamma	B-GENE
globulin	I-GENE
factors	I-GENE
(	O
rheumatoid	B-GENE
factors	I-GENE
)	O
using	O
laser	O
-	O
nephelometry	O
in	O
comparison	O
with	O
the	O
latex	O
agglutination	O
test	O
and	O
the	O
Waaler	O
-	O
Rose	O
test	O

The	O
densities	O
ranged	O
between	O
2	O
and	O
3976	O
neurites	O
/	O
mm2	O
skin	O
surface	O
,	O
but	O
the	O
overlap	O
between	O
subjects	O
and	O
without	O
PHN	O
was	O
small	O
.	O

Zoonotic	O
areas	O
in	O
which	O
HIV	O
co	O
-	O
infection	O
is	O
common	O
could	O
also	O
be	O
at	O
risk	O
as	O
sandflies	O
can	O
become	O
infected	O
from	O
co	O
-	O
infected	O
individuals	O
.	O

The	O
determination	O
of	O
antithrombin	B-GENE
III	I-GENE
(	O
AT	B-GENE
III	I-GENE
)	O
and	O
its	O
clinical	O
significance	O

The	O
kinetics	O
of	O
erythromycin	O
(	O
E	O
.	O
)	O
was	O
studied	O
in	O
16	O
patients	O
with	O
different	O
degrees	O
of	O
impairment	O
of	O
renal	O
function	O
after	O
a	O
single	O
intravenous	O
dose	O
.	O

Base	O
substitutions	O
within	O
this	O
NFIL	B-GENE
-	I-GENE
6	I-GENE
site	I-GENE
resulted	O
in	O
virtual	O
elimination	O
of	O
LPS	O
-	O
induced	O
IL	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
gene	I-GENE
transcription	O
.	O

Mortality	O
rates	O
were	O
not	O
different	O
(	O
chi2	O
:	O
0	O
.	O
0298	O
,	O
p	O
>	O
0	O
.	O
5	O
)	O
.	O

The	O
MALDI	O
-	O
TOF	O
experiment	O
,	O
however	O
,	O
proved	O
to	O
be	O
superior	O
to	O
the	O
GC	O
experiment	O
,	O
particularly	O
with	O
regard	O
to	O
baseline	O
resolution	O
of	O
unsaturated	O
acids	O
.	O

Modern	O
aspects	O
of	O
shock	O
-	O
treatment	O
in	O
extensive	O
burns	O
(	O
author	O
'	O
s	O
transl	O
)	O

Of	O
the	O
private	O
practices	O
accredited	O
in	O
August	O
1995	O
,	O
40	O
.	O
6	O
per	O
cent	O
(	O
122	O
)	O
participated	O
.	O

A	O
Drosophila	O
subobscura	O
genomic	O
fragment	O
containing	O
all	O
the	O
exons	O
and	O
the	O
late	O
and	O
early	O
promotors	O
in	O
the	O
Sxl	B-GENE
gene	I-GENE
of	I-GENE
D	I-GENE
.	I-GENE
melanogaster	I-GENE
was	O
isolated	O
.	O

Collectively	O
,	O
a	O
unique	O
mechanism	O
involving	O
NF	B-GENE
-	I-GENE
ATp	I-GENE
appears	O
to	O
regulate	O
the	O
cell	O
type	O
-	O
specific	O
and	O
activation	O
-	O
dependent	O
expression	O
of	O
the	O
SCM	B-GENE
-	I-GENE
1	I-GENE
genes	I-GENE
.	O

The	O
sensitivity	O
of	O
central	B-GENE
dopamine	I-GENE
receptors	I-GENE
was	O
assessed	O
with	O
the	O
growth	B-GENE
hormone	I-GENE
response	O
to	O
apomorphine	O
application	O
.	O

Oral	O
basal	O
body	O
temperature	O
(	O
BBT	O
)	O
recordings	O
of	O
46	O
women	O
that	O
conceived	O
by	O
donor	O
insemination	O
and	O
who	O
had	O
midcycle	O
monitoring	O
of	O
luteinising	B-GENE
hormone	I-GENE
(	O
LH	B-GENE
)	O
were	O
analysed	O
to	O
establish	O
features	O
associated	O
with	O
an	O
optimal	O
cycle	O
.	O

Our	O
results	O
admit	O
that	O
a	O
ribosome	O
scanning	O
mechanism	O
of	O
the	O
MP	B-GENE
gene	I-GENE
expression	O
from	O
I	O
(	O
2	O
)	O
sgRNA	O
operates	O
concurrently	O
.	O

The	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
E	O
.	O
coli	O
CR	O
domain	O
indicates	O
that	O
this	O
sequence	O
conservation	O
is	O
likely	O
to	O
result	O
in	O
a	O
conserved	O
structural	O
motif	O
.	O

Otosclerosis	O
in	O
monozygotic	O
twins	O
:	O
clinical	O
and	O
genetical	O
analysis	O

A	O
DNA	O
fragment	O
that	O
complements	O
the	O
uvs	B-GENE
-	I-GENE
2	I-GENE
mutation	O
was	O
subcloned	O
by	O
monitoring	O
its	O
ability	O
to	O
transform	O
the	O
uvs	B-GENE
-	I-GENE
2	I-GENE
mutant	I-GENE
to	O
MMS	O
resistance	O
.	O

The	O
human	B-GENE
lbc	I-GENE
oncogene	I-GENE
product	I-GENE
is	O
a	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
that	O
specifically	O
activates	O
the	O
Rho	B-GENE
small	I-GENE
GTP	I-GENE
binding	I-GENE
protein	I-GENE
,	O
thus	O
resulting	O
in	O
biologically	O
active	O
,	O
GTP	O
-	O
bound	O
Rho	B-GENE
,	O
which	O
in	O
turn	O
mediates	O
actin	B-GENE
cytoskeletal	O
reorganization	O
,	O
gene	O
transcription	O
,	O
and	O
entry	O
into	O
the	O
mitotic	O
S	O
phase	O
.	O

Insulin	B-GENE
-	O
stimulated	O
autophosphorylation	O
at	O
specific	O
sites	O
in	O
the	O
tyrosine	B-GENE
kinase	I-GENE
domain	I-GENE
of	O
the	O
receptor	O
'	O
s	O
beta	O
-	O
subunit	O
is	O
correlated	O
kinetically	O
with	O
activation	O
of	O
kinase	O
-	O
catalyzed	O
phosphorylation	O
of	O
a	O
model	O
substrate	O
(	O
reduced	O
and	O
carboxyamidomethylated	O
lysozyme	B-GENE
;	O
RCAM	B-GENE
-	I-GENE
lysozyme	I-GENE
)	O
.	O

The	O
critical	O
obstacle	O
in	O
modeling	O
psychiatric	O
disorders	O
has	O
been	O
limited	O
information	O
about	O
their	O
origin	O
and	O
underlying	O
neural	O
mechanisms	O
.	O

BACKGROUND	O
:	O
Allergic	O
rhinoconjunctivitis	O
is	O
a	O
common	O
disorder	O
,	O
affecting	O
>	O
20	O
%	O
of	O
people	O
of	O
all	O
socioeconomic	O
strata	O
.	O

The	O
results	O
of	O
these	O
studies	O
indicate	O
that	O
EHV	B-GENE
-	I-GENE
1	I-GENE
gp13	I-GENE
is	O
the	O
structural	O
homolog	O
of	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
glycoprotein	I-GENE
C	I-GENE
and	O
further	O
suggest	O
that	O
the	O
epitope	O
-	O
containing	O
N	O
-	O
terminal	O
amino	O
acid	O
sequences	O
of	O
the	O
herpesvirus	B-GENE
gC	I-GENE
-	I-GENE
like	I-GENE
glycoproteins	I-GENE
have	O
undergone	O
more	O
extensive	O
evolutionary	O
divergence	O
than	O
the	O
C	O
-	O
terminal	O
sequences	O
.	O

Within	O
the	O
final	O
11	O
amino	O
acids	O
there	O
are	O
5	O
aromatic	O
,	O
2	O
basic	O
,	O
and	O
no	O
acidic	O
residues	O
and	O
it	O
has	O
been	O
proposed	O
that	O
these	O
residues	O
stack	O
with	O
and	O
electrostatically	O
interact	O
with	O
the	O
kinked	O
DNA	O
at	O
the	O
site	O
of	O
a	O
pyrimidine	O
dimer	O
.	O

By	O
contrast	O
,	O
footprint	O
II	O
at	O
position	O
-	O
125	O
is	O
common	O
to	O
both	O
HeLa	O
and	O
GH3	O
cell	O
extracts	O
and	O
overlies	O
a	O
15	O
-	O
base	O
-	O
pair	O
sequence	O
found	O
in	O
all	O
members	O
of	O
the	O
growth	B-GENE
hormone	I-GENE
gene	I-GENE
family	I-GENE
.	O

Significance	O
of	O
the	O
determination	O
of	O
vascular	O
tonus	O
in	O
the	O
differential	O
diagnosis	O
of	O
rheumatic	O
and	O
arteriosclerotic	O
lesions	O
of	O
the	O
heart	O
and	O
vessels	O
in	O
middle	O
-	O
aged	O
and	O
elderly	O
persons	O
with	O
fibrillation	O
arrhythmia	O

The	O
gene	O
responsible	O
for	O
multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	B-GENE
)	O
,	O
a	O
heritable	O
predisposition	O
to	O
endocrine	O
tumours	O
in	O
man	O
,	O
has	O
recently	O
been	O
identified	O
.	O

Toxicological	O
effects	O
of	O
dietary	O
Maillard	O
reaction	O
products	O
in	O
the	O
rat	O
.	O

AST	B-GENE
activity	O
in	O
PMNs	O
was	O
significantly	O
low	O
,	O
approximately	O
2	O
%	O
of	O
that	O
observed	O
in	O
HPLFs	O
.	O

Specifically	O
,	O
we	O
engineered	O
two	O
chimeras	O
in	O
which	O
the	O
N	O
-	O
terminal	O
lobe	O
of	O
the	O
SH1	B-GENE
domain	I-GENE
of	O
c	B-GENE
-	I-GENE
Abl	I-GENE
was	O
swapped	O
with	O
that	O
of	O
v	B-GENE
-	I-GENE
Src	I-GENE
.	O

Biochemical	O
analyses	O
revealed	O
that	O
the	O
concentration	O
of	O
norepinephrine	O
was	O
reduced	O
significantly	O
in	O
cortex	O
-	O
hippocampus	O
and	O
olfactory	O
bulb	O
but	O
not	O
in	O
other	O
regions	O
,	O
while	O
dopamine	O
and	O
serotonin	O
levels	O
were	O
not	O
altered	O
in	O
any	O
brain	O
region	O
examined	O
.	O

The	O
cDNA	O
contains	O
a	O
reading	O
frame	O
for	O
a	O
145	O
-	O
amino	O
-	O
acid	O
protein	O
and	O
it	O
lacks	O
the	O
UGA	O
codons	O
,	O
which	O
have	O
been	O
found	O
in	O
the	O
reading	O
frame	O
of	O
the	O
mouse	B-GENE
MCS	I-GENE
cDNA	I-GENE
and	O
have	O
been	O
presumed	O
to	O
encode	O
the	O
selenocysteine	O
in	O
the	O
amino	O
terminal	O
of	O
the	O
deduced	O
mouse	O
amino	O
acid	O
sequence	O
.	O

These	O
results	O
suggest	O
that	O
repetitive	O
GAA	O
sequences	O
enhance	O
splicing	O
by	O
binding	O
a	O
protein	O
complex	O
containing	O
a	O
sequence	O
-	O
specific	O
RNA	O
binding	O
protein	O
and	O
a	O
general	O
splicing	O
activator	O
that	O
,	O
in	O
turn	O
,	O
recruit	O
additional	O
SR	B-GENE
proteins	I-GENE
.	O

Letter	O
:	O
Dehydrated	O
test	O
strip	O
for	O
the	O
detection	O
of	O
yeasts	O
.	O

Cell	O
sloughing	O
with	O
proparacaine	O
.	O

Cytomegalovirus	O
infection	O
-	O
-	O
modern	O
diagnosis	O

Highly	O
conserved	O
regions	O
called	O
src	B-GENE
homology	I-GENE
2	I-GENE
and	O
3	O
(	O
SH2	B-GENE
and	O
SH3	B-GENE
)	O
,	O
comprising	O
amino	O
acid	O
residues	O
88	O
to	O
250	O
,	O
are	O
believed	O
to	O
modulate	O
the	O
protein	B-GENE
-	I-GENE
tyrosine	I-GENE
kinase	I-GENE
activity	O
present	O
in	O
the	O
carboxy	O
-	O
terminal	O
halves	O
of	O
the	O
src	B-GENE
proteins	I-GENE
.	O

Interestingly	O
,	O
the	O
NES	B-GENE
mutant	I-GENE
proteins	I-GENE
appeared	O
to	O
have	O
altered	O
interactions	O
with	O
the	O
splicing	O
complex	O
,	O
binding	O
more	O
tightly	O
to	O
SC35	B-GENE
in	O
co	O
-	O
immunoprecipitation	O
assays	O
.	O

We	O
propose	O
2	O
separate	O
PAI	B-GENE
-	I-GENE
1	I-GENE
inductory	O
pathways	O
for	O
PMA	O
and	O
IL	B-GENE
-	I-GENE
1alpha	I-GENE
in	O
HepG2	O
,	O
both	O
involving	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
activation	O
;	O
the	O
serum	O
-	O
induced	O
signaling	O
pathway	O
may	O
(	O
partially	O
)	O
overlap	O
with	O
the	O
PMA	O
-	O
activated	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
/	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
pathway	O
,	O
leading	O
to	O
c	B-GENE
-	I-GENE
Jun	I-GENE
homodimer	I-GENE
binding	O
to	O
the	O
PAI	B-GENE
-	I-GENE
1	I-GENE
TRE	O
.	O

We	O
show	O
that	O
sae1	B-GENE
-	I-GENE
1	I-GENE
and	O
sae3	B-GENE
-	I-GENE
1	I-GENE
mutations	I-GENE
each	O
confer	O
a	O
distinct	O
defect	O
in	O
meiotic	O
recombination	O
.	O

sae1	B-GENE
-	I-GENE
1	I-GENE
produces	O
recombinants	O
but	O
very	O
slowly	O
and	O
ultimately	O
to	O
less	O
than	O
half	O
the	O
wild	O
-	O
type	O
level	O
;	O
sae3	B-GENE
-	I-GENE
1	I-GENE
makes	O
persistent	O
hyper	O
-	O
resected	O
meiotic	O
double	O
-	O
strand	O
breaks	O
and	O
has	O
a	O
severe	O
defect	O
in	O
formation	O
of	O
recombinants	O
.	O

G6620	B-GENE
is	O
the	O
3	O
'	O
end	O
of	O
the	O
MOL1	B-GENE
gene	I-GENE
coding	O
for	O
a	O
polypeptide	O
similar	O
to	O
stress	O
-	O
inducible	O
proteins	O
from	O
Fusarium	O
;	O
G6630	B-GENE
is	O
the	O
NAT2	B-GENE
gene	I-GENE
which	O
encodes	O
a	O
methionine	B-GENE
N	I-GENE
-	I-GENE
acetyltransferase	I-GENE
;	O
G6635	B-GENE
is	O
the	O
RPL30B	B-GENE
gene	I-GENE
coding	O
for	O
the	O
ribosomal	B-GENE
protein	I-GENE
L30	I-GENE
;	O
G6658	B-GENE
is	O
RSR1	B-GENE
encoding	O
a	O
ras	B-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
;	O
G6667	B-GENE
is	O
CYS4	B-GENE
,	O
the	O
gene	O
for	O
cystathionine	B-GENE
beta	I-GENE
-	I-GENE
synthase	I-GENE
;	O
G6670	B-GENE
is	O
identical	O
to	O
ORF2	O
located	O
close	O
to	O
CYS4	B-GENE
;	O
G6673	B-GENE
is	O
PEM1	B-GENE
/	O
CHO2	B-GENE
encoding	O
a	O
phosphatidylethanolamine	B-GENE
methyltransferase	I-GENE
;	O
G7001	B-GENE
is	O
the	O
NSR1	B-GENE
gene	I-GENE
coding	O
for	O
a	O
nuclear	O
signal	O
recognition	O
protein	O
.	O

Transcriptional	O
analysis	O
of	O
this	O
gene	O
cluster	O
was	O
performed	O
by	O
detecting	O
the	O
presence	O
of	O
mRNAs	O
spanning	O
adjacent	O
genes	O
as	O
well	O
as	O
by	O
using	O
a	O
promoterless	O
lacZ	B-GENE
reporter	I-GENE
gene	I-GENE
fused	O
to	O
each	O
of	O
the	O
seven	O
genes	O
contained	O
in	O
the	O
tol	B-GENE
-	O
oprL	B-GENE
locus	O
.	O

Serum	O
IgG	B-GENE
and	O
IgA	B-GENE
level	O
were	O
decreased	O
.	O

Histopathologically	O
,	O
(	O
mice	O
killed	O
with	O
high	O
doses	O
of	O
GMC	O
-	O
II	O
,	O
given	O
orally	O
)	O
there	O
were	O
diffuse	O
hyperemia	O
of	O
the	O
liver	O
,	O
parenchymal	O
degeneration	O
of	O
the	O
kidney	O
tubuli	O
epithelium	O
,	O
and	O
edema	O
and	O
emphysema	O
of	O
the	O
lungs	O
.	O

The	O
contribution	O
of	O
reviewers	O
and	O
editors	O
to	O
the	O
scientific	O
work	O
of	O
the	O
authors	O

The	O
effects	O
of	O
space	O
radiation	O
are	O
partially	O
known	O
on	O
astronauts	O
,	O
but	O
much	O
remains	O
to	O
be	O
discovered	O
.	O

Therefore	O
the	O
effect	O
of	O
GAL11	B-GENE
on	O
PGK	B-GENE
transcription	O
must	O
be	O
mediated	O
at	O
the	O
PGK	B-GENE
UAS	I-GENE
,	O
presumably	O
as	O
part	O
of	O
the	O
activation	O
complex	O
.	O

Wingless	B-GENE
/	O
Wnt	B-GENE
signaling	O
directs	O
cell	O
-	O
fate	O
choices	O
during	O
embryonic	O
development	O
.	O

RNase	B-GENE
protection	O
analysis	O
reveals	O
a	O
10	O
-	O
fold	O
increase	O
in	O
the	O
expression	O
of	O
SCD2	B-GENE
mRNA	I-GENE
during	O
3T3	O
-	O
L1	O
preadipocyte	O
differentiation	O
.	O

To	O
determine	O
whether	O
transcription	O
of	O
orfX	O
and	O
vfr	B-GENE
are	O
controlled	O
by	O
the	O
same	O
mechanisms	O
that	O
control	O
transcription	O
of	O
the	O
region	O
of	O
the	O
divergent	O
ORF	O
(	O
dorf	O
)	O
and	O
of	O
crp	B-GENE
,	O
we	O
compared	O
the	O
vfr	B-GENE
-	O
orfX	O
and	O
crp	B-GENE
-	O
dorf	O
intergenic	O
regions	O
.	O

As	O
a	O
member	O
of	O
the	O
uncoupling	B-GENE
protein	I-GENE
family	I-GENE
,	O
UCP2	B-GENE
is	O
ubiquitously	O
expressed	O
in	O
rodents	O
and	O
humans	O
,	O
implicating	O
a	O
major	O
role	O
in	O
thermogenesis	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Parental	O
and	O
vector	O
-	O
transfected	O
MCF7	O
cells	O
,	O
which	O
were	O
sensitive	O
to	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
atRA	O
,	O
exhibited	O
atRA	O
-	O
dependent	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
(	O
RAR	B-GENE
)	O
transactivation	O
and	O
transrepression	O
of	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
-	O
induced	O
AP	B-GENE
-	I-GENE
1	I-GENE
activity	O
.	O

The	O
majority	O
of	O
the	O
respondents	O
(	O
83	O
.	O
4	O
%	O
)	O
considered	O
that	O
coitus	O
should	O
not	O
be	O
stopped	O
during	O
pregnancy	O
.	O

Based	O
on	O
the	O
ratios	O
of	O
the	O
areas	O
under	O
the	O
concentration	O
-	O
time	O
curves	O
in	O
CSF	O
and	O
serum	O
,	O
the	O
overall	O
penetration	O
of	O
rifampicin	O
into	O
CSF	O
was	O
0	O
.	O
13	O
-	O
0	O
.	O
42	O
(	O
median	O
=	O
0	O
.	O
22	O
)	O
.	O

The	O
differential	O
diagnosis	O
of	O
mineral	O
oil	O
lipidosis	O
in	O
lymph	O
nodes	O
with	O
reaction	O
to	O
radiopaque	O
oils	O
and	O
Whipple	O
'	O
s	O
disease	O
is	O
discussed	O
.	O

With	O
rats	O
fed	O
on	O
the	O
Zn	O
-	O
sufficient	O
diet	O
,	O
NaFe3	O
+	O
EDTA	O
and	O
Na2EDTA	O
similarly	O
increased	O
the	O
absorption	O
,	O
urinary	O
excretion	O
and	O
retention	O
of	O
Zn	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

99Tcm	O
-	O
labelled	O
albumin	B-GENE
colloid	O
,	O
albures	O
(	O
radius	O
250	O
nm	O
)	O
or	O
nanocoll	O
(	O
radius	O
25	O
nm	O
)	O
,	O
or	O
both	O
were	O
used	O
as	O
test	O
substances	O
to	O
study	O
the	O
kinetics	O
of	O
vascular	O
clearance	O
after	O
RES	O
stimulation	O
.	O

Meq	B-GENE
/	O
c	B-GENE
-	I-GENE
Jun	I-GENE
heterodimers	O
bind	O
to	O
an	O
AP1	B-GENE
-	I-GENE
like	I-GENE
sequence	I-GENE
in	O
the	O
meq	B-GENE
promoter	I-GENE
region	I-GENE
with	O
an	O
affinity	O
much	O
greater	O
than	O
that	O
of	O
Meq	B-GENE
/	O
Meq	B-GENE
or	O
c	B-GENE
-	I-GENE
Jun	I-GENE
/	O
c	B-GENE
-	I-GENE
Jun	I-GENE
homodimers	O
.	O

Moreover	O
,	O
the	O
noncoordinate	O
effects	O
of	O
FSK	B-GENE
on	O
PMA	O
-	O
stimulated	O
MKK	B-GENE
and	O
MAPK	B-GENE
activities	O
indicates	O
the	O
presence	O
of	O
a	O
additional	O
distal	O
cAMP	O
-	O
dependent	O
inhibitory	O
mechanisms	O
.	O

These	O
findings	O
indicated	O
that	O
p35	B-GENE
is	O
a	O
trans	O
-	O
dominant	O
factor	O
that	O
facilitates	O
AcMNPV	O
growth	O
in	O
a	O
cell	O
line	O
-	O
specific	O
manner	O
.	O

Pseudotumor	O
form	O
of	O
pulmonary	O
nocardia	O
infection	O
(	O
Nocardia	O
nova	O
)	O
in	O
a	O
renal	O
transplant	O
patient	O

Hematological	O
parameters	O
(	O
leukocyte	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
)	O
and	O
liver	O
function	O
tests	O
were	O
determined	O
by	O
standard	O
procedures	O
.	O

Karyo	O
-	O
and	O
cytometric	O
investigations	O
of	O
cortical	O
layer	O
V	O
pyramidal	O
neurons	O
of	O
albino	O
rat	O
after	O
three	O
various	O
fixations	O

Clinical	O
experience	O
gained	O
from	O
a	O
combined	O
study	O
of	O
252Cf	O
brachytherapy	O
by	O
the	O
staff	O
-	O
members	O
of	O
the	O
Research	O
Institute	O
of	O
Medical	O
Radiology	O
,	O
USSR	O
AMS	O
,	O
was	O
generalized	O
.	O

The	O
team	O
physician	O
and	O
conditioning	O
of	O
athletes	O
for	O
sports	O
:	O
a	O
consensus	O
statement	O
.	O

To	O
probe	O
the	O
inter	O
-	O
relationship	O
between	O
the	O
virion	O
-	O
anchoring	O
function	O
and	O
the	O
oligomerization	O
function	O
,	O
we	O
constructed	O
two	O
serotype	O
3	O
(	O
T3	O
)	O
sigma	B-GENE
1	I-GENE
deletion	O
mutants	O
in	O
SV40	O
expression	O
vectors	O
,	O
one	O
lacking	O
the	O
hydrophobic	O
tail	O
and	O
the	O
hinge	O
,	O
and	O
the	O
other	O
lacking	O
an	O
adjacent	O
region	O
which	O
constituted	O
part	O
of	O
the	O
coiled	O
-	O
coil	O
.	O

AIMS	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
static	O
and	O
dynamic	O
bone	O
changes	O
in	O
patients	O
suffering	O
from	O
rickets	O
.	O

The	O
law	O
and	O
the	O
chiropractor	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
the	O
DREB2A	B-GENE
cDNA	I-GENE
induced	O
weak	O
expression	O
of	O
the	O
target	O
genes	O
under	O
unstressed	O
conditions	O
and	O
caused	O
growth	O
retardation	O
of	O
the	O
transgenic	O
plants	O
.	O

Our	O
findings	O
suggest	O
that	O
AIF	O
may	O
be	O
a	O
morphologic	O
correlate	O
of	O
tumor	O
regression	O
following	O
preoperative	O
cytotoxic	O
chemotherapy	O
.	O

Mean	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
was	O
21	O
.	O
1	O
+	O
/	O
-	O
9	O
.	O
5	O
micromol	O
/	O
L	O
and	O
median	O
concentration	O
was	O
19	O
micromol	O
/	O
L	O
.	O

Efficacy	O
of	O
probiotic	O
feed	O
additives	O
:	O
guidelines	O
for	O
the	O
evaluation	O
of	O
the	O
efficiency	O
of	O
microorganisms	O
in	O
dogs	O
,	O
cats	O
,	O
and	O
horses	O
]	O
Probiotic	O
microorganisms	O
are	O
frequently	O
in	O
use	O
as	O
feed	O
additives	O
for	O
farm	O
and	O
pet	O
animals	O
.	O

Lung	O
transplantation	O
is	O
warranted	O
for	O
stable	O
,	O
ventilator	O
-	O
dependent	O
recipients	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
shows	O
that	O
sites	O
throughout	O
the	O
IRE	B-GENE
alter	O
negative	O
control	O
and	O
IRE	B-GENE
-	I-GENE
BP	I-GENE
binding	O
reflecting	O
the	O
fact	O
that	O
the	O
footprint	O
of	O
the	O
IRE	B-GENE
-	I-GENE
BP	I-GENE
is	O
over	O
the	O
entire	O
IRE	B-GENE
.	O

An	O
alternative	O
approach	O
to	O
random	O
integration	O
of	O
large	O
DNA	O
fragments	O
into	O
plants	O
is	O
to	O
utilize	O
one	O
of	O
several	O
site	O
-	O
specific	O
recombination	O
(	O
SSR	O
)	O
systems	O
,	O
such	O
as	O
Cre	B-GENE
/	O
lox	B-GENE
.	O

Neonatal	O
masculinization	O
affects	O
maternal	O
behavior	O
sensitivity	O
in	O
female	O
rats	O
.	O

Recombinant	B-GENE
mouse	I-GENE
GSTT1	I-GENE
-	I-GENE
1	I-GENE
was	O
catalytically	O
active	O
towards	O
1	O
,	O
2	O
-	O
epoxy	O
-	O
3	O
-	O
(	O
p	O
-	O
nitrophenoxy	O
)	O
propane	O
,	O
4	O
-	O
nitrobenzyl	O
chloride	O
and	O
dichloromethane	O
.	O

In	O
addition	O
,	O
six	O
other	O
landmarks	O
favored	O
the	O
xeroradiograph	O
but	O
not	O
to	O
the	O
degree	O
of	O
statistical	O
significance	O
.	O

Nonlethal	O
sec71	B-GENE
-	I-GENE
1	I-GENE
and	O
sec72	B-GENE
-	I-GENE
1	I-GENE
mutations	I-GENE
eliminate	O
proteins	O
associated	O
with	O
the	O
Sec63p	B-GENE
-	O
BiP	B-GENE
complex	O
from	O
S	O
.	O
cerevisiae	O
.	O

Sequence	O
and	O
deletion	O
analysis	O
of	O
the	O
recombination	B-GENE
enhancement	I-GENE
gene	I-GENE
(	O
ref	B-GENE
)	O
of	O
bacteriophage	O
P1	O
:	O
evidence	O
for	O
promoter	O
-	O
operator	O
and	O
attenuator	O
-	O
antiterminator	O
control	O
.	O

A	O
high	O
titer	O
of	O
anti	B-GENE
-	I-GENE
HBc	I-GENE
,	O
thus	O
suggested	O
to	O
be	O
an	O
indicator	O
of	O
persistent	O
hepatitis	O
B	O
virus	O
infection	O
,	O
was	O
found	O
rarely	O
in	O
seronegative	O
patients	O
with	O
chronic	O
hepatitis	O
,	O
non	O
-	O
alcoholic	O
cirrhosis	O
,	O
or	O
alcoholic	O
liver	O
diseases	O
.	O

Adaptability	O
of	O
Nippostrongylus	O
brasiliensis	O
(	O
Travassos	O
,	O
1914	O
)	O
to	O
lead	O
contamination	O

Eph	B-GENE
receptors	I-GENE
and	O
their	O
membrane	O
-	O
associated	O
ephrin	B-GENE
ligands	I-GENE
regulate	O
cell	O
-	O
cell	O
interactions	O
during	O
development	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
DNA	O
-	O
protein	O
interactions	O
at	O
homologous	O
nucleotide	O
sequences	O
like	O
those	O
identified	O
in	O
PII	O
are	O
part	O
of	O
a	O
regulatory	O
gene	O
cascade	O
that	O
participates	O
in	O
timing	O
fla	B-GENE
gene	I-GENE
expression	O
in	O
the	O
C	O
.	O
crescentus	O
cell	O
cycle	O
.	O

Postcontrast	O
images	O
were	O
also	O
acquired	O
in	O
the	O
sagittal	O
(	O
six	O
patients	O
)	O
and	O
coronal	O
(	O
three	O
patients	O
)	O
planes	O
.	O

Nature	O
of	O
the	O
thermopower	O
in	O
bipolar	O
semiconductors	O
.	O

To	O
increase	O
the	O
number	O
of	O
circulating	O
polymorphonuclear	O
neutrophils	O
,	O
the	O
patient	O
was	O
treated	O
with	O
recombinant	O
granulocyte	B-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
(	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
)	O
at	O
a	O
dose	O
of	O
2	O
micrograms	O
protein	O
/	O
kg	O
bodyweight	O
s	O
.	O
c	O
.	O
/	O
12	O
h	O
.	O

By	O
using	O
methanol	O
-	O
0	O
.	O
15	O
M	O
borate	O
buffer	O
of	O
pH	O
8	O
.	O
0	O
,	O
cate	B-GENE
-	I-GENE
chol	I-GENE
-	I-GENE
O	I-GENE
-	I-GENE
methyltransferase	I-GENE
activity	O
might	O
be	O
assayed	O
.	O

All	O
patients	O
were	O
peritonitis	O
-	O
free	O
at	O
least	O
6	O
weeks	O
before	O
each	O
PET	O
.	O

The	O
amino	O
acid	O
residues	O
and	O
subdomains	O
important	O
for	O
DNA	O
binding	O
,	O
hormone	O
binding	O
,	O
dimerization	O
,	O
and	O
transactivation	O
are	O
mostly	O
conserved	O
among	O
all	O
VDR	B-GENE
species	O
.	O

Transcripts	O
appear	O
to	O
be	O
initiated	O
from	O
an	O
upstream	O
promoter	O
,	O
P1	O
,	O
located	O
in	O
front	O
of	O
the	O
tRNA	B-GENE
(	I-GENE
met1	I-GENE
)	I-GENE
gene	I-GENE
and	O
from	O
three	O
internal	O
promoters	O
:	O
P2	O
is	O
located	O
immediately	O
in	O
front	O
of	O
the	O
tRNA	B-GENE
(	I-GENE
met2	I-GENE
)	I-GENE
gene	I-GENE
;	O
PL10	O
is	O
near	O
the	O
beginning	O
of	O
the	O
L1	B-GENE
-	O
L10	B-GENE
intergenic	O
space	O
,	O
and	O
PL12	O
is	O
at	O
the	O
end	O
of	O
the	O
L10	B-GENE
gene	I-GENE
sequence	I-GENE
.	O

Based	O
on	O
the	O
deduced	O
amino	O
acid	O
sequence	O
identity	O
we	O
designated	O
GAPC1	B-GENE
and	O
GAPC2	B-GENE
as	O
group	O
I	O
(	O
97	O
%	O
identical	O
)	O
and	O
GAPC3	B-GENE
and	O
GAPC4	B-GENE
as	O
group	O
II	O
(	O
99	O
.	O
4	O
%	O
identical	O
)	O
.	O

A	O
case	O
of	O
functioning	O
parathyroid	O
carcinoma	O
with	O
hypereninemic	O
hypertension	O
.	O

Finally	O
,	O
gel	O
shift	O
assays	O
showed	O
that	O
ORF2	O
was	O
able	O
to	O
bind	O
to	O
promoter	O
fragment	O
566	O
-	O
888	O
.	O

Critical	O
review	O
of	O
general	O
results	O

Saturated	O
fatty	O
acids	O
induce	O
a	O
1	O
.	O
6	O
-	O
fold	O
increase	O
in	O
transcription	O
activity	O
,	O
whereas	O
a	O
large	O
family	O
of	O
unsaturated	O
fatty	O
acids	O
repress	O
OLE1	B-GENE
transcription	O
as	O
much	O
as	O
60	O
-	O
fold	O
.	O

This	O
polypeptide	O
includes	O
the	O
first	O
three	O
zinc	O
fingers	O
of	O
the	O
TFIIIA	B-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
.	O

An	O
exception	O
is	O
the	O
Bcl	B-GENE
-	I-GENE
6	I-GENE
gene	I-GENE
,	O
encoding	O
a	O
transcription	O
factor	O
,	O
which	O
was	O
found	O
to	O
be	O
mutated	O
in	O
normal	O
human	O
memory	O
B	O
cells	O
.	O

3	O
.	O

A	O
chest	O
-	O
X	O
ray	O
film	O
showed	O
infiltrative	O
shadows	O
in	O
the	O
right	O
middle	O
and	O
lower	O
lung	O
fields	O
,	O
but	O
a	O
chest	O
CT	O
scan	O
showed	O
an	O
abnormal	O
lung	O
density	O
in	O
the	O
right	O
lower	O
lobe	O
.	O

In	O
both	O
liver	O
and	O
pancreatic	O
islet	O
,	O
glucokinase	B-GENE
is	O
subject	O
to	O
inhibition	O
by	O
a	O
regulatory	O
protein	O
(	O
GCKR	B-GENE
)	O
.	O

MRI	O
measurements	O
of	O
the	O
brain	O
.	O

Similarly	O
,	O
TAM	B-GENE
-	I-GENE
67	I-GENE
reverted	O
the	O
morphology	O
of	O
the	O
AdoMetDC	B-GENE
-	I-GENE
antisense	I-GENE
expressors	I-GENE
.	O

Of	O
concern	O
is	O
the	O
high	O
,	O
unexplained	O
prevalence	O
of	O
BV	O
among	O
African	O
-	O
American	O
women	O
,	O
who	O
are	O
also	O
at	O
extremely	O
high	O
risk	O
for	O
preterm	O
birth	O
.	O

The	O
use	O
of	O
bentonite	O
in	O
the	O
compounding	O
of	O
hydrogels	O

Cotransfection	O
of	O
expression	O
plasmids	O
encoding	O
the	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
inhibitor	O
,	O
or	O
an	O
inactive	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
catalytic	O
beta	O
subunit	O
,	O
inhibited	O
both	O
forskolin	O
and	O
PACAP	B-GENE
activation	O
of	O
chromogranin	B-GENE
A	I-GENE
transcription	O
,	O
revealing	O
that	O
PACAP	B-GENE
-	O
induced	O
trans	O
-	O
activation	O
is	O
highly	O
dependent	O
on	O
PKA	B-GENE
.	O

GH	B-GENE
induced	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
at	O
approximately	O
93	O
kDa	O
in	O
normal	O
fibroblasts	O
,	O
and	O
Western	O
blotting	O
with	O
STAT	B-GENE
-	I-GENE
specific	I-GENE
antibodies	I-GENE
revealed	O
STAT5	B-GENE
activation	O
(	O
phosphorylation	O
)	O
by	O
GH	O
.	O

The	O
most	O
valid	O
method	O
was	O
the	O
AXB	O
bearing	O
with	O
the	O
cephalometric	O
clinical	O
diagnosis	O
a	O
90	O
.	O
91	O
%	O
concordance	O
.	O

The	O
cdc42W97R	B-GENE
temperature	I-GENE
-	I-GENE
sensitive	I-GENE
allele	I-GENE
in	O
S	O
.	O
cerevisiae	O
displayed	O
the	O
same	O
cell	O
-	O
division	O
-	O
cycle	O
arrest	O
phenotype	O
(	O
large	O
,	O
round	O
unbudded	O
cells	O
)	O
as	O
the	O
cdc42	B-GENE
-	I-GENE
1ts	I-GENE
mutant	I-GENE
.	O

The	O
cyanobacterial	B-GENE
phycobilisome	I-GENE
is	O
a	O
large	O
protein	O
complex	O
located	O
on	O
the	O
photosynthetic	O
membrane	O
.	O

One	O
day	O
after	O
injection	O
48	O
%	O
of	O
the	O
injected	O
activity	O
was	O
in	O
the	O
skeleton	O
,	O
9	O
.	O
3	O
%	O
in	O
the	O
liver	O
,	O
3	O
%	O
in	O
the	O
kidneys	O
and	O
4	O
.	O
4	O
%	O
in	O
the	O
rest	O
of	O
the	O
organs	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
laboratory	O
practice	O
in	O
the	O
examination	O
of	O
blood	O
films	O
for	O
malarial	O
parasites	O
.	O

BACKGROUND	O
:	O
A	O
thorough	O
understanding	O
of	O
malignant	O
fibrous	O
histiocytoma	O
(	O
MFH	O
)	O
,	O
the	O
most	O
common	O
subtype	O
of	O
soft	O
tissue	O
sarcoma	O
,	O
will	O
lead	O
to	O
improved	O
histologic	O
-	O
specific	O
protocols	O
.	O

Sequence	O
analyses	O
revealed	O
a	O
partial	O
941	O
bp	O
cDNA	O
that	O
encoded	O
a	O
313	O
-	O
amino	O
-	O
acid	O
polypeptide	O
.	O

Furthermore	O
,	O
CBP	B-GENE
/	O
p300	B-GENE
stimulated	O
both	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
-	O
and	O
Smad	B-GENE
-	O
induced	O
transcription	O
in	O
a	O
Smad4	B-GENE
/	O
DPC4	B-GENE
-	O
dependent	O
fashion	O
.	O

Sequences	O
within	O
and	O
flanking	O
hypersensitive	O
sites	O
3	O
and	O
2	O
of	O
the	O
beta	B-GENE
-	I-GENE
globin	I-GENE
locus	O
control	O
region	O
required	O
for	O
synergistic	O
versus	O
additive	O
interaction	O
with	O
the	O
epsilon	B-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

Sequence	O
analysis	O
revealed	O
100	O
%	O
homology	O
of	O
all	O
RA	O
-	O
derived	O
PTEN	B-GENE
fragments	I-GENE
to	O
those	O
from	O
normal	O
SF	O
as	O
well	O
as	O
to	O
the	O
published	O
GenBank	O
sequence	O
(	O
accession	O
number	O
U93051	B-GENE
)	O
.	O

174	O
,	O
233	O
-	O
247	O
)	O
and	O
Serrate	O
(	O
Serrate1	O
and	O
2	O
;	O
Myat	O
,	O
A	O
.	O
,	O
Henrique	O
,	O
D	O
.	O
,	O
Ish	O
-	O
Horowicz	O
,	O
D	O
.	O
and	O
Lewis	O
,	O
J	O
.	O
,	O
1996	O
.	O

Many	O
retroviruses	O
,	O
including	O
the	O
human	O
and	O
simian	O
immunodeficiency	O
viruses	O
,	O
contain	O
a	O
leucine	O
zipper	O
-	O
like	O
repeat	O
in	O
a	O
highly	O
conserved	O
region	O
of	O
the	O
external	O
domain	O
of	O
the	O
transmembrane	O
(	O
TM	O
)	O
glycoprotein	O
.	O

Functional	O
importance	O
of	O
a	O
properly	O
folded	O
surface	O
loop	O
covering	O
the	O
catalytic	O
center	O
.	O

The	O
most	O
frequent	O
abnormality	O
was	O
GH	B-GENE
deficiency	O
(	O
six	O
cases	O
)	O
,	O
followed	O
by	O
gonadotropin	B-GENE
(	O
four	O
cases	O
)	O
,	O
cortisol	O
(	O
four	O
cases	O
)	O
,	O
and	O
TSH	B-GENE
(	O
one	O
case	O
)	O
,	O
whereas	O
four	O
patients	O
showed	O
high	O
serum	B-GENE
PRL	I-GENE
values	O
.	O

Recombinant	O
vaccinia	O
viruses	O
that	O
express	O
the	O
bacteriophage	B-GENE
T3	I-GENE
RNA	I-GENE
polymerase	I-GENE
(	O
VV	B-GENE
-	I-GENE
T3pol	I-GENE
)	O
or	O
the	O
Escherichia	B-GENE
coli	I-GENE
lac	I-GENE
repressor	I-GENE
(	O
VV	B-GENE
-	I-GENE
lacI	I-GENE
)	O
under	O
control	O
of	O
the	O
early	B-GENE
-	I-GENE
late	I-GENE
vaccinia	I-GENE
promoter	I-GENE
P7	I-GENE
.	I-GENE
5	I-GENE
were	O
constructed	O
.	O

Internal	O
controls	O
over	O
the	O
volume	O
of	O
milk	O
suckled	O
do	O
not	O
appear	O
until	O
infant	O
rats	O
are	O
about	O
2	O
weeks	O
of	O
age	O
at	O
which	O
time	O
gastric	O
distension	O
,	O
milk	O
,	O
systemic	O
dehydration	O
,	O
and	O
intestinal	B-GENE
hormone	I-GENE
cholecystokinin	I-GENE
suppress	O
milk	O
intake	O
derived	O
through	O
suckling	O
.	O

Shields	O
needed	O
for	O
pacemakers	O
.	O

Concerning	O
the	O
practical	O
approach	O
in	O
a	O
clinical	O
setting	O
,	O
it	O
has	O
to	O
be	O
pointed	O
out	O
that	O
with	O
these	O
diseases	O
a	O
hepatitis	O
C	O
infection	O
has	O
to	O
be	O
considered	O
and	O
testing	O
for	O
hepatitis	B-GENE
C	I-GENE
antibodies	I-GENE
and	O
,	O
if	O
positive	O
,	O
hepatitis	B-GENE
C	I-GENE
-	I-GENE
RNA	I-GENE
is	O
indicated	O
.	O

Confocal	O
fluorescent	O
microscopy	O
analysis	O
demonstrated	O
that	O
WT	O
,	O
VaI	O
,	O
and	O
VaII	O
all	O
distribute	O
equally	O
to	O
the	O
cell	O
surface	O
while	O
,	O
as	O
expected	O
,	O
a	O
WT	O
mutant	O
lacking	O
the	O
two	O
C	O
-	O
terminal	O
valine	O
residues	O
does	O
not	O
.	O

However	O
,	O
it	O
is	O
not	O
easy	O
to	O
establish	O
the	O
diagnosis	O
of	O
thoracic	O
MFH	O
.	O

In	O
both	O
cell	O
types	O
,	O
insulin	B-GENE
led	O
to	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
association	O
of	O
tyrosine	B-GENE
phosphorylated	I-GENE
IRS	I-GENE
-	I-GENE
1	I-GENE
with	O
the	O
SH2	B-GENE
domain	I-GENE
of	O
the	O
p85	B-GENE
regulatory	I-GENE
subunit	I-GENE
of	O
PI	B-GENE
-	I-GENE
3	I-GENE
kinase	I-GENE
,	O
and	O
also	O
increased	O
the	O
amount	O
of	O
PI	B-GENE
kinase	I-GENE
activity	O
detected	O
in	O
anti	B-GENE
-	I-GENE
IRS	I-GENE
-	I-GENE
1	I-GENE
immunoprecipitates	O
.	O

The	O
"	O
Ulm	O
Zucker	O
Uhr	O
System	O
"	O
comprises	O
a	O
microdialysis	O
probe	O
,	O
a	O
biosensor	O
(	O
Glucosensor	O
Unitec	O
Ulm	O
s	O
.	O
c	O
.	O
)	O
,	O
a	O
sender	O
transferring	O
telemetrically	O
the	O
glucose	O
concentrations	O
,	O
and	O
a	O
receiving	O
indicator	O
.	O

The	O
Xenopus	B-GENE
annexin	I-GENE
II	I-GENE
heavy	I-GENE
chain	I-GENE
lacks	O
the	O
highly	O
conserved	O
tyrosine	O
at	O
position	O
23	O
which	O
is	O
the	O
site	O
of	O
src	B-GENE
oncogene	I-GENE
tyrosine	B-GENE
kinase	I-GENE
phosphorylation	O
in	O
the	O
murine	O
protein	O
.	O

No	O
bafilomycin	O
-	O
sensitive	O
ATPase	B-GENE
is	O
detected	O
in	O
a	O
vacuolar	O
fraction	O
.	O

Plasmids	O
bearing	O
the	O
P	B-GENE
.	I-GENE
stipitis	I-GENE
URA3	I-GENE
gene	I-GENE
and	O
ARS2	O
element	O
produced	O
more	O
than	O
30	O
,	O
000	O
transformants	O
per	O
micrograms	O
of	O
plasmid	O
DNA	O
.	O

Unfractionated	O
heparin	O
(	O
UFH	O
)	O
given	O
at	O
a	O
dose	O
of	O
0	O
.	O
3	O
mg	O
x	O
kg	O
-	O
1	O
bolus	O
+	O
0	O
.	O
3	O
mg	O
x	O
kg	O
-	O
1	O
x	O
h	O
-	O
1	O
infusion	O
did	O
not	O
improve	O
the	O
incidence	O
of	O
reperfusion	O
or	O
lower	O
the	O
incidence	O
of	O
reocclusion	O
.	O

The	O
scores	O
for	O
these	O
three	O
factors	O
,	O
which	O
corresponded	O
to	O
recognizable	O
dimensions	O
of	O
depressive	O
illness	O
,	O
were	O
then	O
correlated	O
with	O
rCBF	O
.	O

Cloning	O
,	O
sequence	O
analysis	O
,	O
and	O
expression	O
of	O
the	O
gene	B-GENE
encoding	I-GENE
formaldehyde	I-GENE
dismutase	I-GENE
from	I-GENE
Pseudomonas	I-GENE
putida	I-GENE
F61	I-GENE
.	O

However	O
,	O
at	O
the	O
time	O
of	O
salvage	O
treatment	O
,	O
the	O
mean	O
serum	B-GENE
PSA	I-GENE
levels	O
were	O
9	O
.	O
1	O
and	O
1	O
.	O
1	O
ng	O
/	O
mL	O
for	O
the	O
salvage	O
RP	O
and	O
salvage	O
RT	O
groups	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

Protease	O
digestion	O
and	O
alkaline	O
extraction	O
of	O
microsomes	O
containing	O
labeled	O
mutant	O
proteins	O
further	O
showed	O
that	O
segment	O
3	O
was	O
sufficient	O
for	O
stable	O
membrane	O
anchoring	O
of	O
the	O
glycoproteins	O
,	O
indicating	O
that	O
this	O
segment	O
may	O
specify	O
the	O
transmembrane	O
domain	O
of	O
the	O
gB	B-GENE
glycoprotein	I-GENE
.	O

The	O
mean	O
times	O
to	O
LNR	O
in	O
these	O
groups	O
were	O
42	O
.	O
0	O
months	O
(	O
range	O
,	O
3	O
.	O
0	O
-	O
194	O
.	O
5	O
months	O
)	O
and	O
49	O
.	O
0	O
months	O
(	O
range	O
,	O
3	O
.	O
6	O
-	O
209	O
.	O
0	O
months	O
)	O
respectively	O
.	O

A	O
gene	O
(	O
FMR	B-GENE
-	I-GENE
1	I-GENE
)	O
was	O
identified	O
within	O
a	O
four	O
cosmid	O
contig	O
of	O
YAC	O
DNA	O
that	O
expresses	O
a	O
4	O
.	O
8	O
kb	O
message	O
in	O
human	O
brain	O
.	O

Detailed	O
comparison	O
of	O
the	O
sequences	O
of	O
cp35	B-GENE
and	O
human	B-GENE
calpactin	I-GENE
II	I-GENE
shows	O
that	O
the	O
only	O
substantial	O
sequence	O
dissimilarity	O
is	O
a	O
domain	O
encoding	O
amino	O
acids	O
between	O
residues	O
20	O
and	O
40	O
which	O
includes	O
a	O
tyrosine	O
phosphorylation	O
site	O
in	O
the	O
human	O
molecule	O
,	O
along	O
with	O
other	O
residues	O
of	O
possible	O
physiological	O
significance	O
.	O

Exogenous	O
heart	O
stress	O
raised	O
log	O
circulating	O
NE	O
concentration	O
in	O
proportion	O
to	O
the	O
rise	O
in	O
heart	O
rate	O
at	O
a	O
given	O
work	O
load	O
so	O
that	O
the	O
usual	O
relationship	O
between	O
these	O
variables	O
,	O
previously	O
observed	O
during	O
other	O
stresses	O
,	O
was	O
preserved	O
.	O

The	O
implication	O
of	O
Rac	B-GENE
and	O
Cdc42	B-GENE
was	O
analyzed	O
in	O
transient	O
transfection	O
experiments	O
using	O
either	O
constitutively	O
active	O
(	O
V12	O
)	O
or	O
dominant	O
-	O
interfering	O
(	O
N17	O
)	O
mutants	O
.	O

Alternative	O
immune	B-GENE
globulin	I-GENE
preparation	O
when	O
standard	O
immune	B-GENE
serum	I-GENE
globulin	I-GENE
is	O
not	O
available	O
.	O

Plasma	B-GENE
insulin	I-GENE
responses	O
to	O
glucose	O
in	O
femoral	O
,	O
hepatic	O
,	O
and	O
pancreatic	O
veins	O
in	O
dogs	O
.	O

The	O
bioconversion	O
of	O
penicillin	O
G	O
,	O
an	O
inexpensive	O
substrate	O
,	O
to	O
the	O
valuable	O
intermediate	O
for	O
semisynthetic	O
cephalosporin	O
production	O
,	O
deacetoxycephalosporin	O
G	O
(	O
DAOG	O
)	O
,	O
had	O
been	O
recently	O
shown	O
to	O
be	O
increased	O
by	O
eliminating	O
agitation	O
and	O
adding	O
decane	O
.	O

Elevated	O
potassium	O
stimulation	O
of	O
GAL	B-GENE
mRNA	I-GENE
was	O
completely	O
blocked	O
,	O
but	O
pituitary	O
adenylyl	B-GENE
cyclase	I-GENE
-	I-GENE
activating	I-GENE
polypeptide	I-GENE
and	O
histamine	O
stimulations	O
were	O
only	O
partially	O
blocked	O
,	O
by	O
cycloheximide	O
.	O

In	O
lyzozyme	B-GENE
activity	O
there	O
was	O
periodicity	O
in	O
three	O
groups	O
but	O
not	O
in	O
the	O
youngest	O
foals	O
.	O

GBF1	B-GENE
and	O
GBF2	B-GENE
mRNA	I-GENE
is	O
present	O
in	O
light	O
and	O
dark	O
grown	O
leaves	O
as	O
well	O
as	O
in	O
roots	O
.	O

We	O
now	O
report	O
identification	O
and	O
analysis	O
of	O
transcriptional	O
activities	O
mediated	O
by	O
three	O
cis	O
-	O
acting	O
sites	O
within	O
a	O
90	O
-	O
bp	O
portion	O
of	O
the	O
rDNA	O
enhancer	O
designated	O
the	O
modulator	O
region	O
.	O

A	O
porcine	O
model	O
of	O
diffuse	O
axonal	O
injury	O
,	O
developed	O
with	O
information	O
from	O
these	O
physical	O
models	O
and	O
earlier	O
in	O
vitro	O
tissue	O
modeling	O
studies	O
,	O
is	O
used	O
to	O
correlate	O
histologic	O
and	O
radiologic	O
evidence	O
of	O
axonal	O
injury	O
to	O
predicted	O
regions	O
of	O
injury	O
from	O
the	O
experimental	O
and	O
theoretical	O
analysis	O
.	O

Sample	O
size	O
requirement	O
for	O
repeated	O
measurements	O
in	O
continuous	O
data	O
.	O

A	O
transient	O
induction	O
of	O
both	O
c	B-GENE
-	I-GENE
fos	I-GENE
and	O
c	B-GENE
-	I-GENE
jun	I-GENE
mRNAs	I-GENE
by	O
TPA	O
was	O
observed	O
in	O
both	O
cell	O
populations	O
,	O
together	O
with	O
an	O
associated	O
suppression	O
of	O
BSP	B-GENE
mRNA	I-GENE
in	O
the	O
fetal	O
rat	O
calvarial	O
cells	O
.	O

Videoanalysis	O
confirms	O
the	O
ballistic	O
character	O
of	O
the	O
initial	O
phase	O
of	O
the	O
reaching	O
movement	O
.	O

The	O
isomerization	O
of	O
the	O
pre	O
-	O
existing	O
closed	O
complex	O
to	O
an	O
open	O
promoter	O
form	O
,	O
as	O
judged	O
by	O
the	O
local	O
denaturation	O
of	O
promoter	O
DNA	O
which	O
rendered	O
sequences	O
from	O
+	O
5	O
to	O
-	O
10	O
reactive	O
towards	O
KMnO4	O
,	O
was	O
shown	O
to	O
be	O
fully	O
dependent	O
on	O
NifA	B-GENE
.	O

HPV	O
-	O
16	O
MARs	O
are	O
context	O
dependent	O
transcriptional	O
enhancers	O
,	O
and	O
activated	O
expression	O
of	O
HPV	O
-	O
16	O
oncogenes	O
dependent	O
on	O
chromosomal	O
integration	O
may	O
positively	O
select	O
tumorigenic	O
cells	O
during	O
the	O
multistep	O
etiology	O
of	O
cervical	O
cancer	O
.	O

Sociological	O
analysis	O
of	O
the	O
family	O
.	O

This	O
enhancer	O
element	O
functioned	O
in	O
a	O
position	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
both	O
on	O
the	O
Pax	B-GENE
-	I-GENE
QNR	I-GENE
P0	I-GENE
promoter	I-GENE
and	O
the	O
heterologous	B-GENE
thymidine	I-GENE
kinase	I-GENE
promoter	I-GENE
.	O

These	O
data	O
suggest	O
that	O
overexpression	O
of	O
MT	B-GENE
potentiates	O
the	O
growth	O
of	O
MCF7	O
cells	O
,	O
whereas	O
downregulation	O
of	O
MT	B-GENE
elicits	O
antiproliferative	O
effects	O
.	O

A	O
multivariant	O
study	O
of	O
pituitary	O
adenoma	O
,	O
obtainment	O
of	O
two	O
logistic	O
regression	O
equations	O
as	O
an	O
auxiliary	O
support	O
in	O
the	O
diagnosis	O
of	O
these	O
tumors	O
.	O

Bile	O
salts	O
,	O
hormonal	O
control	O
,	O
and	O
the	O
male	O
disadvantage	O
.	O

Number	O
of	O
warm	O
-	O
units	O
with	O
higher	O
rates	O
of	O
firing	O
and	O
greater	O
thermal	O
coefficients	O
,	O
comparable	O
to	O
those	O
of	O
warm	O
-	O
units	O
in	O
the	O
adult	O
,	O
gradually	O
increased	O
with	O
growth	O
.	O

Such	O
unique	O
recognition	O
capabilities	O
are	O
generated	O
with	O
minimal	O
alterations	O
in	O
the	O
CDR3	B-GENE
loops	O
of	O
the	O
TCR	B-GENE
.	O

To	O
this	O
effect	O
,	O
the	O
present	O
survey	O
puts	O
in	O
evidence	O
that	O
the	O
maximum	O
delay	O
of	O
stream	O
that	O
guarantees	O
the	O
good	O
dimensional	O
stability	O
of	O
these	O
class	O
A	O
alginates	O
is	O
of	O
45	O
minutes	O
in	O
the	O
hot	O
and	O
humid	O
climatic	O
tropical	O
country	O
conditions	O
.	O

Gene	B-GENE
1	I-GENE
of	I-GENE
the	I-GENE
murine	I-GENE
coronavirus	I-GENE
,	I-GENE
MHV	I-GENE
-	I-GENE
A59	I-GENE
,	O
encodes	O
approximately	O
800	O
kDa	O
of	O
protein	O
products	O
within	O
two	O
overlapping	O
open	O
reading	O
frames	O
(	O
ORFs	O
1a	O
and	O
1b	O
)	O
.	O

For	O
this	O
interaction	O
,	O
the	O
C	O
-	O
terminal	O
part	O
of	O
Sp1	B-GENE
and	O
the	O
N	O
terminus	O
of	O
E2F1	B-GENE
,	O
a	O
domain	O
also	O
present	O
in	O
E2F2	B-GENE
and	O
E2F3	B-GENE
but	O
absent	O
in	O
E2F4	B-GENE
and	O
E2F5	B-GENE
,	O
were	O
essential	O
.	O

Our	O
results	O
suggest	O
a	O
biological	O
role	O
for	O
Elf	B-GENE
-	I-GENE
1	I-GENE
in	O
the	O
regulation	O
of	O
IgH	B-GENE
gene	I-GENE
expression	O
,	O
attribute	O
a	O
functional	O
role	O
for	O
receptor	O
-	O
induced	O
AP	B-GENE
-	I-GENE
1	I-GENE
proteins	I-GENE
in	O
B	O
lymphocytes	O
and	O
provide	O
evidence	O
for	O
a	O
direct	O
link	O
between	O
IgM	B-GENE
receptor	I-GENE
-	O
mediated	O
signalling	O
and	O
3	O
'	O
enhancer	O
activation	O
.	O

Oncogenic	O
activation	O
of	O
RET	B-GENE
is	O
detected	O
in	O
human	O
papillary	O
thyroid	O
tumours	O
and	O
in	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
syndromes	O
.	O

CD4	B-GENE
degradation	O
mediated	O
by	O
Vpu	B-GENE
does	O
not	O
require	O
the	O
ER	O
chaperone	O
calnexin	B-GENE
and	O
is	O
dependent	O
on	O
an	O
intact	O
ubiquitin	B-GENE
-	O
conjugating	O
system	O
.	O

The	O
maternal	B-GENE
par	I-GENE
genes	I-GENE
and	O
the	O
segregation	O
of	O
cell	O
fate	O
specification	O
activities	O
in	O
early	O
Caenorhabditis	O
elegans	O
embryos	O
.	O

These	O
effects	O
were	O
antagonized	O
by	O
prior	O
administration	O
of	O
1	O
-	O
(	O
2	O
-	O
methoxyphenyl	O
)	O
-	O
4	O
-	O
[	O
-	O
(	O
2	O
-	O
phthalimido	O
)	O
butyl	O
]	O
piperazine	O
)	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
adding	O
a	O
pulsating	O
bristle	O
action	O
to	O
the	O
established	O
oscillating	O
/	O
rotating	O
action	O
of	O
the	O
Braun	O
Oral	O
-	O
B	O
Ultra	O
Plaque	O
Remover	O
(	O
D9	O
)	O
on	O
plaque	O
removal	O
.	O

Detailed	O
analysis	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
revealed	O
sequence	O
elements	O
which	O
are	O
conserved	O
in	O
many	O
DNA	B-GENE
and	I-GENE
RNA	I-GENE
polymerases	I-GENE
.	O

Sub	O
-	O
inhibitory	O
and	O
post	O
-	O
antibiotic	O
effects	O
of	O
spiramycin	O
and	O
erythromycin	O
on	O
Staphylococcus	O
aureus	O
.	O

The	O
CydDC	B-GENE
system	I-GENE
appears	O
to	O
be	O
the	O
first	O
prokaryotic	O
example	O
of	O
a	O
heterodimeric	B-GENE
ABC	I-GENE
transport	I-GENE
system	I-GENE
in	O
which	O
each	O
polypeptide	O
contains	O
both	O
hydrophobic	O
and	O
ATP	O
-	O
binding	O
domains	O
.	O

The	O
single	O
-	O
copy	O
U20	B-GENE
sequence	I-GENE
is	O
located	O
on	O
the	O
same	O
DNA	O
strand	O
as	O
the	O
nucleolin	B-GENE
mRNA	I-GENE
.	O

Gel	O
shift	O
and	O
southwestern	O
experiments	O
revealed	O
nuclear	O
proteins	O
of	O
43	O
kDa	O
and	O
30	O
kDa	O
in	O
GC	O
and	O
fish	O
cells	O
,	O
respectively	O
,	O
that	O
bind	O
specifically	O
to	O
the	O
tGH	B-GENE
CRE	O
,	O
suggesting	O
the	O
involvement	O
of	O
CRE	B-GENE
-	I-GENE
binding	I-GENE
-	I-GENE
protein	I-GENE
/	O
activating	B-GENE
-	I-GENE
transcription	I-GENE
-	I-GENE
factor	I-GENE
-	I-GENE
l	I-GENE
-	O
related	O
peptides	O
in	O
cAMP	O
response	O
.	O

The	O
coding	O
sequence	O
of	O
rat	B-GENE
MEK	I-GENE
kinase	I-GENE
1	I-GENE
(	O
MEKK1	B-GENE
)	O
has	O
been	O
determined	O
from	O
multiple	O
,	O
independent	O
cDNA	O
clones	O
.	O

In	O
response	O
to	O
the	O
need	O
for	O
better	O
quantitative	O
estimates	O
of	O
the	O
regional	O
distribution	O
of	O
the	O
active	O
bone	O
marrow	O
organ	O
in	O
infants	O
and	O
children	O
,	O
a	O
method	O
using	O
various	O
anatomical	O
data	O
has	O
been	O
developed	O
.	O

We	O
compared	O
these	O
responses	O
for	O
six	O
hatchling	O
and	O
eight	O
adult	O
Chrysemys	O
picta	O
from	O
an	O
Ohio	O
population	O
.	O

On	O
the	O
basis	O
of	O
experiments	O
with	O
mutant	O
virus	O
and	O
transfection	O
with	O
isolated	O
genes	O
,	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
immediate	I-GENE
-	I-GENE
early	I-GENE
gene	I-GENE
product	O
ICP4	B-GENE
is	O
known	O
to	O
positively	O
regulate	O
the	O
transcription	O
of	O
viral	B-GENE
early	I-GENE
and	I-GENE
late	I-GENE
genes	I-GENE
and	O
negatively	O
regulate	O
expression	O
from	O
its	O
own	O
promoter	O
.	O

A	O
female	O
infant	O
with	O
isolated	O
noncompaction	O
of	O
ventricular	O
myocardium	O
who	O
developed	O
ventricular	O
tachyarrhythmia	O
is	O
described	O
.	O

Recent	O
,	O
highly	O
visible	O
reviews	O
on	O
the	O
subject	O
have	O
clearly	O
pointed	O
out	O
that	O
little	O
is	O
known	O
about	O
the	O
cellular	O
mechanisms	O
through	O
which	O
inhaled	O
asbestos	O
fibers	O
cause	O
the	O
well	O
known	O
,	O
debilitating	O
lung	O
disease	O
-	O
asbestosis	O
(	O
i	O
.	O
e	O
.	O
interstitial	O
pulmonary	O
fibrosis	O
)	O
.	O

The	O
POU	B-GENE
-	O
specific	O
domain	O
of	O
Pit	B-GENE
-	I-GENE
1	I-GENE
is	O
essential	O
for	O
sequence	O
-	O
specific	O
,	O
high	O
affinity	O
DNA	O
binding	O
and	O
DNA	O
-	O
dependent	O
Pit	B-GENE
-	I-GENE
1	I-GENE
-	O
Pit	B-GENE
-	I-GENE
1	I-GENE
interactions	O
.	O

Also	O
,	O
the	O
placebo	O
nondepressed	O
patients	O
had	O
significantly	O
better	O
treatment	O
outcome	O
compared	O
with	O
the	O
placebo	O
depressed	O
patients	O
.	O

Obtaining	O
kidney	O
cells	O
from	O
a	O
beagle	O
puppy	O
(	O
RPB	O
-	O
1	O
)	O
and	O
the	O
establishment	O
of	O
a	O
cryopreservation	O
bank	O

These	O
results	O
suggest	O
an	O
essential	O
role	O
of	O
the	O
binding	O
of	O
HNF	B-GENE
-	I-GENE
4	I-GENE
and	O
/	O
or	O
HNF	B-GENE
-	I-GENE
4	I-GENE
-	I-GENE
related	I-GENE
nuclear	I-GENE
factors	I-GENE
to	O
the	O
6	O
beta	O
A	O
-	O
A	O
site	O
on	O
the	O
basal	O
transcriptional	O
activation	O
of	O
the	O
CYP3A2	B-GENE
gene	I-GENE
in	O
liver	O
cells	O
.	O

It	O
is	O
envisaged	O
that	O
the	O
WHOQOL	O
-	O
BREF	O
will	O
be	O
most	O
useful	O
in	O
studies	O
that	O
require	O
a	O
brief	O
assessment	O
of	O
quality	O
of	O
life	O
,	O
for	O
example	O
,	O
in	O
large	O
epidemiological	O
studies	O
and	O
clinical	O
trials	O
where	O
quality	O
of	O
life	O
is	O
of	O
interest	O
.	O

Restriction	O
mapping	O
showed	O
that	O
the	O
two	O
recombinant	O
plasmids	O
shared	O
an	O
EcoRI	B-GENE
fragment	I-GENE
of	O
8	O
.	O
9	O
kb	O
.	O

Usefulness	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
congestive	O
heart	O
failure	O

The	O
chromosomal	O
location	O
of	O
these	O
YACs	O
was	O
verified	O
using	O
FISH	O
,	O
which	O
also	O
demonstrated	O
their	O
nonchimeric	O
nature	O
.	O

After	O
first	O
strand	O
cDNA	O
synthesis	O
from	O
fetal	O
brain	O
mRNAs	O
,	O
short	O
fragment	O
cDNAs	O
(	O
sf	O
-	O
cDNAs	O
)	O
were	O
synthesized	O
with	O
a	O
two	O
-	O
step	O
amplification	O
system	O
by	O
use	O
of	O
our	O
modified	O
Degenerate	O
Oligonucleotide	O
Primed	O
Shuttle	O
Polymerase	O
Chain	O
Reaction	O
(	O
DOP	O
-	O
Shuttle	O
-	O
PCR	O
)	O
method	O
.	O

For	O
evaluation	O
of	O
the	O
model	O
,	O
simulations	O
of	O
physiological	O
excitation	O
and	O
of	O
pathologies	O
(	O
Wolff	O
-	O
Parkinson	O
-	O
White	O
syndrome	O
,	O
complete	O
AV	O
-	O
block	O
,	O
inferior	O
wall	O
ischaemia	O
)	O
were	O
examined	O
.	O

Profilins	B-GENE
IIa	I-GENE
and	I-GENE
IIb	I-GENE
are	O
also	O
present	O
in	O
humans	O
,	O
suggesting	O
that	O
all	O
mammals	O
have	O
three	O
profilin	B-GENE
isoforms	I-GENE
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
have	O
isolated	O
an	O
835	O
amino	O
acid	O
RING	O
finger	O
(	O
C3HC4	O
zinc	O
finger	O
)	O
protein	O
,	O
TIF1	B-GENE
beta	I-GENE
(	O
also	O
named	O
KAP	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
that	O
specifically	O
interacts	O
with	O
the	O
KRAB	B-GENE
domain	I-GENE
of	O
the	O
human	O
zinc	O
finger	O
factor	O
KOX1	B-GENE
/	O
ZNF10	B-GENE
.	O

The	O
authors	O
report	O
about	O
the	O
exeresis	O
of	O
a	O
pyelonephrictic	O
left	O
small	O
kidney	O
with	O
laparoscopic	O
surgery	O
.	O

New	O
protein	O
-	O
free	O
products	O
for	O
diet	O
therapy	O
in	O
chronic	O
renal	O
insufficiency	O

Unestablished	O
quail	O
myoblasts	O
were	O
infected	O
with	O
a	O
retroviral	O
vector	O
encoding	O
the	O
oncogenic	O
form	O
of	O
H	B-GENE
-	I-GENE
Ras	I-GENE
in	O
order	O
to	O
investigate	O
the	O
mechanism	O
by	O
which	O
this	O
oncoprotein	O
interferes	O
with	O
terminal	O
differentiation	O
.	O

Early	O
detection	O
and	O
signs	O
of	O
hepatoangiosarcoma	O
among	O
vinyl	O
chloride	O
workers	O
.	O

The	O
reduced	O
expression	O
caused	O
by	O
multimerization	O
of	O
UAS2	O
in	O
the	O
native	O
promoter	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
ADR1	B-GENE
.	O

VP4	B-GENE
differentially	O
regulates	O
TRAF2	B-GENE
signaling	O
,	O
disengaging	O
JNK	B-GENE
activation	O
while	O
directing	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
to	O
effect	O
rotavirus	O
-	O
specific	O
cellular	O
responses	O
.	O

On	O
the	O
3rd	O
day	O
after	O
ischemia	O
of	O
the	O
remained	O
kidney	O
for	O
30	O
min	O
,	O
structural	O
components	O
of	O
the	O
walls	O
of	O
the	O
glomerular	O
arterioles	O
and	O
those	O
of	O
the	O
filtration	O
-	O
reabsorption	O
barrier	O
undergo	O
certain	O
ultrastructural	O
changes	O
,	O
that	O
with	O
time	O
elapsed	O
(	O
7	O
,	O
14	O
days	O
)	O
gradually	O
pass	O
away	O
,	O
and	O
amount	O
of	O
cells	O
with	O
hypertrophic	O
processes	O
increases	O
.	O

The	O
purified	O
RAG1	B-GENE
protein	I-GENE
overexpressed	O
in	O
E	O
.	O
coli	O
exhibited	O
the	O
expected	O
cleavage	O
activity	O
when	O
combined	O
with	O
RAG2	B-GENE
purified	O
from	O
transfected	O
293T	O
cells	O
.	O

19	O
,	O
4967	O
-	O
4973	O
)	O
.	O

Preventing	O
the	O
heterosexual	O
spread	O
of	O
HIV	O
into	O
this	O
vulnerable	O
population	O
is	O
a	O
formidable	O
public	O
health	O
challenge	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
GATA	B-GENE
-	I-GENE
1	I-GENE
and	O
Sp1	B-GENE
synergize	O
from	O
a	O
distance	O
in	O
constructs	O
designed	O
to	O
mimic	O
the	O
architecture	O
of	O
globin	B-GENE
locus	I-GENE
control	I-GENE
regions	I-GENE
and	O
downstream	O
globin	B-GENE
promoters	I-GENE
.	O

Superovulation	O
with	O
intrauterine	O
insemination	O
(	O
SO	O
-	O
IUI	O
)	O
has	O
been	O
suggested	O
as	O
an	O
alternative	O
to	O
gamete	O
intrafallopian	O
transfer	O
(	O
GIFT	O
)	O
,	O
despite	O
the	O
absence	O
of	O
controlled	O
or	O
comparative	O
trials	O
.	O

Mammalian	O
chromosome	O
ends	O
contain	O
long	O
arrays	O
of	O
TTAGGG	O
repeats	O
that	O
are	O
complexed	O
to	O
a	O
telomere	O
specific	O
protein	O
,	O
the	O
TTAGGG	B-GENE
repeat	I-GENE
binding	I-GENE
factor	I-GENE
,	O
TRF1	B-GENE
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
male	O
patients	O
with	O
a	O
partial	O
nullisomy	O
of	O
the	O
X	O
chromosome	O
have	O
suggested	O
that	O
at	O
least	O
one	O
locus	O
involved	O
in	O
MRX	O
is	O
on	O
Xp22	O
.	O
3	O
.	O

Mean	O
disposition	O
constants	O
(	O
+	O
/	O
-	O
SD	O
)	O
were	O
obtained	O
from	O
individualized	O
fits	O
(	O
V1	O
:	O
0	O
.	O
398	O
+	O
/	O
-	O
0	O
.	O
336	O
LITER	O
/	O
KG	O
,	O
Vdarea	O
:	O
2	O
.	O
53	O
+	O
/	O
-	O
0	O
.	O
72	O
liter	O
/	O
kg	O
,	O
alpha	O
:	O
0	O
.	O
316	O
+	O
/	O
-	O
0	O
.	O
294	O
min	O
-	O
1	O
,	O
beta	O
:	O
0	O
.	O
00204	O
+	O
/	O
-	O
0	O
.	O
00262	O
min	O
-	O
1	O
,	O
k2	O
:	O
0	O
.	O
0305	O
+	O
/	O
-	O
0	O
.	O
0101	O
min	O
-	O
1	O
)	O
.	O

The	O
gene	O
,	O
from	O
the	O
initiator	O
methionine	O
to	O
the	O
polyadenylation	O
site	O
,	O
is	O
contained	O
within	O
13	O
244	O
basepairs	O
and	O
contains	O
19	O
exons	O
.	O

In	O
the	O
unit	O
housing	O
of	O
a	O
compact	O
cyclotron	O
and	O
positron	O
emission	O
CT	O
(	O
PET	O
)	O
,	O
positron	O
emitting	O
gas	O
such	O
as	O
15O	O
,	O
11C	O
,	O
C15O2	O
,	O
C15O	O
etc	O
.	O

is	O
supplied	O
from	O
a	O
cyclotron	O
to	O
a	O
PET	O
room	O
through	O
a	O
transportation	O
pipe	O
with	O
an	O
appropriate	O
shield	O
to	O
reduce	O
positron	O
annihilation	O
radiation	O
.	O

Adhesion	O
was	O
inhibited	O
by	O
mAbs	O
against	O
the	O
COOH	O
-	O
terminus	O
and	O
central	O
cell	O
binding	O
domains	O
of	O
fibronectin	B-GENE
,	O
as	O
well	O
as	O
by	O
the	O
corresponding	O
CS1	B-GENE
and	O
RGD	B-GENE
peptides	I-GENE
.	O

These	O
results	O
were	O
not	O
obtained	O
using	O
either	O
preimmune	O
sera	O
or	O
antiserum	O
specific	O
for	O
the	O
luminal	O
portion	O
of	O
the	O
glycoprotein	O
precursor	O
.	O

Cerebral	O
blood	O
flow	O
was	O
measured	O
using	O
the	O
iv	O
method	O
of	O
133	O
-	O
Xe	O
CBF	O
determination	O
and	O
AVDO2	O
was	O
measured	O
using	O
systemic	O
arterial	O
-	O
jugular	O
venous	O
oxygen	O
content	O
differences	O
.	O

Activation	O
of	O
the	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
pathway	O
enhances	O
long	O
-	O
range	O
transactivation	O
by	O
the	O
beta	B-GENE
-	I-GENE
globin	I-GENE
locus	I-GENE
control	I-GENE
region	I-GENE
(	O
LCR	O
)	O
(	O
W	O
.	O

In	O
situ	O
hybridization	O
of	O
whole	O
-	O
mount	O
mouse	O
embryos	O
with	O
Mex5	B-GENE
antisense	I-GENE
RNA	I-GENE
provide	O
no	O
evidence	O
for	O
the	O
exclusion	O
of	O
Mex5	B-GENE
during	O
embryonic	O
development	O
.	O

In	O
three	O
other	O
patients	O
the	O
electrophysiologic	O
characteristics	O
of	O
atrioventricular	O
conduction	O
prevented	O
a	O
demonstration	O
of	O
these	O
differences	O
.	O

Human	O
psychophysical	O
analysis	O
of	O
receptive	O
field	O
-	O
like	O
properties	O
-	O
-	O
II	O
.	O

3	O
.	O

New	O
strategies	O
are	O
needed	O
to	O
prevent	O
coronary	O
rethrombosis	O
in	O
patients	O
with	O
minimal	O
atherosclerosis	O
after	O
thrombolytic	O
therapy	O
for	O
acute	O
myocardial	O
infarction	O
.	O

The	O
Ick	B-GENE
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
is	O
not	O
involved	O
in	O
antibody	O
-	O
mediated	O
CD4	B-GENE
(	O
CDR3	B-GENE
-	I-GENE
loop	I-GENE
)	O
signal	O
transduction	O
that	O
inhibits	O
HIV	O
-	O
1	O
transcription	O
.	O

Programmed	O
peritoneal	O
lavage	O
in	O
suppurative	O
complications	O
of	O
perforated	O
ulcer	O
of	O
the	O
stomach	O

Deletion	O
analysis	O
of	O
the	O
7	B-GENE
.	I-GENE
3	I-GENE
-	I-GENE
kb	I-GENE
GATA	I-GENE
-	I-GENE
2	I-GENE
promoter	I-GENE
region	I-GENE
revealed	O
that	O
a	O
1	O
.	O
1	O
-	O
kb	O
DNA	O
sequence	O
is	O
critical	O
for	O
expression	O
of	O
GATA	B-GENE
-	I-GENE
2	I-GENE
in	O
neurons	O
.	O

The	O
model	O
therefore	O
predicts	O
that	O
1	O
)	O
on	O
-	O
line	O
calculation	O
of	O
airway	O
dead	O
space	O
and	O
end	O
-	O
expired	O
lung	O
volume	O
can	O
be	O
made	O
by	O
the	O
addition	O
of	O
an	O
oxygen	O
sine	O
-	O
wave	O
perturbation	O
component	O
to	O
the	O
mean	O
FIO2	O
;	O
and	O
(	O
2	O
)	O
QS	O
/	O
QT	O
can	O
be	O
measured	O
from	O
the	O
resultant	O
oxygen	O
perturbation	O
sine	O
-	O
wave	O
amplitudes	O
in	O
the	O
expired	O
gas	O
and	O
in	O
arterial	O
and	O
mixed	O
-	O
venous	O
blood	O
and	O
is	O
independent	O
of	O
the	O
mean	O
blood	O
oxygen	O
partial	O
pressure	O
and	O
oxyhemoglobin	B-GENE
saturation	O
values	O
.	O

Consistent	O
with	O
this	O
,	O
rh5	B-GENE
expression	O
in	O
R8	B-GENE
disappears	O
when	O
R7	O
cells	O
are	O
absent	O
(	O
in	O
sevenless	B-GENE
mutant	I-GENE
)	O
.	O

The	O
fusion	O
gene	O
cassette	O
was	O
placed	O
under	O
the	O
control	O
of	O
a	O
vaccinia	B-GENE
virus	I-GENE
early	I-GENE
promoter	I-GENE
and	O
cloned	O
in	O
a	O
host	O
-	O
restricted	O
fowlpox	O
viral	O
vector	O
.	O

Psoriasis	O
on	O
tumor	O
.	O

Fulminant	O
hepatic	O
failure	O
in	O
these	O
cases	O
could	O
be	O
characterized	O
by	O
:	O
(	O
1	O
)	O
rapid	O
decrease	O
in	O
serum	B-GENE
alanine	I-GENE
transaminase	I-GENE
(	O
ALT	B-GENE
)	O
level	O
after	O
discontinuation	O
of	O
ecarazine	O
,	O
(	O
2	O
)	O
prolonged	O
jaundice	O
despite	O
discontinuation	O
of	O
ecarazine	O
,	O
(	O
3	O
)	O
high	O
incidence	O
of	O
anti	B-GENE
-	I-GENE
nuclear	I-GENE
antibody	I-GENE
(	O
ANA	B-GENE
)	O
(	O
57	O
%	O
)	O
,	O
and	O
(	O
4	O
)	O
histological	O
findings	O
of	O
extensive	O
hepatocellular	O
necrosis	O
ranging	O
from	O
bridging	O
necrosis	O
to	O
massive	O
necrosis	O
.	O

These	O
data	O
suggest	O
that	O
the	O
secreted	O
,	O
truncated	O
receptor	O
encoded	O
by	O
the	O
2	B-GENE
.	I-GENE
6	I-GENE
-	I-GENE
kb	I-GENE
c	I-GENE
-	I-GENE
erbB	I-GENE
transcript	I-GENE
can	O
bind	O
to	O
TGF	B-GENE
alpha	I-GENE
and	O
may	O
play	O
an	O
important	O
growth	O
-	O
regulatory	O
function	O
in	O
vitro	O
.	O

Localization	O
of	O
the	O
porcine	O
enzyme	O
in	O
the	O
endoplasmic	O
reticulum	O
is	O
consistent	O
with	O
immuno	O
-	O
electron	O
-	O
microscopic	O
studies	O
using	O
pig	O
hepatocytes	O
.	O

A	O
close	O
homologue	O
of	O
the	O
APK2a	B-GENE
gene	I-GENE
,	O
named	O
APK2b	B-GENE
,	O
was	O
also	O
isolated	O
from	O
the	O
Arabidopsis	O
cDNA	O
library	O
.	O

Thus	O
,	O
the	O
rates	O
of	O
a	B-GENE
-	I-GENE
factor	I-GENE
receptor	I-GENE
endocytosis	O
and	O
consequent	O
vacuolar	O
turnover	O
depend	O
on	O
the	O
available	O
level	O
of	O
ubiquitin	B-GENE
in	O
the	O
cell	O
.	O

Using	O
the	O
same	O
approach	O
we	O
have	O
shown	O
that	O
hFIRE	B-GENE
binds	O
the	O
stimulatory	O
proteins	O
Sp1	B-GENE
and	O
Sp3	B-GENE
in	O
addition	O
to	O
CBF	B-GENE
.	O

Non	O
-	O
specific	O
immunological	O
abnormalities	O
were	O
detected	O
in	O
8	O
of	O
the	O
13	O
patients	O
in	O
whom	O
they	O
were	O
looked	O
for	O
.	O

Using	O
a	O
combined	O
pharmacokinetic	O
-	O
pharmacodynamic	O
model	O
,	O
the	O
impact	O
of	O
various	O
factors	O
on	O
the	O
effective	O
bioavailability	O
and	O
on	O
its	O
estimation	O
,	O
using	O
the	O
intravenous	O
-	O
to	O
-	O
oral	O
dose	O
ratio	O
required	O
to	O
produce	O
the	O
same	O
area	O
under	O
the	O
response	O
time	O
curve	O
after	O
acute	O
administration	O
,	O
are	O
explored	O
.	O

CONCLUSIONS	O
:	O
The	O
RRM	O
is	O
one	O
of	O
the	O
most	O
common	O
and	O
best	O
characterized	O
RNA	O
-	O
binding	O
motifs	O
.	O

The	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
Cdk2	B-GENE
associates	O
with	O
cyclins	B-GENE
A	I-GENE
,	I-GENE
D	I-GENE
,	I-GENE
and	I-GENE
E	I-GENE
and	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
the	O
G1	O
to	O
S	O
phase	O
transition	O
in	O
mammals	O
.	O

Mol	O
.	O

The	O
amino	B-GENE
-	I-GENE
terminal	I-GENE
gag	I-GENE
-	I-GENE
encoded	I-GENE
region	I-GENE
of	O
P140gag	B-GENE
-	O
fps	B-GENE
contains	O
a	O
phosphotyrosine	O
residue	O
in	O
addition	O
to	O
normal	O
gag	B-GENE
phosphorylation	O
sites	O
.	O

Rad18	B-GENE
is	O
required	O
for	O
DNA	O
repair	O
and	O
checkpoint	O
responses	O
in	O
fission	O
yeast	O
.	O

A	O
less	O
common	O
and	O
much	O
more	O
perplexing	O
circumstance	O
occurs	O
when	O
evaluating	O
patients	O
with	O
sarcoidosis	O
established	O
for	O
several	O
years	O
present	O
with	O
evidence	O
of	O
progressive	O
or	O
chronic	O
pulmonary	O
involvement	O
and	O
dyspnea	O
.	O

2	O
,	O
4	O
-	O
and	O
2	O
,	O
6	O
-	O
toluenediamine	O
in	O
hydrolysed	O
plasma	O
and	O
urine	O
after	O
test	O
-	O
chamber	O
exposure	O
of	O
humans	O
to	O
2	O
,	O
4	O
-	O
and	O
2	O
,	O
6	O
-	O
toluene	O
diisocyanate	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
whether	O
these	O
findings	O
are	O
idiosyncratic	O
,	O
coincidental	O
,	O
or	O
a	O
more	O
general	O
phenomenon	O
.	O

After	O
1	O
day	O
,	O
none	O
of	O
the	O
labeled	O
erythrocytes	O
were	O
detected	O
.	O

This	O
substrate	O
was	O
cleaved	O
efficiently	O
in	O
trans	O
by	O
protease	B-GENE
3C	I-GENE
derived	O
from	O
another	O
recombinant	O
vaccinia	O
virus	O
expressing	O
a	O
3C	B-GENE
precursor	I-GENE
protein	I-GENE
.	O

The	O
activity	O
of	O
gamma	B-GENE
-	I-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
in	O
the	O
serum	O
of	O
problem	O
drinkers	O
.	O

Patients	O
with	O
endocarditis	O
or	O
vascular	O
infection	O
were	O
more	O
frequently	O
immunocompromised	O
and	O
older	O
than	O
those	O
with	O
acute	O
Q	O
fever	O
.	O

The	O
effects	O
of	O
oxalate	O
-	O
containing	O
products	O
on	O
the	O
exposed	O
dentine	O
surface	O
:	O
an	O
SEM	O
investigation	O
.	O

The	O
technique	O
used	O
by	O
this	O
system	O
involves	O
a	O
transient	O
,	O
externally	O
applied	O
increase	O
in	O
resistance	O
to	O
breathing	O
.	O

We	O
evaluated	O
99mTc	O
-	O
ECD	O
SPECT	O
comparing	O
with	O
rCBF	O
images	O
obtained	O
by	O
PET	O
in	O
12	O
patients	O
with	O
spinocerebellar	O
degeneration	O
(	O
SCD	O
)	O
.	O

Monoclonal	O
antibodies	O
to	O
the	O
hapten	O
phenyloxazolone	O
were	O
raised	O
7	O
days	O
after	O
immunization	O
in	O
mice	O
of	O
six	O
strains	O
(	O
BALB	O
/	O
c	O
,	O
C57BL	O
-	O
Igha	O
,	O
DBA2	O
,	O
RF	O
,	O
A	O
/	O
J	O
,	O
and	O
CE	O
)	O
.	O

In	O
particular	O
,	O
lacZ	B-GENE
transcripts	I-GENE
synthesised	O
this	O
way	O
are	O
highly	O
unstable	O
and	O
yield	O
little	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
.	O

Six	O
cDNAs	O
represent	O
human	O
homologs	O
of	O
genes	O
known	O
in	O
other	O
species	O
,	O
namely	O
,	O
mouse	B-GENE
HSPE71	I-GENE
,	O
Rat	B-GENE
RhoGAP	I-GENE
protein	I-GENE
,	O
S	B-GENE
cerevisiae	I-GENE
leucyl	I-GENE
tRNA	I-GENE
synthetase	I-GENE
and	O
S	B-GENE
cerevisiae	I-GENE
chromosome	I-GENE
II	I-GENE
ORF	I-GENE
YBLO44W	I-GENE
.	O

The	O
thalamic	O
SD	O
was	O
regularly	O
triggered	O
by	O
short	O
(	O
0	O
.	O
02	O
-	O
0	O
.	O
05	O
s	O
)	O
high	O
-	O
frequency	O
(	O
200	O
-	O
500	O
Hz	O
)	O
ES	O
of	O
the	O
parietal	O
cortical	O
surface	O
.	O

All	O
three	O
SSV	O
-	O
transformed	O
cells	O
secreted	O
v	B-GENE
-	I-GENE
sis	I-GENE
gene	I-GENE
product	I-GENE
(	O
p44	B-GENE
)	O
.	O

p44	B-GENE
was	O
secreted	O
but	O
remained	O
tightly	O
associated	O
with	O
the	O
cell	O
surface	O
.	O

It	O
is	O
suggested	O
that	O
the	O
mechanism	O
of	O
intestinal	O
absorption	O
of	O
vitamin	O
D	O
and	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
may	O
differ	O
in	O
man	O
,	O
the	O
absorption	O
of	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
possibly	O
being	O
less	O
dependent	O
on	O
bile	O
acids	O
.	O

To	O
determine	O
the	O
role	O
of	O
elevated	O
FAK	B-GENE
expression	O
in	O
facilitating	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
-	O
stimulated	O
human	O
adenocarcinoma	O
(	O
A549	O
)	O
cell	O
motility	O
,	O
antisense	O
oligonucleotides	O
were	O
used	O
to	O
reduce	O
FAK	B-GENE
protein	I-GENE
expression	O
>	O
75	O
%	O
.	O

It	O
tends	O
to	O
be	O
higher	O
between	O
frazioni	O
of	O
the	O
same	O
community	O
than	O
between	O
communities	O
.	O

The	O
BRSV	B-GENE
L	I-GENE
gene	I-GENE
is	O
6573	O
nt	O
in	O
length	O
and	O
the	O
derived	O
polypeptide	O
has	O
2162	O
aa	O
.	O

To	O
further	O
study	O
the	O
role	O
of	O
tTG	B-GENE
in	O
liver	O
disease	O
,	O
we	O
initiated	O
investigations	O
into	O
the	O
effect	O
of	O
a	O
proinflammatory	O
mediator	O
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	I-GENE
TNF	I-GENE
)	I-GENE
-	I-GENE
alpha	I-GENE
,	O
on	O
tTG	B-GENE
activity	O
in	O
cultured	O
liver	O
cells	O
.	O

Availability	O
of	O
a	O
less	O
palatable	O
diet	O
(	O
chow	O
)	O
following	O
presentation	O
of	O
palatable	O
diets	O
will	O
not	O
result	O
in	O
diminished	O
caloric	O
intake	O
,	O
body	O
weight	O
,	O
obesity	O
and	O
hyperinsulinemia	O
.	O

By	O
contrast	O
,	O
CIS	B-GENE
failed	O
to	O
affect	O
the	O
IL	B-GENE
-	I-GENE
9	I-GENE
response	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
With	O
an	O
array	O
of	O
112	O
unipole	O
,	O
epicardial	O
maps	O
of	O
electrically	O
induced	O
AF	O
in	O
6	O
dogs	O
(	O
acute	O
group	O
)	O
,	O
self	O
-	O
sustained	O
AF	O
in	O
6	O
dogs	O
(	O
chronic	O
group	O
)	O
,	O
and	O
sinus	O
rhythm	O
and	O
atrial	O
pacing	O
in	O
3	O
dogs	O
(	O
control	O
group	O
)	O
were	O
analyzed	O
before	O
and	O
after	O
creating	O
linear	O
radiofrequency	O
ablation	O
lesions	O
in	O
both	O
atria	O
that	O
eliminated	O
the	O
AF	O
.	O

In	O
response	O
to	O
phosphorus	O
limitation	O
,	O
the	O
fungus	O
Neurospora	O
crassa	O
synthesizes	O
a	O
number	O
of	O
enzymes	O
that	O
function	O
to	O
bring	O
more	O
phosphate	O
into	O
the	O
cell	O
.	O

The	O
effects	O
of	O
inoculum	O
size	O
,	O
medium	O
,	O
temperature	O
,	O
and	O
duration	O
of	O
growth	O
on	O
the	O
in	O
vitro	O
susceptibility	O
testing	O
of	O
Aspergillus	O
fumigatus	O
were	O
investigated	O
using	O
broth	O
micro	O
-	O
and	O
macro	O
-	O
dilution	O
techniques	O
.	O

We	O
have	O
analyzed	O
the	O
function	O
of	O
these	O
putative	O
SL	O
structures	O
in	O
RNA	O
translation	O
by	O
constructing	O
chimeric	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	B-GENE
CAT	I-GENE
)	I-GENE
RNAs	I-GENE
,	O
flanked	O
either	O
by	O
both	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
terminal	O
sequence	O
domains	O
from	O
the	O
RV	O
genome	O
or	O
several	O
deletion	O
derivatives	O
of	O
the	O
same	O
sequences	O
.	O

Periarteritis	O
nodosa	O
with	O
ruptures	O
of	O
the	O
renal	O
vessels	O
and	O
the	O
persistence	O
of	O
the	O
hepatitis	O
B	O
and	O
C	O
viruses	O
in	O
the	O
blood	O

Despite	O
the	O
fact	O
that	O
biochemical	O
estimates	O
of	O
bone	O
turnover	O
indicate	O
that	O
(	O
short	O
-	O
term	O
)	O
administration	O
of	O
rhGH	B-GENE
and	O
IGF	B-GENE
-	I-GENE
I	I-GENE
stimulates	O
bone	O
metabolism	O
in	O
non	O
-	O
osteoporotic	O
older	O
people	O
,	O
no	O
significant	O
changes	O
have	O
been	O
observed	O
in	O
bone	O
mineral	O
density	O
at	O
the	O
proximal	O
femur	O
.	O

Compression	O
of	O
pulmonary	O
artery	O
and	O
right	O
ventricular	O
outflow	O
tract	O
by	O
aneurysm	O
of	O
ascending	O
aorta	O
.	O

However	O
,	O
patients	O
with	O
DPX	O
should	O
be	O
observed	O
for	O
the	O
potential	O
occurrence	O
of	O
an	O
associated	O
condition	O
.	O

Blood	O
pressure	O
was	O
controlled	O
long	O
term	O
(	O
with	O
/	O
without	O
diuretics	O
/	O
beta	B-GENE
-	I-GENE
adrenoreceptor	I-GENE
blocking	O
drugs	O
)	O
in	O
sixteen	O
out	O
of	O
nineteen	O
patients	O
with	O
mild	O
-	O
moderate	O
hypertension	O
.	O

However	O
,	O
FosB	B-GENE
-	I-GENE
L	I-GENE
and	O
FosB	B-GENE
-	I-GENE
S	I-GENE
do	O
not	O
differ	O
in	O
all	O
trans	O
-	O
regulatory	O
properties	O
:	O
Trans	O
-	O
activation	O
of	O
a	O
5x	O
TRE	B-GENE
-	I-GENE
CAT	I-GENE
reporter	O
construct	O
in	O
HeLa	O
and	O
NIH	O
-	O
3T3	O
cells	O
was	O
found	O
with	O
both	O
FosB	B-GENE
forms	O
.	O

Mutations	O
in	O
glnB	B-GENE
,	O
nifR1	B-GENE
(	O
ntrC	B-GENE
)	O
,	O
and	O
NifR4	B-GENE
(	O
ntrA	B-GENE
encoding	O
sigma	B-GENE
54	I-GENE
)	O
had	O
no	O
influence	O
on	O
put	B-GENE
gene	I-GENE
expression	O
.	O

Disruption	O
of	O
INP53	B-GENE
,	O
but	O
not	O
the	O
related	O
INP51	B-GENE
and	O
INP52	B-GENE
genes	I-GENE
,	O
resulted	O
in	O
alpha	B-GENE
-	I-GENE
factor	I-GENE
maturation	O
defects	O
and	O
exacerbated	O
alpha	B-GENE
-	I-GENE
factor	I-GENE
maturation	O
defects	O
when	O
combined	O
with	O
chc1	B-GENE
-	I-GENE
521	I-GENE
.	O

Impact	O
of	O
cytokine	O
gene	O
polymorphisms	O
on	O
outcomes	O
of	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
.	O

Regardless	O
of	O
muscle	O
tensioning	O
or	O
marination	O
treatments	O
,	O
aging	O
of	O
the	O
carcass	O
for	O
24	O
h	O
(	O
T1	O
,	O
T2	O
,	O
and	O
T3	O
)	O
produced	O
meats	O
with	O
lower	O
shear	O
values	O
than	O
those	O
from	O
hot	O
-	O
boned	O
carcasses	O
(	O
T4	O
and	O
T5	O
)	O
.	O

Blood	O
and	O
whole	O
-	O
brain	O
mercury	O
concentrations	O
were	O
determined	O
in	O
pups	O
on	O
PN	O
0	O
(	O
birth	O
)	O
and	O
PN	O
21	O
(	O
weaning	O
)	O
.	O

By	O
subtractive	O
and	O
differential	O
screening	O
,	O
we	O
have	O
cloned	O
12	O
of	O
these	O
sequences	O
,	O
2	O
of	O
which	O
were	O
c	B-GENE
-	I-GENE
fos	I-GENE
and	O
krox	B-GENE
-	I-GENE
24	I-GENE
.	O

When	O
stratifying	O
FLM	O
values	O
<	O
34	O
and	O
>	O
34	O
wks	O
'	O
gestation	O
,	O
again	O
no	O
difference	O
was	O
found	O
in	O
mean	O
difference	O
of	O
L	O
/	O
S	O
and	O
LB	O
before	O
and	O
after	O
34	O
wks	O
.	O

Cotransfection	O
of	O
a	O
junB	B-GENE
stimulated	O
the	O
basal	O
activity	O
of	O
the	O
alpha	B-GENE
2	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
promoter	I-GENE
93	O
-	O
fold	O
,	O
respectively	O
.	O

Glutathione	B-GENE
reductase	I-GENE
(	O
GR	B-GENE
)	O
was	O
purified	O
from	O
the	O
cyanobacterium	O
Anabaena	O
PCC	O
7120	O
.	O

Additional	O
simulations	O
account	O
for	O
interactions	O
of	O
spatial	O
frequency	O
with	O
stimulus	O
duration	O
,	O
effects	O
of	O
adaptation	O
,	O
and	O
properties	O
of	O
residual	O
traces	O
,	O
as	O
opposed	O
to	O
visual	O
persistence	O
.	O

Fractional	O
Ca	O
retention	O
was	O
measured	O
from	O
the	O
72	O
-	O
h	O
postdose	O
WBR	O
divided	O
by	O
WBR	O
at	O
time	O
0	O
.	O

METHODS	O
:	O
The	O
study	O
population	O
included	O
70	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
(	O
14	O
with	O
recent	O
acute	O
myocardial	O
infarction	O
and	O
56	O
with	O
unstable	O
angina	O
pectoris	O
)	O
,	O
105	O
patients	O
with	O
stable	O
angina	O
pectoris	O
,	O
and	O
75	O
control	O
subjects	O
.	O

Furthermore	O
,	O
rubella	B-GENE
IgM	I-GENE
antibody	I-GENE
was	O
never	O
detected	O
after	O
immunization	O
in	O
women	O
who	O
were	O
HAI	O
-	O
negative	O
and	O
LA	O
-	O
positive	O
during	O
pregnancy	O
.	O

Disease	O
-	O
free	O
interval	O
was	O
greater	O
in	O
node	O
-	O
negative	O
Lx	O
patients	O
for	O
both	O
T1	O
(	O
P	O
less	O
than	O
0	O
.	O
007	O
)	O
and	O
T2	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
presentations	O
.	O

5	O
'	O
-	O
Deletion	O
of	O
the	O
Stat	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
abolished	O
all	O
promoter	O
-	O
reporter	O
activity	O
in	O
response	O
to	O
PRL	B-GENE
.	O

A	O
review	O
of	O
156	O
patients	O
younger	O
than	O
40	O
treated	O
at	O
our	O
Department	O
between	O
1960	O
and	O
1991	O
with	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
revealed	O
that	O
89	O
.	O
1	O
%	O
had	O
superficial	O
(	O
Ta	O
/	O
T1	O
)	O
disease	O
and	O
the	O
remaining	O
10	O
.	O
9	O
%	O
presented	O
with	O
invasive	O
disease	O
.	O

Plasma	B-GENE
beta	I-GENE
-	I-GENE
thromboglobulin	I-GENE
(	O
beta	B-GENE
-	I-GENE
TG	I-GENE
)	O
,	O
a	O
platelet	O
-	O
specific	O
protein	O
,	O
is	O
a	O
marker	O
of	O
intravascular	O
platelet	O
degranulation	O
.	O

John	O
'	O
s	O
wort	O

DESIGN	O
,	O
SETTING	O
AND	O
SUBJECTS	O
:	O
The	O
analysis	O
is	O
based	O
on	O
data	O
collected	O
in	O
the	O
first	O
two	O
rounds	O
of	O
the	O
nationally	O
representative	O
Ghana	O
Living	O
Standards	O
Survey	O
,	O
held	O
in	O
1987	O
/	O
88	O
(	O
GLSS	O
-	O
I	O
)	O
and	O
1988	O
/	O
89	O
(	O
GLSS	O
-	O
II	O
)	O
,	O
with	O
both	O
surveys	O
covering	O
approximately	O
3000	O
households	O
.	O

The	O
DNA	O
-	O
binding	O
proteins	O
are	O
without	O
effect	O
on	O
the	O
transcription	O
of	O
plasmids	O
lacking	O
binding	O
sites	O
or	O
when	O
the	O
binding	O
sites	O
are	O
located	O
further	O
upstream	O
.	O

The	O
Gastrointestinal	O
Tumor	O
Study	O
Group	O
(	O
GITSG	O
)	O
protocol	O
GI	O
-	O
7175	O
randomized	O
227	O
patients	O
between	O
1975	O
and	O
1980	O
following	O
complete	O
surgical	O
resection	O
of	O
stages	O
B2	O
and	O
C	O
rectal	O
adenocarcinoma	O
to	O
four	O
treatment	O
arms	O
:	O
(	O
1	O
)	O
no	O
adjuvant	O
therapy	O
,	O
(	O
2	O
)	O
chemotherapy	O
only	O
,	O
(	O
3	O
)	O
radiotherapy	O
only	O
,	O
and	O
(	O
4	O
)	O
radiotherapy	O
and	O
chemotherapy	O
(	O
combined	O
modality	O
)	O
.	O

The	O
RTI40	B-GENE
gene	I-GENE
spans	O
35	O
kilobase	O
pairs	O
;	O
it	O
contains	O
6	O
exons	O
and	O
at	O
least	O
6	O
rat	O
Identifier	O
repetitive	O
elements	O
.	O

The	O
DNA	O
element	O
through	O
which	O
EBNA	B-GENE
-	I-GENE
3C	I-GENE
activates	O
the	O
LMP	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
includes	O
a	O
Spi	B-GENE
-	I-GENE
1	I-GENE
/	O
Spi	B-GENE
-	I-GENE
B	I-GENE
binding	O
site	O
,	O
previously	O
characterized	O
as	O
an	O
important	O
EBNA	B-GENE
-	I-GENE
2	I-GENE
response	I-GENE
element	I-GENE
.	O

DP	B-GENE
-	I-GENE
1	I-GENE
and	O
DP	B-GENE
-	I-GENE
2	I-GENE
encode	O
maternally	O
stored	O
transcripts	O
that	O
are	O
expressed	O
during	O
early	O
development	O
.	O

Furthermore	O
,	O
deletion	O
of	O
two	O
potential	O
Ste11	B-GENE
recognition	I-GENE
sites	I-GENE
in	O
the	O
fus1	B-GENE
promoter	I-GENE
region	O
abolished	O
transcription	O
,	O
and	O
expression	O
could	O
be	O
restored	O
when	O
we	O
inserted	O
a	O
different	O
Ste11	B-GENE
site	I-GENE
from	O
the	O
mat1	B-GENE
-	I-GENE
P	I-GENE
promoter	I-GENE
.	O

However	O
,	O
an	O
analogous	O
myristoylated	O
peptide	O
derived	O
from	O
c	B-GENE
-	I-GENE
Yes	I-GENE
also	O
has	O
no	O
inhibitory	O
activity	O
.	O

The	O
oral	O
movements	O
which	O
did	O
occur	O
in	O
the	O
HAL	O
-	O
treated	O
rats	O
were	O
slower	O
than	O
normal	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
animals	O
carrying	O
a	O
snf	B-GENE
mutation	O
that	O
converts	O
SNF	B-GENE
from	O
a	O
bifunctional	O
protein	O
to	O
a	O
U1	B-GENE
snRNP	I-GENE
-	I-GENE
specific	I-GENE
protein	I-GENE
are	O
viable	O
.	O

These	O
sequence	O
differences	O
are	O
reflected	O
in	O
differences	O
in	O
gene	O
expression	O
in	O
three	O
cell	O
lines	O
.	O

This	O
pathway	O
has	O
been	O
reported	O
to	O
mediate	O
heterodimer	O
interactions	O
with	O
the	O
proapoptotic	O
regulator	O
,	O
Bad	B-GENE
.	O

Mutating	O
bases	O
-	O
142	O
to	O
-	O
151	O
abolishes	O
formation	O
of	O
complex	O
VII	O
and	O
partially	O
inhibits	O
complex	O
IV	O
,	O
suggesting	O
that	O
the	O
proteins	O
forming	O
these	O
complexes	O
bind	O
neighboring	O
segments	O
of	O
DNA	O
.	O

The	O
DFA	O
slide	O
prepared	O
from	O
the	O
ThinPrep	O
Test	O
and	O
the	O
conventional	O
DFA	O
sample	O
prepared	O
from	O
the	O
endocervical	O
swab	O
were	O
evaluated	O
independently	O
.	O

Moclobemide	O
is	O
a	O
well	O
-	O
tolerated	O
alternative	O
antidepressant	O
,	O
but	O
there	O
is	O
a	O
need	O
for	O
prospective	O
controlled	O
trials	O
to	O
evaluate	O
its	O
long	O
-	O
term	O
efficacy	O
.	O

METHODS	O
:	O
Autocapture	O
devices	O
(	O
Pacesetter	O
Microny	O
SR	O
+	O
/	O
-	O
and	O
Regency	O
SR	O
+	O
/	O
-	O
;	O
Pacesetter	O
,	O
Solna	O
,	O
Sweden	O
)	O
and	O
steroid	O
-	O
eluting	O
epicardial	O
pacing	O
leads	O
(	O
Medtronic	O
CapSure	O
Epi	O
10366	O
;	O
Medtronic	O
,	O
Inc	O
,	O
Minneapolis	O
,	O
MN	O
)	O
were	O
implanted	O
in	O
14	O
children	O
.	O

Hormonal	O
replacement	O
therapy	O
for	O
women	O
with	O
a	O
personal	O
history	O
of	O
breast	O
cancer	O
?	O

Recently	O
,	O
we	O
reported	O
that	O
SMRT	B-GENE
also	O
directly	O
associates	O
with	O
LAZ3	B-GENE
(	O
BCL	B-GENE
-	I-GENE
6	I-GENE
)	O
,	O
a	O
POZ	O
/	O
Zn	O
finger	O
transcriptional	O
repressor	O
involvedin	O
the	O
pathogenesis	O
of	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O

Using	O
reporter	O
gene	O
constructs	O
driven	O
by	O
the	O
CD4	B-GENE
promoter	I-GENE
,	O
we	O
report	O
that	O
HHV	O
-	O
6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	O
elements	O
.	O

Characterization	O
of	O
a	O
cDNA	B-GENE
encoding	I-GENE
CNN	I-GENE
predicts	O
a	O
novel	O
structural	O
protein	O
with	O
three	O
leucine	O
zipper	O
motifs	O
and	O
several	O
coiled	O
-	O
coil	O
domains	O
exhibiting	O
limited	O
homology	O
to	O
the	O
rod	O
portion	O
of	O
myosin	B-GENE
.	O

A	O
preformed	O
SREBP	B-GENE
-	I-GENE
1a	I-GENE
:	I-GENE
[	I-GENE
32P	I-GENE
]	I-GENE
DNA	I-GENE
complex	I-GENE
bound	O
specifically	O
to	O
membrane	O
-	O
immobilized	O
GST	B-GENE
-	O
CBP	B-GENE
fusion	O
proteins	O
that	O
contained	O
amino	O
-	O
terminal	O
portions	O
of	O
CBP	B-GENE
.	O

Pyridostigmine	O
pretreatment	O
was	O
supplemented	O
by	O
therapy	O
with	O
two	O
doses	O
of	O
an	O
antidotal	O
combination	O
(	O
A	O
,	O
TM	O
,	O
B	O
)	O
consisting	O
of	O
0	O
.	O
05	O
mg	O
/	O
kg	O
atropine	O
,	O
2	O
.	O
24	O
mg	O
/	O
kg	O
TMB	O
-	O
4	O
,	O
and	O
0	O
.	O
4	O
mg	O
/	O
kg	O
benactyzine	O
which	O
assured	O
survival	O
in	O
five	O
of	O
six	O
animals	O
following	O
three	O
separate	O
exposures	O
to	O
10	O
LD50	O
soman	O
.	O

Previous	O
work	O
established	O
that	O
the	O
TAL1	B-GENE
proteins	I-GENE
are	O
phosphorylated	O
exclusively	O
on	O
serine	O
and	O
identified	O
Ser122	O
as	O
a	O
substrate	O
for	O
the	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
ERK	B-GENE
-	I-GENE
1	I-GENE
.	O

Rapid	O
,	O
sensitive	O
gas	O
chromatographic	O
analysis	O
of	O
8	O
-	O
methoxypsoralen	O
in	O
human	O
plasma	O
.	O

If	O
the	O
size	O
of	O
the	O
cystic	O
liver	O
-	O
lesions	O
excludes	O
a	O
curative	O
operative	O
treatment	O
or	O
if	O
the	O
patient	O
refuses	O
surgery	O
,	O
the	O
indication	O
for	O
chemotherapy	O
with	O
mebendazole	O
is	O
given	O
.	O

When	O
cotransfected	O
with	O
the	O
HIV	B-GENE
LTR	I-GENE
CAT	B-GENE
into	O
CV	O
-	O
1	O
cells	O
,	O
both	O
the	O
pCD41	B-GENE
and	O
pGD41	B-GENE
clones	O
trans	O
-	O
activated	O
the	O
HIV	B-GENE
LTR	I-GENE
.	O

The	O
induction	O
of	O
the	O
composite	O
H	B-GENE
-	I-GENE
PK	I-GENE
/	O
Tag	B-GENE
and	O
SV	B-GENE
-	I-GENE
PK	I-GENE
/	O
Tag	B-GENE
transgenes	O
by	O
a	O
carbohydrate	O
-	O
rich	O
diet	O
in	O
the	O
liver	O
was	O
similar	O
to	O
that	O
of	O
the	O
endogenous	B-GENE
L	I-GENE
-	I-GENE
PK	I-GENE
gene	I-GENE
.	O

Patients	O
with	O
advanced	O
ovarian	O
carcinoma	O
,	O
Stage	O
III	O
or	O
IV	O
(	O
International	O
Federation	O
of	O
Gynaecology	O
and	O
Obstetrics	O
)	O
,	O
were	O
randomized	O
to	O
primary	O
chemotherapy	O
with	O
doxorubicin	O
(	O
Adriamycin	O
)	O
and	O
cisplatin	O
plus	O
or	O
minus	O
hexamethylmelamine	O
,	O
and	O
cyclophosphamide	O
(	O
CHAP	O
)	O
.	O

Exit	O
from	O
mitosis	O
in	O
Drosophila	O
syncytial	O
embryos	O
requires	O
proteolysis	O
and	O
cyclin	B-GENE
degradation	O
,	O
and	O
is	O
associated	O
with	O
localized	O
dephosphorylation	O
.	O

Cough	O
-	O
CPR	O
,	O
a	O
deep	O
rhythmic	O
forceful	O
cough	O
repeated	O
30	O
-	O
60	O
times	O
per	O
minute	O
,	O
can	O
be	O
an	O
effective	O
resuscitative	O
technique	O
during	O
emergencies	O
occurring	O
in	O
the	O
cardiac	O
catheterization	O
laboratory	O
.	O

To	O
understand	O
this	O
dramatic	O
effect	O
,	O
we	O
examined	O
the	O
localization	O
of	O
SR	B-GENE
proteins	I-GENE
and	O
found	O
that	O
SC35	B-GENE
was	O
shifted	O
to	O
the	O
cytoplasm	O
in	O
sky1Delta	B-GENE
yeast	O
,	O
although	O
this	O
phenomenon	O
was	O
not	O
obvious	O
with	O
ASF	B-GENE
/	O
SF2	B-GENE
,	O
indicating	O
that	O
nuclear	O
import	O
of	O
SR	B-GENE
proteins	I-GENE
may	O
be	O
differentially	O
regulated	O
by	O
phosphorylation	O
.	O

Probiotics	O
,	O
prebiotics	O
,	O
vaccination	O
,	O
and	O
acidification	O
of	O
drinking	O
water	O
were	O
assessed	O
as	O
means	O
of	O
reducing	O
Salmonella	O
.	O

On	O
the	O
contrary	O
i	O
.	O
v	O
.	O
administration	O
of	O
calcitonin	B-GENE
increased	O
intrapyloric	O
pressure	O
via	O
vagal	O
nerves	O
in	O
atropinized	O
or	O
gallaminized	O
animals	O
.	O

We	O
conclude	O
that	O
in	O
the	O
presence	O
of	O
fatty	O
acids	O
in	O
the	O
medium	O
transcription	O
of	O
SPS19	B-GENE
is	O
directly	O
regulated	O
by	O
both	O
Pip2p	B-GENE
-	O
Oaf1p	B-GENE
and	O
Adr1p	B-GENE
.	O

Gas	O
exchange	O
was	O
measured	O
breath	O
by	O
breath	O
.	O

We	O
found	O
that	O
in	O
premature	O
infants	O
plasminogen	B-GENE
levels	O
are	O
low	O
;	O
thus	O
,	O
defense	O
against	O
intra	O
-	O
alveolar	O
fibrin	B-GENE
deposition	O
during	O
birth	O
trauma	O
is	O
reduced	O
.	O

Analysis	O
of	O
nt	O
sequence	O
was	O
carried	O
out	O
on	O
three	O
out	O
of	O
the	O
more	O
than	O
15	O
of	O
these	O
regions	O
present	O
in	O
the	O
mouse	O
genome	O
.	O

Studies	O
on	O
the	O
reaction	O
of	O
cytochrome	B-GENE
c	I-GENE
with	O
corticosteroids	O
.	O

However	O
,	O
both	O
RAR	B-GENE
-	O
and	O
RXR	B-GENE
-	O
specific	O
ligands	O
increase	O
CaSki	O
number	O
by	O
>	O
or	O
=	O
20	O
%	O
.	O

Also	O
,	O
in	O
patients	O
with	O
MYD	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
arterial	O
PO2	O
from	O
the	O
seated	O
posture	O
to	O
the	O
supine	O
posture	O
,	O
without	O
a	O
significant	O
change	O
in	O
the	O
arterial	O
PCO2	O
.	O

The	O
primary	O
structures	O
of	O
the	O
human	B-GENE
KB	I-GENE
cell	I-GENE
(	I-GENE
FR	I-GENE
-	I-GENE
KB1	I-GENE
)	I-GENE
folate	I-GENE
receptor	I-GENE
(	O
FR	B-GENE
)	O
and	O
of	O
a	O
human	B-GENE
placental	I-GENE
(	I-GENE
FR	I-GENE
-	I-GENE
P2	I-GENE
)	I-GENE
FR	I-GENE
,	O
proteins	O
important	O
in	O
cellular	O
accumulation	O
of	O
folates	O
,	O
have	O
been	O
deduced	O
from	O
cDNA	O
sequences	O
.	O

The	O
general	O
concept	O
of	O
RARE	B-GENE
-	O
cleavage	O
mapping	O
as	O
well	O
as	O
its	O
applications	O
and	O
limitations	O
are	O
discussed	O
.	O

To	O
further	O
investigate	O
the	O
role	O
of	O
PKR	B-GENE
in	O
transcriptional	O
signaling	O
,	O
we	O
expressed	O
the	O
wild	B-GENE
type	I-GENE
human	I-GENE
PKR	I-GENE
and	O
a	O
catalytically	O
inactive	O
dominant	O
negative	O
PKR	B-GENE
mutant	I-GENE
in	O
the	O
murine	O
pre	O
-	O
B	O
lymphoma	O
70Z	O
/	O
3	O
cells	O
.	O

Selective	O
upper	O
abdominal	O
sympathectomy	O
increased	O
basal	O
acid	O
output	O
in	O
rats	O
but	O
was	O
without	O
effect	O
on	O
stimulated	O
acid	O
output	O
,	O
serum	B-GENE
gastrin	I-GENE
concentration	O
,	O
and	O
gastric	B-GENE
mucosal	I-GENE
histidine	I-GENE
decarboxylase	I-GENE
activity	O
.	O

Reasons	O
are	O
presented	O
to	O
support	O
the	O
contention	O
that	O
this	O
increase	O
is	O
in	O
part	O
real	O
.	O

Patients	O
received	O
either	O
sodium	O
cephalothin	O
or	O
placebo	O
intravenously	O
before	O
the	O
procedure	O
and	O
for	O
up	O
to	O
8	O
additional	O
doses	O
.	O

In	O
-	O
111	O
-	O
BLMC	O
uptake	O
was	O
directly	O
proportional	O
to	O
Ki	B-GENE
-	I-GENE
67	I-GENE
/	O
MIB	B-GENE
-	I-GENE
1	I-GENE
activity	O
and	O
number	O
of	O
mitoses	O
in	O
tumor	O
tissue	O
.	O

Heating	O
had	O
no	O
effect	O
upon	O
either	O
force	O
decline	O
or	O
slowing	O
of	O
relaxation	O
during	O
fatiguing	O
contractions	O
.	O

Binding	O
of	O
transformed	O
Ah	B-GENE
receptor	I-GENE
complex	I-GENE
to	O
a	O
dioxin	O
responsive	O
transcriptional	O
enhancer	O
:	O
evidence	O
for	O
two	O
distinct	O
heteromeric	O
DNA	O
-	O
binding	O
forms	O
.	O

Interestingly	O
,	O
VDR	B-GENE
was	O
able	O
to	O
bind	O
to	O
VDREs	O
with	O
high	O
affinity	O
and	O
to	O
fully	O
activate	O
transcription	O
in	O
intact	O
yeast	O
cells	O
in	O
the	O
presence	O
of	O
the	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
(	O
RXR	B-GENE
)	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
moxalactam	O
is	O
a	O
reliable	O
and	O
useful	O
antibiotic	O
for	O
the	O
treatment	O
of	O
complicated	O
urinary	O
tract	O
infections	O
.	O

A	O
fine	O
-	O
structure	O
radiation	O
hybrid	O
map	O
for	O
the	O
region	O
that	O
extends	O
from	O
D8S520	B-GENE
(	O
distal	O
)	O
to	O
D8S1759	B-GENE
(	O
proximal	O
)	O
was	O
prepared	O
,	O
followed	O
by	O
construction	O
of	O
a	O
single	O
,	O
integrated	O
YAC	O
/	O
BAC	O
contig	O
for	O
the	O
interval	O
.	O

The	O
protein	O
contains	O
a	O
SHAQKYF	O
amino	O
acid	O
signature	O
motif	O
in	O
the	O
second	O
myb	B-GENE
-	I-GENE
like	I-GENE
repeat	I-GENE
,	O
which	O
is	O
highly	O
conserved	O
in	O
a	O
number	O
of	O
recently	O
identified	O
plant	B-GENE
myb	I-GENE
-	I-GENE
related	I-GENE
genes	I-GENE
,	O
thus	O
defining	O
a	O
new	O
class	O
of	O
plant	O
DNA	O
-	O
binding	O
proteins	O
.	O

IV	O
.	O

It	O
has	O
been	O
shown	O
that	O
renin	B-GENE
secretion	O
is	O
stimulated	O
by	O
endothelin	B-GENE
,	O
a	O
recently	O
discovered	O
peptide	O
with	O
strong	O
vasoconstrictive	O
properties	O
and	O
stimulating	O
effects	O
on	O
renin	B-GENE
secretion	O
.	O

Here	O
we	O
describe	O
the	O
cloning	O
and	O
initial	O
characterization	O
of	O
IPP	B-GENE
,	O
a	O
novel	O
human	O
gene	O
that	O
predicts	O
a	O
kelch	B-GENE
family	I-GENE
protein	I-GENE
homologous	O
to	O
the	O
mouse	B-GENE
Ipp	I-GENE
gene	I-GENE
,	O
a	O
previously	O
described	O
kelch	B-GENE
family	I-GENE
member	I-GENE
.	O

The	O
encoded	O
260	B-GENE
-	I-GENE
amino	I-GENE
-	I-GENE
acid	I-GENE
(	I-GENE
aa	I-GENE
)	I-GENE
(	I-GENE
H1	I-GENE
-	I-GENE
I	I-GENE
)	I-GENE
and	O
240	B-GENE
-	I-GENE
aa	I-GENE
(	I-GENE
H1	I-GENE
-	I-GENE
II	I-GENE
)	I-GENE
polypeptides	I-GENE
possess	O
the	O
typical	O
tripartite	O
organization	O
of	O
animal	B-GENE
H1	I-GENE
histones	I-GENE
,	O
with	O
variable	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
flanking	O
a	O
conserved	O
'	O
globular	O
'	O
DNA	O
-	O
binding	O
domain	O
.	O

Instead	O
,	O
the	O
large	O
difference	O
in	O
ssDNA	O
-	O
binding	O
affinities	O
reflects	O
the	O
loss	O
of	O
hexamerization	O
ability	O
by	O
uvsY	B-GENE
,	O
suggesting	O
that	O
a	O
form	O
of	O
intrahexamer	O
synergism	O
or	O
cooperativity	O
between	O
binding	O
sites	O
within	O
the	O
uvsY	B-GENE
hexamer	I-GENE
leads	O
to	O
its	O
high	O
observed	O
affinity	O
for	O
ssDNA	O
.	O

No	O
significant	O
difference	O
was	O
seen	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
degree	O
of	O
postoperative	O
deterioration	O
in	O
cardiopulmonary	O
function	O
or	O
in	O
interleukin	B-GENE
-	I-GENE
6	I-GENE
levels	O
.	O

The	O
PK	O
domain	O
showed	O
pairwise	O
in	O
vitro	O
binding	O
interactions	O
with	O
the	O
pseudokinase	O
,	O
HisRS	B-GENE
,	O
and	O
C	O
-	O
term	O
domains	O
;	O
additionally	O
,	O
the	O
HisRS	B-GENE
domain	I-GENE
interacted	O
with	O
the	O
C	O
-	O
term	O
region	O
.	O

The	O
effects	O
of	O
erythrosine	O
(	O
Red	O
3	O
)	O
,	O
rose	O
bengal	O
B	O
(	O
Red	O
105	O
)	O
and	O
thyroidectomy	O
on	O
the	O
development	O
of	O
thyroid	O
tumor	O
were	O
examined	O
in	O
male	O
Wistar	O
rats	O
treated	O
with	O
N	O
-	O
bis	O
(	O
2	O
-	O
hydroxypropyl	O
)	O
nitrosamine	O
(	O
DHPN	O
)	O
.	O

The	O
AmyI	B-GENE
specific	O
3	O
'	O
-	O
UTR	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
IR	O
sequences	O
and	O
the	O
presence	O
of	O
a	O
putative	O
'	O
AATAAA	O
'	O
polyadenylation	O
signal	O
.	O

To	O
initiate	O
our	O
analysis	O
of	O
factors	O
required	O
for	O
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
expression	O
,	O
selected	O
a	O
CAP	O
-	O
proximal	O
element	O
shown	O
by	O
in	O
vivo	O
methylation	O
protection	O
analysis	O
to	O
bind	O
a	O
potential	O
regulatory	O
factor	O
.	O

Furthermore	O
,	O
addition	O
of	O
the	O
recombinant	B-GENE
NF	I-GENE
-	I-GENE
YA	I-GENE
subunit	I-GENE
restores	O
NF	B-GENE
-	I-GENE
Y	I-GENE
binding	O
.	O

Reversible	O
pressure	O
-	O
induced	O
amorphization	O
in	O
solid	O
C70	O
:	O
Raman	O
and	O
photoluminescence	O
study	O
.	O

Alternative	O
roles	O
of	O
these	O
DNA	O
motifs	O
as	O
activators	O
of	O
early	O
mRNA	O
transcription	O
and	O
as	O
an	O
initiator	O
element	O
for	O
late	O
mRNA	O
transcription	O
help	O
explain	O
how	O
polyomavirus	O
gene	O
expression	O
is	O
regulated	O
during	O
lytic	O
growth	O
and	O
provides	O
a	O
model	O
for	O
cellular	O
transcription	O
during	O
development	O
.	O

Our	O
results	O
suggest	O
that	O
Sp1	B-GENE
binding	I-GENE
site	I-GENE
can	O
function	O
as	O
a	O
distinct	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
responsive	I-GENE
element	I-GENE
for	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
mediated	O
promoter	O
expression	O
and	O
Sp1	B-GENE
per	O
se	O
can	O
mediate	O
this	O
response	O
.	O

Effect	O
of	O
bromocriptine	O
and	O
metoclopramide	O
on	O
serum	B-GENE
prolactin	I-GENE
levels	O
in	O
patients	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Phase	O
I	O
study	O
of	O
5	O
-	O
fluorouracil	O
and	O
leucovorin	O
by	O
a	O
14	O
-	O
day	O
circadian	O
infusion	O
in	O
metastatic	O
adenocarcinoma	O
patients	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
release	O
of	O
a	O
single	O
pulley	O
after	O
repair	O
of	O
the	O
tendons	O
in	O
this	O
area	O
improved	O
gliding	O
excursions	O
of	O
the	O
tendons	O
and	O
reduced	O
resistance	O
to	O
motion	O
of	O
the	O
repaired	O
tendons	O
,	O
and	O
provide	O
support	O
for	O
partial	O
A2	O
pulley	O
incision	O
after	O
repair	O
of	O
the	O
tendons	O
in	O
the	O
area	O
of	O
the	O
pulley	O
.	O

Heart	O
rate	O
and	O
oxygen	O
consumption	O
increased	O
75	O
+	O
/	O
-	O
4	O
bpm	O
and	O
26	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
ml	O
O2	O
/	O
kg	O
x	O
min	O
(	O
-	O
1	O
)	O
from	O
supine	O
resting	O
values	O
,	O
respectively	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
selective	O
thromboxane	O
A2	O
blockade	O
on	O
clinical	O
findings	O
and	O
platelet	O
reactivity	O
in	O
refractory	O
unstable	O
angina	O
,	O
OKY	O
-	O
046	O
(	O
600	O
mg	O
/	O
day	O
,	O
p	O
.	O
o	O
.	O
)	O
was	O
administered	O
to	O
another	O
14	O
patients	O
with	O
refractory	O
unstable	O
angina	O
in	O
addition	O
to	O
the	O
conventional	O
therapy	O
.	O

Prolongation	O
of	O
prothrombin	B-GENE
time	O
was	O
not	O
due	O
to	O
depletion	O
of	O
vitamin	O
K	O
-	O
dependent	O
coagulation	O
factors	O
or	O
manifest	O
fibrinolysis	O
,	O
but	O
due	O
to	O
the	O
presence	O
of	O
circulating	O
fibrinogen	B-GENE
fibrinmonomer	I-GENE
-	O
FDP	O
complexes	O
.	O

Effect	O
of	O
tetracycline	O
on	O
the	O
glycogen	O
-	O
producing	O
function	O
of	O
the	O
liver	O
and	O
intestinal	O
microflora	O
in	O
white	O
mice	O

A	O
case	O
report	O
.	O

Mutation	O
of	O
K14	O
in	O
H3	B-GENE
,	O
which	O
serves	O
as	O
the	O
major	O
target	O
of	O
recombinant	B-GENE
Gcn5p	I-GENE
acetylation	O
in	O
vitro	O
,	O
confers	O
a	O
strong	O
,	O
synthetic	O
growth	O
defect	O
in	O
gcn5	B-GENE
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
V3	O
"	O
values	O
were	O
not	O
significantly	O
correlated	O
with	O
the	O
degree	O
of	O
tremor	O
,	O
seborrhea	O
,	O
and	O
duration	O
of	O
the	O
illness	O
.	O

All	O
patients	O
whose	O
PSA	B-GENE
levels	O
reached	O
0	O
.	O
1	O
ng	O
.	O
/	O
ml	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
transactivation	O
mediated	O
by	O
the	O
p68c	B-GENE
-	I-GENE
ets	I-GENE
-	I-GENE
1	I-GENE
pr	I-GENE
p55erg	B-GENE
through	O
the	O
Polyomavirus	B-GENE
enhancer	I-GENE
sequence	I-GENE
is	O
specifically	O
inhibited	O
by	O
the	O
p46kDaPax	B-GENE
-	I-GENE
QNR	I-GENE
in	O
transient	O
transfection	O
assay	O
.	O

Treatment	O
with	O
ACE	B-GENE
inhibitors	O
after	O
acute	O
myocardial	O
infarction	O

Conversely	O
,	O
as	O
a	O
GAL	B-GENE
-	I-GENE
4	I-GENE
chimera	I-GENE
,	O
the	O
isolated	O
LAZ3	B-GENE
/	O
BCL6	B-GENE
BTB	B-GENE
/	O
POZ	O
domain	O
appears	O
nearly	O
as	O
efficient	O
as	O
the	O
entire	O
protein	O
at	O
inducing	O
transcriptional	O
repression	O
.	O

A	O
new	O
myocyte	B-GENE
-	I-GENE
specific	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
that	O
recognizes	O
a	O
conserved	O
element	O
associated	O
with	O
multiple	O
muscle	O
-	O
specific	O
genes	O
.	O

Diclofenac	O
sodium	O
:	O
blood	O
concentration	O
of	O
the	O
slow	O
-	O
release	O
form	O
and	O
influence	O
on	O
the	O
metabolism	O
of	O
kallikrein	B-GENE
.	O

The	O
LS	B-GENE
gene	I-GENE
promoter	I-GENE
sequence	I-GENE
has	O
homology	O
with	O
Escherichia	O
coli	O
promoter	O
sequences	O
;	O
its	O
terminator	O
sequence	O
is	O
capable	O
of	O
forming	O
a	O
stem	O
-	O
and	O
-	O
loop	O
structure	O
.	O

We	O
demonstrate	O
that	O
the	O
recently	O
proposed	O
synthetic	O
imaging	O
technique	O
[	O
J	O
.	O

Overexpression	O
of	O
either	O
Sp1	B-GENE
or	O
phosphorylated	B-GENE
CREB	I-GENE
transactivated	O
the	O
mCgA	B-GENE
promoter	I-GENE
dose	O
dependently	O
,	O
while	O
coexpression	O
of	O
both	O
transcription	O
factors	O
resulted	O
in	O
an	O
additive	O
mCgA	B-GENE
promoter	I-GENE
response	O
.	O

mCgA	B-GENE
-	O
92	O
to	O
-	O
64	O
bp	O
,	O
comprising	O
the	O
Sp1	B-GENE
/	O
Egr	B-GENE
-	I-GENE
1	I-GENE
site	O
and	O
the	O
CRE	O
motif	O
,	O
conferred	O
gastrin	B-GENE
responsiveness	O
to	O
a	O
heterologous	B-GENE
thymidine	I-GENE
kinase	I-GENE
promoter	I-GENE
system	O
,	O
and	O
therefore	O
functions	O
as	O
a	O
"	O
true	O
"	O
enhancer	O
element	O
.	O

Together	O
with	O
the	O
up	O
-	O
regulation	O
of	O
the	O
cAMP	B-GENE
response	I-GENE
element	I-GENE
modulator	I-GENE
protein	I-GENE
(	O
CREM	B-GENE
)	O
mRNA	O
and	O
protein	O
levels	O
demonstrated	O
previously	O
in	O
CREB	B-GENE
mutant	I-GENE
mice	O
,	O
we	O
suggest	O
that	O
the	O
up	O
-	O
regulation	O
of	O
CREB	B-GENE
beta	I-GENE
may	O
also	O
contribute	O
to	O
compensation	O
within	O
the	O
CREB	B-GENE
/	O
ATF	B-GENE
family	O
of	O
transcription	O
factors	O
,	O
when	O
CREB	B-GENE
delta	I-GENE
and	O
CREB	B-GENE
alpha	I-GENE
are	O
absent	O
.	O

The	O
data	O
obtained	O
with	O
cellular	O
RNA	O
from	O
HepG2	O
cells	O
demonstrated	O
that	O
transcription	O
is	O
initiated	O
891	O
bases	O
upstream	O
of	O
the	O
translation	O
-	O
start	O
site	O
and	O
that	O
the	O
polyadenylation	O
site	O
is	O
located	O
550	O
bases	O
downstream	O
of	O
the	O
stop	O
codon	O
.	O

Finally	O
,	O
there	O
is	O
now	O
appropriate	O
recognition	O
of	O
the	O
pivotal	O
role	O
of	O
BP	O
reduction	O
in	O
forestalling	O
pressure	O
-	O
related	O
cardiovascular	O
complications	O
,	O
even	O
among	O
high	O
-	O
risk	O
persons	O
with	O
diabetes	O
mellitus	O
and	O
renal	O
insufficiency	O
.	O

Individual	O
and	O
combined	O
effects	O
of	O
fumonisin	B-GENE
B1	I-GENE
present	O
in	O
Fusarium	O
moniliforme	O
culture	O
material	O
and	O
diacetoxyscirpenol	O
or	O
ochratoxin	O
A	O
in	O
turkey	O
poults	O
.	O

It	O
is	O
hypothesized	O
this	O
occurs	O
through	O
antagonism	O
of	O
PML	B-GENE
/	O
RAR	B-GENE
alpha	I-GENE
actions	O
in	O
these	O
leukemic	O
cells	O
.	O

13	O
:	O
961	O
-	O
969	O
,	O
1993	O
)	O
suggested	O
that	O
T	B-GENE
antigen	I-GENE
could	O
mediate	O
transcriptional	O
activation	O
through	O
interaction	O
with	O
the	O
TATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
as	O
well	O
as	O
upstream	O
bound	O
transcription	O
factors	O
.	O

The	O
Grb2	B-GENE
SH3	B-GENE
(	I-GENE
C	I-GENE
)	I-GENE
binding	I-GENE
region	I-GENE
of	O
Gab1	B-GENE
has	O
significant	O
homology	O
to	O
a	O
region	O
of	O
the	O
adapter	B-GENE
protein	I-GENE
SLP	I-GENE
-	I-GENE
76	I-GENE
.	O

A	O
phase	O
II	O
study	O
of	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
,	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
and	O
5	O
-	O
fluorouracil	O
in	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
data	O
and	O
laboratory	O
evidence	O
of	O
protease	O
activation	O
.	O

Activation	O
of	O
the	O
cytotactin	B-GENE
promoter	I-GENE
by	O
the	O
homeobox	B-GENE
-	I-GENE
containing	I-GENE
gene	I-GENE
Evx	I-GENE
-	I-GENE
1	I-GENE
.	O

CONCLUSION	O
/	O
INTERPRETATION	O
:	O
We	O
found	O
an	O
increased	O
risk	O
of	O
hip	O
fracture	O
in	O
women	O
younger	O
than	O
75	O
years	O
with	O
Type	O
I	O
diabetes	O
or	O
with	O
Type	O
II	O
diabetes	O
of	O
long	O
duration	O
.	O

Maternal	O
behavior	O
was	O
assessed	O
using	O
observational	O
techniques	O
.	O

Rat	B-GENE
p8	I-GENE
mRNA	I-GENE
was	O
discovered	O
because	O
of	O
its	O
strong	O
activation	O
in	O
pancreas	O
during	O
the	O
acute	O
phase	O
of	O
pancreatitis	O
.	O

LV	O
compliance	O
was	O
determined	O
from	O
the	O
slope	O
of	O
the	O
LV	O
end	O
-	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
vs	O
.	O

The	O
practice	O
of	O
measuring	O
of	O
AChE	B-GENE
levels	O
in	O
acute	O
poisoning	O
is	O
limited	O
.	O

Vasodilation	O
in	O
congestive	O
heart	O
failure	O
is	O
an	O
established	O
therapeutic	O
principal	O
.	O

The	O
collicular	O
labels	O
found	O
after	O
injections	O
within	O
the	O
MST	O
area	O
exhibited	O
their	O
distribution	O
over	O
the	O
deep	O
SC	O
subdivision	O
,	O
whereas	O
they	O
spared	O
all	O
the	O
superficial	O
layers	O
but	O
the	O
deep	O
part	O
of	O
the	O
SO	O
.	O

When	O
furA	B-GENE
alone	O
was	O
introduced	O
into	O
the	O
Delta	O
(	O
furA	B-GENE
-	O
katG	B-GENE
)	O
mutant	O
,	O
survival	O
in	O
mouse	O
lungs	O
was	O
moderately	O
increased	O
,	O
suggesting	O
that	O
FurA	B-GENE
could	O
regulate	O
genes	O
,	O
other	O
than	O
katG	B-GENE
,	O
that	O
are	O
involved	O
in	O
pathogenesis	O
.	O

The	O
effects	O
of	O
cefazolin	O
,	O
given	O
into	O
the	O
III	O
cerebral	O
ventricle	O
at	O
different	O
doses	O
were	O
studied	O
on	O
GABA	O
content	O
,	O
GAD	O
and	O
GABA	O
-	O
T	O
in	O
the	O
brain	O
-	O
stem	O
of	O
young	O
chickens	O
(	O
Gallus	O
domesticus	O
)	O
.	O

Subclones	O
of	O
R15	O
which	O
reverted	O
to	O
kappa	B-GENE
light	I-GENE
chain	I-GENE
production	O
contained	O
genomic	O
deletions	O
of	O
R15ns	O
and	O
/	O
or	O
the	O
surrounding	O
intron	O
.	O

The	O
disorders	O
are	O
accompanied	O
by	O
consistent	O
,	O
but	O
similarly	O
reversible	O
,	O
electroencephalographic	O
changes	O
.	O

The	O
delayed	O
activation	O
of	O
the	O
prostaglandin	B-GENE
G	I-GENE
/	I-GENE
H	I-GENE
synthase	I-GENE
-	I-GENE
2	I-GENE
promoter	O
in	O
bovine	O
granulosa	O
cells	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
truncated	O
upstream	B-GENE
stimulatory	I-GENE
factor	I-GENE
-	I-GENE
2	I-GENE
.	O

The	O
authors	O
recommend	O
in	O
cases	O
with	O
an	O
elevated	O
transaminase	O
serum	O
activity	O
more	O
frequent	O
check	O
-	O
up	O
examinations	O
to	O
avoid	O
missing	O
of	O
a	O
relapse	O
,	O
and	O
to	O
examine	O
repeatedly	O
IgM	B-GENE
anti	B-GENE
-	I-GENE
HAV	I-GENE
as	O
in	O
protracted	O
forms	O
of	O
hepatitis	O
IgM	B-GENE
anti	B-GENE
-	I-GENE
HAV	I-GENE
may	O
persist	O
even	O
when	O
the	O
transaminase	O
activity	O
is	O
normal	O
.	O

Mean	O
latency	O
periods	O
were	O
29	O
.	O
6	O
among	O
insulators	O
,	O
35	O
.	O
4	O
among	O
dock	O
workers	O
,	O
43	O
.	O
7	O
in	O
a	O
heterogeneous	O
group	O
defined	O
as	O
various	O
,	O
46	O
.	O
4	O
in	O
non	O
-	O
shipbuilding	O
industry	O
workers	O
,	O
49	O
.	O
4	O
in	O
shipyard	O
workers	O
,	O
51	O
.	O
7	O
among	O
women	O
with	O
a	O
history	O
of	O
domestic	O
exposure	O
to	O
asbestos	O
,	O
and	O
56	O
.	O
2	O
in	O
people	O
employed	O
in	O
maritime	O
trades	O
.	O

The	O
strategy	O
uses	O
RNA	B-GENE
ligase	I-GENE
to	O
add	O
DNA	O
oligonucleotide	O
priming	O
sites	O
to	O
the	O
RNA	O
for	O
subsequent	O
reverse	O
transcription	O
and	O
PCR	O
(	O
RNA	B-GENE
ligase	I-GENE
,	O
reverse	O
transcription	O
-	O
PCR	O
,	O
or	O
RL	O
/	O
RT	O
/	O
PCR	O
)	O
.	O

We	O
analyzed	O
the	O
effects	O
of	O
light	O
on	O
tubulin	B-GENE
mRNA	I-GENE
abundance	O
in	O
Arabidopsis	O
seedlings	O
using	O
RNA	O
gel	O
blot	O
hybridizations	O
and	O
gene	O
-	O
specific	O
probes	O
.	O

More	O
important	O
,	O
ligand	O
-	O
activated	O
insulin	B-GENE
and	O
IGF	B-GENE
-	I-GENE
I	I-GENE
receptors	I-GENE
phosphorylate	O
SHC	B-GENE
proteins	I-GENE
in	O
vitro	O
,	O
indicating	O
that	O
SHC	B-GENE
proteins	I-GENE
could	O
be	O
direct	O
substrates	O
for	O
insulin	B-GENE
and	O
IGF	B-GENE
-	I-GENE
I	I-GENE
receptors	I-GENE
.	O

This	O
chimera	O
transduced	O
IL	B-GENE
-	I-GENE
4	I-GENE
-	O
specific	O
signals	O
in	O
response	O
to	O
IL	B-GENE
-	I-GENE
2	I-GENE
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL	B-GENE
-	I-GENE
4	I-GENE
,	O
IL	B-GENE
-	I-GENE
5	I-GENE
,	O
and	O
immunoglobulin	B-GENE
E	I-GENE
production	O
)	O
upon	O
in	O
vitro	O
TCR	B-GENE
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O

A	O
distinct	O
5	O
'	O
-	O
sequence	O
in	O
clone	O
hMIWC2	O
suggested	O
an	O
alternative	O
upstream	O
transcription	O
initiation	O
site	O
.	O

Two	O
human	B-GENE
beta	I-GENE
-	I-GENE
1	I-GENE
,	I-GENE
6	I-GENE
-	I-GENE
N	I-GENE
-	I-GENE
acetylglucosaminyltransferases	I-GENE
forming	O
the	O
core	O
2	O
O	O
-	O
glycan	O
branch	O
,	O
C2GnT	O
and	O
the	O
I	B-GENE
antigen	I-GENE
,	O
IGnT	B-GENE
,	O
are	O
homologous	O
to	O
each	O
other	O
in	O
three	O
regions	O
of	O
the	O
catalytic	O
domain	O
(	O
A	O
,	O
B	O
,	O
C	O
)	O
and	O
their	O
genes	O
reside	O
at	O
the	O
same	O
locus	O
,	O
chromosome	O
9	O
,	O
band	O
q21	O
(	O
Bierhuizen	O
,	O
M	O
.	O
F	O
.	O
A	O
.	O
,	O
Mattei	O
,	O
M	O
.	O
-	O
G	O
.	O
and	O
Fukuda	O
,	O
M	O
.	O
,	O
Genes	O
Dev	O
.	O
,	O
7	O
,	O
468	O
-	O
478	O
,	O
1993	O
)	O
.	O

Significantly	O
higher	O
levels	O
of	O
vitamin	O
C	O
and	O
catalase	B-GENE
activity	O
were	O
found	O
in	O
vegetarians	O
(	O
C	O
-	O
63	O
.	O
6	O
and	O
86	O
.	O
5	O
mumol	O
/	O
l	O
;	O
CAT	O
-	O
1497	O
and	O
1313	O
U	O
/	O
ml	O
for	O
males	O
and	O
females	O
,	O
respectively	O
)	O
when	O
compared	O
to	O
nonvegetarians	O
(	O
C	O
-	O
41	O
.	O
3	O
and	O
54	O
.	O
4	O
mumol	O
/	O
l	O
;	O
CAT	O
-	O
1192	O
and	O
1086	O
U	O
/	O
ml	O
)	O
.	O

Cutting	O
the	O
intraorbital	O
nerves	O
produced	O
a	O
temporary	O
retrieval	O
impairment	O
that	O
was	O
indistinguishable	O
from	O
that	O
produced	O
by	O
intramystacial	O
lidocaine	O
injection	O
.	O

Developmental	O
regulation	O
of	O
expression	O
of	O
the	O
malate	B-GENE
synthase	I-GENE
gene	I-GENE
in	O
transgenic	O
plants	O
.	O

In	O
contrast	O
,	O
no	O
change	O
in	O
the	O
level	O
of	O
either	O
p53	B-GENE
or	O
activation	O
of	O
mdm2	B-GENE
protein	I-GENE
by	O
p53	B-GENE
was	O
observed	O
in	O
hamster	O
UV61	O
cells	O
after	O
UV	O
exposure	O
.	O

On	O
day	O
1	O
at	O
3500	O
m	O
,	O
RI	O
showed	O
a	O
significant	O
fall	O
in	O
body	O
weight	O
(	O
BW	O
)	O
with	O
respect	O
to	O
SL	O
but	O
AI	O
maintained	O
it	O
.	O

Transcriptional	O
activation	O
of	O
the	O
proopiomelanocortin	B-GENE
gene	I-GENE
by	O
cyclic	B-GENE
AMP	I-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
binding	I-GENE
protein	I-GENE
.	O

The	O
NF1	B-GENE
family	I-GENE
members	O
and	O
HNF4	B-GENE
interacted	O
with	O
overlapping	O
sequences	O
of	O
the	O
L	O
-	O
II	O
element	O
,	O
wherein	O
the	O
5	O
'	O
half	O
-	O
site	O
was	O
more	O
critical	O
for	O
NF1	B-GENE
binding	O
,	O
and	O
the	O
3	O
'	O
site	O
was	O
more	O
important	O
for	O
HNF4	B-GENE
binding	O
.	O

RAP	B-GENE
has	O
been	O
shown	O
to	O
be	O
a	O
useful	O
vaccine	O
target	O
site	O
,	O
and	O
RIP	B-GENE
and	O
inhibitory	O
AIPs	B-GENE
as	O
therapeutic	O
molecules	O
to	O
prevent	O
and	O
suppress	O
S	O
.	O
aureus	O
infections	O
.	O

After	O
institution	O
of	O
insulin	B-GENE
treatment	O
,	O
diabetic	O
control	O
was	O
improved	O
as	O
demonstrated	O
by	O
decreasing	O
levels	O
of	O
HbA1	B-GENE
.	O

The	O
mouse	O
lactoferrin	B-GENE
gene	O
promoter	O
was	O
active	O
in	O
human	O
endometrium	O
carcinoma	O
RL	O
95	O
-	O
2	O
cells	O
and	O
in	O
rat	O
glioma	O
C6	O
cells	O
.	O

The	O
1	O
-	O
year	O
and	O
2	O
-	O
year	O
survival	O
rates	O
for	O
the	O
patients	O
with	O
N0	O
-	O
3	O
significantly	O
exceeded	O
those	O
of	O
N4	O
patients	O
.	O

Measurement	O
of	O
the	O
spectral	O
sensitivity	O
and	O
the	O
ERG	O
can	O
thus	O
help	O
in	O
the	O
diagnosis	O
of	O
these	O
three	O
hereditary	O
diseases	O
.	O

As	O
a	O
quantitative	O
index	O
of	O
cochlear	O
function	O
,	O
2f1	O
-	O
f2	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
were	O
monitored	O
systematically	O
over	O
time	O
in	O
three	O
groups	O
of	O
rabbits	O
,	O
with	O
each	O
group	O
experiencing	O
a	O
unique	O
paradigm	O
that	O
incorporated	O
repeated	O
exposure	O
to	O
the	O
low	O
-	O
frequency	O
tone	O
.	O

The	O
subjects	O
'	O
lungs	O
were	O
ventilated	O
with	O
N2O	O
in	O
O2	O
(	O
FIO2	O
0	O
.	O
3	O
)	O
to	O
the	O
end	O
-	O
tidal	O
CO2	O
present	O
before	O
anesthesia	O
,	O
and	O
then	O
CBF	O
was	O
measured	O
using	O
intravenous	O
133Xe	O
and	O
ten	O
scintillation	O
counters	O
,	O
five	O
over	O
each	O
cerebral	O
hemisphere	O
.	O

This	O
indicates	O
changes	O
in	O
postvaccination	O
allergy	O
to	O
BCG	O
.	O

Analysis	O
of	O
1	O
Mb	O
of	O
published	O
sequence	O
from	O
the	O
region	O
of	O
conserved	O
synteny	O
on	O
human	O
chromosome	O
5q31	O
-	O
q33	O
identified	O
45	O
gene	O
candidates	O
,	O
including	O
35	O
expressed	O
genes	O
in	O
the	O
human	B-GENE
IL	I-GENE
-	I-GENE
4	I-GENE
cytokine	I-GENE
gene	I-GENE
cluster	O
.	O

There	O
is	O
no	O
indication	O
from	O
these	O
experiments	O
that	O
linker	B-GENE
histones	I-GENE
bind	O
fundamentally	O
differently	O
to	O
5	B-GENE
S	I-GENE
and	O
bulk	O
nucleosomes	O
.	O

Km	O
values	O
of	O
the	O
uncoupled	O
enzymes	O
IIGlc	B-GENE
for	O
glucose	O
ranged	O
from	O
0	O
.	O
5	O
to	O
2	O
.	O
5	O
mM	O
,	O
2	O
orders	O
of	O
magnitude	O
higher	O
than	O
the	O
value	O
of	O
normal	O
IIGlc	B-GENE
.	O

Cytochrome	B-GENE
bd	I-GENE
biosynthesis	O
in	O
Escherichia	O
coli	O
:	O
the	O
sequences	O
of	O
the	O
cydC	B-GENE
and	O
cydD	B-GENE
genes	I-GENE
suggest	O
that	O
they	O
encode	O
the	O
components	O
of	O
an	O
ABC	B-GENE
membrane	I-GENE
transporter	I-GENE
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
MAPK	B-GENE
activity	O
by	O
MAPK	B-GENE
kinase	I-GENE
inhibitor	O
(	O
PD	O
98059	O
)	O
or	O
by	O
overexpression	O
of	O
kinase	O
-	O
deficient	O
MAPKs	B-GENE
activated	O
basal	O
and	O
GnRH	B-GENE
-	I-GENE
A	I-GENE
-	O
stimulated	O
GnRHR	B-GENE
-	O
Luc	B-GENE
activity	O
.	O

The	O
influence	O
of	O
gas	O
composition	O
in	O
the	O
air	O
cell	O
on	O
pipping	O
and	O
liver	O
metabolism	O
in	O
embryonic	O
chicks	O
.	O

Historically	O
,	O
Cyps	B-GENE
were	O
first	O
identified	O
by	O
their	O
ability	O
to	O
bind	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
with	O
high	O
affinity	O
;	O
they	O
later	O
were	O
found	O
to	O
have	O
peptidyl	B-GENE
-	I-GENE
prolyl	I-GENE
cis	I-GENE
-	I-GENE
trans	I-GENE
isomerase	I-GENE
(	O
PPIase	B-GENE
)	O
activity	O
,	O
which	O
catalyzes	O
the	O
folding	O
of	O
oligopeptides	O
at	O
proline	O
-	O
peptide	O
bonds	O
in	O
vitro	O
and	O
may	O
be	O
important	O
for	O
protein	O
folding	O
in	O
vivo	O
.	O

Thus	O
,	O
oxyR	B-GENE
mutants	I-GENE
are	O
locked	O
on	O
for	O
Ag43	B-GENE
expression	O
,	O
whereas	O
dam	B-GENE
mutants	I-GENE
are	O
locked	O
off	O
for	O
Ag43	B-GENE
expression	O
.	O

A	O
rare	O
tRNA	B-GENE
-	I-GENE
Arg	I-GENE
(	I-GENE
CCU	I-GENE
)	I-GENE
that	O
regulates	O
Ty1	B-GENE
element	I-GENE
ribosomal	O
frameshifting	O
is	O
essential	O
for	O
Ty1	B-GENE
retrotransposition	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Several	O
35	O
-	O
mm	O
slides	O
of	O
dystrophin	B-GENE
-	O
,	O
laminin	B-GENE
-	O
,	O
and	O
concanavalin	B-GENE
A	I-GENE
(	O
ConA	B-GENE
)	O
-	O
stained	O
muscle	O
sections	O
were	O
used	O
to	O
calculate	O
myofiber	O
cross	O
-	O
sectional	O
areas	O
and	O
to	O
compare	O
different	O
techniques	O
and	O
settings	O
of	O
an	O
image	O
capture	O
system	O
.	O

In	O
addition	O
,	O
both	O
inhibitors	O
blocked	O
phosphatidylcholine	O
hydrolysis	O
and	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
translocation	O
.	O

New	O
,	O
selective	O
catechol	B-GENE
-	I-GENE
O	I-GENE
-	I-GENE
methyltransferase	I-GENE
inhibitors	O
as	O
therapeutic	O
agents	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
the	O
social	O
learning	O
theory	O
of	O
depression	O
,	O
developed	O
by	O
Lewinsohn	O
,	O
is	O
described	O
.	O

Laser	O
soldering	O
with	O
exogenous	O
fibrinogen	B-GENE
is	O
feasible	O
without	O
topical	O
administration	O
of	O
additional	O
clotting	O
agents	O
,	O
significantly	O
improves	O
the	O
bursting	O
strength	O
of	O
primary	O
laser	O
welded	O
anastomoses	O
,	O
and	O
appears	O
to	O
result	O
from	O
urokinase	B-GENE
-	O
resistant	O
fibrinogen	B-GENE
cross	O
-	O
linking	O
.	O

Intensity	O
variations	O
from	O
the	O
variable	O
TR	O
were	O
removed	O
,	O
and	O
the	O
data	O
were	O
evaluated	O
for	O
correlation	O
with	O
the	O
lateralized	O
stimulus	O
.	O

Routine	O
imaging	O
modalities	O
revealed	O
a	O
total	O
of	O
79	O
metastases	O
.	O

We	O
have	O
previously	O
reported	O
that	O
analgesic	O
doses	O
of	O
morphine	O
accelerate	O
mortality	O
of	O
rats	O
exposed	O
to	O
hemorrhage	O
(	O
Feuerstein	O
and	O
Siren	O
:	O
Circ	O
Shock	O
19	O
:	O
293	O
-	O
300	O
,	O
1986	O
)	O
.	O

We	O
describe	O
a	O
novel	O
stat	B-GENE
-	I-GENE
related	I-GENE
factor	I-GENE
,	O
p93	B-GENE
,	O
that	O
is	O
found	O
in	O
EGF	B-GENE
-	O
treated	O
A431	O
cell	O
extracts	O
but	O
appears	O
to	O
be	O
absent	O
in	O
bovine	B-GENE
fibroblast	I-GENE
growth	I-GENE
factor	I-GENE
(	O
bFGF	B-GENE
)	O
,	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
(	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
)	O
,	O
and	O
untreated	O
cells	O
.	O

p93	B-GENE
appears	O
to	O
be	O
antigenically	O
related	O
to	O
stat91	B-GENE
.	O

p185c	B-GENE
-	O
neu	B-GENE
+	O
,	O
EGFr	B-GENE
+	I-GENE
(	O
M1	B-GENE
)	O
,	O
and	O
p185c	B-GENE
-	O
neu	B-GENE
-	O
kinase	O
inactive	O
,	O
EGFr	B-GENE
+	I-GENE
(	O
NEN757	B-GENE
)	O
expressing	O
cells	O
undergo	O
different	O
mitotic	O
responses	O
to	O
EGF	B-GENE
.	O

In	O
addition	O
,	O
Fc	B-GENE
epsilon	I-GENE
R1	I-GENE
cross	O
-	O
linking	O
activates	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
.	O

When	O
single	O
-	O
point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	O
box	O
,	O
EBS	B-GENE
,	O
and	O
GT	O
box	O
in	O
PFP9a20	B-GENE
,	O
at	O
least	O
3	O
-	O
fold	O
less	O
CAT	B-GENE
activity	O
was	O
observed	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

Ribosome	O
association	O
of	O
GCN2	B-GENE
protein	I-GENE
kinase	I-GENE
,	O
a	O
translational	O
activator	O
of	O
the	O
GCN4	B-GENE
gene	I-GENE
of	O
Saccharomyces	O
cerevisiae	O
.	O

Treatment	O
with	O
H7	O
did	O
not	O
affect	O
IL	B-GENE
-	I-GENE
4R	I-GENE
-	O
mediated	O
immediate	O
signaling	O
events	O
such	O
as	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-GENE
,	O
Jak3	B-GENE
,	O
insulin	B-GENE
receptor	I-GENE
substrate	I-GENE
(	I-GENE
IRS	I-GENE
)	I-GENE
-	I-GENE
1	I-GENE
and	O
IRS	B-GENE
-	I-GENE
2	I-GENE
,	O
or	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
Stat6	B-GENE
.	O

Thus	O
,	O
STK1	B-GENE
is	O
most	O
likely	O
the	O
human	B-GENE
homologue	I-GENE
of	I-GENE
MO15	I-GENE
.	O

BACKGROUND	O
:	O
Recent	O
iterative	O
methods	O
for	O
sequence	O
alignment	O
have	O
indicated	O
that	O
the	O
380	O
kDa	O
motor	O
unit	O
of	O
dynein	B-GENE
belongs	O
to	O
the	O
AAA	B-GENE
class	I-GENE
of	O
chaperone	B-GENE
-	I-GENE
like	I-GENE
ATPases	I-GENE
.	O

When	O
the	O
VBP	B-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
was	O
solely	O
expressed	O
,	O
it	O
located	O
to	O
the	O
cytoplasm	O
and	O
did	O
not	O
localize	O
to	O
the	O
nucleus	O
.	O

Consistent	O
with	O
other	O
experiments	O
with	O
these	O
compounds	O
,	O
cocaine	O
was	O
the	O
most	O
potent	O
of	O
the	O
group	O
.	O

The	O
significance	O
of	O
these	O
changes	O
in	O
relation	O
to	O
the	O
control	O
of	O
phosphorus	O
balance	O
in	O
ruminants	O
is	O
discussed	O
.	O

Transfection	O
assays	O
using	O
the	O
first	O
600	O
bp	O
of	O
the	O
upstream	O
nucleotide	O
sequences	O
indicated	O
that	O
a	O
region	O
from	O
-	O
75	O
to	O
-	O
120	O
was	O
necessary	O
for	O
the	O
ALDH2	B-GENE
gene	I-GENE
expression	O
,	O
and	O
especially	O
NF	B-GENE
-	I-GENE
Y	I-GENE
/	O
CP1	B-GENE
binding	O
site	O
from	O
-	O
92	O
to	O
-	O
96	O
(	O
CCAAT	O
box	O
)	O
is	O
important	O
in	O
the	O
expression	O
of	O
the	O
gene	O
.	O

This	O
distinct	O
biochemical	O
difference	O
between	O
STAT5A	B-GENE
and	O
STAT5B	B-GENE
was	O
confirmed	O
with	O
purified	O
activated	O
STAT5	B-GENE
recombinant	I-GENE
proteins	I-GENE
.	O

The	O
results	O
show	O
that	O
in	O
uninfected	O
NIH	O
-	O
3T3	O
cells	O
Avarol	O
(	O
i	O
)	O
causes	O
a	O
50	O
%	O
reduction	O
of	O
the	O
growth	O
rate	O
only	O
at	O
the	O
high	O
concentration	O
of	O
29	O
.	O
6	O
microM	O
and	O
(	O
ii	O
)	O
is	O
accumulated	O
in	O
the	O
cytoplasm	O
close	O
to	O
the	O
nucleus	O
.	O

Blood	B-GENE
coagulation	I-GENE
Factor	I-GENE
X	I-GENE
and	O
its	O
activated	O
form	O
Factor	B-GENE
Xa	I-GENE
play	O
an	O
essential	O
role	O
in	O
the	O
midphase	O
of	O
the	O
clotting	O
cascade	O
.	O

The	O
exon	O
sequences	O
determined	O
from	O
genomic	O
DNA	O
sequencing	O
showed	O
some	O
differences	O
when	O
compared	O
to	O
the	O
published	O
rat	B-GENE
GLUT2	I-GENE
cDNA	I-GENE
.	O

Intramolecular	O
interaction	O
is	O
believed	O
to	O
result	O
in	O
the	O
formation	O
of	O
MxA	B-GENE
monomers	I-GENE
,	O
whereas	O
intermolecular	O
interaction	O
may	O
induce	O
the	O
formation	O
of	O
large	B-GENE
MxA	I-GENE
oligomers	I-GENE
.	O

The	O
psbA	B-GENE
gene	I-GENE
encodes	O
the	O
D1	B-GENE
protein	I-GENE
of	O
photosystem	B-GENE
II	I-GENE
,	O
which	O
is	O
synthesized	O
at	O
very	O
high	O
rates	O
in	O
the	O
light	O
in	O
order	O
to	O
replace	O
photodamaged	O
protein	O
.	O

The	O
three	O
more	O
slower	O
migrating	O
Stat5B	B-GENE
bands	O
observed	O
in	O
response	O
to	O
GH	B-GENE
contain	O
phosphorylated	O
tyrosyl	O
residues	O
.	O

The	O
maximum	O
levels	O
of	O
reporter	O
proteins	O
attained	O
in	O
transformed	O
cells	O
after	O
prolonged	O
induction	O
represented	O
from	O
1	O
%	O
to	O
7	O
%	O
of	O
total	O
cellular	O
protein	O
.	O

Specifically	O
,	O
we	O
demonstrate	O
that	O
this	O
25	O
-	O
base	O
pair	O
region	O
mediates	O
the	O
up	O
-	O
regulatory	O
effect	O
of	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
on	O
COL1A2	B-GENE
promoter	I-GENE
activity	O
and	O
allows	O
antagonistic	O
activity	O
of	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
on	O
the	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
effect	O
.	O

Sin4	B-GENE
and	O
Srb10	B-GENE
,	O
components	O
of	O
specific	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
sub	I-GENE
-	I-GENE
complexes	I-GENE
that	O
are	O
required	O
for	O
Ssn6	B-GENE
-	O
Tup1	B-GENE
repression	O
activity	O
,	O
are	O
found	O
to	O
be	O
required	O
for	O
Sfl1	B-GENE
repression	O
function	O
.	O

Translation	O
of	O
mok	B-GENE
is	O
tightly	O
regulated	O
by	O
Sok	B-GENE
RNA	I-GENE
,	O
and	O
Sok	B-GENE
RNA	I-GENE
thus	O
regulates	O
hok	B-GENE
translation	O
indirectly	O
through	O
mok	B-GENE
.	O

Depending	O
on	O
the	O
patient	O
'	O
s	O
body	O
position	O
telemetrically	O
measured	O
CSF	O
-	O
pressures	O
varied	O
between	O
-	O
20	O
cmH2O	O
in	O
erect	O
and	O
15	O
cmH2O	O
in	O
supine	O
position	O
.	O

One	O
-	O
hour	O
O3	O
,	O
NO2	O
,	O
and	O
SO2	O
personal	O
exposures	O
were	O
measured	O
using	O
samplers	O
developed	O
in	O
our	O
laboratory	O
,	O
while	O
short	O
-	O
term	O
PM2	O
.	O
5	O
,	O
CO	O
,	O
and	O
VOCs	O
exposures	O
were	O
measured	O
using	O
currently	O
available	O
monitors	O
.	O

These	O
Tlr	B-GENE
family	I-GENE
members	I-GENE
,	O
unlike	O
others	O
reported	O
to	O
date	O
,	O
were	O
identified	O
within	O
a	O
genomic	O
database	O
.	O

We	O
hypothesized	O
that	O
subjects	O
would	O
demonstrate	O
PKAR	O
during	O
both	O
hopping	O
and	O
stepping	O
,	O
adding	O
support	O
to	O
the	O
hypothesis	O
that	O
PKAR	O
is	O
a	O
centrally	O
mediated	O
adaptation	O
of	O
general	O
locomotor	O
trajectory	O
that	O
is	O
not	O
specific	O
to	O
the	O
form	O
of	O
locomotion	O
used	O
while	O
on	O
the	O
rotating	O
disk	O
.	O

In	O
this	O
study	O
,	O
transcriptional	O
fusions	O
were	O
constructed	O
between	O
the	O
xcpP	B-GENE
and	O
xcpR	B-GENE
genes	I-GENE
and	O
the	O
lacZ	B-GENE
reporter	I-GENE
.	O

To	O
explore	O
the	O
mechanism	O
of	O
insulin	B-GENE
receptor	I-GENE
phosphorylation	O
we	O
have	O
used	O
NIH3T3	O
cells	O
transfected	O
with	O
two	O
receptor	O
constructs	O
:	O
one	O
encoding	O
a	O
chimeric	O
receptor	O
composed	O
of	O
the	O
extracellular	O
domain	O
of	O
the	O
human	B-GENE
EGF	I-GENE
receptor	I-GENE
and	O
the	O
cytosolic	O
domain	O
of	O
the	O
human	B-GENE
insulin	I-GENE
receptor	I-GENE
beta	I-GENE
-	I-GENE
subunit	I-GENE
,	O
and	O
a	O
second	O
construct	O
encoding	O
a	O
kinase	O
-	O
defiecient	O
human	B-GENE
insulin	I-GENE
receptor	I-GENE
.	O

It	O
is	O
pathogenetically	O
proved	O
to	O
use	O
antithrombin	B-GENE
III	I-GENE
concentrate	O
preparations	O
with	O
anti	O
-	O
and	O
dysaggregatory	O
properties	O
,	O
fibronectin	B-GENE
preparations	O
,	O
trasylol	O
or	O
its	O
analogs	O
during	O
complex	O
preoperative	O
preparation	O
of	O
patients	O
.	O

Stimulation	O
of	O
the	O
endosteal	O
bone	O
formation	O
rate	O
was	O
mainly	O
impaired	O
in	O
D	O
-	O
depleted	O
rats	O
,	O
resulting	O
in	O
trabecular	O
bone	O
loss	O
,	O
which	O
,	O
in	O
-	O
D	O
mother	O
rats	O
,	O
was	O
associated	O
with	O
decreased	O
bone	O
ash	O
and	O
total	O
bone	O
calcium	O
.	O

Hematopoietic	B-GENE
progenitor	I-GENE
kinase	I-GENE
1	I-GENE
(	O
HPK1	B-GENE
)	O
is	O
a	O
member	O
of	O
the	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
kinase	I-GENE
kinase	I-GENE
(	O
MAP4K	B-GENE
)	O
family	O
and	O
an	O
upstream	O
activator	O
of	O
the	O
c	B-GENE
-	I-GENE
Jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
signaling	O
cascade	O
.	O

We	O
have	O
used	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
gene	O
system	O
to	O
study	O
the	O
effect	O
of	O
T	B-GENE
on	O
the	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
of	O
a	O
large	O
family	O
of	O
human	O
endogenous	O
retrovirus	O
-	O
like	O
sequences	O
,	O
RTVL	O
-	O
H	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
conducted	O
split	O
-	O
visual	O
-	O
field	O
studies	O
in	O
which	O
we	O
manipulated	O
stimulus	O
sets	O
,	O
recognition	O
task	O
,	O
and	O
exposure	O
duration	O
.	O

In	O
conclusion	O
,	O
ANH	O
had	O
no	O
negative	O
effects	O
on	O
the	O
endocrine	O
stress	O
response	O
during	O
orthopedic	O
surgery	O
under	O
epidural	O
anesthesia	O
.	O

Finally	O
,	O
the	O
conservation	O
of	O
the	O
two	O
residues	O
most	O
sensitive	O
to	O
mutations	O
(	O
Y949	O
and	O
Y953	O
)	O
in	O
TM11	O
,	O
and	O
in	O
the	O
homologous	O
TM5	O
,	O
of	O
all	O
mammalian	B-GENE
P	I-GENE
-	I-GENE
gps	I-GENE
and	O
also	O
in	O
other	O
ABC	B-GENE
transporters	I-GENE
,	O
suggests	O
that	O
these	O
residues	O
and	O
domains	O
may	O
play	O
an	O
important	O
role	O
in	O
structural	O
as	O
well	O
as	O
mechanistic	O
aspects	O
common	O
to	O
this	O
family	O
of	O
proteins	O
.	O

Based	O
on	O
the	O
requirement	O
for	O
CREM	B-GENE
/	O
ICER	B-GENE
and	O
Rad6B	B-GENE
proteins	I-GENE
in	O
spermatogenesis	O
,	O
we	O
determined	O
expression	O
of	O
Cdc34	B-GENE
,	O
Rad6B	B-GENE
,	O
CREM	B-GENE
/	O
ICER	B-GENE
isoforms	O
,	O
and	O
the	O
Skp1	B-GENE
-	O
Cullin	B-GENE
-	O
F	O
-	O
box	O
ubiquitin	B-GENE
protein	O
ligase	O
subunits	O
Cul	B-GENE
-	I-GENE
1	I-GENE
and	O
Cul	B-GENE
-	I-GENE
2	I-GENE
,	O
which	O
are	O
associated	O
with	O
Cdc34	B-GENE
activity	O
during	O
murine	O
testicular	O
development	O
.	O

The	O
enigma	O
of	O
aging	O
bone	O
loss	O
.	O

Transcription	B-GENE
factor	I-GENE
IIIC	I-GENE
(	O
TFIIIC	B-GENE
)	O
is	O
required	O
for	O
the	O
assembly	O
of	O
a	O
preinitiation	O
complex	O
on	O
5S	B-GENE
RNA	I-GENE
,	O
tRNA	O
,	O
and	O
adenovirus	B-GENE
VA	I-GENE
RNA	O
genes	O
and	O
contains	O
two	O
separable	O
components	O
,	O
TFIIIC1	B-GENE
and	O
TFIIIC2	B-GENE
.	O

Furthermore	O
,	O
we	O
show	O
that	O
Nck	B-GENE
-	I-GENE
2	I-GENE
is	O
capable	O
of	O
recognizing	O
several	O
key	O
components	O
of	O
growth	B-GENE
factor	I-GENE
receptor	I-GENE
kinase	I-GENE
-	O
signaling	O
pathways	O
including	O
EGF	B-GENE
receptors	I-GENE
,	O
PDGF	B-GENE
receptor	I-GENE
-	I-GENE
beta	I-GENE
,	O
and	O
IRS	B-GENE
-	I-GENE
1	I-GENE
.	O

These	O
two	O
enhancer	O
elements	O
also	O
enhanced	O
transcription	O
when	O
fused	O
separately	O
to	O
the	O
basal	O
promoter	O
region	O
of	O
the	O
chicken	B-GENE
vimentin	I-GENE
gene	I-GENE
.	O

When	O
they	O
were	O
exposed	O
to	O
intermittent	O
schedules	O
of	O
punishment	O
(	O
fixed	O
-	O
interval	O
[	O
FI	O
]	O
120	O
s	O
or	O
FI	O
300	O
s	O
)	O
,	O
SIB	O
for	O
all	O
but	O
1	O
of	O
the	O
participants	O
increased	O
to	O
levels	O
similar	O
to	O
those	O
observed	O
during	O
baseline	O
.	O

Deep	O
bite	O
CL	O
II	O
Div	O
.	O

Patients	O
with	O
binocular	O
pregeniculate	O
visual	O
loss	O
,	O
patients	O
with	O
balanced	O
binocular	O
pregeniculate	O
loss	O
without	O
RAPD	O
,	O
and	O
patients	O
with	O
monocular	O
pregeniculate	O
visual	O
loss	O
had	O
significantly	O
larger	O
pupils	O
than	O
age	O
-	O
matched	O
controls	O
.	O

Protein	O
sequencing	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
immunoblot	O
analyses	O
identify	O
p54	B-GENE
and	O
p47	B-GENE
/	I-GENE
48	I-GENE
as	O
members	O
of	O
the	O
hepatocyte	B-GENE
nuclear	I-GENE
factor	I-GENE
3	I-GENE
(	O
HNF3	B-GENE
[	O
forkhead	B-GENE
]	O
)	O
family	O
of	O
transcription	O
factors	O
.	O

p54	B-GENE
belongs	O
to	O
the	O
subfamily	O
of	O
HNF3	B-GENE
beta	I-GENE
proteins	I-GENE
,	O
while	O
p47	B-GENE
/	I-GENE
48	I-GENE
binding	O
activity	O
includes	O
HNF3	B-GENE
gamma	I-GENE
.	O

In	O
this	O
cross	O
-	O
over	O
controlled	O
study	O
,	O
five	O
male	O
volunteers	O
donated	O
one	O
unit	O
of	O
red	O
cells	O
by	O
MCS	O
and	O
one	O
unit	O
of	O
whole	O
blood	O
by	O
the	O
conventional	O
manual	O
method	O
,	O
3	O
months	O
apart	O
.	O

Promoter	O
activity	O
was	O
assayed	O
by	O
transient	O
transfection	O
of	O
luciferase	B-GENE
reporter	I-GENE
constructs	I-GENE
containing	O
nested	O
deletions	O
of	O
the	O
upstream	O
sequence	O
in	O
the	O
human	O
RPE	O
cell	O
lines	O
ARPE19	O
and	O
D407	O
,	O
as	O
well	O
as	O
in	O
the	O
SK	O
-	O
Mel	O
-	O
28	O
and	O
HeLa	O
cell	O
lines	O
.	O

This	O
model	O
system	O
exploits	O
the	O
polyomavirus	O
late	O
transcription	O
termination	O
and	O
polyadenylation	O
signals	O
,	O
which	O
are	O
sufficiently	O
weak	O
to	O
allow	O
the	O
production	O
of	O
many	O
multigenome	O
-	O
length	O
primary	O
transcripts	O
with	O
repeating	O
introns	O
,	O
exons	O
,	O
and	O
poly	O
(	O
A	O
)	O
sites	O
.	O

Magnification	O
-	O
corrected	O
planimetry	O
of	O
the	O
parapapillary	O
region	O
was	O
performed	O
according	O
to	O
Littmann	O
'	O
s	O
method	O
in	O
312	O
unselected	O
eyes	O
with	O
chronic	O
primary	O
open	O
-	O
angle	O
glaucoma	O
and	O
in	O
125	O
normal	O
eyes	O
of	O
an	O
age	O
-	O
and	O
refraction	O
-	O
matched	O
control	O
group	O
using	O
optic	O
disk	O
photographs	O
.	O

Although	O
the	O
elevated	O
signalling	O
is	O
eliminated	O
by	O
deletion	O
of	O
Ste20p	B-GENE
(	O
or	O
components	O
downstream	O
of	O
Ste20p	B-GENE
)	O
,	O
the	O
growth	O
and	O
morphological	O
abnormalities	O
of	O
cells	O
lacking	O
Akr1p	B-GENE
are	O
not	O
rescued	O
by	O
deletion	O
of	O
any	O
of	O
the	O
known	O
pheromone	O
response	O
pathway	O
components	O
.	O

Southern	O
hybridization	O
of	O
genomic	O
DNA	O
from	O
WT	O
and	O
Lp	B-GENE
/	O
Lp	B-GENE
embryos	O
failed	O
to	O
identify	O
specific	O
rearrangements	O
at	O
or	O
near	O
the	O
Nhlh1	B-GENE
locus	I-GENE
,	O
and	O
Northern	O
RNA	O
blotting	O
and	O
RT	O
-	O
PCR	O
evaluation	O
of	O
Nhlh1	B-GENE
mRNA	I-GENE
expression	O
indicated	O
that	O
both	O
the	O
levels	O
and	O
types	O
of	O
Nhlh1	B-GENE
mRNAs	I-GENE
produced	O
in	O
WT	O
and	O
Lp	B-GENE
/	O
Lp	B-GENE
embryos	O
were	O
indistinguishable	O
.	O

In	O
addition	O
,	O
mrp17	B-GENE
-	I-GENE
1	I-GENE
,	O
in	O
combination	O
with	O
some	O
mutations	O
affecting	O
another	O
mitochondrial	O
ribosomal	O
protein	O
,	O
caused	O
a	O
synthetic	O
defective	O
phenotype	O
.	O

Expression	O
,	O
characterization	O
,	O
and	O
genomic	O
structure	O
of	O
carp	B-GENE
JAK1	I-GENE
kinase	I-GENE
gene	I-GENE
.	O

Significantly	O
,	O
the	O
murine	B-GENE
P	I-GENE
-	I-GENE
selectin	I-GENE
gene	I-GENE
had	O
several	O
features	O
not	O
found	O
in	O
the	O
human	O
gene	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
showed	O
that	O
the	O
novel	O
regions	O
involved	O
in	O
the	O
NFKB2	B-GENE
rearrangement	O
originated	O
from	O
chromosome	O
7q34	O
,	O
thus	O
implying	O
the	O
occurrence	O
of	O
a	O
t	O
(	O
7	O
;	O
10	O
)	O
(	O
q34	O
;	O
q24	O
)	O
reciprocal	O
chromosomal	O
translocation	O
.	O

Transient	O
-	O
expression	O
assay	O
analysis	O
of	O
subclones	O
of	O
pPstI	O
-	O
G	O
localized	O
the	O
trans	O
-	O
active	O
factor	O
to	O
a	O
3	B-GENE
.	I-GENE
0	I-GENE
-	I-GENE
kilobase	I-GENE
XbaI	I-GENE
fragment	I-GENE
.	O

MGF	B-GENE
is	O
a	O
novel	O
member	O
of	O
the	O
cytokine	B-GENE
-	I-GENE
regulated	I-GENE
transcription	I-GENE
factor	I-GENE
gene	I-GENE
family	I-GENE
.	O

This	O
is	O
the	O
first	O
report	O
that	O
the	O
PH	B-GENE
domain	I-GENE
of	O
an	O
IRS	B-GENE
protein	I-GENE
can	O
function	O
in	O
a	O
dominant	O
negative	O
manner	O
to	O
inhibit	O
insulin	B-GENE
signaling	O
.	O

A	O
29	O
.	O
425	O
kb	O
segment	O
on	O
the	O
left	O
arm	O
of	O
yeast	O
chromosome	O
XV	O
contains	O
more	O
than	O
twice	O
as	O
many	O
unknown	O
as	O
known	O
open	O
reading	O
frames	O
.	O

This	O
result	O
,	O
together	O
with	O
the	O
fact	O
that	O
unrearranged	B-GENE
V	I-GENE
kappa	I-GENE
genes	I-GENE
are	O
transcriptionally	O
silent	O
,	O
suggests	O
that	O
structural	O
features	O
of	O
both	O
the	O
V	B-GENE
kappa	I-GENE
and	O
C	B-GENE
kappa	I-GENE
loci	I-GENE
contribute	O
to	O
the	O
overall	O
transcriptional	O
efficiency	O
of	O
a	O
rearranged	O
V	B-GENE
kappa	I-GENE
-	O
C	B-GENE
kappa	I-GENE
gene	O
.	O

The	O
first	O
270	O
bp	O
of	O
the	O
promoter	O
region	O
were	O
sequenced	O
and	O
found	O
to	O
contain	O
a	O
CATAA	O
box	O
rather	O
than	O
a	O
TATAA	O
box	O
and	O
several	O
DNA	O
motifs	O
found	O
in	O
activation	O
genes	O
.	O

C	O
.	O
glabrata	O
cells	O
containing	O
the	O
CBF1	B-GENE
gene	I-GENE
under	O
the	O
influence	O
of	O
a	O
shutdown	O
promoter	O
(	O
tetO	O
-	O
ScHOP	O
)	O
arrested	O
their	O
growth	O
after	O
5	O
h	O
of	O
cultivation	O
in	O
the	O
presence	O
of	O
the	O
reactive	O
drug	O
doxycycline	O
.	O

SF1	B-GENE
/	O
mBBP	B-GENE
utilizes	O
a	O
"	B-GENE
maxi	I-GENE
-	I-GENE
K	I-GENE
homology	I-GENE
"	I-GENE
(	O
maxi	B-GENE
-	I-GENE
KH	I-GENE
)	O
domain	O
for	O
recognition	O
of	O
the	O
single	O
-	O
stranded	O
BPS	O
and	O
requires	O
a	O
cooperative	O
interaction	O
with	O
splicing	O
factor	O
U2AF65	B-GENE
bound	O
to	O
an	O
adjacent	O
polypyrimidine	O
tract	O
(	O
PPT	O
)	O
for	O
high	O
-	O
affinity	O
binding	O
.	O

An	O
X	O
-	O
linked	O
zinc	B-GENE
finger	I-GENE
gene	I-GENE
mapping	O
to	O
Xq21	O
.	O
1	O
-	O
q21	O
.	O
3	O
closely	O
related	O
to	O
ZFX	B-GENE
and	O
ZFY	B-GENE
:	O
possible	O
origins	O
from	O
a	O
common	O
ancestral	O
gene	O
.	O

Validity	O
of	O
the	O
short	O
-	O
form	O
QIF	O
was	O
assessed	O
by	O
correlation	O
with	O
motor	O
scores	O
and	O
using	O
analysis	O
of	O
variance	O
by	O
motor	O
levels	O
and	O
motor	O
score	O
groupings	O
.	O

Juvenile	O
angiofibromas	O
.	O

Comment	O
on	O
"	O
Critical	O
behavior	O
of	O
a	O
binary	O
mixture	O
of	O
protein	O
and	O
salt	O
water	O
"	O

The	O
pineal	O
hormone	O
melatonin	O
(	O
MLT	O
)	O
is	O
able	O
to	O
exert	O
an	O
oncostatic	O
action	O
.	O

In	O
addition	O
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p120	B-GENE
Ras	I-GENE
-	O
specific	O
GTPase	B-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
(	O
GAP	B-GENE
)	O
and	O
GAP	B-GENE
-	O
associated	O
p190	O
.	O

Additional	O
transection	O
of	O
both	O
ADN	O
eliminated	O
the	O
remaining	O
sigmoidal	O
correlation	O
between	O
MAP	O
and	O
RSNA	O
with	O
further	O
increases	O
in	O
resting	O
MAP	O
and	O
RSNA	O
.	O

Pregnancy	O
was	O
ensued	O
in	O
4	O
cases	O
in	O
group	O
I	O
.	O

The	O
1	O
.	O
3	O
-	O
kb	O
DNA	O
,	O
when	O
placed	O
upstream	O
of	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
,	O
was	O
shown	O
to	O
be	O
functionally	O
active	O
.	O

Controversy	O
exists	O
regarding	O
both	O
the	O
natural	O
life	O
cycle	O
for	O
this	O
parasite	O
as	O
well	O
as	O
the	O
species	O
identity	O
of	O
opossum	O
Sarcocystis	O
.	O

The	O
mean	O
was	O
66	O
cells	O
/	O
mm2	O
in	O
the	O
laser	O
group	O
and	O
63	O
.	O
7	O
cells	O
/	O
mm2	O
in	O
the	O
control	O
group	O
.	O

Prazosin	O
in	O
the	O
treatment	O
of	O
high	O
blood	O
pressure	O

The	O
5	B-GENE
-	I-GENE
HT3	I-GENE
antagonist	O
ondansetron	O
reduced	O
alcohol	O
intake	O
in	O
both	O
the	O
medium	O
and	O
high	O
alcohol	O
preferring	O
rats	O
at	O
doses	O
between	O
0	O
.	O
01	O
and	O
0	O
.	O
16	O
mg	O
/	O
kg	O
.	O

Oral	O
hypoglycemic	O
agents	O

1	O
.	O

In	O
this	O
system	O
,	O
enhancers	O
act	O
primarily	O
to	O
increase	O
the	O
probability	O
of	O
rapid	O
and	O
efficient	O
transcription	O
complex	O
formation	O
and	O
initiation	O
.	O

The	O
relationship	O
between	O
donor	O
status	O
for	O
antibody	O
to	O
hepatitis	B-GENE
B	I-GENE
core	I-GENE
antigen	I-GENE
and	O
the	O
occurrence	O
of	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
posttransfusion	O
hepatitis	O
in	O
the	O
recipient	O
was	O
prospectively	O
studied	O
in	O
112	O
patients	O
undergoing	O
open	O
-	O
heart	O
surgery	O
who	O
were	O
followed	O
for	O
6	O
.	O
5	O
months	O
after	O
surgery	O
.	O

By	O
sequencing	O
of	O
exonuclease	B-GENE
III	I-GENE
deletion	O
clones	O
an	O
open	O
reading	O
frame	O
of	O
405	O
nucleotides	O
was	O
found	O
coding	O
for	O
a	O
protein	O
of	O
135	O
amino	O
acids	O
with	O
a	O
molecular	O
mass	O
of	O
15	O
kDa	O
.	O

The	O
pepI	B-GENE
gene	I-GENE
was	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

Treatment	O
of	O
steroid	O
resistant	O
rejection	O
following	O
renal	O
transplantation	O
:	O
benefits	O
and	O
risks	O
of	O
OKT3	B-GENE
therapy	O
.	O

The	O
level	O
of	O
transcription	O
generated	O
by	O
all	O
of	O
these	O
activators	O
is	O
greater	O
than	O
the	O
sum	O
of	O
the	O
levels	O
generated	O
by	O
individual	O
factors	O
,	O
a	O
phenomenon	O
designated	O
transcriptional	O
synergy	O
.	O

Conservation	O
of	O
this	O
zinc	O
finger	O
motif	O
from	O
yeast	O
to	O
mouse	O
and	O
human	O
implies	O
functional	O
importance	O
.	O

This	O
nuclear	O
/	O
organellar	O
gene	O
transfer	O
event	O
is	O
strikingly	O
similar	O
to	O
the	O
experimentally	O
accessible	O
process	O
of	O
nuclear	O
integration	O
of	O
introduced	O
heterologous	O
DNA	O
.	O

RESULTS	O
:	O
In	O
the	O
test	O
data	O
set	O
,	O
the	O
single	O
-	O
sample	O
model	O
was	O
confirmed	O
to	O
give	O
excellent	O
estimation	O
of	O
the	O
AUC	O
:	O
AUC	O
(	O
mg	O
/	O
ml	O
x	O
min	O
)	O
=	O
0	O
.	O
93	O
x	O
C3h	O
+	O
0	O
.	O
47	O
(	O
MPE	O
%	O
=	O
4	O
.	O
4	O
%	O
,	O
RMSE	O
%	O
=	O
8	O
.	O
9	O
%	O
)	O
.	O

SH3A	B-GENE
competes	O
with	O
the	O
SH3	B-GENE
domains	I-GENE
of	O
Grb2	B-GENE
in	O
binding	O
to	O
mSos1	B-GENE
,	O
and	O
the	O
intersectin	B-GENE
-	O
mSos1	B-GENE
complex	O
can	O
be	O
separated	O
from	O
Grb2	B-GENE
by	O
sucrose	O
gradient	O
centrifugation	O
.	O

Comparison	O
between	O
the	O
Ricketts	O
and	O
Bimler	O
therapeutic	O
technics	O
in	O
the	O
treatment	O
of	O
cases	O
of	O
class	O
II	O
,	O
division	O
I	O
mmalocclusion	O

This	O
resulted	O
in	O
a	O
shift	O
of	O
C1	O
/	O
C2	O
,	O
so	O
that	O
the	O
effect	O
of	O
collagen	B-GENE
was	O
more	O
pronounced	O
(	O
maximal	O
increase	O
of	O
C1	O
/	O
C2	O
=	O
134	O
%	O
)	O
than	O
ADP	O
(	O
maximal	O
increase	O
of	O
C1	O
/	O
C2	O
=	O
79	O
%	O
)	O
.	O

We	O
conclude	O
that	O
exercise	O
-	O
induced	O
ST	O
-	O
segment	O
elevation	O
in	O
patients	O
without	O
a	O
history	O
of	O
myocardial	O
infarction	O
or	O
left	O
ventricular	O
aneurysm	O
is	O
caused	O
by	O
coronary	O
spasm	O
of	O
a	O
major	O
coronary	O
vessel	O
.	O

Xnr3	B-GENE
is	O
transcriptionally	O
activated	O
by	O
wnt	B-GENE
signaling	O
during	O
gastrulation	O
in	O
the	O
Xenopus	O
embryo	O
.	O

For	O
economical	O
reasons	O
,	O
we	O
could	O
not	O
send	O
a	O
questionnaire	O
to	O
all	O
the	O
35	O
,	O
779	O
individuals	O
,	O
but	O
based	O
the	O
investigation	O
on	O
a	O
SRS	O
of	O
4	O
,	O
000	O
men	O
,	O
post	O
-	O
stratified	O
in	O
a	O
high	O
-	O
risk	O
and	O
a	O
low	O
-	O
risk	O
group	O
.	O

Several	O
waveforms	O
of	O
both	O
the	O
somatosensory	O
(	O
N20	O
,	O
P	O
/	O
N	O
30	O
,	O
and	O
P200	O
)	O
and	O
the	O
brainstem	O
auditory	O
-	O
evoked	O
response	O
(	O
I	O
,	O
III	O
,	O
IV	O
,	O
and	O
V	O
)	O
demonstrated	O
shorter	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
latencies	O
in	O
growth	O
-	O
retarded	O
fetuses	O
relative	O
to	O
normal	O
-	O
sized	O
fetuses	O
.	O

Effect	O
of	O
choline	O
magnesium	O
trisalicylate	O
on	O
prostacyclin	O
production	O
by	O
isolated	O
vascular	O
tissue	O
of	O
the	O
rat	O
.	O

The	O
sequences	O
of	O
two	O
previously	O
known	O
tail	B-GENE
genes	I-GENE
,	O
R	B-GENE
and	O
S	B-GENE
,	O
of	O
the	O
temperate	O
bacteriophage	O
P2	O
and	O
the	O
sequence	O
of	O
an	O
additional	O
open	O
reading	O
frame	O
(	O
orf	O
-	O
30	O
)	O
located	O
between	O
S	B-GENE
and	O
V	B-GENE
,	O
were	O
determined	O
.	O

The	O
high	O
prevalence	O
of	O
atrial	O
septal	O
defect	O
in	O
tetralogy	O
of	O
Fallot	O
is	O
cited	O
as	O
a	O
possible	O
analogy	O
because	O
right	O
ventricular	O
pressure	O
is	O
high	O
and	O
right	O
ventricular	O
compliance	O
is	O
low	O
from	O
birth	O
.	O

The	O
stress	O
/	O
BHV	O
-	O
1	O
model	O
resulted	O
in	O
a	O
mild	O
respiratory	O
infection	O
in	O
all	O
calves	O
with	O
no	O
difference	O
observed	O
between	O
treatment	O
groups	O
.	O

Solution	O
of	O
the	O
Boltzmann	O
equation	O
in	O
a	O
random	O
magnetic	O
field	O
.	O

GH	B-GENE
signals	O
by	O
interacting	O
with	O
GH	B-GENE
receptor	I-GENE
(	O
GHR	B-GENE
)	O
.	O

Ultraviolet	O
crosslinking	O
experiments	O
using	O
element	O
B	O
revealed	O
the	O
specific	O
binding	O
of	O
two	O
proteins	O
of	O
approximately	O
43	O
and	O
80	O
kDa	O
.	O

RESULTS	O
:	O
At	O
short	O
dwell	O
times	O
,	O
uncorrected	O
(	O
whole	O
plasma	O
)	O
D	O
/	O
P	O
and	O
Cp	O
of	O
urea	O
values	O
were	O
higher	O
than	O
the	O
corrected	O
(	O
plasma	O
water	O
)	O
values	O
by	O
5	O
.	O
7	O
%	O
-	O
5	O
.	O
9	O
%	O
.	O

The	O
recovery	O
of	O
xanthomegnin	O
added	O
to	O
corn	O
samples	O
at	O
levels	O
of	O
0	O
.	O
75	O
-	O
-	O
9	O
.	O
6	O
mg	O
/	O
kg	O
averaged	O
41	O
%	O
with	O
a	O
coefficient	O
of	O
variation	O
of	O
25	O
%	O
.	O

The	O
extraordinary	O
high	O
substrate	O
specificity	O
of	O
rPulA	B-GENE
together	O
with	O
its	O
thermal	O
stability	O
makes	O
this	O
enzyme	O
a	O
good	O
candidate	O
for	O
biotechnological	O
applications	O
in	O
the	O
starch	O
-	O
processing	O
industry	O
.	O

A	O
relationship	O
between	O
the	O
immunological	O
changes	O
and	O
the	O
disease	O
stage	O
was	O
discovered	O
:	O
the	O
index	O
of	O
the	O
3H	O
-	O
thymidine	O
incorporation	O
was	O
found	O
to	O
be	O
67	O
.	O
9	O
at	O
the	O
stage	O
of	O
disease	O
exacerbation	O
,	O
and	O
208	O
.	O
8	O
at	O
the	O
stage	O
of	O
remission	O
;	O
the	O
complement	O
titre	O
reached	O
,	O
respectively	O
,	O
46	O
.	O
64	O
+	O
/	O
-	O
5	O
.	O
28	O
and	O
112	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
0	O
units	O
per	O
ml	O
.	O

Sodium	O
dodecylsulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
showed	O
two	O
bands	O
of	O
about	O
the	O
same	O
intensity	O
with	O
apparent	O
molecular	O
masses	O
of	O
24	O
.	O
5	O
and	O
22	O
.	O
5	O
kDa	O
.	O

Consistent	O
with	O
an	O
effect	O
on	O
transcription	O
,	O
p21	B-GENE
was	O
localized	O
in	O
nuclei	O
of	O
transfected	O
cells	O
.	O

Analysis	O
of	O
pseudo	B-GENE
VH	I-GENE
gene	I-GENE
segment	I-GENE
recombination	I-GENE
products	I-GENE
reveals	O
no	O
bias	O
in	O
D	B-GENE
gene	I-GENE
segment	I-GENE
reading	O
frame	O
utilization	O
.	O

Plasma	B-GENE
prolactin	I-GENE
concentrations	O
during	O
incubation	O
,	O
25	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
3	O
ng	O
/	O
ml	O
,	O
decreased	O
to	O
baseline	O
levels	O
,	O
10	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
9	O
ng	O
/	O
ml	O
,	O
within	O
24	O
hr	O
after	O
nestbox	O
removal	O
.	O

After	O
30	O
weeks	O
of	O
amifostine	O
therapy	O
,	O
the	O
morphology	O
of	O
the	O
MDS	O
switched	O
to	O
a	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMML	O
)	O
-	O
like	O
appearance	O
,	O
with	O
continuously	O
increasing	O
leukocytes	O
,	O
so	O
that	O
we	O
discontinued	O
amifostine	O
therapy	O
for	O
1	O
month	O
to	O
exclude	O
a	O
possible	O
side	O
effect	O
of	O
amifostine	O
.	O

Heart	O
disease	O
.	O

A	O
new	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	B-GENE
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	B-GENE
immunoglobulin	I-GENE
heavy	I-GENE
-	I-GENE
chain	I-GENE
gene	I-GENE
enhancer	I-GENE
.	O

CONCLUSIONS	O
:	O
This	O
initial	O
experience	O
indicates	O
that	O
there	O
is	O
short	O
-	O
to	O
middle	O
-	O
term	O
efficiency	O
and	O
safety	O
when	O
using	O
GKS	O
to	O
treat	O
MTLE	O
.	O

Two	O
cases	O
of	O
Paraquat	O
poisoning	O
of	O
anticonservative	O
origin	O
are	O
described	O
.	O

Genetic	O
mutation	O
or	O
loss	O
of	O
activin	B-GENE
/	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
(	I-GENE
TGFbeta	I-GENE
)	I-GENE
receptor	I-GENE
function	O
has	O
been	O
shown	O
in	O
human	O
lymphoid	O
,	O
breast	O
,	O
and	O
colorectal	O
tumors	O
as	O
well	O
as	O
Hep2B	O
and	O
Mv1Lu	O
cell	O
lines	O
.	O

A	O
poly	O
(	O
ortho	O
ester	O
)	O
designed	O
for	O
combined	O
ocular	O
delivery	O
of	O
dexamethasone	O
sodium	O
phosphate	O
and	O
5	O
-	O
fluorouracil	O
:	O
subconjunctival	O
tolerance	O
and	O
in	O
vitro	O
release	O
.	O

We	O
now	O
describe	O
a	O
HepG2	B-GENE
cell	I-GENE
casein	I-GENE
kinase	I-GENE
II	I-GENE
beta	I-GENE
subunit	I-GENE
cDNA	I-GENE
of	O
2	O
.	O
57	O
kb	O
containing	O
96	O
bases	O
of	O
5	O
'	O
untranslated	O
sequence	O
,	O
645	O
bases	O
of	O
open	O
reading	O
frame	O
,	O
and	O
1832	O
bases	O
of	O
3	O
'	O
untranslated	O
sequence	O
with	O
two	O
polyadenylation	O
consensus	O
signal	O
sequences	O
and	O
two	O
poly	O
(	O
A	O
)	O
stretches	O
.	O

Brome	B-GENE
mosaic	I-GENE
virus	I-GENE
polymerase	I-GENE
-	O
like	O
protein	B-GENE
2a	I-GENE
is	O
directed	O
to	O
the	O
endoplasmic	O
reticulum	O
by	O
helicase	B-GENE
-	O
like	O
viral	B-GENE
protein	I-GENE
1a	I-GENE
.	O

Diagnostic	O
importance	O
of	O
determining	O
leucine	B-GENE
aminotransferase	I-GENE
activity	O
in	O
acute	O
pancreatitis	O

Therapeutic	O
iodine	O
125	O
for	O
hyperthyroidism	O
:	O
evidence	O
for	O
a	O
special	O
radiobiological	O
effect	O
on	O
the	O
follicular	O
cell	O
.	O

Maintenance	O
metabolizable	O
-	O
energy	O
(	O
ME	O
)	O
requirement	O
averaged	O
31	O
.	O
0	O
kcal	O
/	O
kg	O
body	O
wt	O
.	O

This	O
finding	O
is	O
of	O
importance	O
because	O
it	O
completes	O
an	O
explanation	O
for	O
central	O
near	O
-	O
location	O
errors	O
in	O
the	O
partial	O
-	O
report	O
bar	O
-	O
probe	O
task	O
.	O

A	O
DNA	O
binding	O
protein	O
was	O
identified	O
which	O
binds	O
to	O
two	O
novel	O
target	O
-	O
like	O
sequences	O
:	O
(	O
i	O
)	O
at	O
the	O
5	O
'	O
flanking	O
site	O
of	O
the	O
breakpoint	O
junction	O
of	O
chromosome	O
8	O
in	O
a	O
patient	O
with	O
T	O
-	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
carrying	O
the	O
t	O
(	O
8	O
;	O
14	O
)	O
(	O
q24	O
;	O
q11	O
)	O
rearrangement	O
and	O
(	O
ii	O
)	O
on	O
chromosome	O
1	O
in	O
three	O
of	O
five	O
T	O
-	O
ALL	O
patients	O
with	O
the	O
t	O
(	O
1	O
;	O
14	O
)	O
(	O
p32	O
;	O
q11	O
)	O
rearrangement	O
.	O

Nedocromil	O
sodium	O
shifted	O
the	O
severity	O
of	O
the	O
early	O
allergic	O
reaction	O
(	O
EAR	O
)	O
from	O
mean	O
-	O
34	O
.	O
8	O
%	O
to	O
-	O
6	O
.	O
9	O
%	O
and	O
inhibited	O
the	O
later	O
allergic	O
reaction	O
(	O
LAR	O
)	O
from	O
-	O
30	O
.	O
5	O
%	O
to	O
+	O
0	O
.	O
4	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

The	O
Mer1	B-GENE
protein	I-GENE
contains	O
the	O
KH	O
motif	O
found	O
in	O
some	O
RNA	O
-	O
binding	O
proteins	O
,	O
and	O
RNA	O
gel	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
Mer1	B-GENE
binds	O
specifically	O
to	O
MER2	B-GENE
RNA	I-GENE
.	O

Results	O
obtained	O
from	O
the	O
tritium	O
test	O
and	O
direct	O
chemical	O
analysis	O
were	O
compared	O
.	O

We	O
found	O
that	O
in	O
anesthetized	O
,	O
paralyzed	O
cats	O
,	O
the	O
visual	O
evoked	O
potential	O
(	O
VEP	O
)	O
was	O
dependent	O
only	O
on	O
magnitude	O
of	O
delta	O
C	O
at	O
each	O
pattern	O
transition	O
,	O
and	O
was	O
independent	O
of	O
the	O
starting	O
or	O
ending	O
contrast	O
level	O
.	O

Experiment	O
B	O
:	O
Clinical	O
,	O
biochemical	O
,	O
and	O
histological	O
variables	O
were	O
measured	O
over	O
a	O
12	O
-	O
day	O
period	O
after	O
the	O
zymosan	O
had	O
been	O
given	O
.	O

Direct	O
saturation	O
analysis	O

From	O
this	O
asymmetry	O
,	O
we	O
suggested	O
previously	O
that	O
GCN4	B-GENE
interacts	O
with	O
nonequivalent	O
and	O
possibly	O
overlapping	O
half	O
-	O
sites	O
(	O
ATGAC	O
and	O
ATGAG	O
)	O
that	O
have	O
different	O
affinities	O
.	O

Furthermore	O
the	O
aldosterone	O
stimulating	O
effect	O
of	O
low	O
sodium	O
diet	O
(	O
17	O
children	O
)	O
,	O
severe	O
and	O
prolonged	O
vomiting	O
(	O
19	O
children	O
)	O
and	O
synthetic	O
ACTH	B-GENE
(	O
10	O
children	O
)	O
has	O
been	O
studied	O
by	O
our	O
modified	O
method	O
.	O

A	O
case	O
control	O
study	O
(	O
1	O
:	O
2	O
)	O
of	O
182	O
pairs	O
of	O
Hepatitis	O
A	O
was	O
carried	O
out	O
in	O
Weng	O
-	O
ling	O
Zhe	O
-	O
jiang	O
during	O
April	O
1988	O
.	O

The	O
mutant	O
strain	O
carries	O
three	O
tandem	O
copies	O
of	O
the	O
18	O
bp	O
sequence	O
that	O
is	O
duplicated	O
in	O
the	O
amdI66	B-GENE
mutation	O
.	O

Although	O
cDNA	O
encoding	O
a	O
human	B-GENE
phagocyte	I-GENE
formyl	I-GENE
peptide	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
has	O
been	O
reported	O
recently	O
(	O
Boulay	O
,	O
F	O
.	O
,	O
Tardif	O
,	O
M	O
.	O
,	O
Brouchon	O
,	O
L	O
.	O
,	O
and	O
Vignais	O
,	O
P	O
.	O

In	O
NIH	O
3T3	O
fibroblasts	O
the	O
high	O
affinity	O
IL	B-GENE
-	I-GENE
2R	I-GENE
bearing	O
a	O
deletion	O
of	O
a	O
region	O
rich	O
in	O
acidic	O
amino	O
acids	O
(	O
the	O
"	O
acidic	O
"	O
region	O
)	O
in	O
the	O
IL	B-GENE
-	I-GENE
2R	I-GENE
beta	I-GENE
-	I-GENE
chain	I-GENE
failed	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
MAP	B-GENE
kinase	I-GENE
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
all	O
three	O
nuclear	O
proto	O
-	O
oncogenes	O
.	O

A	O
small	O
molecule	O
ILK	B-GENE
inhibitor	O
suppresses	O
the	O
phosphorylation	O
of	O
PKB	B-GENE
at	O
the	O
Ser	O
-	O
473	O
but	O
not	O
the	O
Thr	O
-	O
308	O
site	O
in	O
the	O
PTEN	B-GENE
mutant	O
cells	O
.	O

The	O
avian	O
carcinoma	O
virus	O
MH2	O
contains	O
a	O
hybrid	O
gene	O
delta	B-GENE
gag	I-GENE
-	O
mht	B-GENE
with	O
a	O
contiguous	O
open	O
reading	O
frame	O
of	O
2682	O
base	O
pairs	O
as	O
well	O
as	O
v	B-GENE
-	I-GENE
myc	I-GENE
and	O
avian	O
helper	O
virus	O
-	O
related	O
sequences	O
.	O
delta	B-GENE
gag	I-GENE
is	O
a	O
partial	O
retroviral	B-GENE
core	I-GENE
protein	I-GENE
gene	I-GENE
while	O
v	B-GENE
-	I-GENE
mht	I-GENE
and	O
v	B-GENE
-	I-GENE
myc	I-GENE
are	O
cell	O
-	O
drived	O
sequences	O
.	O

The	O
results	O
in	O
the	O
untreated	O
patients	O
demonstrate	O
the	O
primary	O
importance	O
of	O
bulk	O
reduction	O
at	O
initial	O
laparotomy	O
.	O

Of	O
3841	O
serum	O
samples	O
from	O
sows	O
received	O
from	O
the	O
Tennessee	O
State	O
Diagnostic	O
Laboratory	O
in	O
1991	O
-	O
1992	O
,	O
1130	O
were	O
positive	O
for	O
Toxoplasma	B-GENE
gondii	I-GENE
antibody	I-GENE
.	O

These	O
findings	O
also	O
demonstrate	O
that	O
unless	O
excluded	O
by	O
other	O
factors	O
,	O
the	O
C	B-GENE
proteins	I-GENE
are	O
likely	O
to	O
be	O
located	O
along	O
the	O
length	O
of	O
nascent	O
transcripts	O
.	O

In	O
this	O
group	O
of	O
patients	O
,	O
the	O
mean	O
LH	B-GENE
(	O
9	O
.	O
3	O
+	O
/	O
-	O
5	O
.	O
9	O
IU	O
/	O
l	O
)	O
and	O
sex	B-GENE
-	I-GENE
hormone	I-GENE
binding	I-GENE
globulin	I-GENE
(	O
SHBG	B-GENE
)	O
(	O
54	O
.	O
5	O
+	O
/	O
-	O
22	O
.	O
9	O
nmol	O
/	O
l	O
)	O
concentrations	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
five	O
normal	O
control	O
subjects	O
(	O
4	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
11	O
IU	O
/	O
l	O
and	O
26	O
.	O
0	O
+	O
/	O
-	O
7	O
.	O
0	O
nmol	O
/	O
l	O
respectively	O
)	O
.	O

We	O
have	O
now	O
completed	O
the	O
primary	O
structure	O
of	O
fibrillin	B-GENE
,	O
elucidated	O
the	O
exon	O
/	O
intron	O
organization	O
of	O
the	O
gene	O
and	O
derived	O
a	O
physical	O
map	O
of	O
the	O
genetic	O
locus	O
.	O

The	O
BCL	B-GENE
-	I-GENE
6	I-GENE
POZ	O
domain	O
and	O
other	O
POZ	O
domains	O
interact	O
with	O
the	O
co	O
-	O
repressors	O
N	B-GENE
-	I-GENE
CoR	I-GENE
and	O
SMRT	B-GENE
.	O

Cytokine	O
inducibility	O
of	O
VCAM1	B-GENE
in	O
endothelial	O
cells	O
utilizes	O
the	O
interaction	O
of	O
heterodimeric	O
p50	B-GENE
/	O
p65	B-GENE
proteins	O
with	O
IRF	B-GENE
-	I-GENE
1	I-GENE
.	O

In	O
particular	O
,	O
MF	O
males	O
receiving	O
either	O
a	O
5	O
.	O
0	O
-	O
mg	O
/	O
kg	O
CDP	O
dose	O
or	O
a	O
3	O
.	O
0	O
-	O
mg	O
/	O
kg	O
RO	O
dose	O
explored	O
the	O
object	O
more	O
often	O
than	O
MM	O
males	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

To	O
gain	O
additional	O
insights	O
into	O
this	O
novel	O
apoptotic	O
checkpoint	O
,	O
we	O
have	O
now	O
characterized	O
the	O
mouse	B-GENE
survivin	I-GENE
locus	I-GENE
.	O

Both	O
proteins	O
share	O
sequence	O
similarity	O
with	O
the	O
myelin	B-GENE
-	I-GENE
associated	I-GENE
glycoprotein	I-GENE
,	O
an	O
adhesion	O
molecule	O
of	O
oligodendrocytes	O
and	O
Schwann	O
cells	O
that	O
has	O
been	O
implicated	O
in	O
the	O
process	O
of	O
myelination	O
,	O
raising	O
the	O
important	O
question	O
of	O
whether	O
myelin	B-GENE
-	I-GENE
associated	I-GENE
glycoprotein	I-GENE
is	O
also	O
a	O
sialic	B-GENE
acid	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
.	O

Localized	O
Bicaudal	B-GENE
-	I-GENE
C	I-GENE
RNA	I-GENE
encodes	O
a	O
protein	O
containing	O
a	O
KH	O
domain	O
,	O
the	O
RNA	O
binding	O
motif	O
of	O
FMR1	B-GENE
.	O

To	O
facilitate	O
the	O
characterization	O
of	O
NF	B-GENE
-	I-GENE
E2	I-GENE
functions	O
in	O
human	O
cells	O
,	O
we	O
isolated	O
cDNAs	O
encoding	O
two	O
members	O
of	O
the	O
small	B-GENE
Maf	I-GENE
family	I-GENE
,	O
MafK	B-GENE
and	O
MafG	B-GENE
.	O

Indigenous	O
microbial	O
flora	O
and	O
the	O
large	O
intestine	O
in	O
tadpoles	O
.	O

Copyright	O
1998	O
The	O
Association	O
for	O
the	O
Study	O
of	O
Animal	O
Behaviour	O
.	O

In	O
contrast	O
to	O
the	O
restricted	O
tissue	O
expression	O
of	O
gonadotropin	B-GENE
and	O
TSH	B-GENE
receptors	I-GENE
in	O
gonads	O
and	O
thyroid	O
,	O
respectively	O
,	O
LGR4	B-GENE
is	O
expressed	O
in	O
diverse	O
tissues	O
including	O
ovary	O
,	O
testis	O
,	O
adrenal	O
,	O
placenta	O
,	O
thymus	O
,	O
spinal	O
cord	O
,	O
and	O
thyroid	O
,	O
whereas	O
LGR5	B-GENE
is	O
found	O
in	O
muscle	O
,	O
placenta	O
,	O
spinal	O
cord	O
,	O
and	O
brain	O
.	O

Not	O
only	O
will	O
it	O
substantially	O
reduce	O
incident	O
cases	O
of	O
hepatitis	O
B	O
for	O
the	O
next	O
decade	O
,	O
it	O
will	O
also	O
provide	O
a	O
framework	O
for	O
the	O
successful	O
introduction	O
of	O
future	O
adolescent	O
vaccine	O
initiatives	O
in	O
Australia	O
.	O

A	O
new	O
technique	O
for	O
the	O
identification	O
of	O
phases	O
contained	O
within	O
a	O
polymer	O
blend	O
is	O
described	O
in	O
this	O
paper	O
.	O

Radioactively	O
labeled	O
microspheres	O
were	O
used	O
to	O
determine	O
and	O
compare	O
the	O
hemodynamic	O
effects	O
of	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
,	O
nitroglycerin	O
(	O
NTG	O
)	O
,	O
and	O
deep	O
enflurane	O
anesthesia	O
on	O
oral	O
tissues	O
during	O
controlled	O
hypotension	O
when	O
compared	O
with	O
controls	O
.	O

Their	O
central	O
projections	O
were	O
indistinguishable	O
from	O
those	O
of	O
control	O
axons	O
in	O
all	O
four	O
trigeminal	O
subnuclei	O
.	O

The	O
JNK	B-GENE
/	O
SAPK	B-GENE
activator	O
mixed	B-GENE
lineage	I-GENE
kinase	I-GENE
3	I-GENE
(	O
MLK3	B-GENE
)	O
transforms	O
NIH	O
3T3	O
cells	O
in	O
a	O
MEK	B-GENE
-	O
dependent	O
fashion	O
.	O

The	O
decision	O
support	O
system	O
uses	O
the	O
network	O
at	O
its	O
core	O
and	O
helps	O
not	O
only	O
in	O
reaching	O
a	O
diagnosis	O
but	O
also	O
in	O
finding	O
the	O
optimal	O
way	O
to	O
reach	O
that	O
diagnosis	O
.	O

In	O
contrast	O
to	O
the	O
effect	O
on	O
DNA	O
replication	O
,	O
the	O
L13V	O
substitution	O
in	O
large	B-GENE
T	I-GENE
antigen	I-GENE
did	O
not	O
prevent	O
complex	O
formation	O
with	O
Hsc70	B-GENE
and	O
the	O
Rb	B-GENE
protein	I-GENE
.	O

To	O
explore	O
the	O
effect	O
of	O
persistent	O
cardiomegaly	O
on	O
cardiovascular	O
function	O
,	O
groups	O
of	O
newborn	O
rats	O
inhaled	O
up	O
to	O
500	O
ppm	O
CO	O
for	O
33	O
days	O
,	O
after	O
which	O
development	O
continued	O
in	O
ambient	O
air	O
.	O

Bandwidth	O
of	O
auditory	O
units	O
in	O
the	O
chick	O
forebrain	O
(	O
field	O
L	O
/	O
Hv	O
complex	O
)	O
was	O
measured	O
with	O
isointensity	O
tone	O
stimuli	O
.	O

Members	O
of	O
the	O
steroid	B-GENE
/	I-GENE
hormone	I-GENE
nuclear	I-GENE
receptor	I-GENE
superfamily	I-GENE
regulate	O
target	O
gene	O
transcription	O
via	O
recognition	O
and	O
association	O
with	O
specific	O
cis	O
-	O
acting	O
sequences	O
of	O
DNA	O
,	O
called	O
hormone	O
response	O
elements	O
(	O
HREs	O
)	O
.	O

Indeed	O
,	O
DEX	O
also	O
enhanced	O
the	O
RA	O
-	O
dependent	O
increase	O
in	O
RARbeta	B-GENE
mRNA	I-GENE
in	O
a	O
cycloheximide	O
-	O
sensitive	O
manner	O
.	O

The	O
highest	O
concentration	O
of	O
respirable	O
mineral	O
fibres	O
was	O
found	O
during	O
the	O
overhaul	O
of	O
a	O
truck	O
with	O
asbestos	O
insulation	O
;	O
respirable	O
fibre	O
concentration	O
reached	O
the	O
value	O
of	O
5	O
f	O
/	O
cm3	O
,	O
and	O
total	O
dust	O
concentration	O
-	O
the	O
value	O
of	O
about	O
80	O
mg	O
/	O
m3	O
.	O

Avian	B-GENE
EMILIN	I-GENE
was	O
extracted	O
from	O
19	O
-	O
day	O
-	O
old	O
embryonic	O
chick	O
aortas	O
and	O
associated	O
blood	O
vessels	O
and	O
purified	O
by	O
ion	O
-	O
exchange	O
chromatography	O
and	O
gel	O
filtration	O
.	O

CYP51P1	B-GENE
is	O
96	O
.	O
5	O
%	O
identical	O
to	O
the	O
human	B-GENE
CYP51	I-GENE
coding	O
sequence	O
and	O
is	O
not	O
interrupted	O
with	O
introns	O
but	O
has	O
six	O
in	O
-	O
frame	O
stop	O
codons	O
resulting	O
from	O
point	O
mutations	O
.	O

We	O
report	O
here	O
that	O
AChE	B-GENE
activity	O
tends	O
to	O
decrease	O
in	O
individuals	O
sampled	O
in	O
tanks	O
at	O
a	O
salinity	O
of	O
30	O
per	O
thousand	O
as	O
temperature	O
increases	O
.	O

Three	O
RasV12	B-GENE
mutants	I-GENE
(	O
S35	B-GENE
,	O
G37	B-GENE
,	O
and	O
C40	B-GENE
)	O
which	O
differ	O
by	O
their	O
ability	O
to	O
bind	O
to	O
Ras	B-GENE
effectors	I-GENE
(	O
Raf	B-GENE
,	O
Ral	B-GENE
-	I-GENE
GEFs	I-GENE
,	O
and	O
the	O
p110	B-GENE
subunit	I-GENE
of	I-GENE
PI	I-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
,	O
respectively	O
)	O
were	O
able	O
to	O
induce	O
sustained	O
NR	O
cell	O
proliferation	O
,	O
although	O
none	O
of	O
these	O
mutants	O
was	O
reported	O
to	O
transform	O
NIH	O
3T3	O
cells	O
.	O

Mating	O
response	O
,	O
ovulation	O
rate	O
,	O
follicle	O
and	O
corpus	O
luteum	O
size	O
,	O
gestation	O
length	O
,	O
pregnancy	O
rate	O
,	O
lambing	O
rate	O
,	O
and	O
lamb	O
birth	O
weight	O
were	O
recorded	O
.	O

Membrane	O
extraction	O
has	O
been	O
interfaced	O
with	O
gas	O
chromatography	O
and	O
mass	O
spectroscopy	O
for	O
the	O
analysis	O
of	O
volatile	O
organics	O
in	O
water	O
.	O

A	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
antibodies	O
to	O
thyroglobulin	B-GENE
and	O
thyroid	B-GENE
peroxidase	I-GENE
was	O
found	O
in	O
subgroup	O
2	O
.	O

Here	O
,	O
we	O
characterize	O
TCR	B-GENE
/	O
CD48	B-GENE
and	O
TCR	B-GENE
/	O
CD28	B-GENE
costimulation	O
in	O
T	O
cells	O
expressing	O
Lck	B-GENE
Src	B-GENE
homology	I-GENE
3	I-GENE
(	O
SH3	B-GENE
)	O
mutants	O
.	O

High	O
expression	O
of	O
p51A	B-GENE
(	O
TAp63gamma	B-GENE
)	O
in	O
the	O
skeletal	O
muscle	O
tissue	O
drove	O
us	O
to	O
investigate	O
a	O
differentiation	O
-	O
inducible	O
myoblastic	O
cell	O
line	O
which	O
showed	O
increased	O
p51A	B-GENE
expression	O
after	O
differentiation	O
induction	O
.	O

The	O
rate	O
for	O
Arm	O
III	O
(	O
CAF	O
therapy	O
)	O
was	O
61	O
.	O
5	O
%	O
(	O
32	O
/	O
52	O
)	O
,	O
a	O
little	O
higher	O
than	O
that	O
for	O
the	O
other	O
two	O
.	O

These	O
results	O
induce	O
that	O
the	O
putative	O
TATA	O
box	O
and	O
initiator	O
are	O
not	O
involved	O
in	O
the	O
promoter	O
activity	O
,	O
and	O
that	O
the	O
vitronectin	B-GENE
promoter	I-GENE
lacks	O
the	O
TATA	O
box	O
,	O
initiator	O
and	O
GC	O
box	O
.	O

Using	O
the	O
interaction	O
-	O
trap	O
assay	O
to	O
identify	O
candidate	O
proteins	O
that	O
bind	O
the	O
cytoplasmic	O
region	O
of	O
the	O
LAR	B-GENE
transmembrane	I-GENE
protein	I-GENE
tyrosine	I-GENE
phosphatase	I-GENE
(	O
PT	B-GENE
-	I-GENE
Pase	I-GENE
)	O
,	O
we	O
isolated	O
a	O
cDNA	O
encoding	O
a	O
2861	O
-	O
amino	O
acid	O
protein	O
termed	O
Trio	B-GENE
that	O
contains	O
three	O
enzyme	O
domains	O
:	O
two	O
functional	O
GEF	B-GENE
domains	I-GENE
and	O
a	O
protein	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
(	O
PSK	B-GENE
)	O
domain	O
.	O

We	O
have	O
isolated	O
two	O
H19	B-GENE
cDNAs	I-GENE
(	O
AP	B-GENE
and	O
ES	B-GENE
)	O
that	O
contain	O
this	O
ORF4	O
and	O
correspond	O
to	O
incomplete	O
copies	O
of	O
the	O
unique	O
2	B-GENE
.	I-GENE
3	I-GENE
kb	I-GENE
H19	I-GENE
RNA	I-GENE
.	O

The	O
combined	O
in	O
vitro	O
effects	O
of	O
ethanol	O
wih	O
methaqualone	O
,	O
phenobarbital	O
,	O
pyrazole	O
or	O
disulfiram	O
were	O
studied	O
using	O
rat	B-GENE
brain	I-GENE
microsomal	I-GENE
NA	I-GENE
-	I-GENE
K	I-GENE
-	I-GENE
ATPase	I-GENE
.	O

The	O
related	O
adhesion	B-GENE
focal	I-GENE
tyrosine	I-GENE
kinase	I-GENE
is	O
tyrosine	O
-	O
phosphorylated	O
after	O
beta1	B-GENE
-	I-GENE
integrin	I-GENE
stimulation	O
in	O
B	O
cells	O
and	O
binds	O
to	O
p130cas	B-GENE
.	O

Earlier	O
reports	O
have	O
localized	O
mutations	O
which	O
affect	O
the	O
processing	O
and	O
transport	O
of	O
herpes	O
simplex	O
virus	O
1	O
glycoproteins	O
to	O
a	O
region	O
located	O
between	O
the	O
genes	O
specifying	O
glycoprotein	B-GENE
B	I-GENE
and	O
the	O
major	O
viral	O
DNA	O
-	O
binding	O
protein	O
(	O
beta	B-GENE
8	I-GENE
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
2127	O
-	O
bp	O
cDNA	O
encodes	O
a	O
functional	O
feline	O
L	B-GENE
/	I-GENE
B	I-GENE
/	I-GENE
K	I-GENE
-	I-GENE
type	I-GENE
ALP	I-GENE
expressed	O
on	O
cell	O
surfaces	O
via	O
phosphatidylinositol	O
-	O
glycan	O
linkage	O
.	O

Our	O
experience	O
suggests	O
that	O
T2	O
weighting	O
is	O
adequate	O
and	O
is	O
the	O
method	O
of	O
choice	O
for	O
the	O
early	O
recognition	O
of	O
necrosis	O
of	O
the	O
lunate	O
.	O

Analysis	O
of	O
a	O
Het	B-GENE
-	O
mutation	O
in	O
Anabaena	O
sp	O
.	O
strain	O
PCC	O
7120	O
implicates	O
a	O
secondary	O
metabolite	O
in	O
the	O
regulation	O
of	O
heterocyst	O
spacing	O
.	O

Here	O
we	O
report	O
that	O
components	O
of	O
the	O
Ras	B-GENE
/	O
Raf	B-GENE
/	O
MAPK	B-GENE
pathway	O
are	O
constitutively	O
activated	O
in	O
these	O
lck	B-GENE
-	O
transformed	O
immature	O
thymoblasts	O
.	O

p56	B-GENE
(	O
lck	B-GENE
)	O
utilizes	O
Shc	B-GENE
and	O
Grb2	B-GENE
adaptors	I-GENE
to	O
mediate	O
activation	O
of	O
p21	B-GENE
(	O
ras	B-GENE
)	O
in	O
the	O
thymoblast	O
lines	O
by	O
promoting	O
tyrosine	O
phosphorylation	O
of	O
the	O
Shc	B-GENE
protein	I-GENE
and	O
constitutive	O
interaction	O
between	O
Shc	B-GENE
and	O
Grb2	B-GENE
.	O

The	O
rec8	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
,	O
rec10	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
,	O
and	O
rec11	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
genes	I-GENE
of	I-GENE
the	I-GENE
fission	I-GENE
yeast	I-GENE
Schizosaccharomyces	I-GENE
pombe	I-GENE
exhibit	O
similar	O
specificities	O
for	O
meiotic	O
recombination	O
and	O
rec8	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
is	O
required	O
for	O
sister	O
chromatid	O
cohesion	O
and	O
homolog	O
pairing	O
.	O

Based	O
on	O
the	O
results	O
of	O
this	O
analysis	O
,	O
we	O
also	O
predict	O
that	O
the	O
budding	B-GENE
yeast	I-GENE
arsenate	I-GENE
resistance	I-GENE
protein	I-GENE
Acr2	B-GENE
and	O
the	O
ORF	B-GENE
Ygr203w	I-GENE
encode	O
protein	O
phosphatases	O
with	O
catalytic	O
properties	O
similar	O
to	O
that	O
of	O
the	O
Cdc25	B-GENE
family	I-GENE
.	O

At	O
onset	O
of	O
first	O
post	O
-	O
weaning	O
estrus	O
,	O
sows	O
received	O
either	O
an	O
intravulval	O
injection	O
of	O
3	O
.	O
75	O
mg	O
of	O
prostaglandin	O
analogue	O
(	O
PGF	O
)	O
or	O
,	O
served	O
as	O
a	O
non	O
-	O
injected	O
control	O
(	O
CON	O
)	O
.	O

We	O
concluded	O
that	O
HFV	O
can	O
achieve	O
values	O
of	O
CO2	O
elimination	O
close	O
to	O
the	O
estimated	O
metabolic	O
CO2	O
production	O
in	O
normal	O
unintubated	O
subjects	O
over	O
short	O
periods	O
of	O
time	O
.	O

The	O
PHO5	B-GENE
gene	I-GENE
is	O
activated	O
by	O
the	O
Pho4p	B-GENE
transcription	I-GENE
factor	I-GENE
,	O
which	O
itself	O
is	O
negatively	O
regulated	O
through	O
phosphorylation	O
by	O
the	O
products	O
of	O
PHO80	B-GENE
and	O
PHO85	B-GENE
.	O

Although	O
the	O
only	O
authoritative	O
way	O
to	O
determine	O
the	O
effect	O
of	O
diet	O
on	O
urinary	O
pH	O
is	O
a	O
feeding	O
trial	O
,	O
there	O
is	O
no	O
universally	O
accepted	O
protocol	O
for	O
measuring	O
urinary	O
pH	O
.	O

Analysis	O
of	O
the	O
DNA	O
sequence	O
upstream	O
of	O
the	O
narQ	B-GENE
gene	I-GENE
,	O
which	O
encodes	O
the	O
second	O
nitrate	O
-	O
responsive	O
sensor	O
-	O
transmitter	O
protein	O
in	O
Escherichia	O
coli	O
,	O
revealed	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
product	O
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
a	O
number	O
of	O
iron	B-GENE
-	I-GENE
sulfur	I-GENE
proteins	I-GENE
as	O
well	O
as	O
to	O
the	O
beta	O
subunit	O
of	O
glutamate	B-GENE
synthase	I-GENE
(	O
gltD	B-GENE
)	O
of	O
E	O
.	O
coli	O
.	O

Endothelial	O
purine	O
content	O
.	O

We	O
suggest	O
that	O
the	O
responses	O
to	O
types	B-GENE
I	I-GENE
and	I-GENE
II	I-GENE
collagen	I-GENE
were	O
caused	O
by	O
a	O
cross	O
-	O
reaction	O
with	O
type	B-GENE
III	I-GENE
collagen	I-GENE
peptides	O
.	O

Possibilities	O
and	O
limints	O
of	O
immunofluorescence	O
in	O
the	O
laboratory	O
diagnosis	O
of	O
rabies	O

The	O
5	O
'	O
half	O
of	O
the	O
EWS	B-GENE
gene	I-GENE
has	O
recently	O
been	O
described	O
to	O
be	O
fused	O
to	O
the	O
3	O
'	O
regions	O
of	O
genes	O
encoding	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
several	O
transcriptional	O
regulators	O
,	O
including	O
ATF1	B-GENE
,	O
FLI	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
ERG	B-GENE
,	O
in	O
several	O
human	O
tumors	O
.	O

PDGF	B-GENE
stimulated	O
CDK2	B-GENE
activity	O
in	O
mesangial	O
cells	O
and	O
decreased	O
the	O
level	O
of	O
p27	B-GENE
(	O
kip1	B-GENE
)	O
cyclin	O
kinase	O
inhibitor	O
protein	O
.	O

Recombinant	B-GENE
apoA	I-GENE
-	I-GENE
I	I-GENE
protein	I-GENE
recovered	O
from	O
the	O
soluble	O
fraction	O
of	O
the	O
bacterial	O
cell	O
pellet	O
was	O
purified	O
to	O
greater	O
than	O
95	O
%	O
homogeneity	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

The	O
influence	O
of	O
different	O
temperatures	O
between	O
13	O
degrees	O
C	O
and	O
45	O
degrees	O
C	O
on	O
coagulation	O
factors	O
in	O
vitro	O
was	O
studied	O
by	O
measuring	O
clotting	O
time	O
with	O
the	O
recalcification	O
time	O
,	O
partial	O
thromboplastin	B-GENE
time	O
(	O
PTT	O
)	O
,	O
and	O
thromboplastin	B-GENE
time	O
test	O
.	O

On	O
average	O
,	O
rCMRglc	O
values	O
were	O
23	O
%	O
below	O
control	O
values	O
for	O
all	O
regions	O
studied	O
,	O
with	O
the	O
greatest	O
differences	O
in	O
posterior	O
brain	O
regions	O
(	O
visual	O
association	O
cortex	O
,	O
primary	O
visual	O
cortex	O
,	O
and	O
parietal	O
cortex	O
)	O
and	O
thalamus	O
.	O

Thus	O
,	O
transgene	O
expression	O
directed	O
by	O
both	O
the	O
human	O
and	O
mouse	B-GENE
Rb	I-GENE
promoters	I-GENE
is	O
restricted	O
to	O
a	O
subset	O
of	O
tissues	O
in	O
which	O
Rb	B-GENE
is	O
normally	O
expressed	O
during	O
embryogenesis	O
.	O

Thus	O
,	O
Tax1	B-GENE
activates	O
CArG	O
-	O
mediated	O
transcription	O
without	O
mitogenic	O
signals	O
through	O
interaction	O
with	O
a	O
CArG	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
,	O
p67SRF	B-GENE
.	O

In	O
experiment	O
1	O
,	O
subjects	O
were	O
required	O
to	O
discriminate	O
male	O
from	O
female	O
faces	O
and	O
no	O
hemispheric	O
asymmetries	O
were	O
found	O
.	O

Membrane	O
depolarization	O
is	O
a	O
critical	O
element	O
of	O
neuronal	O
signaling	O
.	O

The	O
transcription	O
start	O
site	O
was	O
localized	O
224	O
bp	O
upstream	O
the	O
ATG	O
codon	O
by	O
RNase	B-GENE
protection	O
and	O
primer	O
extension	O
mapping	O
.	O

All	O
the	O
cognate	O
gene	O
clones	O
were	O
constructed	O
,	O
using	O
either	O
PCR	O
products	O
amplified	O
from	O
genomic	O
DNA	O
,	O
or	O
gap	O
-	O
repair	O
.	O

Rising	O
antibody	O
titres	O
to	O
the	O
astrovirus	O
particles	O
were	O
demonstrated	O
in	O
one	O
child	O
,	O
and	O
IgM	B-GENE
was	O
also	O
demonstrated	O
in	O
this	O
patient	O
'	O
s	O
serum	O
.	O

Effect	O
of	O
isobarin	O
on	O
electrocardiographic	O
indices	O
in	O
hypertensive	O
disease	O

Although	O
RAD17	B-GENE
,	O
RAD24	B-GENE
and	O
MEC3	B-GENE
are	O
not	O
required	O
for	O
cell	O
cycle	O
arrest	O
when	O
S	O
phase	O
is	O
inhibited	O
by	O
hydroxyurea	O
(	O
HU	O
)	O
,	O
they	O
do	O
contribute	O
to	O
the	O
viability	O
of	O
yeast	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
HU	O
,	O
possibly	O
because	O
they	O
are	O
required	O
for	O
the	O
repair	O
of	O
HU	O
-	O
induced	O
DNA	O
damage	O
.	O

Long	O
chain	O
acyl	O
-	O
CoA	O
esters	O
are	O
important	O
intermediates	O
in	O
degradation	O
and	O
synthesis	O
of	O
fatty	O
acids	O
,	O
as	O
well	O
as	O
having	O
important	O
functions	O
in	O
regulation	O
of	O
intermediary	O
metabolism	O
and	O
gene	O
expression	O
.	O

PTP1	B-GENE
-	O
lacZ	B-GENE
studies	O
indicate	O
that	O
PTP1	B-GENE
is	O
spatially	O
localized	O
to	O
prestalk	O
and	O
anterior	O
-	O
like	O
cell	O
types	O
.	O

When	O
translated	O
in	O
-	O
frame	O
with	O
PKC	B-GENE
zeta	I-GENE
,	O
a	O
stop	O
codon	O
is	O
located	O
28	O
amino	O
acids	O
towards	O
the	O
N	O
-	O
terminus	O
of	O
the	O
divergence	O
point	O
and	O
the	O
intervening	O
sequence	O
lacks	O
an	O
expected	O
initiating	O
methionine	O
.	O
psi	B-GENE
PKC	I-GENE
zeta	I-GENE
is	O
non	O
-	O
functional	O
in	O
terms	O
of	O
protein	O
synthesis	O
since	O
Western	O
blotting	O
with	O
an	O
antibody	O
directed	O
against	O
the	O
C	O
-	O
terminus	O
of	O
PKC	B-GENE
zeta	I-GENE
failed	O
to	O
reveal	O
a	O
protein	O
smaller	O
than	O
PKC	B-GENE
zeta	I-GENE
,	O
and	O
synthetic	O
psi	B-GENE
PKC	I-GENE
zeta	I-GENE
RNA	I-GENE
failed	O
to	O
support	O
protein	O
synthesis	O
in	O
a	O
translation	O
system	O
in	O
vitro	O
.	O

W	O
.	O
,	O
and	O
Touster	O
,	O
O	O
.	O

Electrically	O
induced	O
undulations	O
and	O
their	O
competition	O
with	O
electrically	O
induced	O
convection	O
in	O
cholesteric	O
liquid	O
crystals	O
.	O

The	O
sequence	O
immediately	O
upstream	O
of	O
the	O
translation	O
start	O
site	O
was	O
G	O
+	O
C	O
rich	O
(	O
greater	O
than	O
75	O
%	O
)	O
and	O
contained	O
a	O
consensus	O
CCAAT	O
sequence	O
despite	O
the	O
absence	O
of	O
a	O
TATA	O
box	O
.	O

These	O
conditions	O
may	O
determine	O
an	O
increase	O
in	O
the	O
level	O
of	O
indoor	O
pollutants	O
(	O
tobacco	O
smoke	O
,	O
gases	O
produced	O
by	O
cooling	O
processes	O
etc	O
.	O
)	O
and	O
of	O
allergens	O
derived	O
from	O
mites	O
,	O
domestic	O
animals	O
and	O
cockroaches	O
.	O

Nevertheless	O
,	O
lower	O
doses	O
which	O
alone	O
were	O
lacking	O
in	O
activity	O
(	O
100	O
-	O
250	O
mg	O
/	O
kg	O
B1	O
and	O
B6	O
,	O
1	O
-	O
2	O
.	O
5	O
mg	O
/	O
kg	O
B12	O
p	O
.	O
o	O
.	O
)	O
dose	O
-	O
dependently	O
potentiated	O
the	O
antinociceptive	O
of	O
diclofenac	O
.	O

For	O
O3	O
,	O
the	O
correlation	O
between	O
personal	O
exposures	O
and	O
ambient	O
levels	O
was	O
weakest	O
in	O
the	O
winter	O
for	O
residential	O
microenvironments	O
(	O
rs	O
=	O
0	O
.	O
05	O
,	O
p	O
>	O
0	O
.	O
05	O
)	O
,	O
and	O
was	O
strongest	O
in	O
the	O
summer	O
for	O
outdoor	O
near	O
-	O
roadway	O
microenvironments	O
(	O
rs	O
=	O
0	O
.	O
91	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Changes	O
in	O
water	O
and	O
electrolyte	O
content	O
of	O
the	O
brain	O
and	O
edema	O
formation	O
after	O
acute	O
,	O
drug	O
-	O
induced	O
hypertension	O
were	O
studied	O
in	O
albino	O
rabbits	O
.	O

Like	O
Rev	B-GENE
-	O
Erb	B-GENE
,	O
BD73	B-GENE
binds	O
as	O
a	O
monomer	O
to	O
a	O
DNA	O
sequence	O
which	O
consists	O
of	O
a	O
specific	O
A	O
/	O
T	O
-	O
rich	O
sequence	O
upstream	O
of	O
the	O
consensus	O
hexameric	O
half	O
-	O
site	O
specified	O
by	O
the	O
P	O
box	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
.	O

In	O
contrast	O
,	O
the	O
holo	B-GENE
-	I-GENE
dTFIIA	I-GENE
(	O
L	O
/	O
S	O
)	O
binds	O
TBP	B-GENE
with	O
high	O
affinity	O
.	O

Overexpression	O
of	O
wild	O
type	O
and	O
SeCys	O
/	O
Cys	O
mutant	O
of	O
human	B-GENE
thioredoxin	I-GENE
reductase	I-GENE
in	O
E	O
.	O
coli	O
:	O
the	O
role	O
of	O
selenocysteine	O
in	O
the	O
catalytic	O
activity	O
.	O

Biopsy	O
of	O
the	O
lesion	O
revealed	O
granulomatous	O
inflammation	O
and	O
numerous	O
septate	O
hyphae	O
.	O

Western	O
and	O
immunocytochemical	O
analysis	O
implied	O
that	O
PREB	B-GENE
accumulates	O
specifically	O
in	O
GH3	O
cell	O
nuclei	O
.	O

Two	O
genes	O
from	O
the	O
family	O
encoding	O
mouse	B-GENE
ribosomal	I-GENE
protein	I-GENE
S16	I-GENE
were	O
cloned	O
,	O
sequenced	O
,	O
and	O
analyzed	O
.	O

A	O
novel	O
serine	B-GENE
kinase	I-GENE
activated	O
by	O
rac1	B-GENE
/	O
CDC42Hs	B-GENE
-	O
dependent	O
autophosphorylation	O
is	O
related	O
to	O
PAK65	B-GENE
and	O
STE20	B-GENE
.	O

The	O
deduced	O
gene	O
product	O
was	O
found	O
to	O
have	O
significant	O
sequence	O
similarity	O
to	O
the	O
yeast	B-GENE
and	I-GENE
prokaryotic	I-GENE
RNA	I-GENE
polymerase	I-GENE
subunits	I-GENE
involved	O
with	O
subunit	O
assembly	O
.	O

Maximum	O
overexpression	O
of	O
holoenzyme	O
activity	O
was	O
achieved	O
by	O
the	O
inclusion	O
in	O
such	O
plasmids	O
of	O
Salmonella	O
typhimurium	O
cysG	O
,	O
which	O
encodes	O
a	O
uroporphyrinogen	B-GENE
III	I-GENE
methyltransferase	I-GENE
required	O
for	O
the	O
synthesis	O
of	O
siroheme	O
,	O
a	O
cofactor	O
for	O
the	O
hemoprotein	O
.	O

Overexpression	O
of	O
SNURF	B-GENE
in	O
cultured	O
mammalian	O
cells	O
enhanced	O
not	O
only	O
androgen	O
,	O
glucocorticoid	O
,	O
and	O
progesterone	B-GENE
receptor	I-GENE
-	O
dependent	O
transactivation	O
but	O
also	O
basal	O
transcription	O
from	O
steroid	O
-	O
regulated	O
promoters	O
.	O

The	O
human	O
protein	O
binds	O
most	O
strongly	O
to	O
the	O
SH3	B-GENE
domain	I-GENE
from	O
the	O
abl	B-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
.	O

Suprapubic	O
and	O
intravesical	O
methods	O

These	O
data	O
show	O
that	O
tyrosine	O
phosphorylation	O
by	O
FES	B-GENE
affects	O
the	O
interaction	O
of	O
BCR	B-GENE
with	O
multiple	O
signaling	O
partners	O
and	O
suggest	O
a	O
general	O
role	O
for	O
BCR	B-GENE
in	O
non	O
-	O
receptor	O
protein	B-GENE
-	I-GENE
tyrosine	I-GENE
kinase	I-GENE
regulation	O
and	O
signal	O
transduction	O
.	O

We	O
have	O
shown	O
that	O
the	O
human	O
cell	O
MRC	O
closely	O
resembles	O
the	O
murine	O
cell	O
MRC	O
,	O
in	O
both	O
its	O
protein	O
composition	O
and	O
its	O
fractionation	O
and	O
chromatographic	O
profile	O
.	O

From	O
1977	O
to	O
1985	O
,	O
42	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
anal	O
canal	O
were	O
treated	O
with	O
mitomycin	O
C	O
(	O
15	O
mg	O
/	O
m2	O
)	O
and	O
5	O
-	O
fluorouracil	O
(	O
750	O
mg	O
/	O
m2	O
)	O
on	O
day	O
1	O
,	O
5	O
-	O
FU	O
(	O
750	O
mg	O
/	O
m2	O
/	O
d	O
)	O
alone	O
on	O
days	O
2	O
to	O
5	O
,	O
and	O
radiation	O
therapy	O
(	O
3000	O
cGy	O
)	O
on	O
days	O
7	O
to	O
28	O
.	O

For	O
any	O
given	O
age	O
,	O
high	O
-	O
stressed	O
plantaris	O
tendons	O
were	O
of	O
a	O
higher	O
fatigue	O
quality	O
than	O
low	O
-	O
stressed	O
extensor	O
tendons	O
.	O

In	O
addition	O
to	O
TAK1	B-GENE
,	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
also	O
stimulated	O
JNK	B-GENE
activity	O
.	O

Foamy	O
viruses	O
(	O
FVs	O
)	O
express	O
the	O
Gag	B-GENE
protein	I-GENE
as	O
a	O
precursor	O
with	O
a	O
molecular	O
mass	O
of	O
74	O
kDa	O
(	O
pr74	B-GENE
)	O
from	O
which	O
a	O
70	O
-	O
kDa	O
protein	O
(	O
p70	B-GENE
)	O
is	O
cleaved	O
by	O
the	O
viral	O
protease	O
.	O

Our	O
results	O
suggest	O
that	O
at	O
least	O
some	O
chloroplast	B-GENE
-	I-GENE
like	I-GENE
tRNA	I-GENE
genes	I-GENE
in	O
wheat	O
mtDNA	O
are	O
transcribed	O
,	O
with	O
transcripts	O
undergoing	O
processing	O
,	O
post	O
-	O
transcriptional	O
modification	O
and	O
3	O
'	O
-	O
CCA	O
addition	O
,	O
to	O
produce	O
mature	O
tRNAs	O
that	O
may	O
participate	O
in	O
mitochondrial	O
protein	O
synthesis	O
.	O

If	O
,	O
however	O
,	O
myocardial	O
stunning	O
is	O
severe	O
,	O
and	O
it	O
involves	O
large	O
parts	O
of	O
the	O
LV	O
and	O
thus	O
impairs	O
global	O
LV	O
function	O
,	O
it	O
can	O
be	O
reversed	O
with	O
inotropic	O
agents	O
and	O
procedures	O
.	O

268	O
,	O
6858	O
-	O
6861	O
)	O
.	O

The	O
occurrence	O
of	O
the	O
different	O
types	O
of	O
TCRB	B-GENE
rearrangement	O
patterns	O
has	O
implications	O
for	O
PCR	O
-	O
based	O
clonality	O
assessment	O
and	O
for	O
PCR	O
-	O
based	O
detection	O
of	O
minimal	O
residual	O
disease	O
via	O
TCRB	B-GENE
gene	I-GENE
analysis	O
.	O

Under	O
control	O
conditions	O
,	O
pretreatment	O
with	O
lithium	O
during	O
7	O
days	O
did	O
not	O
modify	O
the	O
hyperlocomotion	O
produced	O
by	O
d	O
-	O
amphetamine	O
.	O

Six	O
patients	O
underwent	O
an	O
electrophysiologic	O
study	O
.	O

Rats	O
on	O
the	O
multiple	O
oral	O
dosage	O
regimen	O
were	O
given	O
unlabelled	O
HMCF	O
in	O
their	O
drinking	O
water	O
for	O
13	O
days	O
before	O
the	O
administration	O
of	O
a	O
bolus	O
dose	O
of	O
[	O
14C	O
]	O
HMCF	O
on	O
day	O
14	O
.	O

After	O
multivariate	O
analysis	O
,	O
TWA	O
correlated	O
with	O
age	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
LV	O
function	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
and	O
occurred	O
more	O
often	O
in	O
patients	O
after	O
nonanterior	O
MI	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

No	O
patient	O
demonstrated	O
a	O
decrease	O
in	O
bone	O
marrow	O
fibrosis	O
as	O
determined	O
by	O
serial	O
procollagen	B-GENE
(	O
PC	B-GENE
III	I-GENE
)	O
serum	O
level	O
analysis	O
.	O

Asthma	O
diagnoses	O
were	O
made	O
according	O
to	O
recommended	O
National	O
Asthma	O
Expert	O
Panel	O
Guidelines	O
.	O

Charcot	O
joints	O
.	O

Idealized	O
versus	O
realized	O
overall	O
treatment	O
times	O
.	O

Non	O
-	O
suppressed	O
thyroidal	O
radioactive	O
iodine	O
uptake	O
(	O
RAIU	O
)	O
in	O
thyrotoxic	O
phase	O
in	O
a	O
case	O
of	O
subacute	O
thyroiditis	O
with	O
thyroid	O
-	O
stimulating	O
antibodies	O
(	O
TSAb	O
)	O
.	O

Ultra	O
-	O
energy	O
(	O
UHE	O
)	O
imaging	O
is	O
usually	O
performed	O
in	O
simultaneous	O
F	O
-	O
18	O
FDG	O
/	O
Tc	O
-	O
99m	O
MIBI	O
studies	O
.	O

Bilateral	O
renal	O
oncocytoma	O
in	O
a	O
Greyhound	O
dog	O
.	O

Uncoupling	O
gene	O
activity	O
from	O
chromatin	O
structure	O
:	O
promoter	O
mutations	O
can	O
inactivate	O
transcription	O
of	O
the	O
yeast	B-GENE
HSP82	I-GENE
gene	I-GENE
without	O
eliminating	O
nucleosome	O
-	O
free	O
regions	O
.	O

Ectopic	O
expression	O
of	O
cyclin	B-GENE
D1	I-GENE
in	O
progestin	O
-	O
inhibited	O
cells	O
led	O
to	O
the	O
reappearance	O
of	O
the	O
120	O
-	O
kDa	O
active	O
form	O
of	O
cyclin	B-GENE
E	I-GENE
-	O
Cdk2	B-GENE
preceding	O
the	O
resumption	O
of	O
cell	O
cycle	O
progression	O
.	O

Unlike	O
these	O
contaminant	O
-	O
responsive	O
T	O
cells	O
,	O
those	O
that	O
are	O
truly	O
specific	O
for	O
natural	O
AChR	B-GENE
epitopes	I-GENE
appear	O
less	O
heterogeneous	O
and	O
therefore	O
more	O
suitable	O
targets	O
for	O
selective	O
immunotherapy	O
.	O

Because	O
the	O
wa	B-GENE
-	I-GENE
2	I-GENE
mutation	I-GENE
was	O
mapped	O
previously	O
to	O
the	O
vicinity	O
of	O
the	O
EGF	B-GENE
/	I-GENE
TGF	I-GENE
-	I-GENE
alpha	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
gene	O
on	O
mouse	O
chromosome	O
11	O
,	O
we	O
hypothesized	O
that	O
the	O
wa	B-GENE
-	I-GENE
2	I-GENE
phenotype	I-GENE
might	O
result	O
from	O
a	O
defect	O
in	O
either	O
the	O
expression	O
or	O
activity	O
of	O
EGFR	B-GENE
,	O
or	O
both	O
.	O

Region	O
I	O
includes	O
the	O
two	O
cysteine	O
-	O
cysteine	O
zinc	O
fingers	O
that	O
comprise	O
a	O
DNA	O
-	O
binding	O
domain	O
which	O
typifies	O
all	O
members	O
of	O
the	O
superfamily	O
.	O

Southern	O
zoo	O
blot	O
analysis	O
indicated	O
that	O
ZNF236	B-GENE
is	O
conserved	O
in	O
the	O
genomes	O
of	O
all	O
mammalian	O
species	O
tested	O
,	O
but	O
not	O
in	O
yeast	O
.	O

RNA	O
determinants	O
required	O
for	O
L4	B-GENE
-	O
mediated	O
attenuation	O
control	O
of	O
the	O
S10	B-GENE
r	I-GENE
-	I-GENE
protein	I-GENE
operon	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

Spodoptera	O
frugiperda	O
(	O
Sf9	O
)	O
cells	O
have	O
proved	O
a	O
suitable	O
cell	O
system	O
in	O
which	O
to	O
study	O
this	O
association	O
and	O
to	O
produce	O
recombinant	B-GENE
CR3	I-GENE
,	O
and	O
we	O
show	O
here	O
that	O
another	O
lepidopteran	O
cell	O
line	O
,	O
Trichoplusia	O
niTN	O
-	O
5B1	O
-	O
4	O
(	O
High	O
-	O
Five	O
)	O
cells	O
,	O
allows	O
the	O
recovery	O
of	O
large	O
amounts	O
of	O
functional	B-GENE
recombinant	I-GENE
CR3	I-GENE
.	O

INTERVENTIONS	O
:	O
Postoperative	O
follow	O
-	O
up	O
consisted	O
of	O
serial	O
determination	O
of	O
different	O
biochemical	O
markers	O
(	O
CK	B-GENE
,	O
CK	B-GENE
-	I-GENE
MB	I-GENE
,	O
cTnI	B-GENE
)	O
,	O
ECGs	O
,	O
and	O
echocardiography	O
.	O

At	O
the	O
first	O
phase	O
(	O
1	O
-	O
43	O
ms	O
for	O
the	O
VMN	O
and	O
1	O
-	O
10	O
ms	O
for	O
the	O
LN	O
)	O
the	O
hypothalamic	O
-	O
cortical	O
responses	O
completely	O
inhibited	O
the	O
formation	O
of	O
the	O
VC	O
response	O
to	O
the	O
light	O
stimulus	O
.	O

6	O
,	O
320	O
cells	O
/	O
mm3	O
,	O
respectively	O
;	O
P	O
less	O
than	O
.	O
005	O
)	O
;	O
twelve	O
(	O
86	O
%	O
)	O
of	O
the	O
14	O
inmates	O
who	O
developed	O
AIDS	O
had	O
counts	O
of	O
less	O
than	O
5	O
,	O
000	O
cells	O
/	O
mm3	O
,	O
compared	O
with	O
only	O
six	O
(	O
14	O
%	O
)	O
of	O
the	O
42	O
controls	O
(	O
P	O
less	O
than	O
.	O
00001	O
)	O
.	O

There	O
is	O
,	O
however	O
,	O
uncertainty	O
as	O
to	O
how	O
results	O
obtained	O
in	O
recent	O
experiments	O
scale	O
up	O
to	O
landscape	O
and	O
regional	O
levels	O
and	O
generalize	O
across	O
ecosystem	O
types	O
and	O
processes	O
.	O

The	O
facilitation	O
started	O
preceding	O
the	O
onset	O
of	O
electromyographic	O
activity	O
of	O
the	O
masseter	O
muscle	O
.	O

The	O
recruitment	O
of	O
constitutively	O
phosphorylated	O
p185	B-GENE
(	O
neu	B-GENE
)	O
and	O
the	O
activated	O
mitogenic	O
pathway	O
proteins	O
to	O
this	O
membrane	O
-	O
microfilament	O
interaction	O
site	O
provides	O
a	O
physical	O
model	O
for	O
integrating	O
the	O
assembly	O
of	O
the	O
mitogenic	O
pathway	O
with	O
the	O
transmission	O
of	O
growth	O
factor	O
signal	O
to	O
the	O
cytoskeleton	O
.	O

Deletion	O
of	O
the	O
region	O
from	O
amino	O
acid	O
residues	O
2	O
-	O
67	O
in	O
E1A	B-GENE
,	O
which	O
has	O
been	O
postulated	O
to	O
interact	O
with	O
p300	B-GENE
/	O
CBP	B-GENE
,	O
also	O
abolished	O
the	O
inhibitory	O
effect	O
of	O
E1A	B-GENE
,	O
whereas	O
deletion	O
of	O
the	O
region	O
from	O
residues	O
120	O
to	O
140	O
had	O
no	O
effect	O
.	O

Quantitative	O
Tl	O
-	O
201	O
analysis	O
after	O
stress	O
has	O
also	O
shown	O
viable	O
myocardium	O
in	O
most	O
mild	O
to	O
moderate	O
(	O
51	O
%	O
to	O
85	O
%	O
of	O
normal	O
uptake	O
)	O
irreversible	O
Tl	O
-	O
201	O
defects	O
.	O

The	O
point	O
mutation	O
Asp	O
-	O
316	O
-	O
-	O
>	O
Asn	O
in	O
the	O
C	O
-	O
terminus	O
of	O
p38	B-GENE
,	O
analogous	O
to	O
the	O
ERK2	B-GENE
(	O
extracellular	B-GENE
-	I-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
2	I-GENE
)	O
sevenmaker	B-GENE
mutation	O
,	O
dramatically	O
decreases	O
its	O
binding	O
to	O
MKP	B-GENE
-	I-GENE
1	I-GENE
and	O
substantially	O
compromises	O
its	O
stimulatory	O
effect	O
on	O
the	O
catalytic	O
activity	O
of	O
this	O
phosphatase	O
.	O

J	O
.	O

Causal	O
modeling	O
combines	O
theory	O
and	O
research	O
,	O
and	O
because	O
the	O
interpretation	O
of	O
data	O
is	O
possible	O
only	O
within	O
the	O
context	O
of	O
the	O
proposed	O
theory	O
,	O
it	O
offers	O
an	O
important	O
method	O
for	O
advancing	O
the	O
science	O
while	O
maintaining	O
the	O
specificity	O
of	O
the	O
practice	O
.	O

In	O
one	O
trial	O
,	O
116	O
subjects	O
with	O
transfusion	O
-	O
related	O
chronic	O
hepatitis	O
C	O
were	O
treated	O
with	O
lymphoblastoid	B-GENE
interferon	I-GENE
(	O
5	O
MU	O
/	O
m2	O
three	O
times	O
a	O
week	O
for	O
2	O
mo	O
,	O
then	O
3	O
MU	O
/	O
m2	O
three	O
times	O
a	O
week	O
for	O
4	O
or	O
10	O
mo	O
)	O
.	O

A	O
derived	O
RA	O
-	O
resistant	O
line	O
,	O
NT2	O
/	O
D1	O
-	O
R1	O
,	O
is	O
deficient	O
in	O
this	O
activity	O
and	O
is	O
co	O
-	O
resistant	O
to	O
cisplatin	O
.	O

BCR	B-GENE
-	O
ABL	B-GENE
elicits	O
transformation	O
of	O
both	O
fibroblast	O
and	O
hematopoietic	O
cells	O
and	O
blocks	O
apoptosis	O
following	O
cytokine	O
deprivation	O
in	O
various	O
factor	O
-	O
dependent	O
cells	O
.	O

Aggregation	O
in	O
washed	O
platelets	O
from	O
rats	O
with	O
diabetes	O
was	O
enhanced	O
.	O

Sequence	O
analysis	O
of	O
this	O
region	O
showed	O
it	O
contained	O
five	O
potential	O
copies	O
of	O
the	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
-	O
1	O
)	O
(	O
Smith	O
,	O
J	O
.	O
R	O
.	O
,	O
Osborne	O
,	O
T	O
.	O
F	O
.	O
,	O
Brown	O
,	O
M	O
.	O
S	O
.	O
,	O
Goldstein	O
,	O
J	O
.	O
L	O
.	O
,	O
and	O
Gil	O
,	O
G	O
.	O

Mutations	O
in	O
Saccharomyces	O
cerevisiae	O
that	O
block	O
meiotic	O
prophase	O
chromosome	O
metabolism	O
and	O
confer	O
cell	O
cycle	O
arrest	O
at	O
pachytene	O
identify	O
two	O
new	O
meiosis	B-GENE
-	I-GENE
specific	I-GENE
genes	I-GENE
SAE1	I-GENE
and	O
SAE3	B-GENE
.	O

Isolation	O
and	O
characterization	O
of	O
human	O
orthologs	O
of	O
yeast	O
CCR4	B-GENE
-	O
NOT	B-GENE
complex	O
subunits	O
.	O

Thus	O
,	O
the	O
i	B-GENE
-	I-GENE
leader	I-GENE
protein	I-GENE
is	O
a	O
viral	O
gene	O
product	O
of	O
unknown	O
function	O
and	O
high	O
stability	O
that	O
is	O
made	O
in	O
large	O
quantities	O
at	O
intermediate	O
times	O
of	O
productive	O
infection	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

CONCLUSIONS	O
:	O
Latanoprost	O
administered	O
once	O
daily	O
was	O
significantly	O
more	O
effective	O
in	O
reducing	O
IOP	O
compared	O
with	O
unoprostone	O
administered	O
twice	O
daily	O
in	O
patients	O
with	O
POAG	O
and	O
OH	O
.	O

The	O
molecular	O
dynamics	O
simulations	O
provide	O
insight	O
into	O
the	O
conformational	O
flexibility	O
of	O
these	O
analogs	O
.	O

In	O
alfalfa	O
,	O
the	O
insecticides	O
caused	O
significant	O
mortality	O
to	O
most	O
of	O
the	O
insects	O
evaluated	O
.	O

Therefore	O
,	O
we	O
have	O
reevaluated	O
the	O
age	O
-	O
related	O
changes	O
in	O
serum	B-GENE
leptin	I-GENE
levels	O
and	O
their	O
relationship	O
with	O
adiposity	O
and	O
androgen	O
levels	O
in	O
a	O
large	O
group	O
of	O
community	O
dwelling	O
men	O
.	O

Injections	O
of	O
PD	O
solutions	O
with	O
13	O
.	O
6	O
,	O
22	O
.	O
7	O
,	O
and	O
38	O
.	O
6	O
g	O
/	O
liter	O
of	O
glucose	O
reduced	O
the	O
ingestion	O
of	O
sucrose	O
by	O
12	O
.	O
4	O
%	O
,	O
23	O
.	O
6	O
%	O
and	O
36	O
.	O
1	O
%	O
,	O
respectively	O
,	O
but	O
did	O
not	O
affect	O
the	O
ingestion	O
of	O
protein	O
.	O

It	O
is	O
recommended	O
that	O
area	O
correction	O
be	O
attempted	O
in	O
bioequivalence	O
studies	O
of	O
drugs	O
where	O
high	O
intrasubject	O
variability	O
in	O
clearance	O
is	O
known	O
or	O
suspected	O
.	O

Expression	O
of	O
the	O
E2	B-GENE
protein	I-GENE
resulted	O
in	O
rapid	O
repression	O
of	O
HPV	B-GENE
E6	I-GENE
and	O
E7	B-GENE
expression	O
,	O
followed	O
approximately	O
12	O
h	O
later	O
by	O
profound	O
inhibition	O
of	O
cellular	O
DNA	O
synthesis	O
.	O

Plasma	B-GENE
renin	I-GENE
activity	O
in	O
end	O
-	O
stage	O
kidney	O
disease	O
.	O

Immunoblotting	O
with	O
antiphosphotyrosine	O
antibody	O
showed	O
that	O
many	O
yeast	O
proteins	O
,	O
including	O
the	O
p34CDC28	B-GENE
kinase	I-GENE
,	O
became	O
phosphorylated	O
at	O
tyrosine	O
in	O
cells	O
expressing	O
v	B-GENE
-	I-GENE
src	I-GENE
.	O

Renal	O
cell	O
carcinoma	O
induced	O
Coombs	O
negative	O
autoimmune	O
hemolytic	O
anemia	O
and	O
severe	O
thrombocytopenia	O
responsive	O
to	O
nephrectomy	O
.	O

Pretreatment	O
of	O
rats	O
with	O
different	O
dose	O
levels	O
of	O
CCl4	O
resulted	O
in	O
a	O
prolongation	O
of	O
TMO	O
half	O
-	O
life	O
,	O
and	O
increase	O
of	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
,	O
and	O
a	O
decrease	O
of	O
clearance	O
,	O
but	O
the	O
apparent	O
volume	O
of	O
distribution	O
(	O
Vd	O
)	O
was	O
not	O
significantly	O
decreased	O
.	O

In	O
cells	O
co	O
-	O
expressing	O
high	O
levels	O
of	O
the	O
p38	B-GENE
(	O
MAPK	B-GENE
)	O
kinase	O
(	O
MKK3	B-GENE
)	O
together	O
with	O
the	O
p38	B-GENE
(	O
MAPK	B-GENE
)	O
,	O
a	O
significant	O
inhibition	O
of	O
mitogen	O
-	O
induced	O
cyclin	B-GENE
D1	I-GENE
expression	O
was	O
observed	O
.	O

In	O
patients	O
autografted	O
in	O
CR1	O
,	O
the	O
transplant	O
-	O
related	O
mortality	O
(	O
TRM	O
)	O
was	O
15	O
+	O
/	O
-	O
4	O
%	O
,	O
the	O
relapse	O
incidence	O
(	O
RI	O
)	O
was	O
58	O
+	O
/	O
-	O
5	O
%	O
,	O
the	O
leukaemia	O
-	O
free	O
survival	O
(	O
LFS	O
)	O
was	O
36	O
+	O
/	O
-	O
5	O
%	O
and	O
the	O
overall	O
survival	O
was	O
47	O
+	O
/	O
-	O
5	O
%	O
at	O
3	O
years	O
.	O

Administration	O
of	O
FR	O
34235	O
reduced	O
aortic	O
blood	O
pressure	O
and	O
increased	O
cardiac	O
output	O
in	O
anesthetized	O
dogs	O
with	O
an	O
ameroid	O
-	O
induced	O
coronary	O
artery	O
occlusion	O
.	O

The	O
primary	O
conditions	O
for	O
acceptable	O
hospital	O
use	O
were	O
that	O
exhaled	O
-	O
volume	O
monitoring	O
be	O
performed	O
for	O
all	O
patients	O
and	O
that	O
O2	O
monitoring	O
be	O
performed	O
both	O
when	O
setting	O
FIO2	O
and	O
continuously	O
when	O
FIO2	O
levels	O
are	O
critical	O
.	O

The	O
RHO1	B-GENE
gene	I-GENE
encodes	O
a	O
homolog	O
of	O
the	O
mammalian	O
RhoA	B-GENE
small	I-GENE
GTP	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

As	O
regards	O
the	O
short	O
stature	O
,	O
they	O
have	O
proved	O
that	O
the	O
syndrome	O
is	O
related	O
to	O
low	O
levels	O
of	O
somatomedin	B-GENE
C	I-GENE
(	O
SmC	B-GENE
)	O
.	O

2	O
.	O

Menstrual	O
and	O
lunar	O
cycles	O
.	O

HBO	O
had	O
marked	O
effects	O
on	O
these	O
enzymes	O
:	O
lung	B-GENE
SOD	I-GENE
increased	O
(	O
guinea	O
pigs	O
47	O
%	O
,	O
rats	O
88	O
%	O
)	O
and	O
CAT	B-GENE
and	O
GSHPx	B-GENE
activities	O
decreased	O
(	O
33	O
%	O
)	O
in	O
brain	O
and	O
lung	O
.	O

Smectic	O
-	O
A	O
ordering	O
at	O
a	O
liquid	O
-	O
vapor	O
interface	O
.	O

Phylogenetic	O
analysis	O
of	O
yeast	O
,	O
invertebrate	O
,	O
and	O
multiple	O
mammalian	O
isoforms	O
of	O
SNF4	B-GENE
shows	O
that	O
the	O
gene	O
duplication	O
likely	O
occurred	O
early	O
in	O
the	O
metazoan	O
lineage	O
,	O
as	O
the	O
protein	O
products	O
of	O
the	O
different	O
loci	O
are	O
relatively	O
divergent	O
.	O

Hard	O
methacrylic	O
polymers	O
.	O

Thus	O
the	O
Hi	O
-	O
RARE	O
represents	O
a	O
new	O
type	O
of	O
RA	O
response	O
element	O
with	O
a	O
role	O
in	O
the	O
modulation	O
of	O
the	O
expression	O
of	O
MHC	B-GENE
class	I-GENE
1	I-GENE
family	O
genes	O
.	O

We	O
found	O
multiple	O
transcription	O
start	O
sites	O
located	O
within	O
a	O
15	O
-	O
base	O
pair	O
region	O
,	O
205	O
base	O
pairs	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
.	O

During	O
the	O
last	O
three	O
days	O
of	O
the	O
study	O
,	O
mean	O
urine	O
osmolality	O
(	O
Uosm	O
)	O
and	O
free	O
water	O
reabsorption	O
(	O
TCH2O	O
)	O
increased	O
significantly	O
:	O
[	O
formula	O
:	O
see	O
text	O
]	O
.	O

The	O
structural	O
intestinal	O
defects	O
are	O
presumed	O
to	O
be	O
the	O
result	O
of	O
defective	O
collagen	B-GENE
synthesis	O
in	O
these	O
hereditary	O
connective	O
tissue	O
disorders	O
.	O

Rev	O
.	O

Although	O
indomethacin	O
is	O
useful	O
for	O
examining	O
the	O
role	O
of	O
cyclooxygenase	B-GENE
products	I-GENE
in	O
asthmatic	O
responses	O
,	O
it	O
should	O
not	O
be	O
considered	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Incidence	O
of	O
beta	O
-	O
thalassemia	O
carriers	O
and	O
those	O
deficient	O
in	O
erythrocyte	B-GENE
glucose	I-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
in	O
the	O
greater	O
Buenos	O
Aires	O
area	O

Both	O
v	B-GENE
-	I-GENE
Myb	I-GENE
and	O
c	B-GENE
-	I-GENE
Myb	I-GENE
bind	O
specifically	O
to	O
delta	B-GENE
E3	I-GENE
.	O

Anatomical	O
considerations	O
in	O
transsphenoidal	O
hypophysectomy	O
.	O

The	O
salt	O
sensitivity	O
of	O
the	O
interaction	O
indicated	O
that	O
two	O
ion	O
pairs	O
are	O
involved	O
in	O
the	O
association	O
of	O
Zn2	O
+	O
(	O
NC	O
-	O
F1	O
)	O
with	O
polynucleotide	O
,	O
whereas	O
one	O
ion	O
pair	O
is	O
found	O
in	O
the	O
metal	O
-	O
free	O
peptide	O
-	O
nucleic	O
acid	O
complex	O
.	O

Investigation	O
on	O
the	O
asymmetrical	O
induced	O
yields	O
in	O
90Sr	O
-	O
90Y	O
-	O
beta	O
-	O
irradiated	O
D	O
-	O
and	O
L	O
-	O
alanines	O
.	O

An	O
hcr1	B-GENE
null	O
mutant	O
was	O
viable	O
,	O
but	O
showed	O
slight	O
reduction	O
of	O
growth	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Serum	O
levels	O
of	O
total	O
and	O
specific	B-GENE
immunoglobulin	I-GENE
E	I-GENE
(	O
IgE	B-GENE
)	O
have	O
been	O
determined	O
by	O
radioimmunoassays	O
in	O
sixty	O
-	O
nine	O
allergic	O
subjects	O
.	O

IgE	B-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
of	O
Psocoptera	O
were	O
determined	O
by	O
immunoblotting	O
experiments	O
.	O

We	O
also	O
show	O
that	O
the	O
products	O
of	O
both	O
the	O
GIY	B-GENE
-	I-GENE
YIG	I-GENE
ORF	O
and	O
the	O
non	O
-	O
canonical	O
LAGLI	B-GENE
-	I-GENE
DADG	I-GENE
-	I-GENE
GIY	I-GENE
-	I-GENE
YIG	I-GENE
ORF	O
,	O
which	O
is	O
generated	O
by	O
its	O
integration	O
,	O
have	O
endonuclease	O
activities	O
which	O
recognize	O
and	O
cut	O
the	O
insertion	O
site	O
of	O
the	O
optional	O
sequence	O
.	O

Further	O
,	O
we	O
find	O
that	O
the	O
BMI1	B-GENE
protein	I-GENE
can	O
also	O
interact	O
with	O
itself	O
.	O

Indeed	O
,	O
ectopic	O
expression	O
of	O
MOX4	B-GENE
in	O
aerobic	O
cells	O
resulted	O
in	O
partially	O
constitutive	O
expression	O
of	O
DAN1	B-GENE
.	O

We	O
measured	O
electromyograms	O
(	O
EMG	O
)	O
of	O
the	O
alae	O
nasi	O
to	O
determine	O
the	O
relationship	O
between	O
their	O
activity	O
and	O
timing	O
to	O
contraction	O
of	O
the	O
rib	O
cage	O
muscles	O
and	O
diaphragm	O
during	O
obstructive	O
apnea	O
in	O
nine	O
patients	O
.	O

Hybridization	O
was	O
detected	O
between	O
polyadenylated	B-GENE
H	I-GENE
chain	I-GENE
mRNA	I-GENE
,	O
isolated	O
from	O
the	O
majority	O
of	O
the	O
hybridomas	O
,	O
and	O
the	O
VH	B-GENE
probe	O
.	O

Identification	O
of	O
a	O
putative	O
infC	B-GENE
-	O
rpmI	B-GENE
-	O
rplT	B-GENE
operon	O
flanked	O
by	O
long	O
inverted	O
repeats	O
in	O
Mycoplasma	O
fermentans	O
(	O
incognitus	O
strain	O
)	O
.	O

The	O
standardized	O
incidence	O
in	O
Europeans	O
has	O
risen	O
significantly	O
to	O
4	O
.	O
7	O
/	O
10	O
(	O
5	O
)	O
/	O
year	O
from	O
3	O
.	O
4	O
/	O
10	O
(	O
5	O
)	O
/	O
year	O
in	O
the	O
1970s	O
(	O
chi	O
2	O
=	O
8	O
.	O
1	O
,	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Neurological	O
toxicity	O
occurred	O
in	O
8	O
/	O
219	O
patients	O
treated	O
with	O
fludarabine	O
(	O
FAMP	O
)	O
,	O
30	O
mg	O
/	O
m2	O
per	O
day	O
and	O
cytosine	O
arabinoside	O
(	O
Ara	O
-	O
C	O
)	O
,	O
0	O
.	O
5	O
g	O
/	O
m2	O
per	O
hour	O
for	O
2	O
-	O
6	O
hours	O
for	O
5	O
days	O
,	O
for	O
new	O
or	O
relapsed	O
acute	O
leukemia	O
or	O
myelodysplasia	O
.	O

Evaluation	O
of	O
gamma	B-GENE
-	I-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
in	O
myocardial	O
infarction	O
.	O

Loss	O
of	O
pRb	B-GENE
or	O
p107	B-GENE
binding	O
results	O
in	O
the	O
loss	O
of	O
transforming	O
activity	O
.	O

The	O
analysis	O
of	O
results	O
suggests	O
that	O
seroprevalence	O
of	O
Lyme	O
borreliosis	O
in	O
dogs	O
of	O
the	O
Kosice	O
region	O
is	O
not	O
negligible	O
.	O

Peak	O
insulin	B-GENE
response	O
to	O
glucose	O
infusion	O
declined	O
from	O
Groups	O
1	O
to	O
3	O
(	O
51	O
+	O
/	O
-	O
14	O
,	O
42	O
.	O
4	O
+	O
/	O
-	O
31	O
,	O
20	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
8	O
microU	O
/	O
ml	O
,	O
respectively	O
)	O
with	O
Group	O
3	O
exhibiting	O
a	O
significantly	O
decreased	O
mean	O
peak	O
level	O
compared	O
to	O
the	O
other	O
groups	O
.	O

Iris	O
binding	O
and	O
bioavailability	O
.	O

The	O
influence	O
of	O
a	O
high	O
n	O
-	O
3	O
PUFA	O
intake	O
on	O
measures	O
of	O
lipid	O
peroxidation	O
has	O
been	O
equivocal	O
.	O

The	O
proliferative	O
potential	O
of	O
the	O
pilocytic	O
astrocytoma	O
:	O
the	O
relation	O
between	O
MIB	B-GENE
-	I-GENE
1	I-GENE
labeling	O
and	O
clinical	O
and	O
neuro	O
-	O
radiological	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
major	O
and	O
novel	O
Shc	B-GENE
tyrosine	O
phosphorylation	O
sites	O
,	O
Y239	O
and	O
Y240	O
.	O

Dominant	O
-	O
negative	O
upf1	B-GENE
mutations	O
were	O
isolated	O
following	O
in	O
vitro	O
mutagenesis	O
of	O
a	O
plasmid	O
containing	O
the	O
UPF1	B-GENE
gene	I-GENE
.	O

The	O
tensile	O
strengths	O
of	O
an	O
adhesive	O
luting	O
resin	O
'	O
Panavia	O
EX	O
'	O
to	O
the	O
bovine	O
dentin	O
decreased	O
significantly	O
by	O
the	O
zinc	O
iontophoresis	O
.	O

We	O
previously	O
identified	O
a	O
highly	O
conserved	O
L	O
-	O
X	O
-	O
X	O
-	O
L	O
-	O
F	O
sequence	O
near	O
the	O
C	O
terminus	O
of	O
the	O
p6	B-GENE
domain	I-GENE
of	O
the	O
Gag	B-GENE
precursor	I-GENE
as	O
the	O
major	O
virion	O
association	O
motif	O
for	O
HIV	B-GENE
-	I-GENE
1	I-GENE
Vpr	I-GENE
.	O

Papillomavirus	O
type	O
16	O
oncogenes	O
downregulate	O
expression	O
of	O
interferon	B-GENE
-	O
responsive	O
genes	O
and	O
upregulate	O
proliferation	O
-	O
associated	O
and	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	O
responsive	O
genes	O
in	O
cervical	O
keratinocytes	O
.	O

The	O
A3B3	O
domain	O
had	O
a	O
mass	O
of	O
34	O
,	O
462	O
,	O
with	O
a	O
glycosylation	O
mass	O
of	O
14	O
,	O
900	O
,	O
in	O
good	O
agreement	O
with	O
seven	O
N	O
-	O
linked	O
glycosylation	O
sites	O
of	O
average	O
mass	O
2100	O
.	O

We	O
found	O
that	O
the	O
frequency	O
spectrum	O
of	O
physiologic	O
chest	O
sounds	O
is	O
contained	O
entirely	O
within	O
that	O
of	O
jet	O
rotocraft	O
noise	O
.	O

The	O
human	B-GENE
CA11	I-GENE
gene	I-GENE
appears	O
to	O
be	O
located	O
between	O
the	O
secretor	B-GENE
type	I-GENE
alpha	I-GENE
(	I-GENE
1	I-GENE
,	I-GENE
2	I-GENE
)	I-GENE
-	I-GENE
fucosyltransferase	I-GENE
gene	I-GENE
cluster	I-GENE
(	O
FUT1	B-GENE
-	O
FUT2	B-GENE
-	O
FUT2P	B-GENE
)	O
and	O
the	O
D	B-GENE
-	I-GENE
site	I-GENE
binding	I-GENE
protein	I-GENE
gene	I-GENE
(	O
DBP	B-GENE
)	O
on	O
chromosome	O
19q13	O
.	O
3	O
.	O

An	O
anoerxiant	O
,	O
mazindol	O
suppresses	O
food	O
intake	O
by	O
1	O
)	O
stimulating	O
beta	B-GENE
-	I-GENE
adrenergic	I-GENE
receptors	I-GENE
,	O
2	O
)	O
inhibiting	O
the	O
feeding	O
center	O
and	O
,	O
3	O
)	O
stimulating	O
the	O
satiety	O
center	O
in	O
the	O
hypothalamus	O
.	O

These	O
segments	O
may	O
represent	O
pseudogenes	O
.	O

The	O
fusion	O
of	O
AML1	B-GENE
to	O
MDS1	B-GENE
is	O
in	O
frame	O
,	O
and	O
adds	O
127	O
codons	O
to	O
the	O
interrupted	O
AML1	B-GENE
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
the	O
antibiotic	O
lasalocid	O
on	O
the	O
rumen	O
anaerobic	O
fungus	O
Neocallimastix	O
frontalis	O
RK	O
21	O
was	O
examined	O
.	O

WBC	O
differential	O
(	O
SEG	O
,	O
BAND	O
,	O
LYMPH	O
,	O
MONO	O
,	O
EOSINO	O
,	O
BASO	O
)	O
usually	O
showed	O
log	O
-	O
normal	O
distribution	O
.	O

A	O
model	O
for	O
oligomerization	O
-	O
dependent	O
subunit	O
folding	O
.	O

Chromosome	O
-	O
specific	O
STSs	O
for	O
27	O
telomeres	O
were	O
identified	O
from	O
the	O
196	O
TYACs	O
.	O

Second	O
,	O
overexpression	O
of	O
RIM11	B-GENE
can	O
suppress	O
an	O
ime1	B-GENE
missense	O
mutation	O
(	O
ime1	B-GENE
-	I-GENE
L321F	I-GENE
)	O
but	O
not	O
an	O
ime1	B-GENE
deletion	O
.	O

Calculation	O
of	O
energy	O
levels	O
,	O
E1	O
transition	O
amplitudes	O
,	O
and	O
parity	O
violation	O
in	O
francium	O
.	O

All	O
except	O
the	O
last	O
two	O
interventions	O
are	O
physical	O
treatments	O
that	O
create	O
a	O
wound	O
-	O
tissue	O
environment	O
conducive	O
to	O
healing	O
.	O

This	O
50	O
-	O
kDa	O
protein	O
contains	O
two	O
SH2	B-GENE
domains	I-GENE
and	O
an	O
inter	B-GENE
-	I-GENE
SH2	I-GENE
domain	I-GENE
of	O
p85alpha	B-GENE
,	O
but	O
the	O
SH3	B-GENE
and	O
bcr	B-GENE
homology	I-GENE
domains	I-GENE
of	O
p85alpha	B-GENE
were	O
replaced	O
by	O
a	O
unique	O
6	O
-	O
amino	O
acid	O
sequence	O
.	O

Hydropathy	O
analysis	O
of	O
deduced	O
A4	O
amino	O
acid	O
sequence	O
revealed	O
four	O
putative	O
membrane	O
-	O
spanning	O
alpha	O
-	O
helices	O
.	O

A	O
clinical	O
double	O
-	O
blind	O
trial	O
of	O
topical	O
miconazole	O
and	O
clotrimazole	O
against	O
superficial	O
fungal	O
infections	O
and	O
erythrasma	O
.	O

Studies	O
on	O
low	O
-	O
dose	O
oral	O
contraceptives	O
:	O
cervical	O
mucus	O
and	O
plasma	O
hormone	O
changes	O
in	O
relation	O
to	O
circulating	O
D	O
-	O
norgestrel	O
and	O
17alpha	O
ethynyl	O
-	O
estradiol	O
concentrations	O
.	O

Herewith	O
C	O
.	O
psittaci	O
could	O
be	O
diagnosed	O
in	O
all	O
positive	O
samples	O
.	O

The	O
more	O
sustained	O
effect	O
of	O
cyclofenil	O
on	O
prolactin	B-GENE
secretion	O
with	O
a	O
reduced	O
frequency	O
of	O
relapse	O
,	O
and	O
the	O
lower	O
oestradiol	O
level	O
,	O
which	O
might	O
indicate	O
a	O
reduced	O
risk	O
of	O
thromboembolism	O
,	O
suggest	O
that	O
this	O
drug	O
has	O
some	O
advantage	O
over	O
bromocriptine	O
in	O
the	O
inhibition	O
of	O
postpartum	O
lactation	O
.	O

Response	O
surface	O
methodology	O
was	O
employed	O
to	O
describe	O
the	O
relationship	O
between	O
soman	O
-	O
induced	O
incapacitation	O
and	O
the	O
ATR	O
/	O
DZ	O
or	O
ATR	O
/	O
SCP	O
dosages	O
.	O

The	O
brains	O
were	O
bisected	O
and	O
T1	O
and	O
T2	O
relaxation	O
times	O
were	O
determined	O
for	O
the	O
right	O
and	O
left	O
hemispheres	O
by	O
MR	O
spectroscopy	O
immediately	O
after	O
dissection	O
.	O

Simulations	O
of	O
velocities	O
,	O
vorticity	O
,	O
pressure	O
and	O
certain	O
stress	O
values	O
were	O
developed	O
by	O
a	O
computer	O
and	O
displayed	O
for	O
man	O
-	O
machine	O
interaction	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
entire	O
genomic	O
structure	O
of	O
KCNQ1	B-GENE
,	O
which	O
consists	O
of	O
19	O
exons	O
spanning	O
400	O
kb	O
on	O
chromosome	O
11p15	O
.	O
5	O
.	O

Northern	O
(	O
RNA	O
)	O
blot	O
hybridization	O
analysis	O
with	O
the	O
p68c	B-GENE
-	I-GENE
ets	I-GENE
-	I-GENE
1	I-GENE
-	O
specific	O
sequence	O
and	O
RNase	B-GENE
protection	O
experiments	O
showed	O
that	O
the	O
corresponding	O
mRNA	O
was	O
expressed	O
in	O
normal	O
chicken	O
spleen	O
and	O
not	O
in	O
normal	O
chicken	O
thymus	O
or	O
in	O
various	O
T	O
lymphoid	O
cell	O
lines	O
.	O

To	O
investigate	O
this	O
issue	O
,	O
we	O
used	O
a	O
recognition	O
task	O
in	O
which	O
two	O
strings	O
of	O
letters	O
are	O
presented	O
sequentially	O
.	O

Kettin	B-GENE
is	O
a	O
large	O
modular	O
protein	O
associated	O
with	O
thin	O
filaments	O
in	O
the	O
Z	O
-	O
disc	O
region	O
of	O
insect	O
muscles	O
.	O

Enzymatic	O
and	O
chemical	O
structure	O
probing	O
revealed	O
mainly	O
the	O
conserved	O
terminal	O
part	O
(	O
termed	O
3	O
'	O
C	O
)	O
of	O
the	O
DI9c	O
3	O
'	O
UTR	O
containing	O
distinctive	O
RNA	O
motifs	O
,	O
i	O
.	O
e	O
.	O
,	O
a	O
stable	O
stem	O
-	O
loop	O
,	O
SL	O
I	O
,	O
near	O
the	O
RNA	O
3	O
'	O
terminus	O
and	O
a	O
considerably	O
less	O
stable	O
stem	O
-	O
loop	O
,	O
SL	O
II	O
,	O
that	O
forms	O
the	O
5	O
'	O
portion	O
of	O
3	O
'	O
C	O
.	O

This	O
review	O
chronicles	O
the	O
characteristics	O
of	O
deliberate	O
and	O
accidental	O
mass	O
poisonings	O
that	O
occurred	O
in	O
World	O
Wars	O
I	O
and	O
II	O
,	O
in	O
Bhopal	O
,	O
and	O
in	O
other	O
historical	O
cases	O
up	O
to	O
and	O
including	O
modern	O
wars	O
.	O

The	O
effects	O
of	O
4	O
weeks	O
of	O
cyclosporin	O
A	O
(	O
7	O
mg	O
/	O
kg	O
per	O
day	O
)	O
(	O
CyA	O
)	O
on	O
the	O
survival	O
of	O
vascularized	O
osteochondral	O
grafts	O
between	O
rat	O
strains	O
[	O
DA	O
(	O
donor	O
)	O
and	O
Lewis	O
(	O
recipient	O
)	O
]	O
and	O
the	O
presence	O
and	O
significance	O
of	O
host	O
immune	O
tolerance	O
and	O
graft	O
antigen	O
modulation	O
after	O
cessation	O
of	O
immunosuppression	O
have	O
been	O
examined	O
.	O

By	O
incorporating	O
a	O
stent	O
with	O
posts	O
that	O
pivot	O
about	O
their	O
base	O
,	O
such	O
that	O
a	O
10	O
%	O
expansion	O
at	O
the	O
commissures	O
is	O
realized	O
,	O
we	O
were	O
able	O
to	O
reduce	O
the	O
compressive	O
commissural	O
stressing	O
from	O
250	O
to	O
150	O
kPa	O
.	O

In	O
group	O
1	O
,	O
mean	O
z	O
-	O
score	O
for	O
GFR	O
was	O
-	O
0	O
.	O
27	O
(	O
94	O
.	O
6	O
%	O
of	O
normal	O
)	O
and	O
in	O
group	O
2	O
mean	O
z	O
-	O
score	O
was	O
-	O
1	O
.	O
51	O
(	O
72	O
.	O
7	O
%	O
of	O
normal	O
for	O
two	O
kidneys	O
)	O
(	O
P	O
=	O
0	O
.	O
022	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O

The	O
cooperation	O
between	O
health	O
and	O
hospital	O
services	O

The	O
free	O
fraction	O
of	O
amitriptyline	O
(	O
AT	O
)	O
,	O
measured	O
by	O
equilibrium	O
dialysis	O
in	O
plasma	O
from	O
29	O
AT	O
-	O
treated	O
depressed	O
patients	O
,	O
was	O
5	O
.	O
4	O
-	O
9	O
.	O
8	O
%	O
(	O
mean	O
7	O
.	O
7	O
%	O
)	O
,	O
which	O
was	O
the	O
same	O
as	O
the	O
values	O
in	O
26	O
healthy	O
controls	O
(	O
4	O
.	O
9	O
-	O
9	O
.	O
6	O
%	O
,	O
mean	O
7	O
.	O
6	O
%	O
)	O
.	O

Different	O
effects	O
of	O
reoxygenation	O
on	O
the	O
electrical	O
activity	O
of	O
ventricular	O
muscle	O
.	O

Metastatic	O
tumours	O
of	O
bone	O
in	O
Nigerians	O
.	O

However	O
,	O
microinjection	O
of	O
reconstituted	O
mRNPs	O
into	O
Xenopus	O
oocytes	O
demonstrates	O
that	O
although	O
translational	O
repression	O
occurs	O
in	O
the	O
absence	O
of	O
consensus	O
RNA	O
binding	O
sequences	O
for	O
FRGY2	B-GENE
,	O
the	O
presence	O
of	O
FRGY2	B-GENE
recognition	I-GENE
elements	I-GENE
within	O
mRNA	O
potentiates	O
translational	O
repression	O
.	O

Any	O
respectative	O
material	O
(	O
class	O
0	O
)	O
was	O
not	O
obtained	O
from	O
334	O
patients	O
(	O
4	O
.	O
2	O
%	O
)	O
,	O
class	O
I	O
-	O
II	O
findings	O
belonged	O
to	O
6m141	O
patients	O
(	O
76	O
.	O
7	O
%	O
)	O
,	O
950	O
patients	O
(	O
11	O
.	O
9	O
%	O
)	O
were	O
classified	O
as	O
class	O
HII	O
and	O
IV	O
,	O
578	O
patients	O
(	O
7	O
.	O
2	O
%	O
)	O
as	O
class	O
V	O
.	O

However	O
,	O
whether	O
this	O
was	O
associated	O
with	O
spleen	O
removal	O
after	O
adjustment	O
for	O
risk	O
factors	O
was	O
not	O
determined	O
.	O

Virgin	O
,	O
P	O
.	O

IL	B-GENE
-	I-GENE
6	I-GENE
was	O
detected	O
in	O
the	O
urine	O
of	O
52	O
%	O
of	O
children	O
with	O
pyelonephritis	O
compared	O
with	O
15	O
%	O
of	O
other	O
children	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
have	O
determined	O
the	O
complete	O
cDNA	O
sequence	O
of	O
rat	B-GENE
plectin	I-GENE
from	O
a	O
number	O
of	O
well	O
-	O
characterized	O
overlapping	O
lambda	O
gt11	O
clones	O
.	O

SETTING	O
-	O
-	O
Hospital	O
laboratories	O
in	O
the	O
United	O
States	O
submitting	O
pneumococcal	O
isolates	O
to	O
the	O
CDC	O
between	O
October	O
1	O
,	O
1991	O
,	O
and	O
September	O
30	O
,	O
1992	O
.	O

The	O
terminal	O
a	O
sequence	O
of	O
the	O
herpes	O
simplex	O
virus	O
genome	O
contains	O
the	O
promoter	O
of	O
a	O
gene	O
located	O
in	O
the	O
repeat	O
sequences	O
of	O
the	O
L	O
component	O
.	O

In	O
contrast	O
to	O
p62	B-GENE
(	O
dok	B-GENE
)	O
,	O
DOKL	B-GENE
lacks	O
YxxP	O
motifs	O
in	O
the	O
C	O
terminus	O
and	O
does	O
not	O
bind	O
to	O
Ras	B-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
(	O
RasGAP	B-GENE
)	O
upon	O
phosphorylation	O
.	O

These	O
observations	O
demonstrate	O
that	O
KSR	B-GENE
is	O
capable	O
of	O
uncoupling	O
the	O
MAP	B-GENE
kinase	I-GENE
activation	O
from	O
its	O
target	O
phosphorylation	O
,	O
and	O
thus	O
provide	O
a	O
novel	O
mechanism	O
for	O
modulating	O
the	O
Ras	B-GENE
-	O
MAP	B-GENE
kinase	I-GENE
signaling	O
pathway	O
.	O

G	B-GENE
-	I-GENE
CSF	I-GENE
(	O
10	O
microg	O
/	O
kg	O
)	O
was	O
started	O
on	O
day	O
+	O
1	O
and	O
all	O
patients	O
engrafted	O
within	O
a	O
median	O
day	O
number	O
of	O
12	O
(	O
range	O
,	O
10	O
-	O
22	O
)	O
until	O
leukocytes	O
>	O
1	O
.	O
0	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
and	O
a	O
median	O
day	O
number	O
of	O
56	O
(	O
range	O
,	O
10	O
-	O
180	O
)	O
until	O
platelets	O
>	O
20	O
.	O
0	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
(	O
ie	O
platelet	O
transfusion	O
independence	O
)	O
.	O

A	O
higher	O
percentage	O
of	O
children	O
with	O
cerebral	O
malaria	O
(	O
40	O
per	O
cent	O
)	O
than	O
with	O
non	O
-	O
cerebral	O
malaria	O
(	O
29	O
per	O
cent	O
)	O
or	O
controls	O
(	O
20	O
per	O
cent	O
)	O
also	O
had	O
either	O
serum	B-GENE
ferritin	I-GENE
<	O
100	O
micrograms	O
/	O
l	O
and	O
inflammation	O
or	O
sTfR	B-GENE
>	O
7	O
.	O
3	O
mg	O
/	O
l	O
or	O
both	O
.	O

During	O
the	O
burst	O
period	O
(	O
approximately	O
5	O
-	O
10	O
min	O
)	O
,	O
local	O
blood	O
H2O2	O
concentrations	O
and	O
xanthine	B-GENE
oxidase	I-GENE
activities	O
were	O
highly	O
correlated	O
(	O
r	O
=	O
0	O
.	O
999	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
21	O
-	O
or	O
the	O
72	O
-	O
bp	O
repeat	O
transcriptional	O
control	O
elements	O
enhance	O
the	O
efficiency	O
of	O
SV40	O
DNA	O
replication	O
in	O
vivo	O
,	O
provided	O
either	O
of	O
these	O
repeats	O
is	O
located	O
near	O
the	O
end	O
of	O
the	O
core	O
replication	O
origin	O
containing	O
the	O
17	O
-	O
bp	O
A	O
+	O
T	O
-	O
containing	O
sequence	O
.	O

UV	O
cross	O
-	O
linking	O
and	O
Southwestern	O
analysis	O
suggested	O
that	O
KTP1	B-GENE
is	O
a	O
DNA	O
-	O
binding	O
protein	O
clearly	O
distinct	O
from	O
AP2	B-GENE
,	O
and	O
this	O
protein	O
may	O
be	O
responsible	O
for	O
the	O
basal	O
keratinocyte	O
-	O
specific	O
expression	O
of	O
the	O
BPAG1	B-GENE
gene	I-GENE
.	O

The	O
model	O
of	O
the	O
complex	O
provides	O
a	O
rationale	O
for	O
conserved	O
ITAM	B-GENE
residues	O
,	O
substrate	O
specificity	O
,	O
and	O
suggests	O
that	O
substrate	O
binds	O
only	O
the	O
active	O
conformation	O
of	O
the	O
Src	B-GENE
family	I-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
unlike	O
the	O
ATP	O
cofactor	O
,	O
which	O
can	O
bind	O
the	O
inactive	O
form	O
.	O

Here	O
we	O
demonstrate	O
that	O
a	O
region	O
of	O
high	O
homology	O
between	O
the	O
members	O
of	O
this	O
class	O
of	O
proteins	O
contains	O
a	O
type	O
A	O
nucleotide	O
binding	O
site	O
consensus	O
sequence	O
which	O
has	O
ATPase	B-GENE
activity	O
and	O
is	O
sufficient	O
to	O
bind	O
DNA	O
containing	O
specific	O
mismatched	O
residues	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Nickel	O
release	O
from	O
tools	O
on	O
the	O
Swedish	O
market	O
.	O

S	O
-	O
phase	O
-	O
promoting	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinases	I-GENE
(	O
Cdks	B-GENE
)	O
and	O
the	O
kinase	O
Dbf4	B-GENE
-	O
Cdc7	B-GENE
then	O
act	O
to	O
initiate	O
replication	O
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
only	O
partially	O
mediates	O
Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
latent	I-GENE
membrane	I-GENE
protein	I-GENE
1	I-GENE
activation	O
of	O
B	O
cells	O
.	O

Purified	O
fER	B-GENE
exhibited	O
a	O
distribution	O
constant	O
(	O
KD	O
)	O
for	O
17	O
beta	O
-	O
estradiol	O
of	O
0	O
.	O
45	O
nM	O
.	O

The	O
long	O
terminal	O
repeat	O
is	O
590	O
bp	O
in	O
length	O
,	O
with	O
the	O
U3	O
region	O
containing	O
consensus	O
sequences	O
likely	O
to	O
be	O
involved	O
in	O
viral	O
gene	O
expression	O
.	O

An	O
incorrect	O
response	O
on	O
the	O
previous	O
trial	O
enhanced	O
the	O
accuracy	O
in	O
the	O
current	O
trial	O
only	O
in	O
the	O
left	O
visual	O
field	O
(	O
LVF	O
)	O
.	O

The	O
peptides	O
are	O
generated	O
in	O
the	O
cytosol	O
,	O
then	O
translocated	O
across	O
the	O
membrane	O
of	O
the	O
endoplasmic	O
reticulum	O
by	O
the	O
transporter	B-GENE
associated	I-GENE
with	I-GENE
antigen	I-GENE
processing	I-GENE
(	O
TAP	B-GENE
)	O
.	O

It	O
competes	O
with	O
the	O
calcium	O
ion	O
which	O
brings	O
about	O
inhibition	O
of	O
myosine	B-GENE
kinase	I-GENE
,	O
and	O
therefore	O
a	O
drop	O
in	O
phosphorylated	O
myosine	O
.	O

Comparison	O
with	O
the	O
data	O
of	O
clinical	O
development	O
and	O
hemodynamic	O
results	O

Sera	O
collected	O
in	O
1973	O
-	O
1975	O
from	O
3053	O
residents	O
of	O
12	O
selected	O
Alaskan	O
Eskimo	O
villages	O
were	O
tested	O
for	O
evidence	O
of	O
hepatitis	O
B	O
virus	O
infection	O
.	O

Injection	O
of	O
horseradish	B-GENE
peroxidase	I-GENE
(	O
HRP	B-GENE
)	O
into	O
the	O
cerebellar	O
flocculus	O
of	O
the	O
rat	O
was	O
employed	O
to	O
identify	O
neurons	O
in	O
the	O
abducens	O
nucleus	O
that	O
project	O
to	O
the	O
flocculus	O
.	O

To	O
assay	O
for	O
sequences	O
that	O
could	O
potentially	O
regulate	O
Xenopus	B-GENE
proenkephalin	I-GENE
expression	O
,	O
we	O
transfected	O
constructs	O
that	O
contained	O
upstream	O
genomic	O
sequences	O
linked	O
to	O
the	O
CAT	B-GENE
reporter	I-GENE
gene	I-GENE
into	O
various	O
eukaryotic	O
cell	O
lines	O
.	O

This	O
suggests	O
that	O
the	O
ratio	O
of	O
IL	B-GENE
-	I-GENE
6	I-GENE
to	O
IL	B-GENE
-	I-GENE
10	I-GENE
may	O
be	O
used	O
to	O
predict	O
the	O
injury	O
severity	O
after	O
trauma	O
.	O

UVB	O
-	O
induced	O
association	O
of	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	I-GENE
TNF	I-GENE
)	I-GENE
receptor	I-GENE
1	I-GENE
/	O
TNF	B-GENE
receptor	I-GENE
-	I-GENE
associated	I-GENE
factor	I-GENE
-	I-GENE
2	I-GENE
mediates	O
activation	O
of	O
Rel	B-GENE
proteins	I-GENE
.	O

A	O
major	O
feature	O
of	O
this	O
genomic	O
sequence	O
is	O
the	O
presence	O
of	O
a	O
first	O
intron	O
(	O
Il	O
)	O
,	O
215	O
bp	O
long	O
,	O
located	O
48	O
bp	O
downstream	O
of	O
the	O
translation	O
start	O
ATG	O
codon	O
.	O

Experimental	O
studies	O
and	O
clinical	O
application	O
of	O
plasma	B-GENE
ACTH	I-GENE
radioimmunoassay	O
kit	O
without	O
extraction	O
process	O

In	O
the	O
cervical	O
enlargement	O
they	O
were	O
located	O
in	O
the	O
middle	O
part	O
of	O
lamina	O
VII	O
and	O
in	O
lamina	O
VIII	O
,	O
accounting	O
for	O
about	O
25	O
%	O
of	O
the	O
total	O
labeled	O
neurons	O
.	O

Nature	O
and	O
incidence	O
of	O
conditioned	O
responses	O
in	O
a	O
methadone	O
population	O
:	O
a	O
comparison	O
of	O
laboratory	O
,	O
clinic	O
,	O
and	O
naturalistic	O
settings	O
.	O

While	O
some	O
still	O
automatically	O
refuse	O
all	O
patients	O
with	O
positive	O
mediastinoscopy	O
,	O
most	O
authors	O
still	O
remain	O
very	O
interventionistic	O
for	O
N2	O
patients	O
selected	O
on	O
very	O
accurate	O
criteria	O
that	O
are	O
analyzed	O
above	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
the	O
promyelocytic	O
leukemia	O
gene	O
,	O
PML	B-GENE
which	O
involved	O
in	O
the	O
15	O
;	O
17	O
translocation	O
in	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
growth	O
and	O
transformation	O
suppressor	O
.	O

A	O
sharp	O
transition	O
from	O
a	O
random	O
chaotic	O
state	O
to	O
a	O
correlated	O
turbulent	O
state	O
of	O
finite	O
coherence	O
time	O
is	O
found	O
when	O
the	O
Rayleigh	O
number	O
becomes	O
larger	O
than	O
a	O
critical	O
value	O
Ra	O
(	O
c	O
)	O
approximately	O
equal	O
to	O
5	O
x	O
10	O
(	O
7	O
)	O
.	O

Our	O
data	O
define	O
Ile	O
(	O
16	O
)	O
,	O
Val	O
(	O
18	O
)	O
,	O
Val	O
(	O
31	O
)	O
,	O
and	O
Ile	O
(	O
33	O
)	O
as	O
crucial	O
for	O
protein	B-GENE
S	I-GENE
binding	O
,	O
with	O
secondary	O
effects	O
from	O
Leu	O
(	O
38	O
)	O
and	O
Val	O
(	O
39	O
)	O
.	O

In	O
the	O
yeast	O
two	O
-	O
hybrid	O
assays	O
,	O
PNRC	B-GENE
interacted	O
with	O
the	O
orphan	O
receptors	O
SF1	B-GENE
and	O
ERRalpha1	B-GENE
in	O
a	O
ligand	O
-	O
independent	O
manner	O
.	O

Nuclear	O
export	O
of	O
proteins	O
in	O
plants	O
:	O
AtXPO1	B-GENE
is	O
the	O
export	O
receptor	O
for	O
leucine	O
-	O
rich	O
nuclear	O
export	O
signals	O
in	O
Arabidopsis	O
thaliana	O
.	O

Thus	O
,	O
CR2	B-GENE
possesses	O
an	O
essential	O
function	O
besides	O
pRb	B-GENE
-	O
binding	O
.	O

From	O
the	O
autopsy	O
findings	O
,	O
in	O
5	O
out	O
of	O
the	O
remaining	O
23	O
expired	O
patients	O
,	O
Legionella	O
pneumonia	O
seemed	O
to	O
be	O
successfully	O
treated	O
,	O
but	O
other	O
disease	O
or	O
other	O
bacterial	O
pneumonia	O
put	O
an	O
end	O
to	O
the	O
patients	O
.	O

Nitroglycerin	O
(	O
glyceryl	O
trinitrate	O
)	O
as	O
a	O
monoamine	B-GENE
oxidase	I-GENE
inhibitor	O
.	O

This	O
high	O
dose	O
5	O
-	O
FU	O
+	O
Act	O
-	O
D	O
protocol	O
was	O
effective	O
for	O
drug	O
resistant	O
cases	O
with	O
MEA	O
protocol	O
.	O

With	O
stimulation	O
beyond	O
the	O
theta	O
-	O
range	O
three	O
phenomena	O
occurred	O
:	O
shift	O
of	O
the	O
burst	O
frequencies	O
to	O
higher	O
or	O
lower	O
harmonics	O
of	O
stimulation	O
frequencies	O
;	O
complex	O
interactions	O
of	O
basic	O
background	O
frequency	O
with	O
rhythm	O
of	O
stimulation	O
(	O
"	O
beating	O
"	O
)	O
;	O
return	O
to	O
background	O
theta	O
-	O
burst	O
frequency	O
in	O
spite	O
of	O
continuing	O
stimulation	O
(	O
"	O
escape	O
"	O
)	O
.	O

CONCLUSIONS	O
:	O
Transpulmonary	O
stable	O
air	O
microbubbles	O
bound	O
to	O
a	O
galactose	O
carrier	O
represent	O
a	O
useful	O
and	O
safe	O
contrast	O
agent	O
in	O
case	O
of	O
an	O
insufficient	O
native	O
signal	O
in	O
transcranial	O
Doppler	O
investigation	O
.	O

K562	O
erythroleukemia	O
cells	O
stably	O
transfected	O
with	O
constructs	O
containing	O
the	O
human	B-GENE
Agamma	I-GENE
-	I-GENE
globin	I-GENE
promoter	I-GENE
linked	O
to	O
an	O
enhanced	B-GENE
green	I-GENE
fluorescent	I-GENE
protein	I-GENE
(	O
EGFP	B-GENE
)	O
reporter	O
,	O
with	O
or	O
without	O
HS2	O
,	O
were	O
analyzed	O
for	O
EGFP	B-GENE
expression	O
by	O
flow	O
cytometry	O
.	O

Gastrin	B-GENE
stimulates	O
transcription	O
of	O
the	O
human	B-GENE
histidine	I-GENE
decarboxylase	I-GENE
(	O
HDC	B-GENE
)	O
gene	O
through	O
binding	O
to	O
the	O
G	B-GENE
-	I-GENE
protein	I-GENE
-	O
coupled	O
cholecystokinin	B-GENE
-	I-GENE
B	I-GENE
/	O
gastrin	B-GENE
receptor	I-GENE
.	O

Here	O
,	O
we	O
report	O
the	O
isolation	O
of	O
a	O
new	O
spindle	O
checkpoint	O
gene	O
,	O
mph1	B-GENE
(	O
Mps1p	B-GENE
-	I-GENE
like	I-GENE
pombe	I-GENE
homolog	I-GENE
)	O
,	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
,	O
that	O
is	O
required	O
for	O
checkpoint	O
activation	O
in	O
response	O
to	O
spindle	O
defects	O
.	O

mph1	B-GENE
functions	O
upstream	O
of	O
mad2	B-GENE
,	O
a	O
previously	O
characterized	O
component	O
of	O
the	O
spindle	O
checkpoint	O
.	O

Hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
HGF	B-GENE
)	O
is	O
an	O
inducible	O
cytokine	O
that	O
is	O
essential	O
for	O
the	O
normal	O
growth	O
and	O
development	O
of	O
various	O
tissues	O
,	O
such	O
as	O
the	O
liver	O
.	O

However	O
,	O
all	O
pathophysiologic	O
assessments	O
reported	O
to	O
date	O
have	O
been	O
carried	O
out	O
during	O
or	O
immediately	O
after	O
IVOX	O
utilization	O
.	O

Reduced	O
concentrations	O
of	O
antithrombin	B-GENE
III	I-GENE
,	O
plasminogen	B-GENE
,	O
(	O
free	O
)	O
protein	B-GENE
S	I-GENE
,	O
and	O
protein	B-GENE
C	I-GENE
were	O
found	O
in	O
some	O
patients	O
but	O
were	O
not	O
associated	O
with	O
either	O
thrombosis	O
or	O
lupus	O
anticoagulant	O
.	O

The	O
first	O
decision	O
in	O
management	O
is	O
to	O
consider	O
cardioversion	O
which	O
can	O
be	O
achieved	O
in	O
suitable	O
cases	O
electrically	O
,	O
or	O
pharmacologically	O
with	O
a	O
class	O
Ic	O
antiarrhythmic	O
drug	O
like	O
flecainide	O
or	O
propafenone	O
.	O

Structure	O
and	O
chromosomal	O
localization	O
of	O
the	O
human	O
gene	O
of	O
the	O
phosphotyrosyl	B-GENE
phosphatase	I-GENE
activator	I-GENE
(	O
PTPA	B-GENE
)	O
of	O
protein	B-GENE
phosphatase	I-GENE
2A	I-GENE
.	O

R	O
of	O
the	O
chest	O
wall	O
was	O
maximum	O
(	O
35	O
.	O
6	O
cmH2O	O
.	O
L	O
-	O
1	O
.	O
sec	O
-	O
1	O
+	O
/	O
-	O
2	O
.	O
2	O
SE	O
)	O
at	O
0	O
.	O
2	O
Hz	O
-	O
10	O
ml	O
and	O
decreased	O
with	O
increasing	O
f	O
and	O
VT	O
,	O
although	O
the	O
VT	O
effect	O
diminished	O
at	O
the	O
higher	O
f	O
.	O

Since	O
1988	O
Modulit	O
-	O
SZ	O
-	O
20	O
has	O
been	O
tested	O
for	O
localization	O
of	O
nephroliths	O
and	O
ureteroliths	O
.	O

JCAHO	O
moves	O
to	O
rewrite	O
many	O
rules	O
to	O
lessen	O
hospitals	O
'	O
regulatory	O
burden	O
.	O

These	O
transcripts	O
directed	O
the	O
synthesis	O
of	O
three	O
proteins	O
:	O
the	O
virus	B-GENE
trans	I-GENE
-	I-GENE
activator	I-GENE
protein	I-GENE
(	O
EIAV	B-GENE
Tat	I-GENE
)	O
encoded	O
by	O
ORF	O
S1	O
,	O
a	O
protein	O
of	O
unknown	O
function	O
encoded	O
by	O
ORF	O
S2	O
,	O
and	O
the	O
virus	O
envelope	B-GENE
glycoprotein	I-GENE
.	O

However	O
,	O
no	O
significant	O
difference	O
in	O
either	O
the	O
Valsalva	O
ratio	O
or	O
delta	O
SBP	O
was	O
found	O
between	O
diabetic	O
patients	O
and	O
controls	O
.	O

Transmural	O
metabolic	O
heterogeneity	O
at	O
high	O
cardiac	O
work	O
states	O
.	O

We	O
therefore	O
investigated	O
whether	O
the	O
promoter	O
activity	O
of	O
the	O
mouse	B-GENE
TRH	I-GENE
gene	I-GENE
is	O
directly	O
regulated	O
by	O
RA	O
using	O
a	O
transient	O
transfection	O
assay	O
into	O
CV	O
-	O
1	O
cells	O
.	O

Spinal	O
injuries	O
in	O
a	O
multiple	O
trauma	O
patient	O
.	O

The	O
unusual	O
properties	O
of	O
TRAC	B-GENE
activity	O
and	O
its	O
relationship	O
,	O
if	O
any	O
,	O
with	O
the	O
enigmatic	O
Ku	B-GENE
protein	I-GENE
,	O
are	O
discussed	O
.	O

Statistical	O
aspects	O
of	O
the	O
relation	O
of	O
the	O
radioprotective	O
action	O
of	O
mercaptoethylamine	O
derivatives	O
and	O
analogs	O
to	O
their	O
electron	O
parameters	O

Cerebellar	O
functional	O
compensation	O
after	O
its	O
complete	O
destruction	O
by	O
a	O
neoplasm	O

The	O
RNA	O
,	O
whether	O
antisense	O
,	O
ribozyme	O
,	O
or	O
RNA	O
aptamer	O
,	O
must	O
be	O
efficiently	O
transcribed	O
,	O
stabilized	O
against	O
rapid	O
degradation	O
,	O
folded	O
correctly	O
,	O
and	O
directed	O
to	O
the	O
part	O
of	O
the	O
cell	O
where	O
it	O
can	O
be	O
most	O
effective	O
.	O

We	O
have	O
isolated	O
and	O
determined	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
another	O
operon	O
,	O
cpeCD	B-GENE
,	O
that	O
encodes	O
the	O
linker	O
proteins	O
associated	O
with	O
phycoerythrin	B-GENE
hexamers	I-GENE
in	O
the	O
phycobilisome	B-GENE
.	O

A	B-GENE
.	I-GENE
thaliana	I-GENE
cystathionine	I-GENE
beta	I-GENE
-	I-GENE
lyase	I-GENE
exhibits	O
22	O
%	O
sequence	O
identity	O
with	O
the	O
E	O
.	O
coli	O
corresponding	O
enzyme	O
and	O
contains	O
a	O
70	O
amino	O
acid	O
N	O
-	O
terminal	O
additional	O
sequence	O
compared	O
with	O
the	O
bacterial	O
protein	O
.	O

The	O
enzyme	B-GENE
ACC	I-GENE
oxidase	I-GENE
catalyses	O
the	O
last	O
step	O
of	O
ethylene	O
biosynthesis	O
in	O
plants	O
,	O
converting	O
1	O
-	O
aminocyclopropane	O
-	O
1	O
-	O
carboxylic	O
acid	O
(	O
ACC	O
)	O
to	O
ethylene	O
.	O

A	O
99m	O
Tc	O
bone	O
scan	O
showed	O
a	O
focal	O
area	O
of	O
an	O
increased	O
uptake	O
at	O
the	O
site	O
of	O
the	O
mass	O
below	O
the	O
calcaneus	O
.	O

Renal	O
function	O
was	O
evaluated	O
in	O
a	O
group	O
of	O
24	O
patients	O
(	O
21	O
men	O
and	O
3	O
women	O
,	O
mean	O
age	O
47	O
years	O
)	O
who	O
had	O
survived	O
the	O
malignant	O
phase	O
of	O
hypertension	O
during	O
the	O
period	O
of	O
1969	O
-	O
1979	O
.	O

The	O
need	O
for	O
such	O
guidelines	O
is	O
clear	O
on	O
both	O
clinical	O
and	O
scientific	O
grounds	O
.	O

When	O
expressed	O
in	O
thymidine	B-GENE
kinase	I-GENE
-	O
deficient	O
L	O
cells	O
or	O
3T3	O
cells	O
,	O
C	B-GENE
/	I-GENE
EBPalpha	I-GENE
is	O
detected	O
in	O
a	O
protein	O
complex	O
which	O
binds	O
to	O
the	O
E2F	B-GENE
binding	I-GENE
sites	I-GENE
found	O
in	O
the	O
promoters	O
of	O
the	O
genes	O
for	O
E2F	B-GENE
-	I-GENE
1	I-GENE
and	O
dihydrofolate	B-GENE
reductase	I-GENE
(	O
DHFR	B-GENE
)	O
.	O

Members	O
of	O
the	O
CRE	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
/	O
activating	B-GENE
transcription	I-GENE
factor	I-GENE
transcription	O
family	O
as	O
well	O
as	O
members	O
of	O
the	O
Jun	B-GENE
/	O
Fos	B-GENE
family	O
have	O
been	O
shown	O
to	O
bind	O
to	O
this	O
sequence	O
.	O

Csk	B-GENE
(	O
C	B-GENE
-	I-GENE
terminal	I-GENE
Src	I-GENE
kinase	I-GENE
)	O
is	O
a	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
that	O
phosphorylates	O
Src	B-GENE
family	I-GENE
member	I-GENE
C	I-GENE
-	I-GENE
terminal	I-GENE
tails	I-GENE
,	O
resulting	O
in	O
downregulation	O
of	O
Src	B-GENE
family	O
members	O
.	O

Role	O
of	O
double	B-GENE
-	I-GENE
stranded	I-GENE
RNA	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
in	O
mediating	O
hypersensitivity	O
of	O
Fanconi	O
anemia	O
complementation	O
group	O
C	O
cells	O
to	O
interferon	B-GENE
gamma	I-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
,	O
and	O
double	O
-	O
stranded	O
RNA	O
.	O

In	O
clinical	O
stroke	O
cardiovascular	O
abnormalities	O
are	O
frequently	O
neglected	O
although	O
they	O
occur	O
more	O
often	O
than	O
it	O
is	O
generally	O
assumed	O
.	O

In	O
the	O
presence	O
of	O
high	O
concentrations	O
(	O
propofol	O
100	O
microg	O
mL	O
-	O
1	O
,	O
thiopental	O
50	O
microg	O
mL	O
-	O
1	O
)	O
marked	O
relaxation	O
was	O
observed	O
(	O
propofol	O
-	O
32	O
%	O
up	O
to	O
-	O
49	O
%	O
,	O
P	O
<	O
0	O
,	O
05	O
;	O
thiopental	O
-	O
23	O
%	O
up	O
to	O
-	O
67	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
results	O
suggest	O
a	O
dose	O
-	O
dependent	O
activity	O
of	O
lysine	B-GENE
vasopressin	I-GENE
on	O
the	O
EEG	O
,	O
which	O
might	O
be	O
similar	O
to	O
that	O
observed	O
in	O
animal	O
and	O
man	O
after	O
administration	O
of	O
nicotine	O
.	O

Mutations	O
of	O
the	O
human	B-GENE
PTEN	I-GENE
gene	I-GENE
.	O

Guanylyl	B-GENE
cyclase	I-GENE
C	I-GENE
,	O
the	O
apparent	O
guanylin	B-GENE
receptor	I-GENE
,	O
was	O
found	O
in	O
abundant	O
amounts	O
in	O
the	O
intestine	O
by	O
Northern	O
analysis	O
,	O
and	O
by	O
the	O
polymerase	O
chain	O
reaction	O
or	O
cDNA	O
cloning	O
it	O
was	O
also	O
found	O
in	O
adrenal	O
gland	O
,	O
airway	O
epithelial	O
cells	O
,	O
brain	O
,	O
and	O
olfactory	O
and	O
tracheal	O
mucosa	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
used	O
Southern	O
blot	O
analysis	O
to	O
demonstrate	O
that	O
TSG6	B-GENE
is	O
a	O
single	O
-	O
copy	O
gene	O
in	O
the	O
human	O
and	O
murine	O
species	O
.	O

Reaction	O
of	O
aromatic	O
/	O
heterocyclic	O
sulfonamides	O
possessing	O
free	O
amino	O
,	O
imino	O
or	O
hydrazino	O
moieties	O
with	O
7	O
-	O
chloro	O
-	O
4	O
-	O
chloromethylcoumarin	O
afforded	O
a	O
series	O
of	O
N	O
-	O
[	O
(	O
7	O
-	O
chloro	O
-	O
4	O
-	O
coumarinyl	O
)	O
-	O
methyl	O
]	O
-	O
derivatives	O
which	O
showed	O
effective	O
inhibition	O
of	O
three	O
carbonic	B-GENE
anhydrase	I-GENE
(	O
CA	B-GENE
)	O
isozymes	O
.	O

As	O
well	O
,	O
variation	O
in	O
capillary	O
size	O
and	O
density	O
was	O
apparent	O
between	O
ventricles	O
in	O
the	O
fetal	O
and	O
neonatal	O
periods	O
.	O

The	O
Polycomb	B-GENE
group	I-GENE
proteins	I-GENE
are	O
involved	O
in	O
maintenance	O
of	O
the	O
silenced	O
state	O
of	O
several	O
developmentally	O
regulated	O
genes	O
.	O

Uncertainty	O
exists	O
about	O
the	O
function	O
of	O
these	O
potential	O
isoforms	O
of	O
the	O
Cbfa1	B-GENE
gene	I-GENE
.	O

When	O
using	O
the	O
high	O
-	O
impedance	O
testing	O
device	O
,	O
the	O
post	O
shock	O
rhythm	O
was	O
initially	O
displayed	O
as	O
'	O
no	O
signal	O
'	O
(	O
Hewlett	O
Packard	O
XL	O
)	O
or	O
'	O
asystole	O
'	O
(	O
Physio	O
-	O
Control	O
LIFEPAK	O
9	O
)	O
.	O

Human	B-GENE
CD38	I-GENE
,	O
a	O
leukocyte	O
receptor	O
and	O
ectoenzyme	O
,	O
is	O
a	O
member	O
of	O
a	O
novel	O
eukaryotic	O
gene	O
family	O
of	O
nicotinamide	B-GENE
adenine	I-GENE
dinucleotide	I-GENE
+	I-GENE
-	I-GENE
converting	I-GENE
enzymes	I-GENE
:	O
extensive	O
structural	O
homology	O
with	O
the	O
genes	O
for	O
murine	B-GENE
bone	I-GENE
marrow	I-GENE
stromal	I-GENE
cell	I-GENE
antigen	I-GENE
1	I-GENE
and	O
aplysian	B-GENE
ADP	I-GENE
-	I-GENE
ribosyl	I-GENE
cyclase	I-GENE
.	O

It	O
is	O
noteworthy	O
that	O
under	O
more	O
physiological	O
conditions	O
mimicking	O
the	O
cellular	O
GDP	O
/	O
GTP	O
ratio	O
,	O
Raf	B-GENE
enhances	O
the	O
GEF	B-GENE
-	O
stimulated	O
GDP	O
/	O
GTP	O
exchange	O
on	O
Ha	B-GENE
-	I-GENE
Ras	I-GENE
,	O
in	O
agreement	O
with	O
the	O
sequestration	O
of	O
Ras	B-GENE
.	I-GENE
GTP	I-GENE
by	O
Raf	B-GENE
.	O

When	O
O	O
-	O
2A	O
/	O
c	B-GENE
-	I-GENE
myc	I-GENE
cells	O
underwent	O
terminal	O
differentiation	O
APprog	B-GENE
complexes	I-GENE
were	O
lost	O
and	O
conventional	O
AP	B-GENE
-	I-GENE
1	I-GENE
DNA	O
-	O
binding	O
activity	O
became	O
evident	O
,	O
particularly	O
in	O
astrocytes	O
.	O

From	O
the	O
deduced	O
amino	O
acid	O
sequence	O
,	O
a	O
molecular	O
weight	O
of	O
38	O
,	O
549	O
was	O
calculated	O
for	O
the	O
ADH	B-GENE
subunit	I-GENE
.	O

The	O
higher	O
level	O
of	O
calories	O
was	O
attained	O
by	O
an	O
increased	O
intake	O
of	O
carbohydrates	O
.	O

A	O
simple	O
algorithm	O
fitting	O
the	O
data	O
for	O
the	O
moving	O
192Ir	O
source	O
is	O
proposed	O
.	O

TAF	B-GENE
-	I-GENE
1	I-GENE
activates	O
transcription	O
constitutively	O
and	O
was	O
mapped	O
to	O
the	O
first	O
32	O
amino	O
acids	O
of	O
the	O
A	O
-	O
region	O
.	O

For	O
the	O
first	O
,	O
short	O
-	O
term	O
(	O
concurrent	O
)	O
TAL	O
,	O
two	O
different	O
-	O
flavored	O
stimuli	O
were	O
presented	O
at	O
the	O
same	O
time	O
,	O
one	O
associated	O
with	O
simultaneous	O
intragastric	O
administration	O
of	O
an	O
aversive	O
product	O
,	O
hypertonic	O
NaCl	O
,	O
and	O
the	O
other	O
with	O
saline	O
.	O

The	O
great	O
cardiac	O
vein	O
flow	O
became	O
zero	O
due	O
to	O
the	O
cardiac	O
arrest	O
and	O
remained	O
at	O
zero	O
for	O
a	O
moment	O
(	O
dead	O
time	O
)	O
after	O
the	O
initiation	O
of	O
reperfusion	O
.	O

INTERNET	O
is	O
literally	O
a	O
world	O
of	O
data	O
,	O
dialogue	O
,	O
and	O
discourse	O
on	O
any	O
topic	O
imaginable	O
,	O
right	O
at	O
your	O
fingertips	O
.	O

Attention	O
is	O
devoted	O
in	O
particular	O
to	O
the	O
action	O
of	O
thermoregulating	O
nervous	O
and	O
hormonal	O
mechanisms	O
.	O

The	O
mammalian	O
UPR	O
is	O
mediated	O
by	O
the	O
cis	O
-	O
acting	O
ER	O
stress	O
response	O
element	O
consisting	O
of	O
19	O
nt	O
(	O
CCAATN	O
(	O
9	O
)	O
CCACG	O
)	O
,	O
the	O
CCACG	O
part	O
of	O
which	O
is	O
considered	O
to	O
provide	O
specificity	O
.	O

The	O
formation	O
of	O
a	O
D	O
-	O
loop	O
is	O
an	O
essential	O
step	O
in	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
through	O
recombination	O
.	O

The	O
cDNA	O
is	O
predicted	O
to	O
encode	O
a	O
polypeptide	O
of	O
298	O
amino	O
acids	O
that	O
is	O
homologous	O
to	O
the	O
Y	B-GENE
-	I-GENE
box	I-GENE
(	I-GENE
inverted	I-GENE
CCAAT	I-GENE
)	I-GENE
family	I-GENE
of	I-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
transcription	I-GENE
factors	I-GENE
.	O

Toward	O
this	O
end	O
,	O
we	O
used	O
two	O
cultured	O
colon	O
cancer	O
cell	O
lines	O
;	O
one	O
(	O
RKO	O
)	O
has	O
a	O
transcriptionally	O
activated	O
u	B-GENE
-	I-GENE
PAR	I-GENE
gene	I-GENE
,	O
and	O
the	O
other	O
(	O
GEO	O
)	O
overexpresses	O
the	O
receptor	O
only	O
after	O
phorbol	O
ester	O
treatment	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
conserved	O
cysteine	O
residue	O
(	O
tom1C3235A	B-GENE
)	O
in	O
the	O
hect	B-GENE
-	I-GENE
domain	I-GENE
,	O
supposed	O
to	O
be	O
necessary	O
for	O
thioester	O
-	O
bond	O
formation	O
with	O
ubiquitin	B-GENE
,	O
abolished	O
the	O
gene	O
function	O
.	O

The	O
two	O
yeast	B-GENE
pheromone	I-GENE
receptors	I-GENE
,	O
the	O
a	B-GENE
and	I-GENE
alpha	I-GENE
-	I-GENE
factor	I-GENE
receptors	I-GENE
,	O
share	O
many	O
functional	O
similarities	O
:	O
both	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptors	I-GENE
couple	O
to	O
the	O
same	O
downstream	O
signal	O
transduction	O
pathway	O
,	O
and	O
both	O
receptors	O
undergo	O
feedback	O
regulation	O
involving	O
increased	O
phosphorylation	O
on	O
their	O
C	O
-	O
terminal	O
domains	O
in	O
response	O
to	O
ligand	O
challenge	O
.	O

Moreover	O
,	O
the	O
formation	O
of	O
the	O
complex	O
between	O
IclR	B-GENE
and	O
the	O
operator	O
/	O
promoter	O
region	O
has	O
been	O
found	O
to	O
be	O
impaired	O
by	O
phosphoenol	O
pyruvate	O
but	O
insensitive	O
to	O
acetate	O
,	O
acetyl	O
-	O
CoA	O
,	O
pyruvate	O
,	O
and	O
oxaloacetate	O
.	O

After	O
enzymatic	O
hydrolysis	O
of	O
the	O
water	O
soluble	O
fraction	O
,	O
it	O
is	O
shown	O
that	O
28	O
%	O
is	O
again	O
extractable	O
by	O
DCM	O
of	O
which	O
57	O
%	O
consists	O
of	O
unchanged	O
SC4453	O
which	O
is	O
therefore	O
the	O
main	O
partner	O
of	O
conjugated	O
products	O
.	O

The	O
expression	O
pattern	O
of	O
the	O
reporter	O
gene	O
was	O
compared	O
to	O
that	O
of	O
the	O
endogenous	B-GENE
PDGFbeta	I-GENE
r	I-GENE
gene	I-GENE
.	O

The	O
two	O
SH3	B-GENE
domains	I-GENE
are	O
separated	O
by	O
a	O
54	O
amino	O
acid	O
linker	O
region	O
,	O
whose	O
length	O
is	O
highly	O
conserved	O
in	O
xenopus	O
,	O
chicken	O
,	O
and	O
mamalian	B-GENE
Crk	I-GENE
II	I-GENE
proteins	I-GENE
.	O

This	O
complex	O
was	O
eliminated	O
by	O
mutation	O
of	O
either	O
half	O
-	O
site	O
,	O
and	O
it	O
was	O
supershifted	O
by	O
antibodies	O
against	O
chicken	B-GENE
ovalbumin	I-GENE
upstream	I-GENE
promoter	I-GENE
-	I-GENE
transcription	I-GENE
factor	I-GENE
(	O
COUP	B-GENE
-	I-GENE
TF	I-GENE
)	O
.	O

The	O
fz	B-GENE
-	I-GENE
1	I-GENE
and	O
fz	B-GENE
-	I-GENE
2	I-GENE
genes	I-GENE
are	O
widely	O
expressed	O
in	O
rat	O
tissues	O
with	O
the	O
highest	O
steady	O
-	O
state	O
levels	O
of	O
mRNA	O
in	O
kidney	O
,	O
liver	O
,	O
heart	O
,	O
uterus	O
,	O
and	O
ovary	O
.	O

fz	B-GENE
-	I-GENE
1	I-GENE
and	I-GENE
-	I-GENE
2	I-GENE
mRNA	I-GENE
levels	O
were	O
greater	O
in	O
neonatal	O
than	O
in	O
corresponding	O
adult	O
tissues	O
.	O

These	O
results	O
indicate	O
that	O
the	O
changes	O
in	O
the	O
patient	O
'	O
s	O
thyroid	O
scan	O
and	O
RAIU	O
were	O
attributable	O
to	O
the	O
presence	O
of	O
TSAb	O
.	O

The	O
methods	O
used	O
were	O
the	O
AOAC	O
method	O
of	O
dilution	O
and	O
heating	O
;	O
the	O
addition	O
of	O
mercuric	O
chloride	O
,	O
charcoal	O
,	O
and	O
Carrez	O
reagents	O
at	O
2	O
different	O
pH	O
values	O
;	O
and	O
direct	O
analysis	O
of	O
sample	O
supernatants	O
with	O
no	O
treatment	O
(	O
control	O
)	O
.	O

Cytochemical	O
and	O
ultrastructural	O
observations	O
on	O
the	O
tegument	O
of	O
the	O
trematode	O
Megalodiscus	O
temperatus	O
.	O

In	O
this	O
report	O
,	O
we	O
establish	O
that	O
the	O
heteromeric	O
CCAAT	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
CBF	B-GENE
is	O
the	O
major	O
component	O
of	O
the	O
C1	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
(	O
C1F	B-GENE
)	O
in	O
human	O
cells	O
.	O

A	O
40	O
-	O
fold	O
stimulation	O
of	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
activity	O
mediated	O
by	O
four	O
tandem	O
repeats	O
of	O
the	O
SNE	B-GENE
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250	O
-	O
fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA	O
-	O
transfected	O
U	O
-	O
937	O
cells	O
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
-	O
mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

This	O
increased	O
frequency	O
of	O
infection	O
has	O
been	O
accompanied	O
by	O
significant	O
excess	O
mortality	O
.	O

Deletion	O
mutants	O
of	O
the	O
human	B-GENE
CHOP	I-GENE
promoter	I-GENE
identify	O
a	O
region	O
comprising	O
nucleotides	O
-	O
75	O
to	O
-	O
104	O
required	O
for	O
both	O
constitutive	O
and	O
ER	O
-	O
stress	O
-	O
inducible	O
expression	O
.	O

The	O
duration	O
of	O
PGE2	O
and	O
PGF2	O
alpha	O
elevations	O
as	O
well	O
as	O
the	O
peak	O
values	O
were	O
influenced	O
by	O
day	O
of	O
the	O
cycle	O
.	O

We	O
propose	O
that	O
the	O
cDNA	O
encodes	O
an	O
apical	O
plasma	O
membrane	O
protein	O
that	O
plays	O
a	O
role	O
in	O
the	O
functional	O
expression	O
of	O
the	O
amiloride	O
-	O
sensitive	O
epithelial	O
sodium	O
channel	O
.	O

Electrophysiology	O
and	O
pharmacology	O
of	O
epicardial	O
,	O
endocardial	O
,	O
and	O
M	O
cells	O
.	O

In	O
contrast	O
,	O
an	O
N	B-GENE
-	I-GENE
terminal	I-GENE
RNAP	I-GENE
mutant	I-GENE
that	O
has	O
a	O
decreased	O
capacity	O
to	O
bind	O
single	O
-	O
stranded	O
RNA	O
forms	O
halted	O
complexes	O
with	O
much	O
lower	O
levels	O
of	O
stability	O
than	O
the	O
WT	O
enzyme	O
,	O
and	O
these	O
complexes	O
are	O
not	O
stabilized	O
by	O
the	O
presence	O
of	O
the	O
NT	O
strand	O
.	O

A	O
cephalothoracophagus	O
disymmetros	O
buffalo	O
calf	O
.	O

A	O
mouse	O
brain	O
cDNA	O
library	O
in	O
lambdagt11	O
was	O
screened	O
for	O
this	O
association	O
,	O
and	O
two	O
positive	O
clones	O
encoding	O
tyrosine	B-GENE
phosphatase	I-GENE
SH	B-GENE
-	I-GENE
PTP2	I-GENE
were	O
isolated	O
.	O

Disorganization	O
scores	O
of	O
the	O
hypertrophy	O
zone	O
and	O
trabecular	O
bone	O
were	O
low	O
,	O
approaching	O
normal	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
for	O
turkey	O
poults	O
fed	O
on	O
diets	O
with	O
phytase	B-GENE
supplementation	O
,	O
and	O
tibial	O
abnormality	O
scores	O
were	O
linearly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
as	O
nP	O
levels	O
increased	O
(	O
zero	O
score	O
is	O
considered	O
normal	O
)	O
.	O

Repression	O
was	O
strictly	O
dependent	O
on	O
the	O
presence	O
of	O
upstream	O
Oshox1	B-GENE
binding	O
sites	O
in	O
the	O
reporter	O
gene	O
constructs	O
and	O
a	O
function	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Oshox1	B-GENE
,	O
preceding	O
the	O
homeodomain	B-GENE
.	O

Ondansetron	O
is	O
thus	O
an	O
effective	O
first	O
-	O
line	O
antiemetic	O
in	O
children	O
undergoing	O
chemotherapy	O
,	O
radiotherapy	O
and	O
surgery	O
.	O

To	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
the	O
Ras	B-GENE
signaling	O
pathway	O
activates	O
a	O
cell	O
-	O
type	O
-	O
specific	O
gene	O
,	O
we	O
have	O
used	O
the	O
pituitary	B-GENE
-	I-GENE
specific	I-GENE
rat	I-GENE
prolactin	I-GENE
(	O
rPRL	B-GENE
)	O
promoter	O
as	O
a	O
target	O
of	O
oncogenic	B-GENE
Ras	I-GENE
and	O
Raf	B-GENE
in	O
GH4	O
rat	O
pituitary	O
cells	O
.	O

The	O
human	O
RFC	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
differs	O
from	O
the	O
mouse	O
and	O
hamster	O
genes	O
both	O
in	O
terms	O
of	O
the	O
total	O
number	O
of	O
exons	O
and	O
in	O
regard	O
to	O
alternatives	O
of	O
exon	O
1	O
which	O
encode	O
5	O
'	O
end	O
heterogeneity	O
.	O

Type	O
C	O
units	O
summate	O
the	O
responses	O
to	O
the	O
two	O
-	O
tone	O
stimulus	O
,	O
and	O
show	O
little	O
or	O
no	O
inhibitory	O
influences	O
.	O

HGF	B-GENE
treatment	O
increased	O
cyclin	B-GENE
A	I-GENE
,	O
cyclin	B-GENE
G1	I-GENE
and	O
nuclear	O
transcriptional	O
factor	O
(	O
NFkappaB	B-GENE
)	O
protein	O
expression	O
.	O

Since	O
blood	O
serotonin	O
is	O
primarily	O
produced	O
peripherally	O
,	O
these	O
results	O
suggest	O
that	O
some	O
aspect	O
of	O
peripheral	O
serotonin	O
metabolism	O
is	O
abnormal	O
in	O
major	O
depression	O
.	O

Although	O
several	O
large	O
waterborne	O
outbreaks	O
occurred	O
during	O
the	O
past	O
decade	O
,	O
most	O
were	O
in	O
small	O
communities	O
.	O

Cytogenetic	O
structures	O
showed	O
a	O
mixte	O
karyotype	O
:	O
mosaicim	O
46	O
XX	O
/	O
46	O
XY	O
with	O
a	O
ratio	O
of	O
a	O
80	O
/	O
20	O
.	O

The	O
1	O
.	O
6	O
-	O
kb	O
cDNA	O
(	O
CBF	B-GENE
-	I-GENE
A	I-GENE
)	O
encoding	O
285	O
amino	O
acids	O
(	O
aa	O
)	O
was	O
obtained	O
,	O
and	O
a	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
fusion	I-GENE
protein	I-GENE
,	O
bacterially	O
produced	O
from	O
the	O
cDNA	O
,	O
bound	O
to	O
DNA	O
fragments	O
containing	O
several	O
CArG	O
boxes	O
.	O

Mutant	B-GENE
M	I-GENE
proteins	I-GENE
were	O
tested	O
for	O
their	O
ability	O
to	O
complement	O
growth	O
of	O
the	O
temperature	O
-	O
sensitive	O
M	B-GENE
protein	I-GENE
mutant	I-GENE
virus	O
tsO23	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

In	O
this	O
paper	O
we	O
review	O
evidence	O
on	O
smoking	O
and	O
lung	O
cancer	O
among	O
Latinos	O
,	O
including	O
findings	O
from	O
several	O
unpublished	O
studies	O
and	O
technical	O
reports	O
.	O

The	O
yjr041c	B-GENE
delta	I-GENE
haploid	O
cells	O
gave	O
rise	O
to	O
microcolonies	O
comprising	O
about	O
20	O
to	O
50	O
cells	O
.	O

Despite	O
these	O
high	O
initial	O
rates	O
of	O
transcription	O
,	O
of	O
all	O
the	O
promoter	O
constructs	O
only	O
LAT	B-GENE
-	O
LTR	O
was	O
able	O
to	O
remain	O
transcriptionally	O
active	O
after	O
the	O
establishment	O
of	O
a	O
latent	O
state	O
.	O

Two	O
mutants	O
,	O
mapping	O
at	O
the	O
HindIII	B-GENE
site	I-GENE
(	O
between	O
the	O
consensus	O
sequences	O
)	O
of	O
the	O
pSC101	B-GENE
tetA	I-GENE
promoter	I-GENE
,	O
were	O
studied	O
:	O
MA2	O
corresponds	O
to	O
a	O
4	O
bp	O
deletion	O
between	O
positions	O
-	O
12	O
and	O
-	O
15	O
;	O
B30	O
bears	O
a	O
44	O
bp	O
insertion	O
C	O
(	O
TA	O
)	O
21	O
G	O
at	O
the	O
HindIII	B-GENE
site	I-GENE
.	O

We	O
concluded	O
that	O
these	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
N	O
-	O
of	O
-	O
1	O
RCT	O
in	O
rheumatology	O
practice	O
.	O

Sci	O
.	O

Effects	O
of	O
timepidium	O
bromide	O
(	O
TB	O
;	O
anticholinergic	O
agent	O
)	O
,	O
acetylcholine	O
(	O
ACh	O
)	O
and	O
neostigmine	O
(	O
Neost	O
)	O
on	O
gastric	O
and	O
duodenal	O
blood	O
flow	O
distribution	O
were	O
studied	O
by	O
the	O
use	O
of	O
131I	O
-	O
labeled	O
macroaggregated	O
human	O
serum	O
albumin	O
(	O
MAA	B-GENE
)	O
in	O
rabbits	O
.	O

These	O
extrachromosomal	O
copies	O
can	O
be	O
isolated	O
as	O
covalently	O
closed	O
molecules	O
with	O
lengths	O
around	O
3mu	O
.	O

Comparison	O
of	O
the	O
footprint	O
patterns	O
of	O
the	O
mouse	B-GENE
and	I-GENE
human	I-GENE
HPRT	I-GENE
genes	I-GENE
demonstrated	O
that	O
the	O
in	O
vivo	O
binding	O
of	O
regulatory	O
proteins	O
between	O
these	O
species	O
is	O
generally	O
conserved	O
but	O
not	O
identical	O
.	O

Here	O
,	O
we	O
describe	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
enzyme	O
from	O
Escherichia	O
colidetermined	O
and	O
refined	O
to	O
2	O
.	O
0	O
A	O
resolution	O
.	O

Our	O
Northern	O
and	O
Southern	O
blot	O
analyses	O
of	O
meningiomas	O
clearly	O
suggest	O
the	O
CLH	B-GENE
-	I-GENE
22	I-GENE
gene	I-GENE
may	O
be	O
involved	O
in	O
the	O
tumor	O
development	O
and	O
can	O
be	O
considered	O
as	O
a	O
candidate	O
for	O
a	O
tumor	O
suppressor	O
.	O

Plasmodium	O
vivax	O
malaria	O
.	O

This	O
set	O
of	O
genetic	O
and	O
physical	O
interactions	O
suggests	O
a	O
role	O
for	O
yeast	O
RNA	O
-	O
binding	O
proteins	O
in	O
transcriptional	O
regulation	O
.	O

POPULATION	O
AND	O
METHODS	O
:	O
105	O
patients	O
were	O
followed	O
prospectively	O
(	O
male	O
:	O
87	O
%	O
;	O
age	O
:	O
56	O
+	O
/	O
-	O
10	O
)	O
;	O
clinical	O
evaluation	O
was	O
performed	O
in	O
the	O
1st	O
,	O
3rd	O
and	O
6th	O
month	O
,	O
SEKG	O
in	O
the	O
4th	O
month	O
and	O
recatheterization	O
for	O
angiographic	O
control	O
in	O
the	O
6th	O
month	O
.	O

All	O
other	O
cysts	O
showed	O
a	O
unilocular	O
,	O
purely	O
cystic	O
pattern	O
,	O
with	O
homogeneous	O
fluids	O
,	O
although	O
the	O
T2	O
relaxation	O
times	O
of	O
four	O
lesions	O
overlapped	O
those	O
of	O
odontogenic	O
keratocysts	O
.	O

Genetic	O
diagnosis	O
of	O
respiratory	O
diseases	O

The	O
c	B-GENE
-	I-GENE
Jun	I-GENE
delta	I-GENE
-	I-GENE
domain	I-GENE
inhibits	O
neuroendocrine	O
promoter	O
activity	O
in	O
a	O
DNA	O
sequence	O
-	O
and	O
pituitary	O
-	O
specific	O
manner	O
.	O

Cross	O
-	O
sectional	O
studies	O
continue	O
to	O
dominate	O
.	O

The	O
role	O
of	O
the	O
medical	O
facilities	O
in	O
the	O
prognosis	O
of	O
the	O
patient	O
with	O
tetanus	O
specially	O
the	O
importance	O
of	O
considering	O
at	O
the	O
same	O
time	O
the	O
severity	O
of	O
the	O
disease	O
and	O
the	O
characteristics	O
of	O
the	O
therapy	O
deserve	O
further	O
study	O
in	O
order	O
to	O
contribute	O
to	O
the	O
development	O
of	O
the	O
medical	O
assistance	O
to	O
the	O
patients	O
with	O
tetanus	O
.	O

Differences	O
were	O
not	O
found	O
in	O
colons	O
by	O
SEM	O
.	O

Increasing	O
the	O
height	O
of	O
the	O
agar	O
column	O
overlying	O
the	O
SN	O
fabric	O
diminished	O
the	O
inhibitory	O
effect	O
of	O
SN	O
on	O
microbial	O
growth	O
.	O

Neither	O
raw	O
nor	O
retrograded	O
resistant	O
starch	O
lowers	O
fasting	O
serum	O
cholesterol	O
concentrations	O
in	O
healthy	O
normolipidemic	O
subjects	O
.	O

(	O
5	O
)	O
.	O

Hepatitis	O
B	O
markers	O
in	O
Lancashire	O
police	O
officers	O
.	O

In	O
the	O
other	O
two	O
groups	O
(	O
NAAR	O
and	O
PLA	O
)	O
,	O
no	O
variation	O
in	O
this	O
serum	O
protease	O
was	O
observed	O
.	O

Maximum	O
likelihood	O
estimation	O
in	O
covariance	O
structure	O
analysis	O
with	O
truncated	O
data	O
.	O

A	O
single	O
dose	O
of	O
Cef	O
was	O
administered	O
intravenously	O
to	O
11	O
patients	O
with	O
autoimmune	O
diseases	O
and	O
varying	O
degrees	O
of	O
renal	O
impairment	O
(	O
Group	O
I	O
CLCR	O
less	O
than	O
50	O
ml	O
/	O
min	O
,	O
Group	O
II	O
CLCR	O
greater	O
than	O
50	O
ml	O
/	O
min	O
)	O
.	O

The	O
liver	O
-	O
specific	O
sequence	O
contains	O
unique	O
consensus	O
sites	O
for	O
phosphorylation	O
by	O
cyclic	B-GENE
AMP	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
and	O
by	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
.	O

Effect	O
of	O
gentamycin	O
on	O
the	O
kidney	O
functional	O
state	O
in	O
experimental	O
pyelonephritis	O

They	O
represent	O
a	O
physiologically	O
more	O
meaningful	O
pattern	O
than	O
the	O
arithmetic	O
mean	O
with	O
standard	O
deviation	O
.	O

The	O
Valpha	B-GENE
and	O
Vbeta	B-GENE
domains	I-GENE
have	O
the	O
canonical	O
features	O
of	O
known	O
teleost	B-GENE
and	I-GENE
mammalian	I-GENE
TCR	I-GENE
V	I-GENE
domains	I-GENE
,	O
including	O
conserved	O
residues	O
in	O
the	O
beginning	O
of	O
FR2	B-GENE
and	O
at	O
the	O
end	O
of	O
FR3	B-GENE
.	O

Whether	O
this	O
lack	O
of	O
preferential	O
repair	O
has	O
to	O
be	O
explained	O
by	O
a	O
defect	O
in	O
repair	O
or	O
in	O
general	O
transcription	O
is	O
unclear	O
at	O
present	O
.	O

This	O
study	O
examines	O
LEIBNIZ	O
'	O
idea	O
of	O
Veterinary	O
medicine	O
in	O
a	O
biographical	O
context	O
.	O

Dipetalonema	O
(	O
Acanthocheilonema	O
)	O
didelphis	O
sp	O
.	O

n	O
.	O

However	O
,	O
the	O
MCMI	O
-	O
III	O
group	O
profile	O
was	O
significantly	O
lower	O
in	O
magnitude	O
compared	O
with	O
the	O
MCMI	O
-	O
II	O
.	O

While	O
there	O
is	O
growing	O
evidence	O
that	O
perception	O
and	O
imagery	O
share	O
common	O
neural	O
substrates	O
,	O
the	O
fact	O
that	O
D	O
.	O
F	O
.	O
shows	O
intact	O
visual	O
imagery	O
in	O
the	O
face	O
of	O
a	O
massive	O
perceptual	O
deficit	O
in	O
form	O
vision	O
challenges	O
recent	O
suggestions	O
that	O
these	O
two	O
psychological	O
processes	O
share	O
common	O
input	O
pathways	O
in	O
early	O
vision	O
.	O

An	O
ethnic	O
analysis	O
was	O
made	O
of	O
8947	O
cases	O
of	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	O
seen	O
at	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
(	O
AFIP	O
)	O
,	O
Washington	O
,	O
DC	O
,	O
from	O
1971	O
to	O
1985	O
.	O

The	O
exact	O
function	O
of	O
IP	B-GENE
-	I-GENE
30	I-GENE
is	O
not	O
yet	O
known	O
,	O
but	O
it	O
may	O
play	O
a	O
role	O
in	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
mediated	O
immune	O
reactions	O
.	O

The	O
levels	O
of	O
products	O
expressed	O
from	O
these	O
chimeric	O
cDNAs	O
in	O
COS	O
cells	O
were	O
assessed	O
by	O
activity	O
assay	O
and	O
by	O
metabolic	O
labeling	O
of	O
the	O
proteins	O
followed	O
by	O
immunoprecipitation	O
and	O
SDS	O
-	O
PAGE	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
FRS2	B-GENE
forms	O
a	O
complex	O
with	O
the	O
N	B-GENE
-	I-GENE
terminal	I-GENE
SH2	I-GENE
domain	I-GENE
of	O
the	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
Shp2	I-GENE
in	O
response	O
to	O
FGF	B-GENE
stimulation	O
.	O

It	O
is	O
concluded	O
that	O
the	O
drinking	O
ampules	O
of	O
VP	O
-	O
16	O
-	O
213	O
can	O
be	O
replaced	O
with	O
the	O
new	O
oral	O
capsules	O
with	O
a	O
recommended	O
initial	O
dose	O
of	O
100	O
-	O
130	O
mg	O
/	O
m2	O
given	O
in	O
5	O
-	O
day	O
courses	O
every	O
21	O
-	O
28	O
days	O
.	O

The	O
H5	B-GENE
mutants	I-GENE
were	O
:	O
DH5	B-GENE
(	O
all	O
amino	O
acids	O
in	O
D	O
configuration	O
)	O
and	O
H5F	B-GENE
(	O
where	O
all	O
His	O
are	O
replaced	O
by	O
Phe	O
at	O
positions	O
3	O
,	O
7	O
,	O
8	O
,	O
15	O
,	O
18	O
,	O
19	O
,	O
21	O
)	O
.	O

Although	O
the	O
number	O
of	O
kits	O
has	O
increased	O
,	O
the	O
precision	O
has	O
improved	O
,	O
showing	O
that	O
more	O
robust	O
methods	O
are	O
now	O
employed	O
.	O

These	O
results	O
establish	O
that	O
the	O
DNA	O
fragment	O
we	O
have	O
isolated	O
contains	O
the	O
human	B-GENE
gp130	I-GENE
promoter	I-GENE
and	O
that	O
interleukin	B-GENE
-	I-GENE
6	I-GENE
type	I-GENE
cytokines	I-GENE
may	O
influence	O
the	O
activity	O
of	O
this	O
promoter	O
via	O
activated	O
STATs	B-GENE
.	O

When	O
targeted	O
to	O
the	O
GAL1	B-GENE
promoter	I-GENE
by	O
fusing	O
with	O
the	O
Gal4p	B-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
domain	I-GENE
,	O
Sko1p	B-GENE
acts	O
as	O
an	O
Ssn6	B-GENE
/	O
Tup1p	B-GENE
-	O
dependent	O
repressor	O
regulated	O
by	O
osmotic	O
stress	O
.	O

The	O
unexpected	O
prevalence	O
of	O
c	B-GENE
-	I-GENE
myc	I-GENE
and	O
alpha	B-GENE
-	I-GENE
tubulin	I-GENE
in	O
the	O
S	O
-	O
phase	O
library	O
is	O
supported	O
by	O
Northern	O
analysis	O
of	O
RNA	O
from	O
phase	O
-	O
synchronous	O
cells	O
.	O

Growth	O
factors	O
promote	O
cell	O
survival	O
through	O
phosphorylation	O
of	O
Bad	B-GENE
,	O
resulting	O
in	O
its	O
dissociation	O
from	O
Bcl	B-GENE
-	I-GENE
2	I-GENE
and	O
Bcl	B-GENE
-	I-GENE
x	I-GENE
(	I-GENE
L	I-GENE
)	I-GENE
and	O
its	O
association	O
with	O
14	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
3tau	I-GENE
.	O

A	O
representative	O
group	O
of	O
patients	O
undergoing	O
open	O
radical	O
nephrectomy	O
for	O
clinical	O
T1	O
,	O
T2	O
lesions	O
was	O
also	O
identified	O
.	O

By	O
applying	O
a	O
sufficiently	O
strong	O
crusher	O
gradient	O
in	O
the	O
EPI	O
pulse	O
sequence	O
,	O
the	O
temporal	O
variation	O
induced	O
by	O
SSFP	O
disturbance	O
can	O
be	O
suppressed	O
due	O
to	O
diffusion	O
.	O

However	O
,	O
in	O
each	O
case	O
in	O
which	O
either	O
the	O
DQ	B-GENE
alpha	I-GENE
-	I-GENE
or	I-GENE
DQ	I-GENE
beta	I-GENE
-	I-GENE
chain	I-GENE
was	O
exchanged	O
,	O
major	O
alterations	O
or	O
reversals	O
of	O
this	O
pattern	O
of	O
interaction	O
were	O
observed	O
.	O

Only	O
the	O
native	O
structure	O
of	O
phosphorylated	O
ERK	B-GENE
was	O
recognized	O
by	O
VHR	B-GENE
and	O
was	O
inactivated	O
with	O
a	O
second	O
-	O
order	O
rate	O
constant	O
of	O
40	O
,	O
000	O
M	O
-	O
1	O
s	O
-	O
1	O
.	O

From	O
1998	O
to	O
1999	O
,	O
a	O
large	O
number	O
of	O
community	O
-	O
acquired	O
respiratory	O
tract	O
isolates	O
of	O
Streptococcus	O
pneumoniae	O
(	O
n	O
=	O
566	O
)	O
,	O
Haemophilus	O
influenzae	O
(	O
n	O
=	O
513	O
)	O
and	O
Moraxella	O
catarrhalis	O
(	O
n	O
=	O
228	O
)	O
were	O
collected	O
from	O
15	O
centres	O
in	O
Australia	O
,	O
Hong	O
Kong	O
,	O
Japan	O
,	O
China	O
,	O
the	O
Philippines	O
,	O
Singapore	O
,	O
South	O
Africa	O
and	O
Taiwan	O
through	O
the	O
SENTRY	O
Antimicrobial	O
Surveillance	O
Program	O
.	O

Diethyldithiocarbamate	O
and	O
amphetamine	O
stereotype	O
behavior	O
.	O

We	O
used	O
an	O
immobilized	O
template	O
-	O
based	O
assay	O
to	O
examine	O
transcription	O
termination	O
by	O
VA1	B-GENE
,	O
7SL	B-GENE
,	O
and	O
Alu	B-GENE
class	I-GENE
III	I-GENE
templates	O
and	O
the	O
role	O
of	O
transcript	O
release	O
in	O
the	O
pol	B-GENE
III	I-GENE
terminator	O
-	O
dependent	O
inhibition	O
of	O
processing	O
of	O
B1	B-GENE
-	O
Alu	B-GENE
transcripts	O
.	O

A	O
novel	O
zinc	O
finger	O
-	O
containing	O
RNA	O
-	O
binding	O
protein	O
conserved	O
from	O
fruitflies	O
to	O
humans	O
.	O

Although	O
IL	B-GENE
-	I-GENE
6	I-GENE
can	O
activate	O
ERK	B-GENE
-	I-GENE
1	I-GENE
in	O
HepG2	O
cells	O
,	O
STAT3	B-GENE
transactivation	O
and	O
Ser	O
(	O
727	O
)	O
phosphorylation	O
were	O
not	O
reduced	O
by	O
using	O
the	O
MAP	B-GENE
kinase	I-GENE
/	O
ERK	B-GENE
kinase	I-GENE
(	O
MEK	B-GENE
)	O
inhibitor	O
PD98059	O
or	O
by	O
overexpression	O
of	O
dominant	O
-	O
negative	O
Raf	B-GENE
.	O

6	O
h	O
after	O
ingestion	O
of	O
aspirin	O
on	O
day	O
1	O
to	O
day	O
14	O
,	O
both	O
TX	O
and	O
PGI2	O
levels	O
also	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Tritiated	O
1	O
,	O
24	O
,	O
25	O
-	O
trihydroxyvitamin	O
D3	O
was	O
synthesized	O
biologically	O
and	O
used	O
as	O
tracer	O
to	O
monitor	O
the	O
recovery	O
of	O
endogenous	O
metabolite	O
during	O
isolation	O
from	O
serum	O
.	O

Joint	O
ultrasonography	O
demonstrating	O
thickening	O
of	O
synoviae	O
and	O
tendons	O
has	O
become	O
a	O
useful	O
non	O
-	O
invasive	O
diagnostic	O
tool	O
,	O
although	O
it	O
is	O
not	O
specific	O
for	O
beta	B-GENE
2	I-GENE
-	I-GENE
M	I-GENE
amyloidosis	O
,	O
and	O
results	O
depend	O
on	O
observer	O
experience	O
.	O

Immunofluorescence	O
tests	O
for	O
Borrelia	B-GENE
burgdorferi	I-GENE
serum	I-GENE
antibodies	I-GENE
had	O
positive	O
results	O
,	O
but	O
G	O
-	O
penicillin	O
treatment	O
was	O
ineffective	O
.	O

The	O
size	O
and	O
the	O
predicted	O
N	O
-	O
terminal	O
sequence	O
of	O
the	O
mouse	O
protein	O
were	O
confirmed	O
experimentally	O
.	O

Nuclear	O
runoff	O
assays	O
show	O
that	O
complementation	O
by	O
HPV16	B-GENE
E7	I-GENE
restores	O
the	O
ability	O
of	O
the	O
E1A	B-GENE
mutants	I-GENE
to	O
stimulate	O
early	B-GENE
gene	I-GENE
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Yet	O
IL	B-GENE
-	I-GENE
2	I-GENE
and	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
production	O
are	O
independently	O
regulated	O
,	O
as	O
demonstrated	O
by	O
their	O
differential	O
expression	O
in	O
certain	O
T	O
cell	O
subsets	O
,	O
suggesting	O
that	O
the	O
regulatory	O
elements	O
in	O
these	O
two	O
genes	O
must	O
differ	O
.	O

We	O
conclude	O
that	O
a	O
0	O
.	O
25	O
mg	O
dose	O
of	O
triazolam	O
does	O
not	O
effectively	O
counteract	O
a	O
posture	O
-	O
induced	O
sleep	O
disturbance	O
,	O
but	O
induces	O
changes	O
in	O
the	O
EEG	O
spectra	O
which	O
are	O
typical	O
for	O
benzodiazepine	B-GENE
receptor	I-GENE
agonists	O
.	O

Anisotropy	O
of	O
Hc2	O
and	O
the	O
breadth	O
of	O
the	O
resistive	O
transition	O
of	O
polycrystalline	O
YBa2Cu	O

Microscopic	O
examination	O
of	O
these	O
colonies	O
showed	O
a	O
high	O
percentage	O
of	O
histiocytes	O
identical	O
to	O
those	O
seen	O
in	O
the	O
patient	O
'	O
s	O
bone	O
marrow	O
.	O

Functional	O
uncoupling	O
of	O
the	O
Janus	B-GENE
kinase	I-GENE
3	I-GENE
-	O
Stat5	B-GENE
pathway	O
in	O
malignant	O
growth	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
-	O
transformed	O
human	O
T	O
cells	O
.	O

The	O
herpesvirus	B-GENE
entry	I-GENE
mediator	I-GENE
C	I-GENE
(	O
HveC	B-GENE
)	O
,	O
previously	O
known	O
as	O
poliovirus	B-GENE
receptor	I-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
1	I-GENE
(	O
PRR1	B-GENE
)	O
,	O
and	O
the	O
herpesvirus	B-GENE
Ig	I-GENE
-	I-GENE
like	I-GENE
receptor	I-GENE
(	O
HIgR	B-GENE
)	O
are	O
the	O
bona	O
fide	O
receptors	O
employed	O
by	O
herpes	O
simplex	O
virus	O
-	O
1	O
and	O
-	O
2	O
(	O
HSV	O
-	O
1	O
and	O
-	O
2	O
)	O
for	O
entry	O
into	O
the	O
human	O
cell	O
lines	O
most	O
frequently	O
used	O
in	O
HSV	O
studies	O
.	O

4	O
-	O
Hydroxyproline	O
assays	O
were	O
performed	O
to	O
determine	O
collagen	B-GENE
content	O
.	O

The	O
combination	O
of	O
ICP47	B-GENE
and	O
US11	B-GENE
rendered	O
fibroblasts	O
negative	O
for	O
surface	B-GENE
class	I-GENE
I	I-GENE
MHC	I-GENE
and	O
allowed	O
a	O
class	B-GENE
I	I-GENE
MHC	I-GENE
-	O
low	O
population	O
of	O
T	O
cells	O
to	O
be	O
sorted	O
by	O
flow	O
cytometry	O
.	O

Although	O
IRS	B-GENE
-	I-GENE
1	I-GENE
,	I-GENE
-	I-GENE
2	I-GENE
,	I-GENE
and	I-GENE
-	I-GENE
4	I-GENE
are	O
similar	O
in	O
overall	O
structure	O
,	O
IRS	B-GENE
-	I-GENE
3	I-GENE
is	O
approximately	O
50	O
%	O
shorter	O
and	O
differs	O
with	O
respect	O
to	O
sites	O
of	O
tyrosine	O
phosphorylation	O
.	O

The	O
interaction	O
of	O
different	O
protein	O
systems	O
with	O
microtubules	O
is	O
a	O
critical	O
step	O
in	O
the	O
cellular	O
function	O
of	O
these	O
organelles	O
.	O

In	O
addition	O
,	O
we	O
mapped	O
a	O
putative	O
hnRNP	B-GENE
A1	I-GENE
binding	I-GENE
site	I-GENE
in	O
U5	B-GENE
RNA	I-GENE
and	O
demonstrated	O
that	O
p40CRS	B-GENE
(	O
hnRNP	B-GENE
A1	I-GENE
)	O
binding	O
to	O
that	O
site	O
correlates	O
with	O
CRS	B-GENE
function	O
.	O

Sailer	O
,	O
K	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

This	O
element	O
was	O
required	O
for	O
both	O
basal	O
and	O
activated	O
expression	O
and	O
almost	O
certainly	O
functions	O
as	O
a	O
TATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
interaction	O
site	O
.	O

In	O
HepG2	O
cells	O
,	O
SREBP	B-GENE
-	I-GENE
1c	I-GENE
mRNA	I-GENE
and	O
precursor	O
protein	O
levels	O
were	O
induced	O
by	O
treatment	O
with	O
22	O
(	O
R	O
)	O
-	O
hydroxycholesterol	O
and	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
,	O
confirming	O
that	O
endogenous	O
LXR	B-GENE
-	O
RXR	B-GENE
activation	O
can	O
induce	O
endogenous	B-GENE
SREBP	I-GENE
-	I-GENE
1c	I-GENE
expression	O
.	O

Univariate	O
and	O
multivariate	O
analysis	O
was	O
used	O
to	O
calculate	O
the	O
5	O
-	O
year	O
survival	O
probabilities	O
with	O
respect	O
to	O
the	O
following	O
variables	O
:	O
age	O
(	O
<	O
or	O
=	O
65	O
,	O
>	O
65	O
)	O
,	O
sex	O
,	O
depth	O
of	O
invasion	O
(	O
mucosal	O
,	O
submucosal	O
)	O
tumor	O
location	O
(	O
upper	O
,	O
middle	O
and	O
lower	O
third	O
)	O
,	O
gross	O
appearance	O
(	O
type	O
I	O
,	O
type	O
II	O
and	O
type	O
III	O
)	O
,	O
size	O
(	O
<	O
or	O
=	O
1	O
.	O
5	O
cm	O
,	O
>	O
1	O
.	O
5	O
cm	O
)	O
,	O
presence	O
or	O
absence	O
of	O
lymph	O
node	O
metastasis	O
,	O
histological	O
type	O
(	O
intestinal	O
,	O
diffuse	O
)	O
,	O
extent	O
of	O
lymphadenectomy	O
(	O
limited	O
or	O
extended	O
)	O
,	O
and	O
type	O
of	O
gastrectomy	O
(	O
total	O
or	O
distal	O
subtotal	O
)	O
.	O

This	O
integration	O
results	O
in	O
the	O
production	O
of	O
MMTV	B-GENE
/	I-GENE
mdr3	I-GENE
fusion	I-GENE
transcripts	I-GENE
that	O
originate	O
from	O
the	O
antisense	O
5	B-GENE
'	I-GENE
LTR	I-GENE
of	O
the	O
provirus	O
.	O

In	O
32	O
of	O
them	O
the	O
results	O
of	O
an	O
exercise	O
performance	O
test	O
based	O
on	O
heart	O
rate	O
response	O
to	O
submaximal	O
exercise	O
(	O
VO2	O
,	O
170	O
[	O
bpm	O
]	O
)	O
was	O
compared	O
with	O
another	O
index	O
of	O
physical	O
performance	O
capacity	O
,	O
which	O
is	O
independent	O
from	O
heart	O
rate	O
:	O
the	O
ventilatory	O
threshold	O
.	O

Sequence	O
comparisons	O
reveal	O
that	O
the	O
P	B-GENE
.	I-GENE
woesei	I-GENE
GTP	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
is	O
strikingly	O
related	O
in	O
sequence	O
to	O
eubacterial	B-GENE
FtsZ	I-GENE
and	O
is	O
marginally	O
more	O
similar	O
to	O
eukaryotic	B-GENE
tubulins	I-GENE
than	O
are	O
bacterial	B-GENE
FtsZ	I-GENE
proteins	I-GENE
.	O

Four	O
of	O
15	O
patients	O
with	O
R2	B-GENE
had	O
rheumatoid	O
arthritis	O
and	O
in	O
two	O
of	O
these	O
four	O
cases	O
the	O
antibody	O
was	O
of	O
the	O
IgA	B-GENE
class	O
.	O

Phosphate	O
compounds	O
in	O
isolated	O
,	O
perfused	O
hearts	O
during	O
pH	O
variation	O
due	O
to	O
changes	O
in	O
extracellular	O
PCO2	O
and	O
bicarbonate	O

Vav	B-GENE
and	O
Dbl	B-GENE
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
oncogene	O
proteins	O
that	O
share	O
significant	O
sequence	O
identity	O
in	O
a	O
approximately	O
250	O
-	O
amino	O
-	O
acid	O
domain	O
,	O
designated	O
the	O
Dbl	B-GENE
homology	I-GENE
domain	I-GENE
.	O

Serum	O
AFP	B-GENE
is	O
a	O
useful	O
tumor	O
marker	O
for	O
monitoring	O
the	O
results	O
of	O
therapy	O
.	O

The	O
possible	O
equivalency	O
of	O
a	O
short	O
form	O
and	O
the	O
long	O
form	O
of	O
the	O
Multiple	O
Affect	O
Adjective	O
Check	O
List	O
-	O
Revised	O
(	O
MAACL	O
-	O
R	O
;	O
Zuckerman	O
&	O
Lubin	O
,	O
1985	O
)	O
was	O
studied	O
by	O
correlating	O
both	O
forms	O
of	O
the	O
MAACL	O
-	O
R	O
with	O
the	O
State	O
Trait	O
Personality	O
Inventory	O
(	O
Spielberger	O
,	O
1995	O
)	O
;	O
the	O
Affect	O
Balance	O
Scale	O
(	O
Bradburn	O
,	O
1969	O
)	O
;	O
and	O
the	O
Sensation	O
Seeking	O
Scale	O
(	O
Zuckerman	O
,	O
1978	O
)	O
.	O

The	O
data	O
show	O
that	O
processing	O
time	O
as	O
a	O
function	O
of	O
intensity	O
is	O
modified	O
not	O
only	O
at	O
the	O
retina	O
but	O
also	O
at	O
later	O
processing	O
sites	O
.	O

Identification	O
of	O
masked	O
toxins	O
in	O
the	O
exotoxin	O
complex	O
of	O
Staphylococcus	O
pyogenes	O
und	O
Cl	O
.	O
perfringens	O
;	O
significance	O
of	O
their	O
existence	O
for	O
clarifying	O
of	O
the	O
masking	O
mechanism	O

Unlike	O
LANA1	B-GENE
,	O
LANA2	B-GENE
does	O
not	O
elicit	O
a	O
serologic	O
response	O
from	O
patients	O
with	O
KS	O
,	O
PEL	O
,	O
or	O
CD	O
as	O
measured	O
by	O
Western	O
blot	O
hybridization	O
.	O

However	O
,	O
this	O
posttranslational	O
modification	O
of	O
the	O
gar2	B-GENE
protein	I-GENE
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
production	O
of	O
18S	B-GENE
rRNA	I-GENE
.	O

Here	O
,	O
we	O
analyzed	O
the	O
interaction	O
of	O
CYT	B-GENE
-	I-GENE
18	I-GENE
with	O
a	O
small	O
RNA	O
(	O
P4	B-GENE
-	I-GENE
P6	I-GENE
RNA	I-GENE
)	O
corresponding	O
to	O
the	O
isolated	O
P4	B-GENE
-	I-GENE
P6	I-GENE
domain	I-GENE
of	O
the	O
N	B-GENE
.	I-GENE
crassa	I-GENE
mitochondrial	I-GENE
large	I-GENE
subunit	I-GENE
ribosomal	I-GENE
RNA	I-GENE
intron	I-GENE
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
PutR	B-GENE
(	O
154	O
amino	O
acid	O
residues	O
)	O
showed	O
homology	O
to	O
the	O
small	O
regulatory	O
proteins	O
Lrp	B-GENE
,	O
BkdR	B-GENE
,	O
and	O
AsnC	B-GENE
.	O

When	O
yeast	O
cells	O
reach	O
a	O
critical	O
size	O
in	O
late	O
G1	O
they	O
simultaneously	O
start	O
budding	O
,	O
initiate	O
DNA	O
synthesis	O
,	O
and	O
activate	O
transcription	O
of	O
a	O
set	O
of	O
genes	O
that	O
includes	O
G1	B-GENE
cyclins	I-GENE
CLN1	B-GENE
,	O
CLN2	B-GENE
,	O
and	O
many	O
DNA	O
synthesis	O
genes	O
.	O

Functional	O
PET	O
scanning	O
in	O
the	O
preoperative	O
assessment	O
of	O
cerebral	O
arteriovenous	O
malformations	O
.	O

In	O
addition	O
,	O
269	O
mice	O
from	O
a	O
(	O
Mus	O
spretus	O
x	O
C57BL	O
/	O
6J	O
)	O
F1	O
x	O
C57BL	O
/	O
6J	O
interspecific	O
backcross	O
were	O
also	O
used	O
to	O
order	O
marker	O
loci	O
and	O
calculate	O
intergene	O
distances	O
for	O
this	O
region	O
.	O

Accordingly	O
,	O
superpeptide	O
antigenic	O
material	O
was	O
readily	O
detected	O
by	O
immunoblotting	O
cell	O
extracts	O
and	O
enriched	O
in	O
vacuolar	O
preparations	O
of	O
PrA	B-GENE
deficient	O
mutant	O
cells	O
.	O

Blockade	O
of	O
T	O
cell	O
activation	O
using	O
a	O
surface	O
-	O
linked	O
single	O
-	O
chain	O
antibody	O
to	O
CTLA	B-GENE
-	I-GENE
4	I-GENE
(	O
CD152	B-GENE
)	O
.	O

Water	O
pair	O
and	O
three	O
-	O
body	O
potential	O
of	O
spectroscopic	O
quality	O
from	O
Ab	O
initio	O
calculations	O

4	O
)	O
Mutation	O
of	O
the	O
three	O
extracellular	O
cysteine	O
residues	O
of	O
GFKAR	B-GENE
beta	I-GENE
indicated	O
that	O
the	O
two	O
conserved	O
cysteine	O
residues	O
(	O
C305	O
and	O
C385	O
)	O
,	O
located	O
between	O
two	O
transmembrane	O
segments	O
,	O
form	O
a	O
solvent	O
-	O
accessible	O
disulfide	O
bond	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
used	O
Xenopus	O
oocyte	O
maturation	O
as	O
a	O
read	O
-	O
out	O
for	O
examining	O
the	O
ability	O
of	O
the	O
neu	B-GENE
tyrosine	B-GENE
kinase	I-GENE
(	O
p185neu	B-GENE
)	O
to	O
participate	O
with	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
EGF	I-GENE
)	I-GENE
receptor	I-GENE
in	O
a	O
common	O
signal	O
transduction	O
pathway	O
.	O

The	O
best	O
-	O
studied	O
neurotrophin	O
,	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
(	O
NGF	B-GENE
)	O
,	O
is	O
a	O
major	O
survival	O
factor	O
in	O
sympathetic	O
and	O
sensory	O
neurons	O
and	O
promotes	O
differentiation	O
in	O
a	O
well	O
-	O
studied	O
model	O
system	O
,	O
PC12	O
cells	O
.	O

In	O
contrast	O
,	O
MAPK	B-GENE
activation	O
stimulated	O
by	O
the	O
Gq	B-GENE
-	O
coupled	O
alpha	O
1B	O
AR	O
or	O
M1	B-GENE
muscarinic	B-GENE
cholinergic	I-GENE
receptor	I-GENE
is	O
unaffected	O
by	O
expression	O
of	O
beta	B-GENE
ARKct	I-GENE
or	O
RasN17	B-GENE
expression	O
or	O
by	O
PTK	B-GENE
inhibitors	O
,	O
but	O
is	O
blocked	O
by	O
expression	O
of	O
N	B-GENE
delta	I-GENE
Raf	I-GENE
or	O
by	O
PKC	B-GENE
depletion	O
.	O

Transcriptional	O
analysis	O
indicates	O
that	O
human	B-GENE
TBP	I-GENE
functions	O
poorly	O
at	O
promoters	O
recognized	O
by	O
RNA	B-GENE
polymerases	I-GENE
I	I-GENE
and	I-GENE
III	I-GENE
and	O
at	O
RNA	B-GENE
Pol	I-GENE
II	I-GENE
promoters	I-GENE
lacking	O
a	O
conventional	O
TATA	O
element	O
.	O

The	O
steady	O
-	O
state	O
levels	O
of	O
Cdk2	B-GENE
,	O
Cdk4	B-GENE
and	O
Cyclin	B-GENE
A	I-GENE
proteins	I-GENE
were	O
unaffected	O
by	O
HPR	O
,	O
while	O
those	O
of	O
Cyclin	B-GENE
D1	I-GENE
were	O
significantly	O
reduced	O
in	O
all	O
three	O
cell	O
lines	O
.	O

Mapping	O
the	O
5	O
'	O
and	O
3	O
'	O
termini	O
of	O
TED	B-GENE
RNAs	I-GENE
indicated	O
that	O
the	O
LTRs	O
have	O
a	O
retroviral	O
U3	O
-	O
R	O
-	O
U5	O
structural	O
organization	O
that	O
is	O
capable	O
of	O
directing	O
the	O
synthesis	O
of	O
transcripts	O
that	O
represent	O
potential	O
substrates	O
for	O
reverse	O
transcription	O
and	O
intermediates	O
in	O
transposition	O
.	O

Human	O
forearm	O
was	O
used	O
as	O
a	O
dummy	O
ear	O
and	O
the	O
electrode	O
HN	O
-	O
5	O
was	O
fixed	O
thereon	O
,	O
and	O
a	O
sound	O
stimulus	O
of	O
90dBnHL	O
was	O
delivered	O
by	O
the	O
earphone	O
(	O
NC	O
-	O
3	O
)	O
.	O

These	O
proteins	O
were	O
detected	O
by	O
an	O
antibody	O
which	O
recognizes	O
the	O
N	O
-	O
terminus	O
of	O
SRK3	B-GENE
and	O
,	O
in	O
an	O
F2	O
progeny	O
segregating	O
for	O
the	O
S3	B-GENE
haplotype	I-GENE
,	O
were	O
only	O
expressed	O
in	O
plants	O
possessing	O
the	O
S3	B-GENE
haplotype	I-GENE
.	O

The	O
blood	O
pressures	O
in	O
43	O
subjects	O
were	O
compared	O
during	O
rapid	O
weight	O
loss	O
and	O
at	O
identical	O
weights	O
during	O
post	O
-	O
fast	O
weight	O
gain	O
(	O
Study	O
A	O
)	O
.	O

The	O
animals	O
were	O
followed	O
over	O
a	O
1	O
-	O
to	O
6	O
-	O
h	O
posttraumatic	O
course	O
,	O
and	O
processed	O
for	O
the	O
LM	O
and	O
TEM	O
visualization	O
of	O
HRP	B-GENE
.	O

Total	O
body	O
water	O
and	O
distribution	O
space	O
of	O
Na24	O
in	O
women	O
with	O
various	O
body	O
weight	O

Three	O
experiments	O
using	O
20	O
microM	O
2	O
-	O
(	O
hydroxyamino	O
)	O
-	O
1	O
-	O
methyl	O
-	O
6	O
-	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
b	O
]	O
pyridine	O
(	O
N	O
-	O
OH	O
-	O
PhIP	O
)	O
were	O
performed	O
to	O
induce	O
mutations	O
in	O
the	O
dihydrofolate	B-GENE
reductase	I-GENE
(	O
DHFR	B-GENE
)	O
gene	O
of	O
a	O
hemizygous	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
line	O
(	O
UA21	O
)	O
.	O

This	O
is	O
mediated	O
by	O
vascular	O
remodeling	O
,	O
an	O
active	O
process	O
that	O
results	O
in	O
a	O
change	O
in	O
the	O
geometry	O
of	O
the	O
blood	O
vessel	O
.	O

Our	O
results	O
separate	O
these	O
factors	O
into	O
four	O
regulatory	O
classes	O
:	O
(	O
i	O
)	O
constitutive	O
factors	O
,	O
such	O
as	O
Oct	B-GENE
-	I-GENE
1	I-GENE
and	O
probably	O
Sp1	B-GENE
,	O
that	O
are	O
expressed	O
in	O
thymocytes	O
at	O
all	O
stages	O
;	O
(	O
ii	O
)	O
inducible	O
factors	O
,	O
such	O
as	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
and	O
complexes	O
binding	O
to	O
the	O
region	O
of	O
a	O
CD28	B-GENE
response	I-GENE
element	I-GENE
,	O
that	O
can	O
be	O
activated	O
in	O
all	O
thymocytes	O
,	O
including	O
those	O
cells	O
(	O
CD4	B-GENE
+	I-GENE
CD8	B-GENE
+	I-GENE
TcRlow	B-GENE
)	O
that	O
can	O
undergo	O
selection	O
;	O
(	O
iii	O
)	O
inducible	O
factors	O
,	O
such	O
as	O
NF	B-GENE
-	I-GENE
AT	I-GENE
and	O
AP	B-GENE
-	I-GENE
1	I-GENE
,	O
that	O
can	O
be	O
activated	O
in	O
mature	O
(	O
CD4	B-GENE
+	I-GENE
CD8	B-GENE
-	I-GENE
TcRhigh	B-GENE
)	O
and	O
immature	O
(	O
CD4	B-GENE
-	I-GENE
CD8	B-GENE
-	I-GENE
TcR	B-GENE
-	I-GENE
)	O
thymocytes	O
alike	O
but	O
not	O
in	O
the	O
transitional	O
stages	O
when	O
the	O
cells	O
(	O
CD4	B-GENE
+	I-GENE
CD8	B-GENE
+	I-GENE
TcRlow	B-GENE
)	O
are	O
subject	O
to	O
selection	O
;	O
and	O
(	O
iv	O
)	O
a	O
factor	O
containing	O
CREB	B-GENE
,	O
which	O
can	O
be	O
activated	O
in	O
thymocytes	O
of	O
all	O
developmental	O
stages	O
by	O
culture	O
but	O
does	O
not	O
require	O
specific	O
induction	O
.	O

Thus	O
,	O
22	O
%	O
of	O
MDS	O
responded	O
to	O
oral	O
PLAC	O
.	O

Posterior	O
osteophytes	O
around	O
the	O
posterior	O
edges	O
of	O
vertebral	O
body	O
resulted	O
in	O
intervertebral	O
insufficiency	O
,	O
and	O
corresponded	O
to	O
hypertrophic	O
spur	O
in	O
osteochondrosis	O
.	O

They	O
showed	O
moderate	O
in	O
vitro	O
antifungal	O
activity	O
against	O
a	O
wide	O
variety	O
of	O
fungi	O
and	O
yeasts	O
including	O
clinically	O
important	O
pathogens	O
,	O
and	O
were	O
highly	O
effective	O
in	O
systemic	O
infection	O
with	O
Candida	O
albicans	O
in	O
mice	O
after	O
iv	O
and	O
im	O
administrations	O
.	O

Of	O
these	O
four	O
PP2C	B-GENE
genes	I-GENE
,	O
the	O
expression	O
of	O
the	O
PP2Cbeta	B-GENE
gene	I-GENE
has	O
been	O
reported	O
to	O
be	O
tissue	O
-	O
specific	O
and	O
development	O
-	O
dependent	O
.	O

We	O
also	O
show	O
that	O
in	O
fusions	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	B-GENE
,	O
full	O
activity	O
requires	O
the	O
entire	O
BHV	B-GENE
-	I-GENE
alpha	I-GENE
TIF	I-GENE
,	O
although	O
both	O
amino	O
and	O
carboxyl	O
termini	O
display	O
some	O
activity	O
on	O
their	O
own	O
.	O

The	O
induction	O
by	O
dexamethasone	O
of	O
rat	B-GENE
liver	I-GENE
CYP3A1	I-GENE
differs	O
from	O
classical	O
glucocorticoid	O
gene	O
regulation	O
in	O
part	O
because	O
both	O
glucocorticoids	O
and	O
antiglucocorticoids	O
such	O
as	O
pregnenolone	O
16	O
alpha	O
-	O
carbonitrile	O
(	O
PCN	O
)	O
induce	O
CYP3A1	B-GENE
through	O
transcriptional	O
gene	O
activation	O
.	O

Moreover	O
,	O
antibody	O
binding	O
to	O
the	O
same	O
two	O
determinants	O
was	O
also	O
inhibited	O
when	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
or	O
the	O
SH2	B-GENE
domains	I-GENE
bound	O
to	O
the	O
zeta	O
chain	O
or	O
to	O
a	O
2pY	B-GENE
-	I-GENE
ITAM	I-GENE
.	O

This	O
surface	O
in	O
specimens	O
from	O
unfertilized	O
eggs	O
is	O
almost	O
flat	O
.	O

Fetal	O
transplants	O
rescue	O
axial	O
muscle	O
representations	O
in	O
M1	O
cortex	O
of	O
neonatally	O
transected	O
rats	O
that	O
develop	O
weight	O
support	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
M	B-GENE
-	I-GENE
MuLV	I-GENE
enhancers	I-GENE
to	O
the	O
transcriptional	O
activity	O
and	O
pathogenesis	O
of	O
M	O
-	O
MuLV	O
by	O
constructing	O
LTRs	O
containing	O
heterologous	O
enhancer	O
elements	O
.	O

There	O
were	O
no	O
major	O
postoperative	O
complications	O
and	O
at	O
follow	O
-	O
up	O
of	O
the	O
13	O
patients	O
at	O
10	O
to	O
26	O
months	O
after	O
operation	O
the	O
results	O
were	O
satisfactory	O
.	O

The	O
immunoreactive	O
antithrombin	B-GENE
III	I-GENE
increased	O
significantly	O
while	O
the	O
increase	O
in	O
antithrombin	B-GENE
III	I-GENE
activity	O
was	O
insignificant	O
in	O
20	O
male	O
Caucasian	O
Danes	O
upon	O
3	O
weeks	O
supplementation	O
of	O
the	O
diet	O
with	O
10	O
ml	O
daily	O
of	O
a	O
cod	O
liver	O
oil	O
concentrate	O
.	O

Northern	O
blot	O
analysis	O
confirmed	O
that	O
ADAMTS	B-GENE
-	I-GENE
1	I-GENE
was	O
up	O
-	O
regulated	O
in	O
both	O
metaphyseal	O
(	O
14	O
-	O
to	O
35	O
-	O
fold	O
)	O
and	O
diaphyseal	O
(	O
4	O
.	O
2	O
-	O
fold	O
)	O
bone	O
1	O
h	O
after	O
PTH	B-GENE
-	I-GENE
(	I-GENE
1	I-GENE
-	I-GENE
38	I-GENE
)	I-GENE
injection	O
and	O
returned	O
to	O
control	O
levels	O
by	O
24	O
h	O
.	O

The	O
transcriptional	B-GENE
transactivator	I-GENE
(	O
Tas	B-GENE
)	O
of	O
simian	O
foamy	O
virus	O
type	O
1	O
strongly	O
augments	O
gene	O
expression	O
directed	O
by	O
both	O
the	O
promoter	O
in	O
the	O
viral	O
long	O
terminal	O
repeat	O
and	O
the	O
newly	O
discovered	O
internal	O
promoter	O
located	O
within	O
the	O
env	B-GENE
gene	I-GENE
.	O

In	O
the	O
other	O
two	O
cases	O
,	O
fluoxetine	O
adjunct	O
produced	O
benefits	O
with	O
no	O
additional	O
side	O
effects	O
.	O

Deletion	O
of	O
this	O
consensus	O
element	O
from	O
the	O
spo6	B-GENE
promoter	I-GENE
abolished	O
the	O
transcription	O
of	O
spo6	B-GENE
+	I-GENE
and	O
resulted	O
in	O
a	O
sporulation	O
deficiency	O
.	O

Chem	O
.	O

Mutations	O
in	O
the	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
gene	I-GENE
result	O
in	O
the	O
lysosomal	O
storage	O
disorders	O
GM1	O
-	O
gangliosidosis	O
and	O
Morquio	O
B	O
syndrome	O
.	O

Results	O
indicated	O
that	O
hobbies	O
/	O
leisure	O
activities	O
,	O
mobility	O
,	O
transport	O
,	O
social	O
relationships	O
,	O
working	O
capacity	O
,	O
energy	O
and	O
doing	O
things	O
slower	O
were	O
aspects	O
relevant	O
to	O
IPF	O
patients	O
'	O
QOL	O
.	O

We	O
have	O
generated	O
transgenic	O
fly	O
strains	O
with	O
mutations	O
affecting	O
specific	O
TRA	B-GENE
-	I-GENE
2	I-GENE
isoforms	I-GENE
to	O
investigate	O
their	O
individual	O
roles	O
in	O
regulating	O
the	O
alternative	O
processing	O
of	O
doublesex	B-GENE
,	O
exuperantia	B-GENE
and	O
tra	B-GENE
-	I-GENE
2	I-GENE
pre	I-GENE
-	I-GENE
mRNA	I-GENE
.	O

The	O
IR4	O
ORF	O
exhibits	O
significant	O
homology	O
to	O
the	O
immediate	B-GENE
-	I-GENE
early	I-GENE
gene	I-GENE
US1	B-GENE
(	O
ICP22	B-GENE
)	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
and	O
to	O
the	O
ICP22	B-GENE
homologs	O
of	O
varicella	O
-	O
zoster	O
virus	O
(	O
ORF63	B-GENE
)	O
,	O
pseudorabies	O
virus	O
(	O
RSp40	B-GENE
)	O
,	O
and	O
equine	O
herpesvirus	O
4	O
(	O
ORF4	O
)	O
.	O

These	O
studies	O
define	O
a	O
class	O
of	O
DNA	O
elements	O
with	O
a	O
mode	O
of	O
action	O
that	O
has	O
not	O
been	O
heretofore	O
described	O
.	O

We	O
were	O
able	O
to	O
demonstrate	O
a	O
significant	O
statistical	O
interaction	O
effect	O
between	O
gender	O
and	O
globulin	B-GENE
protein	I-GENE
concentration	O
on	O
Vu	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O

Chest	O
X	O
-	O
P	O
revealed	O
an	O
abnormal	O
shadow	O
in	O
the	O
left	O
upper	O
lobe	O
.	O

From	O
the	O
frozen	O
specimen	O
,	O
a	O
large	O
number	O
of	O
sections	O
with	O
good	O
morphologic	O
characteristics	O
may	O
be	O
produced	O
.	O

These	O
include	O
not	O
only	O
antioxidants	O
,	O
N	B-GENE
-	I-GENE
methyl	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
aspartate	I-GENE
receptor	I-GENE
antagonists	O
,	O
inhibitors	O
of	O
glutamate	O
release	O
,	O
calcium	O
channel	O
blockers	O
,	O
polyamine	O
antagonists	O
,	O
and	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
inhibitors	O
,	O
but	O
cannabinoids	O
,	O
aspirin	O
,	O
melatonin	O
,	O
and	O
vitamin	O
B	O
-	O
12	O
.	O

A	O
series	O
of	O
mutations	O
were	O
constructed	O
within	O
the	O
E2	B-GENE
open	O
reading	O
frame	O
which	O
delete	O
various	O
regions	O
of	O
the	O
conserved	O
DNA	O
binding	O
and	O
transactivation	O
domains	O
as	O
well	O
as	O
the	O
internal	O
hinge	O
region	O
.	O

CrkII	B-GENE
and	O
CrkL	B-GENE
constitutively	O
formed	O
complex	O
with	O
the	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
C3G	B-GENE
,	O
in	O
unstimulated	O
as	O
well	O
as	O
PDGF	B-GENE
-	O
stimulated	O
cells	O
.	O

In	O
further	O
support	O
of	O
the	O
biological	O
significance	O
of	O
these	O
DNA	O
-	O
protein	O
interactions	O
,	O
the	O
IL2RA	B-GENE
oligonucleotide	O
from	O
-	O
291	O
to	O
-	O
245	O
proved	O
to	O
be	O
sufficient	O
in	O
either	O
orientation	O
to	O
confer	O
PMA	O
inducibility	O
to	O
the	O
mitogen	O
-	O
insensitive	O
thymidine	B-GENE
kinase	I-GENE
gene	I-GENE
promoter	I-GENE
in	O
Jurkat	O
cells	O
.	O

The	O
plasma	O
steroid	O
levels	O
in	O
the	O
CAPD	O
patients	O
after	O
each	O
infusion	O
rate	O
were	O
equal	O
to	O
or	O
greater	O
than	O
the	O
levels	O
in	O
normal	O
subjects	O
.	O

With	O
BCPP	O
protocol	O
,	O
12	O
achieved	O
a	O
complete	O
response	O
,	O
11	O
evidenced	O
a	O
75	O
%	O
response	O
,	O
and	O
7	O
displayed	O
a	O
50	O
%	O
response	O
.	O

The	O
RPC31	B-GENE
gene	I-GENE
encoding	O
the	O
C31	B-GENE
subunit	I-GENE
of	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
RNA	I-GENE
polymerase	I-GENE
C	I-GENE
(	I-GENE
III	I-GENE
)	I-GENE
has	O
been	O
isolated	O
,	O
starting	O
from	O
a	O
C	O
-	O
terminal	O
fragment	O
cloned	O
on	O
a	O
lambda	O
gt11	O
library	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
sequences	O
within	O
this	O
region	O
bind	O
members	O
of	O
the	O
Sp1	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
.	O

The	O
phosphatase	O
active	O
site	O
is	O
located	O
within	O
residues	O
367	O
-	O
374	O
.	O

After	O
at	O
least	O
one	O
year	O
follow	O
-	O
up	O
,	O
argon	O
laser	O
showed	O
a	O
statistically	O
significant	O
effect	O
(	O
p	O
less	O
of	O
0	O
,	O
01	O
;	O
Kolmogorow	O
-	O
Smirnov	O
test	O
)	O
on	O
the	O
stabilization	O
or	O
the	O
amelioration	O
of	O
visual	O
acuity	O
compared	O
with	O
the	O
non	O
treated	O
group	O
.	O

Further	O
studies	O
aim	O
at	O
characterizing	O
the	O
trans	O
-	O
acting	O
factors	O
that	O
mediate	O
the	O
spatial	O
and	O
temporal	O
expression	O
of	O
Hox	B-GENE
genes	I-GENE
in	O
the	O
developing	O
embryo	O
.	O

Contraindications	O
to	O
adenosine	O
and	O
drug	O
interactions	O
are	O
noted	O
in	O
this	O
article	O
.	O

As	O
to	O
the	O
side	O
effects	O
of	O
SISO	O
,	O
cylindruria	O
with	O
aggravation	O
of	O
microscopic	O
hematuria	O
and	O
elevations	O
of	O
GOT	B-GENE
,	O
GPT	B-GENE
and	O
A1	B-GENE
-	I-GENE
P	I-GENE
were	O
observed	O
each	O
one	O
of	O
them	O
,	O
respectively	O
.	O

Serum	B-GENE
C3	I-GENE
was	O
measured	O
in	O
1	O
,	O
282	O
school	O
children	O
with	O
abnormal	O
urinary	O
findings	O
between	O
1980	O
and	O
1997	O
.	O

Two	O
measures	O
of	O
sensory	O
inhibition	O
were	O
employed	O
,	O
S2	O
/	O
S1	O
x	O
100	O
amplitude	O
ratio	O
and	O
S1	O
-	O
S2	O
amplitude	O
difference	O
.	O

Computer	O
analysis	O
revealed	O
that	O
the	O
human	B-GENE
protein	I-GENE
P1	I-GENE
sequence	I-GENE
corresponding	O
to	O
amino	O
acid	O
residues	O
within	O
the	O
N	O
-	O
terminal	O
RNA	O
binding	O
domain	O
displays	O
high	O
homology	O
(	O
greater	O
than	O
54	O
%	O
identity	O
;	O
61	O
to	O
94	O
%	O
similarity	O
)	O
with	O
two	O
animal	O
virus	O
proteins	O
which	O
possess	O
RNA	O
binding	O
activity	O
(	O
vaccinia	B-GENE
virus	I-GENE
E3L	I-GENE
;	O
rotavirus	B-GENE
VP2	I-GENE
)	O
and	O
two	O
proteins	O
of	O
unknown	O
function	O
(	O
murine	B-GENE
TIK	I-GENE
;	O
rotavirus	B-GENE
NS34	I-GENE
)	O
,	O
but	O
which	O
are	O
likely	O
RNA	O
binding	O
proteins	O
.	O

Determinants	O
of	O
recurrent	O
ischaemia	O
and	O
revascularisation	O
procedures	O
after	O
thrombolysis	O
with	O
recombinant	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
in	O
primary	O
coronary	O
occlusion	O
.	O

For	O
large	O
breasts	O
(	O
>	O
70	O
mm	O
)	O
the	O
use	O
of	O
X	O
-	O
ray	O
sets	O
such	O
as	O
the	O
IGE	O
DMR	O
,	O
which	O
automatically	O
select	O
the	O
beam	O
quality	O
for	O
each	O
breast	O
,	O
resulted	O
in	O
lower	O
doses	O
compared	O
with	O
sets	O
using	O
manual	O
tube	O
potential	O
selection	O
.	O

Experimental	O
exposure	O
of	O
poults	O
with	O
each	O
of	O
two	O
strains	O
representing	O
the	O
rarely	O
reported	O
capsular	O
group	O
B	O
indicated	O
that	O
both	O
were	O
virulent	O
.	O

Computer	O
system	O
trains	O
employees	O
to	O
meet	O
JCAHO	O
safety	O
ED	O
requirements	O
.	O

Finally	O
,	O
transfection	O
of	O
Grb10	B-GENE
genes	I-GENE
with	O
specific	O
mutations	O
in	O
their	O
SH2	B-GENE
domains	I-GENE
induces	O
apoptosis	O
in	O
HTC	O
-	O
IR	O
and	O
COS	O
-	O
7	O
cells	O
.	O

Comparison	O
of	O
dose	O
volume	O
histograms	O
revealed	O
that	O
the	O
6	O
-	O
field	O
plan	O
spared	O
relatively	O
more	O
heart	O
whereas	O
the	O
8	O
-	O
field	O
plan	O
spared	O
relatively	O
more	O
lung	O
.	O

We	O
have	O
demonstrated	O
that	O
a	O
putative	O
HOX	B-GENE
cofactor	I-GENE
,	O
PBX1A	B-GENE
,	O
participates	O
in	O
cooperative	O
DNA	O
binding	O
with	O
HOXA	B-GENE
-	I-GENE
1	I-GENE
and	O
the	O
Deformed	B-GENE
group	O
protein	O
HOXD	B-GENE
-	I-GENE
4	I-GENE
.	O

The	O
CHL	B-GENE
1	I-GENE
(	O
CTF	B-GENE
1	I-GENE
)	O
gene	O
product	O
of	O
Saccharomyces	O
cerevisiae	O
is	O
important	O
for	O
chromosome	O
transmission	O
and	O
normal	O
cell	O
cycle	O
progression	O
in	O
G2	O
/	O
M	O
.	O

Heterotrimeric	O
guanine	B-GENE
nucleotide	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
(	O
G	B-GENE
-	I-GENE
proteins	I-GENE
)	O
function	O
as	O
signal	O
transducers	O
for	O
a	O
variety	O
of	O
hormone	O
-	O
coupled	O
enzyme	O
and	O
ion	O
transport	O
systems	O
in	O
eukaryotic	O
cells	O
.	O

In	O
contrast	O
,	O
polypropylene	O
glycol	O
,	O
PG	O
-	O
C	O
,	O
and	O
corn	O
oil	O
all	O
removed	O
68	O
-	O
86	O
%	O
of	O
the	O
MDI	O
in	O
the	O
first	O
h	O
,	O
74	O
-	O
79	O
%	O
at	O
4	O
h	O
,	O
and	O
72	O
-	O
86	O
%	O
at	O
8	O
h	O
.	O

DDD	O
(	O
R	O
)	O
pacing	O
with	O
automatic	O
mode	O
switch	O
in	O
patients	O
with	O
paroxysmal	O
atrial	O
fibrillation	O
following	O
AV	O
nodal	O
ablation	O
.	O

There	O
was	O
a	O
highly	O
significant	O
decrease	O
in	O
serum	B-GENE
eosinophil	I-GENE
cationic	I-GENE
protein	I-GENE
in	O
patients	O
with	O
elevated	O
AGA	B-GENE
.	O

Sequence	O
analysis	O
revealed	O
that	O
Hv	B-GENE
-	I-GENE
p68	I-GENE
belongs	O
to	O
the	O
large	O
family	O
of	O
FAD	B-GENE
-	I-GENE
dependent	I-GENE
glucose	I-GENE
methanol	I-GENE
choline	I-GENE
oxidoreductases	I-GENE
and	O
that	O
it	O
shares	O
significant	O
sequence	O
identity	O
(	O
>	O
67	O
%	O
)	O
with	O
the	O
alcohol	B-GENE
oxidases	I-GENE
of	O
the	O
methylotrophic	O
yeasts	O
.	O

It	O
is	O
required	O
for	O
correct	O
expression	O
of	O
both	O
genes	O
.	O

In	O
the	O
HIV	B-GENE
LTR	I-GENE
,	O
this	O
region	O
has	O
been	O
demonstrated	O
to	O
have	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
HIV	O
gene	O
expression	O
.	O

A	O
comparison	O
between	O
attenuation	O
-	O
corrected	O
and	O
-	O
uncorrected	O
transmission	O
-	O
emission	O
SPECT	O
images	O
obtained	O
with	O
Tl	O
-	O
201	O
in	O
CAD	O
patients	O

Accumulation	O
of	O
amines	O
in	O
the	O
isolated	O
perfused	O
rabbit	O
lung	O
.	O

Since	O
it	O
is	O
often	O
necessary	O
to	O
resort	O
to	O
thoracotomy	O
as	O
a	O
final	O
step	O
in	O
making	O
such	O
a	O
diagnosis	O
,	O
we	O
have	O
sought	O
a	O
procedure	O
that	O
is	O
simpler	O
while	O
capable	O
of	O
providing	O
the	O
same	O
information	O
.	O

Both	O
control	O
and	O
Mn	O
-	O
exposed	O
quail	O
accumulated	O
5	O
to	O
10	O
times	O
more	O
Mn	O
in	O
their	O
livers	O
than	O
similarly	O
treated	O
rodents	O
.	O

Small	B-GENE
t	I-GENE
also	O
inhibited	O
the	O
dephosphorylation	O
of	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
PKA	B-GENE
)	O
-	O
phosphorylated	O
CREB	B-GENE
in	O
rat	O
liver	O
nuclear	O
extracts	O
.	O

A	O
retrospective	O
analysis	O
of	O
data	O
accumulated	O
over	O
a	O
21	O
-	O
month	O
period	O
,	O
from	O
December	O
1989	O
to	O
September	O
1991	O
,	O
regarding	O
investigational	O
use	O
of	O
a	O
308	O
nanometer	O
Xenon	O
Chloride	O
Excimer	O
Laser	O
Coronary	O
Angioplasty	O
(	O
ELCA	O
)	O
system	O
(	O
Advanced	O
Interventional	O
Systems	O
,	O
Inc	O
.	O
,	O
Irvine	O
,	O
CA	O
)	O
was	O
performed	O
.	O

Presently	O
,	O
we	O
made	O
chain	O
pair	O
switch	O
,	O
chimeric	O
,	O
and	O
site	O
mutant	B-GENE
gamma	I-GENE
delta	I-GENE
TCRs	I-GENE
and	O
transfected	O
them	O
into	O
TCR	O
-	O
mutant	O
Jurkat	O
T	O
cells	O
to	O
examine	O
the	O
effects	O
of	O
changing	O
the	O
TCR	B-GENE
gamma	I-GENE
junctional	I-GENE
region	I-GENE
sequences	I-GENE
on	O
reactivity	O
to	O
prenyl	B-GENE
pyrophosphate	I-GENE
Ags	I-GENE
.	O

Fos	B-GENE
/	O
Jun	B-GENE
bound	O
to	O
an	O
unacetylated	O
nucleosome	O
with	O
only	O
a	O
4	O
-	O
to	O
5	O
-	O
fold	O
reduction	O
in	O
DNA	O
binding	O
affinity	O
compared	O
with	O
naked	O
DNA	O
.	O

Activated	B-GENE
Ki	I-GENE
-	I-GENE
Ras	I-GENE
suppresses	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
-	O
induced	O
activation	O
of	O
the	O
c	B-GENE
-	I-GENE
Jun	I-GENE
NH2	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
pathway	I-GENE
in	O
human	O
colon	O
cancer	O
cells	O
.	O

Electromobility	O
shift	O
analysis	O
using	O
oligonucleotides	O
encompassing	O
the	O
proximal	O
,	O
distal	O
,	O
and	O
BED	O
/	O
AP	B-GENE
-	I-GENE
1	I-GENE
-	O
binding	O
regions	O
failed	O
to	O
demonstrate	O
selective	O
transactivation	O
after	O
CD2	B-GENE
signaling	O
of	O
LPMC	O
.	O

The	O
present	O
report	O
shows	O
that	O
a	O
cis	O
-	O
acting	O
element	O
between	O
-	O
189	O
and	O
-	O
175	O
bp	O
,	O
which	O
binds	O
thyroid	B-GENE
transcription	I-GENE
factor	I-GENE
-	I-GENE
1	I-GENE
(	O
TTF	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
is	O
involved	O
in	O
both	O
activities	O
.	O

Increased	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
production	O
and	O
intimal	O
thickening	O
during	O
healing	O
of	O
Dacron	O
grafts	O
in	O
a	O
canine	O
model	O
.	O

Despite	O
their	O
high	O
degree	O
of	O
sequence	O
similarity	O
,	O
all	O
five	O
RFC	B-GENE
genes	I-GENE
are	O
essential	O
for	O
cell	O
proliferation	O
in	O
S	O
.	O
cerevisiae	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
E2A	B-GENE
protein	I-GENE
E12	B-GENE
in	O
this	O
macrophage	O
line	O
results	O
in	O
the	O
induction	O
of	O
many	O
B	O
lineage	O
genes	O
,	O
including	O
EBF	B-GENE
,	O
IL7Ralpha	B-GENE
,	O
lambda5	B-GENE
,	O
and	O
Rag	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
the	O
ability	O
to	O
induce	O
kappa	B-GENE
light	I-GENE
chain	I-GENE
in	O
response	O
to	O
mitogen	O
.	O

Also	O
,	O
anti	B-GENE
-	I-GENE
HIV	I-GENE
gp120	I-GENE
and	O
anti	B-GENE
-	I-GENE
CD4	I-GENE
crosslinking	O
induced	O
a	O
10	O
-	O
15	O
-	O
fold	O
increase	O
in	O
levels	O
of	O
both	O
PI	B-GENE
3	I-GENE
-	I-GENE
and	I-GENE
PI	I-GENE
4	I-GENE
-	I-GENE
kinase	I-GENE
activity	O
in	O
anti	B-GENE
-	I-GENE
CD4	I-GENE
precipitates	O
.	O

The	O
differences	O
of	O
percentages	O
for	O
HIV	O
-	O
1	O
infection	O
in	O
intravenous	O
drug	O
users	O
(	O
IVDU	O
)	O
were	O
67	O
.	O
7	O
%	O
and	O
in	O
non	O
IVDU	O
were	O
3	O
.	O
8	O
%	O
with	O
a	O
significant	O
statistical	O
difference	O
(	O
chi	O
2	O
=	O
557	O
.	O
5	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

One	O
of	O
the	O
ORFs	O
in	O
the	O
Methanococcus	O
jannaschii	O
genome	O
possesses	O
high	O
similarity	O
to	O
the	O
M	B-GENE
.	I-GENE
aeolicus	I-GENE
ilvB	I-GENE
,	O
indicating	O
that	O
it	O
is	O
an	O
authentic	O
AHAS	B-GENE
.	O

More	O
than	O
80	O
%	O
appropriate	O
lever	O
responding	O
was	O
established	O
after	O
27	O
,	O
38	O
and	O
44	O
daily	O
training	O
sessions	O
with	O
DN	O
-	O
2327	O
,	O
diazepam	O
and	O
PTZ	O
,	O
respectively	O
,	O
as	O
the	O
training	O
drug	O
.	O

We	O
have	O
used	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
to	O
obtain	O
the	O
structure	O
of	O
an	O
RNA	O
"	O
kissing	O
"	O
hairpin	O
complex	O
formed	O
between	O
the	O
HIV	O
-	O
2	O
TAR	O
hairpin	O
loop	O
and	O
a	O
hairpin	O
with	O
a	O
complementary	O
loop	O
sequence	O
.	O

RESULTS	O
:	O
In	O
men	O
,	O
weight	O
/	O
height2	O
met	O
the	O
criteria	O
for	O
a	O
satisfactory	O
index	O
in	O
that	O
there	O
was	O
a	O
very	O
strong	O
correlation	O
with	O
triceps	O
skinfold	O
,	O
and	O
a	O
negligible	O
correlation	O
with	O
height	O
.	O

PRP20	B-GENE
is	O
related	O
,	O
both	O
in	O
structure	O
and	O
function	O
,	O
to	O
the	O
RCC1	B-GENE
gene	I-GENE
of	O
mammals	O
and	O
the	O
PIM1	B-GENE
gene	I-GENE
of	O
Schizosaccharomyces	O
pombe	O
,	O
both	O
of	O
which	O
appear	O
to	O
regulate	O
entry	O
into	O
mitosis	O
and	O
chromosome	O
condensation	O
.	O

No	O
consensus	O
binding	O
sequence	O
could	O
be	O
discerned	O
in	O
these	O
fragments	O
and	O
bound	O
factor	O
is	O
in	O
rapid	O
equilibrium	O
with	O
unbound	O
.	O

A	O
selective	O
transcriptional	O
induction	O
system	O
for	O
mammalian	O
cells	O
based	O
on	O
Gal4	B-GENE
-	O
estrogen	B-GENE
receptor	I-GENE
fusion	O
proteins	O
.	O

Kinase	O
renaturation	O
tests	O
designed	O
to	O
detect	O
reactivated	O
protein	O
kinases	O
after	O
electrophoresis	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
revealed	O
the	O
presence	O
of	O
a	O
60	O
-	O
kDa	O
kinase	O
in	O
the	O
washed	O
immunoprecipitate	O
obtained	O
from	O
liver	O
cytosol	O
using	O
anti	B-GENE
-	I-GENE
AHR	I-GENE
antibody	I-GENE
(	O
IgG	B-GENE
)	O
and	O
protein	O
A	O
/	O
G	O
/	O
agarose	O
beads	O
but	O
not	O
when	O
a	O
nonspecific	O
IgG	B-GENE
was	O
used	O
instead	O
of	O
anti	B-GENE
-	I-GENE
AHR	I-GENE
antibody	I-GENE
.	O

Immunoblotting	O
using	O
a	O
phosphospecific	B-GENE
anti	I-GENE
-	I-GENE
Src	I-GENE
(	I-GENE
416Y	I-GENE
)	I-GENE
antibody	I-GENE
showed	O
a	O
ceramide	O
-	O
induced	O
increase	O
in	O
pp60	B-GENE
(	O
src	B-GENE
)	O
tyrosine	O
phosphorylation	O
.	O

In	O
contrast	O
,	O
dominant	B-GENE
negative	I-GENE
Rac	I-GENE
(	O
N17Rac1	B-GENE
)	O
inhibited	O
JNK	B-GENE
activation	O
by	O
Galpha12	B-GENE
in	O
HEK293	O
cells	O
as	O
well	O
as	O
three	O
other	O
cell	O
lines	O
.	O

Metabolic	O
studies	O
of	O
tetrabenazine	O
,	O
a	O
psychotropic	O
drug	O
in	O
animals	O
and	O
man	O
.	O

Reading	O
disability	O
in	O
twins	O
.	O

These	O
results	O
suggest	O
that	O
1a	B-GENE
,	O
which	O
also	O
interacts	O
independently	O
with	O
the	O
ER	O
and	O
viral	O
RNA	O
,	O
is	O
a	O
key	O
organizer	O
of	O
RNA	O
replication	O
complex	O
assembly	O
.	O

HrpE	B-GENE
is	O
similar	O
to	O
YscL	B-GENE
of	O
Yersinia	O
spp	O
.	O

Effect	O
of	O
a	O
high	O
sugar	O
intake	O
on	O
some	O
metabolic	O
and	O
regulatory	O
indicators	O
in	O
young	O
men	O
.	O

Production	O
of	O
a	O
chicken	O
meat	O
infusion	O
broth	O
suitable	O
for	O
the	O
mass	O
production	O
of	O
a	O
Haemophilus	O
gallinarum	O
bacterin	O
.	O

The	O
results	O
indicate	O
that	O
expression	O
of	O
proU	B-GENE
in	O
E	O
.	O
coli	O
is	O
directed	O
from	O
two	O
promoters	O
,	O
one	O
(	O
P2	O
)	O
characterized	O
earlier	O
by	O
other	O
workers	O
with	O
the	O
start	O
site	O
of	O
transcription	O
60	O
nucleotides	O
upstream	O
of	O
the	O
initiation	O
codon	O
of	O
the	O
first	O
structural	O
gene	O
(	O
proV	B-GENE
)	O
,	O
and	O
the	O
other	O
(	O
P1	O
)	O
situated	O
250	O
nucleotides	O
upstream	O
of	O
proV	B-GENE
.	O

The	O
maximal	O
rise	O
in	O
plasma	O
adrenaline	O
was	O
of	O
similar	O
magnitude	O
in	O
all	O
three	O
groups	O
but	O
a	O
lower	O
plasma	O
glucose	O
was	O
required	O
to	O
stimulate	O
this	O
hormonal	O
response	O
in	O
the	O
'	O
unaware	O
'	O
patients	O
,	O
in	O
whom	O
the	O
plasma	O
adrenaline	O
concentration	O
was	O
lower	O
at	O
the	O
time	O
of	O
the	O
reaction	O
.	O

Through	O
interactions	O
with	O
the	O
pre	O
-	O
mRNA	O
and	O
the	O
CTD	O
domain	O
of	O
the	O
Polymerase	B-GENE
II	I-GENE
,	O
SR	B-GENE
proteins	I-GENE
have	O
been	O
shown	O
to	O
regulate	O
alternative	O
splicing	O
.	O

One	O
child	O
,	O
recently	O
fed	O
,	O
vomited	O
a	O
small	O
amount	O
of	O
breast	O
milk	O
after	O
a	O
short	O
period	O
of	O
crying	O
and	O
apparently	O
had	O
a	O
laryngospasm	O
,	O
shown	O
by	O
a	O
sudden	O
drop	O
in	O
the	O
PtcO2	O
level	O
without	O
any	O
other	O
signs	O
of	O
discomfort	O
.	O

Changes	O
in	O
the	O
size	O
and	O
organisation	O
of	O
the	O
brain	O
in	O
man	O
and	O
his	O
ancestors	O
.	O

Only	O
Staphylococcus	O
xylosus	O
SX63	O
was	O
detected	O
as	O
a	O
strain	O
with	O
high	O
adherence	O
activity	O
.	O

It	O
also	O
produces	O
an	O
NH2	O
terminus	O
that	O
corresponds	O
to	O
an	O
equivalent	O
NH2	O
terminus	O
on	O
the	O
processed	O
matrix	O
form	O
of	O
the	O
similar	O
alpha1	B-GENE
(	I-GENE
XI	I-GENE
)	I-GENE
chain	I-GENE
,	O
thus	O
suggesting	O
physiological	O
significance	O
.	O

Transmission	O
of	O
mutans	O
streptococci	O
to	O
infants	O
following	O
short	O
term	O
application	O
of	O
an	O
iodine	O
-	O
NaF	O
solution	O
to	O
mothers	O
'	O
dentition	O
.	O

Expression	O
of	O
Msx	B-GENE
-	I-GENE
1	I-GENE
and	O
Msx	B-GENE
-	I-GENE
2	I-GENE
has	O
been	O
studied	O
during	O
development	O
of	O
the	O
osteoblast	O
phenotype	O
,	O
but	O
the	O
role	O
of	O
Dlx	B-GENE
in	O
this	O
context	O
and	O
in	O
the	O
regulation	O
of	O
bone	O
-	O
expressed	O
genes	O
is	O
unknown	O
.	O

Scalp	O
blood	O
flow	O
was	O
recorded	O
by	O
a	O
laser	O
Doppler	O
flow	O
sensor	O
that	O
was	O
incorporated	O
in	O
the	O
transcutaneous	O
PO2	O
electrode	O
.	O

DESIGN	O
:	O
Activating	B-GENE
protein	I-GENE
-	I-GENE
1	I-GENE
(	O
AP	B-GENE
-	I-GENE
1	I-GENE
)	O
and	O
Tat	B-GENE
-	O
induced	O
transcription	O
were	O
assessed	O
using	O
Jun	B-GENE
and	O
hybrid	O
Tat	B-GENE
/	O
Jun	B-GENE
-	O
expression	O
plasmids	O
and	O
reporter	O
gene	O
constructs	O
which	O
contained	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
sites	I-GENE
upstream	O
of	O
the	O
rat	B-GENE
prolactin	I-GENE
TATAA	I-GENE
element	I-GENE
or	O
an	O
HIV	B-GENE
-	I-GENE
1	I-GENE
LTR	I-GENE
construct	I-GENE
in	O
which	O
AP	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
sites	I-GENE
replaced	O
the	O
TAR	O
element	O
.	O

Mycobacterium	O
tuberculosis	O
inhibits	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
transcriptional	O
responses	O
without	O
inhibiting	O
activation	O
of	O
STAT1	B-GENE
.	O

Rabbit	B-GENE
KCC1	I-GENE
(	O
rbKCC1	B-GENE
)	O
and	O
rat	B-GENE
KCC1	I-GENE
(	O
rtKCC1	B-GENE
)	O
were	O
cloned	O
by	O
screening	O
rabbit	O
kidney	O
and	O
rat	O
brain	O
cDNA	O
libraries	O
using	O
homologous	O
cDNA	O
probes	O
.	O

However	O
,	O
using	O
wet	O
weight	O
/	O
dry	O
weight	O
methodology	O
,	O
we	O
found	O
that	O
administration	O
of	O
U74006F	O
significantly	O
reduced	O
water	O
content	O
in	O
the	O
right	O
hippocampus	O
(	O
contralateral	O
to	O
the	O
site	O
of	O
injury	O
)	O
compared	O
to	O
saline	O
-	O
treated	O
animals	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

GH	B-GENE
stimulated	O
the	O
activity	O
of	O
promoter	O
fragments	O
with	O
5	O
'	O
-	O
ends	O
between	O
nucleotide	O
(	O
nt	O
)	O
-	O
2001	O
and	O
nt	O
-	O
653	O
by	O
1	O
.	O
9	O
-	O
to	O
2	O
.	O
7	O
-	O
fold	O
.	O

We	O
have	O
recently	O
shown	O
that	O
induced	O
expression	O
of	O
a	O
CDK	B-GENE
target	O
site	O
-	O
deficient	O
mutant	O
,	O
Op18	B-GENE
-	O
S25A	O
,	O
S38A	O
,	O
blocks	O
human	O
cell	O
lines	O
during	O
G2	O
/	O
M	O
transition	O
.	O

A	O
protein	O
which	O
promotes	O
DNA	O
strand	O
transfer	O
between	O
linear	O
double	O
-	O
stranded	O
M13mp19	O
DNA	O
and	O
single	O
-	O
stranded	O
viral	O
M13mp19	O
DNA	O
has	O
been	O
isolated	O
from	O
recA	B-GENE
-	I-GENE
E	O
.	O
coli	O
.	O

The	O
brains	O
were	O
processed	O
according	O
to	O
the	O
tetramethylbenzidine	O
(	O
TMB	O
)	O
protocol	O
of	O
Mesulam	O
(	O
'	O
78	O
)	O
and	O
studied	O
with	O
darkfield	O
microscopy	O
.	O

Seizure	O
recurrence	O
(	O
HR	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
84	O
,	O
2	O
.	O
01	O
)	O
and	O
antiepileptic	O
drug	O
treatment	O
(	O
HR	O
0	O
.	O
97	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
67	O
,	O
1	O
.	O
38	O
)	O
did	O
not	O
influence	O
mortality	O
rate	O
.	O

One	O
day	O
postoperatively	O
,	O
the	O
mononuclear	O
leukocyte	O
beta	B-GENE
2	I-GENE
-	I-GENE
receptor	I-GENE
density	O
decreased	O
maximally	O
by	O
45	O
+	O
/	O
-	O
11	O
%	O
in	O
the	O
enflurane	O
patients	O
,	O
and	O
by	O
53	O
+	O
/	O
-	O
6	O
%	O
in	O
the	O
neurolept	O
patients	O
.	O

The	O
serum	O
levels	O
of	O
cortisol	O
and	O
prolactin	B-GENE
after	O
nasal	O
instillation	O
of	O
a	O
suspension	O
of	O
vaginal	O
exudate	O
showed	O
lower	O
values	O
than	O
in	O
control	O
conditions	O
(	O
nasal	O
instillation	O
of	O
saline	O
)	O
.	O

IgE	B-GENE
antibody	I-GENE
to	O
twelve	O
common	O
food	O
and	O
inhalant	O
allergens	O
was	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
in	O
the	O
sera	O
of	O
thirteen	O
atopic	O
patients	O
with	O
one	O
or	O
more	O
allergic	O
disorders	O
(	O
asthma	O
occurring	O
in	O
eleven	O
;	O
rhinitis	O
in	O
ten	O
;	O
eczema	O
in	O
six	O
;	O
urticaria	O
in	O
four	O
;	O
mouth	O
and	O
gastro	O
-	O
intestinal	O
symptoms	O
in	O
six	O
)	O
,	O
of	O
twelve	O
non	O
-	O
atopic	O
patients	O
with	O
various	O
clinical	O
symptoms	O
(	O
asthma	O
in	O
four	O
;	O
rhinitis	O
in	O
four	O
;	O
eczema	O
in	O
one	O
;	O
urticaria	O
in	O
two	O
;	O
mouth	O
and	O
gastro	O
-	O
intestinal	O
symptoms	O
in	O
four	O
)	O
and	O
sixteen	O
cord	O
blood	O
sera	O
.	O

Innervation	O
of	O
reticular	O
papillae	O
in	O
sheep	O
and	O
goats	O
.	O

Biochemical	O
status	O
was	O
examined	O
using	O
erythrocyte	O
enzyme	O
function	O
and	O
blood	O
vitamin	O
levels	O
.	O

Sexual	O
adventurism	O
,	O
high	O
-	O
risk	O
behavior	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
seroconversion	O
among	O
the	O
Chicago	O
MACS	O
-	O
CCS	O
cohort	O
,	O
1984	O
to	O
1992	O
.	O

Pendulin	B-GENE
,	O
a	O
Drosophila	O
protein	O
with	O
cell	O
cycle	O
-	O
dependent	O
nuclear	O
localization	O
,	O
is	O
required	O
for	O
normal	O
cell	O
proliferation	O
.	O

Paradoxically	O
there	O
is	O
a	O
decrease	O
in	O
the	O
level	O
of	O
soluble	B-GENE
A	I-GENE
beta	I-GENE
secreted	O
from	O
the	O
cells	O
.	O

Signaling	O
through	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
and	O
Rac	B-GENE
/	O
Rho	B-GENE
does	O
not	O
duplicate	O
the	O
effects	O
of	O
activated	O
Ras	B-GENE
on	O
skeletal	O
myogenesis	O
.	O

Internalization	O
of	O
prolactin	B-GENE
receptor	I-GENE
and	O
prolactin	B-GENE
in	O
transfected	O
cells	O
does	O
not	O
involve	O
nuclear	O
translocation	O
.	O

Using	O
mammalian	O
expression	O
vectors	O
(	O
pRSV	O
-	O
neo	O
and	O
pSV2	O
-	O
neo	O
)	O
,	O
antisense	O
constructs	O
for	O
perforin	B-GENE
and	O
granzyme	B-GENE
B	I-GENE
were	O
independently	O
electroporated	O
into	O
YT	O
-	O
INDY	O
,	O
a	O
human	O
non	O
-	O
MHC	B-GENE
-	O
restricted	O
,	O
IL	B-GENE
-	I-GENE
2	I-GENE
-	O
independent	O
,	O
cytotoxic	O
lymphocyte	O
.	O

When	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
SH	B-GENE
-	I-GENE
PTP2	I-GENE
displays	O
tyrosine	B-GENE
-	I-GENE
specific	I-GENE
phosphatase	I-GENE
activity	O
.	O

The	O
structure	O
elucidation	O
of	O
the	O
iridoid	O
compounds	O
2	O
and	O
3	O
are	O
discussed	O
in	O
detail	O
.	O

The	O
results	O
of	O
a	O
study	O
to	O
investigate	O
the	O
effectiveness	O
of	O
a	O
propolis	O
-	O
containing	O
mouthrinse	O
in	O
the	O
inhibition	O
of	O
de	O
novo	O
plaque	O
formation	O
are	O
presented	O
.	O

Effects	O
of	O
shosaikoto	O
,	O
an	O
oriental	O
herbal	O
medicinal	O
mixture	O
,	O
on	O
restraint	O
-	O
stressed	O
mice	O
.	O

The	O
region	O
surrounding	O
the	O
ZNF35	B-GENE
zinc	I-GENE
finger	I-GENE
protein	I-GENE
gene	I-GENE
on	O
3p21	O
is	O
of	O
particular	O
interest	O
,	O
as	O
this	O
region	O
of	O
chromosome	O
3	O
is	O
frequently	O
involved	O
in	O
rearrangements	O
and	O
/	O
or	O
deletions	O
associated	O
with	O
various	O
human	O
tumors	O
including	O
lung	O
and	O
renal	O
carcinoma	O
.	O

In	O
the	O
promoters	O
of	O
many	O
immediate	B-GENE
early	I-GENE
genes	I-GENE
,	O
including	O
c	B-GENE
-	I-GENE
fos	I-GENE
,	O
CArG	O
DNA	O
regulatory	O
elements	O
mediate	O
basal	O
constituitive	O
expression	O
and	O
rapid	O
and	O
transient	O
serum	O
induction	O
.	O

The	O
biological	O
activity	O
of	O
these	O
mutants	O
was	O
tested	O
by	O
determining	O
their	O
capacity	O
to	O
(	O
i	O
)	O
reconstitute	O
RNA	B-GENE
polymerase	I-GENE
activity	O
in	O
vivo	O
by	O
cotransfection	O
with	O
proteins	O
NP	B-GENE
,	O
PB1	B-GENE
,	O
and	O
PA	B-GENE
and	O
a	O
virion	O
-	O
like	O
RNA	O
encoding	O
the	O
cat	B-GENE
gene	O
into	O
vaccinia	O
virus	O
T7	O
-	O
infected	O
COS	O
-	O
1	O
cells	O
and	O
(	O
ii	O
)	O
complete	O
with	O
the	O
wild	B-GENE
-	I-GENE
type	I-GENE
PB2	I-GENE
activity	O
.	O

Transient	O
thyrotoxicosis	O
in	O
primary	O
anti	O
-	O
phospholipid	O
syndrome	O
.	O

We	O
were	O
unable	O
to	O
construct	O
chvI	B-GENE
or	O
chvG	B-GENE
insertion	I-GENE
mutants	I-GENE
of	O
R	O
.	O
meliloti	O
,	O
whereas	O
mutants	O
carrying	O
insertions	O
outside	O
of	O
these	O
genes	O
were	O
readily	O
obtained	O
.	O

Western	O
blot	O
analyses	O
reveals	O
that	O
cJun	B-GENE
and	O
the	O
C	B-GENE
/	I-GENE
EBP	I-GENE
family	I-GENE
member	I-GENE
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
beta	I-GENE
are	O
physiologically	O
relevant	O
transcription	O
factors	O
whose	O
expression	O
corresponds	O
with	O
mda	B-GENE
-	I-GENE
7	I-GENE
mRNA	I-GENE
expression	O
.	O

In	O
isolated	O
olfactory	O
cilia	O
certain	O
odorants	O
elicit	O
a	O
rapid	O
and	O
transient	O
cAMP	O
response	O
,	O
terminated	O
by	O
a	O
concerted	O
process	O
which	O
requires	O
the	O
action	O
of	O
two	O
protein	O
kinases	O
,	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
and	O
a	O
receptor	B-GENE
-	I-GENE
specific	I-GENE
kinase	I-GENE
(	O
GRK3	B-GENE
)	O
(	O
Schleicher	O
,	O
S	O
.	O
,	O
Boekhoff	O
,	O
I	O
.	O

Acetyl	B-GENE
-	I-GENE
CoA	I-GENE
carboxylase	I-GENE
from	O
yeast	O
is	O
an	O
essential	O
enzyme	O
and	O
is	O
regulated	O
by	O
factors	O
that	O
control	O
phospholipid	O
metabolism	O
.	O

To	O
investigate	O
the	O
role	O
of	O
this	O
domain	O
in	O
the	O
incorporation	O
of	O
the	O
SIV	B-GENE
Env	I-GENE
into	O
virions	O
,	O
we	O
generated	O
a	O
series	O
of	O
SIV	B-GENE
Env	I-GENE
mutants	I-GENE
carrying	O
small	O
in	O
-	O
frame	O
deletions	O
within	O
the	O
cytoplasmic	O
domain	O
.	O

Computer	O
analysis	O
,	O
simple	O
correlation	O
hypothesis	O
,	O
and	O
distribution	O
method	O
with	O
1	O
degree	O
of	O
freedom	O
revealed	O
significant	O
correlation	O
between	O
vertical	O
root	O
fracture	O
and	O
the	O
technique	O
of	O
instrumentation	O
and	O
obturation	O
of	O
the	O
canal	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
,	O
the	O
length	O
of	O
the	O
post	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
and	O
the	O
existence	O
of	O
the	O
post	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O

Minute	B-GENE
virus	I-GENE
of	I-GENE
mice	I-GENE
NS1	I-GENE
,	O
an	O
83	O
-	O
kDa	O
mainly	O
nuclear	O
phosphoprotein	O
,	O
is	O
the	O
only	O
viral	O
nonstructural	O
protein	O
required	O
in	O
all	O
cell	O
types	O
and	O
it	O
is	O
involved	O
in	O
multiple	O
processes	O
necessary	O
for	O
virus	O
propagation	O
.	O

The	O
TDx	O
assay	O
for	O
cyclosporine	O
and	O
its	O
metabolites	O
in	O
blood	O
samples	O
compared	O
with	O
HPLC	O
and	O
RIA	O
methods	O
.	O

However	O
,	O
the	O
sequence	O
of	O
mRAR	B-GENE
-	I-GENE
beta	I-GENE
3	I-GENE
region	I-GENE
A	I-GENE
differs	O
from	O
that	O
of	O
mRAR	B-GENE
-	I-GENE
beta	I-GENE
1	I-GENE
by	O
an	O
additional	O
27	O
C	O
-	O
terminal	O
amino	O
acids	O
encoded	O
in	O
an	O
81	O
nucleotide	O
-	O
long	O
putative	O
exon	O
which	O
is	O
spliced	O
in	O
between	O
the	O
exons	O
encoding	O
the	O
A	B-GENE
and	I-GENE
B	I-GENE
regions	I-GENE
of	I-GENE
mRAR	I-GENE
-	I-GENE
beta	I-GENE
1	I-GENE
.	O

We	O
propose	O
that	O
GCD7	B-GENE
and	O
GCD2	B-GENE
play	O
important	O
roles	O
in	O
the	O
regulatory	O
interaction	O
between	O
eIF	B-GENE
-	I-GENE
2	I-GENE
and	O
eIF	B-GENE
-	I-GENE
2B	I-GENE
and	O
that	O
the	O
suppressor	O
mutations	O
we	O
isolated	O
in	O
these	O
genes	O
decrease	O
the	O
susceptibility	O
of	O
eIF	B-GENE
-	I-GENE
2B	I-GENE
to	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF	B-GENE
-	I-GENE
2	I-GENE
without	O
impairing	O
the	O
essential	O
catalytic	O
function	O
of	O
eIF	B-GENE
-	I-GENE
2B	I-GENE
in	O
translation	O
initiation	O
.	O

The	O
3	O
'	O
region	O
of	O
the	O
transcript	O
contained	O
a	O
fully	O
conserved	O
,	O
correctly	O
spliced	O
TCR	B-GENE
alpha	I-GENE
C	I-GENE
region	I-GENE
which	O
was	O
polyadenylated	O
at	O
the	O
3	O
'	O
end	O
.	O

These	O
data	O
demonstrate	O
that	O
CCTalpha	B-GENE
can	O
be	O
regulated	O
by	O
lipids	O
by	O
two	O
independent	O
domains	O
:	O
(	O
i	O
)	O
the	O
three	O
amphipathic	O
alpha	O
-	O
helical	O
repeats	O
that	O
interact	O
with	O
both	O
neutral	O
and	O
anionic	O
lipid	O
mixtures	O
and	O
(	O
ii	O
)	O
the	O
last	O
57	O
residues	O
that	O
interact	O
with	O
anionic	O
lipids	O
.	O

Sorting	O
information	O
to	O
the	O
chloroplastic	O
inner	O
envelope	O
is	O
contained	O
in	O
an	O
NH2	O
-	O
proximal	O
part	O
of	O
mature	B-GENE
IEP110	I-GENE
(	O
110N	B-GENE
)	O
.	O

Most	O
of	O
these	O
elements	O
are	O
adjacent	O
to	O
type	O
X	O
telomeric	O
repeats	O
,	O
and	O
regions	O
flanking	O
four	O
of	O
five	O
characterized	O
S	O
.	O
paradoxus	O
insertions	O
carry	O
autonomously	O
replicating	O
sequences	O
.	O

From	O
1981	O
to	O
1989	O
,	O
a	O
total	O
of	O
26	O
women	O
with	O
locally	O
or	O
regionally	O
advanced	O
carcinoma	O
of	O
the	O
uterine	O
cervix	O
were	O
treated	O
with	O
radiotherapy	O
(	O
RT	O
)	O
and	O
pelvic	O
regional	O
hyperthermia	O
(	O
HT	O
)	O
,	O
in	O
the	O
Divisions	O
of	O
Radiation	O
Oncology	O
at	O
the	O
University	O
of	O
Utah	O
Medical	O
Center	O
(	O
UU	O
)	O
and	O
the	O
Kenneth	O
Norris	O
Jr	O
Cancer	O
Hospital	O
of	O
the	O
University	O
of	O
Southern	O
California	O
(	O
USC	O
)	O
.	O

The	O
ARE	O
is	O
loosely	O
defined	O
as	O
the	O
five	O
-	O
nucleotide	O
sequence	O
AUUUA	O
embedded	O
in	O
a	O
uracil	O
-	O
rich	O
region	O
.	O

Lack	O
of	O
changes	O
in	O
milk	O
production	O
and	O
milk	O
composition	O
suggest	O
that	O
acute	O
increases	O
in	O
somatotropin	B-GENE
with	O
concomitant	O
increases	O
in	O
insulin	B-GENE
are	O
not	O
sufficient	O
to	O
stimulate	O
synthesis	O
of	O
milk	O
and	O
milk	O
components	O
by	O
cows	O
during	O
established	O
lactation	O
.	O

The	O
material	O
then	O
was	O
cut	O
with	O
a	O
diamond	O
saw	O
into	O
sheets	O
of	O
8	O
x	O
10	O
x	O
3	O
mm	O
,	O
and	O
the	O
upper	O
surface	O
was	O
polished	O
by	O
colloidal	O
SiO2	O
and	O
/	O
or	O
covered	O
with	O
a	O
carbon	O
-	O
titanium	O
(	O
C	O
:	O
Ti	O
)	O
layer	O
(	O
3	O
.	O
3	O
microm	O
)	O
using	O
the	O
plasma	O
-	O
enhanced	O
physical	O
vapor	O
deposition	O
method	O
.	O

Iomazenil	O
-	O
SPECT	O
revealed	O
a	O
highly	O
significant	O
increase	O
in	O
the	O
benzodiazepine	B-GENE
receptor	I-GENE
uptake	O
in	O
all	O
studied	O
cortical	O
regions	O
except	O
temporal	O
cortices	O
.	O

Both	O
in	O
the	O
Federal	O
Republic	O
of	O
Germany	O
and	O
in	O
some	O
neighbouring	O
countries	O
the	O
epizootic	O
situation	O
of	O
Aujeszky	O
'	O
s	O
disease	O
has	O
been	O
unsatisfactory	O
for	O
a	O
long	O
time	O
,	O
especially	O
in	O
areas	O
with	O
a	O
high	O
pig	O
density	O
.	O

Since	O
RIP140	B-GENE
generally	O
down	O
-	O
regulates	O
receptor	O
activity	O
in	O
mammalian	O
cells	O
and	O
specifically	O
down	O
-	O
regulates	O
coactivation	O
mediated	O
by	O
SRC	B-GENE
-	I-GENE
1	I-GENE
,	O
we	O
propose	O
a	O
model	O
in	O
which	O
RIP140	B-GENE
indirectly	O
regulates	O
nuclear	B-GENE
receptor	I-GENE
AF	I-GENE
-	I-GENE
2	I-GENE
activity	O
by	O
competition	O
for	O
coactivators	O
such	O
as	O
SRC	B-GENE
-	I-GENE
1	I-GENE
.	O

DIC	O
and	O
low	O
grade	O
fibrinolysis	O
may	O
account	O
for	O
the	O
coagulation	O
abnormalities	O
of	O
the	O
syndrome	O
.	O

As	O
in	O
the	O
case	O
of	O
the	O
chicken	O
homologue	O
,	O
there	O
are	O
two	O
hPR	B-GENE
forms	O
,	O
A	O
and	O
B	O
,	O
which	O
originate	O
from	O
translational	O
initiation	O
at	O
AUG2	O
(	O
codon	O
165	O
)	O
and	O
AUG1	O
,	O
respectively	O
.	O

Fluctuations	O
of	O
the	O
measured	O
ECF	O
energy	O
-	O
related	O
substances	O
corresponded	O
to	O
various	O
clinical	O
events	O
presumably	O
involving	O
hypoxia	O
/	O
ischemia	O
.	O

Using	O
lasers	O
in	O
diabetic	O
wound	O
healing	O
.	O

Furthermore	O
,	O
the	O
zincon	O
-	O
loaded	O
resin	O
was	O
applied	O
to	O
the	O
selective	O
concentration	O
of	O
trace	O
amounts	O
of	O
chalcophile	O
elements	O
in	O
natural	O
water	O
samples	O
prior	O
to	O
neutron	O
activation	O
analysis	O
.	O

In	O
cells	O
stably	O
transfected	O
with	O
G	B-GENE
alpha	I-GENE
i	I-GENE
-	I-GENE
2	I-GENE
or	O
G	B-GENE
alpha	I-GENE
i	I-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
5	O
'	O
-	O
flanking	O
sequences	O
fused	O
to	O
firefly	O
luciferase	B-GENE
cDNA	O
reporter	O
,	O
temporal	O
10	O
-	O
15	O
-	O
fold	O
transcriptional	O
activation	O
of	O
both	O
genes	O
occurred	O
before	O
cellular	O
polarization	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
histamine	B-GENE
-	I-GENE
2	I-GENE
receptor	I-GENE
activation	O
mechanisms	O
may	O
not	O
be	O
involved	O
in	O
postoperative	O
IL	B-GENE
-	I-GENE
6	I-GENE
synthesis	O
.	O

In	O
resume	O
response	O
to	O
treatment	O
with	O
usual	O
regimens	O
,	O
doxycycline	O
plus	O
streptomycin	O
of	O
doxycycline	O
rifampicin	O
is	O
good	O
,	O
being	O
however	O
time	O
elapsed	O
until	O
pain	O
ceases	O
of	O
mean	O
length	O
in	O
hospital	O
stay	O
shorter	O
in	O
the	O
group	O
receiving	O
doxycycline	O
plus	O
streptomycin	O
.	O

Fibrosis	O
of	O
the	O
adjacent	O
myocardium	O
was	O
seen	O
in	O
five	O
cases	O
.	O

Purified	O
preparations	O
of	O
all	O
four	O
AGT	O
mutants	O
showed	O
an	O
approximately	O
similar	O
degree	O
(	O
74	O
-	O
120	O
-	O
fold	O
)	O
of	O
reduction	O
in	O
the	O
rate	O
of	O
reaction	O
with	O
O6	O
-	O
benzylguanine	O
.	O

Significant	O
reductions	O
were	O
noted	O
in	O
vertical	O
GRFs	O
per	O
newton	O
of	O
body	O
weight	O
exerted	O
at	O
10	O
%	O
(	O
P	O
=	O
0	O
.	O
0009	O
)	O
and	O
20	O
%	O
(	O
P	O
=	O
0	O
.	O
0383	O
)	O
of	O
stance	O
phase	O
and	O
in	O
anteroposterior	O
GRFs	O
exerted	O
at	O
10	O
%	O
(	O
P	O
=	O
0	O
.	O
0009	O
)	O
and	O
50	O
%	O
(	O
P	O
=	O
0	O
.	O
0033	O
)	O
of	O
stance	O
phase	O
when	O
ambulation	O
was	O
compared	O
with	O
and	O
without	O
the	O
orthotic	O
device	O
.	O

Identification	O
of	O
a	O
68	B-GENE
-	I-GENE
kilodalton	I-GENE
nuclear	I-GENE
ATP	I-GENE
-	I-GENE
binding	I-GENE
phosphoprotein	I-GENE
encoded	O
by	O
bovine	O
papillomavirus	O
type	O
1	O
.	O

It	O
is	O
suggested	O
that	O
biliary	O
secretion	O
of	O
both	O
TBZ	O
and	O
FBZ	O
and	O
their	O
metabolites	O
may	O
contribute	O
to	O
this	O
recycling	O
.	O

During	O
chordotonal	O
organ	O
development	O
,	O
the	O
3	O
'	O
enhancer	O
directs	O
expression	O
in	O
proneural	O
clusters	O
;	O
whereas	O
successive	O
modular	O
enhancers	O
located	O
in	O
the	O
5	O
'	O
region	O
drive	O
tissue	O
-	O
specific	O
expression	O
in	O
chordotonal	O
organ	O
precursors	O
in	O
the	O
embryo	O
and	O
larval	O
leg	O
,	O
wing	O
and	O
antennal	O
imaginal	O
discs	O
.	O

The	O
use	O
of	O
self	O
-	O
measured	O
blood	O
pressure	O
determinations	O
in	O
assessing	O
dynamics	O
of	O
drug	O
compliance	O
in	O
a	O
study	O
with	O
amlodipine	O
once	O
a	O
day	O
,	O
morning	O
versus	O
evening	O
.	O

Nucleocapsid	O
structure	O
and	O
thermostability	O
of	O
the	O
virion	O
,	O
nucleocapsid	O
and	O
polymerase	O
complex	O
.	O

A	O
vascular	O
component	O
to	O
impotence	O
was	O
shown	O
to	O
be	O
common	O
in	O
those	O
with	O
neurological	O
impairment	O
,	O
and	O
may	O
alter	O
management	O
.	O

RESULTS	O
-	O
-	O
The	O
maximal	O
early	O
asthmatic	O
response	O
after	O
allergen	O
with	O
placebo	O
treatment	O
was	O
18	O
.	O
4	O
%	O
(	O
SE	O
4	O
.	O
4	O
%	O
)	O
and	O
with	O
WEB	O
2086	O
18	O
.	O
9	O
%	O
(	O
4	O
.	O
4	O
%	O
)	O
.	O

Column	O
chromatographic	O
determination	O
of	O
polymyxin	O
B	O
sulfate	O
.	O

Usefulness	O
of	O
computerized	O
tomography	O
in	O
hemodialysis	O
patients	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
determine	O
whether	O
exercise	O
training	O
can	O
augment	O
left	O
ventricular	O
diastolic	O
filling	O
at	O
rest	O
and	O
during	O
exercise	O
in	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
and	O
whether	O
any	O
correlation	O
exists	O
between	O
changes	O
in	O
diastolic	O
filling	O
and	O
changes	O
in	O
exercise	O
tolerance	O
.	O

On	O
the	O
pharmacology	O
of	O
9	O
,	O
10	O
-	O
dihydro	O
-	O
10	O
-	O
(	O
1	O
-	O
methyl	O
-	O
4	O
-	O
piperidylidene	O
)	O
-	O
9	O
-	O
anthrol	O
(	O
WA	O
335	O
)	O
,	O
a	O
histamine	O
and	O
serotonin	O
antagonist	O

METHODOLOGY	O
:	O
A	O
case	O
control	O
study	O
of	O
survivors	O
with	O
gestational	O
age	O
(	O
GA	O
)	O
<	O
28	O
weeks	O
or	O
birthweight	O
(	O
BW	O
)	O
<	O
1000	O
g	O
using	O
data	O
collected	O
prospectively	O
in	O
our	O
Neonatal	O
Intensive	O
Care	O
Unit	O
database	O
.	O

There	O
are	O
two	O
regulatory	O
regions	O
between	O
the	O
US3	B-GENE
and	O
the	O
US6	B-GENE
transcription	I-GENE
units	I-GENE
.	O

Database	O
searches	O
revealed	O
a	O
50	O
-	O
63	O
%	O
similarity	O
and	O
34	O
-	O
42	O
%	O
identity	O
with	O
several	O
families	O
of	O
serine	B-GENE
proteases	I-GENE
,	O
in	O
particular	O
the	O
trypsin	B-GENE
-	I-GENE
like	I-GENE
proteases	I-GENE
,	O
members	O
of	O
the	O
glandular	B-GENE
kallikrein	I-GENE
family	I-GENE
(	O
including	O
prostate	B-GENE
-	I-GENE
specific	I-GENE
antigen	I-GENE
,	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
gamma	I-GENE
,	O
and	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
)	O
and	O
the	O
activators	O
for	O
the	O
kringle	B-GENE
family	I-GENE
proteins	I-GENE
(	O
including	O
the	O
human	B-GENE
tissue	I-GENE
plasminogen	I-GENE
activator	I-GENE
and	O
human	B-GENE
hepatocyte	I-GENE
growth	I-GENE
factor	I-GENE
activator	I-GENE
)	O
.	O

Manifestation	O
of	O
superfluidity	O
in	O
an	O
evolving	O
bose	O
-	O
einstein	O
condensed	O
Gas	O
We	O
study	O
the	O
generation	O
of	O
excitations	O
due	O
to	O
an	O
"	O
impurity	O
"	O
(	O
static	O
perturbation	O
)	O
placed	O
into	O
an	O
oscillating	O
Bose	O
-	O
Einstein	O
condensed	O
gas	O
in	O
the	O
time	O
-	O
dependent	O
trapping	O
field	O
.	O

4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
micromol	O
.	O

kg	O
-	O
1	O
.	O

min	O
-	O
1	O
)	O
but	O
was	O
not	O
changed	O
by	O
training	O
.	O

We	O
established	O
that	O
,	O
in	O
unstimulated	O
lymphocytes	O
,	O
the	O
Src	B-GENE
homology	I-GENE
2	I-GENE
(	O
SH2	B-GENE
)	O
and	O
SH3	B-GENE
domain	I-GENE
-	I-GENE
containing	I-GENE
protein	I-GENE
Grb2	B-GENE
and	O
the	O
p85	B-GENE
subunit	O
of	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
,	O
associate	O
constitutively	O
with	O
Cbl	B-GENE
via	O
their	O
SH3	B-GENE
domains	I-GENE
.	O

Zta	B-GENE
stimulated	O
the	O
HAT	B-GENE
activity	O
of	O
CBP	B-GENE
that	O
had	O
been	O
partially	O
purified	O
or	O
immunoprecipitated	O
from	O
mammalian	O
cells	O
as	O
well	O
as	O
from	O
affinity	O
-	O
purified	O
,	O
baculovirus	O
expressed	O
CBP	B-GENE
.	O

Increased	O
gliadin	B-GENE
antibody	I-GENE
levels	O
were	O
found	O
more	O
frequently	O
in	O
patients	O
with	O
subtotal	O
villous	O
atrophy	O
(	O
9	O
out	O
of	O
17	O
patients	O
,	O
or	O
53	O
%	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
than	O
in	O
patients	O
with	O
partial	O
villous	O
atrophy	O
(	O
2	O
out	O
of	O
13	O
patients	O
,	O
or	O
15	O
%	O
)	O
or	O
normal	O
villous	O
appearance	O
(	O
2	O
out	O
of	O
10	O
patients	O
,	O
or	O
20	O
%	O
)	O
.	O

However	O
,	O
the	O
optimum	O
compressive	O
strength	O
reached	O
values	O
up	O
to	O
40	O
%	O
higher	O
than	O
CC	O
-	O
free	O
samples	O
.	O

Expression	O
of	O
the	O
Hox	B-GENE
genes	I-GENE
egl	B-GENE
-	I-GENE
5	I-GENE
and	O
mab	B-GENE
-	I-GENE
5	I-GENE
is	O
reduced	O
in	O
lin	B-GENE
-	I-GENE
49	I-GENE
and	O
lin	B-GENE
-	I-GENE
59	I-GENE
mutants	I-GENE
,	O
suggesting	O
lin	B-GENE
-	I-GENE
49	I-GENE
and	O
lin	B-GENE
-	I-GENE
59	I-GENE
regulate	O
HOM	B-GENE
-	I-GENE
C	I-GENE
gene	I-GENE
expression	O
in	O
C	O
.	O
elegans	O
as	O
the	O
trx	B-GENE
-	I-GENE
G	I-GENE
genes	I-GENE
do	O
in	O
Drosophila	O
.	O

lin	B-GENE
-	I-GENE
49	I-GENE
and	O
lin	B-GENE
-	I-GENE
59	I-GENE
transgenes	I-GENE
are	O
expressed	O
widely	O
throughout	O
C	O
.	O
elegans	O
animals	O
.	O

Interleukin	B-GENE
-	I-GENE
1	I-GENE
increased	O
the	O
noradrenaline	O
release	O
.	O

Magnetic	O
field	O
influence	O
on	O
central	O
nervous	O
system	O
function	O
.	O

3	O
patients	O
with	O
acute	O
leukaemia	O
,	O
HLA	B-GENE
antibodies	O
and	O
thrombocytopenia	O
refractory	O
to	O
random	O
donor	O
platelet	O
transfusions	O
were	O
treated	O
with	O
high	O
-	O
dose	O
i	O
.	O
v	O
.	O
immunoglobulin	B-GENE
.	O

Two	O
genes	O
(	O
ptsI	B-GENE
and	O
ptsA	B-GENE
)	O
that	O
encode	O
homologues	O
of	O
the	O
energy	O
coupling	O
Enzyme	B-GENE
I	I-GENE
of	O
the	O
phosphoenolpyruvate	B-GENE
-	I-GENE
dependent	I-GENE
sugar	I-GENE
-	I-GENE
transporting	I-GENE
phosphotransferase	I-GENE
system	O
(	O
PTS	O
)	O
have	O
previously	O
been	O
identified	O
on	O
the	O
Escherichia	O
coli	O
chromosome	O
.	O

Eight	O
of	O
these	O
suppressors	O
for	O
into	O
two	O
complementation	O
groups	O
,	O
designated	O
KCS1	B-GENE
and	O
KCS2	B-GENE
.	O

These	O
results	O
point	O
towards	O
post	O
-	O
translational	O
steric	O
and	O
/	O
or	O
allosteric	O
control	O
of	O
EKLF	B-GENE
function	O
that	O
may	O
be	O
important	O
not	O
just	O
for	O
its	O
DNA	O
binding	O
ability	O
,	O
but	O
also	O
for	O
its	O
potential	O
to	O
interact	O
with	O
other	O
proteins	O
that	O
fully	O
establish	O
the	O
correct	O
stereospecific	O
array	O
leading	O
to	O
efficient	O
switching	O
of	O
beta	B-GENE
-	I-GENE
globin	I-GENE
transcription	O
during	O
development	O
.	O

Oxalates	O
and	O
the	O
digestive	O
tract	O

However	O
,	O
the	O
addition	O
of	O
intravenous	O
injection	O
of	O
FPFD	O
101	O
resulted	O
in	O
a	O
marked	O
improvement	O
in	O
their	O
symptoms	O
.	O

Western	O
blot	O
experiments	O
detected	O
SMBP	B-GENE
as	O
a	O
70	O
kDa	O
protein	O
that	O
may	O
be	O
further	O
cleaved	O
into	O
an	O
active	O
34	O
kDa	O
N	O
-	O
terminal	O
polypeptide	O
.	O

The	O
aetiology	O
and	O
management	O
of	O
diabetic	O
impotence	O
is	O
well	O
-	O
documented	O
;	O
the	O
effects	O
of	O
diabetes	O
on	O
female	O
sexuality	O
are	O
not	O
so	O
clear	O
.	O

Treatment	O
of	O
diabetes	O
and	O
retinal	O
complications	O

The	O
activated	O
glucocorticoid	B-GENE
receptor	I-GENE
forms	O
a	O
complex	O
with	O
Stat5	B-GENE
and	O
enhances	O
Stat5	B-GENE
-	O
mediated	O
transcriptional	O
induction	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
ZNF76	B-GENE
and	O
ZNF143	B-GENE
are	O
two	O
members	O
of	O
a	O
same	O
family	O
of	O
transactivator	O
proteins	O
.	O

For	O
example	O
,	O
the	O
presence	O
of	O
two	O
related	O
genes	O
,	O
b	B-GENE
and	O
b	B-GENE
'	I-GENE
,	O
in	O
the	O
cyanobacterium	O
suggests	O
that	O
its	O
ATP	B-GENE
synthase	I-GENE
is	O
a	O
complex	O
of	O
nine	O
polypeptides	O
,	O
and	O
that	O
it	O
may	O
have	O
single	O
copies	O
of	O
related	O
b	B-GENE
and	O
b	B-GENE
'	I-GENE
proteins	I-GENE
rather	O
than	O
two	O
copies	O
of	O
identical	O
b	B-GENE
subunits	I-GENE
as	O
found	O
in	O
the	O
E	O
.	O
coli	O
enzyme	O
.	O
4	O
+	O
off	O

Antiserum	O
raised	O
against	O
rat	B-GENE
liver	I-GENE
S6	I-GENE
kinase	I-GENE
specifically	O
immunoprecipitates	O
the	O
purified	O
32P	O
-	O
labeled	O
H4	O
hepatoma	O
insulin	O
-	O
stimulated	O
S6	B-GENE
kinase	I-GENE
.	O

CRKL	B-GENE
,	O
an	O
SH2	B-GENE
-	O
SH3	B-GENE
-	O
SH3	B-GENE
adapter	O
protein	O
,	O
is	O
one	O
of	O
the	O
major	O
tyrosine	B-GENE
phosphoproteins	I-GENE
detected	O
in	O
primary	O
leukemic	O
neutrophils	O
from	O
patients	O
with	O
CML	O
.	O

KU	O
-	O
1257	O
also	O
significantly	O
accelerated	O
the	O
healing	O
of	O
acetic	O
acid	O
-	O
induced	O
duodenal	O
ulcers	O
as	O
well	O
as	O
famotidine	O
and	O
roxatidine	O
acetate	O
.	O

To	O
further	O
identify	O
the	O
residues	O
responsible	O
for	O
the	O
activity	O
,	O
we	O
isolated	O
the	O
mutant	O
viruses	O
that	O
were	O
not	O
neutralized	O
with	O
the	O
soluble	O
form	O
of	O
MHV	B-GENE
receptor	I-GENE
proteins	I-GENE
,	O
since	O
such	O
mutants	O
were	O
expected	O
to	O
have	O
mutations	O
in	O
amino	O
acids	O
responsible	O
for	O
receptor	O
-	O
binding	O
activity	O
.	O

It	O
is	O
suggested	O
that	O
death	O
of	O
S	O
.	O
mansoni	O
cercariae	O
during	O
penetration	O
of	O
mammalian	O
host	O
skin	O
is	O
probably	O
due	O
to	O
exhaustion	O
of	O
their	O
energy	O
reserves	O
.	O

Especially	O
if	O
the	O
number	O
of	O
dimensions	O
of	O
the	O
samples	O
is	O
large	O
,	O
it	O
can	O
be	O
said	O
that	O
BPN	O
is	O
better	O
than	O
k	O
-	O
NN	O
in	O
classification	O
ability	O
.	O

In	O
contrast	O
,	O
inactivation	O
of	O
the	O
Sir4p	B-GENE
-	I-GENE
interacting	I-GENE
protein	I-GENE
Rap1p	I-GENE
reduces	O
partitioning	O
by	O
a	O
LexA	B-GENE
-	O
Sir4p	B-GENE
fusion	O
.	O

Nine	O
individuals	O
who	O
were	O
stable	O
after	O
1	O
month	O
of	O
therapy	O
at	O
low	O
dosage	O
were	O
randomized	O
to	O
a	O
further	O
month	O
of	O
therapy	O
at	O
low	O
or	O
high	O
dosage	O
,	O
during	O
which	O
one	O
of	O
four	O
at	O
high	O
dosage	O
had	O
a	O
partial	O
response	O
,	O
and	O
none	O
of	O
five	O
at	O
low	O
dosage	O
manifested	O
response	O
.	O

BACKGROUND	O
:	O
Murine	B-GENE
Nramp	I-GENE
is	O
a	O
candidate	O
for	O
the	O
macrophage	O
resistance	O
gene	O
Ity	B-GENE
/	O
Lsh	B-GENE
/	O
Bcg	B-GENE
.	O

In	O
cases	O
in	O
which	O
it	O
was	O
identified	O
,	O
insulitis	O
affected	O
23	O
%	O
of	O
islets	O
containing	O
insulin	B-GENE
,	O
but	O
affected	O
only	O
1	O
%	O
of	O
islets	O
which	O
were	O
insulin	B-GENE
deficient	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
insulitis	O
represents	O
an	O
immunologically	O
mediated	O
destruction	O
of	O
insulin	B-GENE
secreting	O
B	O
cells	O
.	O

(	O
4	O
)	O
Expression	O
in	O
different	O
sites	O
in	O
the	O
central	O
nervous	O
system	O
is	O
driven	O
by	O
separable	O
elements	O
widely	O
dispersed	O
throughout	O
8	O
kb	O
3	O
'	O
of	O
the	O
gene	O
.	O

To	O
investigate	O
possible	O
roles	O
for	O
HCP	B-GENE
during	O
late	O
erythroid	O
differentiation	O
,	O
effects	O
of	O
manipulating	O
HCP	B-GENE
expression	O
or	O
recruitment	O
on	O
EPO	B-GENE
-	O
induced	O
hemoglobinization	O
in	O
erythroleukemic	O
SKT6	O
cells	O
have	O
been	O
investigated	O
.	O

The	O
other	O
end	O
of	O
this	O
cluster	O
contained	O
the	O
human	B-GENE
type	I-GENE
I	I-GENE
cytokeratin	I-GENE
K20	B-GENE
and	O
K12	B-GENE
gene	I-GENE
loci	O
.	O

An	O
11	O
.	O
5	O
-	O
kb	O
intron	O
is	O
found	O
at	O
the	O
end	O
of	O
transmembrane	O
6	O
,	O
and	O
the	O
rest	O
of	O
the	O
ORF	O
is	O
in	O
exon	O
3	O
.	O

Are	O
there	O
any	O
lessons	O
to	O
be	O
learnt	O
?	O

Eighteen	O
patients	O
with	O
advanced	O
epidermoid	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
were	O
entered	O
into	O
a	O
phase	O
II	O
trial	O
of	O
N	O
-	O
Methylformamide	O
(	O
NMF	O
)	O
,	O
800	O
mg	O
/	O
M2	O
IV	O
daily	O
for	O
5	O
days	O
every	O
4	O
weeks	O
.	O

We	O
provided	O
evidence	O
that	O
CaM	B-GENE
kinase	I-GENE
II	I-GENE
played	O
a	O
role	O
in	O
regulating	O
neurite	O
outgrowth	O
and	O
growth	O
cone	O
motility	O
in	O
these	O
cells	O
,	O
and	O
that	O
the	O
autophosphorylation	O
is	O
essential	O
for	O
the	O
kinase	O
to	O
sufficiently	O
exert	O
its	O
cellular	O
function	O
in	O
vivo	O
[	O
Y	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
a	O
truncation	O
of	O
as	O
little	O
as	O
15	O
Nurr1	B-GENE
COOH	O
-	O
terminal	O
amino	O
acids	O
diminished	O
transcriptional	O
activation	O
of	O
B1A	B-GENE
-	O
thymidine	B-GENE
kinase	I-GENE
-	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	O
.	O

All	O
sows	O
nursed	O
nine	O
pigs	O
.	O

In	O
the	O
second	O
group	O
the	O
untreated	O
fellow	O
eye	O
was	O
microscopically	O
intact	O
,	O
but	O
was	O
shown	O
(	O
as	O
the	O
treated	O
eye	O
)	O
to	O
alter	O
the	O
concentration	O
of	O
uronic	O
acid	O
in	O
different	O
parts	O
of	O
the	O
sclera	O
.	O

Effects	O
were	O
studied	O
of	O
extremely	O
high	O
-	O
frequency	O
electromagnetic	O
radiation	O
(	O
EHF	O
EMR	O
)	O
on	O
indices	O
for	O
the	O
immune	O
and	O
endocrine	O
systems	O
in	O
a	O
series	O
of	O
48	O
patients	O
presenting	O
with	O
hyperplastic	O
processes	O
in	O
endometrium	O
.	O

Characterization	O
of	O
human	B-GENE
activating	I-GENE
transcription	I-GENE
factor	I-GENE
4	I-GENE
,	O
a	O
transcriptional	O
activator	O
that	O
interacts	O
with	O
multiple	O
domains	O
of	O
cAMP	B-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
-	O
binding	O
protein	O
.	O

Effect	O
of	O
a	O
constant	O
magnetic	O
field	O
on	O
different	O
models	O
of	O
carcinogenesis	O

In	O
contrast	O
to	O
the	O
reciprocal	O
effects	O
of	O
Gab1	B-GENE
and	O
Gab2	B-GENE
in	O
mediating	O
Elk	B-GENE
-	I-GENE
1	I-GENE
induction	O
,	O
these	O
two	O
molecules	O
have	O
a	O
similar	O
function	O
in	O
extracellular	B-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
activation	O
induced	O
by	O
either	O
oncogenic	O
Ras	B-GENE
or	O
growth	O
factor	O
stimulation	O
.	O

This	O
result	O
is	O
consistent	O
with	O
the	O
previous	O
observation	O
that	O
expression	O
of	O
the	O
hsp70	B-GENE
genes	I-GENE
in	I-GENE
T	I-GENE
.	I-GENE
brucei	I-GENE
is	O
mainly	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
.	O

A	O
definition	O
of	O
bias	O
founded	O
on	O
the	O
concept	O
of	O
the	O
study	O
base	O
.	O

Chromaffin	O
cells	O
transfected	O
with	O
a	O
plasmid	O
with	O
the	O
entire	O
coding	O
sequence	O
of	O
c	B-GENE
-	I-GENE
Rabphilin3a	I-GENE
inserted	O
in	O
the	O
antisense	O
orientation	O
inhibited	O
secretion	O
of	O
co	O
-	O
expressed	O
GH	B-GENE
by	O
approximately	O
30	O
%	O
.	O

Using	O
a	O
set	O
of	O
sera	O
for	O
which	O
full	O
chlamydial	O
micro	O
-	O
immunofluorescence	O
results	O
suggested	O
a	O
clear	O
diagnosis	O
,	O
we	O
have	O
evaluated	O
the	O
Chlamydia	O
Spot	O
-	O
IF	O
test	O
(	O
bioMerieux	O
)	O
,	O
which	O
allows	O
a	O
comparison	O
of	O
titres	O
to	O
Chlamydia	B-GENE
trachomatis	I-GENE
and	I-GENE
C	I-GENE
.	I-GENE
psittaci	I-GENE
antigens	I-GENE
.	O

An	O
environmental	O
investigation	O
found	O
evidence	O
of	O
suboptimal	O
food	O
storage	O
and	O
cooking	O
temperatures	O
at	O
Restaurant	O
A	O
;	O
cross	O
contamination	O
of	O
foods	O
may	O
have	O
contributed	O
to	O
the	O
low	O
attributable	O
risk	O
identified	O
for	O
chile	O
rellenos	O
.	O

Evidence	O
from	O
four	O
areas	O
-	O
-	O
sensory	O
deprivation	O
,	O
enriched	O
environments	O
,	O
nervous	O
system	O
plasticity	O
,	O
and	O
sensitive	O
periods	O
of	O
neurodevelopment	O
-	O
-	O
suggests	O
that	O
sensory	O
stimulation	O
programs	O
are	O
potentially	O
beneficial	O
for	O
STR	O
patients	O
.	O

In	O
each	O
study	O
group	O
,	O
elevated	O
levels	O
of	O
serum	O
I	O
were	O
observed	O
.	O

With	O
repetitive	O
intermittent	O
exercise	O
,	O
gradual	O
increases	O
in	O
blood	O
lactate	O
concentration	O
[	O
(	O
LA	O
]	O
b	O
)	O
occurred	O
,	O
whereas	O
its	O
rate	O
of	O
accumulation	O
(	O
delta	O
[	O
LA	O
]	O
b	O
)	O
decreased	O
.	O

A	O
physical	O
and	O
genetic	O
map	O
covering	O
the	O
entire	O
RP12	B-GENE
candidate	I-GENE
gene	I-GENE
region	I-GENE
was	O
constructed	O
.	O

The	O
single	O
copy	O
flotillin	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
is	O
located	O
at	O
6p21	O
.	O
3	O
in	O
the	O
MHC	B-GENE
class	I-GENE
I	I-GENE
region	I-GENE
and	O
consists	O
of	O
13	O
exons	O
over	O
15	O
kb	O
.	O

An	O
atypical	O
form	O
of	O
juvenile	O
myasthenia	O
gravis	O
associated	O
with	O
severe	O
emaciation	O
,	O
muscle	O
atrophy	O
,	O
ophthalmoplegia	O
,	O
bulbar	O
signs	O
and	O
joint	O
contracture	O

The	O
in	O
vivo	O
response	O
of	O
the	O
PacC	B-GENE
-	I-GENE
like	I-GENE
decamers	I-GENE
to	O
external	O
pH	O
was	O
dependent	O
on	O
the	O
status	O
of	O
the	O
pH	O
-	O
regulated	O
activator	O
YlRim101p	B-GENE
,	O
which	O
is	O
homologous	O
to	O
the	O
A	O
.	O
nidulans	O
PacC	B-GENE
regulator	O
.	O

Electron	O
microscopic	O
visualization	O
of	O
the	O
general	O
population	O
of	O
active	O
genes	O
in	O
flies	O
overexpressing	O
hnRNP	B-GENE
proteins	I-GENE
also	O
indicated	O
that	O
the	O
great	O
majority	O
of	O
genes	O
seemed	O
normal	O
in	O
terms	O
of	O
cotranscriptional	O
RNA	O
processing	O
events	O
,	O
although	O
there	O
were	O
a	O
few	O
abnormalities	O
consistent	O
with	O
rare	O
exon	O
-	O
skipping	O
events	O
.	O

Having	O
demonstrated	O
proper	O
localization	O
of	O
GFP	B-GENE
-	O
calmodulin	B-GENE
in	O
budding	O
yeast	O
,	O
we	O
examined	O
the	O
localization	O
of	O
a	O
fusion	O
between	O
GFP	B-GENE
and	O
calmodulin	B-GENE
(	O
GFP	B-GENE
-	I-GENE
Camlp	I-GENE
)	O
in	O
fission	O
yeast	O
,	O
where	O
calmodulin	B-GENE
had	O
not	O
been	O
localized	O
by	O
any	O
method	O
.	O

Sera	O
from	O
33	O
newborn	O
infants	O
with	O
gestational	O
ages	O
ranging	O
from	O
27	O
to	O
41	O
weeks	O
were	O
tested	O
by	O
radioimmunoassay	O
for	O
IgG	B-GENE
antibodies	O
to	O
surface	O
antigens	O
of	O
group	O
B	O
streptococci	O
(	O
GBS	O
)	O
types	O
Ia	O
,	O
Ib	O
,	O
II	O
and	O
III	O
.	O

In	O
frozen	O
sections	O
the	O
spots	O
appear	O
as	O
blue	O
labelled	O
neurones	O
with	O
a	O
light	O
microscope	O
,	O
or	O
as	O
a	O
brilliant	O
red	O
neurones	O
surrounded	O
by	O
reddish	O
tissue	O
with	O
a	O
fluorescence	O
microscope	O
.	O

The	O
percentage	O
distribution	O
of	O
types	O
of	O
fixation	O
disparity	O
curves	O
was	O
found	O
to	O
be	O
similar	O
to	O
some	O
previous	O
studies	O
,	O
with	O
a	O
higher	O
prevalence	O
of	O
Type	O
I	O
curve	O
(	O
64	O
.	O
3	O
%	O
)	O
,	O
followed	O
by	O
Type	O
II	O
(	O
28	O
.	O
6	O
%	O
)	O
and	O
Type	O
III	O
(	O
7	O
.	O
1	O
%	O
)	O
curves	O
.	O

The	O
BUR	O
was	O
set	O
at	O
20	O
/	O
min	O
and	O
the	O
IT	O
at	O
.	O
5	O
seconds	O
.	O

These	O
data	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
pathogenesis	O
and	O
differential	O
diagnosis	O
of	O
EEC	O
.	O

Seminal	O
prolactin	B-GENE
levels	O
were	O
significantly	O
elevated	O
in	O
all	O
infertile	O
males	O
.	O

Northern	O
blot	O
analysis	O
identified	O
retina	O
-	O
specific	O
transcripts	O
of	O
3	O
.	O
0	O
kb	O
for	O
rod	B-GENE
G	I-GENE
alpha	I-GENE
t	I-GENE
and	O
2	O
.	O
6	O
kb	O
for	O
cone	B-GENE
G	I-GENE
alpha	I-GENE
t	I-GENE
.	O

In	O
the	O
univariate	O
models	O
of	O
either	O
fixed	O
or	O
time	O
dependent	O
covariates	O
,	O
many	O
variables	O
were	O
significantly	O
associated	O
with	O
risk	O
of	O
progression	O
to	O
AIDS	O
(	O
T4	O
cell	O
count	O
,	O
T4	O
/	O
T8	O
ratio	O
,	O
blastogenic	O
responses	O
to	O
phytohemagglutinin	B-GENE
,	O
concanavalin	B-GENE
A	I-GENE
,	O
and	O
pokeweed	B-GENE
mitogen	I-GENE
,	O
serum	B-GENE
IgA	I-GENE
,	O
appearance	O
of	O
p24	B-GENE
antigen	I-GENE
,	O
and	O
the	O
development	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
thrush	O
,	O
or	O
herpes	O
zoster	O
)	O
.	O

Adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
MMAC1	B-GENE
/	O
PTEN	B-GENE
to	O
glioblastoma	O
cells	O
inhibits	O
S	O
phase	O
entry	O
by	O
the	O
recruitment	O
of	O
p27Kip1	B-GENE
into	O
cyclin	B-GENE
E	I-GENE
/	O
CDK2	B-GENE
complexes	O
.	O

Cost	O
analysis	O
and	O
the	O
HSA	O
:	O
a	O
framework	O
.	O

These	O
cells	O
also	O
showed	O
an	O
increase	O
in	O
cyclin	B-GENE
A	I-GENE
and	O
cyclin	B-GENE
A	I-GENE
-	I-GENE
and	I-GENE
E	I-GENE
-	I-GENE
associated	I-GENE
kinase	I-GENE
activities	O
characteristic	O
of	O
S	O
phase	O
induction	O
.	O

Characterization	O
of	O
a	O
tonB	B-GENE
-	O
phoA	B-GENE
gene	O
fusion	O
suggests	O
that	O
the	O
amino	O
-	O
terminal	O
41	O
amino	O
acids	O
of	O
TonB	B-GENE
are	O
sufficient	O
to	O
promote	O
export	O
of	O
the	O
fusion	O
protein	O
and	O
presumably	O
TonB	B-GENE
as	O
well	O
.	O

Calcium	O
bilirubinate	O
crystals	O
were	O
seen	O
in	O
gallbladder	O
bile	O
or	O
wall	O
scrapings	O
of	O
7	O
of	O
8	O
TPN	O
animals	O
but	O
in	O
none	O
of	O
the	O
controls	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

This	O
domain	O
encompasses	O
the	O
region	O
of	O
ARP	B-GENE
-	I-GENE
1	I-GENE
/	O
COUP	B-GENE
-	I-GENE
TFII	I-GENE
corresponding	O
to	O
helices	O
3	O
to	O
12	O
in	O
the	O
recently	O
published	O
crystal	O
structure	O
of	O
other	O
members	O
of	O
the	O
nuclear	B-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

Different	O
clinical	O
variants	O
of	O
the	O
empty	O
sella	O
turcica	O
syndrome	O
are	O
demonstrated	O
,	O
including	O
variants	O
resultant	O
from	O
substitution	O
therapy	O
of	O
thyroid	O
hypofunction	O
,	O
from	O
dopamine	O
agonist	O
therapy	O
for	O
hyperprolactinemic	O
hypogonadism	O
,	O
from	O
radiotherapy	O
of	O
hypophyseal	O
adenoma	O
.	O

Both	O
genes	B-GENE
ARO3	I-GENE
and	O
ARO4	B-GENE
are	O
strongly	O
regulated	O
under	O
the	O
general	O
control	O
regulatory	O
system	O
.	O

Polar	O
effects	O
of	O
transposon	O
insertions	O
demonstrated	O
that	O
all	O
of	O
these	O
mRNAs	O
arose	O
from	O
a	O
single	O
promoter	O
region	O
,	O
where	O
transcription	O
initiated	O
80	O
bp	O
5	O
'	O
to	O
nifH	B-GENE
.	O

J	O
.	O
,	O
&	O
Olefsky	O
,	O
J	O
.	O

Importantly	O
,	O
a	O
single	O
base	O
change	O
in	O
the	O
fifth	O
position	O
of	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
sequence	I-GENE
(	O
GGTCTnnnAGACC	O
to	O
GGTCA	O
/	O
GnnnAGACC	O
)	O
produced	O
an	O
element	O
that	O
bound	O
the	O
estrogen	B-GENE
receptor	I-GENE
and	O
conferred	O
estrogen	O
-	O
dependent	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
gene	O
.	O

Measuring	O
the	O
dim	O
light	O
melatonin	O
onset	O
(	O
DLMO	O
)	O
is	O
a	O
useful	O
and	O
practical	O
way	O
to	O
assess	O
circadian	O
phase	O
position	O
in	O
humans	O
.	O

Co	O
-	O
expression	O
of	O
a	O
gag	B-GENE
-	O
TRalpha	B-GENE
fusion	O
protein	O
in	O
AEV	O
-	O
transformed	O
cells	O
and	O
addition	O
of	O
ligand	O
derepresses	O
CAII	B-GENE
transcription	O
.	O

The	O
IB2	B-GENE
gene	I-GENE
(	O
HGMW	O
-	O
approved	O
symbol	O
MAPK8IP2	B-GENE
)	O
maps	O
to	O
human	O
chromosome	O
22q13	O
and	O
contains	O
10	O
coding	O
exons	O
.	O

Transcription	O
start	O
sites	O
of	O
sal	B-GENE
and	O
salR	B-GENE
genes	I-GENE
were	O
determined	O
to	O
lie	O
30	O
-	O
and	O
24	O
-	O
bp	O
upstream	O
of	O
the	O
respective	O
initiation	O
codons	O
and	O
separated	O
from	O
each	O
other	O
by	O
78	O
nucleotides	O
.	O

1	O
.	O
23	O
)	O
as	O
a	O
PPARalpha	B-GENE
-	I-GENE
interacting	I-GENE
protein	I-GENE
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
T	B-GENE
cell	I-GENE
antigen	I-GENE
receptor	I-GENE
zeta	I-GENE
-	I-GENE
chain	I-GENE
-	I-GENE
associated	I-GENE
ZAP	I-GENE
-	I-GENE
70	I-GENE
kinase	I-GENE
and	O
T	B-GENE
cell	I-GENE
antigen	I-GENE
receptor	I-GENE
zeta	I-GENE
-	I-GENE
chain	I-GENE
immunoreceptor	I-GENE
tyrosine	I-GENE
-	I-GENE
based	I-GENE
activation	I-GENE
motifs	I-GENE
are	O
essential	O
for	O
the	O
membrane	O
recruitment	O
of	O
SOS	B-GENE
and	O
Vav	B-GENE
.	O

We	O
carried	O
out	O
two	O
experiments	O
to	O
investigate	O
this	O
problem	O
.	O

When	O
linked	O
to	O
the	O
herpes	O
simplex	O
thymidine	B-GENE
kinase	I-GENE
minimal	O
promoter	O
,	O
this	O
fragment	O
acts	O
as	O
an	O
enhancing	O
element	O
in	O
Rcho	O
but	O
not	O
GC	O
cells	O
.	O

A	O
mammalian	O
protein	O
called	O
RFX	B-GENE
or	O
NF	B-GENE
-	I-GENE
X	I-GENE
binds	O
to	O
the	O
X	O
box	O
(	O
or	O
X1	O
box	O
)	O
in	O
the	O
promoters	O
of	O
a	O
number	O
of	O
major	B-GENE
histocompatibility	I-GENE
(	I-GENE
MHC	I-GENE
)	I-GENE
class	I-GENE
II	I-GENE
genes	I-GENE
.	O

Site	O
-	O
directed	O
mutagenesis	O
was	O
conducted	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
this	O
element	O
and	O
the	O
3	O
'	O
minus	O
-	O
strand	O
terminal	O
sequence	O
"	O
3	O
'	O
-	O
OH	O
-	O
CCCUAU	O
,	O
"	O
which	O
contains	O
the	O
minus	O
-	O
strand	O
3	O
'	O
-	O
end	O
sequence	O
"	O
3	O
'	O
-	O
OH	O
-	O
CC	O
(	O
1	O
-	O
2	O
)	O
(	O
A	O
/	O
U	O
)	O
(	O
A	O
/	O
U	O
)	O
(	O
A	O
/	O
U	O
)	O
"	O
found	O
in	O
all	O
carmovirus	O
RNAs	O
.	O

The	O
incidence	O
of	O
the	O
variability	O
of	O
the	O
free	O
PSA	B-GENE
/	O
total	O
PSA	B-GENE
ratio	O
on	O
the	O
early	O
diagnosis	O
of	O
prostate	O
cancer	O

VBP	B-GENE
and	O
a1	B-GENE
/	I-GENE
EBP	I-GENE
could	O
mediate	O
the	O
high	O
rates	O
of	O
ALV	O
and	O
RSV	B-GENE
LTR	I-GENE
-	O
enhanced	O
transcription	O
in	O
bursal	O
lymphoma	O
cells	O
and	O
many	O
other	O
cell	O
types	O
.	O

In	O
the	O
second	O
,	O
37	O
students	O
were	O
given	O
trimethoprim	O
/	O
sulphamethoxazole	O
(	O
160	O
mg	O
TMP	O
-	O
SMX	O
800	O
mg	O
)	O
,	O
38	O
TMP	O
(	O
200	O
mg	O
)	O
,	O
and	O
in	O
35	O
a	O
placebo	O
was	O
given	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
five	O
days	O
.	O

Developmental	O
slot	O
blots	O
demonstrate	O
that	O
mRNAs	O
corresponding	O
to	O
the	O
three	O
LHM	B-GENE
cDNAs	I-GENE
are	O
transcribed	O
from	O
prophase	O
of	O
meiosis	O
I	O
to	O
the	O
uninucleate	O
microspore	O
stage	O
,	O
while	O
Northern	O
analysis	O
reveals	O
these	O
tapetally	O
expressed	O
cDNAs	O
to	O
correspond	O
with	O
transcripts	O
of	O
some	O
500	O
bp	O
.	O

One	O
hundred	O
men	O
who	O
received	O
alpha	O
-	O
tocopherol	O
were	O
matched	O
on	O
age	O
,	O
study	O
center	O
,	O
and	O
length	O
of	O
time	O
between	O
blood	O
draws	O
to	O
100	O
men	O
who	O
received	O
a	O
placebo	O
.	O

The	O
contribution	O
of	O
residues	O
outside	O
the	O
Ras	B-GENE
binding	I-GENE
domain	I-GENE
of	O
Raf	B-GENE
(	O
RafRBD	B-GENE
)	O
to	O
Ras	B-GENE
-	O
Raf	B-GENE
interaction	O
and	O
Ras	B-GENE
-	O
dependent	O
Raf	B-GENE
activation	O
has	O
remained	O
unresolved	O
.	O

Other	O
recommendations	O
for	O
enhancing	O
the	O
safety	O
of	O
potent	O
antiplatelet	O
agents	O
in	O
a	O
variety	O
of	O
clinical	O
situations	O
are	O
provided	O
.	O

RESULTS	O
-	O
-	O
261	O
patients	O
were	O
enrolled	O
into	O
this	O
study	O
;	O
of	O
these	O
,	O
138	O
(	O
53	O
%	O
)	O
patients	O
attended	O
for	O
repeat	O
colposcopy	O
and	O
cytology	O
at	O
one	O
year	O
.	O

Changes	O
in	O
the	O
greater	O
omentum	O
of	O
mice	O
of	O
different	O
strains	O
after	O
intraperitoneal	O
immunization	O
with	O
sheep	O
erythrocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
determine	O
the	O
specific	O
effect	O
of	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
on	O
patient	O
weight	O
.	O

However	O
massive	O
necrosis	O
of	O
the	O
renal	O
tubules	O
had	O
been	O
found	O
with	O
more	O
than	O
15mg	O
of	O
DSM	O
administration	O
.	O

The	O
characteristics	O
of	O
a	O
simple	O
apparatus	O
for	O
clinical	O
use	O
to	O
measure	O
DEOAEs	O
are	O
described	O
together	O
with	O
typical	O
examples	O
of	O
emissions	O
.	O

To	O
obtain	O
information	O
on	O
the	O
functional	O
role	O
of	O
the	O
Rac1	B-GENE
/	O
p38	B-GENE
/	O
MAPKAPK	B-GENE
-	I-GENE
2	I-GENE
pathway	O
in	O
RA	O
signaling	O
,	O
the	O
effects	O
of	O
pharmacological	O
inhibition	O
of	O
p38	B-GENE
on	O
RA	O
-	O
induced	O
gene	O
transcription	O
and	O
cell	O
differentiation	O
were	O
determined	O
.	O

The	O
cost	O
and	O
effectiveness	O
of	O
nurse	O
education	O
-	O
-	O
1	O
.	O

The	O
ATF	B-GENE
/	O
CRE	O
site	O
is	O
also	O
essential	O
for	O
CD4	B-GENE
promoter	I-GENE
activation	O
by	O
forskolin	O
,	O
an	O
activator	O
of	O
adenylate	B-GENE
cyclase	I-GENE
.	O

YLL031c	B-GENE
is	O
an	O
essential	O
gene	O
.	O

Restricted	O
expression	O
of	O
a	O
novel	O
murine	B-GENE
atonal	I-GENE
-	I-GENE
related	I-GENE
bHLH	I-GENE
protein	I-GENE
in	O
undifferentiated	O
neural	O
precursors	O
.	O

Since	O
the	O
early	O
1900s	O
,	O
a	O
genetic	O
hypothesis	O
has	O
been	O
suggested	O
.	O

We	O
report	O
the	O
genomic	O
organization	O
of	O
the	O
mouse	O
orphan	B-GENE
receptor	I-GENE
related	I-GENE
to	I-GENE
tyrosine	I-GENE
kinases	I-GENE
(	O
Ryk	B-GENE
)	O
,	O
a	O
structurally	O
unclassified	O
member	O
of	O
the	O
growth	B-GENE
factor	I-GENE
receptor	I-GENE
family	O
.	O

In	O
contrast	O
,	O
T229E	B-GENE
-	I-GENE
p70s6k	I-GENE
migrated	O
more	O
slowly	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
,	O
but	O
demonstrated	O
partial	O
kinase	O
activity	O
(	O
approximately	O
20	O
%	O
compared	O
with	O
the	O
wild	O
type	O
)	O
.	O

The	O
structure	O
and	O
expression	O
of	O
the	O
murine	B-GENE
gene	I-GENE
encoding	I-GENE
granulocyte	I-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
stimulating	I-GENE
factor	I-GENE
:	O
evidence	O
for	O
utilisation	O
of	O
alternative	O
promoters	O
.	O

Thus	O
,	O
the	O
search	O
for	O
genetic	O
and	O
acquired	O
susceptibility	O
to	O
nontuberculous	O
mycobacteria	O
is	O
also	O
a	O
search	O
for	O
susceptibility	O
factors	O
for	O
MTB	O
as	O
well	O
as	O
an	O
opportunity	O
to	O
recognize	O
endogenous	O
pathways	O
that	O
can	O
be	O
exploited	O
therapeutically	O
.	O

Liver	O
disease	O
and	O
HCV	O
infection	O
after	O
transplantation	O
of	O
organs	O
from	O
hepatitis	B-GENE
C	I-GENE
antibody	I-GENE
positive	O
donors	O
.	O

After	O
dialysis	O
online	O
,	O
lactate	O
was	O
converted	O
by	O
means	O
of	O
lactate	B-GENE
oxidase	I-GENE
immobilized	O
to	O
porous	O
glass	O
,	O
and	O
the	O
depletion	O
of	O
oxygen	O
was	O
registered	O
by	O
means	O
of	O
a	O
Clark	O
electrode	O
.	O

The	O
deduced	O
amino	O
-	O
acid	O
sequence	O
of	O
the	O
mature	O
enzyme	O
showed	O
very	O
low	O
homology	O
(	O
<	O
20	O
.	O
4	O
%	O
identity	O
)	O
to	O
those	O
of	O
known	O
pectinolytic	O
enzymes	O
in	O
the	O
large	O
pectate	B-GENE
lyase	I-GENE
superfamily	I-GENE
(	O
the	O
polysaccharide	B-GENE
lyase	I-GENE
family	I-GENE
1	I-GENE
)	O
.	O

Incubation	O
of	O
HeLa	O
cell	O
cytoplasmic	O
extracts	O
with	O
a	O
purified	O
recombinant	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
-	O
raf	B-GENE
fusion	O
protein	O
in	O
the	O
presence	O
of	O
ATP	O
released	O
active	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
that	O
could	O
be	O
detected	O
by	O
electrophoretic	O
gel	O
mobility	O
shift	O
assay	O
.	O

Despite	O
this	O
loss	O
,	O
YEpFAS1	B-GENE
is	O
still	O
able	O
to	O
complement	O
a	O
fas1	B-GENE
mutation	O
at	O
the	O
enoyl	B-GENE
reductase	I-GENE
domain	O
.	O

Cross	O
-	O
species	O
characterization	O
of	O
the	O
promoter	B-GENE
region	I-GENE
of	I-GENE
the	I-GENE
cystic	I-GENE
fibrosis	I-GENE
transmembrane	I-GENE
conductance	I-GENE
regulator	I-GENE
gene	I-GENE
reveals	O
multiple	O
levels	O
of	O
regulation	O
.	O

Pretreatment	O
with	O
lipid	O
X	O
was	O
not	O
necessary	O
to	O
improve	O
survival	O
:	O
16	O
of	O
17	O
(	O
94	O
%	O
)	O
infected	O
and	O
visibly	O
ill	O
animals	O
that	O
received	O
lipid	O
X	O
and	O
ticarcillin	O
6	O
h	O
after	O
thigh	O
inoculation	O
survived	O
versus	O
30	O
of	O
44	O
(	O
68	O
%	O
)	O
control	O
animals	O
treated	O
with	O
ticarcillin	O
alone	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
predicted	O
vav	B-GENE
oncogene	I-GENE
protein	I-GENE
sequence	I-GENE
exhibits	O
several	O
motifs	O
reminiscent	O
of	O
transcriptional	O
factors	O
.	O

The	O
pharmacokinetics	O
were	O
best	O
described	O
by	O
a	O
two	O
-	O
compartment	O
open	O
model	O
giving	O
distribution	O
half	O
-	O
lives	O
of	O
0	O
.	O
31	O
h	O
and	O
1	O
.	O
53	O
h	O
,	O
and	O
elimination	O
half	O
-	O
lives	O
of	O
69	O
.	O
7	O
h	O
and	O
60	O
.	O
3	O
h	O
for	O
oxolinic	O
acid	O
and	O
oxytetracycline	O
,	O
respectively	O
.	O

The	O
predictive	O
value	O
of	O
the	O
remotely	O
sensed	O
map	O
based	O
on	O
NDVI	O
data	O
appears	O
to	O
be	O
better	O
than	O
that	O
from	O
forecast	O
indices	O
based	O
only	O
on	O
climatic	O
data	O
.	O

It	O
has	O
been	O
confirmed	O
in	O
animal	O
experiments	O
that	O
the	O
number	O
of	O
microspheres	O
in	O
a	O
myocardial	O
sample	O
approximately	O
follows	O
a	O
Poisson	O
distribution	O
,	O
under	O
adequate	O
experimental	O
conditions	O
.	O

Hepatitis	B-GENE
B	I-GENE
immune	I-GENE
globulins	I-GENE
and	O
HIV	B-GENE
antibodies	I-GENE
.	O

This	O
gene	O
is	O
divided	O
into	O
six	O
exons	O
spanning	O
about	O
3kb	O
,	O
and	O
encodes	O
a	O
175	O
amino	O
acid	O
protein	O
with	O
40	O
-	O
52	O
%	O
identity	O
with	O
the	O
other	O
five	O
mouse	B-GENE
Reg	I-GENE
(	O
regenerating	B-GENE
gene	I-GENE
product	I-GENE
)	O
proteins	O
.	O

The	O
p63	B-GENE
sequence	I-GENE
also	O
features	O
an	O
acidic	O
domain	O
characteristic	O
of	O
transcriptional	O
activation	O
factors	O
,	O
as	O
well	O
as	O
sequence	O
blocks	O
displaying	O
limited	O
similarity	O
to	O
positionally	O
equivalent	O
regions	O
in	O
sigma	B-GENE
factors	I-GENE
from	O
eubacteria	O
related	O
to	O
mitochondria	O
.	O

In	O
contrast	O
,	O
a	O
similar	O
fusion	O
protein	O
(	O
hGH	B-GENE
-	O
LDLR	B-GENE
-	O
DAF17	B-GENE
,	O
abbreviated	O
HLD	B-GENE
)	O
containing	O
a	O
fragment	O
of	O
the	O
serine	O
/	O
threonine	O
-	O
rich	O
domain	O
of	O
the	O
LDL	B-GENE
receptor	I-GENE
(	O
LDLR	B-GENE
)	O
in	O
place	O
of	O
the	O
DAF	B-GENE
-	I-GENE
derived	I-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
-	I-GENE
rich	I-GENE
sequences	I-GENE
,	O
does	O
not	O
become	O
GPI	O
anchored	O
.	O

Thus	O
,	O
the	O
pathway	O
to	O
Fc	B-GENE
epsilonRI	I-GENE
-	O
mediated	O
MEK	B-GENE
/	O
ERK	B-GENE
and	O
ERK	B-GENE
activation	O
can	O
apparently	O
bypass	O
Ras	B-GENE
and	O
Raf	B-GENE
-	I-GENE
1	I-GENE
.	O

To	O
assess	O
whether	O
thallium	O
-	O
201	O
thallous	O
chloride	O
(	O
Tl	O
)	O
can	O
detect	O
childhood	O
tumors	O
and	O
whether	O
diagnostic	O
effectiveness	O
improves	O
with	O
combined	O
blood	O
flow	O
imaging	O
,	O
28	O
children	O
(	O
1	O
.	O
0	O
-	O
18	O
.	O
6	O
years	O
)	O
were	O
studied	O
using	O
single	O
photon	O
emission	O
computed	O
tomography	O
(	O
SPECT	O
)	O
:	O
Tl	O
(	O
1	O
.	O
3	O
-	O
1	O
.	O
8	O
mCi	O
intravenously	O
)	O
,	O
followed	O
in	O
13	O
of	O
the	O
patients	O
by	O
technetium	O
-	O
99m	O
-	O
hexamethylpropyleneamine	O
oxime	O
(	O
99mTc	O
-	O
HMPAO	O
;	O
8	O
-	O
18	O
mCi	O
intravenously	O
)	O
.	O

Ftz	B-GENE
,	O
on	O
the	O
other	O
hand	O
,	O
influences	O
Ftz	B-GENE
-	O
F1	B-GENE
activity	O
by	O
interacting	O
with	O
its	O
AF	O
-	O
2	O
domain	O
in	O
a	O
manner	O
that	O
mimics	O
a	O
nuclear	O
receptor	O
coactivator	O
.	O

Successive	O
5	O
'	O
deletions	O
of	O
the	O
[	O
-	O
326	O
;	O
+	O
20	O
]	O
type	B-GENE
II	I-GENE
sPLA2	I-GENE
promoter	I-GENE
indicated	O
that	O
the	O
region	O
upstream	O
of	O
position	O
-	O
195	O
inhibits	O
the	O
transcription	O
activity	O
sixfold	O
in	O
HepG2	O
cells	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

Forty	O
-	O
five	O
patients	O
with	O
recent	O
-	O
onset	O
hyperthyroidism	O
(	O
<	O
12	O
weeks	O
)	O
were	O
sex	O
and	O
menopause	O
stratified	O
and	O
randomly	O
allocated	O
to	O
treatment	O
with	O
carbimazole	O
(	O
Neotomizol	O
)	O
,	O
carbimazole	O
plus	O
low	O
dose	O
CT	O
(	O
Calsynar	O
;	O
100	O
IU	O
/	O
day	O
,	O
2	O
days	O
/	O
week	O
)	O
,	O
or	O
carbimazole	O
plus	O
high	O
dose	O
CT	O
(	O
Calsynar	O
;	O
100	O
IU	O
/	O
day	O
,	O
14	O
days	O
/	O
month	O
)	O
.	O

The	O
cloning	O
of	O
CWH43	B-GENE
showed	O
that	O
it	O
corresponds	O
to	O
YCR017c	B-GENE
and	O
encodes	O
a	O
protein	O
with	O
14	O
-	O
16	O
transmembrane	O
segments	O
containing	O
several	O
putative	O
phosphorylation	O
and	O
glycosylation	O
sites	O
.	O

However	O
,	O
strains	O
in	O
which	O
both	O
of	O
the	O
two	O
most	O
highly	O
related	O
genes	O
,	O
DdPIK1	B-GENE
and	O
DdPIK2	B-GENE
,	O
were	O
disrupted	O
showed	O
both	O
growth	O
and	O
developmental	O
defects	O
,	O
while	O
double	O
knockouts	O
of	O
DdPIK1	B-GENE
and	O
DdPIK3	B-GENE
and	O
DdPIK2	B-GENE
and	O
DdPIK3	B-GENE
appear	O
to	O
be	O
lethal	O
.	O

This	O
mechanism	O
seems	O
to	O
be	O
involved	O
in	O
VIP	B-GENE
-	O
induced	O
PRL	B-GENE
gene	I-GENE
regulation	O
.	O

Competition	O
and	O
methylation	O
interference	O
assays	O
showed	O
that	O
the	O
binding	O
site	O
for	O
the	O
novel	O
factor	O
was	O
limited	O
to	O
nucleotides	O
in	O
the	O
3	O
'	O
half	O
of	O
the	O
kappa	B-GENE
B	I-GENE
site	I-GENE
.	O

These	O
properties	O
prompted	O
us	O
to	O
investigate	O
Ets	B-GENE
-	I-GENE
1	I-GENE
expression	O
in	O
32	O
human	O
astroglial	O
tumors	O
of	O
WHO	O
grades	O
I	O
-	O
IV	O
and	O
to	O
correlate	O
the	O
data	O
with	O
the	O
expression	O
pattern	O
of	O
VEGF	B-GENE
,	O
Flt	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
KDR	B-GENE
.	O

Mean	O
concentration	O
of	O
insulin	B-GENE
in	O
maternal	O
plasma	O
across	O
all	O
sampling	O
times	O
was	O
higher	O
in	O
ethanol	O
treated	O
animals	O
.	O

The	O
strongly	O
DNA	O
binding	O
p50	B-GENE
subunit	I-GENE
showed	O
only	O
very	O
weak	O
,	O
if	O
any	O
,	O
induction	O
of	O
gene	O
expression	O
.	O

The	O
results	O
obtained	O
demonstrate	O
the	O
applicability	O
of	O
countercurrent	O
chromatography	O
to	O
the	O
determination	O
of	O
ultratrace	O
elements	O
.	O

E1A	B-GENE
+	O
cHa	B-GENE
-	I-GENE
ras	I-GENE
transformed	O
rat	O
embryo	O
fibroblast	O
cells	O
are	O
characterized	O
by	O
high	O
and	O
constitutive	O
DNA	O
binding	O
activities	O
of	O
AP	B-GENE
-	I-GENE
1	I-GENE
dimers	I-GENE
with	O
significantly	O
altered	O
composition	O
.	O

Minor	O
changes	O
within	O
the	O
transmembrane	O
domains	O
(	O
TMs	O
)	O
sometimes	O
produced	O
major	O
effects	O
and	O
more	O
drastic	O
changes	O
in	O
the	O
TMs	O
ablated	O
surface	O
expression	O
entirely	O
.	O

Nuclear	O
localization	O
of	O
this	O
SNF2	B-GENE
-	I-GENE
like	I-GENE
putative	O
helicase	B-GENE
is	O
dependent	O
on	O
a	O
nuclear	O
localization	O
sequence	O
located	O
in	O
the	O
NH2	O
-	O
terminal	O
region	O
.	O

The	O
feasibility	O
of	O
creating	O
CR1	B-GENE
/	O
Ig	B-GENE
chimeras	O
makes	O
possible	O
a	O
new	O
strategy	O
of	O
targeting	O
complement	O
inhibition	O
by	O
the	O
use	O
of	O
Ig	B-GENE
fusion	I-GENE
partners	I-GENE
having	O
particular	O
antigenic	O
specificities	O
.	O

Morphological	O
-	O
functional	O
status	O
of	O
the	O
edentulous	O
mandible	O
and	O
selection	O
of	O
the	O
most	O
effective	O
method	O
for	O
functional	O
impression	O
-	O
taking	O

They	O
are	O
both	O
insensitive	O
to	O
inhibitors	O
of	O
serine	B-GENE
and	I-GENE
aspartyl	I-GENE
proteinases	I-GENE
but	O
are	O
sensitive	O
to	O
sulfhydryl	O
reagents	O
and	O
0	O
.	O
5	O
mM	O
ZnCl2	O
.	O

The	O
tau	O
v	O
at	O
rest	O
was	O
4	O
.	O
06	O
+	O
/	O
-	O
2	O
.	O
16	O
s	O
and	O
decreased	O
to	O
2	O
.	O
44	O
+	O
/	O
-	O
1	O
.	O
07	O
s	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
1	O
Hz	O
and	O
to	O
1	O
.	O
81	O
+	O
/	O
-	O
0	O
.	O
4	O
s	O
at	O
5	O
Hz	O
.	O

The	O
authors	O
investigate	O
in	O
a	O
group	O
of	O
211	O
children	O
aged	O
2	O
-	O
6	O
years	O
,	O
incl	O
.	O
in	O
particular	O
a	O
group	O
of	O
33	O
2	O
-	O
year	O
-	O
old	O
ones	O
,	O
in	O
1990	O
and	O
checked	O
in	O
1991	O
at	O
two	O
sites	O
in	O
Bratislava	O
-	O
-	O
a	O
town	O
with	O
a	O
varying	O
concentration	O
of	O
NOX	O
,	O
SO2	O
,	O
dustiness	O
and	O
dust	O
fallout	O
-	O
-	O
their	O
influence	O
on	O
the	O
incidence	O
,	O
type	O
and	O
course	O
of	O
relapsing	O
respiratory	O
disease	O
.	O

However	O
,	O
no	O
statistical	O
difference	O
in	O
the	O
Ca	O
/	O
P	O
ratio	O
,	O
carbon	O
concentration	O
and	O
surface	O
energy	O
were	O
observed	O
with	O
different	O
heat	O
treatments	O
.	O

Using	O
in	O
vivo	O
genomic	O
dimethyl	O
sulfate	O
and	O
KMnO4	O
footprinting	O
,	O
we	O
showed	O
that	O
the	O
promoter	O
region	O
is	O
differentially	O
protected	O
,	O
depending	O
upon	O
which	O
holoenzyme	O
is	O
bound	O
.	O

Here	O
we	O
show	O
that	O
inhibition	O
occurs	O
with	O
a	O
NS1	B-GENE
-	O
Rev	B-GENE
chimera	O
in	O
which	O
the	O
78	O
amino	O
-	O
terminal	O
amino	O
acids	O
of	O
the	O
NS1A	B-GENE
protein	I-GENE
comprising	O
its	O
entire	O
RNA	O
-	O
binding	O
domain	O
is	O
deleted	O
,	O
thereby	O
establishing	O
that	O
this	O
carboxyl	O
portion	O
of	O
the	O
NS1A	B-GENE
protein	I-GENE
can	O
function	O
as	O
an	O
independent	O
effector	O
domain	O
.	O

Overall	O
,	O
it	O
appears	O
that	O
prenatal	O
exposure	O
to	O
androgen	O
-	O
based	O
synthetic	O
progestin	O
exerted	O
a	O
masculinizing	O
and	O
/	O
or	O
defeminizing	O
influence	O
on	O
human	O
behavioral	O
development	O
,	O
whereas	O
prenatal	O
exposure	O
to	O
natural	O
progesterone	O
and	O
progesterone	O
-	O
based	O
synthetic	O
progestin	O
had	O
a	O
feminizing	O
and	O
/	O
or	O
demasculinizing	O
influence	O
,	O
particularly	O
among	O
female	O
subjects	O
.	O

The	O
testes	O
of	O
8	O
specimens	O
of	O
Triturus	O
marmoratus	O
were	O
collected	O
during	O
each	O
month	O
of	O
1987	O
and	O
processed	O
for	O
electron	O
microscopy	O
and	O
light	O
microscopy	O
demonstration	O
of	O
testosterone	O
(	O
T	O
)	O
following	O
the	O
ABC	B-GENE
(	O
avidin	B-GENE
-	I-GENE
biotin	I-GENE
peroxidase	I-GENE
complex	I-GENE
)	O
method	O
.	O

MTX	O
therapy	O
decreased	O
Ga	O
-	O
67	O
uptake	O
in	O
liver	O
,	O
tumor	O
,	O
and	O
muscle	O
.	O

In	O
stage	O
I	O
,	O
histochemistry	O
for	O
copper	O
was	O
positive	O
in	O
11	O
out	O
of	O
21	O
cases	O
:	O
6	O
cases	O
were	O
T	O
+	O
;	O
1	O
case	O
R	O
+	O
and	O
2	O
cases	O
O	O
+	O
;	O
2	O
cases	O
were	O
T	O
+	O
,	O
R	O
+	O
,	O
O	O
+	O
.	O

Encapsulation	O
of	O
sodium	O
fluorescein	O
for	O
dye	O
release	O
studies	O
.	O

Primer	O
extension	O
analysis	O
and	O
subcloning	O
of	O
the	O
virJ	B-GENE
-	O
phoA	B-GENE
fusion	O
indicate	O
that	O
the	O
acetosyringone	O
-	O
inducible	O
promoter	O
lies	O
directly	O
upstream	O
of	O
the	O
virJ	B-GENE
structural	I-GENE
gene	I-GENE
.	O

To	O
isolate	O
genes	O
that	O
contain	O
zinc	O
finger	O
motifs	O
,	O
a	O
human	O
brain	O
cDNA	O
library	O
was	O
screened	O
with	O
an	O
oligonucleotide	O
complementary	O
to	O
the	O
conserved	O
"	O
linker	O
"	O
sequence	O
between	O
adjacent	O
zinc	O
fingers	O
.	O

Percentage	O
incremental	O
18	O
-	O
OHB	O
responses	O
to	O
metoclopramide	O
were	O
greater	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
in	O
the	O
subjects	O
after	O
5	O
days	O
on	O
a	O
200	O
-	O
meq	O
sodium	O
intake	O
than	O
after	O
5	O
days	O
on	O
a	O
10	O
-	O
meq	O
sodium	O
intake	O
.	O

Using	O
in	O
vivo	O
screening	O
,	O
we	O
first	O
identified	O
a	O
gene	O
that	O
appeared	O
to	O
interfere	O
with	O
the	O
His	O
-	O
Asp	O
phosphorelay	O
between	O
the	O
HPt	O
domain	O
and	O
the	O
receiver	O
domain	O
of	O
OmpR	B-GENE
,	O
provided	O
that	O
the	O
gene	O
product	O
was	O
expressed	O
through	O
a	O
multicopy	O
plasmid	O
.	O

The	O
non	B-GENE
-	I-GENE
major	I-GENE
histocompatibility	I-GENE
complex	I-GENE
(	O
MHC	B-GENE
)	O
-	O
encoded	O
CD1	B-GENE
family	I-GENE
has	O
recently	O
emerged	O
as	O
a	O
new	O
antigen	O
-	O
presenting	O
system	O
that	O
is	O
distinct	O
from	O
either	O
MHC	B-GENE
class	I-GENE
I	I-GENE
or	I-GENE
class	I-GENE
II	I-GENE
molecules	I-GENE
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
Pst1p	B-GENE
possessed	O
high	O
sequence	O
homology	O
with	O
the	O
Sin3	B-GENE
family	I-GENE
of	O
proteins	O
,	O
known	O
for	O
their	O
interaction	O
with	O
histone	B-GENE
deacetylases	I-GENE
.	O

Quinethazone	O

Studies	O
on	O
nitrogen	O
-	O
containing	O
heterocyclic	O
compounds	O
.	O

Removal	O
of	O
ink4a	B-GENE
dramatically	O
reduces	O
the	O
lymphoid	O
and	O
neurological	O
defects	O
seen	O
in	O
bmi	B-GENE
-	I-GENE
1	I-GENE
-	O
deficient	O
mice	O
,	O
indicating	O
that	O
ink4a	B-GENE
is	O
a	O
critical	O
in	O
vivo	O
target	O
for	O
Bmi	B-GENE
-	I-GENE
1	I-GENE
.	O

We	O
found	O
that	O
RXR	B-GENE
and	O
VDR	B-GENE
transactivated	O
selectively	O
from	O
VDRE	O
-	O
linked	O
templates	O
exclusively	O
as	O
a	O
heterodimeric	O
complex	O
,	O
since	O
neither	O
receptor	O
alone	O
enhanced	O
transcription	O
in	O
vitro	O
.	O

METHODS	O
:	O
We	O
performed	O
nasal	O
mupirocin	O
treatment	O
on	O
10	O
infants	O
who	O
were	O
MRSA	O
-	O
positive	O
either	O
in	O
the	O
nose	O
or	O
the	O
pharynx	O
and	O
evaluated	O
the	O
effect	O
of	O
mupirocin	O
on	O
the	O
eradication	O
of	O
MRSA	O
.	O

RESULTS	O
:	O
Of	O
10	O
,	O
709	O
,	O
701	O
chemistry	O
specimens	O
submitted	O
to	O
the	O
participating	O
laboratories	O
during	O
the	O
data	O
collection	O
period	O
,	O
37	O
,	O
208	O
(	O
0	O
.	O
35	O
%	O
)	O
were	O
rejected	O
prior	O
to	O
testing	O
.	O

Early	O
complement	O
components	O
,	O
C1q	B-GENE
and	O
C4	B-GENE
,	O
and	O
IgA	B-GENE
secretory	O
piece	O
were	O
absent	O
.	O

Administration	O
of	O
SnCl2	O
and	O
ZnSO4	O
(	O
group	O
V	O
)	O
resulted	O
in	O
a	O
decrease	O
of	O
ALA	B-GENE
-	I-GENE
D	I-GENE
activity	O
and	O
in	O
an	O
increase	O
in	O
CP	O
-	O
U	O
.	O

Using	O
a	O
dominant	O
negative	O
form	O
of	O
Sp3	B-GENE
and	O
transcriptional	O
activation	O
assays	O
in	O
Schneider	O
SL	O
-	O
2	O
insect	O
cells	O
,	O
it	O
was	O
confirmed	O
that	O
ERalpha	B-GENE
-	O
Sp3	B-GENE
interactions	O
define	O
a	O
pathway	O
for	O
E2	B-GENE
-	O
mediated	O
inhibition	O
of	O
gene	O
expression	O
,	O
and	O
this	O
represents	O
a	O
new	O
mechanism	O
for	O
decreased	O
gene	O
expression	O
by	O
E2	B-GENE
.	O

From	O
the	O
supposition	O
that	O
there	O
exists	O
a	O
possible	O
connection	O
between	O
certain	O
psychopathological	O
symptoms	O
,	O
and	O
/	O
or	O
syndromes	O
(	O
e	O
.	O
g	O
.	O
,	O
hallucinations	O
)	O
and	O
regional	O
cerebral	O
dysfunction	O
,	O
patients	O
suffering	O
from	O
auditory	O
and	O
tactile	O
hallucinations	O
were	O
investigated	O
,	O
in	O
a	O
symptom	O
-	O
oriented	O
study	O
,	O
using	O
the	O
method	O
of	O
technetium	O
-	O
99m	O
-	O
Hexamethyl	O
-	O
propylenamine	O
Oxime	O
(	O
99m	O
-	O
Tc	O
-	O
HMPAO	O
)	O
-	O
Single	O
Photon	O
Emission	O
Computed	O
Tomography	O
(	O
SPECT	O
)	O
and	O
compared	O
with	O
normal	O
controls	O
.	O

The	O
lack	O
of	O
chronically	O
depressed	O
LCBF	O
(	O
after	O
1	O
day	O
)	O
may	O
be	O
related	O
to	O
the	O
quick	O
structural	O
repair	O
of	O
endothelium	O
.	O

In	O
this	O
study	O
,	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
of	O
action	O
of	O
EM	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
expression	O
of	O
neutrophil	O
adhesion	O
molecules	O
such	O
as	O
L	B-GENE
-	I-GENE
selectin	I-GENE
and	O
Mac	B-GENE
-	I-GENE
1	I-GENE
.	O

Tissue	O
expansion	O
was	O
used	O
successfully	O
to	O
prepare	O
adequate	O
soft	O
tissue	O
for	O
closure	O
following	O
a	O
difficult	O
clubfoot	O
correction	O
.	O

The	O
transcription	O
start	O
site	O
was	O
identified	O
by	O
primer	O
extension	O
analysis	O
and	O
over	O
800	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
was	O
sequenced	O
.	O

The	O
reporter	O
gene	O
with	O
two	O
copies	O
of	O
the	O
wild	O
-	O
type	O
Repeat	O
2	O
+	O
3	O
sequence	O
was	O
transcribed	O
actively	O
in	O
sterol	O
-	O
deprived	O
cells	O
and	O
was	O
repressed	O
by	O
more	O
than	O
80	O
%	O
when	O
sterols	O
were	O
present	O
.	O

Changes	O
in	O
tension	O
were	O
monitored	O
isometrically	O
on	O
spiral	O
strips	O
of	O
freshly	O
obtained	O
bovine	O
basilar	O
arteries	O
.	O

A	O
1	O
.	O
5	O
-	O
month	O
-	O
old	O
boy	O
with	O
Sandifer	O
'	O
s	O
syndrome	O
is	O
described	O
.	O

However	O
,	O
PC12	O
cell	O
clones	O
which	O
expressed	O
p33rsu	B-GENE
-	I-GENE
1	I-GENE
at	O
an	O
increased	O
level	O
in	O
a	O
regulatable	O
fashion	O
in	O
response	O
to	O
dexamethasone	O
were	O
isolated	O
.	O

In	O
this	O
study	O
,	O
we	O
verified	O
that	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
associates	O
with	O
the	O
CD4	B-GENE
:	O
p56lck	B-GENE
complex	I-GENE
as	O
judged	O
by	O
the	O
presence	O
of	O
PI	O
3	O
-	O
phosphate	O
generated	O
from	O
anti	B-GENE
-	I-GENE
CD4	I-GENE
immunoprecipitates	O
and	O
detected	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatographic	O
analysis	O
.	O

The	O
clinical	O
picture	O
,	O
the	O
light	O
and	O
electron	O
microscopic	O
appearance	O
,	O
and	O
the	O
histochemical	O
findings	O
are	O
described	O
in	O
six	O
cases	O
of	O
fibroma	O
of	O
tendon	O
sheath	O
.	O

However	O
,	O
their	O
stability	O
was	O
low	O
as	O
already	O
reported	O
for	O
the	O
ARS	O
in	O
S	O
.	O
occidentalis	O
.	O

In	O
this	O
study	O
,	O
a	O
site	O
of	O
PDGF	B-GENE
-	O
induced	O
tyrosine	O
phosphorylation	O
was	O
mapped	O
to	O
Tyr	O
138	O
in	O
the	O
SH3	B-GENE
domain	I-GENE
;	O
Tyr	O
138	O
is	O
exposed	O
on	O
the	O
SH3	B-GENE
peptide	I-GENE
binding	I-GENE
surface	I-GENE
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
in	O
patients	O
with	O
syndrome	O
X	O
,	O
myocardial	O
ischemia	O
frequently	O
develops	O
during	O
daily	O
life	O
;	O
silent	O
ischemia	O
is	O
an	O
important	O
component	O
of	O
this	O
syndrome	O
;	O
and	O
increased	O
oxygen	O
demand	O
in	O
the	O
presence	O
of	O
impaired	O
coronary	O
vasodilatory	O
capacity	O
is	O
not	O
the	O
only	O
cause	O
of	O
myocardial	O
ischemia	O
.	O

We	O
also	O
identified	O
a	O
DNA	O
fragment	O
,	O
10	O
.	O
7	O
kbp	O
upstream	O
from	O
the	O
first	O
coding	O
exon	O
of	O
human	B-GENE
aFGF	I-GENE
,	O
whose	O
sequence	O
is	O
conserved	O
in	O
both	O
the	O
primate	O
and	O
rodent	O
genomes	O
.	O

The	O
false	O
positive	O
fraction	O
(	O
FPF	O
)	O
decreased	O
significantly	O
if	O
the	O
count	O
density	O
increased	O
;	O
no	O
difference	O
in	O
FPF	O
was	O
found	O
for	O
a	O
change	O
in	O
lesion	O
tracer	O
concentration	O
.	O

These	O
events	O
were	O
only	O
weakly	O
stimulated	O
by	O
the	O
activated	B-GENE
PDGF	I-GENE
alpha	I-GENE
-	I-GENE
receptor	I-GENE
.	O

Human	B-GENE
plastin	I-GENE
genes	I-GENE
.	O

Buserelin	O
offers	O
an	O
effective	O
alternative	O
medical	O
treatment	O
of	O
carcinoma	O
of	O
the	O
prostate	O
and	O
,	O
apart	O
from	O
impotence	O
,	O
does	O
not	O
have	O
the	O
side	O
effects	O
of	O
oestrogens	O
.	O

C	B-GENE
/	I-GENE
EBP	I-GENE
delta	I-GENE
(	O
NFIL	B-GENE
-	I-GENE
6	I-GENE
beta	I-GENE
)	O
was	O
not	O
detected	O
in	O
complexes	O
utilizing	O
extracts	O
from	O
the	O
IL	B-GENE
-	I-GENE
1	I-GENE
nonproducing	O
T	O
cell	O
line	O
.	O

Reduced	O
risk	O
of	O
upper	O
gastrointestinal	O
ulcer	O
complications	O
with	O
celecoxib	O
,	O
a	O
novel	O
COX	B-GENE
-	I-GENE
2	I-GENE
inhibitor	O
.	O

Moreover	O
,	O
our	O
recent	O
findings	O
on	O
the	O
Tc52	B-GENE
encoding	I-GENE
gene	I-GENE
underline	O
the	O
interest	O
of	O
genetic	O
manipulation	O
of	O
T	O
.	O
cruzi	O
,	O
not	O
only	O
making	O
it	O
possible	O
to	O
use	O
more	O
closely	O
an	O
in	O
vitro	O
approach	O
to	O
find	O
out	O
how	O
genes	O
function	O
,	O
but	O
also	O
to	O
obtain	O
'	O
attenuated	O
'	O
strains	O
that	O
could	O
be	O
used	O
in	O
the	O
development	O
of	O
vaccinal	O
strategies	O
.	O

Infra	O
-	O
red	O
spectroscopy	O
of	O
tissues	O
in	O
the	O
700	O
-	O
400	O
cm	O
-	O
1	O
region	O
.	O

YDL003w	B-GENE
(	O
also	O
termed	O
MCD1	B-GENE
)	O
is	O
a	O
homologue	O
of	O
Schizosaccharomyces	B-GENE
pombe	I-GENE
rad21	I-GENE
,	O
an	O
essential	O
gene	O
implicated	O
in	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
and	O
nuclear	O
organization	O
in	O
fission	O
yeast	O
.	O

The	O
recent	O
concept	O
of	O
a	O
bioartificial	O
organ	O
is	O
an	O
attempt	O
to	O
avoid	O
such	O
disadvantages	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
1	O
)	O
to	O
quantify	O
the	O
comparative	O
structural	O
static	O
and	O
fatigue	O
properties	O
of	O
the	O
pointe	O
shoe	O
toe	O
box	O
,	O
and	O
2	O
)	O
to	O
evaluate	O
the	O
preferred	O
shoe	O
characteristics	O
as	O
determined	O
by	O
a	O
survey	O
of	O
local	O
dancers	O
.	O

In	O
the	O
postoperative	O
patient	O
with	O
tetralogy	O
of	O
Fallot	O
with	O
symptomatic	O
ventricular	O
arrhythmias	O
,	O
it	O
is	O
concluded	O
that	O
electrophysiologic	O
study	O
is	O
useful	O
in	O
reproducing	O
clinical	O
episodes	O
of	O
VT	O
and	O
in	O
selecting	O
effective	O
antiarrhythmic	O
medication	O
;	O
a	O
small	O
number	O
of	O
patients	O
with	O
ventricular	O
premature	O
complexes	O
alone	O
will	O
have	O
inducible	O
sustained	O
VT	O
during	O
electrophysiologic	O
study	O
;	O
prognosis	O
of	O
these	O
patients	O
may	O
be	O
improved	O
by	O
treatment	O
that	O
results	O
in	O
prevention	O
of	O
VT	O
induction	O
;	O
and	O
in	O
patients	O
with	O
right	O
ventricular	O
hypertension	O
,	O
VT	O
is	O
likely	O
to	O
be	O
refractory	O
to	O
drug	O
treatment	O
.	O

Indications	O
for	O
therapy	O
using	O
MAO	B-GENE
inhibitors	O

The	O
absorbance	O
of	O
the	O
eluent	O
was	O
monitored	O
at	O
254	O
nm	O
.	O

Here	O
,	O
we	O
describe	O
the	O
results	O
of	O
a	O
detailed	O
study	O
aimed	O
at	O
identifying	O
the	O
gene	O
or	O
genes	O
responsible	O
for	O
the	O
rapid	O
growth	O
-	O
arrest	O
response	O
obtained	O
with	O
human	O
chromosome	O
-	O
9	O
.	O

Footprints	O
on	O
the	O
HPV	B-GENE
18	I-GENE
enhancer	I-GENE
show	O
five	O
protected	O
regions	O
with	O
homologies	O
to	O
NF1	B-GENE
,	O
AP1	B-GENE
and	O
EFII	B-GENE
transcription	I-GENE
factor	I-GENE
binding	I-GENE
motifs	I-GENE
.	O

Insulin	B-GENE
binding	O
to	O
the	O
alpha	O
-	O
subunit	O
of	O
its	O
receptor	O
stimulates	O
the	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
to	O
phosphorylate	O
the	O
beta	O
-	O
subunit	O
and	O
several	O
endogenous	O
protein	O
substrates	O
,	O
including	O
pp120	B-GENE
/	O
HA4	B-GENE
,	O
a	O
liver	O
-	O
specific	O
plasma	O
membrane	O
glycoprotein	O
of	O
M	O
(	O
r	O
)	O
20	O
,	O
000	O
.	O

Motilin	B-GENE
serum	O
levels	O
were	O
measured	O
for	O
one	O
hour	O
.	O

The	O
role	O
of	O
phosphorylation	O
on	O
receptor	O
desensitization	O
was	O
assessed	O
using	O
receptor	O
mutants	O
expressed	O
in	O
COS	O
cells	O
or	O
Chinese	O
hamster	O
lung	O
fibroblasts	O
.	O

First	O
aid	O
.	O

Improvement	O
of	O
some	O
pharmaceutical	O
properties	O
of	O
clofibrate	O
by	O
cyclodextrin	O
complexation	O
.	O

The	O
detection	O
limits	O
obtained	O
by	O
using	O
the	O
mixed	O
eluent	O
were	O
0	O
.	O
05	O
-	O
0	O
.	O
13	O
mg	O
/	O
L	O
,	O
several	O
times	O
lower	O
than	O
those	O
obtained	O
by	O
using	O
single	O
KHPh	O
eluent	O
.	O

Early	O
diagnosis	O
and	O
early	O
surgical	O
division	O
of	O
the	O
biliary	O
tract	O
and	O
pancreatic	O
duct	O
is	O
recommended	O
for	O
children	O
with	O
AAPBD	O
.	O

We	O
have	O
analyzed	O
herein	O
the	O
roles	O
that	O
four	O
different	O
PIAS	B-GENE
proteins	I-GENE
(	O
ARIP3	B-GENE
/	O
PIASx	B-GENE
alpha	I-GENE
,	O
Miz1	B-GENE
/	O
PIASx	B-GENE
beta	I-GENE
,	O
GBP	B-GENE
/	O
PIAS1	B-GENE
,	O
and	O
PIAS3	B-GENE
)	O
play	O
in	O
the	O
regulation	O
of	O
steroid	B-GENE
receptor	I-GENE
-	O
or	O
STAT	B-GENE
-	O
mediated	O
transcriptional	O
activation	O
.	O

Comparison	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
with	O
that	O
of	O
the	O
Drosophila	B-GENE
virilis	I-GENE
gene	I-GENE
shows	O
that	O
several	O
blocks	O
of	O
amino	O
acid	O
sequence	O
have	O
been	O
very	O
highly	O
conserved	O
.	O

Analyses	O
focused	O
on	O
two	O
platyrrhine	O
(	O
New	O
World	O
monkey	O
)	O
species	O
:	O
the	O
common	O
marmoset	O
(	O
Callithrix	O
jacchus	O
)	O
and	O
the	O
brown	O
capuchin	O
monkey	O
(	O
Cebus	O
apella	O
)	O
,	O
each	O
of	O
which	O
has	O
paired	O
,	O
non	O
-	O
allelic	O
gamma	O
loci	O
(	O
5	O
'	O
-	O
gamma	O
1	O
-	O
gamma	O
2	O
-	O
3	O
'	O
)	O
.	O

A	O
phase	O
II	O
clinical	O
trial	O
on	O
MDS	O
was	O
conducted	O
in	O
a	O
cooperative	O
study	O
with	O
orally	O
administrable	O
ara	O
-	O
C	O
analogue	O
,	O
PLAC	O
,	O
which	O
is	O
resistant	O
to	O
cytidine	B-GENE
deaminase	I-GENE
and	O
had	O
shown	O
an	O
anti	O
-	O
tumor	O
activity	O
on	O
various	O
experimental	O
tumors	O
by	O
oral	O
route	O
.	O

A	O
decrease	O
was	O
also	O
found	O
of	O
the	O
levels	O
of	O
total	O
cholesterol	O
and	O
LDL	B-GENE
-	I-GENE
cholesterol	I-GENE
.	O

Previously	O
,	O
we	O
had	O
shown	O
that	O
interleukin	B-GENE
8	I-GENE
(	O
IL	B-GENE
-	I-GENE
8	I-GENE
)	O
is	O
constitutively	O
expressed	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
cells	O
and	O
in	O
cells	O
transiently	O
expressing	O
Tax	B-GENE
.	O

Unlike	O
JNK	B-GENE
activation	O
,	O
ERK	B-GENE
activation	O
could	O
not	O
be	O
mapped	O
to	O
specific	O
reovirus	O
gene	O
segments	O
,	O
suggesting	O
that	O
ERK	B-GENE
activation	O
and	O
JNK	B-GENE
activation	O
are	O
triggered	O
by	O
different	O
events	O
during	O
virus	O
-	O
host	O
cell	O
interaction	O
.	O

Despite	O
the	O
same	O
decreases	O
or	O
increases	O
in	O
MAP	O
,	O
RSNA	O
was	O
attenuated	O
after	O
15	O
and	O
30	O
min	O
of	O
propofol	O
infusion	O
in	O
both	O
groups	O
compared	O
with	O
control	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

To	O
address	O
this	O
question	O
with	O
respect	O
to	O
skeletal	O
muscle	O
,	O
we	O
have	O
examined	O
the	O
effects	O
of	O
the	O
Providence	O
mutation	O
in	O
cultured	O
muscle	O
cells	O
,	O
after	O
adoptive	O
gene	O
transfer	O
to	O
adult	O
mice	O
,	O
and	O
in	O
two	O
infants	O
homozygous	O
for	O
spectrin	B-GENE
Providence	I-GENE
.	O

It	O
appears	O
to	O
be	O
useful	O
in	O
untreated	O
patients	O
with	O
stage	O
I	O
or	O
II	O
NHL	O
but	O
no	O
definite	O
radiographic	O
abnormalities	O
,	O
or	O
with	O
abnormal	O
radiographs	O
but	O
no	O
extrathoracic	O
spread	O
,	O
and	O
in	O
treated	O
patients	O
with	O
questionable	O
radiographs	O
.	O

B	B-GENE
and	O
C1	B-GENE
fusions	I-GENE
with	O
yeast	B-GENE
GAL4	I-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
and	I-GENE
transcriptional	I-GENE
activation	I-GENE
domains	I-GENE
were	O
also	O
found	O
to	O
interact	O
when	O
synthesized	O
and	O
assayed	O
in	O
yeast	O
.	O

Because	O
of	O
the	O
data	O
,	O
we	O
suggest	O
that	O
LAC9	B-GENE
contacts	O
positions	O
6	O
,	O
7	O
,	O
and	O
8	O
,	O
both	O
plus	O
and	O
minus	O
,	O
of	O
the	O
UAS	O
,	O
which	O
are	O
separated	O
by	O
more	O
than	O
one	O
turn	O
of	O
the	O
DNA	O
helix	O
,	O
and	O
twists	O
part	O
way	O
around	O
the	O
DNA	O
,	O
thus	O
protecting	O
the	O
broad	O
region	O
of	O
the	O
minor	O
groove	O
between	O
the	O
major	O
-	O
groove	O
contacts	O
.	O

On	O
the	O
optic	O
tentacle	O
-	O
gonadal	O
axis	O
in	O
the	O
control	O
of	O
the	O
male	O
-	O
phase	O
ovotestis	O
in	O
the	O
slug	O
(	O
Ariolimax	O
californicus	O
)	O
.	O

Substitution	O
of	O
cholinergic	O
drugs	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
type	O
dementia	O
(	O
AD	O
/	O
SDAT	O
)	O
has	O
hitherto	O
not	O
been	O
very	O
successful	O
.	O

Here	O
we	O
show	O
that	O
the	O
nucleotide	O
in	O
the	O
middle	O
of	O
the	O
anticodon	O
(	O
i	O
.	O
e	O
.	O
,	O
psi	O
35	O
)	O
also	O
contributes	O
to	O
the	O
suppressor	O
efficiency	O
displayed	O
by	O
cytoplasmic	B-GENE
tRNA	I-GENE
(	I-GENE
Tyr	I-GENE
)	I-GENE
.	O

The	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
of	O
bond	O
lengths	O
from	O
the	O
ideal	O
values	O
is	O
0	O
.	O
02	O
A	O
.	O

Jet	O
lag	O
and	O
melatonin	O
.	O

In	O
addition	O
,	O
these	O
results	O
suggest	O
that	O
the	O
interactions	O
,	O
and	O
consequently	O
the	O
mechanisms	O
,	O
governing	O
transcriptional	O
activation	O
by	O
CTF	B-GENE
are	O
distinct	O
from	O
those	O
mediating	O
DNA	O
replication	O
.	O

A	O
TAAATA	O
sequence	O
is	O
present	O
26	O
nt	O
upstream	O
from	O
the	O
major	O
CAP	O
site	O
,	O
and	O
within	O
the	O
5	O
'	O
-	O
flanking	O
region	O
there	O
are	O
several	O
putative	O
transcription	O
factor	O
binding	O
sites	O
.	O

It	O
was	O
found	O
that	O
both	O
versions	O
of	O
the	O
brief	O
SL	O
&	O
amp	O
;	O
shy	O
;	O
ASIA	O
had	O
similar	O
correlations	O
to	O
the	O
target	O
variables	O
as	O
the	O
full	O
scale	O
SL	O
&	O
amp	O
;	O
shy	O
;	O
ASIA	O
.	O

The	O
reconstituted	O
enzyme	O
binds	O
DNA	O
with	O
an	O
affinity	O
that	O
is	O
approximately	O
20	O
-	O
fold	O
lower	O
than	O
that	O
of	O
the	O
intact	O
topo70	B-GENE
.	O

Treatment	O
with	O
KP	O
-	O
45	O
preparation	O
usually	O
resulted	O
in	O
partial	O
regression	O
of	O
tumor	O
growth	O
,	O
accompanied	O
by	O
improvement	O
of	O
the	O
clinical	O
state	O
of	O
these	O
patients	O
,	O
as	O
well	O
as	O
reappearance	O
of	O
normal	O
values	O
of	O
blood	O
picture	O
and	O
biochemical	O
parameters	O
.	O

Istanbul	O
,	O
Turkey	O
.	O

We	O
propose	O
that	O
optimal	O
transcription	O
of	O
the	O
gD	B-GENE
gene	I-GENE
depends	O
on	O
the	O
interaction	O
of	O
ICP4	B-GENE
with	O
multiple	O
binding	O
sites	O
across	O
the	O
gene	O
and	O
cellular	O
factors	O
that	O
recognize	O
specific	O
sequence	O
elements	O
in	O
the	O
promoter	O
.	O

Recently	O
,	O
we	O
and	O
other	O
laboratories	O
have	O
identified	O
a	O
family	O
of	O
caveolin	B-GENE
-	I-GENE
related	I-GENE
proteins	I-GENE
;	O
caveolin	B-GENE
has	O
been	O
re	O
-	O
termed	O
caveolin	B-GENE
-	I-GENE
1	I-GENE
.	O

Role	O
of	O
zinc	B-GENE
-	I-GENE
finger	I-GENE
proteins	I-GENE
Sp1	I-GENE
and	O
zif268	B-GENE
/	O
egr	B-GENE
-	I-GENE
1	I-GENE
in	O
transcriptional	O
regulation	O
of	O
the	O
human	B-GENE
synaptobrevin	I-GENE
II	I-GENE
gene	I-GENE
.	O

The	O
human	B-GENE
Fc	I-GENE
gamma	I-GENE
receptor	I-GENE
gene	I-GENE
Fc	B-GENE
gamma	I-GENE
RIIA	I-GENE
is	O
expressed	O
in	O
platelets	O
,	O
neutrophils	O
,	O
monocytes	O
and	O
macrophages	O
.	O

This	O
dip	O
also	O
occurred	O
during	O
prednisone	O
and	O
vitamin	O
D	O
treatment	O
,	O
but	O
did	O
not	O
occur	O
when	O
calcium	O
was	O
added	O
to	O
prednisone	O
,	O
although	O
the	O
baseline	O
value	O
was	O
lower	O
at	O
the	O
start	O
of	O
combined	O
treatment	O
with	O
prednisone	O
and	O
calcium	O
.	O

E	O
.	O
granulosus	O
infection	O
has	O
been	O
confirmed	O
in	O
25	O
patients	O
(	O
20	O
.	O
6	O
%	O
)	O
,	O
in	O
16	O
cases	O
by	O
finding	O
parasite	O
protoscoleces	O
or	O
hooks	O
and	O
in	O
nine	O
cases	O
by	O
detection	O
of	O
an	O
antigen	O
specific	O
for	O
E	B-GENE
.	I-GENE
granulosus	I-GENE
,	I-GENE
antigen	I-GENE
5	I-GENE
(	O
Ag5	B-GENE
)	O
.	O

The	O
effect	O
of	O
stimulation	O
of	O
the	O
entopeduncular	O
nucleus	O
(	O
EP	O
)	O
on	O
the	O
jaw	O
-	O
opening	O
reflex	O
(	O
JOR	O
)	O
was	O
studied	O
in	O
the	O
cat	O
anesthetized	O
with	O
sodium	O
pentobarbital	O
.	O

A	O
Premenstrual	O
Syndrome	O
,	O
the	O
late	O
luteal	O
phase	O
disorder	O
of	O
DSM	O
-	O
IIIR	O
criteria	O
,	O
was	O
identified	O
in	O
6	O
%	O
of	O
the	O
women	O
.	O

First	O
,	O
mutations	O
in	O
the	O
IFNgamma	B-GENE
-	I-GENE
activated	I-GENE
sequence	I-GENE
(	O
GAS	B-GENE
)	O
,	O
either	O
multimerized	O
or	O
in	O
the	O
context	O
of	O
the	O
1	B-GENE
.	I-GENE
7	I-GENE
-	I-GENE
kb	I-GENE
IRF	I-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
,	O
failed	O
to	O
mediate	O
a	O
PRL	B-GENE
response	O
,	O
showing	O
that	O
the	O
IRF	B-GENE
-	I-GENE
1	I-GENE
GAS	B-GENE
is	O
a	O
target	O
of	O
PRL	B-GENE
signaling	O
.	O

025	O
)	O
.	O

RESULTS	O
:	O
PET	O
revealed	O
wide	O
variations	O
in	O
CBF	O
between	O
regions	O
during	O
isoflurane	O
anaesthesia	O
,	O
particularly	O
in	O
comparison	O
with	O
propofol	O
anaesthesia	O
,	O
while	O
rCMRO2	O
decreased	O
globally	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
during	O
both	O
isoflurane	O
and	O
propofol	O
anaesthesia	O
.	O

This	O
selective	O
squelching	O
activity	O
suggests	O
that	O
GRIM	B-GENE
can	O
interact	O
with	O
an	O
essential	O
component	O
of	O
the	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
transcription	O
machinery	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
integron	O
located	O
on	O
a	O
composite	O
transposon	O
.	O

The	O
nine	O
subjects	O
were	O
treated	O
in	O
random	O
sequence	O
with	O
cimetidine	O
0	O
-	O
8	O
-	O
1	O
-	O
0	O
g	O
on	O
one	O
day	O
and	O
placebo	O
capsules	O
on	O
the	O
other	O
.	O

The	O
protein	O
was	O
overexpressed	O
in	O
Escherichia	O
coli	O
and	O
purified	O
to	O
homogeneity	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
yeast	O
gene	O
encoding	O
the	O
U2	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
particle	I-GENE
B	I-GENE
"	I-GENE
protein	I-GENE
.	O

A	O
360	O
-	O
bp	O
DNA	O
fragment	O
located	O
over	O
500	O
bp	O
upstream	O
from	O
the	O
cfl	B-GENE
transcriptional	O
start	O
site	O
was	O
used	O
in	O
DNase	B-GENE
I	I-GENE
protection	O
assays	O
to	O
define	O
the	O
specific	O
bases	O
bound	O
by	O
CorR	B-GENE
.	O

Taking	O
into	O
account	O
certain	O
well	O
defined	O
conditions	O
(	O
frequent	O
feedings	O
,	O
no	O
supplementary	O
feeding	O
before	O
4	O
-	O
6	O
months	O
,	O
method	O
only	O
to	O
be	O
used	O
in	O
the	O
absence	O
of	O
menstruation	O
)	O
,	O
LAM	O
can	O
be	O
relied	O
on	O
for	O
contraceptive	O
protection	O
for	O
up	O
to	O
1	O
year	O
post	O
partum	O
.	O

Nramp2	B-GENE
contains	O
a	O
classical	O
iron	O
responsive	O
element	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
that	O
confers	O
iron	O
dependent	O
mRNA	O
stabilization	O
.	O

Likewise	O
,	O
epidural	O
morphine	O
does	O
not	O
modify	O
the	O
intraoperative	O
metabolic	O
and	O
hormonal	O
responses	O
.	O

CONCLUSIONS	O
-	O
-	O
Postlumbar	O
puncture	O
headache	O
may	O
be	O
mediated	O
by	O
the	O
release	O
of	O
substance	B-GENE
P	I-GENE
triggered	O
by	O
lumbar	O
puncture	O
,	O
in	O
patients	O
predisposed	O
to	O
headache	O
by	O
a	O
hypersensitivity	O
to	O
substance	B-GENE
P	I-GENE
.	O

Continuous	O
arterial	O
blood	O
sampling	O
method	O
based	O
on	O
the	O
microsphere	O
model	O
was	O
used	O
as	O
a	O
quantitative	O
rCBF	O
measurement	O
.	O

A	O
mutated	B-GENE
ABF1	I-GENE
site	I-GENE
that	O
displays	O
a	O
very	O
low	O
affinity	O
for	O
ABF1	B-GENE
does	O
not	O
functionally	O
replace	O
the	O
ILV1	B-GENE
REB1	B-GENE
site	I-GENE
.	O

Given	O
a	O
rapid	O
induction	O
of	O
Egr	B-GENE
-	I-GENE
1	I-GENE
on	O
stimulation	O
with	O
growth	O
factors	O
or	O
injury	O
,	O
these	O
findings	O
may	O
represent	O
at	O
least	O
one	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
phenotypic	O
modulation	O
of	O
smooth	O
muscles	O
after	O
vascular	O
injury	O
.	O

A	O
nationwide	O
survey	O
uncovered	O
a	O
tenfold	O
variation	O
between	O
counties	O
in	O
the	O
prescribing	O
of	O
IFNB	B-GENE
.	O

In	O
this	O
first	O
-	O
person	O
account	O
,	O
the	O
author	O
chronicles	O
her	O
experience	O
of	O
being	O
mentally	O
ill	O
and	O
homeless	O
in	O
New	O
York	O
and	O
New	O
Jersey	O
in	O
the	O
early	O
1980s	O
.	O

Rectal	O
temperatures	O
after	O
the	O
walk	O
were	O
greater	O
(	O
P	O
<	O
.	O
001	O
)	O
in	O
native	O
Simmental	O
(	O
39	O
.	O
87	O
+	O
/	O
-	O
.	O
05	O
degrees	O
C	O
)	O
than	O
in	O
Bos	O
indicus	O
(	O
39	O
.	O
46	O
+	O
/	O
-	O
.	O
05	O
degrees	O
C	O
)	O
.	O

Dominant	O
-	O
negative	O
mutations	O
in	O
the	O
G	B-GENE
-	I-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
alpha	I-GENE
-	I-GENE
factor	I-GENE
receptor	I-GENE
map	O
to	O
the	O
extracellular	O
ends	O
of	O
the	O
transmembrane	O
segments	O
.	O

Such	O
simple	O
injuries	O
may	O
however	O
be	O
accompanied	O
by	O
far	O
reaching	O
consequences	O
.	O

This	O
is	O
the	O
first	O
report	O
which	O
clearly	O
proved	O
CEA	B-GENE
synthesis	O
in	O
the	O
cells	O
of	O
HCC	O
.	O

By	O
screening	O
a	O
human	O
testis	O
cDNA	O
library	O
with	O
a	O
probe	O
containing	O
the	O
mouse	B-GENE
PEA3	I-GENE
ETS	B-GENE
domain	O
,	O
we	O
isolated	O
a	O
2	O
.	O
2	O
kb	O
clone	O
containing	O
a	O
510	O
AA	O
open	O
reading	O
frame	O
.	O

AU	O
-	O
rich	O
elements	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
a	O
new	O
mucin	B-GENE
-	I-GENE
type	I-GENE
gene	I-GENE
family	O
of	O
Trypanosoma	O
cruzi	O
confers	O
mRNA	O
instability	O
and	O
modulates	O
translation	O
efficiency	O
.	O

These	O
findings	O
suggest	O
that	O
IL	B-GENE
-	I-GENE
1	I-GENE
-	O
stimulated	O
,	O
Rho	B-GENE
-	O
dependent	O
cytoskeletal	O
reorganization	O
may	O
cluster	O
signaling	O
molecules	O
in	O
specific	O
architectures	O
that	O
are	O
necessary	O
for	O
persistent	O
cell	O
activation	O
in	O
chronic	O
inflammatory	O
disease	O
.	O

Changes	O
in	O
testicular	O
testosterone	O
and	O
acid	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
activity	O
in	O
testis	O
and	O
accessory	O
sex	O
organs	O
after	O
induction	O
of	O
varicocele	O
in	O
Noble	O
rats	O
.	O

M	O
.	O
,	O
Apps	O
,	O
D	O
.	O

These	O
data	O
suggest	O
that	O
weight	O
gain	O
or	O
increased	O
caloric	O
intake	O
,	O
in	O
contrast	O
to	O
its	O
large	O
effect	O
on	O
peripheral	O
thyroid	O
function	O
,	O
has	O
relatively	O
little	O
effect	O
on	O
CNS	B-GENE
TRH	I-GENE
activity	O
.	O

Alfalfa	O
phosphorus	O
release	O
kinetics	O
showed	O
high	O
bacterial	O
phosphorus	O
contamination	O
.	O

The	O
quantitative	O
analysis	O
of	O
1	O
-	O
alpha	O
-	O
acetylmethadol	O
and	O
its	O
principal	O
metabolites	O
in	O
biological	O
specimens	O
by	O
gas	O
chromatography	O
-	O
chemical	O
ionization	O
-	O
multiple	O
ion	O
monitoring	O
mass	O
spectrometry	O
.	O

Clinical	O
evidence	O
provides	O
tentative	O
suggestions	O
on	O
(	O
a	O
)	O
possible	O
additional	O
risk	O
of	O
cigarette	O
smoking	O
(	O
b	O
)	O
avoidance	O
of	O
venography	O
(	O
c	O
)	O
avoidance	O
of	O
varicose	O
vein	O
surgery	O
.	O

Effects	O
of	O
prolonged	O
inhibition	O
of	O
labour	O
pains	O
with	O
Th	O
1165a	O
and	O
Isoptin	O
on	O
the	O
heart	O
,	O
circulation	O
,	O
organ	O
-	O
and	O
metabolic	O
parameters	O
of	O
the	O
mother	O

Skytthe	O
,	O
and	O
K	O
.	O

In	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
actin	I-GENE
intron	I-GENE
a	O
silent	O
branch	O
point	O
-	O
like	O
sequence	O
(	O
UACUAAG	O
)	O
is	O
located	O
7	O
nt	O
upstream	O
of	O
the	O
canonical	O
sequence	O
.	O

The	O
requirement	O
for	O
an	O
essential	O
interaction	O
between	O
NPH	B-GENE
I	I-GENE
and	O
H4L	B-GENE
provides	O
an	O
explanation	O
for	O
the	O
observed	O
restriction	O
of	O
transcription	O
termination	O
to	O
early	O
viral	O
genes	O
.	O

After	O
birth	O
,	O
there	O
was	O
a	O
significantly	O
higher	O
increase	O
of	O
IgA	B-GENE
and	O
IgM	B-GENE
anti	I-GENE
-	I-GENE
M	I-GENE
.	I-GENE
leprae	I-GENE
antibody	I-GENE
activity	O
in	O
sera	O
taken	O
3	O
-	O
6	O
months	O
after	O
birth	O
from	O
babies	O
of	O
Group	O
1	O
compared	O
to	O
Group	O
2	O
,	O
but	O
the	O
IgA	B-GENE
and	O
IgM	B-GENE
activity	O
in	O
sera	O
taken	O
after	O
6	O
months	O
of	O
age	O
showed	O
the	O
same	O
increase	O
in	O
the	O
two	O
groups	O
.	O

The	O
relation	O
between	O
the	O
changes	O
of	O
bone	O
density	O
and	O
the	O
level	O
of	O
blood	O
calcium	O
,	O
blood	O
phosphorus	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
(	O
AKP	B-GENE
)	O
as	O
well	O
as	O
the	O
metabolism	O
of	O
vitamin	O
D	O
was	O
studied	O
.	O

These	O
results	O
demonstrate	O
the	O
extensive	O
homology	O
in	O
sequence	O
among	O
light	O
chains	O
of	O
IgM	B-GENE
kappa	I-GENE
autoantibodies	I-GENE
and	O
indicate	O
that	O
a	O
particular	O
V	B-GENE
kappa	I-GENE
germ	I-GENE
line	I-GENE
gene	I-GENE
,	O
kappa	B-GENE
IIIb	I-GENE
,	O
is	O
expressed	O
as	O
a	O
phylogenetic	O
response	O
to	O
certain	O
self	O
antigens	O
or	O
as	O
part	O
of	O
a	O
selection	O
process	O
by	O
which	O
these	O
autoimmune	O
responses	O
are	O
regulated	O
.	O

In	O
addition	O
,	O
the	O
findings	O
confirmed	O
previous	O
studies	O
which	O
showed	O
that	O
monkeys	O
with	O
total	O
bilateral	O
striatectomies	O
could	O
require	O
the	O
ability	O
to	O
execute	O
accurate	O
visually	O
guided	O
reaches	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
the	O
alpha	B-GENE
-	I-GENE
like	I-GENE
DNA	I-GENE
polymerases	I-GENE
including	O
E	B-GENE
.	I-GENE
coli	I-GENE
DNA	I-GENE
polymerase	I-GENE
II	I-GENE
showed	O
that	O
there	O
were	O
nine	O
highly	O
conserved	O
regions	O
,	O
and	O
we	O
constructed	O
an	O
unrooted	O
phylogenetic	O
tree	O
of	O
the	O
DNA	B-GENE
polymerases	I-GENE
based	O
on	O
the	O
differences	O
in	O
these	O
conserved	O
regions	O
.	O

Before	O
and	O
6	O
and	O
12	O
months	O
after	O
H	O
.	O
pylori	O
eradication	O
the	O
patients	O
were	O
evaluated	O
for	O
fasting	O
gastrinemia	O
and	O
pepsinogen	B-GENE
I	I-GENE
,	O
basal	O
and	O
peak	O
acid	O
output	O
,	O
and	O
detailed	O
histological	O
assessment	O
including	O
the	O
ECL	O
cell	O
proliferative	O
patterns	O
.	O

Four	O
experiments	O
examined	O
the	O
role	O
of	O
the	O
cholinergic	O
projections	O
from	O
the	O
septum	O
and	O
vertical	O
limb	O
nucleus	O
of	O
the	O
diagonal	O
band	O
of	O
Broca	O
(	O
VDB	O
)	O
in	O
acquisition	O
and	O
performance	O
of	O
a	O
conditional	O
visual	O
discrimination	O
.	O

trans	O
-	O
activation	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
LTR	I-GENE
by	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
Tat	I-GENE
and	O
HTLV	B-GENE
-	I-GENE
I	I-GENE
Tax	I-GENE
proteins	I-GENE
is	O
mediated	O
by	O
different	O
cis	O
-	O
acting	O
sequences	O
.	O

Defective	O
concanavalin	B-GENE
A	I-GENE
-	O
induced	O
suppression	O
in	O
bancroftian	O
filariasis	O
.	O

For	O
more	O
detailed	O
mapping	O
,	O
we	O
constructed	O
mouse	O
A9	O
cells	O
containing	O
STFs	O
derived	O
from	O
human	O
chromosome	O
2	O
tagged	O
with	O
pSTneo	O
at	O
different	O
regions	O
in	O
2q31	O
-	O
qter	O
.	O

Left	O
ventricular	O
insufficiency	O
requires	O
two	O
SP	O
/	O
patient	O
,	O
with	O
good	O
results	O
in	O
approximately	O
81	O
p	O
.	O
cent	O
.	O

However	O
,	O
there	O
are	O
some	O
cows	O
that	O
fail	O
to	O
produce	O
adequate	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
at	O
the	O
onset	O
of	O
lactation	O
.	O

Acidic	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
gene	B-GENE
2	I-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
of	I-GENE
bacteriophage	I-GENE
T7	I-GENE
is	O
essential	O
for	O
protein	O
-	O
protein	O
interactions	O
.	O

This	O
result	O
,	O
together	O
with	O
the	O
fact	O
that	O
unrearranged	B-GENE
V	I-GENE
kappa	I-GENE
genes	I-GENE
are	O
transcriptionally	O
silent	O
,	O
suggests	O
that	O
structural	O
features	O
of	O
both	O
the	O
V	B-GENE
kappa	I-GENE
and	O
C	B-GENE
kappa	I-GENE
loci	I-GENE
contribute	O
to	O
the	O
overall	O
transcriptional	O
efficiency	O
of	O
a	O
rearranged	B-GENE
V	I-GENE
kappa	I-GENE
-	I-GENE
C	I-GENE
kappa	I-GENE
gene	I-GENE
.	O

A	O
total	O
of	O
10	O
,	O
763	O
men	O
and	O
3	O
,	O
118	O
women	O
has	O
been	O
studied	O
,	O
of	O
whom	O
97	O
%	O
and	O
89	O
%	O
,	O
respectively	O
,	O
have	O
been	O
traced	O
and	O
36	O
%	O
and	O
16	O
%	O
have	O
died	O
.	O

NSD1	B-GENE
contains	O
a	O
SET	B-GENE
domain	I-GENE
and	O
multiple	O
PHD	O
fingers	O
.	O

EMG	O
-	O
based	O
measures	O
of	O
fatigue	O
during	O
a	O
repetitive	O
squat	O
exercise	O
.	O

We	O
have	O
introduced	O
the	O
same	O
change	O
in	O
a	O
yeast	B-GENE
tRNA	I-GENE
(	I-GENE
Trp	I-GENE
)	I-GENE
gene	I-GENE
and	O
demonstrated	O
that	O
the	O
tRNA	O
acts	O
as	O
an	O
efficient	O
amber	O
suppressor	O
in	O
vivo	O
.	O

This	O
evaluation	O
examines	O
several	O
analytical	O
and	O
cost	O
parameters	O
for	O
five	O
representative	O
assays	O
:	O
IgG	B-GENE
,	O
IgA	B-GENE
,	O
IgM	B-GENE
,	O
phenytoin	O
,	O
and	O
phenobarbital	O
.	O

These	O
results	O
suggest	O
that	O
UvrA	B-GENE
is	O
involved	O
in	O
triplet	O
repeat	O
instability	O
in	O
cells	O
.	O

Among	O
women	O
,	O
plasma	B-GENE
factor	I-GENE
VII	I-GENE
:	O
Ag	O
was	O
inversely	O
associated	O
with	O
income	O
.	O

A	O
novel	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
-	O
interacting	O
protein	O
was	O
identified	O
by	O
the	O
yeast	O
two	O
-	O
hybrid	O
screening	O
using	O
the	O
regulatory	O
domain	O
of	O
PKC	B-GENE
beta	I-GENE
I	I-GENE
as	O
a	O
bait	O
.	O

CONCLUSIONS	O
:	O
The	O
number	O
of	O
Spanish	O
articles	O
published	O
in	O
Anesthesiology	O
,	O
BJA	O
,	O
and	O
Anesth	O
Analg	O
is	O
low	O
,	O
although	O
the	O
comparison	O
of	O
our	O
productivity	O
with	O
that	O
of	O
other	O
EU	O
countries	O
in	O
function	O
of	O
GNPpc	O
places	O
us	O
in	O
an	O
intermediate	O
position	O
.	O

One	O
of	O
the	O
repeating	O
domains	O
(	O
Yheb1	B-GENE
)	O
,	O
consisting	O
of	O
67	O
amino	O
acids	O
,	O
was	O
cloned	O
from	O
the	O
E	O
.	O
coli	O
chromosome	O
and	O
purified	O
by	O
metal	O
chelating	O
chromatography	O
.	O

Phosphorylation	O
at	O
Ser	O
(	O
670	O
)	O
impairs	O
the	O
ability	O
of	O
GRK2	B-GENE
to	O
phosphorylate	O
both	O
soluble	O
and	O
membrane	O
-	O
incorporated	O
receptor	O
substrates	O
and	O
dramatically	O
attenuates	O
Gbetagamma	B-GENE
-	O
mediated	O
activation	O
of	O
this	O
enzyme	O
.	O

METHODS	O
:	O
CD4	B-GENE
cell	O
counts	O
and	O
interview	O
data	O
were	O
recorded	O
in	O
a	O
survey	O
of	O
136	O
adult	O
patients	O
attending	O
a	O
community	O
hospital	O
-	O
based	O
HIV	O
outpatient	O
clinic	O
.	O

Biol	O
.	O

Inhibition	O
of	O
endogenous	B-GENE
Cdk2	I-GENE
by	O
dominant	B-GENE
negative	I-GENE
Cdk2	I-GENE
attenuated	O
phosphorylation	O
of	O
Thr447	O
,	O
Thr490	O
and	O
Thr497	O
,	O
but	O
had	O
no	O
effect	O
upon	O
Ser581	O
modification	O
.	O

A	O
rabbit	O
antiserum	O
raised	O
against	O
a	O
unique	O
(	O
V3	O
domain	O
)	O
bacterially	O
expressed	O
PKC	B-GENE
theta	I-GENE
fragment	I-GENE
immunoprecipitated	O
specifically	O
an	O
82	O
-	O
kDa	O
protein	O
from	O
Jurkat	O
cell	O
lysates	O
.	O

Histological	O
examination	O
revealed	O
variable	O
loss	O
of	O
motor	O
neurons	O
limited	O
to	O
the	O
injection	O
site	O
.	O

This	O
is	O
the	O
most	O
northern	O
and	O
,	O
at	O
the	O
same	O
time	O
largest	O
,	O
Q	O
fever	O
epidemic	O
recorded	O
in	O
Germany	O
over	O
the	O
last	O
28	O
years	O
.	O

Symptoms	O
,	O
skin	O
-	O
prick	O
tests	O
(	O
SPT	O
)	O
with	O
environmental	O
allergens	O
and	O
Pt	O
salt	O
,	O
total	O
serum	B-GENE
IgE	I-GENE
,	O
lung	O
function	O
,	O
and	O
bronchial	O
hyperresponsiveness	O
were	O
assessed	O
by	O
standard	O
procedures	O
.	O

Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O

Complementary	O
DNA	O
libraries	O
from	O
liver	O
and	O
ovary	O
of	O
an	O
immature	O
female	O
channel	O
catfish	O
were	O
screened	O
with	O
a	O
homologous	B-GENE
ERalpha	I-GENE
cDNA	I-GENE
probe	O
.	O

The	O
binding	O
of	O
PTB	B-GENE
was	O
antagonistic	O
to	O
the	O
binding	O
of	O
U2AF	B-GENE
to	O
the	O
enhancer	O
-	O
located	O
pyrimidine	O
tract	O
.	O

VLA	B-GENE
-	I-GENE
4	I-GENE
integrin	I-GENE
cross	O
-	O
linking	O
on	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
induces	O
tissue	O
factor	O
expression	O
by	O
a	O
mechanism	O
involving	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
.	O

However	O
,	O
studies	O
using	O
the	O
A20	B-GENE
promoter	I-GENE
demonstrated	O
that	O
LMP1	B-GENE
transcriptionally	O
activates	O
the	O
A20	B-GENE
gene	I-GENE
through	O
cis	O
-	O
acting	O
kappa	B-GENE
B	I-GENE
sites	I-GENE
.	O

Southern	O
blot	O
analysis	O
revealed	O
that	O
CCaMK	B-GENE
is	O
encoded	O
by	O
a	O
single	O
gene	O
.	O

Surgical	O
methods	O
in	O
the	O
treatment	O
of	O
rhinophyma	O
.	O

Phenazopyridine	O
-	O
induced	O
hemolytic	O
anemia	O
in	O
a	O
patient	O
with	O
G6PD	B-GENE
deficiency	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
although	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
c	B-GENE
-	I-GENE
myb	I-GENE
is	O
required	O
for	O
both	O
the	O
differentiation	O
block	O
and	O
the	O
shift	O
in	O
cell	O
cycle	O
after	O
PMA	O
treatment	O
,	O
phosphorylation	O
by	O
casein	B-GENE
kinase	I-GENE
II	I-GENE
and	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
at	O
positions	O
11	O
and	O
12	O
or	O
532	O
of	O
c	B-GENE
-	I-GENE
myb	I-GENE
,	O
respectively	O
,	O
are	O
not	O
.	O

The	O
activation	O
of	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	O
dependent	O
reporter	O
gene	O
transcription	O
by	O
E1A	B-GENE
was	O
potently	O
suppressed	O
upon	O
coexpression	O
of	O
the	O
E1B	B-GENE
19	I-GENE
-	I-GENE
kDa	I-GENE
protein	I-GENE
(	I-GENE
19K	I-GENE
)	I-GENE
.	O

Our	O
results	O
showed	O
that	O
direct	O
enantiomeric	O
separation	O
of	O
mephenytoin	O
was	O
obtained	O
by	O
using	O
a	O
chiral	O
capillary	O
column	O
,	O
the	O
retention	O
times	O
for	O
S	O
-	O
and	O
R	O
-	O
mephenytoin	O
were	O
25	O
.	O
5	O
and	O
26	O
.	O
2	O
min	O
respectively	O
,	O
with	O
a	O
detection	O
limit	O
less	O
than	O
50	O
ng	O
/	O
ml	O
of	O
mephenytoin	O
.	O

The	O
myeloid	B-GENE
zinc	I-GENE
finger	I-GENE
gene	I-GENE
1	I-GENE
(	O
MZF1	B-GENE
)	O
encodes	O
a	O
C	B-GENE
(	I-GENE
2	I-GENE
)	I-GENE
H	I-GENE
(	I-GENE
2	I-GENE
)	I-GENE
zinc	I-GENE
finger	I-GENE
transcription	I-GENE
factor	I-GENE
that	O
regulates	O
granulopoiesis	O
and	O
may	O
have	O
a	O
regulatory	O
role	O
in	O
cellular	O
proliferation	O
and	O
oncogenesis	O
.	O

Snails	O
infected	O
with	O
three	O
or	O
five	O
miracidia	O
produced	O
more	O
metacercariae	O
than	O
those	O
infected	O
with	O
a	O
single	O
miracidium	O
.	O

We	O
conclude	O
that	O
GRF1	B-GENE
and	O
GRF2	B-GENE
can	O
form	O
homo	O
-	O
and	O
hetero	O
-	O
oligomers	O
via	O
their	O
DH	B-GENE
domains	I-GENE
,	O
that	O
mutational	O
inactivation	O
of	O
oligomer	O
formation	O
by	O
GRF1	B-GENE
is	O
associated	O
with	O
impaired	O
biological	O
and	O
signaling	O
activities	O
,	O
and	O
that	O
in	O
293T	O
cells	O
GRF1	B-GENE
mediates	O
at	O
least	O
two	O
pathways	O
for	O
Raf	B-GENE
activation	O
:	O
one	O
a	O
constitutive	O
signal	O
that	O
is	O
mainly	O
Ras	B-GENE
-	O
dependent	O
,	O
and	O
one	O
an	O
ionomycin	O
-	O
induced	O
signal	O
that	O
cooperates	O
with	O
the	O
constitutive	O
signal	O
without	O
further	O
augmenting	O
the	O
level	O
of	O
GTP	B-GENE
-	I-GENE
Ras	I-GENE
.	O

For	O
the	O
target	O
stimuli	O
,	O
P3	O
amplitude	O
and	O
latency	O
were	O
negatively	O
correlated	O
and	O
most	O
tightly	O
coupled	O
over	O
the	O
frontal	O
-	O
central	O
and	O
right	O
medial	O
/	O
lateral	O
recording	O
sites	O
.	O

Mitoxantrone	O
plus	O
ara	O
-	O
C	O
is	O
an	O
active	O
combination	O
with	O
great	O
promise	O
for	O
the	O
therapy	O
of	O
previously	O
untreated	O
patients	O
with	O
AML	O
.	O

In	O
the	O
renal	O
cortex	O
,	O
spleen	O
,	O
distal	O
colon	O
,	O
ileum	O
,	O
gallbladder	O
,	O
and	O
stomach	O
body	O
,	O
regional	O
O2	O
delivery	O
was	O
significantly	O
decreased	O
with	O
hemodilution	O
to	O
20	O
%	O
in	O
both	O
groups	O
.	O

(	O
A	O
short	O
account	O
of	O
Karl	O
Touton	O
'	O
s	O
life	O
is	O
also	O
included	O
.	O
)	O
After	O
reviewing	O
the	O
historical	O
development	O
of	O
the	O
concept	O
of	O
giant	O
cells	O
and	O
current	O
interpretations	O
of	O
their	O
nature	O
,	O
the	O
unitarian	O
view	O
of	O
polykaryons	O
now	O
favored	O
by	O
workers	O
in	O
the	O
field	O
is	O
extended	O
to	O
include	O
also	O
the	O
"	O
xanthelasmatic	O
giant	O
cell	O
"	O
of	O
Touton	O
,	O
whose	O
characteristic	O
appearance	O
is	O
determined	O
merely	O
by	O
the	O
presence	O
of	O
demonstrable	O
lipid	O
in	O
the	O
cytoplasm	O
.	O

Chronic	O
active	O
hepatitis	O
and	O
pregnancy	O
.	O

Influenza	O
virus	O
-	O
induced	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	I-GENE
dependent	I-GENE
gene	I-GENE
expression	O
is	O
mediated	O
by	O
overexpression	O
of	O
viral	O
proteins	O
and	O
involves	O
oxidative	O
radicals	O
and	O
activation	O
of	O
IkappaB	B-GENE
kinase	I-GENE
.	O

These	O
observed	O
changes	O
were	O
not	O
found	O
when	O
assessing	O
NPY	B-GENE
level	O
in	O
plasma	O
fluid	O
.	O

Reversible	O
topology	O
of	O
a	O
bifunctional	O
transmembrane	O
protein	O
depends	O
upon	O
the	O
charge	O
balance	O
around	O
its	O
transmembrane	O
domain	O
.	O

Protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
activation	O
after	O
treatment	O
of	O
human	O
neuroblastoma	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
C	O
cells	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
was	O
found	O
to	O
enhance	O
transcription	O
of	O
the	O
human	O
dopamine	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
(	O
DBH	B-GENE
)	O
in	O
those	O
cells	O
.	O

The	O
second	O
(	O
control	O
)	O
group	O
was	O
represented	O
by	O
cases	O
diagnosed	O
as	O
HSIL	O
by	O
cytology	O
.	O

The	O
illuminator	O
uses	O
a	O
grain	O
-	O
of	O
-	O
wheat	O
light	O
bulb	O
and	O
an	O
adjustable	O
bulb	O
holder	O
fashioned	O
from	O
bent	O
paper	O
clips	O
.	O

Bedbug	O
(	O
Cimex	O
lectularius	O
)	O
samples	O
adult	O
and	O
nymphs	O
either	O
engorged	O
or	O
starved	O
from	O
Central	O
Security	O
Forces	O
sleeping	O
wards	O
,	O
laboratory	O
animal	O
house	O
and	O
control	O
samples	O
from	O
laboratory	O
reared	O
colonies	O
were	O
ground	O
and	O
subjected	O
to	O
ELISA	O
test	O
of	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
together	O
with	O
276	O
serum	O
samples	O
from	O
the	O
recruits	O
slept	O
in	O
those	O
wards	O
.	O

The	O
genomic	O
organization	O
in	O
this	O
region	O
is	O
similar	O
to	O
the	O
neural	O
-	O
restricted	O
family	O
members	O
,	O
Hel	B-GENE
-	I-GENE
N1	I-GENE
(	O
ELAVL2	B-GENE
)	O
and	O
mHuD	B-GENE
(	O
Elavl4	B-GENE
)	O
.	O

Synergistic	O
induction	O
of	O
apoptosis	O
in	O
human	O
leukemia	O
cells	O
(	O
U937	O
)	O
exposed	O
to	O
bryostatin	O
1	O
and	O
the	O
proteasome	O
inhibitor	O
lactacystin	O
involves	O
dysregulation	O
of	O
the	O
PKC	B-GENE
/	O
MAPK	B-GENE
cascade	O
.	O

With	O
the	O
help	O
of	O
partially	O
overlapping	O
parenchymatous	O
sutures	O
,	O
different	O
renal	O
segments	O
were	O
devitalized	O
.	O

Promoter	O
elements	O
and	O
transcriptional	O
control	O
of	O
the	O
mouse	B-GENE
acetylcholinesterase	I-GENE
gene	I-GENE
.	O

The	O
average	O
cumulative	O
UVA	O
dose	O
was	O
65	O
J	O
/	O
cm2	O
;	O
40	O
patients	O
had	O
received	O
more	O
than	O
200	O
J	O
/	O
cm2	O
.	O

Malformations	O
of	O
the	O
regenerating	O
optic	O
tectum	O
of	O
larvae	O
of	O
the	O
Egyptian	O
toad	O
,	O
Bufo	O
regularis	O
Reuss	O
.	O

These	O
morphological	O
changes	O
are	O
associated	O
with	O
a	O
marked	O
induction	O
of	O
P450arom	B-GENE
gene	I-GENE
expression	O
.	O

The	O
immunoprofile	O
of	O
60	O
adult	O
patients	O
of	O
pulmonary	O
tuberculosis	O
was	O
studied	O
and	O
compared	O
with	O
22	O
normal	O
controls	O
.	O

Central	O
-	O
venous	O
-	O
catheter	O
-	O
related	O
infection	O
is	O
readily	O
diagnosed	O
by	O
comparing	O
simultaneous	O
quantitative	O
cultures	O
of	O
blood	O
samples	O
obtained	O
via	O
the	O
catheter	O
and	O
a	O
peripheral	O
vein	O
.	O

The	O
role	O
of	O
haptoglobin	B-GENE
in	O
asphyxia	O
mechanism	O
(	O
II	O
)	O
-	O
-	O
Acute	O
drowning	O
and	O
hanging	O

Processing	O
MES	O
data	O
requires	O
large	O
bit	O
manipulations	O
and	O
heavy	O
memory	O
storage	O
requirements	O
.	O

Thus	O
,	O
BCR	B-GENE
ligation	O
initiates	O
a	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
/	O
Akt	B-GENE
/	O
GSK	B-GENE
-	I-GENE
3	I-GENE
signaling	O
pathway	O
.	O

cDNA	O
cloning	O
and	O
transcriptional	O
properties	O
of	O
a	O
novel	O
GC	B-GENE
box	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
BTEB2	B-GENE
.	O

This	O
activity	O
creates	O
a	O
4	O
-	O
bp	O
staggered	O
cut	O
with	O
3	O
'	O
OH	O
overhangs	O
within	O
a	O
specific	O
sequence	O
of	O
the	O
21S	B-GENE
rRNA	I-GENE
gene	I-GENE
of	O
omega	O
-	O
strains	O
.	O

The	O
two	O
ORFs	O
had	O
significant	O
similarity	O
with	O
the	O
putative	O
replication	O
protein	O
from	O
plasmid	O
pTiK12	O
of	O
Thiobacillus	O
intermedius	O
and	O
other	O
CoIE2	O
-	O
related	O
plasmids	O
.	O

In	O
contrast	O
SF	B-GENE
,	O
but	O
not	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
or	O
IL	B-GENE
-	I-GENE
3	I-GENE
,	O
induced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	B-GENE
C	I-GENE
-	I-GENE
gamma	I-GENE
(	O
PLC	B-GENE
-	I-GENE
gamma	I-GENE
)	O
.	O

Phase	O
I	O
clinical	O
trial	O
with	O
a	O
combination	O
of	O
methotrexate	O
and	O
mitomycin	O
C	O
.	O

Replacement	O
of	O
Val20	O
-	O
Leu21	O
with	O
Ala	O
-	O
Ala	O
produced	O
a	O
dimeric	B-GENE
RII	I-GENE
beta	I-GENE
protein	I-GENE
that	O
binds	O
AKAP75	B-GENE
approximately	O
4	O
%	O
as	O
avidly	O
as	O
wild	B-GENE
-	I-GENE
type	I-GENE
RII	I-GENE
beta	I-GENE
.	O

The	O
temporal	O
expression	O
of	O
CRAlBP	B-GENE
is	O
similar	O
to	O
IRBP	B-GENE
while	O
bFGF	B-GENE
is	O
not	O
expressed	O
until	O
after	O
photoreceptor	O
differentiation	O
is	O
complete	O
.	O

I	O
.	O

In	O
T	O
cells	O
these	O
two	O
signal	O
pathways	O
are	O
critical	O
for	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
production	O
.	O

Replacement	O
of	O
a	O
valine	O
(	O
V68	O
)	O
in	O
the	O
ETS	B-GENE
domain	O
of	O
SAP1a	B-GENE
by	O
aspartic	O
acid	O
(	O
as	O
found	O
in	O
c	B-GENE
-	I-GENE
Ets	I-GENE
-	I-GENE
1	I-GENE
,	O
Elk	B-GENE
-	I-GENE
1	I-GENE
,	O
and	O
Net	B-GENE
)	O
enhanced	O
ternary	O
complex	O
formation	O
by	O
more	O
than	O
60	O
-	O
fold	O
.	O

In	O
order	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
local	O
direct	O
action	O
of	O
danazol	O
upon	O
endometriosis	O
,	O
intravaginal	O
and	O
intrauterine	O
application	O
were	O
tried	O
.	O

The	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
/	O
Rel	B-GENE
transcription	O
factors	O
participate	O
in	O
the	O
activation	O
of	O
immune	O
system	O
regulatory	O
genes	O
and	O
viral	B-GENE
early	I-GENE
genes	I-GENE
including	O
the	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
long	I-GENE
terminal	I-GENE
repeat	I-GENE
.	O

A	O
total	O
of	O
4	O
,	O
916	O
children	O
were	O
examined	O
and	O
the	O
questionnaire	O
satisfactorily	O
completed	O
by	O
a	O
relative	O
or	O
guardian	O
(	O
usually	O
the	O
mother	O
)	O
of	O
4	O
,	O
651	O
.	O

cDNA	O
cloning	O
reveals	O
two	O
mouse	B-GENE
beta5	I-GENE
integrin	I-GENE
transcripts	I-GENE
distinct	O
in	O
cytoplasmic	O
domains	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
.	O

Earlier	O
nonoptical	O
methods	O
probably	O
did	O
not	O
include	O
the	O
portion	O
of	O
the	O
film	O
that	O
contained	O
mucus	O
.	O

OBJECTIVE	O
:	O
To	O
summarise	O
quantitatively	O
the	O
association	O
between	O
moderate	O
alcohol	O
intake	O
and	O
biological	O
markers	O
of	O
risk	O
of	O
coronary	O
heart	O
disease	O
and	O
to	O
predict	O
how	O
these	O
changes	O
would	O
lower	O
the	O
risk	O
.	O

Like	O
other	O
known	O
GCD	B-GENE
genes	I-GENE
,	O
GCD14	B-GENE
and	O
GCD15	B-GENE
are	O
therefore	O
probably	O
required	O
for	O
general	O
translation	O
initiation	O
in	O
addition	O
to	O
their	O
roles	O
in	O
GCN4	B-GENE
-	O
specific	O
translational	O
control	O
.	O

The	O
presence	O
of	O
highly	O
correlated	O
frequencies	O
provided	O
strong	O
evidence	O
of	O
a	O
medium	O
-	O
frequency	O
pattern	O
generator	O
which	O
may	O
remain	O
operative	O
beyond	O
the	O
neonatal	O
period	O
.	O

This	O
gene	O
is	O
named	O
PKNOX1	B-GENE
by	O
the	O
Human	O
Nomenclature	O
Committee	O
.	O

Differentiation	O
of	O
porcine	O
mycoplasma	O
strains	O
by	O
means	O
of	O
a	O
simple	O
paper	O
chromatography	O
test	O
.	O

HIV	O
-	O
2	O
in	O
Spain	O
.	O

No	O
effect	O
of	O
4	O
beta	O
-	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
was	O
observed	O
on	O
the	O
expression	O
of	O
hnRNP	B-GENE
H	I-GENE
.	O

Patients	O
commonly	O
considered	O
the	O
external	O
frame	O
cumbersome	O
.	O

D	O
.	O

The	O
atf1	B-GENE
+	I-GENE
gene	I-GENE
of	I-GENE
Schizosaccharomyces	I-GENE
pombe	I-GENE
encodes	O
a	O
bZIP	B-GENE
transcription	I-GENE
factor	I-GENE
with	O
strong	O
homology	O
to	O
the	O
mammalian	B-GENE
factor	I-GENE
ATF	I-GENE
-	I-GENE
2	I-GENE
.	O

The	O
effects	O
of	O
different	O
sources	O
of	O
commercial	O
rations	O
on	O
the	O
humoral	O
immune	O
response	O
of	O
broilers	O
to	O
Newcastle	O
disease	O
vaccination	O
.	O

Multiple	O
attempts	O
aimed	O
at	O
disruption	O
of	O
the	O
chromosomal	B-GENE
fabG	I-GENE
gene	I-GENE
were	O
unsuccessful	O
.	O

Primary	O
TJRs	O
were	O
clinically	O
evaluated	O
for	O
degree	O
of	O
osteoarthrosis	O
.	O

Radiation	O
sensitivity	O
of	O
rats	O
irradiated	O
in	O
a	O
condition	O
of	O
hypoxia	O

The	O
activity	O
of	O
plasminogen	B-GENE
activator	I-GENE
has	O
been	O
measured	O
in	O
tissue	O
sections	O
with	O
the	O
aid	O
of	O
a	O
modified	O
Todd	O
technique	O
.	O

The	O
complexity	O
of	O
some	O
of	O
the	O
reports	O
of	O
VACURG	O
studies	O
has	O
led	O
some	O
to	O
believe	O
that	O
this	O
group	O
was	O
opposed	O
to	O
estrogens	O
,	O
but	O
that	O
is	O
not	O
true	O
.	O

Thus	O
,	O
the	O
mutants	O
are	O
deficient	O
in	O
production	O
of	O
the	O
O	B-GENE
-	I-GENE
antigen	I-GENE
polymerase	I-GENE
and	O
were	O
termed	O
rfc	B-GENE
mutants	I-GENE
.	O

Up	O
to	O
1988	O
,	O
145	O
cases	O
had	O
been	O
reported	O
in	O
literature	O
and	O
32	O
cases	O
in	O
our	O
country	O
.	O

Focal	O
glomerulosclerosis	O
-	O
like	O
disease	O
with	O
nephrotic	O
syndrome	O
in	O
a	O
horse	O
.	O

The	O
antihypertensive	O
action	O
corresponds	O
to	O
those	O
of	O
established	O
diuretics	O
.	O

Interconversions	O
between	O
haloperidol	O
and	O
reduced	O
haloperidol	O
in	O
schizophrenic	O
patients	O
and	O
guinea	O
pigs	O
:	O
a	O
steady	O
-	O
state	O
study	O
.	O

The	O
frequency	O
of	O
eating	O
dark	O
-	O
meat	O
fish	O
was	O
positively	O
associated	O
with	O
serum	O
eicosapentaenoic	O
acid	O
and	O
docosahexaenoic	O
acid	O
,	O
omega3	O
fatty	O
acids	O
,	O
and	O
inversely	O
associated	O
with	O
serum	O
stearic	O
acid	O
and	O
linoleic	O
acid	O
.	O

Effect	O
of	O
food	O
on	O
hemodynamics	O
.	O

The	O
D443N	B-GENE
substitution	I-GENE
is	O
an	O
activating	O
mutation	O
that	O
increases	O
the	O
activity	O
of	O
SCAP	B-GENE
and	O
renders	O
it	O
resistant	O
to	O
inhibition	O
by	O
25	O
-	O
hydroxycholesterol	O
.	O

Central	O
(	O
heart	O
rate	O
,	O
VE	O
,	O
VO2	O
)	O
or	O
local	O
(	O
muscle	O
and	O
blood	O
lactate	O
,	O
adenosine	O
triphosphate	O
,	O
creatine	B-GENE
phosphokinase	I-GENE
,	O
glycogen	O
)	O
cues	O
highlighted	O
in	O
these	O
studies	O
demonstrate	O
both	O
the	O
complexity	O
of	O
effort	O
perception	O
,	O
and	O
the	O
need	O
for	O
better	O
understanding	O
of	O
the	O
physiological	O
components	O
upon	O
which	O
it	O
is	O
based	O
.	O

The	O
gene	O
is	O
predicted	O
to	O
encode	O
an	O
880	O
-	O
amino	O
-	O
acid	O
protein	O
which	O
contains	O
two	O
C2H2	O
zinc	O
fingers	O
,	O
a	O
nuclear	O
localization	O
sequence	O
and	O
two	O
transcriptional	O
activation	O
domains	O
.	O

This	O
approach	O
allowed	O
examination	O
of	O
baseline	O
factors	O
as	O
well	O
as	O
the	O
effect	O
of	O
change	O
in	O
mileage	O
,	O
the	O
occurrence	O
of	O
a	O
musculoskeletal	O
problem	O
,	O
or	O
the	O
occurrence	O
of	O
another	O
health	O
problem	O
on	O
the	O
rate	O
of	O
dropout	O
.	O

Microalbuminuria	O
:	O
a	O
marker	O
of	O
systemic	O
disease	O
.	O

Regulation	O
of	O
activating	B-GENE
transcription	I-GENE
factor	I-GENE
-	I-GENE
1	I-GENE
and	O
the	O
cAMP	B-GENE
response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
by	O
Ca2	B-GENE
+	I-GENE
/	I-GENE
calmodulin	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinases	I-GENE
type	I-GENE
I	I-GENE
,	I-GENE
II	I-GENE
,	I-GENE
and	I-GENE
IV	I-GENE
.	O

Coronary	O
arteries	O
were	O
found	O
in	O
the	O
biopsy	O
tissue	O
of	O
30	O
(	O
76	O
%	O
)	O
of	O
the	O
39	O
patients	O
who	O
formed	O
the	O
study	O
group	O
.	O

Serum	B-GENE
amyloid	I-GENE
A	I-GENE
(	O
SAA	B-GENE
)	O
is	O
a	O
plasma	O
protein	O
which	O
has	O
been	O
associated	O
with	O
several	O
diseases	O
,	O
including	O
amyloidosis	O
,	O
arthritis	O
,	O
and	O
atherosclerosis	O
,	O
and	O
its	O
abnormal	O
expression	O
,	O
particularly	O
in	O
nonhepatic	O
cells	O
,	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O

Phenacetin	O
nephritis	O

We	O
have	O
been	O
developing	O
a	O
digital	O
fluoroscopic	O
imaging	O
system	O
to	O
replace	O
the	O
portal	O
films	O
that	O
are	O
currently	O
used	O
to	O
verify	O
patient	O
positioning	O
during	O
radiotherapy	O
treatments	O
.	O

The	O
human	B-GENE
p18	I-GENE
gene	I-GENE
spans	O
at	O
least	O
7	O
.	O
5	O
kb	O
and	O
is	O
composed	O
of	O
three	O
exons	O
,	O
two	O
of	O
which	O
encode	O
the	O
p18	B-GENE
protein	I-GENE
.	O

Serum	O
creatinine	B-GENE
kinase	I-GENE
activity	O
was	O
7	O
,	O
800	O
-	O
17	O
,	O
500	O
U	O
/	O
l	O
,	O
making	O
acute	O
muscle	O
damage	O
likely	O
,	O
probably	O
rhabdomyolysis	O
.	O

These	O
results	O
suggest	O
that	O
termination	O
is	O
a	O
highly	O
specific	O
event	O
,	O
and	O
not	O
merely	O
a	O
consequence	O
of	O
decreased	O
stability	O
of	O
the	O
EC	O
.	O

Like	O
Mdm2	B-GENE
,	O
MdmX	B-GENE
is	O
able	O
to	O
bind	O
p53	B-GENE
and	O
inhibit	O
p53	B-GENE
transactivation	O
;	O
however	O
,	O
the	O
ability	O
of	O
MdmX	B-GENE
to	O
degrade	O
p53	B-GENE
has	O
yet	O
to	O
be	O
examined	O
.	O

PURPOSE	O
:	O
Second	O
malignant	O
neoplasms	O
(	O
SMNs	O
)	O
are	O
a	O
rare	O
occurrence	O
after	O
the	O
successful	O
treatment	O
of	O
childhood	O
cancer	O
.	O

Recent	O
geological	O
studies	O
focusing	O
on	O
the	O
Davie	O
Fracture	O
Zone	O
of	O
the	O
Mozambique	O
Channel	O
offer	O
a	O
resolution	O
to	O
this	O
situation	O
,	O
by	O
suggesting	O
the	O
presence	O
of	O
a	O
land	O
-	O
bridge	O
from	O
the	O
mid	O
-	O
Eocene	O
to	O
the	O
early	O
Miocene	O
,	O
an	O
interval	O
that	O
matches	O
the	O
ages	O
of	O
Madagascar	O
'	O
s	O
mammalian	O
groups	O
.	O

The	O
nucleotide	O
sequence	O
of	O
a	O
PCR	O
-	O
amplified	O
SMT3A	B-GENE
genomic	O
DNA	O
fragment	O
was	O
found	O
to	O
be	O
identical	O
to	O
that	O
of	O
SMT3A	B-GENE
cDNA	I-GENE
,	O
indicating	O
the	O
absence	O
of	O
intron	O
(	O
s	O
)	O
in	O
its	O
protein	O
coding	O
region	O
.	O

Mutant	O
p53	B-GENE
DNA	I-GENE
clones	O
from	O
human	O
colon	O
carcinomas	O
cooperate	O
with	O
ras	B-GENE
in	O
transforming	O
primary	O
rat	O
cells	O
:	O
a	O
comparison	O
of	O
the	O
"	O
hot	O
spot	O
"	O
mutant	O
phenotypes	O
.	O

Gas	O
chromatographic	O
analysis	O
of	O
headspace	O
samples	O
of	O
alkalinized	O
vaginal	O
discharges	O
indicated	O
the	O
presence	O
of	O
trimethylamine	O
in	O
all	O
11	O
samples	O
with	O
the	O
fishy	O
odor	O
but	O
not	O
in	O
the	O
other	O
samples	O
.	O

Standing	O
values	O
:	O
placebo	O
114	O
/	O
79	O
;	O
BHT	O
-	O
933	O
92	O
/	O
67	O
.	O

The	O
Ixodes	O
fauna	O
in	O
the	O
Michourin	O
region	O
,	O
where	O
the	O
pastures	O
in	O
1971	O
were	O
grazed	O
only	O
by	O
sheep	O
,	O
shows	O
the	O
following	O
trends	O
:	O
H	O
.	O
punctata	O
and	O
R	O
.	O
turanicus	O
ticks	O
,	O
which	O
are	O
preferably	O
parasitising	O
in	O
sheep	O
,	O
increase	O
their	O
relative	O
share	O
.	O

The	O
SEC27	B-GENE
gene	I-GENE
was	O
cloned	O
,	O
and	O
the	O
sequence	O
predicts	O
a	O
99	O
.	O
4	O
-	O
kDa	O
protein	O
with	O
45	O
%	O
sequence	O
identity	O
to	O
mammalian	O
beta	B-GENE
'	I-GENE
-	I-GENE
COP	I-GENE
.	O

Studies	O
of	O
fetal	O
maturity	O

Fetal	O
arterial	O
and	O
sagittal	O
sinus	O
pH	O
,	O
base	O
excess	O
,	O
po2	O
,	O
and	O
oxygen	O
saturation	O
decreased	O
,	O
and	O
hydrogen	O
ion	O
concentrations	O
and	O
pco2	O
increased	O
during	O
asphyxia	O
alone	O
and	O
asphyxia	O
plus	O
isoflurane	O
-	O
oxygen	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
GCN2	B-GENE
protein	I-GENE
kinase	I-GENE
function	O
is	O
stimulated	O
posttranslationally	O
in	O
amino	O
acid	O
-	O
starved	O
cells	O
.	O

Although	O
paclitaxel	O
alone	O
failed	O
to	O
induce	O
p38	B-GENE
MAPK	O
activation	O
,	O
subsequent	O
(	O
but	O
not	O
prior	O
)	O
exposure	O
to	O
PD98059	O
induced	O
a	O
dramatic	O
increase	O
in	O
p38	B-GENE
MAPK	O
phosphorylation	O
.	O

In	O
3	O
of	O
the	O
5	O
patients	O
with	O
AVNRT	O
and	O
AJR	O
,	O
junctional	O
beats	O
served	O
as	O
a	O
trigger	O
for	O
reentry	O
.	O

The	O
three	O
respective	O
time	O
control	O
groups	O
(	O
C5	O
,	O
C10	O
,	O
and	O
C15	O
)	O
were	O
injected	O
with	O
saline	O
solution	O
.	O

Sequence	O
analysis	O
of	O
cDNA	O
clones	O
encoding	O
human	O
gamma	O
revealed	O
an	O
open	O
reading	O
frame	O
predicting	O
a	O
protein	O
of	O
299	O
amino	O
acids	O
(	O
approximately	O
32	O
kDa	O
)	O
,	O
half	O
the	O
size	O
of	O
the	O
bovine	O
gamma	O
subunit	O
.	O

A	O
positive	O
FTA	B-GENE
-	I-GENE
ABS	I-GENE
-	I-GENE
19S	I-GENE
-	I-GENE
IgM	I-GENE
test	O
indicates	O
the	O
necessity	O
of	O
treatment	O
.	O

Our	O
data	O
suggest	O
that	O
some	O
defects	O
observed	O
in	O
BS	O
,	O
WS	O
or	O
RTS	O
are	O
the	O
consequence	O
of	O
unrestrained	O
recombination	O
.	O

The	O
promoter	O
for	O
HMG	B-GENE
-	I-GENE
CoA	I-GENE
synthase	I-GENE
contains	O
two	O
binding	O
sites	O
for	O
the	O
sterol	B-GENE
regulatory	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
(	O
SREBPs	B-GENE
)	O
.	O

These	O
data	O
indicate	O
that	O
chromatic	O
processing	O
in	O
areas	O
V1	O
and	O
V2	O
is	O
normal	O
after	O
V4	O
lesions	O
and	O
,	O
together	O
with	O
the	O
behavioural	O
evidence	O
,	O
that	O
these	O
areas	O
are	O
sufficient	O
for	O
some	O
basic	O
aspects	O
of	O
colour	O
perception	O
.	O

The	O
curse	O
of	O
the	O
Pharaohs	O
.	O

Covariates	O
were	O
lower	O
extremity	O
range	O
of	O
motion	O
and	O
sensory	O
status	O
.	O

Characterization	O
and	O
targeted	O
disruption	O
of	O
murine	B-GENE
Nup50	I-GENE
,	O
a	O
p27	B-GENE
(	O
Kip1	B-GENE
)	O
-	O
interacting	O
component	O
of	O
the	O
nuclear	O
pore	O
complex	O
.	O

p27	B-GENE
(	O
Kip1	B-GENE
)	O
is	O
a	O
member	O
of	O
the	O
Cip	B-GENE
-	O
Kip	B-GENE
family	O
of	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
(	O
Cdk	B-GENE
)	O
inhibitors	O
that	O
binds	O
to	O
cyclin	B-GENE
-	O
Cdk	B-GENE
complexes	O
and	O
inhibits	O
their	O
catalytic	O
activity	O
in	O
response	O
to	O
antiproliferative	O
stimuli	O
.	O

p27	B-GENE
(	O
Kip1	B-GENE
)	O
is	O
regulated	O
by	O
several	O
posttranscriptional	O
mechanisms	O
,	O
including	O
subcellular	O
localization	O
.	O

Therefore	O
,	O
the	O
Ogg1	B-GENE
protein	I-GENE
is	O
a	O
eukaryotic	O
DNA	B-GENE
glycosylase	I-GENE
/	O
AP	B-GENE
lyase	I-GENE
.	O

One	O
patient	O
had	O
chronic	O
dysphoria	O
and	O
one	O
encephalopatia	O
toxica	O
.	O

Alveoli	O
-	O
capillary	O
diffusion	O
.	O

Mutations	O
of	O
SIN4	B-GENE
,	O
ROX3	B-GENE
,	O
SRB8	B-GENE
,	O
SRB9	B-GENE
,	O
SRB10	B-GENE
,	O
SRB11	B-GENE
,	O
and	O
two	O
novel	O
genes	O
,	O
NUT1	B-GENE
and	O
NUT2	B-GENE
,	O
relieve	O
the	O
requirement	O
of	O
Swi4p	B-GENE
for	O
expression	O
of	O
this	O
reporter	O
.	O

The	O
software	O
is	O
in	O
BASIC	O
adapted	O
for	O
the	O
Hewlett	O
-	O
Packard	O
calculators	O
HP	O
-	O
9845B	O
and	O
HP	O
-	O
85A	O
.	O

For	O
Thermus	O
strain	O
ZO5	B-GENE
dihydroorotase	I-GENE
(	O
DHOase	B-GENE
;	O
encoded	O
by	O
pyrC	B-GENE
)	O
,	O
the	O
highest	O
similarity	O
scores	O
(	O
about	O
40	O
%	O
identity	O
)	O
were	O
obtained	O
with	O
DHOases	B-GENE
from	O
B	O
.	O
caldolyticus	O
and	O
Bacillus	O
subtilis	O
.	O

Precision	O
of	O
data	O
from	O
models	O
of	O
sodium	O
kinetics	O
in	O
hemodialysis	O

These	O
data	O
suggest	O
that	O
the	O
fibrinogen	B-GENE
gamma	I-GENE
chain	I-GENE
region	I-GENE
Gly190	I-GENE
-	I-GENE
Val202	I-GENE
functions	O
as	O
a	O
minimal	O
recognition	O
sequence	O
for	O
the	O
leukocyte	O
integrin	O
CD11b	B-GENE
/	O
CD18	B-GENE
.	O

Attenuated	O
serum	O
cortisol	O
responses	O
were	O
found	O
in	O
six	O
of	O
the	O
patients	O
despite	O
a	O
normal	O
ACTH	B-GENE
test	O
.	O

We	O
recently	O
described	O
the	O
isolation	O
and	O
characterization	O
of	O
nontoxic	O
PAP	B-GENE
mutants	I-GENE
,	O
NT123	O
-	O
2	O
,	O
which	O
has	O
a	O
point	O
mutation	O
(	O
E176V	O
)	O
in	O
the	O
active	O
site	O
that	O
abolishes	O
enzymatic	O
activity	O
,	O
and	O
NT124	O
-	O
3	O
,	O
which	O
has	O
a	O
nonsense	O
mutation	O
that	O
results	O
in	O
deletion	O
of	O
the	O
C	O
-	O
terminal	O
25	O
aa	O
(	O
W237Stop	O
)	O
.	O

Toxicity	O
of	O
benzoyl	O
chloride	O
(	O
2	O
,	O
4	O
,	O
6	O
-	O
trichlorophenyl	O
)	O
hydrazone	O
(	O
Banamite	O
)	O
and	O
potential	O
metabolites	O
to	O
twospotted	O
spider	O
mites	O
and	O
potency	O
as	O
inhibitors	O
of	O
rat	B-GENE
liver	I-GENE
monoamine	I-GENE
oxidase	I-GENE
.	O

The	O
screen	O
identifies	O
mutants	O
whose	O
growth	O
depends	O
on	O
high	O
levels	O
of	O
expression	O
of	O
that	O
gene	O
.	O

The	O
genes	O
expressed	O
during	O
the	O
embryonic	O
(	O
zeta	B-GENE
)	O
or	O
fetal	O
and	O
adult	O
stage	O
(	O
alpha	B-GENE
2	I-GENE
and	O
alpha	B-GENE
1	I-GENE
)	O
can	O
be	O
modified	O
by	O
point	O
mutations	O
which	O
affect	O
either	O
the	O
processing	O
-	O
translation	O
of	O
mRNA	O
or	O
make	O
the	O
polypeptide	O
chains	O
extremely	O
unstable	O
.	O

In	O
a	O
study	O
in	O
Singapore	O
,	O
Chinese	O
,	O
Malay	O
and	O
Indian	O
patients	O
with	O
pulmonary	O
tuberculosis	O
received	O
2	O
months	O
of	O
daily	O
treatment	O
with	O
streptomycin	O
,	O
isoniazid	O
,	O
rifampicin	O
,	O
and	O
pyrazinamide	O
followed	O
by	O
daily	O
isoniazid	O
,	O
and	O
rifampicin	O
either	O
with	O
pyrazinamide	O
(	O
SHRZ	O
/	O
HRZ	O
)	O
or	O
without	O
it	O
(	O
SHRZ	O
/	O
HR	O
)	O
,	O
allocated	O
at	O
random	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
/	O
human	O
herpesvirus	O
-	O
8	O
ORF50	B-GENE
gene	O
product	O
contains	O
a	O
potent	O
C	O
-	O
terminal	O
activation	O
domain	O
which	O
activates	O
gene	O
expression	O
via	O
a	O
specific	O
target	O
sequence	O
.	O

NSAIDS	O
and	O
the	O
microcirculation	O
of	O
the	O
stomach	O
.	O

The	O
efficiency	O
of	O
transfections	O
was	O
normalized	O
relative	O
to	O
the	O
net	O
amount	O
of	O
CAT	B-GENE
plasmid	O
actually	O
transfected	O
into	O
recipient	O
cells	O
,	O
determined	O
by	O
a	O
modified	O
Southern	O
hybridization	O
procedure	O
.	O

Genomic	O
Southern	O
blot	O
analysis	O
suggests	O
that	O
the	O
human	O
haploid	O
genome	O
contains	O
a	O
single	O
Gs	B-GENE
alpha	I-GENE
gene	I-GENE
.	O

Evaluation	O
of	O
the	O
effects	O
of	O
chelation	O
therapy	O
with	O
time	O
following	O
strontium	O
exposure	O
to	O
mice	O
.	O

In	O
the	O
present	O
study	O
we	O
found	O
that	O
CD34	B-GENE
downregulation	O
during	O
hematopoiesis	O
occured	O
at	O
the	O
level	O
of	O
transcriptional	O
initiation	O
.	O

Allergen	O
-	O
stimulated	O
levels	O
of	O
PGD2	O
were	O
1274	O
+	O
/	O
-	O
565	O
versus	O
1468	O
+	O
/	O
-	O
679	O
after	O
prednisone	O
;	O
likewise	O
,	O
allergen	O
-	O
stimulated	O
5	O
-	O
HETE	O
levels	O
were	O
95	O
+	O
/	O
-	O
21	O
versus	O
82	O
+	O
/	O
-	O
21	O
;	O
those	O
of	O
LTE4	O
were	O
54	O
+	O
/	O
-	O
20	O
versus	O
91	O
+	O
/	O
-	O
51	O
;	O
and	O
those	O
of	O
15	O
-	O
HETE	O
were	O
63	O
+	O
/	O
-	O
19	O
versus	O
60	O
+	O
/	O
-	O
25	O
.	O

Foreign	O
DNA	O
inserts	O
contained	O
within	O
the	O
fowlpox	O
virus	O
sequence	O
were	O
transferred	O
to	O
the	O
viral	O
genome	O
by	O
homologous	O
recombination	O
occurring	O
in	O
cells	O
infected	O
with	O
a	O
fowlpox	O
virus	O
temperature	O
-	O
sensitive	O
mutant	O
and	O
transfected	O
with	O
both	O
wild	O
-	O
type	O
viral	O
DNA	O
and	O
plasmid	O
DNA	O
.	O

Although	O
there	O
is	O
evidence	O
that	O
cone	O
ratios	O
do	O
determine	O
colour	O
appearance	O
under	O
many	O
conditions	O
,	O
the	O
site	O
or	O
sites	O
of	O
their	O
computation	O
is	O
unknown	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU	B-GENE
.	I-GENE
1	I-GENE
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU	B-GENE
-	I-GENE
SF	I-GENE
)	O
when	O
binding	O
the	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
receptor	I-GENE
alpha	I-GENE
promoter	O
PU	B-GENE
.	I-GENE
1	I-GENE
site	O
.	O

Several	O
components	O
in	O
cytokine	O
signaling	O
remain	O
unidentified	O
.	O

This	O
is	O
the	O
first	O
report	O
demonstrating	O
specificity	O
at	O
the	O
level	O
of	O
the	O
energy	O
coupling	O
proteins	O
of	O
the	O
PTS	O
.	O

In	O
contrast	O
,	O
stem	O
-	O
loop	O
structures	O
2	O
,	O
3	O
,	O
and	O
4	O
of	O
the	O
3	O
'	O
domain	O
showed	O
great	O
variations	O
in	O
size	O
,	O
sequence	O
,	O
and	O
structure	O
.	O

A	O
spectrophotometric	O
method	O
for	O
the	O
microdetermination	O
of	O
periodate	O
.	O

Result	O
were	O
as	O
followed	O
:	O
1	O
)	O
Early	O
cancer	O
-	O
like	O
advanced	O
cancers	O
were	O
consisted	O
of	O
133	O
lesions	O
,	O
of	O
which	O
128	O
lesions	O
(	O
96	O
.	O
2	O
%	O
)	O
had	O
peptic	O
ulcer	O
in	O
cancerous	O
lesion	O
(	O
73	O
lesions	O
were	O
active	O
stage	O
and	O
55	O
lesions	O
were	O
scarring	O
stage	O
)	O
.	O

Effect	O
of	O
hyperaemia	O
on	O
thallium	O
-	O
201	O
redistribution	O
in	O
normal	O
canine	O
myocardium	O
.	O

Immunoblotting	O
showed	O
that	O
both	O
the	O
(	O
1	O
-	O
404	O
)	O
-	O
peptide	O
and	O
(	O
1	O
-	O
506	O
)	O
-	O
peptide	O
are	O
recognized	O
by	O
95J10	B-GENE
,	O
a	O
monoclonal	O
antibody	O
that	O
was	O
previously	O
raised	O
against	O
perlecan	B-GENE
-	I-GENE
(	I-GENE
24	I-GENE
-	I-GENE
404	I-GENE
)	I-GENE
-	I-GENE
peptide	I-GENE
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
anesthesiologist	O
and	O
the	O
cardiac	O
surgeon	O
.	O

To	O
gain	O
further	O
insights	O
into	O
these	O
events	O
,	O
the	O
porcine	B-GENE
G	I-GENE
alpha	I-GENE
i	I-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
minimal	I-GENE
promoter	I-GENE
was	O
characterized	O
and	O
found	O
67	O
base	O
pairs	O
upstream	O
from	O
the	O
major	O
transcription	O
start	O
site	O
.	O

FDP	O
-	O
1	O
(	O
200	O
micrograms	O
.	O
kg	O
-	O
1	O
)	O
of	O
intracoronary	O
injection	O
increased	O
collateral	O
flow	O
,	O
reduced	O
systemic	O
artery	O
resistance	O
,	O
and	O
coronary	O
systolic	O
pressure	O
in	O
infarcted	O
region	O
and	O
the	O
area	O
of	O
infarction	O
decreased	O
from	O
28	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
to	O
15	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
n	O
=	O
6	O
)	O
.	O

Pathophysiologic	O
mechanisms	O
underlying	O
spatial	O
disorientation	O
in	O
patients	O
with	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Many	O
human	O
malignant	O
cells	O
lack	O
methylthioadenosine	B-GENE
phosphorylase	I-GENE
(	O
MTAP	B-GENE
)	O
enzyme	O
activity	O
.	O

Following	O
40	O
min	O
"	O
ischemia	O
"	O
,	O
preparations	O
treated	O
with	O
PC	O
recovered	O
from	O
transmural	O
conduction	O
block	O
more	O
rapidly	O
(	O
PC1	O
group	O
,	O
4	O
min	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
;	O
PC2	O
group	O
,	O
23	O
min	O
,	O
ns	O
)	O
,	O
compared	O
to	O
control	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
novel	O
gene	O
spans	O
16	O
.	O
7	O
kb	O
of	O
genomic	O
sequence	O
and	O
it	O
is	O
formed	O
of	O
11	O
exons	O
and	O
10	O
intervening	O
introns	O
.	O

G	B-GENE
-	I-GENE
box	I-GENE
binding	I-GENE
factors	I-GENE
(	O
GBFs	B-GENE
)	O
constitute	O
a	O
family	O
of	O
plant	O
DNA	O
-	O
binding	O
proteins	O
that	O
bind	O
to	O
the	O
G	O
-	O
box	O
motif	O
,	O
a	O
regulatory	O
cis	O
element	O
present	O
in	O
many	O
plant	O
genes	O
with	O
a	O
palindromic	O
DNA	O
motif	O
of	O
CACGTG	O
.	O

CONCLUSION	O
:	O
In	O
an	O
acute	O
canine	O
model	O
of	O
progressive	O
LCX	O
coronary	O
stenosis	O
,	O
CFR	O
was	O
impaired	O
in	O
both	O
ischemic	O
and	O
remote	O
nonischemic	O
regions	O
in	O
association	O
with	O
mild	O
to	O
moderate	O
ischemic	O
-	O
induced	O
regional	O
myocardial	O
dysfunction	O
.	O

A	O
third	O
-	O
order	O
polynominal	O
fit	O
showed	O
a	O
good	O
correlation	O
for	O
the	O
parameter	O
Q	O
*	O
and	O
MTT	O
,	O
whereas	O
T	O
and	O
SImax	O
were	O
found	O
to	O
have	O
a	O
poor	O
correlation	O
.	O

Late	O
results	O
in	O
the	O
treatment	O
of	O
urotuberculosis	O

Changes	O
in	O
the	O
frequency	O
of	O
X	O
-	O
chromatin	O
in	O
women	O
under	O
Prednisone	O
therapy	O

Other	O
toxicities	O
attributed	O
to	O
CPT	O
-	O
11	O
included	O
dehydration	O
,	O
nausea	O
,	O
vomiting	O
,	O
and	O
asthenia	O
.	O

Proceedings	O
:	O
Influence	O
of	O
halothane	O
on	O
mortality	O
from	O
murine	O
hepatitis	O
virus	O
(	O
MHV3	O
)	O
.	O

These	O
results	O
extend	O
our	O
knowledge	O
of	O
this	O
SNF2	B-GENE
-	I-GENE
like	I-GENE
family	I-GENE
member	I-GENE
and	O
suggest	O
a	O
role	O
for	O
PASG	B-GENE
in	O
leukemogenesis	O
.	O

The	O
difference	O
between	O
the	O
results	O
in	O
the	O
high	O
dose	O
AHLG	B-GENE
and	O
in	O
the	O
control	O
group	O
was	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
when	O
amniotic	O
fluid	O
samples	O
are	O
stored	O
frozen	O
and	O
strict	O
quality	O
control	O
is	O
maintained	O
in	O
analytic	O
procedures	O
,	O
only	O
minimal	O
changes	O
occur	O
in	O
phospholipid	O
concentrations	O
over	O
12	O
months	O
.	O

Retinoic	O
acid	O
,	O
which	O
inhibits	O
the	O
progression	O
of	O
certain	O
cancers	O
,	O
repressed	O
v	B-GENE
-	I-GENE
src	I-GENE
-	O
induced	O
MMP	B-GENE
-	I-GENE
1	I-GENE
transcription	O
.	O

The	O
pattern	O
of	O
net	B-GENE
RNA	I-GENE
expression	O
in	O
adult	O
mouse	O
tissues	O
is	O
different	O
.	O

Immunoprecipitation	O
of	O
spinophilin	B-GENE
or	O
neurabin	B-GENE
from	O
crude	O
brain	O
extracts	O
selectively	O
coprecipitated	O
PP1gamma	B-GENE
(	I-GENE
1	I-GENE
)	I-GENE
over	O
PP1beta	B-GENE
.	O

The	O
authors	O
discussed	O
their	O
experience	O
in	O
investigating	O
20	O
patients	O
with	O
maxillary	O
malignant	O
tumors	O
using	O
routine	O
x	O
-	O
ray	O
studies	O
and	O
MR	O
-	O
tomography	O
,	O
and	O
13	O
patients	O
,	O
investigated	O
in	O
the	O
same	O
way	O
plus	O
CT	O
.	O

Reduction	O
of	O
p53	B-GENE
protein	I-GENE
was	O
detected	O
after	O
1	O
day	O
of	O
OM	B-GENE
treatment	O
and	O
reached	O
maximal	O
suppression	O
of	O
10	O
-	O
20	O
%	O
of	O
control	O
after	O
3	O
days	O
in	O
H3922	O
and	O
40	O
%	O
of	O
control	O
after	O
4	O
days	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Association	O
of	O
Syk	B-GENE
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
PTK	B-GENE
)	O
with	O
LMP2A	B-GENE
occurs	O
at	O
the	O
two	O
tyrosines	O
of	O
the	O
LMP2A	B-GENE
immunoreceptor	I-GENE
tyrosine	O
-	O
based	O
activation	O
motif	O
,	O
and	O
it	O
is	O
hypothesized	O
that	O
Lyn	B-GENE
PTK	B-GENE
associates	O
with	O
the	O
YEEA	O
amino	O
acid	O
motif	O
at	O
LMP2A	B-GENE
tyrosine	O
112	O
(	O
Y112	O
)	O
.	O

The	O
treatment	O
with	O
glucocorticoids	O
and	O
immunosuppressants	O
resulted	O
in	O
a	O
more	O
noticeable	O
decrease	O
in	O
the	O
levels	O
of	O
T3	O
and	O
E	B-GENE
-	I-GENE
RCF	I-GENE
.	O

Four	O
of	O
these	O
fibroblast	O
clones	O
were	O
infected	O
with	O
a	O
retrovirus	O
containing	O
the	O
cDNA	B-GENE
encoding	I-GENE
myoD	I-GENE
and	O
a	O
puromycin	O
selection	O
marker	O
.	O

Serum	O
estriol	O
levels	O
during	O
beta	B-GENE
-	I-GENE
receptor	I-GENE
agonist	O
infusion	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
Tax	B-GENE
activates	O
gene	O
expression	O
in	O
conjunction	O
with	O
members	O
of	O
the	O
ATF	B-GENE
/	O
CREB	B-GENE
family	O
.	O

Four	O
of	O
12	O
patients	O
(	O
33	O
%	O
)	O
were	O
initially	O
diagnosed	O
as	O
having	O
a	O
benign	O
disease	O
(	O
false	O
-	O
negatives	O
)	O
.	O

However	O
,	O
it	O
was	O
observed	O
that	O
storage	O
time	O
affected	O
significantly	O
the	O
biochemical	O
changes	O
occurring	O
in	O
the	O
constituents	O
of	O
carrots	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
.	O

Suppression	O
of	O
the	O
cka1	B-GENE
delta	I-GENE
cka2	I-GENE
-	I-GENE
8	I-GENE
mutant	I-GENE
phenotype	O
occurs	O
by	O
interaction	O
of	O
CKB1	B-GENE
with	O
the	O
defective	O
,	O
cka2	B-GENE
-	I-GENE
8	I-GENE
-	O
encoded	O
,	O
catalytic	O
subunit	O
.	O

The	O
median	O
cumulative	O
incidence	O
rates	O
were	O
found	O
to	O
be	O
341	O
per	O
million	O
for	O
males	O
and	O
296	O
per	O
million	O
for	O
females	O
.	O

Thomas	O
,	O
S	O
.	O
S	O
.	O

Similarly	O
,	O
antisense	B-GENE
TGF	I-GENE
-	I-GENE
beta	I-GENE
type	I-GENE
II	I-GENE
receptor	I-GENE
oligodeoxynucleotides	I-GENE
(	I-GENE
40	I-GENE
microM	I-GENE
)	I-GENE
resulted	O
in	O
a	O
58	O
%	O
increase	O
in	O
branching	O
,	O
compared	O
to	O
scrambled	O
and	O
mismatched	O
sequence	O
controls	O
,	O
while	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
,	I-GENE
type	I-GENE
II	I-GENE
receptor	I-GENE
mRNA	I-GENE
and	O
its	O
protein	O
expression	O
levels	O
were	O
suppressed	O
by	O
95	O
and	O
84	O
%	O
,	O
respectively	O
.	O

Secretion	O
of	O
cuticle	O
over	O
and	O
between	O
the	O
domed	O
apical	O
surfaces	O
of	O
these	O
cells	O
leads	O
to	O
a	O
honeycomb	O
-	O
like	O
structure	O
and	O
gives	O
the	O
superficial	O
wart	O
-	O
like	O
phenotype	O
of	O
mitotic	O
clones	O
on	O
the	O
adult	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
ICSBP	B-GENE
and	O
PU	B-GENE
.	I-GENE
1	I-GENE
are	O
critical	O
elements	O
for	O
IL	B-GENE
-	I-GENE
18	I-GENE
gene	I-GENE
expression	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
has	O
been	O
concluded	O
that	O
an	O
IPFSA	O
can	O
promote	O
the	O
healing	O
process	O
in	O
the	O
avascular	O
zone	O
of	O
a	O
torn	O
meniscus	O
in	O
rabbits	O
and	O
that	O
systemic	O
vascularity	O
to	O
the	O
synovium	O
or	O
the	O
meniscus	O
is	O
not	O
essential	O
for	O
healing	O
to	O
occur	O
.	O

NASA	O
CR	O
-	O
1223	O
.	O

The	O
magnitude	O
of	O
all	O
four	O
parameters	O
increased	O
in	O
an	O
exponential	O
fashion	O
with	O
increasing	O
sperm	O
number	O
up	O
to	O
400	O
x	O
10	O
(	O
6	O
)	O
per	O
ejaculate	O
.	O

We	O
studied	O
about	O
the	O
histological	O
findings	O
of	O
the	O
kidneys	O
including	O
of	O
the	O
infiltrated	O
macrophages	O
in	O
one	O
hour	O
post	O
-	O
transplantation	O
kidney	O
biopsies	O
(	O
one	O
hour	O
biopsies	O
)	O
and	O
re	O
-	O
biopsies	O
on	O
11	O
patients	O
.	O

An	O
additional	O
stimulation	O
of	O
D1	B-GENE
receptors	I-GENE
by	O
giving	O
SKF38393	O
30	O
min	O
later	O
produced	O
an	O
almost	O
continuous	O
pattern	O
of	O
jaw	O
openings	O
but	O
less	O
closure	O
movements	O
from	O
the	O
rest	O
position	O
,	O
and	O
the	O
openings	O
were	O
accompanied	O
by	O
frequent	O
tongue	O
protrusions	O
.	O

(	O
control	O
hearts	O
)	O
.	O

The	O
(	O
0	O
0	O
2	O
)	O
diffraction	O
of	O
the	O
synthesized	O
HAp	O
crystals	O
on	O
a	O
Col	O
fiber	O
showed	O
an	O
around	O
60	O
arching	O
angle	O
,	O
while	O
that	O
on	O
a	O
ChS	O
fiber	O
showed	O
just	O
around	O
10	O
degrees	O
.	O

During	O
4	O
%	O
O2	O
ventilation	O
,	O
baseline	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
and	O
the	O
dilator	O
response	O
to	O
both	O
ACh	O
and	O
SNP	O
were	O
greater	O
in	O
2D	O
lungs	O
.	O

To	O
determine	O
the	O
role	O
of	O
the	O
transmembrane	O
region	O
of	O
HN	B-GENE
on	O
fusion	O
-	O
promoting	O
activity	O
,	O
mutant	B-GENE
HN	I-GENE
proteins	I-GENE
were	O
expressed	O
and	O
their	O
biological	O
activities	O
examined	O
.	O

To	O
be	O
a	O
nurse	O
.	O

Transient	O
transfection	O
assays	O
indicated	O
that	O
the	O
(	O
-	O
4551	O
)	O
UCP1	B-GENE
-	O
CAT	B-GENE
construct	O
,	O
containing	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
rat	B-GENE
ucp	I-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
,	O
was	O
activated	O
by	O
PPARalpha	B-GENE
co	O
-	O
transfection	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
this	O
activation	O
was	O
potentiated	O
by	O
Wy	O
14	O
,	O
643	O
and	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
alpha	I-GENE
.	O

Synthesis	O
of	O
2	O
-	O
(	O
2	O
'	O
-	O
thiazolyl	O
)	O
alkanebenzimidazoles	O
-	O
-	O
potential	O
anthelmintics	O

Human	B-GENE
CR2	I-GENE
has	O
a	O
restricted	O
cellular	O
distribution	O
,	O
being	O
expressed	O
on	O
B	O
lymphocytes	O
,	O
dendritic	O
cells	O
of	O
the	O
spleen	O
,	O
pharyngeal	O
epithelial	O
cells	O
,	O
and	O
at	O
low	O
levels	O
on	O
some	O
T	O
lymphocytes	O
.	O

ADR1	B-GENE
in	O
extracts	O
made	O
from	O
glucose	O
-	O
repressed	O
and	O
-	O
derepressed	O
cells	O
bound	O
UAS1	O
DNA	O
with	O
similar	O
affinities	O
despite	O
having	O
greatly	O
different	O
abilities	O
to	O
activate	O
ADH2	B-GENE
gene	I-GENE
expression	O
in	O
vivo	O
.	O

Furthermore	O
,	O
agonist	O
action	O
at	O
a	O
5	B-GENE
-	I-GENE
HT1	I-GENE
receptor	I-GENE
and	O
antagonist	O
action	O
at	O
5	B-GENE
-	I-GENE
HT2	I-GENE
receptors	I-GENE
both	O
appear	O
to	O
contribute	O
to	O
antidepressant	O
-	O
like	O
activity	O
on	O
the	O
DRL	O
72	O
-	O
s	O
schedule	O
.	O

MsEPV	O
genes	O
with	O
putative	O
functions	O
in	O
prevention	O
and	O
repair	O
of	O
DNA	O
damage	O
include	O
a	O
complete	O
base	O
excision	O
repair	O
pathway	O
(	O
uracil	B-GENE
DNA	I-GENE
glycosylase	I-GENE
,	O
AP	B-GENE
endonuclease	I-GENE
,	O
DNA	B-GENE
polymerase	I-GENE
beta	I-GENE
,	O
and	O
an	O
NAD	B-GENE
+	I-GENE
-	I-GENE
dependent	I-GENE
DNA	I-GENE
ligase	I-GENE
)	O
,	O
a	O
photoreactivation	O
repair	O
pathway	O
(	O
cyclobutane	B-GENE
pyrimidine	I-GENE
dimer	I-GENE
photolyase	I-GENE
)	O
,	O
a	O
LINE	B-GENE
-	I-GENE
type	I-GENE
reverse	I-GENE
transcriptase	I-GENE
,	O
and	O
a	O
mutT	B-GENE
homologue	I-GENE
.	O

These	O
three	O
groups	O
were	O
further	O
examined	O
with	O
regard	O
to	O
the	O
modulation	O
of	O
discharge	O
rate	O
i	O
)	O
during	O
motor	O
activity	O
in	O
W	O
,	O
ii	O
)	O
at	O
the	O
transitional	O
phase	O
from	O
SS	O
to	O
paradoxical	O
sleep	O
(	O
PS	O
)	O
,	O
iii	O
)	O
during	O
rapid	O
eye	O
movements	O
(	O
REMs	O
)	O
in	O
PS	O
,	O
and	O
iv	O
)	O
following	O
electrical	O
stimulation	O
of	O
the	O
midbrain	O
reticular	O
formation	O
(	O
MRF	O
)	O
.	O

Likewise	O
,	O
the	O
consensus	O
signal	O
believed	O
to	O
be	O
involved	O
in	O
terminating	O
VV	B-GENE
early	I-GENE
gene	I-GENE
transcription	O
,	O
TTTTTNT	O
,	O
was	O
evident	O
at	O
the	O
3	O
'	O
-	O
boundary	O
of	O
both	O
the	O
N2	O
and	O
M1	O
ORFs	O
suggesting	O
that	O
these	O
genes	O
may	O
be	O
VV	B-GENE
early	I-GENE
genes	I-GENE
.	O

This	O
radiolabeled	O
,	O
900	O
-	O
bp	O
amplicon	O
was	O
used	O
as	O
a	O
hybridization	O
probe	O
to	O
screen	O
a	O
cDNA	O
library	O
constructed	O
from	O
poly	O
(	O
A	O
)	O
(	O
+	O
)	O
RNA	O
isolated	O
from	O
induced	O
Taxus	O
cells	O
,	O
from	O
which	O
a	O
full	O
-	O
length	O
transacetylase	O
sequence	O
was	O
obtained	O
.	O

Low	O
temperature	O
(	O
8	O
degrees	O
C	O
)	O
impairs	O
secretory	O
activity	O
,	O
again	O
independently	O
of	O
the	O
photoperiod	O
selected	O
.	O

Left	O
ventricle	O
to	O
coronary	O
sinus	O
fistula	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
structure	O
and	O
DNA	O
sequence	O
of	O
transcriptional	O
control	O
regions	O
from	O
both	O
human	B-GENE
and	I-GENE
Wistar	I-GENE
-	I-GENE
rat	I-GENE
single	I-GENE
copy	I-GENE
EGF	I-GENE
genes	I-GENE
and	O
their	O
functional	O
analysis	O
in	O
epithelial	O
cell	O
cultures	O
.	O

The	O
magnesium	O
content	O
in	O
leukocytes	O
could	O
not	O
be	O
estimated	O
because	O
of	O
interaction	O
between	O
the	O
ion	O
and	O
the	O
Percoll	O
(	O
R	O
)	O
media	O
.	O

The	O
sequence	O
of	O
three	O
of	O
them	O
revealed	O
pure	O
CAG	O
stretches	O
.	O

Furthermore	O
,	O
mutations	O
in	O
element	O
II	O
result	O
in	O
changes	O
in	O
the	O
RNA	O
structure	O
near	O
element	O
III	O
,	O
consistent	O
with	O
a	O
long	O
-	O
range	O
interaction	O
that	O
may	O
promote	O
translation	O
.	O

Although	O
the	O
QT	O
duration	O
was	O
higher	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
at	O
night	O
,	O
the	O
beat	O
-	O
to	O
-	O
beat	O
variability	O
of	O
this	O
interval	O
was	O
lower	O
:	O
in	O
the	O
time	O
domain	O
(	O
decreased	O
standard	O
deviation	O
,	O
p	O
=	O
0	O
.	O
0005	O
)	O
,	O
in	O
the	O
frequency	O
domain	O
(	O
decreased	O
low	O
-	O
frequency	O
power	O
of	O
the	O
spectra	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
the	O
chaotic	O
domain	O
(	O
tighter	O
clustering	O
of	O
the	O
points	O
in	O
the	O
Poincare	O
plots	O
)	O
.	O

The	O
biological	O
functions	O
of	O
rat	O
surfactant	B-GENE
protein	I-GENE
A	I-GENE
(	O
SP	B-GENE
-	I-GENE
A	I-GENE
)	O
,	O
an	O
oligomer	O
composed	O
of	O
18	O
polypeptide	O
subunits	O
derived	O
from	O
a	O
single	O
gene	O
,	O
are	O
dependent	O
on	O
intact	O
disulfide	O
bonds	O
.	O

A	O
V1	B-GENE
mutant	I-GENE
generated	O
in	O
vivo	O
with	O
11	O
of	O
the	O
14	O
N	O
-	O
terminal	O
amino	O
acids	O
altered	O
,	O
was	O
viable	O
and	O
produced	O
symptoms	O
typical	O
of	O
a	O
wild	O
-	O
type	O
infection	O
.	O

This	O
seems	O
to	O
take	O
place	O
in	O
the	O
same	O
nuclear	O
compartment	O
as	O
normal	O
cis	O
splicing	O
and	O
proceeds	O
through	O
Y	O
-	O
branched	O
intermediates	O
analogous	O
to	O
the	O
lariats	O
formed	O
in	O
cis	O
splicing	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
specific	O
determination	O
and	O
identification	O
of	O
plasma	O
FbDP	B-GENE
alone	O
is	O
not	O
sufficient	O
to	O
follow	O
the	O
effectiveness	O
of	O
thrombolytic	O
therapy	O
.	O

Chronic	O
,	O
recurrent	O
multifocal	O
osteomyelitis	O
.	O

Maximum	O
baroreceptor	O
activity	O
measured	O
at	O
140	O
mm	O
Hg	O
and	O
the	O
slope	O
of	O
the	O
pressure	O
-	O
activity	O
curve	O
were	O
reduced	O
in	O
atherosclerotic	O
(	O
n	O
=	O
15	O
)	O
compared	O
with	O
normal	O
(	O
n	O
=	O
13	O
)	O
rabbits	O
(	O
425	O
+	O
/	O
-	O
34	O
versus	O
721	O
+	O
/	O
-	O
30	O
spikes	O
per	O
second	O
and	O
6	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
10	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
spikes	O
per	O
second	O
per	O
mm	O
Hg	O
,	O
respectively	O
,	O
P	O
<	O
.	O
05	O
)	O
.	O

A	O
pathogenetic	O
relation	O
with	O
the	O
Eisenmenger	O
'	O
s	O
syndrome	O
is	O
discussed	O
.	O

Coronary	O
vasoconstriction	O
caused	O
by	O
endothelin	B-GENE
-	I-GENE
1	I-GENE
is	O
enhanced	O
by	O
ischemia	O
-	O
reperfusion	O
and	O
by	O
norepinephrine	O
present	O
in	O
concentrations	O
typically	O
observed	O
after	O
neonatal	O
cardiopulmonary	O
bypass	O
.	O

Located	O
between	O
the	O
3	O
'	O
trans	O
-	O
spliced	O
leader	O
acceptor	O
site	O
and	O
the	O
translational	O
initiation	O
codon	O
of	O
the	O
GP63	B-GENE
gene	I-GENE
is	O
an	O
area	O
of	O
conserved	O
hexanucleotide	O
direct	O
repeats	O
(	O
CTCGCC	O
)	O
which	O
vary	O
in	O
number	O
according	O
to	O
species	O
.	O

An	O
association	O
was	O
found	O
between	O
zafirlukast	O
plasma	O
concentrations	O
and	O
increases	O
in	O
PC8SRaw	O
10	O
h	O
after	O
treatment	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Insulin	B-GENE
-	O
secreting	O
islet	O
-	O
cell	O
tumours	O
of	O
the	O
pancreas	O
.	O

Disruption	O
and	O
reconstruction	O
:	O
narrative	O
insights	O
into	O
the	O
experience	O
of	O
family	O
members	O
caring	O
for	O
a	O
relative	O
diagnosed	O
with	O
serious	O
mental	O
illness	O
.	O

The	O
results	O
suggest	O
that	O
the	O
posterior	O
wall	O
is	O
more	O
compliant	O
than	O
the	O
anterior	O
wall	O
(	O
that	O
is	O
,	O
for	O
a	O
given	O
difference	O
in	O
transmural	O
pressure	O
,	O
the	O
local	O
segment	O
length	O
change	O
of	O
the	O
posterior	O
wall	O
was	O
greater	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
pyrene	O
in	O
diesel	O
-	O
exhaust	O
particles	O
(	O
DEP	O
)	O
has	O
an	O
adjuvant	O
activity	O
on	O
immunoglobulin	B-GENE
E	I-GENE
(	O
IgE	B-GENE
)	O
antibody	O
production	O
in	O
mice	O
immunized	O
with	O
Japanese	O
cedar	O
pollen	O
allergen	O
(	O
JCPA	O
)	O
or	O
ovalbumin	B-GENE
(	O
OA	B-GENE
)	O
intraperitoneally	O
.	O

Partial	O
characterization	O
of	O
the	O
CCAAT	O
box	O
in	O
the	O
promoter	O
of	O
the	O
hLGFBP	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
:	O
interaction	O
with	O
negatively	O
acting	O
transcription	O
factors	O
in	O
decidualized	O
human	O
endometrial	O
stromal	O
cells	O
.	O

We	O
conclude	O
that	O
transcription	O
of	O
both	O
SCD1	B-GENE
and	O
SCD2	B-GENE
genes	I-GENE
is	O
responsive	O
to	O
cellular	O
sterol	O
levels	O
and	O
to	O
the	O
levels	O
of	O
nuclear	O
SREBP	B-GENE
/	O
ADD1	B-GENE
and	O
that	O
transcriptional	O
induction	O
requires	O
three	O
spatially	O
conserved	O
cis	O
elements	O
,	O
that	O
bind	O
SREBP	B-GENE
and	O
NF	B-GENE
-	I-GENE
Y	I-GENE
.	O

Three	O
transcriptional	O
control	O
elements	O
within	O
300	O
base	O
pairs	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
rat	B-GENE
glucagon	I-GENE
gene	I-GENE
interact	O
with	O
regulatory	O
cellular	O
proteins	O
and	O
direct	O
transcription	O
only	O
in	O
glucagon	B-GENE
-	O
producing	O
islet	O
cells	O
.	O

A	O
role	O
for	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
in	O
the	O
regulation	O
of	O
beta	B-GENE
1	I-GENE
integrin	I-GENE
activity	O
by	O
the	O
CD2	B-GENE
antigen	O
.	O

Relationship	O
between	O
age	O
-	O
associated	O
endocrine	O
deficiencies	O
and	O
muscle	O
function	O
in	O
elderly	O
women	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
.	O

In	O
contrast	O
,	O
the	O
sequences	O
essential	O
for	O
the	O
transcription	O
of	O
EFT1	B-GENE
were	O
localized	O
to	O
the	O
region	O
between	O
the	O
start	O
ATG	O
and	O
the	O
stop	O
codon	O
of	O
the	O
VPS17	B-GENE
gene	I-GENE
that	O
terminates	O
267	O
nt	O
upstream	O
on	O
the	O
same	O
strand	O
.	O

Exposure	O
of	O
raft	O
cultures	O
to	O
activators	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
,	O
such	O
as	O
phorbol	O
esters	O
,	O
results	O
in	O
the	O
further	O
induction	O
of	O
late	B-GENE
gene	I-GENE
expression	O
as	O
well	O
as	O
virion	O
assembly	O
.	O

A	O
case	O
of	O
2	O
cancers	O
of	O
the	O
colon	O

The	O
"	O
Gregg	O
phenomenon	O
"	O
implies	O
that	O
myocardial	O
function	O
and	O
oxygen	O
consumption	O
(	O
MVO2	O
)	O
increase	O
when	O
coronary	O
perfusion	O
is	O
enhanced	O
within	O
or	O
above	O
the	O
autoregulatory	O
range	O
.	O

We	O
have	O
mapped	O
the	O
specific	O
domains	O
within	O
each	O
of	O
the	O
proteins	O
responsible	O
for	O
this	O
interaction	O
.	O

In	O
each	O
of	O
the	O
studied	O
HPV	O
types	O
,	O
the	O
two	O
CDP	B-GENE
/	O
Cut	B-GENE
binding	O
sites	O
of	O
PSM	B-GENE
overlap	O
with	O
the	O
known	O
or	O
presumed	O
binding	O
sites	O
of	O
the	O
replication	B-GENE
initiator	I-GENE
protein	I-GENE
E1	I-GENE
.	O

Reduced	O
cell	O
numbers	O
72	O
h	O
after	O
insonation	O
were	O
recorded	O
when	O
the	O
cells	O
were	O
insonated	O
at	O
an	O
antinode	O
but	O
not	O
when	O
they	O
were	O
at	O
a	O
node	O
.	O

Hydroxyl	O
radical	O
footprinting	O
of	O
DNA	O
complexes	O
of	O
the	O
ets	B-GENE
domain	I-GENE
of	O
PU	B-GENE
.	I-GENE
1	I-GENE
and	O
its	O
comparison	O
to	O
the	O
crystal	O
structure	O
.	O

ATF	O
is	O
formulated	O
from	O
the	O
prothrombin	B-GENE
time	O
(	O
PT	O
)	O
,	O
fibrinogen	B-GENE
transformation	O
rate	O
(	O
FTR	O
)	O
(	O
a	O
representation	O
of	O
thrombin	B-GENE
activity	O
)	O
,	O
and	O
a	O
consideration	O
of	O
the	O
fibrinogen	B-GENE
(	O
FBG	B-GENE
)	O
content	O
of	O
blood	O
plasma	O
.	O

(	O
LH	B-GENE
P	O
<	O
0	O
.	O
05	O
,	O
LH	B-GENE
/	O
FSH	B-GENE
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Inhibition	O
of	O
Raf	B-GENE
-	I-GENE
1	I-GENE
signaling	O
by	O
a	O
monoclonal	O
antibody	O
,	O
which	O
interferes	O
with	O
Raf	B-GENE
-	I-GENE
1	I-GENE
activation	O
and	O
with	O
Mek	B-GENE
substrate	O
binding	O
.	O

Phenotypic	O
and	O
molecular	O
analyses	O
of	O
patients	O
with	O
partial	O
chromosome	O
21	O
monosomy	O
enabled	O
us	O
to	O
define	O
a	O
region	O
,	O
spanning	O
2	O
.	O
4	O
Mb	O
between	O
D21S190	B-GENE
and	O
D21S226	B-GENE
,	O
associated	O
with	O
arthrogryposis	O
,	O
mental	O
retardation	O
,	O
hypertonia	O
,	O
and	O
several	O
facial	O
anomalies	O
.	O

The	O
classic	O
sterol	O
regulatory	O
cis	O
element	O
(	O
sre	O
-	O
1	O
)	O
in	O
the	O
LDL	B-GENE
receptor	I-GENE
promoter	O
mediates	O
sterol	B-GENE
regulatory	I-GENE
element	I-GENE
binding	I-GENE
protein	I-GENE
(	O
SREBP	B-GENE
)	O
-	O
binding	O
and	O
the	O
effects	O
of	O
insulin	B-GENE
and	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
.	O

The	O
Ca2	O
+	O
concentration	O
in	O
rats	O
serum	O
after	O
intragastrically	O
fenarimol	O
administration	O
(	O
doses	O
1	O
/	O
40	O
,	O
1	O
/	O
20	O
and	O
1	O
/	O
10	O
LD50	O
)	O
during	O
5	O
days	O
was	O
investigated	O
.	O

In	O
Cos	O
7	O
cells	O
transfected	O
with	O
oCRF1var	B-GENE
,	O
cAMP	O
accumulation	O
was	O
only	O
observed	O
at	O
the	O
highest	O
concentration	O
of	O
oCRF	B-GENE
utilized	O
(	O
100	O
nM	O
)	O
.	O

Pyknotic	O
osteocytes	O
increased	O
at	O
12	O
h	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
2	O
days	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
of	O
ischemia	O
.	O

The	O
right	O
cornea	O
of	O
rats	O
was	O
cauterized	O
by	O
drops	O
of	O
1	O
.	O
5	O
N	O
HC1	O
over	O
30	O
s	O
;	O
the	O
left	O
one	O
served	O
as	O
a	O
control	O
.	O

The	O
isoproterenol	O
infusion	O
was	O
adjusted	O
so	O
that	O
heart	O
rate	O
(	O
HR	O
)	O
was	O
at	O
least	O
30	O
beats	O
/	O
min	O
greater	O
than	O
baseline	O
.	O

This	O
is	O
probably	O
because	O
,	O
in	O
vivo	O
,	O
some	O
bacteria	O
(	O
perhaps	O
dormant	O
forms	O
)	O
are	O
not	O
entirely	O
dependent	O
upon	O
urease	B-GENE
for	O
survival	O
.	O

The	O
system	O
consists	O
of	O
a	O
microcomputer	O
and	O
six	O
laboratory	O
analyzers	O
:	O
a	O
blood	O
gas	O
analyzer	O
,	O
a	O
flame	O
photometer	O
,	O
a	O
plasma	O
osmotic	O
pressure	O
meter	O
,	O
a	O
chloride	O
ion	O
titrator	O
,	O
a	O
blood	O
sugar	O
analyzer	O
,	O
and	O
a	O
hemoglobin	B-GENE
concentration	O
and	O
saturation	O
meter	O
.	O

Comparing	O
the	O
outcome	O
of	O
the	O
group	O
having	O
histologically	O
normal	O
biopsies	O
with	O
the	O
group	O
having	O
nonspecifically	O
abnormal	O
ones	O
it	O
is	O
concluded	O
that	O
frontal	O
biopsy	O
is	O
not	O
of	O
such	O
high	O
prognostic	O
value	O
as	O
has	O
been	O
claimed	O
in	O
previous	O
reports	O
.	O

He	O
presented	O
with	O
left	O
lower	O
abdominal	O
pain	O
and	O
hematoma	O
after	O
a	O
fall	O
.	O

Fusion	O
of	O
mouse	B-GENE
CD8	I-GENE
+	I-GENE
class	B-GENE
I	I-GENE
MHC	I-GENE
-	O
restricted	O
T	O
cells	O
with	O
the	O
BW5147	O
thymoma	O
invariably	O
yields	O
CD8	B-GENE
-	I-GENE
hybridomas	O
in	O
which	O
RNA	O
transcribed	O
from	O
the	O
CD8	B-GENE
alpha	I-GENE
(	O
Lyt	B-GENE
-	I-GENE
2	I-GENE
)	O
gene	O
is	O
undetectable	O
.	O

Peak	O
plasma	O
ACTH	B-GENE
responses	O
were	O
not	O
significantly	O
different	O
between	O
control	O
and	O
patient	O
groups	O
.	O

For	O
the	O
P	B-GENE
transcript	I-GENE
from	O
phage	O
with	O
the	O
G	O
(	O
-	O
)	O
orientation	O
,	O
full	O
termination	O
activity	O
required	O
both	O
the	O
region	O
containing	O
the	O
stem	O
-	O
loop	O
structure	O
and	O
upstream	O
sequences	O
.	O

Development	O
of	O
neural	O
control	O
of	O
alimentary	O
motor	O
function	O
in	O
the	O
vertebrates	O
.	O

Nb2	O
-	O
11C	O
cells	O
expressed	O
three	O
PNR	B-GENE
-	I-GENE
related	I-GENE
mRNA	I-GENE
transcripts	I-GENE
of	O
2	O
.	O
5	O
,	O
3	O
.	O
0	O
and	O
>	O
10	O
kb	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Reg1	B-GENE
-	O
Glc7	B-GENE
phosphatase	O
is	O
a	O
cytoplasmic	O
component	O
of	O
the	O
machinery	O
responsible	O
for	O
returning	O
Snf1	B-GENE
kinase	I-GENE
activity	O
to	O
its	O
basal	O
level	O
and	O
reestablishing	O
glucose	O
repression	O
.	O

However	O
,	O
the	O
blend	O
of	O
Metanil	O
yellow	O
and	O
Orange	O
II	O
(	O
1	O
:	O
1	O
)	O
resulted	O
in	O
the	O
D1	O
50	O
.	O
value	O
of	O
288	O
min	O
.	O

The	O
majority	O
of	O
these	O
cells	O
were	O
also	O
OKT4	B-GENE
positive	O
(	O
helper	O
/	O
inducer	O
T	O
lymphocytes	O
)	O
,	O
while	O
the	O
minority	O
were	O
OKT8	B-GENE
positive	O
(	O
suppressor	O
/	O
cytotoxic	O
T	O
lymphocytes	O
)	O
.	O

AIMS	O
:	O
We	O
postulated	O
that	O
perhexiline	O
,	O
a	O
novel	O
anti	O
-	O
ischaemic	O
agent	O
with	O
an	O
oxygen	O
-	O
sparing	O
metabolic	O
effect	O
in	O
the	O
myocardium	O
(	O
via	O
inhibition	O
of	O
carnitine	B-GENE
palmitoyltransferase	I-GENE
-	I-GENE
1	I-GENE
)	O
and	O
no	O
adverse	O
haemodynamic	O
effects	O
,	O
may	O
improve	O
symptomatic	O
status	O
in	O
elderly	O
patients	O
with	O
severe	O
aortic	O
stenosis	O
.	O

The	O
IFNAR	B-GENE
chain	I-GENE
interacts	O
with	O
both	O
IFN	B-GENE
-	I-GENE
alpha	I-GENE
2	I-GENE
and	O
IFN	B-GENE
-	I-GENE
beta	I-GENE
,	O
as	O
demonstrated	O
by	O
cross	O
-	O
linking	O
.	O

To	O
clone	O
cDNAs	O
for	O
the	O
beta	O
subunit	O
of	O
rabbit	B-GENE
eIF	I-GENE
-	I-GENE
2B	I-GENE
,	O
amino	O
acid	O
sequence	O
data	O
was	O
first	O
obtained	O
and	O
used	O
to	O
design	O
redundant	O
oligonucleotide	O
primers	O
for	O
use	O
in	O
PCR	O
.	O

We	O
report	O
the	O
cloning	O
of	O
the	O
ade1	B-GENE
gene	I-GENE
on	O
a	O
4	B-GENE
.	I-GENE
4	I-GENE
kb	I-GENE
Sau3A	I-GENE
insert	I-GENE
in	O
the	O
yeast	O
shuttle	O
vector	O
pWH5	O
.	O

Nimodipine	O
(	O
5	O
micrograms	O
/	O
kg	O
)	O
followed	O
by	O
infusion	O
of	O
0	O
.	O
75	O
microgram	O
/	O
kg	O
/	O
min	O
lowered	O
the	O
blood	O
pressure	O
by	O
10	O
%	O
in	O
both	O
normotensive	O
and	O
hypertensive	O
rats	O
;	O
the	O
same	O
dose	O
schedule	O
of	O
nifedipine	O
did	O
not	O
lower	O
MAP	O
.	O

Results	O
of	O
these	O
in	O
vitro	O
studies	O
may	O
be	O
relevant	O
to	O
the	O
pathogenesis	O
of	O
alveolitis	O
in	O
organic	O
dust	O
-	O
induced	O
lung	O
diseases	O
.	O

The	O
odds	O
of	O
atopy	O
(	O
defined	O
as	O
a	O
positive	O
test	O
for	O
at	O
least	O
one	O
of	O
the	O
antigens	O
)	O
were	O
5	O
times	O
higher	O
(	O
odds	O
ratio	O
=	O
7	O
.	O
0	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1	O
.	O
6	O
-	O
31	O
.	O
1	O
%	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
in	O
the	O
uninfected	O
group	O
,	O
after	O
taking	O
into	O
account	O
the	O
potential	O
influence	O
of	O
gender	O
and	O
age	O
.	O

A	O
selectable	O
marker	O
for	O
transformation	O
was	O
constructed	O
by	O
transcriptional	O
fusion	O
of	O
a	O
Ustilago	B-GENE
maydis	I-GENE
heat	I-GENE
shock	I-GENE
gene	I-GENE
promoter	I-GENE
with	O
the	O
hygromycin	B-GENE
B	I-GENE
phosphotransferase	I-GENE
gene	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

The	O
structure	O
of	O
the	O
mAR	B-GENE
ORF	O
was	O
confirmed	O
by	O
sequence	O
analysis	O
of	O
mAR	B-GENE
cDNA	O
fragments	O
,	O
which	O
were	O
obtained	O
by	O
PCR	O
amplification	O
of	O
mouse	O
testis	O
cDNA	O
,	O
using	O
mAR	B-GENE
specific	O
primers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
response	O
properties	O
of	O
the	O
human	O
visual	O
cortex	O
to	O
chromatic	O
stimuli	O
using	O
magnetoencephalography	O
(	O
MEG	O
)	O
.	O

The	O
role	O
of	O
NUT1	B-GENE
and	O
regulation	O
of	O
nitrogen	O
metabolism	O
in	O
the	O
disease	O
process	O
was	O
evaluated	O
by	O
pathogenicity	O
assays	O
.	O

These	O
three	O
phases	O
of	O
cyclin	B-GENE
E	I-GENE
association	O
with	O
chromatin	O
may	O
facilitate	O
the	O
diverse	O
activities	O
of	O
cyclin	B-GENE
E	I-GENE
-	O
-	O
Cdk2	B-GENE
in	O
initiating	O
replication	O
,	O
blocking	O
rereplication	O
,	O
and	O
allowing	O
resetting	O
of	O
origins	O
after	O
mitosis	O
.	O

No	O
IORT	O
related	O
mortality	O
has	O
been	O
observed	O
.	O

Dermatophagoides	O
farinae	O
-	O
sensitized	O
lymphocytes	O
in	O
asthmatic	O
children	O
as	O
evaluated	O
by	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
(	O
IL	B-GENE
-	I-GENE
2	I-GENE
)	O
production	O
and	O
acquisition	O
of	O
IL	B-GENE
-	I-GENE
2	I-GENE
responsiveness	O

Enterotoxin	O
production	O
by	O
staphylococci	O
isolated	O
from	O
foods	O
in	O
France	O
.	O

Measurements	O
in	O
rats	O
given	O
a	O
dose	O
of	O
propranolol	O
that	O
partially	O
inhibited	O
the	O
NA	O
-	O
induced	O
increase	O
in	O
Q	O
to	O
IBAT	O
indicated	O
that	O
the	O
decline	O
in	O
ENAIBAT	O
was	O
attributable	O
primarily	O
to	O
the	O
increase	O
in	O
Q	O
rather	O
than	O
to	O
increasing	O
saturation	O
of	O
uptake	O
mechanisms	O
.	O

Plasma	B-GENE
LH	I-GENE
and	O
progesterone	O
levels	O
after	O
single	O
or	O
multiple	O
injections	O
of	O
synthetic	O
LH	B-GENE
-	O
RH	B-GENE
in	O
anoestrous	O
ewes	O
and	O
comparison	O
with	O
levels	O
during	O
the	O
oestrous	O
cycle	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O

But	O
,	O
when	O
mated	O
males	O
built	O
nests	O
in	O
the	O
absence	O
of	O
young	O
,	O
T	O
levels	O
were	O
higher	O
than	O
in	O
all	O
other	O
conditions	O
,	O
though	O
only	O
for	O
early	O
broods	O
.	O

Primers	O
were	O
developed	O
for	O
specific	O
amplification	O
of	O
9804	B-GENE
gene	I-GENE
fragments	I-GENE
.	O

The	O
promyelocytic	B-GENE
leukemia	I-GENE
protein	I-GENE
interacts	O
with	O
Sp1	B-GENE
and	O
inhibits	O
its	O
transactivation	O
of	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
promoter	O
.	O

The	O
mutants	O
retained	O
the	O
parental	O
ability	O
to	O
participate	O
in	O
intergeneric	O
coaggregation	O
with	O
human	O
oral	O
actinomyces	O
,	O
indicating	O
the	O
specificity	O
of	O
the	O
mutation	O
in	O
altering	O
intrageneric	O
coaggregations	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
targets	O
of	O
rapamycin	O
,	O
TOR1	B-GENE
and	O
TOR2	B-GENE
,	O
signal	O
activation	O
of	O
cell	O
growth	O
in	O
response	O
to	O
nutrient	O
availability	O
.	O

Biology	O
of	O
Anopheles	O
quadrimaculatus	O
under	O
field	O
conditions	O
in	O
central	O
Florida	O
.	O

Immunogenicity	O
tested	O
in	O
experiments	O
on	O
guinea	O
pigs	O
and	O
rabbits	O
was	O
not	O
reduced	O
and	O
corresponded	O
to	O
that	O
of	O
the	O
reference	O
STI	O
-	O
1	O
vaccine	O
.	O

The	O
Thrombolysis	O
in	O
Myocardial	O
Infarction	O
(	O
TIMI	O
)	O
Phase	O
II	O
Trial	O
randomized	O
3	O
,	O
339	O
patients	O
to	O
either	O
an	O
invasive	O
(	O
INV	O
,	O
n	O
=	O
1	O
,	O
681	O
)	O
or	O
a	O
conservative	O
(	O
CON	O
,	O
n	O
=	O
1	O
,	O
658	O
)	O
strategy	O
after	O
intravenous	O
recombinant	B-GENE
tissue	I-GENE
-	I-GENE
type	I-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
rt	B-GENE
-	I-GENE
PA	I-GENE
)	O
for	O
acute	O
myocardial	O
infarction	O
.	O

In	O
addition	O
,	O
mutations	O
within	O
the	O
Ubx	B-GENE
unit	I-GENE
exons	I-GENE
are	O
known	O
and	O
most	O
of	O
these	O
behave	O
as	O
null	O
alleles	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Smad3	B-GENE
/	O
Smad4	B-GENE
complex	O
has	O
at	O
least	O
two	O
separable	O
nuclear	O
functions	O
:	O
it	O
forms	O
a	O
rapid	O
,	O
yet	O
transient	O
sequence	O
-	O
specific	O
DNA	O
binding	O
complex	O
,	O
and	O
it	O
potentiates	O
AP1	B-GENE
-	O
dependent	O
transcriptional	O
activation	O
.	O

When	O
phentermine	O
was	O
mixed	O
with	O
other	O
unlabeled	O
reversible	O
MAO	B-GENE
inhibitors	O
(	O
e	O
.	O
g	O
.	O
pseudoephedrine	O
,	O
ephedrine	O
,	O
norephedrine	O
;	O
estradiol	O
benzoate	O
)	O
,	O
the	O
degree	O
of	O
MAO	B-GENE
inhibition	O
was	O
additive	O
.	O

Here	O
we	O
report	O
that	O
point	O
mutations	O
of	O
the	O
Abd	B-GENE
-	I-GENE
B	I-GENE
gene	I-GENE
in	O
trans	O
suppress	O
the	O
Fab	B-GENE
-	I-GENE
7	I-GENE
phenotype	I-GENE
in	O
a	O
pairing	O
-	O
dependent	O
manner	O
and	O
thus	O
represent	O
a	O
type	O
of	O
transvection	O
.	O

4	O
382	O
new	O
mothers	O
were	O
examined	O
retrospectively	O
with	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
IgG	B-GENE
activity	O
to	O
cytomegalovirus	O
(	O
CMV	O
)	O
during	O
pregnancy	O
.	O

Also	O
,	O
residues	O
273	O
to	O
287	O
,	O
which	O
are	O
identical	O
in	O
sequence	O
to	O
a	O
15	O
-	O
amino	O
-	O
acid	O
segment	O
near	O
the	O
carboxy	O
terminus	O
of	O
the	O
simian	B-GENE
foamy	I-GENE
virus	I-GENE
transcriptional	I-GENE
activator	I-GENE
Taf	I-GENE
,	O
can	O
independently	O
enhance	O
the	O
activity	O
of	O
the	O
minimal	O
activator	O
region	O
.	O

An	O
analogue	O
of	O
calcium	O
,	O
strontium	O
chloride	O
Sr	O
89	O
is	O
rapidly	O
cleared	O
from	O
the	O
blood	O
after	O
i	O
.	O
v	O
.	O
injection	O
.	O

The	O
effect	O
of	O
pneumoperitoneum	O
on	O
dissemination	O
and	O
scar	O
implantation	O
of	O
intra	O
-	O
abdominal	O
tumor	O
cells	O
.	O

In	O
two	O
of	O
these	O
nine	O
patients	O
,	O
a	O
decrease	O
in	O
dyskinesia	O
score	O
was	O
observed	O
without	O
a	O
concomitant	O
worsening	O
of	O
parkinsonian	O
symptoms	O
,	O
whereas	O
in	O
the	O
remaining	O
seven	O
,	O
full	O
parkinsonian	O
akinesia	O
followed	O
THDL	O
administration	O
.	O

Alterations	O
in	O
TCR	B-GENE
-	O
MHC	B-GENE
contacts	O
subsequent	O
to	O
cross	O
-	O
recognition	O
of	O
class	B-GENE
I	I-GENE
MHC	I-GENE
and	O
singly	O
substituted	O
peptide	O
variants	O
.	O

Two	O
patients	O
with	O
Ewing	O
'	O
s	O
sarcoma	O
relapsed	O
(	O
1	O
patient	O
with	O
both	O
local	O
and	O
distant	O
failure	O
)	O
at	O
26	O
and	O
58	O
months	O
and	O
were	O
again	O
rendered	O
disease	O
-	O
free	O
with	O
surgery	O
,	O
total	O
body	O
irradiation	O
and	O
further	O
chemotherapy	O
.	O

The	O
cloning	O
of	O
human	B-GENE
apo	I-GENE
B	I-GENE
-	I-GENE
100	I-GENE
has	O
provided	O
new	O
insights	O
into	O
the	O
structure	O
and	O
physicochemical	O
properties	O
of	O
apo	B-GENE
B	I-GENE
-	I-GENE
100	I-GENE
and	O
will	O
facilitate	O
studies	O
on	O
the	O
factors	O
modulating	O
apo	B-GENE
B	I-GENE
-	I-GENE
100	I-GENE
biosynthesis	O
and	O
the	O
expression	O
of	O
the	O
apo	B-GENE
B	I-GENE
-	I-GENE
100	I-GENE
gene	I-GENE
in	O
patients	O
with	O
dyslipoproteinemias	O
.	O

Angiographic	O
follow	O
-	O
up	O
was	O
obtained	O
in	O
92	O
%	O
of	O
patients	O
with	O
a	O
primary	O
success	O
of	O
angioplasty	O
.	O

Acceptability	O
of	O
home	O
monitoring	O
as	O
an	O
aid	O
to	O
conception	O
.	O

Repeated	O
interferon	B-GENE
-	I-GENE
beta	I-GENE
(	O
IFN	B-GENE
-	I-GENE
beta	I-GENE
)	O
silencer	O
B	O
motifs	O
and	O
a	O
lysozyme	B-GENE
silencer	I-GENE
1	I-GENE
motif	I-GENE
have	O
been	O
found	O
in	O
the	O
CD95	B-GENE
gene	I-GENE
at	O
approximately	O
-	O
1	O
,	O
600	O
and	O
-	O
1	O
,	O
100	O
,	O
respectively	O
.	O

Action	O
against	O
Vibrio	O
cholerae	O
O1	O
Tox	B-GENE
+	I-GENE
of	O
chemical	O
products	O
used	O
in	O
the	O
lemon	O
production	O
.	O

Patients	O
with	O
the	O
chronic	O
photosensitivity	O
dermatitis	O
with	O
actinic	O
reticuloid	O
syndrome	O
have	O
high	O
total	O
serum	O
IgE	B-GENE
concentrations	O
.	O

The	O
sequence	O
of	O
the	O
25	O
-	O
kDa	O
chain	O
of	O
the	O
alpha	O
subunit	O
was	O
found	O
in	O
a	O
cDNA	O
clone	O
,	O
and	O
the	O
amino	O
acid	O
sequence	O
deduced	O
from	O
the	O
cDNA	O
establishes	O
the	O
complete	O
amino	O
acid	O
sequence	O
of	O
the	O
25	O
-	O
kDa	O
chain	O
.	O

Characterization	O
of	O
the	O
chromosome	O
19	O
breakpoint	O
region	O
revealed	O
that	O
the	O
transcription	B-GENE
factor	I-GENE
-	I-GENE
encoding	I-GENE
USF2	I-GENE
gene	I-GENE
is	O
affected	O
.	O

Tax	B-GENE
and	O
the	O
active	O
Tax	B-GENE
mutants	I-GENE
were	O
able	O
to	O
abrogate	O
the	O
G1	O
arrest	O
and	O
apoptosis	O
induced	O
by	O
p53	B-GENE
,	O
and	O
this	O
effect	O
does	O
not	O
correlate	O
with	O
an	O
altered	O
localization	O
of	O
nuclear	B-GENE
p53	I-GENE
or	O
with	O
the	O
disruption	O
of	O
p53	B-GENE
-	I-GENE
DNA	I-GENE
complexes	I-GENE
.	O

When	O
patients	O
were	O
admitted	O
within	O
one	O
week	O
of	O
the	O
onset	O
of	O
dark	O
urine	O
,	O
45	O
%	O
were	O
found	O
to	O
be	O
shedding	O
HAV	O
,	O
whereas	O
only	O
11	O
%	O
of	O
specimens	O
obtained	O
from	O
patients	O
admitted	O
during	O
the	O
second	O
week	O
contained	O
virus	O
.	O

Biochemical	O
studies	O
have	O
identified	O
a	O
cellular	O
non	B-GENE
-	I-GENE
P	I-GENE
element	I-GENE
-	I-GENE
encoded	I-GENE
DNA	I-GENE
binding	I-GENE
protein	I-GENE
,	O
termed	O
the	O
inverted	B-GENE
repeat	I-GENE
binding	I-GENE
protein	I-GENE
(	O
IRBP	B-GENE
)	O
,	O
that	O
specifically	O
interacts	O
with	O
the	O
outer	O
half	O
of	O
the	O
31	O
-	O
bp	O
terminal	O
inverted	O
repeats	O
.	O

Threefold	O
risks	O
were	O
observed	O
for	O
men	O
with	O
the	O
highest	O
level	O
of	O
intensity	O
and	O
for	O
those	O
with	O
the	O
highest	O
probability	O
of	O
EMF	O
exposure	O
,	O
although	O
women	O
with	O
heavy	O
EMF	O
exposure	O
did	O
not	O
experience	O
increased	O
risk	O
.	O

In	O
the	O
spontaneous	O
abortion	O
group	O
,	O
the	O
levels	O
of	O
PAPP	B-GENE
-	I-GENE
A	I-GENE
were	O
significantly	O
lower	O
than	O
in	O
normal	O
pregnancy	O
but	O
higher	O
than	O
in	O
non	O
-	O
pregnant	O
controls	O
.	O

We	O
report	O
the	O
sequence	O
of	O
a	O
7941	O
bp	O
DNA	O
fragment	O
from	O
the	O
left	O
arm	O
of	O
chromosome	O
VII	O
of	O
Saccharomyces	O
cerevisiae	O
which	O
contains	O
four	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
of	O
greater	O
than	O
100	O
amino	O
acid	O
residues	O
.	O

A	O
4	O
.	O
0	O
-	O
kb	O
Nlk	B-GENE
message	I-GENE
is	O
also	O
present	O
during	O
embryogenesis	O
,	O
detectable	O
at	O
day	O
E10	O
.	O

Promoting	O
fat	O
utilisation	O
by	O
reducing	O
the	O
carbohydrate	O
-	O
fat	O
ratio	O
of	O
the	O
TPN	O
reduces	O
free	O
radical	O
activity	O
to	O
a	O
similar	O
extent	O
as	O
fat	O
exclusion	O
.	O

In	O
cells	O
infected	O
with	O
a	O
recombinant	O
vaccinia	O
virus	O
expressing	O
HCV	O
structural	O
proteins	O
(	O
core	B-GENE
,	O
E1	B-GENE
,	O
and	O
E2	B-GENE
)	O
,	O
DDX3	B-GENE
and	O
core	B-GENE
colocalized	O
in	O
distinct	O
spots	O
in	O
the	O
perinuclear	O
region	O
of	O
the	O
cytoplasm	O
.	O

Mutating	O
this	O
sequence	O
eliminated	O
complex	O
formation	O
and	O
markedly	O
reduced	O
basal	O
and	O
cAMP	O
-	O
dependent	O
promoter	O
activity	O
of	O
transfected	O
reporter	O
genes	O
.	O

The	O
lowest	O
PaCO2	O
values	O
were	O
significantly	O
lower	O
in	O
MCE	O
than	O
in	O
the	O
F	O
,	O
W	O
,	O
and	O
D	O
(	O
F	O
+	O
W	O
+	O
D	O
)	O
group	O
or	O
controls	O
.	O

The	O
translational	O
product	O
of	O
UL26	B-GENE
.	I-GENE
5	I-GENE
is	O
infected	B-GENE
-	I-GENE
cell	I-GENE
protein	I-GENE
35c	I-GENE
,	I-GENE
d	I-GENE
(	O
ICP35c	B-GENE
,	I-GENE
d	I-GENE
)	O
(	O
F	O
.	O

The	O
mouse	B-GENE
tapasin	I-GENE
gene	I-GENE
was	O
mapped	O
about	O
70	O
kilobases	O
from	O
H2	B-GENE
-	I-GENE
K	I-GENE
at	O
the	O
centromeric	O
end	O
of	O
the	O
mouse	B-GENE
MHC	I-GENE
.	O

Due	O
to	O
significant	O
homology	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
Mutator	B-GENE
transposase	I-GENE
this	O
alternative	O
gene	O
product	O
was	O
named	O
Trap	B-GENE
(	O
transposon	B-GENE
-	I-GENE
associated	I-GENE
protein	I-GENE
)	O
.	O

Nonetheless	O
,	O
the	O
majority	O
were	O
located	O
within	O
three	O
short	O
sequences	O
at	O
the	O
N	O
terminus	O
,	O
middle	O
,	O
and	O
C	O
terminus	O
that	O
are	O
phylogenetically	O
conserved	O
among	O
all	O
known	O
eubacterial	O
and	O
chloroplast	O
versions	O
of	O
this	O
protein	O
.	O

The	O
c	B-GENE
-	I-GENE
raf	I-GENE
-	I-GENE
1	I-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
is	O
the	O
cellular	B-GENE
homologue	I-GENE
of	I-GENE
v	I-GENE
-	I-GENE
raf	I-GENE
,	O
the	O
oncogene	O
of	O
the	O
acutely	O
transforming	O
retrovirus	O
3611	O
-	O
MSV	O
.	O

Using	O
gel	O
retardation	O
analysis	O
,	O
four	O
binding	O
sites	O
for	O
Rap1p	B-GENE
have	O
been	O
identified	O
within	O
the	O
promoter	O
of	O
the	O
RAP1	B-GENE
gene	I-GENE
.	O

In	O
general	O
,	O
the	O
scallop	O
extract	O
potentiated	O
phototactic	O
suppression	O
.	O

Alcohol	O
abuse	O
and	O
treatment	O
resistance	O
in	O
skin	O
disease	O
.	O

The	O
mean	O
serum	O
CDT	O
increased	O
from	O
8	O
.	O
5	O
(	O
SD	O
2	O
.	O
2	O
)	O
U	O
/	O
l	O
to	O
16	O
.	O
6	O
(	O
SD	O
7	O
.	O
2	O
)	O
U	O
/	O
l	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Subsequent	O
analysis	O
revealed	O
that	O
MyD88	B-GENE
possesses	O
a	O
unique	O
modular	O
structure	O
,	O
which	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
"	O
death	O
domain	O
,	O
"	O
similar	O
to	O
the	O
intracellular	O
segments	O
of	O
TNF	B-GENE
receptor	I-GENE
1	I-GENE
and	O
Fas	B-GENE
,	O
and	O
a	O
C	O
-	O
terminal	O
region	O
related	O
to	O
the	O
cytoplasmic	O
domains	O
of	O
the	O
Drosophila	B-GENE
morphogen	I-GENE
Toll	I-GENE
and	O
vertebrate	O
interleukin	B-GENE
-	I-GENE
1	I-GENE
receptors	I-GENE
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
FGFR	B-GENE
-	I-GENE
3	I-GENE
mRNA	I-GENE
showed	O
the	O
presence	O
of	O
a	O
splice	O
variant	O
in	O
which	O
exons	O
7	O
and	O
8	O
are	O
deleted	O
.	O

In	O
human	O
myxoid	O
liposarcoma	O
,	O
a	O
chromosomal	O
rearrangement	O
leads	O
to	O
fusion	O
of	O
the	O
growth	O
-	O
arresting	O
and	O
DNA	O
-	O
damage	O
-	O
inducible	O
transcription	O
factor	O
CHOP	B-GENE
(	O
GADD153	B-GENE
)	O
to	O
a	O
peptide	O
fragment	O
encoded	O
by	O
the	O
TLS	B-GENE
gene	I-GENE
.	O

They	O
also	O
show	O
that	O
M	O
.	O
malmoense	O
can	O
be	O
isolated	O
from	O
the	O
environment	O
which	O
may	O
be	O
the	O
source	O
of	O
the	O
infection	O
.	O

The	O
monkeys	O
had	O
been	O
administered	O
a	O
common	O
lead	O
isotope	O
"	O
mix	O
"	O
at	O
the	O
rate	O
of	O
about	O
1300	O
micrograms	O
Pb	O
/	O
kg	O
body	O
wt	O
/	O
day	O
from	O
age	O
10	O
months	O
until	O
the	O
start	O
of	O
the	O
study	O
.	O

We	O
previously	O
described	O
the	O
upregulation	O
of	O
the	O
MT2	B-GENE
antigen	I-GENE
during	O
urodele	O
limb	O
regeneration	O
and	O
characterized	O
the	O
MT2	B-GENE
antigen	I-GENE
as	O
a	O
310	O
-	O
to	O
325	O
-	O
kDa	O
chondroitin	O
-	O
sulfated	O
glycoprotein	O
with	O
a	O
core	O
protein	O
of	O
285	O
-	O
300	O
kDa	O
.	O

Analysis	O
of	O
the	O
MCV	B-GENE
-	I-GENE
1	I-GENE
RPO1	I-GENE
revealed	O
high	O
amino	O
acid	O
homologies	O
to	O
the	O
corresponding	O
polypeptides	O
of	O
vaccinia	O
and	O
variola	O
virus	O
.	O

The	O
effects	O
of	O
dopamine	O
and	O
of	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
blocker	O
haloperidol	O
on	O
the	O
activity	O
of	O
carotid	O
chemoreceptors	O
were	O
studied	O
in	O
24	O
anesthetized	O
,	O
paralyzed	O
and	O
artificially	O
ventilated	O
newborn	O
kittens	O
aged	O
0	O
-	O
17	O
days	O
.	O

Fifty	O
-	O
seven	O
per	O
cent	O
of	O
the	O
primary	O
patients	O
reporting	O
mild	O
symptoms	O
had	O
abnormal	O
levels	O
of	O
leucocytes	O
in	O
their	O
CSF	O
.	O

When	O
proper	O
controls	O
were	O
used	O
,	O
the	O
psychophysical	O
data	O
and	O
computer	O
simulation	O
gave	O
remarkably	O
comparable	O
results	O
.	O

Patients	O
were	O
treated	O
with	O
either	O
4	O
.	O
8	O
million	O
units	O
of	O
procaine	O
penicillin	O
with	O
1	O
g	O
probenecid	O
,	O
3	O
.	O
5	O
or	O
4	O
.	O
5	O
g	O
of	O
ampicillin	O
with	O
1	O
g	O
probenecid	O
,	O
or	O
9	O
.	O
5	O
g	O
of	O
tetracycline	O
given	O
over	O
4	O
days	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
Improved	O
Crest	O
Complete	O
with	O
longer	O
rippled	O
outer	O
bristles	O
provided	O
significantly	O
superior	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
interproximal	O
penetration	O
overall	O
and	O
at	O
the	O
gumline	O
than	O
the	O
Colgate	O
Total	O
and	O
Oral	O
-	O
B	O
Advantage	O
brushes	O
.	O

Cardiac	O
NE	O
spillover	O
was	O
higher	O
(	O
P	O
<	O
.	O
05	O
)	O
at	O
baseline	O
in	O
the	O
patient	O
group	O
than	O
in	O
healthy	O
subjects	O
,	O
whereas	O
renal	O
and	O
whole	O
-	O
body	O
NE	O
spillovers	O
were	O
similar	O
between	O
the	O
study	O
groups	O
.	O

The	O
activity	O
of	O
platelet	B-GENE
factor	I-GENE
4	I-GENE
in	O
plasma	O
of	O
healthy	O
and	O
high	O
risk	O
newborns	O
.	O

Plasma	B-GENE
renin	I-GENE
activity	O
in	O
essential	O
arterial	O
hypertension	O
.	O

A	O
trend	O
was	O
observed	O
toward	O
increased	O
graft	O
half	O
-	O
life	O
in	O
era	O
2	O
(	O
p	O
=	O
NS	O
)	O
.	O

The	O
proteins	O
encoded	O
by	O
these	O
genes	O
,	O
called	O
GF14	B-GENE
proteins	I-GENE
,	O
participate	O
in	O
protein	O
/	O
DNA	O
complexes	O
and	O
show	O
more	O
than	O
60	O
%	O
identity	O
with	O
a	O
highly	O
conserved	O
,	O
widely	O
distributed	O
protein	O
family	O
,	O
collectively	O
referred	O
to	O
as	O
14	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
3	I-GENE
proteins	O
.	O

The	O
p58	B-GENE
(	O
PITSLRE	B-GENE
beta	I-GENE
1	I-GENE
)	O
protein	O
kinase	O
(	O
PK	O
)	O
is	O
a	O
member	O
of	O
a	O
large	O
supergene	O
family	O
related	O
to	O
the	O
master	B-GENE
mitotic	I-GENE
protein	I-GENE
kinase	I-GENE
,	O
p34cdc2	B-GENE
.	O

Maximal	O
exercise	O
duration	O
and	O
peak	O
oxygen	O
consumption	O
were	O
not	O
changed	O
.	O

In	O
contrast	O
,	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
activation	O
was	O
observed	O
in	O
these	O
cells	O
after	O
PMA	O
stimulation	O
.	O

PtdIns	B-GENE
(	I-GENE
4	I-GENE
,	I-GENE
5	I-GENE
)	I-GENE
P2	I-GENE
synthesis	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
only	O
moderately	O
affected	O
even	O
in	O
fab1Delta	B-GENE
mutants	I-GENE
.	O

A	O
simple	O
procedure	O
for	O
accurate	O
quantitation	O
of	O
factor	B-GENE
VIII	I-GENE
inhibitors	O
.	O

We	O
found	O
that	O
48	O
%	O
of	O
the	O
patients	O
had	O
their	O
thoracolumbar	O
blood	O
supply	O
based	O
on	O
two	O
anterior	O
radiculospinal	O
arteries	O
the	O
lowest	O
of	O
which	O
was	O
located	O
at	O
,	O
or	O
lower	O
than	O
,	O
T12	O
,	O
and	O
the	O
second	O
and	O
higher	O
one	O
between	O
T6	O
and	O
T10	O
.	O

Low	O
serum	B-GENE
C3	I-GENE
values	O
were	O
observed	O
in	O
all	O
11	O
children	O
at	O
some	O
stage	O
of	O
their	O
illness	O
.	O

The	O
plants	O
were	O
then	O
brought	O
to	O
our	O
Houston	O
laboratory	O
where	O
they	O
were	O
measured	O
and	O
analyzed	O
for	O
lignin	O
and	O
protein	O
content	O
and	O
for	O
phenylalanine	B-GENE
ammonia	I-GENE
-	I-GENE
lyase	I-GENE
(	O
PAL	B-GENE
)	O
and	O
peroxidase	B-GENE
activities	O
.	O

Pax	B-GENE
-	I-GENE
6	I-GENE
constructs	O
lacking	O
the	O
C	O
-	O
terminal	O
activation	O
domain	O
repressed	O
betaB1	B-GENE
-	I-GENE
crystallin	I-GENE
promoter	I-GENE
activity	O
as	O
effectively	O
as	O
the	O
full	O
-	O
length	O
protein	O
,	O
but	O
the	O
PD	B-GENE
alone	O
or	O
Pax	B-GENE
-	I-GENE
6	I-GENE
(	I-GENE
5a	I-GENE
)	I-GENE
,	O
a	O
splice	O
variant	O
with	O
an	O
altered	O
PD	B-GENE
affecting	O
its	O
DNA	O
binding	O
specificity	O
,	O
did	O
not	O
.	O

A	O
regression	O
analysis	O
showed	O
that	O
86	O
%	O
of	O
the	O
variance	O
in	O
weight	O
gain	O
was	O
predicted	O
by	O
two	O
leading	O
indicators	O
in	O
the	O
middle	O
phase	O
of	O
treatment	O
.	O

OBJECTIVE	O
:	O
Respiratory	O
-	O
related	O
electromyographic	O
(	O
EMG	O
)	O
activity	O
of	O
the	O
superior	O
pharyngeal	O
constrictor	O
(	O
SPC	O
)	O
muscle	O
was	O
analyzed	O
during	O
the	O
early	O
stage	O
of	O
forced	O
breathing	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
contained	O
all	O
consensus	O
regions	O
for	O
S	B-GENE
-	I-GENE
adenosyl	I-GENE
methionine	I-GENE
methyltransferases	I-GENE
and	O
presented	O
26	O
%	O
identity	O
with	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
DHHB	I-GENE
-	I-GENE
methyltransferase	I-GENE
and	O
38	O
%	O
identity	O
with	O
the	O
rat	O
protein	O
,	O
as	O
well	O
as	O
with	O
a	O
bacterial	O
(	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
)	O
methyltransferase	B-GENE
encoded	O
by	O
the	O
UBIG	B-GENE
gene	I-GENE
.	O

Letter	O
:	O
Ballistocardiography	O
.	O

The	O
introduction	O
of	O
FWD1	B-GENE
into	O
cells	O
significantly	O
promotes	O
ubiquitination	O
and	O
degradation	O
of	O
IkappaBalpha	B-GENE
in	O
concert	O
with	O
IkappaB	B-GENE
kinases	I-GENE
,	O
resulting	O
in	O
nuclear	O
translocation	O
of	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
.	O

Fosinopril	O
decreased	O
blood	O
pressure	O
from	O
174	O
/	O
101	O
mm	O
Hg	O
to	O
149	O
/	O
88	O
mm	O
Hg	O
in	O
patients	O
with	O
diastolic	O
hypertension	O
and	O
from	O
182	O
/	O
86	O
mm	O
Hg	O
to	O
151	O
/	O
80	O
mm	O
Hg	O
in	O
patients	O
with	O
ISH	O
.	O

Although	O
CB	O
-	O
4	O
isolates	O
were	O
less	O
resistant	O
to	O
chlorine	O
than	O
CB	O
-	O
5	O
isolates	O
,	O
after	O
1	O
,	O
000	O
min	O
of	O
contact	O
0	O
.	O
01	O
%	O
of	O
the	O
input	O
virus	O
was	O
still	O
infectious	O
.	O

The	O
treatment	O
of	O
Sudeck	O
'	O
s	O
atrophy	O
in	O
the	O
upper	O
limb	O
by	O
sympathetic	O
blockade	O
.	O

To	O
assess	O
the	O
effect	O
on	O
thrombus	O
growth	O
,	O
we	O
determined	O
the	O
accretion	O
of	O
125I	O
-	O
labeled	O
fibrinogen	B-GENE
onto	O
autologous	O
non	O
-	O
radioactive	O
thrombi	O
preformed	O
in	O
the	O
jugular	O
veins	O
of	O
rabbits	O
.	O

Thallium	O
-	O
201	O
scintigraphy	O
after	O
dipyridamole	O
infusion	O
with	O
low	O
level	O
exercise	O
.	O

A	O
kinetic	O
model	O
for	O
99mTc	O
-	O
DMSA	O
in	O
the	O
rat	O
.	O

Crude	O
drugs	O
from	O
aquatic	O
plants	O
.	O

Yet	O
testosterone	O
was	O
predominant	O
in	O
the	O
plasma	O
of	O
the	O
Type	O
II	O
male	O
morph	O
which	O
neither	O
courts	O
females	O
nor	O
nests	O
,	O
but	O
instead	O
parasitizes	O
Type	O
I	O
males	O
with	O
sneak	O
or	O
satellite	O
spawning	O
tactics	O
.	O

Comparison	O
of	O
the	O
therapeutic	O
effectiveness	O
of	O
membrane	O
and	O
centrifugation	O
plasmapheresis	O

Amino	O
-	O
terminal	O
polymorphisms	O
of	O
the	O
human	B-GENE
beta	I-GENE
2	I-GENE
-	I-GENE
adrenergic	I-GENE
receptor	I-GENE
impart	O
distinct	O
agonist	O
-	O
promoted	O
regulatory	O
properties	O
.	O

Hence	O
,	O
it	O
is	O
perhaps	O
not	O
necessary	O
to	O
perform	O
spinal	O
puncture	O
if	O
the	O
only	O
purpose	O
is	O
to	O
determine	O
the	O
CSF	O
/	O
serum	O
ratio	O
.	O

Two	O
plasmids	O
,	O
one	O
containing	O
the	O
amino	O
terminus	O
of	O
P	O
fused	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
,	O
GAL4	B-GENE
,	O
and	O
the	O
other	O
containing	O
the	O
amino	O
terminus	O
of	O
NP	B-GENE
fused	O
to	O
the	O
herpesvirus	O
transactivator	O
,	O
VP16	B-GENE
,	O
were	O
transfected	O
in	O
COS	O
-	O
1	O
cells	O
along	O
with	O
a	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
plasmid	O
containing	O
GAL4	B-GENE
DNA	O
-	O
binding	O
sites	O
.	O

Biochemical	O
experiments	O
and	O
genome	O
sequencing	O
have	O
shown	O
that	O
,	O
despite	O
the	O
prokaryotic	O
cell	O
and	O
genome	O
organization	O
,	O
basal	O
transcriptional	O
elements	O
of	O
members	O
of	O
the	O
domain	O
Archaea	O
(	O
i	O
.	O
e	O
.	O
,	O
TATA	O
box	O
-	O
like	O
sequences	O
,	O
RNA	B-GENE
polymerase	I-GENE
,	O
and	O
transcription	O
factors	O
TBP	B-GENE
,	O
TFIIB	B-GENE
,	O
and	O
TFIIS	B-GENE
)	O
are	O
of	O
the	O
eukaryotic	O
type	O
.	O

Humoral	O
immunity	O
is	O
altered	O
with	O
the	O
drop	O
in	O
IgG	B-GENE
levels	O
.	O

For	O
the	O
second	O
phase	O
,	O
it	O
was	O
12	O
.	O
5	O
wk	O
for	O
RIR	O
and	O
10	O
for	O
WL	O
males	O
,	O
whereas	O
it	O
was	O
5	O
wk	O
for	O
RIR	O
and	O
6	O
for	O
WL	O
females	O
.	O

Modified	O
Grocott	O
'	O
s	O
methenamine	O
silver	O
nitrate	O
method	O
for	O
quick	O
staining	O
of	O
Pneumocystis	O
carinii	O
.	O

Additionally	O
,	O
VAHS	O
is	O
often	O
associated	O
with	O
fatal	O
infectious	O
mononucleosis	O
(	O
IM	O
)	O
.	O

RESULTS	O
:	O
In	O
patients	O
with	O
necrotising	O
fasciitis	O
the	O
arterial	O
PO2	O
rose	O
about	O
7	O
-	O
fold	O
whereas	O
the	O
arterial	O
PCO2	O
increased	O
only	O
slightly	O
during	O
exposure	O
to	O
2	O
.	O
5	O
absolute	O
atmospheres	O
(	O
ATA	O
)	O
of	O
oxygen	O
.	O

We	O
report	O
on	O
a	O
case	O
of	O
a	O
43	O
-	O
old	O
-	O
male	O
with	O
a	O
bronchogenic	O
cyst	O
in	O
the	O
distal	O
esophagus	O
,	O
which	O
was	O
misdiagnosed	O
as	O
a	O
malignant	O
esophageal	O
tumor	O
based	O
on	O
preoperative	O
imaging	O
and	O
high	O
levels	O
of	O
the	O
tumor	O
markers	O
CA	B-GENE
19	I-GENE
-	I-GENE
9	I-GENE
and	O
CA	B-GENE
125	I-GENE
.	O

100	O
and	O
51	O
p	O
.	O

A	O
plasma	O
cell	O
-	O
rich	O
infiltrate	O
was	O
present	O
in	O
the	O
connective	O
tissue	O
cores	O
of	O
the	O
papillae	O
.	O

During	O
normoxic	O
exercise	O
,	O
at	O
a	O
mean	O
O2	O
uptake	O
(	O
VO2	O
)	O
of	O
4	O
.	O
0	O
l	O
/	O
min	O
,	O
almitrine	O
increased	O
arterial	O
PO2	O
(	O
PaO2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
SaO2	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
VE	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
decreased	O
arterial	O
PCO2	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
without	O
affecting	O
pulmonary	O
hemodynamics	O
or	O
ventilation	O
-	O
perfusion	O
distributions	O
.	O

Gene	B-GENE
GPR	I-GENE
51	I-GENE
was	O
localized	O
by	O
radiation	O
hybrid	O
mapping	O
to	O
chromosome	O
9	O
,	O
4	O
.	O
81	O
cR	O
from	O
the	O
WI	O
-	O
8684	O
marker	O
,	O
and	O
proximal	O
to	O
the	O
hereditary	B-GENE
sensory	I-GENE
neuropathy	I-GENE
type	I-GENE
1	I-GENE
locus	I-GENE
.	O

We	O
conclude	O
that	O
the	O
outcome	O
of	O
patients	O
with	O
uterine	O
MMMT	O
is	O
mainly	O
influenced	O
by	O
the	O
initial	O
stage	O
and	O
the	O
type	O
of	O
epithelial	O
component	O
.	O

The	O
expression	O
of	O
the	O
leukocyte	B-GENE
EL	I-GENE
-	I-GENE
246	I-GENE
antigen	I-GENE
was	O
regulated	O
in	O
the	O
same	O
manner	O
as	O
L	B-GENE
-	I-GENE
selectin	I-GENE
and	O
EL	B-GENE
-	I-GENE
246	I-GENE
recognized	O
anti	B-GENE
-	I-GENE
L	I-GENE
-	I-GENE
selectin	I-GENE
mAb	I-GENE
affinity	O
-	O
purified	O
antigen	O
in	O
SDS	O
/	O
PAGE	O
Western	O
blot	O
analysis	O
.	O

Other	O
Fischer	O
-	O
344	O
rats	O
were	O
also	O
exposed	O
for	O
1	O
hr	O
to	O
0	O
.	O
0	O
or	O
to	O
0	O
.	O
6	O
ppm	O
O3	O
.	O

A	O
computerized	O
database	O
of	O
veterans	O
discharged	O
from	O
the	O
military	O
after	O
1967	O
was	O
selected	O
as	O
the	O
source	O
because	O
it	O
contains	O
about	O
50	O
%	O
of	O
the	O
total	O
Vietnam	O
era	O
veteran	O
population	O
,	O
is	O
reasonably	O
unbiased	O
,	O
and	O
provides	O
a	O
feasible	O
method	O
for	O
identifying	O
twins	O
.	O

To	O
examine	O
the	O
functional	O
relationship	O
between	O
distinct	O
cis	O
-	O
active	O
elements	O
within	O
the	O
distal	O
enhancer	O
region	O
of	O
the	O
rat	B-GENE
PRL	I-GENE
gene	I-GENE
,	O
we	O
have	O
used	O
deletional	O
and	O
mutational	O
analysis	O
of	O
that	O
region	O
in	O
transient	O
transfection	O
studies	O
in	O
GH3	O
pituitary	O
tumor	O
cells	O
.	O

The	O
entire	O
coding	O
region	O
of	O
an	O
ovine	B-GENE
endometrial	I-GENE
oxytocin	I-GENE
receptor	I-GENE
(	O
OTR	B-GENE
)	O
cDNA	O
was	O
generated	O
by	O
PCR	O
,	O
subcloned	O
into	O
the	O
SV40	B-GENE
major	I-GENE
late	I-GENE
promoter	I-GENE
expression	O
vector	O
pSVLJ	O
and	O
transiently	O
expressed	O
in	O
Cos	O
-	O
7	O
cells	O
.	O

Alcohol	O
and	O
stomach	O
diseases	O

These	O
operons	O
encode	O
subunits	O
of	O
photosystems	B-GENE
I	I-GENE
(	O
psa	B-GENE
)	O
and	O
II	O
(	O
psb	B-GENE
)	O
,	O
the	O
cytochrome	B-GENE
bGf	I-GENE
complex	I-GENE
(	O
pet	B-GENE
)	O
,	O
the	O
plastid	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
dehydrogenase	I-GENE
(	O
ndh	B-GENE
)	O
,	O
and	O
the	O
unidentified	O
open	O
reading	O
frame	O
ycf9	B-GENE
.	O

The	O
phosphatidylglycerol	B-GENE
/	I-GENE
phosphatidylinositol	I-GENE
transfer	I-GENE
protein	I-GENE
(	O
PG	B-GENE
/	I-GENE
PI	I-GENE
-	I-GENE
TP	I-GENE
)	O
is	O
a	O
new	O
and	O
original	O
phospholipid	B-GENE
transfer	I-GENE
protein	I-GENE
(	O
PLTP	B-GENE
)	O
isolated	O
from	O
the	O
Deuteromycete	O
,	O
Aspergillus	O
oryzae	O
.	O

Transcriptional	O
modulation	O
of	O
the	O
anti	B-GENE
-	I-GENE
apoptotic	I-GENE
protein	I-GENE
BCL	I-GENE
-	I-GENE
XL	I-GENE
by	O
the	O
paired	B-GENE
box	I-GENE
transcription	I-GENE
factors	I-GENE
PAX3	B-GENE
and	O
PAX3	B-GENE
/	O
FKHR	B-GENE
.	O

The	O
level	O
of	O
expression	O
of	O
the	O
PDE	B-GENE
protein	I-GENE
was	O
monitored	O
by	O
immunoblot	O
analysis	O
using	O
two	O
specific	O
cAMP	B-GENE
-	I-GENE
PDE	I-GENE
polyclonal	I-GENE
antibodies	I-GENE
and	O
by	O
measuring	O
the	O
PDE	B-GENE
activity	O
.	O

Blotting	O
analysis	O
of	O
intestinal	O
RNA	O
and	O
hybridization	O
of	O
the	O
blots	O
with	O
carboxy	O
apoB	B-GENE
cDNA	O
probes	O
produced	O
a	O
single	O
15	O
-	O
kb	O
hybridization	O
band	O
whereas	O
hybridization	O
with	O
amino	O
terminal	O
probes	O
produced	O
two	O
hybridization	O
bands	O
of	O
15	O
and	O
8	O
kb	O
.	O

Since	O
UmuD	B-GENE
protein	I-GENE
is	O
proteolytically	O
processed	O
to	O
an	O
active	O
form	O
(	O
UmuD	B-GENE
*	I-GENE
)	O
in	O
a	O
RecA	B-GENE
*	O
-	O
dependent	O
fashion	O
,	O
and	O
MucA	B-GENE
shares	O
extensive	O
amino	O
acid	O
homology	O
with	O
UmuD	B-GENE
,	O
we	O
examined	O
whether	O
MucA	B-GENE
is	O
similarly	O
processed	O
in	O
the	O
cell	O
,	O
using	O
antiserum	O
against	O
a	O
LacZ	B-GENE
'	I-GENE
-	O
'	B-GENE
MucA	I-GENE
fusion	O
protein	O
.	O

Influence	O
of	O
long	O
-	O
term	O
zimelidine	O
treatment	O
on	O
LSD	O
-	O
induced	O
behavioural	O
effects	O
.	O

We	O
have	O
determined	O
the	O
molecular	O
organization	O
and	O
transcription	O
start	O
points	O
(	O
tsp	O
)	O
for	O
the	O
murine	O
gene	O
(	O
TK	B-GENE
)	O
encoding	O
thymidine	B-GENE
kinase	I-GENE
.	O

Together	O
with	O
a	O
number	O
of	O
phase	O
II	O
trials	O
,	O
phase	O
I	O
trials	O
utilizing	O
escalating	O
doses	O
of	O
carboplatin	O
and	O
paclitaxel	O
with	O
growth	O
factor	O
or	O
growth	O
factor	O
and	O
blood	O
stem	O
-	O
cell	O
support	O
have	O
shown	O
that	O
substantial	O
increases	O
in	O
dose	O
intensity	O
can	O
be	O
achieved	O
.	O

It	O
is	O
an	O
untested	O
argument	O
that	O
conventional	O
beta	B-GENE
-	I-GENE
adrenoceptor	I-GENE
antagonists	O
possess	O
unwanted	O
metabolic	O
effects	O
that	O
may	O
counter	O
some	O
of	O
their	O
potential	O
cardiac	O
benefits	O
.	O

Genetic	O
polymorphisms	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
change	O
transcriptional	O
regulation	O
of	O
the	O
human	B-GENE
cytochrome	I-GENE
P450IIE1	I-GENE
gene	I-GENE
.	O

Although	O
the	O
occurrence	O
of	O
any	O
ventricular	O
ectopic	O
activity	O
,	O
as	O
detected	O
by	O
either	O
or	O
both	O
methods	O
,	O
was	O
common	O
,	O
the	O
incidence	O
was	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
86	O
percent	O
;	O
77	O
/	O
90	O
)	O
,	O
as	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
(	O
40	O
percent	O
;	O
12	O
/	O
30	O
)	O
.	O

Increased	O
trabecular	O
spacing	O
,	O
such	O
as	O
it	O
occurs	O
in	O
osteoporosis	O
,	O
reduces	O
the	O
spatial	O
field	O
inhomogeneity	O
and	O
thus	O
prolongs	O
T2	O
*	O
,	O
which	O
has	O
been	O
shown	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Healthy	O
preterm	O
infants	O
of	O
gestational	O
age	O
26	O
-	O
29	O
weeks	O
showed	O
a	O
'	O
mature	O
'	O
pattern	O
of	O
permeability	O
at	O
birth	O
,	O
followed	O
by	O
a	O
temporary	O
period	O
of	O
enhanced	O
permeability	O
after	O
3	O
-	O
4	O
weeks	O
of	O
life	O
.	O

These	O
studies	O
reveal	O
that	O
CREM	B-GENE
,	O
a	O
tissue	O
-	O
specific	O
factor	O
,	O
is	O
expressed	O
and	O
regulated	O
by	O
gonadotropins	B-GENE
in	O
the	O
ovary	O
,	O
that	O
the	O
predominant	O
CREM	B-GENE
transcripts	O
encode	O
the	O
repressor	B-GENE
protein	I-GENE
ICER	I-GENE
,	O
and	O
that	O
ICER	B-GENE
is	O
capable	O
of	O
inhibiting	O
cAMP	O
-	O
induced	O
expression	O
of	O
the	O
inhibin	B-GENE
alpha	I-GENE
-	I-GENE
subunit	I-GENE
gene	I-GENE
.	O

The	O
Brassica	B-GENE
BTH1	I-GENE
gene	I-GENE
may	O
correspond	O
to	O
the	O
Arabidopsis	B-GENE
TH	I-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
.	O

The	O
same	O
pattern	O
of	O
firing	O
was	O
seen	O
with	O
saccades	O
in	O
light	O
and	O
in	O
complete	O
darkness	O
.	O

While	O
these	O
could	O
be	O
unusual	O
cases	O
of	O
chronic	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
,	O
this	O
can	O
be	O
only	O
speculation	O
until	O
a	O
serologic	O
test	O
for	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
becomes	O
available	O
.	O

Acanthamoeba	B-GENE
myosin	I-GENE
I	I-GENE
heavy	I-GENE
chain	I-GENE
kinase	I-GENE
(	O
MIHCK	B-GENE
)	O
phosphorylates	O
the	O
heavy	O
chains	O
of	O
amoeba	B-GENE
myosins	I-GENE
I	I-GENE
,	O
increasing	O
their	O
actin	B-GENE
-	O
activated	O
ATPase	B-GENE
activities	O
.	O

Mutation	O
of	O
the	O
HNF3	B-GENE
element	I-GENE
significantly	O
reduced	O
promoter	O
activity	O
in	O
HepG2	O
cells	O
,	O
whereas	O
this	O
element	O
in	O
isolation	O
conferred	O
HNF3beta	B-GENE
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

The	O
mitochondrial	B-GENE
tyrosyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
of	O
Podospora	O
anserina	O
is	O
a	O
bifunctional	O
enzyme	O
active	O
in	O
protein	O
synthesis	O
and	O
RNA	O
splicing	O
.	O

The	O
findings	O
in	O
the	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	O
cells	O
with	O
downregulated	O
PU	B-GENE
.	I-GENE
1	I-GENE
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU	B-GENE
.	I-GENE
1	I-GENE
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	O
cell	O
lines	O
.	O

The	O
traW	B-GENE
gene	I-GENE
of	I-GENE
the	I-GENE
Escherichia	I-GENE
coli	I-GENE
K	I-GENE
-	I-GENE
12	I-GENE
sex	I-GENE
factor	I-GENE
,	O
F	O
,	O
encodes	O
one	O
of	O
the	O
numerous	O
proteins	O
required	O
for	O
conjugative	O
transfer	O
of	O
this	O
plasmid	O
.	O

Mibefradil	O
(	O
Ro	O
40	O
-	O
5967	O
)	O
is	O
a	O
novel	O
nondihydropyridine	O
calcium	O
antagonist	O
.	O

However	O
,	O
technical	O
advances	O
have	O
shown	O
the	O
limitations	O
of	O
these	O
tests	O
as	O
tests	O
for	O
IgM	B-GENE
can	O
be	O
positive	O
because	O
of	O
residual	O
specific	O
IgM	B-GENE
or	O
even	O
in	O
subjects	O
free	O
of	O
acute	O
infection	O
due	O
to	O
the	O
existence	O
of	O
natural	O
interfering	O
IgM	B-GENE
.	O

Carcinogenic	O
action	O
of	O
groundnut	O
meal	O
containing	O
aflatoxin	O
in	O
rats	O
.	O

(	O
1991	O
)	O
EMBO	O
J	O
.	O

We	O
have	O
utilized	O
transient	O
transfections	O
,	O
mutation	O
analysis	O
,	O
electromobility	O
gel	O
-	O
shifts	O
,	O
and	O
immunoblot	O
analysis	O
to	O
test	O
the	O
hypothesis	O
that	O
expression	O
of	O
the	O
CTalpha	B-GENE
gene	I-GENE
is	O
controlled	O
in	O
part	O
by	O
the	O
binding	O
of	O
three	O
trans	O
-	O
acting	O
nuclear	O
factors	O
,	O
Sp1	B-GENE
,	O
Sp2	B-GENE
,	O
and	O
Sp3	B-GENE
.	O

AMPK	B-GENE
is	O
a	O
heterotrimer	O
composed	O
of	O
a	O
catalytic	O
subunit	O
(	O
alpha	O
)	O
and	O
two	O
regulatory	O
subunits	O
(	O
beta	O
and	O
gamma	O
)	O
.	O

The	O
evolutionary	O
significance	O
of	O
the	O
similarities	O
of	O
intron	O
secondary	O
structures	O
and	O
open	O
reading	O
frames	O
of	O
the	O
ND3	B-GENE
,	I-GENE
4	I-GENE
and	I-GENE
ATPase	I-GENE
6	I-GENE
genes	I-GENE
is	O
discussed	O
,	O
including	O
the	O
possible	O
separate	O
evolution	O
of	O
structural	O
and	O
coding	O
sequences	O
.	O

Antinuclear	O
antibodies	O
,	O
rheumatoid	B-GENE
factor	I-GENE
and	O
C	B-GENE
-	I-GENE
reactive	I-GENE
protein	I-GENE
in	O
serum	O
of	O
normal	O
women	O
using	O
oral	O
contraceptives	O
.	O

The	O
destruction	O
of	O
the	O
mesometrium	O
did	O
not	O
lengthen	O
the	O
oestrous	O
cycle	O
.	O

Concentrations	O
of	O
platelet	O
nitrite	O
and	O
total	O
nitrate	O
/	O
nitrite	O
were	O
determined	O
using	O
simple	O
and	O
sensitive	O
nitrate	O
/	O
nitrite	O
fluorometric	O
assay	O
techniques	O
.	O

Power	O
deposition	O
by	O
inverse	O
-	O
bremsstrahlung	O
is	O
modeled	O
with	O
a	O
scheme	O
based	O
on	O
Gaussian	O
quadrature	O
to	O
accommodate	O
a	O
deposition	O
rate	O
whose	O
spatial	O
variation	O
is	O
highly	O
nonuniform	O
.	O

The	O
sulfur	O
species	O
could	O
be	O
separated	O
within	O
less	O
than	O
4	O
min	O
by	O
CZE	O
with	O
a	O
pyromellitic	O
acid	O
electrolyte	O
at	O
pH	O
3	O
.	O
5	O
to	O
5	O
.	O
0	O
.	O

We	O
propose	O
that	O
unc	B-GENE
-	I-GENE
37	I-GENE
may	O
be	O
regulated	O
by	O
unc	B-GENE
-	I-GENE
4	I-GENE
.	O

Adenovirus	O
infection	O
of	O
hepatoma	O
cells	O
inhibited	O
transcription	O
of	O
the	O
phosphoenolpyruvate	B-GENE
carboxykinase	I-GENE
(	O
GTP	O
)	O
(	O
EC	B-GENE
4	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
32	I-GENE
)	O
(	O
PEPCK	B-GENE
)	O
gene	O
and	O
virtually	O
eliminated	O
transcription	O
of	O
a	O
chimeric	O
gene	O
which	O
contained	O
the	O
PEPCK	B-GENE
promoter	I-GENE
linked	O
to	O
the	O
structural	O
gene	O
for	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
.	O

After	O
discharge	O
,	O
he	O
was	O
finally	O
given	O
a	O
diagnosis	O
of	O
PCH	O
because	O
a	O
Donath	O
-	O
Landsteiner	O
test	O
was	O
positive	O
.	O

The	O
second	O
intron	O
is	O
the	O
smallest	O
of	O
all	O
the	O
introns	O
(	O
116	O
bp	O
)	O
.	O

Expression	O
of	O
the	O
gene	O
encoding	O
transcription	B-GENE
factor	I-GENE
cyclic	I-GENE
adenosine	I-GENE
3	I-GENE
'	I-GENE
,	I-GENE
5	I-GENE
'	I-GENE
-	I-GENE
monophosphate	I-GENE
(	I-GENE
cAMP	I-GENE
)	I-GENE
response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
:	O
regulation	O
by	O
follicle	B-GENE
-	I-GENE
stimulating	I-GENE
hormone	I-GENE
-	O
induced	O
cAMP	O
signaling	O
in	O
primary	O
rat	O
Sertoli	O
cells	O
.	O

Efficacy	O
was	O
evaluated	O
in	O
24	O
patients	O
,	O
of	O
whom	O
eight	O
received	O
RD	O
and	O
16	O
SD	O
.	O

A	O
silica	O
-	O
based	O
,	O
fluoride	O
-	O
free	O
placebo	O
containing	O
NaTPP	O
,	O
and	O
a	O
NaF	O
-	O
containing	O
silica	O
-	O
based	O
USP	O
reference	O
standard	O
toothpaste	O
were	O
used	O
as	O
negative	O
and	O
positive	O
control	O
toothpastes	O
,	O
respectively	O
.	O

The	O
overall	O
response	O
rate	O
including	O
CR	O
and	O
PR	O
was	O
23	O
.	O
5	O
%	O
(	O
4	O
/	O
17	O
)	O
.	O

High	O
and	O
pathological	O
PAI	B-GENE
-	I-GENE
1	I-GENE
levels	O
before	O
and	O
after	O
the	O
VO	O
test	O
were	O
consistent	O
with	O
a	O
defective	O
fibrinolytic	O
potential	O
due	O
to	O
the	O
inhibitory	O
effect	O
of	O
PAI	B-GENE
-	I-GENE
1	I-GENE
on	O
plasminogen	B-GENE
activation	O
.	O

During	O
hexamethylene	O
bisactamide	O
(	O
HMBA	O
)	O
-	O
induced	O
differentiation	O
of	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
erythroid	O
genes	O
are	O
transcriptionally	O
activated	O
while	O
c	B-GENE
-	I-GENE
myb	I-GENE
and	O
several	O
other	O
nuclear	O
proto	O
-	O
oncogenes	O
are	O
down	O
-	O
regulated	O
.	O

The	O
recovery	O
of	O
adults	O
schistosomes	O
by	O
extracorporeal	O
filtration	O
.	O

Torsion	O
of	O
the	O
contralateral	O
testis	O
5	O
years	O
after	O
orchiopexy	O
.	O

Frequency	O
of	O
recurrence	O
of	O
fibroids	O
after	O
myomectomy	O
has	O
been	O
evaluated	O
in	O
145	O
women	O
(	O
median	O
age	O
38	O
years	O
,	O
range	O
21	O
-	O
52	O
)	O
who	O
underwent	O
myomectomy	O
.	O

Choline	B-GENE
acetyltransferase	I-GENE
immunohistochemistry	O
combined	O
with	O
the	O
retrograde	O
transport	O
of	O
horseradish	B-GENE
peroxidase	I-GENE
showed	O
that	O
the	O
reticular	O
and	O
mediodorsal	O
thalamic	O
nuclei	O
of	O
the	O
cat	O
receive	O
an	O
important	O
input	O
from	O
cholinergic	O
and	O
non	O
-	O
cholinergic	O
neurons	O
of	O
substantia	O
innominata	O
and	O
adjacent	O
structures	O
in	O
the	O
basal	O
forebrain	O
.	O

(	O
i	O
)	O
The	O
chimeric	O
gene	O
consisting	O
of	O
the	O
coding	O
and	O
5	O
'	O
nontranslated	O
leader	O
regions	O
of	O
the	O
TK	B-GENE
gene	I-GENE
fused	O
to	O
portions	O
of	O
the	O
domain	O
of	O
alpha	B-GENE
gene	I-GENE
0	I-GENE
extending	O
largely	O
upstream	O
from	O
the	O
site	O
of	O
initiation	O
of	O
transcription	O
of	O
alpha	B-GENE
gene	I-GENE
0	I-GENE
was	O
regulated	O
in	O
the	O
same	O
fashion	O
as	O
the	O
alpha	B-GENE
4	I-GENE
-	I-GENE
and	I-GENE
alpha	I-GENE
27	I-GENE
-	I-GENE
TK	I-GENE
chimeras	O
.	O

Ethanol	O
preference	O
in	O
strains	O
of	O
rats	O
selectively	O
bred	O
for	O
behavioral	O
characteristics	O
.	O

For	O
the	O
albino	O
,	O
both	O
the	O
ST1	O
and	O
ST2	O
spatial	O
responses	O
peak	O
at	O
around	O
0	O
.	O
3	O
cycles	O
deg	O
-	O
1	O
,	O
and	O
both	O
curves	O
are	O
displaced	O
considerably	O
to	O
the	O
low	O
spatial	O
frequency	O
side	O
of	O
the	O
normal	O
ST2	O
spatial	O
response	O
.	O

Nuclear	O
proteins	O
bound	O
the	O
cad	B-GENE
+	I-GENE
55	I-GENE
/	I-GENE
+	I-GENE
75	I-GENE
element	I-GENE
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
in	O
electromobility	O
shift	O
assays	O
;	O
antibodies	O
specific	O
to	O
USF	B-GENE
and	O
Max	B-GENE
blocked	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
different	O
growth	O
-	O
regulated	O
protein	O
-	O
DNA	O
complexes	O
.	O

Thus	O
,	O
an	O
unmodified	O
threonine	O
at	O
position	O
169	O
in	O
Cdc28	B-GENE
is	O
important	O
for	O
interaction	O
with	O
G1	B-GENE
cyclins	I-GENE
.	O

Additional	O
genetic	O
analyses	O
described	O
herein	O
suggest	O
that	O
Skb1	B-GENE
is	O
a	O
component	O
of	O
the	O
morphology	O
control	O
branch	O
of	O
the	O
Ras	B-GENE
signaling	O
cascade	O
in	O
S	O
.	O
pombe	O
and	O
that	O
it	O
positively	O
modulates	O
Shk1	B-GENE
function	O
.	O

Recent	O
studies	O
have	O
concentrated	O
on	O
the	O
methods	O
of	O
preparation	O
of	O
coffee	O
,	O
which	O
vary	O
from	O
country	O
to	O
country	O
.	O

From	O
a	O
chromosomal	O
cosmid	O
library	O
of	O
Streptomyces	O
argillaceus	O
,	O
a	O
Mtm	B-GENE
producer	O
,	O
a	O
clone	O
(	O
cosAR7	O
)	O
was	O
isolated	O
by	O
homology	O
to	O
the	O
actI	B-GENE
/	I-GENE
III	I-GENE
region	I-GENE
of	O
S	O
.	O
coelicolor	O
and	O
the	O
strDEM	B-GENE
genes	I-GENE
of	O
S	O
.	O
griseus	O
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
whether	O
the	O
cleavage	O
of	O
the	O
RRKR	O
motif	O
of	O
MT	B-GENE
-	I-GENE
MMP1	I-GENE
by	O
Golgi	B-GENE
-	I-GENE
associated	I-GENE
furin	I-GENE
is	O
analogous	O
to	O
a	O
similar	O
enzyme	O
activation	O
mechanism	O
observed	O
with	O
stromelysin	B-GENE
-	I-GENE
3	I-GENE
.	O

Coexpression	O
of	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
altered	O
the	O
cell	O
specificity	O
.	O

A	O
preterm	O
formula	O
with	O
a	O
traditional	O
corn	O
oil	O
/	O
MCT	O
blend	O
containing	O
38	O
%	O
MCTs	O
(	O
MCT	O
group	O
)	O
was	O
compared	O
to	O
a	O
new	O
fat	O
blend	O
,	O
designed	O
to	O
resemble	O
human	O
milk	O
more	O
,	O
containing	O
6	O
%	O
MCTs	O
(	O
LCT	O
group	O
)	O
.	O

Thirty	O
-	O
three	O
small	O
glottic	O
carcinomas	O
(	O
T1	O
and	O
small	O
T2	O
;	O
UICC	O
,	O
1978	O
)	O
were	O
examined	O
by	O
malignancy	O
grading	O
using	O
the	O
8	O
-	O
factor	O
system	O
proposed	O
by	O
Jakobsson	O
et	O
al	O
.	O

Phenylalanine	O
and	O
tyrosine	O
levels	O
were	O
higher	O
in	O
those	O
who	O
received	O
Vamin	O
9	O
glucose	O
but	O
55	O
%	O
of	O
infants	O
given	O
Vamin	O
Infant	O
had	O
tyrosine	O
levels	O
below	O
the	O
lower	O
limit	O
of	O
the	O
target	O
range	O
.	O

We	O
sought	O
to	O
test	O
whether	O
a	O
prolonged	O
infusion	O
of	O
magnesium	O
sulfate	O
(	O
MgSO	O
(	O
4	O
)	O
;	O
40	O
mmol	O
/	O
24	O
hours	O
)	O
would	O
normalize	O
QT	O
interval	O
variability	O
in	O
patients	O
with	O
compensated	O
heart	O
failure	O
.	O

Escherichia	O
coli	O
strains	O
carrying	O
recA730	B-GENE
(	O
or	O
other	O
recA	B-GENE
*	I-GENE
alleles	I-GENE
)	O
exhibit	O
dramatic	O
increases	O
in	O
SOS	O
-	O
dependent	O
spontaneous	O
mutator	O
activity	O
.	O

Outlook	O
in	O
oral	O
and	O
cutaneous	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

We	O
report	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
the	O
camC	B-GENE
gene	I-GENE
along	O
with	O
155	O
base	O
pairs	O
of	O
5	O
'	O
and	O
175	O
base	O
pairs	O
of	O
3	O
'	O
flanking	O
sequence	O
.	O

However	O
,	O
it	O
is	O
only	O
loosely	O
associated	O
,	O
or	O
not	O
associated	O
,	O
with	O
viral	O
particles	O
.	O

gp170	B-GENE
is	O
generated	O
by	O
an	O
alternatively	O
spliced	O
Env	B-GENE
mRNA	I-GENE
using	O
a	O
splice	O
donor	O
and	O
splice	O
acceptor	O
pair	O
localized	O
within	O
the	O
env	B-GENE
open	I-GENE
reading	I-GENE
frame	I-GENE
(	I-GENE
ORF	I-GENE
)	I-GENE
,	O
which	O
is	O
normally	O
used	O
to	O
generate	O
Bell	B-GENE
and	O
Bet	B-GENE
transcripts	I-GENE
derived	O
from	O
the	O
internal	O
promoter	O
within	O
the	O
env	B-GENE
ORF	I-GENE
.	O

gp170	B-GENE
is	O
expressed	O
at	O
a	O
level	O
30	O
to	O
50	O
%	O
of	O
the	O
Env	B-GENE
precursor	I-GENE
gp130	B-GENE
.	O

In	O
marked	O
contrast	O
to	O
the	O
previously	O
published	O
human	B-GENE
CD6	I-GENE
sequence	I-GENE
,	O
the	O
mouse	O
sequence	O
predicts	O
a	O
long	O
cytoplasmic	O
tail	O
that	O
is	O
not	O
closely	O
related	O
to	O
other	O
proteins	O
and	O
possesses	O
two	O
proline	O
-	O
rich	O
motifs	O
containing	O
the	O
SH3	B-GENE
-	I-GENE
domain	I-GENE
binding	I-GENE
consensus	I-GENE
sequence	I-GENE
,	O
three	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
phosphorylation	I-GENE
site	I-GENE
motifs	I-GENE
,	O
nine	O
casein	B-GENE
kinase	I-GENE
-	I-GENE
2	I-GENE
phosphorylation	I-GENE
site	I-GENE
motifs	I-GENE
,	O
and	O
a	O
serine	O
-	O
threonine	O
-	O
rich	O
motif	O
repeated	O
three	O
times	O
.	O

ET	B-GENE
-	I-GENE
1	I-GENE
limited	O
the	O
electrocardiographic	O
evidence	O
of	O
subendocardial	O
ischemia	O
and	O
attenuated	O
contractile	O
dysfunction	O
compared	O
with	O
mechanical	O
stenosis	O
at	O
the	O
same	O
coronary	O
flows	O
,	O
even	O
though	O
lactate	O
flux	O
was	O
similar	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
TCOF1	B-GENE
mutations	I-GENE
leading	O
to	O
the	O
Treacher	O
Collins	O
syndrome	O
phenotype	O
.	O

Experimental	O
production	O
of	O
a	O
syndrome	O
analogous	O
to	O
hydramnios	O
in	O
the	O
rat	O
fetus	O

Total	O
cross	O
sections	O
for	O
electron	O
scattering	O
by	O
CO2	O
molecules	O
in	O
the	O
energy	O
range	O
400	O
-	O
5000	O
eV	O
.	O

Thus	O
,	O
the	O
cognitive	O
performance	O
of	O
elderly	O
subjects	O
could	O
be	O
trained	O
to	O
a	O
large	O
extent	O
.	O

Partial	O
albinism	O
and	O
immunodeficiency	O
:	O
ultrastructural	O
study	O
of	O
haemophagocytosis	O
and	O
bone	O
marrow	O
erythroblasts	O
in	O
one	O
case	O
.	O

Residues	O
that	O
affect	O
PLCbeta	B-GENE
and	O
adenylyl	B-GENE
cyclase	I-GENE
II	I-GENE
activity	O
are	O
found	O
on	O
opposite	O
sides	O
of	O
the	O
central	O
tunnel	O
,	O
suggesting	O
that	O
PLC	B-GENE
and	O
adenylyl	B-GENE
cyclase	I-GENE
,	O
like	O
the	O
alpha	O
subunit	O
,	O
make	O
many	O
contacts	O
on	O
the	O
top	O
surface	O
.	O

The	O
dynamics	O
of	O
protozoa	O
were	O
studied	O
in	O
two	O
groups	O
of	O
rumen	O
-	O
fistulated	O
cattle	O
fed	O
on	O
a	O
basal	O
diet	O
of	O
molasses	O
ad	O
lib	O
.	O
,	O
with	O
oaten	O
chaff	O
given	O
at	O
6	O
or	O
18	O
g	O
/	O
kg	O
live	O
weight	O
.	O

The	O
CBS	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
was	O
mapped	O
to	O
human	O
chromosome	O
10p12	O
between	O
markers	O
WI	B-GENE
-	I-GENE
8535	I-GENE
and	O
WI	B-GENE
-	I-GENE
4724	I-GENE
,	O
and	O
is	O
tightly	O
linked	O
to	O
the	O
two	O
STRP	O
markers	O
of	O
D10S1789	B-GENE
and	O
D10S550	B-GENE
.	O

Blood	O
ammonia	O
concentration	O
was	O
significantly	O
higher	O
in	O
males	O
at	O
70	O
,	O
80	O
and	O
90	O
%	O
of	O
VO2	O
peak	O
.	O

Value	O
of	O
bone	O
scintigraphy	O
with	O
Tc99MDP	O
in	O
the	O
early	O
diagnosis	O
of	O
mobilization	O
of	O
the	O
total	O
hip	O
prosthesis	O

Youssoufian	O
,	O
A	O
.	O

The	O
dipper	O
(	O
RONF	O
of	O
BP	O
(	O
or	O
HR	O
)	O
>	O
or	O
=	O
10	O
%	O
2	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
SDZ	O
ENA	O
713	O
on	O
spatial	O
learning	O
deficits	O
in	O
aged	O
rats	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
seven	O
-	O
wavelength	O
frequency	O
-	O
domain	O
photon	O
migration	O
probe	O
was	O
used	O
to	O
perform	O
noninvasive	O
NIR	O
measurements	O
in	O
the	O
breasts	O
of	O
28	O
healthy	O
women	O
,	O
both	O
pre	O
-	O
and	O
postmenopausal	O
,	O
aged	O
18	O
-	O
64	O
years	O
.	O

YACs	O
,	O
BACs	O
,	O
cosmids	O
,	O
and	O
STSs	O
are	O
defined	O
to	O
aid	O
in	O
further	O
study	O
of	O
this	O
gene	O
.	O

HCVR	O
-	O
L	O
significantly	O
increased	O
dVAS	O
/	O
dPCO2	O
to	O
4	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
7	O
mm	O
/	O
Torr	O
compared	O
to	O
HCVR	O
-	O
S	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
MEF	B-GENE
-	I-GENE
2	I-GENE
proteins	I-GENE
are	O
a	O
family	O
of	O
transcriptional	O
activators	O
that	O
have	O
been	O
detected	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

The	O
ferric	B-GENE
uptake	I-GENE
regulation	I-GENE
(	O
fur	B-GENE
)	O
gene	O
product	O
participates	O
in	O
regulating	O
expression	O
of	O
the	O
manganese	O
-	O
and	O
iron	O
-	O
containing	O
superoxide	B-GENE
dismutase	I-GENE
genes	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

To	O
date	O
,	O
6	O
mammalian	O
GRKs	B-GENE
have	O
been	O
identified	O
by	O
molecular	O
cloning	O
.	O

[	O
(	O
OP	O
)	O
2Cu	O
]	O
+	O
also	O
detected	O
protections	O
in	O
the	O
C	O
alpha	O
-	O
helix	O
,	O
the	O
interdomain	O
hinge	O
,	O
and	O
beta	O
-	O
strands	O
2	O
-	O
7	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
long	O
term	O
intravenous	O
administration	O
of	O
naftidrofuryl	O
(	O
Dusodril	O
-	O
Lipha	O
Arzn	O
)	O
twice	O
daily	O
in	O
a	O
dose	O
of	O
200	O
mg	O
in	O
continuous	O
,	O
4	O
-	O
hour	O
infusion	O
in	O
500	O
ml	O
0	O
.	O
9	O
%	O
NaCl	O
to	O
the	O
patients	O
suffering	O
from	O
a	O
peripheral	O
arterial	O
occlusive	O
disease	O
(	O
PAOD	O
)	O
in	O
a	O
clinical	O
condition	O
with	O
special	O
attention	O
paid	O
to	O
transcutaneous	O
partial	O
oxygen	O
pressure	O
measurements	O
(	O
tcPO2	O
)	O
and	O
rheographic	O
parameters	O
.	O

Vertebrate	O
U6	B-GENE
small	I-GENE
nuclear	I-GENE
RNA	I-GENE
(	O
snRNA	O
)	O
loci	O
exemplify	O
a	O
novel	O
class	O
of	O
polymerase	B-GENE
III	I-GENE
-	O
transcribed	O
genes	O
that	O
lack	O
an	O
intragenic	O
control	O
region	O
(	O
ICR	O
)	O
.	O

Elements	O
of	O
the	O
hAT	B-GENE
transposon	I-GENE
family	I-GENE
,	O
such	O
as	O
the	O
maize	B-GENE
activator	I-GENE
(	O
Ac	B-GENE
)	O
,	O
have	O
been	O
discovered	O
in	O
a	O
large	O
number	O
of	O
eukaryotic	O
species	O
.	O

Judge	O
Christian	O
Byk	O
renders	O
service	O
to	O
the	O
Steering	O
Committee	O
on	O
Bioethics	O
of	O
the	O
Council	O
of	O
Europe	O
(	O
CDBI	O
)	O
by	O
proposing	O
a	O
draft	O
of	O
the	O
protocol	O
destined	O
to	O
fill	O
in	O
a	O
gap	O
in	O
international	O
law	O
on	O
the	O
status	O
of	O
the	O
human	O
embryo	O
.	O

Correlation	O
coefficients	O
between	O
SF	O
thickness	O
and	O
NIR	O
optical	O
density	O
readings	O
at	O
940	O
nm	O
(	O
OD1	O
)	O
and	O
950	O
nm	O
(	O
OD2	O
)	O
wavelengths	O
ranged	O
from	O
r	O
=	O
-	O
0	O
.	O
30	O
(	O
subscapula	O
)	O
to	O
r	O
=	O
-	O
0	O
.	O
67	O
(	O
biceps	O
)	O
for	O
OD1	O
and	O
r	O
=	O
-	O
0	O
.	O
39	O
(	O
axilla	O
)	O
to	O
r	O
=	O
-	O
0	O
.	O
68	O
(	O
biceps	O
)	O
for	O
OD2	O
.	O

We	O
found	O
both	O
the	O
v	B-GENE
-	I-GENE
Ras	I-GENE
-	O
and	O
PC	B-GENE
-	I-GENE
PLC	I-GENE
-	O
transformed	O
cells	O
to	O
be	O
insensitive	O
to	O
stimulation	O
with	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
.	O

Analysis	O
of	O
domain	O
deletion	O
mutants	O
demonstrated	O
strong	O
synergy	O
between	O
the	O
RRM	O
and	O
a	O
central	O
degenerate	O
RRM	O
repeat	O
in	O
binding	O
to	O
RNA	O
.	O

Sequence	O
analysis	O
of	O
the	O
catfish	O
JH	B-GENE
-	O
CH	B-GENE
intron	O
suggests	O
that	O
several	O
sequences	O
are	O
present	O
which	O
appear	O
similar	O
to	O
important	O
transcriptional	O
regulatory	O
elements	O
found	O
within	O
JH	B-GENE
-	O
CH	B-GENE
introns	O
of	O
higher	O
vertebrates	O
.	O

The	O
patient	O
groups	O
consisted	O
of	O
31	O
with	O
dilated	O
cardiomyopathy	O
,	O
22	O
with	O
hypertrophic	O
cardiomyopathy	O
,	O
38	O
with	O
myocardial	O
infarction	O
,	O
15	O
with	O
angina	O
pectoris	O
and	O
26	O
with	O
rheumatic	O
valvular	O
disease	O
.	O

100	O
.	O

However	O
,	O
the	O
pre3	B-GENE
-	I-GENE
2	I-GENE
mutation	I-GENE
strengthened	O
phenotypes	O
induced	O
by	O
other	O
20	B-GENE
S	I-GENE
proteasomal	I-GENE
mutations	I-GENE
,	O
indicating	O
that	O
the	O
peptidylglutamyl	O
peptide	O
-	O
hydrolyzing	O
activity	O
has	O
to	O
fulfill	O
some	O
rescue	O
functions	O
.	O

Whereas	O
Sprague	O
-	O
Dawleys	O
displayed	O
lights	O
-	O
off	O
and	O
lights	O
-	O
on	O
peaks	O
of	O
ingestive	O
activity	O
,	O
only	O
a	O
minority	O
of	O
Fisher	O
-	O
344s	O
displayed	O
a	O
consistent	O
lights	O
-	O
on	O
peak	O
of	O
ingestive	O
activity	O
.	O

RESULTS	O
:	O
In	O
76	O
trials	O
,	O
5	O
,	O
351	O
patients	O
received	O
24	O
different	O
regimens	O
of	O
droperidol	O
.	O

The	O
tro	B-GENE
operon	I-GENE
is	O
flanked	O
by	O
a	O
Holliday	B-GENE
structure	I-GENE
DNA	I-GENE
helicase	I-GENE
homolog	O
(	O
upstream	O
)	O
and	O
two	O
ORFs	O
representing	O
a	O
purine	B-GENE
nucleoside	I-GENE
phosphorylase	I-GENE
homolog	O
and	O
tpp15	B-GENE
,	O
a	O
previously	O
characterized	O
gene	O
encoding	O
a	O
membrane	O
lipoprotein	O
(	O
downstream	O
)	O
.	O

We	O
report	O
nine	O
consecutive	O
cases	O
of	O
ACB	O
,	O
which	O
occurred	O
in	O
five	O
males	O
and	O
four	O
females	O
and	O
were	O
detected	O
in	O
11	O
,	O
159	O
routine	O
spiral	O
CT	O
examinations	O
of	O
the	O
chest	O
,	O
performed	O
between	O
1994	O
and	O
1998	O
.	O

In	O
order	O
to	O
search	O
for	O
mutations	O
in	O
the	O
multicopy	B-GENE
RBM	I-GENE
genes	I-GENE
that	O
might	O
be	O
associated	O
with	O
male	O
infertility	O
,	O
we	O
have	O
used	O
sequence	O
data	O
from	O
the	O
reported	O
cDNA	O
clone	O
to	O
determine	O
the	O
intron	O
exon	O
boundaries	O
of	O
the	O
YRRM	B-GENE
1	I-GENE
gene	I-GENE
.	O

98	O
,	O
93	O
-	O
98	O
)	O
.	O

Studies	O
on	O
the	O
excretion	O
of	O
selenium	O
in	O
urine	O
and	O
feces	O
and	O
distribution	O
in	O
the	O
organs	O
of	O
rats	O
by	O
a	O
method	O
of	O
radioactivity	O
measurement	O

The	O
use	O
of	O
the	O
two	O
pharmacokinetic	O
parameters	O
,	O
t1	O
/	O
2	O
and	O
Cltp	O
,	O
as	O
indices	O
of	O
drug	O
elimination	O
ability	O
are	O
discussed	O
.	O

Gastric	O
secretory	O
inhibition	O
induced	O
by	O
three	O
methyl	O
analogs	O
of	O
prostaglandin	O
E2	O
administered	O
intragastrically	O
to	O
man	O
.	O

By	O
RT	O
-	O
PCR	O
,	O
different	O
levels	O
of	O
E75	B-GENE
expression	O
can	O
be	O
detected	O
in	O
the	O
epidermis	O
,	O
nerve	O
cord	O
and	O
the	O
eyestalk	O
of	O
early	O
pre	O
-	O
molt	O
shrimp	O
.	O

The	O
vicinity	O
of	O
large	O
industrial	O
emissions	O
of	O
lead	O
,	O
where	O
mean	O
Pb	O
-	O
B	O
concentrations	O
were	O
usually	O
twice	O
as	O
high	O
as	O
in	O
rural	O
areas	O
of	O
the	O
Katowice	O
voivodship	O
.	O

Forty	O
-	O
five	O
per	O
cent	O
of	O
the	O
dose	O
was	O
excreted	O
as	O
methyldopa	O
as	O
opposed	O
to	O
18	O
%	O
normally	O
seen	O
after	O
oral	O
methyldopa	O
dosages	O
.	O

No	O
cleavage	O
of	O
gp	B-GENE
130	I-GENE
was	O
observed	O
in	O
analogous	O
pulse	O
-	O
chase	O
radiolabelling	O
of	O
Ad	O
-	O
gB	B-GENE
-	O
infected	O
human	O
fibroblasts	O
,	O
even	O
though	O
these	O
cells	O
are	O
permissive	O
for	O
HCMV	O
replication	O
and	O
can	O
process	O
the	O
native	B-GENE
gB	I-GENE
molecule	I-GENE
.	O

A	O
phylogenetic	O
comparison	O
of	O
32	O
species	O
showed	O
minor	O
differences	O
in	O
the	O
apoB	B-GENE
mRNA	I-GENE
sequence	I-GENE
,	O
and	O
the	O
apoB	B-GENE
mRNA	I-GENE
from	O
31	O
species	O
was	O
robustly	O
edited	O
in	O
vitro	O
.	O

The	O
other	O
five	O
from	O
within	O
the	O
SRO	O
may	O
provide	O
an	O
entrance	O
point	O
for	O
the	O
cloning	O
of	O
candidate	O
genes	O
for	O
neuroblastoma	O
.	O

Sugar	O
analysis	O
was	O
performed	O
on	O
alpha	B-GENE
-	I-GENE
TM	I-GENE
to	O
investigate	O
a	O
possible	O
biosynthetic	O
mechanism	O
for	O
part	O
-	O
time	O
PGs	O
.	O

Pediatric	O
patients	O
-	O
-	O
handle	O
with	O
care	O
.	O

These	O
include	O
the	O
genes	O
,	O
undefined	B-GENE
1	I-GENE
(	O
UD1	B-GENE
)	O
,	O
UD2	B-GENE
,	O
and	O
UD3	B-GENE
,	O
each	O
coding	O
for	O
proteins	O
of	O
unknown	O
function	O
,	O
the	O
ken	B-GENE
gene	I-GENE
encoding	O
a	O
new	O
Kruppel	B-GENE
-	I-GENE
like	I-GENE
putative	I-GENE
transcription	I-GENE
factor	I-GENE
,	O
the	O
fly	O
homologues	O
of	O
the	O
mammalian	B-GENE
mitochondrial	I-GENE
trifunctional	I-GENE
enzyme	I-GENE
(	O
thiolase	B-GENE
)	O
,	O
and	O
the	O
TAR	B-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
43	I-GENE
(	O
TBPH	B-GENE
)	O
,	O
the	O
first	O
nonvertebrate	O
member	O
of	O
the	O
transmembrane	B-GENE
4	I-GENE
superfamily	I-GENE
(	O
TM4SF	B-GENE
)	O
gene	O
,	O
a	O
new	O
homeodomain	B-GENE
gene	I-GENE
,	O
and	O
a	O
gene	O
coding	O
for	O
a	O
putative	O
nuclear	O
binding	O
protein	O
(	O
PNBP	O
)	O
that	O
is	O
homologous	O
to	O
maleless	B-GENE
,	O
and	O
a	O
Copia	B-GENE
-	I-GENE
like	I-GENE
element	I-GENE
.	O

TRAF2	B-GENE
has	O
previously	O
been	O
demonstrated	O
to	O
activate	O
both	O
transcription	O
factor	O
nuclear	B-GENE
factor	I-GENE
kappaB	I-GENE
(	O
NFkappaB	B-GENE
)	O
and	O
the	O
c	B-GENE
-	I-GENE
Jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
/	O
stress	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
/	O
SAPK	B-GENE
)	O
pathway	O
,	O
which	O
in	O
turn	O
stimulates	O
transcription	B-GENE
factor	I-GENE
activating	I-GENE
protein	I-GENE
1	I-GENE
(	O
AP1	B-GENE
)	O
mainly	O
via	O
phosphorylation	O
of	O
the	O
c	B-GENE
-	I-GENE
Jun	I-GENE
component	O
.	O

A	O
procaryotic	O
regulatory	O
factor	O
with	O
a	O
histone	B-GENE
H1	I-GENE
-	I-GENE
like	I-GENE
carboxy	I-GENE
-	I-GENE
terminal	I-GENE
domain	I-GENE
:	O
clonal	O
variation	O
of	O
repeats	O
within	O
algP	B-GENE
,	O
a	O
gene	O
involved	O
in	O
regulation	O
of	O
mucoidy	O
in	O
Pseudomonas	O
aeruginosa	O
.	O

The	O
host	O
range	O
(	O
HR	O
)	O
of	O
poliovirus	O
is	O
thought	O
to	O
be	O
primarily	O
determined	O
by	O
a	O
cell	O
surface	O
molecule	O
that	O
functions	O
as	O
poliovirus	B-GENE
receptor	I-GENE
(	O
PVR	B-GENE
)	O
,	O
since	O
it	O
has	O
been	O
shown	O
that	O
transgenic	O
mice	O
are	O
made	O
poliovirus	O
sensitive	O
by	O
introducing	O
the	O
human	B-GENE
PVR	I-GENE
gene	I-GENE
into	O
the	O
genome	O
.	O

Human	B-GENE
alcohol	I-GENE
dehydrogenase	I-GENE
(	O
ADH	B-GENE
)	O
exists	O
as	O
a	O
heterogeneous	O
group	O
of	O
isozymes	O
capable	O
of	O
oxidizing	O
a	O
wide	O
variety	O
of	O
aliphatic	O
and	O
aromatic	O
alcohols	O
.	O

The	O
control	O
of	O
human	B-GENE
aromatase	I-GENE
expression	O
is	O
complex	O
in	O
that	O
several	O
promoters	O
drive	O
aromatase	B-GENE
expression	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

In	O
addition	O
,	O
renal	O
sympathetic	O
activity	O
was	O
measured	O
in	O
a	O
separate	O
group	O
of	O
rats	O
.	O

This	O
incompatibility	O
phenotype	O
requires	O
the	O
global	O
transcriptional	O
repressor	O
,	O
KorB	B-GENE
,	O
and	O
the	O
target	O
for	O
incC	B-GENE
-	O
mediated	O
incompatibility	O
is	O
a	O
KorB	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
(	I-GENE
O	I-GENE
(	I-GENE
B	I-GENE
)	I-GENE
)	I-GENE
.	O

Bodily	O
referents	O
and	O
the	O
experience	O
of	O
affect	O
.	O

The	O
effect	O
of	O
the	O
negative	O
regulatory	O
element	O
is	O
negated	O
by	O
the	O
viral	B-GENE
IE2	I-GENE
protein	I-GENE
(	O
L	O
.	O

RXRalpha	B-GENE
/	O
RARalpha	B-GENE
heterodimers	O
and	O
HNF	B-GENE
-	I-GENE
4	I-GENE
homodimers	I-GENE
bind	O
to	O
DR	O
-	O
1	O
motifs	O
on	O
elements	O
B	O
and	O
I4	O
,	O
respectively	O
.	O

Evidence	O
for	O
involvement	O
of	O
proteins	O
HU	B-GENE
and	O
RpoS	B-GENE
in	O
transcription	O
of	O
the	O
osmoresponsive	O
proU	B-GENE
operon	I-GENE
in	O
Escherichia	O
coli	O
.	O

However	O
,	O
a	O
lesser	O
extent	O
effect	O
was	O
noticed	O
in	O
nonpregnant	O
than	O
seen	O
in	O
pregnant	O
rats	O
.	O

Morphine	O
administration	O
acutely	O
reduced	O
plasma	O
clearance	O
of	O
sulfobromophthalein	O
(	O
BSP	O
)	O
in	O
mice	O
and	O
increased	O
hepatic	O
retention	O
of	O
this	O
dye	O
.	O

Buchstein	O
,	O
L	O
.	O
-	O
L	O
.	O

Intraspinal	O
and	O
mediastinal	O
foregut	O
cyst	O
compressing	O
the	O
spinal	O
cord	O
.	O

The	O
nutraceuticals	O
of	O
specific	O
vitamins	O
,	O
minerals	O
,	O
phytoestrogens	O
,	O
and	O
essential	O
fatty	O
acid	O
supplementations	O
are	O
a	O
vital	O
component	O
of	O
the	O
risk	O
reduction	O
health	O
program	O
.	O

Characterization	O
of	O
a	O
unique	O
protein	O
component	O
of	O
yeast	B-GENE
RNase	I-GENE
MRP	I-GENE
:	O
an	O
RNA	O
-	O
binding	O
protein	O
with	O
a	O
zinc	O
-	O
cluster	O
domain	O
.	O

The	O
present	O
study	O
indicates	O
that	O
the	O
high	O
-	O
dose	O
5	O
-	O
fluorouracil	O
regimen	O
shows	O
weak	O
activity	O
in	O
advanced	O
pancreatic	O
cancer	O
which	O
seems	O
comparable	O
to	O
gemcitabine	O
.	O

Like	O
the	O
nuclear	O
envelope	O
,	O
the	O
intranuclear	O
double	O
membrane	O
lamellae	O
enclosed	O
a	O
defined	O
cisterna	O
that	O
was	O
interrupted	O
by	O
pores	O
but	O
,	O
unlike	O
the	O
nuclear	O
envelope	O
pores	O
,	O
they	O
lacked	O
NPCs	O
.	O

The	O
22	O
-	O
d	O
orbital	O
flight	O
of	O
rats	O
onboard	O
the	O
Cosmos	O
-	O
605	O
biosatellite	O
was	O
followed	O
by	O
inhibition	O
of	O
erythroblastosis	O
,	O
alteration	O
in	O
the	O
morphology	O
of	O
megakaryocytes	O
,	O
and	O
stimulation	O
of	O
myelopoiesis	O
.	O

An	O
OD	O
650	O
greater	O
than	O
0	O
.	O
15	O
appears	O
to	O
be	O
a	O
rapid	O
,	O
reliable	O
indicator	O
of	O
fetal	O
lung	O
maturity	O
.	O

The	O
role	O
of	O
PORT	O
in	O
the	O
treatment	O
of	O
N2	O
tumours	O
is	O
not	O
clear	O
and	O
may	O
justify	O
further	O
research	O
.	O

We	O
concluded	O
that	O
RXR	B-GENE
-	I-GENE
gamma	I-GENE
induced	O
terminal	O
differentiation	O
in	O
SCC	O
lines	O
,	O
suggesting	O
a	O
potential	O
tumor	O
suppressor	O
function	O
for	O
this	O
transcription	O
factor	O
.	O

Phosphorylated	O
tyrosine	O
residues	O
were	O
subsequently	O
identified	O
by	O
sequencing	O
the	O
separated	O
phosphopeptides	O
by	O
matrix	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
MS	O
)	O
and	O
Edman	O
degradation	O
.	O

The	O
infection	O
of	O
cells	O
with	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
causes	O
an	O
increase	O
in	O
specific	O
cellular	O
gene	O
products	O
,	O
including	O
the	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
(	I-GENE
MHC	I-GENE
)	I-GENE
class	I-GENE
I	I-GENE
antigens	I-GENE
.	O

These	O
data	O
demonstrate	O
that	O
oleosin	B-GENE
gene	I-GENE
transcription	O
is	O
regulated	O
in	O
a	O
tissue	O
-	O
specific	O
and	O
temporally	O
regulated	O
manner	O
and	O
clearly	O
indicate	O
that	O
oleosin	B-GENE
protein	I-GENE
expression	O
is	O
co	O
-	O
ordinated	O
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

Myocardial	O
technetium	O
-	O
99m	O
-	O
teboroxime	O
uptake	O
during	O
adenosine	O
-	O
induced	O
hyperemia	O
in	O
dogs	O
with	O
either	O
a	O
critical	O
or	O
mild	O
coronary	O
stenosis	O
:	O
comparison	O
to	O
thallium	O
-	O
201	O
and	O
regional	O
blood	O
flow	O
.	O

UICC	O
criteria	O
)	O
for	O
VM	O
and	O
35	O
%	O
for	O
VE	O
(	O
not	O
significant	O
)	O
.	O

Although	O
immunoglobulin	B-GENE
and	O
CRP	B-GENE
concentration	O
increased	O
,	O
anemia	O
obviously	O
improved	O
with	O
hemoglobin	B-GENE
levels	O
increasing	O
from	O
4	O
.	O
8	O
g	O
/	O
dl	O
to	O
8	O
.	O
5	O
g	O
/	O
dl	O
without	O
any	O
side	O
effects	O
.	O

Diff	O
-	O
Quik	O
stain	O
for	O
Tzanck	O
smears	O
.	O

Experience	O
in	O
using	O
the	O
Romashka	O
-	O
1	O
laser	O
surgical	O
unit	O
in	O
treating	O
suppurative	O
wounds	O

At	O
D28	O
,	O
149	O
of	O
386	O
patients	O
(	O
49	O
%	O
)	O
had	O
had	O
episodes	O
of	O
automatic	O
mode	O
switch	O
prompted	O
by	O
atrial	O
arrhythmias	O
.	O

Together	O
,	O
these	O
results	O
implicate	O
Fal1p	B-GENE
in	O
the	O
18S	B-GENE
rRNA	I-GENE
maturation	O
pathway	O
rather	O
than	O
in	O
translation	O
initiation	O
.	O

Most	O
other	O
differences	O
between	O
these	O
two	O
Leporipoxviruses	O
are	O
located	O
in	O
the	O
telomeres	O
.	O

We	O
challenge	O
each	O
of	O
55	O
consecutive	O
ragweed	O
(	O
RW	O
)	O
-	O
allergic	O
patients	O
with	O
hay	O
fever	O
and	O
with	O
graded	O
increasing	O
doses	O
of	O
ragweed	O
extract	O
to	O
investigate	O
the	O
frequency	O
and	O
relationship	O
between	O
the	O
early	O
(	O
ER	O
)	O
,	O
late	O
(	O
LPR	O
)	O
,	O
and	O
rechallenge	O
reactions	O
(	O
RCRs	O
)	O
to	O
nasal	O
challenge	O
.	O

The	O
expression	O
of	O
CAPL	B-GENE
,	O
a	O
second	O
protein	O
involved	O
in	O
calcium	O
metabolism	O
,	O
was	O
only	O
moderately	O
elevated	O
in	O
the	O
doxorubicin	O
-	O
resistant	O
cells	O
.	O

The	O
central	O
region	O
of	O
the	O
sarcomere	O
,	O
coincident	O
with	O
the	O
M	O
line	O
,	O
was	O
selectively	O
labeled	O
with	O
antibodies	O
to	O
the	O
short	O
C	O
-	O
terminal	O
form	O
.	O

Despite	O
this	O
dependency	O
,	O
however	O
,	O
a	O
B	B-GENE
.	I-GENE
japonicum	I-GENE
fixK	I-GENE
mutant	I-GENE
did	O
not	O
have	O
the	O
phenotypic	O
characteristics	O
of	O
B	B-GENE
.	I-GENE
japonicum	I-GENE
fixL	I-GENE
and	O
fixJ	B-GENE
mutants	I-GENE
:	O
the	O
fixK	B-GENE
mutant	I-GENE
was	O
neither	O
Fix	O
-	O
in	O
symbiosis	O
with	O
soybean	O
plants	O
nor	O
defective	O
in	O
anaerobic	O
respiration	O
with	O
nitrate	O
as	O
the	O
terminal	O
electron	O
acceptor	O
.	O

ANL	O
-	O
7535	O
.	O

The	O
QCS	O
appears	O
comparable	O
with	O
the	O
MMSE	O
and	O
is	O
quicker	O
to	O
administer	O
.	O

We	O
used	O
high	O
-	O
resolution	O
ultrasound	O
to	O
characterize	O
postprandial	O
antral	O
excursion	O
characteristics	O
in	O
15	O
healthy	O
volunteers	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Human	B-GENE
PDNP3	I-GENE
is	O
expressed	O
in	O
glioma	O
cells	O
,	O
prostate	O
,	O
and	O
uterus	O
,	O
but	O
not	O
in	O
the	O
alimentary	O
tract	O
.	O

Epithelial	O
cells	O
had	O
abnormal	O
and	O
accelerated	O
exfoliation	O
which	O
resulted	O
in	O
multifocal	O
epithelial	O
defects	O
.	O

Tight	O
-	O
binding	O
band	O
structure	O
calculations	O
for	O
beta	O
-	O
MNX	O
(	O
M	O
=	O
Zr	O
,	O
X	O
=	O
Cl	O
,	O
Br	O
;	O
M	O
=	O
Hf	O
,	O
X	O
=	O
Cl	O
)	O
,	O
ZrCl	O
,	O
and	O
Y	O
(	O
2	O
)	O
C	O
(	O
2	O
)	O
Br	O
(	O
2	O
)	O
are	O
reported	O
.	O

Screening	O
of	O
a	O
human	O
foetal	O
brain	O
genomic	O
DNA	O
library	O
allowed	O
us	O
to	O
isolate	O
an	O
EcoRI	B-GENE
-	O
EcoRI	B-GENE
fragment	O
containing	O
6	O
kb	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
the	O
open	O
reading	O
frame	O
and	O
4	O
kb	O
of	O
the	O
3	O
'	O
-	O
flanking	O
region	O
of	O
the	O
alpha2C4	B-GENE
gene	I-GENE
.	O

The	O
psychosomatic	O
approach	O
to	O
temporomandibular	O
arthrosis	O

The	O
rate	O
of	O
decrease	O
of	O
PRA	O
after	O
REM	O
onset	O
closely	O
approximates	O
the	O
most	O
recent	O
estimations	O
of	O
PRA	O
half	O
-	O
life	O
,	O
which	O
suggests	O
that	O
REM	O
onset	O
is	O
associated	O
with	O
a	O
virtual	O
cessation	O
in	O
renin	B-GENE
production	O
.	O

Similarly	O
,	O
interfering	O
with	O
MEKK	B-GENE
,	O
which	O
lies	O
upstream	O
of	O
JNK1	B-GENE
,	O
using	O
a	O
dominant	O
negative	O
expression	O
vector	O
reduced	O
MMP	B-GENE
-	I-GENE
9	I-GENE
promoter	I-GENE
activity	O
over	O
the	O
same	O
concentration	O
range	O
which	O
repressed	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
-	O
thymidine	B-GENE
kinase	I-GENE
CAT	B-GENE
reporter	O
construct	O
.	O

There	O
was	O
no	O
difference	O
in	O
serum	B-GENE
albumin	I-GENE
and	O
transferrin	B-GENE
levels	O
,	O
but	O
serum	B-GENE
prealbumin	I-GENE
levels	O
in	O
the	O
group	O
fed	O
early	O
were	O
more	O
desirable	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
from	O
15	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
/	O
dl	O
to	O
28	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
mg	O
/	O
dl	O
vs	O
from	O
18	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
0	O
mg	O
/	O
dl	O
to	O
25	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
9	O
mg	O
/	O
dl	O
)	O
.	O

The	O
repeats	O
are	O
highly	O
conserved	O
both	O
within	O
a	O
given	O
element	O
as	O
well	O
as	O
between	O
different	O
members	O
of	O
the	O
family	O
(	O
less	O
than	O
10	O
%	O
divergence	O
)	O
.	O

Utility	O
of	O
thallium	O
-	O
201	O
scintigraphy	O
in	O
detecting	O
right	O
ventricular	O
dysfunction	O
in	O
pulmonary	O
embolism	O
.	O

CONCLUSIONS	O
:	O
The	O
system	O
developed	O
in	O
this	O
study	O
can	O
be	O
used	O
as	O
a	O
method	O
to	O
detect	O
air	O
-	O
trapping	O
during	O
TGI	O
.	O

The	O
carboxyl	O
-	O
terminal	O
75	O
amino	O
acids	O
of	O
the	O
two	O
proteins	O
contain	O
the	O
bHLH	O
motif	O
and	O
differ	O
from	O
each	O
other	O
by	O
only	O
three	O
conservative	O
amino	O
acid	O
changes	O
,	O
while	O
the	O
amino	O
-	O
terminal	O
portions	O
are	O
markedly	O
divergent	O
from	O
each	O
other	O
.	O

In	O
a	O
rat	O
model	O
of	O
SAH	O
,	O
we	O
assessed	O
BBB	O
changes	O
by	O
means	O
of	O
the	O
quantitative	O
[	O
14C	O
]	O
-	O
alpha	O
-	O
aminoisobutyric	O
acid	O
technique	O
.	O

Pollinosis	O
in	O
the	O
U	O
.	O
A	O
.	O
R	O
.	O

Northern	O
blot	O
analysis	O
of	O
enoyl	B-GENE
-	I-GENE
ACP	I-GENE
reductase	I-GENE
mRNA	I-GENE
steady	O
-	O
state	O
levels	O
during	O
seed	O
development	O
suggests	O
that	O
the	O
increase	O
in	O
enzyme	O
activity	O
during	O
the	O
phase	O
of	O
storage	O
lipid	O
accumulation	O
is	O
regulated	O
at	O
the	O
level	O
of	O
gene	O
expression	O
.	O

Time	O
between	O
tests	O
(	O
usually	O
less	O
than	O
one	O
year	O
)	O
did	O
not	O
affect	O
the	O
correlations	O
,	O
but	O
MMPI	O
response	O
-	O
set	O
variables	O
(	O
L	O
,	O
F	O
,	O
K	O
,	O
F	O
-	O
K	O
)	O
did	O
.	O

The	O
differences	O
in	O
binding	O
(	O
Kdapp	O
)	O
,	O
incorporation	O
,	O
and	O
extension	O
kinetics	O
of	O
8	O
-	O
oxo	O
-	O
dGTP	O
compared	O
to	O
normal	O
dNTP	O
incorporation	O
at	O
template	O
8	O
-	O
oxo	O
-	O
G	O
adducts	O
indicate	O
that	O
polymerase	O
fidelity	O
does	O
not	O
depend	O
solely	O
upon	O
the	O
overall	O
geometry	O
of	O
Watson	O
-	O
Crick	O
base	O
pairs	O
and	O
reflects	O
the	O
asymmetry	O
of	O
the	O
enzyme	O
active	O
site	O
.	O

This	O
constant	O
expression	O
profile	O
,	O
coupled	O
with	O
the	O
observation	O
that	O
over	O
-	O
expression	O
of	O
mSin3A	B-GENE
does	O
not	O
augment	O
the	O
anti	B-GENE
-	I-GENE
Myc	I-GENE
activity	O
of	O
Mxi1	B-GENE
-	O
SR	O
in	O
the	O
rat	O
embryo	O
fibroblast	O
(	O
REF	O
)	O
transformation	O
assay	O
,	O
suggests	O
that	O
mSin3A	B-GENE
is	O
not	O
a	O
limiting	O
factor	O
in	O
the	O
regulation	O
of	O
Myc	B-GENE
superfamily	I-GENE
function	O
.	O

The	O
sequences	O
at	O
-	O
10	O
and	O
-	O
35	O
relative	O
to	O
the	O
transcriptional	O
starting	O
site	O
showed	O
55	O
%	O
homology	O
with	O
the	O
consensus	O
sequences	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
sigma	I-GENE
70	I-GENE
-	I-GENE
type	I-GENE
promoter	I-GENE
.	O

The	O
results	O
were	O
subjected	O
to	O
analysis	O
of	O
23	O
autopsies	O
carried	O
out	O
in	O
children	O
dying	O
of	O
intoxication	O
with	O
Amanita	O
phalloides	O
.	O

METHODS	O
:	O
The	O
Die	O
Deutsche	O
Diabetes	O
Dialyse	O
Studie	O
is	O
a	O
prospective	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
that	O
tests	O
the	O
hypothesis	O
that	O
atorvastatin	O
,	O
a	O
hydroxymethyl	B-GENE
-	I-GENE
glutaryl	I-GENE
coenzyme	I-GENE
A	I-GENE
reductase	I-GENE
inhibitor	O
,	O
decreases	O
the	O
rate	O
of	O
cardiovascular	O
mortality	O
and	O
of	O
nonfatal	O
myocardial	O
infarction	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
have	O
been	O
on	O
hemodialysis	O
treatment	O
for	O
no	O
more	O
than	O
two	O
years	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
serum	O
amiodarone	O
or	O
desethylamiodarone	O
levels	O
and	O
dosage	O
of	O
amiodarone	O
.	O

The	O
effect	O
of	O
monaural	O
middle	O
ear	O
destruction	O
on	O
postnatal	O
development	O
of	O
mouse	O
inferior	O
colliculus	O
.	O

This	O
unusual	O
behaviour	O
may	O
be	O
explained	O
by	O
the	O
18	B-GENE
amino	I-GENE
acid	I-GENE
-	I-GENE
long	I-GENE
CDR	I-GENE
-	I-GENE
H3	I-GENE
and	O
could	O
be	O
of	O
value	O
in	O
the	O
design	O
of	O
'	O
single	O
domain	O
'	O
antibodies	O
.	O

A	O
definitive	O
answer	O
to	O
the	O
question	O
must	O
come	O
from	O
large	O
scale	O
mortality	O
studies	O
of	O
patients	O
in	O
whom	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
thrombolysis	O
is	O
not	O
unacceptably	O
high	O
,	O
in	O
whom	O
electrocardiographic	O
criteria	O
of	O
infarction	O
are	O
unequivocal	O
,	O
and	O
in	O
whom	O
treatment	O
can	O
be	O
initiated	O
early	O
after	O
the	O
onset	O
of	O
symptoms	O
with	O
regimens	O
that	O
will	O
induce	O
not	O
only	O
early	O
recanalization	O
,	O
but	O
also	O
sustained	O
patency	O
in	O
infarct	O
-	O
related	O
arteries	O
.	O

Parameters	O
of	O
sperm	O
quality	O
were	O
evaluated	O
before	O
and	O
after	O
freezing	O
/	O
thawing	O
.	O

It	O
has	O
also	O
been	O
previously	O
demonstrated	O
that	O
LPS	O
treatment	O
of	O
splenic	O
B	O
cells	O
from	O
athymic	O
mice	O
results	O
in	O
a	O
decrease	O
in	O
steady	O
state	O
mRNA	O
encoding	O
the	O
A	B-GENE
alpha	I-GENE
class	I-GENE
II	I-GENE
protein	I-GENE
.	O

Amongst	O
53	O
"	O
inoperable	O
"	O
(	O
T4	O
,	O
N0	O
,	O
N1	O
,	O
T	O
.	O
,	O
N2	O
,	O
N3	O
)	O
cases	O
,	O
5	O
(	O
10	O
%	O
)	O
had	O
a	O
positive	O
scan	O
and	O
5	O
a	O
doubtful	O
scan	O
.	O

Chemical	O
structure	O
of	O
antibiotic	O
SF	O
-	O
837	O
.	O

Aspirin	O
therapy	O
in	O
the	O
rheumatic	O
diseases	O
.	O

Is	O
conventional	O
sperm	O
analysis	O
of	O
any	O
use	O
?	O

The	O
computerised	O
records	O
of	O
867	O
couples	O
were	O
used	O
to	O
investigate	O
the	O
prognostic	O
significance	O
of	O
semen	O
volume	O
,	O
motility	O
,	O
density	O
and	O
morphology	O
.	O

It	O
was	O
observed	O
that	O
muscle	O
infarction	O
in	O
the	O
IPC	O
(	O
24	O
+	O
/	O
-	O
2	O
%	O
)	O
and	O
preischemic	O
LMK	O
(	O
21	O
+	O
/	O
-	O
2	O
%	O
)	O
groups	O
were	O
smaller	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
that	O
in	O
the	O
control	O
(	O
42	O
+	O
/	O
-	O
2	O
%	O
)	O
.	O

High	O
-	O
affinity	O
binding	O
was	O
also	O
observed	O
with	O
recombinant	B-GENE
SH2	I-GENE
domains	I-GENE
from	O
v	B-GENE
-	I-GENE
src	I-GENE
and	O
v	B-GENE
-	I-GENE
fps	I-GENE
,	O
raising	O
the	O
possibility	O
of	O
protein	O
-	O
protein	O
interactions	O
between	O
various	O
members	O
of	O
the	O
cytoplasmic	B-GENE
PTK	I-GENE
family	I-GENE
.	O

Mutational	O
analysis	O
of	O
the	O
putative	O
effector	O
domain	O
of	O
the	O
GTP	B-GENE
-	I-GENE
binding	I-GENE
Ypt1	I-GENE
protein	I-GENE
in	O
yeast	O
suggests	O
specific	O
regulation	O
by	O
a	O
novel	O
GAP	B-GENE
activity	O
.	O

The	O
interaction	O
obtained	O
with	O
DBM	O
scores	O
was	O
further	O
qualified	O
by	O
a	O
three	O
-	O
way	O
interaction	O
that	O
limited	O
this	O
pattern	O
to	O
participants	O
scoring	O
higher	O
on	O
self	O
-	O
deception	O
.	O

The	O
broad	O
range	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitor	O
genistein	O
and	O
the	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
inhibitors	O
wortmannin	O
and	O
LY	O
294002	O
(	O
2	O
-	O
(	O
4	O
-	O
morpholinyl	O
)	O
-	O
8	O
-	O
phenyl	O
-	O
4H	O
-	O
1	O
-	O
benzopyran	O
-	O
4	O
-	O
one	O
)	O
also	O
blocked	O
adenosine	B-GENE
A3	I-GENE
receptor	I-GENE
stimulation	O
of	O
p42	B-GENE
/	O
p44	B-GENE
MAPK	O
.	O

Surprisingly	O
,	O
although	O
Mist1	B-GENE
binds	O
to	O
E	O
-	O
boxes	O
in	O
vivo	O
,	O
the	O
Mist1	B-GENE
protein	I-GENE
lacks	O
a	O
functional	O
transcription	O
activation	O
domain	O
.	O

As	O
exogenously	O
expressed	O
PKR	B-GENE
can	O
form	O
heterodimers	O
with	O
endogenous	B-GENE
PKR	I-GENE
,	O
the	O
results	O
obtained	O
on	O
the	O
functional	O
characterization	O
of	O
mutant	O
forms	O
of	O
PKR	B-GENE
have	O
been	O
taken	O
with	O
caution	O
.	O

Orlistat	O
is	O
a	O
specific	O
lipase	B-GENE
inhibitor	O
that	O
impairs	O
fat	O
absorption	O
,	O
thereby	O
reducing	O
fat	O
uptake	O
.	O

The	O
metalloproteinase	B-GENE
mediating	O
Met	B-GENE
cleavage	O
was	O
specifically	O
inhibited	O
by	O
the	O
tissue	B-GENE
inhibitor	I-GENE
of	I-GENE
metalloproteinases	I-GENE
(	I-GENE
TIMP	I-GENE
)	I-GENE
-	I-GENE
3	I-GENE
,	O
but	O
not	O
by	O
TIMP	B-GENE
-	I-GENE
1	I-GENE
or	O
TIMP	B-GENE
-	I-GENE
2	I-GENE
.	O

This	O
demonstrates	O
a	O
relative	O
independence	O
of	O
the	O
given	O
synchronizer	O
of	O
rhythmicity	O
at	O
a	O
tissue	O
level	O
from	O
any	O
influence	O
of	O
the	O
higher	O
regulatory	O
center	O
.	O

It	O
is	O
also	O
conceivable	O
that	O
elevated	O
insulin	B-GENE
levels	O
may	O
cause	O
hypertriglyceridaemia	O
and	O
possibly	O
other	O
abnormalities	O
of	O
lipid	O
metabolism	O
.	O

Flicker	O
thresholds	O
were	O
measured	O
from	O
1	O
to	O
40	O
Hz	O
with	O
a	O
vertical	O
-	O
line	O
target	O
used	O
for	O
the	O
asynchrony	O
thresholds	O
.	O

The	O
clr1	B-GENE
locus	I-GENE
regulates	O
the	O
expression	O
of	O
the	O
cryptic	B-GENE
mating	I-GENE
-	I-GENE
type	I-GENE
loci	I-GENE
of	I-GENE
fission	I-GENE
yeast	I-GENE
.	O

Use	O
of	O
ELISAs	O
for	O
the	O
diagnosis	O
of	O
canine	O
atopy	O
.	O

A	O
clinical	O
study	O
.	O

METHODS	O
.	O

Instead	O
,	O
HBx	B-GENE
is	O
shown	O
to	O
activate	O
the	O
cyclin	B-GENE
A	I-GENE
promoter	I-GENE
,	O
induce	O
cyclin	B-GENE
A	I-GENE
-	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
2	I-GENE
complexes	O
,	O
and	O
promote	O
cycling	O
of	O
growth	O
-	O
arrested	O
cells	O
into	O
G1	O
through	O
a	O
pathway	O
involving	O
activation	O
of	O
Src	B-GENE
tyrosine	I-GENE
kinases	I-GENE
.	O

Growth	B-GENE
hormone	I-GENE
exerts	O
its	O
effects	O
on	O
the	O
ovarian	O
follicular	O
cycle	O
directly	O
or	O
by	O
local	O
production	O
of	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
1	I-GENE
(	O
IGF	B-GENE
-	I-GENE
1	I-GENE
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
the	O
ESRD	O
treatment	O
modality	O
on	O
the	O
quality	O
of	O
life	O
in	O
patients	O
with	O
Type	O
I	O
(	O
insulin	B-GENE
-	O
dependent	O
)	O
diabetes	O
mellitus	O
.	O

The	O
subjects	O
were	O
started	O
on	O
indomethacin	O
25	O
mg	O
thrice	O
daily	O
.	O

A	O
Buddhist	O
view	O
of	O
abortion	O
.	O

The	O
arterial	O
blood	O
pressure	O
was	O
measured	O
by	O
using	O
bloody	O
method	O
in	O
anesthizied	O
animals	O
.	O

After	O
15	O
min	O
of	O
hemorrhage	O
the	O
cardiovascular	O
parameters	O
were	O
the	O
same	O
in	O
fed	O
and	O
starved	O
animals	O
,	O
but	O
at	O
45	O
min	O
striking	O
differences	O
were	O
observed	O
.	O

Decidual	B-GENE
/	I-GENE
trophoblast	I-GENE
prolactin	I-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
:	O
characterization	O
of	O
gene	O
structure	O
and	O
cell	O
-	O
specific	O
expression	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
was	O
used	O
to	O
investigate	O
the	O
physical	O
distribution	O
and	O
revealed	O
that	O
both	O
retrotransposon	O
families	O
are	O
present	O
on	O
all	O
sugar	O
beet	O
chromosomes	O
and	O
largely	O
excluded	O
from	O
chromosomal	O
regions	O
harbouring	O
the	O
18S	B-GENE
-	O
5	B-GENE
.	I-GENE
8S	I-GENE
-	O
25S	B-GENE
rRNA	O
genes	O
.	O

Plasma	O
NE	O
and	O
E	O
increased	O
to	O
significantly	O
higher	O
values	O
after	O
15	O
min	O
in	O
the	O
young	O
subjects	O
:	O
1	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
18	O
vs	O
.	O

An	O
insertion	O
sequence	O
element	O
(	O
IS1170	O
)	O
was	O
identified	O
upstream	O
of	O
the	O
nimC	B-GENE
gene	I-GENE
.	O

The	O
organelles	O
synthesize	O
their	O
own	O
set	O
of	O
Fe	B-GENE
/	I-GENE
S	I-GENE
proteins	I-GENE
,	O
and	O
they	O
initiate	O
the	O
generation	O
of	O
extramitochondrial	B-GENE
Fe	I-GENE
/	I-GENE
S	I-GENE
proteins	I-GENE
.	O

Most	O
significantly	O
,	O
the	O
cyclin	B-GENE
E	I-GENE
-	O
Cdk2	B-GENE
complex	O
is	O
maximally	O
active	O
at	O
the	O
G1	O
/	O
S	O
transition	O
,	O
and	O
overexpression	O
of	O
cyclin	B-GENE
E	I-GENE
decreases	O
the	O
time	O
it	O
takes	O
the	O
cell	O
to	O
complete	O
G1	O
and	O
enter	O
S	O
phase	O
.	O

A	O
genomic	O
clone	O
of	O
the	O
chicken	B-GENE
osteopontin	I-GENE
-	I-GENE
encoding	I-GENE
gene	I-GENE
(	O
opn	B-GENE
)	O
was	O
isolated	O
and	O
found	O
to	O
be	O
organized	O
as	O
follows	O
:	O
an	O
untranslated	O
5	O
'	O
exon	O
;	O
a	O
signal	O
peptide	O
;	O
a	O
recognition	O
sequence	O
for	O
phosphorylation	O
by	O
casein	B-GENE
kinase	I-GENE
II	I-GENE
;	O
a	O
domain	O
containing	O
a	O
possible	O
O	O
-	O
linkage	O
site	O
for	O
glycosylation	O
;	O
a	O
second	O
casein	B-GENE
kinase	I-GENE
II	I-GENE
phosphorylation	I-GENE
site	I-GENE
;	O
an	O
exon	O
containing	O
three	O
functional	O
regions	O
,	O
the	O
poly	O
-	O
Asp	O
sequence	O
of	O
seven	O
consecutive	O
Asp	O
residues	O
,	O
the	O
RGD	B-GENE
integrin	I-GENE
recognition	I-GENE
site	I-GENE
and	O
a	O
potential	O
N	O
-	O
linkage	O
site	O
for	O
glycosylation	O
;	O
and	O
a	O
large	O
C	O
-	O
terminal	O
exon	O
which	O
also	O
contains	O
a	O
potential	O
N	O
-	O
linkage	O
site	O
for	O
glycosylation	O
.	O

However	O
,	O
neither	O
SF	B-GENE
-	I-GENE
1	I-GENE
nor	O
NGF	B-GENE
-	I-GENE
IB	I-GENE
alone	O
,	O
binding	O
as	O
monomers	O
,	O
increases	O
transcription	O
.	O

Satisfactory	O
correlation	O
was	O
also	O
obtained	O
between	O
the	O
in	O
vivo	O
and	O
the	O
in	O
vitro	O
results	O
.	O

Structural	O
organization	O
of	O
the	O
human	B-GENE
Elk1	I-GENE
gene	I-GENE
and	O
its	O
processed	O
pseudogene	B-GENE
Elk2	I-GENE
.	O

After	O
cumulative	O
occlusions	O
of	O
15	O
,	O
30	O
,	O
45	O
,	O
and	O
90	O
min	O
,	O
transmural	O
needle	O
biopsies	O
were	O
taken	O
from	O
the	O
ischemic	O
area	O
to	O
be	O
analyzed	O
for	O
adenine	O
nucleotides	O
,	O
nucleosides	O
,	O
creatine	O
phosphate	O
,	O
and	O
ultrastructural	O
changes	O
.	O

The	O
prevalence	O
of	O
ocular	O
/	O
adnexal	O
SCC	O
was	O
significantly	O
greater	O
for	O
all	O
hair	O
colors	O
when	O
compared	O
with	O
bay	O
,	O
brown	O
,	O
or	O
black	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Seven	O
patients	O
were	O
without	O
a	O
syndromic	O
diagnosis	O
.	O

In	O
treatments	O
R1	O
and	O
R2	O
,	O
feed	O
quality	O
was	O
restricted	O
by	O
withholding	O
concentrates	O
for	O
3	O
and	O
4	O
.	O
5	O
mo	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
while	O
GCN1	B-GENE
is	O
required	O
in	O
vivo	O
for	O
phosphorylation	O
of	O
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
by	O
GCN2	B-GENE
,	O
cell	O
extracts	O
from	O
gcn1	B-GENE
delta	I-GENE
strains	O
contained	O
wild	O
-	O
type	O
levels	O
of	O
GCN2	B-GENE
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
-	O
kinase	O
activity	O
.	O

SCOF	B-GENE
-	I-GENE
1	I-GENE
localized	O
to	O
the	O
nucleus	O
but	O
did	O
not	O
bind	O
directly	O
to	O
either	O
C	O
-	O
repeat	O
/	O
dehydration	O
(	O
CRT	O
/	O
DRE	O
)	O
or	O
ABA	O
responsive	O
element	O
(	O
ABRE	O
)	O
,	O
cis	O
-	O
acting	O
DNA	O
regulatory	O
elements	O
present	O
in	O
COR	B-GENE
gene	I-GENE
promoters	I-GENE
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
we	O
suggest	O
that	O
the	O
acceptor	O
peptide	O
binds	O
the	O
transferase	O
in	O
a	O
beta	O
-	O
like	O
conformation	O
and	O
that	O
penultimate	O
residue	O
side	O
chain	O
steric	O
interactions	O
may	O
play	O
a	O
role	O
in	O
determining	O
extent	O
that	O
a	O
given	O
Ser	O
or	O
Thr	O
is	O
glycosylated	O
.	O

The	O
concentration	O
of	O
vitamin	O
B1	O
,	O
B2	O
and	O
B6	O
are	O
found	O
to	O
be	O
9	O
.	O
96	O
,	O
9	O
.	O
92	O
and	O
3	O
.	O
01	O
mg	O
,	O
respectively	O
in	O
240	O
mg	O
of	O
capsule	O
powder	O
of	O
a	O
standard	O
company	O
(	O
name	O
has	O
not	O
been	O
disclosed	O
due	O
to	O
secrecy	O
purpose	O
)	O
.	O

Polymorphisms	O
in	O
the	O
CCR5	B-GENE
genes	I-GENE
of	O
African	O
green	O
monkeys	O
and	O
mice	O
implicate	O
specific	O
amino	O
acids	O
in	O
infections	O
by	O
simian	O
and	O
human	O
immunodeficiency	O
viruses	O
.	O

Furthermore	O
,	O
we	O
detect	O
hCoch	B-GENE
-	I-GENE
5B2	I-GENE
on	O
three	O
overlapping	O
YACs	O
,	O
two	O
of	O
which	O
also	O
contain	O
one	O
of	O
the	O
markers	O
linked	O
to	O
DFNA9	B-GENE
.	O

mCoch	B-GENE
-	I-GENE
5B2	I-GENE
was	O
genetically	O
mapped	O
in	O
the	O
mouse	O
to	O
chromosome	O
12	O
,	O
in	O
a	O
region	O
of	O
homologous	O
synteny	O
with	O
human	O
14q11	O
.	O
2	O
-	O
q13	O
,	O
which	O
contains	O
the	O
asp1	B-GENE
(	O
audiogenic	B-GENE
seizure	I-GENE
prone	I-GENE
)	O
locus	O
in	O
the	O
mouse	O
.	O

Absence	O
of	O
nitroso	O
formation	O
from	O
(	O
14C	O
)	O
methomyl	O
and	O
sodium	O
nitrite	O
under	O
simulated	O
stomach	O
conditions	O
.	O

Although	O
no	O
detectable	O
phenotypes	O
are	O
associated	O
with	O
a	O
disruption	O
allele	O
of	O
ABP1	B-GENE
,	O
mutations	O
that	O
create	O
a	O
requirement	O
for	O
this	O
protein	O
have	O
now	O
been	O
isolated	O
in	O
the	O
previously	O
identified	O
gene	B-GENE
SAC6	I-GENE
and	O
in	O
two	O
new	O
genes	O
,	O
SLA1	B-GENE
and	O
SLA2	B-GENE
.	O

The	O
local	O
median	O
scores	O
(	O
ranges	O
)	O
of	O
the	O
above	O
tests	O
were	O
as	O
follows	O
-	O
AMT	O
:	O
9	O
(	O
6	O
-	O
10	O
)	O
;	O
CMMS	O
:	O
25	O
(	O
16	O
-	O
28	O
)	O
;	O
SBT	O
:	O
2	O
(	O
0	O
-	O
10	O
)	O
;	O
WL	O
-	O
i	O
:	O
17	O
(	O
8	O
-	O
27	O
)	O
;	O
WL	O
-	O
d	O
:	O
5	O
(	O
0	O
-	O
10	O
)	O
;	O
WL	O
-	O
r	O
:	O
9	O
(	O
1	O
-	O
10	O
)	O
;	O
ST	O
:	O
13	O
(	O
6	O
-	O
25	O
)	O
;	O
BNT	O
:	O
14	O
(	O
10	O
-	O
15	O
)	O
;	O
CPT	O
:	O
1	O
(	O
0	O
-	O
3	O
)	O
;	O
BDT	O
:	O
19	O
(	O
0	O
-	O
42	O
)	O
;	O
OAT	O
:	O
20	O
(	O
3	O
-	O
33	O
)	O
.	O

Antigen	O
dose	O
-	O
response	O
curves	O
were	O
drawn	O
,	O
and	O
the	O
cumulative	O
dose	O
required	O
for	O
a	O
35	O
%	O
reduction	O
in	O
specific	O
airway	O
conductance	O
was	O
calculated	O
and	O
designated	O
Provocation	O
Dose	O
(	O
PD35	O
)	O
.	O

Cross	O
-	O
talk	O
between	O
transcription	O
factors	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
in	O
the	O
transcriptional	O
regulation	O
of	O
genes	O
.	O

Elective	O
replacement	O
of	O
the	O
aortic	O
root	O
in	O
Marfan	O
'	O
s	O
syndrome	O
.	O

The	O
detergent	O
-	O
solubilized	O
complex	O
oxidizes	O
caldariella	O
quinol	O
at	O
high	O
rates	O
and	O
is	O
completely	O
inhibited	O
by	O
cyanide	O
and	O
by	O
quinolone	O
analogs	O
,	O
potent	O
inhibitors	O
of	O
quinol	B-GENE
oxidases	I-GENE
.	O

We	O
have	O
characterized	O
a	O
new	O
cDNA	O
,	O
33k	O
-	O
6	O
,	O
potentially	O
encoding	O
a	O
tobacco	B-GENE
33	I-GENE
kDa	I-GENE
chloroplast	I-GENE
RNP	I-GENE
(	I-GENE
cp33	I-GENE
)	I-GENE
homologue	I-GENE
.	O

The	O
regions	O
encoding	O
the	O
mature	O
proteinases	O
were	O
cloned	O
into	O
an	O
expression	O
vector	O
and	O
recombinant	O
protein	O
produced	O
in	O
Escherichia	O
coli	O
.	O

Furthermore	O
,	O
CL100	B-GENE
suppresses	O
the	O
[	O
val12	O
]	O
ras	B-GENE
-	O
induced	O
activation	O
of	O
MAP	B-GENE
kinase	I-GENE
in	O
a	O
cell	O
-	O
free	O
system	O
from	O
Xenopus	O
oocytes	O
.	O

The	O
Xenopus	B-GENE
homeobox	I-GENE
gene	I-GENE
twin	I-GENE
mediates	O
Wnt	B-GENE
induction	O
of	O
goosecoid	B-GENE
in	O
establishment	O
of	O
Spemann	O
'	O
s	O
organizer	O
.	O

Between	O
1988	O
and	O
1994	O
,	O
data	O
from	O
3	O
large	O
sites	O
revealed	O
a	O
3	O
-	O
5	O
fold	O
increase	O
in	O
the	O
prevalence	O
of	O
antidepressant	O
(	O
ATD	O
)	O
treatment	O
for	O
U	O
.	O
S	O
.	O
youths	O
aged	O
2	O
-	O
19	O
years	O
.	O

The	O
vaccinia	O
virus	O
D6R	B-GENE
open	O
reading	O
frame	O
encodes	O
the	O
small	O
subunit	O
of	O
the	O
heterodimeric	O
vaccinia	B-GENE
virus	I-GENE
early	I-GENE
transcription	I-GENE
factor	I-GENE
(	O
VETF	B-GENE
)	O
that	O
activates	O
transcription	O
of	O
early	B-GENE
genes	I-GENE
in	O
vitro	O
.	O

The	O
Sensititre	O
MIC	O
panels	O
containing	O
meropenem	O
offer	O
a	O
convenient	O
and	O
valid	O
alternative	O
to	O
the	O
NCCLS	O
reference	O
method	O
for	O
the	O
susceptibility	O
testing	O
of	O
potential	O
pathogens	O
likely	O
to	O
be	O
recovered	O
from	O
mixed	O
infections	O
.	O

Recognition	O
of	O
DNA	O
by	O
single	O
-	O
chain	O
derivatives	O
of	O
the	O
phage	O
434	O
repressor	O
:	O
high	O
affinity	O
binding	O
depends	O
on	O
both	O
the	O
contacted	O
and	O
non	O
-	O
contacted	O
base	O
pairs	O
.	O

The	O
paper	O
calls	O
for	O
standardized	O
question	O
formats	O
and	O
a	O
centralized	O
body	O
to	O
monitor	O
changes	O
in	O
these	O
parameters	O
of	O
sexual	O
behaviour	O
.	O

We	O
show	O
that	O
GCNF	B-GENE
binds	O
to	O
one	O
of	O
the	O
two	O
DRO	O
sequences	O
in	O
the	O
Prm1	B-GENE
promoter	I-GENE
,	O
and	O
to	O
the	O
DRO	O
sequence	O
in	O
the	O
Prm2	B-GENE
promoter	I-GENE
in	O
a	O
specific	O
manner	O
.	O

139La	O
NQR	O
relaxation	O
and	O
microSR	O
study	O
of	O
Zn	O
-	O
doping	O
effects	O
in	O
La2CuO4	O
.	O

The	O
data	O
also	O
suggest	O
that	O
gamma	B-GENE
CACCC	I-GENE
box	I-GENE
binding	I-GENE
factors	I-GENE
mediate	O
LCR	B-GENE
-	I-GENE
gamma	I-GENE
interactions	O
which	O
normally	O
enhance	O
gamma	B-GENE
-	I-GENE
globin	I-GENE
and	O
suppress	O
beta	B-GENE
-	I-GENE
globin	I-GENE
gene	I-GENE
expression	O
in	O
fetal	O
erythroid	O
cells	O
.	O

However	O
,	O
the	O
in	O
vivo	O
attachment	O
strength	O
of	O
the	O
CSTi	O
-	O
2	O
coating	O
was	O
comparable	O
both	O
to	O
CSTi	O
-	O
1	O
and	O
to	O
an	O
HA	O
-	O
coated	O
control	O
after	O
8	O
weeks	O
.	O

Octamer	O
recognition	O
is	O
mediated	O
by	O
the	O
POU	B-GENE
domain	O
,	O
a	O
conserved	O
structural	O
motif	O
which	O
-	O
-	O
like	O
the	O
zinc	O
finger	O
and	O
leucine	O
zipper	O
-	O
-	O
defines	O
a	O
family	O
of	O
related	O
transcription	O
factors	O
.	O

All	O
testosterone	O
treatments	O
raised	O
plasma	O
testosterone	O
concentrations	O
above	O
control	O
and	O
pretreatment	O
levels	O
(	O
testosterone	O
and	O
synovex	O
+	O
testosterone	O
>	O
synovex	O
>	O
control	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Lifestyle	O
characteristics	O
were	O
ascertained	O
by	O
a	O
self	O
-	O
administered	O
questionnaire	O
.	O

The	O
major	O
promoter	O
element	O
of	O
the	O
Xenopus	B-GENE
laevis	I-GENE
5S	I-GENE
RNA	I-GENE
gene	I-GENE
is	O
located	O
within	O
the	O
transcribed	O
region	O
of	O
the	O
gene	O
and	O
forms	O
the	O
binding	O
site	O
for	O
the	O
transcription	O
initiation	O
factor	O
TFIIIA	B-GENE
.	O

During	O
each	O
step	O
of	O
the	O
pulse	O
infusion	O
the	O
osteocalcin	B-GENE
responses	O
to	O
changes	O
in	O
CaI	O
in	O
general	O
were	O
parallel	O
to	O
the	O
changes	O
in	O
PTH	B-GENE
(	O
r	O
=	O
0	O
.	O
462	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
were	O
inversely	O
correlated	O
to	O
CaI	O
(	O
r	O
=	O
-	O
0	O
.	O
562	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

The	O
gamma	B-GENE
-	I-GENE
GCS	I-GENE
gene	I-GENE
is	O
expressed	O
ubiquitously	O
and	O
induced	O
coordinately	O
with	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
:	I-GENE
quinone	I-GENE
oxidoreductase	I-GENE
(	I-GENE
1	I-GENE
)	I-GENE
(	O
NQO1	B-GENE
)	O
and	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
Ya	I-GENE
(	O
GST	B-GENE
Ya	I-GENE
)	O
in	O
response	O
to	O
xenobiotics	O
and	O
antioxidants	O
.	O

Interestingly	O
,	O
the	O
expression	O
of	O
Id4	B-GENE
in	O
Sertoli	O
cells	O
is	O
only	O
detectable	O
after	O
stimulation	O
with	O
FSH	B-GENE
or	O
cAMP	O
.	O

We	O
determined	O
their	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
and	O
found	O
that	O
these	O
polypeptides	O
were	O
CotT	B-GENE
,	O
YeeK	B-GENE
,	O
YxeE	B-GENE
,	O
CotF	B-GENE
,	O
YrbA	B-GENE
(	O
31	O
and	O
45	O
kDa	O
)	O
,	O
and	O
SpoIVA	B-GENE
,	O
respectively	O
.	O

The	O
effect	O
of	O
betamethasone	O
on	O
duodenal	O
calcium	O
absorption	O
and	O
1	O
,	O
25	O
-	O
dihydroxy	O
vitamin	O
D3	O
production	O
in	O
the	O
chick	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
established	O
that	O
serine	O
phosphorylation	O
of	O
STAT5a	B-GENE
transactivation	O
domain	O
,	O
via	O
the	O
MAPK	B-GENE
pathway	O
,	O
is	O
a	O
means	O
of	O
modifying	O
GH	B-GENE
-	O
induced	O
transcriptional	O
activation	O
.	O

ES	O
cells	O
in	O
which	O
the	O
gene	O
for	O
the	O
erythroid	O
transcription	O
factor	O
GATA	B-GENE
-	I-GENE
1	I-GENE
has	O
been	O
disrupted	O
fail	O
to	O
produce	O
mature	O
erythroid	O
cells	O
either	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

Two	O
conserved	O
motifs	O
,	O
W89RKRRY94	O
and	O
P156KKIKP161	O
,	O
seemed	O
to	O
act	O
as	O
nuclear	O
addressing	O
signals	O
.	O

It	O
is	O
concluded	O
that	O
the	O
predominant	O
action	O
of	O
LSD	O
on	O
the	O
female	O
copulatory	O
response	O
is	O
not	O
mediated	O
by	O
increased	O
dopamine	B-GENE
receptor	I-GENE
activity	O
but	O
that	O
the	O
LSD	O
effect	O
might	O
be	O
modulated	O
by	O
decreased	O
dopaminergic	O
activity	O
.	O

Therefore	O
,	O
in	O
VDR	B-GENE
-	O
mediated	O
transcriptional	O
activation	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
VDR	B-GENE
alters	O
the	O
conformation	O
of	O
the	O
ligand	O
binding	O
domain	O
such	O
that	O
it	O
:	O
(	O
i	O
)	O
engages	O
in	O
strong	O
heterodimerization	O
with	O
RXR	B-GENE
to	O
facilitate	O
VDRE	O
binding	O
,	O
(	O
ii	O
)	O
influences	O
the	O
RXR	B-GENE
ligand	I-GENE
binding	I-GENE
domain	I-GENE
such	O
that	O
it	O
is	O
resistant	O
to	O
the	O
binding	O
of	O
9	O
-	O
cis	O
RA	O
but	O
active	O
in	O
recruiting	O
coactivator	O
to	O
its	O
AF	O
-	O
2	O
and	O
(	O
iii	O
)	O
presents	O
the	O
AF	O
-	O
2	O
region	O
in	O
VDR	B-GENE
for	O
coactivator	O
association	O
.	O

In	O
patients	O
,	O
750	O
mL	O
of	O
saline	O
lowered	O
DL	O
(	O
CO	O
)	O
(	O
-	O
8	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
versus	O
baseline	O
)	O
,	O
D	O
(	O
M	O
)	O
(	O
-	O
10	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
versus	O
baseline	O
)	O
,	O
aldosterone	O
(	O
-	O
29	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
versus	O
baseline	O
)	O
,	O
renin	B-GENE
(	O
-	O
52	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
versus	O
baseline	O
)	O
,	O
and	O
hematocrit	O
(	O
-	O
6	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
versus	O
baseline	O
)	O
and	O
increased	O
V	O
(	O
C	O
)	O
(	O
20	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
versus	O
baseline	O
)	O
,	O
without	O
changing	O
rap	O
and	O
wpp	O
.	O

We	O
have	O
previously	O
identified	O
LIT1	B-GENE
,	O
a	O
paternally	O
expressed	O
antisense	O
RNA	O
within	O
the	O
KvLQT1	B-GENE
locus	I-GENE
through	O
a	O
positional	O
screening	O
approach	O
using	O
human	O
monochromosomal	O
hybrids	O
.	O

A	O
series	O
of	O
deletion	O
mutants	O
was	O
expressed	O
transiently	O
in	O
two	O
human	O
hepatocytes	O
,	O
HepG2	O
and	O
PLC	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
FlaB2	B-GENE
polypeptide	I-GENE
was	O
92	O
%	O
identical	O
to	O
that	O
of	O
T	B-GENE
.	I-GENE
pallidum	I-GENE
FlaB2	I-GENE
,	O
with	O
a	O
76	O
%	O
identity	O
at	O
the	O
nucleotide	O
level	O
.	O

Comparative	O
analyses	O
indicate	O
that	O
the	O
5	O
'	O
-	O
peripheral	O
domain	O
exhibits	O
a	O
75	O
-	O
bp	O
length	O
polymorphism	O
near	O
sequences	O
associated	O
with	O
the	O
termination	O
of	O
the	O
H	O
-	O
strand	O
replication	O
.	O

The	O
survival	O
of	O
patients	O
with	O
a	O
short	O
bowel	O
,	O
even	O
if	O
they	O
need	O
long	O
-	O
term	O
parenteral	O
nutrition	O
,	O
is	O
good	O
.	O

Thus	O
,	O
cross	O
-	O
resistance	O
between	O
fluoroquinolones	O
was	O
shown	O
for	O
both	O
enterococci	O
and	O
MRSA	O
.	O

The	O
5	O
'	O
ends	O
of	O
the	O
P	B-GENE
and	O
O	B-GENE
gene	I-GENE
mRNAs	I-GENE
are	O
separated	O
by	O
109	O
nucleotide	O
pairs	O
in	O
the	O
DNA	O
template	O
.	O

Using	O
community	O
development	O
approaches	O
.	O

Biol	O
.	O

We	O
have	O
cloned	O
the	O
cDNA	O
for	O
the	O
SLBP	B-GENE
from	O
humans	O
,	O
mice	O
,	O
and	O
frogs	O
,	O
using	O
the	O
recently	O
developed	O
yeast	O
three	O
-	O
hybrid	O
system	O
.	O

Along	O
with	O
these	O
species	O
,	O
F	O
.	O
graminearum	O
group	O
2	O
(	O
ZON	O
,	O
DON	O
and	O
/	O
or	O
3AcDON	O
or	O
15AcDON	O
)	O
;	O
F	O
.	O
chlamydosporum	O
;	O
F	O
.	O
acuminatum	O
(	O
type	O
-	O
A	O
trichothecene	O
derivatives	O
)	O
;	O
and	O
F	O
.	O
semitectum	O
were	O
often	O
found	O
to	O
be	O
associated	O
.	O

TGF	B-GENE
-	I-GENE
beta1	I-GENE
induced	O
phosphorylation	O
of	O
Smad2	B-GENE
and	O
Smad3	B-GENE
in	O
Mv1Lu	O
mink	O
lung	O
epithelial	O
cells	O
.	O

There	O
is	O
little	O
supportive	O
evidence	O
that	O
ACE	B-GENE
inhibitors	O
(	O
captopril	O
or	O
enalapril	O
)	O
are	O
teratogenic	O
.	O

Thus	O
,	O
the	O
potential	O
induction	O
of	O
this	O
gene	O
rearrangement	O
by	O
E1A	B-GENE
gene	I-GENE
therapy	O
is	O
unlikely	O
to	O
be	O
clinically	O
significant	O
in	O
the	O
treatment	O
of	O
advanced	O
malignant	O
disease	O
.	O

Although	O
the	O
cDNAs	O
of	O
HMG	B-GENE
-	I-GENE
14	I-GENE
and	O
HMG	B-GENE
-	I-GENE
17	I-GENE
do	O
not	O
cross	O
-	O
hybridize	O
,	O
they	O
have	O
several	O
similar	O
structural	O
features	O
:	O
the	O
open	O
reading	O
frame	O
comprises	O
only	O
23	O
%	O
of	O
the	O
transcripts	O
,	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
is	O
extremely	O
GC	O
rich	O
whereas	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
is	O
unusually	O
long	O
and	O
AT	O
rich	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
identification	O
of	O
a	O
23	O
-	O
kD	O
protein	O
that	O
interacts	O
with	O
zyxin	B-GENE
in	O
vitro	O
(	O
Sadler	O
et	O
al	O
.	O
,	O
1992	O
)	O
.	O

If	O
vascular	O
induction	O
between	O
a	O
vascular	O
carrier	O
and	O
the	O
selected	O
jejunal	O
segment	O
is	O
done	O
as	O
a	O
kind	O
of	O
flap	O
prefabrication	O
,	O
the	O
jejunal	O
interposition	O
flap	O
can	O
be	O
used	O
without	O
the	O
need	O
for	O
complex	O
microsurgery	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
high	O
binding	O
activities	O
of	O
ATPC	B-GENE
-	I-GENE
2	I-GENE
and	O
low	O
binding	O
activities	O
of	O
CBF	B-GENE
were	O
observed	O
with	O
nuclear	O
extracts	O
from	O
tissue	O
with	O
low	O
AtpC	B-GENE
expression	O
levels	O
,	O
and	O
the	O
opposite	O
was	O
observed	O
with	O
extracts	O
from	O
tissues	O
with	O
high	O
AtpC	B-GENE
expression	O
levels	O
.	O

Activation	O
of	O
tyrosine	B-GENE
kinase	I-GENE
-	I-GENE
containing	I-GENE
receptors	I-GENE
,	O
heterotrimeric	B-GENE
G	I-GENE
proteins	I-GENE
,	O
and	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
enhanced	O
the	O
activities	O
of	O
both	O
MEK	B-GENE
isoforms	I-GENE
in	O
293	O
and	O
PC12	O
cells	O
.	O

The	O
Fugu	O
rubripes	O
(	O
Fugu	O
)	O
gene	O
fragment	O
was	O
used	O
to	O
isolate	O
the	O
GH	B-GENE
gene	I-GENE
from	O
a	O
Fugu	O
genomic	O
library	O
.	O

An	O
in	O
vitro	O
'	O
glass	O
stomach	O
'	O
(	O
containing	O
various	O
volumes	O
of	O
hydrochloric	O
acid	O
[	O
HCl	O
]	O
and	O
ammonium	O
chloride	O
[	O
NH4Cl	O
]	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
means	O
of	O
increasing	O
'	O
gastric	O
'	O
pH	O
to	O
that	O
of	O
the	O
NH4	O
+	O
-	O
-	O
>	O
NH3	O
transition	O
that	O
occurs	O
significantly	O
at	O
pH	O
9	O
.	O
24	O
.	O

Acyclovir	O
(	O
3	O
%	O
ointment	O
)	O
used	O
topically	O
one	O
to	O
five	O
times	O
a	O
day	O
on	O
acute	O
ocular	O
HSV	O
infection	O
gave	O
beneficial	O
results	O
as	O
measured	O
by	O
a	O
reduction	O
in	O
corneal	O
involvement	O
,	O
conjunctivitis	O
,	O
iritis	O
,	O
and	O
corneal	O
clouding	O
.	O

We	O
have	O
documented	O
previously	O
that	O
glucocorticoid	O
hormones	O
modulate	O
the	O
posttranslational	O
localization	O
of	O
cell	O
surface	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
glycoproteins	O
in	O
the	O
viral	O
-	O
infected	O
M1	O
.	O
54	O
rat	O
HTC	O
hepatoma	O
cell	O
line	O
.	O

Partial	O
proteolysis	O
of	O
cell	O
surface	O
-	O
iodinated	O
B	B-GENE
-	I-GENE
G	I-GENE
molecules	I-GENE
generates	O
extremely	O
similar	O
patterns	O
of	O
spots	O
,	O
both	O
within	O
and	O
between	O
haplotypes	O
.	O

SETTING	O
:	O
University	O
research	O
laboratory	O
.	O

There	O
was	O
a	O
57	O
%	O
reduction	O
in	O
IGF	B-GENE
IR	I-GENE
mRNA	I-GENE
levels	O
in	O
clone	O
CA9	O
after	O
confluence	O
compared	O
with	O
clone	O
ME10	O
.	O

Oligomers	O
corresponding	O
to	O
the	O
region	O
of	O
the	O
mlc	B-GENE
-	I-GENE
1	I-GENE
/	I-GENE
3	I-GENE
enhancer	I-GENE
,	O
which	O
encompasses	O
this	O
conserved	O
sequence	O
,	O
bound	O
MEF	B-GENE
-	I-GENE
2	I-GENE
and	O
competed	O
for	O
its	O
binding	O
to	O
the	O
mck	B-GENE
enhancer	O
.	O

Similar	O
tissue	O
-	O
specific	O
patterns	O
are	O
observed	O
with	O
a	O
fusion	O
between	O
the	O
caufliflower	B-GENE
mosaic	I-GENE
virus	I-GENE
35S	I-GENE
RNA	I-GENE
promotor	I-GENE
and	O
the	O
GUS	B-GENE
gene	I-GENE
.	O

This	O
difference	O
between	O
SP	B-GENE
-	I-GENE
1	I-GENE
and	O
SP	B-GENE
-	I-GENE
2	I-GENE
peptides	I-GENE
was	O
not	O
due	O
to	O
their	O
differential	O
uptake	O
by	O
cell	O
,	O
since	O
approximately	O
100	O
times	O
more	O
SP	B-GENE
-	I-GENE
2	I-GENE
peptide	I-GENE
could	O
be	O
found	O
in	O
cytoplasmic	O
extracts	O
than	O
SP	B-GENE
-	I-GENE
1	I-GENE
peptide	I-GENE
in	O
experiments	O
using	O
radiolabeled	O
peptides	O
.	O

One	O
function	O
of	O
p53	B-GENE
is	O
in	O
regulating	O
cell	O
cycle	O
check	O
-	O
point	O
control	O
after	O
DNA	O
damage	O
.	O

We	O
used	O
event	O
-	O
related	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
during	O
a	O
cued	O
spatial	O
-	O
attention	O
task	O
to	O
dissociate	O
brain	O
activity	O
related	O
to	O
attentional	O
control	O
from	O
that	O
related	O
to	O
selective	O
processing	O
of	O
target	O
stimuli	O
.	O

BACKGROUND	O
:	O
The	O
extract	O
of	O
medicinal	O
plants	O
containing	O
curcumin	O
is	O
traditionally	O
believed	O
to	O
have	O
a	O
positive	O
contraction	O
effect	O
on	O
the	O
human	O
gall	O
-	O
bladder	O
.	O

Apoptosis	O
triggered	O
through	O
Fas	B-GENE
and	O
F	B-GENE
/	I-GENE
F	I-GENE
was	O
inhibited	O
by	O
coexpression	O
of	O
CrmA	B-GENE
and	O
p35	B-GENE
,	O
but	O
not	O
Bcl	B-GENE
-	I-GENE
xL	I-GENE
.	O

The	O
product	O
of	O
one	O
gene	O
,	O
Bv80	B-GENE
,	O
has	O
a	O
single	O
divergent	O
copy	O
of	O
a	O
sequence	O
of	O
149	O
amino	O
acids	O
(	O
approx	O
.	O

The	O
1031	B-GENE
-	I-GENE
bp	I-GENE
wild	I-GENE
-	I-GENE
type	I-GENE
HIT1	I-GENE
DNA	I-GENE
which	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
164	O
amino	O
acids	O
and	O
the	O
AGG	B-GENE
arginine	I-GENE
tRNA	I-GENE
gene	I-GENE
complemented	O
all	O
hit1	B-GENE
-	I-GENE
1	I-GENE
mutant	I-GENE
phenotypes	I-GENE
,	O
indicating	O
that	O
the	O
mutant	O
phenotypes	O
were	O
caused	O
by	O
the	O
deletion	O
of	O
these	O
genes	O
.	O

We	O
found	O
a	O
prevalence	O
of	O
eating	O
disorders	O
of	O
5	O
.	O
9	O
%	O
(	O
lifetime	O
prevalence	O
of	O
10	O
%	O
)	O
,	O
irrespective	O
of	O
gender	O
and	O
type	O
of	O
diabetes	O
;	O
4	O
.	O
1	O
%	O
of	O
the	O
whole	O
sample	O
reported	O
intentional	O
insulin	B-GENE
undertreatment	O
or	O
omission	O
.	O

Tilisolol	O
and	O
carboxymethylcellulose	O
sodium	O
salt	O
(	O
CMC	O
)	O
were	O
used	O
as	O
the	O
model	O
ophthalmic	O
drug	O
and	O
viscous	O
polymer	O
,	O
respectively	O
.	O

These	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
of	O
the	O
myogenic	O
lineage	O
that	O
is	O
based	O
on	O
the	O
expression	O
of	O
desmin	B-GENE
.	O

We	O
identified	O
two	O
potential	O
phosphorylation	O
sites	O
at	O
serine49	O
and	O
serine133	O
,	O
both	O
of	O
which	O
seem	O
to	O
be	O
necessary	O
for	O
Myf	B-GENE
-	I-GENE
5	I-GENE
activity	O
.	O

We	O
constructed	O
a	O
series	O
of	O
chimeric	O
genes	O
containing	O
part	O
of	O
the	O
first	O
exon	O
and	O
increasingly	O
longer	O
5	O
'	O
flanking	O
sequences	O
of	O
the	O
ODC	B-GENE
gene	I-GENE
fused	O
to	O
either	O
bacterial	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
or	O
luciferase	B-GENE
reporter	I-GENE
genes	I-GENE
.	O

CVO2	O
saturation	O
is	O
a	O
reliable	O
and	O
sensitive	O
method	O
for	O
detecting	O
blood	O
loss	O
.	O

The	O
gene	O
encoding	O
the	O
Neisseria	B-GENE
lactamica	I-GENE
III	I-GENE
DNA	I-GENE
methyltransferase	I-GENE
(	O
M	B-GENE
.	I-GENE
NlaIII	I-GENE
)	O
which	O
recognizes	O
the	O
sequence	O
CATG	O
has	O
been	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

This	O
latter	O
complex	O
reacts	O
with	O
an	O
antibody	O
to	O
serum	B-GENE
response	I-GENE
factor	I-GENE
(	O
SRF	B-GENE
)	O
and	O
exhibits	O
the	O
same	O
binding	O
characteristics	O
as	O
purified	O
SRF	B-GENE
.	O

The	O
second	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
.	O

Alignment	O
of	O
the	O
rat	B-GENE
and	I-GENE
human	I-GENE
WIN	I-GENE
cDNAs	I-GENE
and	O
their	O
comparison	O
with	O
mouse	O
genomic	O
sequence	O
revealed	O
that	O
the	O
WIN	B-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
is	O
encoded	O
by	O
four	O
exons	O
,	O
two	O
of	O
which	O
(	O
exons	O
4	O
and	O
6	O
)	O
are	O
alternatively	O
spliced	O
to	O
generate	O
at	O
least	O
three	O
classes	O
of	O
mRNA	O
transcripts	O
.	O

In	O
a	O
pilot	O
study	O
in	O
which	O
two	O
dogs	O
were	O
given	O
parenteral	O
rifampin	O
before	O
and	O
after	O
operation	O
and	O
grafts	O
were	O
preclotted	O
with	O
blood	O
that	O
contained	O
rifampin	O
,	O
it	O
was	O
suggested	O
that	O
there	O
was	O
a	O
slight	O
increase	O
in	O
inhibition	O
at	O
24	O
hours	O
(	O
93	O
%	O
)	O
.	O

A	O
flow	O
probe	O
for	O
direct	O
measurement	O
of	O
blood	O
flow	O
of	O
the	O
mitral	O
valve	O
was	O
devised	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
interaction	O
of	O
the	O
Lactococcus	B-GENE
lactis	I-GENE
Ll	I-GENE
.	I-GENE
LtrB	I-GENE
group	I-GENE
II	I-GENE
intron	I-GENE
endonuclease	I-GENE
with	O
its	O
DNA	O
target	O
site	O
by	O
DNA	O
footprinting	O
and	O
modification	O
-	O
interference	O
approaches	O
.	O

Clinical	O
trials	O
bring	O
informations	O
for	O
pharmacology	O
and	O
epidemiology	O
.	O

In	O
several	O
steps	O
we	O
converted	O
the	O
retinoid	O
specific	O
response	O
element	O
of	O
the	O
human	B-GENE
retinoic	I-GENE
acid	I-GENE
receptor	I-GENE
beta	I-GENE
promoter	I-GENE
into	O
the	O
vitamin	O
D	O
/	O
retinoic	O
acid	O
response	O
element	O
of	O
the	O
human	B-GENE
osteocalcin	I-GENE
promoter	I-GENE
.	O

The	O
immediate	O
5	O
'	O
-	O
flanking	O
region	O
was	O
GC	O
-	O
rich	O
with	O
3	O
SP	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
like	I-GENE
and	O
2	O
AP	B-GENE
-	I-GENE
2	I-GENE
sites	I-GENE
identified	O
in	O
close	O
proximity	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Akt	B-GENE
-	O
dependent	O
antiapoptotic	O
action	O
of	O
insulin	B-GENE
is	O
sensitive	O
to	O
farnesyltransferase	O
inhibitor	O
.	O

For	O
all	O
samples	O
,	O
the	O
sensitivity	O
of	O
the	O
blast	O
flag	O
on	O
the	O
CD3500	O
was	O
85	O
%	O
with	O
a	O
specificity	O
of	O
91	O
%	O
(	O
STKS	O
:	O
sensitivity	O
,	O
75	O
%	O
;	O
specificity	O
,	O
85	O
%	O
)	O
;	O
the	O
sensitivity	O
of	O
the	O
CD3500	O
IG	O
flag	O
was	O
72	O
%	O
with	O
a	O
specificity	O
of	O
76	O
%	O
(	O
STKS	O
:	O
sensitivity	O
,	O
75	O
%	O
:	O
specificity	O
,	O
73	O
%	O
)	O
;	O
and	O
the	O
sensitivity	O
of	O
the	O
NRBC	O
flag	O
was	O
43	O
%	O
with	O
a	O
specificity	O
of	O
94	O
%	O
(	O
STKS	O
sensitivity	O
,	O
37	O
%	O
;	O
specificity	O
,	O
88	O
%	O
)	O
.	O

Control	O
of	O
ovulation	O
in	O
mares	O
in	O
the	O
early	O
breeding	O
season	O
with	O
ovarian	O
steroids	O
and	O
prostaglandin	O
.	O

Reasons	O
are	O
given	O
for	O
suggesting	O
that	O
tiapamil	O
warrants	O
further	O
clinical	O
evaluation	O
,	O
after	O
which	O
it	O
may	O
join	O
the	O
more	O
established	O
calcium	O
antagonists	O
as	O
a	O
valuable	O
therapeutic	O
agent	O
.	O

The	O
central	O
venous	O
O2	O
saturation	O
test	O
in	O
acute	O
pulmonary	O
fat	O
embolism	O
.	O

Two	O
of	O
the	O
proteins	O
UPRF	B-GENE
-	I-GENE
1	I-GENE
and	O
UPRF	B-GENE
-	I-GENE
2	I-GENE
(	O
which	O
is	O
apparently	O
a	O
proteolytic	O
degradation	O
product	O
of	O
UPRF	B-GENE
-	I-GENE
1	I-GENE
)	O
bind	O
inefficiently	O
to	O
mutant	O
versions	O
of	O
the	O
UPR	O
that	O
are	O
unable	O
to	O
confer	O
responsiveness	O
to	O
unfolded	O
proteins	O
to	O
the	O
(	O
CYC1	B-GENE
)	O
promoter	O
.	O

Identification	O
of	O
domains	O
mediating	O
transcription	O
activation	O
,	O
repression	O
,	O
and	O
inhibition	O
in	O
the	O
paired	B-GENE
-	I-GENE
related	I-GENE
homeobox	I-GENE
protein	I-GENE
,	O
Prx2	B-GENE
(	O
S8	B-GENE
)	O
.	O

METHODS	O
:	O
A	O
spatial	O
counting	O
approach	O
in	O
which	O
the	O
location	O
of	O
each	O
and	O
every	O
PN	O
and	O
NP	O
in	O
the	O
stratum	O
pyramidale	O
of	O
sectors	O
CA1	O
-	O
4	O
was	O
applied	O
to	O
11	O
normal	O
control	O
(	O
CONs	O
)	O
and	O
10	O
SZs	O
matched	O
for	O
age	O
and	O
postmortem	O
interval	O
,	O
as	O
well	O
as	O
4	O
manic	O
depressive	O
(	O
MD	O
)	O
subjects	O
matched	O
for	O
age	O
.	O

Analytical	O
scanning	O
isoelectrofocusing	O
.	O

Upstream	B-GENE
stimulatory	I-GENE
factor	I-GENE
USF	B-GENE
is	O
a	O
human	O
transcriptional	O
activation	O
factor	O
,	O
which	O
uses	O
a	O
basic	O
/	O
helix	O
-	O
loop	O
-	O
helix	O
/	O
leucin	O
zipper	O
(	O
b	O
/	O
HLH	O
/	O
Z	O
)	O
motif	O
to	O
homodimerize	O
and	O
recognize	O
specific	O
sequences	O
in	O
the	O
promoter	O
region	O
of	O
both	O
nuclear	O
and	O
viral	O
genes	O
transcribed	O
by	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
.	O

43	O
%	O
,	O
6	O
/	O
14	O
;	O
P	O
=	O
0	O
.	O
013	O
)	O
,	O
whereas	O
,	O
in	O
RCC	O
samples	O
with	O
VHL	B-GENE
methylation	O
or	O
mutation	O
,	O
the	O
frequency	O
of	O
3p14	O
-	O
p21	O
LOH	O
did	O
not	O
differ	O
from	O
that	O
of	O
sp25	O
-	O
p26	O
(	O
72	O
%	O
,	O
18	O
/	O
25	O
vs	O
.	O

Sequences	O
homologous	O
to	O
the	O
consensus	O
TUF	B-GENE
-	I-GENE
binding	I-GENE
UAS	I-GENE
boxes	I-GENE
are	O
present	O
in	O
the	O
5	O
'	O
flanking	O
regions	O
of	O
both	O
genes	O
.	O

The	O
analysis	O
predicted	O
that	O
progressive	O
increases	O
in	O
serum	O
creatinine	O
or	O
aspartate	B-GENE
transaminase	I-GENE
activity	O
will	O
result	O
in	O
only	O
a	O
50	O
%	O
reduction	O
of	O
clearance	O
.	O

RESULTS	O
:	O
Although	O
low	O
levels	O
of	O
vIRF	B-GENE
-	I-GENE
2	I-GENE
mRNAs	I-GENE
can	O
be	O
detected	O
in	O
the	O
HHV	O
-	O
8	O
-	O
positive	O
BCBL	O
-	O
1	O
tumor	O
cell	O
line	O
,	O
12	O
-	O
0	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
treatment	O
does	O
not	O
stimulate	O
expression	O
of	O
vIRF	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
together	O
with	O
primary	O
lytic	O
cycle	O
genes	O
.	O

Central	O
projections	O
of	O
gastric	O
afferent	O
vagal	O
inputs	O
.	O

DNA	O
sequence	O
of	O
the	O
UL6	B-GENE
to	O
UL20	B-GENE
genes	I-GENE
of	O
infectious	O
laryngotracheitis	O
virus	O
and	O
characterization	O
of	O
the	O
UL10	B-GENE
gene	I-GENE
product	I-GENE
as	O
a	O
nonglycosylated	O
and	O
nonessential	O
virion	O
protein	O
.	O

Coimmunoprecipitation	O
analysis	O
suggests	O
that	O
these	O
residues	O
likely	O
contribute	O
to	O
the	O
multimerization	O
function	O
required	O
for	O
homomeric	O
complex	O
formation	O
or	O
heteromeric	O
complex	O
formation	O
with	O
p50	B-GENE
in	O
that	O
no	O
association	O
of	O
p65	B-GENE
delta	I-GENE
with	O
itself	O
or	O
with	O
p50	B-GENE
was	O
evident	O
.	O

Cytostatic	O
activity	O
of	O
some	O
essential	O
oils	O
against	O
HEp	O
-	O
2	O
cells	O
.	O

A	O
yeast	O
mitochondrial	O
translation	O
initiation	O
codon	O
mutation	O
affecting	O
the	O
gene	O
for	O
cytochrome	B-GENE
oxidase	I-GENE
subunit	I-GENE
III	I-GENE
(	O
COX3	B-GENE
)	O
was	O
partially	O
suppressed	O
by	O
a	O
spontaneous	O
nuclear	O
mutation	O
.	O

Only	O
the	O
27	O
-	O
kDa	O
protein	O
was	O
detected	O
after	O
N	B-GENE
-	I-GENE
glycosidase	I-GENE
treatment	O
,	O
indicating	O
that	O
PLP	B-GENE
-	I-GENE
H	I-GENE
is	O
a	O
glycoprotein	O
.	O

Moreover	O
,	O
we	O
studied	O
the	O
relationship	O
between	O
initial	O
percentage	O
of	O
bone	O
marrow	O
plasma	O
cells	O
and	O
prognosis	O
.	O

These	O
results	O
demonstrate	O
that	O
GGTase	B-GENE
-	I-GENE
I	I-GENE
inhibitors	O
arrest	O
cells	O
in	O
G0	O
/	O
G1	O
and	O
induce	O
accumulation	O
of	O
p21WAF	B-GENE
in	O
a	O
p53	B-GENE
-	O
independent	O
manner	O
and	O
that	O
FTase	B-GENE
inhibitors	O
can	O
interfere	O
with	O
cell	O
cycle	O
events	O
by	O
a	O
mechanism	O
that	O
involves	O
neither	O
p21WAF	B-GENE
nor	O
p27KIP	B-GENE
.	O

We	O
report	O
here	O
on	O
an	O
eight	O
-	O
year	O
-	O
old	O
boy	O
who	O
first	O
developed	O
acute	O
intravascular	O
hemolysis	O
following	O
therapy	O
with	O
amphotericin	O
B	O
(	O
AmB	O
)	O
and	O
subsequently	O
a	O
delayed	O
hemolytic	O
transfusion	O
reaction	O
due	O
to	O
alloantibodies	O
.	O

The	O
temporal	O
sequence	O
of	O
organ	O
failure	O
was	O
lung	O
,	O
clotting	O
system	O
,	O
kidney	O
,	O
and	O
liver	O
.	O

The	O
potential	O
biological	O
significance	O
of	O
the	O
identified	O
structural	O
motif	O
shared	O
by	O
the	O
human	B-GENE
CCR5	I-GENE
,	O
CCR3	B-GENE
,	O
CCR2B	B-GENE
and	O
other	O
GPCRs	B-GENE
is	O
discussed	O
.	O

Analysis	O
of	O
rat	O
brain	O
,	O
heart	O
,	O
lung	O
,	O
liver	O
,	O
kidney	O
and	O
skeletal	O
muscle	O
revealed	O
psi	B-GENE
PKC	I-GENE
zeta	I-GENE
mRNA	I-GENE
only	O
in	O
brain	O
.	O

The	O
papers	O
provide	O
a	O
broad	O
perspective	O
of	O
MPAs	O
and	O
include	O
social	O
,	O
economic	O
,	O
cultural	O
,	O
biological	O
and	O
statistical	O
components	O
.	O

Management	O
of	O
patients	O
with	O
Ewing	O
'	O
s	O
sarcoma	O
has	O
been	O
discussed	O
with	O
reference	O
to	O
the	O
need	O
to	O
achieve	O
an	O
excellent	O
local	O
result	O
from	O
radiation	O
therapy	O
now	O
that	O
patients	O
are	O
experiencing	O
long	O
-	O
term	O
survival	O
.	O

Furthermore	O
,	O
the	O
rapid	O
light	O
-	O
mediated	O
increase	O
of	O
CPRF	B-GENE
proteins	I-GENE
was	O
insensitive	O
to	O
transcriptional	O
inhibitors	O
,	O
suggesting	O
that	O
a	O
post	O
-	O
transcriptional	O
mechanism	O
controls	O
CPRF	B-GENE
accumulation	O
.	O

In	O
those	O
patients	O
who	O
before	O
transplantation	O
were	O
serological	O
negative	O
for	O
CMV	O
but	O
had	O
received	O
organs	O
from	O
CMV	B-GENE
-	I-GENE
IgG	I-GENE
positive	O
donors	O
,	O
the	O
incidence	O
of	O
the	O
disease	O
was	O
highest	O
.	O

Since	O
1985	O
the	O
combination	O
of	O
chlorambucil	O
(	O
10	O
mg	O
daily	O
,	O
initially	O
for	O
six	O
weeks	O
,	O
then	O
alternating	O
fortnights	O
for	O
12	O
weeks	O
)	O
and	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
2b	I-GENE
(	O
Schering	O
-	O
Plough	O
;	O
2	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
three	O
times	O
weekly	O
by	O
subcutaneous	O
injection	O
for	O
18	O
weeks	O
)	O
has	O
been	O
compared	O
in	O
a	O
randomised	O
trial	O
with	O
chlorambucil	O
alone	O
in	O
previously	O
untreated	O
patients	O
with	O
stage	O
III	O
or	O
IV	O
follicular	O
lymphoma	O
.	O

The	O
BDU	O
neurons	O
and	O
the	O
ALM	O
touch	O
neurons	O
are	O
lineal	O
sister	O
cells	O
in	O
the	O
AB	O
.	O
a	O
lineage	O
and	O
the	O
VA	O
and	O
VB	O
motor	O
neurons	O
are	O
lineal	O
sister	O
cells	O
in	O
the	O
AB	O
.	O
p	O
lineage	O
.	O

We	O
compared	O
retrospectively	O
the	O
efficacy	O
of	O
granulocyte	B-GENE
colony	I-GENE
stimulating	I-GENE
factor	I-GENE
(	O
G	B-GENE
-	I-GENE
CSF	I-GENE
)	O
alone	O
with	O
chemotherapy	O
plus	O
G	B-GENE
-	I-GENE
CSF	I-GENE
in	O
mobilizing	O
CD34	B-GENE
-	O
positive	O
cells	O
in	O
patients	O
with	O
malignant	O
lymphoma	O
.	O

Serum	O
concentrations	O
of	O
hormones	O
in	O
patients	O
classified	O
as	O
C	O
were	O
characteristically	O
and	O
inclined	O
to	O
be	O
hypergonadotropic	O
and	O
hypoestrogenic	O
.	O

Cervical	O
CT	O
revealed	O
an	O
irregular	O
low	O
density	O
at	O
the	O
periphery	O
of	O
the	O
cervical	O
vertebra	O
from	O
the	O
C2	O
to	O
C4	O
level	O
.	O

Incorporation	O
of	O
this	O
information	O
in	O
the	O
data	O
brought	O
about	O
a	O
revised	O
five	O
-	O
year	O
survival	O
estimate	O
of	O
55	O
percent	O
.	O

These	O
motifs	O
,	O
and	O
their	O
cognate	O
transcription	O
factors	O
,	O
appear	O
to	O
act	O
in	O
concert	O
,	O
with	O
partial	O
redundancy	O
,	O
so	O
that	O
discrete	O
mutations	O
were	O
only	O
partially	O
effective	O
in	O
reducing	O
transcriptional	O
activity	O
.	O

We	O
now	O
show	O
that	O
purified	O
recombinant	O
c	B-GENE
-	I-GENE
sis	I-GENE
/	O
PDGF	B-GENE
can	O
induce	O
this	O
binding	O
activity	O
which	O
we	O
have	O
termed	O
SIF	B-GENE
,	O
for	O
sis	B-GENE
-	I-GENE
inducible	I-GENE
factor	I-GENE
.	O

Statistical	O
conservation	O
laws	O
in	O
turbulent	O
transport	O
.	O

Expression	O
of	O
the	O
bacteriophage	B-GENE
T4	I-GENE
DNA	I-GENE
terminase	I-GENE
genes	I-GENE
16	I-GENE
and	I-GENE
17	I-GENE
yields	O
multiple	O
proteins	O
.	O

Erdheim	O
-	O
Chester	O
disease	O
:	O
a	O
distinct	O
lipoidosis	O
or	O
part	O
of	O
the	O
spectrum	O
of	O
histiocytosis	O
?	O

Erdheim	O
-	O
Chester	O
disease	O
has	O
always	O
been	O
considered	O
a	O
distinct	O
lipoidosis	O
based	O
on	O
clinical	O
and	O
radiographic	O
criteria	O
.	O

Self	O
-	O
consistent	O
calculation	O
of	O
the	O
surface	O
electronic	O
structure	O
of	O
the	O
(	O
1	O
x	O
2	O
)	O
reconstructed	O
Au	O
(	O
110	O
)	O
surface	O
.	O

The	O
plasmid	O
was	O
found	O
to	O
confer	O
drug	O
resistance	O
specifically	O
to	O
LMB	O
.	O

Two	O
pharmacokinetic	O
models	O
were	O
compared	O
.	O

A	O
higher	O
median	O
proportion	O
of	O
spirochaetes	O
was	O
observed	O
in	O
sites	O
after	O
diagnosis	O
of	O
loss	O
of	O
attachment	O
.	O

Ocular	O
injuries	O
during	O
general	O
anesthesia	O
.	O

Of	O
81	O
girls	O
cured	O
from	O
the	O
bacteriuria	O
24	O
recurred	O
,	O
5	O
with	O
a	O
symptomatic	O
pyelonephritis	O
and	O
3	O
with	O
cystitis	O
.	O

The	O
performances	O
of	O
two	O
tests	O
,	O
the	O
ProstAsure	O
index	O
and	O
the	O
percent	O
free	O
PSA	B-GENE
test	O
,	O
were	O
evaluated	O
in	O
detecting	O
cancer	O
.	O

The	O
protein	O
encoded	O
by	O
the	O
NF2	B-GENE
gene	I-GENE
has	O
a	O
similarity	O
to	O
ezrin	B-GENE
,	O
radixin	B-GENE
and	O
moesin	B-GENE
(	O
ERM	B-GENE
)	O
proteins	O
that	O
link	O
membrane	O
proteins	O
to	O
the	O
cytoskeleton	O
.	O

PATIENTS	O
-	O
-	O
125	O
women	O
consulting	O
the	O
general	O
practitioner	O
for	O
symptomatic	O
bacterial	O
vaginosis	O
.	O

In	O
the	O
healing	O
tendons	O
,	O
the	O
rate	O
of	O
collagen	B-GENE
synthesis	O
decreased	O
and	O
the	O
rate	O
of	O
noncollagen	O
protein	O
synthesis	O
remained	O
unchanged	O
.	O

From	O
our	O
own	O
investigations	O
on	O
phantoms	O
,	O
the	O
smallest	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
delta	O
S	O
min	O
/	O
delta	O
R	O
)	O
was	O
obtained	O
which	O
determines	O
the	O
minimal	O
contrast	O
,	O
given	O
the	O
film	O
properties	O
(	O
film	O
response	O
S	O
,	O
film	O
gradient	O
gamma	O
)	O
and	O
the	O
amount	O
of	O
scatter	O
.	O

However	O
,	O
one	O
activity	O
binds	O
preferentially	O
to	O
G	O
+	O
C	O
-	O
rich	O
promoters	O
,	O
and	O
another	O
activity	O
appears	O
to	O
bind	O
preferentially	O
to	O
only	O
two	O
of	O
the	O
promoters	O
tested	O
.	O

Cardiovascular	O
effects	O
in	O
man	O
of	O
intravenous	O
prizidilol	O
hydrochloride	O
(	O
SK	O
&	O
F	O
92657	O
)	O
;	O
a	O
new	O
antihypertensive	O
agent	O
.	O

From	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O

Expression	O
of	O
a	O
cDNA	O
clone	O
in	O
yeast	O
containing	O
a	O
large	O
portion	O
of	O
the	O
open	O
reading	O
frame	O
produced	O
cAMP	B-GENE
PDEase	I-GENE
activity	O
identical	O
in	O
properties	O
to	O
the	O
Drosophila	O
enzyme	O
affected	O
by	O
the	O
dnc	B-GENE
mutation	I-GENE
.	O

FdsR	B-GENE
purified	O
to	O
homogeneity	O
after	O
overexpression	O
of	O
fdsR	B-GENE
in	O
E	O
.	O
coli	O
is	O
a	O
130	O
kDa	O
homotetramer	O
binding	O
to	O
the	O
fds	B-GENE
control	O
region	O
located	O
between	O
the	O
fdsR	B-GENE
and	O
fdsG	B-GENE
genes	I-GENE
.	O

ZNS	O
,	O
in	O
the	O
mmolar	O
range	O
,	O
scavenged	O
hydroxyl	O
and	O
nitric	O
oxide	O
radicals	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
orthologs	O
of	O
the	O
Y	B-GENE
(	I-GENE
1	I-GENE
)	I-GENE
and	O
Y	B-GENE
(	I-GENE
2	I-GENE
)	I-GENE
subtypes	I-GENE
display	O
high	O
amino	O
acid	O
sequence	O
identities	O
between	O
pig	O
,	O
human	O
,	O
and	O
mouse	O
(	O
92	O
%	O
-	O
94	O
%	O
)	O
,	O
whereas	O
the	O
Y	B-GENE
(	I-GENE
4	I-GENE
)	I-GENE
,	O
Y	B-GENE
(	I-GENE
5	I-GENE
)	I-GENE
,	O
and	O
y	B-GENE
(	I-GENE
6	I-GENE
)	I-GENE
subtypes	I-GENE
display	O
lower	O
identities	O
(	O
76	O
%	O
-	O
87	O
%	O
)	O
.	O

Binding	O
of	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
to	O
phospho	O
-	O
TAMs	O
is	O
notable	O
for	O
the	O
high	O
level	O
of	O
cooperativity	O
between	O
the	O
two	O
SH2	B-GENE
domains	I-GENE
,	O
which	O
individually	O
demonstrate	O
low	O
affinity	O
interaction	O
with	O
the	O
ligand	O
.	O

The	O
benzo	O
-	O
pyrone	O
drug	O
Venalot	O
had	O
a	O
considerable	O
effect	O
in	O
reducing	O
the	O
protein	O
concentration	O
in	O
the	O
air	O
spaces	O
and	O
the	O
interstitial	O
tissue	O
,	O
and	O
of	O
the	O
oedema	O
in	O
the	O
latter	O
.	O

Radiation	O
was	O
delivered	O
in	O
a	O
single	O
4	O
-	O
mJ	O
pulse	O
of	O
200	O
microseconds	O
duration	O
by	O
means	O
of	O
an	O
articulated	O
zirconium	O
fluoride	O
optical	O
fibre	O
and	O
a	O
320	O
-	O
microns	O
quartz	O
-	O
fibre	O
tip	O
.	O

Perception	O
of	O
sweetness	O
cannot	O
be	O
used	O
to	O
accurately	O
meter	O
the	O
metabolizable	O
energy	O
or	O
nutritive	O
value	O
of	O
a	O
food	O
.	O

The	O
leader	O
peptide	O
was	O
hypothesized	O
to	O
inhibit	O
ribosome	O
release	O
at	O
the	O
tnaC	B-GENE
stop	I-GENE
codon	I-GENE
,	O
thereby	O
blocking	O
Rho	B-GENE
'	O
s	O
access	O
to	O
the	O
transcript	O
.	O

Response	O
properties	O
of	O
single	O
units	O
in	O
the	O
accessory	O
optic	O
system	O
of	O
the	O
dark	O
-	O
reared	O
cat	O
.	O

Excretion	O
of	O
radiopharmaceuticals	O
into	O
breast	O
milk	O
.	O

Influence	O
of	O
huanglian	O
used	O
in	O
combination	O
with	O
huangqin	O
and	O
gancao	O
on	O
the	O
erythrocytic	O
osmotic	O
fragilitas	O
of	O
experimental	O
glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
deficiency	O
in	O
rats	O
]	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
influence	O
of	O
common	O
combination	O
of	O
Huanglian	O
(	O
Coptis	O
chinensis	O
)	O
on	O
the	O
erythrocytic	O
osmotic	O
fragilitas	O
of	O
glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
G6PD	B-GENE
)	O
deficiency	O
in	O
rats	O
.	O

The	O
leukotriene	B-GENE
receptor	I-GENE
antagonist	O
zafirlukast	O
inhibits	O
sulfur	O
dioxide	O
-	O
induced	O
bronchoconstriction	O
in	O
patients	O
with	O
asthma	O
.	O

This	O
sequence	O
was	O
sufficient	O
to	O
confer	O
p53	B-GENE
-	O
dependent	O
activation	O
to	O
a	O
heterologous	O
promoter	O
and	O
p53	B-GENE
was	O
capable	O
of	O
binding	O
to	O
this	O
sequence	O
as	O
assessed	O
by	O
gel	O
shift	O
analysis	O
.	O

The	O
embryology	O
of	O
the	O
vertebral	O
column	O
is	O
reviewed	O
briefly	O
,	O
and	O
the	O
origin	O
of	O
each	O
anomaly	O
of	O
the	O
C2	O
vertebra	O
is	O
traced	O
to	O
one	O
of	O
the	O
two	O
early	O
stages	O
in	O
development	O
as	O
follows	O
:	O
1	O
)	O
the	O
formation	O
of	O
the	O
mesenchymal	O
vertebra	O
or	O
2	O
)	O
its	O
induction	O
to	O
cartilage	O
.	O

Two	O
of	O
the	O
three	O
groups	O
were	O
submitted	O
to	O
two	O
different	O
levels	O
of	O
hypoxia	O
(	O
FiO2	O
=	O
0	O
.	O
05	O
,	O
group	O
F5	O
and	O
FiO2	O
=	O
0	O
.	O
1	O
,	O
group	O
F10	O
)	O
and	O
the	O
third	O
to	O
normoxia	O
(	O
FiO2	O
=	O
0	O
.	O
21	O
,	O
group	O
F21	O
)	O
in	O
a	O
thermoneutral	O
and	O
controlled	O
environment	O
.	O

Parathyroid	B-GENE
hormone	I-GENE
responses	O
of	O
cyclic	O
AMP	O
-	O
,	O
serum	O
-	O
and	O
phorbol	O
ester	O
-	O
responsive	O
reporter	O
genes	O
in	O
osteoblast	O
-	O
like	O
UMR	O
-	O
106	O
cells	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
activation	O
of	O
the	O
beta	O
origin	O
by	O
a	O
distant	O
replication	O
enhancer	O
element	O
requires	O
a	O
small	O
target	O
sequence	O
essential	O
for	O
initiator	O
protein	O
-	O
mediated	O
DNA	O
looping	O
.	O

HNF4alpha7	B-GENE
mRNA	I-GENE
is	O
also	O
found	O
in	O
totipotent	O
embryonic	O
stem	O
cells	O
.	O

Penicillamine	O
-	O
induced	O
myasthenia	O
gravis	O
associated	O
with	O
antibodies	O
to	O
acetylcholine	B-GENE
receptor	I-GENE
.	O

Magnetic	O
force	O
and	O
torque	O
at	O
1	O
.	O
5	O
T	O
did	O
not	O
dislodge	O
the	O
GF	O
or	O
result	O
in	O
perforation	O
of	O
canine	O
IVC	O
by	O
the	O
GF	O
.	O

A	O
.	O

LCCH1	B-GENE
was	O
identical	O
to	O
the	O
Rdl	B-GENE
gene	I-GENE
,	O
a	O
known	O
GABA	B-GENE
receptor	I-GENE
subunit	I-GENE
gene	I-GENE
from	O
D	O
.	O
melanogaster	O
,	O
whereas	O
LCCH2	B-GENE
and	O
LCCH3	B-GENE
were	O
novel	O
D	O
.	O
melanogaster	O
sequences	O
that	O
exhibited	O
structural	O
similarity	O
to	O
other	O
members	O
of	O
the	O
ligand	B-GENE
-	I-GENE
gated	I-GENE
chloride	I-GENE
channel	I-GENE
gene	I-GENE
family	I-GENE
.	O

A	O
significant	O
increase	O
of	O
gastric	O
mucosal	O
permeability	O
was	O
observed	O
in	O
six	O
normal	O
human	O
subjects	O
after	O
instillation	O
of	O
ethanol	O
(	O
20	O
percent	O
v	O
/	O
v	O
)	O
.	O

Using	O
a	O
simulated	O
cough	O
machine	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
adding	O
tensio	O
-	O
active	O
liquids	O
as	O
sol	O
phase	O
simulant	O
on	O
the	O
clearance	O
of	O
gel	O
mucus	O
simulant	O
by	O
cough	O
.	O

First	O
,	O
the	O
amino	O
-	O
terminal	O
regulatory	O
arm	O
of	O
the	O
GDI	B-GENE
binds	O
to	O
the	O
switch	O
I	O
and	O
II	O
domains	O
of	O
Cdc42	B-GENE
leading	O
to	O
the	O
inhibition	O
of	O
both	O
GDP	O
dissociation	O
and	O
GTP	O
hydrolysis	O
.	O

By	O
a	O
combination	O
of	O
alternative	O
promoter	O
usage	O
and	O
exon	O
splicing	O
,	O
each	O
ROR	B-GENE
gene	I-GENE
generates	O
several	O
isoforms	O
that	O
differ	O
only	O
in	O
their	O
amino	O
terminus	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
showed	O
a	O
rapid	O
induction	O
of	O
nuclear	O
proteins	O
that	O
bound	O
to	O
the	O
consensus	B-GENE
kappa	I-GENE
B	I-GENE
motif	I-GENE
.	O

Analysis	O
of	O
larger	O
cDNA	O
clones	O
demonstrates	O
that	O
there	O
are	O
at	O
least	O
two	O
isoforms	O
of	O
RIP14	B-GENE
that	O
differ	O
in	O
the	O
N	O
-	O
terminal	O
(	O
A	O
and	O
B	O
)	O
and	O
hinge	O
(	O
D	O
)	O
domains	O
.	O

Multiple	O
copies	O
of	O
this	O
binding	O
site	O
are	O
found	O
in	O
the	O
viral	O
genomes	O
.	O

During	O
subsequent	O
CS	O
-	O
alone	O
trials	O
,	O
the	O
responses	O
of	O
(	O
+	O
)	O
MK	O
-	O
801	O
-	O
injected	O
mice	O
were	O
extinguished	O
as	O
easily	O
as	O
those	O
of	O
saline	O
-	O
injected	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
tail	O
deviated	O
ipsilaterally	O
in	O
cats	O
with	O
a	O
hemisection	O
,	O
and	O
the	O
tail	O
was	O
ventroflexed	O
in	O
cats	O
with	O
a	O
transection	O
.	O

The	O
major	O
open	O
reading	O
frame	O
of	O
the	O
cDNA	O
predicts	O
a	O
protein	O
of	O
59	O
kD	O
,	O
with	O
a	O
leucine	O
zipper	O
situated	O
adjacent	O
to	O
an	O
myc	B-GENE
-	I-GENE
related	I-GENE
motif	I-GENE
that	O
has	O
been	O
proposed	O
to	O
assume	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
structure	O
.	O

This	O
residue	O
,	O
although	O
located	O
55	O
rather	O
than	O
35	O
residues	O
NH2	O
-	O
terminal	O
of	O
the	O
essential	O
glutamate	O
,	O
is	O
undoubtedly	O
the	O
analog	O
of	O
the	O
second	O
aspartate	O
of	O
the	O
Asp	O
-	O
Asp	O
-	O
35	O
-	O
Glu	O
motif	O
found	O
in	O
other	O
family	O
members	O
.	O

In	O
addition	O
to	O
loss	O
of	O
digit	O
identity	O
and	O
varying	O
degrees	O
of	O
polydactyly	O
,	O
proximal	O
skeletal	O
elements	O
are	O
severely	O
shortened	O
in	O
Xt	B-GENE
;	O
ld	B-GENE
double	O
homozygous	O
limbs	O
.	O

The	O
PEP4	B-GENE
gene	I-GENE
was	O
isolated	O
from	O
a	O
genomic	O
DNA	O
library	O
by	O
complementation	O
of	O
the	O
pep4	B-GENE
-	I-GENE
3	I-GENE
mutation	O
.	O

A	O
gene	O
with	O
a	O
high	O
degree	O
of	O
sequence	O
identity	O
with	O
mammalian	B-GENE
ADP	I-GENE
-	I-GENE
ribosylation	I-GENE
factors	I-GENE
(	O
ARFs	B-GENE
)	O
,	O
believed	O
to	O
be	O
important	O
in	O
vesicular	O
transport	O
,	O
was	O
identified	O
.	O

Off	O
-	O
shell	O
effect	O
in	O
Rydberg	O
-	O
atom	O
-	O
alkali	O
-	O
metal	O
-	O
atom	O
scattering	O
.	O

Short	O
-	O
term	O
growth	O
:	O
rhythms	O
,	O
chaos	O
,	O
or	O
noise	O
?	O

Association	O
between	O
diaphragm	O
use	O
and	O
asymptomatic	O
bacteriuria	O
.	O

The	O
effect	O
of	O
iron	O
on	O
the	O
toxigenicity	O
of	O
Vibrio	O
cholerae	O
.	O

The	O
Tat	B-GENE
protein	I-GENE
coded	O
by	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
a	O
strong	O
activator	O
of	O
viral	O
gene	O
expression	O
from	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Is	O
it	O
time	O
for	O
a	O
wine	O
trial	O
?	O

The	O
average	O
coefficient	O
of	O
variation	O
between	O
assays	O
for	O
gas	O
chromatography	O
mass	O
spectrometry	O
was	O
5	O
.	O
8	O
%	O
and	O
for	O
radioimmunoassay	O
was	O
12	O
.	O
3	O
%	O
,	O
while	O
the	O
average	O
coefficient	O
of	O
variation	O
within	O
assays	O
for	O
gas	O
chromatography	O
mass	O
spectrometry	O
was	O
4	O
.	O
9	O
%	O
and	O
for	O
radioimmunoassay	O
6	O
.	O
9	O
%	O
.	O

Macrophages	O
:	O
modulators	O
of	O
immunity	O
.	O

The	O
NH2	O
-	O
terminal	O
fragments	O
were	O
tested	O
for	O
susceptibility	O
to	O
modification	O
with	O
Nalpha	O
-	O
(	O
3	O
-	O
maleimidylpropionyl	O
)	O
biocytin	O
,	O
which	O
attaches	O
a	O
biotin	O
group	O
to	O
cysteine	O
sulfhydryls	O
.	O

Production	O
of	O
VT	O
was	O
also	O
examined	O
retrospectively	O
in	O
32	O
E	O
.	O
coli	O
strains	O
of	O
serotype	O
O26	O
:	O
H11	O
isolated	O
from	O
children	O
with	O
diarrhoea	O
;	O
eight	O
(	O
25	O
%	O
)	O
of	O
them	O
produced	O
moderate	O
to	O
high	O
levels	O
of	O
verotoxin	B-GENE
1	I-GENE
despite	O
several	O
years	O
storage	O
in	O
vitro	O
.	O

Serum	O
pituitary	O
and	O
steroid	O
hormone	O
levels	O
in	O
the	O
adult	O
male	O
:	O
one	O
value	O
is	O
as	O
good	O
as	O
the	O
mean	O
of	O
three	O
.	O

The	O
sections	O
were	O
stained	O
with	O
anti	O
-	O
polymorphonuclear	O
leukocyte	O
antibody	O
,	O
the	O
endothelial	O
marker	O
factor	B-GENE
VIII	I-GENE
-	I-GENE
related	I-GENE
antigen	I-GENE
,	O
and	O
with	O
hematoxylin	O
and	O
eosin	O
.	O

Mapping	O
of	O
the	O
region	O
in	O
KAP	B-GENE
-	I-GENE
1	I-GENE
required	O
for	O
HP1	B-GENE
interaction	O
showed	O
that	O
amino	O
acid	O
substitutions	O
which	O
abolish	O
HP1	B-GENE
binding	O
in	O
vitro	O
reduce	O
KAP	B-GENE
-	I-GENE
1	I-GENE
mediated	O
repression	O
in	O
vivo	O
.	O

The	O
flanking	O
open	O
reading	O
frames	O
in	O
pARGC2	O
showed	O
no	O
homologies	O
to	O
arginine	O
biosynthetic	O
genes	O
.	O

Promoter	O
activity	O
of	O
the	O
proliferating	B-GENE
-	I-GENE
cell	I-GENE
nuclear	I-GENE
antigen	I-GENE
gene	I-GENE
is	O
associated	O
with	O
inducible	O
CRE	B-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
in	O
interleukin	B-GENE
2	I-GENE
-	O
stimulated	O
T	O
lymphocytes	O
.	O

METHODS	O
:	O
Levels	O
of	O
sIL	B-GENE
-	I-GENE
2R	I-GENE
were	O
measured	O
simultaneously	O
in	O
plasma	O
and	O
pleural	O
fluid	O
in	O
111	O
patients	O
with	O
pleural	O
effusions	O
of	O
unknown	O
causes	O
.	O

The	O
GIS	O
software	O
program	O
,	O
ArcView	O
,	O
was	O
used	O
for	O
spatial	O
analysis	O
and	O
distance	O
calculations	O
.	O

chi2	O
Tests	O
were	O
used	O
to	O
compare	O
the	O
distribution	O
of	O
the	O
characteristics	O
between	O
intersection	O
and	O
midblock	O
collisions	O
.	O

A	O
phase	O
II	O
study	O
was	O
initiated	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
combination	O
of	O
the	O
pure	O
L	O
-	O
isomer	O
of	O
LV	O
and	O
5	O
-	O
FU	O
along	O
with	O
epirubicin	O
in	O
patients	O
with	O
advanced	O
pancreatic	O
cancer	O
.	O

RESULTS	O
:	O
After	O
3	O
weeks	O
of	O
therapy	O
,	O
the	O
patient	O
had	O
an	O
increase	O
in	O
platelet	O
count	O
from	O
a	O
baseline	O
of	O
5	O
,	O
000	O
to	O
8	O
,	O
000	O
/	O
microliter	O
to	O
a	O
maximal	O
level	O
of	O
33	O
,	O
000	O
/	O
microliter	O
.	O

The	O
specificity	O
of	O
the	O
transcriptional	O
activation	O
by	O
ISGF3	B-GENE
is	O
mediated	O
by	O
specific	O
elements	O
termed	O
IFN	B-GENE
-	I-GENE
stimulatory	I-GENE
response	I-GENE
element	I-GENE
(	O
ISRE	B-GENE
)	O
located	O
in	O
the	O
promoter	O
region	O
of	O
IFN	B-GENE
-	O
inducible	O
genes	O
.	O

It	O
appears	O
that	O
the	O
K	O
-	O
ABC	O
is	O
a	O
relatively	O
nonbiased	O
test	O
suitable	O
for	O
the	O
evaluation	O
of	O
both	O
gifted	O
and	O
nongifted	O
children	O
regardless	O
of	O
race	O
or	O
gender	O
.	O

In	O
another	O
patient	O
,	O
IRPF	O
recurred	O
in	O
the	O
ureter	O
of	O
a	O
living	O
related	O
renal	O
graft	O
6	O
months	O
after	O
transplantation	O
.	O

These	O
mutants	O
,	O
assayed	O
by	O
injection	O
into	O
Xenopus	O
oocyte	O
nuclei	O
,	O
delimit	O
the	O
promoter	O
to	O
36	O
bp	O
of	O
DNA	O
upstream	O
of	O
the	O
cap	O
site	O
and	O
73	O
bp	O
of	O
the	O
untranslated	O
mRNA	O
leader	O
.	O

Upstream	O
tissue	B-GENE
inhibitor	I-GENE
of	I-GENE
metalloproteinases	I-GENE
-	I-GENE
1	I-GENE
(	I-GENE
TIMP	I-GENE
-	I-GENE
1	I-GENE
)	I-GENE
element	I-GENE
-	I-GENE
1	I-GENE
,	O
a	O
novel	O
and	O
essential	O
regulatory	O
DNA	O
motif	O
in	O
the	O
human	B-GENE
TIMP	I-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
promoter	I-GENE
,	O
directly	O
interacts	O
with	O
a	O
30	O
-	O
kDa	O
nuclear	O
protein	O
.	O

The	O
results	O
of	O
these	O
experiments	O
indicated	O
that	O
charcoal	O
,	O
imbiber	O
beads	O
,	O
and	O
the	O
anion	O
exchanges	O
resins	O
,	O
Dowex	O
XFS	O
-	O
4022	O
and	O
Dowex	O
SBR	O
-	O
C1	O
,	O
would	O
not	O
be	O
useful	O
agents	O
for	O
increasing	O
the	O
amount	O
of	O
dieldrin	O
eliminated	O
via	O
feces	O
(	O
droppings	O
)	O
of	O
chickens	O
.	O

The	O
receptor	O
for	O
CSF	B-GENE
-	I-GENE
1	I-GENE
,	O
c	B-GENE
-	I-GENE
Fms	I-GENE
,	O
is	O
expressed	O
in	O
osteoclasts	O
,	O
possesses	O
intrinsic	O
tyrosine	B-GENE
-	I-GENE
kinase	I-GENE
activity	O
,	O
and	O
signals	O
via	O
rapid	O
phosphorylation	O
of	O
selected	O
proteins	O
.	O

Adaptive	O
effects	O
of	O
repeated	O
immersion	O
exposure	O
on	O
the	O
human	O
body	O

To	O
this	O
end	O
we	O
generated	O
a	O
detailed	O
physical	O
map	O
of	O
the	O
genomic	O
region	O
spanning	O
between	O
sequence	O
-	O
tagged	O
site	O
markers	O
D16S518	B-GENE
and	O
D16S516	B-GENE
.	O

Spinophilin	B-GENE
,	O
a	O
novel	O
protein	B-GENE
phosphatase	I-GENE
1	I-GENE
binding	I-GENE
protein	I-GENE
localized	O
to	O
dendritic	O
spines	O
.	O

We	O
have	O
found	O
that	O
pro	B-GENE
-	I-GENE
IGF	I-GENE
-	I-GENE
2	I-GENE
can	O
initially	O
form	O
two	O
disulfide	O
isomers	O
that	O
undergo	O
rearrangement	O
to	O
a	O
single	O
conformation	O
in	O
vivo	O
.	O

While	O
working	O
on	O
the	O
toxicity	O
of	O
war	O
gases	O
.	O

he	O
formulated	O
'	O
Haber	O
'	O
s	O
rule	O
'	O
,	O
also	O
known	O
as	O
C	O
x	O
T	O
=	O
constant	O
in	O
order	O
to	O
characterize	O
the	O
toxicity	O
of	O
an	O
inhalant	O
.	O

The	O
existence	O
of	O
a	O
TFIIIB	B-GENE
assembly	O
pathway	O
leading	O
to	O
the	O
faithful	O
transcription	O
of	O
natural	O
eukaryotic	O
tRNA	O
genes	O
in	O
the	O
absence	O
of	O
TFIIIC	B-GENE
provides	O
novel	O
insights	O
into	O
the	O
functional	O
flexibility	O
of	O
the	O
eukaryotic	O
tRNA	O
gene	O
transcription	O
machinery	O
and	O
on	O
its	O
evolution	O
from	O
an	O
ancestral	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
system	O
relying	O
on	O
upstream	O
,	O
TATA	O
-	O
centered	O
control	O
elements	O
.	O

Ectopic	O
Xbra	B-GENE
can	O
induce	O
Xegr	B-GENE
-	I-GENE
1	I-GENE
transcription	O
by	O
an	O
indirect	O
mechanism	O
that	O
appears	O
to	O
operate	O
via	O
primary	O
activation	O
of	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
secretion	O
.	O

A	O
rapid	O
mixing	O
device	O
for	O
quasielastic	O
light	O
scattering	O
studies	O
of	O
reacting	O
systems	O
.	O

The	O
major	O
transcription	O
start	O
site	O
,	O
designated	O
as	O
+	O
1	O
,	O
was	O
determined	O
by	O
RACE	O
(	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
)	O
analysis	O
of	O
human	O
liver	O
cDNA	O
and	O
was	O
found	O
to	O
be	O
located	O
50	O
bp	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O

These	O
aa	O
residues	O
correspond	O
to	O
codons	O
59	O
and	O
108	O
in	O
the	O
P	B-GENE
.	I-GENE
falciparum	I-GENE
DHFR	I-GENE
active	I-GENE
site	I-GENE
in	O
which	O
similar	O
aa	O
substitutions	O
(	O
Cys	O
Arg	O
-	O
59	O
and	O
Ser	O
Asn	O
-	O
108	O
)	O
are	O
associated	O
with	O
pyrimethamine	O
resistance	O
.	O

Of	O
all	O
YASR	O
syndromes	O
,	O
the	O
highest	O
stability	O
was	O
for	O
the	O
Anxious	O
/	O
Depressed	O
scale	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
of	O
TPA	O
induction	O
of	O
FGF	B-GENE
-	I-GENE
BP	I-GENE
gene	O
expression	O
in	O
the	O
human	O
ME	O
-	O
180	O
SCC	O
cell	O
line	O
.	O

Between	O
the	O
RNA	O
initiation	O
site	O
and	O
the	O
coding	O
region	O
is	O
a	O
GC	O
-	O
rich	O
hairpin	O
structure	O
followed	O
by	O
8	O
T	O
residues	O
that	O
looks	O
like	O
a	O
rho	B-GENE
-	I-GENE
independent	I-GENE
transcription	I-GENE
terminator	I-GENE
.	O

Conversely	O
the	O
rate	O
of	O
bioavailability	O
was	O
significantly	O
different	O
,	O
because	O
from	O
the	O
Reference	O
patch	O
the	O
release	O
rate	O
is	O
fast	O
in	O
the	O
first	O
24	O
h	O
,	O
leading	O
to	O
an	O
E2	O
peak	O
at	O
8	O
h	O
and	O
to	O
a	O
Cmax	O
in	O
average	O
at	O
23	O
h	O
.	O

3	O
)	O
The	O
progress	O
of	O
fibrinolysis	O
was	O
observed	O
by	O
serial	O
collection	O
of	O
middle	O
ear	O
fluid	O
in	O
the	O
same	O
side	O
ear	O
of	O
5	O
cases	O
out	O
of	O
17	O
cases	O
having	O
much	O
activity	O
for	O
fibrin	B-GENE
degradation	O
,	O
and	O
lowering	O
of	O
fibrinolytic	O
activity	O
was	O
revealed	O
in	O
4	O
out	O
of	O
these	O
5	O
cases	O
as	O
the	O
result	O
.	O

Thus	O
G17	B-GENE
targets	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
promoter	I-GENE
CArG	I-GENE
sequence	I-GENE
via	O
Rho	B-GENE
A	I-GENE
-	O
dependent	O
pathways	O
,	O
and	O
Rho	B-GENE
A	I-GENE
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
trophic	O
action	O
of	O
G17	B-GENE
.	O

The	O
MIC90	O
of	O
ABK	O
against	O
coagulase	B-GENE
type	I-GENE
IV	I-GENE
strains	O
was	O
rather	O
high	O
,	O
12	O
.	O
5	O
micrograms	O
/	O
ml	O
.	O

In	O
each	O
patient	O
,	O
MBF	O
was	O
quantified	O
in	O
the	O
three	O
major	O
vascular	O
territories	O
:	O
the	O
left	O
anterior	O
descending	O
and	O
left	O
circumflex	O
coronary	O
artery	O
territories	O
and	O
the	O
right	O
coronary	O
artery	O
(	O
control	O
region	O
)	O
territory	O
.	O

These	O
results	O
demonstrate	O
that	O
m2	B-GENE
receptors	I-GENE
couple	O
to	O
both	O
G	B-GENE
alpha	I-GENE
i2	I-GENE
and	O
G	B-GENE
alpha	I-GENE
i3	I-GENE
in	O
vivo	O
and	O
that	O
this	O
interaction	O
is	O
integral	O
to	O
both	O
positive	O
and	O
negative	O
regulatory	O
pathways	O
leading	O
to	O
activation	O
of	O
PLC	B-GENE
and	O
desensitization	O
of	O
receptor	O
signaling	O
.	O

Platelet	O
count	O
and	O
plasma	O
volume	O
were	O
significantly	O
higher	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
throughout	O
pregnancy	O
.	O

The	O
fru	B-GENE
gene	I-GENE
has	O
seven	O
exons	O
spanning	O
15	O
-	O
kb	O
encoding	O
two	O
transcripts	O
with	O
ORFs	O
of	O
841	O
and	O
695	O
amino	O
acids	O
.	O

HC	B-GENE
-	I-GENE
toxin	I-GENE
exerts	O
a	O
potent	O
cytostatic	O
effect	O
on	O
plant	O
and	O
animal	O
cells	O
by	O
inhibiting	O
histone	B-GENE
deacetylase	I-GENE
.	O

The	O
human	O
RIL	B-GENE
gene	I-GENE
:	O
mapping	O
to	O
human	O
chromosome	O
5q31	O
.	O
1	O
,	O
genomic	O
organization	O
and	O
alternative	O
transcripts	O
.	O

The	O
delta	O
mean	O
VAF	O
and	O
delta	O
mean	O
SABP	O
indicated	O
varied	O
mean	O
values	O
of	O
VAF	O
and	O
SABP	O
,	O
respectively	O
.	O

Azoospermia	O
was	O
graded	O
in	O
the	O
following	O
way	O
:	O
adequate	O
spermatozoa	O
(	O
A1	O
)	O
,	O
low	O
,	O
scanty	O
or	O
rare	O
spermatozoa	O
(	O
A2	O
)	O
,	O
spermatid	O
arrest	O
(	O
B1	O
)	O
,	O
spermatocyte	O
arrest	O
(	O
B2	O
)	O
,	O
Sertoli	O
cell	O
-	O
only	O
pattern	O
(	O
C	O
)	O
and	O
sclerosis	O
(	O
D	O
)	O
.	O

